assay_tissue,bao_format,assay_id,relationship_type,description,curated_by,cell_id,tid,variant_id,doc_id,tissue_id,assay_tax_id,assay_organism,assay_category,chembl_id,assay_cell_type,src_assay_id,assay_test_type,assay_subcellular_fraction,assay_type,src_id,confidence_score,assay_strain
,BAO_0000019,1,H,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,Autocuration,,12052,,11087,,,,,CHEMBL615117,,,,,B,1,8,
,BAO_0000219,2,U,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,Autocuration,,22226,,684,,,,,CHEMBL615118,,,,,F,1,0,
,BAO_0000019,3,U,,Autocuration,,22226,,15453,,,,,CHEMBL615119,,,,,B,1,0,
,BAO_0000249,4,H,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,Autocuration,,104729,,17841,,9913.0,Bos taurus,,CHEMBL615120,,,,,B,1,4,
,BAO_0000219,5,N,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),Intermediate,163.0,80001,,17430,,9606.0,Homo sapiens,,CHEMBL615121,143B,,,,F,1,1,
,BAO_0000219,6,N,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),Intermediate,163.0,80001,,17430,,9606.0,Homo sapiens,,CHEMBL615122,143B,,,,F,1,1,
,BAO_0000219,7,N,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,Intermediate,163.0,80001,,13799,,10090.0,Mus musculus,,CHEMBL615123,143B,,,,F,1,1,
,BAO_0000219,8,N,In vitro cell cytotoxicity was determined against 143B cell line,Expert,163.0,80001,,17774,,9606.0,Homo sapiens,,CHEMBL615124,143B,,,,F,1,1,
,BAO_0000219,9,N,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,Intermediate,163.0,80001,,3801,,9606.0,Homo sapiens,,CHEMBL615125,143B,,,,F,1,1,
,BAO_0000219,10,N,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,Intermediate,163.0,80001,,17430,,9606.0,Homo sapiens,,CHEMBL615126,143B,,,,F,1,1,
,BAO_0000219,11,N,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,Intermediate,163.0,80001,,17430,,9606.0,Homo sapiens,,CHEMBL615127,143B,,,,F,1,1,
,BAO_0000219,12,N,In vitro cell cytotoxicity was determined against 143B-LTK cell line,Expert,163.0,80001,,17774,,9606.0,Homo sapiens,,CHEMBL615128,143B,,,,F,1,1,
,BAO_0000218,13,N,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",Intermediate,,50185,,11324,,1280.0,Staphylococcus aureus,,CHEMBL857900,,,,,F,1,1,
,BAO_0000218,14,N,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",Intermediate,,50185,,11324,,1280.0,Staphylococcus aureus,,CHEMBL615129,,,,,F,1,1,
,BAO_0000218,15,N,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",Intermediate,,50185,,11324,,1280.0,Staphylococcus aureus,,CHEMBL615130,,,,,F,1,1,
,BAO_0000218,16,N,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",Intermediate,,50185,,11324,,1280.0,Staphylococcus aureus,,CHEMBL615131,,,,,F,1,1,
,BAO_0000357,17,D,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,Expert,,100122,,11347,,10116.0,Rattus norvegicus,,CHEMBL884521,,,,,A,1,9,
,BAO_0000357,18,H,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),Autocuration,,12054,,16474,,,,,CHEMBL615132,,,,,B,1,8,
,BAO_0000019,19,H,Inhibition of partially purified 15-lipoxygenase from human leukocytes,Autocuration,,12054,,10091,,,,,CHEMBL615133,,,,,B,1,8,
,BAO_0000357,20,H,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),Autocuration,,12054,,16474,,,,,CHEMBL615134,,,,,B,1,8,
,BAO_0000357,21,H,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),Autocuration,,12054,,16474,,,,,CHEMBL615135,,,,,B,1,8,
,BAO_0000357,22,H,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),Autocuration,,12054,,16474,,,,,CHEMBL615136,,,,,B,1,8,
,BAO_0000357,23,H,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,Autocuration,,12054,,16474,,,,,CHEMBL615137,,,,,B,1,8,
,BAO_0000357,24,H,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,Autocuration,,12054,,16474,,,,,CHEMBL615138,,,,,B,1,8,
,BAO_0000219,25,U,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",Autocuration,,22226,,14352,,,,,CHEMBL836324,,,,,B,1,0,
,BAO_0000357,26,H,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,Autocuration,,12054,,5646,,9986.0,Oryctolagus cuniculus,,CHEMBL615139,,,,,B,1,8,
,BAO_0000357,27,H,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),Autocuration,,12054,,5646,,9986.0,Oryctolagus cuniculus,,CHEMBL615140,,,,,B,1,8,
,BAO_0000219,28,H,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,Autocuration,,12426,,10997,,,,,CHEMBL615141,,,,,B,1,8,
,BAO_0000357,29,H,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,Autocuration,,12054,,6309,,3847.0,soya bean,,CHEMBL615142,,,,,B,1,8,
,BAO_0000357,30,H,Inhibitory activity against soybean 15-lipoxygenase was evaluated,Autocuration,,12054,,167,,3847.0,Glycine max,,CHEMBL615143,,,,,B,1,8,
,BAO_0000357,31,H,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,Autocuration,,12054,,167,,3847.0,Glycine max,,CHEMBL615144,,,,,B,1,8,
,BAO_0000357,32,H,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,Autocuration,,12054,,11087,,3847.0,Glycine max,,CHEMBL872867,,,,,B,1,8,
,BAO_0000357,33,H,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,Autocuration,,12054,,11087,,3847.0,Glycine max,,CHEMBL615145,,,,,B,1,8,
,BAO_0000357,34,H,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,Autocuration,,12054,,13622,,3847.0,Glycine max,,CHEMBL615146,,,,,B,1,8,
,BAO_0000357,35,H,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,Autocuration,,12054,,13622,,3847.0,Glycine max,,CHEMBL615147,,,,,B,1,8,
,BAO_0000019,36,U,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,Autocuration,,22226,,11347,,10116.0,Rattus norvegicus,,CHEMBL615148,,,,,A,1,0,
,BAO_0000019,37,U,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,Autocuration,,22226,,5926,,562.0,Escherichia coli,,CHEMBL615149,,,,,B,1,0,
,BAO_0000019,38,U,Dissociation constant with dimeric 16S rRNA RNA construct B,Autocuration,,22226,,4567,,,,,CHEMBL615150,,,,,B,1,0,
,BAO_0000225,39,M,Dissociation constant towards 16S rRNA construct A,Intermediate,,22222,,3782,,,,,CHEMBL615151,,,,,B,1,3,
,BAO_0000225,40,M,Dissociation constant towards 16S rRNA construct B,Intermediate,,22222,,3782,,,,,CHEMBL615152,,,,,B,1,3,
,BAO_0000225,41,M,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,Expert,,100263,,4466,,562.0,Escherichia coli,,CHEMBL615153,,,,,B,1,3,
,BAO_0000225,42,M,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,Expert,,100263,,6592,,562.0,Escherichia coli,,CHEMBL615154,,,,,B,1,3,
,BAO_0000019,43,H,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),Autocuration,,13053,,898,,,,,CHEMBL615155,,,,,B,1,8,
,BAO_0000019,44,H,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),Autocuration,,13053,,898,,,,,CHEMBL615156,,,,,B,1,8,
,BAO_0000019,45,H,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,Autocuration,,20001,,13163,,9606.0,Homo sapiens,,CHEMBL615157,,,,,B,1,8,
,BAO_0000019,46,H,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,Autocuration,,20001,,13163,,9606.0,Homo sapiens,,CHEMBL615158,,,,,B,1,8,
,BAO_0000019,47,D,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",Expert,,12971,,10691,,10116.0,Rattus norvegicus,,CHEMBL615159,,,,,B,1,9,
,BAO_0000019,48,D,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",Expert,,12971,,10691,,10116.0,Rattus norvegicus,,CHEMBL615172,,,,,B,1,9,
,BAO_0000019,49,D,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",Expert,,12971,,10691,,10116.0,Rattus norvegicus,,CHEMBL615173,,,,,B,1,9,
,BAO_0000019,50,D,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",Expert,,12971,,10691,,10116.0,Rattus norvegicus,,CHEMBL615174,,,,,B,1,9,
,BAO_0000019,51,H,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),Autocuration,,13053,,898,,,,,CHEMBL884518,,,,,B,1,8,
,BAO_0000357,52,H,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),Autocuration,,11512,,912,,,,,CHEMBL615175,,,,,B,1,8,
,BAO_0000357,53,H,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,Autocuration,,11512,,912,,,,,CHEMBL615176,,,,,B,1,8,
,BAO_0000357,54,H,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,Autocuration,,11512,,912,,,,,CHEMBL615177,,,,,B,1,8,
,BAO_0000249,55,D,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,Autocuration,,104740,,15103,,10116.0,Rattus norvegicus,,CHEMBL615178,,,,Membranes,B,1,5,
,BAO_0000219,56,N,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,Intermediate,506.0,80002,,5116,,9606.0,Homo sapiens,,CHEMBL615179,1A9,,,,F,1,1,
,BAO_0000219,57,D,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,Autocuration,,104835,,14578,,10116.0,Rattus norvegicus,,CHEMBL615180,Oocytes,,,,F,1,7,
,BAO_0000219,58,D,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,Autocuration,,104821,,14578,,10116.0,Rattus norvegicus,,CHEMBL615181,Oocytes,,,,F,1,7,
,BAO_0000219,59,D,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,Autocuration,,104848,,14578,,10116.0,Rattus norvegicus,,CHEMBL615182,Oocytes,,,,F,1,7,
,BAO_0000219,60,N,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,Expert,506.0,80002,,4787,,9606.0,Homo sapiens,,CHEMBL615183,1A9,,,,F,1,1,
,BAO_0000219,61,N,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,Intermediate,506.0,80002,,4787,,9606.0,Homo sapiens,,CHEMBL615184,1A9,,,,F,1,1,
,BAO_0000219,62,N,Cytotoxic activity against human ovarian cancer (1A9) cell line,Intermediate,506.0,80002,,3547,,9606.0,Homo sapiens,,CHEMBL615185,1A9,,,,F,1,1,
,BAO_0000219,63,N,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,Intermediate,506.0,80002,,3547,,9606.0,Homo sapiens,,CHEMBL615186,1A9,,,,F,1,1,
,BAO_0000219,64,N,Effective dose of compound against replication of 1A9 cell line was evaluated,Intermediate,506.0,80002,,6726,,9606.0,Homo sapiens,,CHEMBL615187,1A9,,,,F,1,1,
,BAO_0000219,65,N,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,Expert,506.0,80002,,3455,,9606.0,Homo sapiens,,CHEMBL885343,1A9,,,,F,1,1,
,BAO_0000219,66,N,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),Intermediate,506.0,80002,,5726,,9606.0,Homo sapiens,,CHEMBL615188,1A9,,,,F,1,1,
,BAO_0000219,67,N,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,Intermediate,506.0,80002,,5726,,9606.0,Homo sapiens,,CHEMBL615189,1A9,,,,F,1,1,
,BAO_0000219,68,N,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,Intermediate,506.0,80002,,5726,,9606.0,Homo sapiens,,CHEMBL615190,1A9,,,,F,1,1,
,BAO_0000219,69,N,Inhibitory activity against Taxol resistant 1A9 cell lines,Intermediate,506.0,80002,,3395,,9606.0,Homo sapiens,,CHEMBL615191,1A9,,,,F,1,1,
,BAO_0000219,70,N,Cytotoxicity against human ovarian cancer (1A9) cell lines.,Expert,506.0,80002,,3415,,9606.0,Homo sapiens,,CHEMBL615192,1A9,,,,F,1,1,
,BAO_0000219,71,N,Percentage inhibition of human ovarian cancer (1A9) cell lines.,Expert,506.0,80002,,3415,,9606.0,Homo sapiens,,CHEMBL827083,1A9,,,,F,1,1,
,BAO_0000219,72,N,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,Expert,506.0,80002,,17099,,9606.0,Homo sapiens,,CHEMBL615193,1A9,,,,F,1,1,
,BAO_0000219,73,N,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,Intermediate,506.0,80002,,17099,,9606.0,Homo sapiens,,CHEMBL615194,1A9,,,,F,1,1,
,BAO_0000219,74,N,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,Intermediate,506.0,80002,,17099,,9606.0,Homo sapiens,,CHEMBL615195,1A9,,,,F,1,1,
,BAO_0000219,75,N,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,Intermediate,506.0,80002,,17099,,9606.0,Homo sapiens,,CHEMBL615196,1A9,,,,F,1,1,
,BAO_0000219,76,N,Inhibitory concentration against Jurkat cells,Intermediate,503.0,81072,,17721,,9606.0,Homo sapiens,,CHEMBL615197,Jurkat,,,,F,1,1,
,BAO_0000019,77,U,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,Intermediate,,22226,,1229,,,,,CHEMBL615198,,,,,F,1,0,
,BAO_0000357,78,D,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,Expert,,100121,,11347,,10116.0,Rattus norvegicus,,CHEMBL615199,,,,,A,1,9,
,BAO_0000357,79,H,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",Expert,,11231,,17117,,,,,CHEMBL615200,,,,,B,1,8,
,BAO_0000357,80,H,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",Expert,,11231,,17117,,,,,CHEMBL615201,,,,,B,1,8,
,BAO_0000357,81,H,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",Expert,,11231,,17117,,,,,CHEMBL615202,,,,,B,1,8,
,BAO_0000251,82,H,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",Autocuration,,11231,,11375,,5476.0,Candida albicans,,CHEMBL615203,,,,Microsomes,B,1,8,
,BAO_0000251,83,H,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",Autocuration,,11231,,11375,,5476.0,Candida albicans,,CHEMBL615204,,,,Microsomes,B,1,8,
,BAO_0000251,84,H,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",Autocuration,,11231,,11375,,4932.0,Saccharomyces cerevisiae,,CHEMBL615205,,,,Microsomes,B,1,8,
,BAO_0000251,85,H,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",Autocuration,,11231,,11375,,4932.0,Saccharomyces cerevisiae,,CHEMBL615206,,,,Microsomes,B,1,8,
Liver,BAO_0000251,86,H,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",Autocuration,,12083,,11375,2107.0,9823.0,Sus scrofa,,CHEMBL615207,,,,Microsomes,B,1,8,
,BAO_0000019,87,H,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",Autocuration,,11231,,791,,10116.0,Rattus norvegicus,,CHEMBL827084,,,,,B,1,8,
,BAO_0000019,88,H,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",Autocuration,,11231,,791,,10116.0,Rattus norvegicus,,CHEMBL615208,,,,,B,1,8,
,BAO_0000019,89,H,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",Autocuration,,11231,,791,,10116.0,Rattus norvegicus,,CHEMBL615209,,,,,B,1,8,
Liver,BAO_0000251,90,D,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",Autocuration,,12083,,11375,2107.0,10116.0,Rattus norvegicus,,CHEMBL615210,,,,Microsomes,B,1,9,
Liver,BAO_0000251,91,D,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",Autocuration,,12083,,11375,2107.0,10116.0,Rattus norvegicus,,CHEMBL615211,,,,Microsomes,B,1,9,
Liver,BAO_0000251,92,D,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",Autocuration,,12083,,153,2107.0,10116.0,Rattus norvegicus,,CHEMBL615212,,,,Microsomes,B,1,9,
,BAO_0000357,93,H,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),Expert,,11377,,8269,,,,,CHEMBL615213,,,,,B,1,8,
,BAO_0000357,94,H,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,Expert,,11377,,8269,,,,,CHEMBL615273,,,,,B,1,8,
,BAO_0000219,95,N,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,Expert,726.0,81020,,17653,,9606.0,Homo sapiens,,CHEMBL615274,HepG2,,,,F,1,1,
,BAO_0000219,96,N,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,Intermediate,726.0,81020,,14277,,9606.0,Homo sapiens,,CHEMBL615275,HepG2,,,,F,1,1,
,BAO_0000219,97,N,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,Intermediate,726.0,81020,,1717,,9606.0,Homo sapiens,,CHEMBL615276,HepG2,,,,F,1,1,
,BAO_0000219,98,N,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,Intermediate,726.0,81020,,14091,,9606.0,Homo sapiens,,CHEMBL615277,HepG2,,,,F,1,1,
,BAO_0000219,99,N,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,Intermediate,726.0,81020,,14091,,9606.0,Homo sapiens,,CHEMBL615326,HepG2,,,,F,1,1,
,BAO_0000218,100,N,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,Expert,,50606,,17653,,10407.0,Hepatitis B virus,,CHEMBL883130,,,,,F,1,1,
,BAO_0000219,101,N,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,Intermediate,726.0,81020,,13105,,9606.0,Homo sapiens,,CHEMBL884519,HepG2,,,,F,1,1,
,BAO_0000219,102,N,Concentration required to inhibit 50% of 2.2.15 cell line,Intermediate,726.0,81020,,1717,,9606.0,Homo sapiens,,CHEMBL615327,HepG2,,,,F,1,1,
,BAO_0000219,103,N,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,Intermediate,726.0,81020,,13105,,9606.0,Homo sapiens,,CHEMBL615328,HepG2,,,,A,1,1,
,BAO_0000218,104,N,Cytotoxic activity of compound against uninfected 2.2.15 cells.,Intermediate,,50587,,13600,,9606.0,Homo sapiens,,CHEMBL615329,2.2.15,,,,F,1,1,
,BAO_0000218,105,N,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,Intermediate,,50587,,13467,,9606.0,Homo sapiens,,CHEMBL615330,2.2.15,,,,F,1,1,
,BAO_0000218,106,N,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",Expert,,50606,,17477,,10407.0,Hepatitis B virus,,CHEMBL615331,2.2.15,,,,F,1,1,
,BAO_0000218,107,N,In vitro anti-HBV activity in 2.2.15 cells,Intermediate,,50587,,1593,,9606.0,Homo sapiens,,CHEMBL615332,2.2.15,,,,F,1,1,
,BAO_0000218,108,N,In vitro anti-HBV activity in 2.2.15 cells; Not determined,Intermediate,,50587,,1593,,9606.0,Homo sapiens,,CHEMBL615333,2.2.15,,,,F,1,1,
,BAO_0000218,109,N,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,Intermediate,,50587,,15089,,9606.0,Homo sapiens,,CHEMBL615334,2.2.15,,,,F,1,1,
,BAO_0000218,110,N,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,Intermediate,,50587,,15089,,9606.0,Homo sapiens,,CHEMBL615335,2.2.15,,,,F,1,1,
,BAO_0000218,111,N,Cytotoxicity in 2.2.15 cells,Intermediate,,50587,,1593,,9606.0,Homo sapiens,,CHEMBL615336,2.2.15,,,,F,1,1,
,BAO_0000218,112,N,Cytotoxicity in 2.2.15 cells; Not determined,Intermediate,,50587,,1593,,9606.0,Homo sapiens,,CHEMBL615337,2.2.15,,,,F,1,1,
,BAO_0000218,113,N,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,Intermediate,,50587,,13600,,9606.0,Homo sapiens,,CHEMBL615338,2.2.15,,,,F,1,1,
,BAO_0000218,114,N,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,Intermediate,,50587,,13467,,9606.0,Homo sapiens,,CHEMBL615339,2.2.15,,,,F,1,1,
,BAO_0000218,115,N,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,Intermediate,,50587,,13467,,9606.0,Homo sapiens,,CHEMBL615340,2.2.15,,,,F,1,1,
,BAO_0000219,116,N,Antiviral activity against HBV was determined in 2.215 cell line,Intermediate,726.0,81020,,14764,,9606.0,Homo sapiens,,CHEMBL615341,HepG2,,,,F,1,1,
,BAO_0000251,117,U,Inhibition of 20-HETE synthesis in human renal microsomes,Autocuration,,22226,,6531,,9606.0,Homo sapiens,,CHEMBL615342,,,,Microsomes,B,1,0,
,BAO_0000019,118,U,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,Autocuration,,22226,,17322,,,,,CHEMBL615343,,,,,B,1,0,
,BAO_0000219,119,N,Inhibitory concentration against 2008 (ovarian) cells,Intermediate,388.0,80612,,17072,,9606.0,Homo sapiens,,CHEMBL615344,2008,,,,F,1,1,
,BAO_0000219,120,N,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,Intermediate,388.0,80612,,16936,,9606.0,Homo sapiens,,CHEMBL615345,2008,,,,F,1,1,
,BAO_0000219,121,N,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),Intermediate,388.0,80612,,16936,,9606.0,Homo sapiens,,CHEMBL615346,2008,,,,F,1,1,
,BAO_0000219,122,N,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,Intermediate,388.0,80612,,17146,,9606.0,Homo sapiens,,CHEMBL615347,2008,,,,F,1,1,
,BAO_0000219,123,N,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,Intermediate,388.0,80612,,17146,,9606.0,Homo sapiens,,CHEMBL615348,2008,,,,F,1,1,
,BAO_0000219,124,N,In vitro inhibition of 2008/R ovarian cancer cell line,Intermediate,561.0,80613,,10797,,9606.0,Homo sapiens,,CHEMBL827085,2008/R,,,,F,1,1,
,BAO_0000219,125,N,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,Intermediate,561.0,80613,,10797,,9606.0,Homo sapiens,,CHEMBL615349,2008/R,,,,F,1,1,
,BAO_0000219,126,N,In vitro inhibition of 2008/S ovarian cancer cell line,Intermediate,389.0,80614,,10797,,9606.0,Homo sapiens,,CHEMBL615350,2008/S,,,,F,1,1,
,BAO_0000219,127,N,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,Intermediate,389.0,80614,,10797,,9606.0,Homo sapiens,,CHEMBL615351,2008/S,,,,F,1,1,
,BAO_0000220,128,S,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,Expert,,100256,,4823,,9606.0,Homo sapiens,,CHEMBL615352,,,,,B,1,2,
,BAO_0000220,129,S,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,Intermediate,,100256,,12912,,9606.0,Homo sapiens,,CHEMBL615353,,,,,B,1,2,
,BAO_0000220,130,S,Inhibition of chymotrypsin-like activity of 20S proteasome,Expert,,100256,,2957,,,,,CHEMBL615354,,,,,B,1,2,
,BAO_0000220,131,S,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,Expert,,100256,,2957,,,,,CHEMBL615355,,,,,B,1,2,
,BAO_0000220,132,S,Inhibitory activity against 20S proteosome,Intermediate,,100256,,3260,,,,,CHEMBL615356,,,,,B,1,2,
,BAO_0000019,133,U,Compound was tested for inhibitory activity against tryptase,Autocuration,,22226,,3451,,9606.0,Homo sapiens,,CHEMBL615357,,,,,B,1,0,
,BAO_0000219,134,N,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,Intermediate,726.0,81020,,13885,,9606.0,Homo sapiens,,CHEMBL615358,HepG2,,,,F,1,1,
,BAO_0000219,135,N,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,Intermediate,726.0,81020,,13885,,9606.0,Homo sapiens,,CHEMBL827086,HepG2,,,,F,1,1,
,BAO_0000019,136,U,Compound was tested for the inhibition of Alpha-glucosidase,Autocuration,,22226,,3676,,,,,CHEMBL615359,,,,,B,1,0,
,BAO_0000357,137,H,Inhibitory concentration against human neutrophil elastase (HNE),Autocuration,,235,,6043,,,,,CHEMBL615360,,,,,B,1,8,
Heart,BAO_0000218,138,U,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,Autocuration,,22226,,11140,948.0,10116.0,Rattus norvegicus,,CHEMBL615361,,,,,F,1,0,
,BAO_0000019,139,H,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,Autocuration,,19640,,10543,,,,,CHEMBL615362,,,,,F,1,8,
,BAO_0000019,140,H,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,Expert,,19640,,10543,,,,,CHEMBL615363,,,,,F,1,8,
,BAO_0000357,141,H,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,Autocuration,,19640,,10543,,,,,CHEMBL615364,,,,,B,1,8,
,BAO_0000019,142,H,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,Expert,,19640,,10543,,,,,CHEMBL615365,,,,,F,1,8,
,BAO_0000219,143,N,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,Intermediate,524.0,80360,,11365,,10090.0,Mus musculus,,CHEMBL615366,P338,,,,F,1,1,
,BAO_0000219,144,N,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,Intermediate,524.0,80360,,11365,,10090.0,Mus musculus,,CHEMBL615367,P338,,,,F,1,1,
,BAO_0000219,145,N,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,Intermediate,554.0,80384,,11803,,9606.0,Homo sapiens,,CHEMBL615368,PBL,,,,F,1,1,
,BAO_0000019,146,U,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,Autocuration,,22226,,11803,,9940.0,Ovis aries,,CHEMBL615369,,,,,F,1,0,
,BAO_0000019,147,U,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,Autocuration,,22226,,11803,,9940.0,Ovis aries,,CHEMBL615370,,,,,F,1,0,
,BAO_0000357,148,H,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),Autocuration,,191,,12278,,,,,CHEMBL615673,,,,,B,1,8,
,BAO_0000019,149,U,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,Autocuration,,22226,,8249,,9606.0,Homo sapiens,,CHEMBL615674,,,,,F,1,0,
,BAO_0000019,150,U,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,Autocuration,,22226,,8249,,9606.0,Homo sapiens,,CHEMBL615675,,,,,F,1,0,
,BAO_0000219,151,U,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,Autocuration,635.0,22226,,8249,,9606.0,Homo sapiens,,CHEMBL615676,CCRF-CEM,,,,F,1,0,
,BAO_0000219,152,U,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,Autocuration,635.0,22226,,8249,,9606.0,Homo sapiens,,CHEMBL615677,CCRF-CEM,,,,F,1,0,
,BAO_0000219,153,U,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,Autocuration,635.0,22226,,8249,,9606.0,Homo sapiens,,CHEMBL615678,CCRF-CEM,,,,F,1,0,
,BAO_0000219,154,U,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,Autocuration,635.0,22226,,8249,,9606.0,Homo sapiens,,CHEMBL615679,CCRF-CEM,,,,F,1,0,
,BAO_0000019,155,U,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,Autocuration,,22226,,8249,,9606.0,Homo sapiens,,CHEMBL615680,,,,,F,1,0,
,BAO_0000019,156,U,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,Autocuration,,22226,,8249,,9606.0,Homo sapiens,,CHEMBL615681,,,,,F,1,0,
,BAO_0000249,157,H,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,Autocuration,,104290,,16992,,,,,CHEMBL857972,,,,,B,1,6,
,BAO_0000218,158,N,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,Intermediate,,50264,,10543,,1314.0,Streptococcus pyogenes,,CHEMBL857899,,,,,F,1,1,
,BAO_0000218,159,N,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),Intermediate,,50527,,17833,,10335.0,Human herpesvirus 3,,CHEMBL615371,,,,,F,1,1,
,BAO_0000218,160,N,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,Expert,468.0,50527,,17290,,10335.0,vericilla zoster virus,,CHEMBL615372,HEL,,,,F,1,1,
,BAO_0000218,161,N,Antiviral activity against 07/1 strain of VZV; ND: No data,Intermediate,,50527,,17290,,10335.0,vericilla zoster virus,,CHEMBL615373,,,,,F,1,1,
,BAO_0000218,162,N,Antiviral activity against 07/1 strain of VZV; ND=No data,Intermediate,,50527,,17290,,10335.0,vericilla zoster virus,,CHEMBL615374,,,,,F,1,1,
,BAO_0000218,163,N,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",Intermediate,,50145,,10932,,561.0,escherichia cloac,,CHEMBL615375,,,,,F,1,1,
,BAO_0000019,164,U,Ratio of Ki at A2 to Ki at A1 receptors,Autocuration,,22226,,9707,,,,,CHEMBL615376,,,,,B,1,0,
,BAO_0000249,165,H,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",Expert,,11143,,2346,,5476.0,Candida albicans,,CHEMBL615377,,,,,B,1,8,
,BAO_0000357,166,H,"Inhibition of 1,3-beta-glucan synthase",Expert,,18077,,2205,,284593.0,Candida glabrata CBS 138,,CHEMBL615378,,,,,B,1,8,
,BAO_0000219,167,N,Inhibition of growth of 1-87 human tumor cell line,Intermediate,832.0,80609,,11900,,9606.0,Homo sapiens,,CHEMBL615379,1-87 tumor cell line,,,,F,1,1,
,BAO_0000219,168,D,Inhibition of 1-lipoxygenase (LOX)in RBL cells,Expert,,12166,,14864,,10116.0,Rattus norvegicus,,CHEMBL615380,,,,,B,1,9,
,BAO_0000357,169,D,Inhibitory activity against soybean 1-lipoxygenase (SLO),Autocuration,,100171,,16474,,3847.0,Glycine max,,CHEMBL615381,,,,,B,1,9,
,BAO_0000357,170,D,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,Autocuration,,100171,,16474,,3847.0,Glycine max,,CHEMBL615382,,,,,B,1,9,
,BAO_0000357,171,D,% inhibition against soybean 1-lipoxygenase (SLO),Autocuration,,100171,,16474,,3847.0,Glycine max,,CHEMBL615383,,,,,B,1,9,
,BAO_0000357,172,D,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,Autocuration,,100171,,16474,,3847.0,Glycine max,,CHEMBL615384,,,,,B,1,9,
,BAO_0000357,173,D,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,Autocuration,,100171,,3094,,3847.0,Glycine max,,CHEMBL615385,,,,,B,1,9,
,BAO_0000357,174,D,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,Autocuration,,100171,,3094,,3847.0,Glycine max,,CHEMBL615386,,,,,B,1,9,
,BAO_0000357,175,D,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,Autocuration,,100171,,3094,,3847.0,Glycine max,,CHEMBL615387,,,,,B,1,9,
,BAO_0000357,176,D,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,Autocuration,,100171,,3094,,3847.0,Glycine max,,CHEMBL615388,,,,,B,1,9,
,BAO_0000357,177,D,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,Autocuration,,100171,,3094,,3847.0,Glycine max,,CHEMBL615214,,,,,B,1,9,
,BAO_0000357,178,D,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,Autocuration,,100171,,3094,,3847.0,Glycine max,,CHEMBL827087,,,,,B,1,9,
,BAO_0000357,179,D,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,Autocuration,,100171,,3094,,3847.0,Glycine max,,CHEMBL615215,,,,,B,1,9,
,BAO_0000357,180,D,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,Autocuration,,100171,,3094,,3847.0,Glycine max,,CHEMBL615216,,,,,B,1,9,
,BAO_0000357,181,D,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,Autocuration,,100171,,3094,,3847.0,Glycine max,,CHEMBL615217,,,,,B,1,9,
,BAO_0000357,182,D,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,Autocuration,,100171,,3094,,3847.0,Glycine max,,CHEMBL615218,,,,,B,1,9,
,BAO_0000357,183,D,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,Autocuration,,100171,,3094,,3847.0,Glycine max,,CHEMBL615219,,,,,B,1,9,
,BAO_0000019,184,U,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,Autocuration,,22226,,10413,,10090.0,Mus musculus,,CHEMBL615220,,,,,B,1,0,
,BAO_0000219,185,N,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),Intermediate,294.0,80049,,16929,,10090.0,Mus musculus,,CHEMBL615221,C3H 10T1/2,,,,F,1,1,
,BAO_0000019,186,U,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,Intermediate,,22226,,1229,,,,,CHEMBL615222,,,,,F,1,0,
,BAO_0000357,187,H,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),Autocuration,,11489,,16587,,,,,CHEMBL615223,,,,,B,1,8,
,BAO_0000357,188,H,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),Autocuration,,11862,,16587,,,,,CHEMBL615224,,,,,B,1,8,
,BAO_0000357,189,H,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,Autocuration,,11862,,16587,,,,,CHEMBL615225,,,,,B,1,8,
,BAO_0000357,190,H,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,Autocuration,,11489,,16587,,,,,CHEMBL615226,,,,,B,1,8,
,BAO_0000357,191,H,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,Autocuration,,11862,,16587,,,,,CHEMBL615227,,,,,B,1,8,
,BAO_0000019,192,D,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,Expert,,12347,,8058,,9913.0,Bos taurus,,CHEMBL615228,,,,,F,1,9,
,BAO_0000357,193,D,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,Expert,,100120,,9065,,10116.0,Rattus norvegicus,,CHEMBL615229,,,,,B,1,9,
Adrenal gland,BAO_0000357,194,D,Inhibition of 11 beta-hydroxylase from rat adrenal gland,Expert,,100120,,8865,2369.0,10116.0,Rattus norvegicus,,CHEMBL615230,,,,,B,1,9,
,BAO_0000357,195,D,Inhibition of rat adrenal 11-beta-hydroxylase,Expert,,100120,,9066,,10116.0,Rattus norvegicus,,CHEMBL615231,,,,,B,1,9,
,BAO_0000357,196,D,Inhibition of rat adrenal 11-beta-hydroxylase,Expert,,100120,,8394,,10116.0,Rattus norvegicus,,CHEMBL884520,,,,,B,1,9,
,BAO_0000357,197,D,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,Expert,,100120,,8394,,10116.0,Rattus norvegicus,,CHEMBL615232,,,,,B,1,9,
,BAO_0000019,198,H,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,Autocuration,,10328,,6431,,,,,CHEMBL615233,,,,,B,1,8,
,BAO_0000357,199,H,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,Autocuration,,11490,,6431,,,,,CHEMBL827088,,,,,B,1,8,
,BAO_0000357,200,H,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,Autocuration,,11490,,6431,,,,,CHEMBL615234,,,,,B,1,8,
,BAO_0000019,201,H,Compound was tested for the percent of inhibition against 12-LO at 10 uM,Autocuration,,11134,,9295,,,,,CHEMBL615235,,,,,F,1,8,
,BAO_0000019,202,H,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,Autocuration,,12052,,10193,,,,,CHEMBL615236,,,,,B,1,8,
,BAO_0000019,203,H,Compound was tested in vitro for inhibition of 12-LO human platelet,Autocuration,,11134,,13622,,,,,CHEMBL615237,,,,,B,1,8,
,BAO_0000019,204,H,Inhibitory concentration against human platelet 12-lipoxygenase,Autocuration,,11134,,12079,,,,,CHEMBL615238,,,,,F,1,8,
,BAO_0000019,205,H,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,Autocuration,,11134,,13622,,,,,CHEMBL615239,,,,,B,1,8,
,BAO_0000019,206,D,Inhibitory concentration against human platelet 12-lipoxygenase,Autocuration,,11134,,12079,,9606.0,Homo sapiens,,CHEMBL615240,,,,,F,1,9,
,BAO_0000019,207,H,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,Expert,,11835,,13500,,,,,CHEMBL615241,,,,,B,1,8,
,BAO_0000357,208,H,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,Expert,,11601,,13723,,,,,CHEMBL615242,,,,,B,1,8,
,BAO_0000019,209,H,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),Autocuration,,11134,,16474,,,,,CHEMBL615243,,,,,B,1,8,
,BAO_0000019,210,H,Inhibitory activity against human platelet 12-lipoxygenase,Autocuration,,11134,,1630,,,,,CHEMBL615244,,,,,B,1,8,
,BAO_0000019,211,H,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,Autocuration,,11134,,167,,,,,CHEMBL615245,,,,,B,1,8,
,BAO_0000019,212,H,% inhibition against human platelet 12-lipoxygenase (12-HLO),Autocuration,,11134,,16474,,,,,CHEMBL615246,,,,,B,1,8,
,BAO_0000019,213,H,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,Autocuration,,11134,,167,,,,,CHEMBL615247,,,,,B,1,8,
,BAO_0000019,214,H,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,Autocuration,,11134,,16474,,,,,CHEMBL615248,,,,,B,1,8,
,BAO_0000357,215,H,Inhibitory activity towards porcine 12-lipoxygenase,Autocuration,,11601,,10091,,,,,CHEMBL615249,,,,,B,1,8,
,BAO_0000357,216,H,Tested for inhibition against porcine 12-LO,Autocuration,,11601,,11966,,,,,CHEMBL615250,,,,,B,1,8,
,BAO_0000019,217,H,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,Autocuration,,12052,,951,,,,,CHEMBL615251,,,,,B,1,8,
,BAO_0000019,218,H,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,Autocuration,,12052,,10997,,,,,CHEMBL615252,,,,,B,1,8,
,BAO_0000019,219,H,In vitro inhibition of rat platelet 12-lipoxygenase,Expert,,12052,,10193,,,,,CHEMBL828340,,,,,B,1,8,
,BAO_0000019,220,H,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,Autocuration,,12052,,10193,,,,,CHEMBL615253,,,,,B,1,8,
,BAO_0000019,221,H,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,Autocuration,,12052,,10193,,,,,CHEMBL615254,,,,,B,1,8,
,BAO_0000019,222,H,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,Autocuration,,12052,,10193,,,,,CHEMBL615255,,,,,B,1,8,
,BAO_0000019,223,H,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,Autocuration,,12052,,10193,,,,,CHEMBL615256,,,,,B,1,8,
,BAO_0000019,224,H,In vitro inhibitory activity against rat platelet 12-lipoxygenase,Autocuration,,12052,,10193,,,,,CHEMBL615257,,,,,B,1,8,
,BAO_0000019,225,H,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,Autocuration,,12052,,11087,,,,,CHEMBL615258,,,,,B,1,8,
,BAO_0000219,226,N,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,Intermediate,621.0,80007,,15569,,9606.0,Homo sapiens,,CHEMBL615259,41M,,,,F,1,1,
,BAO_0000219,227,N,In vitro antitumor activity against 41M cell line.,Expert,621.0,80007,,12989,,9606.0,Homo sapiens,,CHEMBL615260,41M,,,,F,1,1,
,BAO_0000219,228,N,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,Intermediate,621.0,80007,,16745,,9606.0,Homo sapiens,,CHEMBL615261,41M,,,,F,1,1,
,BAO_0000219,229,N,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,Intermediate,621.0,80007,,15569,,9606.0,Homo sapiens,,CHEMBL615262,41M,,,,F,1,1,
,BAO_0000219,230,N,In vitro antitumor activity against 41McisR cell line.,Expert,621.0,80007,,12989,,9606.0,Homo sapiens,,CHEMBL615263,41M,,,,F,1,1,
,BAO_0000219,231,N,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,Expert,621.0,80007,,12989,,9606.0,Homo sapiens,,CHEMBL838393,41M,,,,F,1,1,
,BAO_0000219,232,N,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,Intermediate,621.0,80007,,16745,,9606.0,Homo sapiens,,CHEMBL615264,41M,,,,F,1,1,
,BAO_0000357,233,D,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),Expert,,84,,6210,,9606.0,Homo sapiens,,CHEMBL615265,,,,,B,1,9,
,BAO_0000357,234,D,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),Expert,,68,,6210,,9606.0,Homo sapiens,,CHEMBL615266,,,,,B,1,9,
,BAO_0000357,235,H,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),Expert,,68,,6226,,,,,CHEMBL615267,,,,,B,1,8,
,BAO_0000357,236,H,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,Expert,,10201,,17855,,,,,CHEMBL615268,,,,,B,1,8,
,BAO_0000357,237,H,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,Expert,,10201,,17855,,,,,CHEMBL615269,,,,,B,1,8,
,BAO_0000357,238,H,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,Expert,,10201,,17855,,,,,CHEMBL615270,,,,,B,1,8,
,BAO_0000357,239,H,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",Autocuration,,12220,,10413,,,,,CHEMBL615271,,,,,B,1,8,
,BAO_0000357,240,H,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",Autocuration,,11303,,10413,,562.0,Escherichia coli,,CHEMBL615272,,,,,B,1,8,
,BAO_0000357,241,H,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",Autocuration,,11303,,10413,,562.0,Escherichia coli,,CHEMBL615103,,,,,B,1,8,
,BAO_0000357,242,H,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",Autocuration,,11303,,10413,,562.0,Escherichia coli,,CHEMBL615104,,,,,B,1,8,
,BAO_0000357,243,H,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",Autocuration,,12220,,10413,,,,,CHEMBL615105,,,,,B,1,8,
,BAO_0000357,244,H,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",Autocuration,,12220,,10413,,,,,CHEMBL872866,,,,,B,1,8,
,BAO_0000357,245,H,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",Autocuration,,11303,,7587,,9823.0,Sus scrofa,,CHEMBL615106,,,,,B,1,8,
,BAO_0000019,246,H,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",Autocuration,,11303,,7587,,9823.0,Sus scrofa,,CHEMBL615107,,,,,B,1,8,
,BAO_0000357,247,H,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",Autocuration,,11303,,7587,,9823.0,Sus scrofa,,CHEMBL615108,,,,,B,1,8,
,BAO_0000357,248,H,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",Autocuration,,11303,,7587,,9823.0,Sus scrofa,,CHEMBL615109,,,,,B,1,8,
,BAO_0000357,249,H,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",Autocuration,,11303,,7587,,9823.0,Sus scrofa,,CHEMBL615110,,,,,B,1,8,
,BAO_0000019,250,H,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",Autocuration,,11303,,7587,,9823.0,Sus scrofa,,CHEMBL840105,,,,,B,1,8,
,BAO_0000019,251,H,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",Autocuration,,11303,,7587,,9823.0,Sus scrofa,,CHEMBL615111,,,,,B,1,8,
,BAO_0000019,252,H,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",Autocuration,,11303,,7587,,9823.0,Sus scrofa,,CHEMBL615112,,,,,B,1,8,
,BAO_0000019,253,H,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",Autocuration,,11303,,7587,,9823.0,Sus scrofa,,CHEMBL615113,,,,,B,1,8,
,BAO_0000019,254,H,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",Autocuration,,11303,,7587,,9823.0,Sus scrofa,,CHEMBL615114,,,,,B,1,8,
,BAO_0000357,255,H,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",Autocuration,,11303,,7587,,9823.0,Sus scrofa,,CHEMBL615115,,,,,B,1,8,
,BAO_0000019,256,H,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",Autocuration,,11303,,7587,,9823.0,Sus scrofa,,CHEMBL615116,,,,,B,1,8,
,BAO_0000357,257,H,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",Autocuration,,11303,,7323,,,,,CHEMBL615698,,,,,B,1,8,
,BAO_0000019,258,U,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",Autocuration,,22226,,7587,,9823.0,Sus scrofa,,CHEMBL615699,,,,,B,1,0,
,BAO_0000019,259,U,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",Autocuration,,22226,,7587,,9823.0,Sus scrofa,,CHEMBL615700,,,,,B,1,0,
,BAO_0000357,260,H,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,Expert,,100249,,13750,,4932.0,Saccharomyces cerevisiae,,CHEMBL615701,,,,,B,1,8,
,BAO_0000019,261,U,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,Autocuration,,22226,,7662,,10116.0,Rattus norvegicus,,CHEMBL615702,,,,,B,1,0,
,BAO_0000019,262,U,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,Autocuration,,22226,,7662,,10116.0,Rattus norvegicus,,CHEMBL615703,,,,,B,1,0,
,BAO_0000019,263,U,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",Autocuration,,22226,,7662,,10116.0,Rattus norvegicus,,CHEMBL615704,,,,,B,1,0,
,BAO_0000019,264,H,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",Autocuration,,104698,,12211,,,,,CHEMBL615705,,,,,F,1,6,
,BAO_0000019,265,H,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",Autocuration,,104698,,12211,,,,,CHEMBL615706,,,,,F,1,6,
Ileum,BAO_0000221,266,D,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,Intermediate,,20033,,12211,2116.0,10141.0,Cavia porcellus,,CHEMBL615707,,,,,F,1,9,
,BAO_0000019,267,H,Stimulatory activity of intragastric pressure was tested in the rat,Expert,,10623,,12211,,,,,CHEMBL615708,,,,,F,1,8,
,BAO_0000357,268,H,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,Autocuration,,121,,15453,,,,,CHEMBL615709,,,,,B,1,8,
,BAO_0000218,269,U,Dose to reduce neuronal firing against 5-HT cells in rats (iv),Autocuration,,22226,,11884,,10116.0,Rattus norvegicus,,CHEMBL615710,,,,,F,1,0,
,BAO_0000019,270,H,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,Autocuration,,12688,,7185,,,,,CHEMBL615711,,,,,F,1,8,
,BAO_0000357,271,D,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,Expert,,121,,6876,,9606.0,Homo sapiens,,CHEMBL615712,,,,,B,1,9,
,BAO_0000357,272,D,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,Expert,,121,,6876,,9606.0,Homo sapiens,,CHEMBL836325,,,,,B,1,9,
,BAO_0000019,273,H,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,Autocuration,,12198,,11863,,,,,CHEMBL615713,,,,,F,1,8,
,BAO_0000357,274,H,Inhibition constant of high-affinity 5-HT uptake,Autocuration,,12198,,11863,,,,,CHEMBL615714,,,,,B,1,8,
,BAO_0000019,275,H,Michaelis-Menten constant was reported for high affinity transport of 5-HT,Autocuration,,12198,,11863,,,,,CHEMBL615715,,,,,F,1,8,
,BAO_0000019,276,H,Maximum rate was determined for high affinity transport of 5-HT,Autocuration,,12198,,11863,,,,,CHEMBL615716,,,,,F,1,8,
,BAO_0000019,277,H,Compound was tested for agonistic activity against 5-HT uptake,Autocuration,,104714,,4639,,,,,CHEMBL615717,,,,,F,1,4,
,BAO_0000019,278,H,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,Expert,,10577,,15796,,,,,CHEMBL881818,,,,,B,1,8,
,BAO_0000357,279,H,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,Expert,,105,,15796,,9913.0,Bos taurus,,CHEMBL884540,,,,,B,1,8,
,BAO_0000224,280,D,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,Autocuration,,104744,,12801,,10116.0,Rattus norvegicus,,CHEMBL615718,,,,,B,1,5,
,BAO_0000224,281,H,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,Autocuration,,104744,,12801,,,,,CHEMBL615719,,,,,B,1,4,
,BAO_0000249,282,H,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,Autocuration,,104744,,12120,,,,,CHEMBL615720,,,,Membranes,B,1,4,
,BAO_0000249,283,H,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,Autocuration,,104744,,12120,,,,,CHEMBL615721,,,,Membranes,B,1,4,
,BAO_0000019,284,H,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,Autocuration,,104744,,11963,,,,,CHEMBL615722,,,,,B,1,4,
,BAO_0000019,285,H,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,Autocuration,,51,,11701,,,,,CHEMBL615723,,,,,F,1,8,
Hippocampus,BAO_0000221,286,H,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Autocuration,,51,,9995,10000000.0,,,,CHEMBL615724,,,,,B,1,8,
Hippocampus,BAO_0000221,287,H,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,Autocuration,,51,,9995,10000000.0,,,,CHEMBL615725,,,,,B,1,8,
Hippocampus,BAO_0000221,288,H,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Autocuration,,51,,9995,10000000.0,,,,CHEMBL615726,,,,,B,1,8,
,BAO_0000218,289,H,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),Autocuration,,10576,,16394,,,,,CHEMBL615727,,,In vivo,,F,1,8,
,BAO_0000019,290,D,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,Intermediate,,105570,,11574,,10141.0,Cavia porcellus,,CHEMBL615728,,,,,F,1,9,
,BAO_0000219,291,H,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,Autocuration,449.0,279,,15779,,,,,CHEMBL857971,CHO,,,,B,1,8,
,BAO_0000357,292,H,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,Autocuration,,107,,15363,,,,,CHEMBL615729,,,,,B,1,8,
,BAO_0000019,293,D,Efficacy against 5-hydroxytryptamine 2A receptor,Expert,,12687,,15363,,10116.0,Rattus norvegicus,,CHEMBL615730,,,,,F,1,9,
,BAO_0000019,294,H,Intrinsic activity towards 5-HT2A receptor of rat tail artery,Expert,,12687,,15329,,,,,CHEMBL615731,,,,,F,1,8,
,BAO_0000019,295,H,Relative potency towards 5-HT2A receptor of rat tail artery,Expert,,12687,,15329,,,,,CHEMBL615732,,,,,F,1,8,
,BAO_0000019,296,H,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,Expert,,12687,,15329,,,,,CHEMBL615733,,,,,F,1,8,
,BAO_0000019,297,H,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,Expert,,12687,,15329,,,,,CHEMBL615734,,,,,F,1,8,
,BAO_0000019,298,H,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,Autocuration,,12687,,15329,,,,,CHEMBL615735,,,,,F,1,8,
,BAO_0000019,299,H,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,Expert,,12687,,15329,,,,,CHEMBL615736,,,,,F,1,8,
Ileum,BAO_0000221,300,D,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,Intermediate,,20033,,273,2116.0,10141.0,Cavia porcellus,,CHEMBL615737,,,,,F,1,9,
Ileum,BAO_0000221,301,D,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),Intermediate,,20033,,273,2116.0,10141.0,Cavia porcellus,,CHEMBL615738,,,,,F,1,9,
Ileum,BAO_0000221,302,D,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,Intermediate,,20033,,273,2116.0,10141.0,Cavia porcellus,,CHEMBL615739,,,,,F,1,9,
,BAO_0000357,303,H,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,Autocuration,,10623,,12092,,,,,CHEMBL615278,,,,,B,1,8,
,BAO_0000019,304,D,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,Expert,,10623,,1317,,10116.0,Rattus norvegicus,,CHEMBL615279,,,,,F,1,9,
,BAO_0000357,305,H,Binding affinity against 5-hydroxytryptamine 4 receptor,Expert,,168,,12409,,,,,CHEMBL615280,,,,,B,1,8,
,BAO_0000019,306,U,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,Autocuration,,22226,,11126,,9031.0,Gallus gallus,,CHEMBL615281,,,,,B,1,0,
,BAO_0000019,307,U,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,Autocuration,,22226,,11126,,9606.0,Homo sapiens,,CHEMBL615282,,,,,F,1,0,
,BAO_0000019,308,U,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,Autocuration,,22226,,11126,,9606.0,Homo sapiens,,CHEMBL615283,,,,,F,1,0,
,BAO_0000219,309,N,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,Autocuration,649.0,80156,,11126,,9606.0,Homo sapiens,,CHEMBL615284,HL-60,,,,B,1,1,
,BAO_0000019,310,U,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,Autocuration,,22226,,11126,,9606.0,Homo sapiens,,CHEMBL615285,,,,,B,1,0,
,BAO_0000019,311,U,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,Autocuration,,22226,,11126,,9606.0,Homo sapiens,,CHEMBL615286,,,,,B,1,0,
,BAO_0000219,312,D,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,Autocuration,,104703,,17807,,9606.0,Homo sapiens,,CHEMBL615287,Oocytes,,,,B,1,7,
,BAO_0000220,313,S,Chymotryptic inhibitory activity against 26S proteasome,Intermediate,,100256,,16575,,,,,CHEMBL615288,,,,,F,1,2,
,BAO_0000220,314,S,Inhibitory activity against 26S proteasome degradation of IkB,Intermediate,,100256,,15407,,,,,CHEMBL615289,,,,,B,1,2,
,BAO_0000219,315,N,In vitro inhibition of 2780/DOX ovarian cancer cell line,Intermediate,478.0,81034,,10797,,9606.0,Homo sapiens,,CHEMBL615290,A2780,,,,F,1,1,
,BAO_0000219,316,N,In vitro inhibition of 2780/S ovarian cancer cell line,Intermediate,478.0,81034,,10797,,9606.0,Homo sapiens,,CHEMBL884522,A2780,,,,F,1,1,
,BAO_0000019,317,U,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,Autocuration,,22226,,3469,,9606.0,Homo sapiens,,CHEMBL615291,,,,,F,1,0,
,BAO_0000225,318,M,Association constant for binding to AATT 28-mer AATT hairpin,Intermediate,,22222,,16037,,,,,CHEMBL615292,,,,,B,1,3,
,BAO_0000225,319,M,Kinetically Defined Association Constant for 28-mer AATT hairpin.,Intermediate,,22222,,16037,,,,,CHEMBL615293,,,,,B,1,3,
,BAO_0000225,320,M,Reaction Rate Parameter for 28-mer AATT hairpin,Intermediate,,22222,,16037,,,,,CHEMBL615294,,,,,B,1,3,
,BAO_0000225,321,M,Reaction Rate Parameter for 28-mer AATT hairpin,Intermediate,,22222,,16037,,,,,CHEMBL615295,,,,,B,1,3,
,BAO_0000019,322,U,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),Autocuration,,22226,,16524,,9606.0,Homo sapiens,,CHEMBL825021,,,,,F,1,0,
,BAO_0000019,323,U,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),Autocuration,,22226,,16524,,9606.0,Homo sapiens,,CHEMBL615296,,,,,F,1,0,
,BAO_0000019,324,U,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,Autocuration,,22226,,16524,,9606.0,Homo sapiens,,CHEMBL615297,,,,,F,1,0,
,BAO_0000019,325,U,Cytotoxicity against cell line 2SC/20 determined by MTT test,Autocuration,,22226,,16758,,10029.0,Cricetulus griseus,,CHEMBL615298,,,,,F,1,0,
,BAO_0000019,326,U,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,Autocuration,,22226,,16758,,10029.0,Cricetulus griseus,,CHEMBL615299,,,,,F,1,0,
,BAO_0000019,327,U,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,Autocuration,,22226,,16758,,10029.0,Cricetulus griseus,,CHEMBL615300,,,,,F,1,0,
,BAO_0000357,328,H,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,Autocuration,,241,,14360,,,,,CHEMBL615301,,,,,B,1,8,
,BAO_0000357,329,D,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,Expert,,241,,14360,,9606.0,Homo sapiens,,CHEMBL615302,,,,,B,1,9,
,BAO_0000019,330,U,Selectivity ratio of ID50 in liver and heart,Autocuration,,22226,,9964,,10116.0,Rattus norvegicus,,CHEMBL615303,,,,,B,1,0,
,BAO_0000019,331,H,"Selectivity, ratio of relative ID50 in liver and heart",Autocuration,,12132,,9964,,,,,CHEMBL615304,,,,,B,1,8,
,BAO_0000019,332,H,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,Autocuration,,12132,,9964,,,,,CHEMBL615305,,,,,B,1,8,
,BAO_0000218,333,H,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",Autocuration,,12132,,9964,,,,,CHEMBL615306,,,,,B,1,8,
,BAO_0000218,334,H,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",Autocuration,,12132,,9964,,,,,CHEMBL615307,,,,,B,1,8,
,BAO_0000218,335,H,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",Autocuration,,12132,,9964,,,,,CHEMBL615308,,,In vivo,,B,1,8,
,BAO_0000218,336,H,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",Autocuration,,12132,,9964,,,,,CHEMBL615309,,,In vivo,,F,1,8,
,BAO_0000019,337,U,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",Autocuration,,22226,,9964,,,,,CHEMBL615310,,,,,B,1,0,
,BAO_0000019,338,H,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,Autocuration,,12132,,9964,,,,,CHEMBL615311,,,,,B,1,8,
,BAO_0000019,339,U,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",Autocuration,,22226,,9964,,9606.0,Homo sapiens,,CHEMBL615312,,,,,B,1,0,
,BAO_0000019,340,H,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,Autocuration,,12132,,9964,,,,,CHEMBL615313,,,,,B,1,8,
,BAO_0000019,341,H,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,Autocuration,,12132,,9964,,,,,CHEMBL615314,,,,,F,1,8,
,BAO_0000019,342,H,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",Autocuration,,12132,,9964,,,,,CHEMBL615315,,,,,B,1,8,
,BAO_0000218,343,U,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",Autocuration,,22226,,9964,,10116.0,Rattus norvegicus,,CHEMBL615316,,,,,B,1,0,
,BAO_0000218,344,H,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,Autocuration,,12132,,9964,,,,,CHEMBL615317,,,In vivo,,B,1,8,
,BAO_0000218,345,H,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",Autocuration,,12132,,9964,,,,,CHEMBL615318,,,,,B,1,8,
,BAO_0000218,346,U,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",Autocuration,,22226,,9964,,10116.0,Rattus norvegicus,,CHEMBL615319,,,,,B,1,0,
,BAO_0000019,347,H,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",Autocuration,,12132,,9964,,,,,CHEMBL615320,,,,,B,1,8,
,BAO_0000019,348,H,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",Autocuration,,12132,,9964,,,,,CHEMBL615321,,,,,F,1,8,
,BAO_0000019,349,U,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",Autocuration,,22226,,3796,,10116.0,Rattus norvegicus,,CHEMBL615322,,,,,B,1,0,
,BAO_0000357,350,H,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,Autocuration,,19690,,4251,,562.0,Escherichia coli,,CHEMBL615323,,,,,B,1,8,
,BAO_0000357,351,H,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,Autocuration,,19690,,4251,,562.0,Escherichia coli,,CHEMBL615407,,,,,B,1,8,
,BAO_0000357,352,H,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,Autocuration,,19690,,4251,,562.0,Escherichia coli,,CHEMBL857267,,,,,B,1,8,
,BAO_0000357,353,H,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,Autocuration,,19690,,4251,,562.0,Escherichia coli,,CHEMBL615408,,,,,B,1,8,
,BAO_0000357,354,H,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,Autocuration,,19690,,166,,,,,CHEMBL615409,,,,,B,1,8,
,BAO_0000357,355,H,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,Autocuration,,19690,,17861,,,,,CHEMBL615410,,,,,B,1,8,
,BAO_0000357,356,H,Inhibition constant against 3-dehydroquinate synthase,Autocuration,,19690,,166,,,,,CHEMBL615411,,,,,B,1,8,
,BAO_0000357,357,H,Association rate constant against 3-dehydroquinate synthase,Autocuration,,19690,,166,,,,,CHEMBL615412,,,,,B,1,8,
,BAO_0000357,358,H,Rate constant against 3-dehydroquinate synthase,Autocuration,,19690,,166,,,,,CHEMBL615413,,,,,B,1,8,
,BAO_0000019,359,U,Inhibitory activity against fuc-TVII,Autocuration,,22226,,3548,,,,,CHEMBL615414,,,,,B,1,0,
Liver,BAO_0000251,360,D,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Autocuration,,12236,,9877,2107.0,10116.0,Rattus norvegicus,,CHEMBL615415,,,,Microsomes,B,1,9,
Liver,BAO_0000251,361,D,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Autocuration,,12236,,9877,2107.0,10116.0,Rattus norvegicus,,CHEMBL615416,,,,Microsomes,B,1,9,
Liver,BAO_0000251,362,D,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Autocuration,,12236,,9877,2107.0,10116.0,Rattus norvegicus,,CHEMBL615417,,,,Microsomes,B,1,9,
Liver,BAO_0000251,363,D,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Autocuration,,12236,,9877,2107.0,10116.0,Rattus norvegicus,,CHEMBL615418,,,,Microsomes,B,1,9,
Liver,BAO_0000251,364,D,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Autocuration,,12236,,9877,2107.0,10116.0,Rattus norvegicus,,CHEMBL615419,,,,Microsomes,B,1,9,
Liver,BAO_0000251,365,D,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,Autocuration,,12236,,9877,2107.0,10116.0,Rattus norvegicus,,CHEMBL615420,,,,Microsomes,B,1,9,
Liver,BAO_0000251,366,D,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,Autocuration,,12236,,9877,2107.0,10116.0,Rattus norvegicus,,CHEMBL615421,,,,Microsomes,B,1,9,
Liver,BAO_0000251,367,D,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,Autocuration,,12236,,9877,2107.0,10116.0,Rattus norvegicus,,CHEMBL615422,,,,Microsomes,B,1,9,
Liver,BAO_0000251,368,D,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,Autocuration,,12236,,9877,2107.0,10116.0,Rattus norvegicus,,CHEMBL615423,,,,Microsomes,B,1,9,
Liver,BAO_0000251,369,D,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,Autocuration,,12236,,9877,2107.0,10116.0,Rattus norvegicus,,CHEMBL872868,,,,Microsomes,B,1,9,
Liver,BAO_0000251,370,D,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,Autocuration,,12236,,9877,2107.0,10116.0,Rattus norvegicus,,CHEMBL615424,,,,Microsomes,B,1,9,
,BAO_0000224,371,H,Inhibitory activity against 3-phosphoglycerate kinase.,Autocuration,,104832,,3003,,,,,CHEMBL825022,,,,,B,1,4,
,BAO_0000224,372,H,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,Autocuration,,104832,,3003,,,,,CHEMBL615425,,,,,B,1,4,
,BAO_0000224,373,H,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",Autocuration,,104832,,3003,,,,,CHEMBL615426,,,,,B,1,4,
,BAO_0000357,374,D,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,Expert,,10612,,17185,,9606.0,Homo sapiens,,CHEMBL615427,,,,,B,1,9,
,BAO_0000219,375,N,Cytotoxicity on 3677 melanoma cells,Intermediate,844.0,80616,,6072,,9606.0,Homo sapiens,,CHEMBL615428,3677 melanoma cell line,,,,F,1,1,
,BAO_0000219,376,N,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,Intermediate,844.0,80616,,6072,,9606.0,Homo sapiens,,CHEMBL615429,3677 melanoma cell line,,,,F,1,1,
,BAO_0000219,377,N,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,Intermediate,700.0,80617,,5018,,10090.0,Mus musculus,,CHEMBL615430,MC-38,,,,F,1,1,
,BAO_0000019,378,U,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,Intermediate,,22226,,2852,,9606.0,Homo sapiens,,CHEMBL615431,,,,,F,1,0,
,BAO_0000218,379,U,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,Autocuration,798.0,22226,,8663,,,,,CHEMBL615432,B16,,,,F,1,0,
,BAO_0000218,380,U,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,Autocuration,798.0,22226,,8663,,,,,CHEMBL615433,B16,,,,F,1,0,
,BAO_0000019,381,D,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,Expert,,12464,,3245,,12131.0,Human rhinovirus 14,,CHEMBL615434,,,,,F,1,9,
,BAO_0000218,382,N,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,Intermediate,,50085,,3245,,169066.0,Human rhinovirus sp.,,CHEMBL615435,,,,,F,1,1,
,BAO_0000218,383,N,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,Intermediate,,50679,,3877,,169066.0,human rhinovirus type 14,,CHEMBL615436,,,,,F,1,1,
,BAO_0000218,384,N,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,Intermediate,,50679,,3877,,169066.0,human rhinovirus type 14,,CHEMBL615437,,,,,F,1,1,
,BAO_0000019,385,D,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,Expert,,12464,,5861,,12131.0,Human rhinovirus 14,,CHEMBL615438,,,,,F,1,9,
,BAO_0000019,386,D,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,Expert,,12464,,5861,,12131.0,Human rhinovirus 14,,CHEMBL615439,,,,,F,1,9,
,BAO_0000019,387,D,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,Expert,,12464,,5861,,12131.0,Human rhinovirus 14,,CHEMBL615440,,,,,F,1,9,
,BAO_0000019,388,D,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,Expert,,12464,,5861,,12131.0,Human rhinovirus 14,,CHEMBL615441,,,,,F,1,9,
,BAO_0000218,389,N,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,Intermediate,,50665,,13748,,12059.0,Enterovirus,,CHEMBL615641,,,,,F,1,1,
,BAO_0000218,390,N,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,Intermediate,,50665,,13748,,12059.0,Enterovirus,,CHEMBL872065,,,,,F,1,1,
,BAO_0000218,391,N,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,Intermediate,,50665,,13748,,12059.0,Enterovirus,,CHEMBL825023,,,,,F,1,1,
,BAO_0000218,392,N,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,Intermediate,,50665,,13748,,12059.0,Enterovirus,,CHEMBL615642,,,,,F,1,1,
,BAO_0000357,393,H,Inhibition of human rhinovirus 3C protease,Expert,,12464,,13748,,147712.0,Human rhinovirus B,,CHEMBL615643,,,,,B,1,8,
,BAO_0000019,394,U,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,Autocuration,,22226,,17699,,9606.0,Homo sapiens,,CHEMBL615644,,,,,B,1,0,
,BAO_0000218,395,N,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),Intermediate,833.0,80619,,7145,,10090.0,Mus musculus,,CHEMBL615645,3EM 37,,,,F,1,1,
,BAO_0000218,396,N,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),Intermediate,833.0,80619,,7145,,10090.0,Mus musculus,,CHEMBL615646,3EM 37,,,,F,1,1,
,BAO_0000218,397,N,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),Intermediate,833.0,80619,,7145,,10090.0,Mus musculus,,CHEMBL615647,3EM 37,,,,F,1,1,
,BAO_0000218,398,N,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),Intermediate,833.0,80619,,7145,,10090.0,Mus musculus,,CHEMBL615648,3EM 37,,,,F,1,1,
,BAO_0000218,399,N,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,Intermediate,833.0,80619,,7145,,10090.0,Mus musculus,,CHEMBL615649,3EM 37,,,,F,1,1,
,BAO_0000218,400,N,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,Intermediate,833.0,80619,,7145,,10090.0,Mus musculus,,CHEMBL615650,3EM 37,,,,F,1,1,
,BAO_0000218,401,N,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,Intermediate,847.0,80620,,5325,,10090.0,Mus musculus,,CHEMBL615651,3LL cell line,,,,F,1,1,
,BAO_0000218,402,N,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,Intermediate,847.0,80620,,5325,,10090.0,Mus musculus,,CHEMBL615652,3LL cell line,,,,F,1,1,
,BAO_0000218,403,N,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,Expert,847.0,80620,,5325,,10090.0,Mus musculus,,CHEMBL615653,3LL cell line,,,,F,1,1,
,BAO_0000219,404,N,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,Intermediate,847.0,80620,,16169,,10090.0,Mus musculus,,CHEMBL615654,3LL cell line,,,,F,1,1,
,BAO_0000219,405,N,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,Intermediate,847.0,80620,,16169,,10090.0,Mus musculus,,CHEMBL615655,3LL cell line,,,,F,1,1,
,BAO_0000219,406,N,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,Intermediate,847.0,80620,,16169,,10090.0,Mus musculus,,CHEMBL825024,3LL cell line,,,,F,1,1,
,BAO_0000219,407,N,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,Intermediate,847.0,80620,,16169,,10090.0,Mus musculus,,CHEMBL615656,3LL cell line,,,,F,1,1,
,BAO_0000219,408,N,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,Intermediate,847.0,80620,,16169,,10090.0,Mus musculus,,CHEMBL615657,3LL cell line,,,,F,1,1,
,BAO_0000219,409,N,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,Intermediate,847.0,80620,,16169,,10090.0,Mus musculus,,CHEMBL615658,3LL cell line,,,,F,1,1,
,BAO_0000219,410,N,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,Intermediate,847.0,80620,,16169,,10090.0,Mus musculus,,CHEMBL615659,3LL cell line,,,,F,1,1,
,BAO_0000219,411,N,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,Intermediate,847.0,80620,,16169,,10090.0,Mus musculus,,CHEMBL615660,3LL cell line,,,,F,1,1,
,BAO_0000219,412,N,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,Intermediate,847.0,80620,,16169,,10090.0,Mus musculus,,CHEMBL615661,3LL cell line,,,,F,1,1,
,BAO_0000219,413,N,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,Intermediate,847.0,80620,,16169,,10090.0,Mus musculus,,CHEMBL615662,3LL cell line,,,,F,1,1,
,BAO_0000219,414,N,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,Intermediate,847.0,80620,,16169,,10090.0,Mus musculus,,CHEMBL615663,3LL cell line,,,,F,1,1,
,BAO_0000219,415,N,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,Intermediate,847.0,80620,,16169,,10090.0,Mus musculus,,CHEMBL615664,3LL cell line,,,,F,1,1,
,BAO_0000219,416,N,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,Intermediate,847.0,80620,,16169,,10090.0,Mus musculus,,CHEMBL615665,3LL cell line,,,,F,1,1,
,BAO_0000219,417,N,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,Intermediate,847.0,80620,,16169,,10090.0,Mus musculus,,CHEMBL615666,3LL cell line,,,,F,1,1,
,BAO_0000219,418,N,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,Intermediate,847.0,80620,,16169,,10090.0,Mus musculus,,CHEMBL615667,3LL cell line,,,,F,1,1,
,BAO_0000219,419,N,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,Intermediate,847.0,80620,,16169,,10090.0,Mus musculus,,CHEMBL615668,3LL cell line,,,,F,1,1,
,BAO_0000219,420,N,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,Intermediate,847.0,80620,,16169,,10090.0,Mus musculus,,CHEMBL615669,3LL cell line,,,,F,1,1,
,BAO_0000219,421,N,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,Intermediate,847.0,80620,,16169,,10090.0,Mus musculus,,CHEMBL615670,3LL cell line,,,,F,1,1,
,BAO_0000219,422,N,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,Intermediate,847.0,80620,,16169,,10090.0,Mus musculus,,CHEMBL836739,3LL cell line,,,,F,1,1,
,BAO_0000219,423,N,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,Intermediate,847.0,80620,,16169,,10090.0,Mus musculus,,CHEMBL615671,3LL cell line,,,,F,1,1,
,BAO_0000219,424,N,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,Intermediate,847.0,80620,,16169,,10090.0,Mus musculus,,CHEMBL615672,3LL cell line,,,,F,1,1,
,BAO_0000219,425,N,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,Intermediate,847.0,80620,,16169,,10090.0,Mus musculus,,CHEMBL615791,3LL cell line,,,,F,1,1,
,BAO_0000219,426,N,spermine levels in 3LL cells after the treatment of 1 uM of Compound,Intermediate,847.0,80620,,16169,,10090.0,Mus musculus,,CHEMBL615792,3LL cell line,,,,F,1,1,
,BAO_0000219,427,N,spermine levels in 3LL cells after the treatment of 10 uM of Compound,Intermediate,847.0,80620,,16169,,10090.0,Mus musculus,,CHEMBL615793,3LL cell line,,,,F,1,1,
,BAO_0000219,428,N,spermine levels in 3LL cells after the treatment of 250 uM of Compound,Intermediate,847.0,80620,,16169,,10090.0,Mus musculus,,CHEMBL615794,3LL cell line,,,,F,1,1,
,BAO_0000219,429,N,spermine levels in 3LL cells after the treatment of 50 uM of Compound,Intermediate,847.0,80620,,16169,,10090.0,Mus musculus,,CHEMBL615795,3LL cell line,,,,F,1,1,
,BAO_0000219,430,N,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,Intermediate,971.0,80621,,15547,,9606.0,Homo sapiens,,CHEMBL615590,3LLD122,,,,F,1,1,
,BAO_0000218,431,U,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,Autocuration,,22226,,8663,,,,,CHEMBL615591,,,,,F,1,0,
,BAO_0000218,432,U,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,Autocuration,,22226,,8663,,,,,CHEMBL615592,,,,,F,1,0,
,BAO_0000218,433,U,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,Autocuration,,22226,,8663,,,,,CHEMBL615593,,,,,F,1,0,
,BAO_0000218,434,U,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,Autocuration,,22226,,8663,,,,,CHEMBL615594,,,,,F,1,0,
,BAO_0000219,435,N,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,Intermediate,723.0,80951,,4504,,10090.0,Mus musculus,,CHEMBL615595,NIH3T3,,,,F,1,1,
,BAO_0000219,436,N,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,Intermediate,723.0,80951,,4504,,10090.0,Mus musculus,,CHEMBL615596,NIH3T3,,,,F,1,1,
,BAO_0000219,437,H,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,Expert,723.0,11169,,12695,,,,,CHEMBL615597,NIH3T3,,,,F,1,8,
,BAO_0000219,438,N,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,Intermediate,723.0,80951,,12695,,10090.0,Mus musculus,,CHEMBL615598,NIH3T3,,,,F,1,1,
,BAO_0000219,439,N,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,Intermediate,723.0,80951,,12695,,10090.0,Mus musculus,,CHEMBL615599,NIH3T3,,,,F,1,1,
,BAO_0000219,440,N,Effective dose against murine 3T3 fibroblasts cells,Expert,723.0,80951,,17642,,10090.0,Mus musculus,,CHEMBL615600,NIH3T3,,,,F,1,1,
,BAO_0000219,441,N,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,Expert,723.0,80951,,17642,,10090.0,Mus musculus,,CHEMBL615601,NIH3T3,,,,F,1,1,
,BAO_0000219,442,N,Cytotoxic effect on 3T3 cells,Expert,723.0,80951,,12340,,10090.0,Mus musculus,,CHEMBL615602,NIH3T3,,,,F,1,1,
,BAO_0000219,443,N,Cytotoxic effect on 3T3 cells,Expert,723.0,80951,,12340,,10090.0,Mus musculus,,CHEMBL615603,NIH3T3,,,,F,1,1,
,BAO_0000219,444,N,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,Intermediate,723.0,80951,,12716,,10090.0,Mus musculus,,CHEMBL615604,NIH3T3,,,,F,1,1,
,BAO_0000219,445,N,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,Intermediate,723.0,80951,,6277,,10090.0,Mus musculus,,CHEMBL615605,NIH3T3,,,,F,1,1,
,BAO_0000219,446,N,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,Intermediate,723.0,80951,,6277,,10090.0,Mus musculus,,CHEMBL615606,NIH3T3,,,,F,1,1,
,BAO_0000219,447,N,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,Expert,723.0,80951,,6277,,10090.0,Mus musculus,,CHEMBL884526,NIH3T3,,,,F,1,1,
,BAO_0000219,448,N,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,Expert,723.0,80951,,6277,,10090.0,Mus musculus,,CHEMBL615607,NIH3T3,,,,F,1,1,
,BAO_0000219,449,N,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,Intermediate,723.0,80951,,6277,,10090.0,Mus musculus,,CHEMBL615608,NIH3T3,,,,F,1,1,
,BAO_0000219,450,N,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,Expert,723.0,80951,,6277,,10090.0,Mus musculus,,CHEMBL615609,NIH3T3,,,,F,1,1,
,BAO_0000219,451,N,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,Expert,723.0,80951,,6277,,10090.0,Mus musculus,,CHEMBL615682,NIH3T3,,,,F,1,1,
,BAO_0000219,452,N,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,Intermediate,723.0,80951,,6277,,10090.0,Mus musculus,,CHEMBL615683,NIH3T3,,,,F,1,1,
,BAO_0000218,453,N,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,Expert,723.0,80951,,17780,,10090.0,Mus musculus,,CHEMBL615684,NIH3T3,,,,F,1,1,
,BAO_0000219,454,D,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,Autocuration,,104860,,12751,,10090.0,Mus musculus,,CHEMBL615685,,,,,F,1,7,
,BAO_0000219,455,N,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,Expert,723.0,80951,,12380,,10090.0,Mus musculus,,CHEMBL615686,NIH3T3,,,,F,1,1,
,BAO_0000219,456,N,Inhibitory activity against 3T3 cell line,Intermediate,723.0,80951,,14892,,10090.0,Mus musculus,,CHEMBL615687,NIH3T3,,,,F,1,1,
,BAO_0000219,457,N,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,Intermediate,723.0,80951,,12695,,10090.0,Mus musculus,,CHEMBL884523,NIH3T3,,,,F,1,1,
,BAO_0000019,458,H,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,Expert,,11169,,12695,,,,,CHEMBL615688,,,,,F,1,8,
,BAO_0000219,459,N,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,Intermediate,723.0,80951,,12695,,10090.0,Mus musculus,,CHEMBL615689,NIH3T3,,,,F,1,1,
,BAO_0000219,460,N,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,Intermediate,723.0,80951,,12695,,10090.0,Mus musculus,,CHEMBL615690,NIH3T3,,,,F,1,1,
,BAO_0000019,461,H,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,Expert,,11169,,12695,,,,,CHEMBL615691,,,,,F,1,8,
,BAO_0000019,462,H,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,Expert,,11169,,12695,,,,,CHEMBL615692,,,,,F,1,8,
,BAO_0000219,463,N,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,Intermediate,723.0,80951,,6277,,10090.0,Mus musculus,,CHEMBL615693,NIH3T3,,,,F,1,1,
,BAO_0000219,464,N,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,Expert,723.0,80951,,6277,,10090.0,Mus musculus,,CHEMBL615324,NIH3T3,,,,F,1,1,
,BAO_0000219,465,D,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,Expert,723.0,9,,4959,,9606.0,Homo sapiens,,CHEMBL615325,NIH3T3,,,,F,1,9,
,BAO_0000219,466,D,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),Expert,723.0,9,,4959,,9606.0,Homo sapiens,,CHEMBL615490,NIH3T3,,,,F,1,9,
,BAO_0000219,467,D,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,Expert,723.0,188,,4959,,9606.0,Homo sapiens,,CHEMBL615491,NIH3T3,,,,F,1,9,
,BAO_0000219,468,D,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),Expert,723.0,188,,4959,,9606.0,Homo sapiens,,CHEMBL615492,NIH3T3,,,,F,1,9,
,BAO_0000219,469,N,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,Intermediate,723.0,80951,,12082,,10090.0,Mus musculus,,CHEMBL615493,NIH3T3,,,,F,1,1,
,BAO_0000219,470,N,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,Intermediate,723.0,80951,,12082,,10090.0,Mus musculus,,CHEMBL615494,NIH3T3,,,,F,1,1,
,BAO_0000219,471,N,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,Intermediate,723.0,80951,,12082,,10090.0,Mus musculus,,CHEMBL615495,NIH3T3,,,,F,1,1,
,BAO_0000219,472,N,Inhibitory concentration was calculated on 3T3 cells by using growth assay,Intermediate,723.0,80951,,12082,,10090.0,Mus musculus,,CHEMBL615496,NIH3T3,,,,F,1,1,
,BAO_0000219,473,N,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,Intermediate,723.0,80951,,2643,,10090.0,Mus musculus,,CHEMBL615497,NIH3T3,,,,F,1,1,
,BAO_0000219,474,N,Inhibition of Swiss 3T3 mouse fibroblast proliferation,Expert,723.0,80951,,11926,,10090.0,Mus musculus,,CHEMBL615498,NIH3T3,,,,F,1,1,
,BAO_0000219,475,N,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,Intermediate,723.0,80951,,15204,,10090.0,Mus musculus,,CHEMBL615499,NIH3T3,,,,A,1,1,
,BAO_0000219,476,N,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,Expert,723.0,80951,,15992,,10090.0,Mus musculus,,CHEMBL835522,NIH3T3,,,,F,1,1,
,BAO_0000219,477,N,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,Intermediate,723.0,80951,,16279,,10090.0,Mus musculus,,CHEMBL615500,NIH3T3,,,,F,1,1,
,BAO_0000219,478,N,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),Intermediate,723.0,80951,,16279,,10090.0,Mus musculus,,CHEMBL615501,NIH3T3,,,,F,1,1,
,BAO_0000219,479,N,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),Intermediate,723.0,80951,,16279,,10090.0,Mus musculus,,CHEMBL615502,NIH3T3,,,,F,1,1,
,BAO_0000219,480,N,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),Intermediate,723.0,80951,,16279,,10090.0,Mus musculus,,CHEMBL615503,NIH3T3,,,,F,1,1,
,BAO_0000219,481,N,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),Intermediate,723.0,80951,,16279,,10090.0,Mus musculus,,CHEMBL615504,NIH3T3,,,,F,1,1,
,BAO_0000219,482,N,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),Intermediate,723.0,80951,,16279,,10090.0,Mus musculus,,CHEMBL615505,NIH3T3,,,,F,1,1,
,BAO_0000219,483,N,Inhibition of swiss 3T3 mouse fibroblast proliferation,Expert,723.0,80951,,12831,,10090.0,Mus musculus,,CHEMBL615506,NIH3T3,,,,F,1,1,
,BAO_0000219,484,N,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,Intermediate,723.0,80951,,13497,,10090.0,Mus musculus,,CHEMBL615507,NIH3T3,,,,F,1,1,
,BAO_0000218,485,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,Intermediate,620.0,80006,,13715,,,,,CHEMBL615508,3T3-L1,,,,F,1,1,
,BAO_0000219,486,N,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,Intermediate,620.0,80006,,13618,,10090.0,Mus musculus,,CHEMBL615509,3T3-L1,,,,F,1,1,
,BAO_0000219,487,N,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,Intermediate,620.0,80006,,11902,,10090.0,Mus musculus,,CHEMBL615510,3T3-L1,,,,F,1,1,
,BAO_0000219,488,N,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,Intermediate,620.0,80006,,11902,,10090.0,Mus musculus,,CHEMBL615511,3T3-L1,,,,F,1,1,
,BAO_0000219,489,N,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,Intermediate,620.0,80006,,11902,,10090.0,Mus musculus,,CHEMBL615512,3T3-L1,,,,F,1,1,
,BAO_0000218,490,N,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",Intermediate,620.0,80006,,14840,,10090.0,Mus musculus,,CHEMBL615513,3T3-L1,,,,F,1,1,
,BAO_0000218,491,N,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",Intermediate,620.0,80006,,14840,,10090.0,Mus musculus,,CHEMBL615514,3T3-L1,,,,F,1,1,
,BAO_0000219,492,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,Intermediate,620.0,80006,,13715,,,,,CHEMBL615515,3T3-L1,,,,F,1,1,
,BAO_0000219,493,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,Intermediate,620.0,80006,,13715,,,,,CHEMBL615516,3T3-L1,,,,F,1,1,
,BAO_0000219,494,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,Intermediate,620.0,80006,,13715,,,,,CHEMBL615517,3T3-L1,,,,F,1,1,
,BAO_0000219,495,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,Intermediate,620.0,80006,,13715,,,,,CHEMBL615518,3T3-L1,,,,F,1,1,
,BAO_0000219,496,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,Intermediate,620.0,80006,,13715,,,,,CHEMBL615519,3T3-L1,,,,F,1,1,
,BAO_0000218,497,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,Intermediate,620.0,80006,,13715,,,,,CHEMBL615520,3T3-L1,,,,F,1,1,
,BAO_0000218,498,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,Intermediate,620.0,80006,,13715,,,,,CHEMBL615521,3T3-L1,,,,F,1,1,
,BAO_0000218,499,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,Intermediate,620.0,80006,,13715,,,,,CHEMBL615522,3T3-L1,,,,F,1,1,
,BAO_0000218,500,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,Intermediate,620.0,80006,,13715,,,,,CHEMBL615523,3T3-L1,,,,F,1,1,
,BAO_0000218,501,N,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,Expert,620.0,80006,,13715,,,,,CHEMBL615524,3T3-L1,,,,F,1,1,
,BAO_0000218,502,N,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,Expert,620.0,80006,,13715,,,,,CHEMBL615525,3T3-L1,,,,F,1,1,
,BAO_0000218,503,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,Intermediate,620.0,80006,,13715,,,,,CHEMBL615526,3T3-L1,,,,F,1,1,
,BAO_0000218,504,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,Intermediate,620.0,80006,,13715,,,,,CHEMBL615527,3T3-L1,,,,F,1,1,
,BAO_0000218,505,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,Intermediate,620.0,80006,,13715,,,,,CHEMBL615528,3T3-L1,,,,F,1,1,
,BAO_0000218,506,N,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,Expert,620.0,80006,,13715,,,,,CHEMBL615529,3T3-L1,,,,F,1,1,
,BAO_0000218,507,N,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,Expert,620.0,80006,,13715,,,,,CHEMBL615530,3T3-L1,,,,F,1,1,
,BAO_0000218,508,N,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,Expert,620.0,80006,,13715,,,,,CHEMBL615531,3T3-L1,,,,F,1,1,
,BAO_0000219,509,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,Intermediate,620.0,80006,,13715,,,,,CHEMBL615532,3T3-L1,,,,F,1,1,
,BAO_0000219,510,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,Intermediate,620.0,80006,,13715,,,,,CHEMBL615533,3T3-L1,,,,F,1,1,
,BAO_0000219,511,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,Intermediate,620.0,80006,,13715,,,,,CHEMBL615534,3T3-L1,,,,F,1,1,
,BAO_0000218,512,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,Intermediate,620.0,80006,,13715,,,,,CHEMBL615535,3T3-L1,,,,F,1,1,
,BAO_0000218,513,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,Intermediate,620.0,80006,,13715,,,,,CHEMBL615536,3T3-L1,,,,F,1,1,
,BAO_0000218,514,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,Intermediate,620.0,80006,,13715,,,,,CHEMBL615537,3T3-L1,,,,F,1,1,
,BAO_0000218,515,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,Intermediate,620.0,80006,,13715,,,,,CHEMBL615538,3T3-L1,,,,F,1,1,
,BAO_0000218,516,N,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,Intermediate,620.0,80006,,13715,,,,,CHEMBL836166,3T3-L1,,,,F,1,1,
,BAO_0000219,517,H,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,Expert,620.0,11214,,6411,,,,,CHEMBL615539,3T3-L1,,,,F,1,8,
,BAO_0000219,518,N,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,Intermediate,620.0,80006,,6411,,10090.0,Mus musculus,,CHEMBL615540,3T3-L1,,,,F,1,1,
,BAO_0000219,519,H,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,Expert,620.0,11214,,6411,,,,,CHEMBL615541,3T3-L1,,,,F,1,8,
,BAO_0000219,520,N,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,Expert,620.0,80006,,3966,,10090.0,Mus musculus,,CHEMBL615542,3T3-L1,,,,F,1,1,
,BAO_0000219,521,N,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,Intermediate,620.0,80006,,3966,,10090.0,Mus musculus,,CHEMBL615543,3T3-L1,,,,F,1,1,
,BAO_0000219,522,N,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,Expert,620.0,80006,,15556,,10090.0,Mus musculus,,CHEMBL615544,3T3-L1,,,,F,1,1,
,BAO_0000219,523,N,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,Expert,620.0,80006,,5845,,10090.0,Mus musculus,,CHEMBL615545,3T3-L1,,,,F,1,1,
,BAO_0000219,524,N,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,Expert,620.0,80006,,14422,,10090.0,Mus musculus,,CHEMBL615546,3T3-L1,,,,F,1,1,
,BAO_0000219,525,N,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,Expert,620.0,80006,,5845,,10090.0,Mus musculus,,CHEMBL615547,3T3-L1,,,,F,1,1,
,BAO_0000219,526,N,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,Expert,620.0,80006,,14508,,10090.0,Mus musculus,,CHEMBL615548,3T3-L1,,,,F,1,1,
,BAO_0000219,527,N,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,Expert,620.0,80006,,14508,,10090.0,Mus musculus,,CHEMBL615549,3T3-L1,,,,F,1,1,
,BAO_0000219,528,N,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,Expert,620.0,80006,,14508,,10090.0,Mus musculus,,CHEMBL615550,3T3-L1,,,,F,1,1,
,BAO_0000219,529,N,Inhibitory activity against rat fibroblast (3Y1) cell line,Intermediate,1118.0,80622,,6349,,10116.0,Rattus norvegicus,,CHEMBL615551,3Y1 cell line,,,,F,1,1,
,BAO_0000219,530,N,Mean concentration causing inhibition of cell growth in 3Y1 cells.,Expert,1118.0,80622,,15899,,10116.0,Rattus norvegicus,,CHEMBL615552,3Y1 cell line,,,,F,1,1,
,BAO_0000219,531,N,Cytotoxicity in 3Y1 cells.,Expert,1118.0,80622,,15899,,10116.0,Rattus norvegicus,,CHEMBL615553,3Y1 cell line,,,,F,1,1,
,BAO_0000219,532,N,Cytostatic effect in 3Y1 cells.,Expert,1118.0,80622,,15899,,10116.0,Rattus norvegicus,,CHEMBL615554,3Y1 cell line,,,,F,1,1,
,BAO_0000219,533,N,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",Intermediate,1118.0,80622,,15899,,10116.0,Rattus norvegicus,,CHEMBL615555,3Y1 cell line,,,,F,1,1,
,BAO_0000219,534,N,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,Expert,1118.0,80622,,17038,,10116.0,Rattus norvegicus,,CHEMBL615556,3Y1 cell line,,,,F,1,1,
,BAO_0000019,535,U,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,Autocuration,,22226,,12421,,,,,CHEMBL615557,,,,,B,1,0,
,BAO_0000019,536,U,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,Autocuration,,22226,,12947,,,,,CHEMBL615558,,,,,B,1,0,
,BAO_0000019,537,U,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,Autocuration,,22226,,12947,,,,,CHEMBL872066,,,,,B,1,0,
,BAO_0000019,538,D,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,Expert,,11607,,4896,,9823.0,Sus scrofa,,CHEMBL615559,,,,,B,1,9,
,BAO_0000019,539,H,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,Autocuration,,11607,,6148,,,,,CHEMBL615560,,,,,B,1,8,
,BAO_0000019,540,H,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,Autocuration,,11607,,16432,,,,,CHEMBL615561,,,,,B,1,8,
,BAO_0000019,541,H,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,Expert,,11607,,4978,,,,,CHEMBL857062,,,,,B,1,8,
,BAO_0000019,542,H,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),Expert,,11607,,4978,,,,,CHEMBL615562,,,,,B,1,8,
,BAO_0000019,543,H,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,Autocuration,,11607,,3723,,,,,CHEMBL615563,,,,,B,1,8,
,BAO_0000357,544,H,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),Autocuration,,11607,,3518,,,,,CHEMBL615564,,,,,B,1,8,
,BAO_0000019,545,H,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,Autocuration,,11607,,4164,,,,,CHEMBL615565,,,,,B,1,8,
,BAO_0000019,546,H,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,Autocuration,,11607,,3518,,,,,CHEMBL615566,,,,,B,1,8,
,BAO_0000019,547,D,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,Expert,,11607,,4164,,9823.0,Sus scrofa,,CHEMBL615567,,,,,B,1,9,
,BAO_0000019,548,H,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,Autocuration,,11607,,3518,,,,,CHEMBL615568,,,,,B,1,8,
,BAO_0000357,549,H,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),Autocuration,,11607,,3518,,,,,CHEMBL615569,,,,,B,1,8,
,BAO_0000019,550,H,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,Autocuration,,11607,,4978,,,,,CHEMBL615570,,,,,B,1,8,
,BAO_0000019,551,H,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),Autocuration,,11607,,4978,,,,,CHEMBL615571,,,,,B,1,8,
,BAO_0000224,552,H,Binding affinity against melatonin (MT1) receptor (pC1),Autocuration,,104733,,6455,,,,,CHEMBL615572,,,,,B,1,4,
,BAO_0000019,553,U,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,Autocuration,,22226,,2222,,,,,CHEMBL615573,,,,,B,1,0,
,BAO_0000019,554,U,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,Autocuration,,22226,,13020,,,,,CHEMBL615574,,,,,B,1,0,
,BAO_0000019,555,U,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,Autocuration,,22226,,13021,,,,,CHEMBL615575,,,,,B,1,0,
,BAO_0000357,556,H,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,Autocuration,,10619,,14532,,,,,CHEMBL615576,,,,,B,1,8,
,BAO_0000357,557,H,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,Autocuration,,10619,,14118,,,,,CHEMBL615577,,,,,B,1,8,
Hippocampus,BAO_0000221,558,H,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,Autocuration,,51,,11884,10000000.0,,,,CHEMBL615578,,,,,B,1,8,
,BAO_0000357,559,H,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,Expert,,51,,13969,,,,,CHEMBL615579,,,,,B,1,8,
,BAO_0000357,560,H,Binding affinity for 5-hydroxytryptamine 1A receptor,Expert,,51,,13392,,,,,CHEMBL615580,,,,,B,1,8,
,BAO_0000019,561,H,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,Expert,,51,,14430,,,,,CHEMBL615581,,,,,B,1,8,
Hippocampus,BAO_0000221,562,H,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Autocuration,,51,,12248,10000000.0,,,,CHEMBL615582,,,,,B,1,8,
Hippocampus,BAO_0000221,563,H,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Autocuration,,51,,12249,10000000.0,,,,CHEMBL615583,,,,,B,1,8,
Hippocampus,BAO_0000221,564,H,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,Autocuration,,51,,9995,10000000.0,,,,CHEMBL615584,,,,,B,1,8,
Hippocampus,BAO_0000221,565,H,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Autocuration,,51,,9995,10000000.0,,,,CHEMBL833691,,,,,B,1,8,
Hippocampus,BAO_0000221,566,H,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,Autocuration,,51,,9995,10000000.0,,,,CHEMBL615585,,,,,B,1,8,
Hippocampus,BAO_0000221,567,H,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,Autocuration,,51,,9995,10000000.0,,,,CHEMBL615586,,,,,B,1,8,
Hippocampus,BAO_0000221,568,H,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Autocuration,,51,,9995,10000000.0,,,,CHEMBL884524,,,,,B,1,8,
Hippocampus,BAO_0000221,569,H,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Autocuration,,51,,12249,10000000.0,,,,CHEMBL615587,,,,,B,1,8,
Hippocampus,BAO_0000221,570,H,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",Autocuration,,51,,11799,10000000.0,,,,CHEMBL615588,,,,,B,1,8,
,BAO_0000249,571,D,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,Expert,,10576,,14331,,10116.0,Rattus norvegicus,,CHEMBL615589,,,,Membranes,B,1,9,
Hippocampus,BAO_0000221,572,H,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,Expert,,51,,11884,10000000.0,9913.0,Bos taurus,,CHEMBL615442,,,,,B,1,8,
Hippocampus,BAO_0000221,573,H,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,Autocuration,,51,,14331,10000000.0,,,,CHEMBL615443,,,,,B,1,8,
Hippocampus,BAO_0000221,574,H,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,Autocuration,,51,,11701,10000000.0,,,,CHEMBL615444,,,,,B,1,8,
Hippocampus,BAO_0000221,575,H,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,Expert,,51,,11701,10000000.0,,,,CHEMBL615445,,,,,B,1,8,
Hippocampus,BAO_0000221,576,H,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,Autocuration,,51,,12248,10000000.0,,,,CHEMBL615446,,,,,B,1,8,
,BAO_0000219,577,H,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,Autocuration,449.0,51,,12248,,,,,CHEMBL615447,CHO,,,,B,1,8,
Hippocampus,BAO_0000221,578,H,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Expert,,51,,12248,10000000.0,,,,CHEMBL615448,,,,,B,1,8,
Hippocampus,BAO_0000221,579,H,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Expert,,51,,12249,10000000.0,,,,CHEMBL615449,,,,,B,1,8,
,BAO_0000219,580,H,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,Autocuration,449.0,51,,12248,,,,,CHEMBL615450,CHO,,,,B,1,8,
Hippocampus,BAO_0000221,581,H,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",Expert,,51,,11799,10000000.0,,,,CHEMBL615451,,,,,B,1,8,
,BAO_0000357,582,H,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,Autocuration,,51,,634,,,,,CHEMBL615452,,,,,B,1,8,
Hippocampus,BAO_0000221,583,H,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,Autocuration,,51,,9995,10000000.0,,,,CHEMBL615453,,,,,B,1,8,
Hippocampus,BAO_0000221,584,H,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Autocuration,,51,,9995,10000000.0,,,,CHEMBL615454,,,,,B,1,8,
Hippocampus,BAO_0000221,585,H,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,Autocuration,,51,,9995,10000000.0,,,,CHEMBL615455,,,,,B,1,8,
Hippocampus,BAO_0000221,586,H,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Autocuration,,51,,9995,10000000.0,,,,CHEMBL615456,,,,,B,1,8,
Hippocampus,BAO_0000221,587,H,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,Autocuration,,51,,9995,10000000.0,,,,CHEMBL615457,,,,,B,1,8,
Hippocampus,BAO_0000218,588,H,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,Expert,,51,,12210,10000000.0,,,,CHEMBL615458,,,,,B,1,8,
Hippocampus,BAO_0000221,589,H,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,Expert,,51,,13311,10000000.0,,,,CHEMBL615459,,,,,B,1,8,
,BAO_0000219,590,D,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",Expert,449.0,51,,2331,,9606.0,Homo sapiens,,CHEMBL615460,CHO,,,,B,1,9,
,BAO_0000019,591,H,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,Autocuration,,51,,1375,,10141.0,Cavia porcellus,,CHEMBL615461,,,,,F,1,8,
,BAO_0000019,592,H,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,Autocuration,,51,,1375,,10141.0,Cavia porcellus,,CHEMBL615462,,,,,F,1,8,
Hippocampus,BAO_0000221,593,H,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,Autocuration,,51,,11574,10000000.0,10141.0,Cavia porcellus,,CHEMBL615463,,,,,F,1,8,
Ileum,BAO_0000221,594,H,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,Autocuration,,51,,12867,2116.0,10141.0,Cavia porcellus,,CHEMBL615464,,,,,B,1,8,
Ileum,BAO_0000221,595,H,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,Autocuration,,51,,12867,2116.0,10141.0,Cavia porcellus,,CHEMBL615465,,,,,B,1,8,
Ileum,BAO_0000221,596,H,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,Autocuration,,51,,12867,2116.0,10141.0,Cavia porcellus,,CHEMBL615466,,,,,B,1,8,
Ileum,BAO_0000221,597,H,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,Autocuration,,51,,12867,2116.0,10141.0,Cavia porcellus,,CHEMBL615467,,,,,B,1,8,
Ileum,BAO_0000221,598,H,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,Autocuration,,51,,12867,2116.0,10141.0,Cavia porcellus,,CHEMBL615468,,,,,B,1,8,
Ileum,BAO_0000221,599,H,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,Autocuration,,51,,12867,2116.0,10141.0,Cavia porcellus,,CHEMBL615469,,,,,B,1,8,
,BAO_0000357,600,H,Binding affinity against 5-hydroxytryptamine 1A receptor,Autocuration,,51,,11574,,10141.0,Cavia porcellus,,CHEMBL615470,,,,,B,1,8,
,BAO_0000357,601,H,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,Autocuration,,51,,13114,,10141.0,Cavia porcellus,,CHEMBL615471,,,,,B,1,8,
,BAO_0000357,602,H,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,Autocuration,,51,,13181,,10141.0,Cavia porcellus,,CHEMBL615472,,,,,B,1,8,
Hippocampus,BAO_0000221,603,H,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,Autocuration,,106,,10639,10000000.0,10141.0,Cavia porcellus,,CHEMBL883242,,,,,B,1,8,
Hippocampus,BAO_0000221,604,H,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,Autocuration,,106,,10639,10000000.0,10141.0,Cavia porcellus,,CHEMBL615473,,,,,F,1,8,
,BAO_0000218,605,H,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),Autocuration,449.0,11863,,11883,,10029.0,Cricetulus griseus,,CHEMBL615474,CHO,,,,B,1,8,
,BAO_0000357,606,H,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,Autocuration,,51,,17785,,,,,CHEMBL615475,,,,,B,1,8,
,BAO_0000219,607,H,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,Autocuration,308.0,51,,1558,,,,,CHEMBL615476,HeLa,,,,F,1,8,
,BAO_0000219,608,H,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,Autocuration,308.0,51,,1558,,,,,CHEMBL615477,HeLa,,,,F,1,8,
,BAO_0000019,609,H,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,Autocuration,,51,,15740,,,,,CHEMBL615478,,,,,F,1,8,
,BAO_0000219,610,H,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,Autocuration,449.0,51,,17624,,,,,CHEMBL615160,CHO,,,,F,1,8,
,BAO_0000219,611,H,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,Expert,449.0,51,,17624,,,,,CHEMBL615161,CHO,,,,F,1,8,
,BAO_0000219,612,H,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,Autocuration,449.0,51,,17624,,,,,CHEMBL615162,CHO,,,,F,1,8,
,BAO_0000219,613,H,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,Autocuration,449.0,51,,17624,,,,,CHEMBL615163,CHO,,,,F,1,8,
,BAO_0000219,614,H,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,Expert,449.0,51,,17624,,,,,CHEMBL615164,CHO,,,,B,1,8,
,BAO_0000219,615,H,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,Expert,449.0,51,,17624,,,,,CHEMBL615165,CHO,,,,B,1,8,
,BAO_0000219,616,H,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,Autocuration,449.0,51,,17624,,,,,CHEMBL615166,CHO,,,,B,1,8,
,BAO_0000219,617,H,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,Autocuration,,51,,14256,,,,,CHEMBL615167,,,,,F,1,8,
,BAO_0000219,618,D,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,Expert,308.0,51,,3445,,9606.0,Homo sapiens,,CHEMBL615168,HeLa,,,,B,1,9,
,BAO_0000219,619,D,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,Expert,308.0,51,,3445,,9606.0,Homo sapiens,,CHEMBL615169,HeLa,,,,B,1,9,
,BAO_0000219,620,D,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,Expert,449.0,51,,17200,,9606.0,Homo sapiens,,CHEMBL615170,CHO,,,,B,1,9,
,BAO_0000219,621,D,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,Expert,449.0,51,,17200,,9606.0,Homo sapiens,,CHEMBL615171,CHO,,,,B,1,9,
,BAO_0000019,622,H,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,Autocuration,,51,,15180,,,,,CHEMBL615694,,,,,F,1,8,
,BAO_0000019,623,H,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,Autocuration,,51,,15180,,,,,CHEMBL615695,,,,,F,1,8,
,BAO_0000019,624,H,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",Autocuration,,51,,16026,,,,,CHEMBL615696,,,,,F,1,8,
,BAO_0000219,625,H,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,Autocuration,449.0,51,,2759,,,,,CHEMBL615697,CHO,,,,F,1,8,
,BAO_0000219,626,D,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),Expert,449.0,51,,2759,,9606.0,Homo sapiens,,CHEMBL859410,CHO,,,,F,1,9,
,BAO_0000219,627,H,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),Autocuration,449.0,51,,2759,,,,,CHEMBL615841,CHO,,,,F,1,8,
,BAO_0000219,628,D,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),Expert,449.0,51,,2759,,9606.0,Homo sapiens,,CHEMBL615842,CHO,,,,F,1,9,
,BAO_0000219,629,H,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,Autocuration,449.0,51,,2759,,,,,CHEMBL835003,CHO,,,,F,1,8,
,BAO_0000219,630,H,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),Autocuration,449.0,51,,2759,,,,,CHEMBL615843,CHO,,,,F,1,8,
,BAO_0000219,631,D,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),Expert,449.0,51,,2759,,9606.0,Homo sapiens,,CHEMBL615979,CHO,,,,F,1,9,
,BAO_0000219,632,H,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),Autocuration,449.0,51,,2759,,,,,CHEMBL615980,CHO,,,,F,1,8,
,BAO_0000219,633,D,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),Expert,449.0,51,,2759,,9606.0,Homo sapiens,,CHEMBL615981,CHO,,,,F,1,9,
,BAO_0000019,634,D,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,Expert,,51,,3445,,9606.0,Homo sapiens,,CHEMBL615982,,,,,F,1,9,
,BAO_0000019,635,D,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",Expert,,51,,5272,,9606.0,Homo sapiens,,CHEMBL615983,,,,,F,1,9,
,BAO_0000019,636,D,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",Expert,,51,,5272,,9606.0,Homo sapiens,,CHEMBL615984,,,,,F,1,9,
,BAO_0000019,637,D,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",Expert,,51,,5272,,9606.0,Homo sapiens,,CHEMBL615985,,,,,F,1,9,
,BAO_0000219,638,H,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,Autocuration,449.0,51,,17624,,,,,CHEMBL615986,CHO,,,,F,1,8,
,BAO_0000219,639,H,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,Autocuration,449.0,51,,17624,,,,,CHEMBL615987,CHO,,,,F,1,8,
,BAO_0000219,640,H,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,Autocuration,449.0,51,,17624,,,,,CHEMBL615988,CHO,,,,F,1,8,
,BAO_0000219,641,H,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,Expert,449.0,51,,17624,,,,,CHEMBL615989,CHO,,,,F,1,8,
,BAO_0000219,642,H,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,Autocuration,449.0,51,,17624,,,,,CHEMBL615990,CHO,,,,F,1,8,
,BAO_0000219,643,H,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,Autocuration,449.0,51,,17624,,,,,CHEMBL615991,CHO,,,,F,1,8,
,BAO_0000219,644,H,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,Autocuration,449.0,51,,17624,,,,,CHEMBL615992,CHO,,,,F,1,8,
,BAO_0000219,645,H,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,Autocuration,449.0,51,,17624,,,,,CHEMBL615993,CHO,,,,F,1,8,
,BAO_0000219,646,H,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,Expert,449.0,51,,17624,,,,,CHEMBL615994,CHO,,,,F,1,8,
,BAO_0000219,647,H,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,Autocuration,449.0,51,,17624,,,,,CHEMBL615995,CHO,,,,F,1,8,
,BAO_0000219,648,H,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,Autocuration,449.0,51,,17624,,,,,CHEMBL615996,CHO,,,,F,1,8,
,BAO_0000219,649,H,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,Autocuration,449.0,51,,17624,,,,,CHEMBL615997,CHO,,,,F,1,8,
,BAO_0000019,650,H,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",Autocuration,,51,,6563,,,,,CHEMBL615998,,,,,F,1,8,
,BAO_0000019,651,H,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",Autocuration,,51,,6563,,,,,CHEMBL615999,,,,,F,1,8,
,BAO_0000019,652,H,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,Autocuration,,51,,6563,,,,,CHEMBL616000,,,,,F,1,8,
,BAO_0000219,653,H,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,Autocuration,722.0,51,,17296,,,,,CHEMBL616001,HEK293,,,,F,1,8,
,BAO_0000019,654,D,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",Expert,,51,,6876,,9606.0,Homo sapiens,,CHEMBL616002,,,,,F,1,9,
,BAO_0000019,655,H,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",Expert,,51,,6876,,,,,CHEMBL616003,,,,,F,1,8,
,BAO_0000019,656,D,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,Expert,,51,,5272,,9606.0,Homo sapiens,,CHEMBL616004,,,,,F,1,9,
,BAO_0000019,657,D,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,Expert,,51,,5272,,9606.0,Homo sapiens,,CHEMBL616005,,,,,F,1,9,
,BAO_0000019,658,H,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",Autocuration,,51,,5548,,,,,CHEMBL616006,,,,,F,1,8,
,BAO_0000019,659,H,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",Expert,,51,,5548,,,,,CHEMBL616007,,,,,F,1,8,
,BAO_0000019,660,H,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",Autocuration,,51,,5548,,,,,CHEMBL616008,,,,,F,1,8,
,BAO_0000019,661,H,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",Autocuration,,51,,5548,,,,,CHEMBL616009,,,,,F,1,8,
,BAO_0000019,662,H,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",Expert,,51,,5929,,,,,CHEMBL616010,,,,,F,1,8,
,BAO_0000019,663,D,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",Expert,,51,,5929,,9606.0,Homo sapiens,,CHEMBL616011,,,,,F,1,9,
,BAO_0000019,664,D,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",Expert,,51,,5929,,9606.0,Homo sapiens,,CHEMBL615740,,,,,F,1,9,
,BAO_0000019,665,H,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",Autocuration,,51,,16245,,,,,CHEMBL615741,,,,,F,1,8,
,BAO_0000019,666,H,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",Expert,,51,,5640,,,,,CHEMBL615742,,,,,F,1,8,
,BAO_0000019,667,H,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",Autocuration,,51,,5640,,,,,CHEMBL615743,,,,,F,1,8,
,BAO_0000219,668,H,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,Autocuration,449.0,51,,14509,,,,,CHEMBL615744,CHO,,,,F,1,8,
,BAO_0000219,669,H,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,Expert,449.0,51,,14509,,,,,CHEMBL615745,CHO,,,,F,1,8,
,BAO_0000357,670,H,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,Autocuration,,51,,15331,,,,,CHEMBL615746,,,,,B,1,8,
,BAO_0000357,671,H,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,Autocuration,,51,,15331,,,,,CHEMBL615747,,,,,B,1,8,
,BAO_0000019,672,H,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",Autocuration,,51,,6563,,,,,CHEMBL615748,,,,,F,1,8,
,BAO_0000019,673,H,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",Autocuration,,51,,6563,,,,,CHEMBL615749,,,,,F,1,8,
,BAO_0000019,674,H,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,Autocuration,,51,,6563,,,,,CHEMBL615750,,,,,F,1,8,
,BAO_0000019,675,D,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,Expert,,51,,6563,,9606.0,Homo sapiens,,CHEMBL616259,,,,,F,1,9,
,BAO_0000019,676,H,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",Autocuration,,51,,6563,,,,,CHEMBL616260,,,,,F,1,8,
,BAO_0000019,677,D,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,Expert,,51,,5272,,9606.0,Homo sapiens,,CHEMBL616261,,,,,F,1,9,
,BAO_0000019,678,D,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",Expert,,51,,5272,,9606.0,Homo sapiens,,CHEMBL616262,,,,,F,1,9,
,BAO_0000019,679,D,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",Expert,,51,,5272,,9606.0,Homo sapiens,,CHEMBL616263,,,,,F,1,9,
,BAO_0000019,680,D,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,Expert,,51,,5272,,9606.0,Homo sapiens,,CHEMBL616264,,,,,F,1,9,
,BAO_0000019,681,D,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,Expert,,51,,5272,,9606.0,Homo sapiens,,CHEMBL616265,,,,,F,1,9,
,BAO_0000019,682,D,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",Expert,,51,,5272,,9606.0,Homo sapiens,,CHEMBL616266,,,,,F,1,9,
,BAO_0000019,683,D,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",Expert,,51,,5272,,9606.0,Homo sapiens,,CHEMBL616267,,,,,F,1,9,
,BAO_0000019,684,D,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,Expert,,51,,5272,,9606.0,Homo sapiens,,CHEMBL616268,,,,,F,1,9,
,BAO_0000357,685,D,Inhibition of human 5-hydroxytryptamine 1A receptor,Expert,,51,,16146,,9606.0,Homo sapiens,,CHEMBL616269,,,,,B,1,9,
,BAO_0000219,686,H,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,Autocuration,449.0,51,,17624,,,,,CHEMBL884528,CHO,,,,B,1,8,
,BAO_0000219,687,D,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,Expert,722.0,105,,13706,,,,,CHEMBL616270,HEK293,,,,B,1,9,
,BAO_0000219,688,H,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,Autocuration,449.0,51,,15250,,,,,CHEMBL616271,CHO,,,,B,1,8,
,BAO_0000219,689,H,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,Autocuration,449.0,51,,17624,,,,,CHEMBL616272,CHO,,,,F,1,8,
,BAO_0000357,690,H,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,Expert,,51,,6861,,,,,CHEMBL616273,,,,,B,1,8,
,BAO_0000357,691,D,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,Expert,,51,,17200,,9606.0,Homo sapiens,,CHEMBL616274,,,,,B,1,9,
,BAO_0000219,692,H,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,Autocuration,449.0,51,,17624,,,,,CHEMBL616275,CHO,,,,B,1,8,
,BAO_0000219,693,H,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,Autocuration,449.0,51,,17624,,,,,CHEMBL616276,CHO,,,,B,1,8,
,BAO_0000218,694,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,Autocuration,,22226,,12058,,10116.0,Rattus norvegicus,,CHEMBL616277,,,In vivo,,F,1,0,
,BAO_0000218,695,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,Autocuration,,22226,,12058,,10116.0,Rattus norvegicus,,CHEMBL616278,,,In vivo,,F,1,0,
,BAO_0000218,696,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,Autocuration,,22226,,12058,,10116.0,Rattus norvegicus,,CHEMBL616279,,,In vivo,,F,1,0,
,BAO_0000218,697,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,Autocuration,,22226,,12058,,10116.0,Rattus norvegicus,,CHEMBL616280,,,In vivo,,F,1,0,
,BAO_0000218,698,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,Autocuration,,22226,,12058,,10116.0,Rattus norvegicus,,CHEMBL616281,,,In vivo,,F,1,0,
,BAO_0000218,699,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,Autocuration,,22226,,12058,,10116.0,Rattus norvegicus,,CHEMBL616282,,,In vivo,,F,1,0,
,BAO_0000218,700,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,Autocuration,,22226,,12058,,10116.0,Rattus norvegicus,,CHEMBL616283,,,In vivo,,F,1,0,
,BAO_0000218,701,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,Autocuration,,22226,,12058,,10116.0,Rattus norvegicus,,CHEMBL616284,,,In vivo,,F,1,0,
,BAO_0000218,702,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,Autocuration,,22226,,12058,,10116.0,Rattus norvegicus,,CHEMBL616285,,,In vivo,,F,1,0,
,BAO_0000218,703,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,Autocuration,,22226,,12058,,10116.0,Rattus norvegicus,,CHEMBL616286,,,In vivo,,F,1,0,
,BAO_0000218,704,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,Autocuration,,22226,,12058,,10116.0,Rattus norvegicus,,CHEMBL616287,,,In vivo,,F,1,0,
,BAO_0000218,705,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,Autocuration,,22226,,12058,,10116.0,Rattus norvegicus,,CHEMBL616288,,,In vivo,,F,1,0,
,BAO_0000218,706,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,Autocuration,,22226,,12058,,10116.0,Rattus norvegicus,,CHEMBL616289,,,In vivo,,F,1,0,
,BAO_0000218,707,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,Autocuration,,22226,,12058,,10116.0,Rattus norvegicus,,CHEMBL615610,,,In vivo,,F,1,0,
,BAO_0000218,708,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,Autocuration,,22226,,12058,,10116.0,Rattus norvegicus,,CHEMBL615611,,,In vivo,,F,1,0,
,BAO_0000218,709,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,Autocuration,,22226,,12058,,10116.0,Rattus norvegicus,,CHEMBL615612,,,In vivo,,F,1,0,
,BAO_0000218,710,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,Autocuration,,22226,,12058,,10116.0,Rattus norvegicus,,CHEMBL615613,,,In vivo,,F,1,0,
,BAO_0000218,711,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,Autocuration,,22226,,12058,,10116.0,Rattus norvegicus,,CHEMBL615614,,,In vivo,,F,1,0,
,BAO_0000218,712,U,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,Autocuration,,22226,,12058,,10116.0,Rattus norvegicus,,CHEMBL615615,,,In vivo,,F,1,0,
,BAO_0000019,713,H,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,Autocuration,,105093,,11440,,,,,CHEMBL615616,,,,,B,1,4,
Hypothalamus,BAO_0000249,714,H,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,Autocuration,,11923,,6238,1898.0,,,,CHEMBL615617,,,,,B,1,8,
,BAO_0000019,715,H,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,Autocuration,,10577,,10046,,,,,CHEMBL615618,,,,,B,1,8,
,BAO_0000019,716,H,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,Autocuration,,10577,,10046,,,,,CHEMBL615619,,,,,B,1,8,
,BAO_0000019,717,H,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,Expert,,10577,,10046,,,,,CHEMBL615620,,,,,B,1,8,
,BAO_0000357,718,H,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",Autocuration,,55,,167,,,,,CHEMBL615621,,,,,B,1,8,
,BAO_0000357,719,H,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",Autocuration,,55,,167,,,,,CHEMBL615622,,,,,B,1,8,
,BAO_0000019,720,H,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),Autocuration,,12166,,11520,,,,,CHEMBL615623,,,,,F,1,8,
,BAO_0000019,721,H,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,Autocuration,,12166,,11520,,,,,CHEMBL615624,,,,,F,1,8,
,BAO_0000019,722,H,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,Autocuration,,12166,,11520,,,,,CHEMBL615625,,,,,F,1,8,
,BAO_0000019,723,H,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,Autocuration,,12166,,11520,,,,,CHEMBL767045,,,,,F,1,8,
,BAO_0000019,724,H,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,Autocuration,,55,,135,,10141.0,Cavia porcellus,,CHEMBL615626,,,,,F,1,8,
,BAO_0000019,725,H,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,Autocuration,,55,,135,,10141.0,Cavia porcellus,,CHEMBL615627,,,,,F,1,8,
,BAO_0000019,726,H,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,Autocuration,,55,,11311,,10141.0,Cavia porcellus,,CHEMBL615628,,,,,B,1,8,
,BAO_0000357,727,H,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,Autocuration,,55,,10193,,10141.0,Cavia porcellus,,CHEMBL615629,,,,,B,1,8,
,BAO_0000357,728,D,Inhibitory concentration against 5-lipoxygenase from human whole blood,Expert,,55,,12281,,9606.0,Homo sapiens,,CHEMBL615630,,,,,B,1,9,
,BAO_0000219,729,H,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],Autocuration,,55,,11311,,,,,CHEMBL615631,,,,,B,1,8,
,BAO_0000218,730,H,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,Autocuration,,17087,,12576,,,,,CHEMBL615632,,,,,F,1,8,
,BAO_0000357,731,H,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,Autocuration,,17087,,12281,,,,,CHEMBL615633,,,,,B,1,8,
,BAO_0000218,732,H,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,Autocuration,,17087,,12576,,,,,CHEMBL615634,,,,,F,1,8,
,BAO_0000019,733,H,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,Expert,,55,,11089,,9823.0,Sus scrofa,,CHEMBL615635,,,,,B,1,8,
,BAO_0000357,734,H,In vitro inhibition of rat 5-Lipoxygenase,Expert,,12166,,11006,,,,,CHEMBL615636,,,,,B,1,8,
,BAO_0000357,735,D,Inhibitory activity against 5-Lipoxygenase,Expert,,12166,,11481,,10116.0,Rattus norvegicus,,CHEMBL615637,,,,,B,1,9,
,BAO_0000219,736,H,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,Expert,702.0,12166,,10864,,,,,CHEMBL615638,RBL-1,,,,B,1,8,
,BAO_0000219,737,H,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),Autocuration,702.0,12166,,3595,,,,,CHEMBL615639,RBL-1,,,,B,1,8,
,BAO_0000219,738,H,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,Autocuration,702.0,12166,,11311,,,,,CHEMBL615640,RBL-1,,,,B,1,8,
,BAO_0000019,739,H,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,Autocuration,,12166,,11311,,,,,CHEMBL615796,,,,,B,1,8,
,BAO_0000219,740,H,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],Autocuration,,12166,,11311,,,,,CHEMBL615845,,,,,B,1,8,
,BAO_0000357,741,H,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,Autocuration,,12166,,11006,,,,,CHEMBL615846,,,,,B,1,8,
,BAO_0000219,742,H,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,Autocuration,702.0,12166,,3595,,,,,CHEMBL615847,RBL-1,,,,B,1,8,
,BAO_0000357,743,H,The compound was tested for inhibition of isolated 5-Lipoxygenase,Autocuration,,12166,,11311,,,,,CHEMBL615848,,,,,B,1,8,
,BAO_0000019,744,U,Ratio of IC50 against 5-LO and COX,Autocuration,,22226,,11481,,10116.0,Rattus norvegicus,,CHEMBL615849,,,,,B,1,0,
,BAO_0000357,745,H,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,Autocuration,,12166,,11006,,,,,CHEMBL615850,,,,,B,1,8,
,BAO_0000357,746,H,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,Autocuration,,12166,,11006,,,,,CHEMBL615851,,,,,B,1,8,
,BAO_0000219,747,H,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,Autocuration,,12166,,11311,,,,,CHEMBL615852,,,,,B,1,8,
,BAO_0000019,748,H,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,Autocuration,,12166,,11006,,,,,CHEMBL615853,,,,,F,1,8,
Prostate gland,BAO_0000357,749,H,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,Autocuration,,120,,4288,2367.0,,,,CHEMBL884527,,,,,B,1,8,
,BAO_0000019,750,U,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,Autocuration,,22226,,7587,,8932.0,Columba livia,,CHEMBL872871,,,,,B,1,0,
,BAO_0000019,751,U,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,Autocuration,,22226,,7587,,8932.0,Columba livia,,CHEMBL615854,,,,,B,1,0,
,BAO_0000019,752,U,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,Autocuration,,22226,,7587,,8932.0,Columba livia,,CHEMBL767046,,,,,B,1,0,
,BAO_0000357,753,H,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,Autocuration,,10732,,11249,,,,,CHEMBL615855,,,,,B,1,8,
,BAO_0000019,754,D,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,Expert,,12198,,8003,,10116.0,Rattus norvegicus,,CHEMBL615856,,,,,F,1,9,
,BAO_0000019,755,D,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),Expert,,12198,,8003,,10116.0,Rattus norvegicus,,CHEMBL615857,,,,,F,1,9,
,BAO_0000019,756,D,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),Expert,,12198,,8003,,10116.0,Rattus norvegicus,,CHEMBL615858,,,,,F,1,9,
Hippocampus,BAO_0000221,757,H,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,Expert,,10576,,12416,10000000.0,,,,CHEMBL615859,,,,,B,1,8,
,BAO_0000357,758,H,Binding affinity towards human 5-hydroxytryptamine 1 receptor,Autocuration,,51,,16293,,,,,CHEMBL615860,,,,,B,1,8,
,BAO_0000019,759,U,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,Autocuration,,22226,,13047,,9986.0,Oryctolagus cuniculus,,CHEMBL615861,,,,,B,1,0,
,BAO_0000019,760,U,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,Autocuration,,22226,,13047,,9986.0,Oryctolagus cuniculus,,CHEMBL615862,,,,,B,1,0,
,BAO_0000019,761,U,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,Autocuration,,22226,,13047,,9986.0,Oryctolagus cuniculus,,CHEMBL615863,,,,,B,1,0,
,BAO_0000019,762,U,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,Autocuration,,22226,,13047,,9986.0,Oryctolagus cuniculus,,CHEMBL615864,,,,,B,1,0,
Hippocampus,BAO_0000221,763,H,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,Autocuration,,104744,,10085,10000000.0,,,,CHEMBL615865,,,,,B,1,4,
Hippocampus,BAO_0000221,764,H,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,Autocuration,,104744,,10085,10000000.0,,,,CHEMBL615866,,,,,B,1,4,
Hippocampus,BAO_0000221,765,H,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,Autocuration,,104744,,10085,10000000.0,,,,CHEMBL615867,,,,,B,1,4,
,BAO_0000249,766,H,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,Autocuration,,104744,,9841,,,,,CHEMBL615868,,,,Membranes,B,1,4,
,BAO_0000249,767,D,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,Autocuration,,104744,,8822,,10116.0,Rattus norvegicus,,CHEMBL615869,,,,,B,1,5,
,BAO_0000019,768,D,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,Autocuration,,104744,,9806,,10116.0,Rattus norvegicus,,CHEMBL615870,,,,,B,1,5,
,BAO_0000019,769,D,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,Autocuration,,104744,,9806,,10116.0,Rattus norvegicus,,CHEMBL615871,,,,,B,1,5,
,BAO_0000224,770,H,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,Autocuration,,104744,,8868,,,,,CHEMBL615872,,,,,B,1,4,
Hippocampus,BAO_0000221,771,H,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,Autocuration,,104744,,9036,10000000.0,,,,CHEMBL833492,,,,,B,1,4,
Hippocampus,BAO_0000221,772,H,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,Autocuration,,104744,,11374,10000000.0,,,,CHEMBL615873,,,,,B,1,4,
,BAO_0000224,773,H,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,Autocuration,,104744,,10881,,,,,CHEMBL615479,,,,,B,1,4,
,BAO_0000019,774,H,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,Autocuration,,104744,,8822,,,,,CHEMBL615480,,,,,B,1,4,
,BAO_0000249,775,D,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,Autocuration,,104744,,9806,,10116.0,Rattus norvegicus,,CHEMBL615481,,,,,B,1,5,
,BAO_0000019,776,H,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,Autocuration,,104744,,15463,,,,,CHEMBL872869,,,,,B,1,4,
,BAO_0000019,777,H,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,Autocuration,,104744,,15463,,,,,CHEMBL615482,,,,,B,1,4,
Brain,BAO_0000221,778,H,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,Autocuration,,104744,,14542,955.0,,,,CHEMBL615483,,,,,B,1,4,
Brain,BAO_0000221,779,H,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,Autocuration,,104744,,14542,955.0,,,,CHEMBL615484,,,,,B,1,4,
,BAO_0000019,780,H,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,Autocuration,,104744,,8569,,,,,CHEMBL615485,,,,,B,1,4,
,BAO_0000224,781,D,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,Autocuration,,104744,,10062,,10116.0,Rattus norvegicus,,CHEMBL615486,,,,,B,1,5,
,BAO_0000224,782,H,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,Autocuration,,104744,,4771,,,,,CHEMBL615487,,,,,B,1,4,
,BAO_0000224,783,H,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,Autocuration,,104744,,10062,,,,,CHEMBL615488,,,,,B,1,4,
,BAO_0000224,784,H,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,Autocuration,,104744,,10062,,,,,CHEMBL615489,,,,,B,1,4,
,BAO_0000224,785,H,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,Autocuration,,104744,,10062,,,,,CHEMBL615389,,,,,B,1,4,
,BAO_0000019,786,H,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,Autocuration,,104744,,15463,,,,,CHEMBL615390,,,,,B,1,4,
,BAO_0000019,787,H,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,Autocuration,,104744,,15463,,,,,CHEMBL615391,,,,,B,1,4,
,BAO_0000224,788,H,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,Autocuration,,104744,,9098,,,,,CHEMBL615392,,,,,B,1,4,
,BAO_0000019,789,U,Affinity for 5-hydroxytryptamine 1 receptor,Autocuration,,22226,,3070,,10116.0,Rattus norvegicus,,CHEMBL615393,,,,,B,1,0,
Brain,BAO_0000221,790,H,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,Autocuration,,104744,,14542,955.0,,,,CHEMBL615394,,,,,B,1,4,
Brain,BAO_0000221,791,H,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,Autocuration,,104744,,14542,955.0,,,,CHEMBL615395,,,,,B,1,4,
,BAO_0000224,792,H,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,Autocuration,,104744,,6398,,,,,CHEMBL615396,,,,,B,1,4,
Brain,BAO_0000221,793,H,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,Autocuration,,104744,,1344,955.0,,,,CHEMBL615397,,,,,B,1,4,
,BAO_0000019,794,H,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,Autocuration,,104744,,11963,,,,,CHEMBL615398,,,,,B,1,4,
,BAO_0000019,795,U,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,Autocuration,,22226,,8908,,10116.0,Rattus norvegicus,,CHEMBL615399,,,,,B,1,0,
,BAO_0000019,796,H,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,Autocuration,,104744,,9098,,,,,CHEMBL615400,,,,,B,1,4,
,BAO_0000019,797,D,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,Autocuration,,104744,,8841,,10116.0,Rattus norvegicus,,CHEMBL615401,,,,,B,1,5,
,BAO_0000019,798,U,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,Autocuration,,22226,,8814,,10116.0,Rattus norvegicus,,CHEMBL615402,,,,,B,1,0,
,BAO_0000019,799,H,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,Autocuration,,104744,,11752,,,,,CHEMBL615403,,,,,B,1,4,
Brain,BAO_0000221,800,H,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,Autocuration,,104744,,11642,955.0,,,,CHEMBL615404,,,,,B,1,4,
,BAO_0000019,801,H,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,Autocuration,,104744,,11642,,,,,CHEMBL615781,,,,,B,1,4,
Brain,BAO_0000220,802,H,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,Autocuration,,104744,,9231,955.0,,,,CHEMBL615782,,,,,B,1,4,
Brain,BAO_0000221,803,H,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,Autocuration,,104744,,11351,955.0,,,,CHEMBL615783,,,,,B,1,4,
,BAO_0000019,804,U,Compound was tested for binding affinity against 5-HT1 receptor,Autocuration,,22226,,4639,,,,,CHEMBL873481,,,,,B,1,0,
,BAO_0000019,805,U,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,Autocuration,,22226,,1205,,,,,CHEMBL615784,,,,,B,1,0,
,BAO_0000357,806,H,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,Expert,,10576,,10025,,,,,CHEMBL615785,,,,,B,1,8,
,BAO_0000249,807,H,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",Autocuration,,10576,,13241,,,,,CHEMBL615786,,,,,F,1,8,
,BAO_0000218,808,H,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,Autocuration,,10576,,16245,,,,,CHEMBL615787,,,In vivo,,F,1,8,
,BAO_0000218,809,H,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,Autocuration,,10576,,16245,,,,,CHEMBL615788,,,In vivo,,F,1,8,
,BAO_0000019,810,H,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,Autocuration,,10576,,12438,,,,,CHEMBL767044,,,,,F,1,8,
,BAO_0000218,811,H,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,Autocuration,,10576,,16245,,,,,CHEMBL615789,,,In vivo,,F,1,8,
,BAO_0000218,812,H,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,Autocuration,,10576,,16245,,,,,CHEMBL615790,,,In vivo,,F,1,8,
,BAO_0000019,813,H,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,Autocuration,,10576,,15740,,,,,CHEMBL615813,,,,,F,1,8,
,BAO_0000219,814,H,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,Autocuration,,10576,,15535,,,,,CHEMBL615814,,,,,F,1,8,
,BAO_0000219,815,H,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,Expert,,51,,15535,,,,,CHEMBL615815,,,,,F,1,8,
,BAO_0000219,816,H,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,Autocuration,,10576,,15535,,,,,CHEMBL615816,,,,,F,1,8,
,BAO_0000249,817,H,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,Expert,,10576,,9888,,,,,CHEMBL615817,,,,,B,1,8,
Hippocampus,BAO_0000221,818,H,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,Autocuration,,10576,,10085,10000000.0,,,,CHEMBL615818,,,,,B,1,8,
Hippocampus,BAO_0000221,819,H,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,Autocuration,,10576,,10085,10000000.0,,,,CHEMBL615819,,,,,B,1,8,
,BAO_0000249,820,H,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,Expert,,10576,,17331,,,,,CHEMBL615820,,,,Membranes,B,1,8,
Hippocampus,BAO_0000221,821,D,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,Expert,,10576,,10845,10000000.0,10116.0,Rattus norvegicus,,CHEMBL615821,,,,,B,1,9,
Hippocampus,BAO_0000221,822,D,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,Expert,,10576,,10845,10000000.0,10116.0,Rattus norvegicus,,CHEMBL615822,,,,,B,1,9,
Hippocampus,BAO_0000221,823,H,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,Expert,,10576,,10845,10000000.0,,,,CHEMBL615823,,,,,B,1,8,
Hippocampus,BAO_0000221,824,D,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,Expert,,10576,,10845,10000000.0,10116.0,Rattus norvegicus,,CHEMBL615824,,,,,B,1,9,
Hippocampus,BAO_0000221,825,D,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,Expert,,10576,,10845,10000000.0,10116.0,Rattus norvegicus,,CHEMBL615825,,,,,B,1,9,
,BAO_0000357,826,H,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,Expert,,10576,,13730,,,,,CHEMBL615826,,,,,B,1,8,
,BAO_0000249,827,H,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,Expert,,10576,,13508,,,,,CHEMBL615827,,,,,B,1,8,
Hippocampus,BAO_0000249,828,H,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,Expert,,10576,,13508,10000000.0,,,,CHEMBL615828,,,,,B,1,8,
Hippocampus,BAO_0000221,829,H,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,Expert,,10576,,12073,10000000.0,,,,CHEMBL615829,,,,,B,1,8,
Hippocampus,BAO_0000221,830,H,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,Autocuration,,10576,,4671,10000000.0,,,,CHEMBL615830,,,,,B,1,8,
Hippocampus,BAO_0000221,831,H,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,Expert,,10576,,13631,10000000.0,,,,CHEMBL615831,,,,,B,1,8,
,BAO_0000357,832,H,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,Autocuration,,10576,,12438,,,,,CHEMBL615832,,,,,B,1,8,
,BAO_0000019,833,H,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,Autocuration,,10576,,10483,,,,,CHEMBL615833,,,,,B,1,8,
Hippocampus,BAO_0000221,834,H,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,Autocuration,,10576,,10483,10000000.0,,,,CHEMBL615834,,,,,B,1,8,
,BAO_0000249,835,H,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,Intermediate,,10576,,12352,,,,,CHEMBL615835,,,,,B,1,8,
Hippocampus,BAO_0000249,836,H,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,Autocuration,,10576,,14732,10000000.0,,,,CHEMBL615836,,,,,B,1,8,
,BAO_0000019,837,D,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,Expert,,10576,,11049,,10116.0,Rattus norvegicus,,CHEMBL615837,,,,,B,1,9,
,BAO_0000019,838,D,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,Expert,,10576,,11049,,10116.0,Rattus norvegicus,,CHEMBL615838,,,,,B,1,9,
,BAO_0000249,839,H,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",Expert,,10576,,13657,,,,,CHEMBL615839,,,,,B,1,8,
,BAO_0000019,840,H,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,Autocuration,,10576,,11473,,,,,CHEMBL884525,,,,,B,1,8,
,BAO_0000249,841,H,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,Autocuration,,10576,,2014,,,,,CHEMBL615840,,,,,B,1,8,
Hippocampus,BAO_0000221,842,H,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,Expert,,10576,,3086,10000000.0,,,,CHEMBL615405,,,,,B,1,8,
,BAO_0000019,843,H,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,Expert,,10576,,15854,,,,,CHEMBL615406,,,,,B,1,8,
Hippocampus,BAO_0000221,844,H,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,Expert,,10576,,10922,10000000.0,,,,CHEMBL615900,,,,,B,1,8,
Hippocampus,BAO_0000221,845,H,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,Expert,,10576,,13346,10000000.0,,,,CHEMBL615901,,,,,B,1,8,
,BAO_0000357,846,H,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,Expert,,10576,,15311,,,,,CHEMBL615902,,,,,B,1,8,
Hippocampus,BAO_0000221,847,H,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,Autocuration,,10576,,10922,10000000.0,,,,CHEMBL615903,,,,,B,1,8,
,BAO_0000357,848,H,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,Autocuration,,10576,,10025,,,,,CHEMBL615904,,,,,B,1,8,
,BAO_0000357,849,H,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,Expert,,10576,,10025,,,,,CHEMBL615905,,,,,B,1,8,
,BAO_0000019,850,H,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,Autocuration,,10576,,9742,,,,,CHEMBL615906,,,,,B,1,8,
,BAO_0000019,851,H,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,Autocuration,,10576,,9742,,,,,CHEMBL615907,,,,,F,1,8,
,BAO_0000019,852,H,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,Expert,,10576,,12304,,,,,CHEMBL615908,,,,,B,1,8,
Hippocampus,BAO_0000221,853,H,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,Autocuration,,10576,,15789,10000000.0,,,,CHEMBL615909,,,,,B,1,8,
,BAO_0000019,854,H,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",Autocuration,,10576,,9912,,,,,CHEMBL615910,,,,,B,1,8,
,BAO_0000019,855,H,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",Autocuration,,10576,,9912,,,,,CHEMBL615911,,,,,B,1,8,
,BAO_0000019,856,H,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",Autocuration,,10576,,9912,,,,,CHEMBL615912,,,,,B,1,8,
,BAO_0000019,857,H,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,Expert,,10576,,16693,,,,,CHEMBL615913,,,,,B,1,8,
,BAO_0000357,858,H,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,Expert,,10576,,13276,,,,,CHEMBL615914,,,,,B,1,8,
Hippocampus,BAO_0000221,859,H,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,Autocuration,,10576,,12678,10000000.0,,,,CHEMBL615915,,,,,B,1,8,
,BAO_0000357,860,H,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,Autocuration,,10576,,11825,,,,,CHEMBL615916,,,,,B,1,8,
,BAO_0000357,861,H,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,Expert,,10576,,12443,,,,,CHEMBL615917,,,,,B,1,8,
,BAO_0000357,862,H,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,Expert,,10576,,13830,,,,,CHEMBL615918,,,,,B,1,8,
Hippocampus,BAO_0000249,863,H,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,Expert,,10576,,14286,10000000.0,,,,CHEMBL615919,,,,,B,1,8,
Hippocampus,BAO_0000221,864,D,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,Expert,,10576,,14356,10000000.0,10116.0,Rattus norvegicus,,CHEMBL615920,,,,,B,1,9,
,BAO_0000357,865,H,Inhibition concentration against 5-hydroxytryptamine 1A receptor,Autocuration,,10576,,15306,,,,,CHEMBL615921,,,,,B,1,8,
,BAO_0000357,866,H,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),Expert,,10576,,15306,,,,,CHEMBL615922,,,,,B,1,8,
,BAO_0000249,867,D,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",Expert,,10576,,16616,,10116.0,Rattus norvegicus,,CHEMBL881290,,,,,F,1,9,
Hippocampus,BAO_0000221,868,H,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",Autocuration,,10576,,3651,10000000.0,,,,CHEMBL615923,,,,,B,1,8,
Hippocampus,BAO_0000221,869,H,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,Autocuration,,10576,,14331,10000000.0,,,,CHEMBL615924,,,,,F,1,8,
Hippocampus,BAO_0000221,870,H,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,Autocuration,,10576,,14331,10000000.0,,,,CHEMBL615925,,,,,F,1,8,
,BAO_0000357,871,D,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,Expert,,10576,,14178,,10116.0,Rattus norvegicus,,CHEMBL615926,,,,,B,1,9,
,BAO_0000019,872,D,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,Expert,,10576,,10639,,10116.0,Rattus norvegicus,,CHEMBL615927,,,,,B,1,9,
Hippocampus,BAO_0000221,873,H,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Autocuration,,10576,,12306,10000000.0,,,,CHEMBL615928,,,,,B,1,8,
,BAO_0000357,874,D,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,Expert,,10576,,1348,,10116.0,Rattus norvegicus,,CHEMBL615929,,,,,B,1,9,
Hippocampus,BAO_0000221,875,H,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,Autocuration,,10576,,13605,10000000.0,,,,CHEMBL615930,,,,,B,1,8,
,BAO_0000219,876,H,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,Autocuration,449.0,51,,17624,,,,,CHEMBL615931,CHO,,,,B,1,8,
,BAO_0000219,877,H,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,Autocuration,449.0,51,,17624,,,,,CHEMBL615932,CHO,,,,F,1,8,
,BAO_0000219,878,H,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,Autocuration,449.0,51,,17624,,,,,CHEMBL615933,CHO,,,,F,1,8,
,BAO_0000357,879,H,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,Autocuration,,51,,15267,,,,,CHEMBL615934,,,,,B,1,8,
,BAO_0000357,880,H,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,Autocuration,,51,,16532,,,,,CHEMBL615935,,,,,B,1,8,
,BAO_0000019,881,H,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",Autocuration,,51,,6563,,,,,CHEMBL615936,,,,,F,1,8,
,BAO_0000219,882,H,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,Autocuration,449.0,51,,4751,,,,,CHEMBL615937,CHO,,,,B,1,8,
,BAO_0000357,883,H,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,Autocuration,,51,,15463,,,,,CHEMBL615938,,,,,B,1,8,
,BAO_0000357,884,H,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),Autocuration,,51,,3805,,,,,CHEMBL615797,,,,,B,1,8,
,BAO_0000357,885,H,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,51,,5640,,,,,CHEMBL615798,,,,,B,1,8,
,BAO_0000357,886,H,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,Autocuration,,51,,6563,,,,,CHEMBL872870,,,,,B,1,8,
,BAO_0000357,887,H,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,Autocuration,,51,,5548,,,,,CHEMBL615799,,,,,B,1,8,
,BAO_0000357,888,H,Percent binding affinity against 5-hydroxytryptamine 1A receptor,Autocuration,,51,,6347,,,,,CHEMBL615800,,,,,B,1,8,
,BAO_0000219,889,H,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,Autocuration,722.0,51,,17296,,,,,CHEMBL615801,HEK293,,,,F,1,8,
,BAO_0000019,890,H,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,Autocuration,,51,,13047,,,,,CHEMBL615802,,,,,B,1,8,
,BAO_0000357,891,H,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,Autocuration,,51,,15740,,,,,CHEMBL615803,,,,,B,1,8,
,BAO_0000019,892,H,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",Expert,,51,,5640,,,,,CHEMBL835002,,,,,F,1,8,
,BAO_0000019,893,H,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",Autocuration,,51,,5640,,,,,CHEMBL615804,,,,,F,1,8,
,BAO_0000219,894,H,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,Expert,308.0,51,,17211,,,,,CHEMBL615805,HeLa,,,,B,1,8,
,BAO_0000219,895,H,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,Autocuration,449.0,51,,4751,,,,,CHEMBL615806,CHO,,,,B,1,8,
,BAO_0000357,896,D,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,Expert,,51,,6491,,9606.0,Homo sapiens,,CHEMBL615807,,,,,B,1,9,
,BAO_0000357,897,H,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,Autocuration,,51,,4707,,,,,CHEMBL615808,,,,,B,1,8,
,BAO_0000357,898,D,Binding affinity against 5-hydroxytryptamine 1A receptor,Expert,,51,,13910,,9606.0,Homo sapiens,,CHEMBL615809,,,,,B,1,9,
,BAO_0000219,899,H,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,Autocuration,308.0,51,,16190,,,,,CHEMBL615810,HeLa,,,,B,1,8,
,BAO_0000357,900,H,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,51,,16633,,,,,CHEMBL615811,,,,,B,1,8,
,BAO_0000219,901,H,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,Autocuration,449.0,51,,11898,,,,,CHEMBL615812,CHO,,,,B,1,8,
,BAO_0000219,902,H,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,Autocuration,449.0,51,,11898,,,,,CHEMBL615751,CHO,,,,B,1,8,
,BAO_0000357,903,H,Binding affinity against human 5-hydroxytryptamine 1A receptor,Autocuration,,51,,14331,,,,,CHEMBL615752,,,,,B,1,8,
,BAO_0000219,904,H,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,Expert,449.0,51,,17624,,,,,CHEMBL615753,CHO,,,,B,1,8,
,BAO_0000219,905,H,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,Autocuration,449.0,51,,17624,,,,,CHEMBL615754,CHO,,,,B,1,8,
,BAO_0000357,906,H,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,Autocuration,,51,,3307,,,,,CHEMBL615755,,,,,B,1,8,
,BAO_0000219,907,D,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,Expert,449.0,51,,6563,,9606.0,Homo sapiens,,CHEMBL615756,CHO,,,,B,1,9,
,BAO_0000019,908,H,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,Autocuration,,51,,14165,,,,,CHEMBL615757,,,,,B,1,8,
,BAO_0000357,909,H,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,Autocuration,,51,,5732,,,,,CHEMBL615758,,,,,B,1,8,
,BAO_0000357,910,H,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,Expert,,51,,13366,,,,,CHEMBL615759,,,,,B,1,8,
,BAO_0000357,911,H,Binding affinity towards human 5-hydroxytryptamine 1A receptor,Autocuration,,51,,17626,,,,,CHEMBL615760,,,,,B,1,8,
,BAO_0000219,912,H,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,Expert,308.0,51,,6588,,,,,CHEMBL615761,HeLa,,,,B,1,8,
,BAO_0000357,913,H,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,Autocuration,,51,,16209,,,,,CHEMBL872104,,,,,B,1,8,
,BAO_0000357,914,H,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,Autocuration,,51,,15463,,,,,CHEMBL615762,,,,,B,1,8,
,BAO_0000357,915,H,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,Autocuration,,51,,15463,,,,,CHEMBL615763,,,,,B,1,8,
,BAO_0000357,916,H,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,Autocuration,,51,,14770,,,,,CHEMBL615764,,,,,B,1,8,
,BAO_0000219,917,H,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),Autocuration,1167.0,51,,16245,,,,,CHEMBL615765,Cell line,,,,B,1,8,
,BAO_0000019,918,H,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),Autocuration,,51,,16245,,,,,CHEMBL615766,,,,,B,1,8,
,BAO_0000357,919,H,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,51,,5548,,,,,CHEMBL615767,,,,,B,1,8,
,BAO_0000357,920,H,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Expert,,51,,5548,,,,,CHEMBL615768,,,,,B,1,8,
,BAO_0000357,921,H,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,51,,5548,,,,,CHEMBL615769,,,,,B,1,8,
,BAO_0000357,922,H,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,Expert,,51,,6876,,,,,CHEMBL615770,,,,,B,1,8,
,BAO_0000357,923,H,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,51,,2598,,,,,CHEMBL615771,,,,,B,1,8,
,BAO_0000357,924,H,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,Expert,,51,,17785,,,,,CHEMBL615772,,,,,B,1,8,
,BAO_0000357,925,H,Binding affinity towards 5-hydroxytryptamine 1A receptor,Autocuration,,51,,6013,,,,,CHEMBL615773,,,,,B,1,8,
,BAO_0000357,926,H,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,Expert,,51,,5929,,,,,CHEMBL615774,,,,,B,1,8,
,BAO_0000357,927,H,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,51,,16633,,,,,CHEMBL615775,,,,,B,1,8,
,BAO_0000357,928,H,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,Autocuration,,51,,1558,,,,,CHEMBL615776,,,,,B,1,8,
,BAO_0000357,929,H,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Expert,,51,,16026,,,,,CHEMBL615777,,,,,B,1,8,
,BAO_0000219,930,H,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,Autocuration,,51,,12469,,,,,CHEMBL615778,,,,,B,1,8,
,BAO_0000357,931,D,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,Expert,,51,,15874,,9606.0,Homo sapiens,,CHEMBL615779,,,,,B,1,9,
,BAO_0000357,932,H,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,Autocuration,,51,,15874,,,,,CHEMBL615780,,,,,B,1,8,
,BAO_0000357,933,H,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,Autocuration,,51,,3935,,,,,CHEMBL616298,,,,,B,1,8,
,BAO_0000357,934,H,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,Autocuration,,51,,15818,,,,,CHEMBL616299,,,,,B,1,8,
,BAO_0000219,935,H,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,Autocuration,485.0,51,,13706,,,,,CHEMBL616300,CHO-K1,,,,B,1,8,
,BAO_0000219,936,H,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,Expert,485.0,51,,13729,,,,,CHEMBL616301,CHO-K1,,,,F,1,8,
,BAO_0000019,937,H,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,Autocuration,,51,,15413,,,,,CHEMBL616302,,,,,B,1,8,
,BAO_0000019,938,H,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),Autocuration,,51,,15413,,,,,CHEMBL616117,,,,,B,1,8,
,BAO_0000019,939,H,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),Autocuration,,51,,15413,,,,,CHEMBL616118,,,,,B,1,8,
,BAO_0000019,940,H,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,Autocuration,,51,,15413,,,,,CHEMBL616119,,,,,B,1,8,
,BAO_0000219,941,D,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,Expert,308.0,51,,3445,,9606.0,Homo sapiens,,CHEMBL616120,HeLa,,,,B,1,9,
,BAO_0000357,942,H,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,Autocuration,,51,,15740,,,,,CHEMBL616121,,,,,B,1,8,
,BAO_0000357,943,H,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,Autocuration,,51,,15740,,,,,CHEMBL616122,,,,,B,1,8,
,BAO_0000357,944,H,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,Autocuration,,51,,17626,,,,,CHEMBL616123,,,,,B,1,8,
,BAO_0000357,945,D,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,Expert,,51,,4234,,9606.0,Homo sapiens,,CHEMBL616124,,,,,B,1,9,
,BAO_0000357,946,H,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,Expert,,51,,5640,,,,,CHEMBL616125,,,,,B,1,8,
,BAO_0000357,947,H,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,Expert,,51,,5272,,10116.0,Rattus norvegicus,,CHEMBL616126,,,,,B,1,8,
,BAO_0000219,948,H,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,Autocuration,449.0,51,,4622,,,,,CHEMBL616127,CHO,,,,B,1,8,
,BAO_0000019,949,H,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,Expert,,51,,17085,,,,,CHEMBL616128,,,,,B,1,8,
,BAO_0000357,950,H,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,Autocuration,,51,,3025,,,,,CHEMBL616129,,,,,B,1,8,
,BAO_0000357,951,H,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,Expert,,51,,15315,,,,,CHEMBL616130,,,,,B,1,8,
,BAO_0000357,952,H,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,Autocuration,,51,,15267,,,,,CHEMBL616131,,,,,B,1,8,
,BAO_0000219,953,H,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,Autocuration,308.0,51,,17158,,,,,CHEMBL616132,HeLa,,,,B,1,8,
,BAO_0000219,954,D,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,Expert,308.0,51,,14214,,9606.0,Homo sapiens,,CHEMBL616133,HeLa,,,,B,1,9,
,BAO_0000357,955,H,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,51,,17133,,,,,CHEMBL616134,,,,,B,1,8,
,BAO_0000357,956,H,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,Autocuration,,51,,16532,,,,,CHEMBL616135,,,,,B,1,8,
,BAO_0000357,957,D,Affinity for 5-hydroxytryptamine 1A receptor subtype,Expert,,51,,2391,,9606.0,Homo sapiens,,CHEMBL616136,,,,,B,1,9,
,BAO_0000019,958,H,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,Autocuration,,51,,14447,,,,,CHEMBL616137,,,,,B,1,8,
,BAO_0000019,959,H,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,Autocuration,,51,,14447,,,,,CHEMBL872105,,,,,B,1,8,
,BAO_0000357,960,H,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,Autocuration,,51,,15086,,,,,CHEMBL616138,,,,,B,1,8,
,BAO_0000357,961,D,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,Expert,,51,,13051,,9606.0,Homo sapiens,,CHEMBL616139,,,,,B,1,9,
,BAO_0000019,962,H,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",Autocuration,,51,,16026,,,,,CHEMBL616140,,,,,F,1,8,
,BAO_0000019,963,H,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,Expert,,51,,17085,,,,,CHEMBL616141,,,,,B,1,8,
,BAO_0000357,964,H,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,51,,17133,,,,,CHEMBL616142,,,,,B,1,8,
,BAO_0000357,965,H,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,Autocuration,,51,,17133,,,,,CHEMBL616143,,,,,B,1,8,
,BAO_0000219,966,H,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,Autocuration,308.0,51,,17211,,,,,CHEMBL616144,HeLa,,,,B,1,8,
,BAO_0000219,967,H,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,Autocuration,308.0,51,,17211,,,,,CHEMBL616145,HeLa,,,,B,1,8,
,BAO_0000219,968,H,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,Autocuration,308.0,51,,17211,,,,,CHEMBL616012,HeLa,,,,B,1,8,
,BAO_0000219,969,H,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,Autocuration,308.0,51,,17211,,,,,CHEMBL616013,HeLa,,,,B,1,8,
,BAO_0000019,970,H,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",Autocuration,,51,,16394,,,,,CHEMBL616014,,,,,F,1,8,
,BAO_0000019,971,H,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",Autocuration,,51,,16394,,,,,CHEMBL616015,,,,,F,1,8,
,BAO_0000019,972,H,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",Autocuration,,51,,16394,,,,,CHEMBL616016,,,,,F,1,8,
,BAO_0000218,973,H,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,Autocuration,,51,,16394,,,,,CHEMBL616017,,,In vivo,,F,1,8,
,BAO_0000019,974,H,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,Autocuration,,51,,16394,,,,,CHEMBL616018,,,,,B,1,8,
,BAO_0000019,975,H,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,Autocuration,,51,,15740,,,,,CHEMBL616019,,,,,F,1,8,
,BAO_0000019,976,H,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,Autocuration,,51,,15740,,,,,CHEMBL616020,,,,,F,1,8,
,BAO_0000357,977,H,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,Autocuration,,51,,15740,,,,,CHEMBL858018,,,,,B,1,8,
,BAO_0000219,978,H,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,Autocuration,722.0,51,,17296,,,,,CHEMBL616021,HEK293,,,,F,1,8,
,BAO_0000019,979,H,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",Expert,,51,,5640,,,,,CHEMBL616022,,,,,F,1,8,
,BAO_0000019,980,H,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",Autocuration,,51,,5640,,,,,CHEMBL616023,,,,,F,1,8,
,BAO_0000019,981,H,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",Autocuration,,51,,5640,,,,,CHEMBL616024,,,,,F,1,8,
,BAO_0000019,982,H,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",Autocuration,,51,,5640,,,,,CHEMBL616025,,,,,F,1,8,
,BAO_0000219,983,H,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,Autocuration,449.0,51,,2759,,,,,CHEMBL616026,CHO,,,,F,1,8,
,BAO_0000019,984,H,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",Autocuration,,51,,16394,,,,,CHEMBL616027,,,,,F,1,8,
,BAO_0000019,985,D,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",Expert,,51,,16394,,9606.0,Homo sapiens,,CHEMBL616028,,,,,F,1,9,
,BAO_0000019,986,D,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,Expert,,51,,3445,,9606.0,Homo sapiens,,CHEMBL616029,,,,,F,1,9,
,BAO_0000219,987,H,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,Expert,449.0,51,,4316,,,,,CHEMBL616030,CHO,,,,B,1,8,
,BAO_0000019,988,H,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,Expert,,51,,4316,,,,,CHEMBL616031,,,,,B,1,8,
,BAO_0000019,989,D,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,Expert,,51,,15180,,9606.0,Homo sapiens,,CHEMBL616032,,,,,F,1,9,
,BAO_0000019,990,D,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,Expert,,51,,15180,,9606.0,Homo sapiens,,CHEMBL616033,,,,,F,1,9,
,BAO_0000019,991,H,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,Autocuration,,51,,15042,,,,,CHEMBL616034,,,,,F,1,8,
,BAO_0000019,992,H,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,Autocuration,,51,,15042,,,,,CHEMBL616035,,,,,F,1,8,
,BAO_0000019,993,H,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,Autocuration,,51,,15042,,,,,CHEMBL616036,,,,,F,1,8,
,BAO_0000019,994,H,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,Autocuration,,51,,15042,,,,,CHEMBL616037,,,,,F,1,8,
,BAO_0000019,995,H,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,Autocuration,,51,,15042,,,,,CHEMBL616038,,,,,F,1,8,
,BAO_0000019,996,H,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,Autocuration,,51,,15042,,,,,CHEMBL616039,,,,,F,1,8,
,BAO_0000019,997,H,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,Autocuration,,51,,15042,,,,,CHEMBL616040,,,,,F,1,8,
,BAO_0000219,998,D,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,Expert,308.0,51,,15180,,9606.0,Homo sapiens,,CHEMBL616041,HeLa,,,,F,1,9,
,BAO_0000219,999,D,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,Expert,308.0,51,,15180,,9606.0,Homo sapiens,,CHEMBL616042,HeLa,,,,F,1,9,
,BAO_0000219,1000,D,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,Expert,308.0,51,,15180,,9606.0,Homo sapiens,,CHEMBL616043,HeLa,,,,F,1,9,
,BAO_0000019,1001,H,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",Autocuration,,51,,16245,,,,,CHEMBL616044,,,,,F,1,8,
,BAO_0000019,1002,H,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",Autocuration,,51,,16026,,,,,CHEMBL616045,,,,,F,1,8,
,BAO_0000219,1003,H,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,Autocuration,722.0,51,,17296,,,,,CHEMBL616046,HEK293,,,,F,1,8,
,BAO_0000219,1004,H,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),Autocuration,449.0,51,,2759,,,,,CHEMBL616047,CHO,,,,F,1,8,
,BAO_0000219,1005,H,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,Autocuration,449.0,51,,2759,,,,,CHEMBL616048,CHO,,,,F,1,8,
,BAO_0000219,1006,D,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),Expert,449.0,51,,2759,,9606.0,Homo sapiens,,CHEMBL616049,CHO,,,,F,1,9,
,BAO_0000219,1007,H,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),Autocuration,449.0,51,,2759,,,,,CHEMBL616050,CHO,,,,F,1,8,
,BAO_0000219,1008,H,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,Expert,,51,,15419,,,,,CHEMBL616051,,,,,F,1,8,
,BAO_0000219,1009,H,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,Autocuration,,51,,15419,,,,,CHEMBL616212,,,,,F,1,8,
,BAO_0000019,1010,H,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",Autocuration,,51,,16026,,,,,CHEMBL616213,,,,,F,1,8,
,BAO_0000219,1011,H,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,Expert,,51,,1414,,,,,CHEMBL616214,,,In vitro,,B,1,8,
,BAO_0000219,1012,H,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,Expert,,51,,1414,,,,,CHEMBL616215,,,In vitro,,B,1,8,
,BAO_0000357,1013,H,Binding activity radioligand.,Autocuration,,51,,12861,,,,,CHEMBL616216,,,,,B,1,8,
,BAO_0000019,1014,H,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,Autocuration,,51,,12861,,,,,CHEMBL616217,,,,,B,1,8,
,BAO_0000357,1015,H,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,Autocuration,,51,,5104,,,,,CHEMBL616218,,,,,B,1,8,
,BAO_0000357,1016,H,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,Autocuration,,51,,5105,,,,,CHEMBL616219,,,,,B,1,8,
,BAO_0000357,1017,H,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,Autocuration,,51,,16312,,,,,CHEMBL616220,,,,,B,1,8,
,BAO_0000357,1018,D,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,Expert,,51,,15180,,9606.0,Homo sapiens,,CHEMBL833493,,,,,B,1,9,
,BAO_0000357,1019,H,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,Autocuration,,51,,5033,,,,,CHEMBL616221,,,,,B,1,8,
,BAO_0000219,1020,D,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,Expert,449.0,51,,16909,,9606.0,Homo sapiens,,CHEMBL616222,CHO,,,,B,1,9,
,BAO_0000019,1021,H,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,Autocuration,,51,,2590,,,,,CHEMBL616223,,,,,F,1,8,
,BAO_0000019,1022,H,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,Autocuration,,51,,2590,,,,,CHEMBL616224,,,,,F,1,8,
,BAO_0000019,1023,H,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,Expert,,51,,16394,,,,,CHEMBL616225,,,,,B,1,8,
,BAO_0000219,1024,D,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,Expert,722.0,51,,4540,,9606.0,Homo sapiens,,CHEMBL616226,HEK293,,,,B,1,9,
,BAO_0000219,1025,H,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,Autocuration,722.0,51,,17296,,,,,CHEMBL616227,HEK293,,,,B,1,8,
,BAO_0000219,1026,H,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,Autocuration,722.0,51,,17296,,,,,CHEMBL616228,HEK293,,,,B,1,8,
,BAO_0000219,1027,H,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,Autocuration,722.0,51,,15779,,,,,CHEMBL616229,HEK293,,,,B,1,8,
,BAO_0000219,1028,H,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,Autocuration,722.0,51,,15779,,,,,CHEMBL616230,HEK293,,,,B,1,8,
,BAO_0000219,1029,H,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,Autocuration,722.0,51,,15779,,,,,CHEMBL616231,HEK293,,,,B,1,8,
,BAO_0000357,1030,H,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,Autocuration,,51,,6166,,,,,CHEMBL616232,,,,,B,1,8,
,BAO_0000219,1031,H,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,Autocuration,722.0,51,,15779,,,,,CHEMBL616233,HEK293,,,,B,1,8,
,BAO_0000219,1032,H,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,Autocuration,722.0,51,,4199,,,,,CHEMBL857973,HEK293,,,,B,1,8,
,BAO_0000219,1033,H,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,Autocuration,,51,,15316,,,,,CHEMBL616234,,,,,B,1,8,
,BAO_0000357,1034,H,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,Autocuration,,51,,14875,,,,,CHEMBL616235,,,,,B,1,8,
,BAO_0000219,1035,H,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,Expert,308.0,51,,14727,,,,,CHEMBL616236,HeLa,,,,B,1,8,
,BAO_0000019,1036,H,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,Expert,,51,,14727,,,,,CHEMBL616237,,,,,B,1,8,
,BAO_0000219,1037,H,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,Autocuration,722.0,51,,15146,,,,,CHEMBL616238,HEK293,,,,B,1,8,
,BAO_0000219,1038,H,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,Autocuration,722.0,51,,5213,,,,,CHEMBL616239,HEK293,,,,B,1,8,
,BAO_0000219,1039,H,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,Autocuration,,51,,16429,,,,,CHEMBL616240,,,,,B,1,8,
,BAO_0000219,1040,D,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,Expert,308.0,51,,15042,,9606.0,Homo sapiens,,CHEMBL616241,HeLa,,,,B,1,9,
,BAO_0000219,1041,H,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,Autocuration,722.0,51,,14818,,,,,CHEMBL616242,HEK293,,,,B,1,8,
,BAO_0000219,1042,H,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",Autocuration,722.0,51,,4829,,,,,CHEMBL616243,HEK293,,,,B,1,8,
,BAO_0000357,1043,D,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,Expert,,51,,17200,,,,,CHEMBL616244,,,,,B,1,9,
,BAO_0000357,1044,D,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,Autocuration,,51,,13051,,9606.0,Homo sapiens,,CHEMBL616245,,,,,B,1,9,
,BAO_0000357,1045,H,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,Autocuration,,106,,5486,,,,,CHEMBL616246,,,,,B,1,8,
,BAO_0000357,1046,H,Binding affinity against 5-HT1D receptor,Autocuration,,105,,5254,,,,,CHEMBL616247,,,,,B,1,8,
,BAO_0000357,1047,H,Binding affinity against 5-hydroxytryptamine 1A receptor,Autocuration,,105,,5254,,,,,CHEMBL616248,,,,,B,1,8,
,BAO_0000357,1048,H,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,Autocuration,,107,,15331,,,,,CHEMBL616249,,,,,B,1,8,
,BAO_0000357,1049,H,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,Autocuration,,10576,,13506,,9606.0,Homo sapiens,,CHEMBL616250,,,,,B,1,8,
,BAO_0000357,1050,H,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,Autocuration,,51,,15267,,,,,CHEMBL616251,,,,,B,1,8,
,BAO_0000218,1051,H,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,Autocuration,,11863,,16616,,,,,CHEMBL616252,,,In vivo,,F,1,8,
,BAO_0000218,1052,H,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,Autocuration,,11863,,16616,,,,,CHEMBL616253,,,In vivo,,F,1,8,
,BAO_0000218,1053,H,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,Autocuration,,11863,,16616,,,,,CHEMBL616254,,,In vivo,,F,1,8,
,BAO_0000218,1054,D,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,Expert,,11863,,16616,,10090.0,Mus musculus,,CHEMBL616255,,,,,F,1,9,
,BAO_0000218,1055,D,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,Expert,,11863,,16616,,10090.0,Mus musculus,,CHEMBL832872,,,,,F,1,9,
,BAO_0000218,1056,D,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,Expert,,11863,,16616,,10090.0,Mus musculus,,CHEMBL616256,,,,,F,1,9,
,BAO_0000218,1057,D,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,Expert,,11863,,16616,,10090.0,Mus musculus,,CHEMBL616257,,,,,F,1,9,
,BAO_0000218,1058,D,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,Expert,,11863,,16616,,10090.0,Mus musculus,,CHEMBL616258,,,,,F,1,9,
,BAO_0000218,1059,D,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,Expert,,11863,,16616,,10090.0,Mus musculus,,CHEMBL616384,,,,,F,1,9,
Hippocampus,BAO_0000221,1060,H,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,Autocuration,,11863,,10297,10000000.0,,,,CHEMBL616385,,,,,B,1,8,
,BAO_0000357,1061,H,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,Expert,,11863,,13704,,,,,CHEMBL616386,,,,,B,1,8,
Hippocampus,BAO_0000221,1062,D,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,Expert,,11863,,10297,10000000.0,10090.0,Mus musculus,,CHEMBL616387,,,,,B,1,9,
Hippocampus,BAO_0000221,1063,H,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,Autocuration,,11863,,10297,10000000.0,,,,CHEMBL616388,,,,,B,1,8,
Hippocampus,BAO_0000221,1064,D,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,Expert,,11863,,10297,10000000.0,10090.0,Mus musculus,,CHEMBL616389,,,,,B,1,9,
Hippocampus,BAO_0000221,1065,H,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,Autocuration,,11863,,10297,10000000.0,,,,CHEMBL616390,,,,,B,1,8,
,BAO_0000357,1066,H,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,Autocuration,,11863,,217,,,,,CHEMBL616391,,,,,B,1,8,
Hippocampus,BAO_0000221,1067,D,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,Expert,,11863,,10297,10000000.0,10090.0,Mus musculus,,CHEMBL616392,,,,,B,1,9,
,BAO_0000357,1068,H,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,Autocuration,,51,,4921,,9823.0,Sus scrofa,,CHEMBL616393,,,,,B,1,8,
,BAO_0000357,1069,H,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,Autocuration,,51,,4921,,9823.0,Sus scrofa,,CHEMBL616394,,,,,B,1,8,
,BAO_0000019,1070,H,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,Autocuration,,51,,4996,,9823.0,Sus scrofa,,CHEMBL616395,,,,,B,1,8,
,BAO_0000357,1071,H,Compound was evaluated for the binding affinity at 5- HT1A receptor,Autocuration,,51,,12918,,9823.0,Sus scrofa,,CHEMBL616396,,,,,B,1,8,
,BAO_0000019,1072,H,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,Autocuration,,51,,5333,,9823.0,Sus scrofa,,CHEMBL872907,,,,,B,1,8,
,BAO_0000019,1073,H,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,Autocuration,,51,,4437,,9823.0,Sus scrofa,,CHEMBL616397,,,,,B,1,8,
,BAO_0000019,1074,H,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,Autocuration,,51,,1742,,9823.0,Sus scrofa,,CHEMBL616398,,,,,B,1,8,
,BAO_0000357,1075,H,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,Expert,,51,,16688,,9823.0,Sus scrofa,,CHEMBL616399,,,,,B,1,8,
,BAO_0000357,1076,H,Binding activity radioligand.,Autocuration,,51,,12861,,9823.0,Sus scrofa,,CHEMBL857065,,,,,B,1,8,
,BAO_0000019,1077,H,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,Expert,,51,,12861,,9823.0,Sus scrofa,,CHEMBL616400,,,,,B,1,8,
,BAO_0000019,1078,H,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,Autocuration,,51,,12861,,9823.0,Sus scrofa,,CHEMBL616401,,,,,B,1,8,
,BAO_0000019,1079,H,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,Expert,,10624,,12490,,,,,CHEMBL616402,,,,,B,1,8,
,BAO_0000019,1080,H,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,Expert,,51,,11828,,9823.0,Sus scrofa,,CHEMBL616403,,,,,B,1,8,
Hippocampus,BAO_0000221,1081,H,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,Autocuration,,51,,11866,10000000.0,9823.0,Sus scrofa,,CHEMBL616404,,,,,B,1,8,
,BAO_0000249,1082,H,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,Autocuration,,51,,12827,,9823.0,Sus scrofa,,CHEMBL616405,,,,,B,1,8,
,BAO_0000019,1083,H,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,Autocuration,,51,,12918,,9823.0,Sus scrofa,,CHEMBL616406,,,,,B,1,8,
,BAO_0000019,1084,H,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,Expert,,51,,12919,,9823.0,Sus scrofa,,CHEMBL616407,,,,,F,1,8,
,BAO_0000019,1085,H,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,Autocuration,,51,,13047,,9986.0,Oryctolagus cuniculus,,CHEMBL616408,,,,,B,1,8,
,BAO_0000249,1086,D,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,Expert,,10576,,15796,,10116.0,Rattus norvegicus,,CHEMBL616409,,,,,B,1,9,
Hippocampus,BAO_0000221,1087,D,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",Expert,,10576,,3651,10000000.0,10116.0,Rattus norvegicus,,CHEMBL616410,,,,,B,1,9,
,BAO_0000357,1088,H,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,Autocuration,,10576,,188,,,,,CHEMBL616411,,,,,B,1,8,
,BAO_0000249,1089,D,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",Expert,,10576,,16616,,10116.0,Rattus norvegicus,,CHEMBL616412,,,,Membranes,F,1,9,
Hippocampus,BAO_0000249,1090,D,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",Expert,,10576,,16616,10000000.0,10116.0,Rattus norvegicus,,CHEMBL616413,,,,Membranes,F,1,9,
Hippocampus,BAO_0000221,1091,H,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Autocuration,,10576,,12306,10000000.0,,,,CHEMBL616414,,,,,B,1,8,
Hippocampus,BAO_0000221,1092,D,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,Expert,,10576,,17167,10000000.0,10116.0,Rattus norvegicus,,CHEMBL616415,,,,,B,1,9,
,BAO_0000019,1093,H,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,Autocuration,,10576,,14776,,,,,CHEMBL616416,,,,,B,1,8,
,BAO_0000357,1094,H,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,Expert,,10576,,12158,,,,,CHEMBL616417,,,,,B,1,8,
,BAO_0000357,1095,H,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,Autocuration,,10576,,13481,,,,,CHEMBL616418,,,,,B,1,8,
,BAO_0000219,1096,H,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,Autocuration,,10576,,13427,,,,,CHEMBL616419,,,In vitro,,B,1,8,
,BAO_0000357,1097,H,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,Autocuration,,10576,,10210,,,,,CHEMBL616420,,,,,B,1,8,
,BAO_0000249,1098,H,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,Autocuration,,10576,,10205,,,,,CHEMBL616421,,,,Membranes,B,1,8,
,BAO_0000249,1099,H,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,Autocuration,,10576,,10205,,,,,CHEMBL616422,,,,Membranes,B,1,8,
,BAO_0000249,1100,H,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,Expert,,10576,,10205,,,,,CHEMBL616423,,,,Membranes,B,1,8,
,BAO_0000357,1101,D,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,Expert,,10576,,12280,,10116.0,Rattus norvegicus,,CHEMBL616424,,,,,B,1,9,
,BAO_0000357,1102,H,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,Expert,,10576,,17386,,,,,CHEMBL616425,,,,,B,1,8,
,BAO_0000357,1103,H,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,Expert,,10576,,13654,,,,,CHEMBL616426,,,,,B,1,8,
Hippocampus,BAO_0000221,1104,H,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,Autocuration,,10576,,14423,10000000.0,,,,CHEMBL616427,,,,,B,1,8,
Hippocampus,BAO_0000221,1105,H,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,Autocuration,,10576,,15412,10000000.0,,,,CHEMBL616428,,,,,B,1,8,
Hippocampus,BAO_0000221,1106,H,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,Autocuration,,10576,,12073,10000000.0,,,,CHEMBL616290,,,,,B,1,8,
,BAO_0000357,1107,D,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,Expert,,10576,,4101,,10116.0,Rattus norvegicus,,CHEMBL616052,,,,,B,1,9,
,BAO_0000357,1108,H,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,Autocuration,,10576,,10062,,,,,CHEMBL616053,,,,,B,1,8,
,BAO_0000249,1109,H,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,Autocuration,,10576,,6238,,,,,CHEMBL616054,,,,,B,1,8,
,BAO_0000357,1110,H,Binding affinity towards 5-hydroxytryptamine 1A receptor,Autocuration,,10576,,16273,,,,,CHEMBL616055,,,,,B,1,8,
,BAO_0000357,1111,H,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,Autocuration,,10576,,11139,,,,,CHEMBL616056,,,,,B,1,8,
,BAO_0000019,1112,H,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,Expert,,10576,,16796,,,,,CHEMBL616057,,,,,B,1,8,
Brain,BAO_0000221,1113,D,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,Expert,,10576,,9548,955.0,10116.0,Rattus norvegicus,,CHEMBL616058,,,,,B,1,9,
Brain,BAO_0000221,1114,H,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,Autocuration,,10576,,10381,955.0,,,,CHEMBL616059,,,,,B,1,8,
,BAO_0000249,1115,H,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,Autocuration,,10576,,13408,,,,,CHEMBL616060,,,,,B,1,8,
Hippocampus,BAO_0000221,1116,D,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,Expert,,10576,,13825,10000000.0,10116.0,Rattus norvegicus,,CHEMBL616061,,,,,B,1,9,
Hippocampus,BAO_0000221,1117,H,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,Expert,,10576,,11147,10000000.0,,,,CHEMBL616062,,,,,B,1,8,
,BAO_0000249,1118,H,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,Autocuration,,10576,,10552,,,,,CHEMBL616063,,,,,B,1,8,
Striatum,BAO_0000249,1119,H,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",Autocuration,,10576,,10552,2435.0,,,,CHEMBL616064,,,,,B,1,8,
,BAO_0000249,1120,D,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,Expert,,10576,,17136,,10116.0,Rattus norvegicus,,CHEMBL616065,,,,Membranes,B,1,9,
,BAO_0000249,1121,D,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,Expert,,10576,,5778,,10116.0,Rattus norvegicus,,CHEMBL616066,,,,Membranes,B,1,9,
Hippocampus,BAO_0000221,1122,H,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,10576,,13481,10000000.0,,,,CHEMBL616067,,,,,B,1,8,
Hippocampus,BAO_0000221,1123,H,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,Autocuration,,10576,,13481,10000000.0,,,,CHEMBL616068,,,,,B,1,8,
Hippocampus,BAO_0000221,1124,H,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,Intermediate,,10576,,13630,10000000.0,,,,CHEMBL616069,,,,,B,1,8,
,BAO_0000249,1125,H,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,Expert,,10576,,16245,,,,,CHEMBL616070,,,,,B,1,8,
Hippocampus,BAO_0000221,1126,H,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,Autocuration,,10576,,14509,10000000.0,,,,CHEMBL616071,,,,,B,1,8,
Hippocampus,BAO_0000221,1127,H,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,Expert,,10576,,14509,10000000.0,,,,CHEMBL616072,,,,,B,1,8,
Hippocampus,BAO_0000221,1128,H,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,Autocuration,,10576,,14509,10000000.0,,,,CHEMBL616073,,,,,B,1,8,
Hippocampus,BAO_0000221,1129,H,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,Autocuration,,10576,,14509,10000000.0,,,,CHEMBL616074,,,,,B,1,8,
,BAO_0000019,1130,H,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,Expert,,10576,,14256,,,,,CHEMBL616075,,,,,B,1,8,
,BAO_0000357,1131,H,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,Autocuration,,10576,,11139,,,,,CHEMBL616076,,,,,B,1,8,
,BAO_0000019,1132,D,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,Expert,,10576,,11047,,10116.0,Rattus norvegicus,,CHEMBL616077,,,,,B,1,9,
,BAO_0000019,1133,D,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,Expert,,10576,,11047,,10116.0,Rattus norvegicus,,CHEMBL616078,,,,,B,1,9,
,BAO_0000019,1134,D,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,Expert,,10576,,11047,,10116.0,Rattus norvegicus,,CHEMBL616079,,,,,B,1,9,
,BAO_0000219,1135,D,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,Expert,485.0,10576,,2395,,10116.0,Rattus norvegicus,,CHEMBL616080,CHO-K1,,,,B,1,9,
,BAO_0000357,1136,H,Binding affinity towards 5-hydroxytryptamine 1A receptor,Autocuration,,10576,,9699,,,,,CHEMBL616081,,,,,B,1,8,
Hippocampus,BAO_0000221,1137,D,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,Expert,,10576,,12028,10000000.0,10116.0,Rattus norvegicus,,CHEMBL616082,,,,,B,1,9,
Hippocampus,BAO_0000221,1138,H,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,Autocuration,,10576,,12028,10000000.0,,,,CHEMBL616083,,,,,B,1,8,
,BAO_0000019,1139,H,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,Autocuration,,10576,,5815,,,,,CHEMBL616084,,,,,B,1,8,
,BAO_0000019,1140,H,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,Expert,,10576,,16616,,,,,CHEMBL616085,,,,,B,1,8,
,BAO_0000019,1141,H,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,Autocuration,,10576,,5815,,,,,CHEMBL616086,,,,,B,1,8,
Hippocampus,BAO_0000221,1142,H,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",Autocuration,,10576,,2761,10000000.0,,,,CHEMBL616087,,,,,B,1,8,
,BAO_0000357,1143,H,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,Expert,,10576,,13133,,,,,CHEMBL616088,,,,,B,1,8,
,BAO_0000019,1144,H,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,Autocuration,,10576,,10444,,,,,CHEMBL616089,,,,,B,1,8,
,BAO_0000357,1145,D,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,Expert,,10576,,13278,,10116.0,Rattus norvegicus,,CHEMBL616090,,,,,B,1,9,
,BAO_0000357,1146,H,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,Autocuration,,10576,,15874,,,,,CHEMBL616091,,,,,B,1,8,
Striatum,BAO_0000249,1147,H,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",Autocuration,,10576,,10552,2435.0,,,,CHEMBL616092,,,,Membranes,B,1,8,
,BAO_0000357,1148,H,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),Autocuration,,10576,,11130,,,,,CHEMBL616093,,,,,B,1,8,
,BAO_0000218,1149,H,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),Autocuration,,10576,,11130,,,,,CHEMBL616094,,,In vivo,,B,1,8,
Brain,BAO_0000221,1150,H,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,Autocuration,,10576,,14542,955.0,,,,CHEMBL616095,,,,,B,1,8,
,BAO_0000357,1151,D,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,Expert,,10576,,13670,,10116.0,Rattus norvegicus,,CHEMBL616096,,,,,B,1,9,
,BAO_0000249,1152,H,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,Expert,,10576,,9888,,,,,CHEMBL616097,,,,,B,1,8,
,BAO_0000249,1153,D,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,Expert,,10576,,3678,,10116.0,Rattus norvegicus,,CHEMBL616098,,,,Membranes,B,1,9,
Hippocampus,BAO_0000221,1154,H,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,Autocuration,,10576,,11332,10000000.0,,,,CHEMBL616099,,,,,B,1,8,
Hippocampus,BAO_0000221,1155,H,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,Autocuration,,10576,,11332,10000000.0,,,,CHEMBL616100,,,,,B,1,8,
,BAO_0000357,1156,H,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,Expert,,10576,,1185,,,,,CHEMBL616101,,,,,B,1,8,
,BAO_0000249,1157,H,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,Expert,,10576,,2014,,,,,CHEMBL616102,,,,,B,1,8,
,BAO_0000357,1158,H,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,Autocuration,,10576,,1185,,,,,CHEMBL616103,,,,,B,1,8,
,BAO_0000019,1159,H,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,Expert,,10576,,14429,,,,,CHEMBL616104,,,,,B,1,8,
,BAO_0000019,1160,H,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",Expert,,10576,,16288,,,,,CHEMBL616105,,,,,B,1,8,
,BAO_0000019,1161,D,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,Expert,,10576,,5432,,10116.0,Rattus norvegicus,,CHEMBL616106,,,,,B,1,9,
,BAO_0000019,1162,H,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,Autocuration,,10576,,14429,,,,,CHEMBL616107,,,,,B,1,8,
,BAO_0000357,1163,H,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,Expert,,10576,,13672,,,,,CHEMBL616108,,,,,B,1,8,
Hippocampus,BAO_0000221,1164,H,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,Expert,,10576,,11296,10000000.0,,,,CHEMBL616109,,,,,B,1,8,
,BAO_0000357,1165,H,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,Autocuration,,10576,,11296,,,,,CHEMBL616110,,,,,B,1,8,
,BAO_0000219,1166,H,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,Expert,449.0,10576,,14749,,,,,CHEMBL616111,CHO,,,,B,1,8,
,BAO_0000019,1167,H,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,Expert,,10576,,15086,,,,,CHEMBL616112,,,,,B,1,8,
Hippocampus,BAO_0000221,1168,H,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,Autocuration,,10576,,13462,10000000.0,,,,CHEMBL616113,,,,,B,1,8,
,BAO_0000019,1169,H,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,Autocuration,,10576,,15363,,,,,CHEMBL616114,,,,,B,1,8,
,BAO_0000019,1170,H,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,Autocuration,,10576,,15363,,,,,CHEMBL616115,,,,,B,1,8,
,BAO_0000357,1171,H,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,Autocuration,,10576,,10796,,,,,CHEMBL616116,,,,,B,1,8,
Brain,BAO_0000221,1172,H,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,Expert,,10576,,12816,955.0,,,,CHEMBL615844,,,,,B,1,8,
Hippocampus,BAO_0000221,1173,H,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,Expert,,10576,,13542,10000000.0,,,,CHEMBL615939,,,,,B,1,8,
,BAO_0000019,1174,H,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,Expert,,10576,,13308,,,,,CHEMBL615940,,,,,B,1,8,
Hippocampus,BAO_0000221,1175,H,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,Expert,,10576,,13541,10000000.0,,,,CHEMBL615941,,,,,B,1,8,
Hippocampus,BAO_0000221,1176,H,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,Autocuration,,10576,,10058,10000000.0,,,,CHEMBL615942,,,,,B,1,8,
Hippocampus,BAO_0000221,1177,H,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,Autocuration,,10576,,10058,10000000.0,,,,CHEMBL615943,,,,,B,1,8,
Hippocampus,BAO_0000221,1178,H,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,Autocuration,,10576,,10058,10000000.0,,,,CHEMBL615944,,,,,B,1,8,
Hippocampus,BAO_0000221,1179,H,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,Autocuration,,10576,,10058,10000000.0,,,,CHEMBL615945,,,,,B,1,8,
Hippocampus,BAO_0000221,1180,H,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,Autocuration,,10576,,10058,10000000.0,,,,CHEMBL615946,,,,,B,1,8,
Hippocampus,BAO_0000221,1181,H,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,Autocuration,,10576,,10058,10000000.0,,,,CHEMBL615947,,,,,B,1,8,
Hippocampus,BAO_0000221,1182,H,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,Autocuration,,10576,,10058,10000000.0,,,,CHEMBL615948,,,,,B,1,8,
Hippocampus,BAO_0000221,1183,H,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,Autocuration,,10576,,10058,10000000.0,,,,CHEMBL615949,,,,,B,1,8,
Hippocampus,BAO_0000221,1184,H,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,Autocuration,,10576,,10058,10000000.0,,,,CHEMBL615950,,,,,B,1,8,
Hippocampus,BAO_0000221,1185,H,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,Autocuration,,10576,,10058,10000000.0,,,,CHEMBL615951,,,,,B,1,8,
Hippocampus,BAO_0000221,1186,H,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,Autocuration,,10576,,10058,10000000.0,,,,CHEMBL615952,,,,,B,1,8,
Hippocampus,BAO_0000221,1187,H,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,Autocuration,,10576,,10058,10000000.0,,,,CHEMBL615953,,,,,B,1,8,
Hippocampus,BAO_0000221,1188,H,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,Autocuration,,10576,,10058,10000000.0,,,,CHEMBL615954,,,,,B,1,8,
Hippocampus,BAO_0000221,1189,D,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,Expert,,10576,,10058,10000000.0,10116.0,Rattus norvegicus,,CHEMBL615955,,,,,B,1,9,
Hippocampus,BAO_0000221,1190,H,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,Autocuration,,10576,,10058,10000000.0,,,,CHEMBL615956,,,,,B,1,8,
Hippocampus,BAO_0000221,1191,H,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,Autocuration,,10576,,10058,10000000.0,,,,CHEMBL615957,,,,,B,1,8,
,BAO_0000019,1192,H,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,Expert,,10576,,12879,,,,,CHEMBL615958,,,,,B,1,8,
,BAO_0000019,1193,H,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,Expert,,10576,,11964,,,,,CHEMBL615959,,,,,B,1,8,
,BAO_0000019,1194,H,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),Autocuration,,10576,,11964,,,,,CHEMBL615960,,,,,B,1,8,
,BAO_0000019,1195,H,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),Autocuration,,10576,,11964,,,,,CHEMBL615961,,,,,B,1,8,
Brain,BAO_0000221,1196,H,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,Expert,,10576,,9548,955.0,,,,CHEMBL615962,,,,,B,1,8,
,BAO_0000019,1197,H,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,Expert,,10576,,9098,,,,,CHEMBL615963,,,,,B,1,8,
,BAO_0000019,1198,H,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,Autocuration,,10576,,9098,,,,,CHEMBL615964,,,,,B,1,8,
,BAO_0000019,1199,H,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,Autocuration,,10576,,9098,,,,,CHEMBL615965,,,,,B,1,8,
,BAO_0000219,1200,H,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,Expert,449.0,10576,,13248,,,,,CHEMBL615966,CHO,,,,B,1,8,
,BAO_0000249,1201,H,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,Expert,,10576,,3147,,,,,CHEMBL615967,,,,,B,1,8,
,BAO_0000019,1202,H,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,Expert,,10576,,13949,,,,,CHEMBL615968,,,,,B,1,8,
,BAO_0000218,1203,H,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),Autocuration,449.0,10576,,11883,,,,,CHEMBL615969,CHO,,,,B,1,8,
,BAO_0000218,1204,H,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),Autocuration,,10576,,11883,,,,,CHEMBL615970,,,,,B,1,8,
,BAO_0000357,1205,D,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,Expert,,10576,,11883,,10116.0,Rattus norvegicus,,CHEMBL615971,,,,,B,1,9,
,BAO_0000249,1206,H,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,Expert,,10576,,15535,,,,,CHEMBL615972,,,,Membranes,B,1,8,
,BAO_0000249,1207,H,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,Autocuration,,10576,,15535,,,,,CHEMBL615973,,,,,B,1,8,
,BAO_0000249,1208,H,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,Autocuration,,10576,,15535,,,,,CHEMBL615974,,,,,B,1,8,
,BAO_0000219,1209,D,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,Expert,449.0,51,,16372,,9606.0,Homo sapiens,,CHEMBL615975,CHO,,,,B,1,9,
,BAO_0000249,1210,H,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,Expert,,10576,,14608,,,,,CHEMBL615976,,,,,B,1,8,
Hippocampus,BAO_0000221,1211,D,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,Expert,,10576,,4795,10000000.0,10116.0,Rattus norvegicus,,CHEMBL872106,,,,,B,1,9,
,BAO_0000357,1212,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,Autocuration,,10576,,13863,,,,,CHEMBL615977,,,,,B,1,8,
,BAO_0000357,1213,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,Autocuration,,10576,,13863,,,,,CHEMBL615978,,,,,B,1,8,
,BAO_0000357,1214,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,Autocuration,,10576,,13863,,,,,CHEMBL616166,,,,,B,1,8,
,BAO_0000357,1215,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,Autocuration,,10576,,13863,,,,,CHEMBL616167,,,,,B,1,8,
,BAO_0000357,1216,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,Autocuration,,10576,,13863,,,,,CHEMBL616168,,,,,B,1,8,
,BAO_0000357,1217,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,Autocuration,,10576,,13863,,,,,CHEMBL616169,,,,,B,1,8,
,BAO_0000357,1218,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,Autocuration,,10576,,13863,,,,,CHEMBL616170,,,,,B,1,8,
,BAO_0000357,1219,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,Autocuration,,10576,,13863,,,,,CHEMBL616171,,,,,B,1,8,
,BAO_0000357,1220,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,Autocuration,,10576,,13863,,,,,CHEMBL616172,,,,,B,1,8,
,BAO_0000357,1221,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,Autocuration,,10576,,13863,,,,,CHEMBL616173,,,,,B,1,8,
,BAO_0000357,1222,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,Autocuration,,10576,,13863,,,,,CHEMBL616174,,,,,B,1,8,
,BAO_0000357,1223,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,Autocuration,,10576,,13863,,,,,CHEMBL616175,,,,,B,1,8,
,BAO_0000357,1224,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,Autocuration,,10576,,13863,,,,,CHEMBL616176,,,,,B,1,8,
,BAO_0000357,1225,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,Autocuration,,10576,,13863,,,,,CHEMBL616177,,,,,B,1,8,
,BAO_0000357,1226,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,Autocuration,,10576,,13863,,,,,CHEMBL616178,,,,,B,1,8,
,BAO_0000019,1227,H,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,Autocuration,,10576,,9742,,,,,CHEMBL616179,,,,,B,1,8,
,BAO_0000357,1228,H,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,Autocuration,,10576,,12073,,,,,CHEMBL616180,,,,,B,1,8,
,BAO_0000357,1229,H,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,Autocuration,,10576,,4101,,,,,CHEMBL616181,,,,,B,1,8,
,BAO_0000019,1230,H,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,Autocuration,,10576,,15360,,,,,CHEMBL616182,,,,,B,1,8,
Hippocampus,BAO_0000221,1231,H,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,Autocuration,,10576,,11576,10000000.0,,,,CHEMBL616183,,,,,B,1,8,
,BAO_0000019,1232,H,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,Expert,,10576,,5834,,,,,CHEMBL615874,,,,,B,1,8,
,BAO_0000219,1233,D,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,Expert,485.0,10576,,2395,,10116.0,Rattus norvegicus,,CHEMBL615875,CHO-K1,,,,B,1,9,
,BAO_0000019,1234,H,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,Autocuration,,10576,,1375,,,,,CHEMBL615876,,,,,B,1,8,
,BAO_0000019,1235,H,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,Autocuration,,10576,,1375,,,,,CHEMBL615877,,,,,B,1,8,
,BAO_0000357,1236,H,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),Autocuration,,10576,,3967,,,,,CHEMBL615878,,,,,B,1,8,
,BAO_0000357,1237,H,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,Expert,,10576,,12884,,,,,CHEMBL615879,,,,,B,1,8,
,BAO_0000357,1238,H,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,Expert,,10576,,2343,,,,,CHEMBL615880,,,,,B,1,8,
,BAO_0000019,1239,H,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",Autocuration,,10576,,11511,,,,,CHEMBL615881,,,,,B,1,8,
,BAO_0000019,1240,D,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",Expert,,10576,,11511,,10116.0,Rattus norvegicus,,CHEMBL615882,,,,,B,1,9,
,BAO_0000218,1241,H,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,Autocuration,,10576,,16394,,,,,CHEMBL615883,,,In vivo,,F,1,8,
,BAO_0000218,1242,H,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),Autocuration,,10576,,16394,,,,,CHEMBL615884,,,In vivo,,F,1,8,
,BAO_0000218,1243,H,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),Autocuration,,10576,,16394,,,,,CHEMBL615885,,,In vivo,,F,1,8,
,BAO_0000218,1244,H,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),Autocuration,,10576,,16394,,,,,CHEMBL615886,,,In vivo,,F,1,8,
,BAO_0000218,1245,H,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),Autocuration,,10576,,16394,,,,,CHEMBL615887,,,In vivo,,F,1,8,
,BAO_0000218,1246,H,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),Autocuration,,10576,,16394,,,,,CHEMBL615888,,,In vivo,,F,1,8,
,BAO_0000218,1247,H,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),Autocuration,,10576,,16394,,,,,CHEMBL615889,,,In vivo,,F,1,8,
,BAO_0000218,1248,H,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),Autocuration,,10576,,16394,,,,,CHEMBL615890,,,In vivo,,F,1,8,
,BAO_0000218,1249,H,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),Autocuration,,10576,,16394,,,,,CHEMBL615891,,,In vivo,,F,1,8,
,BAO_0000218,1250,H,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),Autocuration,,10576,,16394,,,,,CHEMBL615892,,,In vivo,,F,1,8,
,BAO_0000218,1251,H,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),Autocuration,,10576,,16394,,,,,CHEMBL615893,,,In vivo,,F,1,8,
,BAO_0000218,1252,H,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),Autocuration,,10576,,16394,,,,,CHEMBL615894,,,In vivo,,F,1,8,
,BAO_0000218,1253,H,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),Autocuration,,10576,,16394,,,,,CHEMBL615895,,,In vivo,,F,1,8,
,BAO_0000218,1254,H,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),Autocuration,,10576,,16394,,,,,CHEMBL615896,,,In vivo,,F,1,8,
,BAO_0000218,1255,H,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,Autocuration,,10576,,16394,,,,,CHEMBL615897,,,In vivo,,F,1,8,
,BAO_0000249,1256,D,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",Expert,,10576,,16616,,10116.0,Rattus norvegicus,,CHEMBL615898,,,,Membranes,F,1,9,
,BAO_0000019,1257,H,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,Autocuration,,10576,,16796,,,,,CHEMBL615899,,,,,B,1,8,
,BAO_0000019,1258,H,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,Autocuration,,10576,,16796,,,,,CHEMBL616291,,,,,B,1,8,
,BAO_0000357,1259,H,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,Autocuration,,10576,,15629,,,,,CHEMBL616292,,,,,B,1,8,
,BAO_0000249,1260,H,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",Autocuration,,10576,,13241,,,,,CHEMBL616293,,,,,F,1,8,
Hippocampus,BAO_0000221,1261,H,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,Expert,,10576,,12073,10000000.0,,,,CHEMBL616294,,,,,B,1,8,
Hippocampus,BAO_0000249,1262,H,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,Autocuration,,10576,,14286,10000000.0,,,,CHEMBL616295,,,,,B,1,8,
Brain,BAO_0000221,1263,H,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,Autocuration,,10576,,14542,955.0,,,,CHEMBL616296,,,,,B,1,8,
,BAO_0000019,1264,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,Autocuration,,10576,,13630,,,,,CHEMBL616297,,,,,F,1,8,
,BAO_0000019,1265,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,Autocuration,,10576,,13630,,,,,CHEMBL616605,,,,,F,1,8,
,BAO_0000019,1266,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,Autocuration,,10576,,13630,,,,,CHEMBL616606,,,,,F,1,8,
,BAO_0000019,1267,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,Autocuration,,10576,,13630,,,,,CHEMBL616607,,,,,F,1,8,
,BAO_0000019,1268,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,Expert,,10576,,13630,,,,,CHEMBL616608,,,,,F,1,8,
,BAO_0000019,1269,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,Autocuration,,10576,,13630,,,,,CHEMBL616609,,,,,F,1,8,
,BAO_0000019,1270,D,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,Expert,,10576,,13630,,10116.0,Rattus norvegicus,,CHEMBL616610,,,,,F,1,9,
,BAO_0000019,1271,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,Autocuration,,10576,,13630,,,,,CHEMBL616611,,,,,F,1,8,
,BAO_0000019,1272,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,Expert,,10576,,13630,,,,,CHEMBL616612,,,,,F,1,8,
,BAO_0000019,1273,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,Autocuration,,10576,,13630,,,,,CHEMBL616613,,,,,F,1,8,
,BAO_0000019,1274,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,Expert,,10576,,13630,,,,,CHEMBL616614,,,,,F,1,8,
,BAO_0000019,1275,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,Autocuration,,10576,,13630,,,,,CHEMBL616615,,,,,F,1,8,
,BAO_0000019,1276,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,Expert,,10576,,13630,,,,,CHEMBL616616,,,,,F,1,8,
,BAO_0000019,1277,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,Autocuration,,10576,,13630,,,,,CHEMBL616617,,,,,F,1,8,
,BAO_0000019,1278,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,Autocuration,,10576,,13630,,,,,CHEMBL616618,,,,,F,1,8,
,BAO_0000019,1279,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,Autocuration,,10576,,13630,,,,,CHEMBL616619,,,,,F,1,8,
,BAO_0000019,1280,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,Expert,,10576,,13630,,,,,CHEMBL616620,,,,,F,1,8,
,BAO_0000019,1281,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,Expert,,10576,,13630,,,,,CHEMBL616621,,,,,F,1,8,
,BAO_0000019,1282,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,Autocuration,,10576,,13630,,,,,CHEMBL616622,,,,,F,1,8,
,BAO_0000019,1283,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,Expert,,10576,,13630,,,,,CHEMBL616146,,,,,F,1,8,
,BAO_0000019,1284,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,Autocuration,,10576,,13630,,,,,CHEMBL832873,,,,,F,1,8,
,BAO_0000019,1285,H,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,Autocuration,,10576,,13630,,,,,CHEMBL616147,,,,,F,1,8,
,BAO_0000019,1286,H,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,Autocuration,,10576,,13630,,,,,CHEMBL872872,,,,,F,1,8,
,BAO_0000019,1287,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,Autocuration,,10576,,13630,,,,,CHEMBL616148,,,,,F,1,8,
Hippocampus,BAO_0000221,1288,H,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,Autocuration,,10576,,9783,10000000.0,,,,CHEMBL616149,,,,,B,1,8,
Hippocampus,BAO_0000221,1289,H,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,Expert,,10576,,9783,10000000.0,,,,CHEMBL616150,,,,,B,1,8,
,BAO_0000249,1290,D,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,Expert,,10576,,14331,,10116.0,Rattus norvegicus,,CHEMBL616151,,,,Membranes,B,1,9,
Hippocampus,BAO_0000221,1291,H,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,Expert,,10576,,15260,10000000.0,,,,CHEMBL872873,,,,,B,1,8,
Hippocampus,BAO_0000221,1292,H,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,Autocuration,,10576,,15260,10000000.0,,,,CHEMBL616670,,,,,B,1,8,
Hippocampus,BAO_0000221,1293,H,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,Autocuration,,10576,,15260,10000000.0,,,,CHEMBL616671,,,,,B,1,8,
,BAO_0000249,1294,D,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",Expert,,10576,,16616,,10116.0,Rattus norvegicus,,CHEMBL884861,,,,,F,1,9,
,BAO_0000357,1295,H,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,Autocuration,,10576,,15629,,,,,CHEMBL616672,,,,,B,1,8,
,BAO_0000019,1296,H,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,Autocuration,,10576,,15086,,,,,CHEMBL616673,,,,,B,1,8,
,BAO_0000019,1297,H,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,Expert,,10576,,5717,,,,,CHEMBL616674,,,,,F,1,8,
,BAO_0000357,1298,H,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,Autocuration,,10576,,12652,,,,,CHEMBL616675,,,,,B,1,8,
Hippocampus,BAO_0000221,1299,H,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,Autocuration,,10576,,14608,10000000.0,,,,CHEMBL616676,,,,,B,1,8,
Hippocampus,BAO_0000221,1300,H,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Autocuration,,10576,,12306,10000000.0,,,,CHEMBL616677,,,,,B,1,8,
Hippocampus,BAO_0000221,1301,H,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Autocuration,,10576,,12306,10000000.0,,,,CHEMBL616678,,,,,B,1,8,
,BAO_0000357,1302,D,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,Expert,,10576,,15247,,10116.0,Rattus norvegicus,,CHEMBL616679,,,,,B,1,9,
Hippocampus,BAO_0000221,1303,H,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,Expert,,10576,,17529,10000000.0,,,,CHEMBL616680,,,,,B,1,8,
Hippocampus,BAO_0000221,1304,H,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,Autocuration,,10576,,14826,10000000.0,,,,CHEMBL616681,,,,,B,1,8,
Hippocampus,BAO_0000221,1305,H,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,Autocuration,,10576,,14826,10000000.0,,,,CHEMBL616682,,,,,B,1,8,
Hippocampus,BAO_0000221,1306,H,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,Autocuration,,10576,,13241,10000000.0,,,,CHEMBL616683,,,,,B,1,8,
Hippocampus,BAO_0000221,1307,H,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,Autocuration,,10576,,14093,10000000.0,,,,CHEMBL616684,,,,,B,1,8,
Hippocampus,BAO_0000221,1308,H,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,Autocuration,,10576,,14093,10000000.0,,,,CHEMBL616685,,,,,B,1,8,
Brain,BAO_0000221,1309,H,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,Autocuration,,10576,,14442,955.0,,,,CHEMBL616686,,,,,B,1,8,
,BAO_0000357,1310,H,Affinity for 5-hydroxytryptamine 1A receptor site,Autocuration,,10576,,9919,,,,,CHEMBL616687,,,,,B,1,8,
,BAO_0000357,1311,H,Affinity for 5-hydroxytryptamine 1A receptor site,Autocuration,,10576,,9919,,,,,CHEMBL616688,,,,,B,1,8,
Hippocampus,BAO_0000221,1312,H,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,Autocuration,,10576,,11440,10000000.0,,,,CHEMBL616689,,,,,B,1,8,
,BAO_0000357,1313,H,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,Autocuration,,10576,,11257,,,,,CHEMBL616690,,,,,B,1,8,
,BAO_0000357,1314,H,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,Expert,,10576,,10330,,,,,CHEMBL616691,,,,,B,1,8,
Hippocampus,BAO_0000221,1315,D,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,Expert,,10576,,17331,10000000.0,10116.0,Rattus norvegicus,,CHEMBL616692,,,,,B,1,9,
,BAO_0000249,1316,H,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,Expert,,10576,,16567,,,,,CHEMBL616693,,,,,B,1,8,
,BAO_0000019,1317,D,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",Expert,,10576,,12058,,10116.0,Rattus norvegicus,,CHEMBL616694,,,,,B,1,9,
Hippocampus,BAO_0000221,1318,H,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,Autocuration,,10576,,9699,10000000.0,,,,CHEMBL616695,,,,,B,1,8,
,BAO_0000357,1319,H,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,Autocuration,,10576,,9547,,,,,CHEMBL616696,,,,,B,1,8,
,BAO_0000357,1320,H,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,Autocuration,,10576,,10330,,,,,CHEMBL616697,,,,,B,1,8,
,BAO_0000357,1321,H,Binding affinity against rat 5-hydroxytryptamine 1A receptor,Autocuration,,10576,,14331,,,,,CHEMBL616698,,,,,B,1,8,
,BAO_0000019,1322,D,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,Expert,,10576,,14060,,10116.0,Rattus norvegicus,,CHEMBL616949,,,,,B,1,9,
Hippocampus,BAO_0000221,1323,H,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,Autocuration,,10576,,14744,10000000.0,,,,CHEMBL616950,,,,,B,1,8,
,BAO_0000357,1324,H,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,Autocuration,,10576,,13506,,,,,CHEMBL832875,,,,,B,1,8,
Brain,BAO_0000221,1325,H,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,Expert,,10576,,10862,955.0,,,,CHEMBL616951,,,,,B,1,8,
Brain,BAO_0000221,1326,H,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,Expert,,10576,,10862,955.0,,,,CHEMBL616952,,,,,B,1,8,
,BAO_0000357,1327,H,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,Expert,,10576,,10062,,,,,CHEMBL616953,,,,,B,1,8,
,BAO_0000357,1328,H,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,Autocuration,,10576,,12073,,,,,CHEMBL616954,,,,,B,1,8,
,BAO_0000357,1329,H,GTPgammaS radioligand binding assay,Autocuration,,106,,14875,,,,,CHEMBL616955,,,,,B,1,8,
,BAO_0000357,1330,H,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,Autocuration,,106,,2391,,,,,CHEMBL616956,,,,,B,1,8,
,BAO_0000019,1331,H,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,Autocuration,,106,,2391,,,,,CHEMBL616957,,,,,F,1,8,
,BAO_0000019,1332,H,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,Autocuration,,106,,2391,,,,,CHEMBL616958,,,,,F,1,8,
,BAO_0000357,1333,H,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,Autocuration,,106,,2391,,,,,CHEMBL616959,,,,,B,1,8,
,BAO_0000357,1334,H,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,Autocuration,,106,,2391,,,,,CHEMBL616960,,,,,B,1,8,
,BAO_0000019,1335,H,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,Autocuration,,106,,2391,,,,,CHEMBL616961,,,,,F,1,8,
,BAO_0000219,1336,H,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,Expert,308.0,106,,17211,,,,,CHEMBL616962,HeLa,,,,B,1,8,
,BAO_0000219,1337,H,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,Autocuration,308.0,106,,17211,,,,,CHEMBL616963,HeLa,,,,B,1,8,
,BAO_0000357,1338,D,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,Expert,,106,,6491,,9606.0,Homo sapiens,,CHEMBL616524,,,,,B,1,9,
,BAO_0000219,1339,H,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,Autocuration,449.0,106,,16190,,,,,CHEMBL616525,CHO,,,,B,1,8,
,BAO_0000019,1340,H,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,Autocuration,,106,,14165,,,,,CHEMBL872908,,,,,B,1,8,
,BAO_0000019,1341,H,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,Autocuration,,106,,14165,,,,,CHEMBL616526,,,,,B,1,8,
,BAO_0000357,1342,D,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,Expert,,106,,4234,,9606.0,Homo sapiens,,CHEMBL616527,,,,,B,1,9,
,BAO_0000219,1343,H,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,Expert,,106,,6328,,,,,CHEMBL616528,,,,,B,1,8,
,BAO_0000357,1344,H,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,Autocuration,,106,,14770,,,,,CHEMBL616529,,,,,B,1,8,
,BAO_0000357,1345,H,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,Autocuration,,106,,2598,,,,,CHEMBL616530,,,,,B,1,8,
,BAO_0000357,1346,H,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,Expert,,106,,6897,,,,,CHEMBL616531,,,,,B,1,8,
,BAO_0000357,1347,H,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,Autocuration,,106,,6897,,,,,CHEMBL616532,,,,,B,1,8,
,BAO_0000357,1348,H,Binding affinity towards 5-hydroxytryptamine 1B receptor,Autocuration,,106,,6013,,,,,CHEMBL616533,,,,,B,1,8,
,BAO_0000357,1349,H,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,Expert,,106,,5843,,,,,CHEMBL616534,,,,,B,1,8,
,BAO_0000357,1350,H,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,Expert,,106,,14454,,,,,CHEMBL616535,,,,,B,1,8,
,BAO_0000357,1351,H,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,Autocuration,,106,,16209,,,,,CHEMBL616536,,,,,B,1,8,
,BAO_0000357,1352,H,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,Autocuration,,106,,3935,,,,,CHEMBL616537,,,,,B,1,8,
,BAO_0000219,1353,H,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,Expert,485.0,106,,13729,,,,,CHEMBL616538,CHO-K1,,,,F,1,8,
,BAO_0000019,1354,H,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,Expert,,106,,14251,,,,,CHEMBL616539,,,,,F,1,8,
,BAO_0000019,1355,H,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,Expert,,106,,17085,,,,,CHEMBL616540,,,,,B,1,8,
,BAO_0000357,1356,H,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,Autocuration,,106,,3025,,,,,CHEMBL616429,,,,,B,1,8,
,BAO_0000357,1357,H,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,Expert,,106,,15315,,,,,CHEMBL616430,,,,,B,1,8,
,BAO_0000219,1358,D,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,Expert,,106,,14214,,9606.0,Homo sapiens,,CHEMBL616431,,,,,B,1,9,
,BAO_0000357,1359,D,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,Expert,,106,,3804,,9606.0,Homo sapiens,,CHEMBL616432,,,,,B,1,9,
,BAO_0000357,1360,D,Affinity for 5-hydroxytryptamine 1B receptor subtype,Expert,,106,,2391,,9606.0,Homo sapiens,,CHEMBL616433,,,,,B,1,9,
,BAO_0000357,1361,D,Binding affinity for human 5-hydroxytryptamine 1B receptor,Expert,,106,,4175,,9606.0,Homo sapiens,,CHEMBL616434,,,,,B,1,9,
,BAO_0000219,1362,H,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,Autocuration,449.0,106,,17296,,,,,CHEMBL616435,CHO,,,,B,1,8,
,BAO_0000019,1363,H,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,Expert,,106,,17085,,,,,CHEMBL616436,,,,,B,1,8,
,BAO_0000219,1364,H,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,Autocuration,308.0,106,,17211,,,,,CHEMBL616437,HeLa,,,,B,1,8,
,BAO_0000219,1365,H,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,Autocuration,308.0,106,,17211,,,,,CHEMBL616438,HeLa,,,,B,1,8,
,BAO_0000219,1366,H,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,Autocuration,308.0,106,,17211,,,,,CHEMBL616439,HeLa,,,,B,1,8,
,BAO_0000357,1367,D,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,Expert,,106,,15926,,9606.0,Homo sapiens,,CHEMBL616440,,,,,B,1,9,
,BAO_0000219,1368,H,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,Autocuration,485.0,106,,16312,,,,,CHEMBL616441,CHO-K1,,,,B,1,8,
,BAO_0000357,1369,H,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,Expert,,106,,5843,,,,,CHEMBL616442,,,,,B,1,8,
,BAO_0000357,1370,H,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,Autocuration,,106,,5843,,,,,CHEMBL616443,,,,,B,1,8,
,BAO_0000219,1371,H,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,Expert,485.0,106,,16312,,,,,CHEMBL616444,CHO-K1,,,,B,1,8,
,BAO_0000357,1372,D,Binding activity against human 5-hydroxytryptamine 1B receptor,Expert,,106,,15926,,9606.0,Homo sapiens,,CHEMBL616445,,,,,B,1,9,
,BAO_0000357,1373,D,Binding activity against human 5-hydroxytryptamine 1B receptor,Expert,,106,,15926,,9606.0,Homo sapiens,,CHEMBL616446,,,,,B,1,9,
,BAO_0000219,1374,D,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,Expert,449.0,106,,4540,,9606.0,Homo sapiens,,CHEMBL616447,CHO,,,,B,1,9,
,BAO_0000357,1375,H,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,Autocuration,,106,,6166,,,,,CHEMBL616448,,,,,B,1,8,
,BAO_0000219,1376,H,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,Autocuration,449.0,106,,17296,,,,,CHEMBL616449,CHO,,,,B,1,8,
,BAO_0000219,1377,H,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,Autocuration,449.0,106,,17296,,,,,CHEMBL616450,CHO,,,,B,1,8,
,BAO_0000219,1378,H,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,Autocuration,449.0,106,,17296,,,,,CHEMBL857974,CHO,,,,B,1,8,
,BAO_0000219,1379,H,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,Autocuration,449.0,106,,15779,,,,,CHEMBL616451,CHO,,,,B,1,8,
,BAO_0000219,1380,H,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,Autocuration,449.0,106,,15779,,,,,CHEMBL616452,CHO,,,,B,1,8,
,BAO_0000219,1381,H,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,Autocuration,449.0,106,,15779,,,,,CHEMBL616453,CHO,,,,B,1,8,
,BAO_0000219,1382,H,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,Autocuration,449.0,106,,4199,,,,,CHEMBL616454,CHO,,,,B,1,8,
,BAO_0000357,1383,D,Binding affinity for human 5-hydroxytryptamine 1B receptor,Expert,,106,,14875,,9606.0,Homo sapiens,,CHEMBL616455,,,,,B,1,9,
,BAO_0000219,1384,H,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,Autocuration,449.0,106,,15146,,,,,CHEMBL616456,CHO,,,,B,1,8,
,BAO_0000357,1385,H,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,Autocuration,,106,,5213,,,,,CHEMBL616457,,,,,B,1,8,
,BAO_0000219,1386,H,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,Autocuration,449.0,106,,14818,,,,,CHEMBL616458,CHO,,,,B,1,8,
,BAO_0000219,1387,H,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",Autocuration,449.0,106,,4829,,,,,CHEMBL616459,CHO,,,,B,1,8,
,BAO_0000019,1388,H,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,Expert,,106,,14454,,,,,CHEMBL616460,,,,,F,1,8,
,BAO_0000019,1389,H,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,Expert,,106,,14454,,,,,CHEMBL616461,,,,,F,1,8,
,BAO_0000219,1390,H,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",Autocuration,449.0,106,,14875,,,,,CHEMBL616462,CHO,,,,F,1,8,
,BAO_0000219,1391,H,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",Autocuration,449.0,106,,14875,,,,,CHEMBL616463,CHO,,,,F,1,8,
,BAO_0000019,1392,H,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",Autocuration,,105,,15250,,,,,CHEMBL616464,,,,,F,1,8,
,BAO_0000219,1393,H,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,Autocuration,449.0,105,,15250,,,,,CHEMBL616465,CHO,,,,B,1,8,
,BAO_0000357,1394,H,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,Autocuration,,17105,,15086,,,,,CHEMBL832874,,,,,B,1,8,
,BAO_0000019,1395,H,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,Autocuration,,106,,3025,,9986.0,Oryctolagus cuniculus,,CHEMBL616184,,,,,F,1,8,
,BAO_0000019,1396,H,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,Autocuration,,106,,14998,,9986.0,Oryctolagus cuniculus,,CHEMBL616185,,,,,B,1,8,
,BAO_0000019,1397,H,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",Intermediate,,106,,14998,,9986.0,Oryctolagus cuniculus,,CHEMBL616186,,,,,B,1,8,
,BAO_0000019,1398,H,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,Autocuration,,106,,14998,,9986.0,Oryctolagus cuniculus,,CHEMBL616187,,,,,B,1,8,
,BAO_0000357,1399,H,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,Expert,,10577,,13969,,,,,CHEMBL616188,,,,,B,1,8,
,BAO_0000357,1400,D,Binding affinity for 5-hydroxytryptamine 1B receptor,Intermediate,,10577,,13392,,,,,CHEMBL873475,,,,,B,1,9,
Striatum,BAO_0000019,1401,D,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,Expert,,10577,,3651,2435.0,10116.0,Rattus norvegicus,,CHEMBL616189,,,,,B,1,9,
,BAO_0000357,1402,H,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,Expert,,10577,,10025,,,,,CHEMBL616190,,,,,B,1,8,
,BAO_0000357,1403,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,Autocuration,,10576,,13863,,,,,CHEMBL616191,,,,,B,1,8,
,BAO_0000357,1404,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,Autocuration,,10576,,13863,,,,,CHEMBL616192,,,,,B,1,8,
,BAO_0000357,1405,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,Autocuration,,10576,,13863,,,,,CHEMBL616193,,,,,B,1,8,
,BAO_0000357,1406,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,Autocuration,,10576,,13863,,,,,CHEMBL616194,,,,,B,1,8,
,BAO_0000357,1407,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,Autocuration,,10576,,13863,,,,,CHEMBL616195,,,,,B,1,8,
,BAO_0000357,1408,H,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,Autocuration,,10576,,13863,,,,,CHEMBL616196,,,,,B,1,8,
Hippocampus,BAO_0000249,1409,H,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,Autocuration,,10576,,4622,10000000.0,,,,CHEMBL616197,,,,,B,1,8,
,BAO_0000019,1410,H,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,Intermediate,,10576,,14911,,,,,CHEMBL616198,,,,,B,1,8,
Hippocampus,BAO_0000221,1411,H,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,Autocuration,,10576,,12678,10000000.0,,,,CHEMBL616199,,,,,B,1,8,
Hippocampus,BAO_0000221,1412,H,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,Expert,,10576,,12678,10000000.0,,,,CHEMBL616200,,,,,B,1,8,
Hippocampus,BAO_0000221,1413,H,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,Expert,,10576,,14235,10000000.0,,,,CHEMBL616201,,,,,B,1,8,
Hippocampus,BAO_0000221,1414,H,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,Expert,,10576,,14949,10000000.0,,,,CHEMBL616202,,,,,B,1,8,
Hippocampus,BAO_0000221,1415,H,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,Expert,,10576,,14949,10000000.0,,,,CHEMBL616203,,,,,B,1,8,
Hippocampus,BAO_0000221,1416,H,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,Expert,,10576,,14949,10000000.0,,,,CHEMBL616204,,,,,B,1,8,
Hippocampus,BAO_0000221,1417,H,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,Expert,,10576,,14949,10000000.0,,,,CHEMBL616205,,,,,B,1,8,
Hippocampus,BAO_0000221,1418,H,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,Expert,,10576,,14949,10000000.0,,,,CHEMBL616206,,,,,B,1,8,
,BAO_0000249,1419,H,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,Expert,,10576,,16118,,,,,CHEMBL616207,,,,,B,1,8,
,BAO_0000249,1420,H,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,Autocuration,,10576,,3268,,,,,CHEMBL616208,,,,,B,1,8,
,BAO_0000249,1421,H,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,Autocuration,,10576,,3268,,,,,CHEMBL616209,,,,,B,1,8,
,BAO_0000357,1422,H,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,Expert,,10576,,16117,,,,,CHEMBL616210,,,,,B,1,8,
Hippocampus,BAO_0000221,1423,H,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,Expert,,10576,,9783,10000000.0,,,,CHEMBL616211,,,,,B,1,8,
Hippocampus,BAO_0000221,1424,H,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,Autocuration,,10576,,9783,10000000.0,,,,CHEMBL616504,,,,,B,1,8,
Hippocampus,BAO_0000221,1425,D,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,Expert,,10576,,14356,10000000.0,10116.0,Rattus norvegicus,,CHEMBL616505,,,,,B,1,9,
,BAO_0000019,1426,H,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,Autocuration,,10576,,15740,,,,,CHEMBL616506,,,,,F,1,8,
Hippocampus,BAO_0000221,1427,H,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Autocuration,,10576,,12306,10000000.0,,,,CHEMBL872107,,,,,B,1,8,
Hippocampus,BAO_0000221,1428,D,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,Expert,,10576,,13348,10000000.0,10116.0,Rattus norvegicus,,CHEMBL616507,,,,,B,1,9,
,BAO_0000249,1429,H,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,Autocuration,,10576,,10394,,,,,CHEMBL616303,,,,,B,1,8,
Hippocampus,BAO_0000221,1430,H,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,Autocuration,,10576,,15260,10000000.0,,,,CHEMBL616304,,,,,B,1,8,
Hippocampus,BAO_0000221,1431,H,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,Expert,,10576,,10046,10000000.0,,,,CHEMBL616305,,,,,B,1,8,
Hippocampus,BAO_0000221,1432,H,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,Intermediate,,10576,,15260,10000000.0,,,,CHEMBL616306,,,,,F,1,8,
,BAO_0000357,1433,H,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,Autocuration,,10576,,12851,,,,,CHEMBL616307,,,,,B,1,8,
Hippocampus,BAO_0000221,1434,D,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,Expert,,10576,,2148,10000000.0,10116.0,Rattus norvegicus,,CHEMBL881829,,,,,B,1,9,
,BAO_0000357,1435,H,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,Expert,,10576,,13134,,,,,CHEMBL616308,,,,,B,1,8,
,BAO_0000019,1436,H,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,Autocuration,,10576,,12462,,,,,CHEMBL616309,,,,,B,1,8,
,BAO_0000019,1437,H,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,Expert,,10576,,12462,,,,,CHEMBL616310,,,,,B,1,8,
,BAO_0000219,1438,H,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,Autocuration,449.0,10576,,12462,,,,,CHEMBL616311,CHO,,,,B,1,8,
,BAO_0000357,1439,H,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,Expert,,10576,,11933,,,,,CHEMBL616312,,,,,B,1,8,
,BAO_0000357,1440,H,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,Autocuration,,10576,,11933,,,,,CHEMBL616313,,,,,B,1,8,
Hippocampus,BAO_0000221,1441,D,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,Expert,,10576,,403,10000000.0,10116.0,Rattus norvegicus,,CHEMBL616314,,,,,B,1,9,
Hippocampus,BAO_0000221,1442,H,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,Autocuration,,10576,,15538,10000000.0,,,,CHEMBL616315,,,,,B,1,8,
Hippocampus,BAO_0000221,1443,H,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,Autocuration,,10576,,15538,10000000.0,,,,CHEMBL616567,,,,,B,1,8,
Hippocampus,BAO_0000221,1444,H,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,Autocuration,,10576,,15538,10000000.0,,,,CHEMBL616568,,,,,B,1,8,
,BAO_0000019,1445,H,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,Intermediate,,10576,,12464,,,,,CHEMBL616569,,,,,B,1,8,
,BAO_0000357,1446,H,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,Expert,,10576,,1455,,,,,CHEMBL616570,,,,,B,1,8,
,BAO_0000357,1447,H,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,Autocuration,,10576,,12652,,,,,CHEMBL616571,,,,,B,1,8,
Hippocampus,BAO_0000221,1448,H,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,Autocuration,,10576,,12639,10000000.0,,,,CHEMBL616572,,,,,B,1,8,
,BAO_0000249,1449,H,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,Expert,,10576,,13949,,,,,CHEMBL616573,,,,,B,1,8,
,BAO_0000357,1450,D,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,Expert,,10576,,12463,,10116.0,Rattus norvegicus,,CHEMBL616574,,,,,B,1,9,
Hippocampus,BAO_0000221,1451,H,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,Expert,,10576,,14829,10000000.0,,,,CHEMBL616575,,,,,B,1,8,
Hippocampus,BAO_0000221,1452,H,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,Autocuration,,10576,,14829,10000000.0,,,,CHEMBL872108,,,,,B,1,8,
,BAO_0000357,1453,H,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,Autocuration,,10576,,12092,,,,,CHEMBL616576,,,,,B,1,8,
,BAO_0000249,1454,H,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,Autocuration,,10576,,403,,,,,CHEMBL616577,,,,,B,1,8,
,BAO_0000249,1455,H,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,Autocuration,,10576,,403,,,,,CHEMBL616578,,,,,B,1,8,
,BAO_0000357,1456,H,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,Expert,,10576,,3967,,,,,CHEMBL616579,,,,,B,1,8,
,BAO_0000019,1457,D,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,Expert,,10576,,12771,,10116.0,Rattus norvegicus,,CHEMBL616580,,,,,B,1,9,
,BAO_0000019,1458,H,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,Autocuration,,10576,,15086,,,,,CHEMBL616581,,,,,B,1,8,
Hippocampus,BAO_0000221,1459,H,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,Autocuration,,10576,,14909,10000000.0,,,,CHEMBL616582,,,,,B,1,8,
Hippocampus,BAO_0000221,1460,H,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,Expert,,10576,,14949,10000000.0,,,,CHEMBL616583,,,,,B,1,8,
Hippocampus,BAO_0000221,1461,D,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,Expert,,10576,,2309,10000000.0,10116.0,Rattus norvegicus,,CHEMBL616584,,,,,B,1,9,
,BAO_0000357,1462,H,Binding affinity towards 5-hydroxytryptamine 1A receptor,Expert,,10576,,4170,,,,,CHEMBL616585,,,,,B,1,8,
Hippocampus,BAO_0000221,1463,D,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,Expert,,10576,,11642,10000000.0,10116.0,Rattus norvegicus,,CHEMBL616586,,,,,B,1,9,
Hippocampus,BAO_0000221,1464,H,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,Autocuration,,10576,,11642,10000000.0,,,,CHEMBL616587,,,,,B,1,8,
Hippocampus,BAO_0000221,1465,H,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,Autocuration,,10576,,12953,10000000.0,,,,CHEMBL616588,,,,,B,1,8,
Hippocampus,BAO_0000221,1466,H,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,Autocuration,,10576,,12953,10000000.0,,,,CHEMBL616589,,,,,B,1,8,
Hippocampus,BAO_0000221,1467,H,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,Expert,,10576,,12953,10000000.0,,,,CHEMBL616590,,,,,B,1,8,
,BAO_0000219,1468,H,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",Expert,449.0,10576,,12903,,,,,CHEMBL616591,CHO,,,,B,1,8,
,BAO_0000357,1469,H,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,Expert,,10576,,12536,,,,,CHEMBL616592,,,,,B,1,8,
,BAO_0000357,1470,H,The inhibition activity of 5-HT1A at 1 uM,Autocuration,,10576,,10058,,,,,CHEMBL616593,,,,,B,1,8,
,BAO_0000219,1471,H,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",Expert,485.0,10576,,12902,,,,,CHEMBL616594,CHO-K1,,,,B,1,8,
,BAO_0000249,1472,H,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,Expert,,10576,,14057,,,,,CHEMBL616595,,,,,B,1,8,
,BAO_0000357,1473,H,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,Autocuration,,10576,,11296,,,,,CHEMBL616596,,,,,B,1,8,
Hippocampus,BAO_0000221,1474,H,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,Autocuration,,10576,,11296,10000000.0,,,,CHEMBL616597,,,,,B,1,8,
Hippocampus,BAO_0000221,1475,H,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,Expert,,10576,,11296,10000000.0,,,,CHEMBL616598,,,,,B,1,8,
,BAO_0000249,1476,D,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,Expert,,10576,,16616,,10116.0,Rattus norvegicus,,CHEMBL616599,,,,Membranes,F,1,9,
Hippocampus,BAO_0000249,1477,D,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",Expert,,10576,,16616,10000000.0,10116.0,Rattus norvegicus,,CHEMBL616600,,,,Membranes,F,1,9,
,BAO_0000019,1478,H,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,Autocuration,,10576,,16567,,,,,CHEMBL616601,,,,,B,1,8,
,BAO_0000019,1479,H,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,Autocuration,,10576,,16567,,,,,CHEMBL616602,,,,,B,1,8,
,BAO_0000019,1480,H,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,Autocuration,,10576,,16567,,,,,CHEMBL616603,,,,,B,1,8,
,BAO_0000019,1481,H,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,Autocuration,,10576,,16567,,,,,CHEMBL616604,,,,,B,1,8,
,BAO_0000249,1482,H,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,Autocuration,,10576,,17136,,,,,CHEMBL616316,,,,,B,1,8,
,BAO_0000249,1483,H,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,Autocuration,,10576,,17136,,,,,CHEMBL616317,,,,,B,1,8,
,BAO_0000019,1484,D,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,Expert,,10576,,16616,,10116.0,Rattus norvegicus,,CHEMBL616318,,,,,B,1,9,
Hippocampus,BAO_0000221,1485,H,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,Autocuration,,10576,,17331,10000000.0,,,,CHEMBL616319,,,,,B,1,8,
Hippocampus,BAO_0000221,1486,H,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,Autocuration,,10576,,17331,10000000.0,,,,CHEMBL616320,,,,,B,1,8,
Hippocampus,BAO_0000221,1487,D,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,Expert,,10576,,17167,10000000.0,10116.0,Rattus norvegicus,,CHEMBL616321,,,,,B,1,9,
,BAO_0000019,1488,H,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,Autocuration,,10576,,15740,,,,,CHEMBL616322,,,,,F,1,8,
,BAO_0000019,1489,H,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,Autocuration,,10576,,15740,,,,,CHEMBL616323,,,,,F,1,8,
,BAO_0000357,1490,H,Ratio of binding affinity to 5-HT 1A and D2 receptor,Autocuration,,10576,,4671,,,,,CHEMBL616324,,,,,B,1,8,
Hippocampus,BAO_0000221,1491,H,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,Autocuration,,10576,,10058,10000000.0,,,,CHEMBL616325,,,,,B,1,8,
Hippocampus,BAO_0000221,1492,H,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,Autocuration,,10576,,10058,10000000.0,,,,CHEMBL616326,,,,,B,1,8,
Hippocampus,BAO_0000221,1493,H,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,Autocuration,,10576,,10058,10000000.0,,,,CHEMBL616327,,,,,B,1,8,
,BAO_0000357,1494,H,Percentage inhibition against 5-hydroxytryptamine 1A receptor,Autocuration,,10576,,12073,,,,,CHEMBL616328,,,,,B,1,8,
,BAO_0000249,1495,H,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),Autocuration,,10576,,2759,,,,,CHEMBL858110,,,,,B,1,8,
,BAO_0000249,1496,H,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),Autocuration,,10576,,2759,,,,,CHEMBL616329,,,,,F,1,8,
,BAO_0000249,1497,H,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),Autocuration,,10576,,2759,,,,,CHEMBL616330,,,,,B,1,8,
,BAO_0000249,1498,H,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),Autocuration,,10576,,2759,,,,,CHEMBL616331,,,,,F,1,8,
,BAO_0000249,1499,H,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,Autocuration,,10576,,2759,,,,,CHEMBL616332,,,,,F,1,8,
Brain,BAO_0000249,1500,H,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,Autocuration,,10576,,9737,955.0,,,,CHEMBL857063,,,,,B,1,8,
,BAO_0000019,1501,H,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,Autocuration,,10576,,9737,,,,,CHEMBL616333,,,,,B,1,8,
,BAO_0000019,1502,H,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,Expert,,10576,,5717,,,,,CHEMBL616334,,,,,F,1,8,
Hippocampus,BAO_0000221,1503,H,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,Autocuration,,10576,,12253,10000000.0,,,,CHEMBL616335,,,,,B,1,8,
,BAO_0000019,1504,H,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,Autocuration,,10576,,14025,,,,,CHEMBL616336,,,,,B,1,8,
,BAO_0000249,1505,H,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,Expert,,10576,,10425,,,,,CHEMBL616337,,,,,B,1,8,
,BAO_0000019,1506,H,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,Autocuration,,10576,,14998,,,,,CHEMBL616338,,,,,B,1,8,
Hippocampus,BAO_0000221,1507,H,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,Autocuration,,10576,,13694,10000000.0,,,,CHEMBL616339,,,,,B,1,8,
Hippocampus,BAO_0000221,1508,H,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,Autocuration,,10576,,13694,10000000.0,,,,CHEMBL616340,,,,,B,1,8,
,BAO_0000357,1509,H,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,Autocuration,,10576,,4342,,,,,CHEMBL616341,,,,,B,1,8,
,BAO_0000357,1510,D,Binding affinity against rat 5-hydroxytryptamine 1A receptor,Expert,,10576,,12936,,10116.0,Rattus norvegicus,,CHEMBL616342,,,,,B,1,9,
,BAO_0000019,1511,D,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,Expert,,10576,,13144,,10116.0,Rattus norvegicus,,CHEMBL616343,,,,,B,1,9,
,BAO_0000019,1512,H,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,Expert,,10576,,13343,,,,,CHEMBL616344,,,,,B,1,8,
,BAO_0000357,1513,H,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,Expert,,10576,,12132,,,,,CHEMBL616345,,,,,B,1,8,
,BAO_0000019,1514,H,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,Expert,,10576,,15419,,,,,CHEMBL616346,,,,,B,1,8,
Hippocampus,BAO_0000221,1515,H,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,Autocuration,,10576,,1479,10000000.0,,,,CHEMBL616347,,,,,B,1,8,
,BAO_0000019,1516,H,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,Expert,,10576,,14287,,,,,CHEMBL616348,,,,,B,1,8,
,BAO_0000357,1517,H,Binding affinity at 5-hydroxytryptamine 1A receptor,Expert,,10576,,13116,,,,,CHEMBL616349,,,,,B,1,8,
,BAO_0000249,1518,D,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,Expert,,10576,,2759,,10116.0,Rattus norvegicus,,CHEMBL616152,,,,Membranes,B,1,9,
,BAO_0000249,1519,H,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,Autocuration,,10576,,2759,,,,,CHEMBL616153,,,,,B,1,8,
,BAO_0000019,1520,H,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",Expert,,10576,,14748,,,,,CHEMBL616154,,,,,B,1,8,
,BAO_0000019,1521,H,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,Autocuration,,10576,,12304,,,,,CHEMBL616155,,,,,B,1,8,
Hippocampus,BAO_0000221,1522,D,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,Expert,,10576,,12409,10000000.0,10116.0,Rattus norvegicus,,CHEMBL616156,,,,,B,1,9,
Hippocampus,BAO_0000221,1523,D,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,Expert,,10576,,12409,10000000.0,10116.0,Rattus norvegicus,,CHEMBL616157,,,,,B,1,9,
Hippocampus,BAO_0000221,1524,H,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,Autocuration,,10576,,13267,10000000.0,,,,CHEMBL616158,,,,,B,1,8,
,BAO_0000357,1525,H,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,Autocuration,,10576,,15194,,,,,CHEMBL616159,,,,,B,1,8,
,BAO_0000357,1526,H,pKi value against rat 5-hydroxytryptamine 1A receptor.,Expert,,10576,,14256,,,,,CHEMBL616160,,,,,B,1,8,
,BAO_0000019,1527,H,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,Autocuration,,10576,,16567,,,,,CHEMBL616161,,,,,B,1,8,
,BAO_0000019,1528,H,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,Autocuration,,10576,,15740,,,,,CHEMBL616162,,,,,F,1,8,
,BAO_0000357,1529,D,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,Expert,,12687,,13278,,10116.0,Rattus norvegicus,,CHEMBL616163,,,,,B,1,9,
,BAO_0000249,1530,H,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,Expert,,10626,,1970,,,,,CHEMBL616164,,,,Membranes,B,1,8,
Brain,BAO_0000221,1531,H,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,Autocuration,,10576,,10034,955.0,,,,CHEMBL616165,,,,,B,1,8,
,BAO_0000019,1532,H,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,Autocuration,,51,,13348,,10116.0,Rattus norvegicus,,CHEMBL616355,,,,,B,1,8,
,BAO_0000019,1533,H,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,Autocuration,,10576,,13630,,,,,CHEMBL616356,,,,,F,1,8,
Brain,BAO_0000221,1534,H,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,Autocuration,,10576,,10862,955.0,,,,CHEMBL616357,,,,,B,1,8,
,BAO_0000019,1535,H,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",Autocuration,,10576,,12058,,,,,CHEMBL616358,,,,,B,1,8,
,BAO_0000357,1536,H,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,Autocuration,,51,,4639,,,,,CHEMBL616359,,,,,B,1,8,
,BAO_0000357,1537,H,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,Expert,,51,,15453,,,,,CHEMBL616360,,,,,B,1,8,
,BAO_0000357,1538,H,Binding affinity towards 5-hydroxytryptamine 1A receptor,Expert,,51,,4820,,,,,CHEMBL616361,,,,,B,1,8,
,BAO_0000357,1539,H,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,Autocuration,,51,,1089,,,,,CHEMBL616362,,,,,B,1,8,
,BAO_0000249,1540,H,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,Autocuration,,51,,386,,,,,CHEMBL616363,,,,Brain membranes,B,1,8,
,BAO_0000357,1541,H,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,Autocuration,,51,,6011,,,,,CHEMBL616364,,,,,B,1,8,
,BAO_0000357,1542,H,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,Autocuration,,51,,5014,,,,,CHEMBL616365,,,,,B,1,8,
,BAO_0000357,1543,H,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,Expert,,51,,4402,,,,,CHEMBL616366,,,,,B,1,8,
,BAO_0000357,1544,H,Binding affinity towards 5-hydroxytryptamine 1A receptor,Expert,,51,,17066,,,,,CHEMBL872906,,,,,B,1,8,
,BAO_0000357,1545,H,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,Autocuration,,51,,17515,,,,,CHEMBL616367,,,,,B,1,8,
,BAO_0000357,1546,H,Binding affinity against 5-hydroxytryptamine 1A receptor,Autocuration,,51,,2474,,,,,CHEMBL616368,,,,,B,1,8,
,BAO_0000357,1547,H,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,Autocuration,,51,,4775,,,,,CHEMBL616369,,,,,B,1,8,
,BAO_0000357,1548,D,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,Expert,,51,,14294,,9606.0,Homo sapiens,,CHEMBL616370,,,,,B,1,9,
,BAO_0000357,1549,D,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,Expert,,51,,14294,,9606.0,Homo sapiens,,CHEMBL616371,,,,,B,1,9,
,BAO_0000219,1550,H,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,Autocuration,449.0,51,,12249,,,,,CHEMBL616372,CHO,,,,B,1,8,
,BAO_0000219,1551,H,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,Expert,,51,,11376,,,,,CHEMBL616373,,,,,B,1,8,
,BAO_0000218,1552,H,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Autocuration,,51,,2474,,,,,CHEMBL616374,,,In vivo,,B,1,8,
Hippocampus,BAO_0000221,1553,H,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,Autocuration,,51,,13311,10000000.0,,,,CHEMBL616375,,,,,B,1,8,
,BAO_0000357,1554,H,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,Autocuration,,51,,4373,,,,,CHEMBL616376,,,,,B,1,8,
,BAO_0000357,1555,H,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,Expert,,51,,1633,,,,,CHEMBL857064,,,,,B,1,8,
,BAO_0000357,1556,H,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,Autocuration,,51,,11866,,,,,CHEMBL616377,,,,,B,1,8,
,BAO_0000357,1557,H,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,Autocuration,,51,,4373,,,,,CHEMBL616378,,,,,B,1,8,
,BAO_0000357,1558,H,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,Autocuration,,51,,4687,,,,,CHEMBL616379,,,,,B,1,8,
,BAO_0000357,1559,H,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,Autocuration,,11863,,16946,,,,,CHEMBL616380,,,,,B,1,8,
,BAO_0000357,1560,H,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,Autocuration,,11863,,13291,,,,,CHEMBL616381,,,,,B,1,8,
,BAO_0000357,1561,H,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,Autocuration,,11863,,14159,,,,,CHEMBL616382,,,,,B,1,8,
,BAO_0000357,1562,H,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,Autocuration,,11863,,10812,,,,,CHEMBL616383,,,,,B,1,8,
,BAO_0000219,1563,D,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,Expert,449.0,11863,,3032,,10090.0,Mus musculus,,CHEMBL616350,CHO,,,,B,1,9,
,BAO_0000357,1564,H,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,Autocuration,,11863,,16655,,,,,CHEMBL616351,,,,,B,1,8,
,BAO_0000357,1565,H,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,Autocuration,,11863,,14532,,,,,CHEMBL616352,,,,,B,1,8,
,BAO_0000357,1566,H,Binding affinity against 5-hydroxytryptamine 1A receptor,Autocuration,,11863,,13944,,,,,CHEMBL616353,,,,,B,1,8,
,BAO_0000357,1567,H,Binding affinity against serotonergic 5-HT1a receptor,Autocuration,,11863,,13033,,,,,CHEMBL616354,,,,,B,1,8,
,BAO_0000357,1568,H,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,Autocuration,,11863,,10321,,,,,CHEMBL616508,,,,,B,1,8,
,BAO_0000357,1569,D,Binding affinity for 5-hydroxytryptamine 1A receptor,Expert,,11863,,2968,,10090.0,Mus musculus,,CHEMBL616559,,,,,B,1,9,
,BAO_0000357,1570,H,Binding affinity at 5-hydroxytryptamine 1A receptor,Autocuration,,11863,,13964,,,,,CHEMBL616560,,,,,B,1,8,
,BAO_0000357,1571,H,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",Autocuration,,11863,,15527,,,,,CHEMBL616561,,,,,B,1,8,
,BAO_0000219,1572,H,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,Autocuration,449.0,11863,,12248,,,,,CHEMBL616562,CHO,,,,B,1,8,
,BAO_0000219,1573,H,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,Autocuration,449.0,11863,,12249,,,,,CHEMBL616563,CHO,,,,B,1,8,
,BAO_0000357,1574,H,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,Autocuration,,11863,,15120,,,,,CHEMBL616564,,,,,B,1,8,
,BAO_0000357,1575,H,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,Autocuration,,11863,,13313,,,,,CHEMBL616565,,,,,B,1,8,
,BAO_0000218,1576,H,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,Autocuration,,11863,,2613,,,,,CHEMBL616566,,,,,B,1,8,
,BAO_0000357,1577,H,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,Autocuration,,11863,,16700,,,,,CHEMBL616989,,,,,B,1,8,
,BAO_0000357,1578,H,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,Autocuration,,11863,,2201,,,,,CHEMBL857975,,,,,B,1,8,
,BAO_0000357,1579,D,Binding affinity against 5-hydroxytryptamine 1A receptor,Expert,,11863,,1274,,10090.0,Mus musculus,,CHEMBL616990,,,,,B,1,9,
,BAO_0000357,1580,H,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,Autocuration,,11863,,1317,,,,,CHEMBL616991,,,,,B,1,8,
,BAO_0000357,1581,H,Tested against 5-hydroxytryptamine 1A receptor,Autocuration,,11863,,12146,,,,,CHEMBL616992,,,,,B,1,8,
,BAO_0000357,1582,H,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,Autocuration,,11863,,14059,,,,,CHEMBL616993,,,,,B,1,8,
,BAO_0000019,1583,H,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,Expert,,106,,14025,,9986.0,Oryctolagus cuniculus,,CHEMBL616994,,,,,B,1,8,
,BAO_0000019,1584,H,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,Autocuration,,106,,14025,,9986.0,Oryctolagus cuniculus,,CHEMBL616995,,,,,B,1,8,
,BAO_0000219,1585,D,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,Intermediate,722.0,105571,,14447,,9593.0,Gorilla gorilla,,CHEMBL616996,HEK293,,,,B,1,9,
,BAO_0000218,1586,H,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,Autocuration,,106,,3025,,10141.0,Cavia porcellus,,CHEMBL616997,,,In vivo,,F,1,8,
,BAO_0000218,1587,H,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,Autocuration,,106,,3025,,10141.0,Cavia porcellus,,CHEMBL616998,,,In vivo,,F,1,8,
,BAO_0000019,1588,H,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,Autocuration,,106,,15329,,10141.0,Cavia porcellus,,CHEMBL616999,,,,,F,1,8,
,BAO_0000019,1589,H,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,Autocuration,,106,,15329,,10141.0,Cavia porcellus,,CHEMBL617000,,,,,F,1,8,
,BAO_0000019,1590,H,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,Autocuration,,106,,15847,,10141.0,Cavia porcellus,,CHEMBL617001,,,,,F,1,8,
,BAO_0000019,1591,H,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,Autocuration,,106,,15847,,10141.0,Cavia porcellus,,CHEMBL858111,,,,,F,1,8,
,BAO_0000019,1592,H,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,Autocuration,,106,,14165,,,,,CHEMBL617002,,,,,F,1,8,
,BAO_0000019,1593,H,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),Autocuration,,106,,14214,,,,,CHEMBL617003,,,,,F,1,8,
,BAO_0000019,1594,H,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),Autocuration,,106,,14214,,,,,CHEMBL617004,,,,,F,1,8,
,BAO_0000019,1595,D,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,Expert,,106,,14214,,9606.0,Homo sapiens,,CHEMBL617005,,,,,F,1,9,
,BAO_0000219,1596,D,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,Expert,485.0,106,,13729,,9606.0,Homo sapiens,,CHEMBL616623,CHO-K1,,,,F,1,9,
,BAO_0000219,1597,H,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,Autocuration,449.0,106,,3025,,,,,CHEMBL616624,CHO,,,,F,1,8,
,BAO_0000357,1598,H,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,Autocuration,,106,,2391,,,,,CHEMBL883243,,,,,B,1,8,
,BAO_0000019,1599,H,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,Autocuration,,106,,2391,,,,,CHEMBL616625,,,,,F,1,8,
,BAO_0000219,1600,H,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",Expert,449.0,106,,14956,,,,,CHEMBL616626,CHO,,,,F,1,8,
,BAO_0000219,1601,H,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,Autocuration,449.0,106,,2598,,,,,CHEMBL616627,CHO,,,,F,1,8,
,BAO_0000219,1602,H,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,Autocuration,449.0,106,,2598,,,,,CHEMBL616628,CHO,,,,F,1,8,
,BAO_0000219,1603,H,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,Autocuration,449.0,106,,2598,,,,,CHEMBL616629,CHO,,,,F,1,8,
,BAO_0000219,1604,H,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,Autocuration,449.0,106,,2598,,,,,CHEMBL616630,CHO,,,,F,1,8,
,BAO_0000019,1605,H,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",Expert,,106,,14956,,,,,CHEMBL616631,,,,,F,1,8,
,BAO_0000019,1606,H,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",Autocuration,,106,,14956,,,,,CHEMBL616632,,,,,F,1,8,
,BAO_0000357,1607,D,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,Expert,,106,,14214,,9606.0,Homo sapiens,,CHEMBL616633,,,,,B,1,9,
,BAO_0000219,1608,H,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,Expert,449.0,106,,3463,,,,,CHEMBL616634,CHO,,,,B,1,8,
,BAO_0000357,1609,H,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,Autocuration,,106,,15331,,,,,CHEMBL616635,,,,,B,1,8,
,BAO_0000357,1610,D,Binding affinity against 5-hydroxytryptamine 1B receptor,Expert,,106,,16146,,9606.0,Homo sapiens,,CHEMBL885358,,,,,B,1,9,
,BAO_0000219,1611,D,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,Expert,449.0,106,,14159,,9606.0,Homo sapiens,,CHEMBL616636,CHO,,,,B,1,9,
,BAO_0000219,1612,H,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,Expert,449.0,106,,14158,,,,,CHEMBL616637,CHO,,,,B,1,8,
,BAO_0000357,1613,H,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,Autocuration,,106,,14159,,,,,CHEMBL616638,,,,,B,1,8,
,BAO_0000219,1614,H,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,Expert,449.0,106,,15250,,,,,CHEMBL616639,CHO,,,,B,1,8,
,BAO_0000219,1615,H,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,Expert,449.0,106,,15250,,,,,CHEMBL616640,CHO,,,,B,1,8,
,BAO_0000219,1616,H,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,Expert,449.0,106,,15331,,,,,CHEMBL616641,CHO,,,,B,1,8,
,BAO_0000219,1617,H,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,Expert,449.0,106,,15332,,,,,CHEMBL616642,CHO,,,,B,1,8,
,BAO_0000219,1618,H,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,Expert,449.0,106,,14956,,,,,CHEMBL616643,CHO,,,,B,1,8,
,BAO_0000357,1619,H,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),Autocuration,,106,,3805,,,,,CHEMBL616644,,,,,B,1,8,
,BAO_0000357,1620,H,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,Autocuration,,106,,14875,,,,,CHEMBL616645,,,,,B,1,8,
,BAO_0000019,1621,H,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),Autocuration,,105,,14454,,9986.0,Oryctolagus cuniculus,,CHEMBL616646,,,,,F,1,8,
,BAO_0000019,1622,H,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),Expert,,105,,14454,,9986.0,Oryctolagus cuniculus,,CHEMBL616647,,,,,F,1,8,
,BAO_0000357,1623,H,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),Autocuration,,105,,16288,,,,,CHEMBL616509,,,,,B,1,8,
,BAO_0000357,1624,H,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),Autocuration,,105,,16288,,,,,CHEMBL616510,,,,,B,1,8,
,BAO_0000357,1625,H,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,Autocuration,,105,,16312,,,,,CHEMBL616511,,,,,B,1,8,
,BAO_0000357,1626,H,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,Expert,,105,,1348,,9913.0,Bos taurus,,CHEMBL616512,,,,,B,1,8,
,BAO_0000357,1627,H,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,Autocuration,,105,,5834,,9913.0,Bos taurus,,CHEMBL616513,,,,,B,1,8,
Striatum,BAO_0000019,1628,H,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,Autocuration,,105,,13366,2435.0,9913.0,Bos taurus,,CHEMBL616514,,,,,B,1,8,
,BAO_0000357,1629,H,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,Expert,,105,,1414,,9913.0,Bos taurus,,CHEMBL616515,,,,,B,1,8,
,BAO_0000019,1630,H,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,Autocuration,,105,,14998,,9913.0,Bos taurus,,CHEMBL616516,,,,,B,1,8,
,BAO_0000357,1631,H,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,Autocuration,,105,,11473,,9913.0,Bos taurus,,CHEMBL616517,,,,,B,1,8,
,BAO_0000357,1632,H,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,Autocuration,,105,,11473,,9913.0,Bos taurus,,CHEMBL616518,,,,,B,1,8,
,BAO_0000357,1633,H,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,Autocuration,,105,,10639,,9913.0,Bos taurus,,CHEMBL616519,,,,,B,1,8,
,BAO_0000357,1634,H,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,Autocuration,,105,,10639,,9913.0,Bos taurus,,CHEMBL616520,,,,,B,1,8,
,BAO_0000357,1635,H,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,Autocuration,,105,,1375,,9913.0,Bos taurus,,CHEMBL616521,,,,,B,1,8,
,BAO_0000357,1636,H,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,Autocuration,,105,,1375,,9913.0,Bos taurus,,CHEMBL616522,,,,,B,1,8,
,BAO_0000357,1637,H,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,Autocuration,,105,,16532,,9913.0,Bos taurus,,CHEMBL884531,,,,,B,1,8,
,BAO_0000357,1638,H,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,Autocuration,,105,,11147,,9913.0,Bos taurus,,CHEMBL616523,,,,,B,1,8,
Striatum,BAO_0000019,1639,H,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,Autocuration,,105,,13366,2435.0,9913.0,Bos taurus,,CHEMBL616731,,,,,B,1,8,
,BAO_0000019,1640,H,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,Autocuration,,105,,10444,,9913.0,Bos taurus,,CHEMBL616732,,,,,B,1,8,
,BAO_0000357,1641,H,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,Autocuration,,105,,16532,,9913.0,Bos taurus,,CHEMBL616733,,,,,B,1,8,
,BAO_0000357,1642,H,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,Autocuration,,105,,16532,,9913.0,Bos taurus,,CHEMBL616734,,,,,B,1,8,
,BAO_0000249,1643,H,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,Autocuration,,105,,12827,,9913.0,Bos taurus,,CHEMBL616735,,,,,B,1,8,
,BAO_0000249,1644,H,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,Autocuration,,105,,12827,,9913.0,Bos taurus,,CHEMBL616736,,,,,B,1,8,
,BAO_0000019,1645,H,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,Expert,,105,,12919,,9913.0,Bos taurus,,CHEMBL616737,,,,,F,1,8,
,BAO_0000019,1646,H,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,Autocuration,,105,,14025,,9913.0,Bos taurus,,CHEMBL616738,,,,,B,1,8,
,BAO_0000019,1647,H,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,Expert,,105,,12919,,9913.0,Bos taurus,,CHEMBL616739,,,,,F,1,8,
,BAO_0000019,1648,H,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,Expert,,105,,12919,,9913.0,Bos taurus,,CHEMBL616740,,,,,F,1,8,
,BAO_0000019,1649,H,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,Expert,,105,,12919,,9913.0,Bos taurus,,CHEMBL616741,,,,,F,1,8,
,BAO_0000219,1650,H,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,Autocuration,722.0,105,,14447,,9593.0,Gorilla gorilla,,CHEMBL616742,HEK293,,,,B,1,8,
,BAO_0000019,1651,D,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,Intermediate,,105570,,1375,,10141.0,Cavia porcellus,,CHEMBL616743,,,,,B,1,9,
,BAO_0000019,1652,D,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,Intermediate,,105570,,1375,,10141.0,Cavia porcellus,,CHEMBL616744,,,,,B,1,9,
,BAO_0000019,1653,D,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,Intermediate,,105570,,12409,,10141.0,Cavia porcellus,,CHEMBL616745,,,,,F,1,9,
,BAO_0000019,1654,D,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,Intermediate,,105570,,12409,,10141.0,Cavia porcellus,,CHEMBL616746,,,,,F,1,9,
,BAO_0000019,1655,D,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,Intermediate,,105570,,12409,,10141.0,Cavia porcellus,,CHEMBL616747,,,,,F,1,9,
,BAO_0000019,1656,D,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,Intermediate,,105570,,12409,,10141.0,Cavia porcellus,,CHEMBL616748,,,,,F,1,9,
,BAO_0000019,1657,D,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,Intermediate,,105570,,12409,,10141.0,Cavia porcellus,,CHEMBL616648,,,,,F,1,9,
,BAO_0000357,1658,D,Binding affinity against 5-hydroxytryptamine 1D receptor,Intermediate,,105570,,11574,,10141.0,Cavia porcellus,,CHEMBL616649,,,,,B,1,9,
,BAO_0000357,1659,D,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,Intermediate,,105570,,1558,,10141.0,Cavia porcellus,,CHEMBL616650,,,,,B,1,9,
,BAO_0000218,1660,D,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,Intermediate,,105570,,12409,,10141.0,Cavia porcellus,,CHEMBL616651,,,,,F,1,9,
,BAO_0000218,1661,D,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,Intermediate,,105570,,12409,,10141.0,Cavia porcellus,,CHEMBL616652,,,,,F,1,9,
,BAO_0000218,1662,D,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,Intermediate,,105570,,12409,,10141.0,Cavia porcellus,,CHEMBL616653,,,,,F,1,9,
,BAO_0000218,1663,D,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,Intermediate,,105570,,12409,,10141.0,Cavia porcellus,,CHEMBL616654,,,,,F,1,9,
,BAO_0000019,1664,D,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,Intermediate,,105570,,12253,,10141.0,Cavia porcellus,,CHEMBL616655,,,,,B,1,9,
,BAO_0000357,1665,D,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,Intermediate,,105570,,12936,,10141.0,Cavia porcellus,,CHEMBL616656,,,,,B,1,9,
,BAO_0000019,1666,H,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,Autocuration,,105,,13181,,10141.0,Cavia porcellus,,CHEMBL616657,,,,,B,1,8,
Striatum,BAO_0000357,1667,D,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,Intermediate,,105570,,12409,2435.0,10141.0,Cavia porcellus,,CHEMBL616658,,,,,B,1,9,
,BAO_0000357,1668,D,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,Intermediate,,105570,,10639,,10141.0,Cavia porcellus,,CHEMBL616659,,,,,B,1,9,
,BAO_0000357,1669,H,Binding affinity against 5-hydroxytryptamine 1D receptor,Autocuration,,51,,5254,,,,,CHEMBL616660,,,,,B,1,8,
,BAO_0000357,1670,H,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,Autocuration,,106,,13051,,,,,CHEMBL616661,,,,,B,1,8,
,BAO_0000019,1671,H,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,Expert,,105,,3463,,,,,CHEMBL616662,,,,,F,1,8,
,BAO_0000019,1672,H,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,Autocuration,,105,,15315,,,,,CHEMBL616663,,,,,F,1,8,
,BAO_0000019,1673,H,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,Autocuration,,105,,6011,,,,,CHEMBL616664,,,,,F,1,8,
,BAO_0000219,1674,D,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",Expert,449.0,105,,14159,,9606.0,Homo sapiens,,CHEMBL881820,CHO,,,,F,1,9,
,BAO_0000219,1675,H,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",Autocuration,449.0,105,,14159,,,,,CHEMBL616665,CHO,,,,F,1,8,
,BAO_0000219,1676,H,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,Expert,449.0,105,,15250,,,,,CHEMBL616666,CHO,,,,B,1,8,
,BAO_0000219,1677,H,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,Autocuration,449.0,105,,15250,,,,,CHEMBL616667,CHO,,,,B,1,8,
,BAO_0000219,1678,H,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",Expert,449.0,105,,15331,,,,,CHEMBL616668,CHO,,,,F,1,8,
,BAO_0000219,1679,D,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",Expert,449.0,105,,15332,,9606.0,Homo sapiens,,CHEMBL616669,CHO,,,,F,1,9,
,BAO_0000219,1680,H,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",Expert,449.0,105,,15332,,,,,CHEMBL617040,CHO,,,,F,1,8,
,BAO_0000219,1681,H,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",Autocuration,449.0,105,,3294,,,,,CHEMBL617041,CHO,,,,F,1,8,
,BAO_0000219,1682,H,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",Expert,449.0,105,,14158,,,,,CHEMBL617042,CHO,,,,F,1,8,
,BAO_0000219,1683,H,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",Expert,449.0,105,,14956,,,,,CHEMBL617043,CHO,,,,F,1,8,
,BAO_0000019,1684,H,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,Autocuration,,105,,12469,,,,,CHEMBL617044,,,,,F,1,8,
,BAO_0000219,1685,H,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,Expert,449.0,105,,3463,,,,,CHEMBL617045,CHO,,,,F,1,8,
,BAO_0000219,1686,D,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",Expert,449.0,105,,15250,,9606.0,Homo sapiens,,CHEMBL617046,CHO,,,,F,1,9,
,BAO_0000219,1687,D,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",Expert,449.0,105,,15250,,9606.0,Homo sapiens,,CHEMBL617047,CHO,,,,F,1,9,
,BAO_0000019,1688,H,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",Expert,,105,,14956,,,,,CHEMBL617048,,,,,F,1,8,
,BAO_0000019,1689,H,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",Autocuration,,105,,14159,,,,,CHEMBL616897,,,,,F,1,8,
,BAO_0000019,1690,D,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",Expert,,105,,14159,,9606.0,Homo sapiens,,CHEMBL616898,,,,,F,1,9,
,BAO_0000219,1691,D,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,Expert,449.0,105,,14499,,9606.0,Homo sapiens,,CHEMBL858201,CHO,,,,F,1,9,
,BAO_0000019,1692,H,Intrinsic activity for 5-hydroxytryptamine 1D receptor,Autocuration,,105,,15315,,,,,CHEMBL616899,,,,,F,1,8,
,BAO_0000219,1693,H,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),Autocuration,,105,,3294,,,,,CHEMBL616900,,,In vitro,,B,1,8,
,BAO_0000219,1694,H,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,Expert,449.0,105,,3463,,,,,CHEMBL616901,CHO,,,,B,1,8,
,BAO_0000357,1695,H,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,Autocuration,,105,,15331,,,,,CHEMBL616902,,,,,B,1,8,
,BAO_0000219,1696,D,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,Expert,449.0,105,,14159,,9606.0,Homo sapiens,,CHEMBL616903,CHO,,,,B,1,9,
,BAO_0000219,1697,H,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,Expert,449.0,105,,14158,,,,,CHEMBL616904,CHO,,,,B,1,8,
,BAO_0000357,1698,H,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,Autocuration,,105,,14159,,,,,CHEMBL616905,,,,,B,1,8,
,BAO_0000219,1699,H,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,Expert,449.0,105,,15250,,,,,CHEMBL616906,CHO,,,,B,1,8,
,BAO_0000219,1700,H,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,Expert,449.0,105,,15250,,,,,CHEMBL616907,CHO,,,,B,1,8,
,BAO_0000219,1701,H,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,Expert,449.0,105,,15331,,,,,CHEMBL616908,CHO,,,,B,1,8,
,BAO_0000219,1702,D,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,Expert,449.0,105,,15332,,9606.0,Homo sapiens,,CHEMBL616909,CHO,,,,B,1,9,
,BAO_0000219,1703,D,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,Expert,449.0,105,,14499,,9606.0,Homo sapiens,,CHEMBL616910,CHO,,,,B,1,9,
,BAO_0000219,1704,H,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,Expert,449.0,105,,15332,,,,,CHEMBL616911,CHO,,,,B,1,8,
,BAO_0000219,1705,H,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,Expert,449.0,105,,14956,,,,,CHEMBL616912,CHO,,,,B,1,8,
,BAO_0000357,1706,H,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),Autocuration,,105,,3805,,,,,CHEMBL616913,,,,,B,1,8,
,BAO_0000219,1707,D,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,Expert,449.0,105,,6011,,9606.0,Homo sapiens,,CHEMBL616914,CHO,,,,B,1,9,
,BAO_0000219,1708,H,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,Autocuration,449.0,105,,16190,,,,,CHEMBL616915,CHO,,,,B,1,8,
,BAO_0000019,1709,H,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,Autocuration,,105,,14165,,,,,CHEMBL616916,,,,,B,1,8,
,BAO_0000357,1710,D,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,Expert,,105,,4234,,9606.0,Homo sapiens,,CHEMBL616917,,,,,B,1,9,
,BAO_0000357,1711,H,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",Autocuration,,105,,15527,,,,,CHEMBL616918,,,,,B,1,8,
,BAO_0000219,1712,H,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,Expert,,105,,6328,,,,,CHEMBL616919,,,,,B,1,8,
,BAO_0000357,1713,H,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,Autocuration,,105,,16209,,,,,CHEMBL616920,,,,,B,1,8,
,BAO_0000357,1714,H,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,Autocuration,,105,,14770,,,,,CHEMBL872914,,,,,B,1,8,
,BAO_0000357,1715,H,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,Autocuration,,105,,2598,,,,,CHEMBL616921,,,,,B,1,8,
,BAO_0000357,1716,H,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,Expert,,105,,6897,,,,,CHEMBL616922,,,,,B,1,8,
,BAO_0000357,1717,H,Binding affinity towards 5-hydroxytryptamine 1D receptor,Autocuration,,105,,6013,,,,,CHEMBL616923,,,,,B,1,8,
,BAO_0000357,1718,H,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,Expert,,105,,5843,,,,,CHEMBL616924,,,,,B,1,8,
,BAO_0000357,1719,H,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,Expert,,105,,14454,,,,,CHEMBL875909,,,,,B,1,8,
,BAO_0000357,1720,H,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,Autocuration,,105,,14454,,,,,CHEMBL616925,,,,,B,1,8,
,BAO_0000357,1721,H,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,Autocuration,,105,,14454,,,,,CHEMBL616926,,,,,B,1,8,
,BAO_0000357,1722,H,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,Autocuration,,105,,15818,,,,,CHEMBL616927,,,,,B,1,8,
,BAO_0000219,1723,H,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,Expert,485.0,105,,13729,,,,,CHEMBL616928,CHO-K1,,,,F,1,8,
,BAO_0000219,1724,D,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),Expert,,105,,6011,,9606.0,Homo sapiens,,CHEMBL616929,,,In vitro,,B,1,9,
,BAO_0000357,1725,D,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,Expert,,105,,4234,,9606.0,Homo sapiens,,CHEMBL616930,,,,,B,1,9,
,BAO_0000019,1726,H,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,Expert,,105,,17085,,,,,CHEMBL616931,,,,,B,1,8,
,BAO_0000357,1727,H,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,Autocuration,,105,,3025,,,,,CHEMBL616932,,,,,B,1,8,
,BAO_0000357,1728,H,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,Expert,,105,,15315,,,,,CHEMBL616933,,,,,B,1,8,
,BAO_0000219,1729,D,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,Expert,,105,,14214,,9606.0,Homo sapiens,,CHEMBL616934,,,,,B,1,9,
,BAO_0000357,1730,D,Binding affinity for human 5-hydroxytryptamine 1D receptor,Expert,,105,,3804,,9606.0,Homo sapiens,,CHEMBL616935,,,,,B,1,9,
,BAO_0000357,1731,H,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,Autocuration,,105,,16700,,,,,CHEMBL616936,,,,,B,1,8,
,BAO_0000357,1732,D,Affinity for 5-hydroxytryptamine 1D receptor subtype,Expert,,105,,2391,,9606.0,Homo sapiens,,CHEMBL616937,,,,,B,1,9,
,BAO_0000357,1733,D,Binding affinity for human 5-hydroxytryptamine 1D receptor,Expert,,105,,4175,,9606.0,Homo sapiens,,CHEMBL616938,,,,,B,1,9,
,BAO_0000019,1734,H,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,Autocuration,,105,,17085,,,,,CHEMBL616939,,,,,B,1,8,
,BAO_0000019,1735,H,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,Expert,,105,,17085,,,,,CHEMBL616940,,,,,B,1,8,
,BAO_0000357,1736,D,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,Expert,,105,,15926,,9606.0,Homo sapiens,,CHEMBL616941,,,,,B,1,9,
,BAO_0000219,1737,H,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,Autocuration,485.0,105,,16312,,,,,CHEMBL616942,CHO-K1,,,,B,1,8,
,BAO_0000219,1738,H,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,Autocuration,485.0,105,,16312,,,,,CHEMBL616943,CHO-K1,,,,B,1,8,
,BAO_0000219,1739,H,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,Autocuration,449.0,104802,,14956,,,,,CHEMBL616944,CHO,,,,B,1,4,
,BAO_0000019,1740,H,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",Autocuration,,105,,3294,,,,,CHEMBL616945,,,,,F,1,8,
,BAO_0000357,1741,H,Binding activity radioligand.,Autocuration,,105,,12861,,,,,CHEMBL616946,,,,,B,1,8,
,BAO_0000019,1742,H,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,Autocuration,,105,,12861,,,,,CHEMBL616947,,,,,B,1,8,
,BAO_0000219,1743,H,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,Expert,485.0,105,,16312,,,,,CHEMBL616948,CHO-K1,,,,B,1,8,
,BAO_0000357,1744,H,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,Autocuration,,105,,5104,,,,,CHEMBL616851,,,,,B,1,8,
,BAO_0000357,1745,H,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,Autocuration,,105,,5105,,,,,CHEMBL616852,,,,,B,1,8,
,BAO_0000357,1746,H,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,Autocuration,,105,,14499,,,,,CHEMBL616853,,,,,B,1,8,
,BAO_0000357,1747,D,Binding activity against human 5-hydroxytryptamine 1D receptor,Expert,,105,,15926,,9606.0,Homo sapiens,,CHEMBL616854,,,,,B,1,9,
,BAO_0000219,1748,D,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,Expert,449.0,105,,4540,,9606.0,Homo sapiens,,CHEMBL616855,CHO,,,,B,1,9,
,BAO_0000219,1749,H,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,Autocuration,449.0,105,,15779,,,,,CHEMBL616856,CHO,,,,B,1,8,
,BAO_0000219,1750,H,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,Autocuration,449.0,105,,15779,,,,,CHEMBL616857,CHO,,,,B,1,8,
,BAO_0000357,1751,H,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,Autocuration,,105,,6166,,,,,CHEMBL616858,,,,,B,1,8,
,BAO_0000219,1752,H,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,Autocuration,449.0,105,,15779,,,,,CHEMBL616859,CHO,,,,B,1,8,
,BAO_0000219,1753,H,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,Autocuration,449.0,105,,15779,,,,,CHEMBL616860,CHO,,,,B,1,8,
,BAO_0000219,1754,H,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,Autocuration,722.0,105,,17451,,,,,CHEMBL616861,HEK293,,,,B,1,8,
,BAO_0000219,1755,H,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,Autocuration,722.0,105,,17451,,,,,CHEMBL616541,HEK293,,,,B,1,8,
,BAO_0000219,1756,H,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,Autocuration,722.0,105,,17451,,,,,CHEMBL616542,HEK293,,,,B,1,8,
,BAO_0000219,1757,H,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,Autocuration,449.0,105,,4199,,,,,CHEMBL616543,CHO,,,,B,1,8,
,BAO_0000357,1758,D,Binding affinity for human 5-hydroxytryptamine 1D receptor,Expert,,105,,14875,,9606.0,Homo sapiens,,CHEMBL616544,,,,,B,1,9,
,BAO_0000219,1759,H,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,Autocuration,449.0,105,,15146,,,,,CHEMBL616545,CHO,,,,B,1,8,
,BAO_0000357,1760,H,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,Autocuration,,105,,5213,,,,,CHEMBL616546,,,,,B,1,8,
,BAO_0000219,1761,H,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,Autocuration,449.0,105,,14818,,,,,CHEMBL616547,CHO,,,,B,1,8,
,BAO_0000219,1762,H,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",Autocuration,449.0,105,,4829,,,,,CHEMBL616548,CHO,,,,B,1,8,
,BAO_0000019,1763,H,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,Expert,,105,,14454,,,,,CHEMBL616549,,,,,F,1,8,
,BAO_0000019,1764,H,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,Expert,,105,,14454,,,,,CHEMBL616550,,,,,F,1,8,
,BAO_0000357,1765,H,Binding affinity against 5-HT2C receptor,Autocuration,,108,,5254,,,,,CHEMBL857066,,,,,B,1,8,
,BAO_0000357,1766,H,Binding affinity against 5-hydroxytryptamine 1D receptor,Autocuration,,108,,5254,,,,,CHEMBL616551,,,,,B,1,8,
,BAO_0000357,1767,H,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,Autocuration,,10577,,10639,,,,,CHEMBL616552,,,,,B,1,8,
,BAO_0000019,1768,H,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,Autocuration,,10577,,10639,,,,,CHEMBL832876,,,,,F,1,8,
,BAO_0000019,1769,H,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",Expert,,10577,,12352,,,,,CHEMBL616553,,,,,B,1,8,
,BAO_0000357,1770,H,Binding affinity towards 5-HT1B was determined,Autocuration,,10577,,9098,,,,,CHEMBL616554,,,,,B,1,8,
,BAO_0000019,1771,H,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,Expert,,10577,,14430,,,,,CHEMBL616555,,,,,B,1,8,
,BAO_0000019,1772,H,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",Expert,,10577,,13657,,,,,CHEMBL616556,,,,,B,1,8,
,BAO_0000019,1773,H,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",Autocuration,,10577,,13657,,,,,CHEMBL616557,,,,,B,1,8,
,BAO_0000019,1774,H,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,Expert,,10577,,15854,,,,,CHEMBL616558,,,,,B,1,8,
,BAO_0000019,1775,D,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,Expert,,10577,,10639,,10116.0,Rattus norvegicus,,CHEMBL616749,,,,,B,1,9,
,BAO_0000357,1776,H,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,Autocuration,,10577,,10025,,,,,CHEMBL616750,,,,,B,1,8,
,BAO_0000357,1777,H,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",Autocuration,,10577,,10025,,,,,CHEMBL616751,,,,,B,1,8,
,BAO_0000249,1778,H,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,Autocuration,,10577,,14286,,,,,CHEMBL616752,,,,,B,1,8,
Striatum,BAO_0000019,1779,H,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,Autocuration,,10577,,3651,2435.0,,,,CHEMBL616753,,,,,B,1,8,
,BAO_0000357,1780,D,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,Expert,,10577,,14178,,10116.0,Rattus norvegicus,,CHEMBL616754,,,,,B,1,9,
,BAO_0000019,1781,H,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,Autocuration,,10577,,10639,,,,,CHEMBL616755,,,,,B,1,8,
Striatum,BAO_0000019,1782,H,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,Autocuration,,10577,,13605,2435.0,,,,CHEMBL616756,,,,,B,1,8,
Striatum,BAO_0000019,1783,H,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,Autocuration,,10577,,5834,2435.0,,,,CHEMBL616757,,,,,B,1,8,
Striatum,BAO_0000357,1784,H,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,Autocuration,,10577,,10922,2435.0,,,,CHEMBL616758,,,,,B,1,8,
,BAO_0000249,1785,H,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,Autocuration,,10577,,14286,,,,,CHEMBL616759,,,,,B,1,8,
,BAO_0000357,1786,H,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,Autocuration,,10577,,11825,,,,,CHEMBL616760,,,,,B,1,8,
Striatum,BAO_0000019,1787,H,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,Autocuration,,10577,,14826,2435.0,,,,CHEMBL616761,,,,,B,1,8,
Striatum,BAO_0000019,1788,H,Binding affinity against 5-HT1B serotonin receptor in rat striatum,Autocuration,,10577,,9699,2435.0,,,,CHEMBL616762,,,,,B,1,8,
,BAO_0000019,1789,H,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,Autocuration,,10577,,14423,,,,,CHEMBL616763,,,,,B,1,8,
,BAO_0000357,1790,H,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,Expert,,10577,,10062,,,,,CHEMBL872909,,,,,B,1,8,
,BAO_0000357,1791,H,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,Autocuration,,10577,,10062,,,,,CHEMBL616764,,,,,B,1,8,
,BAO_0000357,1792,D,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,Expert,,10577,,12280,,10116.0,Rattus norvegicus,,CHEMBL616765,,,,,B,1,9,
Striatum,BAO_0000357,1793,H,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,Autocuration,,10577,,15412,2435.0,,,,CHEMBL616766,,,,,B,1,8,
Striatum,BAO_0000357,1794,H,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,Autocuration,,10577,,15412,2435.0,,,,CHEMBL616767,,,,,B,1,8,
,BAO_0000357,1795,H,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,Autocuration,,10577,,10062,,,,,CHEMBL616768,,,,,B,1,8,
,BAO_0000357,1796,H,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,Autocuration,,10577,,11147,,,,,CHEMBL616769,,,,,B,1,8,
,BAO_0000019,1797,H,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,Autocuration,,10577,,9547,,,,,CHEMBL616770,,,,,B,1,8,
,BAO_0000019,1798,H,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,Autocuration,,10577,,10444,,,,,CHEMBL616771,,,,,B,1,8,
Striatum,BAO_0000019,1799,H,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,Autocuration,,10577,,12469,2435.0,,,,CHEMBL616772,,,,,B,1,8,
,BAO_0000019,1800,H,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,Expert,,10577,,9098,,,,,CHEMBL616773,,,,,B,1,8,
,BAO_0000019,1801,H,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,Autocuration,,10577,,9098,,,,,CHEMBL616774,,,,,B,1,8,
,BAO_0000357,1802,H,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,Autocuration,,10577,,9699,,,,,CHEMBL616775,,,,,B,1,8,
,BAO_0000249,1803,H,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,Autocuration,,10577,,10394,,,,,CHEMBL616776,,,,,B,1,8,
,BAO_0000357,1804,H,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,Autocuration,,10577,,12092,,,,,CHEMBL616777,,,,,B,1,8,
,BAO_0000357,1805,H,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,Autocuration,,10577,,16700,,,,,CHEMBL616778,,,,,B,1,8,
,BAO_0000249,1806,D,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,Expert,,10577,,403,,10116.0,Rattus norvegicus,,CHEMBL616779,,,,,B,1,9,
,BAO_0000357,1807,D,Binding affinity towards 5-hydroxytryptamine 1B receptor,Expert,,10577,,12771,,10116.0,Rattus norvegicus,,CHEMBL616780,,,,,B,1,9,
,BAO_0000019,1808,H,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,Autocuration,,10577,,11642,,,,,CHEMBL616781,,,,,B,1,8,
,BAO_0000357,1809,H,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,Autocuration,,10577,,12953,,,,,CHEMBL616782,,,,,B,1,8,
,BAO_0000357,1810,H,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,Autocuration,,10577,,12953,,,,,CHEMBL616783,,,,,B,1,8,
Striatum,BAO_0000019,1811,H,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,Expert,,10577,,12953,2435.0,,,,CHEMBL616784,,,,,B,1,8,
,BAO_0000357,1812,H,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,Autocuration,,10577,,12953,,,,,CHEMBL616785,,,,,B,1,8,
Brain,BAO_0000249,1813,H,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,Autocuration,,10577,,9737,955.0,,,,CHEMBL857067,,,,,B,1,8,
,BAO_0000019,1814,H,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,Autocuration,,10577,,9737,,,,,CHEMBL616786,,,,,B,1,8,
Brain,BAO_0000249,1815,H,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,Autocuration,,10577,,9737,955.0,,,,CHEMBL616787,,,,,B,1,8,
,BAO_0000357,1816,H,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,Autocuration,,10577,,12827,,,,,CHEMBL616788,,,,,B,1,8,
,BAO_0000357,1817,H,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,Autocuration,,10577,,5033,,,,,CHEMBL616789,,,,,B,1,8,
,BAO_0000019,1818,D,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,Expert,,10577,,9786,,10116.0,Rattus norvegicus,,CHEMBL616790,,,,,B,1,9,
,BAO_0000357,1819,H,Binding affinity at 5-hydroxytryptamine 1B receptor,Expert,,10577,,13116,,,,,CHEMBL616791,,,,,B,1,8,
,BAO_0000019,1820,H,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,Autocuration,,10577,,16429,,,,,CHEMBL616792,,,,,B,1,8,
,BAO_0000249,1821,D,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,Expert,,10577,,12409,,10116.0,Rattus norvegicus,,CHEMBL616793,,,,,B,1,9,
,BAO_0000357,1822,H,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,Autocuration,,10577,,15194,,,,,CHEMBL616794,,,,,B,1,8,
,BAO_0000357,1823,H,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,Autocuration,,10577,,15194,,,,,CHEMBL616795,,,,,B,1,8,
,BAO_0000019,1824,H,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,Autocuration,,104686,,5486,,,,,CHEMBL616796,,,,,B,1,4,
,BAO_0000357,1825,H,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,Autocuration,,106,,4639,,,,,CHEMBL616797,,,,,B,1,8,
,BAO_0000249,1826,H,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,Autocuration,,106,,386,,,,,CHEMBL616798,,,,Brain membranes,B,1,8,
,BAO_0000357,1827,H,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,Autocuration,,106,,2474,,,,,CHEMBL616799,,,,,B,1,8,
,BAO_0000357,1828,H,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,Autocuration,,106,,6011,,,,,CHEMBL616800,,,,,B,1,8,
,BAO_0000357,1829,H,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,Autocuration,,106,,5014,,,,,CHEMBL616801,,,,,B,1,8,
,BAO_0000357,1830,H,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,Autocuration,,106,,17515,,,,,CHEMBL616802,,,,,B,1,8,
,BAO_0000357,1831,H,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,Autocuration,,106,,4373,,,,,CHEMBL616803,,,,,B,1,8,
,BAO_0000357,1832,H,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,Expert,,106,,1633,,,,,CHEMBL857068,,,,,B,1,8,
,BAO_0000357,1833,H,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,Autocuration,,106,,1633,,,,,CHEMBL616804,,,,,B,1,8,
,BAO_0000357,1834,H,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,Autocuration,,106,,4373,,,,,CHEMBL616805,,,,,B,1,8,
,BAO_0000357,1835,H,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,Autocuration,,106,,4687,,,,,CHEMBL616806,,,,,B,1,8,
,BAO_0000357,1836,H,Binding affinity against 5-hydroxytryptamine 1B receptor,Autocuration,,106,,11574,,,,,CHEMBL616807,,,,,B,1,8,
,BAO_0000357,1837,H,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,Autocuration,,106,,10321,,,,,CHEMBL616808,,,,,B,1,8,
,BAO_0000357,1838,H,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,Autocuration,,106,,15527,,,,,CHEMBL616809,,,,,B,1,8,
,BAO_0000357,1839,H,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,Autocuration,,106,,17200,,,,,CHEMBL616810,,,,,B,1,8,
,BAO_0000224,1840,H,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,Autocuration,,104802,,14423,,,,,CHEMBL616811,,,,,B,1,4,
,BAO_0000357,1841,H,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,Autocuration,,108,,5834,,9913.0,Bos taurus,,CHEMBL616812,,,,,B,1,8,
,BAO_0000357,1842,H,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,Autocuration,,108,,11473,,9823.0,Sus scrofa,,CHEMBL616813,,,,,B,1,8,
,BAO_0000357,1843,H,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,Autocuration,,108,,11473,,9823.0,Sus scrofa,,CHEMBL616814,,,,,B,1,8,
,BAO_0000357,1844,H,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,Autocuration,,108,,10639,,9823.0,Sus scrofa,,CHEMBL616815,,,,,B,1,8,
,BAO_0000357,1845,H,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,Autocuration,,108,,10639,,9823.0,Sus scrofa,,CHEMBL616816,,,,,B,1,8,
,BAO_0000357,1846,H,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,Autocuration,,108,,14331,,9823.0,Sus scrofa,,CHEMBL616817,,,,,B,1,8,
,BAO_0000357,1847,H,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,Autocuration,,108,,10796,,9823.0,Sus scrofa,,CHEMBL616818,,,,,B,1,8,
,BAO_0000357,1848,H,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,Expert,,108,,9098,,9823.0,Sus scrofa,,CHEMBL616819,,,,,B,1,8,
,BAO_0000357,1849,H,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,Expert,,108,,14331,,9823.0,Sus scrofa,,CHEMBL616820,,,,,B,1,8,
,BAO_0000019,1850,H,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,Expert,,108,,11828,,9823.0,Sus scrofa,,CHEMBL616821,,,,,B,1,8,
,BAO_0000357,1851,H,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,Autocuration,,108,,11866,,9823.0,Sus scrofa,,CHEMBL616822,,,,,B,1,8,
,BAO_0000019,1852,H,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,Autocuration,,108,,13047,,9986.0,Oryctolagus cuniculus,,CHEMBL616823,,,,,B,1,8,
,BAO_0000357,1853,D,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,Autocuration,,12689,,188,,10116.0,Rattus norvegicus,,CHEMBL616824,,,,,B,1,9,
,BAO_0000357,1854,D,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,Autocuration,,12689,,11825,,10116.0,Rattus norvegicus,,CHEMBL616825,,,,,B,1,9,
,BAO_0000357,1855,D,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,Autocuration,,12689,,11825,,10116.0,Rattus norvegicus,,CHEMBL616826,,,,,B,1,9,
,BAO_0000019,1856,D,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,Expert,,12689,,11624,,10116.0,Rattus norvegicus,,CHEMBL616827,,,,,B,1,9,
,BAO_0000357,1857,D,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,Autocuration,,12689,,11139,,10116.0,Rattus norvegicus,,CHEMBL616828,,,,,B,1,9,
,BAO_0000357,1858,D,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,Autocuration,,12689,,11147,,10116.0,Rattus norvegicus,,CHEMBL616829,,,,,B,1,9,
,BAO_0000019,1859,D,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,Autocuration,,12689,,10444,,10116.0,Rattus norvegicus,,CHEMBL616830,,,,,B,1,9,
,BAO_0000357,1860,D,Binding affinity against 5-hydroxytryptamine 1C receptor,Expert,,12689,,11624,,10116.0,Rattus norvegicus,,CHEMBL616831,,,,,B,1,9,
,BAO_0000019,1861,D,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",Autocuration,,12689,,11662,,10116.0,Rattus norvegicus,,CHEMBL616832,,,,,B,1,9,
,BAO_0000019,1862,D,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",Autocuration,,12689,,11662,,10116.0,Rattus norvegicus,,CHEMBL616833,,,,,B,1,9,
,BAO_0000019,1863,D,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",Expert,,12689,,11662,,10116.0,Rattus norvegicus,,CHEMBL616834,,,,,B,1,9,
,BAO_0000019,1864,D,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",Autocuration,,12689,,11662,,10116.0,Rattus norvegicus,,CHEMBL829595,,,,,B,1,9,
,BAO_0000357,1865,D,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,Autocuration,,12689,,9098,,10116.0,Rattus norvegicus,,CHEMBL616835,,,,,B,1,9,
,BAO_0000249,1866,D,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,Autocuration,,12689,,10394,,10116.0,Rattus norvegicus,,CHEMBL872910,,,,,B,1,9,
,BAO_0000357,1867,H,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,Expert,,12689,,11933,,,,,CHEMBL616836,,,,,B,1,8,
,BAO_0000357,1868,D,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,Autocuration,,12689,,12092,,10116.0,Rattus norvegicus,,CHEMBL616837,,,,,B,1,9,
,BAO_0000019,1869,D,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,Autocuration,,12689,,12253,,10116.0,Rattus norvegicus,,CHEMBL616466,,,,,B,1,9,
,BAO_0000219,1870,D,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,Autocuration,722.0,12689,,12253,,10116.0,Rattus norvegicus,,CHEMBL616467,HEK293,,,,B,1,9,
,BAO_0000357,1871,H,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,Autocuration,,108,,1558,,,,,CHEMBL616468,,,,,B,1,8,
,BAO_0000357,1872,H,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,Autocuration,,108,,2474,,,,,CHEMBL616469,,,,,B,1,8,
,BAO_0000357,1873,H,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,Autocuration,,108,,2474,,,,,CHEMBL616470,,,,,B,1,8,
,BAO_0000357,1874,H,Binding affinity against 5-hydroxytryptamine 1C receptor,Autocuration,,12689,,11574,,,,,CHEMBL616471,,,,,B,1,8,
,BAO_0000357,1875,H,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,Autocuration,,12689,,1558,,,,,CHEMBL616472,,,,,B,1,8,
,BAO_0000357,1876,H,Binding affinity against 5-hydroxytryptamine 1C receptor,Autocuration,,12689,,13944,,,,,CHEMBL616473,,,,,B,1,8,
,BAO_0000357,1877,H,Binding affinity against serotonergic 5-HT1c receptor,Autocuration,,12689,,13033,,,,,CHEMBL616474,,,,,B,1,8,
,BAO_0000357,1878,H,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,Autocuration,,12689,,10321,,,,,CHEMBL616475,,,,,B,1,8,
,BAO_0000357,1879,H,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,Autocuration,,12689,,11866,,,,,CHEMBL616476,,,,,B,1,8,
,BAO_0000019,1880,H,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),Autocuration,,105,,14454,,9986.0,Oryctolagus cuniculus,,CHEMBL616477,,,,,B,1,8,
,BAO_0000224,1881,H,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,Autocuration,,104686,,11574,,,,,CHEMBL616478,,,,,B,1,4,
,BAO_0000224,1882,H,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,Autocuration,,104686,,11574,,,,,CHEMBL616479,,,,,B,1,4,
,BAO_0000019,1883,H,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,Autocuration,,104686,,13631,,,,,CHEMBL616480,,,,,B,1,4,
,BAO_0000019,1884,D,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,Autocuration,,104686,,9630,,10116.0,Rattus norvegicus,,CHEMBL616481,,,,,B,1,5,
,BAO_0000249,1885,D,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,Autocuration,,104686,,8822,,10116.0,Rattus norvegicus,,CHEMBL616482,,,,,B,1,5,
Brain,BAO_0000221,1886,D,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,Autocuration,,104686,,9064,955.0,10116.0,Rattus norvegicus,,CHEMBL884713,,,,,B,1,5,
,BAO_0000224,1887,H,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,Autocuration,,104686,,8868,,,,,CHEMBL616483,,,,,B,1,4,
,BAO_0000224,1888,H,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,Autocuration,,104686,,9064,,,,,CHEMBL616484,,,,,B,1,4,
,BAO_0000019,1889,H,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,Autocuration,,104686,,9806,,,,,CHEMBL616485,,,,,B,1,4,
,BAO_0000224,1890,H,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,Autocuration,,104686,,9098,,,,,CHEMBL616486,,,,,B,1,4,
,BAO_0000224,1891,H,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,Autocuration,,104686,,8868,,,,,CHEMBL616487,,,,,B,1,4,
,BAO_0000224,1892,H,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,Autocuration,,104686,,12765,,,,,CHEMBL616488,,,,,B,1,4,
,BAO_0000019,1893,H,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,Autocuration,,104686,,11049,,,,,CHEMBL616489,,,,,B,1,4,
,BAO_0000019,1894,H,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,Autocuration,,104686,,11049,,,,,CHEMBL616490,,,,,B,1,4,
,BAO_0000019,1895,H,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,Autocuration,,104686,,11049,,,,,CHEMBL616491,,,,,B,1,4,
,BAO_0000019,1896,H,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,Autocuration,,104686,,11049,,,,,CHEMBL616492,,,,,B,1,4,
,BAO_0000019,1897,H,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,Autocuration,,104686,,11049,,,,,CHEMBL616493,,,,,B,1,4,
,BAO_0000019,1898,H,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,Autocuration,,104686,,11473,,,,,CHEMBL616494,,,,,B,1,4,
,BAO_0000019,1899,H,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,Autocuration,,104686,,11473,,,,,CHEMBL616495,,,,,B,1,4,
,BAO_0000019,1900,H,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,Autocuration,,104686,,3086,,,,,CHEMBL616496,,,,,B,1,4,
,BAO_0000019,1901,H,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,Autocuration,,104686,,11049,,,,,CHEMBL616497,,,,,B,1,4,
,BAO_0000019,1902,H,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,Autocuration,,104686,,11049,,,,,CHEMBL616498,,,,,B,1,4,
,BAO_0000019,1903,H,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,Autocuration,,104686,,10639,,,,,CHEMBL616499,,,,,B,1,4,
,BAO_0000019,1904,H,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,Autocuration,,104686,,10922,,,,,CHEMBL616500,,,,,B,1,4,
Brain,BAO_0000221,1905,D,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,Autocuration,,104686,,9064,955.0,10116.0,Rattus norvegicus,,CHEMBL616501,,,,,B,1,5,
Brain,BAO_0000221,1906,H,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,Autocuration,,104686,,10748,955.0,,,,CHEMBL616502,,,,,B,1,4,
,BAO_0000249,1907,H,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,Autocuration,,104686,,11614,,,,,CHEMBL884529,,,,Membranes,B,1,4,
,BAO_0000249,1908,H,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,Autocuration,,104686,,11615,,,,,CHEMBL616503,,,,Membranes,B,1,4,
,BAO_0000224,1909,H,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,Autocuration,,104686,,11615,,,,,CHEMBL616964,,,,,B,1,4,
,BAO_0000249,1910,H,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,Autocuration,,104686,,11614,,,,,CHEMBL616965,,,,Membranes,B,1,4,
,BAO_0000224,1911,H,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,Autocuration,,104686,,11702,,,,,CHEMBL616966,,,,,B,1,4,
,BAO_0000224,1912,H,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,Autocuration,,104686,,11702,,,,,CHEMBL616967,,,,,B,1,4,
,BAO_0000224,1913,D,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,Autocuration,,104686,,11702,,10116.0,Rattus norvegicus,,CHEMBL616968,,,,,B,1,5,
,BAO_0000224,1914,H,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,Autocuration,,104686,,11702,,,,,CHEMBL616969,,,,,B,1,4,
,BAO_0000019,1915,H,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,Autocuration,,104686,,13346,,,,,CHEMBL884530,,,,,B,1,4,
,BAO_0000224,1916,H,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,Autocuration,,104686,,10025,,,,,CHEMBL616970,,,,,B,1,4,
,BAO_0000224,1917,H,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,Autocuration,,104686,,10025,,,,,CHEMBL616971,,,,,B,1,4,
,BAO_0000224,1918,H,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",Autocuration,,104686,,10025,,,,,CHEMBL616972,,,,,B,1,4,
,BAO_0000224,1919,H,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,Autocuration,,104686,,9036,,,,,CHEMBL616973,,,,,B,1,4,
,BAO_0000224,1920,H,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,Autocuration,,104686,,9036,,,,,CHEMBL616974,,,,,B,1,4,
,BAO_0000019,1921,H,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,Autocuration,,104686,,9161,,,,,CHEMBL616975,,,,,B,1,4,
,BAO_0000019,1922,H,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,Autocuration,,104686,,12304,,,,,CHEMBL616976,,,,,B,1,4,
,BAO_0000224,1923,H,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,Autocuration,,104686,,13276,,,,,CHEMBL616977,,,,,B,1,4,
,BAO_0000224,1924,H,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,Autocuration,,104686,,11825,,,,,CHEMBL616978,,,,,B,1,4,
,BAO_0000224,1925,H,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,Autocuration,,104686,,12443,,,,,CHEMBL616979,,,,,B,1,4,
,BAO_0000224,1926,H,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,Autocuration,,104686,,13830,,,,,CHEMBL616980,,,,,B,1,4,
,BAO_0000249,1927,H,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,Autocuration,,104686,,9592,,,,,CHEMBL616981,,,,Membranes,B,1,4,
,BAO_0000249,1928,H,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,Autocuration,,104686,,9592,,,,,CHEMBL616982,,,,Membranes,B,1,4,
,BAO_0000224,1929,H,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,Autocuration,,104686,,10881,,,,,CHEMBL616983,,,,,B,1,4,
,BAO_0000019,1930,H,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,Autocuration,,104686,,13605,,,,,CHEMBL616984,,,,,B,1,4,
,BAO_0000224,1931,D,Inhibitory activity against 5-hydroxytryptamine 2 receptor,Autocuration,,104686,,11624,,10116.0,Rattus norvegicus,,CHEMBL616985,,,,,B,1,5,
,BAO_0000224,1932,H,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,Autocuration,,104686,,4101,,,,,CHEMBL616986,,,,,B,1,4,
,BAO_0000224,1933,H,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,Autocuration,,104686,,4101,,,,,CHEMBL616987,,,,,B,1,4,
,BAO_0000019,1934,H,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,Autocuration,,104686,,15360,,,,,CHEMBL616988,,,,,B,1,4,
,BAO_0000019,1935,H,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,Autocuration,,104686,,11576,,,,,CHEMBL617243,,,,,B,1,4,
,BAO_0000019,1936,H,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,Autocuration,,104686,,5834,,,,,CHEMBL617244,,,,,B,1,4,
,BAO_0000219,1937,D,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,Autocuration,485.0,104686,,2395,,10116.0,Rattus norvegicus,,CHEMBL617245,CHO-K1,,,,B,1,5,
,BAO_0000249,1938,H,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,Autocuration,,104686,,11965,,,,,CHEMBL617246,,,,Membranes,B,1,4,
,BAO_0000224,1939,H,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),Autocuration,,104686,,3967,,,,,CHEMBL617546,,,,,B,1,4,
,BAO_0000249,1940,H,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),Autocuration,,104686,,11130,,,,,CHEMBL617547,,,,Brain membranes,B,1,4,
,BAO_0000219,1941,H,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,Autocuration,,104686,,13427,,,,,CHEMBL617548,,,In vitro,,B,1,4,
,BAO_0000224,1942,H,Binding affinity towards 5-hydroxytryptamine 2 receptor,Autocuration,,104686,,9443,,,,,CHEMBL617549,,,,,B,1,4,
,BAO_0000224,1943,H,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,Autocuration,,104686,,9443,,,,,CHEMBL617550,,,,,B,1,4,
,BAO_0000224,1944,H,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,Autocuration,,104686,,11825,,,,,CHEMBL617551,,,,,B,1,4,
,BAO_0000249,1945,H,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,Autocuration,,104686,,12120,,,,,CHEMBL617552,,,,Membranes,B,1,4,
,BAO_0000249,1946,H,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,Autocuration,,104686,,12120,,,,,CHEMBL617553,,,,Membranes,B,1,4,
Thoracic aorta,BAO_0000019,1947,H,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,Autocuration,,104686,,11963,1515.0,,,,CHEMBL617554,,,,,F,1,4,
,BAO_0000019,1948,H,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,Autocuration,,104686,,9069,,,,,CHEMBL617555,,,,,B,1,4,
,BAO_0000224,1949,H,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,Autocuration,,104686,,8868,,,,,CHEMBL617556,,,,,B,1,4,
,BAO_0000357,1950,H,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,Autocuration,,10624,,17200,,,,,CHEMBL617557,,,,,B,1,8,
,BAO_0000357,1951,H,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,Autocuration,,10624,,17200,,,,,CHEMBL617558,,,,,B,1,8,
,BAO_0000357,1952,H,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,Expert,,17106,,13969,,,,,CHEMBL617559,,,,,B,1,8,
,BAO_0000357,1953,D,Binding affinity for 5-hydroxytryptamine 1D receptor,Expert,,17106,,13392,,,,,CHEMBL617560,,,,,B,1,9,
,BAO_0000249,1954,H,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,Autocuration,,17106,,1742,,,,,CHEMBL617561,,,,,B,1,8,
,BAO_0000249,1955,H,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,Autocuration,,17106,,1742,,,,,CHEMBL617562,,,,,B,1,8,
Striatum,BAO_0000357,1956,H,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,Autocuration,,17106,,14331,2435.0,,,,CHEMBL617563,,,,,B,1,8,
,BAO_0000019,1957,H,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,Autocuration,,17106,,12861,,,,,CHEMBL617564,,,,,F,1,8,
,BAO_0000019,1958,H,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,Expert,,17106,,12861,,,,,CHEMBL617565,,,,,B,1,8,
,BAO_0000357,1959,H,Binding activity radioligand.,Autocuration,,17106,,12861,,,,,CHEMBL856076,,,,,B,1,8,
,BAO_0000019,1960,H,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,Autocuration,,17106,,12861,,,,,CHEMBL617566,,,,,B,1,8,
,BAO_0000019,1961,H,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,Expert,,17106,,12861,,,,,CHEMBL875911,,,,,B,1,8,
,BAO_0000019,1962,H,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,Autocuration,,17106,,12861,,,,,CHEMBL617567,,,,,B,1,8,
,BAO_0000249,1963,H,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,Autocuration,,17106,,675,,,,,CHEMBL617568,,,,,B,1,8,
,BAO_0000019,1964,H,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,Expert,,17106,,12490,,,,,CHEMBL617569,,,,,B,1,8,
,BAO_0000249,1965,H,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,Expert,,17106,,11828,,,,,CHEMBL617570,,,,,B,1,8,
,BAO_0000357,1966,H,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,Autocuration,,17106,,11866,,,,,CHEMBL617571,,,,,B,1,8,
,BAO_0000357,1967,H,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,Autocuration,,105,,773,,9823.0,Sus scrofa,,CHEMBL617572,,,,,B,1,8,
,BAO_0000357,1968,H,The compound was tested for intrinsic activity against 5-HT1D receptor,Expert,,105,,13047,,9986.0,Oryctolagus cuniculus,,CHEMBL617573,,,,,B,1,8,
,BAO_0000019,1969,H,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,Autocuration,,105,,13047,,9986.0,Oryctolagus cuniculus,,CHEMBL617574,,,,,B,1,8,
,BAO_0000357,1970,H,The compound was tested for binding affinity against 5-HT1D receptor,Expert,,105,,13047,,9986.0,Oryctolagus cuniculus,,CHEMBL617575,,,,,B,1,8,
,BAO_0000357,1971,H,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,Autocuration,,10578,,188,,,,,CHEMBL617576,,,,,B,1,8,
,BAO_0000019,1972,H,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,Autocuration,,10578,,10639,,,,,CHEMBL617577,,,,,F,1,8,
,BAO_0000019,1973,H,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,Autocuration,,10578,,12438,,,,,CHEMBL617578,,,,,F,1,8,
,BAO_0000357,1974,H,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,Autocuration,,10578,,12438,,,,,CHEMBL617579,,,,,B,1,8,
,BAO_0000019,1975,H,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,Expert,,10578,,15854,,,,,CHEMBL617580,,,,,B,1,8,
,BAO_0000249,1976,H,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,Autocuration,,10578,,10394,,,,,CHEMBL617581,,,,,B,1,8,
,BAO_0000357,1977,H,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,Autocuration,,10578,,12092,,,,,CHEMBL617582,,,,,B,1,8,
,BAO_0000019,1978,H,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,Expert,,10578,,3389,,,,,CHEMBL617583,,,,,B,1,8,
,BAO_0000357,1979,H,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,Autocuration,,105,,6011,,,,,CHEMBL617584,,,,,B,1,8,
,BAO_0000357,1980,H,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,Autocuration,,105,,4639,,,,,CHEMBL617585,,,,,B,1,8,
,BAO_0000357,1981,H,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,Autocuration,,105,,2474,,,,,CHEMBL875912,,,,,B,1,8,
,BAO_0000357,1982,H,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,Autocuration,,105,,5014,,,,,CHEMBL617586,,,,,B,1,8,
,BAO_0000357,1983,H,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,Autocuration,,105,,17515,,,,,CHEMBL617587,,,,,B,1,8,
,BAO_0000357,1984,H,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,Autocuration,,105,,11866,,,,,CHEMBL617588,,,,,B,1,8,
,BAO_0000357,1985,H,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,Autocuration,,105,,4687,,,,,CHEMBL857980,,,,,B,1,8,
,BAO_0000357,1986,H,Tested against 5-hydroxytryptamine 1D receptor,Autocuration,,105,,12146,,,,,CHEMBL617589,,,,,B,1,8,
,BAO_0000357,1987,H,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,Autocuration,,105,,10321,,,,,CHEMBL617590,,,,,B,1,8,
,BAO_0000219,1988,H,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,Autocuration,722.0,105,,13267,,,,,CHEMBL617591,HEK293,,,,B,1,8,
,BAO_0000357,1989,D,Binding affinity against 5-Hydroxytryptamine 1D receptor,Expert,,105,,1274,,9606.0,Homo sapiens,,CHEMBL617592,,,,,B,1,9,
,BAO_0000357,1990,H,,Autocuration,,105,,15250,,,,,CHEMBL617593,,,,,B,1,8,
,BAO_0000219,1991,H,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,Autocuration,485.0,106,,13706,,,,,CHEMBL617594,CHO-K1,,,,B,1,8,
,BAO_0000219,1992,H,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,Autocuration,485.0,105,,13706,,,,,CHEMBL617595,CHO-K1,,,,B,1,8,
,BAO_0000219,1993,H,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,Autocuration,722.0,105,,13706,,,,,CHEMBL617596,HEK293,,,,B,1,8,
,BAO_0000219,1994,H,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,Autocuration,722.0,105,,13706,,,,,CHEMBL617597,HEK293,,,,B,1,8,
,BAO_0000019,1995,H,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,Autocuration,,105,,13047,,,,,CHEMBL617598,,,,,B,1,8,
,BAO_0000357,1996,H,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,Autocuration,,105,,13366,,,,,CHEMBL872916,,,,,B,1,8,
,BAO_0000357,1997,H,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,Expert,,105,,13366,,,,,CHEMBL617599,,,,,B,1,8,
,BAO_0000357,1998,H,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,Autocuration,,105,,1558,,,,,CHEMBL617091,,,,,B,1,8,
,BAO_0000219,1999,H,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",Expert,485.0,105,,12902,,,,,CHEMBL617092,CHO-K1,,,,B,1,8,
,BAO_0000219,2000,H,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,Autocuration,485.0,105,,13706,,,,,CHEMBL617093,CHO-K1,,,,B,1,8,
,BAO_0000019,2001,H,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,Autocuration,,105,,13706,,,,,CHEMBL617094,,,,,F,1,8,
,BAO_0000019,2002,H,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,Autocuration,,105,,13706,,,,,CHEMBL617095,,,,,F,1,8,
,BAO_0000019,2003,H,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,Autocuration,,105,,14251,,,,,CHEMBL617096,,,,,F,1,8,
,BAO_0000019,2004,H,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,Autocuration,,105,,14251,,,,,CHEMBL617097,,,,,F,1,8,
,BAO_0000019,2005,H,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,Autocuration,,105,,14251,,,,,CHEMBL617098,,,,,F,1,8,
,BAO_0000357,2006,H,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,Autocuration,,105,,13313,,,,,CHEMBL617301,,,,,B,1,8,
,BAO_0000357,2007,H,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,Autocuration,,105,,13313,,,,,CHEMBL617302,,,,,B,1,8,
,BAO_0000357,2008,H,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,Autocuration,,105,,13366,,,,,CHEMBL617303,,,,,B,1,8,
,BAO_0000357,2009,H,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,Expert,,105,,13051,,,,,CHEMBL617304,,,,,B,1,8,
,BAO_0000219,2010,H,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",Expert,449.0,105,,12903,,,,,CHEMBL617305,CHO,,,,B,1,8,
,BAO_0000219,2011,D,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,Autocuration,,105,,12469,,9606.0,Homo sapiens,,CHEMBL617306,,,,,B,1,9,
,BAO_0000357,2012,H,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,Autocuration,,17106,,5619,,,,,CHEMBL617307,,,,,B,1,8,
,BAO_0000019,2013,H,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,Autocuration,,105,,13047,,9986.0,Oryctolagus cuniculus,,CHEMBL617308,,,,,B,1,8,
,BAO_0000357,2014,H,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,Autocuration,,105,,16633,,,,,CHEMBL617309,,,,,B,1,8,
,BAO_0000357,2015,H,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,Autocuration,,105,,16633,,,,,CHEMBL617310,,,,,B,1,8,
,BAO_0000357,2016,H,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,Autocuration,,105,,16633,,,,,CHEMBL617311,,,,,B,1,8,
,BAO_0000357,2017,H,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,Autocuration,,105,,16633,,,,,CHEMBL617312,,,,,B,1,8,
,BAO_0000357,2018,H,Affinity against 5-hydroxytryptamine 1D receptor alpha,Autocuration,,105,,3269,,,,,CHEMBL617313,,,,,B,1,8,
,BAO_0000357,2019,H,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,Expert,,105,,12409,,,,,CHEMBL617314,,,,,B,1,8,
,BAO_0000019,2020,H,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,Autocuration,,106,,13706,,,,,CHEMBL617315,,,,,F,1,8,
,BAO_0000219,2021,H,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,Autocuration,722.0,106,,13706,,,,,CHEMBL617316,HEK293,,,,B,1,8,
,BAO_0000219,2022,H,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,Autocuration,722.0,106,,13706,,,,,CHEMBL617317,HEK293,,,,B,1,8,
,BAO_0000219,2023,H,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",Autocuration,449.0,106,,12903,,,,,CHEMBL617318,CHO,,,,B,1,8,
,BAO_0000019,2024,H,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,Autocuration,,106,,13047,,,,,CHEMBL617319,,,,,B,1,8,
,BAO_0000357,2025,D,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,Expert,,106,,13366,,,,,CHEMBL617320,,,,,B,1,9,
,BAO_0000357,2026,D,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,Expert,,106,,13366,,,,,CHEMBL617321,,,,,B,1,9,
,BAO_0000357,2027,D,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,Expert,,106,,13366,,,,,CHEMBL617322,,,,,B,1,9,
,BAO_0000357,2028,H,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,Autocuration,,106,,13366,,,,,CHEMBL616862,,,,,B,1,8,
,BAO_0000357,2029,H,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,Autocuration,,106,,13366,,,,,CHEMBL616863,,,,,B,1,8,
,BAO_0000219,2030,H,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,Autocuration,449.0,106,,12469,,,,,CHEMBL616864,CHO,,,,B,1,8,
,BAO_0000219,2031,H,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,Autocuration,485.0,106,,13706,,,,,CHEMBL616865,CHO-K1,,,,B,1,8,
,BAO_0000219,2032,H,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,Autocuration,485.0,106,,13706,,,,,CHEMBL616866,CHO-K1,,,,B,1,8,
,BAO_0000019,2033,H,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,Autocuration,,106,,13706,,,,,CHEMBL616867,,,,,F,1,8,
,BAO_0000219,2034,H,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",Expert,485.0,106,,12902,,,,,CHEMBL616868,CHO-K1,,,,B,1,8,
,BAO_0000357,2035,H,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,Expert,,105,,13051,,,,,CHEMBL616869,,,,,B,1,8,
,BAO_0000219,2036,H,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",Expert,449.0,106,,12903,,,,,CHEMBL616870,CHO,,,,B,1,8,
,BAO_0000219,2037,H,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,Autocuration,485.0,105,,1558,,,,,CHEMBL616871,CHO-K1,,,,F,1,8,
,BAO_0000219,2038,H,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,Autocuration,485.0,105,,1558,,,,,CHEMBL616872,CHO-K1,,,,F,1,8,
,BAO_0000219,2039,H,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,Autocuration,485.0,105,,1558,,,,,CHEMBL616873,CHO-K1,,,,F,1,8,
,BAO_0000219,2040,H,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,Autocuration,485.0,105,,1558,,,,,CHEMBL616838,CHO-K1,,,,F,1,8,
,BAO_0000357,2041,H,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,Autocuration,,105,,1558,,,,,CHEMBL616839,,,,,B,1,8,
,BAO_0000019,2042,H,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,Autocuration,,106,,13047,,9986.0,Oryctolagus cuniculus,,CHEMBL616840,,,,,B,1,8,
,BAO_0000357,2043,H,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,Autocuration,,105,,13313,,,,,CHEMBL616841,,,,,B,1,8,
,BAO_0000357,2044,H,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,Autocuration,,105,,13313,,,,,CHEMBL616842,,,,,B,1,8,
,BAO_0000357,2045,H,Binding affinity against 5-hydroxytryptamine 1D receptor beta,Expert,,105,,12409,,,,,CHEMBL857976,,,,,B,1,8,
,BAO_0000219,2046,H,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,Autocuration,449.0,10618,,15250,,,,,CHEMBL616843,CHO,,,,B,1,8,
,BAO_0000357,2047,D,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,Expert,,10618,,1348,,9606.0,Homo sapiens,,CHEMBL616844,,,,,B,1,9,
,BAO_0000357,2048,H,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,Autocuration,,10618,,1348,,,,,CHEMBL616845,,,,,B,1,8,
,BAO_0000357,2049,D,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,Expert,,10618,,4234,,9606.0,Homo sapiens,,CHEMBL616846,,,,,B,1,9,
,BAO_0000357,2050,H,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,Autocuration,,10618,,16209,,,,,CHEMBL616847,,,,,B,1,8,
,BAO_0000019,2051,H,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,Autocuration,,10618,,10444,,,,,CHEMBL616848,,,,,B,1,8,
,BAO_0000357,2052,H,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,Autocuration,,10618,,3935,,,,,CHEMBL616849,,,,,B,1,8,
,BAO_0000357,2053,H,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,Autocuration,,10618,,15818,,,,,CHEMBL872911,,,,,B,1,8,
,BAO_0000019,2054,H,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,Autocuration,,10618,,17085,,,,,CHEMBL616850,,,,,B,1,8,
,BAO_0000219,2055,D,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,Expert,449.0,10618,,12936,,9606.0,Homo sapiens,,CHEMBL616699,CHO,,,,B,1,9,
,BAO_0000357,2056,H,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,Autocuration,,10618,,6166,,,,,CHEMBL616700,,,,,B,1,8,
,BAO_0000219,2057,H,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,Autocuration,449.0,10618,,15779,,,,,CHEMBL616701,CHO,,,,B,1,8,
,BAO_0000219,2058,H,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,Autocuration,449.0,10618,,15779,,,,,CHEMBL616702,CHO,,,,B,1,8,
,BAO_0000219,2059,H,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,Autocuration,449.0,10618,,15779,,,,,CHEMBL616703,CHO,,,,B,1,8,
,BAO_0000357,2060,H,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,Autocuration,,10618,,13181,,,,,CHEMBL616704,,,,,B,1,8,
,BAO_0000219,2061,H,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,Autocuration,449.0,10618,,4199,,,,,CHEMBL616705,CHO,,,,B,1,8,
,BAO_0000357,2062,H,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,Autocuration,,10618,,14875,,,,,CHEMBL616706,,,,,B,1,8,
,BAO_0000219,2063,H,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,Autocuration,449.0,10618,,15146,,,,,CHEMBL616707,CHO,,,,B,1,8,
,BAO_0000357,2064,H,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,Autocuration,,10618,,5213,,,,,CHEMBL616708,,,,,B,1,8,
,BAO_0000357,2065,H,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,Autocuration,,10618,,12146,,,,,CHEMBL616709,,,,,B,1,8,
,BAO_0000219,2066,H,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,Autocuration,449.0,10618,,13267,,,,,CHEMBL616710,CHO,,,,B,1,8,
,BAO_0000219,2067,H,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,Autocuration,449.0,10618,,14818,,,,,CHEMBL616711,CHO,,,,B,1,8,
,BAO_0000219,2068,H,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",Autocuration,449.0,10618,,4829,,,,,CHEMBL616712,CHO,,,,B,1,8,
,BAO_0000357,2069,H,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,Autocuration,,10618,,4373,,,,,CHEMBL616713,,,,,B,1,8,
,BAO_0000357,2070,H,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,Autocuration,,10618,,4373,,,,,CHEMBL616714,,,,,B,1,8,
,BAO_0000357,2071,H,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,Autocuration,,10618,,14159,,,,,CHEMBL616715,,,,,B,1,8,
,BAO_0000357,2072,H,Binding affinity towards 5-hydroxytryptamine 1E receptor,Autocuration,,10618,,16633,,,,,CHEMBL616716,,,,,B,1,8,
,BAO_0000019,2073,H,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",Autocuration,,279,,17085,,,,,CHEMBL616717,,,,,F,1,8,
,BAO_0000019,2074,H,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",Expert,,279,,17085,,,,,CHEMBL616718,,,,,F,1,8,
,BAO_0000019,2075,H,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,Autocuration,,279,,16209,,,,,CHEMBL875905,,,,,F,1,8,
,BAO_0000019,2076,H,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,Autocuration,,279,,16209,,,,,CHEMBL616719,,,,,F,1,8,
,BAO_0000019,2077,H,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",Expert,,279,,17085,,,,,CHEMBL616720,,,,,F,1,8,
,BAO_0000357,2078,H,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,Autocuration,,279,,14159,,,,,CHEMBL616721,,,,,B,1,8,
,BAO_0000219,2079,H,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,Autocuration,449.0,279,,15250,,,,,CHEMBL616722,CHO,,,,B,1,8,
,BAO_0000357,2080,H,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),Autocuration,,279,,3805,,,,,CHEMBL616723,,,,,B,1,8,
,BAO_0000219,2081,H,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,Autocuration,449.0,279,,16190,,,,,CHEMBL616724,CHO,,,,B,1,8,
,BAO_0000357,2082,H,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,Autocuration,,279,,16190,,,,,CHEMBL616725,,,,,B,1,8,
,BAO_0000357,2083,H,Binding affinity towards human 5-hydroxytryptamine 1F receptor,Autocuration,,279,,16209,,,,,CHEMBL616726,,,,,B,1,8,
,BAO_0000357,2084,H,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,Autocuration,,279,,16209,,,,,CHEMBL616727,,,,,B,1,8,
,BAO_0000357,2085,H,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,Autocuration,,279,,16209,,,,,CHEMBL616728,,,,,B,1,8,
,BAO_0000357,2086,H,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,Autocuration,,279,,6866,,,,,CHEMBL616729,,,,,B,1,8,
,BAO_0000019,2087,H,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,Expert,,279,,17085,,,,,CHEMBL616730,,,,,B,1,8,
,BAO_0000357,2088,H,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,Autocuration,,279,,16312,,,,,CHEMBL617125,,,,,B,1,8,
,BAO_0000357,2089,H,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,Autocuration,,279,,6166,,,,,CHEMBL857977,,,,,B,1,8,
,BAO_0000219,2090,H,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,Autocuration,449.0,279,,15779,,,,,CHEMBL617126,CHO,,,,B,1,8,
,BAO_0000219,2091,H,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,Autocuration,449.0,279,,4199,,,,,CHEMBL617127,CHO,,,,B,1,8,
,BAO_0000357,2092,H,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,Autocuration,,279,,14875,,,,,CHEMBL617128,,,,,B,1,8,
,BAO_0000219,2093,H,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,Autocuration,449.0,279,,15146,,,,,CHEMBL617129,CHO,,,,B,1,8,
,BAO_0000357,2094,H,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,Autocuration,,279,,5213,,,,,CHEMBL617130,,,,,B,1,8,
,BAO_0000219,2095,H,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,Autocuration,449.0,279,,14818,,,,,CHEMBL617131,CHO,,,,B,1,8,
,BAO_0000219,2096,H,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",Autocuration,449.0,279,,4829,,,,,CHEMBL617132,CHO,,,,B,1,8,
,BAO_0000219,2097,H,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",Autocuration,449.0,279,,4829,,,,,CHEMBL617133,CHO,,,,B,1,8,
,BAO_0000357,2098,H,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,Autocuration,,279,,4373,,,,,CHEMBL617134,,,,,B,1,8,
,BAO_0000357,2099,H,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,Autocuration,,279,,4373,,,,,CHEMBL617135,,,,,B,1,8,
,BAO_0000357,2100,H,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,Autocuration,,279,,5014,,,,,CHEMBL617136,,,,,B,1,8,
,BAO_0000019,2101,H,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",Autocuration,,104686,,11662,,,,,CHEMBL617137,,,,,B,1,4,
,BAO_0000019,2102,H,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",Autocuration,,104686,,11662,,,,,CHEMBL617138,,,,,B,1,4,
,BAO_0000019,2103,H,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",Autocuration,,104686,,11662,,,,,CHEMBL617139,,,,,B,1,4,
,BAO_0000019,2104,H,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,Autocuration,,12687,,14093,,,,,CHEMBL617140,,,,,B,1,8,
,BAO_0000218,2105,H,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",Autocuration,,104686,,11200,,,,,CHEMBL617141,,,In vivo,,F,1,4,
,BAO_0000019,2106,H,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,Autocuration,,104686,,11200,,,,,CHEMBL858112,,,,,F,1,4,
,BAO_0000019,2107,H,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,Intermediate,,17005,,12352,,,,,CHEMBL617142,,,,,B,1,8,
,BAO_0000019,2108,U,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",Autocuration,,22226,,13657,,9913.0,Bos taurus,,CHEMBL617143,,,,,B,1,0,
,BAO_0000019,2109,U,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,Autocuration,,22226,,14331,,9913.0,Bos taurus,,CHEMBL617144,,,,,B,1,0,
,BAO_0000019,2110,U,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,Autocuration,,22226,,14331,,9913.0,Bos taurus,,CHEMBL617145,,,,,B,1,0,
,BAO_0000019,2111,U,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,Autocuration,,22226,,14331,,,,,CHEMBL617146,,,,,B,1,0,
,BAO_0000019,2112,H,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,Autocuration,,104784,,12685,,10141.0,Cavia porcellus,,CHEMBL617147,,,,,B,1,4,
,BAO_0000019,2113,H,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,Autocuration,,104784,,14389,,10141.0,Cavia porcellus,,CHEMBL617148,,,,,B,1,4,
,BAO_0000019,2114,H,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,Autocuration,,104784,,14386,,10141.0,Cavia porcellus,,CHEMBL617149,,,,,B,1,4,
,BAO_0000224,2115,H,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,Autocuration,,104784,,5732,,,,,CHEMBL617150,,,,,B,1,4,
,BAO_0000224,2116,H,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,Autocuration,,104784,,16293,,,,,CHEMBL617151,,,,,B,1,4,
,BAO_0000224,2117,H,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,Autocuration,,104784,,2078,,,,,CHEMBL617201,,,,,B,1,4,
,BAO_0000357,2118,H,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,Autocuration,,10209,,5486,,,,,CHEMBL617202,,,,,B,1,8,
,BAO_0000218,2119,H,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,Autocuration,,104826,,11820,,,,,CHEMBL617203,,,In vivo,,B,1,4,
,BAO_0000019,2120,H,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,Autocuration,,104826,,10297,,,,,CHEMBL617204,,,,,B,1,4,
,BAO_0000224,2121,H,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,Autocuration,,104826,,13704,,,,,CHEMBL617205,,,,,B,1,4,
,BAO_0000019,2122,D,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,Autocuration,,104826,,10297,,10090.0,Mus musculus,,CHEMBL617206,,,,,B,1,5,
,BAO_0000218,2123,H,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,Autocuration,,104826,,11820,,,,,CHEMBL617207,,,In vivo,,B,1,4,
,BAO_0000019,2124,D,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,Autocuration,,104826,,10297,,10090.0,Mus musculus,,CHEMBL617208,,,,,B,1,5,
,BAO_0000224,2125,H,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,Autocuration,,104826,,11555,,,,,CHEMBL617209,,,,,B,1,4,
,BAO_0000224,2126,H,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,Autocuration,,104826,,11555,,,,,CHEMBL617210,,,,,B,1,4,
,BAO_0000224,2127,H,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,Autocuration,,104826,,11555,,,,,CHEMBL617211,,,,,B,1,4,
,BAO_0000019,2128,D,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,Autocuration,,104826,,10297,,10090.0,Mus musculus,,CHEMBL617212,,,,,B,1,5,
,BAO_0000224,2129,H,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,Autocuration,,104784,,16688,,9823.0,Sus scrofa,,CHEMBL617213,,,,,B,1,4,
,BAO_0000224,2130,H,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,Autocuration,,104784,,16688,,9823.0,Sus scrofa,,CHEMBL617214,,,,,B,1,4,
,BAO_0000221,2131,U,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,Autocuration,,22226,,5333,,,,,CHEMBL617215,,,,,B,1,0,
,BAO_0000221,2132,U,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,Autocuration,,22226,,4437,,,,,CHEMBL617216,,,,,B,1,0,
,BAO_0000357,2133,H,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,Autocuration,,17005,,5033,,9823.0,Sus scrofa,,CHEMBL617217,,,,,B,1,8,
,BAO_0000019,2134,H,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,Autocuration,,104686,,15267,,,,,CHEMBL617218,,,,,B,1,4,
,BAO_0000019,2135,H,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,Autocuration,,104686,,15267,,,,,CHEMBL872913,,,,,B,1,4,
,BAO_0000019,2136,H,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,Autocuration,,104826,,11820,,,,,CHEMBL617219,,,,,B,1,4,
,BAO_0000224,2137,H,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,Autocuration,,104686,,9069,,,,,CHEMBL873482,,,,,B,1,4,
,BAO_0000019,2138,D,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,Autocuration,,104686,,9162,,10116.0,Rattus norvegicus,,CHEMBL617220,,,,,B,1,5,
,BAO_0000019,2139,H,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,Autocuration,,104686,,9162,,,,,CHEMBL617221,,,,,B,1,4,
,BAO_0000019,2140,H,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,Autocuration,,104686,,9162,,,,,CHEMBL617222,,,,,B,1,4,
,BAO_0000019,2141,H,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,Autocuration,,104686,,10428,,,,,CHEMBL875906,,,,,F,1,4,
,BAO_0000019,2142,H,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,Autocuration,,104686,,9628,,,,,CHEMBL617223,,,,,B,1,4,
,BAO_0000224,2143,H,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,Autocuration,,104686,,12704,,,,,CHEMBL617224,,,,,B,1,4,
,BAO_0000224,2144,D,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,Autocuration,,104686,,15453,,10116.0,Rattus norvegicus,,CHEMBL617225,,,,,B,1,5,
,BAO_0000224,2145,H,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,Autocuration,,104686,,188,,,,,CHEMBL617226,,,,,B,1,4,
,BAO_0000224,2146,H,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,Autocuration,,104686,,10349,,,,,CHEMBL617227,,,,,B,1,4,
,BAO_0000224,2147,H,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,Autocuration,,104686,,10349,,,,,CHEMBL617228,,,,,B,1,4,
,BAO_0000224,2148,H,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,Autocuration,,104686,,8868,,,,,CHEMBL617229,,,,,B,1,4,
,BAO_0000224,2149,H,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,Autocuration,,104686,,10025,,,,,CHEMBL617230,,,,,B,1,4,
,BAO_0000224,2150,H,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",Autocuration,,104686,,10025,,,,,CHEMBL617231,,,,,B,1,4,
,BAO_0000224,2151,H,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,Autocuration,,104686,,11702,,,,,CHEMBL617232,,,,,B,1,4,
,BAO_0000224,2152,H,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,Autocuration,,104686,,11702,,,,,CHEMBL617233,,,,,B,1,4,
,BAO_0000224,2153,H,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,Autocuration,,104686,,11702,,,,,CHEMBL617234,,,,,B,1,4,
,BAO_0000019,2154,H,Compound was tested for the inhibition of quipazine induced head twitches in rats,Autocuration,,104686,,11702,,,,,CHEMBL617235,,,,,F,1,4,
,BAO_0000019,2155,H,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,Autocuration,,104686,,11702,,,,,CHEMBL617236,,,,,F,1,4,
Hippocampus,BAO_0000221,2156,H,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,Autocuration,,104686,,10085,10000000.0,,,,CHEMBL617237,,,,,B,1,4,
Hippocampus,BAO_0000221,2157,H,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,Autocuration,,104686,,10085,10000000.0,,,,CHEMBL617238,,,,,B,1,4,
Brain,BAO_0000221,2158,D,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,Autocuration,,104686,,9630,955.0,10116.0,Rattus norvegicus,,CHEMBL617239,,,,,B,1,5,
,BAO_0000019,2159,H,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,Autocuration,,104686,,11070,,,,,CHEMBL617240,,,,,B,1,4,
,BAO_0000249,2160,H,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,Autocuration,,104686,,9841,,,,,CHEMBL617241,,,,Membranes,B,1,4,
,BAO_0000249,2161,H,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,Autocuration,,104686,,9841,,,,,CHEMBL875907,,,,Membranes,B,1,4,
,BAO_0000019,2162,H,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,Autocuration,,104686,,13291,,,,,CHEMBL617242,,,,,B,1,4,
,BAO_0000019,2163,H,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,Autocuration,,104686,,10590,,,,,CHEMBL617152,,,,,F,1,4,
Brain,BAO_0000221,2164,D,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,Autocuration,,104686,,9064,955.0,10116.0,Rattus norvegicus,,CHEMBL617153,,,,,B,1,5,
,BAO_0000249,2165,D,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,Autocuration,,104686,,12268,,10116.0,Rattus norvegicus,,CHEMBL617154,,,,Membranes,B,1,5,
Brain,BAO_0000221,2166,H,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,Autocuration,,104686,,13508,955.0,,,,CHEMBL617155,,,,,B,1,4,
,BAO_0000019,2167,H,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,Autocuration,,104686,,11279,,,,,CHEMBL617156,,,,,F,1,4,
,BAO_0000019,2168,H,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,Autocuration,,104686,,11200,,,,,CHEMBL617157,,,,,F,1,4,
,BAO_0000019,2169,H,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,Autocuration,,104686,,11200,,,,,CHEMBL617158,,,,,F,1,4,
,BAO_0000019,2170,H,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,Autocuration,,104686,,11200,,,,,CHEMBL617159,,,,,F,1,4,
,BAO_0000019,2171,H,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,Autocuration,,104686,,11200,,,,,CHEMBL617160,,,,,F,1,4,
,BAO_0000019,2172,H,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,Autocuration,,104686,,11200,,,,,CHEMBL858113,,,,,F,1,4,
Brain,BAO_0000220,2173,H,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,Autocuration,,104686,,9231,955.0,,,,CHEMBL617247,,,,,B,1,4,
,BAO_0000019,2174,H,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,Autocuration,,104686,,9737,,,,,CHEMBL617248,,,,,B,1,4,
Brain,BAO_0000249,2175,H,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,Autocuration,,104686,,9737,955.0,,,,CHEMBL617249,,,,,B,1,4,
,BAO_0000019,2176,H,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,Autocuration,,104686,,9737,,,,,CHEMBL617250,,,,,B,1,4,
,BAO_0000019,2177,H,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,Autocuration,,104686,,9737,,,,,CHEMBL617251,,,,,B,1,4,
,BAO_0000019,2178,D,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,Autocuration,,104686,,11828,,10116.0,Rattus norvegicus,,CHEMBL617252,,,,,B,1,5,
,BAO_0000019,2179,H,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,Autocuration,,104686,,12253,,,,,CHEMBL617006,,,,,B,1,4,
,BAO_0000019,2180,H,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,Autocuration,,104686,,12253,,,,,CHEMBL617007,,,,,B,1,4,
,BAO_0000019,2181,H,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",Autocuration,,104686,,11279,,,,,CHEMBL617008,,,,,F,1,4,
,BAO_0000019,2182,H,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,Autocuration,,104686,,11866,,,,,CHEMBL617009,,,,,B,1,4,
,BAO_0000224,2183,D,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,Autocuration,,104686,,14424,,10116.0,Rattus norvegicus,,CHEMBL617010,,,,,B,1,5,
,BAO_0000019,2184,D,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,Autocuration,,104686,,15180,,10116.0,Rattus norvegicus,,CHEMBL857978,,,,,B,1,5,
,BAO_0000019,2185,D,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,Autocuration,,104686,,15180,,10116.0,Rattus norvegicus,,CHEMBL617011,,,,,B,1,5,
,BAO_0000019,2186,D,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,Autocuration,,104686,,9786,,10116.0,Rattus norvegicus,,CHEMBL617012,,,,,B,1,5,
,BAO_0000224,2187,H,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,Autocuration,,104686,,12132,,,,,CHEMBL617013,,,,,B,1,4,
,BAO_0000249,2188,H,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,Autocuration,,104686,,5486,,,,,CHEMBL617014,,,,,B,1,4,
,BAO_0000019,2189,H,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,Autocuration,,104686,,15316,,,,,CHEMBL617015,,,,,B,1,4,
,BAO_0000019,2190,H,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,Autocuration,,104686,,16429,,,,,CHEMBL617016,,,,,B,1,4,
,BAO_0000224,2191,H,pKi value for 5-hydroxytryptamine 2 receptor binding site,Autocuration,,104686,,14617,,,,,CHEMBL617017,,,,,B,1,4,
Brain,BAO_0000221,2192,H,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,Autocuration,,104686,,11351,955.0,,,,CHEMBL617018,,,,,B,1,4,
,BAO_0000019,2193,H,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,Autocuration,,104686,,11279,,,,,CHEMBL617019,,,,,F,1,4,
,BAO_0000019,2194,H,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,Autocuration,,105075,,9523,,,,,CHEMBL617020,,,,,B,1,4,
,BAO_0000019,2195,H,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,Autocuration,,105075,,9523,,,,,CHEMBL617021,,,,,B,1,4,
,BAO_0000019,2196,H,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,Autocuration,,105075,,9523,,,,,CHEMBL617022,,,,,B,1,4,
,BAO_0000019,2197,H,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,Autocuration,,105075,,9523,,,,,CHEMBL617023,,,,,B,1,4,
,BAO_0000019,2198,H,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,Autocuration,,105075,,9523,,,,,CHEMBL617024,,,,,B,1,4,
,BAO_0000019,2199,H,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,Autocuration,,105075,,9523,,,,,CHEMBL617025,,,,,B,1,4,
,BAO_0000224,2200,H,Hill coefficient of compound was determined,Autocuration,,105075,,9523,,,,,CHEMBL617026,,,,,B,1,4,
,BAO_0000019,2201,U,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,Autocuration,,22226,,4771,,,,,CHEMBL617027,,,,,B,1,0,
,BAO_0000019,2202,D,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,Autocuration,,104686,,5033,,10116.0,Rattus norvegicus,,CHEMBL617028,,,,,B,1,5,
,BAO_0000019,2203,H,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,Expert,,12687,,10845,,,,,CHEMBL617029,,,,,B,1,8,
,BAO_0000019,2204,H,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,Expert,,12687,,10845,,,,,CHEMBL875908,,,,,B,1,8,
,BAO_0000357,2205,H,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),Autocuration,,12687,,16288,,,,,CHEMBL617030,,,,,B,1,8,
,BAO_0000019,2206,H,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),Autocuration,,12687,,16288,,,,,CHEMBL617031,,,,,B,1,8,
,BAO_0000019,2207,H,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,Autocuration,,12687,,16190,,,,,CHEMBL617032,,,,,B,1,8,
,BAO_0000224,2208,D,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,Autocuration,,104686,,12463,,10116.0,Rattus norvegicus,,CHEMBL617033,,,,,B,1,5,
,BAO_0000224,2209,H,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",Autocuration,,104686,,9699,,,,,CHEMBL617034,,,,,B,1,4,
,BAO_0000224,2210,H,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,Autocuration,,104686,,9699,,,,,CHEMBL617035,,,,,B,1,4,
,BAO_0000019,2211,H,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",Autocuration,,104686,,11662,,,,,CHEMBL617036,,,,,B,1,4,
,BAO_0000224,2212,H,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,Autocuration,,104784,,1205,,,,,CHEMBL617037,,,,,B,1,4,
,BAO_0000219,2213,U,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,Autocuration,,22226,,11376,,,,,CHEMBL617038,,,,,B,1,0,
,BAO_0000219,2214,H,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",Autocuration,,104784,,11376,,,,,CHEMBL617039,,,,,B,1,4,
,BAO_0000224,2215,H,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,Autocuration,,104784,,4639,,,,,CHEMBL617161,,,,,B,1,4,
,BAO_0000224,2216,H,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,Autocuration,,104784,,2222,,,,,CHEMBL617162,,,,,B,1,4,
,BAO_0000224,2217,H,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,Autocuration,,104784,,1558,,,,,CHEMBL617163,,,,,B,1,4,
,BAO_0000224,2218,H,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,Autocuration,,104784,,1089,,,,,CHEMBL617164,,,,,B,1,4,
,BAO_0000249,2219,H,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,Autocuration,,104784,,386,,,,,CHEMBL617165,,,,Brain membranes,B,1,4,
,BAO_0000224,2220,H,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,Autocuration,,104784,,2474,,,,,CHEMBL617166,,,,,B,1,4,
,BAO_0000224,2221,H,Binding affinity towards 5-HT2 receptor,Autocuration,,104784,,17066,,,,,CHEMBL617167,,,,,B,1,4,
,BAO_0000224,2222,H,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,Autocuration,,104784,,959,,,,,CHEMBL872912,,,,,B,1,4,
,BAO_0000224,2223,H,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,Autocuration,,104784,,6398,,,,,CHEMBL617168,,,,,B,1,4,
,BAO_0000224,2224,H,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,Autocuration,,104686,,11889,,,,,CHEMBL617169,,,,,B,1,4,
,BAO_0000224,2225,H,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,Autocuration,,104784,,4221,,,,,CHEMBL617170,,,,,B,1,4,
,BAO_0000224,2226,H,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,Autocuration,,104784,,11026,,,,,CHEMBL617171,,,,,B,1,4,
,BAO_0000224,2227,H,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,Autocuration,,104784,,11866,,,,,CHEMBL617172,,,,,B,1,4,
,BAO_0000224,2228,H,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,Autocuration,,104784,,4221,,,,,CHEMBL617173,,,,,B,1,4,
,BAO_0000019,2229,U,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,Autocuration,,22226,,13950,,,,,CHEMBL617174,,,,,B,1,0,
,BAO_0000224,2230,H,5-hydroxytryptamine 2 receptor binding affinity,Autocuration,,104784,,1263,,,,,CHEMBL617175,,,,,B,1,4,
,BAO_0000357,2231,H,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,Autocuration,,17005,,13291,,,,,CHEMBL617176,,,,,B,1,8,
,BAO_0000357,2232,H,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,Autocuration,,17005,,10812,,,,,CHEMBL617177,,,,,B,1,8,
,BAO_0000224,2233,H,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,Autocuration,,104784,,13020,,,,,CHEMBL617178,,,,,B,1,4,
,BAO_0000224,2234,H,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,Autocuration,,104784,,13021,,,,,CHEMBL617179,,,,,B,1,4,
,BAO_0000224,2235,H,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,Autocuration,,104784,,13020,,,,,CHEMBL617180,,,,,B,1,4,
,BAO_0000357,2236,H,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,Autocuration,,17005,,14532,,,,,CHEMBL617181,,,,,B,1,8,
,BAO_0000357,2237,H,Binding affinity against 5-hydroxytryptamine 2 receptor,Autocuration,,17005,,13944,,,,,CHEMBL617182,,,,,B,1,8,
,BAO_0000357,2238,H,Binding affinity against 5-hydroxytryptamine 2 receptor,Autocuration,,17005,,14331,,,,,CHEMBL617183,,,,,B,1,8,
,BAO_0000357,2239,H,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,Autocuration,,17005,,14118,,,,,CHEMBL617184,,,,,B,1,8,
,BAO_0000357,2240,H,Binding affinity against serotonergic 5-HT2 receptor,Autocuration,,17005,,13033,,,,,CHEMBL617185,,,,,B,1,8,
,BAO_0000357,2241,H,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,Autocuration,,17005,,10321,,,,,CHEMBL617186,,,,,B,1,8,
,BAO_0000357,2242,H,Compound was evaluated for the binding affinity at 5- HT2 receptor,Autocuration,,17005,,12918,,,,,CHEMBL617187,,,,,B,1,8,
,BAO_0000357,2243,H,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,Autocuration,,17005,,15120,,,,,CHEMBL617188,,,,,B,1,8,
,BAO_0000218,2244,H,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,Autocuration,,17005,,2613,,,,,CHEMBL617189,,,,,B,1,8,
,BAO_0000224,2245,D,Inhibitory activity against cloned human 5-HT2 receptor,Autocuration,,104784,,13378,,9606.0,Homo sapiens,,CHEMBL617190,,,,,B,1,5,
,BAO_0000219,2246,D,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",Autocuration,449.0,104784,,2331,,9606.0,Homo sapiens,,CHEMBL617191,CHO,,,,B,1,5,
,BAO_0000219,2247,D,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",Autocuration,449.0,104784,,2331,,9606.0,Homo sapiens,,CHEMBL617192,CHO,,,,B,1,5,
,BAO_0000219,2248,D,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",Autocuration,449.0,104784,,2331,,9606.0,Homo sapiens,,CHEMBL617193,CHO,,,,B,1,5,
,BAO_0000219,2249,D,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",Autocuration,449.0,104784,,2331,,9606.0,Homo sapiens,,CHEMBL617194,CHO,,,,B,1,5,
,BAO_0000224,2250,H,Binding affinity towards 5-hydroxytryptamine 2 receptor,Autocuration,,104784,,4170,,,,,CHEMBL617195,,,,,B,1,4,
,BAO_0000224,2251,H,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,Autocuration,,104784,,15453,,,,,CHEMBL881830,,,,,B,1,4,
,BAO_0000357,2252,H,Binding affinity towards 5-hydroxytryptamine 2 receptor,Autocuration,,17005,,1479,,,,,CHEMBL617196,,,,,B,1,8,
,BAO_0000224,2253,H,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,Autocuration,,104686,,11139,,,,,CHEMBL617197,,,,,B,1,4,
,BAO_0000357,2254,H,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,Expert,,17005,,13969,,,,,CHEMBL617198,,,,,B,1,8,
,BAO_0000357,2255,H,Binding affinity towards 5-hydroxytryptamine 2A receptor,Expert,,17005,,13392,,,,,CHEMBL873476,,,,,B,1,8,
,BAO_0000019,2256,H,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,Expert,,17005,,14430,,,,,CHEMBL617199,,,,,B,1,8,
,BAO_0000357,2257,H,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,Autocuration,,107,,13181,,10141.0,Cavia porcellus,,CHEMBL617200,,,,,B,1,8,
,BAO_0000357,2258,H,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,Autocuration,,51,,17200,,,,,CHEMBL617484,,,,,B,1,8,
,BAO_0000357,2259,H,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,Autocuration,,107,,17200,,,,,CHEMBL617485,,,,,B,1,8,
,BAO_0000357,2260,H,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,Autocuration,,51,,17200,,,,,CHEMBL617486,,,,,B,1,8,
,BAO_0000357,2261,H,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,Autocuration,,107,,13463,,,,,CHEMBL858022,,,,,B,1,8,
,BAO_0000219,2262,H,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,Autocuration,449.0,107,,6347,,,,,CHEMBL617049,CHO,,,,B,1,8,
,BAO_0000219,2263,D,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,Expert,449.0,107,,6857,,9606.0,Homo sapiens,,CHEMBL617050,CHO,,,,F,1,9,
,BAO_0000219,2264,H,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,Autocuration,,107,,4176,,,,,CHEMBL617051,,,,,F,1,8,
,BAO_0000219,2265,H,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,Autocuration,,107,,4176,,,,,CHEMBL617052,,,,,F,1,8,
,BAO_0000219,2266,H,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,Autocuration,,107,,4176,,,,,CHEMBL617053,,,,,F,1,8,
,BAO_0000219,2267,H,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",Autocuration,449.0,107,,6347,,,,,CHEMBL617054,CHO,,,,B,1,8,
,BAO_0000219,2268,H,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",Autocuration,449.0,107,,6347,,,,,CHEMBL617055,CHO,,,,B,1,8,
,BAO_0000357,2269,H,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,Autocuration,,107,,15331,,,,,CHEMBL882924,,,,,B,1,8,
,BAO_0000357,2270,D,Inhibition of human 5-hydroxytryptamine 2A receptor,Expert,,107,,16146,,9606.0,Homo sapiens,,CHEMBL617056,,,,,B,1,9,
,BAO_0000219,2271,H,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,Autocuration,449.0,107,,15250,,,,,CHEMBL617057,CHO,,,,B,1,8,
,BAO_0000219,2272,H,Inhibitory concentration against human 5-HT2A receptor in BEK cells,Expert,,107,,13631,,,,,CHEMBL617058,,,,,B,1,8,
,BAO_0000357,2273,H,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),Autocuration,,107,,3805,,,,,CHEMBL617059,,,,,B,1,8,
,BAO_0000219,2274,H,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,Autocuration,449.0,107,,4011,,,,,CHEMBL617060,CHO,,,,B,1,8,
,BAO_0000219,2275,H,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,Expert,449.0,107,,4012,,,,,CHEMBL617061,CHO,,,,B,1,8,
,BAO_0000219,2276,H,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,Expert,307.0,107,,6366,,,,,CHEMBL617062,L929,,,,B,1,8,
,BAO_0000219,2277,H,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,Expert,449.0,107,,15949,,,,,CHEMBL617063,CHO,,,,B,1,8,
,BAO_0000019,2278,H,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,Autocuration,,107,,14093,,,,,CHEMBL617064,,,,,F,1,8,
,BAO_0000019,2279,H,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,Autocuration,,107,,13481,,,,,CHEMBL617065,,,,,F,1,8,
,BAO_0000219,2280,H,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,Autocuration,449.0,107,,6347,,,,,CHEMBL617066,CHO,,,,B,1,8,
,BAO_0000219,2281,H,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,Autocuration,449.0,107,,6347,,,,,CHEMBL617067,CHO,,,,B,1,8,
,BAO_0000019,2282,H,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,Autocuration,,107,,14093,,,,,CHEMBL617068,,,,,F,1,8,
,BAO_0000019,2283,H,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,Autocuration,,107,,14093,,,,,CHEMBL617069,,,,,F,1,8,
,BAO_0000019,2284,H,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,Autocuration,,107,,13481,,,,,CHEMBL617070,,,,,F,1,8,
,BAO_0000357,2285,H,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,Autocuration,,107,,14442,,,,,CHEMBL617071,,,,,B,1,8,
,BAO_0000357,2286,H,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,Autocuration,,107,,14442,,,,,CHEMBL872915,,,,,B,1,8,
,BAO_0000357,2287,H,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,Autocuration,,107,,14755,,,,,CHEMBL617072,,,,,B,1,8,
,BAO_0000357,2288,H,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,Autocuration,,107,,16441,,,,,CHEMBL617073,,,,,B,1,8,
,BAO_0000357,2289,H,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,Autocuration,,107,,14744,,,,,CHEMBL617074,,,,,B,1,8,
,BAO_0000219,2290,H,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,Expert,449.0,107,,16659,,,,,CHEMBL617075,CHO,,,,B,1,8,
,BAO_0000357,2291,H,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,Autocuration,,107,,3307,,,,,CHEMBL617076,,,,,B,1,8,
,BAO_0000019,2292,D,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,Expert,,107,,6857,,9606.0,Homo sapiens,,CHEMBL617077,,,,,B,1,9,
,BAO_0000357,2293,H,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,Expert,,107,,5635,,,,,CHEMBL617078,,,,,B,1,8,
,BAO_0000357,2294,D,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,Expert,,107,,4234,,9606.0,Homo sapiens,,CHEMBL617079,,,,,B,1,9,
,BAO_0000357,2295,H,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,Autocuration,,107,,15527,,,,,CHEMBL617080,,,,,B,1,8,
,BAO_0000219,2296,H,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,Expert,449.0,107,,6588,,,,,CHEMBL617081,CHO,,,,B,1,8,
,BAO_0000219,2297,H,Binding affinity towards human 5-HT2A receptor in BEK cells,Expert,,107,,13631,,,,,CHEMBL617082,,,,,B,1,8,
,BAO_0000357,2298,H,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,Autocuration,,107,,17723,,,,,CHEMBL617083,,,,,B,1,8,
,BAO_0000357,2299,H,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,Autocuration,,107,,14770,,,,,CHEMBL617084,,,,,B,1,8,
,BAO_0000357,2300,D,Binding affinity for human 5-hydroxytryptamine 2A receptor,Expert,,107,,16293,,9606.0,Homo sapiens,,CHEMBL617085,,,,,B,1,9,
,BAO_0000357,2301,H,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,Autocuration,,107,,16209,,,,,CHEMBL617086,,,,,B,1,8,
,BAO_0000219,2302,H,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,Autocuration,,107,,12469,,,,,CHEMBL617087,,,,,B,1,8,
,BAO_0000357,2303,H,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,Autocuration,,107,,15363,,,,,CHEMBL617088,,,,,B,1,8,
,BAO_0000357,2304,H,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,Autocuration,,107,,15363,,,,,CHEMBL617089,,,,,B,1,8,
,BAO_0000019,2305,H,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",Expert,,107,,16441,,,,,CHEMBL617090,,,,,B,1,8,
,BAO_0000357,2306,H,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,Autocuration,,107,,8,,,,,CHEMBL617513,,,,,B,1,8,
,BAO_0000219,2307,H,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,Autocuration,722.0,107,,4176,,,,,CHEMBL617514,HEK293,,,,B,1,8,
,BAO_0000019,2308,H,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,Autocuration,,107,,17085,,,,,CHEMBL617515,,,,,B,1,8,
,BAO_0000357,2309,H,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,Autocuration,,107,,17200,,,,,CHEMBL617516,,,,,B,1,8,
,BAO_0000357,2310,D,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,Expert,,107,,17200,,9606.0,Homo sapiens,,CHEMBL617517,,,,,B,1,9,
,BAO_0000219,2311,D,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,Expert,449.0,107,,4013,,9606.0,Homo sapiens,,CHEMBL617518,CHO,,,,B,1,9,
,BAO_0000357,2312,H,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,Autocuration,,107,,5088,,,,,CHEMBL617519,,,,,B,1,8,
,BAO_0000357,2313,D,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,Expert,,107,,5088,,9606.0,Homo sapiens,,CHEMBL617520,,,,,B,1,9,
,BAO_0000357,2314,H,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,Autocuration,,107,,5088,,,,,CHEMBL617521,,,,,B,1,8,
,BAO_0000357,2315,D,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,Expert,,107,,5088,,9606.0,Homo sapiens,,CHEMBL617522,,,,,B,1,9,
,BAO_0000357,2316,H,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,Autocuration,,107,,5088,,,,,CHEMBL617523,,,,,B,1,8,
,BAO_0000357,2317,H,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,Autocuration,,107,,5088,,,,,CHEMBL617524,,,,,B,1,8,
,BAO_0000019,2318,H,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,Autocuration,,104686,,9786,,,,,CHEMBL617525,,,,,B,1,4,
,BAO_0000019,2319,D,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,Autocuration,,104686,,9205,,10116.0,Rattus norvegicus,,CHEMBL617526,,,,,B,1,5,
,BAO_0000224,2320,H,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,Autocuration,,104686,,11257,,,,,CHEMBL617527,,,,,B,1,4,
,BAO_0000019,2321,H,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,Autocuration,,104686,,9362,,,,,CHEMBL617528,,,,,B,1,4,
,BAO_0000019,2322,H,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,Autocuration,,104686,,9362,,,,,CHEMBL617529,,,,,B,1,4,
,BAO_0000224,2323,H,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,Autocuration,,104686,,10590,,,,,CHEMBL617530,,,,,B,1,4,
,BAO_0000019,2324,H,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,Autocuration,,104686,,10468,,,,,CHEMBL617531,,,,,B,1,4,
,BAO_0000019,2325,H,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,Autocuration,,104686,,13050,,,,,CHEMBL617532,,,,,B,1,4,
,BAO_0000019,2326,H,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,Autocuration,,104686,,11624,,,,,CHEMBL617533,,,,,B,1,4,
,BAO_0000019,2327,H,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,Autocuration,,104686,,10468,,,,,CHEMBL617534,,,,,B,1,4,
,BAO_0000224,2328,H,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,Autocuration,,104686,,10330,,,,,CHEMBL617535,,,,,B,1,4,
,BAO_0000224,2329,H,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,Autocuration,,104686,,10062,,,,,CHEMBL617536,,,,,B,1,4,
,BAO_0000224,2330,H,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,Autocuration,,104686,,11642,,,,,CHEMBL617537,,,,,B,1,4,
,BAO_0000224,2331,H,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,Autocuration,,104686,,10062,,,,,CHEMBL617538,,,,,B,1,4,
,BAO_0000219,2332,H,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,Autocuration,,104686,,13427,,,,,CHEMBL617539,,,In vitro,,B,1,4,
,BAO_0000224,2333,D,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,Autocuration,,104686,,12280,,10116.0,Rattus norvegicus,,CHEMBL617540,,,,,B,1,5,
,BAO_0000224,2334,D,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,Autocuration,,104686,,4101,,10116.0,Rattus norvegicus,,CHEMBL617541,,,,,B,1,5,
,BAO_0000224,2335,H,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,Autocuration,,104686,,10062,,,,,CHEMBL617542,,,,,B,1,4,
,BAO_0000224,2336,H,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,Autocuration,,104686,,11147,,,,,CHEMBL617543,,,,,B,1,4,
,BAO_0000219,2337,D,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,Autocuration,485.0,104686,,2395,,10116.0,Rattus norvegicus,,CHEMBL617544,CHO-K1,,,,B,1,5,
,BAO_0000219,2338,D,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,Autocuration,485.0,104686,,2395,,10116.0,Rattus norvegicus,,CHEMBL617545,CHO-K1,,,,B,1,5,
,BAO_0000019,2339,D,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,Autocuration,,104686,,9098,,10116.0,Rattus norvegicus,,CHEMBL617413,,,,,B,1,5,
,BAO_0000019,2340,H,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,Autocuration,,104686,,9098,,,,,CHEMBL617414,,,,,B,1,4,
,BAO_0000019,2341,D,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,Autocuration,,104686,,9098,,10116.0,Rattus norvegicus,,CHEMBL617415,,,,,B,1,5,
,BAO_0000224,2342,H,Binding affinity towards 5-hydroxytryptamine 2 receptor,Autocuration,,104686,,9443,,,,,CHEMBL617416,,,,,B,1,4,
,BAO_0000224,2343,H,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,Autocuration,,104686,,9443,,,,,CHEMBL617417,,,,,B,1,4,
,BAO_0000019,2344,H,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",Autocuration,,104686,,9699,,,,,CHEMBL617418,,,,,B,1,4,
,BAO_0000019,2345,H,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,Autocuration,,104686,,9699,,,,,CHEMBL617419,,,,,B,1,4,
,BAO_0000224,2346,H,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,Autocuration,,104686,,9098,,,,,CHEMBL617420,,,,,B,1,4,
,BAO_0000224,2347,D,Affinity for 5-hydroxytryptamine 2 receptor,Autocuration,,104686,,3070,,10116.0,Rattus norvegicus,,CHEMBL617421,,,,,B,1,5,
,BAO_0000224,2348,H,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,Autocuration,,104686,,9547,,,,,CHEMBL617422,,,,,B,1,4,
,BAO_0000019,2349,H,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,Autocuration,,104686,,10444,,,,,CHEMBL617423,,,,,B,1,4,
,BAO_0000019,2350,H,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,Autocuration,,104686,,14617,,,,,CHEMBL617424,,,,,B,1,4,
,BAO_0000019,2351,H,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,Autocuration,,104686,,14617,,,,,CHEMBL617425,,,,,B,1,4,
,BAO_0000224,2352,H,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),Autocuration,,104686,,11130,,,,,CHEMBL617426,,,,,B,1,4,
,BAO_0000218,2353,H,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),Autocuration,,104686,,11130,,,,,CHEMBL617427,,,In vivo,,B,1,4,
Brain,BAO_0000221,2354,H,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,Autocuration,,104686,,14542,955.0,,,,CHEMBL617428,,,,,B,1,4,
,BAO_0000224,2355,H,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,Autocuration,,104686,,2797,,,,,CHEMBL617429,,,,,B,1,4,
,BAO_0000019,2356,H,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,Autocuration,,104686,,11332,,,,,CHEMBL617430,,,,,B,1,4,
,BAO_0000019,2357,H,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,Autocuration,,104686,,11332,,,,,CHEMBL617431,,,,,B,1,4,
Frontal cortex,BAO_0000019,2358,H,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,Autocuration,,104686,,10752,1870.0,,,,CHEMBL617432,,,,,B,1,4,
,BAO_0000224,2359,H,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,Autocuration,,104686,,1185,,,,,CHEMBL617433,,,,,B,1,4,
,BAO_0000224,2360,H,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,Autocuration,,104686,,1185,,,,,CHEMBL617434,,,,,B,1,4,
,BAO_0000224,2361,D,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,Autocuration,,104686,,11624,,10116.0,Rattus norvegicus,,CHEMBL617435,,,,,B,1,5,
,BAO_0000019,2362,H,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,Autocuration,,104686,,1344,,,,,CHEMBL617436,,,,,B,1,4,
Striatum,BAO_0000019,2363,D,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,Autocuration,,104686,,15453,2435.0,10116.0,Rattus norvegicus,,CHEMBL617437,,,,,B,1,5,
,BAO_0000019,2364,H,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",Autocuration,,104686,,11662,,,,,CHEMBL617438,,,,,B,1,4,
,BAO_0000019,2365,H,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",Autocuration,,104686,,11662,,,,,CHEMBL617439,,,,,B,1,4,
,BAO_0000224,2366,H,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,Autocuration,,104686,,10796,,,,,CHEMBL617440,,,,,B,1,4,
,BAO_0000224,2367,H,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,Autocuration,,104686,,9069,,,,,CHEMBL617441,,,,,B,1,4,
,BAO_0000019,2368,D,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,Autocuration,,104686,,8814,,10116.0,Rattus norvegicus,,CHEMBL872918,,,,,B,1,5,
,BAO_0000019,2369,D,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,Autocuration,,104686,,8908,,10116.0,Rattus norvegicus,,CHEMBL617442,,,,,B,1,5,
,BAO_0000019,2370,H,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,Autocuration,,104686,,9098,,,,,CHEMBL617443,,,,,B,1,4,
,BAO_0000019,2371,H,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,Autocuration,,104686,,9098,,,,,CHEMBL617444,,,,,B,1,4,
,BAO_0000019,2372,H,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,Autocuration,,104686,,9098,,,,,CHEMBL617445,,,,,B,1,4,
,BAO_0000019,2373,H,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,Autocuration,,104686,,9098,,,,,CHEMBL617446,,,,,B,1,4,
,BAO_0000249,2374,H,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,Autocuration,,104686,,9098,,,,,CHEMBL617447,,,,,B,1,4,
,BAO_0000019,2375,H,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,Autocuration,,104686,,9098,,,,,CHEMBL617448,,,,,B,1,4,
,BAO_0000019,2376,H,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,Autocuration,,104686,,9098,,,,,CHEMBL617449,,,,,B,1,4,
,BAO_0000019,2377,H,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,Autocuration,,104686,,9161,,,,,CHEMBL617450,,,,,B,1,4,
,BAO_0000019,2378,H,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,Autocuration,,104686,,9161,,,,,CHEMBL617451,,,,,B,1,4,
,BAO_0000019,2379,H,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,Autocuration,,104686,,9161,,,,,CHEMBL617452,,,,,B,1,4,
,BAO_0000019,2380,H,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,Autocuration,,104686,,9161,,,,,CHEMBL617453,,,,,B,1,4,
,BAO_0000019,2381,H,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,Autocuration,,104686,,9161,,,,,CHEMBL617660,,,,,B,1,4,
,BAO_0000019,2382,H,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,Autocuration,,104686,,9161,,,,,CHEMBL617661,,,,,B,1,4,
,BAO_0000019,2383,H,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,Autocuration,,104686,,9161,,,,,CHEMBL617662,,,,,B,1,4,
,BAO_0000019,2384,H,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,Autocuration,,104686,,9161,,,,,CHEMBL872919,,,,,B,1,4,
,BAO_0000019,2385,H,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,Autocuration,,104686,,9161,,,,,CHEMBL617663,,,,,B,1,4,
,BAO_0000019,2386,H,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,Autocuration,,104686,,9161,,,,,CHEMBL617664,,,,,B,1,4,
,BAO_0000019,2387,H,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,Autocuration,,104686,,9161,,,,,CHEMBL617665,,,,,B,1,4,
,BAO_0000019,2388,H,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,Autocuration,,104686,,9161,,,,,CHEMBL617666,,,,,B,1,4,
,BAO_0000019,2389,H,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,Autocuration,,104686,,12094,,,,,CHEMBL617667,,,,,B,1,4,
,BAO_0000249,2390,H,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,Autocuration,,104686,,12018,,,,,CHEMBL617668,,,,,B,1,4,
,BAO_0000249,2391,H,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,Autocuration,,104686,,10394,,,,,CHEMBL617669,,,,,B,1,4,
,BAO_0000224,2392,H,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,Autocuration,,104686,,15260,,,,,CHEMBL617670,,,,,B,1,4,
,BAO_0000224,2393,D,Inhibitory constant against 5-hydroxytryptamine 2 receptor,Autocuration,,104686,,11624,,10116.0,Rattus norvegicus,,CHEMBL617671,,,,,B,1,5,
,BAO_0000224,2394,H,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,Autocuration,,104686,,13654,,,,,CHEMBL617672,,,,,B,1,4,
,BAO_0000019,2395,H,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,Autocuration,,104686,,9541,,,,,CHEMBL617673,,,,,B,1,4,
,BAO_0000224,2396,H,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,Autocuration,,104686,,11933,,,,,CHEMBL617674,,,,,B,1,4,
,BAO_0000019,2397,H,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,Autocuration,,104686,,15538,,,,,CHEMBL617675,,,,,B,1,4,
,BAO_0000019,2398,H,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,Autocuration,,104686,,15538,,,,,CHEMBL617676,,,,,B,1,4,
,BAO_0000019,2399,H,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,Autocuration,,104686,,15538,,,,,CHEMBL617677,,,,,B,1,4,
,BAO_0000019,2400,D,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,Autocuration,,104686,,8841,,,,,CHEMBL617678,,,,,B,1,5,
,BAO_0000224,2401,H,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,Autocuration,,104686,,1455,,,,,CHEMBL617679,,,,,B,1,4,
,BAO_0000224,2402,H,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,Autocuration,,104686,,1455,,,,,CHEMBL617680,,,,,B,1,4,
,BAO_0000019,2403,H,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,Autocuration,,104686,,11752,,,,,CHEMBL617681,,,,,B,1,4,
Brain,BAO_0000221,2404,H,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,Autocuration,,104686,,11642,955.0,,,,CHEMBL617682,,,,,B,1,4,
,BAO_0000224,2405,H,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,Autocuration,,104686,,12092,,,,,CHEMBL617683,,,,,B,1,4,
,BAO_0000224,2406,H,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,Autocuration,,104686,,3967,,,,,CHEMBL617684,,,,,B,1,4,
,BAO_0000224,2407,D,Binding affinity towards 5-hydroxytryptamine 2 receptor,Autocuration,,104686,,12771,,10116.0,Rattus norvegicus,,CHEMBL617685,,,,,B,1,5,
,BAO_0000019,2408,H,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,Autocuration,,104686,,11642,,,,,CHEMBL617686,,,,,B,1,4,
,BAO_0000224,2409,H,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,Autocuration,,104686,,11628,,,,,CHEMBL617687,,,,,B,1,4,
,BAO_0000224,2410,H,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,Autocuration,,104686,,13654,,,,,CHEMBL617688,,,,,B,1,4,
,BAO_0000019,2411,H,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,Autocuration,,104686,,11200,,,,,CHEMBL617689,,,,,F,1,4,
,BAO_0000019,2412,H,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,Autocuration,,104686,,11200,,,,,CHEMBL617690,,,,,F,1,4,
,BAO_0000218,2413,H,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",Autocuration,,104686,,11200,,,,,CHEMBL617691,,,In vivo,,F,1,4,
,BAO_0000218,2414,H,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",Autocuration,,104686,,11200,,,,,CHEMBL617692,,,In vivo,,F,1,4,
,BAO_0000218,2415,H,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",Autocuration,,104686,,11200,,,,,CHEMBL617693,,,In vivo,,F,1,4,
,BAO_0000218,2416,H,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",Autocuration,,104686,,11200,,,,,CHEMBL617694,,,In vivo,,F,1,4,
Brain,BAO_0000221,2417,H,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,Expert,,12687,,15436,955.0,,,,CHEMBL857985,,,,,B,1,8,
,BAO_0000019,2418,D,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,Expert,,12687,,15436,,10116.0,Rattus norvegicus,,CHEMBL617695,,,,,B,1,9,
,BAO_0000019,2419,H,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,Autocuration,,12687,,14025,,,,,CHEMBL617696,,,,,B,1,8,
,BAO_0000357,2420,H,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,Autocuration,,12687,,4342,,,,,CHEMBL617697,,,,,B,1,8,
,BAO_0000019,2421,D,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,Expert,,12687,,13735,,10116.0,Rattus norvegicus,,CHEMBL617257,,,,,B,1,9,
,BAO_0000357,2422,D,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,Expert,,12687,,5816,,10116.0,Rattus norvegicus,,CHEMBL617258,,,,,B,1,9,
,BAO_0000019,2423,H,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,Expert,,12687,,14287,,,,,CHEMBL617259,,,,,B,1,8,
,BAO_0000357,2424,H,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,Autocuration,,12687,,15738,,,,,CHEMBL617260,,,,,B,1,8,
,BAO_0000357,2425,D,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,Expert,,12687,,15738,,10116.0,Rattus norvegicus,,CHEMBL617261,,,,,B,1,9,
,BAO_0000019,2426,H,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,Autocuration,,12687,,15026,,,,,CHEMBL617262,,,,,B,1,8,
,BAO_0000019,2427,H,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,Expert,,12687,,16647,,,,,CHEMBL617263,,,,,B,1,8,
,BAO_0000019,2428,H,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,Autocuration,,12687,,16647,,,,,CHEMBL617264,,,,,B,1,8,
,BAO_0000019,2429,D,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,Expert,,12687,,13345,,10116.0,Rattus norvegicus,,CHEMBL617265,,,,,B,1,9,
,BAO_0000249,2430,H,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,Autocuration,,12687,,1543,,,,,CHEMBL617266,,,,Membranes,B,1,8,
,BAO_0000019,2431,H,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,Autocuration,,12687,,12444,,,,,CHEMBL617267,,,,,B,1,8,
,BAO_0000019,2432,H,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,Expert,,12687,,16404,,,,,CHEMBL617268,,,,,B,1,8,
,BAO_0000219,2433,H,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,Autocuration,449.0,12687,,16404,,,,,CHEMBL617269,CHO,,,,B,1,8,
,BAO_0000357,2434,H,Kinetic inhibition constant evaluated by measuring serotonergic activity,Expert,,12687,,15577,,,,,CHEMBL617323,,,,,B,1,8,
,BAO_0000357,2435,H,Serotonergic activity of the compound.,Autocuration,,12687,,15577,,,,,CHEMBL617324,,,,,B,1,8,
,BAO_0000249,2436,H,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,Autocuration,,12687,,2495,,,,,CHEMBL617325,,,,,B,1,8,
,BAO_0000019,2437,D,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,Expert,,12687,,15042,,10116.0,Rattus norvegicus,,CHEMBL617326,,,,,B,1,9,
,BAO_0000249,2438,H,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,Expert,,12687,,15026,,,,,CHEMBL617327,,,,,B,1,8,
,BAO_0000019,2439,D,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,Expert,,12687,,12919,,10116.0,Rattus norvegicus,,CHEMBL617328,,,,,F,1,9,
,BAO_0000019,2440,D,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,Expert,,12687,,12919,,10116.0,Rattus norvegicus,,CHEMBL617329,,,,,F,1,9,
,BAO_0000019,2441,D,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,Expert,,12687,,12919,,10116.0,Rattus norvegicus,,CHEMBL617330,,,,,F,1,9,
,BAO_0000357,2442,H,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,Autocuration,,12687,,15194,,,,,CHEMBL617331,,,,,B,1,8,
,BAO_0000357,2443,H,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,Autocuration,,12687,,15194,,,,,CHEMBL617332,,,,,B,1,8,
,BAO_0000357,2444,H,Binding affinity towards 5-hydroxytryptamine 2A receptor,Expert,,107,,4820,,,,,CHEMBL617333,,,,,B,1,8,
,BAO_0000357,2445,H,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,Autocuration,,107,,6736,,,,,CHEMBL617334,,,,,B,1,8,
,BAO_0000357,2446,H,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,Autocuration,,107,,5163,,,,,CHEMBL617335,,,,,B,1,8,
,BAO_0000357,2447,H,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,Autocuration,,107,,5163,,,,,CHEMBL617336,,,,,B,1,8,
,BAO_0000357,2448,H,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,Autocuration,,107,,6011,,,,,CHEMBL617337,,,,,B,1,8,
,BAO_0000357,2449,D,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,Expert,,107,,14294,,9606.0,Homo sapiens,,CHEMBL617338,,,,,B,1,9,
,BAO_0000357,2450,H,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,Autocuration,,107,,5014,,,,,CHEMBL617339,,,,,B,1,8,
,BAO_0000357,2451,H,Binding affinity towards 5-hydroxytryptamine 2A receptor,Expert,,107,,17066,,,,,CHEMBL617340,,,,,B,1,8,
,BAO_0000357,2452,H,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,Autocuration,,107,,17515,,,,,CHEMBL617341,,,,,B,1,8,
,BAO_0000357,2453,H,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,Expert,,107,,6736,,,,,CHEMBL617342,,,,,B,1,8,
,BAO_0000357,2454,H,Affinity for 5-hydroxytryptamine 2A receptor,Expert,,107,,5163,,,,,CHEMBL617343,,,,,B,1,8,
,BAO_0000219,2455,H,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,Expert,723.0,107,,16911,,,,,CHEMBL617344,NIH3T3,,,,B,1,8,
,BAO_0000357,2456,H,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,Expert,,107,,6841,,,,,CHEMBL617345,,,,,B,1,8,
,BAO_0000357,2457,H,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,Expert,,107,,6119,,,,,CHEMBL617346,,,,,B,1,8,
,BAO_0000357,2458,H,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,Autocuration,,107,,3962,,,,,CHEMBL617347,,,,,B,1,8,
,BAO_0000357,2459,H,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,Autocuration,,107,,4373,,,,,CHEMBL617348,,,,,B,1,8,
,BAO_0000357,2460,H,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,Autocuration,,107,,4373,,,,,CHEMBL617349,,,,,B,1,8,
,BAO_0000019,2461,H,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,Autocuration,,107,,3962,,,,,CHEMBL617350,,,,,F,1,8,
,BAO_0000357,2462,H,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,Expert,,107,,1633,,,,,CHEMBL872339,,,,,B,1,8,
,BAO_0000357,2463,H,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,Autocuration,,107,,4373,,,,,CHEMBL617351,,,,,B,1,8,
,BAO_0000357,2464,H,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,Expert,,107,,6576,,,,,CHEMBL617352,,,,,B,1,8,
,BAO_0000357,2465,H,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,Autocuration,,107,,4687,,,,,CHEMBL617353,,,,,B,1,8,
,BAO_0000357,2466,H,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,Autocuration,,107,,16946,,,,,CHEMBL617354,,,,,B,1,8,
,BAO_0000357,2467,H,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,Autocuration,,107,,14159,,,,,CHEMBL617355,,,,,B,1,8,
,BAO_0000219,2468,H,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,Expert,449.0,107,,3032,,10090.0,Mus musculus,,CHEMBL617356,CHO,,,,B,1,8,
,BAO_0000357,2469,H,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,Autocuration,,107,,16655,,,,,CHEMBL617357,,,,,B,1,8,
,BAO_0000357,2470,H,Binding affinity at 5-hydroxytryptamine 2A receptor,Autocuration,,107,,13964,,,,,CHEMBL617358,,,,,B,1,8,
,BAO_0000357,2471,H,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,Expert,,107,,16989,,,,,CHEMBL617359,,,,,B,1,8,
,BAO_0000357,2472,H,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,Autocuration,,107,,16117,,,,,CHEMBL617360,,,,,B,1,8,
,BAO_0000357,2473,H,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,Autocuration,,107,,16700,,,,,CHEMBL875913,,,,,B,1,8,
,BAO_0000357,2474,H,Affinity against 5-hydroxytryptamine 2A receptor,Autocuration,,107,,3269,,,,,CHEMBL617361,,,,,B,1,8,
,BAO_0000357,2475,D,Binding affinity against 5-Hydroxytryptamine 2A receptor,Expert,,107,,1274,,9606.0,Homo sapiens,,CHEMBL617362,,,,,B,1,9,
,BAO_0000357,2476,H,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,Autocuration,,107,,1317,,,,,CHEMBL617363,,,,,B,1,8,
,BAO_0000357,2477,H,Tested against 5-hydroxytryptamine 2A receptor,Autocuration,,107,,12146,,,,,CHEMBL617364,,,,,B,1,8,
,BAO_0000224,2478,H,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,Autocuration,,105075,,12652,,,,,CHEMBL617365,,,,,B,1,4,
,BAO_0000224,2479,H,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,Autocuration,,105075,,12652,,,,,CHEMBL617366,,,,,B,1,4,
,BAO_0000224,2480,H,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,Autocuration,,105075,,12652,,,,,CHEMBL617367,,,,,B,1,4,
,BAO_0000224,2481,H,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,Autocuration,,105075,,12652,,,,,CHEMBL617368,,,,,B,1,4,
,BAO_0000357,2482,H,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),Autocuration,,107,,16647,,,,,CHEMBL617369,,,,,B,1,8,
,BAO_0000219,2483,D,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,Expert,722.0,227,,15851,,9606.0,Homo sapiens,,CHEMBL617370,HEK293,,,,B,1,9,
,BAO_0000219,2484,D,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,Expert,449.0,227,,6857,,9606.0,Homo sapiens,,CHEMBL617371,CHO,,,,F,1,9,
,BAO_0000357,2485,H,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),Autocuration,,227,,3805,,,,,CHEMBL617372,,,,,B,1,8,
,BAO_0000357,2486,D,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,Expert,,227,,6491,,9606.0,Homo sapiens,,CHEMBL617373,,,,,B,1,9,
,BAO_0000019,2487,H,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,Autocuration,,227,,14093,,,,,CHEMBL617374,,,,,F,1,8,
,BAO_0000019,2488,H,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,Autocuration,,227,,13481,,,,,CHEMBL617375,,,,,F,1,8,
,BAO_0000019,2489,H,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,Autocuration,,227,,14093,,,,,CHEMBL617376,,,,,F,1,8,
,BAO_0000019,2490,H,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,Autocuration,,227,,14093,,,,,CHEMBL617377,,,,,F,1,8,
,BAO_0000019,2491,H,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,Autocuration,,227,,14093,,,,,CHEMBL617378,,,,,F,1,8,
,BAO_0000019,2492,H,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,Autocuration,,227,,13481,,,,,CHEMBL617379,,,,,F,1,8,
,BAO_0000357,2493,H,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,Autocuration,,227,,14442,,,,,CHEMBL617380,,,,,B,1,8,
,BAO_0000357,2494,H,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,Autocuration,,227,,14442,,,,,CHEMBL617381,,,,,B,1,8,
,BAO_0000357,2495,H,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,Autocuration,,227,,14442,,,,,CHEMBL617382,,,,,B,1,8,
,BAO_0000357,2496,H,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,Autocuration,,107,,12369,,,,,CHEMBL617383,,,,,B,1,8,
,BAO_0000357,2497,H,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,Expert,,107,,12369,,,,,CHEMBL617384,,,,,B,1,8,
,BAO_0000357,2498,H,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,Expert,,107,,12369,,,,,CHEMBL617385,,,,,B,1,8,
,BAO_0000019,2499,H,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,Autocuration,,107,,14447,,,,,CHEMBL617386,,,,,B,1,8,
,BAO_0000019,2500,H,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,Autocuration,,107,,14447,,,,,CHEMBL617387,,,,,B,1,8,
,BAO_0000219,2501,H,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,Autocuration,723.0,107,,17451,,,,,CHEMBL617388,NIH3T3,,,,B,1,8,
,BAO_0000219,2502,H,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,Autocuration,449.0,107,,6857,,,,,CHEMBL617389,CHO,,,,F,1,8,
,BAO_0000219,2503,D,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,Expert,449.0,107,,6857,,9606.0,Homo sapiens,,CHEMBL617390,CHO,,,,F,1,9,
,BAO_0000224,2504,H,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,Autocuration,,104817,,5635,,,,,CHEMBL617391,,,,,B,1,4,
,BAO_0000357,2505,H,Binding activity radioligand.,Autocuration,,107,,12861,,,,,CHEMBL617392,,,,,B,1,8,
,BAO_0000019,2506,H,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,Autocuration,,107,,12861,,,,,CHEMBL617393,,,,,B,1,8,
,BAO_0000219,2507,H,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,Autocuration,307.0,107,,5105,,,,,CHEMBL617394,L929,,,,B,1,8,
,BAO_0000219,2508,H,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,Expert,307.0,107,,5104,,,,,CHEMBL617395,L929,,,,B,1,8,
,BAO_0000219,2509,H,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,Expert,307.0,107,,5105,,,,,CHEMBL617396,L929,,,,B,1,8,
,BAO_0000219,2510,H,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,Autocuration,307.0,107,,5105,,,,,CHEMBL617397,L929,,,,B,1,8,
,BAO_0000357,2511,H,Binding affinity against 5-HT2A receptor,Autocuration,,107,,5254,,,,,CHEMBL617398,,,,,B,1,8,
,BAO_0000357,2512,H,Binding affinity against 5-hydroxytryptamine 2A receptor,Autocuration,,107,,5254,,,,,CHEMBL617399,,,,,B,1,8,
,BAO_0000219,2513,H,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,Autocuration,722.0,107,,13267,,,,,CHEMBL617400,HEK293,,,,B,1,8,
,BAO_0000219,2514,H,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,Autocuration,722.0,107,,13267,,,,,CHEMBL617401,HEK293,,,,B,1,8,
,BAO_0000219,2515,D,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,Expert,722.0,107,,14157,,9606.0,Homo sapiens,,CHEMBL617402,HEK293,,,,B,1,9,
,BAO_0000219,2516,D,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,Expert,722.0,107,,12936,,9606.0,Homo sapiens,,CHEMBL617403,HEK293,,,,B,1,9,
,BAO_0000357,2517,H,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,Expert,,107,,14068,,,,,CHEMBL617404,,,,,B,1,8,
,BAO_0000219,2518,D,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,Expert,722.0,107,,12936,,9606.0,Homo sapiens,,CHEMBL857981,HEK293,,,,B,1,9,
,BAO_0000219,2519,D,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,Expert,722.0,107,,12936,,9606.0,Homo sapiens,,CHEMBL617405,HEK293,,,,B,1,9,
,BAO_0000219,2520,D,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,Expert,722.0,107,,4540,,9606.0,Homo sapiens,,CHEMBL617253,HEK293,,,,B,1,9,
,BAO_0000357,2521,H,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,Expert,,107,,6166,,,,,CHEMBL617254,,,,,B,1,8,
,BAO_0000219,2522,H,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,Autocuration,722.0,107,,17296,,,,,CHEMBL617255,HEK293,,,,B,1,8,
,BAO_0000219,2523,H,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,Autocuration,722.0,107,,17296,,,,,CHEMBL617256,HEK293,,,,B,1,8,
,BAO_0000219,2524,H,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,Autocuration,722.0,107,,17296,,,,,CHEMBL616874,HEK293,,,,B,1,8,
,BAO_0000219,2525,D,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,Expert,722.0,107,,15779,,9606.0,Homo sapiens,,CHEMBL616875,HEK293,,,,B,1,9,
,BAO_0000219,2526,H,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,Expert,722.0,107,,14391,,,,,CHEMBL616876,HEK293,,,,B,1,8,
,BAO_0000219,2527,H,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",Expert,722.0,107,,15851,,,,,CHEMBL616877,HEK293,,,,B,1,8,
,BAO_0000219,2528,D,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,Expert,722.0,107,,15851,,9606.0,Homo sapiens,,CHEMBL616878,HEK293,,,,B,1,9,
,BAO_0000219,2529,H,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,Expert,722.0,107,,3832,,,,,CHEMBL616879,HEK293,,,,B,1,8,
,BAO_0000219,2530,H,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,Expert,722.0,107,,3833,,,,,CHEMBL616880,HEK293,,,,B,1,8,
,BAO_0000219,2531,D,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,Expert,722.0,107,,12936,,9606.0,Homo sapiens,,CHEMBL616881,HEK293,,,,B,1,9,
,BAO_0000219,2532,H,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,Autocuration,723.0,107,,17451,,,,,CHEMBL616882,NIH3T3,,,,B,1,8,
,BAO_0000219,2533,H,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,Autocuration,723.0,107,,17451,,,,,CHEMBL616883,NIH3T3,,,,B,1,8,
,BAO_0000219,2534,H,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,Autocuration,723.0,107,,17451,,,,,CHEMBL616884,NIH3T3,,,,B,1,8,
,BAO_0000219,2535,H,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,Autocuration,722.0,107,,4199,,,,,CHEMBL616885,HEK293,,,,B,1,8,
,BAO_0000219,2536,H,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,Autocuration,485.0,107,,1883,,,,,CHEMBL616886,CHO-K1,,,,B,1,8,
,BAO_0000219,2537,H,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,Expert,485.0,107,,1883,,,,,CHEMBL616887,CHO-K1,,,,B,1,8,
,BAO_0000357,2538,D,Binding affinity for human 5-hydroxytryptamine 2A receptor,Expert,,107,,14875,,9606.0,Homo sapiens,,CHEMBL616888,,,,,B,1,9,
,BAO_0000219,2539,H,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,Autocuration,722.0,107,,15146,,,,,CHEMBL616889,HEK293,,,,B,1,8,
,BAO_0000219,2540,H,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,Autocuration,722.0,107,,5213,,,,,CHEMBL616890,HEK293,,,,B,1,8,
,BAO_0000219,2541,D,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,Expert,449.0,107,,16404,,9606.0,Homo sapiens,,CHEMBL616891,CHO,,,,B,1,9,
,BAO_0000219,2542,H,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,Autocuration,722.0,107,,14818,,,,,CHEMBL616892,HEK293,,,,B,1,8,
,BAO_0000219,2543,H,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",Autocuration,722.0,107,,4829,,,,,CHEMBL616893,HEK293,,,,B,1,8,
,BAO_0000219,2544,H,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,Autocuration,723.0,10620,,12652,,,,,CHEMBL616894,NIH3T3,,,,F,1,8,
,BAO_0000219,2545,H,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,Expert,723.0,107,,4682,,,,,CHEMBL616895,NIH3T3,,,,B,1,8,
,BAO_0000019,2546,H,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,Autocuration,,10620,,12652,,,,,CHEMBL616896,,,,,F,1,8,
,BAO_0000357,2547,H,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,Autocuration,,10621,,4921,,,,,CHEMBL617099,,,,,B,1,8,
,BAO_0000357,2548,H,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,Autocuration,,10621,,4921,,,,,CHEMBL617100,,,,,B,1,8,
,BAO_0000357,2549,H,Binding affinity against rabbit aorta 5-HT2A receptor,Autocuration,,107,,16312,,9986.0,Oryctolagus cuniculus,,CHEMBL884532,,,,,B,1,8,
,BAO_0000357,2550,H,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,Expert,,107,,14998,,9986.0,Oryctolagus cuniculus,,CHEMBL617101,,,,,B,1,8,
,BAO_0000357,2551,H,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,Expert,,107,,14025,,9986.0,Oryctolagus cuniculus,,CHEMBL617102,,,,,B,1,8,
,BAO_0000019,2552,H,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,Autocuration,,107,,13047,,9986.0,Oryctolagus cuniculus,,CHEMBL617103,,,,,B,1,8,
,BAO_0000357,2553,H,The compound was tested for binding affinity against 5-HT2A receptor,Expert,,107,,13047,,9986.0,Oryctolagus cuniculus,,CHEMBL617104,,,,,B,1,8,
,BAO_0000219,2554,H,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,Autocuration,485.0,10576,,1883,,,,,CHEMBL857979,CHO-K1,,,,B,1,8,
,BAO_0000019,2555,H,Binding affinity analysed towards 5-HT 2A in rat jugular vein,Autocuration,,12687,,13463,,,,,CHEMBL857502,,,,,B,1,8,
,BAO_0000019,2556,H,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,Autocuration,,12687,,13463,,,,,CHEMBL617105,,,,,B,1,8,
Stomach,BAO_0000019,2557,H,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,Autocuration,,12687,,13463,945.0,,,,CHEMBL858021,,,,,B,1,8,
Stomach,BAO_0000019,2558,D,Binding affinity for 5-HT 2A in rat stomach fundus,Expert,,12687,,13463,945.0,10116.0,Rattus norvegicus,,CHEMBL875910,,,,,B,1,9,
,BAO_0000019,2559,H,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,Autocuration,,12687,,13463,,,,,CHEMBL617106,,,,,B,1,8,
,BAO_0000219,2560,H,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,Expert,723.0,12687,,16326,,,,,CHEMBL617107,NIH3T3,,,,B,1,8,
,BAO_0000019,2561,H,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,Autocuration,,12687,,14093,,,,,CHEMBL617108,,,,,F,1,8,
,BAO_0000019,2562,H,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,Autocuration,,12687,,14093,,,,,CHEMBL617109,,,,,F,1,8,
,BAO_0000357,2563,H,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,Autocuration,,12687,,15740,,,,,CHEMBL617110,,,,,B,1,8,
,BAO_0000357,2564,H,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,Autocuration,,12687,,16633,,,,,CHEMBL617111,,,,,B,1,8,
,BAO_0000019,2565,D,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,Expert,,12687,,17200,,10116.0,Rattus norvegicus,,CHEMBL617112,,,,,F,1,9,
,BAO_0000357,2566,H,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,Autocuration,,12687,,17133,,,,,CHEMBL617113,,,,,B,1,8,
,BAO_0000357,2567,H,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,Autocuration,,12687,,17133,,,,,CHEMBL617114,,,,,B,1,8,
,BAO_0000357,2568,H,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,Autocuration,,12687,,17133,,,,,CHEMBL617115,,,,,B,1,8,
,BAO_0000219,2569,H,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,Autocuration,,12687,,17200,,,,,CHEMBL617116,,,,,F,1,8,
,BAO_0000019,2570,H,Efficacy at 5-hydroxytryptamine 2A receptor,Autocuration,,12687,,15363,,,,,CHEMBL617117,,,,,F,1,8,
,BAO_0000357,2571,H,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),Autocuration,,12687,,17200,,,,,CHEMBL617118,,,,,B,1,8,
,BAO_0000357,2572,D,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),Expert,,12687,,17200,,10116.0,Rattus norvegicus,,CHEMBL617119,,,,,B,1,9,
,BAO_0000357,2573,D,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),Expert,,12687,,17200,,10116.0,Rattus norvegicus,,CHEMBL617120,,,,,B,1,9,
,BAO_0000219,2574,D,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,Expert,,12687,,17200,,10116.0,Rattus norvegicus,,CHEMBL617121,,,,,F,1,9,
,BAO_0000219,2575,H,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,Autocuration,,12687,,17200,,,,,CHEMBL617122,,,,,F,1,8,
,BAO_0000019,2576,H,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,Autocuration,,12687,,17211,,,,,CHEMBL617123,,,,,B,1,8,
,BAO_0000019,2577,H,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,Expert,,12687,,17331,,,,,CHEMBL617124,,,,,B,1,8,
,BAO_0000249,2578,H,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,Expert,,12687,,13565,,,,,CHEMBL617600,,,,,B,1,8,
,BAO_0000357,2579,H,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,Expert,,12687,,13730,,,,,CHEMBL617601,,,,,B,1,8,
,BAO_0000019,2580,H,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,Expert,,12687,,12416,,,,,CHEMBL882923,,,,,B,1,8,
,BAO_0000357,2581,H,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,Autocuration,,12687,,15295,,,,,CHEMBL617602,,,,,B,1,8,
,BAO_0000019,2582,H,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,Autocuration,,12687,,1742,,,,,CHEMBL617603,,,,,B,1,8,
,BAO_0000357,2583,H,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,Autocuration,,12687,,15295,,,,,CHEMBL617604,,,,,B,1,8,
,BAO_0000019,2584,H,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,Expert,,12687,,14970,,,,,CHEMBL617605,,,,,B,1,8,
,BAO_0000019,2585,H,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,Expert,,12687,,16693,,,,,CHEMBL617606,,,,,B,1,8,
,BAO_0000019,2586,D,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,Expert,,12687,,14776,,10116.0,Rattus norvegicus,,CHEMBL617607,,,,,B,1,9,
,BAO_0000249,2587,H,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,Autocuration,,12687,,14286,,,,,CHEMBL617455,,,,,B,1,8,
,BAO_0000019,2588,D,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,Expert,,12687,,17200,,10116.0,Rattus norvegicus,,CHEMBL617456,,,,,B,1,9,
,BAO_0000357,2589,H,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),Expert,,12687,,15306,,,,,CHEMBL617457,,,,,B,1,8,
,BAO_0000357,2590,D,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,Expert,,12687,,14178,,10116.0,Rattus norvegicus,,CHEMBL617458,,,,,B,1,9,
,BAO_0000019,2591,D,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,Expert,,12687,,14229,,10116.0,Rattus norvegicus,,CHEMBL617459,,,,,B,1,9,
,BAO_0000357,2592,H,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,Expert,,12687,,12884,,,,,CHEMBL617460,,,,,B,1,8,
,BAO_0000357,2593,H,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",Expert,,12687,,13149,,,,,CHEMBL617461,,,,,B,1,8,
,BAO_0000019,2594,D,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,Expert,,12687,,15295,,10116.0,Rattus norvegicus,,CHEMBL617462,,,,,B,1,9,
,BAO_0000357,2595,H,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,Autocuration,,12687,,15740,,,,,CHEMBL617463,,,,,B,1,8,
,BAO_0000019,2596,H,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",Autocuration,,12687,,15185,,,,,CHEMBL617464,,,,,B,1,8,
,BAO_0000019,2597,H,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",Autocuration,,12687,,15185,,,,,CHEMBL617465,,,,,B,1,8,
,BAO_0000019,2598,H,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,Expert,,12687,,17529,,,,,CHEMBL617466,,,,,B,1,8,
,BAO_0000019,2599,H,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,Autocuration,,12687,,14826,,,,,CHEMBL617467,,,,,B,1,8,
,BAO_0000019,2600,H,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,Expert,,12687,,17211,,,,,CHEMBL617468,,,,,B,1,8,
,BAO_0000019,2601,H,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,Autocuration,,12687,,14826,,,,,CHEMBL617469,,,,,B,1,8,
,BAO_0000019,2602,H,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,Autocuration,,12687,,14093,,,,,CHEMBL617470,,,,,B,1,8,
,BAO_0000019,2603,H,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,Autocuration,,12687,,14093,,,,,CHEMBL617471,,,,,B,1,8,
,BAO_0000219,2604,H,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,Expert,723.0,12687,,13246,,,,,CHEMBL617472,NIH3T3,,,,B,1,8,
,BAO_0000357,2605,H,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,Expert,,12687,,13246,,,,,CHEMBL617473,,,,,B,1,8,
,BAO_0000019,2606,D,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,Expert,,12687,,15436,,10116.0,Rattus norvegicus,,CHEMBL617474,,,,,B,1,9,
,BAO_0000019,2607,D,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,Expert,,12687,,15436,,10116.0,Rattus norvegicus,,CHEMBL617475,,,,,B,1,9,
Brain,BAO_0000221,2608,H,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,Autocuration,,12687,,14442,955.0,,,,CHEMBL617476,,,,,B,1,8,
,BAO_0000357,2609,H,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,Expert,,12687,,12457,,,,,CHEMBL617477,,,,,B,1,8,
,BAO_0000219,2610,H,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,Expert,723.0,12687,,12457,,,,,CHEMBL617478,NIH3T3,,,,B,1,8,
,BAO_0000221,2611,H,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",Autocuration,,12687,,14755,,,,,CHEMBL617479,,,,,F,1,8,
,BAO_0000357,2612,H,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,Autocuration,,12687,,4707,,,,,CHEMBL617480,,,,,B,1,8,
,BAO_0000357,2613,H,Binding affinity against 5-hydroxytryptamine 2A receptor,Expert,,12687,,13297,,,,,CHEMBL617481,,,,,B,1,8,
,BAO_0000019,2614,H,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,Expert,,12687,,17331,,,,,CHEMBL617482,,,,,B,1,8,
,BAO_0000019,2615,H,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,Autocuration,,12687,,4664,,,,,CHEMBL617483,,,,,B,1,8,
,BAO_0000357,2616,H,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,Autocuration,,12687,,16633,,,,,CHEMBL621528,,,,,B,1,8,
,BAO_0000219,2617,D,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,Expert,723.0,12687,,4664,,10116.0,Rattus norvegicus,,CHEMBL621529,NIH3T3,,,,B,1,9,
,BAO_0000357,2618,H,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,Expert,,12687,,16133,,,,,CHEMBL621530,,,,,B,1,8,
,BAO_0000357,2619,H,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,Expert,,12687,,16133,,,,,CHEMBL621531,,,,,B,1,8,
,BAO_0000019,2620,D,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,Expert,,12687,,14060,,10116.0,Rattus norvegicus,,CHEMBL621532,,,,,B,1,9,
,BAO_0000357,2621,H,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,Expert,,12687,,16326,,,,,CHEMBL621533,,,,,B,1,8,
,BAO_0000219,2622,H,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,Expert,449.0,12687,,16659,,,,,CHEMBL621534,CHO,,,,B,1,8,
,BAO_0000019,2623,H,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,Autocuration,,12687,,14776,,,,,CHEMBL621535,,,,,B,1,8,
,BAO_0000357,2624,H,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,Autocuration,,12687,,13481,,,,,CHEMBL621536,,,,,B,1,8,
,BAO_0000357,2625,H,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,Autocuration,,12687,,17386,,,,,CHEMBL621537,,,,,B,1,8,
,BAO_0000357,2626,D,Binding affinity for 5-hydroxytryptamine 2A receptor,Expert,,12687,,6611,,10116.0,Rattus norvegicus,,CHEMBL621538,,,,,B,1,9,
,BAO_0000019,2627,H,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,Autocuration,,12687,,14423,,,,,CHEMBL621539,,,,,B,1,8,
,BAO_0000019,2628,H,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,Autocuration,,12687,,15412,,,,,CHEMBL621540,,,,,B,1,8,
,BAO_0000019,2629,H,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,Autocuration,,12687,,15412,,,,,CHEMBL621541,,,,,B,1,8,
,BAO_0000019,2630,H,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,Autocuration,,12687,,6238,,,,,CHEMBL621542,,,,,B,1,8,
,BAO_0000357,2631,H,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,Expert,,12687,,6648,,,,,CHEMBL621543,,,,,B,1,8,
,BAO_0000357,2632,H,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,Expert,,12687,,5667,,,,,CHEMBL621544,,,,,B,1,8,
,BAO_0000357,2633,D,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,Expert,,12687,,6611,,10116.0,Rattus norvegicus,,CHEMBL621545,,,,,B,1,9,
,BAO_0000357,2634,H,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,Autocuration,,12687,,13481,,,,,CHEMBL621546,,,,,B,1,8,
,BAO_0000357,2635,H,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,Autocuration,,12687,,13481,,,,,CHEMBL621547,,,,,B,1,8,
,BAO_0000219,2636,H,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,Expert,723.0,12687,,15558,,,,,CHEMBL618692,NIH3T3,,,,B,1,8,
,BAO_0000357,2637,H,Binding affinity towards 5-hydroxytryptamine 2A receptor,Autocuration,,12687,,6013,,,,,CHEMBL618693,,,,,B,1,8,
,BAO_0000357,2638,H,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,Autocuration,,12687,,16633,,,,,CHEMBL872922,,,,,B,1,8,
,BAO_0000357,2639,H,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,Autocuration,,12687,,6013,,,,,CHEMBL618694,,,,,B,1,8,
,BAO_0000357,2640,D,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,Expert,,12687,,6013,,10116.0,Rattus norvegicus,,CHEMBL618695,,,,,B,1,9,
,BAO_0000357,2641,H,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,Autocuration,,12687,,6013,,,,,CHEMBL618696,,,,,B,1,8,
,BAO_0000357,2642,H,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,Expert,,12687,,6013,,,,,CHEMBL618697,,,,,B,1,8,
,BAO_0000357,2643,H,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,Autocuration,,12687,,6013,,,,,CHEMBL618892,,,,,B,1,8,
,BAO_0000357,2644,H,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,Autocuration,,12687,,6013,,,,,CHEMBL618893,,,,,B,1,8,
,BAO_0000357,2645,H,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,Autocuration,,12687,,16293,,,,,CHEMBL618894,,,,,B,1,8,
,BAO_0000219,2646,H,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,Expert,723.0,12687,,17175,,,,,CHEMBL618895,NIH3T3,,,,B,1,8,
,BAO_0000357,2647,D,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,Expert,,12687,,13278,,10116.0,Rattus norvegicus,,CHEMBL618896,,,,,B,1,9,
Caudate-putamen,BAO_0000019,2648,H,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,Autocuration,,12687,,3682,5383.0,,,,CHEMBL618897,,,,,B,1,8,
,BAO_0000357,2649,H,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,Autocuration,,12687,,2014,,,,,CHEMBL618898,,,,,B,1,8,
,BAO_0000357,2650,H,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,Autocuration,,12687,,2014,,,,,CHEMBL618899,,,,,B,1,8,
,BAO_0000357,2651,H,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,Autocuration,,12687,,4932,,,,,CHEMBL618900,,,,,B,1,8,
,BAO_0000019,2652,H,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,Autocuration,,12687,,4932,,,,,CHEMBL618901,,,,,B,1,8,
,BAO_0000357,2653,H,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,Autocuration,,12687,,3935,,,,,CHEMBL618902,,,,,B,1,8,
Hippocampus,BAO_0000221,2654,D,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,Expert,,12687,,5432,10000000.0,10116.0,Rattus norvegicus,,CHEMBL618903,,,,,B,1,9,
,BAO_0000357,2655,H,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,Autocuration,,12687,,15818,,,,,CHEMBL618904,,,,,B,1,8,
,BAO_0000357,2656,H,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,Autocuration,,12687,,13672,,,,,CHEMBL618905,,,,,B,1,8,
,BAO_0000357,2657,H,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,Autocuration,,12687,,13672,,,,,CHEMBL618906,,,,,B,1,8,
,BAO_0000219,2658,H,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,Expert,723.0,12687,,14749,,,,,CHEMBL618907,NIH3T3,,,,B,1,8,
,BAO_0000019,2659,H,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,Autocuration,,12687,,13462,,,,,CHEMBL618908,,,,,B,1,8,
,BAO_0000357,2660,H,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,Autocuration,,12687,,15740,,,,,CHEMBL617909,,,,,B,1,8,
,BAO_0000019,2661,H,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,Expert,,12687,,16647,,,,,CHEMBL617910,,,,,B,1,8,
Brain,BAO_0000221,2662,H,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,Autocuration,,12687,,13345,955.0,,,,CHEMBL617911,,,,,B,1,8,
,BAO_0000249,2663,H,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,Autocuration,,12687,,16740,,,,,CHEMBL872923,,,,,B,1,8,
,BAO_0000249,2664,H,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,Autocuration,,12687,,16740,,,,,CHEMBL617912,,,,,B,1,8,
,BAO_0000019,2665,D,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,Expert,,12687,,15535,,10116.0,Rattus norvegicus,,CHEMBL617913,,,,,B,1,9,
,BAO_0000249,2666,H,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,Expert,,12687,,16740,,,,,CHEMBL617914,,,,,B,1,8,
,BAO_0000249,2667,H,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,Autocuration,,12687,,16740,,,,,CHEMBL617915,,,,,B,1,8,
,BAO_0000249,2668,H,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,Autocuration,,12687,,16740,,,,,CHEMBL617916,,,,,B,1,8,
,BAO_0000019,2669,D,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,Expert,,12687,,4795,,10116.0,Rattus norvegicus,,CHEMBL617917,,,,,B,1,9,
,BAO_0000019,2670,H,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,Expert,,12687,,8,,,,,CHEMBL617918,,,,,B,1,8,
,BAO_0000019,2671,H,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,Autocuration,,12687,,8,,,,,CHEMBL617919,,,,,B,1,8,
,BAO_0000019,2672,D,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,Expert,,12687,,17200,,10116.0,Rattus norvegicus,,CHEMBL617920,,,,,B,1,9,
,BAO_0000019,2673,D,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,Expert,,12687,,2148,,10116.0,Rattus norvegicus,,CHEMBL617921,,,,,B,1,9,
,BAO_0000224,2674,D,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",Expert,,105102,,13345,,10116.0,Rattus norvegicus,,CHEMBL617922,,,,,B,1,5,
,BAO_0000357,2675,H,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,Autocuration,,12687,,5088,,,,,CHEMBL617923,,,,,B,1,8,
,BAO_0000357,2676,H,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,Autocuration,,12687,,5088,,,,,CHEMBL617924,,,,,B,1,8,
,BAO_0000357,2677,H,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,Autocuration,,12687,,17133,,,,,CHEMBL617925,,,,,B,1,8,
,BAO_0000357,2678,D,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,Expert,,12687,,17133,,10116.0,Rattus norvegicus,,CHEMBL617926,,,,,B,1,9,
,BAO_0000357,2679,H,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,Autocuration,,12687,,16532,,,,,CHEMBL617927,,,,,B,1,8,
,BAO_0000357,2680,H,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,Autocuration,,12687,,15086,,,,,CHEMBL617928,,,,,B,1,8,
,BAO_0000019,2681,D,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,Expert,,12687,,2309,,10116.0,Rattus norvegicus,,CHEMBL617929,,,,,B,1,9,
,BAO_0000019,2682,H,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,Expert,,12687,,12953,,,,,CHEMBL617930,,,,,B,1,8,
,BAO_0000019,2683,H,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,Autocuration,,12687,,12953,,,,,CHEMBL617931,,,,,B,1,8,
,BAO_0000019,2684,H,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,Autocuration,,12687,,12953,,,,,CHEMBL617932,,,,,B,1,8,
,BAO_0000219,2685,H,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,Autocuration,449.0,12687,,16659,,,,,CHEMBL617933,CHO,,,,B,1,8,
,BAO_0000019,2686,H,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,Autocuration,,12687,,16740,,,,,CHEMBL617934,,,,,B,1,8,
,BAO_0000019,2687,H,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,Autocuration,,12687,,16740,,,,,CHEMBL617935,,,,,B,1,8,
,BAO_0000357,2688,H,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,Autocuration,,12687,,17133,,,,,CHEMBL617936,,,,,B,1,8,
,BAO_0000019,2689,H,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,Autocuration,,12687,,17211,,,,,CHEMBL617937,,,,,B,1,8,
,BAO_0000019,2690,H,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,Autocuration,,12687,,17331,,,,,CHEMBL617938,,,,,B,1,8,
,BAO_0000218,2691,H,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,Autocuration,,12687,,16633,,,,,CHEMBL617939,,,,,B,1,8,
,BAO_0000218,2692,H,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,Autocuration,,12687,,16633,,,,,CHEMBL617940,,,,,B,1,8,
,BAO_0000218,2693,H,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,Autocuration,,12687,,16633,,,,,CHEMBL617941,,,,,B,1,8,
,BAO_0000357,2694,H,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,Expert,,12687,,15026,,,,,CHEMBL617942,,,,,B,1,8,
,BAO_0000357,2695,H,Ratio of pKi of 5-HT2A to that of D2 receptor,Expert,,12687,,15026,,,,,CHEMBL617943,,,,,B,1,8,
,BAO_0000224,2696,H,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,Expert,,105093,,16404,,,,,CHEMBL617944,,,,,B,1,4,
,BAO_0000224,2697,H,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,Expert,,105093,,16404,,,,,CHEMBL617945,,,,,B,1,4,
,BAO_0000224,2698,H,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,Expert,,105075,,16404,,,,,CHEMBL617946,,,,,B,1,4,
,BAO_0000357,2699,H,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,Autocuration,,12687,,16404,,,,,CHEMBL617947,,,,,B,1,8,
,BAO_0000357,2700,H,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,Expert,,12687,,16326,,,,,CHEMBL617948,,,,,B,1,8,
,BAO_0000019,2701,H,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,Autocuration,,12687,,15847,,,,,CHEMBL858116,,,,,F,1,8,
,BAO_0000019,2702,H,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,Autocuration,,12687,,15847,,,,,CHEMBL617949,,,,,F,1,8,
,BAO_0000019,2703,H,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,Autocuration,,12687,,15329,,,,,CHEMBL617950,,,,,F,1,8,
Thoracic aorta,BAO_0000019,2704,H,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,Expert,,12687,,16404,1515.0,,,,CHEMBL617951,,,,,F,1,8,
Thoracic aorta,BAO_0000019,2705,H,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,Expert,,12687,,16404,1515.0,,,,CHEMBL617952,,,,,F,1,8,
Thoracic aorta,BAO_0000019,2706,H,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,Autocuration,,12687,,16404,1515.0,,,,CHEMBL617953,,,,,F,1,8,
,BAO_0000357,2707,H,Binding activity radioligand.,Autocuration,,12687,,12861,,,,,CHEMBL617954,,,,,B,1,8,
,BAO_0000019,2708,H,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,Expert,,12687,,12861,,,,,CHEMBL617955,,,,,B,1,8,
,BAO_0000019,2709,H,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,Autocuration,,12687,,12861,,,,,CHEMBL857071,,,,,B,1,8,
,BAO_0000019,2710,H,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,Expert,,12687,,12490,,,,,CHEMBL617270,,,,,B,1,8,
,BAO_0000219,2711,H,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,Autocuration,339.0,12687,,12827,,,,,CHEMBL617271,N1E-115,,,,B,1,8,
,BAO_0000219,2712,H,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,Autocuration,339.0,12687,,12827,,,,,CHEMBL617272,N1E-115,,,,B,1,8,
,BAO_0000019,2713,H,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,Autocuration,,12687,,12918,,,,,CHEMBL617273,,,,,B,1,8,
,BAO_0000019,2714,D,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,Expert,,12687,,12919,,10116.0,Rattus norvegicus,,CHEMBL617274,,,,,F,1,9,
,BAO_0000357,2715,H,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,Autocuration,,108,,17723,,,,,CHEMBL617275,,,,,B,1,8,
,BAO_0000357,2716,H,Binding affinity towards 5-hydroxytryptamine 2C receptor,Autocuration,,108,,6013,,,,,CHEMBL617276,,,,,B,1,8,
,BAO_0000357,2717,H,Binding affinity towards human 5-hydroxytryptamine 2C receptor,Autocuration,,108,,16293,,,,,CHEMBL617277,,,,,B,1,8,
,BAO_0000019,2718,H,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,Expert,,108,,3857,,,,,CHEMBL617278,,,,,B,1,8,
,BAO_0000019,2719,H,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,Expert,,108,,3857,,,,,CHEMBL617279,,,,,B,1,8,
,BAO_0000019,2720,H,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,Expert,,108,,3857,,,,,CHEMBL617280,,,,,B,1,8,
,BAO_0000357,2721,H,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,Autocuration,,108,,15363,,,,,CHEMBL617281,,,,,B,1,8,
,BAO_0000357,2722,H,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,Autocuration,,108,,15363,,,,,CHEMBL617282,,,,,B,1,8,
,BAO_0000019,2723,H,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,Expert,,108,,16441,,,,,CHEMBL617283,,,,,B,1,8,
,BAO_0000019,2724,H,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,Expert,,108,,16441,,,,,CHEMBL617284,,,,,B,1,8,
,BAO_0000219,2725,H,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,Autocuration,722.0,108,,4176,,,,,CHEMBL617285,HEK293,,,,B,1,8,
,BAO_0000019,2726,H,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,Autocuration,,108,,17085,,,,,CHEMBL617286,,,,,B,1,8,
,BAO_0000357,2727,D,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,Expert,,108,,17200,,9606.0,Homo sapiens,,CHEMBL617287,,,,,B,1,9,
,BAO_0000357,2728,H,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,Expert,,108,,5088,,,,,CHEMBL617288,,,,,B,1,8,
,BAO_0000357,2729,H,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,Autocuration,,108,,5088,,,,,CHEMBL617289,,,,,B,1,8,
,BAO_0000357,2730,H,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,Autocuration,,108,,5088,,,,,CHEMBL872917,,,,,B,1,8,
,BAO_0000357,2731,H,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,Autocuration,,108,,5088,,,,,CHEMBL617290,,,,,B,1,8,
,BAO_0000219,2732,H,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,Autocuration,449.0,108,,16659,,,,,CHEMBL617291,CHO,,,,B,1,8,
,BAO_0000219,2733,H,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,Autocuration,449.0,108,,16659,,,,,CHEMBL617292,CHO,,,,B,1,8,
,BAO_0000219,2734,H,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,Autocuration,723.0,108,,17451,,,,,CHEMBL617293,NIH3T3,,,,B,1,8,
,BAO_0000219,2735,D,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,Expert,449.0,108,,6857,,9606.0,Homo sapiens,,CHEMBL617294,CHO,,,,F,1,9,
,BAO_0000019,2736,H,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,Expert,,108,,3857,,,,,CHEMBL617295,,,,,B,1,8,
,BAO_0000357,2737,H,Binding activity radioligand.,Autocuration,,108,,12861,,,,,CHEMBL617296,,,,,B,1,8,
,BAO_0000019,2738,H,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,Autocuration,,108,,12861,,,,,CHEMBL617297,,,,,B,1,8,
,BAO_0000219,2739,H,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,Expert,449.0,108,,5104,,,,,CHEMBL617298,CHO,,,,B,1,8,
,BAO_0000219,2740,H,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,Expert,449.0,108,,5105,,,,,CHEMBL617299,CHO,,,,B,1,8,
,BAO_0000219,2741,H,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,Autocuration,449.0,108,,5105,,,,,CHEMBL617300,CHO,,,,B,1,8,
,BAO_0000357,2742,H,Binding affinity against 5-HT2C receptor,Autocuration,,108,,5254,,,,,CHEMBL617454,,,,,B,1,8,
,BAO_0000219,2743,H,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,Autocuration,722.0,108,,13267,,,,,CHEMBL617505,HEK293,,,,B,1,8,
,BAO_0000219,2744,D,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,Expert,722.0,108,,14157,,9606.0,Homo sapiens,,CHEMBL617506,HEK293,,,,B,1,9,
,BAO_0000219,2745,D,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,Expert,722.0,108,,12936,,9606.0,Homo sapiens,,CHEMBL617507,HEK293,,,,B,1,9,
,BAO_0000357,2746,H,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,Expert,,108,,14068,,,,,CHEMBL617508,,,,,B,1,8,
,BAO_0000219,2747,D,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,Expert,722.0,108,,12936,,9606.0,Homo sapiens,,CHEMBL857982,HEK293,,,,B,1,9,
,BAO_0000219,2748,D,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,Expert,722.0,108,,4540,,9606.0,Homo sapiens,,CHEMBL617509,HEK293,,,,B,1,9,
,BAO_0000219,2749,D,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,Expert,722.0,108,,4540,,9606.0,Homo sapiens,,CHEMBL617510,HEK293,,,,B,1,9,
,BAO_0000357,2750,H,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,Autocuration,,108,,6166,,,,,CHEMBL617511,,,,,B,1,8,
,BAO_0000219,2751,H,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,Autocuration,722.0,108,,17296,,,,,CHEMBL617512,HEK293,,,,B,1,8,
,BAO_0000219,2752,H,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,Autocuration,722.0,108,,17296,,,,,CHEMBL617749,HEK293,,,,B,1,8,
,BAO_0000219,2753,H,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,Autocuration,722.0,108,,15779,,,,,CHEMBL617750,HEK293,,,,B,1,8,
,BAO_0000219,2754,H,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,Autocuration,722.0,108,,15779,,,,,CHEMBL617751,HEK293,,,,B,1,8,
,BAO_0000219,2755,H,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,Expert,722.0,108,,14391,,,,,CHEMBL617752,HEK293,,,,B,1,8,
,BAO_0000219,2756,H,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",Autocuration,722.0,108,,15779,,,,,CHEMBL617753,HEK293,,,,B,1,8,
,BAO_0000219,2757,H,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",Expert,722.0,108,,15851,,,,,CHEMBL617754,HEK293,,,,B,1,8,
,BAO_0000219,2758,D,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,Expert,722.0,108,,15851,,9606.0,Homo sapiens,,CHEMBL617755,HEK293,,,,B,1,9,
,BAO_0000219,2759,H,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",Autocuration,722.0,108,,15779,,,,,CHEMBL617756,HEK293,,,,B,1,8,
,BAO_0000219,2760,H,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,Expert,722.0,108,,3832,,,,,CHEMBL617757,HEK293,,,,B,1,8,
,BAO_0000219,2761,H,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,Expert,722.0,108,,3833,,,,,CHEMBL617758,HEK293,,,,B,1,8,
,BAO_0000219,2762,H,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,Autocuration,723.0,108,,17451,,,,,CHEMBL617759,NIH3T3,,,,B,1,8,
,BAO_0000219,2763,H,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,Autocuration,722.0,108,,4199,,,,,CHEMBL617760,HEK293,,,,B,1,8,
,BAO_0000219,2764,H,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,Expert,485.0,108,,1883,,,,,CHEMBL617761,CHO-K1,,,,B,1,8,
,BAO_0000357,2765,D,Binding affinity against 5-hydroxytryptamine 2C receptor,Expert,,108,,4321,,9606.0,Homo sapiens,,CHEMBL617762,,,,,B,1,9,
,BAO_0000357,2766,H,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,Autocuration,,108,,14875,,,,,CHEMBL617763,,,,,B,1,8,
,BAO_0000219,2767,H,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,Autocuration,722.0,108,,15146,,,,,CHEMBL857983,HEK293,,,,B,1,8,
,BAO_0000219,2768,H,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,Autocuration,722.0,108,,5213,,,,,CHEMBL617764,HEK293,,,,B,1,8,
,BAO_0000219,2769,H,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,Autocuration,308.0,108,,16404,,,,,CHEMBL617765,HeLa,,,,B,1,8,
,BAO_0000019,2770,H,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,Autocuration,,108,,13267,,,,,CHEMBL617766,,,,,F,1,8,
Hippocampus,BAO_0000221,2771,H,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,Autocuration,,108,,13267,10000000.0,,,,CHEMBL617767,,,,,F,1,8,
,BAO_0000219,2772,H,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,Autocuration,722.0,108,,14818,,,,,CHEMBL617768,HEK293,,,,B,1,8,
,BAO_0000219,2773,H,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",Autocuration,722.0,108,,4829,,,,,CHEMBL617769,HEK293,,,,B,1,8,
,BAO_0000357,2774,H,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,Autocuration,,11864,,13463,,,,,CHEMBL858023,,,,,B,1,8,
Stomach,BAO_0000019,2775,H,Binding affinity analysed on 5-HT 2C in rat stomach fundus,Autocuration,,11864,,13463,945.0,,,,CHEMBL617770,,,,,B,1,8,
Stomach,BAO_0000019,2776,H,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,Autocuration,,11864,,13463,945.0,,,,CHEMBL617771,,,,,B,1,8,
,BAO_0000219,2777,H,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,Autocuration,625.0,11864,,12652,,,,,CHEMBL617772,A9,,,,F,1,8,
,BAO_0000219,2778,H,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,Autocuration,723.0,11864,,4682,,,,,CHEMBL617773,NIH3T3,,,,B,1,8,
,BAO_0000219,2779,H,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,Autocuration,723.0,11864,,4682,,,,,CHEMBL617850,NIH3T3,,,,B,1,8,
,BAO_0000219,2780,H,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,Autocuration,723.0,11864,,4682,,,,,CHEMBL617851,NIH3T3,,,,B,1,8,
,BAO_0000019,2781,H,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,Autocuration,,11864,,12652,,,,,CHEMBL617852,,,,,F,1,8,
Stomach,BAO_0000019,2782,H,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,Autocuration,,12689,,13463,945.0,10090.0,Mus musculus,,CHEMBL858024,,,,,B,1,8,
Stomach,BAO_0000019,2783,D,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,Expert,,12689,,13463,945.0,10116.0,Rattus norvegicus,,CHEMBL617853,,,,,B,1,9,
,BAO_0000357,2784,H,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,Expert,,108,,13969,,,,,CHEMBL617854,,,,,B,1,8,
,BAO_0000357,2785,H,Binding affinity for 5-hydroxytryptamine 2C receptor,Expert,,108,,13392,,9823.0,Sus scrofa,,CHEMBL873477,,,,,B,1,8,
,BAO_0000357,2786,H,Binding affinity towards 5-hydroxytryptamine 2C receptor,Expert,,108,,13392,,,,,CHEMBL617855,,,,,B,1,8,
,BAO_0000019,2787,H,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,Expert,,108,,14430,,,,,CHEMBL617856,,,,,B,1,8,
,BAO_0000019,2788,H,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,Autocuration,,108,,1742,,,,,CHEMBL617857,,,,,B,1,8,
,BAO_0000249,2789,H,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,Autocuration,,108,,14286,,,,,CHEMBL617858,,,,,B,1,8,
,BAO_0000357,2790,H,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,Autocuration,,108,,5619,,,,,CHEMBL617859,,,,,B,1,8,
,BAO_0000357,2791,H,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,Autocuration,,108,,15086,,,,,CHEMBL617860,,,,,B,1,8,
,BAO_0000357,2792,H,Binding activity radioligand.,Autocuration,,108,,12861,,,,,CHEMBL617861,,,,,B,1,8,
,BAO_0000019,2793,H,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,Expert,,108,,12861,,,,,CHEMBL617862,,,,,B,1,8,
,BAO_0000019,2794,H,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,Autocuration,,108,,12861,,,,,CHEMBL617863,,,,,B,1,8,
,BAO_0000249,2795,H,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,Autocuration,,108,,12827,,,,,CHEMBL617864,,,,,B,1,8,
,BAO_0000249,2796,H,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,Autocuration,,108,,12827,,,,,CHEMBL617649,,,,,B,1,8,
,BAO_0000019,2797,H,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,Expert,,108,,12919,,9823.0,Sus scrofa,,CHEMBL617650,,,,,F,1,8,
,BAO_0000019,2798,H,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,Expert,,108,,12919,,9823.0,Sus scrofa,,CHEMBL617651,,,,,F,1,8,
,BAO_0000357,2799,H,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,Autocuration,,108,,16429,,9823.0,Sus scrofa,,CHEMBL617652,,,,,B,1,8,
,BAO_0000019,2800,H,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,Autocuration,,108,,773,,9823.0,Sus scrofa,,CHEMBL857072,,,,,B,1,8,
,BAO_0000357,2801,H,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,Autocuration,,108,,5033,,9823.0,Sus scrofa,,CHEMBL617653,,,,,B,1,8,
,BAO_0000019,2802,H,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,Autocuration,,12687,,12861,,,,,CHEMBL617654,,,,,B,1,8,
,BAO_0000019,2803,H,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,Autocuration,,12689,,14093,,,,,CHEMBL617655,,,,,F,1,8,
,BAO_0000357,2804,H,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,Expert,,12689,,14970,,,,,CHEMBL617656,,,,,B,1,8,
,BAO_0000357,2805,H,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,Autocuration,,12689,,14970,,,,,CHEMBL617657,,,,,B,1,8,
,BAO_0000357,2806,H,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,Autocuration,,12689,,14970,,,,,CHEMBL617658,,,,,B,1,8,
,BAO_0000357,2807,D,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,Expert,,12689,,14178,,10116.0,Rattus norvegicus,,CHEMBL617659,,,,,B,1,9,
,BAO_0000357,2808,D,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,Expert,,12689,,14178,,10116.0,Rattus norvegicus,,CHEMBL617838,,,,,B,1,9,
,BAO_0000249,2809,D,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,Expert,,12689,,14229,,10116.0,Rattus norvegicus,,CHEMBL617839,,,,Brain membranes,B,1,9,
,BAO_0000357,2810,H,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,Autocuration,,12689,,16532,,,,,CHEMBL617840,,,,,B,1,8,
,BAO_0000019,2811,H,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,Autocuration,,12689,,14826,,,,,CHEMBL617841,,,,,B,1,8,
,BAO_0000019,2812,H,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,Autocuration,,12689,,17211,,,,,CHEMBL875915,,,,,B,1,8,
,BAO_0000219,2813,H,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,Expert,,12689,,17211,,,,,CHEMBL617842,,,In vitro,,B,1,8,
,BAO_0000219,2814,H,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,Expert,723.0,12689,,13246,,,,,CHEMBL617843,NIH3T3,,,,B,1,8,
,BAO_0000357,2815,H,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,Expert,,12689,,13246,,,,,CHEMBL617844,,,,,B,1,8,
,BAO_0000357,2816,H,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,Expert,,12689,,12457,,,,,CHEMBL617845,,,,,B,1,8,
,BAO_0000219,2817,H,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,Expert,723.0,12689,,12457,,,,,CHEMBL617846,NIH3T3,,,,B,1,8,
,BAO_0000357,2818,H,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,Autocuration,,12689,,4707,,,,,CHEMBL617847,,,,,B,1,8,
,BAO_0000357,2819,H,Binding affinity against 5-hydroxytryptamine 2C receptor,Expert,,12689,,13297,,,,,CHEMBL617848,,,,,B,1,8,
,BAO_0000357,2820,H,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,Autocuration,,12689,,16633,,,,,CHEMBL617849,,,,,B,1,8,
,BAO_0000357,2821,H,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,Expert,,12689,,16133,,,,,CHEMBL621507,,,,,B,1,8,
,BAO_0000357,2822,H,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,Expert,,12689,,16326,,,,,CHEMBL621508,,,,,B,1,8,
,BAO_0000019,2823,H,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,Autocuration,,12689,,14423,,,,,CHEMBL621509,,,,,B,1,8,
,BAO_0000019,2824,H,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,Autocuration,,12689,,15412,,,,,CHEMBL621510,,,,,B,1,8,
,BAO_0000019,2825,H,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,Autocuration,,12689,,15412,,,,,CHEMBL621511,,,,,B,1,8,
,BAO_0000219,2826,H,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,Expert,625.0,12689,,15558,,,,,CHEMBL621512,A9,,,,B,1,8,
,BAO_0000357,2827,H,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,Autocuration,,12689,,16633,,,,,CHEMBL621513,,,,,B,1,8,
,BAO_0000357,2828,H,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,Expert,,12689,,6013,,,,,CHEMBL621514,,,,,B,1,8,
,BAO_0000219,2829,H,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,Expert,,12689,,17175,,,,,CHEMBL621515,,,In vitro,,B,1,8,
,BAO_0000219,2830,H,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,Autocuration,,12689,,12469,,,,,CHEMBL621516,,,,,B,1,8,
Caudate-putamen,BAO_0000019,2831,H,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,Autocuration,,12689,,3682,5383.0,,,,CHEMBL621517,,,,,B,1,8,
,BAO_0000357,2832,H,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,Autocuration,,12689,,4932,,,,,CHEMBL621518,,,,,B,1,8,
,BAO_0000019,2833,H,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,Autocuration,,12689,,4932,,,,,CHEMBL621519,,,,,B,1,8,
,BAO_0000357,2834,H,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,Autocuration,,12689,,3935,,,,,CHEMBL621520,,,,,B,1,8,
,BAO_0000357,2835,H,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,Autocuration,,12689,,15818,,,,,CHEMBL621521,,,,,B,1,8,
,BAO_0000357,2836,H,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,Autocuration,,12689,,15818,,,,,CHEMBL621522,,,,,B,1,8,
,BAO_0000219,2837,H,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,Expert,,12689,,14749,,,,,CHEMBL621523,,,,,B,1,8,
,BAO_0000357,2838,H,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,Autocuration,,12689,,15740,,,,,CHEMBL621524,,,,,B,1,8,
,BAO_0000357,2839,D,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,Expert,,12689,,17133,,10116.0,Rattus norvegicus,,CHEMBL621525,,,,,B,1,9,
,BAO_0000357,2840,H,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,Autocuration,,12689,,16532,,,,,CHEMBL872921,,,,,B,1,8,
,BAO_0000357,2841,H,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,Autocuration,,12689,,12369,,,,,CHEMBL621526,,,,,B,1,8,
,BAO_0000219,2842,H,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,Expert,,12689,,12369,,,,,CHEMBL621527,,,,,B,1,8,
,BAO_0000019,2843,D,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,Expert,,12689,,2309,,10116.0,Rattus norvegicus,,CHEMBL617865,,,,,B,1,9,
,BAO_0000357,2844,H,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,Autocuration,,12689,,12953,,,,,CHEMBL617866,,,,,B,1,8,
,BAO_0000019,2845,H,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,Autocuration,,12689,,12953,,,,,CHEMBL617867,,,,,B,1,8,
,BAO_0000357,2846,H,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,Autocuration,,12689,,12953,,,,,CHEMBL617487,,,,,B,1,8,
,BAO_0000357,2847,H,Binding affinity for 5-hydroxytryptamine 2C receptor,Expert,,12689,,12953,,,,,CHEMBL617488,,,,,B,1,8,
,BAO_0000357,2848,H,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,Autocuration,,12689,,17133,,,,,CHEMBL617489,,,,,B,1,8,
,BAO_0000019,2849,H,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,Autocuration,,12689,,17211,,,,,CHEMBL617490,,,,,B,1,8,
,BAO_0000019,2850,H,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,Autocuration,,12689,,17211,,,,,CHEMBL617491,,,,,B,1,8,
,BAO_0000019,2851,H,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,Autocuration,,12689,,14025,,,,,CHEMBL617492,,,,,B,1,8,
,BAO_0000019,2852,H,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,Autocuration,,12689,,14998,,,,,CHEMBL617493,,,,,B,1,8,
,BAO_0000357,2853,H,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,Autocuration,,12689,,4342,,,,,CHEMBL617494,,,,,B,1,8,
,BAO_0000019,2854,D,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,Expert,,12689,,13735,,10116.0,Rattus norvegicus,,CHEMBL617495,,,,,B,1,9,
,BAO_0000357,2855,H,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,Autocuration,,12689,,13181,,,,,CHEMBL617496,,,,,B,1,8,
,BAO_0000219,2856,H,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,Autocuration,485.0,12689,,1883,,,,,CHEMBL617497,CHO-K1,,,,B,1,8,
,BAO_0000357,2857,H,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,Autocuration,,12689,,15194,,,,,CHEMBL617498,,,,,B,1,8,
,BAO_0000357,2858,H,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,Autocuration,,12689,,15194,,,,,CHEMBL617499,,,,,B,1,8,
,BAO_0000019,2859,H,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,Autocuration,,12689,,14579,,,,,CHEMBL617500,,,,,F,1,8,
,BAO_0000357,2860,H,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,Autocuration,,108,,4639,,,,,CHEMBL617501,,,,,B,1,8,
,BAO_0000357,2861,H,Binding affinity towards 5-hydroxytryptamine 2C receptor,Expert,,108,,4820,,,,,CHEMBL617502,,,,,B,1,8,
,BAO_0000357,2862,H,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,Autocuration,,227,,14442,,,,,CHEMBL617503,,,,,B,1,8,
,BAO_0000357,2863,H,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,Autocuration,,227,,14755,,,,,CHEMBL617504,,,,,B,1,8,
,BAO_0000357,2864,H,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,Autocuration,,227,,14744,,,,,CHEMBL617406,,,,,B,1,8,
,BAO_0000019,2865,D,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,Expert,,227,,6857,,9606.0,Homo sapiens,,CHEMBL617407,,,,,B,1,9,
,BAO_0000357,2866,H,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,Autocuration,,227,,16209,,,,,CHEMBL617408,,,,,B,1,8,
,BAO_0000357,2867,H,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,Autocuration,,227,,15363,,,,,CHEMBL617409,,,,,B,1,8,
,BAO_0000357,2868,H,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,Autocuration,,227,,15363,,,,,CHEMBL617410,,,,,B,1,8,
,BAO_0000357,2869,H,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,Autocuration,,227,,15363,,,,,CHEMBL617411,,,,,B,1,8,
,BAO_0000019,2870,H,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,Autocuration,,227,,17085,,,,,CHEMBL617412,,,,,B,1,8,
,BAO_0000357,2871,D,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,Expert,,227,,17200,,9606.0,Homo sapiens,,CHEMBL617774,,,,,B,1,9,
,BAO_0000219,2872,D,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,Expert,722.0,227,,15851,,9606.0,Homo sapiens,,CHEMBL617775,HEK293,,,,B,1,9,
,BAO_0000219,2873,D,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,Expert,722.0,227,,15851,,9606.0,Homo sapiens,,CHEMBL617776,HEK293,,,,B,1,9,
,BAO_0000219,2874,D,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,Expert,449.0,227,,6857,,9606.0,Homo sapiens,,CHEMBL617777,CHO,,,,F,1,9,
,BAO_0000219,2875,D,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,Expert,449.0,227,,6857,,9606.0,Homo sapiens,,CHEMBL617778,CHO,,,,F,1,9,
,BAO_0000219,2876,H,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",Autocuration,722.0,227,,15779,,,,,CHEMBL617779,HEK293,,,,B,1,8,
,BAO_0000219,2877,H,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,Expert,722.0,227,,15851,,,,,CHEMBL617780,HEK293,,,,B,1,8,
,BAO_0000219,2878,H,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",Autocuration,722.0,227,,15779,,,,,CHEMBL617781,HEK293,,,,B,1,8,
,BAO_0000219,2879,D,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,Expert,722.0,227,,14157,,9606.0,Homo sapiens,,CHEMBL617782,HEK293,,,,B,1,9,
,BAO_0000219,2880,D,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,Expert,722.0,227,,4540,,9606.0,Homo sapiens,,CHEMBL617783,HEK293,,,,B,1,9,
,BAO_0000357,2881,H,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,Autocuration,,227,,6166,,,,,CHEMBL617784,,,,,B,1,8,
,BAO_0000219,2882,H,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,Autocuration,722.0,227,,15779,,,,,CHEMBL617785,HEK293,,,,B,1,8,
,BAO_0000219,2883,H,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,Expert,722.0,227,,14391,,,,,CHEMBL857984,HEK293,,,,B,1,8,
,BAO_0000219,2884,H,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,Expert,722.0,227,,3832,,,,,CHEMBL617786,HEK293,,,,B,1,8,
,BAO_0000219,2885,H,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,Expert,722.0,227,,3833,,,,,CHEMBL617787,HEK293,,,,B,1,8,
,BAO_0000219,2886,D,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,Expert,722.0,227,,15851,,9606.0,Homo sapiens,,CHEMBL617788,HEK293,,,,B,1,9,
,BAO_0000219,2887,D,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,Expert,722.0,227,,15851,,9606.0,Homo sapiens,,CHEMBL617789,HEK293,,,,B,1,9,
,BAO_0000219,2888,H,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,Autocuration,722.0,227,,4199,,,,,CHEMBL617790,HEK293,,,,B,1,8,
,BAO_0000219,2889,H,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,Expert,485.0,227,,1883,,,,,CHEMBL617791,CHO-K1,,,,B,1,8,
,BAO_0000357,2890,H,Binding affinity against 5-hydroxytryptamine 2B receptor,Expert,,227,,4321,,,,,CHEMBL617608,,,,,B,1,8,
,BAO_0000219,2891,H,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,Autocuration,722.0,227,,15146,,,,,CHEMBL617609,HEK293,,,,B,1,8,
,BAO_0000219,2892,H,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,Autocuration,722.0,227,,5213,,,,,CHEMBL617610,HEK293,,,,B,1,8,
,BAO_0000219,2893,H,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,Autocuration,722.0,227,,14818,,,,,CHEMBL617611,HEK293,,,,B,1,8,
,BAO_0000219,2894,H,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",Autocuration,722.0,227,,4829,,,,,CHEMBL617612,HEK293,,,,B,1,8,
,BAO_0000219,2895,H,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",Autocuration,722.0,227,,4829,,,,,CHEMBL617613,HEK293,,,,B,1,8,
,BAO_0000019,2896,H,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,Autocuration,,227,,14025,,9986.0,Oryctolagus cuniculus,,CHEMBL617614,,,,,B,1,8,
Stomach,BAO_0000019,2897,H,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,Expert,,12688,,13463,945.0,,,,CHEMBL617615,,,,,B,1,8,
Stomach,BAO_0000357,2898,H,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,Expert,,12688,,7259,945.0,,,,CHEMBL858114,,,,,B,1,8,
Stomach,BAO_0000357,2899,H,Affinity against serotonergic receptor in the isolated rat stomach fundus,Autocuration,,12688,,7259,945.0,,,,CHEMBL617616,,,,,B,1,8,
Stomach,BAO_0000019,2900,D,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,Expert,,12688,,7185,945.0,10116.0,Rattus norvegicus,,CHEMBL617617,,,,,F,1,9,
,BAO_0000019,2901,D,Antagonistic against 5-hydroxytryptamine 2B receptor,Expert,,12688,,7185,,10116.0,Rattus norvegicus,,CHEMBL875914,,,,,F,1,9,
Stomach,BAO_0000019,2902,H,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,Autocuration,,12688,,13267,945.0,,,,CHEMBL617618,,,,,F,1,8,
Stomach,BAO_0000357,2903,D,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,Expert,,12688,,13735,945.0,10116.0,Rattus norvegicus,,CHEMBL617619,,,,,B,1,9,
,BAO_0000019,2904,H,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,Autocuration,,12688,,15738,,,,,CHEMBL617620,,,,,F,1,8,
,BAO_0000019,2905,H,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,Autocuration,,12688,,15738,,,,,CHEMBL617621,,,,,F,1,8,
,BAO_0000019,2906,H,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,Autocuration,,12688,,15738,,,,,CHEMBL617622,,,,,F,1,8,
Stomach,BAO_0000357,2907,D,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Expert,,12688,,12936,945.0,10116.0,Rattus norvegicus,,CHEMBL617623,,,,,B,1,9,
Stomach,BAO_0000357,2908,D,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Expert,,12688,,12936,945.0,10116.0,Rattus norvegicus,,CHEMBL617624,,,,,B,1,9,
Stomach,BAO_0000357,2909,D,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Expert,,12688,,12936,945.0,10116.0,Rattus norvegicus,,CHEMBL617625,,,,,B,1,9,
Stomach,BAO_0000357,2910,D,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Expert,,12688,,12936,945.0,10116.0,Rattus norvegicus,,CHEMBL617626,,,,,B,1,9,
Stomach,BAO_0000019,2911,H,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,Autocuration,,12688,,16404,945.0,,,,CHEMBL617627,,,,,F,1,8,
Stomach,BAO_0000019,2912,H,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,Expert,,12688,,16404,945.0,,,,CHEMBL617628,,,,,F,1,8,
Stomach,BAO_0000019,2913,H,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,Autocuration,,12688,,16404,945.0,,,,CHEMBL617629,,,,,F,1,8,
Stomach,BAO_0000019,2914,H,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,Autocuration,,12688,,16404,945.0,,,,CHEMBL858115,,,,,F,1,8,
Stomach,BAO_0000019,2915,D,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,Expert,,12688,,16404,945.0,10116.0,Rattus norvegicus,,CHEMBL617630,,,,,F,1,9,
Thoracic aorta,BAO_0000019,2916,H,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,Autocuration,,12688,,16404,1515.0,,,,CHEMBL617631,,,,,F,1,8,
,BAO_0000357,2917,H,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,Autocuration,,12688,,7483,,,,,CHEMBL617632,,,,,B,1,8,
,BAO_0000357,2918,H,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,Expert,,12688,,7483,,,,,CHEMBL617633,,,,,B,1,8,
,BAO_0000357,2919,H,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,Autocuration,,12688,,7483,,,,,CHEMBL617634,,,,,B,1,8,
,BAO_0000357,2920,H,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,Autocuration,,12688,,7483,,,,,CHEMBL617635,,,,,B,1,8,
Stomach,BAO_0000019,2922,D,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,Autocuration,,12688,,16404,945.0,10116.0,Rattus norvegicus,,CHEMBL617637,,,,,F,1,9,
,BAO_0000357,2923,H,Binding affinity against 5-hydroxytryptamine 1A receptor,Autocuration,,227,,6347,,,,,CHEMBL617638,,,,,B,1,8,
,BAO_0000357,2924,H,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,Autocuration,,227,,4373,,,,,CHEMBL617639,,,,,B,1,8,
,BAO_0000357,2925,H,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,Autocuration,,227,,4373,,,,,CHEMBL617640,,,,,B,1,8,
,BAO_0000357,2926,H,Evaluated for the binding affinity to 5-HT 2B receptor,Autocuration,,227,,4687,,,,,CHEMBL617641,,,,,B,1,8,
,BAO_0000357,2927,H,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,Autocuration,,227,,16946,,,,,CHEMBL617642,,,,,B,1,8,
,BAO_0000357,2928,H,Binding affinities against 5-hydroxytryptamine 2B receptor,Autocuration,,227,,16633,,,,,CHEMBL617643,,,,,B,1,8,
,BAO_0000357,2929,H,Binding affinities towards 5-hydroxytryptamine 2B receptor,Autocuration,,227,,16633,,,,,CHEMBL617644,,,,,B,1,8,
,BAO_0000357,2930,H,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,Autocuration,,227,,16633,,,,,CHEMBL617645,,,,,B,1,8,
,BAO_0000357,2931,H,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,Expert,,108,,15026,,,,,CHEMBL617646,,,,,B,1,8,
,BAO_0000357,2932,H,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,Autocuration,,108,,15738,,9913.0,Bos taurus,,CHEMBL617647,,,,,B,1,8,
,BAO_0000357,2933,H,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,Autocuration,,108,,15738,,9913.0,Bos taurus,,CHEMBL617648,,,,,B,1,8,
,BAO_0000357,2934,H,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,Autocuration,,108,,15738,,9913.0,Bos taurus,,CHEMBL617875,,,,,B,1,8,
,BAO_0000357,2935,H,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,Autocuration,,108,,15738,,9913.0,Bos taurus,,CHEMBL617876,,,,,B,1,8,
,BAO_0000357,2936,H,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,Expert,,108,,16404,,9913.0,Bos taurus,,CHEMBL617877,,,,,B,1,8,
,BAO_0000357,2937,H,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,Expert,,108,,15026,,9913.0,Bos taurus,,CHEMBL617878,,,,,B,1,8,
,BAO_0000357,2938,H,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,Autocuration,,108,,15738,,9913.0,Bos taurus,,CHEMBL617879,,,,,B,1,8,
,BAO_0000019,2939,H,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,Autocuration,,108,,16312,,10141.0,Cavia porcellus,,CHEMBL617880,,,,,B,1,8,
Striatum,BAO_0000357,2940,D,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,Intermediate,,20033,,5486,2435.0,10141.0,Cavia porcellus,,CHEMBL617881,,,,,B,1,9,
,BAO_0000357,2941,H,Binding affinity against 5-HT1A receptor,Autocuration,,51,,5254,,,,,CHEMBL857073,,,,,B,1,8,
,BAO_0000219,2942,H,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,Expert,449.0,108,,3857,,,,,CHEMBL617882,CHO,,,,F,1,8,
,BAO_0000219,2943,D,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,Expert,449.0,108,,6857,,9606.0,Homo sapiens,,CHEMBL617883,CHO,,,,F,1,9,
,BAO_0000219,2944,H,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,Autocuration,,108,,4176,,,,,CHEMBL617884,,,,,F,1,8,
,BAO_0000219,2945,H,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,Autocuration,449.0,108,,6347,,,,,CHEMBL617885,CHO,,,,B,1,8,
,BAO_0000219,2946,H,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",Autocuration,449.0,108,,6347,,,,,CHEMBL617886,CHO,,,,B,1,8,
,BAO_0000357,2947,D,Inhibition of human 5-hydroxytryptamine 2C receptor,Expert,,108,,16146,,9606.0,Homo sapiens,,CHEMBL617887,,,,,B,1,9,
,BAO_0000357,2948,H,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),Autocuration,,108,,3805,,,,,CHEMBL617888,,,,,B,1,8,
,BAO_0000019,2949,H,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,Autocuration,,108,,3857,,,,,CHEMBL617889,,,,,B,1,8,
,BAO_0000357,2950,H,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,Autocuration,,108,,5635,,,,,CHEMBL617890,,,,,B,1,8,
,BAO_0000357,2951,H,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,Autocuration,,108,,5635,,,,,CHEMBL617891,,,,,B,1,8,
,BAO_0000357,2952,H,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,Autocuration,,108,,5635,,,,,CHEMBL617892,,,,,B,1,8,
,BAO_0000219,2953,H,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,Expert,449.0,108,,4012,,,,,CHEMBL617893,CHO,,,,B,1,8,
,BAO_0000219,2954,H,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,Expert,449.0,108,,6366,,,,,CHEMBL617894,CHO,,,,B,1,8,
,BAO_0000219,2955,H,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,Expert,449.0,108,,15949,,,,,CHEMBL617895,CHO,,,,B,1,8,
,BAO_0000219,2956,H,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,Autocuration,449.0,108,,17211,,,,,CHEMBL617896,CHO,,,,B,1,8,
,BAO_0000357,2957,D,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,Expert,,108,,6491,,9606.0,Homo sapiens,,CHEMBL617897,,,,,B,1,9,
,BAO_0000019,2958,H,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,Autocuration,,108,,14093,,,,,CHEMBL617898,,,,,F,1,8,
,BAO_0000019,2959,H,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,Autocuration,,108,,13481,,,,,CHEMBL617899,,,,,F,1,8,
,BAO_0000219,2960,H,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,Expert,449.0,108,,6347,,10116.0,Rattus norvegicus,,CHEMBL617900,CHO,,,,B,1,8,
,BAO_0000019,2961,H,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,Autocuration,,108,,14093,,,,,CHEMBL617901,,,,,F,1,8,
,BAO_0000019,2962,H,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,Autocuration,,108,,14093,,,,,CHEMBL617902,,,,,F,1,8,
,BAO_0000019,2963,H,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,Autocuration,,108,,13481,,,,,CHEMBL617903,,,,,F,1,8,
,BAO_0000357,2964,H,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,Autocuration,,108,,14442,,,,,CHEMBL617904,,,,,B,1,8,
,BAO_0000357,2965,H,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,Autocuration,,108,,14442,,,,,CHEMBL617905,,,,,B,1,8,
,BAO_0000357,2966,H,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,Autocuration,,108,,14442,,,,,CHEMBL617906,,,,,B,1,8,
,BAO_0000357,2967,H,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,Autocuration,,108,,14755,,,,,CHEMBL617907,,,,,B,1,8,
,BAO_0000357,2968,H,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,Autocuration,,108,,14744,,,,,CHEMBL617908,,,,,B,1,8,
,BAO_0000219,2969,H,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,Expert,449.0,108,,16659,,,,,CHEMBL620617,CHO,,,,B,1,8,
,BAO_0000019,2970,D,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,Expert,,108,,6857,,9606.0,Homo sapiens,,CHEMBL620618,,,,,B,1,9,
,BAO_0000357,2971,H,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,Expert,,108,,5635,,,,,CHEMBL620619,,,,,B,1,8,
,BAO_0000357,2972,D,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,Expert,,108,,4234,,9606.0,Homo sapiens,,CHEMBL620620,,,,,B,1,9,
,BAO_0000357,2973,H,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,Autocuration,,108,,16209,,,,,CHEMBL620621,,,,,B,1,8,
,BAO_0000249,2974,D,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,Autocuration,,104698,,5778,,10116.0,Rattus norvegicus,,CHEMBL872920,,,,Membranes,B,1,7,
,BAO_0000223,2975,H,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,Autocuration,,104698,,5094,,,,,CHEMBL620622,,,,,B,1,6,
,BAO_0000019,2976,D,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,Autocuration,,104698,,809,,10116.0,Rattus norvegicus,,CHEMBL620623,,,,,B,1,7,
,BAO_0000019,2977,H,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,Autocuration,,104698,,1578,,,,,CHEMBL620624,,,,,B,1,6,
,BAO_0000019,2978,H,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,Autocuration,,104698,,809,,,,,CHEMBL620625,,,,,B,1,6,
,BAO_0000219,2979,H,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,Autocuration,,104698,,12469,,,,,CHEMBL620626,,,,,B,1,6,
,BAO_0000019,2980,H,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,Autocuration,,104698,,14290,,,,,CHEMBL621307,,,,,B,1,6,
,BAO_0000019,2981,H,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,Autocuration,,104698,,14290,,,,,CHEMBL621308,,,,,B,1,6,
,BAO_0000223,2982,H,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,Autocuration,,104698,,10609,,,,,CHEMBL621309,,,,,B,1,6,
,BAO_0000223,2983,H,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,Autocuration,,104698,,10609,,,,,CHEMBL621310,,,,,B,1,6,
,BAO_0000223,2984,H,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,Autocuration,,104698,,10609,,,,,CHEMBL621311,,,,,B,1,6,
,BAO_0000249,2985,H,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",Autocuration,,104698,,15253,,,,,CHEMBL621502,,,,,B,1,6,
,BAO_0000249,2986,H,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",Autocuration,,104698,,15253,,,,,CHEMBL621503,,,,,B,1,6,
,BAO_0000249,2987,H,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,Autocuration,,104698,,11683,,,,,CHEMBL621504,,,,Membranes,B,1,6,
,BAO_0000223,2988,H,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,Autocuration,,104698,,12092,,,,,CHEMBL621505,,,,,B,1,6,
,BAO_0000019,2989,H,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,Autocuration,,104698,,1946,,,,,CHEMBL621506,,,,,B,1,6,
,BAO_0000223,2990,H,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,Autocuration,,104698,,11623,,,,,CHEMBL619781,,,,,B,1,6,
,BAO_0000223,2991,H,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,Autocuration,,104698,,11623,,,,,CHEMBL619782,,,,,B,1,6,
,BAO_0000019,2992,H,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,Autocuration,,104698,,14788,,,,,CHEMBL619783,,,,,B,1,6,
,BAO_0000019,2993,D,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,Autocuration,,104698,,5432,,10116.0,Rattus norvegicus,,CHEMBL619784,,,,,B,1,7,
,BAO_0000249,2994,H,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,Autocuration,,104698,,14826,,,,,CHEMBL619785,,,,,B,1,6,
,BAO_0000223,2995,H,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,Autocuration,,104698,,2222,,,,,CHEMBL619786,,,,,B,1,6,
,BAO_0000019,2996,H,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,Autocuration,,104698,,11963,,,,,CHEMBL619787,,,,,B,1,6,
,BAO_0000019,2997,H,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,Autocuration,,104698,,14145,,,,,CHEMBL872925,,,,,B,1,6,
,BAO_0000019,2998,H,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,Autocuration,,104698,,17819,,,,,CHEMBL619788,,,,,B,1,6,
,BAO_0000249,2999,H,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,Autocuration,,104698,,10394,,,,,CHEMBL619789,,,,,B,1,6,
,BAO_0000249,3000,H,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,Autocuration,,104698,,10394,,,,,CHEMBL619790,,,,,B,1,6,
,BAO_0000019,3001,H,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,Autocuration,,104698,,15034,,,,,CHEMBL619791,,,,,B,1,6,
,BAO_0000019,3002,H,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,Autocuration,,104698,,691,,,,,CHEMBL619792,,,,,B,1,6,
,BAO_0000249,3003,H,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,Autocuration,,104698,,12092,,,,,CHEMBL619793,,,,Membranes,B,1,6,
,BAO_0000223,3004,D,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,Autocuration,,104698,,11752,,10116.0,Rattus norvegicus,,CHEMBL619794,,,,,B,1,7,
Brain,BAO_0000221,3005,H,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,Autocuration,,104698,,11752,955.0,,,,CHEMBL619795,,,,,B,1,6,
,BAO_0000019,3006,H,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,Autocuration,,104698,,301,,,,,CHEMBL619796,,,,,B,1,6,
,BAO_0000223,3007,H,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,Autocuration,,104698,,16532,,,,,CHEMBL620448,,,,,B,1,6,
,BAO_0000223,3008,H,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,Autocuration,,104698,,16532,,,,,CHEMBL620449,,,,,B,1,6,
,BAO_0000223,3009,H,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,Autocuration,,104698,,12092,,,,,CHEMBL620450,,,,,B,1,6,
,BAO_0000223,3010,H,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,Autocuration,,104698,,11684,,,,,CHEMBL620451,,,,,B,1,6,
,BAO_0000223,3011,H,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,Autocuration,,104698,,11684,,,,,CHEMBL620631,,,,,B,1,6,
,BAO_0000019,3012,H,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,Autocuration,,104698,,12953,,,,,CHEMBL620632,,,,,B,1,6,
,BAO_0000019,3013,H,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,Autocuration,,104698,,12953,,,,,CHEMBL620633,,,,,B,1,6,
,BAO_0000223,3014,H,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,Autocuration,,104698,,12953,,,,,CHEMBL620634,,,,,B,1,6,
,BAO_0000019,3015,H,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,Autocuration,,104698,,12861,,,,,CHEMBL620635,,,,,B,1,6,
,BAO_0000218,3016,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,Autocuration,,104698,,11454,,,,,CHEMBL620636,,,In vivo,,F,1,6,
,BAO_0000218,3017,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,Autocuration,,104698,,11454,,,,,CHEMBL620637,,,In vivo,,F,1,6,
,BAO_0000218,3018,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,Autocuration,,104698,,11454,,,,,CHEMBL620638,,,In vivo,,F,1,6,
,BAO_0000218,3019,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,Autocuration,,104698,,11454,,,,,CHEMBL620639,,,In vivo,,F,1,6,
,BAO_0000218,3020,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,Autocuration,,104698,,11454,,,,,CHEMBL620640,,,In vivo,,F,1,6,
,BAO_0000218,3021,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,Autocuration,,104698,,11454,,,,,CHEMBL620641,,,In vivo,,F,1,6,
,BAO_0000218,3022,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,Autocuration,,104698,,11454,,,,,CHEMBL620642,,,In vivo,,F,1,6,
,BAO_0000218,3023,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,Autocuration,,104698,,11454,,,,,CHEMBL620643,,,In vivo,,F,1,6,
,BAO_0000218,3024,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,Autocuration,,104698,,11454,,,,,CHEMBL620644,,,In vivo,,F,1,6,
,BAO_0000218,3025,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,Autocuration,,104698,,11454,,,,,CHEMBL620645,,,In vivo,,F,1,6,
,BAO_0000218,3026,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,Autocuration,,104698,,11454,,,,,CHEMBL620646,,,In vivo,,F,1,6,
,BAO_0000218,3027,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,Autocuration,,104698,,11454,,,,,CHEMBL620647,,,In vivo,,F,1,6,
,BAO_0000218,3028,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,Autocuration,,104698,,11454,,,,,CHEMBL620648,,,In vivo,,F,1,6,
,BAO_0000218,3029,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,Autocuration,,104698,,11454,,,,,CHEMBL620649,,,In vivo,,F,1,6,
,BAO_0000218,3030,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,Autocuration,,104698,,11454,,,,,CHEMBL620650,,,In vivo,,F,1,6,
,BAO_0000218,3031,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,Autocuration,,104698,,11454,,,,,CHEMBL620651,,,In vivo,,F,1,6,
,BAO_0000218,3032,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,Autocuration,,104698,,11454,,,,,CHEMBL872875,,,In vivo,,F,1,6,
,BAO_0000218,3033,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,Autocuration,,104698,,11454,,,,,CHEMBL620652,,,In vivo,,F,1,6,
,BAO_0000019,3034,H,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,Autocuration,,104698,,10609,,,,,CHEMBL620653,,,,,F,1,6,
,BAO_0000019,3035,H,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,Autocuration,,104698,,12861,,,,,CHEMBL857076,,,,,B,1,6,
,BAO_0000019,3036,D,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,Autocuration,,104698,,12861,,10116.0,Rattus norvegicus,,CHEMBL620654,,,,,B,1,7,
,BAO_0000223,3037,H,Binding activity radioligand.,Autocuration,,104698,,12861,,,,,CHEMBL620655,,,,,B,1,6,
,BAO_0000249,3038,H,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,Autocuration,,104698,,10728,,,,,CHEMBL620656,,,,Brain membranes,B,1,6,
,BAO_0000249,3039,H,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,Autocuration,,104698,,10728,,,,,CHEMBL620657,,,,Brain membranes,B,1,6,
,BAO_0000357,3040,H,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,Autocuration,,108,,5163,,,,,CHEMBL620658,,,,,B,1,8,
,BAO_0000357,3041,H,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,Autocuration,,108,,5163,,,,,CHEMBL620659,,,,,B,1,8,
,BAO_0000357,3042,H,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,Autocuration,,108,,6011,,,,,CHEMBL620660,,,,,B,1,8,
,BAO_0000357,3043,H,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,Autocuration,,108,,5014,,,,,CHEMBL620661,,,,,B,1,8,
,BAO_0000357,3044,H,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,Autocuration,,108,,5635,,,,,CHEMBL620662,,,,,B,1,8,
,BAO_0000357,3045,H,Affinity for 5-hydroxytryptamine 2C receptor,Expert,,108,,5163,,,,,CHEMBL620663,,,,,B,1,8,
,BAO_0000357,3046,H,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,Autocuration,,108,,6841,,,,,CHEMBL620664,,,,,B,1,8,
,BAO_0000357,3047,H,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,Expert,,108,,6119,,,,,CHEMBL620665,,,,,B,1,8,
,BAO_0000357,3048,H,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,Autocuration,,108,,4373,,,,,CHEMBL620666,,,,,B,1,8,
,BAO_0000357,3049,H,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,Autocuration,,108,,1633,,,,,CHEMBL620667,,,,,B,1,8,
,BAO_0000357,3050,H,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,Expert,,108,,1633,,,,,CHEMBL620668,,,,,B,1,8,
,BAO_0000357,3051,H,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,Autocuration,,108,,4373,,,,,CHEMBL620669,,,,,B,1,8,
,BAO_0000357,3052,H,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,Expert,,108,,6576,,,,,CHEMBL620670,,,,,B,1,8,
,BAO_0000357,3053,H,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,Autocuration,,108,,4687,,,,,CHEMBL620671,,,,,B,1,8,
,BAO_0000357,3054,H,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,Autocuration,,108,,12146,,,,,CHEMBL620672,,,,,B,1,8,
,BAO_0000357,3055,H,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,Autocuration,,108,,12146,,,,,CHEMBL620673,,,,,B,1,8,
,BAO_0000357,3056,H,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,Autocuration,,108,,16946,,,,,CHEMBL620674,,,,,B,1,8,
,BAO_0000357,3057,H,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,Autocuration,,108,,14159,,,,,CHEMBL620675,,,,,B,1,8,
,BAO_0000357,3058,H,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,Autocuration,,108,,16700,,,,,CHEMBL620676,,,,,B,1,8,
,BAO_0000357,3059,H,Affinity against 5-hydroxytryptamine 2C receptor,Autocuration,,108,,3269,,,,,CHEMBL621382,,,,,B,1,8,
,BAO_0000357,3060,D,Binding affinity against 5-hydroxytryptamine 2C receptor,Expert,,108,,1274,,9606.0,Homo sapiens,,CHEMBL621383,,,,,B,1,9,
,BAO_0000357,3061,H,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,Autocuration,,108,,1317,,,,,CHEMBL621384,,,,,B,1,8,
,BAO_0000357,3062,H,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,Autocuration,,144,,5834,,9913.0,Bos taurus,,CHEMBL621385,,,,,B,1,8,
,BAO_0000357,3063,H,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,Autocuration,,144,,11147,,9913.0,Bos taurus,,CHEMBL617989,,,,,B,1,8,
,BAO_0000019,3064,H,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,Expert,,104714,,14145,,10141.0,Cavia porcellus,,CHEMBL617990,,,,,F,1,4,
Ileum,BAO_0000221,3065,H,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,Autocuration,,104714,,10561,2116.0,10141.0,Cavia porcellus,,CHEMBL875085,,,,,B,1,4,
,BAO_0000019,3066,H,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,Autocuration,,104714,,15847,,10141.0,Cavia porcellus,,CHEMBL617991,,,,,F,1,4,
,BAO_0000019,3067,H,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,Autocuration,,104714,,15847,,10141.0,Cavia porcellus,,CHEMBL617992,,,,,F,1,4,
Ileum,BAO_0000221,3068,H,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,Autocuration,,104714,,10561,2116.0,10141.0,Cavia porcellus,,CHEMBL617993,,,,,B,1,4,
Ileum,BAO_0000221,3069,H,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,Autocuration,,104714,,11454,2116.0,10141.0,Cavia porcellus,,CHEMBL617994,,,,,B,1,4,
,BAO_0000019,3070,H,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,Autocuration,,104714,,4639,,10141.0,Cavia porcellus,,CHEMBL617995,,,,,F,1,4,
,BAO_0000019,3071,H,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,Autocuration,,104714,,4639,,10141.0,Cavia porcellus,,CHEMBL617996,,,,,F,1,4,
,BAO_0000019,3072,H,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,Autocuration,,104714,,4639,,10141.0,Cavia porcellus,,CHEMBL617997,,,,,F,1,4,
,BAO_0000019,3073,H,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,Autocuration,,104714,,4639,,10141.0,Cavia porcellus,,CHEMBL617998,,,,,F,1,4,
,BAO_0000019,3074,H,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,Autocuration,,104714,,4639,,10141.0,Cavia porcellus,,CHEMBL617999,,,,,F,1,4,
,BAO_0000019,3075,H,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,Autocuration,,104714,,4639,,10141.0,Cavia porcellus,,CHEMBL618000,,,,,F,1,4,
Ileum,BAO_0000221,3076,H,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",Autocuration,,104714,,15253,2116.0,10141.0,Cavia porcellus,,CHEMBL617815,,,,,F,1,4,
Ileum,BAO_0000221,3077,H,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",Autocuration,,104714,,15253,2116.0,10141.0,Cavia porcellus,,CHEMBL617816,,,,,F,1,4,
Ileum,BAO_0000221,3078,H,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,Autocuration,,104714,,11963,2116.0,10141.0,Cavia porcellus,,CHEMBL617817,,,,,F,1,4,
Ileum,BAO_0000221,3079,H,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,Autocuration,,104714,,1946,2116.0,10141.0,Cavia porcellus,,CHEMBL617818,,,,,B,1,4,
Ileum,BAO_0000221,3080,H,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,Autocuration,,104714,,1946,2116.0,10141.0,Cavia porcellus,,CHEMBL617819,,,,,B,1,4,
,BAO_0000223,3081,H,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,Autocuration,,104714,,12045,,10141.0,Cavia porcellus,,CHEMBL617820,,,,,B,1,4,
Ileum,BAO_0000221,3082,H,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,Autocuration,,104714,,1559,2116.0,10141.0,Cavia porcellus,,CHEMBL617821,,,,,B,1,4,
Ileum,BAO_0000221,3083,H,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),Autocuration,,104714,,273,2116.0,10141.0,Cavia porcellus,,CHEMBL617822,,,,,F,1,4,
Ileum,BAO_0000221,3084,H,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),Autocuration,,104714,,273,2116.0,10141.0,Cavia porcellus,,CHEMBL617823,,,,,F,1,4,
Ileum,BAO_0000221,3085,H,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,Autocuration,,104714,,188,2116.0,10141.0,Cavia porcellus,,CHEMBL617824,,,,,F,1,4,
Ileum,BAO_0000221,3086,H,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,Autocuration,,104714,,12919,2116.0,10141.0,Cavia porcellus,,CHEMBL617825,,,,,F,1,4,
Ileum,BAO_0000221,3087,H,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,Autocuration,,104714,,12918,2116.0,10141.0,Cavia porcellus,,CHEMBL617826,,,,,F,1,4,
Ileum,BAO_0000221,3088,H,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,Autocuration,,104714,,1559,2116.0,10141.0,Cavia porcellus,,CHEMBL617827,,,,,B,1,4,
Ileum,BAO_0000221,3089,H,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),Autocuration,,104714,,273,2116.0,10141.0,Cavia porcellus,,CHEMBL617828,,,,,F,1,4,
Ileum,BAO_0000221,3090,H,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,Autocuration,,104714,,1559,2116.0,10141.0,Cavia porcellus,,CHEMBL617829,,,,,B,1,4,
Ileum,BAO_0000221,3091,H,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,Autocuration,,104714,,1559,2116.0,10141.0,Cavia porcellus,,CHEMBL617830,,,,,B,1,4,
Ileum,BAO_0000221,3092,H,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,Autocuration,,104714,,1559,2116.0,10141.0,Cavia porcellus,,CHEMBL617831,,,,,B,1,4,
Ileum,BAO_0000221,3093,H,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,Autocuration,,104714,,14424,2116.0,10141.0,Cavia porcellus,,CHEMBL617832,,,,,B,1,4,
,BAO_0000019,3094,U,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,Autocuration,,22226,,13181,,10141.0,Cavia porcellus,,CHEMBL617833,,,,,B,1,0,
,BAO_0000357,3095,H,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,Autocuration,,51,,5486,,,,,CHEMBL617834,,,,,B,1,8,
,BAO_0000223,3096,D,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,Expert,,104714,,6491,,9606.0,Homo sapiens,,CHEMBL617835,,,,,B,1,5,
,BAO_0000223,3097,H,Binding affinity towards 5-HT3 receptor,Autocuration,,104714,,6013,,,,,CHEMBL617836,,,,,B,1,4,
,BAO_0000223,3098,H,Binding activity radioligand.,Autocuration,,104714,,12861,,,,,CHEMBL617837,,,,,B,1,4,
,BAO_0000019,3099,H,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,Autocuration,,104714,,12861,,,,,CHEMBL620392,,,,,B,1,4,
,BAO_0000223,3100,H,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,Autocuration,,104714,,5104,,,,,CHEMBL620393,,,,,B,1,4,
,BAO_0000223,3101,H,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,Autocuration,,104714,,5105,,,,,CHEMBL620394,,,,,B,1,4,
,BAO_0000223,3102,H,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,Autocuration,,104714,,5104,,,,,CHEMBL620395,,,,,B,1,4,
,BAO_0000019,3103,U,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,Autocuration,,22226,,3935,,,,,CHEMBL620396,,,,,B,1,0,
,BAO_0000219,3104,H,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,Expert,433.0,105030,,13657,,,,,CHEMBL620582,NG108-15,,,,B,1,4,
,BAO_0000218,3105,H,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",Autocuration,,105030,,10369,,,,,CHEMBL620583,,,In vivo,,B,1,4,
,BAO_0000019,3106,H,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),Autocuration,,105030,,10369,,,,,CHEMBL620584,,,,,B,1,4,
,BAO_0000224,3107,H,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,Autocuration,,105030,,12918,,,,,CHEMBL620585,,,,,B,1,4,
,BAO_0000224,3108,H,Compound was evaluated for the binding affinity at 5- HT3 receptor,Autocuration,,105030,,12918,,,,,CHEMBL620586,,,,,B,1,4,
,BAO_0000019,3109,H,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),Autocuration,,105030,,10369,,,,,CHEMBL620587,,,,,B,1,4,
,BAO_0000019,3110,H,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,Autocuration,,105030,,773,,,,,CHEMBL620588,,,,,B,1,4,
,BAO_0000218,3111,H,5-hydroxytryptamine 3 receptor agonism in mouse,Autocuration,,105030,,12918,,,,,CHEMBL620589,,,,,F,1,4,
,BAO_0000219,3112,H,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,Autocuration,,105030,,10561,,,,,CHEMBL620590,,,,,B,1,4,
,BAO_0000019,3113,H,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,Autocuration,,105030,,12827,,,,,CHEMBL617956,,,,,B,1,4,
,BAO_0000019,3114,H,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,Autocuration,,105030,,12827,,,,,CHEMBL617957,,,,,B,1,4,
,BAO_0000224,3115,H,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,Autocuration,,105030,,12918,,,,,CHEMBL617958,,,,,B,1,4,
,BAO_0000219,3116,H,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,Autocuration,,105030,,273,,,,,CHEMBL617959,,,,,B,1,4,
,BAO_0000219,3117,H,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,Autocuration,,105030,,273,,,,,CHEMBL617960,,,,,B,1,4,
,BAO_0000224,3118,H,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,Autocuration,,105030,,10561,,,,,CHEMBL617961,,,,,B,1,4,
,BAO_0000219,3119,H,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,Autocuration,,105030,,5033,,,,,CHEMBL617962,,,In vitro,,B,1,4,
,BAO_0000219,3120,H,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,Autocuration,339.0,105030,,16429,,,,,CHEMBL617963,N1E-115,,,,B,1,4,
,BAO_0000019,3121,H,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,Autocuration,,11765,,10322,,,,,CHEMBL617964,,,,,B,1,8,
,BAO_0000219,3122,H,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,Autocuration,,11765,,14331,,,,,CHEMBL617965,,,,,B,1,8,
,BAO_0000357,3123,D,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,Autocuration,,10630,,13462,,10090.0,Mus musculus,,CHEMBL617966,,,,,B,1,9,
,BAO_0000019,3124,H,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,Autocuration,,17106,,12861,,,,,CHEMBL857074,,,,,B,1,8,
,BAO_0000357,3125,H,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,Autocuration,,144,,15086,,9823.0,Sus scrofa,,CHEMBL617967,,,,,B,1,8,
,BAO_0000357,3126,H,Binding activity radioligand.,Autocuration,,144,,12861,,9823.0,Sus scrofa,,CHEMBL617968,,,,,B,1,8,
,BAO_0000223,3127,H,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,Autocuration,,104714,,10561,,9986.0,Oryctolagus cuniculus,,CHEMBL617969,,,,,B,1,4,
,BAO_0000223,3128,H,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,Autocuration,,104714,,10561,,9986.0,Oryctolagus cuniculus,,CHEMBL617970,,,,,B,1,4,
,BAO_0000223,3129,H,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,Autocuration,,104714,,10561,,9986.0,Oryctolagus cuniculus,,CHEMBL617971,,,,,B,1,4,
,BAO_0000019,3130,H,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,Autocuration,,104714,,10561,,9986.0,Oryctolagus cuniculus,,CHEMBL617972,,,,,B,1,4,
,BAO_0000019,3131,H,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),Autocuration,,104714,,273,,9986.0,Oryctolagus cuniculus,,CHEMBL617973,,,,,F,1,4,
,BAO_0000019,3132,H,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),Autocuration,,104714,,273,,9986.0,Oryctolagus cuniculus,,CHEMBL617974,,,,,F,1,4,
Ileum,BAO_0000221,3133,H,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),Autocuration,,104714,,273,2116.0,9986.0,Oryctolagus cuniculus,,CHEMBL617975,,,,,F,1,4,
,BAO_0000019,3134,H,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),Autocuration,,104714,,273,,9986.0,Oryctolagus cuniculus,,CHEMBL617976,,,,,F,1,4,
,BAO_0000019,3135,H,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),Autocuration,,104714,,273,,9986.0,Oryctolagus cuniculus,,CHEMBL617977,,,,,F,1,4,
,BAO_0000019,3136,H,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),Autocuration,,104714,,273,,9986.0,Oryctolagus cuniculus,,CHEMBL617978,,,,,F,1,4,
,BAO_0000019,3137,H,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),Autocuration,,104714,,273,,9986.0,Oryctolagus cuniculus,,CHEMBL617979,,,,,F,1,4,
,BAO_0000219,3138,H,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,Autocuration,449.0,104714,,13047,,9986.0,Oryctolagus cuniculus,,CHEMBL617980,CHO,,,,B,1,4,
,BAO_0000019,3139,D,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,Autocuration,,104698,,1650,,10116.0,Rattus norvegicus,,CHEMBL617981,,,,,B,1,7,
,BAO_0000019,3140,H,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),Autocuration,,12020,,16288,,,,,CHEMBL617982,,,,,B,1,8,
,BAO_0000357,3141,H,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),Autocuration,,12020,,16288,,,,,CHEMBL617983,,,,,B,1,8,
,BAO_0000019,3142,D,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,Autocuration,,104698,,10254,,10116.0,Rattus norvegicus,,CHEMBL617984,,,,,B,1,7,
,BAO_0000019,3143,H,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",Autocuration,,104698,,14532,,,,,CHEMBL617985,,,,,B,1,6,
Heart,BAO_0000218,3144,H,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",Autocuration,,104698,,13392,948.0,,,,CHEMBL617986,,,In vivo,,F,1,6,
Heart,BAO_0000019,3145,H,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",Autocuration,,104698,,13392,948.0,,,,CHEMBL617987,,,,,F,1,6,
Heart,BAO_0000019,3146,H,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",Autocuration,,104698,,13392,948.0,,,,CHEMBL617988,,,,,F,1,6,
Heart,BAO_0000019,3147,H,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",Autocuration,,104698,,13392,948.0,,,,CHEMBL617792,,,,,F,1,6,
Heart,BAO_0000019,3148,H,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",Autocuration,,104698,,13392,948.0,,,,CHEMBL617793,,,,,F,1,6,
,BAO_0000019,3149,H,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",Autocuration,,104698,,13392,,,,,CHEMBL617794,,,,,F,1,6,
,BAO_0000019,3150,H,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",Autocuration,,104698,,13392,,,,,CHEMBL617795,,,,,F,1,6,
,BAO_0000019,3151,H,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",Autocuration,,104698,,13392,,,,,CHEMBL617796,,,,,F,1,6,
,BAO_0000019,3152,H,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",Autocuration,,104698,,13392,,,,,CHEMBL617797,,,,,F,1,6,
,BAO_0000218,3153,D,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),Autocuration,,104698,,1089,,10116.0,Rattus norvegicus,,CHEMBL617798,,,In vivo,,F,1,7,
,BAO_0000218,3154,H,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),Autocuration,,104698,,1089,,,,,CHEMBL617799,,,In vivo,,F,1,6,
,BAO_0000218,3155,D,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,Autocuration,,104698,,11454,,10116.0,Rattus norvegicus,,CHEMBL617800,,,In vivo,,F,1,7,
,BAO_0000019,3156,D,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,Autocuration,,104698,,11454,,10116.0,Rattus norvegicus,,CHEMBL617801,,,,,F,1,7,
,BAO_0000218,3157,D,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,Autocuration,,104698,,12205,,10116.0,Rattus norvegicus,,CHEMBL617802,,,In vivo,,F,1,7,
,BAO_0000019,3158,D,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),Autocuration,,104698,,1089,,10116.0,Rattus norvegicus,,CHEMBL617803,,,,,F,1,7,
,BAO_0000019,3159,H,Binding affinity towards 5-HT3 receptor in rat was evaluated,Autocuration,,104698,,5094,,,,,CHEMBL617804,,,,,B,1,6,
,BAO_0000019,3160,D,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,Autocuration,,104698,,2622,,10116.0,Rattus norvegicus,,CHEMBL617805,,,,,B,1,7,
,BAO_0000223,3161,H,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,Autocuration,,104698,,245,,,,,CHEMBL617806,,,,,B,1,6,
,BAO_0000019,3162,H,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,Autocuration,,104698,,14788,,,,,CHEMBL617807,,,,,B,1,6,
,BAO_0000019,3163,H,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,Autocuration,,104698,,14788,,,,,CHEMBL617808,,,,,B,1,6,
,BAO_0000249,3164,H,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,Autocuration,,104698,,3020,,,,,CHEMBL617809,,,,,B,1,6,
,BAO_0000019,3165,H,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,Autocuration,,104698,,1742,,,,,CHEMBL617810,,,,,B,1,6,
Brain,BAO_0000249,3166,H,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,Autocuration,,104698,,17394,955.0,,,,CHEMBL617811,,,,,B,1,6,
Brain,BAO_0000221,3167,H,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,Autocuration,,104698,,17394,955.0,,,,CHEMBL617812,,,,,B,1,6,
,BAO_0000249,3168,H,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,Autocuration,,104698,,17394,,,,,CHEMBL617813,,,,,B,1,6,
,BAO_0000249,3169,H,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,Autocuration,,104698,,14286,,,,,CHEMBL617814,,,,,B,1,6,
,BAO_0000019,3170,H,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,Autocuration,,104698,,14178,,,,,CHEMBL617698,,,,,B,1,6,
,BAO_0000019,3171,D,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,Autocuration,,104698,,14178,,10116.0,Rattus norvegicus,,CHEMBL617699,,,,,B,1,7,
,BAO_0000019,3172,D,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,Autocuration,,104698,,14178,,10116.0,Rattus norvegicus,,CHEMBL617700,,,,,B,1,7,
,BAO_0000223,3173,D,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,Autocuration,,104698,,14178,,10116.0,Rattus norvegicus,,CHEMBL617701,,,,,B,1,7,
,BAO_0000019,3174,H,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,Autocuration,,104698,,15034,,,,,CHEMBL617702,,,,,B,1,6,
,BAO_0000249,3175,H,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",Autocuration,,104698,,1089,,,,,CHEMBL617703,,,,Membranes,B,1,6,
,BAO_0000019,3176,D,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,Autocuration,,104698,,1089,,10116.0,Rattus norvegicus,,CHEMBL617704,,,,,B,1,7,
,BAO_0000223,3177,H,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,Autocuration,,104698,,16532,,,,,CHEMBL617705,,,,,B,1,6,
,BAO_0000223,3178,D,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,Autocuration,,104698,,12801,,10116.0,Rattus norvegicus,,CHEMBL617706,,,,,B,1,7,
,BAO_0000219,3179,H,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),Autocuration,433.0,104698,,15194,,,,,CHEMBL617707,NG108-15,,,,B,1,6,
,BAO_0000219,3180,H,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,Autocuration,433.0,104698,,15194,,,,,CHEMBL617708,NG108-15,,,,B,1,6,
,BAO_0000019,3181,H,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,Autocuration,,104698,,15194,,,,,CHEMBL617709,,,,,B,1,6,
,BAO_0000019,3182,H,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,Autocuration,,104698,,15194,,,,,CHEMBL617710,,,,,B,1,6,
,BAO_0000019,3183,H,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,Autocuration,,104698,,15194,,,,,CHEMBL882925,,,,,B,1,6,
,BAO_0000019,3184,H,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,Autocuration,,104698,,15194,,,,,CHEMBL617711,,,,,B,1,6,
,BAO_0000019,3185,H,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,Autocuration,,104698,,10610,,,,,CHEMBL617712,,,,,F,1,6,
,BAO_0000019,3186,D,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,Autocuration,,104698,,10355,,10116.0,Rattus norvegicus,,CHEMBL617713,,,,,F,1,7,
,BAO_0000019,3187,H,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",Autocuration,,104698,,691,,,,,CHEMBL617714,,,,,F,1,6,
,BAO_0000218,3188,H,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,Autocuration,,104698,,10611,,,,,CHEMBL617715,,,,,F,1,6,
,BAO_0000218,3189,H,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,Autocuration,,104698,,12801,,,,,CHEMBL617716,,,In vivo,,F,1,6,
,BAO_0000218,3190,H,Inhibition of 5-HT evoked reflex bradycardia in rat.,Autocuration,,104698,,10609,,,,,CHEMBL617717,,,,,F,1,6,
,BAO_0000218,3191,H,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,Autocuration,,104698,,11454,,,,,CHEMBL617718,,,In vivo,,F,1,6,
,BAO_0000218,3192,H,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,Autocuration,,104698,,11454,,,,,CHEMBL617719,,,In vivo,,F,1,6,
,BAO_0000218,3193,H,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),Autocuration,,104698,,11454,,,,,CHEMBL617720,,,In vivo,,F,1,6,
,BAO_0000218,3194,D,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,Autocuration,,104698,,11454,,10116.0,Rattus norvegicus,,CHEMBL617721,,,In vivo,,F,1,7,
,BAO_0000218,3195,H,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,Autocuration,,104698,,11454,,,,,CHEMBL617722,,,In vivo,,F,1,6,
,BAO_0000218,3196,H,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,Autocuration,,104698,,11454,,,,,CHEMBL617723,,,In vivo,,F,1,6,
,BAO_0000218,3197,H,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,Autocuration,,104698,,11454,,,,,CHEMBL617724,,,In vivo,,F,1,6,
,BAO_0000218,3198,H,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,Autocuration,,104698,,11454,,,,,CHEMBL617725,,,In vivo,,F,1,6,
,BAO_0000218,3199,H,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,Autocuration,,104698,,11454,,,,,CHEMBL617726,,,In vivo,,F,1,6,
,BAO_0000218,3200,H,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,Autocuration,,104698,,11454,,,,,CHEMBL617727,,,In vivo,,F,1,6,
,BAO_0000218,3201,H,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,Autocuration,,104698,,11454,,,,,CHEMBL617728,,,In vivo,,F,1,6,
,BAO_0000218,3202,H,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,Autocuration,,104698,,11454,,,,,CHEMBL617729,,,In vivo,,F,1,6,
,BAO_0000218,3203,H,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,Autocuration,,104698,,11454,,,,,CHEMBL617730,,,In vivo,,F,1,6,
,BAO_0000218,3204,H,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,Autocuration,,104698,,11454,,,,,CHEMBL617731,,,In vivo,,F,1,6,
,BAO_0000218,3205,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,Autocuration,,104698,,11454,,,,,CHEMBL617732,,,In vivo,,F,1,6,
,BAO_0000218,3206,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,Autocuration,,104698,,11454,,,,,CHEMBL617733,,,In vivo,,F,1,6,
,BAO_0000218,3207,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,Autocuration,,104698,,11454,,,,,CHEMBL617734,,,In vivo,,F,1,6,
,BAO_0000218,3208,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,Autocuration,,104698,,11454,,,,,CHEMBL872874,,,In vivo,,F,1,6,
,BAO_0000218,3209,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,Autocuration,,104698,,11454,,,,,CHEMBL617735,,,In vivo,,F,1,6,
,BAO_0000218,3210,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,Autocuration,,104698,,11454,,,,,CHEMBL617736,,,In vivo,,F,1,6,
,BAO_0000218,3211,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,Autocuration,,104698,,11454,,,,,CHEMBL617737,,,In vivo,,F,1,6,
,BAO_0000218,3212,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,Autocuration,,104698,,11454,,,,,CHEMBL617738,,,In vivo,,F,1,6,
,BAO_0000218,3213,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,Autocuration,,104698,,11454,,,,,CHEMBL617739,,,In vivo,,F,1,6,
,BAO_0000218,3214,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,Autocuration,,104698,,11454,,,,,CHEMBL617740,,,In vivo,,F,1,6,
,BAO_0000218,3215,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,Autocuration,,104698,,11454,,,,,CHEMBL617741,,,In vivo,,F,1,6,
,BAO_0000218,3216,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,Autocuration,,104698,,11454,,,,,CHEMBL617742,,,In vivo,,F,1,6,
,BAO_0000218,3217,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,Autocuration,,104698,,11454,,,,,CHEMBL617743,,,In vivo,,F,1,6,
,BAO_0000218,3218,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,Autocuration,,104698,,11454,,,,,CHEMBL617744,,,In vivo,,F,1,6,
,BAO_0000218,3219,H,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,Autocuration,,104698,,11454,,,,,CHEMBL617745,,,In vivo,,F,1,6,
,BAO_0000218,3220,H,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",Autocuration,,104698,,670,,,,,CHEMBL617746,,,,,F,1,6,
,BAO_0000218,3221,H,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",Autocuration,,104698,,670,,,,,CHEMBL617747,,,,,F,1,6,
,BAO_0000218,3222,H,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,Autocuration,,104698,,10321,,,,,CHEMBL617748,,,In vivo,,F,1,6,
,BAO_0000218,3223,H,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,Autocuration,,104698,,10321,,,,,CHEMBL618909,,,In vivo,,F,1,6,
,BAO_0000218,3224,H,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,Autocuration,,104698,,10321,,,,,CHEMBL618910,,,In vivo,,F,1,6,
,BAO_0000218,3225,H,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,Autocuration,,104698,,10321,,,,,CHEMBL618911,,,In vivo,,F,1,6,
,BAO_0000218,3226,H,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,Autocuration,,104698,,10321,,,,,CHEMBL618912,,,In vivo,,F,1,6,
,BAO_0000218,3227,H,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),Autocuration,,104698,,10322,,,,,CHEMBL618913,,,In vivo,,F,1,6,
,BAO_0000019,3228,H,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,Autocuration,,104698,,15412,,,,,CHEMBL618914,,,,,F,1,6,
,BAO_0000019,3229,H,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,Autocuration,,104698,,15412,,,,,CHEMBL618915,,,,,F,1,6,
,BAO_0000223,3230,D,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,Autocuration,,104698,,15412,,10116.0,Rattus norvegicus,,CHEMBL618916,,,,,B,1,7,
,BAO_0000019,3231,H,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,Autocuration,,104698,,15412,,,,,CHEMBL618917,,,,,F,1,6,
Hippocampus,BAO_0000221,3232,D,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,Intermediate,,104698,,15412,10000000.0,,,,CHEMBL618918,,,,,B,1,7,
,BAO_0000019,3233,D,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,Autocuration,,104698,,15412,,10116.0,Rattus norvegicus,,CHEMBL618919,,,,,B,1,7,
,BAO_0000019,3234,D,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,Autocuration,,104698,,17394,,10116.0,Rattus norvegicus,,CHEMBL618920,,,,,B,1,7,
,BAO_0000223,3235,H,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,Autocuration,,104698,,12457,,,,,CHEMBL618921,,,,,B,1,6,
,BAO_0000019,3236,H,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,Autocuration,,104698,,12457,,,,,CHEMBL618922,,,,,B,1,6,
,BAO_0000019,3237,H,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,Autocuration,,104698,,12205,,,,,CHEMBL618923,,,,,B,1,6,
,BAO_0000019,3238,H,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,Autocuration,,104698,,14532,,,,,CHEMBL618924,,,,,B,1,6,
,BAO_0000019,3239,H,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,Autocuration,,104698,,1122,,,,,CHEMBL618925,,,,,B,1,6,
,BAO_0000019,3240,H,Binding affinity towards 5-HT3 receptor in rat was evaluated,Autocuration,,104698,,5094,,,,,CHEMBL618926,,,,,B,1,6,
Ileum,BAO_0000221,3241,D,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,Intermediate,,20033,,809,2116.0,10141.0,Cavia porcellus,,CHEMBL618927,,,,,F,1,9,
Ileum,BAO_0000221,3242,D,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,Intermediate,,20033,,809,2116.0,10141.0,Cavia porcellus,,CHEMBL618928,,,,,F,1,9,
Ileum,BAO_0000221,3243,D,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",Intermediate,,20033,,14290,2116.0,10141.0,Cavia porcellus,,CHEMBL618929,,,,,F,1,9,
Ileum,BAO_0000221,3244,D,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",Intermediate,,20033,,14290,2116.0,10141.0,Cavia porcellus,,CHEMBL618930,,,,,F,1,9,
Ileum,BAO_0000221,3245,D,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",Intermediate,,20033,,14290,2116.0,10141.0,Cavia porcellus,,CHEMBL618931,,,,,F,1,9,
Ileum,BAO_0000221,3246,D,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",Intermediate,,20033,,14290,2116.0,10141.0,Cavia porcellus,,CHEMBL619594,,,,,F,1,9,
Ileum,BAO_0000221,3247,D,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",Intermediate,,20033,,14290,2116.0,10141.0,Cavia porcellus,,CHEMBL619595,,,,,F,1,9,
Ileum,BAO_0000221,3248,D,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,Intermediate,,20033,,13961,2116.0,10141.0,Cavia porcellus,,CHEMBL619596,,,,,F,1,9,
Ileum,BAO_0000221,3249,D,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,Intermediate,,20033,,13961,2116.0,10141.0,Cavia porcellus,,CHEMBL619755,,,,,F,1,9,
Ileum,BAO_0000221,3250,D,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,Intermediate,,20033,,809,2116.0,10141.0,Cavia porcellus,,CHEMBL619756,,,,,F,1,9,
Ileum,BAO_0000221,3251,D,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,Intermediate,,20033,,809,2116.0,10141.0,Cavia porcellus,,CHEMBL619757,,,,,F,1,9,
Ileum,BAO_0000221,3252,D,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,Intermediate,,20033,,809,2116.0,10141.0,Cavia porcellus,,CHEMBL619758,,,,,F,1,9,
Ileum,BAO_0000221,3253,D,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",Intermediate,,20033,,14290,2116.0,10141.0,Cavia porcellus,,CHEMBL619759,,,,,F,1,9,
Ileum,BAO_0000221,3254,D,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",Intermediate,,20033,,14290,2116.0,10141.0,Cavia porcellus,,CHEMBL619760,,,,,F,1,9,
Ileum,BAO_0000221,3255,D,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",Intermediate,,20033,,14290,2116.0,10141.0,Cavia porcellus,,CHEMBL619761,,,,,F,1,9,
Ileum,BAO_0000221,3256,D,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,Intermediate,,20033,,14290,2116.0,10141.0,Cavia porcellus,,CHEMBL619762,,,,,F,1,9,
Ileum,BAO_0000221,3257,D,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",Intermediate,,20033,,14290,2116.0,10141.0,Cavia porcellus,,CHEMBL619763,,,,,F,1,9,
Ileum,BAO_0000221,3258,D,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",Intermediate,,20033,,14290,2116.0,10141.0,Cavia porcellus,,CHEMBL617868,,,,,F,1,9,
,BAO_0000357,3259,D,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,Intermediate,,20033,,15034,,10141.0,Cavia porcellus,,CHEMBL617869,,,,,B,1,9,
Striatum,BAO_0000249,3260,D,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,Intermediate,,20033,,5094,2435.0,10141.0,Cavia porcellus,,CHEMBL882926,,,,,B,1,9,
Striatum,BAO_0000249,3261,D,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,Intermediate,,20033,,5094,2435.0,10141.0,Cavia porcellus,,CHEMBL617870,,,,,B,1,9,
Striatum,BAO_0000357,3262,D,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,Intermediate,,20033,,5399,2435.0,10141.0,Cavia porcellus,,CHEMBL617871,,,,,B,1,9,
Striatum,BAO_0000357,3263,D,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,Intermediate,,20033,,17394,2435.0,10141.0,Cavia porcellus,,CHEMBL617872,,,,,B,1,9,
Striatum,BAO_0000357,3264,D,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,Intermediate,,20033,,17394,2435.0,10141.0,Cavia porcellus,,CHEMBL617873,,,,,B,1,9,
Striatum,BAO_0000357,3265,D,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,Intermediate,,20033,,17394,2435.0,10141.0,Cavia porcellus,,CHEMBL617874,,,,,B,1,9,
Ileum,BAO_0000221,3266,D,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,Intermediate,,20033,,13961,2116.0,10141.0,Cavia porcellus,,CHEMBL619067,,,,,F,1,9,
Ileum,BAO_0000221,3267,D,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,Intermediate,,20033,,13961,2116.0,10141.0,Cavia porcellus,,CHEMBL619068,,,,,F,1,9,
Ileum,BAO_0000221,3268,D,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,Intermediate,,20033,,13961,2116.0,10141.0,Cavia porcellus,,CHEMBL619069,,,,,F,1,9,
,BAO_0000357,3269,D,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,Intermediate,,20033,,16946,,10141.0,Cavia porcellus,,CHEMBL619070,,,,,B,1,9,
,BAO_0000357,3270,D,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,Intermediate,,20033,,16946,,10141.0,Cavia porcellus,,CHEMBL619071,,,,,B,1,9,
,BAO_0000019,3271,D,Agonistic activity against 5-hydroxytryptamine 4 receptor,Intermediate,,20033,,15034,,10141.0,Cavia porcellus,,CHEMBL619072,,,,,F,1,9,
,BAO_0000019,3272,D,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,Intermediate,,20033,,15034,,10141.0,Cavia porcellus,,CHEMBL619073,,,,,F,1,9,
,BAO_0000019,3273,D,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,Intermediate,,20033,,12918,,10141.0,Cavia porcellus,,CHEMBL619074,,,,,F,1,9,
,BAO_0000357,3274,D,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,Intermediate,,20033,,16946,,10141.0,Cavia porcellus,,CHEMBL619075,,,,,B,1,9,
Striatum,BAO_0000357,3275,D,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,Intermediate,,20033,,17394,2435.0,10141.0,Cavia porcellus,,CHEMBL619076,,,,,B,1,9,
Striatum,BAO_0000357,3276,D,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,Intermediate,,20033,,15034,2435.0,10141.0,Cavia porcellus,,CHEMBL619077,,,,,B,1,9,
Striatum,BAO_0000249,3277,D,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,Intermediate,,20033,,5094,2435.0,10141.0,Cavia porcellus,,CHEMBL619078,,,,,B,1,9,
Striatum,BAO_0000249,3278,D,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,Intermediate,,20033,,5094,2435.0,10141.0,Cavia porcellus,,CHEMBL619079,,,,,B,1,9,
Ileum,BAO_0000221,3279,D,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,Intermediate,,20033,,17358,2116.0,10141.0,Cavia porcellus,,CHEMBL619080,,,,,B,1,9,
,BAO_0000357,3280,D,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,Expert,,20033,,12953,,10141.0,Cavia porcellus,,CHEMBL619081,,,,,B,1,9,
,BAO_0000357,3281,D,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,Intermediate,,20033,,12953,,10141.0,Cavia porcellus,,CHEMBL619082,,,,,B,1,9,
,BAO_0000357,3282,D,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,Intermediate,,20033,,12953,,10141.0,Cavia porcellus,,CHEMBL619083,,,,,B,1,9,
,BAO_0000357,3283,D,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,Intermediate,,20033,,12953,,10141.0,Cavia porcellus,,CHEMBL619084,,,,,B,1,9,
Ileum,BAO_0000221,3284,D,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,Intermediate,,20033,,273,2116.0,10141.0,Cavia porcellus,,CHEMBL859397,,,,,F,1,9,
Ileum,BAO_0000221,3285,D,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,Intermediate,,20033,,12918,2116.0,10141.0,Cavia porcellus,,CHEMBL619085,,,,,F,1,9,
Ileum,BAO_0000221,3286,D,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,Intermediate,,20033,,12919,2116.0,10141.0,Cavia porcellus,,CHEMBL619086,,,,,F,1,9,
Ileum,BAO_0000221,3287,D,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,Intermediate,,20033,,273,2116.0,10141.0,Cavia porcellus,,CHEMBL619087,,,,,F,1,9,
Ileum,BAO_0000221,3288,D,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,Intermediate,,20033,,273,2116.0,10141.0,Cavia porcellus,,CHEMBL619088,,,,,F,1,9,
,BAO_0000357,3289,D,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,Intermediate,,20033,,13181,,10141.0,Cavia porcellus,,CHEMBL619089,,,,,B,1,9,
,BAO_0000357,3290,H,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,Autocuration,,168,,13181,,10141.0,Cavia porcellus,,CHEMBL619090,,,,,B,1,8,
,BAO_0000019,3291,D,Antagonistic activity against 5-hydroxytryptamine 4 receptor,Intermediate,,20033,,15034,,10141.0,Cavia porcellus,,CHEMBL619091,,,,,F,1,9,
,BAO_0000357,3292,D,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,Intermediate,,20033,,5033,,10141.0,Cavia porcellus,,CHEMBL619092,,,,,B,1,9,
,BAO_0000019,3293,D,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,Intermediate,,20033,,1980,,10141.0,Cavia porcellus,,CHEMBL619093,,,,,B,1,9,
,BAO_0000219,3294,H,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,Autocuration,722.0,168,,13181,,10141.0,Cavia porcellus,,CHEMBL619094,HEK293,,,,B,1,8,
,BAO_0000019,3295,D,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,Intermediate,,20033,,14287,,10141.0,Cavia porcellus,,CHEMBL619095,,,,,B,1,9,
,BAO_0000357,3296,D,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,Intermediate,,20033,,1317,,10141.0,Cavia porcellus,,CHEMBL857988,,,,,B,1,9,
,BAO_0000357,3297,D,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,Intermediate,,20033,,15316,,10141.0,Cavia porcellus,,CHEMBL619096,,,,,B,1,9,
Striatum,BAO_0000357,3298,D,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,Intermediate,,20033,,16429,2435.0,10141.0,Cavia porcellus,,CHEMBL619097,,,,,B,1,9,
Hippocampus,BAO_0000221,3299,D,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,Intermediate,,20033,,14818,10000000.0,10141.0,Cavia porcellus,,CHEMBL619098,,,,,B,1,9,
,BAO_0000357,3300,D,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,Intermediate,,20033,,15194,,10141.0,Cavia porcellus,,CHEMBL619751,,,,,B,1,9,
,BAO_0000357,3301,D,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,Intermediate,,20033,,15194,,10141.0,Cavia porcellus,,CHEMBL619752,,,,,B,1,9,
Ileum,BAO_0000221,3302,D,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,Intermediate,,20033,,13961,2116.0,10141.0,Cavia porcellus,,CHEMBL875096,,,,,F,1,9,
,BAO_0000357,3303,H,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,Autocuration,,108,,5486,,,,,CHEMBL619004,,,,,B,1,8,
,BAO_0000357,3304,H,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,Autocuration,,168,,16209,,,,,CHEMBL619005,,,,,B,1,8,
,BAO_0000019,3305,H,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,Autocuration,,168,,17085,,,,,CHEMBL619006,,,,,B,1,8,
,BAO_0000219,3306,H,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,Autocuration,308.0,168,,4199,,,,,CHEMBL619007,HeLa,,,,B,1,8,
,BAO_0000357,3307,H,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,Autocuration,,168,,15146,,,,,CHEMBL619008,,,,,B,1,8,
,BAO_0000357,3308,H,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,Autocuration,,168,,5213,,,,,CHEMBL619009,,,,,B,1,8,
,BAO_0000219,3309,H,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",Autocuration,308.0,168,,4829,,,,,CHEMBL619010,HeLa,,,,B,1,8,
,BAO_0000357,3310,H,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,Autocuration,,10622,,17358,,,,,CHEMBL619011,,,,,B,1,8,
,BAO_0000357,3311,H,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,Autocuration,,10622,,17358,,,,,CHEMBL619012,,,,,B,1,8,
,BAO_0000219,3312,H,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,Autocuration,,10622,,16946,,,,,CHEMBL619013,,,,,B,1,8,
,BAO_0000357,3313,H,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,Autocuration,,10622,,17358,,,,,CHEMBL619014,,,,,B,1,8,
Cardiac atrium,BAO_0000019,3314,H,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,Autocuration,,11249,,268,2081.0,,,,CHEMBL857503,,,,,F,1,8,
Cardiac atrium,BAO_0000019,3315,H,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,Autocuration,,11249,,268,2081.0,,,,CHEMBL619015,,,,,F,1,8,
,BAO_0000357,3316,H,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,Autocuration,,11249,,15086,,,,,CHEMBL619016,,,,,B,1,8,
Hippocampus,BAO_0000221,3317,H,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,Autocuration,,11249,,14875,10000000.0,,,,CHEMBL619017,,,,,B,1,8,
Hippocampus,BAO_0000221,3318,H,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,Autocuration,,168,,13267,10000000.0,9823.0,Sus scrofa,,CHEMBL619018,,,,,B,1,8,
,BAO_0000019,3319,H,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,Autocuration,,168,,13047,,9986.0,Oryctolagus cuniculus,,CHEMBL619019,,,,,B,1,8,
,BAO_0000357,3320,D,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,Expert,,10623,,1650,,10116.0,Rattus norvegicus,,CHEMBL619020,,,,,B,1,9,
,BAO_0000019,3321,H,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,Autocuration,,10623,,567,,,,,CHEMBL619021,,,,,F,1,8,
,BAO_0000357,3322,H,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,Autocuration,,10623,,17358,,,,,CHEMBL619022,,,,,B,1,8,
,BAO_0000357,3323,H,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,Autocuration,,10623,,188,,,,,CHEMBL619023,,,,,B,1,8,
,BAO_0000019,3324,H,lntrinsic activity relative to 5-HT receptor,Autocuration,,10623,,670,,,,,CHEMBL619024,,,,,F,1,8,
,BAO_0000019,3325,H,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,Autocuration,,10623,,204,,,,,CHEMBL619025,,,,,F,1,8,
,BAO_0000019,3326,H,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,Expert,,10623,,1946,,,,,CHEMBL619026,,,,,F,1,8,
,BAO_0000019,3327,H,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,Autocuration,,10623,,6398,,,,,CHEMBL619027,,,,,F,1,8,
,BAO_0000019,3328,H,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,Autocuration,,10623,,6398,,,,,CHEMBL619028,,,,,F,1,8,
,BAO_0000019,3329,H,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,Autocuration,,10623,,17358,,,,,CHEMBL619029,,,,,F,1,8,
,BAO_0000019,3330,H,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,Autocuration,,10623,,6398,,,,,CHEMBL619030,,,,,F,1,8,
,BAO_0000357,3331,H,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,Expert,,10623,,11752,,,,,CHEMBL619031,,,,,B,1,8,
,BAO_0000019,3332,H,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,Autocuration,,10623,,809,,,,,CHEMBL619032,,,,,F,1,8,
,BAO_0000357,3333,D,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,Expert,,10623,,14178,,10116.0,Rattus norvegicus,,CHEMBL619033,,,,,B,1,9,
,BAO_0000357,3334,H,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,Autocuration,,10623,,567,,,,,CHEMBL619034,,,,,B,1,8,
,BAO_0000357,3335,H,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,Autocuration,,10623,,1946,,,,,CHEMBL619035,,,,,B,1,8,
,BAO_0000357,3336,H,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,Autocuration,,10623,,1946,,,,,CHEMBL619036,,,,,B,1,8,
,BAO_0000019,3337,D,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,Expert,,10623,,13961,,10116.0,Rattus norvegicus,,CHEMBL619037,,,,,B,1,9,
Striatum,BAO_0000249,3338,H,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,Autocuration,,10623,,6238,2435.0,,,,CHEMBL619038,,,,,B,1,8,
,BAO_0000249,3339,H,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,Autocuration,,10623,,14290,,,,,CHEMBL619039,,,,,B,1,8,
,BAO_0000249,3340,H,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,Expert,,10623,,14290,,,,,CHEMBL619040,,,,,B,1,8,
Striatum,BAO_0000019,3341,D,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,Expert,,10623,,809,2435.0,10116.0,Rattus norvegicus,,CHEMBL619041,,,,,B,1,9,
Striatum,BAO_0000019,3342,H,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,Autocuration,,10623,,1578,2435.0,,,,CHEMBL619042,,,,,B,1,8,
Striatum,BAO_0000249,3343,H,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,Expert,,10623,,16709,2435.0,,,,CHEMBL619043,,,,,B,1,8,
Striatum,BAO_0000019,3344,H,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,Expert,,10623,,1946,2435.0,,,,CHEMBL619044,,,,,B,1,8,
Striatum,BAO_0000249,3345,H,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,Expert,,10623,,15253,2435.0,,,,CHEMBL619045,,,,,B,1,8,
Striatum,BAO_0000249,3346,H,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,Expert,,10623,,4535,2435.0,,,,CHEMBL619046,,,,,B,1,8,
,BAO_0000249,3347,H,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,Expert,,10623,,13961,,,,,CHEMBL619047,,,,,B,1,8,
Brain,BAO_0000221,3348,H,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,Autocuration,,10623,,17358,955.0,,,,CHEMBL619048,,,,,F,1,8,
,BAO_0000019,3349,H,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,Autocuration,,10623,,15847,,,,,CHEMBL859398,,,,,F,1,8,
,BAO_0000019,3350,H,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,Autocuration,,10623,,15847,,,,,CHEMBL619049,,,,,F,1,8,
,BAO_0000019,3351,H,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,Autocuration,,10623,,670,,,,,CHEMBL857886,,,,,F,1,8,
,BAO_0000019,3352,H,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,Autocuration,,10623,,670,,,,,CHEMBL619050,,,,,F,1,8,
,BAO_0000019,3353,H,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,Autocuration,,10623,,1317,,,,,CHEMBL620591,,,,,F,1,8,
,BAO_0000357,3354,D,Binding affinity against rat 5-hydroxytryptamine 4 receptor,Expert,,10623,,12936,,10116.0,Rattus norvegicus,,CHEMBL620592,,,,,B,1,9,
Striatum,BAO_0000249,3355,H,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,Expert,,10623,,4535,2435.0,,,,CHEMBL620593,,,,,B,1,8,
,BAO_0000019,3356,D,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,Expert,,10623,,14424,,10116.0,Rattus norvegicus,,CHEMBL620594,,,,,F,1,9,
,BAO_0000019,3357,H,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,Expert,,10623,,14424,,,,,CHEMBL875079,,,,,F,1,8,
,BAO_0000019,3358,H,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,Expert,,10623,,14424,,,,,CHEMBL620595,,,,,F,1,8,
,BAO_0000019,3359,D,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,Expert,,10623,,14424,,10116.0,Rattus norvegicus,,CHEMBL620596,,,,,F,1,9,
,BAO_0000019,3360,H,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,Autocuration,,10623,,14424,,,,,CHEMBL620597,,,,,F,1,8,
,BAO_0000019,3361,H,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,Expert,,10623,,14424,,,,,CHEMBL620598,,,,,F,1,8,
,BAO_0000218,3362,H,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),Expert,,10623,,14424,,,,,CHEMBL620599,,,,,F,1,8,
,BAO_0000019,3363,H,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,Autocuration,,10623,,14424,,,,,CHEMBL620600,,,,,F,1,8,
,BAO_0000019,3364,H,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,Autocuration,,168,,1980,,10116.0,Rattus norvegicus,,CHEMBL620601,,,,,F,1,8,
,BAO_0000019,3365,H,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,Autocuration,,168,,4639,,,,,CHEMBL620602,,,,,F,1,8,
,BAO_0000357,3366,H,Tested for affinity towards 5-hydroxytryptamine 4 receptor,Autocuration,,168,,17358,,,,,CHEMBL620603,,,,,B,1,8,
,BAO_0000357,3367,H,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,Autocuration,,168,,17358,,,,,CHEMBL620604,,,,,B,1,8,
,BAO_0000357,3368,H,Compound was tested for 5-hydroxytryptamine 4 binding affinity,Autocuration,,168,,17358,,,,,CHEMBL620605,,,,,B,1,8,
,BAO_0000357,3369,H,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,Autocuration,,168,,1558,,,,,CHEMBL620606,,,,,B,1,8,
,BAO_0000019,3370,H,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,Autocuration,,168,,17358,,,,,CHEMBL620607,,,,,F,1,8,
,BAO_0000357,3371,H,In vitro binding affinity towards 5-HT4 receptor was determined,Autocuration,,168,,16117,,,,,CHEMBL620608,,,,,B,1,8,
,BAO_0000019,3372,H,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,Autocuration,,168,,17358,,,,,CHEMBL620609,,,,,F,1,8,
,BAO_0000019,3373,H,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,Autocuration,,168,,17358,,,,,CHEMBL620610,,,,,F,1,8,
,BAO_0000357,3374,H,Tested for selectivity for 5-hydroxytryptamine 4 receptor,Autocuration,,168,,17358,,,,,CHEMBL620611,,,,,B,1,8,
,BAO_0000357,3375,H,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,Autocuration,,168,,17358,,,,,CHEMBL620612,,,,,B,1,8,
,BAO_0000357,3376,H,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,Autocuration,,168,,17358,,,,,CHEMBL620613,,,,,B,1,8,
,BAO_0000357,3377,H,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,Autocuration,,168,,17358,,,,,CHEMBL620614,,,,,B,1,8,
,BAO_0000357,3378,H,Binding affinity against 5-Hydroxytryptamine 4 receptor,Expert,,168,,1274,,,,,CHEMBL620615,,,,,B,1,8,
,BAO_0000249,3379,H,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,Autocuration,,104698,,10728,,,,,CHEMBL857075,,,,Brain membranes,B,1,6,
,BAO_0000249,3380,H,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,Autocuration,,104698,,11695,,,,,CHEMBL620616,,,,Brain membranes,B,1,6,
,BAO_0000249,3381,H,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,Autocuration,,104698,,11695,,,,,CHEMBL619411,,,,Brain membranes,B,1,6,
,BAO_0000019,3382,H,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,Autocuration,,104698,,12490,,,,,CHEMBL619412,,,,,B,1,6,
,BAO_0000019,3383,D,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,Autocuration,,104698,,11828,,10116.0,Rattus norvegicus,,CHEMBL619413,,,,,B,1,7,
Hippocampus,BAO_0000221,3384,H,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,Autocuration,,104698,,12253,10000000.0,,,,CHEMBL619414,,,,,B,1,6,
,BAO_0000019,3385,H,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,Autocuration,,104698,,10561,,,,,CHEMBL619415,,,,,B,1,6,
,BAO_0000019,3386,H,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,Autocuration,,104698,,10561,,,,,CHEMBL619416,,,,,B,1,6,
,BAO_0000019,3387,H,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,Autocuration,,104698,,14432,,,,,CHEMBL619417,,,,,F,1,6,
,BAO_0000223,3388,D,Binding affinity against rat 5-hydroxytryptamine 3 receptor,Autocuration,,104698,,12936,,10116.0,Rattus norvegicus,,CHEMBL619418,,,,,B,1,7,
,BAO_0000223,3389,D,Binding affinity against 5-Hydroxytryptamine 3 receptor,Autocuration,,104698,,1274,,10116.0,Rattus norvegicus,,CHEMBL619419,,,,,B,1,7,
,BAO_0000019,3390,H,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,Autocuration,,104698,,1980,,,,,CHEMBL619420,,,,,B,1,6,
,BAO_0000249,3391,H,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,Autocuration,,104698,,670,,,,,CHEMBL619421,,,,,B,1,6,
,BAO_0000019,3392,D,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,Autocuration,,104698,,968,,10116.0,Rattus norvegicus,,CHEMBL619422,,,,,B,1,7,
,BAO_0000019,3393,H,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,Autocuration,,104698,,14287,,,,,CHEMBL619423,,,,,B,1,6,
,BAO_0000019,3394,H,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,Autocuration,,104698,,567,,,,,CHEMBL875080,,,,,B,1,6,
,BAO_0000019,3395,H,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,Autocuration,,104698,,13267,,,,,CHEMBL619424,,,,,B,1,6,
,BAO_0000249,3396,H,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,Autocuration,,104698,,14826,,,,,CHEMBL619425,,,,,B,1,6,
,BAO_0000223,3397,H,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,Autocuration,,104698,,15194,,,,,CHEMBL619426,,,,,B,1,6,
,BAO_0000223,3398,H,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,Autocuration,,104698,,15194,,,,,CHEMBL619427,,,,,B,1,6,
,BAO_0000223,3399,D,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,Autocuration,,104698,,10394,,10116.0,Rattus norvegicus,,CHEMBL619645,,,,,B,1,7,
,BAO_0000249,3400,D,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",Expert,,10576,,13657,,,,,CHEMBL619646,,,,,B,1,9,
Brain,BAO_0000221,3401,H,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,Autocuration,,12020,,1879,955.0,,,,CHEMBL619647,,,,,F,1,8,
,BAO_0000019,3402,H,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,Autocuration,,12020,,1879,,,,,CHEMBL619648,,,,,F,1,8,
,BAO_0000019,3403,H,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,Autocuration,,12020,,1879,,,,,CHEMBL619165,,,,,F,1,8,
,BAO_0000218,3404,H,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,Autocuration,,12020,,204,,,,,CHEMBL620719,,,In vivo,,F,1,8,
,BAO_0000019,3405,H,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,Autocuration,,12020,,1879,,,,,CHEMBL872924,,,,,B,1,8,
,BAO_0000357,3406,H,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,12020,,1879,,,,,CHEMBL620720,,,,,B,1,8,
,BAO_0000019,3407,H,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,Autocuration,,12020,,1879,,,,,CHEMBL620721,,,,,B,1,8,
,BAO_0000019,3408,H,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,Autocuration,,12020,,1879,,,,,CHEMBL620722,,,,,B,1,8,
,BAO_0000019,3409,H,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",Autocuration,,104698,,10641,,,,,CHEMBL620723,,,,,B,1,6,
,BAO_0000019,3410,H,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,Autocuration,,12020,,773,,,,,CHEMBL620724,,,,,B,1,8,
,BAO_0000249,3411,H,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,Autocuration,,104698,,11952,,,,,CHEMBL620725,,,,,B,1,6,
,BAO_0000019,3412,D,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,Autocuration,,12020,,14145,,10116.0,Rattus norvegicus,,CHEMBL620726,,,,,F,1,9,
,BAO_0000357,3413,H,Binding affinity towards 5-hydroxytryptamine 3 receptor,Expert,,144,,17066,,,,,CHEMBL620727,,,,,B,1,8,
,BAO_0000223,3414,H,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,Autocuration,,104714,,6398,,,,,CHEMBL620728,,,,,B,1,4,
,BAO_0000019,3415,U,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,Autocuration,,22226,,10321,,,,,CHEMBL620729,,,,,B,1,0,
,BAO_0000019,3416,H,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,Autocuration,,104714,,511,,,,,CHEMBL858288,,,,,F,1,4,
,BAO_0000223,3417,H,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,104714,,4639,,,,,CHEMBL620730,,,,,B,1,4,
,BAO_0000223,3418,H,Binding affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,104714,,4639,,,,,CHEMBL620731,,,,,B,1,4,
,BAO_0000019,3419,H,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,Autocuration,,104714,,4639,,10141.0,Cavia porcellus,,CHEMBL620732,,,,,F,1,4,
,BAO_0000019,3420,H,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,Autocuration,,104714,,4639,,10141.0,Cavia porcellus,,CHEMBL618042,,,,,F,1,4,
,BAO_0000019,3421,H,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,Autocuration,,104714,,4639,,10141.0,Cavia porcellus,,CHEMBL618043,,,,,F,1,4,
,BAO_0000223,3422,H,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,104714,,1558,,,,,CHEMBL618044,,,,,B,1,4,
,BAO_0000019,3423,H,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,Autocuration,,104714,,268,,,,,CHEMBL618045,,,,,F,1,4,
,BAO_0000223,3424,H,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,Autocuration,,104714,,2474,,,,,CHEMBL618046,,,,,B,1,4,
,BAO_0000019,3425,H,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,Autocuration,,104714,,5067,,,,,CHEMBL618047,,,,,F,1,4,
,BAO_0000019,3426,H,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,Autocuration,,104714,,5067,,,,,CHEMBL875084,,,,,F,1,4,
,BAO_0000019,3427,H,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,Autocuration,,104714,,5067,,,,,CHEMBL618048,,,,,F,1,4,
,BAO_0000223,3428,H,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,Autocuration,,104714,,5067,,,,,CHEMBL618049,,,,,B,1,4,
,BAO_0000019,3429,H,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,Autocuration,,104714,,5067,,,,,CHEMBL619764,,,,,F,1,4,
,BAO_0000019,3430,H,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,Autocuration,,104714,,5067,,,,,CHEMBL619765,,,,,F,1,4,
,BAO_0000019,3431,H,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,Autocuration,,104714,,5067,,,,,CHEMBL619766,,,,,F,1,4,
,BAO_0000223,3432,H,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,Autocuration,,104714,,5067,,,,,CHEMBL619767,,,,,B,1,4,
,BAO_0000223,3433,H,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,Autocuration,,104714,,5067,,,,,CHEMBL619768,,,,,B,1,4,
,BAO_0000019,3434,H,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,Autocuration,,104714,,5067,,,,,CHEMBL619769,,,,,F,1,4,
,BAO_0000223,3435,H,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,Autocuration,,104714,,5067,,,,,CHEMBL619770,,,,,B,1,4,
,BAO_0000223,3436,H,Binding affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,104714,,5067,,,,,CHEMBL619771,,,,,B,1,4,
,BAO_0000219,3437,H,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,Autocuration,,104714,,14331,,,,,CHEMBL619772,,,,,B,1,4,
,BAO_0000223,3438,H,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,Autocuration,,104714,,5067,,,,,CHEMBL619773,,,,,B,1,4,
,BAO_0000219,3439,H,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,Autocuration,433.0,104714,,6179,,,,,CHEMBL619774,NG108-15,,,,B,1,4,
,BAO_0000019,3440,H,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,Autocuration,,104714,,4265,,,,,CHEMBL875083,,,,,B,1,4,
,BAO_0000219,3441,H,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,Autocuration,433.0,104714,,4265,,,,,CHEMBL620718,NG108-15,,,,B,1,4,
,BAO_0000223,3442,H,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,Autocuration,,104714,,17358,,,,,CHEMBL618127,,,,,B,1,4,
,BAO_0000223,3443,H,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,Autocuration,,104714,,17358,,,,,CHEMBL618128,,,,,B,1,4,
,BAO_0000219,3444,H,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,Autocuration,,104714,,13628,,,,,CHEMBL618129,,,In vitro,,B,1,4,
,BAO_0000223,3445,H,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,Autocuration,,104714,,4612,,,,,CHEMBL618130,,,,,B,1,4,
,BAO_0000019,3446,H,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,Autocuration,,104714,,17358,,,,,CHEMBL618131,,,,,F,1,4,
,BAO_0000019,3447,H,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,Autocuration,,104714,,4639,,10141.0,Cavia porcellus,,CHEMBL618132,,,,,F,1,4,
,BAO_0000019,3448,H,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,Autocuration,,104714,,4639,,10141.0,Cavia porcellus,,CHEMBL618133,,,,,F,1,4,
,BAO_0000019,3449,H,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,Autocuration,,104714,,4639,,10141.0,Cavia porcellus,,CHEMBL618134,,,,,F,1,4,
,BAO_0000019,3450,H,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,Autocuration,,104714,,4639,,10141.0,Cavia porcellus,,CHEMBL618135,,,,,F,1,4,
,BAO_0000223,3451,H,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,Autocuration,,104714,,511,,,,,CHEMBL618136,,,,,B,1,4,
,BAO_0000223,3452,H,Binding affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,104714,,1479,,,,,CHEMBL618137,,,,,B,1,4,
,BAO_0000223,3453,H,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,Autocuration,,104714,,1317,,,,,CHEMBL618138,,,,,B,1,4,
,BAO_0000223,3454,H,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,Autocuration,,104714,,12146,,,,,CHEMBL618139,,,,,B,1,4,
,BAO_0000223,3455,H,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,Autocuration,,104714,,12146,,,,,CHEMBL618140,,,,,B,1,4,
,BAO_0000223,3456,H,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,Autocuration,,104714,,13969,,,,,CHEMBL618141,,,,,B,1,4,
,BAO_0000357,3457,H,Binding affinity for 5-hydroxytryptamine 2C receptor,Expert,,108,,13392,,,,,CHEMBL873478,,,,,B,1,8,
,BAO_0000223,3458,H,Binding affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,104698,,13392,,,,,CHEMBL618142,,,,,B,1,6,
,BAO_0000357,3459,H,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,Autocuration,,144,,14159,,,,,CHEMBL618143,,,,,B,1,8,
,BAO_0000357,3460,H,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,144,,1558,,,,,CHEMBL618144,,,,,B,1,8,
,BAO_0000357,3461,H,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,Autocuration,,144,,16655,,,,,CHEMBL618145,,,,,B,1,8,
,BAO_0000223,3462,H,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,Autocuration,,104714,,13020,,,,,CHEMBL618146,,,,,B,1,4,
,BAO_0000223,3463,H,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,Autocuration,,104714,,13021,,,,,CHEMBL618147,,,,,B,1,4,
,BAO_0000223,3464,H,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,Autocuration,,104714,,13020,,,,,CHEMBL618148,,,,,B,1,4,
,BAO_0000019,3465,H,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,Autocuration,,144,,10321,,,,,CHEMBL618149,,,,,B,1,8,
,BAO_0000357,3466,H,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,144,,15818,,,,,CHEMBL872927,,,,,B,1,8,
,BAO_0000357,3467,H,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,Autocuration,,144,,15818,,,,,CHEMBL618150,,,,,B,1,8,
,BAO_0000357,3468,H,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,Autocuration,,144,,17358,,,,,CHEMBL618151,,,,,B,1,8,
,BAO_0000357,3469,H,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,Autocuration,,144,,2222,,,,,CHEMBL875094,,,,,B,1,8,
,BAO_0000019,3470,H,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,Autocuration,,144,,10322,,,,,CHEMBL618152,,,,,B,1,8,
,BAO_0000357,3471,H,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,Autocuration,,144,,16117,,,,,CHEMBL618153,,,,,B,1,8,
,BAO_0000357,3472,H,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,Autocuration,,144,,17200,,,,,CHEMBL618888,,,,,B,1,8,
,BAO_0000019,3473,H,Tested for 5-hydroxytryptamine 3 receptor agonist activity,Autocuration,,144,,17358,,,,,CHEMBL618889,,,,,F,1,8,
,BAO_0000357,3474,H,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,Autocuration,,144,,16700,,,,,CHEMBL618890,,,,,B,1,8,
,BAO_0000019,3475,H,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,Autocuration,,144,,1980,,,,,CHEMBL618891,,,,,B,1,8,
,BAO_0000019,3476,H,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,Autocuration,,144,,1980,,,,,CHEMBL619054,,,,,B,1,8,
,BAO_0000223,3477,H,Binding affinity against the 5-hydroxytryptamine 3 receptor,Autocuration,,104714,,12409,,,,,CHEMBL619055,,,,,B,1,4,
,BAO_0000357,3478,H,Binding affinity against human 5-hydroxytryptamine 3A receptor,Autocuration,,144,,4365,,,,,CHEMBL619056,,,,,B,1,8,
,BAO_0000019,3479,H,Percent efficacy against 5-hydroxytryptamine 3A receptor,Autocuration,,144,,4365,,,,,CHEMBL619057,,,,,F,1,8,
,BAO_0000357,3480,H,Binding affinity against human 5-hydroxytryptamine 3A receptor,Autocuration,,144,,4365,,,,,CHEMBL619058,,,,,B,1,8,
,BAO_0000219,3481,D,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,Expert,,12020,,6769,,10116.0,Rattus norvegicus,,CHEMBL619059,Oocytes,,,,F,1,9,
,BAO_0000219,3482,D,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,Expert,,12020,,6769,,10116.0,Rattus norvegicus,,CHEMBL619060,Oocytes,,,,F,1,9,
,BAO_0000219,3483,D,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,Expert,,12020,,6769,,10116.0,Rattus norvegicus,,CHEMBL875095,Oocytes,,,,F,1,9,
Ileum,BAO_0000221,3484,D,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,Intermediate,,20033,,809,2116.0,10141.0,Cavia porcellus,,CHEMBL619061,,,,,F,1,9,
Ileum,BAO_0000221,3485,D,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,Intermediate,,20033,,809,2116.0,10141.0,Cavia porcellus,,CHEMBL619062,,,,,F,1,9,
,BAO_0000019,3486,D,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,Intermediate,,20033,,14290,,10141.0,Cavia porcellus,,CHEMBL619063,,,,,F,1,9,
Ileum,BAO_0000221,3487,D,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,Intermediate,,20033,,17358,2116.0,10141.0,Cavia porcellus,,CHEMBL619064,,,,,B,1,9,
,BAO_0000357,3488,D,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,Intermediate,,20033,,17358,,10141.0,Cavia porcellus,,CHEMBL619065,,,,,B,1,9,
Ileum,BAO_0000221,3489,D,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,Intermediate,,20033,,17358,2116.0,10141.0,Cavia porcellus,,CHEMBL619066,,,,,B,1,9,
Ileum,BAO_0000221,3490,H,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,Autocuration,,10209,,17386,2116.0,,,,CHEMBL619775,,,,,B,1,8,
,BAO_0000357,3491,H,Affinity against 5-hydroxytryptamine 7 receptor,Autocuration,,10209,,3269,,,,,CHEMBL619776,,,,,B,1,8,
,BAO_0000224,3492,H,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,Autocuration,,104841,,7721,,10141.0,Cavia porcellus,,CHEMBL619777,,,,,B,1,4,
,BAO_0000224,3493,H,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,Autocuration,,104841,,7721,,10141.0,Cavia porcellus,,CHEMBL619778,,,,,B,1,4,
Ileum,BAO_0000221,3494,H,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,Autocuration,,104841,,9117,2116.0,10141.0,Cavia porcellus,,CHEMBL619779,,,,,B,1,4,
,BAO_0000224,3495,H,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",Autocuration,,104841,,7721,,10141.0,Cavia porcellus,,CHEMBL619780,,,,,B,1,4,
,BAO_0000224,3496,H,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",Autocuration,,104841,,7721,,10141.0,Cavia porcellus,,CHEMBL619166,,,,,B,1,4,
,BAO_0000019,3497,H,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,Autocuration,,104841,,15796,,10141.0,Cavia porcellus,,CHEMBL619167,,,,,F,1,4,
,BAO_0000019,3498,H,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,Autocuration,,104841,,15796,,10141.0,Cavia porcellus,,CHEMBL619168,,,,,F,1,4,
Cardiac atrium,BAO_0000219,3499,D,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,Expert,,168,,15650,2081.0,9606.0,Homo sapiens,,CHEMBL619169,,,,,B,1,9,
Cardiac atrium,BAO_0000219,3500,D,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,Expert,,168,,15650,2081.0,9606.0,Homo sapiens,,CHEMBL619170,,,,,B,1,9,
,BAO_0000019,3501,D,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",Autocuration,,104841,,6866,,9606.0,Homo sapiens,,CHEMBL619171,,,,,F,1,5,
Cardiac atrium,BAO_0000219,3502,D,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",Expert,,168,,15650,2081.0,9606.0,Homo sapiens,,CHEMBL619172,,,,,F,1,9,
,BAO_0000019,3503,U,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,Autocuration,,22226,,10063,,10090.0,Mus musculus,,CHEMBL619173,,,,,B,1,0,
,BAO_0000019,3504,U,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,Autocuration,,22226,,12665,,10090.0,Mus musculus,,CHEMBL619174,,,,,B,1,0,
,BAO_0000019,3505,H,5-hydroxytryptamine receptor binding affinity was determined in rats,Autocuration,,104705,,7504,,,,,CHEMBL619175,,,,,B,1,4,
,BAO_0000224,3506,H,Binding affinity at rat 5-hydroxytryptamine receptor.,Autocuration,,104705,,7504,,,,,CHEMBL619176,,,,,B,1,4,
,BAO_0000019,3507,H,Affinity against 5-hydroxytryptamine receptors in rat fundus model,Autocuration,,104705,,7038,,,,,CHEMBL619177,,,,,B,1,4,
,BAO_0000224,3508,H,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,Autocuration,,104705,,7626,,,,,CHEMBL619178,,,,,B,1,4,
,BAO_0000224,3509,H,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,Autocuration,,104705,,7626,,,,,CHEMBL619179,,,,,B,1,4,
Stomach,BAO_0000019,3510,H,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,Autocuration,,104705,,7185,945.0,,,,CHEMBL619180,,,,,F,1,4,
Stomach,BAO_0000019,3511,H,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,Autocuration,,104705,,7185,945.0,,,,CHEMBL619181,,,,,F,1,4,
,BAO_0000019,3512,H,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,Autocuration,,104705,,7185,,,,,CHEMBL619182,,,,,F,1,4,
,BAO_0000224,3513,H,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,Autocuration,,104705,,6960,,,,,CHEMBL619183,,,,,B,1,4,
,BAO_0000224,3514,H,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",Autocuration,,104705,,6960,,,,,CHEMBL619184,,,,,B,1,4,
Hippocampus,BAO_0000221,3515,H,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,Autocuration,,10576,,12416,10000000.0,,,,CHEMBL619185,,,,,B,1,8,
,BAO_0000357,3516,H,Binding affinity for rat 5-hydroxytryptamine transporter.,Expert,,12198,,15753,,,,,CHEMBL619186,,,,,B,1,8,
,BAO_0000019,3517,H,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,Autocuration,,104705,,8062,,,,,CHEMBL619187,,,,,B,1,4,
,BAO_0000019,3518,D,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,Autocuration,,104705,,9036,,10116.0,Rattus norvegicus,,CHEMBL619188,,,,,B,1,5,
,BAO_0000224,3519,D,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,Autocuration,,104705,,15067,,10116.0,Rattus norvegicus,,CHEMBL619189,,,,,B,1,5,
Brain,BAO_0000019,3520,D,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,Expert,,12198,,15753,955.0,10116.0,Rattus norvegicus,,CHEMBL619190,,,,,F,1,9,
Cerebellum,BAO_0000221,3521,D,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,Expert,,12198,,15753,2037.0,10116.0,Rattus norvegicus,,CHEMBL619191,,,,,F,1,9,
,BAO_0000019,3522,D,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,Autocuration,,104705,,15295,,10116.0,Rattus norvegicus,,CHEMBL619192,,,,,B,1,5,
,BAO_0000224,3523,D,Percent binding affinity against 5-hydroxytryptamine receptor,Autocuration,,104705,,6347,,10116.0,Rattus norvegicus,,CHEMBL619193,,,,,B,1,5,
,BAO_0000019,3524,U,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,Autocuration,,22226,,6763,,,,,CHEMBL619194,,,,,B,1,0,
,BAO_0000224,3525,D,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,Autocuration,,104705,,12092,,10116.0,Rattus norvegicus,,CHEMBL619195,,,,,B,1,5,
,BAO_0000224,3526,D,Affinity against 5-hydroxytryptamine receptor was determined,Autocuration,,104705,,1579,,10116.0,Rattus norvegicus,,CHEMBL619196,,,,,B,1,5,
Stomach,BAO_0000019,3527,D,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,Autocuration,,104705,,1579,945.0,10116.0,Rattus norvegicus,,CHEMBL619197,,,,,B,1,5,
,BAO_0000219,3528,D,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,Expert,,121,,5963,,9606.0,Homo sapiens,,CHEMBL619198,,,In vitro,,B,1,9,
,BAO_0000219,3529,D,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,Expert,,121,,5963,,9606.0,Homo sapiens,,CHEMBL875081,,,In vitro,,B,1,9,
,BAO_0000357,3530,H,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,Autocuration,,18065,,5030,,,,,CHEMBL884712,,,,,B,1,8,
,BAO_0000357,3531,H,Inhibition of 5-hydroxytryptamine reuptake,Expert,,121,,15796,,,,,CHEMBL884710,,,,,B,1,8,
,BAO_0000019,3532,H,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",Autocuration,,18065,,15413,,,,,CHEMBL619199,,,,,F,1,8,
,BAO_0000019,3533,H,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",Autocuration,,18065,,15413,,,,,CHEMBL619200,,,,,F,1,8,
,BAO_0000019,3534,H,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",Autocuration,,18065,,15413,,,,,CHEMBL619201,,,,,F,1,8,
,BAO_0000019,3535,H,Tested for 5-hydroxytryptamine receptor uptake,Autocuration,,18065,,12409,,,,,CHEMBL619202,,,,,F,1,8,
,BAO_0000219,3536,D,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,Expert,449.0,51,,16909,,9606.0,Homo sapiens,,CHEMBL619203,CHO,,,,B,1,9,
,BAO_0000019,3537,D,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,Expert,,51,,16909,,9606.0,Homo sapiens,,CHEMBL619204,,,,,F,1,9,
,BAO_0000249,3538,H,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,Autocuration,,10576,,15629,,9606.0,Homo sapiens,,CHEMBL619205,,,,,B,1,8,
,BAO_0000357,3539,H,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,Autocuration,,10576,,15629,,,,,CHEMBL619206,,,,,B,1,8,
,BAO_0000249,3540,H,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,Expert,,10576,,15629,,,,,CHEMBL619207,,,,,B,1,8,
Striatum,BAO_0000019,3541,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,Autocuration,,10825,,10034,2435.0,,,,CHEMBL619208,,,,,F,1,8,
Striatum,BAO_0000019,3542,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,Autocuration,,10825,,10034,2435.0,,,,CHEMBL619209,,,,,F,1,8,
Striatum,BAO_0000019,3543,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,Autocuration,,10825,,10034,2435.0,,,,CHEMBL619210,,,,,F,1,8,
Striatum,BAO_0000019,3544,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,Autocuration,,10825,,10034,2435.0,,,,CHEMBL619211,,,,,F,1,8,
Striatum,BAO_0000019,3545,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,Autocuration,,10825,,10034,2435.0,,,,CHEMBL619212,,,,,F,1,8,
Striatum,BAO_0000019,3546,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,Autocuration,,10825,,10034,2435.0,,,,CHEMBL620681,,,,,F,1,8,
Striatum,BAO_0000019,3547,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,Autocuration,,10825,,10034,2435.0,,,,CHEMBL620682,,,,,F,1,8,
Striatum,BAO_0000019,3548,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,Autocuration,,10825,,10034,2435.0,,,,CHEMBL620683,,,,,F,1,8,
Striatum,BAO_0000019,3549,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,Autocuration,,10825,,10034,2435.0,,,,CHEMBL620684,,,,,F,1,8,
Striatum,BAO_0000019,3550,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,Autocuration,,10825,,10034,2435.0,,,,CHEMBL620685,,,,,F,1,8,
Striatum,BAO_0000019,3551,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,Autocuration,,10825,,10034,2435.0,,,,CHEMBL620686,,,,,F,1,8,
Limbic system,BAO_0000019,3552,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,Autocuration,,10825,,10034,349.0,,,,CHEMBL620687,,,,,F,1,8,
Limbic system,BAO_0000019,3553,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,Autocuration,,10825,,10034,349.0,,,,CHEMBL620688,,,,,F,1,8,
Limbic system,BAO_0000019,3554,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,Autocuration,,10825,,10034,349.0,,,,CHEMBL620689,,,,,F,1,8,
Limbic system,BAO_0000019,3555,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,Autocuration,,10825,,10034,349.0,,,,CHEMBL620690,,,,,F,1,8,
Limbic system,BAO_0000019,3556,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,Autocuration,,10825,,10034,349.0,,,,CHEMBL620691,,,,,F,1,8,
Limbic system,BAO_0000019,3557,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,Autocuration,,10825,,10034,349.0,,,,CHEMBL620692,,,,,F,1,8,
Limbic system,BAO_0000019,3558,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,Autocuration,,10825,,10034,349.0,,,,CHEMBL620693,,,,,F,1,8,
,BAO_0000357,3559,H,Binding affinity against 5-hydroxytryptamine 4 receptor,Expert,,168,,1274,,,,,CHEMBL620694,,,,,B,1,8,
,BAO_0000019,3560,H,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,Autocuration,,168,,17358,,,,,CHEMBL857986,,,,,F,1,8,
,BAO_0000357,3561,H,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,Autocuration,,168,,14532,,,,,CHEMBL620695,,,,,B,1,8,
,BAO_0000357,3562,H,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,Expert,,168,,16989,,,,,CHEMBL620696,,,,,B,1,8,
,BAO_0000357,3563,H,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,Autocuration,,168,,17200,,,,,CHEMBL620697,,,,,B,1,8,
,BAO_0000357,3564,H,Binding affinity towards 5-hydroxytryptamine 4 receptor,Autocuration,,168,,15779,,,,,CHEMBL620698,,,,,B,1,8,
,BAO_0000357,3565,H,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,Autocuration,,168,,15779,,,,,CHEMBL620699,,,,,B,1,8,
,BAO_0000357,3566,H,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,Autocuration,,168,,15779,,,,,CHEMBL620700,,,,,B,1,8,
,BAO_0000219,3567,H,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,Autocuration,643.0,168,,15650,,,,,CHEMBL620701,COS-7,,,,B,1,8,
,BAO_0000219,3568,H,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,Autocuration,643.0,168,,15650,,,,,CHEMBL875082,COS-7,,,,B,1,8,
,BAO_0000219,3569,H,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,Autocuration,643.0,168,,15650,,,,,CHEMBL620702,COS-7,,,,B,1,8,
,BAO_0000219,3570,H,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,Autocuration,643.0,168,,15650,,,,,CHEMBL620703,COS-7,,,,B,1,8,
,BAO_0000219,3571,H,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,Autocuration,673.0,168,,17046,,,,,CHEMBL620704,C6,,,,B,1,8,
,BAO_0000219,3572,H,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,Expert,673.0,168,,17046,,,,,CHEMBL620705,C6,,,,B,1,8,
,BAO_0000219,3573,H,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,Expert,673.0,168,,15650,,,,,CHEMBL620706,C6,,,,B,1,8,
,BAO_0000219,3574,H,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,Expert,673.0,168,,17046,,,,,CHEMBL620707,C6,,,,B,1,8,
,BAO_0000357,3575,H,Binding affinity towards 5-hydroxytryptamine 5 receptor,Expert,,10624,,17066,,,,,CHEMBL620708,,,,,B,1,8,
,BAO_0000357,3576,H,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,Autocuration,,105,,17200,,,,,CHEMBL620709,,,,,B,1,8,
,BAO_0000357,3577,D,Binding affinity against 5-hydroxytryptamine 5A receptor,Expert,,10624,,16146,,9606.0,Homo sapiens,,CHEMBL620710,,,,,B,1,9,
,BAO_0000219,3578,H,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,Autocuration,449.0,10624,,15250,,,,,CHEMBL620711,CHO,,,,B,1,8,
,BAO_0000357,3579,D,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,Expert,,10624,,6491,,9606.0,Homo sapiens,,CHEMBL620712,,,,,B,1,9,
,BAO_0000357,3580,D,Binding affinity towards human 5-hydroxytryptamine 5A receptor,Expert,,10624,,17066,,9606.0,Homo sapiens,,CHEMBL620713,,,,,B,1,9,
,BAO_0000357,3581,D,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,Expert,,10624,,17066,,9606.0,Homo sapiens,,CHEMBL620714,,,,,B,1,9,
,BAO_0000357,3582,D,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,Expert,,10624,,4234,,9606.0,Homo sapiens,,CHEMBL620715,,,,,B,1,9,
,BAO_0000357,3583,H,Binding affinity towards 5-HT5A receptor,Autocuration,,10624,,6013,,,,,CHEMBL620716,,,,,B,1,8,
,BAO_0000357,3584,H,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,Expert,,10624,,17175,,,,,CHEMBL620717,,,,,B,1,8,
,BAO_0000357,3585,H,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,Autocuration,,10624,,15818,,,,,CHEMBL618072,,,,,B,1,8,
,BAO_0000357,3586,H,Binding affinity towards cloned human 5-HT5A receptor was determined,Autocuration,,10624,,6166,,,,,CHEMBL857987,,,,,B,1,8,
,BAO_0000219,3587,H,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,Autocuration,722.0,10624,,15779,,,,,CHEMBL618073,HEK293,,,,B,1,8,
,BAO_0000219,3588,H,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,Autocuration,722.0,10624,,15779,,,,,CHEMBL618074,HEK293,,,,B,1,8,
,BAO_0000219,3589,H,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),Autocuration,722.0,10624,,5213,,,,,CHEMBL618075,HEK293,,,,B,1,8,
,BAO_0000357,3590,D,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,Expert,,10625,,17066,,10090.0,Mus musculus,,CHEMBL618076,,,,,B,1,9,
,BAO_0000357,3591,D,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,Expert,,10625,,17066,,10090.0,Mus musculus,,CHEMBL618077,,,,,B,1,9,
,BAO_0000357,3592,D,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,Expert,,10625,,17066,,10090.0,Mus musculus,,CHEMBL618078,,,,,B,1,9,
,BAO_0000357,3593,D,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,Expert,,10625,,17066,,10090.0,Mus musculus,,CHEMBL881821,,,,,B,1,9,
,BAO_0000357,3594,D,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,Expert,,10625,,17066,,10090.0,Mus musculus,,CHEMBL618079,,,,,B,1,9,
,BAO_0000357,3595,H,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,Expert,,10625,,17175,,,,,CHEMBL618080,,,,,B,1,8,
,BAO_0000219,3596,H,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,Autocuration,722.0,10576,,16190,,,,,CHEMBL618081,HEK293,,,,B,1,8,
,BAO_0000219,3597,H,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,Autocuration,722.0,10626,,16190,,,,,CHEMBL618082,HEK293,,,,B,1,8,
,BAO_0000357,3598,H,Binding affinity towards 5-HT5a receptor,Expert,,10624,,4820,,,,,CHEMBL618083,,,,,B,1,8,
,BAO_0000357,3599,D,Binding affinity towards 5-hydroxytryptamine 5A receptor,Expert,,10624,,17066,,9606.0,Homo sapiens,,CHEMBL618084,,,,,B,1,9,
,BAO_0000357,3600,H,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,Expert,,10624,,17066,,,,,CHEMBL618085,,,,,B,1,8,
,BAO_0000357,3601,H,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,Expert,,10624,,17175,,,,,CHEMBL618086,,,,,B,1,8,
,BAO_0000357,3602,H,Binding affinities against 5-hydroxytryptamine 5A receptor,Autocuration,,10624,,16633,,,,,CHEMBL875092,,,,,B,1,8,
,BAO_0000357,3603,H,Binding affinities towards 5-hydroxytryptamine 5A receptor,Autocuration,,10624,,16633,,,,,CHEMBL618087,,,,,B,1,8,
,BAO_0000357,3604,H,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,Autocuration,,10624,,16700,,,,,CHEMBL872926,,,,,B,1,8,
,BAO_0000019,3605,H,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,Autocuration,,104714,,4639,,10141.0,Cavia porcellus,,CHEMBL618088,,,,,F,1,4,
,BAO_0000223,3606,H,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,Autocuration,,104714,,5486,,,,,CHEMBL618089,,,,,B,1,4,
,BAO_0000357,3607,D,Inhibition of human 5-hydroxytryptamine 6 receptor,Expert,,10627,,16146,,9606.0,Homo sapiens,,CHEMBL618090,,,,,B,1,9,
,BAO_0000357,3608,D,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,Expert,,10627,,17273,,9606.0,Homo sapiens,,CHEMBL618091,,,,,B,1,9,
,BAO_0000357,3609,H,Inhibition against human 5-hydroxytryptamine 6 receptor,Autocuration,,10627,,17687,,,,,CHEMBL618092,,,,,B,1,8,
,BAO_0000357,3610,D,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,Expert,,10627,,6491,,9606.0,Homo sapiens,,CHEMBL618093,,,,,B,1,9,
,BAO_0000219,3611,H,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,Expert,308.0,10627,,16190,,,,,CHEMBL618094,HeLa,,,,B,1,8,
,BAO_0000357,3612,D,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,Expert,,10627,,17066,,9606.0,Homo sapiens,,CHEMBL618095,,,,,B,1,9,
,BAO_0000357,3613,D,Binding affinity towards human 5-hydroxytryptamine 6 receptor,Expert,,10627,,17066,,9606.0,Homo sapiens,,CHEMBL875093,,,,,B,1,9,
,BAO_0000357,3614,D,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,Expert,,10627,,17066,,9606.0,Homo sapiens,,CHEMBL618096,,,,,B,1,9,
,BAO_0000357,3615,D,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,Expert,,10627,,17066,,9606.0,Homo sapiens,,CHEMBL618118,,,,,B,1,9,
,BAO_0000357,3616,D,Binding affinity against 5-hydroxytryptamine 6 receptor,Expert,,10627,,3555,,9606.0,Homo sapiens,,CHEMBL618119,,,,,B,1,9,
,BAO_0000357,3617,H,Binding affinity towards human 5-hydroxytryptamine 6 receptor,Expert,,10627,,5808,,,,,CHEMBL618120,,,,,B,1,8,
,BAO_0000357,3618,H,Binding affinity towards human 5-hydroxytryptamine 6 receptor,Autocuration,,10627,,6013,,,,,CHEMBL618121,,,,,B,1,8,
,BAO_0000219,3619,H,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",Expert,722.0,10627,,15818,,,,,CHEMBL618122,HEK293,,,,B,1,8,
,BAO_0000357,3620,H,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,Autocuration,,10627,,16209,,,,,CHEMBL618123,,,,,B,1,8,
,BAO_0000219,3621,H,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,Expert,722.0,10627,,3935,,,,,CHEMBL618124,HEK293,,,,B,1,8,
,BAO_0000357,3622,H,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,Autocuration,,10627,,15818,,,,,CHEMBL618125,,,,,B,1,8,
,BAO_0000219,3623,D,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,Expert,722.0,10627,,3805,,9606.0,Homo sapiens,,CHEMBL618126,HEK293,,,,B,1,9,
,BAO_0000019,3624,H,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,Expert,,10627,,16441,,,,,CHEMBL618236,,,,,B,1,8,
,BAO_0000019,3625,H,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,Expert,,10627,,16441,,,,,CHEMBL618237,,,,,B,1,8,
,BAO_0000219,3626,H,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,Expert,643.0,10627,,6786,,,,,CHEMBL618238,COS-7,,,,B,1,8,
,BAO_0000357,3627,D,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,Expert,,10627,,4234,,9606.0,Homo sapiens,,CHEMBL618239,,,,,B,1,9,
,BAO_0000019,3628,H,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,Autocuration,,10627,,17085,,,,,CHEMBL618240,,,,,B,1,8,
,BAO_0000357,3629,H,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,Autocuration,,10627,,17200,,,,,CHEMBL618241,,,,,B,1,8,
,BAO_0000219,3630,H,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,Autocuration,722.0,10627,,17451,,,,,CHEMBL859399,HEK293,,,,B,1,8,
,BAO_0000019,3631,H,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,Autocuration,,10627,,3935,,,,,CHEMBL618242,,,,,F,1,8,
,BAO_0000357,3632,H,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,Autocuration,,10627,,5033,,,,,CHEMBL857991,,,,,B,1,8,
,BAO_0000357,3633,H,Binding affinity against human 5-hydroxytryptamine 6 receptor,Expert,,10627,,4540,,,,,CHEMBL619951,,,,,B,1,8,
,BAO_0000219,3634,D,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,Expert,308.0,10627,,4540,,9606.0,Homo sapiens,,CHEMBL619952,HeLa,,,,B,1,9,
,BAO_0000219,3635,D,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,Expert,308.0,10627,,4540,,9606.0,Homo sapiens,,CHEMBL619953,HeLa,,,,B,1,9,
,BAO_0000219,3636,H,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,Autocuration,308.0,10627,,17296,,,,,CHEMBL619954,HeLa,,,,B,1,8,
,BAO_0000219,3637,H,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,Autocuration,308.0,10627,,17296,,,,,CHEMBL619955,HeLa,,,,B,1,8,
,BAO_0000219,3638,H,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,Autocuration,308.0,10627,,17296,,,,,CHEMBL619956,HeLa,,,,B,1,8,
,BAO_0000219,3639,H,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,Autocuration,449.0,10627,,15779,,,,,CHEMBL619957,CHO,,,,B,1,8,
,BAO_0000219,3640,H,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,Autocuration,722.0,10627,,15779,,,,,CHEMBL619958,HEK293,,,,B,1,8,
,BAO_0000219,3641,H,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,Autocuration,722.0,10627,,15779,,,,,CHEMBL620627,HEK293,,,,B,1,8,
,BAO_0000219,3642,H,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,Autocuration,722.0,10627,,15779,,,,,CHEMBL620628,HEK293,,,,B,1,8,
,BAO_0000219,3643,H,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,Autocuration,308.0,10627,,15779,,,,,CHEMBL620629,HeLa,,,,B,1,8,
,BAO_0000357,3644,H,Binding affinity towards human 5-hydroxytryptamine 6 receptor,Autocuration,,10627,,6166,,,,,CHEMBL620630,,,,,B,1,8,
,BAO_0000219,3645,H,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,Autocuration,308.0,10627,,17451,,,,,CHEMBL620782,HeLa,,,,B,1,8,
,BAO_0000357,3646,H,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,Autocuration,,10627,,15316,,,,,CHEMBL620783,,,,,B,1,8,
,BAO_0000357,3647,H,Binding affinity against human 5-hydroxytryptamine 6 receptor,Expert,,10627,,4199,,,,,CHEMBL620784,,,,,B,1,8,
,BAO_0000219,3648,H,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,Expert,308.0,10627,,15146,,,,,CHEMBL620785,HeLa,,,,B,1,8,
,BAO_0000357,3649,H,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),Autocuration,,10627,,5213,,,,,CHEMBL857992,,,,,B,1,8,
,BAO_0000219,3650,H,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,Autocuration,,10627,,16429,,,,,CHEMBL620786,,,,,B,1,8,
,BAO_0000219,3651,H,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,Autocuration,308.0,10627,,14818,,,,,CHEMBL620787,HeLa,,,,B,1,8,
,BAO_0000219,3652,H,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",Autocuration,308.0,10627,,4829,,,,,CHEMBL620788,HeLa,,,,B,1,8,
,BAO_0000219,3653,H,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",Autocuration,308.0,10627,,4829,,,,,CHEMBL620789,HeLa,,,,B,1,8,
,BAO_0000219,3654,H,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",Autocuration,308.0,10627,,4829,,,,,CHEMBL620790,HeLa,,,,B,1,8,
,BAO_0000219,3655,H,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,Autocuration,449.0,10628,,15250,,,,,CHEMBL620791,CHO,,,,B,1,8,
,BAO_0000019,3656,H,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,Autocuration,,10628,,14423,,,,,CHEMBL620792,,,,,B,1,8,
,BAO_0000357,3657,H,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,Autocuration,,10628,,15086,,,,,CHEMBL620793,,,,,B,1,8,
,BAO_0000357,3658,H,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,Autocuration,,10628,,4342,,,,,CHEMBL620794,,,,,B,1,8,
,BAO_0000219,3659,D,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,Autocuration,308.0,10627,,16190,,9606.0,Homo sapiens,,CHEMBL620795,HeLa,,,,B,1,9,
,BAO_0000357,3660,H,Binding affinity towards human 5-hydroxytryptamine 6 receptor,Expert,,10627,,4820,,,,,CHEMBL620796,,,,,B,1,8,
,BAO_0000357,3661,H,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,Autocuration,,10627,,4639,,,,,CHEMBL620797,,,,,B,1,8,
,BAO_0000019,3662,D,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,Expert,,10627,,17066,,9606.0,Homo sapiens,,CHEMBL620798,,,,,F,1,9,
,BAO_0000357,3663,H,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,Autocuration,,10627,,6011,,,,,CHEMBL620799,,,,,B,1,8,
,BAO_0000357,3664,H,Binding affinity towards human 5-hydroxytryptamine 6 receptor,Expert,,10627,,17066,,,,,CHEMBL620800,,,,,B,1,8,
,BAO_0000357,3665,H,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,Autocuration,,10627,,17515,,,,,CHEMBL620801,,,,,B,1,8,
,BAO_0000357,3666,H,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,Autocuration,,10627,,5014,,,,,CHEMBL875100,,,,,B,1,8,
,BAO_0000357,3667,H,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,Autocuration,,10627,,4373,,,,,CHEMBL620802,,,,,B,1,8,
,BAO_0000019,3668,H,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,Expert,,10627,,17066,,,,,CHEMBL620803,,,,,F,1,8,
,BAO_0000019,3669,H,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,Expert,,10627,,17066,,,,,CHEMBL620804,,,,,F,1,8,
,BAO_0000357,3670,H,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,Autocuration,,10627,,4373,,,,,CHEMBL620805,,,,,B,1,8,
,BAO_0000357,3671,H,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,Autocuration,,10627,,4687,,,,,CHEMBL620806,,,,,B,1,8,
,BAO_0000357,3672,H,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,Autocuration,,10627,,16946,,,,,CHEMBL620807,,,,,B,1,8,
,BAO_0000357,3673,H,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,Autocuration,,10627,,16946,,,,,CHEMBL620808,,,,,B,1,8,
,BAO_0000357,3674,H,Binding affinities against 5-hydroxytryptamine 6 receptor,Autocuration,,10627,,16633,,,,,CHEMBL620809,,,,,B,1,8,
,BAO_0000357,3675,H,Binding affinities towards 5-hydroxytryptamine 6 receptor,Autocuration,,10627,,16633,,,,,CHEMBL620810,,,,,B,1,8,
,BAO_0000357,3676,D,Binding affinity towards 5-hydroxytryptamine 6 receptor,Expert,,10627,,17066,,9606.0,Homo sapiens,,CHEMBL620811,,,,,B,1,9,
,BAO_0000357,3677,H,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,Autocuration,,10627,,16700,,,,,CHEMBL620812,,,,,B,1,8,
,BAO_0000357,3678,H,Affinity against 5-hydroxytryptamine 6 receptor,Autocuration,,10627,,3269,,,,,CHEMBL620813,,,,,B,1,8,
,BAO_0000357,3679,H,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],Autocuration,,10627,,5486,,,,,CHEMBL620814,,,,,B,1,8,
,BAO_0000357,3680,D,Inhibition of human 5-hydroxytryptamine 7 receptor,Expert,,10209,,16146,,9606.0,Homo sapiens,,CHEMBL620815,,,,,B,1,9,
,BAO_0000219,3681,H,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,Autocuration,722.0,10209,,5014,,,,,CHEMBL620816,HEK293,,,,B,1,8,
,BAO_0000357,3682,H,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,Autocuration,,10209,,15463,,,,,CHEMBL620817,,,,,B,1,8,
,BAO_0000357,3683,H,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),Autocuration,,10209,,3805,,,,,CHEMBL620818,,,,,B,1,8,
,BAO_0000219,3684,H,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,Expert,722.0,10209,,5014,,,,,CHEMBL620819,HEK293,,,,B,1,8,
,BAO_0000357,3685,D,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,Expert,,10209,,6491,,9606.0,Homo sapiens,,CHEMBL620820,,,,,B,1,9,
,BAO_0000219,3686,H,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,Autocuration,449.0,10209,,16190,,,,,CHEMBL620821,CHO,,,,B,1,8,
,BAO_0000357,3687,D,Binding affinity towards human 5-hydroxytryptamine 7 receptor,Expert,,10209,,17066,,9606.0,Homo sapiens,,CHEMBL620822,,,,,B,1,9,
,BAO_0000357,3688,D,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,Expert,,10209,,17066,,9606.0,Homo sapiens,,CHEMBL620823,,,,,B,1,9,
,BAO_0000357,3689,D,Binding affinity against 5-hydroxytryptamine 7 receptor,Expert,,10209,,3555,,9606.0,Homo sapiens,,CHEMBL620824,,,,,B,1,9,
,BAO_0000219,3690,H,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,Expert,449.0,10209,,6588,,,,,CHEMBL620825,CHO,,,,B,1,8,
,BAO_0000357,3691,H,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,Autocuration,,10209,,15463,,,,,CHEMBL872930,,,,,B,1,8,
,BAO_0000357,3692,H,Binding affinity towards 5-hydroxytryptamine 7 receptor,Autocuration,,10209,,6013,,,,,CHEMBL620826,,,,,B,1,8,
,BAO_0000357,3693,H,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,Autocuration,,10209,,16209,,,,,CHEMBL620827,,,,,B,1,8,
,BAO_0000357,3694,H,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,Autocuration,,10209,,3935,,,,,CHEMBL620828,,,,,B,1,8,
,BAO_0000357,3695,H,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,Autocuration,,10209,,15818,,,,,CHEMBL620829,,,,,B,1,8,
,BAO_0000219,3696,H,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,Expert,722.0,10209,,5014,,,,,CHEMBL620830,HEK293,,,,B,1,8,
,BAO_0000019,3697,H,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,Expert,,10209,,16441,,,,,CHEMBL620831,,,,,B,1,8,
,BAO_0000019,3698,H,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,Expert,,10209,,16441,,,,,CHEMBL620832,,,,,B,1,8,
,BAO_0000357,3699,D,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,Expert,,10209,,4234,,9606.0,Homo sapiens,,CHEMBL621548,,,,,B,1,9,
,BAO_0000019,3700,H,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,Autocuration,,10209,,17085,,,,,CHEMBL621549,,,,,B,1,8,
,BAO_0000357,3701,H,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,Autocuration,,10209,,17200,,,,,CHEMBL621550,,,,,B,1,8,
,BAO_0000219,3702,H,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,Autocuration,449.0,10209,,17451,,,,,CHEMBL621551,CHO,,,,B,1,8,
,BAO_0000019,3703,H,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,Autocuration,,10209,,17085,,,,,CHEMBL621552,,,,,B,1,8,
,BAO_0000357,3704,H,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,Autocuration,,10209,,5104,,,,,CHEMBL857077,,,,,B,1,8,
,BAO_0000357,3705,H,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,Autocuration,,10209,,5104,,,,,CHEMBL618158,,,,,B,1,8,
,BAO_0000219,3706,D,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,Expert,643.0,10209,,5033,,9606.0,Homo sapiens,,CHEMBL618159,COS-7,,,,B,1,9,
,BAO_0000219,3707,H,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,Autocuration,643.0,10209,,5486,,,,,CHEMBL875101,COS-7,,,,B,1,8,
,BAO_0000219,3708,D,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,Expert,722.0,10209,,4540,,9606.0,Homo sapiens,,CHEMBL618160,HEK293,,,,B,1,9,
,BAO_0000357,3709,H,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,Expert,,10209,,6166,,,,,CHEMBL618161,,,,,B,1,8,
,BAO_0000219,3710,H,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,Expert,722.0,10209,,17342,,,,,CHEMBL618162,HEK293,,,,B,1,8,
,BAO_0000357,3711,H,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,Expert,,10209,,17342,,,,,CHEMBL618163,,,,,B,1,8,
,BAO_0000357,3712,H,Binding affinity against 5-hydroxytryptamine 7 human receptors,Autocuration,,10209,,17296,,,,,CHEMBL618164,,,,,B,1,8,
,BAO_0000219,3713,H,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,Expert,,10209,,16429,,,,,CHEMBL618165,,,,,B,1,8,
,BAO_0000219,3714,H,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,Autocuration,722.0,10209,,15779,,,,,CHEMBL618166,HEK293,,,,B,1,8,
,BAO_0000219,3715,H,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,Autocuration,722.0,10209,,15779,,,,,CHEMBL857989,HEK293,,,,B,1,8,
,BAO_0000219,3716,H,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,Autocuration,722.0,10209,,15779,,,,,CHEMBL619888,HEK293,,,,B,1,8,
,BAO_0000219,3717,H,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,Autocuration,722.0,10209,,15779,,,,,CHEMBL619889,HEK293,,,,B,1,8,
,BAO_0000219,3718,H,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,Autocuration,722.0,10209,,15779,,,,,CHEMBL619890,HEK293,,,,B,1,8,
,BAO_0000219,3719,H,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,Autocuration,449.0,10209,,17451,,,,,CHEMBL619891,CHO,,,,B,1,8,
,BAO_0000219,3720,H,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),Autocuration,722.0,10209,,4199,,,,,CHEMBL619892,HEK293,,,,B,1,8,
,BAO_0000219,3721,D,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,Expert,722.0,10209,,4199,,,,,CHEMBL619893,HEK293,,,,B,1,9,
,BAO_0000219,3722,H,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),Autocuration,722.0,10209,,4199,,,,,CHEMBL619894,HEK293,,,,B,1,8,
,BAO_0000219,3723,D,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,Intermediate,722.0,10209,,3680,,,,,CHEMBL619895,HEK293,,,,B,1,9,
,BAO_0000357,3724,D,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,Intermediate,,10209,,3680,,,,,CHEMBL619896,,,,,B,1,9,
,BAO_0000219,3725,H,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,Autocuration,643.0,10209,,15316,,,,,CHEMBL619897,COS-7,,,,B,1,8,
,BAO_0000219,3726,H,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,Autocuration,722.0,10209,,15146,,,,,CHEMBL619898,HEK293,,,,B,1,8,
,BAO_0000219,3727,H,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,Expert,722.0,10209,,5213,,,,,CHEMBL619899,HEK293,,,,B,1,8,
,BAO_0000219,3728,H,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),Autocuration,722.0,10209,,5213,,,,,CHEMBL619900,HEK293,,,,B,1,8,
,BAO_0000219,3729,D,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,Expert,722.0,10209,,14818,,9606.0,Homo sapiens,,CHEMBL619901,HEK293,,,,B,1,9,
,BAO_0000219,3730,H,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,Autocuration,722.0,10209,,14818,,,,,CHEMBL620580,HEK293,,,,B,1,8,
,BAO_0000219,3731,H,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,Autocuration,722.0,10209,,14818,,,,,CHEMBL620581,HEK293,,,,B,1,8,
,BAO_0000219,3732,H,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",Autocuration,722.0,10209,,4829,,,,,CHEMBL620733,HEK293,,,,B,1,8,
,BAO_0000357,3733,D,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,Autocuration,,10209,,17200,,9606.0,Homo sapiens,,CHEMBL620734,,,,,B,1,9,
,BAO_0000357,3734,D,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,Expert,,10022,,17066,,10090.0,Mus musculus,,CHEMBL620735,,,,,B,1,9,
,BAO_0000019,3735,H,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,Autocuration,,10209,,14025,,9986.0,Oryctolagus cuniculus,,CHEMBL620736,,,,,B,1,8,
,BAO_0000219,3736,H,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,Autocuration,449.0,11923,,15250,,,,,CHEMBL620737,CHO,,,,B,1,8,
,BAO_0000219,3737,H,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,Autocuration,449.0,11923,,16372,,,,,CHEMBL620738,CHO,,,,B,1,8,
,BAO_0000219,3738,H,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,Autocuration,449.0,11923,,16372,,,,,CHEMBL620739,CHO,,,,B,1,8,
,BAO_0000219,3739,H,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,Autocuration,449.0,11923,,16372,,,,,CHEMBL620740,CHO,,,,B,1,8,
,BAO_0000219,3740,H,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,Autocuration,449.0,11923,,16372,,,,,CHEMBL620741,CHO,,,,B,1,8,
,BAO_0000219,3741,H,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,Autocuration,449.0,11923,,16372,,,,,CHEMBL620742,CHO,,,,B,1,8,
,BAO_0000219,3742,H,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,Autocuration,449.0,11923,,16372,,,,,CHEMBL620743,CHO,,,,B,1,8,
,BAO_0000219,3743,H,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,Autocuration,449.0,11923,,16372,,,,,CHEMBL620744,CHO,,,,B,1,8,
,BAO_0000219,3744,H,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,Autocuration,449.0,11923,,16372,,,,,CHEMBL620745,CHO,,,,B,1,8,
,BAO_0000219,3745,H,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,Autocuration,449.0,11923,,16372,,,,,CHEMBL620746,CHO,,,,B,1,8,
,BAO_0000219,3746,H,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,Autocuration,449.0,11923,,16372,,,,,CHEMBL620747,CHO,,,,B,1,8,
,BAO_0000219,3747,H,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,Autocuration,449.0,11923,,16372,,,,,CHEMBL620748,CHO,,,,B,1,8,
,BAO_0000219,3748,H,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,Autocuration,449.0,11923,,16372,,,,,CHEMBL620749,CHO,,,,B,1,8,
,BAO_0000357,3749,H,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,Expert,,11923,,17066,,,,,CHEMBL620750,,,,,B,1,8,
,BAO_0000357,3750,D,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,Expert,,11923,,17066,,10116.0,Rattus norvegicus,,CHEMBL620751,,,,,B,1,9,
,BAO_0000357,3751,H,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,Expert,,11923,,17386,,,,,CHEMBL620752,,,,,B,1,8,
,BAO_0000019,3752,H,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,Autocuration,,11923,,14423,,,,,CHEMBL872929,,,,,B,1,8,
,BAO_0000357,3753,D,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,Expert,,11923,,15874,,10116.0,Rattus norvegicus,,CHEMBL620753,,,,,B,1,9,
,BAO_0000357,3754,D,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,Expert,,11923,,15874,,10116.0,Rattus norvegicus,,CHEMBL620754,,,,,B,1,9,
,BAO_0000219,3755,D,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,Expert,449.0,11923,,16372,,10116.0,Rattus norvegicus,,CHEMBL620755,CHO,,,,B,1,9,
,BAO_0000357,3756,H,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,Autocuration,,11923,,4622,,,,,CHEMBL620756,,,,,B,1,8,
,BAO_0000357,3757,H,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,Autocuration,,11923,,15086,,,,,CHEMBL620757,,,,,B,1,8,
,BAO_0000219,3758,H,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",Autocuration,449.0,11923,,16372,,,,,CHEMBL620758,CHO,,,,B,1,8,
,BAO_0000219,3759,H,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",Autocuration,449.0,11923,,16372,,,,,CHEMBL620759,CHO,,,,B,1,8,
,BAO_0000219,3760,H,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,Autocuration,449.0,11923,,16372,,,,,CHEMBL620760,CHO,,,,B,1,8,
,BAO_0000219,3761,H,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,Autocuration,449.0,11923,,16372,,,,,CHEMBL620761,CHO,,,,B,1,8,
Ileum,BAO_0000221,3762,H,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,Autocuration,,11923,,17386,2116.0,,,,CHEMBL620762,,,,,F,1,8,
Ileum,BAO_0000221,3763,H,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,Autocuration,,11923,,17386,2116.0,,,,CHEMBL620763,,,,,F,1,8,
Ileum,BAO_0000221,3764,H,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,Autocuration,,11923,,17386,2116.0,,,,CHEMBL620764,,,,,F,1,8,
,BAO_0000249,3765,D,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,Expert,,11923,,5831,,10116.0,Rattus norvegicus,,CHEMBL857990,,,,Membranes,B,1,9,
,BAO_0000357,3766,H,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,Autocuration,,11923,,4342,,,,,CHEMBL620765,,,,,B,1,8,
,BAO_0000357,3767,H,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,Expert,,11923,,17319,,,,,CHEMBL620766,,,,,B,1,8,
Hypothalamus,BAO_0000019,3768,H,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,Expert,,11923,,17342,1898.0,,,,CHEMBL620767,,,,,B,1,8,
,BAO_0000357,3769,H,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,Autocuration,,11923,,17342,,,,,CHEMBL620768,,,,,B,1,8,
Hypothalamus,BAO_0000249,3770,H,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,Expert,,11923,,3680,1898.0,,,,CHEMBL619051,,,,,B,1,8,
,BAO_0000357,3771,H,Binding affinity towards 5-hydroxytryptamine 7 receptor,Expert,,11923,,3680,,,,,CHEMBL619052,,,,,B,1,8,
,BAO_0000219,3772,D,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,Expert,722.0,11923,,17319,,10116.0,Rattus norvegicus,,CHEMBL619053,HEK293,,,,F,1,9,
,BAO_0000219,3773,D,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,Expert,722.0,11923,,17319,,10116.0,Rattus norvegicus,,CHEMBL619703,HEK293,,,,F,1,9,
,BAO_0000219,3774,D,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,Autocuration,722.0,11923,,17319,,10116.0,Rattus norvegicus,,CHEMBL619704,HEK293,,,,F,1,9,
,BAO_0000357,3775,H,Binding affinity towards 5-hydroxytryptamine 7 receptor,Expert,,10209,,4820,,,,,CHEMBL619851,,,,,B,1,8,
,BAO_0000357,3776,H,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,Autocuration,,10209,,4639,,,,,CHEMBL619852,,,,,B,1,8,
,BAO_0000357,3777,H,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,Autocuration,,10209,,6011,,,,,CHEMBL619853,,,,,B,1,8,
,BAO_0000357,3778,D,Binding affinity towards human 5-hydroxytryptamine 7 receptor,Expert,,10209,,17066,,9606.0,Homo sapiens,,CHEMBL619854,,,,,B,1,9,
,BAO_0000357,3779,H,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,Expert,,10209,,17066,,,,,CHEMBL619855,,,,,B,1,8,
,BAO_0000357,3780,H,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,Autocuration,,10209,,17515,,,,,CHEMBL619856,,,,,B,1,8,
,BAO_0000357,3781,H,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,Autocuration,,10209,,4373,,,,,CHEMBL619857,,,,,B,1,8,
,BAO_0000019,3782,H,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,Expert,,10209,,17066,,,,,CHEMBL619858,,,,,F,1,8,
,BAO_0000357,3783,H,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,Autocuration,,10209,,4373,,,,,CHEMBL619859,,,,,B,1,8,
,BAO_0000357,3784,H,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,Autocuration,,10209,,4373,,,,,CHEMBL619860,,,,,B,1,8,
,BAO_0000357,3785,H,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,Autocuration,,10209,,4687,,,,,CHEMBL619861,,,,,B,1,8,
,BAO_0000357,3786,H,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,Expert,,10209,,17342,,,,,CHEMBL619862,,,,,B,1,8,
,BAO_0000357,3787,H,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,Autocuration,,10209,,16946,,,,,CHEMBL619863,,,,,B,1,8,
,BAO_0000357,3788,H,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,Autocuration,,10209,,16946,,,,,CHEMBL619864,,,,,B,1,8,
,BAO_0000357,3789,H,Binding affinities against 5-hydroxytryptamine 7 receptor,Autocuration,,10209,,16633,,,,,CHEMBL872928,,,,,B,1,8,
,BAO_0000357,3790,H,Binding affinities towards 5-hydroxytryptamine 7 receptor,Autocuration,,10209,,16633,,,,,CHEMBL619865,,,,,B,1,8,
,BAO_0000357,3791,H,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,Expert,,10209,,17066,,,,,CHEMBL619866,,,,,B,1,8,
,BAO_0000357,3792,H,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,Autocuration,,10209,,16700,,,,,CHEMBL619867,,,,,B,1,8,
Ileum,BAO_0000221,3793,H,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,Autocuration,,10209,,17386,2116.0,,,,CHEMBL619868,,,,,B,1,8,
,BAO_0000019,3794,H,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,Autocuration,,55,,14080,,,,,CHEMBL619869,,,,,F,1,8,
,BAO_0000019,3795,D,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,Expert,,55,,14080,,9606.0,Homo sapiens,,CHEMBL619870,,,,,F,1,9,
,BAO_0000357,3796,H,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,Autocuration,,55,,409,,,,,CHEMBL619871,,,,,B,1,8,
,BAO_0000357,3797,H,In vitro inhibition of human recombinant lipoxygenase enzyme,Autocuration,,55,,409,,,,,CHEMBL619872,,,,,B,1,8,
,BAO_0000357,3798,H,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,Autocuration,,55,,409,,,,,CHEMBL619873,,,,,B,1,8,
Blood,BAO_0000357,3799,H,Inhibition of 5-lipoxygenase in human whole blood.,Expert,,55,,11090,178.0,,,,CHEMBL619874,,,,,B,1,8,
Blood,BAO_0000357,3800,H,Inhibition of 5-lipoxygenase in human whole blood.,Expert,,55,,11090,178.0,,,,CHEMBL619875,,,,,B,1,8,
,BAO_0000357,3801,H,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,Autocuration,,55,,948,,,,,CHEMBL619876,,,,,B,1,8,
,BAO_0000357,3802,H,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),Autocuration,,55,,948,,,,,CHEMBL619877,,,,,B,1,8,
,BAO_0000219,3803,H,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,Expert,,55,,13622,,,,,CHEMBL619878,,,,,F,1,8,
Blood,BAO_0000019,3804,H,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,Autocuration,,55,,13622,178.0,,,,CHEMBL619879,,,,,F,1,8,
,BAO_0000357,3805,H,In vitro inhibition of 5-lipoxygenase from human polymorphs,Autocuration,,55,,9637,,,,,CHEMBL619880,,,,,B,1,8,
,BAO_0000357,3806,H,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),Autocuration,,55,,11320,,,,,CHEMBL619881,,,,,B,1,8,
,BAO_0000357,3807,H,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,Expert,,55,,11320,,,,,CHEMBL619882,,,,,B,1,8,
,BAO_0000357,3808,H,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,Autocuration,,55,,6838,,,,,CHEMBL619883,,,,,B,1,8,
Blood,BAO_0000357,3809,D,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),Expert,,55,,17667,178.0,9606.0,Homo sapiens,,CHEMBL619884,,,,,B,1,9,
,BAO_0000357,3810,H,In vitro potency against human 5-Lipoxygenase,Autocuration,,55,,12703,,,,,CHEMBL619885,,,,,B,1,8,
,BAO_0000019,3811,D,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,Expert,,55,,14312,,9606.0,Homo sapiens,,CHEMBL619886,,,,,F,1,9,
Blood,BAO_0000019,3812,H,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,Autocuration,,55,,14312,178.0,,,,CHEMBL619887,,,,,F,1,8,
,BAO_0000019,3813,H,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,Autocuration,,55,,5364,,,,,CHEMBL875097,,,,,F,1,8,
,BAO_0000219,3814,H,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,Autocuration,,55,,951,,,,,CHEMBL618001,,,,,B,1,8,
,BAO_0000219,3815,H,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,Autocuration,,55,,951,,,,,CHEMBL618002,,,,,B,1,8,
,BAO_0000219,3816,H,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,Autocuration,,55,,951,,,,,CHEMBL618003,,,,,B,1,8,
,BAO_0000219,3817,H,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,Autocuration,,55,,951,,,,,CHEMBL618004,,,,,B,1,8,
,BAO_0000219,3818,H,Inhibition of human 5-lipoxygenase in human cells,Autocuration,,55,,12365,,,,,CHEMBL618005,,,,,B,1,8,
,BAO_0000357,3819,H,Inhibition of human neutrophil 5-lipoxygenase,Expert,,55,,10603,,,,,CHEMBL618006,,,,,B,1,8,
,BAO_0000019,3820,H,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,Autocuration,,55,,10501,,,,,CHEMBL875086,,,,,B,1,8,
Blood,BAO_0000357,3821,H,Inhibition of 5-lipoxygenase from human whole blood,Expert,,55,,12281,178.0,,,,CHEMBL618007,,,,,B,1,8,
,BAO_0000357,3822,H,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,Autocuration,,55,,2567,,,,,CHEMBL618008,,,,,B,1,8,
,BAO_0000219,3823,H,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,Autocuration,,55,,2567,,,,,CHEMBL618009,,,,,B,1,8,
,BAO_0000357,3824,H,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,Expert,,55,,10193,,,,,CHEMBL618010,,,,,B,1,8,
,BAO_0000357,3825,H,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,Autocuration,,55,,10193,,,,,CHEMBL618011,,,,,B,1,8,
,BAO_0000357,3826,H,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,Expert,,55,,13623,,,,,CHEMBL618012,,,,,B,1,8,
,BAO_0000357,3827,H,Tested against 5-lipoxygenase,Autocuration,,55,,12780,,,,,CHEMBL882927,,,,,B,1,8,
,BAO_0000357,3828,H,Tested for activity against 5-Lipoxygenase (5-LO),Autocuration,,55,,12780,,,,,CHEMBL618013,,,,,B,1,8,
,BAO_0000357,3829,H,Tested for activity against 5-lipoxygenase,Autocuration,,55,,12780,,,,,CHEMBL618014,,,,,B,1,8,
,BAO_0000357,3830,H,Tested for inhibition of 5-HPETE production by human 5-LO,Autocuration,,55,,11966,,,,,CHEMBL618015,,,,,B,1,8,
,BAO_0000019,3831,H,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,Autocuration,,55,,5364,,,,,CHEMBL618016,,,,,F,1,8,
,BAO_0000357,3832,H,Inhibition of Human 5-lipoxygenase,Expert,,55,,13165,,,,,CHEMBL618017,,,,,B,1,8,
,BAO_0000019,3833,H,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,Autocuration,,55,,5364,,,,,CHEMBL618018,,,,,B,1,8,
,BAO_0000219,3834,H,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],Autocuration,,55,,11311,,,,,CHEMBL875087,,,,,B,1,8,
,BAO_0000219,3835,H,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],Autocuration,,55,,11311,,,,,CHEMBL618019,,,,,B,1,8,
,BAO_0000019,3836,H,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,Autocuration,,55,,14863,,,,,CHEMBL618020,,,,,B,1,8,
,BAO_0000019,3837,H,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,Autocuration,,55,,14863,,,,,CHEMBL618021,,,,,B,1,8,
Blood,BAO_0000357,3838,H,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),Autocuration,,55,,11087,178.0,,,,CHEMBL618022,,,,,B,1,8,
,BAO_0000357,3839,H,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,Autocuration,,55,,455,,,,,CHEMBL618023,,,,,B,1,8,
,BAO_0000357,3840,H,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),Autocuration,,55,,13183,,,,,CHEMBL618024,,,,,B,1,8,
,BAO_0000019,3841,H,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,Expert,,55,,10319,,,,,CHEMBL873950,,,,,B,1,8,
,BAO_0000357,3842,H,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,Autocuration,,55,,10193,,,,,CHEMBL618025,,,,,B,1,8,
,BAO_0000219,3843,H,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,Autocuration,,55,,951,,,,,CHEMBL618026,,,,,B,1,8,
,BAO_0000219,3844,H,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,Autocuration,,55,,951,,,,,CHEMBL618027,,,,,B,1,8,
,BAO_0000219,3845,H,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,Autocuration,,55,,951,,,,,CHEMBL618028,,,,,B,1,8,
,BAO_0000219,3846,H,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,Autocuration,,55,,951,,,,,CHEMBL618029,,,,,B,1,8,
,BAO_0000357,3847,H,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,Expert,,55,,9859,,,,,CHEMBL618030,,,,,B,1,8,
,BAO_0000357,3848,H,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,Expert,,55,,9859,,,,,CHEMBL618031,,,,,B,1,8,
,BAO_0000357,3849,H,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,Autocuration,,55,,9859,,,,,CHEMBL618032,,,,,B,1,8,
,BAO_0000357,3850,H,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,Autocuration,,55,,2567,,,,,CHEMBL618033,,,,,B,1,8,
,BAO_0000357,3851,H,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,Autocuration,,55,,10193,,,,,CHEMBL618034,,,,,B,1,8,
,BAO_0000357,3852,H,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,Autocuration,,55,,10193,,,,,CHEMBL875088,,,,,B,1,8,
,BAO_0000019,3853,H,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,Autocuration,,55,,949,,,,,CHEMBL618035,,,,,B,1,8,
,BAO_0000019,3854,H,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,Autocuration,,55,,949,,,,,CHEMBL618036,,,,,B,1,8,
,BAO_0000357,3855,H,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,Expert,,55,,10603,,,,,CHEMBL618037,,,,,B,1,8,
,BAO_0000357,3856,H,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,Expert,,55,,10603,,,,,CHEMBL618038,,,,,B,1,8,
,BAO_0000019,3857,H,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,Autocuration,,55,,10603,,,,,CHEMBL618761,,,,,F,1,8,
,BAO_0000357,3858,H,Inhibition of lipoxygenase at the concentration of 0.1 uM,Expert,,55,,10603,,,,,CHEMBL618762,,,,,B,1,8,
,BAO_0000357,3859,H,Inhibition of lipoxygenase at the concentration of 1 uM,Expert,,55,,10603,,,,,CHEMBL618763,,,,,B,1,8,
,BAO_0000357,3860,H,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,Autocuration,,55,,10193,,,,,CHEMBL618764,,,,,B,1,8,
,BAO_0000357,3861,D,Inhibition of 5-Lipoxygenase (5-LOX),Expert,,55,,14580,,9606.0,Homo sapiens,,CHEMBL618765,,,,,B,1,9,
,BAO_0000357,3862,H,Inhibition of 5-lipoxygenase in mouse macrophages.,Expert,,17087,,11090,,,,,CHEMBL618766,,,,,B,1,8,
,BAO_0000357,3863,H,Inhibition of 5-lipoxygenase in mouse macrophages.,Expert,,17087,,11090,,,,,CHEMBL618767,,,,,B,1,8,
,BAO_0000357,3864,H,Inhibitory activity against lipoxygenase-2 in mice,Autocuration,,17087,,6339,,,,,CHEMBL619380,,,,,B,1,8,
,BAO_0000357,3865,H,Inhibitory activity against murine lipoxygenase-2.,Expert,,17087,,6339,,,,,CHEMBL619381,,,,,B,1,8,
,BAO_0000357,3866,D,Inhibition of 5-lipoxygenase from mouse macrophage,Expert,,17087,,12281,,10090.0,Mus musculus,,CHEMBL619382,,,,,B,1,9,
,BAO_0000357,3867,H,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,Autocuration,,17087,,11311,,,,,CHEMBL619383,,,,,B,1,8,
,BAO_0000019,3868,H,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,Autocuration,,55,,11089,,9823.0,Sus scrofa,,CHEMBL619384,,,,,B,1,8,
,BAO_0000019,3869,H,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,Autocuration,,55,,10091,,9823.0,Sus scrofa,,CHEMBL619385,,,,,B,1,8,
,BAO_0000019,3870,H,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,Autocuration,,55,,14352,,9986.0,Oryctolagus cuniculus,,CHEMBL882928,,,,,B,1,8,
,BAO_0000019,3871,D,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,Expert,,12166,,13329,,10116.0,Rattus norvegicus,,CHEMBL619386,,,,,B,1,9,
,BAO_0000019,3872,H,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",Autocuration,,12166,,13329,,,,,CHEMBL619387,,,,,B,1,8,
,BAO_0000019,3873,H,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",Autocuration,,12166,,13329,,,,,CHEMBL619388,,,,,B,1,8,
,BAO_0000019,3874,H,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",Autocuration,,12166,,13329,,,,,CHEMBL619389,,,,,B,1,8,
,BAO_0000019,3875,H,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),Expert,,12166,,13329,,,,,CHEMBL619390,,,,,B,1,8,
,BAO_0000019,3876,H,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",Expert,,12166,,13329,,,,,CHEMBL619391,,,,,B,1,8,
,BAO_0000019,3877,H,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,Autocuration,,12166,,13329,,,,,CHEMBL619392,,,,,B,1,8,
,BAO_0000019,3878,H,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),Autocuration,,12166,,11311,,,,,CHEMBL619393,,,,,B,1,8,
,BAO_0000019,3879,H,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,Autocuration,,12166,,11311,,,,,CHEMBL619394,,,,,B,1,8,
,BAO_0000219,3880,H,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",Autocuration,702.0,12166,,105,,,,,CHEMBL619395,RBL-1,,,,B,1,8,
,BAO_0000219,3881,H,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",Autocuration,702.0,12166,,105,,,,,CHEMBL619396,RBL-1,,,,B,1,8,
,BAO_0000357,3882,H,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),Autocuration,,12166,,9138,,,,,CHEMBL619397,,,,,B,1,8,
,BAO_0000357,3883,H,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",Autocuration,,12166,,9138,,,,,CHEMBL619398,,,,,B,1,8,
,BAO_0000357,3884,H,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",Autocuration,,12166,,9138,,,,,CHEMBL619399,,,,,B,1,8,
,BAO_0000357,3885,H,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,Autocuration,,12166,,14427,,,,,CHEMBL619400,,,,,B,1,8,
,BAO_0000019,3886,H,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",Autocuration,,12166,,13329,,,,,CHEMBL619401,,,,,B,1,8,
,BAO_0000019,3887,H,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",Autocuration,,12166,,13329,,,,,CHEMBL619402,,,,,B,1,8,
,BAO_0000219,3888,D,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,Expert,663.0,12166,,14427,,10116.0,Rattus norvegicus,,CHEMBL619403,RBL-2H3,,,,B,1,9,
,BAO_0000357,3889,H,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,Autocuration,,12166,,14427,,,,,CHEMBL619404,,,,,B,1,8,
,BAO_0000357,3890,H,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,Autocuration,,12166,,14427,,,,,CHEMBL619405,,,,,B,1,8,
,BAO_0000219,3891,H,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,Expert,702.0,12166,,10293,,,,,CHEMBL619406,RBL-1,,,,B,1,8,
,BAO_0000219,3892,D,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,Expert,702.0,12166,,338,,10116.0,Rattus norvegicus,,CHEMBL619407,RBL-1,,,,B,1,9,
,BAO_0000357,3893,H,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),Autocuration,,12166,,303,,,,,CHEMBL619408,,,,,B,1,8,
,BAO_0000219,3894,H,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,Autocuration,702.0,12166,,303,,,,,CHEMBL619409,RBL-1,,,,B,1,8,
,BAO_0000219,3895,H,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,Expert,702.0,12166,,9247,,,,,CHEMBL619410,RBL-1,,,,B,1,8,
,BAO_0000219,3896,H,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,Autocuration,702.0,12166,,9247,,,,,CHEMBL619753,RBL-1,,,,B,1,8,
,BAO_0000219,3897,H,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,Autocuration,702.0,12166,,137,,,,,CHEMBL619754,RBL-1,,,,B,1,8,
,BAO_0000357,3898,H,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,Expert,,12166,,11481,,,,,CHEMBL619903,,,,,B,1,8,
,BAO_0000357,3899,H,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",Expert,,12166,,11481,,,,,CHEMBL619904,,,,,B,1,8,
,BAO_0000357,3900,H,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,Expert,,12166,,9029,,,,,CHEMBL619905,,,,,B,1,8,
,BAO_0000019,3901,H,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,Autocuration,,12166,,1701,,,,,CHEMBL619906,,,,,B,1,8,
,BAO_0000019,3902,H,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,Autocuration,,12166,,1701,,,,,CHEMBL619907,,,,,B,1,8,
,BAO_0000019,3903,H,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,Autocuration,,12166,,1701,,,,,CHEMBL619908,,,,,B,1,8,
,BAO_0000019,3904,H,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,Autocuration,,12166,,1701,,,,,CHEMBL619909,,,,,B,1,8,
,BAO_0000219,3905,H,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,Expert,702.0,12166,,13358,,,,,CHEMBL619910,RBL-1,,,,F,1,8,
,BAO_0000219,3906,H,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,Expert,702.0,12166,,1175,,,,,CHEMBL882929,RBL-1,,,,B,1,8,
,BAO_0000219,3907,H,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,Expert,702.0,12166,,8797,,,,,CHEMBL619911,RBL-1,,,,B,1,8,
,BAO_0000019,3908,H,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,Autocuration,,12166,,8797,,,,,CHEMBL619912,,,,,B,1,8,
,BAO_0000357,3909,D,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,Expert,,12166,,577,,10116.0,Rattus norvegicus,,CHEMBL619913,,,,,B,1,9,
,BAO_0000219,3910,H,In vitro inhibitory activity against RBL-1 5-LO,Expert,702.0,12166,,9295,,,,,CHEMBL619914,RBL-1,,,,B,1,8,
,BAO_0000219,3911,H,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),Autocuration,702.0,12166,,9295,,,,,CHEMBL619915,RBL-1,,,,B,1,8,
,BAO_0000219,3912,H,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),Autocuration,702.0,12166,,9295,,,,,CHEMBL619916,RBL-1,,,,B,1,8,
,BAO_0000218,3913,H,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,Autocuration,,12166,,9295,,,,,CHEMBL619917,,,,,B,1,8,
,BAO_0000357,3914,H,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,Autocuration,,12166,,9295,,,,,CHEMBL619918,,,,,B,1,8,
,BAO_0000218,3915,H,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,Autocuration,,12166,,216,,,,,CHEMBL619919,,,,,B,1,8,
,BAO_0000219,3916,H,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,Autocuration,702.0,12166,,11090,,,,,CHEMBL883710,RBL-1,,,,B,1,8,
Blood,BAO_0000019,3917,H,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,Autocuration,,12166,,11090,178.0,,,,CHEMBL619920,,,,,B,1,8,
,BAO_0000357,3918,H,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,Expert,,12166,,10091,,,,,CHEMBL619921,,,,,B,1,8,
,BAO_0000019,3919,H,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,Autocuration,,12166,,10274,,,,,CHEMBL619922,,,,,F,1,8,
,BAO_0000219,3920,H,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,Autocuration,,12166,,13622,,,,,CHEMBL619923,,,,,F,1,8,
,BAO_0000219,3921,H,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,Expert,702.0,12166,,12118,,,,,CHEMBL619924,RBL-1,,,,B,1,8,
,BAO_0000357,3922,H,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,Expert,,12166,,12576,,,,,CHEMBL619925,,,,,B,1,8,
,BAO_0000219,3923,H,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,Expert,702.0,12166,,9546,,,,,CHEMBL619926,RBL-1,,,,B,1,8,
,BAO_0000219,3924,H,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,Autocuration,702.0,12166,,9521,,,,,CHEMBL619927,RBL-1,,,,B,1,8,
,BAO_0000219,3925,H,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,Expert,702.0,12166,,10626,,,,,CHEMBL619928,RBL-1,,,,B,1,8,
,BAO_0000219,3926,H,In vitro inhibition of RBL-1 5-lipoxygenase,Autocuration,702.0,12166,,9225,,,,,CHEMBL619929,RBL-1,,,,B,1,8,
,BAO_0000219,3927,H,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,Autocuration,702.0,12166,,9225,,,,,CHEMBL875089,RBL-1,,,,B,1,8,
,BAO_0000219,3928,H,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,Autocuration,702.0,12166,,9225,,,,,CHEMBL619930,RBL-1,,,,B,1,8,
,BAO_0000219,3929,H,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,Autocuration,702.0,12166,,9225,,,,,CHEMBL619931,RBL-1,,,,B,1,8,
,BAO_0000219,3930,H,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,Autocuration,702.0,12166,,9225,,,,,CHEMBL619932,RBL-1,,,,B,1,8,
,BAO_0000219,3931,H,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,Autocuration,702.0,12166,,9225,,,,,CHEMBL619933,RBL-1,,,,B,1,8,
,BAO_0000219,3932,H,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,Autocuration,702.0,12166,,9225,,,,,CHEMBL619934,RBL-1,,,,B,1,8,
,BAO_0000219,3933,H,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,Autocuration,702.0,12166,,9225,,,,,CHEMBL619935,RBL-1,,,,B,1,8,
,BAO_0000219,3934,H,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,Autocuration,702.0,12166,,9225,,,,,CHEMBL619936,RBL-1,,,,B,1,8,
,BAO_0000219,3935,H,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,Autocuration,702.0,12166,,9225,,,,,CHEMBL619937,RBL-1,,,,B,1,8,
,BAO_0000219,3936,H,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,Autocuration,702.0,12166,,9225,,,,,CHEMBL619938,RBL-1,,,,B,1,8,
,BAO_0000219,3937,H,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,Autocuration,702.0,12166,,9225,,,,,CHEMBL619939,RBL-1,,,,B,1,8,
,BAO_0000219,3938,H,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,Autocuration,702.0,12166,,9225,,,,,CHEMBL619940,RBL-1,,,,B,1,8,
,BAO_0000219,3939,H,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,Autocuration,702.0,12166,,9225,,,,,CHEMBL875090,RBL-1,,,,B,1,8,
,BAO_0000219,3940,H,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,Autocuration,702.0,12166,,9225,,,,,CHEMBL619941,RBL-1,,,,B,1,8,
,BAO_0000219,3941,H,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,Autocuration,702.0,12166,,9225,,,,,CHEMBL619942,RBL-1,,,,B,1,8,
,BAO_0000219,3942,H,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,Autocuration,702.0,12166,,9225,,,,,CHEMBL883711,RBL-1,,,,B,1,8,
,BAO_0000219,3943,H,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,Autocuration,702.0,12166,,9225,,,,,CHEMBL619943,RBL-1,,,,B,1,8,
,BAO_0000219,3944,H,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,Autocuration,702.0,12166,,9225,,,,,CHEMBL619944,RBL-1,,,,B,1,8,
,BAO_0000219,3945,H,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,Autocuration,702.0,12166,,9225,,,,,CHEMBL619945,RBL-1,,,,B,1,8,
,BAO_0000219,3946,H,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,Autocuration,702.0,12166,,9225,,,,,CHEMBL619946,RBL-1,,,,B,1,8,
,BAO_0000219,3947,H,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,Autocuration,702.0,12166,,9225,,,,,CHEMBL619947,RBL-1,,,,B,1,8,
,BAO_0000219,3948,H,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,Autocuration,702.0,12166,,9225,,,,,CHEMBL619948,RBL-1,,,,B,1,8,
,BAO_0000219,3949,H,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,Autocuration,702.0,12166,,9225,,,,,CHEMBL619949,RBL-1,,,,B,1,8,
,BAO_0000019,3950,H,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,Expert,,12166,,9401,,,,,CHEMBL619950,,,,,B,1,8,
,BAO_0000019,3951,H,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,Autocuration,,12166,,10325,,,,,CHEMBL618050,,,,,B,1,8,
,BAO_0000219,3952,H,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,Expert,663.0,12166,,1556,,,,,CHEMBL875091,RBL-2H3,,,,F,1,8,
,BAO_0000219,3953,H,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,Expert,663.0,12166,,1556,,,,,CHEMBL618051,RBL-2H3,,,,F,1,8,
,BAO_0000219,3954,D,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,Expert,702.0,12166,,961,,10116.0,Rattus norvegicus,,CHEMBL618052,RBL-1,,,,B,1,9,
,BAO_0000019,3955,H,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,Autocuration,,12166,,6838,,,,,CHEMBL618053,,,,,B,1,8,
,BAO_0000019,3956,H,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),Expert,,12166,,10325,,,,,CHEMBL618054,,,,,B,1,8,
,BAO_0000219,3957,D,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,Expert,702.0,12166,,9209,,10116.0,Rattus norvegicus,,CHEMBL618055,RBL-1,,,,B,1,9,
,BAO_0000219,3958,H,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,Expert,702.0,12166,,11520,,,,,CHEMBL618056,RBL-1,,,,B,1,8,
,BAO_0000357,3959,H,In vitro inhibitory activity against 5-lipoxygenase was determined,Autocuration,,12166,,137,,,,,CHEMBL618057,,,,,B,1,8,
,BAO_0000219,3960,H,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,Autocuration,702.0,12166,,4717,,,,,CHEMBL618058,RBL-1,,,,B,1,8,
,BAO_0000219,3961,H,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,Expert,702.0,12166,,10636,,,,,CHEMBL618059,RBL-1,,,,B,1,8,
,BAO_0000019,3962,D,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,Expert,,12166,,14312,,10116.0,Rattus norvegicus,,CHEMBL618060,,,,,F,1,9,
,BAO_0000219,3963,H,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,Autocuration,702.0,12166,,1203,,,,,CHEMBL618061,RBL-1,,,,B,1,8,
,BAO_0000019,3964,H,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,Autocuration,,12166,,1203,,,,,CHEMBL618062,,,,,B,1,8,
,BAO_0000219,3965,H,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,Expert,702.0,12166,,13622,,,,,CHEMBL618063,RBL-1,,,,B,1,8,
,BAO_0000357,3966,H,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,Autocuration,,12166,,9793,,,,,CHEMBL618064,,,,,B,1,8,
,BAO_0000219,3967,D,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,Expert,702.0,12166,,1143,,10116.0,Rattus norvegicus,,CHEMBL618065,RBL-1,,,,B,1,9,
,BAO_0000219,3968,D,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,Expert,702.0,12166,,11854,,10116.0,Rattus norvegicus,,CHEMBL618066,RBL-1,,,,B,1,9,
,BAO_0000219,3969,H,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),Autocuration,702.0,12166,,3595,,,,,CHEMBL618067,RBL-1,,,,B,1,8,
,BAO_0000219,3970,H,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),Autocuration,702.0,12166,,3595,,,,,CHEMBL618068,RBL-1,,,,B,1,8,
,BAO_0000219,3971,D,Inhibition of 5-lipoxygenase in rat RBL-1 cells,Expert,702.0,12166,,10501,,10116.0,Rattus norvegicus,,CHEMBL618069,RBL-1,,,,B,1,9,
,BAO_0000219,3972,H,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,Expert,702.0,12166,,12526,,,,,CHEMBL618070,RBL-1,,,,B,1,8,
Limbic system,BAO_0000019,3973,H,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,Autocuration,,10825,,10034,349.0,,,,CHEMBL618071,,,,,F,1,8,
Limbic system,BAO_0000019,3974,H,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,Autocuration,,10825,,10034,349.0,,,,CHEMBL619247,,,,,F,1,8,
,BAO_0000019,3975,H,Approximate dose levels for a half maximal reduction of 5-HTP levels,Autocuration,,10825,,10034,,,,,CHEMBL619248,,,,,F,1,8,
Hippocampus,BAO_0000221,3976,H,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,Autocuration,,10576,,10046,10000000.0,,,,CHEMBL619249,,,,,B,1,8,
Hippocampus,BAO_0000221,3977,H,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,Autocuration,,10576,,10046,10000000.0,,,,CHEMBL619250,,,,,B,1,8,
,BAO_0000019,3978,H,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,Autocuration,,10577,,10046,,,,,CHEMBL619251,,,,,B,1,8,
Blood,BAO_0000019,3979,H,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,Autocuration,,55,,12079,178.0,9615.0,Canis lupus familiaris,,CHEMBL619252,,,,,F,1,8,
Blood,BAO_0000019,3980,H,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,Autocuration,,55,,12079,178.0,,,,CHEMBL619253,,,,,F,1,8,
,BAO_0000219,3981,H,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],Autocuration,,12166,,11311,,,,,CHEMBL619254,,,,,B,1,8,
,BAO_0000219,3982,H,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,Expert,,17140,,12338,,,,,CHEMBL619255,,,,,B,1,8,
,BAO_0000219,3983,H,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,Expert,,17140,,12143,,,,,CHEMBL619256,,,,,B,1,8,
,BAO_0000219,3984,H,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),Autocuration,,17140,,12143,,,,,CHEMBL875418,,,,,B,1,8,
,BAO_0000219,3985,H,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,Expert,,17140,,12143,,,,,CHEMBL619257,,,,,B,1,8,
,BAO_0000219,3986,H,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,Autocuration,,17140,,12143,,,,,CHEMBL619258,,,,,B,1,8,
,BAO_0000357,3987,H,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,Expert,,17140,,12365,,,,,CHEMBL619259,,,,,B,1,8,
,BAO_0000357,3988,H,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,Expert,,17140,,13500,,,,,CHEMBL619260,,,,,B,1,8,
Blood,BAO_0000218,3989,H,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,55,,12832,178.0,9615.0,Canis lupus familiaris,,CHEMBL619261,,,In vivo,,F,1,8,
Blood,BAO_0000218,3990,H,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,55,,12832,178.0,9615.0,Canis lupus familiaris,,CHEMBL619263,,,In vivo,,F,1,8,
Blood,BAO_0000218,3991,H,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,55,,12832,178.0,9615.0,Canis lupus familiaris,,CHEMBL619264,,,In vivo,,F,1,8,
Blood,BAO_0000218,3992,H,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,55,,12832,178.0,9615.0,Canis lupus familiaris,,CHEMBL619265,,,In vivo,,F,1,8,
Blood,BAO_0000218,3993,H,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,55,,12832,178.0,9615.0,Canis lupus familiaris,,CHEMBL619266,,,In vivo,,F,1,8,
Blood,BAO_0000218,3994,H,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,55,,12832,178.0,9615.0,Canis lupus familiaris,,CHEMBL619902,,,In vivo,,F,1,8,
Blood,BAO_0000218,3995,H,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,55,,12832,178.0,9615.0,Canis lupus familiaris,,CHEMBL620058,,,In vivo,,F,1,8,
Blood,BAO_0000218,3996,H,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,55,,12832,178.0,9615.0,Canis lupus familiaris,,CHEMBL620059,,,In vivo,,F,1,8,
Blood,BAO_0000218,3997,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,55,,12832,178.0,9615.0,Canis lupus familiaris,,CHEMBL620060,,,In vivo,,F,1,8,
Blood,BAO_0000218,3998,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,55,,12832,178.0,9615.0,Canis lupus familiaris,,CHEMBL620061,,,In vivo,,F,1,8,
Blood,BAO_0000218,3999,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",Autocuration,,55,,12832,178.0,9615.0,Canis lupus familiaris,,CHEMBL620062,,,In vivo,,F,1,8,
Blood,BAO_0000218,4000,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",Autocuration,,55,,12832,178.0,9615.0,Canis lupus familiaris,,CHEMBL620063,,,In vivo,,F,1,8,
Blood,BAO_0000218,4001,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",Autocuration,,55,,12832,178.0,9615.0,Canis lupus familiaris,,CHEMBL620064,,,In vivo,,F,1,8,
Blood,BAO_0000218,4002,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,55,,12832,178.0,9615.0,Canis lupus familiaris,,CHEMBL620065,,,In vivo,,F,1,8,
Blood,BAO_0000218,4003,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",Autocuration,,55,,12832,178.0,9615.0,Canis lupus familiaris,,CHEMBL620066,,,In vivo,,F,1,8,
Blood,BAO_0000218,4004,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",Autocuration,,55,,12832,178.0,9615.0,Canis lupus familiaris,,CHEMBL620067,,,In vivo,,F,1,8,
Blood,BAO_0000218,4005,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",Autocuration,,55,,12832,178.0,9615.0,Canis lupus familiaris,,CHEMBL620068,,,In vivo,,F,1,8,
Blood,BAO_0000218,4006,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,55,,12832,178.0,9615.0,Canis lupus familiaris,,CHEMBL620069,,,In vivo,,F,1,8,
Blood,BAO_0000218,4007,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",Autocuration,,55,,12832,178.0,9615.0,Canis lupus familiaris,,CHEMBL620070,,,In vivo,,F,1,8,
Blood,BAO_0000218,4008,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",Autocuration,,55,,12832,178.0,9615.0,Canis lupus familiaris,,CHEMBL620071,,,In vivo,,F,1,8,
Blood,BAO_0000218,4009,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",Autocuration,,55,,12832,178.0,9615.0,Canis lupus familiaris,,CHEMBL620072,,,In vivo,,F,1,8,
Blood,BAO_0000218,4010,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,55,,12832,178.0,9615.0,Canis lupus familiaris,,CHEMBL620036,,,In vivo,,F,1,8,
Blood,BAO_0000218,4011,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",Autocuration,,55,,12832,178.0,9615.0,Canis lupus familiaris,,CHEMBL857702,,,In vivo,,F,1,8,
Blood,BAO_0000218,4012,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",Autocuration,,55,,12832,178.0,9615.0,Canis lupus familiaris,,CHEMBL620037,,,In vivo,,F,1,8,
Blood,BAO_0000218,4013,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",Autocuration,,55,,12832,178.0,9615.0,Canis lupus familiaris,,CHEMBL620038,,,In vivo,,F,1,8,
Blood,BAO_0000218,4014,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,55,,12832,178.0,9615.0,Canis lupus familiaris,,CHEMBL620039,,,In vivo,,F,1,8,
Blood,BAO_0000218,4015,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",Autocuration,,55,,12832,178.0,9615.0,Canis lupus familiaris,,CHEMBL620040,,,In vivo,,F,1,8,
Blood,BAO_0000218,4016,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",Autocuration,,55,,12832,178.0,9615.0,Canis lupus familiaris,,CHEMBL620041,,,In vivo,,F,1,8,
Blood,BAO_0000218,4017,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",Autocuration,,55,,12832,178.0,9615.0,Canis lupus familiaris,,CHEMBL620042,,,In vivo,,F,1,8,
Blood,BAO_0000218,4018,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,55,,12832,178.0,9615.0,Canis lupus familiaris,,CHEMBL620043,,,In vivo,,F,1,8,
Blood,BAO_0000218,4019,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",Autocuration,,55,,12832,178.0,9615.0,Canis lupus familiaris,,CHEMBL620044,,,In vivo,,F,1,8,
Blood,BAO_0000218,4020,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",Autocuration,,55,,12832,178.0,9615.0,Canis lupus familiaris,,CHEMBL620045,,,In vivo,,F,1,8,
Blood,BAO_0000218,4021,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",Autocuration,,55,,12832,178.0,9615.0,Canis lupus familiaris,,CHEMBL620046,,,In vivo,,F,1,8,
Blood,BAO_0000218,4022,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,55,,12832,178.0,9615.0,Canis lupus familiaris,,CHEMBL620047,,,In vivo,,F,1,8,
Blood,BAO_0000218,4023,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",Autocuration,,55,,12832,178.0,9615.0,Canis lupus familiaris,,CHEMBL620048,,,In vivo,,F,1,8,
Blood,BAO_0000218,4024,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",Autocuration,,55,,12832,178.0,9615.0,Canis lupus familiaris,,CHEMBL857703,,,In vivo,,F,1,8,
Blood,BAO_0000218,4025,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",Autocuration,,55,,12832,178.0,9615.0,Canis lupus familiaris,,CHEMBL620049,,,In vivo,,F,1,8,
Blood,BAO_0000218,4026,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,55,,12832,178.0,9615.0,Canis lupus familiaris,,CHEMBL620050,,,In vivo,,F,1,8,
Blood,BAO_0000218,4027,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,55,,12832,178.0,9615.0,Canis lupus familiaris,,CHEMBL620051,,,In vivo,,F,1,8,
Blood,BAO_0000218,4028,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,55,,12832,178.0,9615.0,Canis lupus familiaris,,CHEMBL619213,,,In vivo,,F,1,8,
Blood,BAO_0000218,4029,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,55,,12832,178.0,9615.0,Canis lupus familiaris,,CHEMBL619214,,,In vivo,,F,1,8,
Blood,BAO_0000218,4030,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,55,,12832,178.0,9615.0,Canis lupus familiaris,,CHEMBL619804,,,In vivo,,F,1,8,
Blood,BAO_0000218,4031,H,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",Autocuration,,55,,12832,178.0,9615.0,Canis lupus familiaris,,CHEMBL619805,,,In vivo,,F,1,8,
Blood,BAO_0000218,4032,H,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,55,,12832,178.0,9615.0,Canis lupus familiaris,,CHEMBL619806,,,In vivo,,F,1,8,
Blood,BAO_0000218,4033,H,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,55,,12832,178.0,9615.0,Canis lupus familiaris,,CHEMBL619807,,,In vivo,,F,1,8,
Blood,BAO_0000218,4034,H,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,55,,12832,178.0,9615.0,Canis lupus familiaris,,CHEMBL619808,,,In vivo,,F,1,8,
,BAO_0000218,4035,H,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,Autocuration,,55,,3595,,9615.0,Canis lupus familiaris,,CHEMBL619809,,,,,B,1,8,
,BAO_0000218,4036,H,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,Autocuration,,55,,3595,,9615.0,Canis lupus familiaris,,CHEMBL619810,,,,,B,1,8,
,BAO_0000218,4037,H,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,Autocuration,,55,,3595,,9615.0,Canis lupus familiaris,,CHEMBL619811,,,,,B,1,8,
,BAO_0000218,4038,H,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,Autocuration,,55,,3595,,9615.0,Canis lupus familiaris,,CHEMBL620769,,,,,B,1,8,
,BAO_0000218,4039,H,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,Autocuration,,55,,3595,,9615.0,Canis lupus familiaris,,CHEMBL620770,,,,,B,1,8,
,BAO_0000218,4040,H,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,Autocuration,,55,,3595,,9615.0,Canis lupus familiaris,,CHEMBL620771,,,,,B,1,8,
,BAO_0000218,4041,H,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,Autocuration,,55,,3595,,9615.0,Canis lupus familiaris,,CHEMBL620772,,,,,B,1,8,
,BAO_0000218,4042,H,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,Autocuration,,55,,3595,,9615.0,Canis lupus familiaris,,CHEMBL620773,,,,,B,1,8,
,BAO_0000357,4043,H,Ability to inhibit 5-lipoxygenase in guinea pig,Autocuration,,55,,9203,,10141.0,Cavia porcellus,,CHEMBL620774,,,,,B,1,8,
,BAO_0000357,4044,H,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),Expert,,55,,82,,10141.0,Cavia porcellus,,CHEMBL620775,,,,,B,1,8,
,BAO_0000357,4045,H,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,Autocuration,,55,,11090,,10141.0,Cavia porcellus,,CHEMBL620776,,,,,B,1,8,
Blood,BAO_0000218,4046,H,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",Autocuration,,55,,12832,178.0,10141.0,Cavia porcellus,,CHEMBL620777,,,,,B,1,8,
,BAO_0000357,4047,H,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,Autocuration,,55,,1065,,10141.0,Cavia porcellus,,CHEMBL620778,,,,,B,1,8,
,BAO_0000357,4048,H,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,Autocuration,,55,,1065,,10141.0,Cavia porcellus,,CHEMBL620779,,,,,B,1,8,
,BAO_0000019,4049,H,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,Expert,,55,,12832,,10141.0,Cavia porcellus,,CHEMBL621500,,,,,B,1,8,
,BAO_0000019,4050,H,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,Expert,,55,,12832,,10141.0,Cavia porcellus,,CHEMBL621501,,,,,B,1,8,
,BAO_0000019,4051,H,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,Autocuration,,55,,12832,,10141.0,Cavia porcellus,,CHEMBL618098,,,,,B,1,8,
,BAO_0000019,4052,H,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,Autocuration,,55,,10504,,10141.0,Cavia porcellus,,CHEMBL618099,,,,,B,1,8,
,BAO_0000357,4053,H,Inhibitory activity against 5-lipoxygenase,Autocuration,,55,,7788,,10141.0,Cavia porcellus,,CHEMBL618100,,,,,B,1,8,
,BAO_0000357,4054,H,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,Autocuration,,55,,10001,,10141.0,Cavia porcellus,,CHEMBL618101,,,,,B,1,8,
,BAO_0000357,4055,H,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,Autocuration,,55,,10193,,10141.0,Cavia porcellus,,CHEMBL618102,,,,,B,1,8,
,BAO_0000357,4056,H,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,Autocuration,,55,,13243,,10141.0,Cavia porcellus,,CHEMBL618103,,,,,B,1,8,
,BAO_0000357,4057,H,Inhibitory activity uM,Autocuration,,55,,13243,,10141.0,Cavia porcellus,,CHEMBL618104,,,,,B,1,8,
,BAO_0000219,4058,H,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,Autocuration,,55,,969,,10141.0,Cavia porcellus,,CHEMBL883712,,,,,B,1,8,
,BAO_0000357,4059,H,Inhibitory activity against 5-lipoxygenase at 10 uM,Autocuration,,55,,10001,,10141.0,Cavia porcellus,,CHEMBL618105,,,,,B,1,8,
,BAO_0000357,4060,H,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,Autocuration,,55,,7788,,10141.0,Cavia porcellus,,CHEMBL618106,,,,,B,1,8,
,BAO_0000357,4061,H,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,Autocuration,,55,,10001,,10141.0,Cavia porcellus,,CHEMBL618107,,,,,B,1,8,
,BAO_0000357,4062,H,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,Autocuration,,55,,10193,,10141.0,Cavia porcellus,,CHEMBL618108,,,,,B,1,8,
,BAO_0000357,4063,H,Inhibitory activity uM,Autocuration,,55,,13243,,10141.0,Cavia porcellus,,CHEMBL618109,,,,,B,1,8,
,BAO_0000357,4064,H,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,Autocuration,,55,,13243,,10141.0,Cavia porcellus,,CHEMBL618110,,,,,B,1,8,
,BAO_0000357,4065,H,Inhibitory activity uM,Expert,,55,,13243,,10141.0,Cavia porcellus,,CHEMBL618111,,,,,B,1,8,
,BAO_0000019,4066,H,Inhibitory activity uM,Autocuration,,55,,13243,,10141.0,Cavia porcellus,,CHEMBL618112,,,,,F,1,8,
,BAO_0000019,4067,H,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,Autocuration,,55,,10504,,10141.0,Cavia porcellus,,CHEMBL618113,,,,,B,1,8,
,BAO_0000357,4068,H,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,Autocuration,,55,,7788,,10141.0,Cavia porcellus,,CHEMBL618114,,,,,B,1,8,
Ileum,BAO_0000221,4069,H,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,Expert,,55,,10546,2116.0,10141.0,Cavia porcellus,,CHEMBL620871,,,,,F,1,8,
,BAO_0000357,4070,H,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),Autocuration,,55,,13183,,,,,CHEMBL620872,,,,,B,1,8,
,BAO_0000357,4071,H,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),Autocuration,,55,,13183,,,,,CHEMBL620873,,,,,B,1,8,
,BAO_0000357,4072,H,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),Autocuration,,55,,2578,,,,,CHEMBL620874,,,,,B,1,8,
,BAO_0000357,4073,H,In vitro inhibition of human 5-Lipoxygenase.,Expert,,55,,12780,,,,,CHEMBL620875,,,,,B,1,8,
Liver,BAO_0000251,4074,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL620876,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4075,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL620877,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4076,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL857854,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4077,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL620878,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4078,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL620879,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4079,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL620880,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4080,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL620881,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4081,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL620882,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4082,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL620883,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4083,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL620884,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4084,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL620885,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4085,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL620886,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4086,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL620887,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4087,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL618039,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4088,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL618040,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4089,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL618041,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4090,U,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL618216,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4091,U,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL618217,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4092,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL618218,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4093,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL618219,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4094,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL618220,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4095,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL618221,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4096,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL618222,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4097,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL618223,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4098,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL618224,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4099,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL618225,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4100,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL618226,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4101,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL618227,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4102,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL618228,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4103,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL618229,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4104,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL618230,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4105,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL618231,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4106,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL618232,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4107,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL618233,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4108,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL618234,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4109,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL618235,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4110,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL618115,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4111,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL618116,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4112,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL618117,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4113,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL619968,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4114,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL619969,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4115,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL619970,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4116,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL619971,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4117,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL619972,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4118,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL619973,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4119,U,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL619974,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4120,U,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL619975,,,,Microsomes,B,1,0,
,BAO_0000251,4121,U,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,Autocuration,,22226,,7411,,10116.0,Rattus norvegicus,,CHEMBL619976,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4122,U,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL619977,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4123,U,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL619978,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4124,U,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL619979,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4125,U,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL619980,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4126,U,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL619981,,,,Microsomes,B,1,0,
,BAO_0000219,4127,N,In vitro inhibition of 7226/S myeloma cancer cell line,Intermediate,741.0,80433,,10797,,9606.0,Homo sapiens,,CHEMBL619982,RPMI-8226,,,,F,1,1,
,BAO_0000219,4128,N,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),Intermediate,993.0,80698,,6881,,9606.0,Homo sapiens,,CHEMBL619983,BEL-7404 tumor cell line,,,,F,1,1,
,BAO_0000219,4129,N,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,Intermediate,391.0,80640,,3838,,9606.0,Homo sapiens,,CHEMBL620031,786-0,,,,F,1,1,
,BAO_0000219,4130,N,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,Intermediate,391.0,80640,,3838,,9606.0,Homo sapiens,,CHEMBL620032,786-0,,,,F,1,1,
,BAO_0000219,4131,N,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,Expert,505.0,81264,,12981,,10029.0,Cricetulus griseus,,CHEMBL620033,V79,,,,F,1,1,
,BAO_0000219,4132,N,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,Expert,505.0,81264,,12981,,10029.0,Cricetulus griseus,,CHEMBL620034,V79,,,,F,1,1,
,BAO_0000219,4133,N,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,Intermediate,1119.0,80635,,7653,,10116.0,Rattus norvegicus,,CHEMBL620035,7800C1 cell line,,,,F,1,1,
,BAO_0000219,4134,N,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,Intermediate,1119.0,80635,,7653,,10116.0,Rattus norvegicus,,CHEMBL618318,7800C1 cell line,,,,F,1,1,
,BAO_0000219,4135,N,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,Intermediate,1119.0,80635,,7653,,10116.0,Rattus norvegicus,,CHEMBL618319,7800C1 cell line,,,,F,1,1,
,BAO_0000219,4136,N,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,Intermediate,1119.0,80635,,7653,,10116.0,Rattus norvegicus,,CHEMBL618320,7800C1 cell line,,,,F,1,1,
,BAO_0000219,4137,N,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,Intermediate,1119.0,80635,,7653,,10116.0,Rattus norvegicus,,CHEMBL618321,7800C1 cell line,,,,F,1,1,
,BAO_0000219,4138,N,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,Intermediate,1119.0,80635,,7653,,10116.0,Rattus norvegicus,,CHEMBL883118,7800C1 cell line,,,,F,1,1,
,BAO_0000219,4139,N,In vitro antitumor activity against renal 786-0 tumor cell lines,Intermediate,391.0,80640,,17229,,9606.0,Homo sapiens,,CHEMBL883795,786-0,,,,F,1,1,
,BAO_0000219,4140,N,Cytotoxic activity against 786-0 Renal cancer cell line,Intermediate,391.0,80640,,12858,,9606.0,Homo sapiens,,CHEMBL618322,786-0,,,,F,1,1,
,BAO_0000219,4141,N,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,Intermediate,391.0,80640,,16325,,9606.0,Homo sapiens,,CHEMBL618323,786-0,,,,F,1,1,
,BAO_0000219,4142,N,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,Intermediate,391.0,80640,,16325,,9606.0,Homo sapiens,,CHEMBL618324,786-0,,,,F,1,1,
,BAO_0000219,4143,N,In vitro antitumor activity against human renal 786-0 cell line,Intermediate,391.0,80640,,5858,,9606.0,Homo sapiens,,CHEMBL618325,786-0,,,,F,1,1,
,BAO_0000219,4144,N,Inhibition of Renal cancer in 786-0 cancer cell lines,Intermediate,391.0,80640,,16325,,9606.0,Homo sapiens,,CHEMBL875416,786-0,,,,F,1,1,
,BAO_0000219,4145,N,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,Intermediate,391.0,80640,,14696,,9606.0,Homo sapiens,,CHEMBL618326,786-0,,,,F,1,1,
,BAO_0000219,4146,N,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,Intermediate,391.0,80640,,3786,,9606.0,Homo sapiens,,CHEMBL618327,786-0,,,,F,1,1,
,BAO_0000219,4147,N,inhibition of the growth of renal cancer(786-0) cell line,Intermediate,391.0,80640,,14696,,9606.0,Homo sapiens,,CHEMBL619215,786-0,,,,F,1,1,
,BAO_0000219,4148,N,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),Intermediate,391.0,80640,,14769,,9606.0,Homo sapiens,,CHEMBL619216,786-0,,,,F,1,1,
,BAO_0000219,4149,N,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,Intermediate,391.0,80640,,15354,,9606.0,Homo sapiens,,CHEMBL619217,786-0,,,,F,1,1,
,BAO_0000219,4150,N,The IC50 value was measured on 786-0 cell line in ovarian tumor,Intermediate,391.0,80640,,14255,,9606.0,Homo sapiens,,CHEMBL619218,786-0,,,,F,1,1,
,BAO_0000219,4151,N,The IC50 value was measured on 786-0 cell line in ovarian tumor t,Intermediate,391.0,80640,,14255,,9606.0,Homo sapiens,,CHEMBL619219,786-0,,,,F,1,1,
,BAO_0000219,4152,N,The IC50 value was measured on 786-0 cell line in renal tumor type.,Intermediate,391.0,80640,,14255,,9606.0,Homo sapiens,,CHEMBL619220,786-0,,,,F,1,1,
,BAO_0000219,4153,N,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,Intermediate,391.0,80640,,14696,,9606.0,Homo sapiens,,CHEMBL619221,786-0,,,,F,1,1,
,BAO_0000219,4154,N,Tested for cytotoxic activity against renal cancer 786-0 cell line,Intermediate,391.0,80640,,12016,,9606.0,Homo sapiens,,CHEMBL619222,786-0,,,,F,1,1,
,BAO_0000219,4155,N,Compound was tested for growth inhibitory activity against 786-0 cell line,Intermediate,391.0,80640,,2597,,9606.0,Homo sapiens,,CHEMBL857454,786-0,,,,F,1,1,
,BAO_0000219,4156,H,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,Autocuration,702.0,12166,,12526,,,,,CHEMBL619223,RBL-1,,,,B,1,8,
,BAO_0000219,4157,H,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,Autocuration,702.0,12166,,12526,,,,,CHEMBL619224,RBL-1,,,,B,1,8,
,BAO_0000019,4158,H,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,Autocuration,,12166,,14799,,,,,CHEMBL619225,,,,,B,1,8,
,BAO_0000219,4159,H,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),Expert,702.0,12166,,3595,,,,,CHEMBL619226,RBL-1,,,,B,1,8,
,BAO_0000219,4160,H,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),Expert,702.0,12166,,3595,,,,,CHEMBL619227,RBL-1,,,,B,1,8,
,BAO_0000357,4161,H,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,Autocuration,,12166,,12767,,,,,CHEMBL619228,,,,,B,1,8,
,BAO_0000219,4162,H,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,Autocuration,,12166,,10997,,,,,CHEMBL619229,,,,,B,1,8,
,BAO_0000219,4163,H,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,Autocuration,702.0,12166,,11388,,,,,CHEMBL619230,RBL-1,,,,B,1,8,
,BAO_0000357,4164,H,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,Autocuration,,12166,,167,,,,,CHEMBL619231,,,,,B,1,8,
,BAO_0000357,4165,H,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",Autocuration,,12166,,167,,,,,CHEMBL619232,,,,,B,1,8,
,BAO_0000357,4166,H,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,Expert,,12166,,13744,,,,,CHEMBL619233,,,,,B,1,8,
,BAO_0000357,4167,H,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,Autocuration,,12166,,1630,,,,,CHEMBL619234,,,,,B,1,8,
,BAO_0000357,4168,H,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),Autocuration,,12166,,1630,,,,,CHEMBL619235,,,,,B,1,8,
,BAO_0000019,4169,D,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",Expert,,12166,,969,,10116.0,Rattus norvegicus,,CHEMBL619236,,,,,B,1,9,
,BAO_0000219,4170,H,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,Autocuration,702.0,12166,,13621,,,,,CHEMBL619237,RBL-1,,,,B,1,8,
,BAO_0000357,4171,H,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,Autocuration,,12166,,10089,,,,,CHEMBL619238,,,,,B,1,8,
,BAO_0000357,4172,H,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,Expert,,12166,,10193,,,,,CHEMBL619239,,,,,B,1,8,
,BAO_0000357,4173,H,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,Autocuration,,12166,,11966,,,,,CHEMBL619240,,,,,B,1,8,
,BAO_0000019,4174,H,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,Autocuration,,12166,,12251,,,,,CHEMBL875417,,,,,B,1,8,
,BAO_0000219,4175,H,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),Autocuration,702.0,12166,,211,,,,,CHEMBL619241,RBL-1,,,,B,1,8,
,BAO_0000019,4176,H,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,Expert,,12166,,12251,,,,,CHEMBL619242,,,,,F,1,8,
,BAO_0000219,4177,H,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,Autocuration,702.0,12166,,12495,,,,,CHEMBL883796,RBL-1,,,,B,1,8,
,BAO_0000357,4178,H,Tested for its inhibitory activity against 5-lipoxygenase,Autocuration,,12166,,414,,,,,CHEMBL619243,,,,,B,1,8,
,BAO_0000357,4179,H,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,Autocuration,,12166,,414,,,,,CHEMBL619244,,,,,B,1,8,
,BAO_0000019,4180,H,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",Expert,,12166,,10325,,,,,CHEMBL619245,,,,,B,1,8,
,BAO_0000019,4181,H,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,Expert,,12166,,11966,,,,,CHEMBL619246,,,,,B,1,8,
,BAO_0000219,4182,H,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,Expert,702.0,12166,,165,,,,,CHEMBL619984,RBL-1,,,,B,1,8,
,BAO_0000219,4183,H,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,Autocuration,702.0,12166,,165,,,,,CHEMBL619985,RBL-1,,,,B,1,8,
,BAO_0000219,4184,H,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,Autocuration,702.0,12166,,165,,,,,CHEMBL619986,RBL-1,,,,B,1,8,
,BAO_0000219,4185,H,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,Expert,702.0,12166,,165,,,,,CHEMBL619987,RBL-1,,,,B,1,8,
,BAO_0000218,4186,H,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,Autocuration,,12166,,11311,,,,,CHEMBL619988,,,,,B,1,8,
,BAO_0000219,4187,H,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,Autocuration,702.0,12166,,11311,,,,,CHEMBL619989,RBL-1,,,,B,1,8,
,BAO_0000219,4188,H,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,Autocuration,702.0,12166,,11311,,,,,CHEMBL619990,RBL-1,,,,B,1,8,
,BAO_0000219,4189,H,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],Autocuration,,12166,,11311,,,,,CHEMBL619991,,,,,B,1,8,
,BAO_0000219,4190,H,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),Autocuration,,12166,,11311,,,,,CHEMBL619992,,,,,B,1,8,
,BAO_0000218,4191,H,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),Autocuration,,12166,,11311,,,,,CHEMBL619993,,,In vivo,,B,1,8,
,BAO_0000219,4192,H,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,Autocuration,663.0,12166,,11311,,,,,CHEMBL619994,RBL-2H3,,,,F,1,8,
,BAO_0000219,4193,H,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,Autocuration,663.0,12166,,11311,,,,,CHEMBL619995,RBL-2H3,,,,F,1,8,
,BAO_0000019,4194,H,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],Autocuration,,12166,,11311,,,,,CHEMBL619996,,,,,B,1,8,
,BAO_0000019,4195,H,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,Autocuration,,12166,,11732,,,,,CHEMBL619997,,,,,B,1,8,
,BAO_0000019,4196,H,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,Expert,,12166,,11732,,,,,CHEMBL619998,,,,,B,1,8,
,BAO_0000019,4197,H,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,Expert,,12166,,11087,,,,,CHEMBL619999,,,,,B,1,8,
,BAO_0000019,4198,H,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,Autocuration,,12166,,11087,,,,,CHEMBL620000,,,,,B,1,8,
,BAO_0000219,4199,H,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,Autocuration,702.0,12166,,11087,,,,,CHEMBL620001,RBL-1,,,,B,1,8,
,BAO_0000357,4200,D,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,Expert,,12166,,11087,,10116.0,Rattus norvegicus,,CHEMBL620002,,,,,B,1,9,
,BAO_0000219,4201,H,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,Autocuration,702.0,12166,,496,,,,,CHEMBL620003,RBL-1,,,,B,1,8,
,BAO_0000219,4202,H,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,Expert,702.0,12166,,13986,,,,,CHEMBL620004,RBL-1,,,,F,1,8,
,BAO_0000357,4203,H,Compound was evaluated for the inhibition of 5-lipoxygenase,Autocuration,,12166,,11520,,,,,CHEMBL874063,,,,,B,1,8,
,BAO_0000219,4204,H,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,Autocuration,702.0,12166,,10293,,,,,CHEMBL620005,RBL-1,,,,B,1,8,
,BAO_0000219,4205,H,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,Autocuration,702.0,12166,,303,,,,,CHEMBL620006,RBL-1,,,,B,1,8,
,BAO_0000219,4206,H,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,Autocuration,702.0,12166,,303,,,,,CHEMBL620007,RBL-1,,,,B,1,8,
,BAO_0000219,4207,H,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,Autocuration,702.0,12166,,9247,,,,,CHEMBL620008,RBL-1,,,,B,1,8,
,BAO_0000219,4208,D,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,Expert,702.0,12166,,9247,,10116.0,Rattus norvegicus,,CHEMBL620009,RBL-1,,,,B,1,9,
,BAO_0000219,4209,H,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,Autocuration,702.0,12166,,9247,,,,,CHEMBL620010,RBL-1,,,,B,1,8,
,BAO_0000219,4210,H,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,Autocuration,702.0,12166,,9247,,,,,CHEMBL620011,RBL-1,,,,B,1,8,
,BAO_0000219,4211,H,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,Autocuration,702.0,12166,,9247,,,,,CHEMBL620677,RBL-1,,,,B,1,8,
,BAO_0000219,4212,H,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,Autocuration,702.0,12166,,9247,,,,,CHEMBL620678,RBL-1,,,,B,1,8,
,BAO_0000219,4213,H,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,Autocuration,702.0,12166,,9247,,,,,CHEMBL620679,RBL-1,,,,B,1,8,
,BAO_0000219,4214,H,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,Autocuration,702.0,12166,,9247,,,,,CHEMBL620680,RBL-1,,,,B,1,8,
,BAO_0000357,4215,D,Inhibitory activity against 5-lipoxygenase at 10 uM,Expert,,12166,,11481,,10116.0,Rattus norvegicus,,CHEMBL620838,,,,,B,1,9,
,BAO_0000357,4216,H,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,Autocuration,,12166,,105,,,,,CHEMBL620839,,,,,B,1,8,
,BAO_0000357,4217,H,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,Expert,,12166,,9029,,,,,CHEMBL620840,,,,,B,1,8,
,BAO_0000219,4218,H,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,Expert,702.0,12166,,1175,,,,,CHEMBL620841,RBL-1,,,,B,1,8,
,BAO_0000219,4219,H,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,Autocuration,702.0,12166,,12118,,,,,CHEMBL620842,RBL-1,,,,B,1,8,
,BAO_0000219,4220,H,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,Autocuration,702.0,12166,,12118,,,,,CHEMBL620843,RBL-1,,,,B,1,8,
,BAO_0000219,4221,H,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,Autocuration,702.0,12166,,12118,,,,,CHEMBL620844,RBL-1,,,,B,1,8,
,BAO_0000219,4222,H,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,Autocuration,702.0,12166,,9225,,,,,CHEMBL620845,RBL-1,,,,B,1,8,
,BAO_0000019,4223,H,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,Autocuration,,12166,,9401,,,,,CHEMBL620846,,,,,B,1,8,
,BAO_0000357,4224,H,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,Autocuration,,12166,,137,,,,,CHEMBL873951,,,,,B,1,8,
,BAO_0000357,4225,H,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,Autocuration,,12166,,137,,,,,CHEMBL620847,,,,,B,1,8,
,BAO_0000219,4226,H,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,Autocuration,702.0,12166,,4717,,,,,CHEMBL620848,RBL-1,,,,B,1,8,
,BAO_0000219,4227,H,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,Autocuration,702.0,12166,,3595,,,,,CHEMBL620849,RBL-1,,,,B,1,8,
,BAO_0000219,4228,H,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,Autocuration,702.0,12166,,10501,,,,,CHEMBL620850,RBL-1,,,,B,1,8,
,BAO_0000219,4229,H,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,Autocuration,702.0,12166,,10501,,,,,CHEMBL620851,RBL-1,,,,B,1,8,
,BAO_0000219,4230,H,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,Autocuration,702.0,12166,,10501,,,,,CHEMBL620852,RBL-1,,,,B,1,8,
,BAO_0000219,4231,H,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,Autocuration,702.0,12166,,12526,,,,,CHEMBL875098,RBL-1,,,,B,1,8,
,BAO_0000219,4232,D,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,Expert,702.0,12166,,14799,,10116.0,Rattus norvegicus,,CHEMBL620853,RBL-1,,,,B,1,9,
,BAO_0000019,4233,H,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,Autocuration,,12166,,14799,,,,,CHEMBL620854,,,,,B,1,8,
,BAO_0000219,4234,H,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,Autocuration,702.0,12166,,3595,,,,,CHEMBL620855,RBL-1,,,,B,1,8,
,BAO_0000219,4235,H,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,Expert,702.0,12166,,3595,,,,,CHEMBL839884,RBL-1,,,,B,1,8,
,BAO_0000219,4236,H,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,Autocuration,702.0,12166,,12526,,,,,CHEMBL620856,RBL-1,,,,B,1,8,
,BAO_0000219,4237,H,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,Autocuration,702.0,12166,,12526,,,,,CHEMBL620857,RBL-1,,,,B,1,8,
,BAO_0000019,4238,H,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,Autocuration,,12166,,10193,,,,,CHEMBL620858,,,,,B,1,8,
,BAO_0000019,4239,H,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,Autocuration,,12166,,10193,,,,,CHEMBL620859,,,,,B,1,8,
,BAO_0000019,4240,H,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,Autocuration,,12166,,10193,,,,,CHEMBL620860,,,,,B,1,8,
,BAO_0000019,4241,H,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,Autocuration,,12166,,10193,,,,,CHEMBL620861,,,,,B,1,8,
,BAO_0000357,4242,H,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),Expert,,12166,,9138,,,,,CHEMBL620862,,,,,B,1,8,
,BAO_0000357,4243,H,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,Autocuration,,12166,,9138,,,,,CHEMBL620863,,,,,B,1,8,
,BAO_0000019,4244,H,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,Autocuration,,12166,,11966,,,,,CHEMBL620864,,,,,B,1,8,
,BAO_0000219,4245,H,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,Autocuration,702.0,12166,,165,,,,,CHEMBL620865,RBL-1,,,,B,1,8,
,BAO_0000219,4246,H,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,Autocuration,702.0,12166,,165,,,,,CHEMBL620866,RBL-1,,,,B,1,8,
,BAO_0000219,4247,H,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,Autocuration,663.0,12166,,11311,,,,,CHEMBL620867,RBL-2H3,,,,B,1,8,
,BAO_0000219,4248,H,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,Autocuration,663.0,12166,,11311,,,,,CHEMBL620868,RBL-2H3,,,,B,1,8,
,BAO_0000219,4249,H,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,Autocuration,663.0,12166,,11311,,,,,CHEMBL620869,RBL-2H3,,,,F,1,8,
,BAO_0000019,4250,H,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,Autocuration,,12166,,11311,,,,,CHEMBL873952,,,,,F,1,8,
,BAO_0000357,4251,H,The compound was tested for inhibition of isolated 5-lipoxygenase,Autocuration,,12166,,11311,,,,,CHEMBL875099,,,,,B,1,8,
,BAO_0000219,4252,H,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,Autocuration,663.0,12166,,11311,,,,,CHEMBL620870,RBL-2H3,,,,F,1,8,
,BAO_0000019,4253,H,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,Autocuration,,12166,,11087,,,,,CHEMBL618261,,,,,B,1,8,
,BAO_0000019,4254,H,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,Autocuration,,12166,,11087,,,,,CHEMBL618262,,,,,B,1,8,
,BAO_0000019,4255,H,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,Autocuration,,12166,,11087,,,,,CHEMBL619428,,,,,B,1,8,
,BAO_0000019,4256,H,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,Autocuration,,12166,,11087,,,,,CHEMBL619429,,,,,B,1,8,
,BAO_0000019,4257,H,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,Autocuration,,12166,,11087,,,,,CHEMBL619430,,,,,B,1,8,
,BAO_0000219,4258,H,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,Autocuration,702.0,12166,,496,,,,,CHEMBL620017,RBL-1,,,,B,1,8,
,BAO_0000219,4259,H,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,Autocuration,702.0,12166,,496,,,,,CHEMBL620018,RBL-1,,,,B,1,8,
,BAO_0000219,4260,H,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,Autocuration,702.0,12166,,13986,,,,,CHEMBL620019,RBL-1,,,,F,1,8,
,BAO_0000219,4261,H,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,Autocuration,702.0,12166,,13986,,,,,CHEMBL620020,RBL-1,,,,F,1,8,
,BAO_0000219,4262,H,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,Autocuration,702.0,12166,,13986,,,,,CHEMBL620021,RBL-1,,,,F,1,8,
,BAO_0000219,4263,H,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,Autocuration,702.0,12166,,13986,,,,,CHEMBL620022,RBL-1,,,,F,1,8,
,BAO_0000219,4264,H,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,Autocuration,702.0,12166,,13986,,,,,CHEMBL620023,RBL-1,,,,F,1,8,
,BAO_0000219,4265,H,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,Autocuration,702.0,12166,,13986,,,,,CHEMBL620024,RBL-1,,,,F,1,8,
,BAO_0000219,4266,H,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,Autocuration,702.0,12166,,13986,,,,,CHEMBL620025,RBL-1,,,,F,1,8,
,BAO_0000219,4267,H,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,Autocuration,702.0,12166,,13986,,,,,CHEMBL620026,RBL-1,,,,F,1,8,
,BAO_0000219,4268,H,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,Autocuration,702.0,12166,,13986,,,,,CHEMBL620027,RBL-1,,,,F,1,8,
,BAO_0000019,4269,D,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,Expert,,12166,,13986,,10116.0,Rattus norvegicus,,CHEMBL620028,,,,,F,1,9,
,BAO_0000357,4270,H,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,Autocuration,,12166,,10193,,,,,CHEMBL620029,,,,,B,1,8,
,BAO_0000357,4271,H,Compound was tested for the percent of inhibition against 5-LO at 10 uM,Autocuration,,12166,,9295,,,,,CHEMBL620030,,,,,B,1,8,
,BAO_0000219,4272,H,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,Autocuration,702.0,12166,,4717,,,,,CHEMBL875415,RBL-1,,,,B,1,8,
,BAO_0000219,4273,H,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,Autocuration,702.0,12166,,4717,,,,,CHEMBL618256,RBL-1,,,,B,1,8,
,BAO_0000219,4274,H,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,Autocuration,702.0,12166,,11854,,,,,CHEMBL618257,RBL-1,,,,B,1,8,
,BAO_0000219,4275,H,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,Autocuration,702.0,12166,,11854,,,,,CHEMBL618258,RBL-1,,,,B,1,8,
,BAO_0000219,4276,H,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,Autocuration,702.0,12166,,11854,,,,,CHEMBL618259,RBL-1,,,,B,1,8,
,BAO_0000019,4277,H,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,Autocuration,,12166,,10193,,,,,CHEMBL618260,,,,,B,1,8,
,BAO_0000219,4278,H,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,Autocuration,702.0,12166,,9295,,,,,CHEMBL618215,RBL-1,,,,B,1,8,
,BAO_0000219,4279,H,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,Autocuration,702.0,12166,,9295,,,,,CHEMBL618390,RBL-1,,,,B,1,8,
,BAO_0000219,4280,H,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,Autocuration,702.0,12166,,9295,,,,,CHEMBL618391,RBL-1,,,,B,1,8,
,BAO_0000219,4281,H,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,Autocuration,702.0,12166,,9295,,,,,CHEMBL618392,RBL-1,,,,B,1,8,
,BAO_0000219,4282,H,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,Autocuration,702.0,12166,,165,,,,,CHEMBL618393,RBL-1,,,,B,1,8,
,BAO_0000219,4283,H,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,Autocuration,,12166,,11311,,,,,CHEMBL618394,,,,,B,1,8,
,BAO_0000219,4284,H,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),Expert,702.0,12166,,10489,,9606.0,Homo sapiens,,CHEMBL618395,RBL-1,,,,B,1,8,
,BAO_0000219,4285,D,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),Expert,702.0,12166,,10489,,10116.0,Rattus norvegicus,,CHEMBL618396,RBL-1,,,,B,1,9,
,BAO_0000219,4286,D,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),Expert,702.0,12166,,10489,,10116.0,Rattus norvegicus,,CHEMBL858253,RBL-1,,,,B,1,9,
,BAO_0000019,4287,D,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,Autocuration,,12166,,14799,,10116.0,Rattus norvegicus,,CHEMBL618397,,,,,B,1,9,
,BAO_0000357,4288,H,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),Autocuration,,12054,,9295,,3847.0,Glycine max,,CHEMBL618398,,,,,B,1,8,
,BAO_0000019,4289,U,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",Autocuration,,22226,,16811,,,,,CHEMBL618399,,,,,B,1,0,
,BAO_0000357,4290,H,In vitro inhibition of 5-Lipoxygenase; Inactive.,Expert,,55,,168,,,,,CHEMBL618400,,,,,B,1,8,
,BAO_0000357,4291,H,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,Autocuration,,55,,6309,,,,,CHEMBL618401,,,,,B,1,8,
,BAO_0000357,4292,H,Inhibitory concentration against 5-lipoxygenase; No inhibition,Autocuration,,55,,6309,,,,,CHEMBL618402,,,,,B,1,8,
,BAO_0000219,4293,H,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,Autocuration,702.0,55,,3092,,,,,CHEMBL876400,RBL-1,,,,B,1,8,
,BAO_0000357,4294,H,Inhibitory activity against 5-lipoxygenase.,Expert,,55,,168,,,,,CHEMBL618403,,,,,B,1,8,
,BAO_0000357,4295,H,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,Autocuration,,55,,168,,,,,CHEMBL618404,,,,,B,1,8,
,BAO_0000357,4296,H,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,Autocuration,,55,,168,,,,,CHEMBL618405,,,,,B,1,8,
,BAO_0000357,4297,H,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,Autocuration,,55,,168,,,,,CHEMBL618406,,,,,B,1,8,
,BAO_0000019,4298,H,Inhibitory concentration against arachidonic acid 5-lipoxygenation,Expert,,55,,12338,,,,,CHEMBL618407,,,,,F,1,8,
,BAO_0000357,4299,H,Tested for the inhibitory activity against 5-lipoxygenase,Autocuration,,55,,4501,,,,,CHEMBL618408,,,,,B,1,8,
,BAO_0000357,4300,H,Compound was tested for its inhibitory activity against 5-lipoxygenase,Autocuration,,55,,1132,,,,,CHEMBL618409,,,,,B,1,8,
,BAO_0000357,4301,H,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,Autocuration,,55,,2117,,,,,CHEMBL618410,,,,,B,1,8,
,BAO_0000357,4302,H,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,Autocuration,,55,,168,,,,,CHEMBL618411,,,,,B,1,8,
,BAO_0000357,4303,H,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,Autocuration,,55,,168,,,,,CHEMBL618412,,,,,B,1,8,
,BAO_0000219,4304,H,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,Autocuration,702.0,12166,,13575,,,,,CHEMBL618413,RBL-1,,,,B,1,8,
,BAO_0000357,4305,H,,Autocuration,,12166,,11089,,,,,CHEMBL618414,,,,,B,1,8,
,BAO_0000357,4306,H,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),Autocuration,,10102,,216,,,,,CHEMBL618415,,,,,B,1,8,
,BAO_0000019,4307,H,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,Autocuration,,10102,,13165,,,,,CHEMBL618416,,,,,B,1,8,
,BAO_0000357,4308,H,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,Autocuration,,10102,,3278,,,,,CHEMBL876401,,,,,B,1,8,
,BAO_0000357,4309,H,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,Expert,,10102,,3278,,,,,CHEMBL618417,,,,,B,1,8,
,BAO_0000357,4310,H,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,Autocuration,,10102,,11966,,,,,CHEMBL618418,,,,,B,1,8,
,BAO_0000357,4311,H,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",Autocuration,,10102,,175,,,,,CHEMBL618419,,,,,B,1,8,
,BAO_0000357,4312,H,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",Autocuration,,10102,,175,,,,,CHEMBL618420,,,,,B,1,8,
,BAO_0000357,4313,H,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,Autocuration,,10102,,13449,,,,,CHEMBL618421,,,,,B,1,8,
,BAO_0000019,4314,H,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,Autocuration,,11238,,12014,,,,,CHEMBL618422,,,,,B,1,8,
,BAO_0000019,4315,H,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),Autocuration,,11238,,12014,,,,,CHEMBL618423,,,,,B,1,8,
,BAO_0000019,4316,H,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),Autocuration,,11238,,12014,,,,,CHEMBL618424,,,,,B,1,8,
,BAO_0000220,4317,S,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,Intermediate,,100284,,99,,,,,CHEMBL618425,,,,,B,1,2,
,BAO_0000019,4318,U,The dark toxicity against 543 human galactophore carcinoma cells,Autocuration,,22226,,4349,,9606.0,Homo sapiens,,CHEMBL618426,,,,,F,1,0,
,BAO_0000219,4319,N,Tested in vitro for cytotoxicity against 56 human tumor cell lines,Expert,390.0,80623,,4071,,9606.0,Homo sapiens,,CHEMBL618427,Panel (56 tumour cell lines),,,,F,1,1,
,BAO_0000219,4320,N,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,Expert,345.0,80008,,17589,,9606.0,Homo sapiens,,CHEMBL618428,5637,,,,F,1,1,
,BAO_0000219,4321,N,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,Intermediate,345.0,80008,,15002,,9606.0,Homo sapiens,,CHEMBL618429,5637,,,,F,1,1,
,BAO_0000219,4322,N,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",Intermediate,345.0,80008,,13958,,9606.0,Homo sapiens,,CHEMBL618430,5637,,,,F,1,1,
,BAO_0000219,4323,N,Growth inhibition against human 5637 cell lines,Expert,345.0,80008,,17589,,9606.0,Homo sapiens,,CHEMBL618431,5637,,,,F,1,1,
,BAO_0000219,4324,N,Antitumor activity against human bladder carcinoma 5637 cells.,Expert,345.0,80008,,16748,,9606.0,Homo sapiens,,CHEMBL883799,5637,,,,F,1,1,
,BAO_0000219,4325,N,Antitumor activity against human bladder carcinoma 5637 cells,Intermediate,345.0,80008,,16747,,9606.0,Homo sapiens,,CHEMBL618432,5637,,,,F,1,1,
,BAO_0000219,4326,N,Antitumor activity against human bladder carcinoma 5637 cells,Intermediate,345.0,80008,,16747,,9606.0,Homo sapiens,,CHEMBL618433,5637,,,,F,1,1,
,BAO_0000357,4327,D,In vitro inhibition of bovine trypsin(Trp).,Expert,,10443,,15285,,9913.0,Bos taurus,,CHEMBL618434,,,,,B,1,9,
,BAO_0000219,4328,H,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,Expert,407.0,240,,3726,,9527.0,Cercopithecidae,,CHEMBL618435,CV-1,,,,B,1,8,
,BAO_0000357,4329,H,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,Autocuration,,10577,,5033,,,,,CHEMBL876402,,,,,B,1,8,
,BAO_0000019,4330,H,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,Autocuration,,104698,,11756,,,,,CHEMBL618436,,,,,F,1,6,
,BAO_0000218,4331,U,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,Autocuration,,22226,,11953,,,,,CHEMBL618437,,,In vivo,,F,1,0,
,BAO_0000357,4332,D,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,Intermediate,,20033,,5033,,10141.0,Cavia porcellus,,CHEMBL618438,,,,,B,1,9,
,BAO_0000251,4333,H,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,Expert,,17045,,11347,,10116.0,Rattus norvegicus,,CHEMBL883800,,,,Microsomes,A,1,8,
,BAO_0000251,4334,H,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,Expert,,17045,,11347,,10116.0,Rattus norvegicus,,CHEMBL618439,,,,Microsomes,A,1,8,
,BAO_0000019,4335,U,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,Intermediate,,22226,,1229,,,,,CHEMBL618440,,,,,F,1,0,
,BAO_0000019,4336,U,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,Intermediate,,22226,,1229,,,,,CHEMBL618441,,,,,F,1,0,
,BAO_0000019,4337,H,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,Expert,,11938,,17588,,5691.0,Trypanosoma brucei,,CHEMBL618442,,,,,B,1,8,
,BAO_0000019,4338,H,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,Autocuration,,11938,,17588,,5691.0,Trypanosoma brucei,,CHEMBL618443,,,,,B,1,8,
,BAO_0000019,4339,H,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,Expert,,11938,,17588,,9940.0,Ovis aries,,CHEMBL619158,,,,,B,1,8,
,BAO_0000019,4340,H,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,Autocuration,,11938,,17588,,9940.0,Ovis aries,,CHEMBL620974,,,,,B,1,8,
,BAO_0000357,4341,H,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,Autocuration,,11938,,16485,,,,,CHEMBL620975,,,,,B,1,8,
,BAO_0000019,4342,U,Average inhibitory concentration against 60 human cell lines was reported,Intermediate,,22226,,4337,,9606.0,Homo sapiens,,CHEMBL620976,,,,,F,1,0,
,BAO_0000019,4343,U,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,Expert,,22226,,4112,,9606.0,Homo sapiens,,CHEMBL620977,,,,,F,1,0,
,BAO_0000219,4344,N,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,Intermediate,542.0,80315,,16160,,9606.0,Homo sapiens,,CHEMBL620978,Panel NCI-60 (60 carcinoma cell lines),,,,F,1,1,
,BAO_0000219,4345,N,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,Intermediate,542.0,80315,,16160,,9606.0,Homo sapiens,,CHEMBL620979,Panel NCI-60 (60 carcinoma cell lines),,,,F,1,1,
,BAO_0000219,4346,N,In vitro mean growth inhibitory activity against 60-cell panel,Expert,542.0,80315,,17376,,,,,CHEMBL620980,Panel NCI-60 (60 carcinoma cell lines),,,,F,1,1,
,BAO_0000219,4347,N,In vitro mean growth lethal concentration against 60-cell panel,Expert,542.0,80315,,17376,,,,,CHEMBL620981,Panel NCI-60 (60 carcinoma cell lines),,,,F,1,1,
,BAO_0000219,4348,N,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,Expert,542.0,80315,,17376,,,,,CHEMBL620982,Panel NCI-60 (60 carcinoma cell lines),,,,F,1,1,
,BAO_0000219,4349,N,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,Expert,542.0,80315,,17376,,,,,CHEMBL620983,Panel NCI-60 (60 carcinoma cell lines),,,,F,1,1,
,BAO_0000019,4350,H,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,Autocuration,,104775,,3241,,,,,CHEMBL620984,,,,,F,1,4,
,BAO_0000019,4351,H,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,Autocuration,,104775,,3241,,,,,CHEMBL620985,,,,,F,1,4,
,BAO_0000357,4352,H,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,Expert,,275,,3725,,,,,CHEMBL620986,,,,,B,1,8,
,BAO_0000218,4353,N,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,Expert,,50425,,10805,,5833.0,Plasmodium falciparum,,CHEMBL620987,,,,,F,1,1,
,BAO_0000218,4354,N,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,Expert,,50425,,10805,,5833.0,Plasmodium falciparum,,CHEMBL620988,,,,,F,1,1,
,BAO_0000218,4355,N,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,Expert,,50425,,10805,,5833.0,Plasmodium falciparum,,CHEMBL620989,,,,,F,1,1,
,BAO_0000218,4356,N,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,Expert,,50425,,10805,,5833.0,Plasmodium falciparum,,CHEMBL620990,,,,,F,1,1,
,BAO_0000218,4357,N,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,Intermediate,,50425,,10805,,5833.0,Plasmodium falciparum,,CHEMBL620991,,,,,F,1,1,
,BAO_0000218,4358,N,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,Intermediate,850.0,80628,,10144,,10090.0,Mus musculus,,CHEMBL620992,6C3HED,,,,F,1,1,
,BAO_0000218,4359,N,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,Intermediate,850.0,80628,,10144,,10090.0,Mus musculus,,CHEMBL620993,6C3HED,,,,F,1,1,
,BAO_0000218,4360,N,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,Intermediate,850.0,80628,,10144,,10090.0,Mus musculus,,CHEMBL620994,6C3HED,,,,F,1,1,
,BAO_0000218,4361,N,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,Intermediate,850.0,80628,,10144,,10090.0,Mus musculus,,CHEMBL620995,6C3HED,,,,F,1,1,
,BAO_0000218,4362,N,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,Intermediate,850.0,80628,,10144,,10090.0,Mus musculus,,CHEMBL620996,6C3HED,,,,F,1,1,
,BAO_0000218,4363,N,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,Intermediate,850.0,80628,,10144,,10090.0,Mus musculus,,CHEMBL875581,6C3HED,,,,F,1,1,
,BAO_0000218,4364,U,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,Autocuration,,22224,,10685,,10090.0,Mus musculus,,CHEMBL620997,,,In vivo,,F,1,0,
,BAO_0000218,4365,U,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,Autocuration,,22224,,10685,,10090.0,Mus musculus,,CHEMBL620998,,,In vivo,,F,1,0,
,BAO_0000218,4366,U,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),Autocuration,,22224,,10685,,10090.0,Mus musculus,,CHEMBL620999,,,In vivo,,F,1,0,
,BAO_0000218,4367,U,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,Autocuration,,22224,,10685,,10090.0,Mus musculus,,CHEMBL621000,,,In vivo,,F,1,0,
,BAO_0000218,4368,U,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,Autocuration,,22224,,10685,,10090.0,Mus musculus,,CHEMBL621001,,,In vivo,,F,1,0,
,BAO_0000218,4369,U,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,Autocuration,,22224,,10685,,10090.0,Mus musculus,,CHEMBL621002,,,In vivo,,F,1,0,
,BAO_0000218,4370,U,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,Autocuration,,22224,,10685,,10090.0,Mus musculus,,CHEMBL621003,,,In vivo,,F,1,0,
,BAO_0000218,4371,U,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",Autocuration,,22224,,10685,,10090.0,Mus musculus,,CHEMBL621004,,,In vivo,,F,1,0,
,BAO_0000218,4372,U,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),Autocuration,,22224,,10685,,10090.0,Mus musculus,,CHEMBL621005,,,In vivo,,F,1,0,
,BAO_0000218,4373,U,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),Autocuration,,22224,,10685,,10090.0,Mus musculus,,CHEMBL621006,,,In vivo,,F,1,0,
,BAO_0000218,4374,U,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,Autocuration,,22224,,10685,,10090.0,Mus musculus,,CHEMBL621007,,,In vivo,,F,1,0,
,BAO_0000218,4375,U,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,Autocuration,,22224,,10144,,10090.0,Mus musculus,,CHEMBL621008,,,,,F,1,0,
,BAO_0000218,4376,U,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,Autocuration,,22224,,10144,,10090.0,Mus musculus,,CHEMBL621009,,,,,F,1,0,
,BAO_0000218,4377,U,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,Autocuration,,22224,,10144,,10090.0,Mus musculus,,CHEMBL857705,,,,,F,1,0,
,BAO_0000218,4378,U,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,Autocuration,,22224,,10144,,10090.0,Mus musculus,,CHEMBL619828,,,,,F,1,0,
,BAO_0000218,4379,U,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,Autocuration,,22224,,10685,,10090.0,Mus musculus,,CHEMBL619829,,,,,F,1,0,
,BAO_0000218,4380,U,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,Autocuration,,22224,,10685,,10090.0,Mus musculus,,CHEMBL619830,,,,,F,1,0,
,BAO_0000218,4381,U,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,Autocuration,,22224,,10685,,10090.0,Mus musculus,,CHEMBL619831,,,,,F,1,0,
,BAO_0000218,4382,U,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,Autocuration,,22224,,10685,,10090.0,Mus musculus,,CHEMBL619832,,,,,F,1,0,
,BAO_0000218,4383,U,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,Autocuration,,22224,,10685,,10090.0,Mus musculus,,CHEMBL619833,,,,,A,1,0,
,BAO_0000218,4384,U,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,Autocuration,,22224,,10685,,10090.0,Mus musculus,,CHEMBL619834,,,,,A,1,0,
,BAO_0000218,4385,U,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,Autocuration,,22224,,10685,,10090.0,Mus musculus,,CHEMBL619835,,,,,A,1,0,
,BAO_0000218,4386,U,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,Autocuration,,22224,,10685,,10090.0,Mus musculus,,CHEMBL619836,,,,,A,1,0,
,BAO_0000218,4387,N,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",Intermediate,850.0,80628,,8831,,10090.0,Mus musculus,,CHEMBL619837,6C3HED,,,,F,1,1,
,BAO_0000218,4388,U,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,Autocuration,,22224,,11704,,,,,CHEMBL619838,,,In vivo,,F,1,0,
,BAO_0000218,4389,N,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,Intermediate,,50594,,11704,,10090.0,Mus musculus,,CHEMBL619839,,,,,A,1,1,
,BAO_0000218,4390,N,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,Intermediate,850.0,80628,,10685,,10090.0,Mus musculus,,CHEMBL619840,6C3HED,,In vivo,,F,1,1,
,BAO_0000218,4391,N,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,Intermediate,850.0,80628,,10685,,10090.0,Mus musculus,,CHEMBL619841,6C3HED,,In vivo,,F,1,1,
,BAO_0000218,4392,N,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),Expert,850.0,80628,,11368,,10090.0,Mus musculus,,CHEMBL857704,6C3HED,,,,F,1,1,
,BAO_0000218,4393,N,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),Intermediate,850.0,80628,,11368,,10090.0,Mus musculus,,CHEMBL619842,6C3HED,,,,F,1,1,
,BAO_0000218,4394,N,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),Expert,850.0,80628,,11368,,10090.0,Mus musculus,,CHEMBL619843,6C3HED,,,,F,1,1,
,BAO_0000019,4395,U,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",Autocuration,,22226,,17763,,1280.0,Staphylococcus aureus,,CHEMBL619844,,,,,B,1,0,
Liver,BAO_0000251,4396,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL857855,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4397,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL619845,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4398,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL619846,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4399,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL619847,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4400,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL619848,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4401,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL620893,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4402,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL620894,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4403,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL620895,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4404,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL620896,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4405,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL620897,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4406,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL620898,,,,Microsomes,B,1,0,
Liver,BAO_0000251,4407,U,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,Autocuration,,22226,,7411,2107.0,10116.0,Rattus norvegicus,,CHEMBL620899,,,,Microsomes,B,1,0,
Plasma,BAO_0000218,4408,U,The apparent total plasma clearance in monkey,Autocuration,,22224,,347,1969.0,9527.0,Cercopithecidae,,CHEMBL620900,,,In vivo,,A,1,0,
,BAO_0000218,4409,U,Compound was evaluated for Hepatic clearance in monkey,Autocuration,,22224,,3341,,9527.0,Cercopithecidae,,CHEMBL620901,,,In vivo,,A,1,0,
,BAO_0000218,4410,U,Lower clearance in monkey (i.v.) at 0.5 mpk,Autocuration,,22224,,17853,,9527.0,Cercopithecidae,,CHEMBL620902,,,In vivo,,A,1,0,
,BAO_0000218,4411,U,Plasma clearance in rhesus monkey,Autocuration,,22224,,4514,,9527.0,Cercopithecidae,,CHEMBL620903,,,In vivo,,A,1,0,
,BAO_0000218,4412,U,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,Autocuration,,22224,,6062,,9527.0,Cercopithecidae,,CHEMBL620904,,,In vivo,,A,1,0,
,BAO_0000218,4413,U,Plasma clearance of compound was determined in monkey,Autocuration,,22224,,6821,,9527.0,Cercopithecidae,,CHEMBL620905,,,In vivo,,A,1,0,
,BAO_0000218,4414,U,Plasma clearance was calculated in rhesus monkey,Autocuration,,22224,,6057,,9527.0,Cercopithecidae,,CHEMBL620906,,,In vivo,,A,1,0,
,BAO_0000218,4415,U,Plasma clearance in rhesus monkey,Autocuration,,22224,,5145,,9527.0,Cercopithecidae,,CHEMBL875420,,,In vivo,,A,1,0,
,BAO_0000218,4416,U,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),Autocuration,,22224,,6641,,9527.0,Cercopithecidae,,CHEMBL620907,,,In vivo,,A,1,0,
,BAO_0000218,4417,U,Plasma clearance was evaluated in rhesus,Autocuration,,22224,,5472,,9527.0,Cercopithecidae,,CHEMBL620908,,,In vivo,,A,1,0,
,BAO_0000218,4418,U,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,Autocuration,,22224,,4257,,9527.0,Cercopithecidae,,CHEMBL620909,,,In vivo,,A,1,0,
,BAO_0000218,4419,U,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,Autocuration,,22224,,5546,,9527.0,Cercopithecidae,,CHEMBL620910,,,In vivo,,A,1,0,
,BAO_0000218,4420,U,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),Autocuration,,22224,,5334,,9527.0,Cercopithecidae,,CHEMBL620911,,,In vivo,,A,1,0,
,BAO_0000218,4421,U,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),Autocuration,,22224,,5334,,9527.0,Cercopithecidae,,CHEMBL620912,,,In vivo,,A,1,0,
,BAO_0000218,4422,U,Cmax 24 hr after 2 mg/kg oral administration in monkeys,Autocuration,,22224,,17509,,9527.0,Cercopithecidae,,CHEMBL620913,,,In vivo,,A,1,0,
,BAO_0000218,4423,U,Cmax in monkey after administration of 1 mg/kg iv,Autocuration,,22224,,6535,,9527.0,Cercopithecidae,,CHEMBL620914,,,In vivo,,A,1,0,
,BAO_0000218,4424,U,Cmax was determine after peroral administration at 10 mpk in Rhesus,Autocuration,,22224,,5668,,9527.0,Cercopithecidae,,CHEMBL620915,,,In vivo,,A,1,0,
,BAO_0000218,4425,U,Cmax in cynomolgus monkey by iv administration,Autocuration,,22224,,5922,,9527.0,Cercopithecidae,,CHEMBL620916,,,In vivo,,A,1,0,
,BAO_0000218,4426,U,Cmax in cynomolgus monkey by po administration,Autocuration,,22224,,5922,,9527.0,Cercopithecidae,,CHEMBL620917,,,In vivo,,A,1,0,
,BAO_0000218,4427,U,Cmax value evaluated in monkey,Autocuration,,22224,,6078,,9527.0,Cercopithecidae,,CHEMBL620918,,,In vivo,,A,1,0,
,BAO_0000218,4428,U,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,Autocuration,,22224,,2661,,9527.0,Cercopithecidae,,CHEMBL620919,,,In vivo,,A,1,0,
Plasma,BAO_0000218,4429,U,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,Autocuration,,22224,,3249,1969.0,9527.0,Cercopithecidae,,CHEMBL620920,,,In vivo,,A,1,0,
Plasma,BAO_0000218,4430,U,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,Autocuration,,22224,,3249,1969.0,9527.0,Cercopithecidae,,CHEMBL620921,,,In vivo,,A,1,0,
Plasma,BAO_0000218,4431,U,Maximal plasma concentration in squirrel monkeys,Autocuration,,22224,,5553,1969.0,9527.0,Cercopithecidae,,CHEMBL620922,,,In vivo,,A,1,0,
,BAO_0000218,4432,U,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,Autocuration,,22224,,1916,,9527.0,Cercopithecidae,,CHEMBL620923,,,In vivo,,A,1,0,
Plasma,BAO_0000218,4433,U,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,Autocuration,,22224,,6227,1969.0,9527.0,Cercopithecidae,,CHEMBL620924,,,In vivo,,A,1,0,
,BAO_0000218,4434,U,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),Autocuration,,22224,,4809,,9527.0,Cercopithecidae,,CHEMBL620925,,,In vivo,,A,1,0,
,BAO_0000218,4435,U,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,Autocuration,,22224,,5355,,9527.0,Cercopithecidae,,CHEMBL620926,,,In vivo,,A,1,0,
,BAO_0000218,4436,U,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,Autocuration,,22224,,5355,,9527.0,Cercopithecidae,,CHEMBL620927,,,In vivo,,A,1,0,
,BAO_0000218,4437,U,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,Autocuration,,22224,,5355,,9527.0,Cercopithecidae,,CHEMBL620928,,,In vivo,,A,1,0,
,BAO_0000218,4438,U,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,Autocuration,,22224,,5355,,9527.0,Cercopithecidae,,CHEMBL620929,,,In vivo,,A,1,0,
Plasma,BAO_0000218,4439,U,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,Autocuration,,22224,,6221,1969.0,9527.0,Cercopithecidae,,CHEMBL620930,,,In vivo,,A,1,0,
,BAO_0000218,4440,U,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,Autocuration,,22224,,167,,9527.0,Cercopithecidae,,CHEMBL620931,,,,,A,1,0,
,BAO_0000218,4441,U,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,Autocuration,,22224,,167,,9527.0,Cercopithecidae,,CHEMBL620932,,,,,A,1,0,
,BAO_0000218,4442,U,Absolute bioavailability was evaluated in monkey,Autocuration,,22224,,4257,,9443.0,monkey,,CHEMBL620933,,,In vivo,,A,1,0,
,BAO_0000218,4443,U,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,Autocuration,,22224,,6221,,9443.0,monkey,,CHEMBL620934,,,In vivo,,A,1,0,
,BAO_0000218,4444,U,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,Autocuration,,22224,,17667,,9443.0,monkey,,CHEMBL620935,,,In vivo,,A,1,0,
,BAO_0000218,4445,U,Bioavailability of compound was determined in rhesus monkey,Autocuration,,22224,,17267,,9544.0,Macaca mulatta,,CHEMBL620936,,,In vivo,,A,1,0,
,BAO_0000218,4446,U,Bioavailability determined after oral administration in marmoset,Autocuration,,22224,,4256,,38020.0,marmosets,,CHEMBL620937,,,In vivo,,A,1,0,
,BAO_0000218,4447,U,Oral bioavailability in cynomolgus monkey,Autocuration,,22224,,4256,,9541.0,Macaca fascicularis,,CHEMBL620938,,,In vivo,,A,1,0,
,BAO_0000218,4448,U,Bioavailability in monkey (p.o.) at 2.0 mpk,Autocuration,,22224,,17853,,9443.0,monkey,,CHEMBL620939,,,In vivo,,A,1,0,
,BAO_0000218,4449,U,Bioavailability was evaluated after oral administration in monkey,Autocuration,,22224,,16365,,9443.0,monkey,,CHEMBL620940,,,In vivo,,A,1,0,
,BAO_0000218,4450,U,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,Autocuration,,22224,,1916,,9541.0,Macaca fascicularis,,CHEMBL620941,,,In vivo,,A,1,0,
,BAO_0000218,4451,U,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),Autocuration,,22224,,5334,,9544.0,Macaca mulatta,,CHEMBL620942,,,In vivo,,A,1,0,
,BAO_0000218,4452,U,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),Autocuration,,22224,,5334,,9544.0,Macaca mulatta,,CHEMBL620943,,,In vivo,,A,1,0,
,BAO_0000218,4453,U,Bioavailability of the compound was determined in monkey,Autocuration,,22224,,17592,,9443.0,monkey,,CHEMBL620944,,,In vivo,,A,1,0,
,BAO_0000218,4454,U,Bioavailability in squirrel monkey (dose 5 mg/kg),Autocuration,,22224,,1399,,9521.0,Saimiri sciureus,,CHEMBL620945,,,In vivo,,A,1,0,
,BAO_0000218,4455,U,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),Autocuration,,22224,,4809,,9443.0,monkey,,CHEMBL620946,,,In vivo,,A,1,0,
,BAO_0000218,4456,U,Oral bioavailability in monkey,Autocuration,,22224,,3341,,9443.0,monkey,,CHEMBL620947,,,In vivo,,A,1,0,
,BAO_0000218,4457,U,Compound was tested for bioavailability in squirrel monkey,Autocuration,,22224,,64,,9521.0,Saimiri sciureus,,CHEMBL620948,,,In vivo,,A,1,0,
,BAO_0000218,4458,U,Oral bioavailability in Rhesus monkey,Autocuration,,22224,,5005,,9544.0,Macaca mulatta,,CHEMBL620949,,,In vivo,,A,1,0,
,BAO_0000218,4459,U,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),Autocuration,,22224,,5005,,9544.0,Macaca mulatta,,CHEMBL620950,,,In vivo,,A,1,0,
,BAO_0000218,4460,U,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,Autocuration,,22224,,5237,,9541.0,Macaca fascicularis,,CHEMBL620951,,,In vivo,,A,1,0,
,BAO_0000218,4461,U,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,Autocuration,,22224,,5237,,9541.0,Macaca fascicularis,,CHEMBL620952,,,In vivo,,A,1,0,
,BAO_0000218,4462,U,Oral bioavailability in monkey (dose 5 mg/kg),Autocuration,,22224,,5302,,9443.0,monkey,,CHEMBL875421,,,In vivo,,A,1,0,
,BAO_0000218,4463,U,Oral bioavailability of compound at 5 mg/kg in monkey,Autocuration,,22224,,17667,,9443.0,monkey,,CHEMBL620953,,,In vivo,,A,1,0,
,BAO_0000218,4464,N,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,Intermediate,,50588,,6161,,9615.0,Canis lupus familiaris,,CHEMBL873491,,,In vivo,,A,1,1,
,BAO_0000218,4465,N,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,Intermediate,,50588,,6161,,9615.0,Canis lupus familiaris,,CHEMBL620954,,,In vivo,,A,1,1,
Plasma,BAO_0000218,4466,N,Plasma half life determined,Intermediate,,50588,,3854,1969.0,9615.0,Canis lupus familiaris,,CHEMBL620955,,,,,A,1,1,
Plasma,BAO_0000218,4467,N,Plasma half life in dog,Intermediate,,50588,,993,1969.0,9615.0,Canis lupus familiaris,,CHEMBL618097,,,,,A,1,1,
Plasma,BAO_0000218,4468,N,Plasma half-life in Beagle dogs,Intermediate,,50588,,4514,1969.0,9615.0,Canis lupus familiaris,,CHEMBL618268,,,,,A,1,1,
Plasma,BAO_0000218,4469,N,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),Intermediate,,50588,,5334,1969.0,9615.0,Canis lupus familiaris,,CHEMBL618269,,,In vivo,,A,1,1,
Plasma,BAO_0000218,4470,N,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),Intermediate,,50588,,5334,1969.0,9615.0,Canis lupus familiaris,,CHEMBL618270,,,In vivo,,A,1,1,
,BAO_0000218,4471,N,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,Intermediate,,50588,,1466,,9615.0,Canis lupus familiaris,,CHEMBL618271,,,In vivo,,A,1,1,
,BAO_0000218,4472,N,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,Intermediate,,50588,,1466,,9615.0,Canis lupus familiaris,,CHEMBL873493,,,In vivo,,A,1,1,
,BAO_0000218,4473,N,Tested for the half life period in dog,Intermediate,,50588,,5313,,9615.0,Canis lupus familiaris,,CHEMBL621031,,,,,A,1,1,
,BAO_0000218,4474,N,Tested for the half life period in dog at dosage of 10 mpk,Intermediate,,50588,,5313,,9615.0,Canis lupus familiaris,,CHEMBL621032,,,In vivo,,A,1,1,
,BAO_0000218,4475,N,The compound was tested for half life in dog,Intermediate,,50588,,3880,,9615.0,Canis lupus familiaris,,CHEMBL621033,,,,,A,1,1,
Plasma,BAO_0000218,4476,N,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",Intermediate,,50588,,3639,1969.0,9615.0,Canis lupus familiaris,,CHEMBL621034,,,,,A,1,1,
,BAO_0000218,4477,N,The half life was determined,Intermediate,,50588,,3880,,9615.0,Canis lupus familiaris,,CHEMBL621035,,,,,A,1,1,
Plasma,BAO_0000218,4478,N,The plasma half-life in dogs,Intermediate,,50588,,3918,1969.0,9615.0,Canis lupus familiaris,,CHEMBL621036,,,,,A,1,1,
Plasma,BAO_0000218,4479,N,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,Intermediate,,50588,,16452,1969.0,9615.0,Canis lupus familiaris,,CHEMBL621037,,,,,A,1,1,
,BAO_0000218,4480,N,Half life in dog,Intermediate,,50588,,17796,,9615.0,Canis lupus familiaris,,CHEMBL619812,,,,,A,1,1,
,BAO_0000218,4481,N,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,Intermediate,,50588,,5983,,9615.0,Canis lupus familiaris,,CHEMBL619813,,,In vivo,,A,1,1,
,BAO_0000218,4482,N,tmax upon peroral administration of 10.0 mg/Kg dose in dog,Intermediate,,50588,,1466,,9615.0,Canis lupus familiaris,,CHEMBL873335,,,In vivo,,A,1,1,
,BAO_0000218,4483,N,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,Intermediate,,50588,,16456,,9615.0,Canis lupus familiaris,,CHEMBL619814,,,In vivo,,A,1,1,
,BAO_0000218,4484,N,Cmax in ferrets after 30 mg/kg oral dose,Expert,,50506,,6113,,9669.0,Mustela putorius furo,,CHEMBL619815,,,In vivo,,A,1,1,
,BAO_0000218,4485,N,Emesis in ferrets at 30 mg/kg oral dose,Expert,,50506,,6113,,9669.0,Mustela putorius furo,,CHEMBL619816,,,In vivo,,F,1,1,
,BAO_0000218,4486,U,Bioavailability in cynomolgus monkey,Autocuration,,22224,,17796,,9541.0,Macaca fascicularis,,CHEMBL619817,,,In vivo,,A,1,0,
,BAO_0000218,4487,N,Volume of distribution in cynomolgus,Intermediate,,100710,,17796,,9541.0,Macaca fascicularis,,CHEMBL619818,,,In vivo,,A,1,1,
Plasma,BAO_0000218,4488,U,AUC tested in guinea pig when 3 mg/kg dose was given perorally,Autocuration,,22224,,5308,1969.0,10141.0,Cavia porcellus,,CHEMBL619819,,,,,A,1,0,
,BAO_0000218,4489,U,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,Autocuration,,22224,,4877,,10141.0,Cavia porcellus,,CHEMBL619820,,,,,A,1,0,
,BAO_0000218,4490,U,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",Autocuration,,22224,,4876,,10141.0,Cavia porcellus,,CHEMBL875419,,,,,A,1,0,
Plasma,BAO_0000218,4491,U,AUC in guinea pig after 3mg/kg oral dose,Autocuration,,22224,,4878,1969.0,10141.0,Cavia porcellus,,CHEMBL619821,,,In vivo,,A,1,0,
,BAO_0000218,4492,U,Bioavailability in guinea pig was tested,Autocuration,,22224,,5308,,10141.0,Cavia porcellus,,CHEMBL619822,,,In vivo,,A,1,0,
,BAO_0000218,4493,U,Tested for oral bioavailability in guinea pig at 5 mg/kg,Autocuration,,22224,,4877,,10141.0,Cavia porcellus,,CHEMBL619823,,,In vivo,,A,1,0,
,BAO_0000218,4494,U,Tested for the oral bioavailability of the compound,Autocuration,,22224,,4876,,10141.0,Cavia porcellus,,CHEMBL619824,,,In vivo,,A,1,0,
,BAO_0000218,4495,U,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,Autocuration,,22224,,4876,,10141.0,Cavia porcellus,,CHEMBL619825,,,In vivo,,A,1,0,
,BAO_0000218,4496,U,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,Autocuration,,22224,,5308,,10141.0,Cavia porcellus,,CHEMBL619826,,,In vivo,,A,1,0,
Lung,BAO_0000218,4497,U,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,Autocuration,,22224,,4877,2048.0,10141.0,Cavia porcellus,,CHEMBL619827,,,In vivo,,A,1,0,
,BAO_0000218,4498,U,Cmax in guinea pig after 3mg/kg oral dose,Autocuration,,22224,,4878,,10141.0,Cavia porcellus,,CHEMBL618167,,,In vivo,,A,1,0,
Blood,BAO_0000019,4499,U,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,Autocuration,,22224,,5689,178.0,10141.0,Cavia porcellus,,CHEMBL618168,,,,,A,1,0,
Brain,BAO_0000019,4500,U,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,Autocuration,,22224,,5689,955.0,10141.0,Cavia porcellus,,CHEMBL618169,,,,,A,1,0,
,BAO_0000019,4501,U,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,Autocuration,,22224,,5689,,10141.0,Cavia porcellus,,CHEMBL618170,,,,,A,1,0,
Intestine,BAO_0000019,4502,U,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,Autocuration,,22224,,5689,160.0,10141.0,Cavia porcellus,,CHEMBL618171,,,,,A,1,0,
Kidney,BAO_0000019,4503,U,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,Autocuration,,22224,,5689,2113.0,10141.0,Cavia porcellus,,CHEMBL618172,,,,,A,1,0,
Liver,BAO_0000019,4504,U,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,Autocuration,,22224,,5689,2107.0,10141.0,Cavia porcellus,,CHEMBL618173,,,,,A,1,0,
,BAO_0000019,4505,U,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,Autocuration,,22224,,5689,,10141.0,Cavia porcellus,,CHEMBL618174,,,,,A,1,0,
Spleen,BAO_0000019,4506,U,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,Autocuration,,22224,,5689,2106.0,10141.0,Cavia porcellus,,CHEMBL875408,,,,,A,1,0,
,BAO_0000218,4507,U,Elimination T1/2 in Guinea pig (PO dose),Autocuration,,22224,,14465,,10141.0,Cavia porcellus,,CHEMBL839827,,,In vivo,,A,1,0,
,BAO_0000019,4508,U,Partition coefficient was measured as -log (counts per min ),Autocuration,,22224,,5689,,10141.0,Cavia porcellus,,CHEMBL618175,,,,,A,1,0,
,BAO_0000218,4509,U,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,Autocuration,,22224,,611,,10141.0,Cavia porcellus,,CHEMBL618176,,,In vivo,,A,1,0,
,BAO_0000218,4510,U,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,Autocuration,,22224,,611,,10141.0,Cavia porcellus,,CHEMBL618177,,,In vivo,,A,1,0,
,BAO_0000218,4511,U,Elimination T1/2 in Guinea pig (PO dose),Autocuration,,22224,,14465,,10141.0,Cavia porcellus,,CHEMBL618178,,,In vivo,,A,1,0,
,BAO_0000218,4512,U,"Tested for the half life period of the compound, intravenously",Autocuration,,22224,,4876,,10141.0,Cavia porcellus,,CHEMBL618179,,,In vivo,,A,1,0,
,BAO_0000019,4513,U,Half-life was measured,Autocuration,,22224,,5689,,10141.0,Cavia porcellus,,CHEMBL873489,,,,,A,1,0,
,BAO_0000019,4514,U,The time required for onset of inotropy after addition of a single dose of delta F75,Autocuration,,22224,,7515,,10141.0,Cavia porcellus,,CHEMBL618180,,,,,A,1,0,
,BAO_0000218,4515,U,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,Autocuration,,22224,,17667,,10141.0,Cavia porcellus,,CHEMBL618181,,,In vivo,,A,1,0,
,BAO_0000218,4516,U,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,Autocuration,,22224,,17667,,10141.0,Cavia porcellus,,CHEMBL618182,,,In vivo,,A,1,0,
,BAO_0000218,4517,U,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,Autocuration,,22224,,4727,,10029.0,Cricetulus griseus,,CHEMBL618183,,,In vivo,,A,1,0,
,BAO_0000218,4518,N,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,50594,,10107,,10090.0,Mus musculus,,CHEMBL618184,,,In vivo,,A,1,1,
,BAO_0000218,4519,N,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Intermediate,,50594,,10107,,10090.0,Mus musculus,,CHEMBL618185,,,In vivo,,A,1,1,
,BAO_0000218,4520,N,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,50594,,10107,,10090.0,Mus musculus,,CHEMBL618186,,,In vivo,,A,1,1,
,BAO_0000218,4521,N,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,50594,,10107,,10090.0,Mus musculus,,CHEMBL618187,,,In vivo,,A,1,1,
,BAO_0000218,4522,N,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,Intermediate,,50594,,10107,,10090.0,Mus musculus,,CHEMBL618188,,,In vivo,,A,1,1,
,BAO_0000218,4523,N,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,50594,,10107,,10090.0,Mus musculus,,CHEMBL875409,,,In vivo,,A,1,1,
,BAO_0000218,4524,N,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,50594,,10107,,10090.0,Mus musculus,,CHEMBL618189,,,In vivo,,A,1,1,
Blood,BAO_0000218,4525,N,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,Intermediate,,50594,,3655,178.0,10090.0,Mus musculus,,CHEMBL618190,,,In vivo,,A,1,1,
Blood,BAO_0000218,4526,N,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,Intermediate,,50594,,3655,178.0,10090.0,Mus musculus,,CHEMBL618191,,,In vivo,,A,1,1,
Blood,BAO_0000218,4527,N,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,Intermediate,,50594,,3655,178.0,10090.0,Mus musculus,,CHEMBL618192,,,In vivo,,A,1,1,
Bone,BAO_0000218,4528,N,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,Intermediate,,50594,,3655,10000001.0,10090.0,Mus musculus,,CHEMBL618193,,,In vivo,,A,1,1,
Bone,BAO_0000218,4529,N,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,Intermediate,,50594,,3655,10000001.0,10090.0,Mus musculus,,CHEMBL618194,,,In vivo,,A,1,1,
Bone,BAO_0000218,4530,N,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,Intermediate,,50594,,3655,10000001.0,10090.0,Mus musculus,,CHEMBL618195,,,In vivo,,A,1,1,
Brain,BAO_0000218,4531,N,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,Intermediate,,50594,,3655,955.0,10090.0,Mus musculus,,CHEMBL618196,,,In vivo,,A,1,1,
Brain,BAO_0000218,4532,N,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,Intermediate,,50594,,3655,955.0,10090.0,Mus musculus,,CHEMBL618197,,,In vivo,,A,1,1,
Brain,BAO_0000218,4533,N,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,Intermediate,,50594,,3655,955.0,10090.0,Mus musculus,,CHEMBL618198,,,In vivo,,A,1,1,
Heart,BAO_0000218,4534,N,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,Intermediate,,50594,,3655,948.0,10090.0,Mus musculus,,CHEMBL618199,,,In vivo,,A,1,1,
Heart,BAO_0000218,4535,N,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,Intermediate,,50594,,3655,948.0,10090.0,Mus musculus,,CHEMBL618200,,,In vivo,,A,1,1,
Heart,BAO_0000218,4536,N,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,Intermediate,,50594,,3655,948.0,10090.0,Mus musculus,,CHEMBL618201,,,In vivo,,A,1,1,
Intestine,BAO_0000218,4537,N,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,Intermediate,,50594,,3655,160.0,10090.0,Mus musculus,,CHEMBL618202,,,In vivo,,A,1,1,
Intestine,BAO_0000218,4538,N,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,Intermediate,,50594,,3655,160.0,10090.0,Mus musculus,,CHEMBL618203,,,In vivo,,A,1,1,
Intestine,BAO_0000218,4539,N,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,Intermediate,,50594,,3655,160.0,10090.0,Mus musculus,,CHEMBL618204,,,In vivo,,A,1,1,
Kidney,BAO_0000218,4540,N,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,Intermediate,,50594,,3655,2113.0,10090.0,Mus musculus,,CHEMBL618205,,,In vivo,,A,1,1,
Kidney,BAO_0000218,4541,N,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,Intermediate,,50594,,3655,2113.0,10090.0,Mus musculus,,CHEMBL618206,,,In vivo,,A,1,1,
Kidney,BAO_0000218,4542,N,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,Intermediate,,50594,,3655,2113.0,10090.0,Mus musculus,,CHEMBL618207,,,In vivo,,A,1,1,
Liver,BAO_0000218,4543,N,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,Intermediate,,50594,,3655,2107.0,10090.0,Mus musculus,,CHEMBL618208,,,In vivo,,A,1,1,
Liver,BAO_0000218,4544,N,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,Intermediate,,50594,,3655,2107.0,10090.0,Mus musculus,,CHEMBL618932,,,In vivo,,A,1,1,
Liver,BAO_0000218,4545,N,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,Intermediate,,50594,,3655,2107.0,10090.0,Mus musculus,,CHEMBL618933,,,In vivo,,A,1,1,
Lung,BAO_0000218,4546,N,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,Intermediate,,50594,,3655,2048.0,10090.0,Mus musculus,,CHEMBL618934,,,In vivo,,A,1,1,
Lung,BAO_0000218,4547,N,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,Intermediate,,50594,,3655,2048.0,10090.0,Mus musculus,,CHEMBL618935,,,In vivo,,A,1,1,
Lung,BAO_0000218,4548,N,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,Intermediate,,50594,,3655,2048.0,10090.0,Mus musculus,,CHEMBL618936,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,4549,N,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,Intermediate,,50594,,3655,2385.0,10090.0,Mus musculus,,CHEMBL618937,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,4550,N,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,Intermediate,,50594,,3655,2385.0,10090.0,Mus musculus,,CHEMBL618938,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,4551,N,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,Intermediate,,50594,,3655,2385.0,10090.0,Mus musculus,,CHEMBL619104,,,In vivo,,A,1,1,
Spleen,BAO_0000218,4552,N,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,Intermediate,,50594,,3655,2106.0,10090.0,Mus musculus,,CHEMBL619105,,,In vivo,,A,1,1,
Spleen,BAO_0000218,4553,N,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,Intermediate,,50594,,3655,2106.0,10090.0,Mus musculus,,CHEMBL619106,,,In vivo,,A,1,1,
Spleen,BAO_0000218,4554,N,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,Intermediate,,50594,,3655,2106.0,10090.0,Mus musculus,,CHEMBL619107,,,In vivo,,A,1,1,
Stomach,BAO_0000218,4555,N,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,Intermediate,,50594,,3655,945.0,10090.0,Mus musculus,,CHEMBL875410,,,In vivo,,A,1,1,
Stomach,BAO_0000218,4556,N,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,Intermediate,,50594,,3655,945.0,10090.0,Mus musculus,,CHEMBL619108,,,In vivo,,A,1,1,
Stomach,BAO_0000218,4557,N,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,Intermediate,,50594,,3655,945.0,10090.0,Mus musculus,,CHEMBL619109,,,In vivo,,A,1,1,
,BAO_0000218,4558,N,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,Intermediate,,50594,,16597,,10090.0,Mus musculus,,CHEMBL619110,,,In vivo,,A,1,1,
,BAO_0000218,4559,N,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,Intermediate,,50594,,16597,,10090.0,Mus musculus,,CHEMBL619111,,,In vivo,,F,1,1,
,BAO_0000218,4560,N,MRT value at a dose of 10 mg/kg intravenous administration in mice.,Intermediate,,50594,,16597,,10090.0,Mus musculus,,CHEMBL619112,,,In vivo,,A,1,1,
,BAO_0000218,4561,N,MRT value at a dose of 10 mg/kg peroral administration in mice.,Intermediate,,50594,,16597,,10090.0,Mus musculus,,CHEMBL619113,,,In vivo,,A,1,1,
,BAO_0000218,4562,N,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,Intermediate,,50594,,17764,,10090.0,Mus musculus,,CHEMBL619114,,,In vivo,,A,1,1,
,BAO_0000218,4563,N,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,Intermediate,,50594,,17764,,10090.0,Mus musculus,,CHEMBL619115,,,In vivo,,F,1,1,
,BAO_0000219,4564,N,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,Intermediate,478.0,81034,,3830,,9606.0,Homo sapiens,,CHEMBL619116,A2780,,,,F,1,1,
,BAO_0000219,4565,N,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,Intermediate,478.0,81034,,3829,,9606.0,Homo sapiens,,CHEMBL619117,A2780,,,,F,1,1,
,BAO_0000219,4566,N,Compound was evaluated for cytotoxicity against A2780 cell lines.,Intermediate,478.0,81034,,2040,,9606.0,Homo sapiens,,CHEMBL619118,A2780,,,,F,1,1,
,BAO_0000219,4567,N,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,Intermediate,478.0,81034,,15684,,9606.0,Homo sapiens,,CHEMBL619119,A2780,,,,F,1,1,
,BAO_0000219,4568,N,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,Intermediate,478.0,81034,,15684,,9606.0,Homo sapiens,,CHEMBL619120,A2780,,,,F,1,1,
,BAO_0000219,4569,N,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,Intermediate,478.0,81034,,15684,,9606.0,Homo sapiens,,CHEMBL619121,A2780,,,,F,1,1,
,BAO_0000219,4570,N,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,Intermediate,478.0,81034,,15684,,9606.0,Homo sapiens,,CHEMBL619122,A2780,,,,F,1,1,
,BAO_0000219,4571,N,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,Intermediate,478.0,81034,,15684,,9606.0,Homo sapiens,,CHEMBL619123,A2780,,,,F,1,1,
,BAO_0000219,4572,N,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,Intermediate,478.0,81034,,15684,,9606.0,Homo sapiens,,CHEMBL619124,A2780,,,,F,1,1,
,BAO_0000219,4573,N,Compound was evaluated for cytotoxicity against A2780 cell line,Intermediate,478.0,81034,,2859,,9606.0,Homo sapiens,,CHEMBL619125,A2780,,,,F,1,1,
,BAO_0000219,4574,N,In vitro inhibitory activity against human tumor cell line A2780,Intermediate,478.0,81034,,5618,,9606.0,Homo sapiens,,CHEMBL875411,A2780,,,,F,1,1,
,BAO_0000219,4575,N,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,Intermediate,478.0,81034,,15684,,9606.0,Homo sapiens,,CHEMBL619126,A2780,,,,F,1,1,
,BAO_0000219,4576,N,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,Intermediate,478.0,81034,,15684,,9606.0,Homo sapiens,,CHEMBL619127,A2780,,,,F,1,1,
,BAO_0000219,4577,N,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,Intermediate,478.0,81034,,15684,,9606.0,Homo sapiens,,CHEMBL619128,A2780,,,,F,1,1,
,BAO_0000219,4578,N,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,Intermediate,478.0,81034,,15684,,9606.0,Homo sapiens,,CHEMBL619129,A2780,,,,F,1,1,
,BAO_0000219,4579,N,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,Intermediate,478.0,81034,,2113,,9606.0,Homo sapiens,,CHEMBL619130,A2780,,,,F,1,1,
,BAO_0000219,4580,N,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,Intermediate,478.0,81034,,2113,,9606.0,Homo sapiens,,CHEMBL619131,A2780,,,,F,1,1,
,BAO_0000219,4581,N,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,Intermediate,478.0,81034,,16745,,9606.0,Homo sapiens,,CHEMBL619132,A2780,,,,F,1,1,
,BAO_0000218,4582,N,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,Expert,478.0,81034,,16597,,9606.0,Homo sapiens,,CHEMBL619133,A2780,,,,F,1,1,
,BAO_0000219,4583,N,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,Intermediate,478.0,81034,,15684,,9606.0,Homo sapiens,,CHEMBL619134,A2780,,,,F,1,1,
,BAO_0000219,4584,N,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,Intermediate,478.0,81034,,15684,,9606.0,Homo sapiens,,CHEMBL619135,A2780,,,,F,1,1,
,BAO_0000219,4585,N,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,Intermediate,478.0,81034,,2040,,9606.0,Homo sapiens,,CHEMBL619136,A2780,,,,F,1,1,
,BAO_0000219,4586,N,Relative resistance factor in A2780 cisplatin-resistant line,Intermediate,478.0,81034,,2040,,9606.0,Homo sapiens,,CHEMBL619137,A2780,,,,F,1,1,
,BAO_0000219,4587,N,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,Intermediate,478.0,81034,,16165,,9606.0,Homo sapiens,,CHEMBL883713,A2780,,,,F,1,1,
,BAO_0000219,4588,N,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,Intermediate,478.0,81034,,16165,,9606.0,Homo sapiens,,CHEMBL875412,A2780,,,,F,1,1,
,BAO_0000218,4589,N,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,Expert,478.0,81034,,16597,,9606.0,Homo sapiens,,CHEMBL619138,A2780,,,,F,1,1,
,BAO_0000218,4590,N,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,Expert,478.0,81034,,16597,,9606.0,Homo sapiens,,CHEMBL619262,A2780,,,,F,1,1,
,BAO_0000219,4591,N,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,Intermediate,478.0,81034,,3992,,9606.0,Homo sapiens,,CHEMBL619139,A2780,,,,F,1,1,
,BAO_0000219,4592,N,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,Intermediate,478.0,81034,,10553,,9606.0,Homo sapiens,,CHEMBL619140,A2780,,,,F,1,1,
,BAO_0000219,4593,N,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,Intermediate,478.0,81034,,15608,,9606.0,Homo sapiens,,CHEMBL619141,A2780,,,,F,1,1,
,BAO_0000219,4594,N,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,Intermediate,478.0,81034,,15608,,9606.0,Homo sapiens,,CHEMBL619142,A2780,,,,F,1,1,
,BAO_0000219,4595,N,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,Intermediate,478.0,81034,,15608,,9606.0,Homo sapiens,,CHEMBL619143,A2780,,,,F,1,1,
,BAO_0000219,4596,N,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,Intermediate,478.0,81034,,15608,,9606.0,Homo sapiens,,CHEMBL619144,A2780,,,,F,1,1,
,BAO_0000219,4597,N,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,Intermediate,478.0,81034,,15608,,9606.0,Homo sapiens,,CHEMBL619145,A2780,,,,F,1,1,
,BAO_0000219,4598,N,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,Intermediate,478.0,81034,,15608,,9606.0,Homo sapiens,,CHEMBL619146,A2780,,,,F,1,1,
,BAO_0000219,4599,N,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,Intermediate,478.0,81034,,15569,,9606.0,Homo sapiens,,CHEMBL619147,A2780,,,,F,1,1,
,BAO_0000219,4600,N,Antiproliferative effect of compound on A2780/DX cell line,Intermediate,478.0,81034,,17420,,9606.0,Homo sapiens,,CHEMBL619148,A2780,,,,F,1,1,
,BAO_0000219,4601,N,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,Intermediate,478.0,81034,,17420,,9606.0,Homo sapiens,,CHEMBL619149,A2780,,,,F,1,1,
,BAO_0000219,4602,N,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),Intermediate,478.0,81034,,15099,,9606.0,Homo sapiens,,CHEMBL619150,A2780,,,,F,1,1,
,BAO_0000219,4603,N,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),Intermediate,478.0,81034,,15099,,9606.0,Homo sapiens,,CHEMBL619151,A2780,,,,F,1,1,
,BAO_0000219,4604,N,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,Intermediate,478.0,81034,,17672,,9606.0,Homo sapiens,,CHEMBL883794,A2780,,,,F,1,1,
,BAO_0000219,4605,N,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,Intermediate,478.0,81034,,17672,,9606.0,Homo sapiens,,CHEMBL619152,A2780,,,,F,1,1,
,BAO_0000219,4606,N,In vitro cytotoxicity against A2780ADR cell line,Intermediate,478.0,81034,,17270,,9606.0,Homo sapiens,,CHEMBL619153,A2780,,,,F,1,1,
,BAO_0000219,4607,N,In vitro cytotoxicity against A2780CIS cell line,Intermediate,478.0,81034,,17270,,9606.0,Homo sapiens,,CHEMBL619154,A2780,,,,F,1,1,
,BAO_0000219,4608,N,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,Intermediate,478.0,81034,,5574,,9606.0,Homo sapiens,,CHEMBL619155,A2780,,,,F,1,1,
,BAO_0000219,4609,N,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,Intermediate,478.0,81034,,2113,,9606.0,Homo sapiens,,CHEMBL619156,A2780,,,,F,1,1,
,BAO_0000219,4610,N,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",Intermediate,478.0,81034,,16913,,9606.0,Homo sapiens,,CHEMBL619157,A2780,,,,F,1,1,
,BAO_0000219,4611,N,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",Intermediate,478.0,81034,,16913,,9606.0,Homo sapiens,,CHEMBL619797,A2780,,,,F,1,1,
,BAO_0000218,4612,U,Oral bioavailability of compound in rhesus macaques,Autocuration,,22224,,17839,,9544.0,Macaca mulatta,,CHEMBL619798,,,In vivo,,A,1,0,
,BAO_0000218,4613,U,Oral bioavailability in monkey,Autocuration,,22224,,6821,,9443.0,monkey,,CHEMBL619799,,,In vivo,,A,1,0,
,BAO_0000218,4614,U,Oral bioavailability evaluated in monkey,Autocuration,,22224,,6078,,9443.0,monkey,,CHEMBL619800,,,In vivo,,A,1,0,
,BAO_0000218,4615,U,Oral bioavailability in monkey (dose 1 mg/kg p.o.),Autocuration,,22224,,6535,,9443.0,monkey,,CHEMBL619801,,,In vivo,,A,1,0,
,BAO_0000218,4616,U,Oral bioavailability in Rhesus monkey,Autocuration,,22224,,4449,,9544.0,Macaca mulatta,,CHEMBL619802,,,In vivo,,A,1,0,
,BAO_0000218,4617,U,Oral bioavailability was calculated in rhesus monkey,Autocuration,,22224,,6057,,9544.0,Macaca mulatta,,CHEMBL619803,,,In vivo,,A,1,0,
,BAO_0000218,4618,U,Oral bioavailability in cynomolgus monkey,Autocuration,,22224,,5922,,9541.0,Macaca fascicularis,,CHEMBL619965,,,In vivo,,A,1,0,
,BAO_0000218,4619,U,Oral bioavailability in monkey,Autocuration,,22224,,5940,,9443.0,monkey,,CHEMBL619966,,,In vivo,,A,1,0,
,BAO_0000218,4620,U,Oral bioavailability in monkey,Autocuration,,22224,,6265,,9443.0,monkey,,CHEMBL619967,,,In vivo,,A,1,0,
,BAO_0000218,4621,U,Oral bioavailability in monkey (dose 1 mg/kg),Autocuration,,22224,,6265,,9443.0,monkey,,CHEMBL620073,,,In vivo,,A,1,0,
,BAO_0000218,4622,U,Oral bioavailability in monkey (dose 5 mg/kg),Autocuration,,22224,,6265,,9443.0,monkey,,CHEMBL620074,,,In vivo,,A,1,0,
,BAO_0000218,4623,U,Oral bioavailability in monkey,Autocuration,,22224,,5940,,9443.0,monkey,,CHEMBL620075,,,In vivo,,A,1,0,
,BAO_0000218,4624,U,Oral bioavailability in monkey,Autocuration,,22224,,5940,,9443.0,monkey,,CHEMBL620076,,,In vivo,,A,1,0,
,BAO_0000218,4625,U,Oral bioavailability in rhesus monkey,Autocuration,,22224,,4514,,9544.0,Macaca mulatta,,CHEMBL620077,,,In vivo,,A,1,0,
,BAO_0000218,4626,U,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,Autocuration,,22224,,5546,,9544.0,Macaca mulatta,,CHEMBL620078,,,In vivo,,A,1,0,
,BAO_0000218,4627,U,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,Autocuration,,22224,,5553,,9521.0,Saimiri sciureus,,CHEMBL620079,,,In vivo,,A,1,0,
,BAO_0000218,4628,U,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),Autocuration,,22224,,6641,,9443.0,monkey,,CHEMBL620080,,,In vivo,,A,1,0,
,BAO_0000218,4629,U,Oral bioavailability in Rhesus monkey,Autocuration,,22224,,5472,,9544.0,Macaca mulatta,,CHEMBL620081,,,In vivo,,A,1,0,
,BAO_0000218,4630,U,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),Autocuration,,22224,,5668,,9544.0,Macaca mulatta,,CHEMBL620082,,,In vivo,,A,1,0,
,BAO_0000218,4631,U,Oral bioavailability in monkey at 10 mg/kg of the compound,Autocuration,,22224,,5711,,9443.0,monkey,,CHEMBL620083,,,In vivo,,A,1,0,
,BAO_0000218,4632,U,Bioavailability in Rhesus monkey,Autocuration,,22224,,5145,,9544.0,Macaca mulatta,,CHEMBL620084,,,In vivo,,A,1,0,
,BAO_0000218,4633,U,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,22224,,3443,,9527.0,Cercopithecidae,,CHEMBL620085,,,,,A,1,0,
,BAO_0000218,4634,U,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,22224,,3443,,9527.0,Cercopithecidae,,CHEMBL874595,,,,,A,1,0,
,BAO_0000218,4635,U,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,Autocuration,,22224,,3249,,9527.0,Cercopithecidae,,CHEMBL873352,,,In vivo,,A,1,0,
,BAO_0000218,4636,U,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,Autocuration,,22224,,3249,,9527.0,Cercopithecidae,,CHEMBL620086,,,In vivo,,A,1,0,
,BAO_0000218,4637,U,Mean residence time was determined after intravenous administration in cynomolgus monkeys,Autocuration,,22224,,5355,,9527.0,Cercopithecidae,,CHEMBL620087,,,In vivo,,A,1,0,
,BAO_0000218,4638,U,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,Autocuration,,22224,,5355,,9527.0,Cercopithecidae,,CHEMBL620088,,,In vivo,,A,1,0,
,BAO_0000218,4639,U,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,Autocuration,,22224,,5355,,9527.0,Cercopithecidae,,CHEMBL620089,,,In vivo,,A,1,0,
,BAO_0000218,4640,U,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),Autocuration,,22224,,4809,,9527.0,Cercopithecidae,,CHEMBL620090,,,In vivo,,A,1,0,
,BAO_0000218,4641,U,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),Autocuration,,22224,,4809,,9527.0,Cercopithecidae,,CHEMBL620091,,,In vivo,,A,1,0,
,BAO_0000251,4642,U,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),Autocuration,,22224,,14294,,9527.0,Cercopithecidae,,CHEMBL620092,,,,Microsomes,A,1,0,
,BAO_0000251,4643,U,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),Autocuration,,22224,,14294,,9527.0,Cercopithecidae,,CHEMBL620093,,,,Microsomes,A,1,0,
,BAO_0000251,4644,U,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),Autocuration,,22224,,14294,,9527.0,Cercopithecidae,,CHEMBL620094,,,,Microsomes,A,1,0,
,BAO_0000251,4645,U,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),Autocuration,,22224,,14294,,9527.0,Cercopithecidae,,CHEMBL620095,,,,Microsomes,A,1,0,
,BAO_0000218,4646,U,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,22224,,3443,,9527.0,Cercopithecidae,,CHEMBL620096,,,In vivo,,A,1,0,
,BAO_0000218,4647,U,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,22224,,3443,,9527.0,Cercopithecidae,,CHEMBL620097,,,In vivo,,A,1,0,
,BAO_0000019,4648,U,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,Autocuration,,22224,,11271,,9527.0,Cercopithecidae,,CHEMBL620098,,,,,A,1,0,
,BAO_0000218,4649,U,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,22224,,3443,,9527.0,Cercopithecidae,,CHEMBL620099,,,,,A,1,0,
,BAO_0000218,4650,U,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,22224,,3443,,9527.0,Cercopithecidae,,CHEMBL620100,,,,,A,1,0,
,BAO_0000019,4651,U,Elimination Half-life of compound was determined in monkey,Autocuration,,22224,,6821,,9527.0,Cercopithecidae,,CHEMBL620101,,,,,A,1,0,
,BAO_0000019,4652,U,Half life of compound was determined in rhesus monkey,Autocuration,,22224,,17267,,9527.0,Cercopithecidae,,CHEMBL620102,,,,,A,1,0,
Plasma,BAO_0000366,4653,U,Half life in monkey plasma,Autocuration,,22224,,5819,1969.0,9527.0,Cercopithecidae,,CHEMBL620103,,,,,A,1,0,
Plasma,BAO_0000366,4654,U,Half life in monkey plasma; Not detected,Autocuration,,22224,,5819,1969.0,9527.0,Cercopithecidae,,CHEMBL620104,,,,,A,1,0,
,BAO_0000218,4655,U,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,Autocuration,,22224,,1916,,9527.0,Cercopithecidae,,CHEMBL874596,,,In vivo,,A,1,0,
,BAO_0000218,4656,U,Half-life 24 hr after 2 mg/kg iv administration in monkeys,Autocuration,,22224,,17509,,9527.0,Cercopithecidae,,CHEMBL873490,,,In vivo,,A,1,0,
,BAO_0000019,4657,U,Terminal half life of the compound.,Autocuration,,22224,,1399,,9527.0,Cercopithecidae,,CHEMBL620105,,,,,A,1,0,
,BAO_0000218,4658,U,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,Autocuration,,22224,,1916,,9527.0,Cercopithecidae,,CHEMBL620780,,,In vivo,,A,1,0,
,BAO_0000218,4659,U,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),Autocuration,,22224,,4809,,9527.0,Cercopithecidae,,CHEMBL620781,,,In vivo,,A,1,0,
,BAO_0000218,4660,U,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,Autocuration,,22224,,5546,,9527.0,Cercopithecidae,,CHEMBL620956,,,,,A,1,0,
Urine,BAO_0000218,4661,U,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,22224,,3443,1088.0,9527.0,Cercopithecidae,,CHEMBL620957,,,,,A,1,0,
Urine,BAO_0000218,4662,U,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,22224,,3443,1088.0,9527.0,Cercopithecidae,,CHEMBL620958,,,,,A,1,0,
,BAO_0000218,4663,U,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,Autocuration,,22224,,4257,,9527.0,Cercopithecidae,,CHEMBL620959,,,In vivo,,A,1,0,
,BAO_0000218,4664,U,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,Autocuration,,22224,,6221,,9527.0,Cercopithecidae,,CHEMBL620960,,,In vivo,,A,1,0,
,BAO_0000218,4665,U,Volume of distribution was evaluated in rhesus,Autocuration,,22224,,5472,,9527.0,Cercopithecidae,,CHEMBL620961,,,In vivo,,A,1,0,
,BAO_0000218,4666,U,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,Autocuration,,22224,,4727,,10029.0,Cricetulus griseus,,CHEMBL620962,,,In vivo,,A,1,0,
,BAO_0000218,4667,U,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,Autocuration,,22224,,4727,,10029.0,Cricetulus griseus,,CHEMBL620963,,,In vivo,,A,1,0,
,BAO_0000218,4668,U,Bioavailability in hamster was determined,Autocuration,,22224,,4727,,10029.0,Cricetulus griseus,,CHEMBL620964,,,In vivo,,A,1,0,
,BAO_0000218,4669,U,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,Autocuration,,22224,,4727,,10029.0,Cricetulus griseus,,CHEMBL620965,,,In vivo,,A,1,0,
,BAO_0000218,4670,U,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,Autocuration,,22224,,4727,,10029.0,Cricetulus griseus,,CHEMBL620966,,,In vivo,,A,1,0,
Blood,BAO_0000221,4671,U,Half life of compound was determined in hamster blood,Autocuration,,22224,,4727,178.0,10029.0,Cricetulus griseus,,CHEMBL620967,,,,,A,1,0,
,BAO_0000019,4672,U,Michaelis-Menten constant of the compound.,Autocuration,,22224,,1452,,9823.0,Sus scrofa,,CHEMBL620968,,,,,A,1,0,
,BAO_0000019,4673,U,Vmax value was measured at 0 uM concentration of silyl ether.,Autocuration,,22224,,1452,,9823.0,Sus scrofa,,CHEMBL874597,,,,,A,1,0,
,BAO_0000019,4674,U,Vmax value was measured at 10 uM concentration of silyl ether.,Autocuration,,22224,,1452,,9823.0,Sus scrofa,,CHEMBL620969,,,,,A,1,0,
,BAO_0000019,4675,U,Vmax value was measured at 5 uM concentration of silyl ether.,Autocuration,,22224,,1452,,9823.0,Sus scrofa,,CHEMBL620970,,,,,A,1,0,
,BAO_0000357,4676,D,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,Expert,,235,,11706,,9606.0,Homo sapiens,,CHEMBL620971,,,,,B,1,9,
,BAO_0000218,4677,U,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,Autocuration,,22224,,1916,,9606.0,Homo sapiens,,CHEMBL620972,,,,,A,1,0,
,BAO_0000019,4678,U,Compound was evaluated for area under the curve expressed as (h*ug/ml),Autocuration,,22224,,17791,,9606.0,Homo sapiens,,CHEMBL620973,,,,,A,1,0,
,BAO_0000019,4679,U,Active metabolite of ifosfamide determined in humans; A-Active,Autocuration,,22224,,7766,,9606.0,Homo sapiens,,CHEMBL618243,,,,,A,1,0,
,BAO_0000019,4680,U,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,Autocuration,,22224,,6567,,9606.0,Homo sapiens,,CHEMBL618244,,,,,A,1,0,
,BAO_0000019,4681,U,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,Autocuration,,22224,,6567,,9606.0,Homo sapiens,,CHEMBL618245,,,,,A,1,0,
,BAO_0000019,4682,U,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,Autocuration,,22224,,6567,,9606.0,Homo sapiens,,CHEMBL618246,,,,,A,1,0,
,BAO_0000019,4683,U,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,Autocuration,,22224,,6567,,9606.0,Homo sapiens,,CHEMBL618247,,,,,A,1,0,
,BAO_0000218,4684,U,Compound was evaluated for oral bioavailability in human,Autocuration,,22224,,17791,,9606.0,Homo sapiens,,CHEMBL618248,,,,,A,1,0,
Urine,BAO_0000019,4685,U,Metabolite of ifosfamide determined in urine; NF-Not found,Autocuration,,22224,,7766,1088.0,9606.0,Homo sapiens,,CHEMBL618249,,,,,A,1,0,
,BAO_0000019,4686,U,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),Autocuration,,22224,,6852,,9606.0,Homo sapiens,,CHEMBL618250,,,,,A,1,0,
,BAO_0000019,4687,U,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,Autocuration,,22224,,6852,,9606.0,Homo sapiens,,CHEMBL874598,,,,,A,1,0,
,BAO_0000019,4688,U,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,Autocuration,,22224,,6852,,9606.0,Homo sapiens,,CHEMBL618251,,,,,A,1,0,
,BAO_0000019,4689,U,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,Autocuration,,22224,,6852,,9606.0,Homo sapiens,,CHEMBL618252,,,,,A,1,0,
,BAO_0000019,4690,U,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,Autocuration,,22224,,6852,,9606.0,Homo sapiens,,CHEMBL618253,,,,,A,1,0,
,BAO_0000019,4691,U,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),Autocuration,,22224,,6852,,9606.0,Homo sapiens,,CHEMBL618254,,,,,A,1,0,
,BAO_0000019,4692,U,Percent of compound in healthy individuals (Group D),Autocuration,,22224,,6852,,9606.0,Homo sapiens,,CHEMBL618255,,,,,A,1,0,
Liver,BAO_0000251,4693,U,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,Autocuration,,22224,,4397,2107.0,9606.0,Homo sapiens,,CHEMBL618983,,,,Microsomes,A,1,0,
,BAO_0000019,4694,U,Binding towards human plasma protein at 10 uM,Autocuration,,22224,,17409,,9606.0,Homo sapiens,,CHEMBL618984,,,,,A,1,0,
,BAO_0000019,4695,U,Binding towards human plasma protein at 100 uM,Autocuration,,22224,,17409,,9606.0,Homo sapiens,,CHEMBL618985,,,,,A,1,0,
,BAO_0000019,4696,U,Human plasma protein binding activity was determined,Autocuration,,22224,,17176,,9606.0,Homo sapiens,,CHEMBL618986,,,,,A,1,0,
,BAO_0000019,4697,U,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),Autocuration,,22224,,15444,,9606.0,Homo sapiens,,CHEMBL618987,,,,,A,1,0,
,BAO_0000019,4698,U,Percent binding of compound towards human plasma protein was determined,Autocuration,,22224,,17267,,9606.0,Homo sapiens,,CHEMBL618988,,,,,A,1,0,
Liver,BAO_0000251,4699,U,Plasma clearance in human liver microsomes,Autocuration,,22224,,5944,2107.0,9606.0,Homo sapiens,,CHEMBL618989,,,In vitro,Microsomes,A,1,0,
Liver,BAO_0000251,4700,U,In vitro intrinsic clearance in human liver microsome,Autocuration,,22224,,5668,2107.0,9606.0,Homo sapiens,,CHEMBL618990,,,In vitro,Microsomes,A,1,0,
Liver,BAO_0000251,4701,U,In vitro intrinsic clearance in human liver microsome,Autocuration,,22224,,5669,2107.0,9606.0,Homo sapiens,,CHEMBL618991,,,In vitro,Microsomes,A,1,0,
,BAO_0000251,4702,U,In vitro microsome metabolism clearance in human was determined,Autocuration,,22224,,5041,,9606.0,Homo sapiens,,CHEMBL876725,,,In vitro,Microsomes,A,1,0,
,BAO_0000251,4703,U,In vitro microsome metabolism clearance in human was determined; High,Autocuration,,22224,,5041,,9606.0,Homo sapiens,,CHEMBL618992,,,In vitro,Microsomes,A,1,0,
,BAO_0000251,4704,U,In vitro microsome metabolism clearance in human was determined; ND denotes no data,Autocuration,,22224,,5041,,9606.0,Homo sapiens,,CHEMBL618993,,,In vitro,Microsomes,A,1,0,
Liver,BAO_0000251,4705,U,Pharmacokinetic property (clearance) in human liver microsome,Autocuration,,22224,,5676,2107.0,9606.0,Homo sapiens,,CHEMBL618994,,,In vitro,Microsomes,A,1,0,
Liver,BAO_0000251,4706,U,Plasma clearance in human liver microsomes,Autocuration,,22224,,5944,2107.0,9606.0,Homo sapiens,,CHEMBL618995,,,In vitro,Microsomes,A,1,0,
Liver,BAO_0000251,4707,U,In vitro clearance in human liver microsomes,Autocuration,,22224,,17538,2107.0,9606.0,Homo sapiens,,CHEMBL618996,,,In vitro,Microsomes,A,1,0,
Liver,BAO_0000251,4708,U,Intrinsic clearance in human liver microsomes was determined,Autocuration,,22224,,6331,2107.0,9606.0,Homo sapiens,,CHEMBL618997,,,In vitro,Microsomes,A,1,0,
Liver,BAO_0000251,4709,U,Intrinsic clearance in human liver microsomes was determined,Autocuration,,22224,,5948,2107.0,9606.0,Homo sapiens,,CHEMBL618998,,,In vitro,Microsomes,A,1,0,
,BAO_0000218,4710,U,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,Autocuration,,22224,,5965,,9606.0,Homo sapiens,,CHEMBL618999,,,In vivo,,A,1,0,
,BAO_0000218,4711,U,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,Autocuration,,22224,,1916,,9606.0,Homo sapiens,,CHEMBL620223,,,In vivo,,A,1,0,
,BAO_0000218,4712,U,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,Autocuration,,22224,,5965,,9606.0,Homo sapiens,,CHEMBL620224,,,,,A,1,0,
,BAO_0000019,4713,U,Stability in human plasma 2 hr after incubation expressed as percent concentration,Autocuration,,22224,,1299,,9606.0,Homo sapiens,,CHEMBL620225,,,,,A,1,0,
,BAO_0000019,4714,U,Stability in human plasma 4 hr after incubation expressed as percent concentration,Autocuration,,22224,,1299,,9606.0,Homo sapiens,,CHEMBL620226,,,,,A,1,0,
Urine,BAO_0000019,4715,U,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Autocuration,,22224,,7766,1088.0,9606.0,Homo sapiens,,CHEMBL620227,,,,,A,1,0,
Urine,BAO_0000019,4716,U,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Autocuration,,22224,,7766,1088.0,9606.0,Homo sapiens,,CHEMBL876726,,,,,A,1,0,
Urine,BAO_0000019,4717,U,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Autocuration,,22224,,7766,1088.0,9606.0,Homo sapiens,,CHEMBL620228,,,,,A,1,0,
Urine,BAO_0000019,4718,U,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Autocuration,,22224,,7766,1088.0,9606.0,Homo sapiens,,CHEMBL620229,,,,,A,1,0,
,BAO_0000218,4719,N,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,Intermediate,,50594,,17764,,10090.0,Mus musculus,,CHEMBL620230,,,In vivo,,F,1,1,
,BAO_0000218,4720,N,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,Intermediate,,50594,,17764,,10090.0,Mus musculus,,CHEMBL620231,,,In vivo,,F,1,1,
,BAO_0000218,4721,N,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,Intermediate,,50594,,17764,,10090.0,Mus musculus,,CHEMBL620232,,,In vivo,,F,1,1,
,BAO_0000218,4722,N,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,Intermediate,,50594,,17764,,10090.0,Mus musculus,,CHEMBL620233,,,In vivo,,F,1,1,
,BAO_0000218,4723,N,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),Intermediate,,50594,,14294,,10090.0,Mus musculus,,CHEMBL620234,,,,,A,1,1,
,BAO_0000218,4724,N,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),Intermediate,,50594,,14294,,10090.0,Mus musculus,,CHEMBL620235,,,,,A,1,1,
,BAO_0000218,4725,N,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),Intermediate,,50594,,14294,,10090.0,Mus musculus,,CHEMBL620236,,,,,A,1,1,
Liver,BAO_0000218,4726,N,In vitro metabolic potential in mouse liver microsomes,Intermediate,,50594,,6251,2107.0,10090.0,Mus musculus,,CHEMBL620237,,,,,A,1,1,
,BAO_0000218,4727,N,Ability of compound to bind to plasma protein was evaluated in HSA cells,Intermediate,,50594,,17582,,10090.0,Mus musculus,,CHEMBL620238,,,,,A,1,1,
Adrenal gland,BAO_0000218,4728,N,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),Intermediate,,50594,,17811,2369.0,10090.0,Mus musculus,,CHEMBL620239,,,,,A,1,1,
Brain,BAO_0000218,4729,N,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,Intermediate,,50594,,17811,955.0,10090.0,Mus musculus,,CHEMBL620240,,,,,A,1,1,
Brain,BAO_0000218,4730,N,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,Intermediate,,50594,,17811,955.0,10090.0,Mus musculus,,CHEMBL620241,,,,,A,1,1,
,BAO_0000218,4731,N,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),Intermediate,,50594,,17811,,10090.0,Mus musculus,,CHEMBL876727,,,,,A,1,1,
Kidney,BAO_0000218,4732,N,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),Intermediate,,50594,,17811,2113.0,10090.0,Mus musculus,,CHEMBL620242,,,,,A,1,1,
,BAO_0000218,4733,N,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),Intermediate,,50594,,17811,,10090.0,Mus musculus,,CHEMBL620243,,,,,A,1,1,
,BAO_0000218,4734,N,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,Intermediate,,50594,,5288,,10090.0,Mus musculus,,CHEMBL620244,,,,,A,1,1,
Serum,BAO_0000218,4735,N,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,Intermediate,,50594,,2717,1977.0,10090.0,Mus musculus,,CHEMBL620245,,,,,A,1,1,
Serum,BAO_0000218,4736,N,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,Intermediate,,50594,,2717,1977.0,10090.0,Mus musculus,,CHEMBL620246,,,,,A,1,1,
Serum,BAO_0000218,4737,N,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,Intermediate,,50594,,2717,1977.0,10090.0,Mus musculus,,CHEMBL620247,,,,,A,1,1,
Plasma,BAO_0000218,4738,N,Half life of compound was determined in plasma of mice at 24 mg/Kg,Intermediate,,50594,,17753,1969.0,10090.0,Mus musculus,,CHEMBL620248,,,In vivo,,A,1,1,
Plasma,BAO_0000218,4739,N,Half life of compound was determined in plasma of mice at 40 mg/Kg,Intermediate,,50594,,17753,1969.0,10090.0,Mus musculus,,CHEMBL873497,,,In vivo,,A,1,1,
Plasma,BAO_0000218,4740,N,Half life of compound was determined in plasma of mice at 5 mg/Kg,Intermediate,,50594,,17753,1969.0,10090.0,Mus musculus,,CHEMBL620249,,,In vivo,,A,1,1,
,BAO_0000218,4741,N,Half life after intraperitoneal administration in mice at 18 uM/kg,Intermediate,,50594,,17764,,10090.0,Mus musculus,,CHEMBL620250,,,In vivo,,F,1,1,
,BAO_0000218,4742,N,Half life after intraperitoneal administration in mice at 23 uM/kg,Intermediate,,50594,,17764,,10090.0,Mus musculus,,CHEMBL620251,,,In vivo,,F,1,1,
,BAO_0000218,4743,N,Half life after intraperitoneal administration in mice at 25 uM/kg,Intermediate,,50594,,17764,,10090.0,Mus musculus,,CHEMBL620252,,,In vivo,,F,1,1,
,BAO_0000218,4744,N,Half life after intraperitoneal administration in mice at 26 uM/kg,Intermediate,,50594,,17764,,10090.0,Mus musculus,,CHEMBL620253,,,In vivo,,F,1,1,
,BAO_0000218,4745,N,Half life after intravenous administration in mice at 23 uM/kg,Intermediate,,50594,,17764,,10090.0,Mus musculus,,CHEMBL620254,,,In vivo,,F,1,1,
,BAO_0000218,4746,N,Half life after intravenous administration in mice at 24 uM/kg,Intermediate,,50594,,17764,,10090.0,Mus musculus,,CHEMBL620255,,,In vivo,,A,1,1,
,BAO_0000218,4747,N,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,Intermediate,,50594,,16597,,10090.0,Mus musculus,,CHEMBL620256,,,In vivo,,A,1,1,
,BAO_0000218,4748,N,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,Intermediate,,50594,,2675,,10090.0,Mus musculus,,CHEMBL876728,,,In vivo,,A,1,1,
,BAO_0000218,4749,N,Maximum time required to reach Cp max was evaluated in mice after oral administration,Intermediate,,50594,,2675,,10090.0,Mus musculus,,CHEMBL620257,,,In vivo,,A,1,1,
,BAO_0000218,4750,N,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),Intermediate,,50594,,16597,,10090.0,Mus musculus,,CHEMBL620258,,,In vivo,,A,1,1,
,BAO_0000218,4751,N,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",Intermediate,,50594,,4890,,10090.0,Mus musculus,,CHEMBL620259,,,In vivo,,A,1,1,
,BAO_0000218,4752,N,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,Intermediate,,50594,,429,,10090.0,Mus musculus,,CHEMBL620260,,,In vivo,,A,1,1,
Blood,BAO_0000218,4753,N,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,Intermediate,,50594,,17837,178.0,10090.0,Mus musculus,,CHEMBL620261,,,In vivo,,A,1,1,
,BAO_0000218,4754,N,Half life at a dose of 10 mg/kg intravenous administration in mice.,Intermediate,,50594,,16597,,10090.0,Mus musculus,,CHEMBL620262,,,In vivo,,A,1,1,
,BAO_0000218,4755,N,Half life at a dose of 10 mg/kg peroral administration in mice.,Intermediate,,50594,,16597,,10090.0,Mus musculus,,CHEMBL620263,,,In vivo,,A,1,1,
,BAO_0000218,4756,N,Half life in ob/ob mice,Intermediate,,50594,,6619,,10090.0,Mus musculus,,CHEMBL620264,,,,,A,1,1,
,BAO_0000218,4757,N,Half-life at a single subcutaneous administration of 40 mg/kg in mice,Intermediate,,50594,,4066,,10090.0,Mus musculus,,CHEMBL620265,,,In vivo,,A,1,1,
,BAO_0000218,4758,N,Half-life was measured in mouse,Intermediate,,50594,,4239,,10090.0,Mus musculus,,CHEMBL620266,,,,,A,1,1,
,BAO_0000218,4759,N,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,Intermediate,,50594,,5969,,10090.0,Mus musculus,,CHEMBL620267,,,In vivo,,A,1,1,
,BAO_0000218,4760,N,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,Intermediate,,50594,,8999,,10090.0,Mus musculus,,CHEMBL619364,,,,,A,1,1,
,BAO_0000218,4761,N,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,Intermediate,,50594,,8999,,10090.0,Mus musculus,,CHEMBL619365,,,,,A,1,1,
Brain,BAO_0000218,4762,N,T2 in brain of mice at the oral dose of 50 mg/kg,Intermediate,,50594,,17641,955.0,10090.0,Mus musculus,,CHEMBL619366,,,,,A,1,1,
Kidney,BAO_0000218,4763,N,T2 in kidney of mice at the oral dose of 50 mg/kg,Intermediate,,50594,,17641,2113.0,10090.0,Mus musculus,,CHEMBL619367,,,,,A,1,1,
Liver,BAO_0000218,4764,N,T2 in liver of mice at the oral dose of 50 mg/kg,Intermediate,,50594,,17641,2107.0,10090.0,Mus musculus,,CHEMBL619368,,,,,A,1,1,
Lung,BAO_0000218,4765,N,T2 in lungs of mice at the oral dose of 50 mg/kg,Intermediate,,50594,,17641,2048.0,10090.0,Mus musculus,,CHEMBL619369,,,,,A,1,1,
Spleen,BAO_0000218,4766,N,T2 in spleen of mice at the oral dose of 50 mg/kg,Intermediate,,50594,,17641,2106.0,10090.0,Mus musculus,,CHEMBL876729,,,,,A,1,1,
,BAO_0000218,4767,N,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,Intermediate,,50594,,16597,,10090.0,Mus musculus,,CHEMBL619370,,,In vivo,,A,1,1,
,BAO_0000218,4768,N,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",Intermediate,,50594,,4890,,10090.0,Mus musculus,,CHEMBL619371,,,In vivo,,A,1,1,
,BAO_0000218,4769,N,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,Intermediate,,50594,,429,,10090.0,Mus musculus,,CHEMBL619372,,,In vivo,,A,1,1,
,BAO_0000218,4770,N,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,Intermediate,,50594,,429,,10090.0,Mus musculus,,CHEMBL620012,,,In vivo,,A,1,1,
,BAO_0000218,4771,N,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,Intermediate,,50594,,5969,,10090.0,Mus musculus,,CHEMBL620013,,,In vivo,,A,1,1,
,BAO_0000219,4772,N,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",Intermediate,478.0,81034,,16913,,9606.0,Homo sapiens,,CHEMBL620014,A2780,,,,F,1,1,
,BAO_0000219,4773,N,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",Intermediate,478.0,81034,,16913,,9606.0,Homo sapiens,,CHEMBL620015,A2780,,,,F,1,1,
,BAO_0000219,4774,N,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",Intermediate,478.0,81034,,16913,,9606.0,Homo sapiens,,CHEMBL621010,A2780,,,,F,1,1,
,BAO_0000219,4775,N,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",Intermediate,478.0,81034,,16913,,9606.0,Homo sapiens,,CHEMBL621011,A2780,,,,F,1,1,
,BAO_0000219,4776,N,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",Intermediate,478.0,81034,,16913,,9606.0,Homo sapiens,,CHEMBL621012,A2780,,,,F,1,1,
,BAO_0000219,4777,N,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",Intermediate,478.0,81034,,16913,,9606.0,Homo sapiens,,CHEMBL621013,A2780,,,,F,1,1,
,BAO_0000219,4778,N,In vitro cytotoxicity against A2780TAX cell line,Intermediate,478.0,81034,,17270,,9606.0,Homo sapiens,,CHEMBL621014,A2780,,,,F,1,1,
,BAO_0000219,4779,N,In vitro inhibitory activity against human tumor cell line A2780cis,Intermediate,481.0,80017,,5618,,9606.0,Homo sapiens,,CHEMBL618154,A2780cisR,,,,F,1,1,
,BAO_0000219,4780,N,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,Expert,478.0,81034,,17777,,9606.0,Homo sapiens,,CHEMBL618155,A2780,,,,F,1,1,
,BAO_0000219,4781,N,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,Intermediate,481.0,80017,,16112,,9606.0,Homo sapiens,,CHEMBL618156,A2780cisR,,,,F,1,1,
,BAO_0000219,4782,N,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),Intermediate,481.0,80017,,15748,,9606.0,Homo sapiens,,CHEMBL618157,A2780cisR,,,,F,1,1,
,BAO_0000219,4783,N,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,Intermediate,478.0,81034,,6633,,9606.0,Homo sapiens,,CHEMBL618328,A2780,,,,F,1,1,
,BAO_0000219,4784,N,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,Intermediate,478.0,81034,,16930,,9606.0,Homo sapiens,,CHEMBL618329,A2780,,,,F,1,1,
,BAO_0000219,4785,N,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,Intermediate,478.0,81034,,17496,,9606.0,Homo sapiens,,CHEMBL618330,A2780,,,,F,1,1,
,BAO_0000219,4786,N,In vitro antitumor activity against A2780cisR cell line.,Expert,478.0,81034,,12989,,9606.0,Homo sapiens,,CHEMBL618331,A2780,,,,F,1,1,
,BAO_0000219,4787,N,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),Intermediate,478.0,81034,,4840,,9606.0,Homo sapiens,,CHEMBL618332,A2780,,,,F,1,1,
,BAO_0000219,4788,N,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,Expert,478.0,81034,,12989,,9606.0,Homo sapiens,,CHEMBL618333,A2780,,,,F,1,1,
,BAO_0000219,4789,N,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,Intermediate,481.0,80017,,16745,,9606.0,Homo sapiens,,CHEMBL618334,A2780cisR,,,,F,1,1,
,BAO_0000219,4790,N,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,Expert,478.0,81034,,16597,,9606.0,Homo sapiens,,CHEMBL618335,A2780,,,,F,1,1,
,BAO_0000019,4791,D,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,Expert,,11736,,16547,,10116.0,Rattus norvegicus,,CHEMBL618336,,,,,B,1,9,
,BAO_0000019,4792,H,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),Expert,,11736,,16547,,,,,CHEMBL618337,,,,,F,1,8,
,BAO_0000019,4793,D,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),Expert,,11736,,16547,,10116.0,Rattus norvegicus,,CHEMBL618338,,,,,F,1,9,
,BAO_0000219,4794,D,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,Expert,722.0,278,,15856,,9606.0,Homo sapiens,,CHEMBL618339,HEK293,,,,F,1,9,
,BAO_0000219,4795,D,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,Expert,722.0,278,,15856,,9606.0,Homo sapiens,,CHEMBL618340,HEK293,,,,F,1,9,
,BAO_0000019,4796,D,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,Expert,,11831,,16547,,10090.0,Mus musculus,,CHEMBL618341,,,,,B,1,9,
,BAO_0000019,4797,H,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),Expert,,11831,,16547,,,,,CHEMBL618342,,,,,F,1,8,
,BAO_0000019,4798,D,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),Expert,,11831,,16547,,10090.0,Mus musculus,,CHEMBL618343,,,,,F,1,9,
,BAO_0000357,4799,H,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,Expert,,280,,17402,,,,,CHEMBL621038,,,,,B,1,8,
,BAO_0000219,4800,U,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),Autocuration,574.0,22226,,11746,,9606.0,Homo sapiens,,CHEMBL621039,T-cells,,,,F,1,0,
,BAO_0000219,4801,U,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,Autocuration,574.0,22226,,11746,,9606.0,Homo sapiens,,CHEMBL621040,T-cells,,,,F,1,0,
,BAO_0000219,4802,N,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,Intermediate,455.0,80018,,5455,,9606.0,Homo sapiens,,CHEMBL621041,A-375,,,,F,1,1,
,BAO_0000219,4803,N,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,Intermediate,455.0,80018,,2068,,9606.0,Homo sapiens,,CHEMBL621042,A-375,,,,F,1,1,
,BAO_0000219,4804,N,In vitro antitumor activity against A375cell line extracted form melanoma,Intermediate,455.0,80018,,2683,,9606.0,Homo sapiens,,CHEMBL621043,A-375,,,,F,1,1,
,BAO_0000219,4805,N,Inhibition of cell growth in (A375) melan cell line,Expert,455.0,80018,,15313,,9606.0,Homo sapiens,,CHEMBL621044,A-375,,,,F,1,1,
,BAO_0000219,4806,N,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,Intermediate,455.0,80018,,13739,,9606.0,Homo sapiens,,CHEMBL621045,A-375,,,,F,1,1,
,BAO_0000219,4807,N,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,Intermediate,455.0,80018,,13739,,9606.0,Homo sapiens,,CHEMBL621046,A-375,,,,F,1,1,
,BAO_0000219,4808,N,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,Intermediate,455.0,80018,,14750,,9606.0,Homo sapiens,,CHEMBL621047,A-375,,,,F,1,1,
,BAO_0000219,4809,N,Antiproliferative activity measured against A427 human lung carcinoma,Intermediate,797.0,80019,,14777,,9606.0,Homo sapiens,,CHEMBL621048,A-427,,,,F,1,1,
,BAO_0000219,4810,N,Antiproliferative activity measured against A427 human lung carcinoma,Intermediate,797.0,80019,,14777,,9606.0,Homo sapiens,,CHEMBL883798,A-427,,,,F,1,1,
,BAO_0000219,4811,N,Cytotoxicity against lung carcinoma A427 tumor cell lines,Intermediate,797.0,80019,,17672,,9606.0,Homo sapiens,,CHEMBL621049,A-427,,,,F,1,1,
,BAO_0000219,4812,N,Inhibition of large cell lung carcinoma (A427),Intermediate,797.0,80019,,14368,,9606.0,Homo sapiens,,CHEMBL621050,A-427,,,,F,1,1,
,BAO_0000219,4813,N,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,Intermediate,797.0,80019,,14368,,9606.0,Homo sapiens,,CHEMBL621051,A-427,,,,F,1,1,
,BAO_0000219,4814,N,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,Intermediate,797.0,80019,,13866,,9606.0,Homo sapiens,,CHEMBL621052,A-427,,,,F,1,1,
,BAO_0000219,4815,N,Inhibitory concentration in human lung carcinoma A427 cell line,Intermediate,797.0,80019,,2545,,9606.0,Homo sapiens,,CHEMBL621053,A-427,,,,F,1,1,
,BAO_0000219,4816,N,Inhibitory concentration in human lung carcinoma A427/VCR cell line,Intermediate,797.0,80019,,2545,,9606.0,Homo sapiens,,CHEMBL621054,A-427,,,,F,1,1,
,BAO_0000218,4817,U,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,Autocuration,,22224,,6062,,9527.0,Cercopithecidae,,CHEMBL621055,,,In vivo,,A,1,0,
,BAO_0000218,4818,U,Tested for volume of distribution upon iv administration to african green monkey,Autocuration,,22224,,4578,,9527.0,Cercopithecidae,,CHEMBL876398,,,In vivo,,A,1,0,
,BAO_0000218,4819,U,Volume of distribution in monkey,Autocuration,,22224,,17592,,9527.0,Cercopithecidae,,CHEMBL621056,,,In vivo,,A,1,0,
,BAO_0000218,4820,U,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Autocuration,,22224,,5005,,9544.0,Macaca mulatta,,CHEMBL621057,,,In vivo,,A,1,0,
,BAO_0000218,4821,U,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,Autocuration,,22224,,5005,,9544.0,Macaca mulatta,,CHEMBL621058,,,In vivo,,A,1,0,
,BAO_0000218,4822,U,Pharmacokinetic property(Vdss) in cynomolgus monkey,Autocuration,,22224,,5922,,9527.0,Cercopithecidae,,CHEMBL621059,,,In vivo,,A,1,0,
,BAO_0000218,4823,U,The distribution volume after intravenous administration in cynomolgus monkeys,Autocuration,,22224,,5355,,9527.0,Cercopithecidae,,CHEMBL621060,,,In vivo,,A,1,0,
,BAO_0000218,4824,U,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,Autocuration,,22224,,5355,,9527.0,Cercopithecidae,,CHEMBL621061,,,In vivo,,A,1,0,
,BAO_0000218,4825,U,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,Autocuration,,22224,,5355,,9527.0,Cercopithecidae,,CHEMBL621062,,,In vivo,,A,1,0,
,BAO_0000218,4826,U,Volume displacement was calculated in rhesus monkey,Autocuration,,22224,,6057,,9527.0,Cercopithecidae,,CHEMBL621063,,,In vivo,,A,1,0,
,BAO_0000218,4827,U,Volume of distribution in steady state was determined in rhesus monkey,Autocuration,,22224,,5145,,9527.0,Cercopithecidae,,CHEMBL621064,,,In vivo,,A,1,0,
,BAO_0000218,4828,U,Volume of distribution of compound was determined in monkey,Autocuration,,22224,,6821,,9527.0,Cercopithecidae,,CHEMBL621065,,,In vivo,,A,1,0,
,BAO_0000218,4829,U,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),Autocuration,,22224,,5334,,9527.0,Cercopithecidae,,CHEMBL621066,,,In vivo,,A,1,0,
,BAO_0000218,4830,U,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),Autocuration,,22224,,5334,,9527.0,Cercopithecidae,,CHEMBL621067,,,In vivo,,A,1,0,
,BAO_0000218,4831,U,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),Autocuration,,22224,,6641,,9527.0,Cercopithecidae,,CHEMBL621068,,,In vivo,,A,1,0,
,BAO_0000218,4832,U,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,Autocuration,,22224,,2661,,9527.0,Cercopithecidae,,CHEMBL876399,,,In vivo,,A,1,0,
,BAO_0000218,4833,U,Volume distribution in monkey after administration of 1 mg/kg iv,Autocuration,,22224,,6535,,9527.0,Cercopithecidae,,CHEMBL621069,,,In vivo,,A,1,0,
,BAO_0000218,4834,U,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),Autocuration,,22224,,4809,,9527.0,Cercopithecidae,,CHEMBL621070,,,In vivo,,A,1,0,
,BAO_0000218,4835,U,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,Autocuration,,22224,,6062,,9527.0,Cercopithecidae,,CHEMBL621071,,,In vivo,,A,1,0,
,BAO_0000218,4836,U,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,22224,,3443,,9527.0,Cercopithecidae,,CHEMBL621072,,,In vivo,,A,1,0,
,BAO_0000218,4837,U,Oral systemic bioavailability upon iv administration to african green monkey,Autocuration,,22224,,4578,,9527.0,Cercopithecidae,,CHEMBL618209,,,In vivo,,A,1,0,
,BAO_0000218,4838,U,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),Autocuration,,22224,,4809,,9527.0,Cercopithecidae,,CHEMBL618210,,,In vivo,,A,1,0,
,BAO_0000019,4839,U,Baboon plasma free fraction. ,Autocuration,,22224,,11271,,9527.0,Cercopithecidae,,CHEMBL618211,,,,,A,1,0,
,BAO_0000218,4840,U,Area under the curve was calculated in rhesus monkey after iv administration,Autocuration,,22224,,6057,,9527.0,Cercopithecidae,,CHEMBL618212,,,,,A,1,0,
,BAO_0000019,4841,U,Area under the curve was calculated in rhesus monkey after peroral administration,Autocuration,,22224,,6057,,9527.0,Cercopithecidae,,CHEMBL618213,,,,,A,1,0,
,BAO_0000019,4842,U,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,Autocuration,,22224,,17853,,9527.0,Cercopithecidae,,CHEMBL618214,,,,,A,1,0,
,BAO_0000218,4843,U,Half life period in monkey after 5 mg/kg dose,Autocuration,,22224,,5302,,9527.0,Cercopithecidae,,CHEMBL873492,,,In vivo,,A,1,0,
,BAO_0000218,4844,U,Half-life was determined in monkey after 3 mg/kg of i.v. dose,Autocuration,,22224,,4257,,9527.0,Cercopithecidae,,CHEMBL618272,,,In vivo,,A,1,0,
,BAO_0000218,4845,U,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,Autocuration,,22224,,4257,,9527.0,Cercopithecidae,,CHEMBL618273,,,In vivo,,A,1,0,
Plasma,BAO_0000218,4846,U,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,Autocuration,,22224,,13501,1969.0,9527.0,Cercopithecidae,,CHEMBL618274,,,In vivo,,A,1,0,
,BAO_0000218,4847,U,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,Autocuration,,22224,,5394,,9527.0,Cercopithecidae,,CHEMBL618275,,,In vivo,,A,1,0,
,BAO_0000218,4848,U,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,Autocuration,,22224,,2661,,9527.0,Cercopithecidae,,CHEMBL618276,,,In vivo,,A,1,0,
,BAO_0000019,4849,U,Compound was evaluated for terminal half life in monkey,Autocuration,,22224,,3341,,9527.0,Cercopithecidae,,CHEMBL618277,,,,,A,1,0,
,BAO_0000218,4850,U,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,Autocuration,,22224,,3045,,9527.0,Cercopithecidae,,CHEMBL618278,,,In vivo,,A,1,0,
Plasma,BAO_0000218,4851,U,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Autocuration,,22224,,5005,1969.0,9544.0,Macaca mulatta,,CHEMBL618279,,,In vivo,,A,1,0,
,BAO_0000019,4852,U,Half life of compound was determined in squirrel monkey,Autocuration,,22224,,4847,,9527.0,Cercopithecidae,,CHEMBL618280,,,,,A,1,0,
,BAO_0000218,4853,U,Half life after iv administration in cynomolgus monkey,Autocuration,,22224,,4256,,9541.0,Macaca fascicularis,,CHEMBL618281,,,In vivo,,A,1,0,
Plasma,BAO_0000218,4854,U,Half life in monkey plasma after administration of 1 mg/kg iv,Autocuration,,22224,,6535,1969.0,9527.0,Cercopithecidae,,CHEMBL618282,,,In vivo,,A,1,0,
,BAO_0000019,4855,U,Half life was calculated in rhesus monkey,Autocuration,,22224,,6057,,9527.0,Cercopithecidae,,CHEMBL618283,,,,,A,1,0,
,BAO_0000019,4856,U,Half life in monkey,Autocuration,,22224,,17592,,9527.0,Cercopithecidae,,CHEMBL618284,,,,,A,1,0,
,BAO_0000218,4857,U,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),Autocuration,,22224,,6641,,9527.0,Cercopithecidae,,CHEMBL618285,,,In vivo,,A,1,0,
,BAO_0000019,4858,U,Half life was evaluated in rhesus,Autocuration,,22224,,5472,,9527.0,Cercopithecidae,,CHEMBL618286,,,,,A,1,0,
,BAO_0000218,4859,U,Half life period after oral administration (2.5 mg/kg) in monkey was determined,Autocuration,,22224,,6221,,9527.0,Cercopithecidae,,CHEMBL618287,,,In vivo,,A,1,0,
,BAO_0000218,4860,U,Half life period was determine after peroral administration at 10 mpk in Rhesus,Autocuration,,22224,,5668,,9527.0,Cercopithecidae,,CHEMBL618288,,,In vivo,,A,1,0,
,BAO_0000218,4861,U,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),Autocuration,,22224,,4809,,9527.0,Cercopithecidae,,CHEMBL876393,,,In vivo,,A,1,0,
,BAO_0000218,4862,U,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,Autocuration,,22224,,5546,,9527.0,Cercopithecidae,,CHEMBL618289,,,In vivo,,A,1,0,
,BAO_0000218,4863,U,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,Autocuration,,22224,,5553,,9527.0,Cercopithecidae,,CHEMBL618290,,,In vivo,,A,1,0,
,BAO_0000019,4864,U,Half-life was calculated in monkey,Autocuration,,22224,,6078,,9527.0,Cercopithecidae,,CHEMBL618291,,,,,A,1,0,
,BAO_0000019,4865,U,Half-life in Squirrel monkey,Autocuration,,22224,,5147,,9527.0,Cercopithecidae,,CHEMBL618292,,,,,A,1,0,
,BAO_0000019,4866,U,Half-life in rhesus monkey,Autocuration,,22224,,5145,,9527.0,Cercopithecidae,,CHEMBL618293,,,,,A,1,0,
,BAO_0000218,4867,U,Half-life was measured in monkey after an iv dose of 1 mg/kg,Autocuration,,22224,,6062,,9527.0,Cercopithecidae,,CHEMBL618294,,,In vivo,,A,1,0,
,BAO_0000218,4868,U,Half-life period after intravenous administration in cynomolgus monkeys,Autocuration,,22224,,5355,,9527.0,Cercopithecidae,,CHEMBL618295,,,In vivo,,A,1,0,
,BAO_0000218,4869,U,Half-life period after oral administration in cynomolgus monkeys,Autocuration,,22224,,5355,,9527.0,Cercopithecidae,,CHEMBL618296,,,In vivo,,A,1,0,
,BAO_0000218,4870,U,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,Autocuration,,22224,,5355,,9527.0,Cercopithecidae,,CHEMBL618297,,,In vivo,,A,1,0,
Urine,BAO_0000019,4871,U,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Autocuration,,22224,,7766,1088.0,9606.0,Homo sapiens,,CHEMBL618298,,,,,A,1,0,
Urine,BAO_0000019,4872,U,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Autocuration,,22224,,7766,1088.0,9606.0,Homo sapiens,,CHEMBL618299,,,,,A,1,0,
Urine,BAO_0000019,4873,U,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Autocuration,,22224,,7766,1088.0,9606.0,Homo sapiens,,CHEMBL618300,,,,,A,1,0,
Urine,BAO_0000019,4874,U,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Autocuration,,22224,,7766,1088.0,9606.0,Homo sapiens,,CHEMBL618301,,,,,A,1,0,
Urine,BAO_0000019,4875,U,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,Autocuration,,22224,,7766,1088.0,9606.0,Homo sapiens,,CHEMBL618302,,,,,A,1,0,
Urine,BAO_0000019,4876,U,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,Autocuration,,22224,,7766,1088.0,9606.0,Homo sapiens,,CHEMBL876394,,,,,A,1,0,
Urine,BAO_0000019,4877,U,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,Autocuration,,22224,,7766,1088.0,9606.0,Homo sapiens,,CHEMBL618303,,,,,A,1,0,
Urine,BAO_0000019,4878,U,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,Autocuration,,22224,,7766,1088.0,9606.0,Homo sapiens,,CHEMBL618304,,,,,A,1,0,
,BAO_0000218,4879,U,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,Autocuration,,22224,,1916,,9606.0,Homo sapiens,,CHEMBL618305,,,In vivo,,A,1,0,
,BAO_0000218,4880,U,Oral bioavailability in human,Autocuration,,22224,,16643,,9606.0,Homo sapiens,,CHEMBL618306,,,In vivo,,A,1,0,
,BAO_0000019,4881,U,Compound was tested for human plasma protein binding,Autocuration,,22224,,17248,,9606.0,Homo sapiens,,CHEMBL618307,,,,,A,1,0,
,BAO_0000019,4882,U,Compound was tested for human plasma protein binding; Not determined,Autocuration,,22224,,17248,,9606.0,Homo sapiens,,CHEMBL618308,,,,,A,1,0,
,BAO_0000019,4883,U,Protein binding activity of compound in human plasma; % Free,Autocuration,,22224,,6241,,9606.0,Homo sapiens,,CHEMBL618309,,,,,A,1,0,
,BAO_0000019,4884,U,Unbound fraction (plasma),Autocuration,,22224,,17716,,9606.0,Homo sapiens,,CHEMBL618310,,,,,A,1,0,
Plasma,BAO_0000366,4885,U,Half life for the hydrolysis of compound in human blood serum,Autocuration,,22224,,17605,1969.0,9606.0,Homo sapiens,,CHEMBL873353,,,,,A,1,0,
Plasma,BAO_0000366,4886,U,Half life period in human plasma using phosphate buffer (0.08 M),Autocuration,,22224,,17625,1969.0,9606.0,Homo sapiens,,CHEMBL618311,,,,,A,1,0,
Plasma,BAO_0000366,4887,U,Half life period in human plasma using phosphate buffer (0.1 M),Autocuration,,22224,,17625,1969.0,9606.0,Homo sapiens,,CHEMBL618312,,,,,A,1,0,
Plasma,BAO_0000366,4888,U,Half-life in human plasma was determined,Autocuration,,22224,,17747,1969.0,9606.0,Homo sapiens,,CHEMBL618313,,,,,A,1,0,
,BAO_0000019,4889,U,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,Autocuration,,22224,,15613,,9606.0,Homo sapiens,,CHEMBL618314,,,,,A,1,0,
,BAO_0000019,4890,U,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),Autocuration,,22224,,354,,9606.0,Homo sapiens,,CHEMBL618315,,,,,A,1,0,
,BAO_0000019,4891,U,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",Autocuration,,22224,,3741,,9606.0,Homo sapiens,,CHEMBL618316,,,,,A,1,0,
,BAO_0000019,4892,U,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",Autocuration,,22224,,3741,,9606.0,Homo sapiens,,CHEMBL618317,,,,,A,1,0,
,BAO_0000019,4893,U,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",Autocuration,,22224,,3741,,9606.0,Homo sapiens,,CHEMBL620138,,,,,A,1,0,
,BAO_0000019,4894,U,Partition coefficient (logP),Autocuration,,22224,,17599,,9606.0,Homo sapiens,,CHEMBL858280,,,,,A,1,0,
,BAO_0000019,4895,U,In vitro metabolic stability in human was measured as pmol/min/mg/protein,Autocuration,,22224,,5486,,9606.0,Homo sapiens,,CHEMBL620139,,,,,A,1,0,
,BAO_0000251,4896,U,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,Autocuration,,22224,,5600,,9606.0,Homo sapiens,,CHEMBL620140,,,,Microsomes,A,1,0,
,BAO_0000019,4897,U,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),Autocuration,,22224,,14294,,9606.0,Homo sapiens,,CHEMBL620141,,,,,A,1,0,
,BAO_0000019,4898,U,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),Autocuration,,22224,,14294,,9606.0,Homo sapiens,,CHEMBL620142,,,,,A,1,0,
,BAO_0000019,4899,U,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),Autocuration,,22224,,14294,,9606.0,Homo sapiens,,CHEMBL620143,,,,,A,1,0,
,BAO_0000251,4900,U,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),Autocuration,,22224,,14294,,9606.0,Homo sapiens,,CHEMBL620144,,,,Microsomes,A,1,0,
,BAO_0000251,4901,U,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),Autocuration,,22224,,14294,,9606.0,Homo sapiens,,CHEMBL620145,,,,Microsomes,A,1,0,
,BAO_0000251,4902,U,Metabolism of compound in human microsomes; Trace,Autocuration,,22224,,14294,,9606.0,Homo sapiens,,CHEMBL620146,,,,Microsomes,A,1,0,
Liver,BAO_0000251,4903,U,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,Autocuration,,22224,,6260,2107.0,9606.0,Homo sapiens,,CHEMBL620147,,,,Microsomes,A,1,0,
,BAO_0000251,4904,U,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,Autocuration,,22224,,6187,,9606.0,Homo sapiens,,CHEMBL620148,,,,Microsomes,A,1,0,
Liver,BAO_0000251,4905,U,In vitro metabolic potential in human liver microsomes,Autocuration,,22224,,6251,2107.0,9606.0,Homo sapiens,,CHEMBL620149,,,,Microsomes,A,1,0,
,BAO_0000019,4906,U,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,Autocuration,,22224,,3246,,9606.0,Homo sapiens,,CHEMBL876412,,,,,A,1,0,
,BAO_0000019,4907,U,Tested for human plasma protein binding of the compound; Not tested,Autocuration,,22224,,17313,,9606.0,Homo sapiens,,CHEMBL619352,,,,,A,1,0,
,BAO_0000019,4908,U,Compound was tested for percent protein binding (PB) in human,Autocuration,,22224,,6227,,9606.0,Homo sapiens,,CHEMBL619353,,,,,A,1,0,
Plasma,BAO_0000019,4909,U,Protein binding in human plasma,Autocuration,,22224,,5530,1969.0,9606.0,Homo sapiens,,CHEMBL619354,,,,,A,1,0,
,BAO_0000019,4910,U,Permeability coefficient (B to A) in Caco-2 cell,Autocuration,,22224,,6108,,9606.0,Homo sapiens,,CHEMBL619355,,,,,A,1,0,
,BAO_0000019,4911,U,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,Autocuration,,22224,,6108,,9606.0,Homo sapiens,,CHEMBL619356,,,,,A,1,0,
,BAO_0000019,4912,U,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),Autocuration,,22224,,2774,,9606.0,Homo sapiens,,CHEMBL619357,,,,,A,1,0,
,BAO_0000019,4913,U,In vitro rate of absorption observed as Caco-2 permeability in humans,Autocuration,,22224,,16643,,9606.0,Homo sapiens,,CHEMBL619358,,,,,A,1,0,
,BAO_0000219,4914,U,Cellular permeability of compound was determined in Caco-2 cells; High,Autocuration,495.0,22224,,17582,,9606.0,Homo sapiens,,CHEMBL619359,Caco-2,,,,A,1,0,
,BAO_0000219,4915,U,Permeability in Caco-2 cells of compound,Autocuration,495.0,22224,,6838,,9606.0,Homo sapiens,,CHEMBL619360,Caco-2,,,,A,1,0,
,BAO_0000019,4916,U,Permeability coefficient (A to B) in Caco-2 cell,Autocuration,,22224,,6108,,9606.0,Homo sapiens,,CHEMBL619361,,,,,A,1,0,
,BAO_0000019,4917,U,Permeability coefficient (B to A) in Caco-2 cell,Autocuration,,22224,,6108,,9606.0,Homo sapiens,,CHEMBL619362,,,,,A,1,0,
,BAO_0000019,4918,U,Permeability coefficient (Papp) (Caco-2 cell monolayer),Autocuration,,22224,,6108,,9606.0,Homo sapiens,,CHEMBL619363,,,,,A,1,0,
,BAO_0000019,4919,U,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,Autocuration,,22224,,2146,,9606.0,Homo sapiens,,CHEMBL618942,,,,,A,1,0,
,BAO_0000019,4920,U,Compound was tested for protein binding in human plasma,Autocuration,,22224,,4514,,9606.0,Homo sapiens,,CHEMBL618943,,,,,A,1,0,
,BAO_0000019,4921,U,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,Autocuration,,22224,,6108,,9606.0,Homo sapiens,,CHEMBL618944,,,,,A,1,0,
Urine,BAO_0000019,4922,U,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,Autocuration,,22224,,7766,1088.0,9606.0,Homo sapiens,,CHEMBL618945,,,,,A,1,0,
,BAO_0000218,4923,N,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,Intermediate,,50594,,5969,,10090.0,Mus musculus,,CHEMBL618946,,,In vivo,,A,1,1,
,BAO_0000218,4924,N,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),Intermediate,,50594,,3277,,10090.0,Mus musculus,,CHEMBL876413,,,In vivo,,A,1,1,
,BAO_0000218,4925,N,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,Intermediate,,50594,,3802,,10090.0,Mus musculus,,CHEMBL618947,,,In vivo,,A,1,1,
Plasma,BAO_0000218,4926,N,Time taken to reach maximum concentration in plasma upon oral administration in mouse,Intermediate,,50594,,2862,1969.0,10090.0,Mus musculus,,CHEMBL618948,,,In vivo,,A,1,1,
Plasma,BAO_0000218,4927,N,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Intermediate,,50594,,6348,1969.0,10090.0,Mus musculus,,CHEMBL618949,,,In vivo,,A,1,1,
,BAO_0000218,4928,N,Tmax after intraperitoneal administration in mice at 23 uM/kg,Intermediate,,50594,,17764,,10090.0,Mus musculus,,CHEMBL618950,,,In vivo,,F,1,1,
,BAO_0000218,4929,N,Tmax after oral administration at 30 mg/kg in ICR mouse,Intermediate,,50594,,5781,,10090.0,Mus musculus,,CHEMBL618951,,,In vivo,,A,1,1,
,BAO_0000218,4930,N,Tmax after peroral administration in mice at 2.4 uM/kg,Intermediate,,50594,,17764,,10090.0,Mus musculus,,CHEMBL618952,,,In vivo,,A,1,1,
,BAO_0000218,4931,N,Tmax at a single subcutaneous administration of 40 mg/kg in mice,Intermediate,,50594,,4066,,10090.0,Mus musculus,,CHEMBL618953,,,In vivo,,A,1,1,
Brain,BAO_0000218,4932,N,Tmax in brain of mice at the oral dose of 50 mg/kg,Intermediate,,50594,,17641,955.0,10090.0,Mus musculus,,CHEMBL618954,,,In vivo,,A,1,1,
Kidney,BAO_0000218,4933,N,Tmax in kidney of mice at the oral dose of 50 mg/kg,Intermediate,,50594,,17641,2113.0,10090.0,Mus musculus,,CHEMBL618955,,,In vivo,,A,1,1,
Liver,BAO_0000218,4934,N,Tmax in liver of mice at the oral dose of 50 mg/kg,Intermediate,,50594,,17641,2107.0,10090.0,Mus musculus,,CHEMBL618956,,,In vivo,,A,1,1,
Lung,BAO_0000218,4935,N,Tmax in lungs of mice at the oral dose of 50 mg/kg,Intermediate,,50594,,17641,2048.0,10090.0,Mus musculus,,CHEMBL618957,,,In vivo,,A,1,1,
,BAO_0000218,4936,N,Tmax in mice at 18 uM/kg i.p. administration,Intermediate,,50594,,17764,,10090.0,Mus musculus,,CHEMBL618958,,,In vivo,,F,1,1,
,BAO_0000218,4937,N,Tmax in mice at 23 uM/kg i.v. administration,Intermediate,,50594,,17764,,10090.0,Mus musculus,,CHEMBL618959,,,In vivo,,F,1,1,
,BAO_0000218,4938,N,Tmax in mice at 25 uM/kg i.p. administration,Intermediate,,50594,,17764,,10090.0,Mus musculus,,CHEMBL618960,,,In vivo,,F,1,1,
,BAO_0000218,4939,N,Tmax in mice at 26 uM/kg i.p. administration,Intermediate,,50594,,17764,,10090.0,Mus musculus,,CHEMBL876723,,,In vivo,,F,1,1,
Spleen,BAO_0000218,4940,N,Tmax in spleen of mice at the oral dose of 50 mg/kg,Intermediate,,50594,,17641,2106.0,10090.0,Mus musculus,,CHEMBL618961,,,In vivo,,A,1,1,
,BAO_0000218,4941,N,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,Intermediate,,50594,,16597,,10090.0,Mus musculus,,CHEMBL618962,,,In vivo,,A,1,1,
,BAO_0000218,4942,N,Tmax value at a dose of 10 mg/kg peroral administration in mice.,Intermediate,,50594,,16597,,10090.0,Mus musculus,,CHEMBL618963,,,In vivo,,A,1,1,
,BAO_0000218,4943,N,Tmax value in IRC mice,Intermediate,,50594,,5951,,10090.0,Mus musculus,,CHEMBL618964,,,,,A,1,1,
,BAO_0000218,4944,N,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,Intermediate,,50594,,5506,,10090.0,Mus musculus,,CHEMBL618965,,,In vivo,,A,1,1,
,BAO_0000218,4945,N,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,Intermediate,,50594,,5506,,10090.0,Mus musculus,,CHEMBL618966,,,In vivo,,A,1,1,
Urine,BAO_0000218,4946,N,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),Intermediate,,50594,,429,1088.0,10090.0,Mus musculus,,CHEMBL618967,,,,,A,1,1,
Urine,BAO_0000218,4947,N,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),Intermediate,,50594,,429,1088.0,10090.0,Mus musculus,,CHEMBL618968,,,,,A,1,1,
Urine,BAO_0000218,4948,N,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),Intermediate,,50594,,4066,1088.0,10090.0,Mus musculus,,CHEMBL618969,,,,,A,1,1,
,BAO_0000218,4949,N,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,Intermediate,,50594,,17734,,10090.0,Mus musculus,,CHEMBL618970,,,,,A,1,1,
,BAO_0000218,4950,N,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,Intermediate,,50594,,17734,,10090.0,Mus musculus,,CHEMBL618971,,,,,A,1,1,
,BAO_0000218,4951,N,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,Intermediate,,50594,,6062,,10090.0,Mus musculus,,CHEMBL618972,,,In vivo,,A,1,1,
,BAO_0000218,4952,N,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,Intermediate,,50594,,5969,,10090.0,Mus musculus,,CHEMBL618973,,,In vivo,,A,1,1,
,BAO_0000218,4953,N,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,Intermediate,,50594,,5969,,10090.0,Mus musculus,,CHEMBL618974,,,In vivo,,A,1,1,
,BAO_0000218,4954,N,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,Intermediate,,50594,,5969,,10090.0,Mus musculus,,CHEMBL618975,,,In vivo,,A,1,1,
,BAO_0000218,4955,N,Vd in mice,Intermediate,,50594,,5980,,10090.0,Mus musculus,,CHEMBL618976,,,In vivo,,A,1,1,
,BAO_0000218,4956,N,Volume of distribution in mouse,Intermediate,,50594,,17592,,10090.0,Mus musculus,,CHEMBL618977,,,In vivo,,A,1,1,
,BAO_0000218,4957,N,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Intermediate,,50594,,6348,,10090.0,Mus musculus,,CHEMBL876724,,,In vivo,,A,1,1,
,BAO_0000218,4958,N,Volume of distribution of compound in plasma was determined at 24 mg/Kg,Intermediate,,50594,,17753,,10090.0,Mus musculus,,CHEMBL618978,,,In vivo,,A,1,1,
,BAO_0000218,4959,N,Volume of distribution of compound in plasma was determined at 40 mg/Kg,Intermediate,,50594,,17753,,10090.0,Mus musculus,,CHEMBL618979,,,In vivo,,A,1,1,
,BAO_0000218,4960,N,Volume of distribution of compound in plasma was determined at 5 mg/Kg,Intermediate,,50594,,17753,,10090.0,Mus musculus,,CHEMBL618980,,,In vivo,,A,1,1,
,BAO_0000218,4961,N,Pharmacokinetic property (vdss) was measured in mouse,Intermediate,,50594,,4239,,10090.0,Mus musculus,,CHEMBL618981,,,In vivo,,A,1,1,
,BAO_0000218,4962,N,Value distribution upon iv administration in mouse,Intermediate,,50594,,2862,,10090.0,Mus musculus,,CHEMBL618982,,,In vivo,,A,1,1,
,BAO_0000218,4963,N,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,Intermediate,,50594,,17734,,10090.0,Mus musculus,,CHEMBL620150,,,In vivo,,A,1,1,
,BAO_0000218,4964,N,Volume of distribution was evaluated in mice after intravenous administration,Intermediate,,50594,,2675,,10090.0,Mus musculus,,CHEMBL620151,,,In vivo,,A,1,1,
,BAO_0000218,4965,N,Volume of distribution was evaluated in mice after oral administration,Intermediate,,50594,,2675,,10090.0,Mus musculus,,CHEMBL620152,,,In vivo,,A,1,1,
,BAO_0000218,4966,N,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,Intermediate,,50594,,17837,,10090.0,Mus musculus,,CHEMBL620153,,,In vivo,,A,1,1,
,BAO_0000218,4967,N,Steady state volume of distribution was determined in mice,Intermediate,,50594,,5727,,10090.0,Mus musculus,,CHEMBL876395,,,In vivo,,A,1,1,
,BAO_0000218,4968,N,Volume distribution (steady state) of compound was determined in mouse,Intermediate,,50594,,17852,,10090.0,Mus musculus,,CHEMBL620154,,,In vivo,,A,1,1,
,BAO_0000218,4969,N,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,Intermediate,,50594,,17764,,10090.0,Mus musculus,,CHEMBL620155,,,In vivo,,A,1,1,
,BAO_0000218,4970,N,Vss value at a dose of 10 mg/kg intravenous administration in mice.,Intermediate,,50594,,16597,,10090.0,Mus musculus,,CHEMBL620156,,,In vivo,,A,1,1,
,BAO_0000218,4971,N,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,Intermediate,,50594,,6062,,10090.0,Mus musculus,,CHEMBL620157,,,In vivo,,A,1,1,
Kidney,BAO_0000218,4972,N,Biodistribution of compound (oxidized form) in in kidney tissue,Intermediate,,50594,,16438,2113.0,10090.0,Mus musculus,,CHEMBL620158,,,In vivo,,A,1,1,
Blood,BAO_0000218,4973,N,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,Intermediate,,50594,,16438,178.0,10090.0,Mus musculus,,CHEMBL620159,,,In vivo,,A,1,1,
Blood,BAO_0000218,4974,N,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",Intermediate,,50594,,16438,178.0,10090.0,Mus musculus,,CHEMBL620160,,,In vivo,,A,1,1,
Blood,BAO_0000218,4975,N,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,,50594,,16438,178.0,10090.0,Mus musculus,,CHEMBL620161,,,In vivo,,A,1,1,
,BAO_0000219,4976,N,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,Intermediate,797.0,80019,,10708,,9606.0,Homo sapiens,,CHEMBL620162,A-427,,,,F,1,1,
,BAO_0000219,4977,N,Inhibition of A431 human squamous cell carcinoma cell proliferation,Expert,500.0,80852,,16597,,9606.0,Homo sapiens,,CHEMBL620163,A-431,,,,F,1,1,
,BAO_0000219,4978,N,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,Expert,500.0,80852,,16062,,9606.0,Homo sapiens,,CHEMBL620833,A-431,,,,F,1,1,
,BAO_0000219,4979,N,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,Expert,500.0,80852,,16062,,9606.0,Homo sapiens,,CHEMBL876396,A-431,,,,F,1,1,
,BAO_0000219,4980,N,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,Expert,500.0,80852,,16958,,9606.0,Homo sapiens,,CHEMBL620834,A-431,,,,F,1,1,
,BAO_0000219,4981,N,Inhibition of A431 human carcinoma cell proliferation,Expert,500.0,80852,,6700,,9606.0,Homo sapiens,,CHEMBL620835,A-431,,,,F,1,1,
,BAO_0000219,4982,N,In vitro inhibition of A431 (human carcinoma) cell basal growth.,Expert,500.0,80852,,17226,,9606.0,Homo sapiens,,CHEMBL620836,A-431,,,,F,1,1,
,BAO_0000219,4983,N,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,Intermediate,500.0,80852,,6828,,9606.0,Homo sapiens,,CHEMBL620837,A-431,,,,F,1,1,
,BAO_0000219,4984,N,In vitro cytotoxicity against epidermoid carcinoma cell line,Intermediate,500.0,80852,,12314,,9606.0,Homo sapiens,,CHEMBL621017,A-431,,,,F,1,1,
,BAO_0000218,4985,D,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",Expert,500.0,9,,13412,,9606.0,Homo sapiens,,CHEMBL621018,A-431,,,,F,1,9,
,BAO_0000219,4986,N,Antiproliferative activity of compound was measured on human tumor cell line A431.,Intermediate,500.0,80852,,13299,,9606.0,Homo sapiens,,CHEMBL621019,A-431,,,,F,1,1,
,BAO_0000219,4987,N,Antiproliferative effect of compound on A431 cell line expressing mutant p53,Intermediate,500.0,80852,,17420,,9606.0,Homo sapiens,,CHEMBL621020,A-431,,,,F,1,1,
,BAO_0000219,4988,N,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,Intermediate,500.0,80852,,13678,,9606.0,Homo sapiens,,CHEMBL621021,A-431,,,,F,1,1,
,BAO_0000219,4989,H,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,Expert,500.0,9,,14171,,,,,CHEMBL621022,A-431,,,,F,1,8,
,BAO_0000219,4990,N,Tested for antiproliferative activity against human A431 cells,Expert,500.0,80852,,6333,,9606.0,Homo sapiens,,CHEMBL621023,A-431,,,,F,1,1,
,BAO_0000219,4991,D,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,Expert,500.0,9,,2356,,9606.0,Homo sapiens,,CHEMBL621024,A-431,,,,F,1,9,
,BAO_0000219,4992,N,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,Expert,500.0,80852,,15578,,9606.0,Homo sapiens,,CHEMBL621025,A-431,,,,F,1,1,
,BAO_0000219,4993,N,Inhibition of A431 cell proliferation,Expert,500.0,80852,,5126,,9606.0,Homo sapiens,,CHEMBL621026,A-431,,,,F,1,1,
,BAO_0000219,4994,N,Cytotoxic effect on A431 human epidermoid carcinoma cells,Expert,500.0,80852,,6844,,9606.0,Homo sapiens,,CHEMBL621027,A-431,,,,F,1,1,
,BAO_0000219,4995,N,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),Expert,500.0,80852,,6844,,9606.0,Homo sapiens,,CHEMBL876397,A-431,,,,F,1,1,
,BAO_0000219,4996,N,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,Intermediate,500.0,80852,,4925,,9606.0,Homo sapiens,,CHEMBL883797,A-431,,,,F,1,1,
,BAO_0000219,4997,N,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,Intermediate,500.0,80852,,4925,,9606.0,Homo sapiens,,CHEMBL621028,A-431,,,,F,1,1,
,BAO_0000219,4998,N,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,Intermediate,500.0,80852,,13978,,9606.0,Homo sapiens,,CHEMBL621029,A-431,,,,F,1,1,
,BAO_0000219,4999,N,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,Intermediate,500.0,80852,,16786,,9606.0,Homo sapiens,,CHEMBL621030,A-431,,,,F,1,1,
,BAO_0000219,5000,H,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,Expert,500.0,9,,13412,,,,,CHEMBL621147,A-431,,,,F,1,8,
,BAO_0000218,5001,N,In vivo antiproliferative activity against A431 cell line,Intermediate,500.0,80852,,17824,,9606.0,Homo sapiens,,CHEMBL621148,A-431,,,,F,1,1,
,BAO_0000219,5002,D,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,Expert,500.0,9,,12751,,9606.0,Homo sapiens,,CHEMBL621149,A-431,,,,F,1,9,
,BAO_0000219,5003,N,Inhibition of A431 human epidermoid carcinoma cell proliferation,Expert,500.0,80852,,12380,,9606.0,Homo sapiens,,CHEMBL621150,A-431,,,,F,1,1,
,BAO_0000219,5004,D,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,Expert,500.0,9,,4959,,9606.0,Homo sapiens,,CHEMBL621151,A-431,,,,F,1,9,
,BAO_0000219,5005,N,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),Intermediate,500.0,80852,,6333,,9606.0,Homo sapiens,,CHEMBL621152,A-431,,,,F,1,1,
,BAO_0000219,5006,N,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),Intermediate,500.0,80852,,6333,,9606.0,Homo sapiens,,CHEMBL621153,A-431,,,,F,1,1,
,BAO_0000219,5007,N,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),Intermediate,500.0,80852,,6333,,9606.0,Homo sapiens,,CHEMBL884000,A-431,,,,F,1,1,
,BAO_0000019,5008,D,Inhibition of EGFR overexpressing A431 cell proliferation,Expert,,9,,5296,,9606.0,Homo sapiens,,CHEMBL621154,,,,,F,1,9,
,BAO_0000219,5009,N,Inhibition of A431 cell proliferation,Expert,500.0,80852,,12624,,9606.0,Homo sapiens,,CHEMBL621155,A-431,,,,F,1,1,
,BAO_0000219,5010,D,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,Expert,500.0,9,,14926,,9606.0,Homo sapiens,,CHEMBL621156,A-431,,,,F,1,9,
,BAO_0000219,5011,D,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",Expert,500.0,9,,14926,,9606.0,Homo sapiens,,CHEMBL621157,A-431,,,,F,1,9,
,BAO_0000219,5012,H,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),Expert,500.0,9,,14926,,,,,CHEMBL621158,A-431,,,,F,1,8,
,BAO_0000219,5013,N,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,Intermediate,500.0,80852,,15144,,9606.0,Homo sapiens,,CHEMBL621159,A-431,,,,F,1,1,
,BAO_0000219,5014,N,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,Intermediate,500.0,80852,,15144,,9606.0,Homo sapiens,,CHEMBL621160,A-431,,,,F,1,1,
,BAO_0000219,5015,N,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,Intermediate,500.0,80852,,5245,,9606.0,Homo sapiens,,CHEMBL621161,A-431,,,,F,1,1,
,BAO_0000219,5016,N,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,Intermediate,500.0,80852,,5245,,9606.0,Homo sapiens,,CHEMBL621162,A-431,,,,F,1,1,
,BAO_0000219,5017,N,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,Intermediate,500.0,80852,,5245,,9606.0,Homo sapiens,,CHEMBL621163,A-431,,,,F,1,1,
,BAO_0000219,5018,N,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,Intermediate,500.0,80852,,5245,,9606.0,Homo sapiens,,CHEMBL621164,A-431,,,,F,1,1,
,BAO_0000219,5019,N,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,Intermediate,500.0,80852,,5245,,9606.0,Homo sapiens,,CHEMBL621165,A-431,,,,F,1,1,
,BAO_0000019,5020,U,Half-life period in cynomolgus monkey,Autocuration,,22224,,5922,,9527.0,Cercopithecidae,,CHEMBL619159,,,,,A,1,0,
Plasma,BAO_0000366,5021,U,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",Autocuration,,22224,,1116,1969.0,9527.0,Cercopithecidae,,CHEMBL619160,,,In vitro,,A,1,0,
,BAO_0000218,5022,U,Longer half-life in monkey (i.v.) at 0.5 mpk,Autocuration,,22224,,17853,,9527.0,Cercopithecidae,,CHEMBL619161,,,In vivo,,A,1,0,
Plasma,BAO_0000366,5023,U,Plasma half life in monkey,Autocuration,,22224,,993,1969.0,9527.0,Cercopithecidae,,CHEMBL619162,,,,,A,1,0,
Plasma,BAO_0000366,5024,U,Plasma half-life in rhesus monkey,Autocuration,,22224,,4514,1969.0,9527.0,Cercopithecidae,,CHEMBL619163,,,,,A,1,0,
Plasma,BAO_0000218,5025,U,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),Autocuration,,22224,,5334,1969.0,9527.0,Cercopithecidae,,CHEMBL619164,,,In vivo,,A,1,0,
Plasma,BAO_0000218,5026,U,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),Autocuration,,22224,,5334,1969.0,9527.0,Cercopithecidae,,CHEMBL619320,,,In vivo,,A,1,0,
,BAO_0000218,5027,U,Tested for half life upon iv administration to african green monkey,Autocuration,,22224,,4578,,9527.0,Cercopithecidae,,CHEMBL619321,,,In vivo,,A,1,0,
,BAO_0000218,5028,U,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,Autocuration,,22224,,2661,,9527.0,Cercopithecidae,,CHEMBL873336,,,In vivo,,A,1,0,
,BAO_0000218,5029,U,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,Autocuration,,22224,,5355,,9527.0,Cercopithecidae,,CHEMBL619322,,,In vivo,,A,1,0,
,BAO_0000218,5030,U,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,Autocuration,,22224,,5355,,9527.0,Cercopithecidae,,CHEMBL619323,,,In vivo,,A,1,0,
,BAO_0000218,5031,U,The time for peak concentration value after oral administration in cynomolgus monkeys,Autocuration,,22224,,5355,,9527.0,Cercopithecidae,,CHEMBL619324,,,In vivo,,A,1,0,
,BAO_0000019,5032,U,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,Autocuration,,22224,,11271,,9527.0,Cercopithecidae,,CHEMBL619325,,,,,A,1,0,
,BAO_0000019,5033,U,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,Autocuration,,22224,,11271,,9527.0,Cercopithecidae,,CHEMBL876411,,,,,A,1,0,
,BAO_0000019,5034,U,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,Autocuration,,22224,,11271,,9527.0,Cercopithecidae,,CHEMBL619326,,,,,A,1,0,
,BAO_0000019,5035,U,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,Autocuration,,22224,,11271,,9527.0,Cercopithecidae,,CHEMBL619327,,,,,A,1,0,
,BAO_0000019,5036,U,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,Autocuration,,22224,,11271,,9527.0,Cercopithecidae,,CHEMBL619328,,,,,A,1,0,
,BAO_0000019,5037,U,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,Autocuration,,22224,,11271,,9527.0,Cercopithecidae,,CHEMBL619329,,,,,A,1,0,
,BAO_0000019,5038,U,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,Autocuration,,22224,,11271,,9527.0,Cercopithecidae,,CHEMBL619330,,,,,A,1,0,
,BAO_0000019,5039,U,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,Autocuration,,22224,,11271,,9527.0,Cercopithecidae,,CHEMBL619331,,,,,A,1,0,
,BAO_0000019,5040,U,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,Autocuration,,22224,,11271,,9527.0,Cercopithecidae,,CHEMBL619332,,,,,A,1,0,
,BAO_0000019,5041,U,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,Autocuration,,22224,,11271,,9527.0,Cercopithecidae,,CHEMBL619333,,,,,A,1,0,
,BAO_0000019,5042,U,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,Autocuration,,22224,,11271,,9527.0,Cercopithecidae,,CHEMBL619334,,,,,A,1,0,
,BAO_0000019,5043,U,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,Autocuration,,22224,,11271,,9527.0,Cercopithecidae,,CHEMBL619335,,,,,A,1,0,
,BAO_0000019,5044,U,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,Autocuration,,22224,,11271,,9527.0,Cercopithecidae,,CHEMBL619336,,,,,A,1,0,
,BAO_0000019,5045,U,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,Autocuration,,22224,,11271,,9527.0,Cercopithecidae,,CHEMBL619337,,,,,A,1,0,
,BAO_0000019,5046,U,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,Autocuration,,22224,,11271,,9527.0,Cercopithecidae,,CHEMBL619338,,,,,A,1,0,
,BAO_0000019,5047,U,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,Autocuration,,22224,,11271,,9527.0,Cercopithecidae,,CHEMBL619339,,,,,A,1,0,
,BAO_0000218,5048,N,Bioavailability in rat (cannulated) (dose 2 mg/kg),Intermediate,,50597,,5809,,10116.0,Rattus norvegicus,,CHEMBL619340,,,In vivo,,A,1,1,
Plasma,BAO_0000218,5049,N,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,Intermediate,,50597,,17720,1969.0,10116.0,Rattus norvegicus,,CHEMBL873496,,,In vivo,,A,1,1,
Plasma,BAO_0000218,5050,N,AUC value in rat after IV administration at a dose of 10 mg/kg,Intermediate,,50597,,3546,1969.0,10116.0,Rattus norvegicus,,CHEMBL619341,,,,,A,1,1,
Plasma,BAO_0000218,5051,N,AUC value in rat after oral administration at a dose of 10 mg/kg,Intermediate,,50597,,3546,1969.0,10116.0,Rattus norvegicus,,CHEMBL619342,,,,,A,1,1,
,BAO_0000218,5052,N,Cmax value in rat after oral administration at a dose of 10 mg/kg,Intermediate,,50597,,3546,,10116.0,Rattus norvegicus,,CHEMBL619343,,,In vivo,,A,1,1,
,BAO_0000218,5053,N,Bioavailability in rat after oral administration at a dose of 10 mg/kg,Intermediate,,50597,,3546,,10116.0,Rattus norvegicus,,CHEMBL619344,,,In vivo,,A,1,1,
,BAO_0000218,5054,N,Tmax value in rat after oral administration at a dose of 10 mg/kg,Intermediate,,50597,,3546,,10116.0,Rattus norvegicus,,CHEMBL619345,,,In vivo,,A,1,1,
,BAO_0000218,5055,N,Vc value in rat after IV administration at a dose of 10 mg/kg,Intermediate,,50597,,3546,,10116.0,Rattus norvegicus,,CHEMBL619346,,,,,A,1,1,
,BAO_0000218,5056,N,Half life period in rat after IV administration at a dose of 10 mg/kg,Intermediate,,50597,,3546,,10116.0,Rattus norvegicus,,CHEMBL619347,,,In vivo,,A,1,1,
,BAO_0000019,5057,U,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,Autocuration,,22224,,10625,,9557.0,Papio hamadryas,,CHEMBL619348,,,,,A,1,0,
,BAO_0000019,5058,U,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),Autocuration,,22224,,10625,,9557.0,Papio hamadryas,,CHEMBL619349,,,,,A,1,0,
,BAO_0000019,5059,U,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),Autocuration,,22224,,10625,,9557.0,Papio hamadryas,,CHEMBL619350,,,,,A,1,0,
,BAO_0000019,5060,U,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,Autocuration,,22224,,10625,,9557.0,Papio hamadryas,,CHEMBL619351,,,,,A,1,0,
,BAO_0000019,5061,U,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,Autocuration,,22224,,10625,,9557.0,Papio hamadryas,,CHEMBL875953,,,,,A,1,0,
,BAO_0000019,5062,U,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,Autocuration,,22224,,10625,,9557.0,Papio hamadryas,,CHEMBL621716,,,,,A,1,0,
,BAO_0000019,5063,U,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,Autocuration,,22224,,10625,,9557.0,Papio hamadryas,,CHEMBL621717,,,,,A,1,0,
,BAO_0000019,5064,U,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,Autocuration,,22224,,10625,,9557.0,Papio hamadryas,,CHEMBL621718,,,,,A,1,0,
,BAO_0000019,5065,U,Area under curve after 1 mpk peroral administration to beagles,Autocuration,,22224,,3510,,9615.0,beagle,,CHEMBL621719,,,,,A,1,0,
,BAO_0000019,5066,U,Area under curve after 2 mpk peroral administration to beagles,Autocuration,,22224,,3510,,9615.0,beagle,,CHEMBL621720,,,,,A,1,0,
,BAO_0000218,5067,U,Cmax value after 1 mpk peroral administration to beagles,Autocuration,,22224,,3510,,9615.0,beagle,,CHEMBL621721,,,In vivo,,A,1,0,
Urine,BAO_0000019,5068,U,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,Autocuration,,22224,,7766,1088.0,9606.0,Homo sapiens,,CHEMBL621722,,,,,A,1,0,
Urine,BAO_0000019,5069,U,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,Autocuration,,22224,,7766,1088.0,9606.0,Homo sapiens,,CHEMBL621723,,,,,A,1,0,
Urine,BAO_0000019,5070,U,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,Autocuration,,22224,,7766,1088.0,9606.0,Homo sapiens,,CHEMBL621724,,,,,A,1,0,
Urine,BAO_0000019,5071,U,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,Autocuration,,22224,,7766,1088.0,9606.0,Homo sapiens,,CHEMBL623443,,,,,A,1,0,
Urine,BAO_0000019,5072,U,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,Autocuration,,22224,,7766,1088.0,9606.0,Homo sapiens,,CHEMBL623444,,,,,A,1,0,
Urine,BAO_0000019,5073,U,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,Autocuration,,22224,,7766,1088.0,9606.0,Homo sapiens,,CHEMBL623445,,,,,A,1,0,
Urine,BAO_0000019,5074,U,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,Autocuration,,22224,,7766,1088.0,9606.0,Homo sapiens,,CHEMBL623446,,,,,A,1,0,
Liver,BAO_0000251,5075,U,Metabolic stability observed at 30 min after administration in human liver microsomes,Autocuration,,22224,,16643,2107.0,9606.0,Homo sapiens,,CHEMBL623447,,,,Microsomes,A,1,0,
,BAO_0000019,5076,U,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,Autocuration,,22224,,6852,,9606.0,Homo sapiens,,CHEMBL623448,,,,,A,1,0,
,BAO_0000019,5077,U,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,Autocuration,,22224,,6852,,9606.0,Homo sapiens,,CHEMBL623449,,,,,A,1,0,
,BAO_0000019,5078,U,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,Autocuration,,22224,,6852,,9606.0,Homo sapiens,,CHEMBL623450,,,,,A,1,0,
Liver,BAO_0000251,5079,U,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",Autocuration,,22224,,6567,2107.0,9606.0,Homo sapiens,,CHEMBL623451,,,,Microsomes,A,1,0,
,BAO_0000019,5080,U,Metabolic stability (% remaining at 30 mins) in human S9.,Autocuration,,22224,,6570,,9606.0,Homo sapiens,,CHEMBL623452,,,,,A,1,0,
,BAO_0000019,5081,U,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,Autocuration,,22224,,6570,,9606.0,Homo sapiens,,CHEMBL623453,,,,,A,1,0,
Liver,BAO_0000251,5082,U,Percent parent compound remaining after 20 min incubation with human liver microsomes,Autocuration,,22224,,5237,2107.0,9606.0,Homo sapiens,,CHEMBL623454,,,,Microsomes,A,1,0,
Liver,BAO_0000251,5083,U,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,Autocuration,,22224,,5237,2107.0,9606.0,Homo sapiens,,CHEMBL623455,,,,Microsomes,A,1,0,
Liver,BAO_0000251,5084,U,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,Autocuration,,22224,,5237,2107.0,9606.0,Homo sapiens,,CHEMBL624371,,,,Microsomes,A,1,0,
,BAO_0000218,5085,U,First pass metabolism and metabolic bioavailability using human hepatic microsomes,Autocuration,,22224,,5202,,9606.0,Homo sapiens,,CHEMBL624372,,,,,A,1,0,
,BAO_0000019,5086,U,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,Autocuration,,22224,,5481,,9606.0,Homo sapiens,,CHEMBL624373,,,,,A,1,0,
,BAO_0000019,5087,U,Percent remaining in human plasma after incubation for 60 min at 37 C.,Autocuration,,22224,,5481,,9606.0,Homo sapiens,,CHEMBL624374,,,,,A,1,0,
,BAO_0000019,5088,U,The percent remaining in human plasma after 30 min was determined,Autocuration,,22224,,3956,,9606.0,Homo sapiens,,CHEMBL624556,,,,,A,1,0,
Plasma,BAO_0000366,5089,U,Conversion rate of the prodrug in human plasma,Autocuration,,22224,,5074,1969.0,9606.0,Homo sapiens,,CHEMBL624557,,,,,A,1,0,
Plasma,BAO_0000366,5090,U,Conversion rate of the prodrug in human plasma; ND means no data,Autocuration,,22224,,5074,1969.0,9606.0,Homo sapiens,,CHEMBL624558,,,,,A,1,0,
Blood,BAO_0000221,5091,U,Half life of compound was determined in human blood,Autocuration,,22224,,4727,178.0,9606.0,Homo sapiens,,CHEMBL624559,,,,,A,1,0,
,BAO_0000019,5092,U,Half life of compound was determined in man with once daily dosing,Autocuration,,22224,,5965,,9606.0,Homo sapiens,,CHEMBL624560,,,,,A,1,0,
,BAO_0000251,5093,U,Half life in human microsomes,Autocuration,,22224,,5732,,9606.0,Homo sapiens,,CHEMBL624561,,,In vitro,Microsomes,A,1,0,
Plasma,BAO_0000366,5094,U,Half life in human plasma,Autocuration,,22224,,5819,1969.0,9606.0,Homo sapiens,,CHEMBL624562,,,,,A,1,0,
Plasma,BAO_0000366,5095,U,Half life in human plasma; Not detected,Autocuration,,22224,,5819,1969.0,9606.0,Homo sapiens,,CHEMBL624563,,,,,A,1,0,
,BAO_0000218,5096,U,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,Autocuration,,22224,,1916,,9606.0,Homo sapiens,,CHEMBL624564,,,In vivo,,A,1,0,
Liver,BAO_0000251,5097,U,Half-life for oxidative metabolic stability was determined using rat liver microsomes,Autocuration,,22224,,6597,2107.0,9606.0,Homo sapiens,,CHEMBL624565,,,In vitro,Microsomes,A,1,0,
Plasma,BAO_0000366,5098,U,Half-life in human plasma,Autocuration,,22224,,5229,1969.0,9606.0,Homo sapiens,,CHEMBL875152,,,,,A,1,0,
Plasma,BAO_0000366,5099,U,Half-life of the parent prodrug in plasma,Autocuration,,22224,,5229,1969.0,9606.0,Homo sapiens,,CHEMBL624566,,,,,A,1,0,
Plasma,BAO_0000366,5100,U,In vitro half life in human plasma was determined,Autocuration,,22224,,2192,1969.0,9606.0,Homo sapiens,,CHEMBL873805,,,In vitro,,A,1,0,
Liver,BAO_0000251,5101,U,The compound was tested In Vitro for half life in human liver microsomes.,Autocuration,,22224,,3032,2107.0,9606.0,Homo sapiens,,CHEMBL624567,,,In vitro,Microsomes,A,1,0,
,BAO_0000218,5102,U,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,Autocuration,,22224,,1916,,9606.0,Homo sapiens,,CHEMBL624568,,,In vivo,,A,1,0,
,BAO_0000218,5103,U,Observed volume of distribution,Autocuration,,22224,,17716,,9606.0,Homo sapiens,,CHEMBL624569,,,In vivo,,A,1,0,
,BAO_0000218,5104,U,Oral bioavailability in human,Autocuration,,22224,,15778,,9606.0,Homo sapiens,,CHEMBL624570,,,In vivo,,A,1,0,
,BAO_0000019,5105,U,Tested for human plasma protein binding of the compound,Autocuration,,22224,,17313,,9606.0,Homo sapiens,,CHEMBL624571,,,,,A,1,0,
,BAO_0000019,5106,U,"First order rate constant, k was determined in human plasma",Autocuration,,22224,,4231,,9606.0,Homo sapiens,,CHEMBL624572,,,,,A,1,0,
,BAO_0000019,5107,U,Observed rate constant in 80% human plasma at 37 degree Centigrade,Autocuration,,22224,,4755,,9606.0,Homo sapiens,,CHEMBL624573,,,,,A,1,0,
,BAO_0000019,5108,U,Observed rate constant in 80% human plasma at 37 degree Centigrade,Autocuration,,22224,,4755,,9606.0,Homo sapiens,,CHEMBL875153,,,,,A,1,0,
Liver,BAO_0000251,5109,U,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,Autocuration,,22224,,16907,2107.0,9606.0,Homo sapiens,,CHEMBL624574,,,,Microsomes,A,1,0,
,BAO_0000019,5110,U,The compound was tested for the plasma binding in human,Autocuration,,22224,,10839,,9606.0,Homo sapiens,,CHEMBL624575,,,,,A,1,0,
,BAO_0000019,5111,U,Plasma protein binding (human),Autocuration,,22224,,10839,,9606.0,Homo sapiens,,CHEMBL624576,,,,,A,1,0,
Liver,BAO_0000251,5112,U,Compound was evaluated for half-life in human liver microsomes,Autocuration,,22224,,3199,2107.0,9606.0,Homo sapiens,,CHEMBL624577,,,In vitro,Microsomes,A,1,0,
Blood,BAO_0000221,5113,U,Half life measured in vitro for its stability in human blood,Autocuration,,22224,,1345,178.0,9606.0,Homo sapiens,,CHEMBL624578,,,In vitro,,A,1,0,
Serum,BAO_0000019,5114,U,Half life in human serum,Autocuration,,22224,,4297,1977.0,9606.0,Homo sapiens,,CHEMBL622796,,,,,A,1,0,
Serum,BAO_0000019,5115,U,Half life in human serum; ND=not determined,Autocuration,,22224,,4297,1977.0,9606.0,Homo sapiens,,CHEMBL622797,,,,,A,1,0,
,BAO_0000019,5116,U,Half life were determined in CEM-SS cell extract in decomposition step 1,Autocuration,,22224,,4297,,9606.0,Homo sapiens,,CHEMBL622798,,,,,A,1,0,
,BAO_0000019,5117,U,Half life were determined in CEM-SS cell extract in decomposition step 2,Autocuration,,22224,,4297,,9606.0,Homo sapiens,,CHEMBL622799,,,,,A,1,0,
Plasma,BAO_0000366,5118,U,Half life of the in human plasma,Autocuration,,22224,,4231,1969.0,9606.0,Homo sapiens,,CHEMBL622800,,,,,A,1,0,
,BAO_0000220,5119,U,Half life period in human hepatic S9 fraction was determined,Autocuration,,22224,,5633,,9606.0,Homo sapiens,,CHEMBL622801,,,In vitro,S9,A,1,0,
Liver,BAO_0000251,5120,U,Half life period in human liver microsome was determined,Autocuration,,22224,,5633,2107.0,9606.0,Homo sapiens,,CHEMBL622802,,,In vitro,Microsomes,A,1,0,
,BAO_0000019,5121,U,Half life period was determined; 6-7,Autocuration,,22224,,17791,,9606.0,Homo sapiens,,CHEMBL622803,,,,,A,1,0,
,BAO_0000019,5122,U,Half life period was evaluated in human,Autocuration,,22224,,17791,,9606.0,Homo sapiens,,CHEMBL875154,,,,,A,1,0,
Plasma,BAO_0000366,5123,U,Half life time in human plasma,Autocuration,,22224,,3160,1969.0,9606.0,Homo sapiens,,CHEMBL622804,,,,,A,1,0,
Brain,BAO_0000218,5124,N,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,,50594,,16438,955.0,10090.0,Mus musculus,,CHEMBL622805,,,In vivo,,A,1,1,
Heart,BAO_0000218,5125,N,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,,50594,,16438,948.0,10090.0,Mus musculus,,CHEMBL622611,,,In vivo,,A,1,1,
Heart,BAO_0000218,5126,N,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,,50594,,16438,948.0,10090.0,Mus musculus,,CHEMBL622612,,,In vivo,,A,1,1,
Kidney,BAO_0000218,5127,N,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,,50594,,16438,2113.0,10090.0,Mus musculus,,CHEMBL875160,,,In vivo,,A,1,1,
Kidney,BAO_0000218,5128,N,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",Intermediate,,50594,,16438,2113.0,10090.0,Mus musculus,,CHEMBL622613,,,In vivo,,A,1,1,
Kidney,BAO_0000218,5129,N,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,,50594,,16438,2113.0,10090.0,Mus musculus,,CHEMBL622614,,,In vivo,,A,1,1,
Liver,BAO_0000218,5130,N,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,,50594,,16438,2107.0,10090.0,Mus musculus,,CHEMBL622615,,,In vivo,,A,1,1,
Liver,BAO_0000218,5131,N,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,Intermediate,,50594,,16438,2107.0,10090.0,Mus musculus,,CHEMBL622616,,,In vivo,,A,1,1,
Liver,BAO_0000218,5132,N,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,,50594,,16438,2107.0,10090.0,Mus musculus,,CHEMBL622617,,,In vivo,,A,1,1,
Spleen,BAO_0000218,5133,N,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,Intermediate,,50594,,16438,2106.0,10090.0,Mus musculus,,CHEMBL622618,,,In vivo,,A,1,1,
Spleen,BAO_0000218,5134,N,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",Intermediate,,50594,,16438,2106.0,10090.0,Mus musculus,,CHEMBL622619,,,In vivo,,A,1,1,
Spleen,BAO_0000218,5135,N,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,,50594,,16438,2106.0,10090.0,Mus musculus,,CHEMBL622620,,,In vivo,,A,1,1,
Brain,BAO_0000218,5136,N,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,,50594,,16438,955.0,10090.0,Mus musculus,,CHEMBL622621,,,In vivo,,A,1,1,
Blood,BAO_0000218,5137,N,Biodistribution of compound (oxidized form) in blood tissue,Intermediate,,50594,,16438,178.0,10090.0,Mus musculus,,CHEMBL622622,,,In vivo,,A,1,1,
Blood,BAO_0000218,5138,N,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,,50594,,16438,178.0,10090.0,Mus musculus,,CHEMBL622623,,,In vivo,,A,1,1,
Blood,BAO_0000218,5139,N,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",Intermediate,,50594,,16438,178.0,10090.0,Mus musculus,,CHEMBL622624,,,In vivo,,A,1,1,
Blood,BAO_0000218,5140,N,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,,50594,,16438,178.0,10090.0,Mus musculus,,CHEMBL622625,,,In vivo,,A,1,1,
Blood,BAO_0000218,5141,N,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,,50594,,16438,178.0,10090.0,Mus musculus,,CHEMBL622626,,,In vivo,,A,1,1,
Blood,BAO_0000218,5142,N,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",Intermediate,,50594,,16438,178.0,10090.0,Mus musculus,,CHEMBL622627,,,In vivo,,A,1,1,
Brain,BAO_0000218,5143,N,Biodistribution of compound (oxidized form) in brain tissue of mice,Intermediate,,50594,,16438,955.0,10090.0,Mus musculus,,CHEMBL622628,,,In vivo,,A,1,1,
Brain,BAO_0000218,5144,N,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,,50594,,16438,955.0,10090.0,Mus musculus,,CHEMBL622629,,,In vivo,,A,1,1,
Brain,BAO_0000218,5145,N,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,,50594,,16438,955.0,10090.0,Mus musculus,,CHEMBL622630,,,In vivo,,A,1,1,
Brain,BAO_0000218,5146,N,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,,50594,,16438,955.0,10090.0,Mus musculus,,CHEMBL622631,,,In vivo,,A,1,1,
Brain,BAO_0000218,5147,N,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",Intermediate,,50594,,16438,955.0,10090.0,Mus musculus,,CHEMBL622632,,,In vivo,,A,1,1,
Brain,BAO_0000218,5148,N,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",Intermediate,,50594,,16438,955.0,10090.0,Mus musculus,,CHEMBL622633,,,In vivo,,A,1,1,
Heart,BAO_0000218,5149,N,Biodistribution of compound (oxidized form) in heart tissue of mice,Intermediate,,50594,,16438,948.0,10090.0,Mus musculus,,CHEMBL622634,,,In vivo,,A,1,1,
Heart,BAO_0000218,5150,N,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,,50594,,16438,948.0,10090.0,Mus musculus,,CHEMBL622635,,,In vivo,,A,1,1,
Heart,BAO_0000218,5151,N,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,,50594,,16438,948.0,10090.0,Mus musculus,,CHEMBL875161,,,In vivo,,A,1,1,
Heart,BAO_0000218,5152,N,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,,50594,,16438,948.0,10090.0,Mus musculus,,CHEMBL622636,,,In vivo,,A,1,1,
Heart,BAO_0000218,5153,N,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,,50594,,16438,948.0,10090.0,Mus musculus,,CHEMBL623335,,,In vivo,,A,1,1,
Heart,BAO_0000218,5154,N,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",Intermediate,,50594,,16438,948.0,10090.0,Mus musculus,,CHEMBL623336,,,In vivo,,A,1,1,
Kidney,BAO_0000218,5155,N,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,,50594,,16438,2113.0,10090.0,Mus musculus,,CHEMBL623337,,,In vivo,,A,1,1,
Kidney,BAO_0000218,5156,N,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",Intermediate,,50594,,16438,2113.0,10090.0,Mus musculus,,CHEMBL623338,,,In vivo,,A,1,1,
Kidney,BAO_0000218,5157,N,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,,50594,,16438,2113.0,10090.0,Mus musculus,,CHEMBL623339,,,In vivo,,A,1,1,
Kidney,BAO_0000218,5158,N,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,,50594,,16438,2113.0,10090.0,Mus musculus,,CHEMBL623524,,,In vivo,,A,1,1,
Kidney,BAO_0000218,5159,N,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",Intermediate,,50594,,16438,2113.0,10090.0,Mus musculus,,CHEMBL623525,,,In vivo,,A,1,1,
Liver,BAO_0000218,5160,N,Biodistribution of compound (oxidized form) in liver tissue,Intermediate,,50594,,16438,2107.0,10090.0,Mus musculus,,CHEMBL623526,,,In vivo,,A,1,1,
Liver,BAO_0000218,5161,N,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,,50594,,16438,2107.0,10090.0,Mus musculus,,CHEMBL623527,,,In vivo,,A,1,1,
Liver,BAO_0000218,5162,N,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,,50594,,16438,2107.0,10090.0,Mus musculus,,CHEMBL623528,,,In vivo,,A,1,1,
,BAO_0000219,5163,N,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,Intermediate,500.0,80852,,5245,,9606.0,Homo sapiens,,CHEMBL624615,A-431,,,,F,1,1,
,BAO_0000219,5164,N,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,Intermediate,500.0,80852,,5245,,9606.0,Homo sapiens,,CHEMBL621672,A-431,,,,F,1,1,
,BAO_0000218,5165,N,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",Expert,500.0,80852,,16289,,,,,CHEMBL621673,A-431,,,,F,1,1,
,BAO_0000218,5166,N,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",Expert,500.0,80852,,16289,,,,,CHEMBL621674,A-431,,,,F,1,1,
,BAO_0000219,5167,D,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,Expert,500.0,9,,16093,,9606.0,Homo sapiens,,CHEMBL884002,A-431,,,,F,1,9,
,BAO_0000219,5168,N,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",Intermediate,500.0,80852,,16825,,9606.0,Homo sapiens,,CHEMBL621850,A-431,,,,F,1,1,
,BAO_0000219,5169,N,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,Intermediate,500.0,80852,,4848,,9606.0,Homo sapiens,,CHEMBL621851,A-431,,,,F,1,1,
,BAO_0000219,5170,D,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,Expert,500.0,9,,14827,,9606.0,Homo sapiens,,CHEMBL621852,A-431,,,,F,1,9,
,BAO_0000219,5171,D,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,Expert,500.0,9,,14827,,9606.0,Homo sapiens,,CHEMBL621853,A-431,,,,F,1,9,
,BAO_0000218,5172,N,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",Expert,500.0,80852,,16289,,,,,CHEMBL621854,A-431,,,,F,1,1,
,BAO_0000218,5173,N,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",Expert,500.0,80852,,16289,,,,,CHEMBL621855,A-431,,,,F,1,1,
,BAO_0000218,5174,N,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",Expert,500.0,80852,,16289,,,,,CHEMBL623724,A-431,,,,F,1,1,
,BAO_0000218,5175,N,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",Expert,500.0,80852,,16289,,,,,CHEMBL623725,A-431,,,,F,1,1,
,BAO_0000218,5176,N,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",Expert,500.0,80852,,16289,,,,,CHEMBL623726,A-431,,,,F,1,1,
,BAO_0000219,5177,D,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",Expert,500.0,9,,16289,,9606.0,Homo sapiens,,CHEMBL623727,A-431,,,,F,1,9,
,BAO_0000219,5178,H,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,Expert,500.0,9,,16289,,,,,CHEMBL623728,A-431,,,,F,1,8,
,BAO_0000218,5179,N,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",Expert,500.0,80852,,16289,,,,,CHEMBL623729,A-431,,,,F,1,1,
,BAO_0000218,5180,N,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",Expert,500.0,80852,,16289,,,,,CHEMBL623730,A-431,,,,F,1,1,
,BAO_0000218,5181,N,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",Expert,500.0,80852,,16289,,,,,CHEMBL623731,A-431,,,,F,1,1,
,BAO_0000218,5182,N,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",Expert,500.0,80852,,14555,,10090.0,Mus musculus,,CHEMBL623732,A-431,,,,F,1,1,
,BAO_0000218,5183,N,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",Expert,500.0,80852,,14555,,10090.0,Mus musculus,,CHEMBL623733,A-431,,,,F,1,1,
,BAO_0000218,5184,N,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",Expert,500.0,80852,,14555,,10090.0,Mus musculus,,CHEMBL623734,A-431,,,,F,1,1,
,BAO_0000218,5185,N,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",Expert,500.0,80852,,14555,,10090.0,Mus musculus,,CHEMBL623735,A-431,,,,F,1,1,
,BAO_0000219,5186,N,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,Expert,500.0,80852,,1937,,9606.0,Homo sapiens,,CHEMBL623736,A-431,,,,F,1,1,
,BAO_0000219,5187,N,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,Intermediate,500.0,80852,,13739,,9606.0,Homo sapiens,,CHEMBL623737,A-431,,,,F,1,1,
,BAO_0000219,5188,N,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,Intermediate,500.0,80852,,3558,,9606.0,Homo sapiens,,CHEMBL623738,A-431,,,,F,1,1,
,BAO_0000219,5189,N,Dose giving a 50% decrease in the living cell number (A437 cells),Intermediate,500.0,80852,,3558,,9606.0,Homo sapiens,,CHEMBL875168,A-431,,,,F,1,1,
,BAO_0000219,5190,N,In vitro inhibitory concentration against proliferation of A459 cell line.,Expert,646.0,80682,,17686,,9606.0,Homo sapiens,,CHEMBL623739,A549,,,,F,1,1,
,BAO_0000219,5191,N,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,Intermediate,646.0,80682,,5305,,9606.0,Homo sapiens,,CHEMBL623740,A549,,,,F,1,1,
,BAO_0000219,5192,N,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,Intermediate,646.0,80682,,3614,,9606.0,Homo sapiens,,CHEMBL624424,A549,,,,F,1,1,
,BAO_0000219,5193,N,In vitro antitumor activity against renal A498 tumor cell lines,Intermediate,624.0,80021,,17229,,9606.0,Homo sapiens,,CHEMBL624425,A498,,,,F,1,1,
,BAO_0000219,5194,N,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",Intermediate,624.0,80021,,15935,,9606.0,Homo sapiens,,CHEMBL624426,A498,,,,F,1,1,
,BAO_0000219,5195,N,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",Intermediate,624.0,80021,,15935,,9606.0,Homo sapiens,,CHEMBL624427,A498,,,,F,1,1,
,BAO_0000219,5196,N,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,Intermediate,624.0,80021,,15560,,9606.0,Homo sapiens,,CHEMBL624428,A498,,,,F,1,1,
,BAO_0000219,5197,N,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,Intermediate,624.0,80021,,13891,,9606.0,Homo sapiens,,CHEMBL624429,A498,,,,F,1,1,
,BAO_0000219,5198,N,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,Intermediate,624.0,80021,,13891,,9606.0,Homo sapiens,,CHEMBL624620,A498,,,,F,1,1,
,BAO_0000219,5199,N,Cytotoxicity on kidney carcinoma (A-498) cell line,Intermediate,624.0,80021,,13788,,9606.0,Homo sapiens,,CHEMBL624621,A498,,,,F,1,1,
,BAO_0000219,5200,N,Compound was evaluated against Human cell line renal A498,Intermediate,624.0,80021,,15403,,9606.0,Homo sapiens,,CHEMBL624622,A498,,,,F,1,1,
,BAO_0000219,5201,N,Compound was tested for inhibition of A498 human renal cancer cell line,Intermediate,624.0,80021,,1009,,9606.0,Homo sapiens,,CHEMBL624623,A498,,,,F,1,1,
,BAO_0000219,5202,N,Growth inhibitory activity against A498 human cancer cell line,Intermediate,624.0,80021,,1043,,9606.0,Homo sapiens,,CHEMBL874365,A498,,,,F,1,1,
,BAO_0000219,5203,N,In vitro antitumor activity against human renal A498 cell line,Intermediate,624.0,80021,,5858,,9606.0,Homo sapiens,,CHEMBL624624,A498,,,,F,1,1,
,BAO_0000219,5204,N,In vitro cytotoxic activity against renal (A498) cell line,Intermediate,624.0,80021,,5958,,9606.0,Homo sapiens,,CHEMBL624625,A498,,,,F,1,1,
,BAO_0000219,5205,N,In vitro cytotoxic activity against human renal cancer (A498) cell line,Intermediate,624.0,80021,,5506,,9606.0,Homo sapiens,,CHEMBL624626,A498,,,,F,1,1,
,BAO_0000219,5206,N,Tested for cytostatic activity against renal A498 cell line,Intermediate,624.0,80021,,12781,,9606.0,Homo sapiens,,CHEMBL624627,A498,,,,F,1,1,
,BAO_0000219,5207,N,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,Intermediate,624.0,80021,,14399,,9606.0,Homo sapiens,,CHEMBL883157,A498,,,,F,1,1,
,BAO_0000219,5208,N,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,Expert,624.0,80021,,5958,,9606.0,Homo sapiens,,CHEMBL624628,A498,,,,F,1,1,
,BAO_0000218,5209,U,Cmax value after 2 mpk peroral administration to beagles,Autocuration,,22224,,3510,,9615.0,beagle,,CHEMBL624629,,,In vivo,,A,1,0,
,BAO_0000218,5210,U,Bioavailability,Autocuration,,22224,,3510,,9615.0,Canis lupus familiaris,,CHEMBL623551,,,In vivo,,A,1,0,beagle
,BAO_0000218,5211,U,Bioavailability after 1 mpk peroral administration to beagles,Autocuration,,22224,,3510,,9615.0,Canis lupus familiaris,,CHEMBL623552,,,In vivo,,A,1,0,beagle
,BAO_0000218,5212,U,Bioavailability after 2 mpk peroral administration to beagles,Autocuration,,22224,,3510,,9615.0,Canis lupus familiaris,,CHEMBL623553,,,In vivo,,A,1,0,beagle
,BAO_0000019,5213,U,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,Autocuration,,22224,,3085,,9913.0,Bos taurus,,CHEMBL623554,,,,,A,1,0,
,BAO_0000019,5214,U,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,Autocuration,,22224,,3085,,9913.0,Bos taurus,,CHEMBL623555,,,,,A,1,0,
,BAO_0000019,5215,U,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,Autocuration,,22224,,3085,,9913.0,Bos taurus,,CHEMBL623556,,,,,A,1,0,
,BAO_0000019,5216,U,Solubility against bovine alpha-chymotrypsin,Autocuration,,22224,,9372,,9913.0,Bos taurus,,CHEMBL623557,,,,,A,1,0,
,BAO_0000019,5217,U,Rate constant of the bovine serum albumin catalyzed reaction of the compound,Autocuration,,22224,,3085,,9913.0,Bos taurus,,CHEMBL623558,,,,,A,1,0,
,BAO_0000019,5218,U,Rate constant of the bovine serum albumin catalyzed reaction of the compound,Autocuration,,22224,,3085,,9913.0,Bos taurus,,CHEMBL623559,,,,,A,1,0,
Spleen,BAO_0000221,5219,U,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,Autocuration,,22224,,1469,2106.0,9913.0,Bos taurus,,CHEMBL623560,,,,,A,1,0,
,BAO_0000019,5220,U,Half life in culture medium containing 10% of heat inactivated foetal calf serum,Autocuration,,22224,,4297,,9913.0,Bos taurus,,CHEMBL623561,,,,,A,1,0,
,BAO_0000019,5221,U,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,Autocuration,,22224,,4297,,9913.0,Bos taurus,,CHEMBL623562,,,,,A,1,0,
,BAO_0000019,5222,U,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,Autocuration,,22224,,17585,,9913.0,Bos taurus,,CHEMBL623563,,,,,A,1,0,
Spleen,BAO_0000221,5223,U,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,Autocuration,,22224,,1336,2106.0,9913.0,Bos taurus,,CHEMBL623564,,,,,A,1,0,
,BAO_0000019,5224,U,Half life in presence of 2 mg/mL BSA at pH 8.8,Autocuration,,22224,,3085,,9913.0,Bos taurus,,CHEMBL873806,,,,,A,1,0,
,BAO_0000019,5225,U,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,Autocuration,,22224,,2857,,9913.0,Bos taurus,,CHEMBL623565,,,,,A,1,0,
,BAO_0000019,5226,U,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,Autocuration,,22224,,2857,,9913.0,Bos taurus,,CHEMBL623566,,,,,A,1,0,
,BAO_0000019,5227,U,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,Autocuration,,22224,,2857,,9913.0,Bos taurus,,CHEMBL623567,,,,,A,1,0,
,BAO_0000019,5228,U,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),Autocuration,,22224,,1540,,9913.0,Bos taurus,,CHEMBL623568,,,,,A,1,0,
Plasma,BAO_0000218,5229,N,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,Intermediate,,50588,,6316,1969.0,9615.0,Canis lupus familiaris,,CHEMBL623569,,,,,A,1,1,
Plasma,BAO_0000218,5230,N,AUC after administration at 100 mg/kg/day in dogs,Intermediate,,50588,,17594,1969.0,9615.0,Canis lupus familiaris,,CHEMBL623570,,,,,A,1,1,
Plasma,BAO_0000218,5231,N,AUC in dog at 0-24 hr by peroral administration at 3 mpk,Intermediate,,50588,,4953,1969.0,9615.0,Canis lupus familiaris,,CHEMBL624254,,,,,A,1,1,
Plasma,BAO_0000218,5232,N,AUC value after 15 mg/kg iv dose in Dogs,Intermediate,,50588,,16907,1969.0,9615.0,Canis lupus familiaris,,CHEMBL624255,,,,,A,1,1,
Plasma,BAO_0000218,5233,N,AUC value after 30 mg/kg po dose in Dogs,Intermediate,,50588,,16907,1969.0,9615.0,Canis lupus familiaris,,CHEMBL624256,,,,,A,1,1,
Plasma,BAO_0000218,5234,N,AUC value after administration of 4 mg/Kg oral dose in dog,Intermediate,,50588,,2959,1969.0,9615.0,Canis lupus familiaris,,CHEMBL624257,,,,,A,1,1,
Plasma,BAO_0000218,5235,N,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,Intermediate,,50588,,17594,1969.0,9615.0,Canis lupus familiaris,,CHEMBL624258,,,,,A,1,1,
,BAO_0000218,5236,N,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,Intermediate,,50588,,5356,,9615.0,Canis lupus familiaris,,CHEMBL875277,,,,,A,1,1,
,BAO_0000218,5237,N,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,Intermediate,,50588,,16807,,9615.0,Canis lupus familiaris,,CHEMBL622667,,,,,A,1,1,
,BAO_0000218,5238,N,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,Intermediate,,50588,,4527,,9615.0,Canis lupus familiaris,,CHEMBL622668,,,,,A,1,1,
,BAO_0000218,5239,N,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,Intermediate,,50588,,4527,,9615.0,Canis lupus familiaris,,CHEMBL622669,,,,,A,1,1,
,BAO_0000218,5240,N,Area under curve determined in dogs after intravenous administration of 3 mg/kg,Intermediate,,50588,,15660,,9615.0,Canis lupus familiaris,,CHEMBL622670,,,,,A,1,1,
,BAO_0000218,5241,N,Area under curve determined in dogs after oral administration of 10 mg/kg,Intermediate,,50588,,15660,,9615.0,Canis lupus familiaris,,CHEMBL622671,,,,,A,1,1,
,BAO_0000218,5242,N,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,Intermediate,,50588,,5802,,9615.0,Canis lupus familiaris,,CHEMBL622672,,,,,A,1,1,
,BAO_0000218,5243,N,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,Expert,,50588,,3598,,9615.0,Canis lupus familiaris,,CHEMBL622673,,,,,A,1,1,
,BAO_0000218,5244,N,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,Expert,,50588,,3598,,9615.0,Canis lupus familiaris,,CHEMBL622674,,,,,A,1,1,
,BAO_0000218,5245,N,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),Intermediate,,50588,,5944,,9615.0,Canis lupus familiaris,,CHEMBL622675,,,,,A,1,1,
,BAO_0000218,5246,N,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,Intermediate,,50588,,5944,,9615.0,Canis lupus familiaris,,CHEMBL622676,,,,,A,1,1,
,BAO_0000218,5247,N,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),Intermediate,,50588,,5944,,9615.0,Canis lupus familiaris,,CHEMBL622677,,,,,A,1,1,
,BAO_0000218,5248,N,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,Intermediate,,50588,,5944,,9615.0,Canis lupus familiaris,,CHEMBL622678,,,,,A,1,1,
,BAO_0000218,5249,N,Area under curve in dog after administration of 20 mg/kg dose through peroral route,Intermediate,,50588,,4186,,9615.0,Canis lupus familiaris,,CHEMBL622679,,,,,A,1,1,
,BAO_0000218,5250,N,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),Intermediate,,50588,,5007,,9615.0,Canis lupus familiaris,,CHEMBL622680,,,,,A,1,1,
,BAO_0000218,5251,N,Area under curve was determine after peroral administration at 10 mpk in dog,Intermediate,,50588,,5668,,9615.0,Canis lupus familiaris,,CHEMBL622681,,,,,A,1,1,
,BAO_0000218,5252,N,Area under curve was determine after peroral administration at 5 mpk in dog,Intermediate,,50588,,5668,,9615.0,Canis lupus familiaris,,CHEMBL875278,,,,,A,1,1,
,BAO_0000218,5253,N,Area under curve was determined,Intermediate,,50588,,5006,,9615.0,Canis lupus familiaris,,CHEMBL622682,,,,,A,1,1,
,BAO_0000218,5254,N,Area under curve in dogs,Intermediate,,50588,,5006,,9615.0,Canis lupus familiaris,,CHEMBL622683,,,,,A,1,1,
,BAO_0000218,5255,N,Area under curve in dogs at 10 mg/kg dose fo oral administration,Intermediate,,50588,,3771,,9615.0,Canis lupus familiaris,,CHEMBL622684,,,,,A,1,1,
,BAO_0000218,5256,N,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),Intermediate,,50588,,3771,,9615.0,Canis lupus familiaris,,CHEMBL622685,,,,,A,1,1,
,BAO_0000218,5257,N,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,Intermediate,,50588,,3771,,9615.0,Canis lupus familiaris,,CHEMBL622686,,,,,A,1,1,
,BAO_0000218,5258,N,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,Intermediate,,50588,,1916,,9615.0,Canis lupus familiaris,,CHEMBL618344,,,,,A,1,1,
,BAO_0000218,5259,N,Area under curve value in dog at a dose of 5 mg/kg,Intermediate,,50588,,5302,,9615.0,Canis lupus familiaris,,CHEMBL875582,,,,,A,1,1,
,BAO_0000218,5260,N,Area under curve was determined after 0.1 mg/kg iv administration in dog,Intermediate,,50588,,5600,,9615.0,Canis lupus familiaris,,CHEMBL618345,,,,,A,1,1,
,BAO_0000218,5261,N,Area under curve was determined after 0.3 mg/kg po administration in dog,Intermediate,,50588,,5600,,9615.0,Canis lupus familiaris,,CHEMBL618346,,,,,A,1,1,
,BAO_0000218,5262,N,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,Intermediate,,50588,,17764,,9615.0,Canis lupus familiaris,,CHEMBL618347,,,,,A,1,1,
,BAO_0000218,5263,N,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,Intermediate,,50588,,4368,,9615.0,Canis lupus familiaris,,CHEMBL618348,,,,,A,1,1,
,BAO_0000019,5264,U,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,Autocuration,,22224,,5318,,9606.0,Homo sapiens,,CHEMBL618349,,,,,A,1,0,
,BAO_0000019,5265,U,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,Autocuration,,22224,,5318,,9606.0,Homo sapiens,,CHEMBL618350,,,,,A,1,0,
,BAO_0000019,5266,U,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,Autocuration,,22224,,5318,,9606.0,Homo sapiens,,CHEMBL618351,,,,,A,1,0,
,BAO_0000019,5267,U,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,Autocuration,,22224,,5318,,9606.0,Homo sapiens,,CHEMBL618352,,,,,A,1,0,
Blood,BAO_0000221,5268,U,Time taken to reduce 50% of the concentration of compound in blood plasma,Autocuration,,22224,,14518,178.0,9606.0,Homo sapiens,,CHEMBL873494,,,,,A,1,0,
Plasma,BAO_0000366,5269,U,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",Autocuration,,22224,,2209,1969.0,9606.0,Homo sapiens,,CHEMBL618353,,,,,A,1,0,
Plasma,BAO_0000366,5270,U,Half life in human plasma,Autocuration,,22224,,6787,1969.0,9606.0,Homo sapiens,,CHEMBL618354,,,,,A,1,0,
Plasma,BAO_0000366,5271,U,Half life in human plasma was reported,Autocuration,,22224,,4898,1969.0,9606.0,Homo sapiens,,CHEMBL875583,,,,,A,1,0,
Serum,BAO_0000019,5272,U,Half life in human serum,Autocuration,,22224,,6072,1977.0,9606.0,Homo sapiens,,CHEMBL618355,,,,,A,1,0,
Plasma,BAO_0000366,5273,U,Half life upon exposure to human plasma,Autocuration,,22224,,16907,1969.0,9606.0,Homo sapiens,,CHEMBL618356,,,,,A,1,0,
,BAO_0000251,5274,U,t1/2 in human microsomes,Autocuration,,22224,,5656,,9606.0,Homo sapiens,,CHEMBL618357,,,In vitro,Microsomes,A,1,0,
Plasma,BAO_0000366,5275,U,Half life period in 80% human plasma at 37 degree Centigrade,Autocuration,,22224,,4755,1969.0,9606.0,Homo sapiens,,CHEMBL618358,,,,,A,1,0,
Zone of skin,BAO_0000221,5276,U,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),Autocuration,,22224,,17503,14.0,9606.0,Homo sapiens,,CHEMBL618359,,,,,A,1,0,
Plasma,BAO_0000366,5277,U,Half-life measured in in vitro Cathepsin B assay in human plasma,Autocuration,,22224,,12357,1969.0,9606.0,Homo sapiens,,CHEMBL618360,,,In vitro,,A,1,0,
,BAO_0000019,5278,U,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,Autocuration,,22224,,3076,,9606.0,Homo sapiens,,CHEMBL618361,,,,,A,1,0,
Liver,BAO_0000251,5279,U,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,Autocuration,,22224,,6410,2107.0,9606.0,Homo sapiens,,CHEMBL618362,,,In vitro,Microsomes,A,1,0,
Plasma,BAO_0000366,5280,U,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",Autocuration,,22224,,3741,1969.0,9606.0,Homo sapiens,,CHEMBL618363,,,,,A,1,0,
Plasma,BAO_0000366,5281,U,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",Autocuration,,22224,,3741,1969.0,9606.0,Homo sapiens,,CHEMBL618364,,,,,A,1,0,
Plasma,BAO_0000366,5282,U,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",Autocuration,,22224,,3741,1969.0,9606.0,Homo sapiens,,CHEMBL875584,,,,,A,1,0,
,BAO_0000019,5283,U,Half-life in the CEM cell extracts,Autocuration,,22224,,1540,,9606.0,Homo sapiens,,CHEMBL618365,,,,,A,1,0,
Plasma,BAO_0000366,5284,U,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,Autocuration,,22224,,2905,1969.0,9606.0,Homo sapiens,,CHEMBL873495,,,,,A,1,0,
Plasma,BAO_0000366,5285,U,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,Autocuration,,22224,,2905,1969.0,9606.0,Homo sapiens,,CHEMBL618366,,,,,A,1,0,
,BAO_0000019,5286,U,Half-life was determined,Autocuration,,22224,,5523,,9606.0,Homo sapiens,,CHEMBL618367,,,,,A,1,0,
Blood,BAO_0000221,5287,U,Half-life (human blood stability),Autocuration,,22224,,1499,178.0,9606.0,Homo sapiens,,CHEMBL618368,,,,,A,1,0,
Blood,BAO_0000221,5288,U,Half-life (human blood stability); no data,Autocuration,,22224,,1499,178.0,9606.0,Homo sapiens,,CHEMBL618369,,,,,A,1,0,
Plasma,BAO_0000366,5289,U,Half-life in human plasma,Autocuration,,22224,,17065,1969.0,9606.0,Homo sapiens,,CHEMBL618370,,,,,A,1,0,
,BAO_0000019,5290,U,CYP3A4 metabolism half-life (t1/2),Autocuration,,22224,,6861,,9606.0,Homo sapiens,,CHEMBL618371,,,,,A,1,0,
Blood,BAO_0000221,5291,U,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),Autocuration,,22224,,1499,178.0,9606.0,Homo sapiens,,CHEMBL618372,,,,,A,1,0,
Plasma,BAO_0000366,5292,U,In vitro half life in human plasma,Autocuration,,22224,,530,1969.0,9606.0,Homo sapiens,,CHEMBL618373,,,In vitro,,A,1,0,
Plasma,BAO_0000366,5293,U,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",Autocuration,,22224,,1116,1969.0,9606.0,Homo sapiens,,CHEMBL618374,,,In vitro,,A,1,0,
Plasma,BAO_0000366,5294,U,In vitro hydrolysis in human plasma,Autocuration,,22224,,6695,1969.0,9606.0,Homo sapiens,,CHEMBL618375,,,In vitro,,A,1,0,
Plasma,BAO_0000366,5295,U,In vitro hydrolysis in human plasma; no data,Autocuration,,22224,,6695,1969.0,9606.0,Homo sapiens,,CHEMBL618376,,,In vitro,,A,1,0,
Liver,BAO_0000251,5296,U,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,Autocuration,,22224,,10,2107.0,9606.0,Homo sapiens,,CHEMBL618377,,,In vitro,Microsomes,A,1,0,
Plasma,BAO_0000366,5297,U,Plasma half life in human,Autocuration,,22224,,993,1969.0,9606.0,Homo sapiens,,CHEMBL618378,,,,,A,1,0,
Plasma,BAO_0000366,5298,U,Stability after incubation with human plasma (at 37 degree C),Autocuration,,22224,,15429,1969.0,9606.0,Homo sapiens,,CHEMBL618379,,,,,A,1,0,
Plasma,BAO_0000366,5299,U,T1/2 was evaluated in human plasma,Autocuration,,22224,,1675,1969.0,9606.0,Homo sapiens,,CHEMBL618380,,,,,A,1,0,
Plasma,BAO_0000366,5300,U,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",Autocuration,,22224,,2209,1969.0,9606.0,Homo sapiens,,CHEMBL618381,,,,,A,1,0,
Plasma,BAO_0000366,5301,U,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",Autocuration,,22224,,2209,1969.0,9606.0,Homo sapiens,,CHEMBL618382,,,,,A,1,0,
,BAO_0000019,5302,U,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,Autocuration,,22224,,5318,,9606.0,Homo sapiens,,CHEMBL618383,,,,,A,1,0,
,BAO_0000019,5303,U,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,Autocuration,,22224,,2412,,9606.0,Homo sapiens,,CHEMBL618384,,,In vitro,,A,1,0,
,BAO_0000019,5304,U,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,Autocuration,,22224,,2412,,9606.0,Homo sapiens,,CHEMBL618385,,,In vitro,,A,1,0,
Plasma,BAO_0000366,5305,U,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,Autocuration,,22224,,2906,1969.0,9606.0,Homo sapiens,,CHEMBL619099,,,,,A,1,0,
Plasma,BAO_0000366,5306,U,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,Autocuration,,22224,,2906,1969.0,9606.0,Homo sapiens,,CHEMBL619100,,,,,A,1,0,
,BAO_0000019,5307,U,Time taken for 50% to be consumed by serum PON1 was determined,Autocuration,,22224,,5495,,9606.0,Homo sapiens,,CHEMBL619101,,,,,A,1,0,
,BAO_0000019,5308,U,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,Autocuration,,22224,,5495,,9606.0,Homo sapiens,,CHEMBL619102,,,,,A,1,0,
Liver,BAO_0000251,5309,U,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,Autocuration,,22224,,4397,2107.0,9606.0,Homo sapiens,,CHEMBL619103,,,,Microsomes,A,1,0,
,BAO_0000218,5310,U,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,Autocuration,,22224,,2413,,10095.0,Mus sp.,,CHEMBL619268,,,,,A,1,0,
,BAO_0000218,5311,U,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,Autocuration,,22224,,2413,,10095.0,Mus sp.,,CHEMBL619269,,,,,A,1,0,
,BAO_0000218,5312,U,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,Autocuration,,22224,,2413,,10095.0,Mus sp.,,CHEMBL619270,,,,,A,1,0,
,BAO_0000218,5313,U,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,Autocuration,,22224,,2413,,10095.0,Mus sp.,,CHEMBL619271,,,,,A,1,0,
,BAO_0000218,5314,U,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,Autocuration,,22224,,2413,,10095.0,Mus sp.,,CHEMBL875585,,,,,A,1,0,
,BAO_0000218,5315,U,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,Autocuration,,22224,,2413,,10095.0,Mus sp.,,CHEMBL619272,,,,,A,1,0,
,BAO_0000219,5316,N,Compound tested for growth inhibition of renal cancer cell line 786-0,Intermediate,391.0,80640,,6058,,9606.0,Homo sapiens,,CHEMBL619273,786-0,,,,F,1,1,
,BAO_0000219,5317,N,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,Intermediate,391.0,80640,,17708,,9606.0,Homo sapiens,,CHEMBL619274,786-0,,,,F,1,1,
,BAO_0000219,5318,N,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,Expert,391.0,80640,,14017,,9606.0,Homo sapiens,,CHEMBL619275,786-0,,,,F,1,1,
,BAO_0000219,5319,N,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",Intermediate,391.0,80640,,16818,,9606.0,Homo sapiens,,CHEMBL619276,786-0,,,,F,1,1,
,BAO_0000219,5320,N,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",Intermediate,391.0,80640,,16818,,9606.0,Homo sapiens,,CHEMBL619277,786-0,,,,F,1,1,
,BAO_0000219,5321,N,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",Intermediate,391.0,80640,,16818,,9606.0,Homo sapiens,,CHEMBL619278,786-0,,,,F,1,1,
,BAO_0000219,5322,N,Tested for cytotoxicity against 786-0 cell lines in renal cancer,Intermediate,391.0,80640,,11970,,9606.0,Homo sapiens,,CHEMBL619279,786-0,,,,F,1,1,
,BAO_0000219,5323,N,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,Intermediate,391.0,80640,,12400,,9606.0,Homo sapiens,,CHEMBL858458,786-0,,,,F,1,1,
,BAO_0000219,5324,N,Cytotoxic effect on renal cancer line 786-0,Expert,391.0,80640,,12888,,9606.0,Homo sapiens,,CHEMBL619280,786-0,,,,F,1,1,
,BAO_0000219,5325,N,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,Intermediate,391.0,80640,,15300,,9606.0,Homo sapiens,,CHEMBL619281,786-0,,,,F,1,1,
,BAO_0000219,5326,N,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),Intermediate,391.0,80640,,14769,,9606.0,Homo sapiens,,CHEMBL619282,786-0,,,,F,1,1,
,BAO_0000219,5327,N,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",Intermediate,391.0,80640,,15895,,9606.0,Homo sapiens,,CHEMBL619283,786-0,,,,F,1,1,
,BAO_0000219,5328,N,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,Intermediate,391.0,80640,,17376,,9606.0,Homo sapiens,,CHEMBL619284,786-0,,,,F,1,1,
,BAO_0000219,5329,N,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,Intermediate,391.0,80640,,14882,,9606.0,Homo sapiens,,CHEMBL619285,786-0,,,,F,1,1,
,BAO_0000219,5330,N,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),Intermediate,391.0,80640,,14882,,9606.0,Homo sapiens,,CHEMBL619286,786-0,,,,F,1,1,
,BAO_0000219,5331,N,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,Intermediate,391.0,80640,,15176,,9606.0,Homo sapiens,,CHEMBL619287,786-0,,,,F,1,1,
,BAO_0000219,5332,N,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,Intermediate,391.0,80640,,12696,,9606.0,Homo sapiens,,CHEMBL857455,786-0,,,,F,1,1,
,BAO_0000219,5333,N,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),Intermediate,391.0,80640,,2496,,9606.0,Homo sapiens,,CHEMBL883801,786-0,,,,F,1,1,
,BAO_0000219,5334,N,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,Intermediate,972.0,80641,,11831,,9606.0,Homo sapiens,,CHEMBL619288,791T cell line,,,,F,1,1,
,BAO_0000219,5335,N,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),Intermediate,972.0,80641,,11831,,9606.0,Homo sapiens,,CHEMBL619289,791T cell line,,,,F,1,1,
,BAO_0000219,5336,N,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,Intermediate,972.0,80641,,11831,,9606.0,Homo sapiens,,CHEMBL619290,791T cell line,,,,F,1,1,
,BAO_0000219,5337,N,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),Intermediate,972.0,80641,,11831,,9606.0,Homo sapiens,,CHEMBL619291,791T cell line,,,,F,1,1,
,BAO_0000219,5338,N,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),Intermediate,972.0,80641,,11831,,9606.0,Homo sapiens,,CHEMBL619292,791T cell line,,,,F,1,1,
,BAO_0000219,5339,N,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,Intermediate,972.0,80641,,11831,,9606.0,Homo sapiens,,CHEMBL619293,791T cell line,,,,F,1,1,
,BAO_0000219,5340,N,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),Intermediate,972.0,80641,,11831,,9606.0,Homo sapiens,,CHEMBL619294,791T cell line,,,,F,1,1,
,BAO_0000219,5341,N,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),Intermediate,972.0,80641,,11831,,9606.0,Homo sapiens,,CHEMBL619295,791T cell line,,,,F,1,1,
,BAO_0000219,5342,N,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),Intermediate,972.0,80641,,11831,,9606.0,Homo sapiens,,CHEMBL619296,791T cell line,,,,F,1,1,
,BAO_0000219,5343,N,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,Intermediate,972.0,80641,,11831,,9606.0,Homo sapiens,,CHEMBL619297,791T cell line,,,,F,1,1,
,BAO_0000219,5344,N,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,Intermediate,391.0,80640,,12782,,9606.0,Homo sapiens,,CHEMBL619298,786-0,,,,F,1,1,
,BAO_0000019,5345,U,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,Intermediate,,22226,,1229,,,,,CHEMBL619299,,,,,F,1,0,
,BAO_0000219,5346,N,Inhibition of cell growth in drug resistant 8226 myeloma cell line,Expert,741.0,80433,,15313,,9606.0,Homo sapiens,,CHEMBL619300,RPMI-8226,,,,F,1,1,
,BAO_0000219,5347,N,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,Expert,741.0,80433,,15313,,9606.0,Homo sapiens,,CHEMBL619301,RPMI-8226,,,,F,1,1,
,BAO_0000219,5348,N,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,Intermediate,741.0,80433,,11544,,9606.0,Homo sapiens,,CHEMBL619302,RPMI-8226,,,,F,1,1,
,BAO_0000219,5349,N,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,Intermediate,741.0,80433,,9424,,9606.0,Homo sapiens,,CHEMBL619303,RPMI-8226,,,,F,1,1,
,BAO_0000219,5350,N,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,Intermediate,741.0,80433,,9424,,9606.0,Homo sapiens,,CHEMBL619304,RPMI-8226,,,,F,1,1,
,BAO_0000219,5351,N,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),Intermediate,741.0,80433,,9424,,9606.0,Homo sapiens,,CHEMBL857706,RPMI-8226,,,,F,1,1,
,BAO_0000219,5352,N,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),Intermediate,741.0,80433,,9424,,9606.0,Homo sapiens,,CHEMBL619305,RPMI-8226,,,,F,1,1,
,BAO_0000219,5353,N,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),Intermediate,741.0,80433,,9424,,9606.0,Homo sapiens,,CHEMBL619306,RPMI-8226,,,,F,1,1,
,BAO_0000219,5354,N,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),Intermediate,741.0,80433,,9424,,9606.0,Homo sapiens,,CHEMBL619307,RPMI-8226,,,,F,1,1,
,BAO_0000219,5355,N,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),Intermediate,741.0,80433,,9424,,9606.0,Homo sapiens,,CHEMBL619308,RPMI-8226,,,,F,1,1,
,BAO_0000219,5356,N,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),Intermediate,741.0,80433,,9424,,9606.0,Homo sapiens,,CHEMBL619309,RPMI-8226,,,,F,1,1,
,BAO_0000219,5357,N,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),Intermediate,741.0,80433,,9424,,9606.0,Homo sapiens,,CHEMBL619310,RPMI-8226,,,,F,1,1,
,BAO_0000219,5358,N,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),Intermediate,624.0,80021,,14769,,9606.0,Homo sapiens,,CHEMBL619311,A498,,,,F,1,1,
,BAO_0000219,5359,N,Compound was tested for the growth inhibition of A498 renal tumor cell line,Intermediate,624.0,80021,,15354,,9606.0,Homo sapiens,,CHEMBL619312,A498,,,,F,1,1,
,BAO_0000219,5360,N,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),Intermediate,624.0,80021,,17445,,9606.0,Homo sapiens,,CHEMBL619313,A498,,,,F,1,1,
,BAO_0000219,5361,N,In vitro inhibitory concentration against renal cancer cell line A498,Intermediate,624.0,80021,,4337,,9606.0,Homo sapiens,,CHEMBL619314,A498,,,,F,1,1,
,BAO_0000219,5362,N,Cytotoxicity against A 498 tumor cell line,Intermediate,624.0,80021,,15277,,9606.0,Homo sapiens,,CHEMBL619959,A498,,,,F,1,1,
,BAO_0000219,5363,N,In vitro antitumor activity against A498 human cancer cell line,Intermediate,624.0,80021,,4812,,9606.0,Homo sapiens,,CHEMBL619960,A498,,,,F,1,1,
,BAO_0000219,5364,N,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),Intermediate,624.0,80021,,4812,,9606.0,Homo sapiens,,CHEMBL619961,A498,,,,F,1,1,
,BAO_0000219,5365,N,Inhibitory dose required against A498 human tumor cell lines,Intermediate,624.0,80021,,4995,,9606.0,Homo sapiens,,CHEMBL619962,A498,,,,F,1,1,
,BAO_0000219,5366,N,Anticancer activity against one renal cancer (A498 cell line),Intermediate,624.0,80021,,5847,,9606.0,Homo sapiens,,CHEMBL875586,A498,,,,F,1,1,
,BAO_0000219,5367,N,In vitro cytotoxicity against melanoma A498 cell line,Intermediate,624.0,80021,,6557,,9606.0,Homo sapiens,,CHEMBL619963,A498,,,,F,1,1,
,BAO_0000219,5368,N,Compound was tested for growth inhibitory activity against A498 cell line,Intermediate,624.0,80021,,2597,,9606.0,Homo sapiens,,CHEMBL619964,A498,,,,F,1,1,
,BAO_0000219,5369,N,Compound tested for growth inhibition of renal cancer cell line A498,Intermediate,624.0,80021,,6058,,9606.0,Homo sapiens,,CHEMBL620108,A498,,,,F,1,1,
,BAO_0000219,5370,N,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,Intermediate,624.0,80021,,17708,,9606.0,Homo sapiens,,CHEMBL620109,A498,,,,F,1,1,
,BAO_0000219,5371,N,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,Intermediate,624.0,80021,,15176,,9606.0,Homo sapiens,,CHEMBL620110,A498,,,,F,1,1,
,BAO_0000219,5372,N,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,Intermediate,624.0,80021,,15300,,9606.0,Homo sapiens,,CHEMBL620111,A498,,,,F,1,1,
,BAO_0000219,5373,N,Tested for cytotoxicity against A498 cell lines in renal cancer,Intermediate,624.0,80021,,11970,,9606.0,Homo sapiens,,CHEMBL620112,A498,,,,F,1,1,
,BAO_0000219,5374,N,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,Intermediate,624.0,80021,,12400,,9606.0,Homo sapiens,,CHEMBL620113,A498,,,,F,1,1,
,BAO_0000219,5375,N,Cytotoxic effect on renal cancer lines A498,Expert,624.0,80021,,12888,,9606.0,Homo sapiens,,CHEMBL620114,A498,,,,F,1,1,
,BAO_0000219,5376,N,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,Intermediate,624.0,80021,,3030,,9606.0,Homo sapiens,,CHEMBL620115,A498,,,,F,1,1,
,BAO_0000219,5377,N,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),Intermediate,624.0,80021,,14769,,9606.0,Homo sapiens,,CHEMBL620116,A498,,,,F,1,1,
,BAO_0000219,5378,N,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,Intermediate,624.0,80021,,17376,,9606.0,Homo sapiens,,CHEMBL620117,A498,,,,F,1,1,
,BAO_0000219,5379,N,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,Intermediate,624.0,80021,,16558,,9606.0,Homo sapiens,,CHEMBL620118,A498,,,,F,1,1,
,BAO_0000219,5380,N,Cytotoxicity against human kidney carcinoma cell lines A4982LM,Intermediate,624.0,80021,,5194,,9606.0,Homo sapiens,,CHEMBL620119,A498,,,,F,1,1,
,BAO_0000219,5381,N,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,Intermediate,624.0,80021,,10708,,9606.0,Homo sapiens,,CHEMBL620120,A498,,,,F,1,1,
,BAO_0000219,5382,N,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,Expert,646.0,80682,,16880,,9606.0,Homo sapiens,,CHEMBL620121,A549,,,,F,1,1,
,BAO_0000219,5383,N,Antitumor activity against A549 human lung carcinoma cell line,Intermediate,646.0,80682,,10196,,9606.0,Homo sapiens,,CHEMBL620122,A549,,,,F,1,1,
,BAO_0000219,5384,N,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,Intermediate,646.0,80682,,10196,,9606.0,Homo sapiens,,CHEMBL620123,A549,,,,F,1,1,
,BAO_0000219,5385,N,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,Intermediate,646.0,80682,,10196,,9606.0,Homo sapiens,,CHEMBL620124,A549,,,,F,1,1,
,BAO_0000219,5386,N,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",Intermediate,646.0,80682,,12083,,9606.0,Homo sapiens,,CHEMBL620125,A549,,,,F,1,1,
,BAO_0000219,5387,N,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,Expert,646.0,80682,,16464,,9606.0,Homo sapiens,,CHEMBL620126,A549,,,,F,1,1,
,BAO_0000219,5388,N,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Intermediate,646.0,80682,,16464,,9606.0,Homo sapiens,,CHEMBL883027,A549,,,,F,1,1,
,BAO_0000219,5389,N,In vitro cytotoxic activity against human lung A549 cell line,Expert,646.0,80682,,16470,,9606.0,Homo sapiens,,CHEMBL620127,A549,,,,F,1,1,
,BAO_0000219,5390,N,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),Intermediate,646.0,80682,,16470,,9606.0,Homo sapiens,,CHEMBL620128,A549,,,,F,1,1,
,BAO_0000219,5391,N,In vitro cytotoxic activity against human lung A549 cell line),Intermediate,646.0,80682,,16470,,9606.0,Homo sapiens,,CHEMBL620129,A549,,,,F,1,1,
,BAO_0000219,5392,N,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,Intermediate,646.0,80682,,16470,,9606.0,Homo sapiens,,CHEMBL620130,A549,,,,F,1,1,
,BAO_0000219,5393,N,In vitro cytotoxicity against human non small-cell-lung cell line A549.,Expert,646.0,80682,,16582,,9606.0,Homo sapiens,,CHEMBL620131,A549,,,,F,1,1,
,BAO_0000219,5394,N,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",Intermediate,646.0,80682,,15935,,9606.0,Homo sapiens,,CHEMBL620132,A549,,,,F,1,1,
,BAO_0000219,5395,N,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",Intermediate,646.0,80682,,15935,,9606.0,Homo sapiens,,CHEMBL620133,A549,,,,F,1,1,
,BAO_0000219,5396,N,Inhibition of A549 human lung carcinoma cell proliferation,Expert,646.0,80682,,16597,,9606.0,Homo sapiens,,CHEMBL620134,A549,,,,F,1,1,
,BAO_0000219,5397,N,Inhibitory activity against A549 lung adenocarcinoma cell line,Intermediate,646.0,80682,,17376,,9606.0,Homo sapiens,,CHEMBL620135,A549,,,,F,1,1,
,BAO_0000219,5398,N,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,Intermediate,646.0,80682,,16496,,9606.0,Homo sapiens,,CHEMBL620136,A549,,,,F,1,1,
,BAO_0000219,5399,N,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,Intermediate,646.0,80682,,16152,,9606.0,Homo sapiens,,CHEMBL620137,A549,,,,F,1,1,
,BAO_0000219,5400,N,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,Intermediate,646.0,80682,,16152,,9606.0,Homo sapiens,,CHEMBL620268,A549,,,,F,1,1,
,BAO_0000219,5401,N,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Intermediate,646.0,80682,,16464,,9606.0,Homo sapiens,,CHEMBL620269,A549,,,,F,1,1,
,BAO_0000219,5402,N,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,Intermediate,646.0,80682,,2288,,9606.0,Homo sapiens,,CHEMBL620270,A549,,,,F,1,1,
,BAO_0000219,5403,N,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,Intermediate,646.0,80682,,17350,,9606.0,Homo sapiens,,CHEMBL620271,A549,,,,F,1,1,
,BAO_0000219,5404,N,Inhibition of A549 cancer cell proliferation,Expert,646.0,80682,,4090,,9606.0,Homo sapiens,,CHEMBL620272,A549,,,,F,1,1,
,BAO_0000219,5405,N,Inhibition of A549 cancer cell proliferation (Not tested),Expert,646.0,80682,,4090,,9606.0,Homo sapiens,,CHEMBL620273,A549,,,,F,1,1,
,BAO_0000219,5406,N,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,Intermediate,646.0,80682,,17350,,9606.0,Homo sapiens,,CHEMBL620274,A549,,,,F,1,1,
,BAO_0000219,5407,N,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,Intermediate,646.0,80682,,4197,,9606.0,Homo sapiens,,CHEMBL620275,A549,,,,F,1,1,
,BAO_0000219,5408,N,Antiproliferative potency determined as inhibitory concentration against A549 cells,Intermediate,646.0,80682,,17072,,9606.0,Homo sapiens,,CHEMBL620276,A549,,,,F,1,1,
,BAO_0000219,5409,N,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,Intermediate,646.0,80682,,17072,,9606.0,Homo sapiens,,CHEMBL620277,A549,,,,F,1,1,
,BAO_0000219,5410,N,Cytotoxicity against Renal cell lines A549 was determined,Intermediate,646.0,80682,,5194,,9606.0,Homo sapiens,,CHEMBL620278,A549,,,,F,1,1,
,BAO_0000218,5411,N,Area under curve was determined in dog after a 3 mg/kg of oral dose,Intermediate,,50588,,4257,,9615.0,Canis lupus familiaris,,CHEMBL620279,,,,,A,1,1,
,BAO_0000218,5412,N,Area under curve was determined in dog after oral administration at 1 mg/kg,Intermediate,,50588,,6123,,9615.0,Canis lupus familiaris,,CHEMBL620280,,,,,A,1,1,
,BAO_0000218,5413,N,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Intermediate,,50588,,1337,,9615.0,Canis lupus familiaris,,CHEMBL620281,,,,,A,1,1,
,BAO_0000218,5414,N,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Intermediate,,50588,,1337,,9615.0,Canis lupus familiaris,,CHEMBL620282,,,,,A,1,1,
,BAO_0000218,5415,N,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),Intermediate,,50588,,8833,,9615.0,Canis lupus familiaris,,CHEMBL621134,,,,,A,1,1,
,BAO_0000218,5416,N,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),Intermediate,,50588,,8833,,9615.0,Canis lupus familiaris,,CHEMBL621135,,,,,A,1,1,
,BAO_0000218,5417,N,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),Intermediate,,50588,,8833,,9615.0,Canis lupus familiaris,,CHEMBL621136,,,,,A,1,1,
,BAO_0000218,5418,N,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),Intermediate,,50588,,8833,,9615.0,Canis lupus familiaris,,CHEMBL621137,,,,,A,1,1,
Plasma,BAO_0000218,5419,N,Area under plasma concentration time curve in dog upon oral administration,Intermediate,,50588,,17657,1969.0,9615.0,Canis lupus familiaris,,CHEMBL621138,,,,,A,1,1,
Plasma,BAO_0000218,5420,N,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,Intermediate,,50588,,17650,1969.0,9615.0,Canis lupus familiaris,,CHEMBL875587,,,,,A,1,1,
,BAO_0000218,5421,N,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,Intermediate,,50588,,1977,,9615.0,Canis lupus familiaris,,CHEMBL621139,,,,,A,1,1,
,BAO_0000218,5422,N,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,Intermediate,,50588,,1977,,9615.0,Canis lupus familiaris,,CHEMBL621140,,,,,A,1,1,
,BAO_0000218,5423,N,Area under the curve for the compound was obtained when tested in dog,Intermediate,,50588,,3132,,9615.0,Canis lupus familiaris,,CHEMBL621141,,,,,A,1,1,
,BAO_0000218,5424,N,Area under the curve at a dose of 1 mg/kg,Intermediate,,50588,,5473,,9615.0,Canis lupus familiaris,,CHEMBL621142,,,,,A,1,1,
,BAO_0000218,5425,N,Area under the curve at a dose of 1 mg/kg (oral),Intermediate,,50588,,5474,,9615.0,Canis lupus familiaris,,CHEMBL621143,,,,,A,1,1,
,BAO_0000218,5426,N,Area under the curve at i.v. dose of 0.2 mg/kg,Intermediate,,50588,,5474,,9615.0,Canis lupus familiaris,,CHEMBL621144,,,,,A,1,1,
,BAO_0000218,5427,N,Area under the curve was measured in dog after an iv dose of 1 mg/kg,Intermediate,,50588,,6062,,9615.0,Canis lupus familiaris,,CHEMBL621145,,,,,A,1,1,
,BAO_0000218,5428,N,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,Intermediate,,50588,,4709,,9615.0,Canis lupus familiaris,,CHEMBL621146,,,,,A,1,1,
,BAO_0000218,5429,N,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,Intermediate,,50588,,2652,,9615.0,Canis lupus familiaris,,CHEMBL622567,,,,,A,1,1,
,BAO_0000218,5430,N,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,Intermediate,,50588,,2652,,9615.0,Canis lupus familiaris,,CHEMBL622568,,,,,A,1,1,
,BAO_0000218,5431,N,Compound was evaluated for area under the curve in dog blood.,Intermediate,,50588,,2877,,9615.0,Canis lupus familiaris,,CHEMBL622569,,,,,A,1,1,
,BAO_0000218,5432,N,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,Intermediate,,50588,,5444,,9615.0,Canis lupus familiaris,,CHEMBL622570,,,,,A,1,1,
Plasma,BAO_0000218,5433,N,AUC in dog after oral dose (1 mg/kg),Intermediate,,50588,,5130,1969.0,9615.0,Canis lupus familiaris,,CHEMBL622571,,,,,A,1,1,
,BAO_0000218,5434,N,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,Intermediate,,50588,,6265,,9615.0,Canis lupus familiaris,,CHEMBL622572,,,,,A,1,1,
,BAO_0000218,5435,N,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",Intermediate,,50588,,4657,,9615.0,Canis lupus familiaris,,CHEMBL622573,,,,,A,1,1,
,BAO_0000218,5436,N,Pharmacokinetic parameter AUC after intravenous administration to dogs,Intermediate,,50588,,16367,,9615.0,Canis lupus familiaris,,CHEMBL622574,,,,,A,1,1,
,BAO_0000218,5437,N,Pharmacokinetic parameter AUC after oral administration to dogs,Intermediate,,50588,,16367,,9615.0,Canis lupus familiaris,,CHEMBL622575,,,,,A,1,1,
,BAO_0000218,5438,N,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,Intermediate,,50588,,9579,,9615.0,Canis lupus familiaris,,CHEMBL622576,,,,,A,1,1,
,BAO_0000218,5439,N,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,Intermediate,,50588,,9579,,9615.0,Canis lupus familiaris,,CHEMBL622577,,,,,A,1,1,
,BAO_0000218,5440,N,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,Intermediate,,50588,,5983,,9615.0,Canis lupus familiaris,,CHEMBL622578,,,,,A,1,1,
,BAO_0000218,5441,N,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,Intermediate,,50588,,6241,,9615.0,Canis lupus familiaris,,CHEMBL622579,,,,,A,1,1,
,BAO_0000218,5442,N,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",Intermediate,,50588,,5313,,9615.0,Canis lupus familiaris,,CHEMBL622580,,,,,A,1,1,
,BAO_0000218,5443,N,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",Intermediate,,50588,,5313,,9615.0,Canis lupus familiaris,,CHEMBL622581,,,,,A,1,1,
,BAO_0000218,5444,N,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),Intermediate,,50588,,6642,,9615.0,Canis lupus familiaris,,CHEMBL622582,,,,,A,1,1,
,BAO_0000218,5445,N,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),Intermediate,,50588,,6642,,9615.0,Canis lupus familiaris,,CHEMBL622583,,,,,A,1,1,
,BAO_0000218,5446,N,Oral AUCN in dog (dosed at 0.5 mpk iv ),Intermediate,,50588,,6641,,9615.0,Canis lupus familiaris,,CHEMBL622584,,,,,A,1,1,
,BAO_0000218,5447,N,Oral AUCN in dog (dosed at 0.5 mpk iv ),Intermediate,,50588,,6642,,9615.0,Canis lupus familiaris,,CHEMBL622585,,,,,A,1,1,
,BAO_0000218,5448,N,Compound was evaluated for oral bioavailability in dog; 90-100,Intermediate,,50588,,17791,,9615.0,Canis lupus familiaris,,CHEMBL622586,,,,,A,1,1,
,BAO_0000218,5449,N,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,Intermediate,,50588,,17655,,9615.0,Canis lupus familiaris,,CHEMBL623281,,,,,A,1,1,
,BAO_0000218,5450,N,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,Intermediate,,50588,,17655,,9615.0,Canis lupus familiaris,,CHEMBL623282,,,,,A,1,1,
,BAO_0000218,5451,N,PAPP (membrane permeability) in dog kidney cell monolayer assay,Intermediate,,50588,,6596,,9615.0,Canis lupus familiaris,,CHEMBL623283,,,,,A,1,1,
,BAO_0000218,5452,N,Oral bioavailability in dog,Intermediate,,50588,,3880,,9615.0,Canis lupus familiaris,,CHEMBL623284,,,,,A,1,1,
,BAO_0000218,5453,N,Bioavailability administered orally at a dose of 10 mg/kg to dogs,Intermediate,,50588,,16367,,9615.0,Canis lupus familiaris,,CHEMBL623285,,,,,A,1,1,
Plasma,BAO_0000218,5454,N,Plasma protein binding towards dog plasma at 10 uM,Intermediate,,50588,,17409,1969.0,9615.0,Canis lupus familiaris,,CHEMBL623463,,,,,A,1,1,
Plasma,BAO_0000218,5455,N,Plasma protein binding towards dog plasma at 100 uM,Intermediate,,50588,,17409,1969.0,9615.0,Canis lupus familiaris,,CHEMBL875952,,,,,A,1,1,
,BAO_0000218,5456,N,Bioavailability in dog (dose 4 mg/kg p.o.),Intermediate,,50588,,2959,,9615.0,Canis lupus familiaris,,CHEMBL621705,,,In vivo,,A,1,1,
,BAO_0000218,5457,N,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,Intermediate,,50588,,13501,,9615.0,Canis lupus familiaris,,CHEMBL621706,,,In vivo,,A,1,1,
,BAO_0000218,5458,N,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,Intermediate,,50588,,4527,,9615.0,Canis lupus familiaris,,CHEMBL621707,,,In vivo,,A,1,1,
,BAO_0000218,5459,N,Bioavailability in dogs,Intermediate,,50588,,15145,,9615.0,Canis lupus familiaris,,CHEMBL621708,,,In vivo,,A,1,1,
,BAO_0000218,5460,N,Bioavailability,Intermediate,,50588,,4219,,9615.0,Canis lupus familiaris,,CHEMBL621709,,,In vivo,,A,1,1,
,BAO_0000218,5461,N,Oral bioavailability in dog (dose 10 mg/kg),Intermediate,,50588,,17538,,9615.0,Canis lupus familiaris,,CHEMBL621710,,,In vivo,,A,1,1,
,BAO_0000218,5462,N,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,Intermediate,,50588,,17538,,9615.0,Canis lupus familiaris,,CHEMBL621711,,,In vivo,,A,1,1,
,BAO_0000218,5463,N,Bioavailability in dog (dose 10.0 mg/kg p.o.),Intermediate,,50588,,1466,,9615.0,Canis lupus familiaris,,CHEMBL621712,,,In vivo,,A,1,1,
,BAO_0000218,5464,N,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,Intermediate,,50588,,17650,,9615.0,Canis lupus familiaris,,CHEMBL621713,,,In vivo,,A,1,1,
,BAO_0000218,5465,N,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,Intermediate,,50588,,3132,,9615.0,Canis lupus familiaris,,CHEMBL621714,,,In vivo,,A,1,1,
,BAO_0000218,5466,U,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,Autocuration,,22224,,2413,,10095.0,Mus sp.,,CHEMBL621715,,,,,A,1,0,
Liver,BAO_0000218,5467,U,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,Autocuration,,22224,,2413,2107.0,10095.0,Mus sp.,,CHEMBL623717,,,,,A,1,0,
Liver,BAO_0000218,5468,U,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,Autocuration,,22224,,2413,2107.0,10095.0,Mus sp.,,CHEMBL623718,,,,,A,1,0,
Liver,BAO_0000218,5469,U,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,Autocuration,,22224,,2413,2107.0,10095.0,Mus sp.,,CHEMBL623719,,,,,A,1,0,
,BAO_0000218,5470,U,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,Autocuration,,22224,,2413,,10095.0,Mus sp.,,CHEMBL623720,,,,,A,1,0,
,BAO_0000218,5471,U,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,Autocuration,,22224,,2413,,10095.0,Mus sp.,,CHEMBL623721,,,,,A,1,0,
Muscle tissue,BAO_0000218,5472,U,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,Autocuration,,22224,,2413,2385.0,10095.0,Mus sp.,,CHEMBL623722,,,,,A,1,0,
Muscle tissue,BAO_0000218,5473,U,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,Autocuration,,22224,,2413,2385.0,10095.0,Mus sp.,,CHEMBL623723,,,,,A,1,0,
Muscle tissue,BAO_0000218,5474,U,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,Autocuration,,22224,,2413,2385.0,10095.0,Mus sp.,,CHEMBL618543,,,,,A,1,0,
Spleen,BAO_0000218,5475,U,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,Autocuration,,22224,,2413,2106.0,10095.0,Mus sp.,,CHEMBL618544,,,,,A,1,0,
Spleen,BAO_0000218,5476,U,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,Autocuration,,22224,,2413,2106.0,10095.0,Mus sp.,,CHEMBL875155,,,,,A,1,0,
,BAO_0000218,5477,U,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,Autocuration,,22224,,2413,,10095.0,Mus sp.,,CHEMBL618545,,,,,A,1,0,
,BAO_0000218,5478,U,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,Autocuration,,22224,,2413,,10095.0,Mus sp.,,CHEMBL618546,,,,,A,1,0,
,BAO_0000218,5479,U,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,Autocuration,,22224,,2413,,10095.0,Mus sp.,,CHEMBL623529,,,,,A,1,0,
,BAO_0000218,5480,U,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,Autocuration,,22224,,2413,,10095.0,Mus sp.,,CHEMBL623530,,,,,A,1,0,
,BAO_0000218,5481,U,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,Autocuration,,22224,,2413,,10095.0,Mus sp.,,CHEMBL621764,,,,,A,1,0,
,BAO_0000019,5482,U,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),Autocuration,,22224,,17827,,9527.0,Cercopithecidae,,CHEMBL621765,,,,,A,1,0,
Cerebellum,BAO_0000019,5483,U,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),Autocuration,,22224,,17827,2037.0,9527.0,Cercopithecidae,,CHEMBL621766,,,,,A,1,0,
Frontal cortex,BAO_0000019,5484,U,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),Autocuration,,22224,,17827,1870.0,9527.0,Cercopithecidae,,CHEMBL621767,,,,,A,1,0,
,BAO_0000019,5485,U,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),Autocuration,,22224,,17827,,9527.0,Cercopithecidae,,CHEMBL621768,,,,,A,1,0,
Striatum,BAO_0000019,5486,U,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),Autocuration,,22224,,17827,2435.0,9527.0,Cercopithecidae,,CHEMBL621769,,,,,A,1,0,
,BAO_0000019,5487,U,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),Autocuration,,22224,,17827,,9527.0,Cercopithecidae,,CHEMBL621770,,,,,A,1,0,
Cerebellum,BAO_0000019,5488,U,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),Autocuration,,22224,,17827,2037.0,9527.0,Cercopithecidae,,CHEMBL621771,,,,,A,1,0,
Frontal cortex,BAO_0000019,5489,U,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),Autocuration,,22224,,17827,1870.0,9527.0,Cercopithecidae,,CHEMBL621772,,,,,A,1,0,
,BAO_0000019,5490,U,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),Autocuration,,22224,,17827,,9527.0,Cercopithecidae,,CHEMBL621773,,,,,A,1,0,
Striatum,BAO_0000019,5491,U,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),Autocuration,,22224,,17827,2435.0,9527.0,Cercopithecidae,,CHEMBL621774,,,,,A,1,0,
,BAO_0000218,5492,U,Compound was evaluated for oral bioavailability in rats,Autocuration,,22224,,17791,,9527.0,Cercopithecidae,,CHEMBL621775,,,,,A,1,0,
Plasma,BAO_0000218,5493,U,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,Autocuration,,22224,,17667,1969.0,9527.0,Cercopithecidae,,CHEMBL621776,,,In vivo,,A,1,0,
,BAO_0000019,5494,U,Half life period was evaluated in monkey,Autocuration,,22224,,17791,,9527.0,Cercopithecidae,,CHEMBL621777,,,,,A,1,0,
,BAO_0000218,5495,U,Half-life in rhesus monkeys by intravenous administration of dose,Autocuration,,22224,,110,,9527.0,Cercopithecidae,,CHEMBL875162,,,In vivo,,A,1,0,
Plasma,BAO_0000218,5496,N,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,Intermediate,,50594,,5781,1969.0,10090.0,Mus musculus,,CHEMBL621778,,,,,A,1,1,
Plasma,BAO_0000218,5497,N,AUC after intraperitoneal administration of 100 mg/kg in mice,Intermediate,,50594,,17734,1969.0,10090.0,Mus musculus,,CHEMBL621779,,,,,A,1,1,
Plasma,BAO_0000218,5498,N,AUC value was determined after oral administration,Intermediate,,50594,,17718,1969.0,10090.0,Mus musculus,,CHEMBL622479,,,,,A,1,1,
,BAO_0000218,5499,N,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,Intermediate,,50594,,4573,,10090.0,Mus musculus,,CHEMBL622480,,,,,A,1,1,
,BAO_0000218,5500,N,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),Intermediate,,50594,,3277,,10090.0,Mus musculus,,CHEMBL622481,,,,,A,1,1,
,BAO_0000218,5501,N,Area under curve by ioral administration in mouse,Intermediate,,50594,,2862,,10090.0,Mus musculus,,CHEMBL622482,,,,,A,1,1,
,BAO_0000218,5502,N,Area under curve by iv administration in mouse,Intermediate,,50594,,2862,,10090.0,Mus musculus,,CHEMBL622483,,,,,A,1,1,
,BAO_0000218,5503,N,Area under curve at 0-8 hr in IRC mice after peroral administration,Intermediate,,50594,,5951,,10090.0,Mus musculus,,CHEMBL622484,,,,,A,1,1,
,BAO_0000218,5504,N,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,Intermediate,,50594,,17729,,10090.0,Mus musculus,,CHEMBL622641,,,,,A,1,1,
,BAO_0000218,5505,N,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,Intermediate,,50594,,17728,,10090.0,Mus musculus,,CHEMBL622642,,,,,A,1,1,
,BAO_0000218,5506,N,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,Intermediate,,50594,,17728,,10090.0,Mus musculus,,CHEMBL622643,,,,,A,1,1,
,BAO_0000218,5507,N,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,Intermediate,,50594,,17729,,10090.0,Mus musculus,,CHEMBL622644,,,,,A,1,1,
,BAO_0000219,5508,N,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,Intermediate,741.0,80433,,9424,,9606.0,Homo sapiens,,CHEMBL622645,RPMI-8226,,,,F,1,1,
,BAO_0000219,5509,N,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,Intermediate,741.0,80433,,9424,,9606.0,Homo sapiens,,CHEMBL622646,RPMI-8226,,,,F,1,1,
,BAO_0000219,5510,N,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),Intermediate,741.0,80433,,9424,,9606.0,Homo sapiens,,CHEMBL621238,RPMI-8226,,,,F,1,1,
,BAO_0000219,5511,N,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),Intermediate,741.0,80433,,9424,,9606.0,Homo sapiens,,CHEMBL621239,RPMI-8226,,,,F,1,1,
,BAO_0000219,5512,N,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),Intermediate,741.0,80433,,9424,,9606.0,Homo sapiens,,CHEMBL621240,RPMI-8226,,,,F,1,1,
,BAO_0000219,5513,N,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),Intermediate,741.0,80433,,9424,,9606.0,Homo sapiens,,CHEMBL621241,RPMI-8226,,,,F,1,1,
,BAO_0000219,5514,N,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),Intermediate,741.0,80433,,9424,,9606.0,Homo sapiens,,CHEMBL621242,RPMI-8226,,,,F,1,1,
,BAO_0000219,5515,N,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),Intermediate,741.0,80433,,9424,,9606.0,Homo sapiens,,CHEMBL620350,RPMI-8226,,,,F,1,1,
,BAO_0000219,5516,N,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,Intermediate,741.0,80433,,9424,,9606.0,Homo sapiens,,CHEMBL620351,RPMI-8226,,,,F,1,1,
,BAO_0000219,5517,N,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,Intermediate,741.0,80433,,9424,,9606.0,Homo sapiens,,CHEMBL620352,RPMI-8226,,,,F,1,1,
,BAO_0000219,5518,N,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),Intermediate,741.0,80433,,9424,,9606.0,Homo sapiens,,CHEMBL620353,RPMI-8226,,,,F,1,1,
,BAO_0000219,5519,N,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),Intermediate,741.0,80433,,9424,,9606.0,Homo sapiens,,CHEMBL620354,RPMI-8226,,,,F,1,1,
,BAO_0000219,5520,N,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),Intermediate,741.0,80433,,9424,,9606.0,Homo sapiens,,CHEMBL620355,RPMI-8226,,,,F,1,1,
,BAO_0000219,5521,N,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),Intermediate,741.0,80433,,9424,,9606.0,Homo sapiens,,CHEMBL620356,RPMI-8226,,,,F,1,1,
,BAO_0000219,5522,N,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),Intermediate,741.0,80433,,9424,,9606.0,Homo sapiens,,CHEMBL620357,RPMI-8226,,,,F,1,1,
,BAO_0000219,5523,N,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),Intermediate,741.0,80433,,9424,,9606.0,Homo sapiens,,CHEMBL620358,RPMI-8226,,,,F,1,1,
,BAO_0000219,5524,N,In vitro inhibition of human 8226 myeloma tumor cell line growth.,Expert,741.0,80433,,9424,,9606.0,Homo sapiens,,CHEMBL620359,RPMI-8226,,,,F,1,1,
,BAO_0000219,5525,N,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,Intermediate,741.0,80433,,11544,,9606.0,Homo sapiens,,CHEMBL620360,RPMI-8226,,,,F,1,1,
,BAO_0000219,5526,N,Cytotoxicity of compound against 8226/DOX1V cells,Intermediate,741.0,80433,,17378,,9606.0,Homo sapiens,,CHEMBL620361,RPMI-8226,,,,F,1,1,
,BAO_0000219,5527,N,Cytotoxicity of compound against 8226/S cells,Intermediate,741.0,80433,,17378,,9606.0,Homo sapiens,,CHEMBL620362,RPMI-8226,,,,F,1,1,
,BAO_0000219,5528,N,Inhibitory concentration against 8226 myeloma cancer cell line,Intermediate,741.0,80433,,17079,,9606.0,Homo sapiens,,CHEMBL620363,RPMI-8226,,,,F,1,1,
,BAO_0000219,5529,N,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,Intermediate,741.0,80433,,17079,,9606.0,Homo sapiens,,CHEMBL620364,RPMI-8226,,,,F,1,1,
,BAO_0000219,5530,N,Inhibition of cell growth was studied in human teratocarcinoma (833K).,Intermediate,854.0,80647,,13466,,9606.0,Homo sapiens,,CHEMBL620365,833K,,,,F,1,1,
,BAO_0000219,5531,N,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',Intermediate,854.0,80647,,13466,,9606.0,Homo sapiens,,CHEMBL620366,833K,,,,F,1,1,
,BAO_0000219,5532,N,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,Expert,854.0,80647,,2392,,9606.0,Homo sapiens,,CHEMBL620367,833K,,,,F,1,1,
,BAO_0000219,5533,N,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,Intermediate,854.0,80647,,2392,,9606.0,Homo sapiens,,CHEMBL620368,833K,,,,F,1,1,
,BAO_0000019,5534,U,Inhibitory activity against caspase-1,Autocuration,,22226,,6608,,,,,CHEMBL620369,,,,,B,1,0,
,BAO_0000357,5535,H,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,Autocuration,,45,,10199,,1351.0,Enterococcus faecalis,,CHEMBL620370,,,,,B,1,8,
,BAO_0000219,5536,N,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,Intermediate,705.0,80648,,17749,,9606.0,Homo sapiens,,CHEMBL620371,8701-BC,,,,F,1,1,
,BAO_0000219,5537,N,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,Intermediate,705.0,80648,,17749,,9606.0,Homo sapiens,,CHEMBL620372,8701-BC,,,,F,1,1,
,BAO_0000019,5538,U,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,Intermediate,,22226,,1229,,,,,CHEMBL876492,,,,,F,1,0,
,BAO_0000019,5539,U,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,Intermediate,,22226,,1229,,,,,CHEMBL620373,,,,,F,1,0,
,BAO_0000019,5540,U,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,Intermediate,,22226,,1229,,,,,CHEMBL620374,,,,,F,1,0,
,BAO_0000019,5541,U,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,Autocuration,,22226,,6390,,,,,CHEMBL620375,,,,,B,1,0,
,BAO_0000019,5542,U,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,Autocuration,,22226,,16219,,1314.0,Streptococcus pyogenes,,CHEMBL857902,,,,,F,1,0,
,BAO_0000019,5543,U,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,Autocuration,,22226,,16219,,1314.0,Streptococcus pyogenes,,CHEMBL620376,,,,,F,1,0,
,BAO_0000357,5544,H,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,Autocuration,,11922,,17043,,,,,CHEMBL620377,,,,,B,1,8,
,BAO_0000219,5545,N,Tested for in vitro cytotoxic potency of compound in 9KB assay,Intermediate,324.0,81115,,6929,,9606.0,Homo sapiens,,CHEMBL620378,KB ,,,,F,1,1,
,BAO_0000219,5546,N,Tested for in vitro cytotoxic potency of compound in 9KB assay,Intermediate,324.0,81115,,6929,,9606.0,Homo sapiens,,CHEMBL620379,KB ,,,,A,1,1,
,BAO_0000219,5547,U,In vitro cytotoxicity of compound was tested against 9KB cells.,Autocuration,,22226,,7083,,9606.0,Homo sapiens,,CHEMBL620380,,,,,F,1,0,
,BAO_0000219,5548,N,Cytotoxic concentration against 9L cells was determined on day 3,Intermediate,392.0,80653,,12446,,10116.0,Rattus norvegicus,,CHEMBL884006,9L,,,,F,1,1,
,BAO_0000219,5549,N,Tested in vitro for anticancer activity against 9L cells,Expert,392.0,80653,,15345,,10116.0,Rattus norvegicus,,CHEMBL620381,9L,,,,F,1,1,
,BAO_0000219,5550,N,Tested in vitro for anticancer activity against 9L cells; Not determined,Expert,392.0,80653,,15345,,10116.0,Rattus norvegicus,,CHEMBL620382,9L,,,,F,1,1,
,BAO_0000219,5551,N,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,Intermediate,646.0,80682,,6301,,9606.0,Homo sapiens,,CHEMBL620383,A549,,,,F,1,1,
,BAO_0000219,5552,N,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,Intermediate,646.0,80682,,4833,,9606.0,Homo sapiens,,CHEMBL876493,A549,,,,F,1,1,
,BAO_0000219,5553,N,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,Intermediate,646.0,80682,,4833,,9606.0,Homo sapiens,,CHEMBL620384,A549,,,,F,1,1,
,BAO_0000219,5554,N,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,Intermediate,646.0,80682,,4833,,9606.0,Homo sapiens,,CHEMBL620385,A549,,,,F,1,1,
,BAO_0000219,5555,N,Cytotoxicity against human lung carcinoma A549 cell line,Expert,646.0,80682,,13330,,9606.0,Homo sapiens,,CHEMBL620386,A549,,,,F,1,1,
,BAO_0000219,5556,D,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,Expert,646.0,25,,17517,,9606.0,Homo sapiens,,CHEMBL620387,A549,,,,F,1,9,
,BAO_0000219,5557,D,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",Expert,646.0,25,,17517,,9606.0,Homo sapiens,,CHEMBL621404,A549,,,,F,1,9,
,BAO_0000219,5558,N,"In vitro growth inhibition of A549, lung carcinoma",Intermediate,646.0,80682,,14425,,9606.0,Homo sapiens,,CHEMBL621405,A549,,,,F,1,1,
,BAO_0000219,5559,N,"In vitro growth inhibition of A549, lung carcinoma.",Intermediate,646.0,80682,,14425,,9606.0,Homo sapiens,,CHEMBL621406,A549,,,,F,1,1,
,BAO_0000219,5560,N,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,Expert,646.0,80682,,5228,,9606.0,Homo sapiens,,CHEMBL621407,A549,,,,F,1,1,
,BAO_0000219,5561,N,Cytotoxic activity against human lung cancer A549 cell line was determined,Intermediate,646.0,80682,,5351,,9606.0,Homo sapiens,,CHEMBL621408,A549,,,,F,1,1,
,BAO_0000219,5562,N,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,Expert,646.0,80682,,12198,,9606.0,Homo sapiens,,CHEMBL885345,A549,,,,F,1,1,
,BAO_0000219,5563,N,Cytotoxicity concentration against human lung carcinoma A-549 cell line,Intermediate,646.0,80682,,13891,,9606.0,Homo sapiens,,CHEMBL621409,A549,,,,F,1,1,
,BAO_0000219,5564,N,Cytotoxicity in A549 (human carcinoma) cell line.,Expert,646.0,80682,,5677,,9606.0,Homo sapiens,,CHEMBL876034,A549,,,,F,1,1,
,BAO_0000219,5565,N,Cytotoxicity on lung carcinoma (A-549) cell line,Intermediate,646.0,80682,,13788,,9606.0,Homo sapiens,,CHEMBL621410,A549,,,,F,1,1,
,BAO_0000219,5566,N,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,Expert,646.0,80682,,13384,,9606.0,Homo sapiens,,CHEMBL621411,A549,,,,F,1,1,
,BAO_0000219,5567,N,Effective dose of compound against replication of A549 cell line was evaluated,Intermediate,646.0,80682,,6726,,9606.0,Homo sapiens,,CHEMBL621412,A549,,,,F,1,1,
,BAO_0000219,5568,N,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,Expert,646.0,80682,,3455,,9606.0,Homo sapiens,,CHEMBL621413,A549,,,,F,1,1,
,BAO_0000219,5569,N,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),Intermediate,646.0,80682,,5726,,9606.0,Homo sapiens,,CHEMBL621414,A549,,,,F,1,1,
,BAO_0000219,5570,N,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,Intermediate,646.0,80682,,5726,,9606.0,Homo sapiens,,CHEMBL621415,A549,,,,F,1,1,
,BAO_0000219,5571,N,The compound was evaluated for antiproliferative activity against A549 cell line,Intermediate,646.0,80682,,3936,,9606.0,Homo sapiens,,CHEMBL621416,A549,,,,F,1,1,
,BAO_0000219,5572,N,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,Intermediate,646.0,80682,,14991,,9606.0,Homo sapiens,,CHEMBL621417,A549,,,,F,1,1,
,BAO_0000219,5573,N,Concentration required for growth inhibition of human lung carcinoma cell line A549,Intermediate,646.0,80682,,5243,,9606.0,Homo sapiens,,CHEMBL621418,A549,,,,F,1,1,
,BAO_0000219,5574,N,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,Intermediate,646.0,80682,,12858,,9606.0,Homo sapiens,,CHEMBL621419,A549,,,,F,1,1,
,BAO_0000219,5575,N,Growth inhibition against A549 cell line was evaluated,Intermediate,646.0,80682,,6776,,9606.0,Homo sapiens,,CHEMBL621420,A549,,,,F,1,1,
,BAO_0000219,5576,N,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,Intermediate,646.0,80682,,16558,,9606.0,Homo sapiens,,CHEMBL875823,A549,,,,F,1,1,
,BAO_0000219,5577,N,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,Expert,646.0,80682,,4583,,9606.0,Homo sapiens,,CHEMBL621421,A549,,,,F,1,1,
,BAO_0000219,5578,N,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,Intermediate,646.0,80682,,13514,,9606.0,Homo sapiens,,CHEMBL621422,A549,,,,F,1,1,
,BAO_0000219,5579,N,Chemosensitivity against DT-diaphorase rich A549 cell lines,Expert,646.0,80682,,15166,,9606.0,Homo sapiens,,CHEMBL884014,A549,,,,F,1,1,
,BAO_0000219,5580,N,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,Intermediate,646.0,80682,,13873,,9606.0,Homo sapiens,,CHEMBL621423,A549,,,,F,1,1,
,BAO_0000219,5581,N,In vitro cytotoxicity against human A549 (lung cancer) cell line.,Expert,646.0,80682,,6447,,9606.0,Homo sapiens,,CHEMBL621424,A549,,,,F,1,1,
,BAO_0000219,5582,N,In vitro antitumor activity against A549 (lung) human tumor cell lines.,Intermediate,646.0,80682,,2068,,9606.0,Homo sapiens,,CHEMBL621425,A549,,,,F,1,1,
,BAO_0000219,5583,N,In vitro cytotoxic activity against human lung carcinoma A549 cell line,Expert,646.0,80682,,1863,,9606.0,Homo sapiens,,CHEMBL621426,A549,,,,F,1,1,
,BAO_0000219,5584,N,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,Intermediate,646.0,80682,,13873,,9606.0,Homo sapiens,,CHEMBL621427,A549,,,,F,1,1,
,BAO_0000219,5585,N,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,Intermediate,646.0,80682,,13873,,9606.0,Homo sapiens,,CHEMBL621428,A549,,,,F,1,1,
,BAO_0000219,5586,N,Tested against A549 lung carcinoma in the sulforhodamine B assay.,Expert,646.0,80682,,13873,,9606.0,Homo sapiens,,CHEMBL621429,A549,,,,F,1,1,
,BAO_0000219,5587,N,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),Intermediate,646.0,80682,,579,,9606.0,Homo sapiens,,CHEMBL621430,A549,,,,F,1,1,
,BAO_0000219,5588,N,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,Intermediate,646.0,80682,,579,,9606.0,Homo sapiens,,CHEMBL621431,A549,,,,F,1,1,
,BAO_0000219,5589,N,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,Intermediate,646.0,80682,,4584,,9606.0,Homo sapiens,,CHEMBL621432,A549,,,,F,1,1,
,BAO_0000219,5590,N,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,Expert,646.0,80682,,5421,,9606.0,Homo sapiens,,CHEMBL621433,A549,,,,F,1,1,
,BAO_0000219,5591,N,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,Intermediate,646.0,80682,,5421,,9606.0,Homo sapiens,,CHEMBL875824,A549,,,,F,1,1,
,BAO_0000219,5592,N,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,Intermediate,646.0,80682,,5421,,9606.0,Homo sapiens,,CHEMBL621434,A549,,,,F,1,1,
,BAO_0000219,5593,N,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,Intermediate,646.0,80682,,5421,,9606.0,Homo sapiens,,CHEMBL621435,A549,,,,F,1,1,
,BAO_0000219,5594,N,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,Intermediate,646.0,80682,,14188,,9606.0,Homo sapiens,,CHEMBL621436,A549,,,,F,1,1,
,BAO_0000219,5595,N,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,Intermediate,646.0,80682,,14188,,9606.0,Homo sapiens,,CHEMBL621437,A549,,,,F,1,1,
,BAO_0000219,5596,N,Compound was tested for the growth inhibition of A549 lung tumor cell line,Intermediate,646.0,80682,,15354,,9606.0,Homo sapiens,,CHEMBL621438,A549,,,,F,1,1,
,BAO_0000219,5597,N,Growth inhibition of human non-small-lung carcinoma (A549) cell line,Expert,646.0,80682,,14253,,9606.0,Homo sapiens,,CHEMBL621439,A549,,,,F,1,1,
,BAO_0000219,5598,N,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,Intermediate,646.0,80682,,13873,,9606.0,Homo sapiens,,CHEMBL621440,A549,,,,F,1,1,
,BAO_0000218,5599,N,Oral bioavailability in dog (conscious),Intermediate,,50588,,3043,,9615.0,Canis lupus familiaris,,CHEMBL621441,,,In vivo,,A,1,1,
,BAO_0000218,5600,N,Compound was evaluated for the oral bioavailability after oral administration in dog.,Intermediate,,50588,,3045,,9615.0,Canis lupus familiaris,,CHEMBL621442,,,In vivo,,A,1,1,
,BAO_0000218,5601,N,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,Intermediate,,50588,,3022,,9615.0,Canis lupus familiaris,,CHEMBL621443,,,In vivo,,A,1,1,
,BAO_0000218,5602,N,Oral bioavailability in dog,Intermediate,,50588,,4453,,9615.0,Canis lupus familiaris,,CHEMBL621444,,,In vivo,,A,1,1,
,BAO_0000218,5603,N,Oral bioavailability in dog,Intermediate,,50588,,1696,,9615.0,Canis lupus familiaris,,CHEMBL625133,,,In vivo,,A,1,1,
,BAO_0000218,5604,N,Oral bioavailability in dog,Intermediate,,50588,,5045,,9615.0,Canis lupus familiaris,,CHEMBL625134,,,In vivo,,A,1,1,
,BAO_0000218,5605,N,Oral bioavailability in dog (fasted),Intermediate,,50588,,5356,,9615.0,Canis lupus familiaris,,CHEMBL625135,,,In vivo,,A,1,1,
,BAO_0000218,5606,N,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,Intermediate,,50588,,17764,,9615.0,Canis lupus familiaris,,CHEMBL625136,,,In vivo,,A,1,1,
,BAO_0000218,5607,N,Oral bioavailability in dog,Intermediate,,50588,,6448,,9615.0,Canis lupus familiaris,,CHEMBL625137,,,In vivo,,A,1,1,
,BAO_0000218,5608,N,Oral bioavailability in dog,Intermediate,,50588,,1475,,9615.0,Canis lupus familiaris,,CHEMBL625138,,,In vivo,,A,1,1,
,BAO_0000218,5609,N,Percent bioavailability in dog,Intermediate,,50588,,3788,,9615.0,Canis lupus familiaris,,CHEMBL625139,,,In vivo,,A,1,1,
,BAO_0000218,5610,N,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,Intermediate,,50588,,3639,,9615.0,Canis lupus familiaris,,CHEMBL872264,,,In vivo,,A,1,1,
,BAO_0000218,5611,N,Oral bioavailability in dog,Intermediate,,50588,,13397,,9615.0,Canis lupus familiaris,,CHEMBL625140,,,In vivo,,A,1,1,
,BAO_0000218,5612,N,The compound was evaluated for bioavailability in dogs; 34-44,Intermediate,,50588,,2137,,9615.0,Canis lupus familiaris,,CHEMBL624436,,,In vivo,,A,1,1,
,BAO_0000218,5613,N,Bioavailability in dog (dose 4 mg/kg p.o.),Intermediate,,50588,,2959,,9615.0,Canis lupus familiaris,,CHEMBL624437,,,In vivo,,A,1,1,
,BAO_0000218,5614,N,Oral bioavailability in dog,Intermediate,,50588,,6448,,9615.0,Canis lupus familiaris,,CHEMBL872261,,,In vivo,,A,1,1,
,BAO_0000218,5615,N,8 hour trough Blood level in dog was measured after administration of compound,Intermediate,,50588,,6084,,9615.0,Canis lupus familiaris,,CHEMBL624438,,,,,A,1,1,
Plasma,BAO_0000218,5616,N,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,Intermediate,,50588,,3639,1969.0,9615.0,Canis lupus familiaris,,CHEMBL624439,,,In vivo,,A,1,1,
,BAO_0000218,5617,N,C24 after oral administration at 5 mg/kg,Intermediate,,50588,,6316,,9615.0,Canis lupus familiaris,,CHEMBL624440,,,,,A,1,1,
,BAO_0000218,5618,N,Clearance after oral and iv dosing in dogs,Intermediate,,50588,,5238,,9615.0,Canis lupus familiaris,,CHEMBL624441,,,,,A,1,1,
Plasma,BAO_0000218,5619,N,Clearance of the drug was measured in the plasma of dog,Intermediate,,50588,,17796,1969.0,9615.0,Canis lupus familiaris,,CHEMBL624442,,,,,A,1,1,
,BAO_0000218,5620,N,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,Intermediate,,50588,,2652,,9615.0,Canis lupus familiaris,,CHEMBL624443,,,,,A,1,1,
,BAO_0000218,5621,N,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,Intermediate,,50588,,5654,,9615.0,Canis lupus familiaris,,CHEMBL624444,,,In vivo,,A,1,1,
,BAO_0000218,5622,N,Clearance of compound was determined in dogs,Intermediate,,50588,,6621,,9615.0,Canis lupus familiaris,,CHEMBL624445,,,In vivo,,A,1,1,
,BAO_0000218,5623,N,Clearance on i.v. administration of 2 mg/kg was measured in dog,Intermediate,,50588,,6505,,9615.0,Canis lupus familiaris,,CHEMBL624446,,,In vivo,,A,1,1,
,BAO_0000218,5624,N,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,Intermediate,,50588,,5802,,9615.0,Canis lupus familiaris,,CHEMBL624447,,,In vivo,,A,1,1,
,BAO_0000218,5625,N,Plasma clearance in dog was determined,Intermediate,,50588,,17267,,9615.0,Canis lupus familiaris,,CHEMBL624448,,,In vivo,,A,1,1,
,BAO_0000218,5626,N,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,Intermediate,,50588,,4521,,9615.0,Canis lupus familiaris,,CHEMBL624449,,,In vivo,,A,1,1,
,BAO_0000218,5627,N,Plasma clearance in dog after administration of 0.25 mg/kg iv,Intermediate,,50588,,6535,,9615.0,Canis lupus familiaris,,CHEMBL624450,,,In vivo,,A,1,1,
,BAO_0000218,5628,N,Plasma clearance in dog after administration of 1 mg/kg iv,Intermediate,,50588,,6535,,9615.0,Canis lupus familiaris,,CHEMBL875942,,,In vivo,,A,1,1,
,BAO_0000218,5629,N,Plasma clearance in dogs,Intermediate,,50588,,6535,,9615.0,Canis lupus familiaris,,CHEMBL624451,,,In vivo,,A,1,1,
,BAO_0000218,5630,N,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,Intermediate,,50588,,5542,,9615.0,Canis lupus familiaris,,CHEMBL624452,,,In vivo,,A,1,1,
,BAO_0000218,5631,N,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,Intermediate,,50588,,5199,,9615.0,Canis lupus familiaris,,CHEMBL624453,,,In vivo,,A,1,1,
,BAO_0000218,5632,N,Plasma clearance after 15 mg/kg iv dose in Dogs,Intermediate,,50588,,16907,,9615.0,Canis lupus familiaris,,CHEMBL624454,,,In vivo,,A,1,1,
,BAO_0000218,5633,N,Plasma clearance after 30 mg/kg po dose in Dogs,Intermediate,,50588,,16907,,9615.0,Canis lupus familiaris,,CHEMBL624455,,,In vivo,,A,1,1,
,BAO_0000218,5634,N,Plasma administration to dogs,Intermediate,,50588,,16367,,9615.0,Canis lupus familiaris,,CHEMBL624456,,,In vivo,,A,1,1,
,BAO_0000218,5635,N,Plasma clearance was determined,Intermediate,,50588,,5505,,9615.0,Canis lupus familiaris,,CHEMBL624457,,,In vivo,,A,1,1,
,BAO_0000218,5636,N,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,Intermediate,,50588,,6215,,9615.0,Canis lupus familiaris,,CHEMBL624458,,,In vivo,,A,1,1,
,BAO_0000218,5637,N,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,Intermediate,,50588,,1466,,9615.0,Canis lupus familiaris,,CHEMBL624459,,,In vivo,,A,1,1,
Liver,BAO_0000251,5638,S,Intrinsic clearance in human liver microsomes,Intermediate,,102164,,5007,2107.0,9606.0,Homo sapiens,,CHEMBL624460,,,In vitro,Microsomes,A,1,2,
Liver,BAO_0000251,5639,S,Intrinsic clearance in human liver microsomes,Intermediate,,102164,,5007,2107.0,9606.0,Homo sapiens,,CHEMBL624461,,,In vitro,Microsomes,A,1,2,
,BAO_0000218,5640,N,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,Intermediate,,50588,,16452,,9615.0,Canis lupus familiaris,,CHEMBL875943,,,In vivo,,A,1,1,
,BAO_0000218,5641,N,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,Intermediate,,50588,,16452,,9615.0,Canis lupus familiaris,,CHEMBL624462,,,In vivo,,A,1,1,
,BAO_0000218,5642,N,Clearance in dog (dose 1 mg/kg i.v.),Intermediate,,50588,,16452,,9615.0,Canis lupus familiaris,,CHEMBL624463,,,In vivo,,A,1,1,
,BAO_0000218,5643,N,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,Intermediate,,50588,,6221,,9615.0,Canis lupus familiaris,,CHEMBL624464,,,In vivo,,A,1,1,
,BAO_0000218,5644,N,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),Intermediate,,50588,,5007,,9615.0,Canis lupus familiaris,,CHEMBL624465,,,In vivo,,A,1,1,
,BAO_0000218,5645,N,Plasma clearance after peroral administration at 10 mpk in dog,Intermediate,,50588,,5668,,9615.0,Canis lupus familiaris,,CHEMBL624466,,,In vivo,,A,1,1,
,BAO_0000218,5646,N,Plasma clearance after peroral administration at 5 mpk in dog,Intermediate,,50588,,5668,,9615.0,Canis lupus familiaris,,CHEMBL624467,,,In vivo,,A,1,1,
,BAO_0000218,5647,N,Plasma clearance after peroral administration at 5 mg/kg in dog,Intermediate,,50588,,5668,,9615.0,Canis lupus familiaris,,CHEMBL624468,,,In vivo,,A,1,1,
,BAO_0000218,5648,N,Plasma clearance was measured in dog,Intermediate,,50588,,15660,,9615.0,Canis lupus familiaris,,CHEMBL624469,,,In vivo,,A,1,1,
,BAO_0000218,5649,N,Plasma clearance was measured in dog,Intermediate,,50588,,15660,,9615.0,Canis lupus familiaris,,CHEMBL624470,,,In vivo,,A,1,1,
,BAO_0000218,5650,N,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,Intermediate,,50588,,5983,,9615.0,Canis lupus familiaris,,CHEMBL624471,,,In vivo,,A,1,1,
,BAO_0000218,5651,N,Total clearance was determined after 0.1 mg/kg iv administration in dog,Intermediate,,50588,,5600,,9615.0,Canis lupus familiaris,,CHEMBL624472,,,In vivo,,A,1,1,
,BAO_0000218,5652,N,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,Intermediate,,50588,,17764,,9615.0,Canis lupus familiaris,,CHEMBL622775,,,In vivo,,A,1,1,
,BAO_0000218,5653,N,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,Intermediate,,50588,,6039,,9615.0,Canis lupus familiaris,,CHEMBL622776,,,In vivo,,A,1,1,
,BAO_0000218,5654,N,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,Intermediate,,50588,,6039,,9615.0,Canis lupus familiaris,,CHEMBL622777,,,In vivo,,A,1,1,
,BAO_0000218,5655,N,Clearance after peroral administration of 0.2 mg/kg in dog was determined,Intermediate,,50588,,6039,,9615.0,Canis lupus familiaris,,CHEMBL622778,,,In vivo,,A,1,1,
,BAO_0000218,5656,N,Clearance by intravenous administration of 1.2 mg/kg in dog,Intermediate,,50588,,4368,,9615.0,Canis lupus familiaris,,CHEMBL622779,,,In vivo,,A,1,1,
,BAO_0000218,5657,N,Clearance by iv administration in dogs at a dose of 1 mg/kg,Intermediate,,50588,,4305,,9615.0,Canis lupus familiaris,,CHEMBL622780,,,In vivo,,A,1,1,
Plasma,BAO_0000218,5658,N,Clearance value was evaluated in dog plasma,Intermediate,,50588,,1918,1969.0,9615.0,Canis lupus familiaris,,CHEMBL622781,,,In vivo,,A,1,1,
,BAO_0000218,5659,N,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,Intermediate,,50588,,6005,,9615.0,Canis lupus familiaris,,CHEMBL622782,,,In vivo,,A,1,1,
Plasma,BAO_0000218,5660,N,Compound was tested for plasma clearance in dog,Intermediate,,50588,,4839,1969.0,9615.0,Canis lupus familiaris,,CHEMBL622783,,,In vivo,,A,1,1,
,BAO_0000218,5661,N,Pharmacokinetic property (Plasma clearance) was measured in dog,Intermediate,,50588,,4239,,9615.0,Canis lupus familiaris,,CHEMBL622784,,,In vivo,,A,1,1,
,BAO_0000218,5662,N,Area under curve when injected perorally in mice at a dose of 50 mg/kg,Intermediate,,50594,,17729,,10090.0,Mus musculus,,CHEMBL622785,,,,,A,1,1,
,BAO_0000218,5663,N,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,Intermediate,,50594,,17728,,10090.0,Mus musculus,,CHEMBL622786,,,,,A,1,1,
,BAO_0000218,5664,N,Area under curve value in mouse at a dose of 10 mg/kg,Intermediate,,50594,,5302,,10090.0,Mus musculus,,CHEMBL622787,,,,,A,1,1,
,BAO_0000218,5665,N,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,Intermediate,,50594,,5506,,10090.0,Mus musculus,,CHEMBL875949,,,,,A,1,1,
,BAO_0000218,5666,N,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,Intermediate,,50594,,5506,,10090.0,Mus musculus,,CHEMBL622788,,,,,A,1,1,
,BAO_0000218,5667,N,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,Intermediate,,50594,,17764,,10090.0,Mus musculus,,CHEMBL622789,,,,,F,1,1,
,BAO_0000218,5668,N,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,Intermediate,,50594,,17764,,10090.0,Mus musculus,,CHEMBL622790,,,,,F,1,1,
,BAO_0000218,5669,N,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,Intermediate,,50594,,17764,,10090.0,Mus musculus,,CHEMBL622791,,,,,F,1,1,
,BAO_0000218,5670,N,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,Intermediate,,50594,,17764,,10090.0,Mus musculus,,CHEMBL622792,,,,,F,1,1,
,BAO_0000218,5671,N,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,Intermediate,,50594,,17764,,10090.0,Mus musculus,,CHEMBL622793,,,,,A,1,1,
,BAO_0000218,5672,N,Area under curve was determined for the compound at 24 mg/Kg,Intermediate,,50594,,17753,,10090.0,Mus musculus,,CHEMBL622794,,,,,A,1,1,
,BAO_0000218,5673,N,Area under curve was determined for the compound at 40 mg/Kg,Intermediate,,50594,,17753,,10090.0,Mus musculus,,CHEMBL622795,,,,,A,1,1,
,BAO_0000218,5674,N,Area under curve was determined for the compound at 5 mg/Kg,Intermediate,,50594,,17753,,10090.0,Mus musculus,,CHEMBL621803,,,,,A,1,1,
,BAO_0000218,5675,N,Area under the curve for the compound is obtained at dose 25 mg/kg,Intermediate,,50594,,3132,,10090.0,Mus musculus,,CHEMBL621804,,,,,A,1,1,
,BAO_0000218,5676,N,Area under the curve for the compound was obtained when tested in mouse,Intermediate,,50594,,3132,,10090.0,Mus musculus,,CHEMBL621805,,,,,A,1,1,
,BAO_0000218,5677,N,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,Intermediate,,50594,,17837,,10090.0,Mus musculus,,CHEMBL621806,,,,,A,1,1,
,BAO_0000218,5678,N,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,Intermediate,,50594,,17837,,10090.0,Mus musculus,,CHEMBL621807,,,,,A,1,1,
,BAO_0000218,5679,N,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,Intermediate,,50594,,6062,,10090.0,Mus musculus,,CHEMBL621808,,,,,A,1,1,
,BAO_0000218,5680,N,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,Intermediate,,50594,,4066,,10090.0,Mus musculus,,CHEMBL621809,,,,,A,1,1,
,BAO_0000218,5681,N,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),Intermediate,,50594,,16597,,10090.0,Mus musculus,,CHEMBL621810,,,,,A,1,1,
,BAO_0000218,5682,N,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,Intermediate,,50594,,14239,,10090.0,Mus musculus,,CHEMBL875164,,,,,A,1,1,
,BAO_0000218,5683,N,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,Intermediate,,50594,,14239,,10090.0,Mus musculus,,CHEMBL621811,,,,,A,1,1,
,BAO_0000218,5684,N,"Compound was evaluated for the pharmacokinetic parameter, area under curve",Intermediate,,50594,,4890,,10090.0,Mus musculus,,CHEMBL621812,,,,,A,1,1,
,BAO_0000218,5685,N,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),Intermediate,,50594,,429,,10090.0,Mus musculus,,CHEMBL621813,,,,,A,1,1,
,BAO_0000218,5686,N,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),Intermediate,,50594,,429,,10090.0,Mus musculus,,CHEMBL621814,,,,,A,1,1,
,BAO_0000218,5687,N,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,Intermediate,,50594,,5969,,10090.0,Mus musculus,,CHEMBL621815,,,,,A,1,1,
,BAO_0000218,5688,N,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,Intermediate,,50594,,5969,,10090.0,Mus musculus,,CHEMBL621816,,,,,A,1,1,
,BAO_0000218,5689,N,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,Intermediate,,50594,,5969,,10090.0,Mus musculus,,CHEMBL621817,,,,,A,1,1,
,BAO_0000218,5690,N,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,Intermediate,,50594,,6091,,10090.0,Mus musculus,,CHEMBL621818,,,,,A,1,1,
,BAO_0000218,5691,N,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,Intermediate,,50594,,6091,,10090.0,Mus musculus,,CHEMBL621819,,,,,A,1,1,
,BAO_0000218,5692,N,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,Intermediate,,50594,,6091,,10090.0,Mus musculus,,CHEMBL621820,,,,,A,1,1,
,BAO_0000218,5693,N,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,Intermediate,,50594,,6091,,10090.0,Mus musculus,,CHEMBL621821,,,,,A,1,1,
,BAO_0000218,5694,N,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,Intermediate,,50594,,6178,,10090.0,Mus musculus,,CHEMBL621822,,,,,A,1,1,
,BAO_0000218,5695,N,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,Intermediate,,50594,,6178,,10090.0,Mus musculus,,CHEMBL619474,,,,,A,1,1,
,BAO_0000218,5696,N,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",Intermediate,,50594,,6619,,10090.0,Mus musculus,,CHEMBL619475,,,,,A,1,1,
,BAO_0000218,5697,N,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",Intermediate,,50594,,6619,,10090.0,Mus musculus,,CHEMBL619476,,,,,A,1,1,
,BAO_0000218,5698,N,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",Intermediate,,50594,,3760,,10090.0,Mus musculus,,CHEMBL619477,,,,,A,1,1,
,BAO_0000218,5699,N,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",Intermediate,,50594,,3760,,10090.0,Mus musculus,,CHEMBL619478,,,,,A,1,1,
,BAO_0000218,5700,N,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",Intermediate,,50594,,3760,,10090.0,Mus musculus,,CHEMBL619479,,,,,A,1,1,
,BAO_0000218,5701,N,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",Intermediate,,50594,,3760,,10090.0,Mus musculus,,CHEMBL619480,,,,,A,1,1,
,BAO_0000218,5702,N,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,Intermediate,,50594,,3192,,10090.0,Mus musculus,,CHEMBL619481,,,,,A,1,1,
,BAO_0000218,5703,N,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,Intermediate,,50594,,3192,,10090.0,Mus musculus,,CHEMBL619482,,,,,A,1,1,
,BAO_0000218,5704,N,Area under the curve was evaluated in mice after intravenous administration,Intermediate,,50594,,2675,,10090.0,Mus musculus,,CHEMBL619483,,,,,A,1,1,
,BAO_0000218,5705,N,Area under the curve was evaluated in mice after oral administration,Intermediate,,50594,,2675,,10090.0,Mus musculus,,CHEMBL619484,,,,,A,1,1,
Plasma,BAO_0000218,5706,N,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,Intermediate,,50594,,16597,1969.0,10090.0,Mus musculus,,CHEMBL619485,,,,,A,1,1,
Plasma,BAO_0000218,5707,N,AUC total value at a dose of 10 mg/kg peroral administration in mice.,Intermediate,,50594,,16597,1969.0,10090.0,Mus musculus,,CHEMBL619486,,,,,A,1,1,
,BAO_0000218,5708,N,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),Intermediate,,50594,,16597,,10090.0,Mus musculus,,CHEMBL619487,,,,,A,1,1,
,BAO_0000218,5709,N,AUMC after intraperitoneal administration of 100 mg/kg in mice,Intermediate,,50594,,17734,,10090.0,Mus musculus,,CHEMBL619488,,,,,A,1,1,
Blood,BAO_0000218,5710,N,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,Intermediate,,50594,,7767,178.0,10090.0,Mus musculus,,CHEMBL620106,,,In vivo,,A,1,1,
,BAO_0000219,5711,N,The compound was tested in vitro for anticancer activity against 9L cells,Intermediate,392.0,80653,,15345,,,,,CHEMBL620107,9L,,,,F,1,1,
,BAO_0000019,5712,U,Anti proliferation activity determined; Weak effect,Autocuration,,22226,,2181,,10116.0,Rattus norvegicus,,CHEMBL620283,,,,,F,1,0,
,BAO_0000219,5713,U,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,Autocuration,,22226,,2181,,10116.0,Rattus norvegicus,,CHEMBL875176,,,,,F,1,0,
,BAO_0000219,5714,U,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,Autocuration,,22226,,2181,,10116.0,Rattus norvegicus,,CHEMBL620284,,,,,F,1,0,
,BAO_0000219,5715,U,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,Autocuration,,22226,,2181,,10116.0,Rattus norvegicus,,CHEMBL623515,,,,,F,1,0,
,BAO_0000019,5716,U,The cytotoxic activity was in vitro tested by 9PS assay method,Autocuration,,22226,,10486,,10090.0,Mus musculus,,CHEMBL623516,,,,,F,1,0,
,BAO_0000019,5717,U,The cytotoxic activity was in vitro tested by 9PS assay method.,Autocuration,,22226,,10486,,10090.0,Mus musculus,,CHEMBL623517,,,,,F,1,0,
,BAO_0000019,5718,U,Partition coefficient (logD6.5),Autocuration,,22224,,15508,,,,,CHEMBL857878,,,,,A,1,0,
,BAO_0000219,5719,N,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,Expert,478.0,81034,,5242,,9606.0,Homo sapiens,,CHEMBL623518,A2780,,,,F,1,1,
,BAO_0000219,5720,N,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),Intermediate,455.0,80018,,16167,,9606.0,Homo sapiens,,CHEMBL624195,A-375,,,,F,1,1,
,BAO_0000219,5721,N,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,Expert,500.0,80852,,4782,,9606.0,Homo sapiens,,CHEMBL624196,A-431,,,,F,1,1,
,BAO_0000219,5722,D,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,Expert,500.0,9,,16093,,9606.0,Homo sapiens,,CHEMBL624197,A-431,,,,F,1,9,
,BAO_0000219,5723,N,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,Intermediate,624.0,80021,,2596,,9606.0,Homo sapiens,,CHEMBL624198,A498,,,,F,1,1,
,BAO_0000219,5724,N,in vitro cytotoxicity against A 498 cancer cell line,Intermediate,624.0,80021,,2596,,9606.0,Homo sapiens,,CHEMBL621287,A498,,,,F,1,1,
,BAO_0000219,5725,N,In vitro cytotoxic activity against renal (A 498) cancer cell line.,Intermediate,624.0,80021,,3239,,9606.0,Homo sapiens,,CHEMBL621288,A498,,,,F,1,1,
,BAO_0000219,5726,N,Cytotoxic activity against A 498 renal cancer cell lines.,Intermediate,624.0,80021,,1847,,9606.0,Homo sapiens,,CHEMBL876496,A498,,,,F,1,1,
,BAO_0000219,5727,N,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,Intermediate,624.0,80021,,10553,,9606.0,Homo sapiens,,CHEMBL621289,A498,,,,F,1,1,
,BAO_0000019,5728,U,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,Autocuration,,22226,,16219,,1280.0,Staphylococcus aureus,,CHEMBL621290,,,,,F,1,0,
,BAO_0000019,5729,U,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,Autocuration,,22226,,16219,,1280.0,Staphylococcus aureus,,CHEMBL621291,,,,,F,1,0,
,BAO_0000019,5730,U,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,Autocuration,,22226,,16219,,1280.0,Staphylococcus aureus,,CHEMBL621292,,,,,F,1,0,
,BAO_0000019,5731,U,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,Autocuration,,22226,,16219,,1280.0,Staphylococcus aureus,,CHEMBL621293,,,,,F,1,0,
,BAO_0000219,5732,N,Inhibitory concentration required against A 549 lung cancer cell line,Intermediate,646.0,80682,,4782,,9606.0,Homo sapiens,,CHEMBL621294,A549,,,,F,1,1,
,BAO_0000219,5733,N,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,Intermediate,646.0,80682,,11805,,9606.0,Homo sapiens,,CHEMBL621295,A549,,,,F,1,1,
,BAO_0000219,5734,N,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,Intermediate,646.0,80682,,11805,,9606.0,Homo sapiens,,CHEMBL884007,A549,,,,F,1,1,
,BAO_0000219,5735,N,In vitro cytotoxicity against lung cancer A 549 cell lines,Intermediate,646.0,80682,,2007,,9606.0,Homo sapiens,,CHEMBL621296,A549,,,,F,1,1,
,BAO_0000219,5736,N,Compound was tested for its cytotoxicity against A 549 cell line,Intermediate,646.0,80682,,4594,,9606.0,Homo sapiens,,CHEMBL621297,A549,,,,F,1,1,
,BAO_0000219,5737,N,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",Expert,646.0,80682,,6018,,9606.0,Homo sapiens,,CHEMBL839828,A549,,,,F,1,1,
,BAO_0000219,5738,N,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",Intermediate,646.0,80682,,6018,,9606.0,Homo sapiens,,CHEMBL620397,A549,,,,F,1,1,
,BAO_0000219,5739,N,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,Expert,646.0,80682,,3599,,9606.0,Homo sapiens,,CHEMBL620398,A549,,,,F,1,1,
,BAO_0000219,5740,N,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,Intermediate,646.0,80682,,2551,,9606.0,Homo sapiens,,CHEMBL620399,A549,,,,F,1,1,
,BAO_0000219,5741,N,In vitro inhibition of A549 (human lung cancer) cell growth.,Expert,646.0,80682,,16132,,9606.0,Homo sapiens,,CHEMBL620400,A549,,,,F,1,1,
,BAO_0000219,5742,N,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,Intermediate,646.0,80682,,16132,,9606.0,Homo sapiens,,CHEMBL620401,A549,,,,F,1,1,
,BAO_0000219,5743,N,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,Expert,646.0,80682,,2551,,9606.0,Homo sapiens,,CHEMBL620402,A549,,,,F,1,1,
,BAO_0000219,5744,N,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),Expert,646.0,80682,,2551,,9606.0,Homo sapiens,,CHEMBL620403,A549,,,,F,1,1,
,BAO_0000218,5745,U,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,Autocuration,,22226,,11913,,,,,CHEMBL620404,,,,,F,1,0,
,BAO_0000218,5746,H,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,Autocuration,,104694,,12621,,,,,CHEMBL620405,,,In vivo,,F,1,4,
,BAO_0000218,5747,H,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,Autocuration,,104694,,12621,,,,,CHEMBL620406,,,In vivo,,F,1,4,
,BAO_0000218,5748,H,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,Autocuration,,104694,,12621,,,,,CHEMBL620407,,,In vivo,,F,1,4,
,BAO_0000218,5749,H,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,Autocuration,,104694,,12621,,,,,CHEMBL620408,,,In vivo,,F,1,4,
,BAO_0000218,5750,H,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,Autocuration,,104694,,12621,,,,,CHEMBL620409,,,In vivo,,F,1,4,
,BAO_0000219,5751,N,Inhibition of A-498 human Renal cell proliferation,Expert,624.0,80021,,3600,,9606.0,Homo sapiens,,CHEMBL620410,A498,,,,F,1,1,
,BAO_0000019,5752,U,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",Autocuration,,22226,,1796,,10116.0,Rattus norvegicus,,CHEMBL620411,,,,,F,1,0,
,BAO_0000019,5753,U,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",Autocuration,,22226,,1796,,10116.0,Rattus norvegicus,,CHEMBL620412,,,,,F,1,0,
,BAO_0000019,5754,U,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",Autocuration,,22226,,1796,,10116.0,Rattus norvegicus,,CHEMBL876596,,,,,F,1,0,
,BAO_0000219,5755,N,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,Expert,622.0,80012,,16464,,9606.0,Homo sapiens,,CHEMBL620413,A 172,,,,F,1,1,
,BAO_0000219,5756,N,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Intermediate,622.0,80012,,16464,,9606.0,Homo sapiens,,CHEMBL620414,A 172,,,,F,1,1,
,BAO_0000219,5757,N,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Intermediate,622.0,80012,,16464,,9606.0,Homo sapiens,,CHEMBL620415,A 172,,,,F,1,1,
,BAO_0000219,5758,N,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,Expert,646.0,80682,,13617,,9606.0,Homo sapiens,,CHEMBL620416,A549,,,,F,1,1,
,BAO_0000219,5759,N,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,Intermediate,646.0,80682,,4584,,9606.0,Homo sapiens,,CHEMBL620417,A549,,,,F,1,1,
,BAO_0000219,5760,N,Cytotoxic activity evaluated against A549 tumor cells,Expert,646.0,80682,,13799,,9606.0,Homo sapiens,,CHEMBL620418,A549,,,,F,1,1,
,BAO_0000219,5761,N,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,Intermediate,646.0,80682,,16726,,9606.0,Homo sapiens,,CHEMBL620419,A549,,,,F,1,1,
,BAO_0000219,5762,N,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,Intermediate,646.0,80682,,16109,,9606.0,Homo sapiens,,CHEMBL620420,A549,,,,F,1,1,
,BAO_0000219,5763,N,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,Intermediate,646.0,80682,,16109,,9606.0,Homo sapiens,,CHEMBL620421,A549,,,,F,1,1,
,BAO_0000219,5764,N,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,Intermediate,646.0,80682,,15474,,9606.0,Homo sapiens,,CHEMBL620422,A549,,,,F,1,1,
,BAO_0000219,5765,N,Cytotoxicity of compound against A549 cell line,Intermediate,646.0,80682,,6851,,9606.0,Homo sapiens,,CHEMBL620423,A549,,,,F,1,1,
,BAO_0000219,5766,N,Cytotoxicity against human lung cell carcinoma A549 cell line,Expert,646.0,80682,,17534,,9606.0,Homo sapiens,,CHEMBL620424,A549,,,,F,1,1,
,BAO_0000219,5767,N,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,Intermediate,646.0,80682,,2621,,9606.0,Homo sapiens,,CHEMBL620425,A549,,,,F,1,1,
,BAO_0000219,5768,N,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,Intermediate,646.0,80682,,830,,9606.0,Homo sapiens,,CHEMBL620426,A549,,,,F,1,1,
,BAO_0000219,5769,N,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,Intermediate,646.0,80682,,14255,,9606.0,Homo sapiens,,CHEMBL620427,A549,,,,F,1,1,
,BAO_0000219,5770,N,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,Intermediate,646.0,80682,,14255,,9606.0,Homo sapiens,,CHEMBL620428,A549,,,,F,1,1,
,BAO_0000219,5771,N,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,Intermediate,646.0,80682,,1590,,9606.0,Homo sapiens,,CHEMBL620429,A549,,,,F,1,1,
,BAO_0000219,5772,N,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,Expert,646.0,80682,,6146,,9606.0,Homo sapiens,,CHEMBL620430,A549,,,,F,1,1,
,BAO_0000219,5773,N,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,Expert,646.0,80682,,17427,,9606.0,Homo sapiens,,CHEMBL839887,A549,,,,F,1,1,
,BAO_0000219,5774,N,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,Intermediate,646.0,80682,,5280,,9606.0,Homo sapiens,,CHEMBL620431,A549,,,,F,1,1,
,BAO_0000219,5775,N,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,Intermediate,646.0,80682,,16786,,9606.0,Homo sapiens,,CHEMBL884010,A549,,,,F,1,1,
,BAO_0000219,5776,N,In vitro cytotoxicity against A549 (human lung cancer),Intermediate,646.0,80682,,5895,,9606.0,Homo sapiens,,CHEMBL620538,A549,,,,F,1,1,
,BAO_0000219,5777,N,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,Expert,646.0,80682,,14297,,9606.0,Homo sapiens,,CHEMBL620539,A549,,,,F,1,1,
,BAO_0000218,5778,N,In vivo antiproliferative activity against A549 cell line,Intermediate,646.0,80682,,17824,,9606.0,Homo sapiens,,CHEMBL623373,A549,,,,F,1,1,
,BAO_0000219,5779,N,Inhibition of non-small-cell lung adenocarcinoma (A549),Intermediate,646.0,80682,,14368,,9606.0,Homo sapiens,,CHEMBL623374,A549,,,,F,1,1,
,BAO_0000219,5780,N,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,Intermediate,646.0,80682,,14368,,9606.0,Homo sapiens,,CHEMBL623375,A549,,,,F,1,1,
,BAO_0000219,5781,N,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,Intermediate,646.0,80682,,14254,,9606.0,Homo sapiens,,CHEMBL623376,A549,,,,F,1,1,
,BAO_0000219,5782,N,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),Intermediate,646.0,80682,,15897,,9606.0,Homo sapiens,,CHEMBL623377,A549,,,,F,1,1,
,BAO_0000219,5783,N,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,Intermediate,646.0,80682,,13866,,9606.0,Homo sapiens,,CHEMBL623378,A549,,,,F,1,1,
,BAO_0000219,5784,N,Inhibitory activity of compound against human A549 lung carcinoma cell line.,Intermediate,646.0,80682,,13370,,9606.0,Homo sapiens,,CHEMBL623379,A549,,,,F,1,1,
,BAO_0000219,5785,N,Inhibitory activity against A549 lung cancer cell line,Intermediate,646.0,80682,,4862,,9606.0,Homo sapiens,,CHEMBL623380,A549,,,,F,1,1,
,BAO_0000219,5786,N,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,Intermediate,646.0,80682,,4862,,9606.0,Homo sapiens,,CHEMBL623381,A549,,,,F,1,1,
,BAO_0000219,5787,N,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,Intermediate,646.0,80682,,4862,,9606.0,Homo sapiens,,CHEMBL623382,A549,,,,F,1,1,
,BAO_0000219,5788,N,Inhibitory concentration against A549 (lung cancer) cell line,Intermediate,646.0,80682,,15970,,9606.0,Homo sapiens,,CHEMBL623383,A549,,,,F,1,1,
,BAO_0000219,5789,N,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,Expert,646.0,80682,,17713,,9606.0,Homo sapiens,,CHEMBL623384,A549,,,,F,1,1,
,BAO_0000219,5790,N,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,Intermediate,646.0,80682,,4833,,9606.0,Homo sapiens,,CHEMBL623385,A549,,,,F,1,1,
,BAO_0000219,5791,N,Activity against A549 cancer cell line.,Expert,646.0,80682,,13736,,9606.0,Homo sapiens,,CHEMBL623386,A549,,,,F,1,1,
,BAO_0000219,5792,N,The compound was evaluated for cytotoxicity against A549 cell line,Intermediate,646.0,80682,,4312,,9606.0,Homo sapiens,,CHEMBL884105,A549,,,,F,1,1,
,BAO_0000219,5793,N,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,Intermediate,646.0,80682,,5421,,9606.0,Homo sapiens,,CHEMBL623387,A549,,,,F,1,1,
,BAO_0000219,5794,N,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,Intermediate,646.0,80682,,5421,,9606.0,Homo sapiens,,CHEMBL621568,A549,,,,F,1,1,
,BAO_0000219,5795,N,Growth inhibitory activity was measured for human A549 tumor cell line.,Intermediate,646.0,80682,,14717,,9606.0,Homo sapiens,,CHEMBL621569,A549,,,,F,1,1,
,BAO_0000219,5796,N,Inhibitory activity against A549 lung cancer cell line,Intermediate,646.0,80682,,4634,,9606.0,Homo sapiens,,CHEMBL621570,A549,,,,F,1,1,
,BAO_0000219,5797,N,Inhibitory activity against A549 cell line; inactive,Intermediate,646.0,80682,,1149,,9606.0,Homo sapiens,,CHEMBL621571,A549,,,,F,1,1,
,BAO_0000219,5798,N,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,Expert,646.0,80682,,5421,,9606.0,Homo sapiens,,CHEMBL621572,A549,,,,F,1,1,
,BAO_0000219,5799,N,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,Expert,646.0,80682,,5421,,9606.0,Homo sapiens,,CHEMBL621573,A549,,,,F,1,1,
,BAO_0000219,5800,N,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,Intermediate,646.0,80682,,5421,,9606.0,Homo sapiens,,CHEMBL621574,A549,,,,F,1,1,
,BAO_0000219,5801,N,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),Intermediate,646.0,80682,,3320,,9606.0,Homo sapiens,,CHEMBL621575,A549,,,,F,1,1,
,BAO_0000219,5802,N,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),Intermediate,646.0,80682,,3320,,9606.0,Homo sapiens,,CHEMBL621576,A549,,,,F,1,1,
,BAO_0000219,5803,N,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),Intermediate,646.0,80682,,3320,,9606.0,Homo sapiens,,CHEMBL621577,A549,,,,F,1,1,
,BAO_0000219,5804,N,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),Intermediate,646.0,80682,,3320,,9606.0,Homo sapiens,,CHEMBL621578,A549,,,,F,1,1,
,BAO_0000219,5805,N,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),Intermediate,646.0,80682,,3320,,9606.0,Homo sapiens,,CHEMBL621579,A549,,,,F,1,1,
,BAO_0000219,5806,N,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,Intermediate,646.0,80682,,5726,,9606.0,Homo sapiens,,CHEMBL621580,A549,,,,F,1,1,
,BAO_0000218,5807,N,Plasma clearance (in vivo) in mongrel dogs was determined,Intermediate,,50588,,17800,,9615.0,Canis lupus familiaris,,CHEMBL621581,,,In vivo,,A,1,1,
,BAO_0000218,5808,N,Plasma clearance was measured in dog,Intermediate,,50588,,5985,,9615.0,Canis lupus familiaris,,CHEMBL621582,,,In vivo,,A,1,1,
,BAO_0000218,5809,N,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,Intermediate,,50588,,5530,,9615.0,Canis lupus familiaris,,CHEMBL621583,,,In vivo,,A,1,1,
,BAO_0000218,5810,N,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,Intermediate,,50588,,5530,,9615.0,Canis lupus familiaris,,CHEMBL621584,,,In vivo,,A,1,1,
Plasma,BAO_0000218,5811,N,Tested for plasma clearance in dog,Intermediate,,50588,,4839,1969.0,9615.0,Canis lupus familiaris,,CHEMBL621585,,,In vivo,,A,1,1,
,BAO_0000218,5812,N,The compound was tested for clearance in dog plasma.,Intermediate,,50588,,3639,,9615.0,Canis lupus familiaris,,CHEMBL621586,,,In vivo,,A,1,1,
,BAO_0000218,5813,N,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",Intermediate,,50588,,4838,,9615.0,Canis lupus familiaris,,CHEMBL875835,,,In vivo,,A,1,1,
,BAO_0000218,5814,N,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,Intermediate,,50588,,4137,,9615.0,Canis lupus familiaris,,CHEMBL621587,,,In vivo,,A,1,1,
Plasma,BAO_0000218,5815,N,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),Intermediate,,50588,,5017,1969.0,9615.0,Canis lupus familiaris,,CHEMBL621588,,,In vivo,,A,1,1,
Liver,BAO_0000218,5816,N,In vitro clearance in dog liver microsomes,Intermediate,,50588,,17538,2107.0,9615.0,Canis lupus familiaris,,CHEMBL621589,,,In vitro,Microsomes,A,1,1,
,BAO_0000218,5817,N,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,Intermediate,,50588,,6161,,9615.0,Canis lupus familiaris,,CHEMBL621590,,,In vivo,,A,1,1,
,BAO_0000218,5818,N,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,Intermediate,,50588,,6161,,9615.0,Canis lupus familiaris,,CHEMBL621591,,,In vivo,,A,1,1,
,BAO_0000218,5819,N,Plasma clearance in dog,Intermediate,,50588,,1696,,9615.0,Canis lupus familiaris,,CHEMBL621592,,,In vivo,,A,1,1,
,BAO_0000218,5820,N,Clearance rate in dog,Intermediate,,50588,,6762,,9615.0,Canis lupus familiaris,,CHEMBL621593,,,In vivo,,A,1,1,
Plasma,BAO_0000218,5821,N,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,Intermediate,,50588,,5932,1969.0,9615.0,Canis lupus familiaris,,CHEMBL621594,,,In vivo,,A,1,1,
,BAO_0000218,5822,N,Clearance in dogs,Intermediate,,50588,,6305,,9615.0,Canis lupus familiaris,,CHEMBL621595,,,In vivo,,A,1,1,
,BAO_0000218,5823,N,Plasma clearance in dogs,Intermediate,,50588,,4942,,9615.0,Canis lupus familiaris,,CHEMBL621596,,,In vivo,,A,1,1,
,BAO_0000218,5824,N,Plasma clearance was determined,Intermediate,,50588,,4219,,9615.0,Canis lupus familiaris,,CHEMBL621597,,,In vivo,,A,1,1,
,BAO_0000218,5825,N,Lower clearance in dog (i.v.) at 0.5 mpk,Intermediate,,50588,,17853,,9615.0,Canis lupus familiaris,,CHEMBL621598,,,In vivo,,A,1,1,
,BAO_0000218,5826,N,Plasma clearance in Beagle dogs,Intermediate,,50588,,4514,,9615.0,Canis lupus familiaris,,CHEMBL621599,,,In vivo,,A,1,1,
,BAO_0000218,5827,N,Plasma clearance (Clp) in dog,Intermediate,,50588,,6448,,9615.0,Canis lupus familiaris,,CHEMBL875836,,,In vivo,,A,1,1,
,BAO_0000218,5828,N,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,Intermediate,,50588,,6227,,9615.0,Canis lupus familiaris,,CHEMBL621600,,,In vivo,,A,1,1,
,BAO_0000218,5829,N,Plasma clearance (pharmacokinetic parameter) in dog was determined,Intermediate,,50588,,6227,,9615.0,Canis lupus familiaris,,CHEMBL621601,,,In vivo,,A,1,1,
,BAO_0000218,5830,N,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,Intermediate,,50588,,6062,,9615.0,Canis lupus familiaris,,CHEMBL618474,,,In vivo,,A,1,1,
,BAO_0000218,5831,N,Plasma clearance of compound was determined in dog,Intermediate,,50588,,6821,,9615.0,Canis lupus familiaris,,CHEMBL618475,,,In vivo,,A,1,1,
,BAO_0000218,5832,N,Plasma clearance after intravenous administration of 1 mg/kg in dog,Intermediate,,50588,,4709,,9615.0,Canis lupus familiaris,,CHEMBL624524,,,In vivo,,A,1,1,
,BAO_0000218,5833,N,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,Intermediate,,50588,,4521,,9615.0,Canis lupus familiaris,,CHEMBL624525,,,In vivo,,A,1,1,
,BAO_0000218,5834,N,Plasma clearance in dog was determined,Intermediate,,50588,,5374,,9615.0,Canis lupus familiaris,,CHEMBL624526,,,In vivo,,A,1,1,
,BAO_0000218,5835,N,Plasma clearance was calculated in dog,Intermediate,,50588,,6057,,9615.0,Canis lupus familiaris,,CHEMBL624527,,,In vivo,,A,1,1,
,BAO_0000218,5836,N,Plasma clearance at the dose of 2 mg/kg in dog,Intermediate,,50588,,4727,,9615.0,Canis lupus familiaris,,CHEMBL624528,,,In vivo,,A,1,1,
,BAO_0000218,5837,N,Plasma clearance in dog,Intermediate,,50588,,5145,,9615.0,Canis lupus familiaris,,CHEMBL624529,,,In vivo,,A,1,1,
,BAO_0000218,5838,N,Plasma clearance in dog,Intermediate,,50588,,17657,,9615.0,Canis lupus familiaris,,CHEMBL624530,,,In vivo,,A,1,1,
,BAO_0000218,5839,N,Plasma clearance in dog; Unable to calculate,Intermediate,,50588,,17657,,9615.0,Canis lupus familiaris,,CHEMBL624531,,,In vivo,,A,1,1,
,BAO_0000218,5840,N,Plasma clearance in rhesus monkey,Intermediate,,50588,,5145,,9615.0,Canis lupus familiaris,,CHEMBL624532,,,In vivo,,A,1,1,
,BAO_0000218,5841,N,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),Intermediate,,50588,,6642,,9615.0,Canis lupus familiaris,,CHEMBL624533,,,In vivo,,A,1,1,
,BAO_0000218,5842,N,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Intermediate,,50588,,6641,,9615.0,Canis lupus familiaris,,CHEMBL624534,,,In vivo,,A,1,1,
,BAO_0000218,5843,N,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Intermediate,,50588,,6642,,9615.0,Canis lupus familiaris,,CHEMBL624535,,,In vivo,,A,1,1,
,BAO_0000218,5844,N,Plasma clearance was evaluated in dog,Intermediate,,50588,,5472,,9615.0,Canis lupus familiaris,,CHEMBL624536,,,In vivo,,A,1,1,
,BAO_0000218,5845,N,Plasma clearance was evaluated in dog; Not tested,Intermediate,,50588,,5472,,9615.0,Canis lupus familiaris,,CHEMBL624537,,,In vivo,,A,1,1,
,BAO_0000218,5846,N,Plasma clearance was evaluated in rhesus,Intermediate,,50588,,5472,,9615.0,Canis lupus familiaris,,CHEMBL624538,,,In vivo,,A,1,1,
,BAO_0000218,5847,N,Plasma clearance was evaluated in rhesus; Not tested,Intermediate,,50588,,5472,,9615.0,Canis lupus familiaris,,CHEMBL624539,,,In vivo,,A,1,1,
,BAO_0000218,5848,N,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,Intermediate,,50588,,4257,,9615.0,Canis lupus familiaris,,CHEMBL624540,,,In vivo,,A,1,1,
,BAO_0000218,5849,N,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Intermediate,,50588,,6679,,9615.0,Canis lupus familiaris,,CHEMBL624541,,,In vivo,,A,1,1,
,BAO_0000218,5850,N,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,Intermediate,,50588,,5546,,9615.0,Canis lupus familiaris,,CHEMBL624542,,,In vivo,,A,1,1,
,BAO_0000218,5851,N,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Intermediate,,50588,,6348,,9615.0,Canis lupus familiaris,,CHEMBL624543,,,In vivo,,A,1,1,
,BAO_0000218,5852,N,Clearance value at a dose of 0.2 mg/kg i.v.,Intermediate,,50588,,5474,,9615.0,Canis lupus familiaris,,CHEMBL624544,,,In vivo,,A,1,1,
Plasma,BAO_0000218,5853,N,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,Intermediate,,50588,,6316,1969.0,9615.0,Canis lupus familiaris,,CHEMBL624545,,,In vivo,,A,1,1,
,BAO_0000218,5854,N,Cmax after oral dose of compound at 3 mg/kg in dogs,Intermediate,,50588,,17594,,9615.0,Canis lupus familiaris,,CHEMBL624546,,,In vivo,,A,1,1,
,BAO_0000218,5855,N,Cmax after single intravenous bolus of 1 mg/kg in dogs,Intermediate,,50588,,17594,,9615.0,Canis lupus familiaris,,CHEMBL875957,,,In vivo,,A,1,1,
,BAO_0000218,5856,N,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,Intermediate,,50588,,5802,,9615.0,Canis lupus familiaris,,CHEMBL624547,,,In vivo,,A,1,1,
,BAO_0000218,5857,N,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,Intermediate,,50588,,6535,,9615.0,Canis lupus familiaris,,CHEMBL624548,,,In vivo,,A,1,1,
,BAO_0000218,5858,N,Cmax in dog after administration of 1 mg/kg iv,Intermediate,,50588,,6535,,9615.0,Canis lupus familiaris,,CHEMBL624549,,,In vivo,,A,1,1,
Plasma,BAO_0000218,5859,N,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,Intermediate,,50588,,1466,1969.0,9615.0,Canis lupus familiaris,,CHEMBL624550,,,In vivo,,A,1,1,
,BAO_0000218,5860,N,Cmax on p.o. administration of 10 mg/kg was measured in dog,Intermediate,,50588,,6505,,9615.0,Canis lupus familiaris,,CHEMBL621613,,,In vivo,,A,1,1,
,BAO_0000218,5861,N,Cmax was determine after peroral administration at 10 mpk in dog,Intermediate,,50588,,5668,,9615.0,Canis lupus familiaris,,CHEMBL621614,,,In vivo,,A,1,1,
,BAO_0000218,5862,N,Cmax was determine after peroral administration at 5 mpk in dog,Intermediate,,50588,,5668,,9615.0,Canis lupus familiaris,,CHEMBL623431,,,In vivo,,A,1,1,
,BAO_0000218,5863,N,Cmax was determine after peroral administration at 5 mg/kg in dog,Intermediate,,50588,,5668,,9615.0,Canis lupus familiaris,,CHEMBL623432,,,In vivo,,A,1,1,
,BAO_0000218,5864,N,Cmax after 0.3 mg/kg po administration in dog,Intermediate,,50588,,5600,,9615.0,Canis lupus familiaris,,CHEMBL623433,,,In vivo,,A,1,1,
,BAO_0000218,5865,N,Cmax after peroral administration in dogs at 2.4 uM/kg,Intermediate,,50588,,17764,,9615.0,Canis lupus familiaris,,CHEMBL623434,,,In vivo,,A,1,1,
,BAO_0000218,5866,N,Cmax in dog after oral administration at 1 mg/kg,Intermediate,,50588,,6123,,9615.0,Canis lupus familiaris,,CHEMBL623435,,,In vivo,,A,1,1,
,BAO_0000218,5867,N,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,Intermediate,,50588,,6123,,9615.0,Canis lupus familiaris,,CHEMBL623436,,,In vivo,,A,1,1,
,BAO_0000218,5868,N,Cmax upon oral administration in male Beagle dog at 10 mg/kg,Intermediate,,50588,,6757,,9615.0,Canis lupus familiaris,,CHEMBL875958,,,In vivo,,A,1,1,
,BAO_0000218,5869,N,Cmax value after 15 mg/kg iv dose in Dogs,Intermediate,,50588,,16907,,9615.0,Canis lupus familiaris,,CHEMBL623437,,,In vivo,,A,1,1,
Blood,BAO_0000218,5870,N,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,50594,,7767,178.0,10090.0,Mus musculus,,CHEMBL623438,,,In vivo,,A,1,1,
Blood,BAO_0000218,5871,N,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,50594,,7767,178.0,10090.0,Mus musculus,,CHEMBL623439,,,In vivo,,A,1,1,
Bone,BAO_0000218,5872,N,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,50594,,7767,10000001.0,10090.0,Mus musculus,,CHEMBL623440,,,In vivo,,A,1,1,
Bone,BAO_0000218,5873,N,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,50594,,7767,10000001.0,10090.0,Mus musculus,,CHEMBL623441,,,In vivo,,A,1,1,
Bone,BAO_0000218,5874,N,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,50594,,7767,10000001.0,10090.0,Mus musculus,,CHEMBL623442,,,In vivo,,A,1,1,
,BAO_0000218,5875,N,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,50594,,7767,,10090.0,Mus musculus,,CHEMBL623469,,,In vivo,,A,1,1,
,BAO_0000218,5876,N,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,50594,,7767,,10090.0,Mus musculus,,CHEMBL623470,,,In vivo,,A,1,1,
,BAO_0000218,5877,N,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,50594,,7767,,10090.0,Mus musculus,,CHEMBL623471,,,In vivo,,A,1,1,
Heart,BAO_0000218,5878,N,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,50594,,7767,948.0,10090.0,Mus musculus,,CHEMBL623472,,,In vivo,,A,1,1,
Heart,BAO_0000218,5879,N,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,50594,,7767,948.0,10090.0,Mus musculus,,CHEMBL623473,,,In vivo,,A,1,1,
Heart,BAO_0000218,5880,N,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,50594,,7767,948.0,10090.0,Mus musculus,,CHEMBL623474,,,In vivo,,A,1,1,
Kidney,BAO_0000218,5881,N,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,50594,,7767,2113.0,10090.0,Mus musculus,,CHEMBL623475,,,In vivo,,A,1,1,
Kidney,BAO_0000218,5882,N,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,50594,,7767,2113.0,10090.0,Mus musculus,,CHEMBL623476,,,In vivo,,A,1,1,
Kidney,BAO_0000218,5883,N,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,50594,,7767,2113.0,10090.0,Mus musculus,,CHEMBL623477,,,In vivo,,A,1,1,
Intestine,BAO_0000218,5884,N,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,50594,,7767,160.0,10090.0,Mus musculus,,CHEMBL621896,,,In vivo,,A,1,1,
Intestine,BAO_0000218,5885,N,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,50594,,7767,160.0,10090.0,Mus musculus,,CHEMBL621897,,,In vivo,,A,1,1,
Intestine,BAO_0000218,5886,N,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,50594,,7767,160.0,10090.0,Mus musculus,,CHEMBL621898,,,In vivo,,A,1,1,
Liver,BAO_0000218,5887,N,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,50594,,7767,2107.0,10090.0,Mus musculus,,CHEMBL621899,,,In vivo,,A,1,1,
Liver,BAO_0000218,5888,N,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,50594,,7767,2107.0,10090.0,Mus musculus,,CHEMBL621900,,,In vivo,,A,1,1,
Liver,BAO_0000218,5889,N,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,50594,,7767,2107.0,10090.0,Mus musculus,,CHEMBL621901,,,In vivo,,A,1,1,
Lung,BAO_0000218,5890,N,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,50594,,7767,2048.0,10090.0,Mus musculus,,CHEMBL621902,,,In vivo,,A,1,1,
Lung,BAO_0000218,5891,N,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,50594,,7767,2048.0,10090.0,Mus musculus,,CHEMBL621903,,,In vivo,,A,1,1,
Lung,BAO_0000218,5892,N,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,50594,,7767,2048.0,10090.0,Mus musculus,,CHEMBL622587,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,5893,N,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,50594,,7767,2385.0,10090.0,Mus musculus,,CHEMBL620285,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,5894,N,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,50594,,7767,2385.0,10090.0,Mus musculus,,CHEMBL875285,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,5895,N,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,50594,,7767,2385.0,10090.0,Mus musculus,,CHEMBL620286,,,In vivo,,A,1,1,
,BAO_0000218,5896,N,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,50594,,7767,,10090.0,Mus musculus,,CHEMBL620287,,,In vivo,,A,1,1,
,BAO_0000218,5897,N,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,50594,,7767,,10090.0,Mus musculus,,CHEMBL620288,,,In vivo,,A,1,1,
,BAO_0000218,5898,N,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,50594,,7767,,10090.0,Mus musculus,,CHEMBL620289,,,In vivo,,A,1,1,
Intestine,BAO_0000218,5899,N,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,50594,,7767,160.0,10090.0,Mus musculus,,CHEMBL620290,,,In vivo,,A,1,1,
Intestine,BAO_0000218,5900,N,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,50594,,7767,160.0,10090.0,Mus musculus,,CHEMBL620291,,,In vivo,,A,1,1,
Intestine,BAO_0000218,5901,N,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,50594,,7767,160.0,10090.0,Mus musculus,,CHEMBL620292,,,In vivo,,A,1,1,
Spleen,BAO_0000218,5902,N,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,50594,,7767,2106.0,10090.0,Mus musculus,,CHEMBL620293,,,In vivo,,A,1,1,
Spleen,BAO_0000218,5903,N,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,50594,,7767,2106.0,10090.0,Mus musculus,,CHEMBL620294,,,In vivo,,A,1,1,
Spleen,BAO_0000218,5904,N,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,50594,,7767,2106.0,10090.0,Mus musculus,,CHEMBL618614,,,In vivo,,A,1,1,
Stomach,BAO_0000218,5905,N,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,50594,,7767,945.0,10090.0,Mus musculus,,CHEMBL618615,,,In vivo,,A,1,1,
Stomach,BAO_0000218,5906,N,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intermediate,,50594,,7767,945.0,10090.0,Mus musculus,,CHEMBL618616,,,In vivo,,A,1,1,
,BAO_0000219,5907,N,Cytotoxicity against A-172 human tumor cell lines,Expert,622.0,80012,,2036,,9606.0,Homo sapiens,,CHEMBL618617,A 172,,,,F,1,1,
,BAO_0000219,5908,N,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,Intermediate,622.0,80012,,2357,,9606.0,Homo sapiens,,CHEMBL618618,A 172,,,,F,1,1,
,BAO_0000219,5909,N,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,Intermediate,623.0,80014,,1457,,9606.0,Homo sapiens,,CHEMBL618619,A204,,,,F,1,1,
,BAO_0000219,5910,N,Tested for antiproliferative activity against A-2780 tumoral cell line,Intermediate,478.0,81034,,4379,,9606.0,Homo sapiens,,CHEMBL618620,A2780,,,,F,1,1,
,BAO_0000219,5911,N,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,Intermediate,455.0,80018,,1093,,9606.0,Homo sapiens,,CHEMBL618621,A-375,,,,F,1,1,
,BAO_0000219,5912,N,Tested in vitro against A-375 cell line human melanoma,Intermediate,455.0,80018,,12152,,9606.0,Homo sapiens,,CHEMBL618622,A-375,,,,F,1,1,
,BAO_0000219,5913,N,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,Expert,797.0,80019,,16464,,9606.0,Homo sapiens,,CHEMBL618623,A-427,,,,F,1,1,
,BAO_0000219,5914,N,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Intermediate,797.0,80019,,16464,,9606.0,Homo sapiens,,CHEMBL618624,A-427,,,,F,1,1,
,BAO_0000219,5915,N,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,Expert,797.0,80019,,16582,,9606.0,Homo sapiens,,CHEMBL618625,A-427,,,,F,1,1,
,BAO_0000219,5916,N,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,Intermediate,797.0,80019,,16464,,9606.0,Homo sapiens,,CHEMBL618626,A-427,,,,F,1,1,
,BAO_0000219,5917,N,Antitumor activity on A-427 lung carcinoma cell lines,Intermediate,797.0,80019,,10413,,9606.0,Homo sapiens,,CHEMBL618627,A-427,,,,F,1,1,
,BAO_0000219,5918,N,Cytotoxic activity against human A-427 lung tumor cell line,Intermediate,797.0,80019,,6418,,9606.0,Homo sapiens,,CHEMBL618628,A-427,,,,F,1,1,
,BAO_0000219,5919,N,In vitro antitumor effects against human A-427 cell lines.,Expert,797.0,80019,,17134,,9606.0,Homo sapiens,,CHEMBL618629,A-427,,,,F,1,1,
,BAO_0000219,5920,N,In vitro inhibition of A-427 (human lung cancer) cell growth.,Expert,797.0,80019,,16132,,9606.0,Homo sapiens,,CHEMBL618630,A-427,,,,F,1,1,
,BAO_0000219,5921,N,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,Intermediate,797.0,80019,,16132,,9606.0,Homo sapiens,,CHEMBL618631,A-427,,,,F,1,1,
,BAO_0000219,5922,N,Cytotoxic activity of compound against A-427 lung human tumor cell line,Intermediate,797.0,80019,,16780,,9606.0,Homo sapiens,,CHEMBL618632,A-427,,,,F,1,1,
,BAO_0000219,5923,N,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,Expert,500.0,80852,,4085,,9606.0,Homo sapiens,,CHEMBL618633,A-431,,,,F,1,1,
,BAO_0000219,5924,N,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,Intermediate,624.0,80021,,1276,,9606.0,Homo sapiens,,CHEMBL619315,A498,,,,F,1,1,
,BAO_0000219,5925,N,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,Expert,624.0,80021,,3498,,9606.0,Homo sapiens,,CHEMBL619316,A498,,,,F,1,1,
,BAO_0000219,5926,N,Cytotoxicity against human kidney carcinoma A-498cell lines,Intermediate,624.0,80021,,1169,,9606.0,Homo sapiens,,CHEMBL619317,A498,,,,F,1,1,
,BAO_0000219,5927,N,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,Intermediate,624.0,80021,,4450,,9606.0,Homo sapiens,,CHEMBL619318,A498,,,,F,1,1,
,BAO_0000219,5928,N,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,Intermediate,624.0,80021,,3311,,9606.0,Homo sapiens,,CHEMBL619319,A498,,,,F,1,1,
,BAO_0000219,5929,N,Antitumor cytotoxic activity against A-498 cell line was determined,Intermediate,624.0,80021,,4461,,9606.0,Homo sapiens,,CHEMBL619739,A498,,,,F,1,1,
,BAO_0000219,5930,N,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,Intermediate,624.0,80021,,3311,,9606.0,Homo sapiens,,CHEMBL619740,A498,,,,F,1,1,
,BAO_0000219,5931,N,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,Intermediate,624.0,80021,,3311,,9606.0,Homo sapiens,,CHEMBL883158,A498,,,,F,1,1,
,BAO_0000219,5932,N,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,Intermediate,624.0,80021,,1457,,9606.0,Homo sapiens,,CHEMBL884012,A498,,,,F,1,1,
,BAO_0000219,5933,N,In vitro inhibitory activity against A-498 ovarian cancer cell lines,Intermediate,624.0,80021,,3664,,9606.0,Homo sapiens,,CHEMBL619741,A498,,,,F,1,1,
,BAO_0000219,5934,N,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",Intermediate,624.0,80021,,15895,,9606.0,Homo sapiens,,CHEMBL619742,A498,,,,F,1,1,
,BAO_0000219,5935,N,Inhibition of growth lung non-small cell carcinoma A-549 cell line,Intermediate,646.0,80682,,11843,,9606.0,Homo sapiens,,CHEMBL876610,A549,,,,F,1,1,
,BAO_0000219,5936,N,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,Intermediate,646.0,80682,,11843,,9606.0,Homo sapiens,,CHEMBL619743,A549,,,,F,1,1,
,BAO_0000219,5937,N,In vitro antiproliferative activity against human A-549 NSCL cell line,Intermediate,646.0,80682,,17705,,9606.0,Homo sapiens,,CHEMBL619744,A549,,,,F,1,1,
,BAO_0000219,5938,N,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,Intermediate,646.0,80682,,17705,,9606.0,Homo sapiens,,CHEMBL619745,A549,,,,F,1,1,
,BAO_0000219,5939,N,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,Intermediate,646.0,80682,,4369,,9606.0,Homo sapiens,,CHEMBL619746,A549,,,,F,1,1,
,BAO_0000219,5940,N,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,Intermediate,646.0,80682,,4369,,9606.0,Homo sapiens,,CHEMBL619747,A549,,,,F,1,1,
,BAO_0000219,5941,N,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,Intermediate,646.0,80682,,4369,,9606.0,Homo sapiens,,CHEMBL619748,A549,,,,F,1,1,
,BAO_0000219,5942,N,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,Intermediate,646.0,80682,,4369,,9606.0,Homo sapiens,,CHEMBL619749,A549,,,,F,1,1,
,BAO_0000219,5943,N,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,Intermediate,646.0,80682,,4369,,9606.0,Homo sapiens,,CHEMBL619750,A549,,,,F,1,1,
,BAO_0000219,5944,N,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,Intermediate,646.0,80682,,4369,,9606.0,Homo sapiens,,CHEMBL624014,A549,,,,F,1,1,
,BAO_0000219,5945,N,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,Intermediate,646.0,80682,,4369,,9606.0,Homo sapiens,,CHEMBL624015,A549,,,,F,1,1,
,BAO_0000219,5946,N,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,Expert,646.0,80682,,4787,,9606.0,Homo sapiens,,CHEMBL885344,A549,,,,F,1,1,
,BAO_0000219,5947,N,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,Intermediate,646.0,80682,,4787,,9606.0,Homo sapiens,,CHEMBL623224,A549,,,,F,1,1,
,BAO_0000219,5948,N,Cytotoxic activity against A-549 cell line,Intermediate,646.0,80682,,6513,,9606.0,Homo sapiens,,CHEMBL623225,A549,,,,F,1,1,
,BAO_0000219,5949,N,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,Intermediate,646.0,80682,,6690,,9606.0,Homo sapiens,,CHEMBL622698,A549,,,,F,1,1,
,BAO_0000219,5950,N,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,Intermediate,646.0,80682,,6690,,9606.0,Homo sapiens,,CHEMBL622699,A549,,,,F,1,1,
,BAO_0000219,5951,N,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",Expert,646.0,80682,,12263,,9606.0,Homo sapiens,,CHEMBL622700,A549,,,,F,1,1,
,BAO_0000219,5952,N,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),Intermediate,646.0,80682,,1054,,9606.0,Homo sapiens,,CHEMBL622701,A549,,,,F,1,1,
,BAO_0000219,5953,N,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),Intermediate,646.0,80682,,1359,,9606.0,Homo sapiens,,CHEMBL622702,A549,,,,F,1,1,
,BAO_0000219,5954,N,Cytotoxic activity against human lung carcinoma (A-549) cell line,Intermediate,646.0,80682,,3547,,9606.0,Homo sapiens,,CHEMBL622703,A549,,,,F,1,1,
,BAO_0000219,5955,N,Cytotoxic activity towards A-549 cells,Expert,646.0,80682,,5771,,9606.0,Homo sapiens,,CHEMBL622704,A549,,,,F,1,1,
,BAO_0000219,5956,N,"In vitro percent inhibition of A549, lung carcinoma.",Intermediate,646.0,80682,,14425,,9606.0,Homo sapiens,,CHEMBL622705,A549,,,,F,1,1,
,BAO_0000219,5957,N,"In vitro percent inhibition of A549, lung carcinoma",Intermediate,646.0,80682,,14425,,9606.0,Homo sapiens,,CHEMBL622706,A549,,,,F,1,1,
,BAO_0000219,5958,N,"In vitro percent inhibition of A549, lung carcinoma.",Intermediate,646.0,80682,,14425,,9606.0,Homo sapiens,,CHEMBL622707,A549,,,,F,1,1,
,BAO_0000219,5959,N,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",Intermediate,646.0,80682,,14425,,9606.0,Homo sapiens,,CHEMBL622708,A549,,,,F,1,1,
,BAO_0000219,5960,N,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,Intermediate,646.0,80682,,5280,,9606.0,Homo sapiens,,CHEMBL622709,A549,,,,F,1,1,
,BAO_0000219,5961,N,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,Intermediate,646.0,80682,,15176,,9606.0,Homo sapiens,,CHEMBL622710,A549,,,,F,1,1,
,BAO_0000219,5962,N,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,Intermediate,646.0,80682,,15300,,9606.0,Homo sapiens,,CHEMBL622711,A549,,,,F,1,1,
,BAO_0000218,5963,N,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",Intermediate,646.0,80682,,17824,,9606.0,Homo sapiens,,CHEMBL622712,A549,,,,F,1,1,
,BAO_0000218,5964,N,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",Intermediate,646.0,80682,,17824,,9606.0,Homo sapiens,,CHEMBL622713,A549,,,,F,1,1,
,BAO_0000218,5965,N,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",Intermediate,646.0,80682,,17824,,9606.0,Homo sapiens,,CHEMBL622714,A549,,,,F,1,1,
,BAO_0000218,5966,N,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",Intermediate,646.0,80682,,17824,,9606.0,Homo sapiens,,CHEMBL622715,A549,,,,F,1,1,
,BAO_0000218,5967,N,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",Intermediate,646.0,80682,,17824,,9606.0,Homo sapiens,,CHEMBL622716,A549,,,,F,1,1,
,BAO_0000219,5968,N,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",Intermediate,646.0,80682,,17824,,9606.0,Homo sapiens,,CHEMBL622717,A549,,,,F,1,1,
,BAO_0000218,5969,N,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),Intermediate,646.0,80682,,17528,,9606.0,Homo sapiens,,CHEMBL622718,A549,,,,F,1,1,
,BAO_0000219,5970,N,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,Expert,646.0,80682,,6870,,9606.0,Homo sapiens,,CHEMBL622719,A549,,,,F,1,1,
,BAO_0000219,5971,N,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,Intermediate,646.0,80682,,6870,,9606.0,Homo sapiens,,CHEMBL622720,A549,,,,F,1,1,
,BAO_0000219,5972,N,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,Intermediate,646.0,80682,,6870,,9606.0,Homo sapiens,,CHEMBL622721,A549,,,,F,1,1,
,BAO_0000219,5973,N,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,Intermediate,646.0,80682,,6870,,9606.0,Homo sapiens,,CHEMBL622722,A549,,,,F,1,1,
,BAO_0000219,5974,N,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,Intermediate,646.0,80682,,16726,,9606.0,Homo sapiens,,CHEMBL876030,A549,,,,F,1,1,
,BAO_0000219,5975,N,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",Intermediate,646.0,80682,,6170,,9606.0,Homo sapiens,,CHEMBL620206,A549,,,,F,1,1,
,BAO_0000219,5976,N,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,Expert,646.0,80682,,6583,,9606.0,Homo sapiens,,CHEMBL620207,A549,,,,F,1,1,
,BAO_0000219,5977,N,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,Expert,646.0,80682,,6583,,9606.0,Homo sapiens,,CHEMBL620208,A549,,,,F,1,1,
,BAO_0000219,5978,N,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,Expert,646.0,80682,,6583,,9606.0,Homo sapiens,,CHEMBL620209,A549,,,,F,1,1,
,BAO_0000219,5979,N,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,Expert,646.0,80682,,6583,,9606.0,Homo sapiens,,CHEMBL620210,A549,,,,F,1,1,
,BAO_0000219,5980,N,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,Expert,646.0,80682,,6583,,9606.0,Homo sapiens,,CHEMBL621639,A549,,,,F,1,1,
,BAO_0000219,5981,N,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,Intermediate,646.0,80682,,17321,,9606.0,Homo sapiens,,CHEMBL621640,A549,,,,F,1,1,
,BAO_0000219,5982,N,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,Expert,646.0,80682,,17528,,9606.0,Homo sapiens,,CHEMBL621641,A549,,,,F,1,1,
,BAO_0000219,5983,N,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,Expert,646.0,80682,,12888,,9606.0,Homo sapiens,,CHEMBL621642,A549,,,,F,1,1,
,BAO_0000219,5984,N,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,Intermediate,646.0,80682,,4312,,9606.0,Homo sapiens,,CHEMBL621643,A549,,,,F,1,1,
,BAO_0000219,5985,N,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,Intermediate,646.0,80682,,4312,,9606.0,Homo sapiens,,CHEMBL621644,A549,,,,F,1,1,
,BAO_0000219,5986,N,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,Intermediate,646.0,80682,,4312,,9606.0,Homo sapiens,,CHEMBL621645,A549,,,,F,1,1,
,BAO_0000219,5987,N,In vitro antiproliferative activity against A549 cell line,Intermediate,646.0,80682,,17737,,10090.0,Mus musculus,,CHEMBL621646,A549,,,,F,1,1,
,BAO_0000219,5988,N,Synergism with indomethacin in A549 cells,Intermediate,646.0,80682,,6630,,,,,CHEMBL621647,A549,,,,F,1,1,
,BAO_0000219,5989,N,Synergism with tolmetin in A549 cells,Intermediate,646.0,80682,,6630,,,,,CHEMBL621648,A549,,,,F,1,1,
,BAO_0000219,5990,N,Synergism with sulindac in A549 cells,Intermediate,646.0,80682,,6630,,,,,CHEMBL621649,A549,,,,F,1,1,
,BAO_0000219,5991,N,Antagonism of indomethacin in A549 cells,Intermediate,646.0,80682,,6630,,,,,CHEMBL621650,A549,,,,F,1,1,
,BAO_0000219,5992,N,Antagonism of sulindac in A549 cells,Intermediate,646.0,80682,,6630,,,,,CHEMBL621651,A549,,,,F,1,1,
,BAO_0000219,5993,N,Antagonism of tolmetin in A549 cells,Intermediate,646.0,80682,,6630,,,,,CHEMBL621652,A549,,,,F,1,1,
,BAO_0000219,5994,N,Synergism with indomethacin in A549 cells,Intermediate,646.0,80682,,6630,,,,,CHEMBL621653,A549,,,,F,1,1,
,BAO_0000219,5995,N,Synergism with sulindac in A549 cells,Intermediate,646.0,80682,,6630,,,,,CHEMBL621654,A549,,,,F,1,1,
,BAO_0000219,5996,N,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,Intermediate,646.0,80682,,6630,,,,,CHEMBL621655,A549,,,,F,1,1,
,BAO_0000218,5997,N,Cmax value after 30 mg/kg po dose in Dogs,Intermediate,,50588,,16907,,9615.0,Canis lupus familiaris,,CHEMBL621656,,,In vivo,,A,1,1,
,BAO_0000218,5998,N,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),Intermediate,,50588,,5944,,9615.0,Canis lupus familiaris,,CHEMBL621657,,,In vivo,,A,1,1,
,BAO_0000218,5999,N,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,Intermediate,,50588,,5944,,9615.0,Canis lupus familiaris,,CHEMBL621658,,,In vivo,,A,1,1,
,BAO_0000218,6000,N,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),Intermediate,,50588,,5944,,9615.0,Canis lupus familiaris,,CHEMBL621659,,,In vivo,,A,1,1,
,BAO_0000218,6001,N,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,Intermediate,,50588,,5944,,9615.0,Canis lupus familiaris,,CHEMBL621660,,,In vivo,,A,1,1,
,BAO_0000218,6002,N,Cmax value after administration of 4 mg/Kg oral dose in dog,Intermediate,,50588,,2959,,9615.0,Canis lupus familiaris,,CHEMBL621661,,,In vivo,,A,1,1,
,BAO_0000218,6003,N,Cmax value in dog,Intermediate,,50588,,6241,,9615.0,Canis lupus familiaris,,CHEMBL621662,,,In vivo,,A,1,1,
,BAO_0000218,6004,N,Cmax value in dogs after oral administration at 1 mg/kg,Intermediate,,50588,,6241,,9615.0,Canis lupus familiaris,,CHEMBL621663,,,In vivo,,A,1,1,
,BAO_0000218,6005,N,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,Intermediate,,50588,,2652,,9615.0,Canis lupus familiaris,,CHEMBL621664,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6006,N,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,Intermediate,,50588,,1806,1969.0,9615.0,Canis lupus familiaris,,CHEMBL621665,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6007,N,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,Intermediate,,50588,,1806,1969.0,9615.0,Canis lupus familiaris,,CHEMBL621666,,,In vivo,,A,1,1,
,BAO_0000218,6008,N,Concentration maxima after oral dosing in dogs,Intermediate,,50588,,1021,,9615.0,Canis lupus familiaris,,CHEMBL621667,,,In vivo,,A,1,1,
,BAO_0000218,6009,N,Concentration maxima after oral dosing in dogs; not available,Intermediate,,50588,,1021,,9615.0,Canis lupus familiaris,,CHEMBL876738,,,In vivo,,A,1,1,
,BAO_0000218,6010,N,Concentration maxima after oral dosing in dogs; not available,Intermediate,,50588,,1021,,9615.0,Canis lupus familiaris,,CHEMBL621668,,,In vivo,,A,1,1,
,BAO_0000218,6011,N,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,Intermediate,,50588,,5444,,9615.0,Canis lupus familiaris,,CHEMBL621669,,,In vivo,,A,1,1,
,BAO_0000218,6012,N,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,Intermediate,,50588,,5444,,9615.0,Canis lupus familiaris,,CHEMBL621670,,,In vivo,,A,1,1,
,BAO_0000218,6013,N,In vivo maximal concentration was calculated at 1 mg/kg in dog,Intermediate,,50588,,5444,,9615.0,Canis lupus familiaris,,CHEMBL621671,,,In vivo,,A,1,1,
,BAO_0000218,6014,N,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,Intermediate,,50588,,5444,,9615.0,Canis lupus familiaris,,CHEMBL622360,,,In vivo,,A,1,1,
,BAO_0000218,6015,N,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,Intermediate,,50588,,5444,,9615.0,Canis lupus familiaris,,CHEMBL622361,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6016,N,Cmax in dog plasma after oral dose (1 mg/kg),Intermediate,,50588,,5130,1969.0,9615.0,Canis lupus familiaris,,CHEMBL622362,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6017,N,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,Intermediate,,50588,,3249,1969.0,9615.0,Canis lupus familiaris,,CHEMBL622363,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6018,N,Maximal plasma concentration at a dose of 1 mg/kg,Intermediate,,50588,,5473,1969.0,9615.0,Canis lupus familiaris,,CHEMBL622364,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6019,N,Maximal plasma concentration at a dose of 1 mg/kg (oral),Intermediate,,50588,,5474,1969.0,9615.0,Canis lupus familiaris,,CHEMBL622365,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6020,N,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,Intermediate,,50588,,4657,1969.0,9615.0,Canis lupus familiaris,,CHEMBL622533,,,In vivo,,A,1,1,
,BAO_0000218,6021,N,Maximum concentration of compound in dog was evaluated.,Intermediate,,50588,,3031,,9615.0,Canis lupus familiaris,,CHEMBL622534,,,In vivo,,A,1,1,
,BAO_0000218,6022,N,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,Intermediate,,50588,,4527,,9615.0,Canis lupus familiaris,,CHEMBL622535,,,In vivo,,A,1,1,
,BAO_0000218,6023,N,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,Intermediate,,50588,,4186,,9615.0,Canis lupus familiaris,,CHEMBL876739,,,In vivo,,A,1,1,
,BAO_0000218,6024,N,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),Intermediate,,50588,,5007,,9615.0,Canis lupus familiaris,,CHEMBL622536,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6025,N,Maximum concentration obtained in dog plasma was determined,Intermediate,,50588,,3132,1969.0,9615.0,Canis lupus familiaris,,CHEMBL622537,,,In vivo,,A,1,1,
,BAO_0000218,6026,N,Maximum concentration was determined,Intermediate,,50588,,5006,,9615.0,Canis lupus familiaris,,CHEMBL622538,,,In vivo,,A,1,1,
,BAO_0000218,6027,N,Maximum concentration at the dose of 2 mg/kg in dog,Intermediate,,50588,,4727,,9615.0,Canis lupus familiaris,,CHEMBL627867,,,In vivo,,A,1,1,
,BAO_0000218,6028,N,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,Intermediate,,50588,,1916,,9615.0,Canis lupus familiaris,,CHEMBL627868,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6029,N,Maximum concentration was evaluated in dog plasma,Intermediate,,50588,,1918,1969.0,9615.0,Canis lupus familiaris,,CHEMBL627869,,,In vivo,,A,1,1,
,BAO_0000218,6030,N,Maximum concentration was evaluated after 75 min after administration in dog,Intermediate,,50588,,3045,,9615.0,Canis lupus familiaris,,CHEMBL627870,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6031,N,Maximum plasma concentration determined in dog after oral administration of 17b,Intermediate,,50588,,9579,1969.0,9615.0,Canis lupus familiaris,,CHEMBL627871,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6032,N,Maximum plasma concentration determined in dog after oral administration of 2b,Intermediate,,50588,,9579,1969.0,9615.0,Canis lupus familiaris,,CHEMBL627872,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6033,N,Maximum plasma concentration in dog,Intermediate,,50588,,933,1969.0,9615.0,Canis lupus familiaris,,CHEMBL627873,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6034,N,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,Intermediate,,50588,,17839,1969.0,9615.0,Canis lupus familiaris,,CHEMBL627874,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6035,N,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,Intermediate,,50588,,17839,1969.0,9615.0,Canis lupus familiaris,,CHEMBL627875,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6036,N,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,Intermediate,,50588,,17839,1969.0,9615.0,Canis lupus familiaris,,CHEMBL627876,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6037,N,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,Intermediate,,50588,,17839,1969.0,9615.0,Canis lupus familiaris,,CHEMBL627877,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6038,N,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Intermediate,,50588,,6348,1969.0,9615.0,Canis lupus familiaris,,CHEMBL627878,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6039,N,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,Intermediate,,50588,,16367,1969.0,9615.0,Canis lupus familiaris,,CHEMBL627879,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6040,N,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Intermediate,,50588,,1337,1969.0,9615.0,Canis lupus familiaris,,CHEMBL875355,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6041,N,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Intermediate,,50588,,1337,1969.0,9615.0,Canis lupus familiaris,,CHEMBL627880,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6042,N,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,Intermediate,,50588,,5199,1969.0,9615.0,Canis lupus familiaris,,CHEMBL627881,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6043,N,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,Intermediate,,50588,,17650,1969.0,9615.0,Canis lupus familiaris,,CHEMBL627882,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6044,N,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,Intermediate,,50588,,6679,1969.0,9615.0,Canis lupus familiaris,,CHEMBL627883,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6045,N,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,Intermediate,,50588,,5356,1969.0,9615.0,Canis lupus familiaris,,CHEMBL628526,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6046,N,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,Intermediate,,50588,,5356,1969.0,9615.0,Canis lupus familiaris,,CHEMBL628527,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6047,N,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,Intermediate,,50588,,6227,1969.0,9615.0,Canis lupus familiaris,,CHEMBL628528,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6048,N,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,Intermediate,,50588,,6227,1969.0,9615.0,Canis lupus familiaris,,CHEMBL628529,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6049,N,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,Intermediate,,50588,,6227,1969.0,9615.0,Canis lupus familiaris,,CHEMBL628530,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6050,N,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,Intermediate,,50588,,6227,1969.0,9615.0,Canis lupus familiaris,,CHEMBL625243,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6051,N,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,Expert,,50588,,3598,1969.0,9615.0,Canis lupus familiaris,,CHEMBL625244,,,In vivo,,A,1,1,
,BAO_0000218,6052,N,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,Intermediate,,50588,,4368,,9615.0,Canis lupus familiaris,,CHEMBL625245,,,In vivo,,A,1,1,
,BAO_0000218,6053,N,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,Intermediate,,50588,,6265,,9615.0,Canis lupus familiaris,,CHEMBL625246,,,In vivo,,A,1,1,
Stomach,BAO_0000218,6054,N,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intermediate,,50594,,7767,945.0,10090.0,Mus musculus,,CHEMBL625247,,,In vivo,,A,1,1,
Urine,BAO_0000218,6055,N,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intermediate,,50594,,7767,1088.0,10090.0,Mus musculus,,CHEMBL625248,,,In vivo,,A,1,1,
Urine,BAO_0000218,6056,N,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,Intermediate,,50594,,7767,1088.0,10090.0,Mus musculus,,CHEMBL625249,,,In vivo,,A,1,1,
Urine,BAO_0000218,6057,N,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,Intermediate,,50594,,7767,1088.0,10090.0,Mus musculus,,CHEMBL625250,,,In vivo,,A,1,1,
,BAO_0000218,6058,N,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,Intermediate,,50594,,17811,,10090.0,Mus musculus,,CHEMBL625251,,,,,A,1,1,
,BAO_0000218,6059,N,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,Intermediate,,50594,,17811,,10090.0,Mus musculus,,CHEMBL875356,,,,,A,1,1,
,BAO_0000218,6060,N,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),Intermediate,,50594,,17827,,10090.0,Mus musculus,,CHEMBL625252,,,,,A,1,1,
Blood,BAO_0000218,6061,N,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),Intermediate,,50594,,17827,178.0,10090.0,Mus musculus,,CHEMBL625253,,,,,A,1,1,
,BAO_0000218,6062,N,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),Intermediate,,50594,,17827,,10090.0,Mus musculus,,CHEMBL625254,,,,,A,1,1,
,BAO_0000218,6063,N,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),Intermediate,,50594,,17827,,10090.0,Mus musculus,,CHEMBL625255,,,,,A,1,1,
,BAO_0000218,6064,N,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),Intermediate,,50594,,17827,,10090.0,Mus musculus,,CHEMBL625256,,,,,A,1,1,
Blood,BAO_0000218,6065,N,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),Intermediate,,50594,,17827,178.0,10090.0,Mus musculus,,CHEMBL625257,,,,,A,1,1,
Blood,BAO_0000218,6066,N,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),Intermediate,,50594,,17827,178.0,10090.0,Mus musculus,,CHEMBL625258,,,,,A,1,1,
,BAO_0000218,6067,N,Compound was evaluated for washout rate in mice (Radiolabeled compound),Intermediate,,50594,,17827,,10090.0,Mus musculus,,CHEMBL625259,,,,,A,1,1,
,BAO_0000218,6068,N,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,Intermediate,,50594,,17827,,10090.0,Mus musculus,,CHEMBL625260,,,,,A,1,1,
,BAO_0000218,6069,N,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",Intermediate,,50594,,17827,,10090.0,Mus musculus,,CHEMBL625261,,,,,A,1,1,
,BAO_0000218,6070,N,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",Intermediate,,50594,,17827,,10090.0,Mus musculus,,CHEMBL625262,,,,,A,1,1,
,BAO_0000218,6071,N,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",Intermediate,,50594,,17827,,10090.0,Mus musculus,,CHEMBL622639,,,,,A,1,1,
,BAO_0000218,6072,N,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,Intermediate,,50594,,17257,,10090.0,Mus musculus,,CHEMBL622640,,,,,A,1,1,
,BAO_0000218,6073,N,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,Intermediate,,50594,,17257,,10090.0,Mus musculus,,CHEMBL622812,,,,,A,1,1,
,BAO_0000218,6074,N,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,Intermediate,,50594,,17257,,10090.0,Mus musculus,,CHEMBL622813,,,,,A,1,1,
,BAO_0000218,6075,N,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,Intermediate,,50594,,17257,,10090.0,Mus musculus,,CHEMBL622814,,,,,A,1,1,
,BAO_0000218,6076,N,Time at maximum activity in mice (Radiolabeled compound),Intermediate,,50594,,17827,,10090.0,Mus musculus,,CHEMBL622815,,,,,A,1,1,
,BAO_0000218,6077,N,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,Intermediate,,50594,,3760,,10090.0,Mus musculus,,CHEMBL625342,,,,,A,1,1,
,BAO_0000218,6078,N,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,Intermediate,,50594,,3760,,10090.0,Mus musculus,,CHEMBL625343,,,,,A,1,1,
,BAO_0000218,6079,N,Binding towards mouse plasma protein at 10 uM,Intermediate,,50594,,17409,,10090.0,Mus musculus,,CHEMBL877591,,,,,A,1,1,
,BAO_0000218,6080,N,Binding towards mouse plasma protein at 100 uM,Intermediate,,50594,,17409,,10090.0,Mus musculus,,CHEMBL625344,,,,,A,1,1,
,BAO_0000218,6081,N,Bioavailability was evaluated in mice after intravenous administration,Intermediate,,50594,,2675,,10090.0,Mus musculus,,CHEMBL625345,,,In vivo,,A,1,1,
,BAO_0000218,6082,N,Bioavailability was evaluated in mice after oral administration,Intermediate,,50594,,2675,,10090.0,Mus musculus,,CHEMBL625346,,,In vivo,,A,1,1,
,BAO_0000218,6083,N,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,Intermediate,,50594,,3132,,10090.0,Mus musculus,,CHEMBL625347,,,In vivo,,A,1,1,
,BAO_0000218,6084,N,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,Intermediate,,50594,,3132,,10090.0,Mus musculus,,CHEMBL625348,,,In vivo,,A,1,1,
,BAO_0000218,6085,N,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,Intermediate,,50594,,16597,,10090.0,Mus musculus,,CHEMBL625349,,,In vivo,,A,1,1,
,BAO_0000218,6086,N,Oral bioavailability in mouse,Intermediate,,50594,,2862,,10090.0,Mus musculus,,CHEMBL625350,,,In vivo,,A,1,1,
,BAO_0000218,6087,N,Oral bioavailability after intravenous administration in mice at 24 uM/kg,Intermediate,,50594,,17764,,10090.0,Mus musculus,,CHEMBL882952,,,In vivo,,A,1,1,
Brain,BAO_0000218,6088,N,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,50594,,846,955.0,10090.0,Mus musculus,,CHEMBL625351,,,In vivo,,A,1,1,
Brain,BAO_0000218,6089,N,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,50594,,846,955.0,10090.0,Mus musculus,,CHEMBL625352,,,In vivo,,A,1,1,
Brain,BAO_0000218,6090,N,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,,50594,,846,955.0,10090.0,Mus musculus,,CHEMBL877592,,,In vivo,,A,1,1,
Brain,BAO_0000218,6091,N,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,50594,,846,955.0,10090.0,Mus musculus,,CHEMBL625353,,,In vivo,,A,1,1,
Brain,BAO_0000218,6092,N,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,,50594,,846,955.0,10090.0,Mus musculus,,CHEMBL625354,,,In vivo,,A,1,1,
Brain,BAO_0000218,6093,N,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,50594,,846,955.0,10090.0,Mus musculus,,CHEMBL626019,,,In vivo,,A,1,1,
Heart,BAO_0000218,6094,N,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,50594,,846,948.0,10090.0,Mus musculus,,CHEMBL626020,,,In vivo,,A,1,1,
Heart,BAO_0000218,6095,N,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,,50594,,846,948.0,10090.0,Mus musculus,,CHEMBL626021,,,In vivo,,A,1,1,
Heart,BAO_0000218,6096,N,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,50594,,846,948.0,10090.0,Mus musculus,,CHEMBL626022,,,In vivo,,A,1,1,
Heart,BAO_0000218,6097,N,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,50594,,846,948.0,10090.0,Mus musculus,,CHEMBL626192,,,In vivo,,A,1,1,
,BAO_0000219,6098,N,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),Intermediate,646.0,80682,,1276,,9606.0,Homo sapiens,,CHEMBL626193,A549,,,,F,1,1,
,BAO_0000219,6099,N,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,Expert,646.0,80682,,3498,,9606.0,Homo sapiens,,CHEMBL626194,A549,,,,F,1,1,
,BAO_0000219,6100,N,Cytotoxicity against human lung carcinoma A-549 cell lines,Intermediate,646.0,80682,,1169,,9606.0,Homo sapiens,,CHEMBL626195,A549,,,,F,1,1,
,BAO_0000219,6101,N,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,Intermediate,646.0,80682,,4450,,9606.0,Homo sapiens,,CHEMBL626196,A549,,,,F,1,1,
,BAO_0000219,6102,N,In vitro cytotoxicity against human lung carcinoma cell line A-549,Intermediate,646.0,80682,,358,,9606.0,Homo sapiens,,CHEMBL626197,A549,,,,F,1,1,
,BAO_0000219,6103,N,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,Intermediate,646.0,80682,,358,,9606.0,Homo sapiens,,CHEMBL626198,A549,,,,F,1,1,
,BAO_0000219,6104,N,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,Intermediate,646.0,80682,,358,,9606.0,Homo sapiens,,CHEMBL626199,A549,,,,F,1,1,
,BAO_0000219,6105,N,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,Intermediate,646.0,80682,,358,,9606.0,Homo sapiens,,CHEMBL626200,A549,,,,F,1,1,
,BAO_0000219,6106,N,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,Intermediate,646.0,80682,,358,,9606.0,Homo sapiens,,CHEMBL626201,A549,,,,F,1,1,
,BAO_0000219,6107,N,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,Intermediate,646.0,80682,,358,,9606.0,Homo sapiens,,CHEMBL626202,A549,,,,F,1,1,
,BAO_0000219,6108,N,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,Intermediate,646.0,80682,,358,,9606.0,Homo sapiens,,CHEMBL626203,A549,,,,F,1,1,
,BAO_0000219,6109,N,In vitro cytotoxicity against A-549 human lung cancer cells,Intermediate,646.0,80682,,15167,,9606.0,Homo sapiens,,CHEMBL626204,A549,,,,F,1,1,
,BAO_0000219,6110,N,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,Intermediate,646.0,80682,,4139,,9606.0,Homo sapiens,,CHEMBL624701,A549,,,,F,1,1,
,BAO_0000219,6111,N,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,Intermediate,646.0,80682,,833,,9606.0,Homo sapiens,,CHEMBL624702,A549,,,,F,1,1,
,BAO_0000219,6112,N,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,Expert,646.0,80682,,15718,,9606.0,Homo sapiens,,CHEMBL624703,A549,,,,F,1,1,
,BAO_0000219,6113,N,Tested in vitro for cytotoxicity against A-549 lung cancer cells,Intermediate,646.0,80682,,12373,,9606.0,Homo sapiens,,CHEMBL624704,A549,,,,F,1,1,
,BAO_0000219,6114,N,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,Intermediate,646.0,80682,,637,,9606.0,Homo sapiens,,CHEMBL624705,A549,,,,F,1,1,
,BAO_0000219,6115,N,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,Expert,646.0,80682,,14867,,9606.0,Homo sapiens,,CHEMBL624706,A549,,,,F,1,1,
,BAO_0000219,6116,N,Antitumor cytotoxic activity against A-549 cell line was determined,Intermediate,646.0,80682,,4461,,9606.0,Homo sapiens,,CHEMBL624707,A549,,,,F,1,1,
,BAO_0000219,6117,N,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",Intermediate,646.0,80682,,5406,,9606.0,Homo sapiens,,CHEMBL624708,A549,,,,F,1,1,
,BAO_0000219,6118,N,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,Intermediate,646.0,80682,,4457,,9606.0,Homo sapiens,,CHEMBL624709,A549,,,,F,1,1,
,BAO_0000219,6119,N,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,Expert,646.0,80682,,1386,,9606.0,Homo sapiens,,CHEMBL884107,A549,,,,F,1,1,
,BAO_0000219,6120,N,Antitumoral activity was assayed against A-549 cell line,Intermediate,646.0,80682,,3265,,9606.0,Homo sapiens,,CHEMBL624710,A549,,,,F,1,1,
,BAO_0000219,6121,N,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,Intermediate,646.0,80682,,2359,,9606.0,Homo sapiens,,CHEMBL624711,A549,,,,F,1,1,
,BAO_0000219,6122,N,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,Intermediate,646.0,80682,,4457,,9606.0,Homo sapiens,,CHEMBL624712,A549,,,,F,1,1,
,BAO_0000219,6123,N,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,Expert,646.0,80682,,12454,,9606.0,Homo sapiens,,CHEMBL624713,A549,,,,F,1,1,
,BAO_0000219,6124,N,Compound was tested for inhibition of cell growth of A-549 cells,Intermediate,646.0,80682,,1481,,9606.0,Homo sapiens,,CHEMBL624714,A549,,,,F,1,1,
,BAO_0000219,6125,N,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,Intermediate,646.0,80682,,1750,,9606.0,Homo sapiens,,CHEMBL624715,A549,,,,F,1,1,
,BAO_0000219,6126,N,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,Intermediate,646.0,80682,,5065,,9606.0,Homo sapiens,,CHEMBL624716,A549,,,,F,1,1,
,BAO_0000219,6127,N,In vitro cytotoxicity against A549-human lung carcinoma cells.,Expert,646.0,80682,,808,,9606.0,Homo sapiens,,CHEMBL619505,A549,,,,F,1,1,
,BAO_0000219,6128,N,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,Expert,646.0,80682,,16364,,9606.0,Homo sapiens,,CHEMBL619506,A549,,,,F,1,1,
,BAO_0000219,6129,N,Cytotoxic activity against A-549 cell lines.,Intermediate,646.0,80682,,1847,,9606.0,Homo sapiens,,CHEMBL619507,A549,,,,F,1,1,
,BAO_0000219,6130,N,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,Expert,646.0,80682,,1747,,9606.0,Homo sapiens,,CHEMBL619508,A549,,,,F,1,1,
,BAO_0000219,6131,N,Cytotoxicity against human A549 non small cell lung cell lines,Intermediate,646.0,80682,,1003,,9606.0,Homo sapiens,,CHEMBL619509,A549,,,,F,1,1,
,BAO_0000219,6132,N,Inhibition of cell growth in (A-549) lung cell line,Expert,646.0,80682,,15313,,9606.0,Homo sapiens,,CHEMBL619510,A549,,,,F,1,1,
,BAO_0000219,6133,N,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,Intermediate,646.0,80682,,3122,,9606.0,Homo sapiens,,CHEMBL619511,A549,,,,F,1,1,
,BAO_0000219,6134,N,In vitro antitumor activity against A-549 tumor cells.,Intermediate,646.0,80682,,16049,,9606.0,Homo sapiens,,CHEMBL619512,A549,,,,F,1,1,
,BAO_0000219,6135,N,In vitro antitumor effects against human A-549 cell lines.,Expert,646.0,80682,,17134,,9606.0,Homo sapiens,,CHEMBL619513,A549,,,,F,1,1,
,BAO_0000219,6136,N,In vitro cytotoxic activity of compound against A-549 cell line,Intermediate,646.0,80682,,6406,,9606.0,Homo sapiens,,CHEMBL619514,A549,,,,F,1,1,
,BAO_0000219,6137,N,In vitro cytotoxicity against human lung carcinoma A-549 cell line,Intermediate,646.0,80682,,627,,9606.0,Homo sapiens,,CHEMBL619515,A549,,,,F,1,1,
,BAO_0000219,6138,N,In vitro cytotoxicity against human non-small cell lung carcinoma A549,Intermediate,646.0,80682,,12307,,9606.0,Homo sapiens,,CHEMBL619516,A549,,,,F,1,1,
,BAO_0000219,6139,N,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,Intermediate,646.0,80682,,17861,,9606.0,Homo sapiens,,CHEMBL884005,A549,,,,F,1,1,
,BAO_0000219,6140,N,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,Expert,646.0,80682,,6682,,9606.0,Homo sapiens,,CHEMBL619517,A549,,,,F,1,1,
,BAO_0000219,6141,N,Inhibitory concentration of compound against A-549 cell line,Intermediate,646.0,80682,,6663,,9606.0,Homo sapiens,,CHEMBL619518,A549,,,,F,1,1,
,BAO_0000219,6142,N,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,Intermediate,646.0,80682,,2454,,9606.0,Homo sapiens,,CHEMBL619519,A549,,,,F,1,1,
,BAO_0000219,6143,N,cytotoxic activity against leukemia (A-549) cancer cell line,Intermediate,646.0,80682,,14709,,9606.0,Homo sapiens,,CHEMBL876489,A549,,,,F,1,1,
,BAO_0000219,6144,N,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,Expert,646.0,80682,,15718,,9606.0,Homo sapiens,,CHEMBL619520,A549,,,,F,1,1,
,BAO_0000219,6145,N,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,Intermediate,646.0,80682,,15718,,9606.0,Homo sapiens,,CHEMBL619521,A549,,,,F,1,1,
,BAO_0000219,6146,N,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),Intermediate,646.0,80682,,17130,,9606.0,Homo sapiens,,CHEMBL619522,A549,,,,F,1,1,
,BAO_0000219,6147,N,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),Intermediate,646.0,80682,,17130,,9606.0,Homo sapiens,,CHEMBL619523,A549,,,,F,1,1,
,BAO_0000219,6148,N,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),Intermediate,646.0,80682,,17130,,9606.0,Homo sapiens,,CHEMBL619524,A549,,,,F,1,1,
,BAO_0000219,6149,N,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),Intermediate,646.0,80682,,17130,,9606.0,Homo sapiens,,CHEMBL619525,A549,,,,F,1,1,
,BAO_0000219,6150,N,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,Intermediate,646.0,80682,,6630,,,,,CHEMBL619526,A549,,,,F,1,1,
,BAO_0000219,6151,N,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,Intermediate,646.0,80682,,16726,,9606.0,Homo sapiens,,CHEMBL619527,A549,,,,F,1,1,
,BAO_0000219,6152,N,Cytotoxicity against A549 cells; No cytotoxicity,Intermediate,646.0,80682,,17846,,9606.0,Homo sapiens,,CHEMBL619528,A549,,,,F,1,1,
,BAO_0000219,6153,N,Cytotoxicity against human lung carcinoma (A549) cell lines,Expert,646.0,80682,,3415,,9606.0,Homo sapiens,,CHEMBL619529,A549,,,,F,1,1,
,BAO_0000219,6154,N,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,Expert,646.0,80682,,3415,,9606.0,Homo sapiens,,CHEMBL619530,A549,,,,F,1,1,
,BAO_0000219,6155,N,In vitro anticancer activity against human lung (A549) cell line,Intermediate,646.0,80682,,5609,,9606.0,Homo sapiens,,CHEMBL876490,A549,,,,F,1,1,
,BAO_0000219,6156,N,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,Intermediate,646.0,80682,,17206,,9606.0,Homo sapiens,,CHEMBL619531,A549,,,,F,1,1,
,BAO_0000219,6157,N,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,Intermediate,646.0,80682,,17206,,9606.0,Homo sapiens,,CHEMBL619532,A549,,,,F,1,1,
,BAO_0000219,6158,N,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,Intermediate,646.0,80682,,17206,,9606.0,Homo sapiens,,CHEMBL619533,A549,,,,F,1,1,
,BAO_0000219,6159,N,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,Intermediate,646.0,80682,,17206,,9606.0,Homo sapiens,,CHEMBL619534,A549,,,,F,1,1,
,BAO_0000219,6160,N,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,Intermediate,646.0,80682,,17206,,9606.0,Homo sapiens,,CHEMBL620164,A549,,,,F,1,1,
,BAO_0000219,6161,N,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,Intermediate,646.0,80682,,17206,,9606.0,Homo sapiens,,CHEMBL620165,A549,,,,F,1,1,
,BAO_0000219,6162,N,Inhibition of A549 human lung tumor cell proliferation,Expert,646.0,80682,,16295,,9606.0,Homo sapiens,,CHEMBL620166,A549,,,,F,1,1,
,BAO_0000219,6163,N,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",Intermediate,646.0,80682,,16825,,9606.0,Homo sapiens,,CHEMBL620167,A549,,,,F,1,1,
,BAO_0000219,6164,N,In vitro cytotoxicity against human tumor cell line A549,Expert,646.0,80682,,3439,,9606.0,Homo sapiens,,CHEMBL620168,A549,,,,F,1,1,
,BAO_0000219,6165,N,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,Intermediate,646.0,80682,,10870,,9606.0,Homo sapiens,,CHEMBL620338,A549,,,,F,1,1,
,BAO_0000219,6166,N,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,Intermediate,646.0,80682,,4845,,9606.0,Homo sapiens,,CHEMBL620339,A549,,,,F,1,1,
,BAO_0000219,6167,N,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,Intermediate,646.0,80682,,5822,,9606.0,Homo sapiens,,CHEMBL620340,A549,,,,F,1,1,
,BAO_0000219,6168,N,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,Intermediate,646.0,80682,,5822,,9606.0,Homo sapiens,,CHEMBL620341,A549,,,,F,1,1,
,BAO_0000219,6169,N,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,Intermediate,646.0,80682,,5822,,9606.0,Homo sapiens,,CHEMBL876491,A549,,,,F,1,1,
,BAO_0000219,6170,N,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,Intermediate,646.0,80682,,16381,,9606.0,Homo sapiens,,CHEMBL620342,A549,,,,F,1,1,
,BAO_0000219,6171,N,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,Intermediate,646.0,80682,,16381,,9606.0,Homo sapiens,,CHEMBL620343,A549,,,,F,1,1,
,BAO_0000219,6172,N,% inhibition against A549 cells (lung cancer) at 4 ug/mL,Intermediate,646.0,80682,,16381,,9606.0,Homo sapiens,,CHEMBL620344,A549,,,,F,1,1,
,BAO_0000219,6173,N,In vitro anticancer activity against human lung (A549) cell line,Intermediate,646.0,80682,,5609,,9606.0,Homo sapiens,,CHEMBL620345,A549,,,,F,1,1,
,BAO_0000219,6174,N,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,Intermediate,646.0,80682,,4644,,9606.0,Homo sapiens,,CHEMBL620346,A549,,,,F,1,1,
,BAO_0000219,6175,N,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,Intermediate,646.0,80682,,4644,,9606.0,Homo sapiens,,CHEMBL620347,A549,,,,F,1,1,
,BAO_0000219,6176,N,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,Intermediate,646.0,80682,,4644,,9606.0,Homo sapiens,,CHEMBL620348,A549,,,,F,1,1,
,BAO_0000219,6177,N,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,Intermediate,646.0,80682,,4644,,9606.0,Homo sapiens,,CHEMBL620349,A549,,,,F,1,1,
,BAO_0000219,6178,N,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,Intermediate,646.0,80682,,5822,,9606.0,Homo sapiens,,CHEMBL618667,A549,,,,F,1,1,
,BAO_0000219,6179,N,Percentage inhibition of human lung carcinoma (A549) cell lines,Expert,646.0,80682,,3415,,9606.0,Homo sapiens,,CHEMBL618668,A549,,,,F,1,1,
,BAO_0000219,6180,N,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,Intermediate,646.0,80682,,16726,,9606.0,Homo sapiens,,CHEMBL876031,A549,,,,F,1,1,
,BAO_0000219,6181,N,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",Intermediate,646.0,80682,,17206,,9606.0,Homo sapiens,,CHEMBL618759,A549,,,,F,1,1,
,BAO_0000219,6182,N,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,Intermediate,646.0,80682,,17206,,9606.0,Homo sapiens,,CHEMBL618760,A549,,,,F,1,1,
,BAO_0000219,6183,N,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,Intermediate,646.0,80682,,17206,,9606.0,Homo sapiens,,CHEMBL619000,A549,,,,F,1,1,
,BAO_0000219,6184,N,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",Intermediate,646.0,80682,,17206,,9606.0,Homo sapiens,,CHEMBL619001,A549,,,,F,1,1,
,BAO_0000219,6185,N,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",Intermediate,646.0,80682,,17206,,9606.0,Homo sapiens,,CHEMBL619002,A549,,,,F,1,1,
,BAO_0000219,6186,N,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",Intermediate,646.0,80682,,17206,,9606.0,Homo sapiens,,CHEMBL619003,A549,,,,F,1,1,
,BAO_0000219,6187,N,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",Intermediate,646.0,80682,,17206,,9606.0,Homo sapiens,,CHEMBL619597,A549,,,,F,1,1,
,BAO_0000219,6188,N,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",Intermediate,646.0,80682,,17206,,9606.0,Homo sapiens,,CHEMBL619598,A549,,,,F,1,1,
,BAO_0000219,6189,N,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,Intermediate,646.0,80682,,17206,,9606.0,Homo sapiens,,CHEMBL619599,A549,,,,F,1,1,
,BAO_0000219,6190,N,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,Intermediate,646.0,80682,,17206,,9606.0,Homo sapiens,,CHEMBL619600,A549,,,,F,1,1,
,BAO_0000219,6191,N,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,Intermediate,646.0,80682,,16726,,9606.0,Homo sapiens,,CHEMBL619601,A549,,,,F,1,1,
,BAO_0000219,6192,N,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,Intermediate,646.0,80682,,17206,,9606.0,Homo sapiens,,CHEMBL619602,A549,,,,F,1,1,
,BAO_0000219,6193,N,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,Intermediate,646.0,80682,,17206,,9606.0,Homo sapiens,,CHEMBL619603,A549,,,,F,1,1,
,BAO_0000219,6194,N,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,Intermediate,646.0,80682,,17206,,9606.0,Homo sapiens,,CHEMBL619604,A549,,,,F,1,1,
,BAO_0000219,6195,N,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,Intermediate,646.0,80682,,17206,,9606.0,Homo sapiens,,CHEMBL619605,A549,,,,F,1,1,
,BAO_0000218,6196,N,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,Intermediate,,50588,,6084,,9615.0,Canis lupus familiaris,,CHEMBL619606,,,In vivo,,A,1,1,
,BAO_0000218,6197,N,Pharmacokinetic activity (Cmax) in dog,Intermediate,,50588,,6084,,9615.0,Canis lupus familiaris,,CHEMBL876032,,,In vivo,,A,1,1,
,BAO_0000218,6198,N,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),Intermediate,,50588,,4809,,9615.0,Canis lupus familiaris,,CHEMBL619607,,,In vivo,,A,1,1,
,BAO_0000218,6199,N,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,Intermediate,,50588,,5983,,9615.0,Canis lupus familiaris,,CHEMBL619608,,,In vivo,,A,1,1,
,BAO_0000218,6200,N,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,Intermediate,,50588,,6251,,9615.0,Canis lupus familiaris,,CHEMBL619609,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6201,N,Cmax in dog plasma after 30mg/kg oral dose,Intermediate,,50588,,5932,1969.0,9615.0,Canis lupus familiaris,,CHEMBL619610,,,In vivo,,A,1,1,
Blood,BAO_0000218,6202,N,Tested for the peak blood level in dog,Intermediate,,50588,,4273,178.0,9615.0,Canis lupus familiaris,,CHEMBL619611,,,In vivo,,A,1,1,
,BAO_0000218,6203,N,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",Intermediate,,50588,,5313,,9615.0,Canis lupus familiaris,,CHEMBL619612,,,In vivo,,A,1,1,
,BAO_0000218,6204,N,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",Intermediate,,50588,,5313,,9615.0,Canis lupus familiaris,,CHEMBL619613,,,In vivo,,A,1,1,
Blood,BAO_0000218,6205,N,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,Intermediate,,50588,,6221,178.0,9615.0,Canis lupus familiaris,,CHEMBL619614,,,In vivo,,A,1,1,
,BAO_0000218,6206,N,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,Intermediate,,50588,,4709,,9615.0,Canis lupus familiaris,,CHEMBL619615,,,,,A,1,1,
,BAO_0000218,6207,N,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,Intermediate,,50588,,167,,9615.0,Canis lupus familiaris,,CHEMBL619616,,,,,A,1,1,
Plasma,BAO_0000218,6208,N,Final plasma concentration in dogs after oral administration at 1 mg/kg,Intermediate,,50588,,6241,1969.0,9615.0,Canis lupus familiaris,,CHEMBL619617,,,,,A,1,1,
,BAO_0000218,6209,N,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,Intermediate,,50588,,344,,9615.0,Canis lupus familiaris,,CHEMBL619618,,,,,A,1,1,
,BAO_0000218,6210,N,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,Intermediate,,50588,,344,,9615.0,Canis lupus familiaris,,CHEMBL876033,,,,,A,1,1,
,BAO_0000218,6211,N,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,Intermediate,,50588,,344,,9615.0,Canis lupus familiaris,,CHEMBL619619,,,,,A,1,1,
,BAO_0000218,6212,N,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,Intermediate,,50588,,2189,,9615.0,Canis lupus familiaris,,CHEMBL619620,,,,,A,1,1,
Urine,BAO_0000218,6213,N,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,Intermediate,,50588,,2189,1088.0,9615.0,Canis lupus familiaris,,CHEMBL619621,,,,,A,1,1,
Urine,BAO_0000218,6214,N,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,Intermediate,,50588,,2189,1088.0,9615.0,Canis lupus familiaris,,CHEMBL619622,,,,,A,1,1,
Urine,BAO_0000218,6215,N,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,Intermediate,,50588,,2189,1088.0,9615.0,Canis lupus familiaris,,CHEMBL618874,,,,,A,1,1,
,BAO_0000218,6216,N,Absolute bioavailability was evaluated in dog,Intermediate,,50588,,4257,,9615.0,Canis lupus familiaris,,CHEMBL618875,,,In vivo,,A,1,1,
,BAO_0000218,6217,N,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,Intermediate,,50588,,6221,,9615.0,Canis lupus familiaris,,CHEMBL618876,,,In vivo,,A,1,1,
,BAO_0000218,6218,N,Bioavailability after peroral administration (1 mg/kg) was determined in dog,Intermediate,,50588,,6215,,9615.0,Canis lupus familiaris,,CHEMBL618877,,,In vivo,,A,1,1,
,BAO_0000218,6219,N,Bioavailability in dog,Intermediate,,50588,,17267,,9615.0,Canis lupus familiaris,,CHEMBL618878,,,In vivo,,A,1,1,
,BAO_0000218,6220,N,Bioavailability in dog,Intermediate,,50588,,6621,,9615.0,Canis lupus familiaris,,CHEMBL618879,,,In vivo,,A,1,1,
,BAO_0000218,6221,N,Bioavailability after intravenous administration in dogs,Intermediate,,50588,,3854,,9615.0,Canis lupus familiaris,,CHEMBL618880,,,In vivo,,A,1,1,
,BAO_0000218,6222,N,Bioavailability after peroral administration in dogs,Intermediate,,50588,,3854,,9615.0,Canis lupus familiaris,,CHEMBL618881,,,In vivo,,A,1,1,
,BAO_0000218,6223,N,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),Intermediate,,50588,,5007,,9615.0,Canis lupus familiaris,,CHEMBL618882,,,In vivo,,A,1,1,
,BAO_0000218,6224,N,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,Intermediate,,50588,,4333,,9615.0,Canis lupus familiaris,,CHEMBL624226,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6225,N,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,Intermediate,,50588,,4333,1969.0,9615.0,Canis lupus familiaris,,CHEMBL624227,,,In vivo,,A,1,1,
,BAO_0000218,6226,N,Bioavailability,Intermediate,,50588,,5006,,9615.0,Canis lupus familiaris,,CHEMBL624228,,,In vivo,,A,1,1,
,BAO_0000218,6227,N,Bioavailability,Intermediate,,50588,,5199,,9615.0,Canis lupus familiaris,,CHEMBL624229,,,In vivo,,A,1,1,
,BAO_0000218,6228,N,Bioavailability by intravenous administration of 1.2 mg/kg in dog,Intermediate,,50588,,4368,,9615.0,Canis lupus familiaris,,CHEMBL624230,,,In vivo,,A,1,1,
,BAO_0000218,6229,N,Bioavailability in dog,Intermediate,,50588,,3771,,9615.0,Canis lupus familiaris,,CHEMBL624231,,,In vivo,,A,1,1,
,BAO_0000218,6230,N,Bioavailability in dog,Intermediate,,50588,,4953,,9615.0,Canis lupus familiaris,,CHEMBL624232,,,In vivo,,A,1,1,
,BAO_0000218,6231,N,Bioavailability in dog,Intermediate,,50588,,5064,,9615.0,Canis lupus familiaris,,CHEMBL625127,,,In vivo,,A,1,1,
,BAO_0000218,6232,N,Bioavailability in dog,Intermediate,,50588,,17657,,9615.0,Canis lupus familiaris,,CHEMBL625128,,,In vivo,,A,1,1,
,BAO_0000218,6233,N,Bioavailability in dog,Intermediate,,50588,,17796,,9615.0,Canis lupus familiaris,,CHEMBL621675,,,In vivo,,A,1,1,
,BAO_0000218,6234,N,Bioavailability in dog (p.o.) at 2.0 mpk,Intermediate,,50588,,17853,,9615.0,Canis lupus familiaris,,CHEMBL621676,,,In vivo,,A,1,1,
,BAO_0000218,6235,N,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),Intermediate,,50588,,4521,,9615.0,Canis lupus familiaris,,CHEMBL621677,,,In vivo,,A,1,1,
,BAO_0000218,6236,N,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,Intermediate,,50588,,4521,,9615.0,Canis lupus familiaris,,CHEMBL621678,,,In vivo,,A,1,1,
,BAO_0000218,6237,N,Bioavailability in dog,Intermediate,,50588,,5006,,9615.0,Canis lupus familiaris,,CHEMBL621679,,,In vivo,,A,1,1,
,BAO_0000218,6238,N,Bioavailability was evaluated after oral administration in dog,Intermediate,,50588,,16365,,9615.0,Canis lupus familiaris,,CHEMBL621680,,,In vivo,,A,1,1,
,BAO_0000218,6239,N,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,Intermediate,,50588,,1916,,9615.0,Canis lupus familiaris,,CHEMBL621681,,,In vivo,,A,1,1,
,BAO_0000218,6240,N,Bioavailability was evaluated in dog,Intermediate,,50588,,1918,,9615.0,Canis lupus familiaris,,CHEMBL876740,,,In vivo,,A,1,1,
,BAO_0000218,6241,N,Bioavailability in dog,Intermediate,,50588,,4239,,9615.0,Canis lupus familiaris,,CHEMBL621682,,,In vivo,,A,1,1,
,BAO_0000218,6242,N,Bioavailability in dog,Intermediate,,50588,,6505,,9615.0,Canis lupus familiaris,,CHEMBL621683,,,In vivo,,A,1,1,
,BAO_0000218,6243,N,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),Intermediate,,50588,,5334,,9615.0,Canis lupus familiaris,,CHEMBL621684,,,In vivo,,A,1,1,
,BAO_0000218,6244,N,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),Intermediate,,50588,,5334,,9615.0,Canis lupus familiaris,,CHEMBL621685,,,In vivo,,A,1,1,
,BAO_0000218,6245,N,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),Intermediate,,50588,,4809,,9615.0,Canis lupus familiaris,,CHEMBL621686,,,In vivo,,A,1,1,
,BAO_0000218,6246,N,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Intermediate,,50588,,6348,,9615.0,Canis lupus familiaris,,CHEMBL621687,,,In vivo,,A,1,1,
,BAO_0000218,6247,N,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,Intermediate,,50588,,6005,,9615.0,Canis lupus familiaris,,CHEMBL621688,,,In vivo,,A,1,1,
,BAO_0000218,6248,N,Bioavailability of compound in dog was determined after peroral administration,Intermediate,,50588,,17804,,9615.0,Canis lupus familiaris,,CHEMBL621689,,,In vivo,,A,1,1,
,BAO_0000218,6249,N,Oral bioavailability in dog,Intermediate,,50588,,3184,,9615.0,Canis lupus familiaris,,CHEMBL621690,,,In vivo,,A,1,1,
,BAO_0000218,6250,N,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,Intermediate,,50588,,1806,,9615.0,Canis lupus familiaris,,CHEMBL621691,,,In vivo,,A,1,1,
,BAO_0000218,6251,N,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,Intermediate,,50588,,1806,,9615.0,Canis lupus familiaris,,CHEMBL875941,,,In vivo,,A,1,1,
,BAO_0000218,6252,N,Compound was evaluated for oral bioavailability in dogs; 37-38 %,Intermediate,,50588,,1806,,9615.0,Canis lupus familiaris,,CHEMBL621692,,,In vivo,,A,1,1,
,BAO_0000218,6253,N,Bioavailability in dog,Intermediate,,50588,,4839,,9615.0,Canis lupus familiaris,,CHEMBL621693,,,In vivo,,A,1,1,
,BAO_0000218,6254,N,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),Intermediate,,50588,,5017,,9615.0,Canis lupus familiaris,,CHEMBL621694,,,In vivo,,A,1,1,
Heart,BAO_0000218,6255,N,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,,50594,,846,948.0,10090.0,Mus musculus,,CHEMBL621695,,,In vivo,,A,1,1,
Heart,BAO_0000218,6256,N,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,50594,,846,948.0,10090.0,Mus musculus,,CHEMBL621696,,,In vivo,,A,1,1,
Kidney,BAO_0000218,6257,N,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,50594,,846,2113.0,10090.0,Mus musculus,,CHEMBL621697,,,In vivo,,A,1,1,
Kidney,BAO_0000218,6258,N,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,50594,,846,2113.0,10090.0,Mus musculus,,CHEMBL621698,,,In vivo,,A,1,1,
Kidney,BAO_0000218,6259,N,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,,50594,,846,2113.0,10090.0,Mus musculus,,CHEMBL623420,,,In vivo,,A,1,1,
Kidney,BAO_0000218,6260,N,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,50594,,846,2113.0,10090.0,Mus musculus,,CHEMBL623421,,,In vivo,,A,1,1,
Kidney,BAO_0000218,6261,N,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,,50594,,846,2113.0,10090.0,Mus musculus,,CHEMBL623422,,,In vivo,,A,1,1,
Kidney,BAO_0000218,6262,N,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,50594,,846,2113.0,10090.0,Mus musculus,,CHEMBL623423,,,In vivo,,A,1,1,
Liver,BAO_0000218,6263,N,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,50594,,846,2107.0,10090.0,Mus musculus,,CHEMBL623424,,,In vivo,,A,1,1,
Liver,BAO_0000218,6264,N,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,50594,,846,2107.0,10090.0,Mus musculus,,CHEMBL623425,,,In vivo,,A,1,1,
Liver,BAO_0000218,6265,N,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,,50594,,846,2107.0,10090.0,Mus musculus,,CHEMBL623426,,,In vivo,,A,1,1,
Liver,BAO_0000218,6266,N,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,50594,,846,2107.0,10090.0,Mus musculus,,CHEMBL623427,,,In vivo,,A,1,1,
Liver,BAO_0000218,6267,N,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,,50594,,846,2107.0,10090.0,Mus musculus,,CHEMBL623428,,,In vivo,,A,1,1,
Liver,BAO_0000218,6268,N,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,50594,,846,2107.0,10090.0,Mus musculus,,CHEMBL875947,,,In vivo,,A,1,1,
Lung,BAO_0000218,6269,N,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,50594,,846,2048.0,10090.0,Mus musculus,,CHEMBL623429,,,In vivo,,A,1,1,
Lung,BAO_0000218,6270,N,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,50594,,846,2048.0,10090.0,Mus musculus,,CHEMBL623430,,,In vivo,,A,1,1,
Lung,BAO_0000218,6271,N,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,,50594,,846,2048.0,10090.0,Mus musculus,,CHEMBL622588,,,In vivo,,A,1,1,
Lung,BAO_0000218,6272,N,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,50594,,846,2048.0,10090.0,Mus musculus,,CHEMBL622589,,,In vivo,,A,1,1,
Lung,BAO_0000218,6273,N,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Intermediate,,50594,,846,2048.0,10090.0,Mus musculus,,CHEMBL622751,,,In vivo,,A,1,1,
Lung,BAO_0000218,6274,N,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Intermediate,,50594,,846,2048.0,10090.0,Mus musculus,,CHEMBL622752,,,In vivo,,A,1,1,
,BAO_0000218,6275,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,Intermediate,42.0,50594,,6599,,10090.0,Mus musculus,,CHEMBL622753,CCRF S-180,,,,A,1,1,
,BAO_0000218,6276,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,Intermediate,42.0,50594,,6599,,10090.0,Mus musculus,,CHEMBL622647,CCRF S-180,,,,A,1,1,
,BAO_0000218,6277,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,Intermediate,42.0,50594,,6599,,10090.0,Mus musculus,,CHEMBL875163,CCRF S-180,,,,A,1,1,
,BAO_0000218,6278,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,Intermediate,42.0,50594,,6599,,10090.0,Mus musculus,,CHEMBL622648,CCRF S-180,,,,A,1,1,
,BAO_0000218,6279,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,Intermediate,42.0,50594,,6599,,10090.0,Mus musculus,,CHEMBL622649,CCRF S-180,,,,A,1,1,
Brain,BAO_0000218,6280,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,Intermediate,42.0,50594,,6599,955.0,10090.0,Mus musculus,,CHEMBL622650,CCRF S-180,,,,A,1,1,
Brain,BAO_0000218,6281,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,Intermediate,42.0,50594,,6599,955.0,10090.0,Mus musculus,,CHEMBL622651,CCRF S-180,,,,A,1,1,
Brain,BAO_0000218,6282,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,Intermediate,42.0,50594,,6599,955.0,10090.0,Mus musculus,,CHEMBL622652,CCRF S-180,,,,A,1,1,
Brain,BAO_0000218,6283,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,Intermediate,42.0,50594,,6599,955.0,10090.0,Mus musculus,,CHEMBL622653,CCRF S-180,,,,A,1,1,
Brain,BAO_0000218,6284,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,Intermediate,42.0,50594,,6599,955.0,10090.0,Mus musculus,,CHEMBL622654,CCRF S-180,,,,A,1,1,
Heart,BAO_0000218,6285,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,Intermediate,42.0,50594,,6599,948.0,10090.0,Mus musculus,,CHEMBL622655,CCRF S-180,,,,A,1,1,
Heart,BAO_0000218,6286,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,Intermediate,42.0,50594,,6599,948.0,10090.0,Mus musculus,,CHEMBL622656,CCRF S-180,,,,A,1,1,
Heart,BAO_0000218,6287,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,Intermediate,42.0,50594,,6599,948.0,10090.0,Mus musculus,,CHEMBL622657,CCRF S-180,,,,A,1,1,
Heart,BAO_0000218,6288,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,Intermediate,42.0,50594,,6599,948.0,10090.0,Mus musculus,,CHEMBL622658,CCRF S-180,,,,A,1,1,
Heart,BAO_0000218,6289,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,Intermediate,42.0,50594,,6599,948.0,10090.0,Mus musculus,,CHEMBL622659,CCRF S-180,,,,A,1,1,
Kidney,BAO_0000218,6290,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,Intermediate,42.0,50594,,6599,2113.0,10090.0,Mus musculus,,CHEMBL624630,CCRF S-180,,,,A,1,1,
Kidney,BAO_0000218,6291,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,Intermediate,42.0,50594,,6599,2113.0,10090.0,Mus musculus,,CHEMBL624631,CCRF S-180,,,,A,1,1,
Kidney,BAO_0000218,6292,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,Intermediate,42.0,50594,,6599,2113.0,10090.0,Mus musculus,,CHEMBL624632,CCRF S-180,,,,A,1,1,
,BAO_0000219,6293,N,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,Intermediate,646.0,80682,,17130,,9606.0,Homo sapiens,,CHEMBL624633,A549,,,,F,1,1,
,BAO_0000219,6294,N,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,Intermediate,646.0,80682,,17130,,9606.0,Homo sapiens,,CHEMBL624634,A549,,,,F,1,1,
,BAO_0000219,6295,N,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),Intermediate,646.0,80682,,17130,,9606.0,Homo sapiens,,CHEMBL624635,A549,,,,F,1,1,
,BAO_0000219,6296,N,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),Intermediate,646.0,80682,,17130,,9606.0,Homo sapiens,,CHEMBL624636,A549,,,,F,1,1,
,BAO_0000219,6297,N,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,Expert,646.0,80682,,3263,,9606.0,Homo sapiens,,CHEMBL857055,A549,,,,F,1,1,
,BAO_0000219,6298,N,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,Expert,646.0,80682,,6663,,9606.0,Homo sapiens,,CHEMBL624637,A549,,,,F,1,1,
,BAO_0000219,6299,N,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,Expert,646.0,80682,,6663,,9606.0,Homo sapiens,,CHEMBL624638,A549,,,,F,1,1,
,BAO_0000219,6300,N,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,Expert,646.0,80682,,6663,,9606.0,Homo sapiens,,CHEMBL874366,A549,,,,F,1,1,
,BAO_0000219,6301,N,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,Expert,646.0,80682,,6663,,9606.0,Homo sapiens,,CHEMBL624639,A549,,,,F,1,1,
,BAO_0000219,6302,N,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,Expert,646.0,80682,,6663,,9606.0,Homo sapiens,,CHEMBL624640,A549,,,,F,1,1,
,BAO_0000219,6303,N,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,Intermediate,646.0,80682,,6663,,9606.0,Homo sapiens,,CHEMBL624641,A549,,,,F,1,1,
,BAO_0000219,6304,N,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,Intermediate,646.0,80682,,6663,,9606.0,Homo sapiens,,CHEMBL624642,A549,,,,F,1,1,
,BAO_0000219,6305,N,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,Intermediate,646.0,80682,,6663,,9606.0,Homo sapiens,,CHEMBL624643,A549,,,,F,1,1,
,BAO_0000219,6306,N,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,Intermediate,646.0,80682,,6663,,9606.0,Homo sapiens,,CHEMBL624644,A549,,,,F,1,1,
,BAO_0000219,6307,N,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,Intermediate,646.0,80682,,6663,,9606.0,Homo sapiens,,CHEMBL624645,A549,,,,F,1,1,
,BAO_0000219,6308,N,The compound was evaluated for its cytotoxic potency against A-549 cell line,Intermediate,646.0,80682,,3983,,9606.0,Homo sapiens,,CHEMBL619445,A549,,,,F,1,1,
,BAO_0000219,6309,N,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,Expert,646.0,80682,,11141,,9606.0,Homo sapiens,,CHEMBL839886,A549,,,,F,1,1,
,BAO_0000219,6310,N,Cytotoxic activity of compound against A-549 tumor cell line.,Intermediate,646.0,80682,,5076,,9606.0,Homo sapiens,,CHEMBL619446,A549,,,,F,1,1,
,BAO_0000219,6311,N,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,Intermediate,646.0,80682,,3311,,9606.0,Homo sapiens,,CHEMBL619447,A549,,,,F,1,1,
,BAO_0000219,6312,N,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,Intermediate,646.0,80682,,3311,,9606.0,Homo sapiens,,CHEMBL619448,A549,,,,F,1,1,
,BAO_0000219,6313,N,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,Intermediate,646.0,80682,,3311,,9606.0,Homo sapiens,,CHEMBL619449,A549,,,,F,1,1,
,BAO_0000219,6314,N,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,Intermediate,646.0,80682,,5076,,9606.0,Homo sapiens,,CHEMBL619450,A549,,,,F,1,1,
,BAO_0000219,6315,N,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),Intermediate,646.0,80682,,4150,,9606.0,Homo sapiens,,CHEMBL619451,A549,,,,F,1,1,
,BAO_0000219,6316,N,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,Expert,646.0,80682,,2150,,9606.0,Homo sapiens,,CHEMBL619452,A549,,,,F,1,1,
,BAO_0000219,6317,N,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,Intermediate,646.0,80682,,4644,,9606.0,Homo sapiens,,CHEMBL619453,A549,,,,F,1,1,
,BAO_0000219,6318,N,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,Intermediate,646.0,80682,,263,,9606.0,Homo sapiens,,CHEMBL874367,A549,,,,F,1,1,
,BAO_0000219,6319,N,Cytotoxic concentration against A-549 tumor cells.,Intermediate,646.0,80682,,11333,,9606.0,Homo sapiens,,CHEMBL619454,A549,,,,F,1,1,
,BAO_0000219,6320,N,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,Intermediate,646.0,80682,,11333,,9606.0,Homo sapiens,,CHEMBL619455,A549,,,,F,1,1,
,BAO_0000219,6321,N,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",Intermediate,646.0,80682,,15895,,9606.0,Homo sapiens,,CHEMBL619456,A549,,,,F,1,1,
,BAO_0000218,6322,N,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,Expert,,50191,,16677,,470.0,Acinetobacter baumannii,,CHEMBL619457,,,,,F,1,1,
,BAO_0000218,6323,N,Activity against Acinetobacter calcoaceticus (AC54),Intermediate,,50192,,10624,,471.0,Acinetobacter calcoaceticus,,CHEMBL619458,,,,,F,1,1,
,BAO_0000218,6324,N,In vitro antifungal activity against Aspergillus flavus CM74,Expert,,50274,,16717,,5059.0,Aspergillus flavus,,CHEMBL619459,,,,,F,1,1,
,BAO_0000218,6325,N,In vitro antifungal activity against Aspergillus flavus CM74,Expert,,50274,,16717,,5059.0,Aspergillus flavus,,CHEMBL619460,,,,,F,1,1,
,BAO_0000218,6326,N,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,Intermediate,,50416,,5513,,746128.0,Aspergillus fumigatus,,CHEMBL619461,,,,,F,1,1,
,BAO_0000218,6327,N,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),Intermediate,,50416,,15962,,746128.0,Aspergillus fumigatus,,CHEMBL619462,,,,,F,1,1,
,BAO_0000218,6328,N,Antimicrobial activity against Aspergillus fumigatus (MIC),Intermediate,,50416,,15962,,746128.0,Aspergillus fumigatus,,CHEMBL620388,,,,,F,1,1,
,BAO_0000218,6329,N,Antimicrobial activity against Aspergillus fumigatus (MIC),Intermediate,,50416,,15962,,746128.0,Aspergillus fumigatus,,CHEMBL620389,,,,,F,1,1,
,BAO_0000218,6330,N,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),Intermediate,,50416,,15962,,746128.0,Aspergillus fumigatus,,CHEMBL620390,,,,,F,1,1,
,BAO_0000218,6331,N,In vitro antifungal activity against Aspergillus fumigatus 48238E,Expert,,50416,,16717,,746128.0,Aspergillus fumigatus,,CHEMBL620391,,,,,F,1,1,
,BAO_0000218,6332,N,In vitro antifungal activity against Aspergillus fumigatus 48238E,Expert,,50416,,16717,,746128.0,Aspergillus fumigatus,,CHEMBL621073,,,,,F,1,1,
,BAO_0000218,6333,N,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,Intermediate,,50296,,8117,,1655.0,Actinomyces naeslundii,,CHEMBL621074,,,,,F,1,1,
,BAO_0000218,6334,N,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,Intermediate,,50366,,8117,,1656.0,Actinomyces viscosus,,CHEMBL621075,,,,,F,1,1,
,BAO_0000218,6335,N,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),Intermediate,,50535,,15472,,6277.0,Acanthocheilonema viteae,,CHEMBL619554,,,,,F,1,1,
,BAO_0000218,6336,N,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),Intermediate,,50535,,15472,,6277.0,Acanthocheilonema viteae,,CHEMBL619555,,,,,F,1,1,
,BAO_0000218,6337,N,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,Intermediate,,50169,,16443,,714.0,Aggregatibacter actinomycetemcomitans,,CHEMBL619556,,,,,F,1,1,
,BAO_0000218,6338,N,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,Intermediate,,50169,,16443,,714.0,Aggregatibacter actinomycetemcomitans,,CHEMBL619557,,,,,F,1,1,
,BAO_0000218,6339,N,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,Intermediate,,50169,,16443,,714.0,Aggregatibacter actinomycetemcomitans,,CHEMBL619558,,,,,F,1,1,
,BAO_0000219,6340,N,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,Intermediate,646.0,80682,,17206,,9606.0,Homo sapiens,,CHEMBL619559,A549,,,,F,1,1,
,BAO_0000219,6341,N,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,Intermediate,646.0,80682,,17206,,9606.0,Homo sapiens,,CHEMBL619560,A549,,,,F,1,1,
,BAO_0000219,6342,N,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,Intermediate,646.0,80682,,16381,,9606.0,Homo sapiens,,CHEMBL619561,A549,,,,F,1,1,
,BAO_0000219,6343,N,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,Intermediate,646.0,80682,,16381,,9606.0,Homo sapiens,,CHEMBL619562,A549,,,,F,1,1,
,BAO_0000219,6344,N,% inhibition against A549 cells (lung cancer) at 4 ug/mL,Intermediate,646.0,80682,,16381,,9606.0,Homo sapiens,,CHEMBL619563,A549,,,,F,1,1,
,BAO_0000219,6345,N,GI values against A549 cells (lung cancer),Intermediate,646.0,80682,,16381,,9606.0,Homo sapiens,,CHEMBL857457,A549,,,,F,1,1,
,BAO_0000219,6346,N,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,Intermediate,646.0,80682,,17206,,9606.0,Homo sapiens,,CHEMBL619564,A549,,,,F,1,1,
,BAO_0000219,6347,N,Inhibitory activity against A549 human adenocarcinoma,Intermediate,646.0,80682,,16325,,9606.0,Homo sapiens,,CHEMBL619565,A549,,,,F,1,1,
,BAO_0000218,6348,N,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,Intermediate,646.0,80682,,10708,,9606.0,Homo sapiens,,CHEMBL619566,A549,,,,F,1,1,
,BAO_0000218,6349,N,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,Intermediate,646.0,80682,,10708,,9606.0,Homo sapiens,,CHEMBL619567,A549,,,,F,1,1,
,BAO_0000219,6350,N,Inhibitory activity against A549 lung adenocarcinoma cell line,Intermediate,646.0,80682,,17376,,9606.0,Homo sapiens,,CHEMBL619568,A549,,,,F,1,1,
,BAO_0000219,6351,N,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,Intermediate,646.0,80682,,17376,,9606.0,Homo sapiens,,CHEMBL619569,A549,,,,F,1,1,
,BAO_0000219,6352,N,Cytotoxicity against human A549 lung cells,Intermediate,646.0,80682,,17488,,9606.0,Homo sapiens,,CHEMBL619570,A549,,,,F,1,1,
,BAO_0000218,6353,N,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,Intermediate,646.0,80682,,17404,,9606.0,Homo sapiens,,CHEMBL619571,A549,,,,F,1,1,
,BAO_0000219,6354,N,Growth inhibition of A549 (human lung carcinoma) cell line.,Expert,646.0,80682,,10958,,9606.0,Homo sapiens,,CHEMBL619572,A549,,,,F,1,1,
,BAO_0000219,6355,N,Effective dose required for inhibitory activity against A549 human tumor cell line.,Expert,646.0,80682,,17099,,9606.0,Homo sapiens,,CHEMBL619573,A549,,,,F,1,1,
,BAO_0000219,6356,N,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,Intermediate,646.0,80682,,17099,,9606.0,Homo sapiens,,CHEMBL619574,A549,,,,F,1,1,
,BAO_0000219,6357,N,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,Intermediate,646.0,80682,,4096,,9606.0,Homo sapiens,,CHEMBL619575,A549,,,,F,1,1,
,BAO_0000219,6358,N,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,Expert,646.0,80682,,4096,,9606.0,Homo sapiens,,CHEMBL619576,A549,,,,F,1,1,
,BAO_0000219,6359,N,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,Intermediate,646.0,80682,,4096,,9606.0,Homo sapiens,,CHEMBL619577,A549,,,,F,1,1,
,BAO_0000219,6360,N,In vitro inhibitory activity against A549 tumor cell culture,Intermediate,646.0,80682,,2525,,9606.0,Homo sapiens,,CHEMBL619578,A549,,,,F,1,1,
,BAO_0000219,6361,N,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,Intermediate,646.0,80682,,2525,,9606.0,Homo sapiens,,CHEMBL884009,A549,,,,F,1,1,
,BAO_0000219,6362,N,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),Intermediate,646.0,80682,,5302,,9606.0,Homo sapiens,,CHEMBL619579,A549,,,,F,1,1,
,BAO_0000219,6363,N,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,Intermediate,646.0,80682,,16325,,9606.0,Homo sapiens,,CHEMBL619580,A549,,,,F,1,1,
,BAO_0000219,6364,N,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,Intermediate,646.0,80682,,16939,,9606.0,Homo sapiens,,CHEMBL619581,A549,,,,F,1,1,
,BAO_0000219,6365,N,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,Intermediate,646.0,80682,,17229,,9606.0,Homo sapiens,,CHEMBL619582,A549,,,,F,1,1,
,BAO_0000219,6366,N,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,Intermediate,646.0,80682,,17380,,9606.0,Homo sapiens,,CHEMBL619583,A549,,,,F,1,1,
,BAO_0000219,6367,N,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,Intermediate,646.0,80682,,17380,,9606.0,Homo sapiens,,CHEMBL876502,A549,,,,F,1,1,
,BAO_0000219,6368,N,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,Intermediate,646.0,80682,,1903,,9606.0,Homo sapiens,,CHEMBL619584,A549,,,,F,1,1,
,BAO_0000219,6369,N,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,Intermediate,646.0,80682,,3838,,9606.0,Homo sapiens,,CHEMBL619585,A549,,,,F,1,1,
,BAO_0000219,6370,N,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,Intermediate,646.0,80682,,14696,,9606.0,Homo sapiens,,CHEMBL619586,A549,,,,F,1,1,
,BAO_0000219,6371,N,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,Intermediate,646.0,80682,,3838,,9606.0,Homo sapiens,,CHEMBL619587,A549,,,,F,1,1,
,BAO_0000219,6372,N,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,Intermediate,646.0,80682,,1522,,9606.0,Homo sapiens,,CHEMBL619588,A549,,,,F,1,1,
,BAO_0000219,6373,N,Tested in vitro for cytotoxicity in A549/ATCC cell lines,Intermediate,646.0,80682,,12400,,9606.0,Homo sapiens,,CHEMBL619589,A549,,,,F,1,1,
,BAO_0000219,6374,N,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,Intermediate,646.0,80682,,14696,,9606.0,Homo sapiens,,CHEMBL619590,A549,,,,F,1,1,
,BAO_0000219,6375,N,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),Intermediate,646.0,80682,,14769,,9606.0,Homo sapiens,,CHEMBL619591,A549,,,,F,1,1,
,BAO_0000219,6376,N,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,Intermediate,646.0,80682,,14696,,9606.0,Homo sapiens,,CHEMBL619592,A549,,,,F,1,1,
,BAO_0000219,6377,N,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,Intermediate,646.0,80682,,1888,,9606.0,Homo sapiens,,CHEMBL619593,A549,,,,F,1,1,
,BAO_0000219,6378,N,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,Intermediate,646.0,80682,,12016,,9606.0,Homo sapiens,,CHEMBL620217,A549,,,,F,1,1,
,BAO_0000219,6379,N,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,Intermediate,646.0,80682,,6058,,9606.0,Homo sapiens,,CHEMBL620218,A549,,,,F,1,1,
,BAO_0000219,6380,N,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,Intermediate,646.0,80682,,17708,,9606.0,Homo sapiens,,CHEMBL620219,A549,,,,F,1,1,
,BAO_0000219,6381,N,Antitumor activity against A549/ATCC cell line,Intermediate,646.0,80682,,12301,,9606.0,Homo sapiens,,CHEMBL620220,A549,,,,F,1,1,
,BAO_0000219,6382,N,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,Intermediate,646.0,80682,,11970,,9606.0,Homo sapiens,,CHEMBL625141,A549,,,,F,1,1,
,BAO_0000219,6383,N,In vitro cytotoxicity against A549/ATCC cell line.,Expert,646.0,80682,,11818,,9606.0,Homo sapiens,,CHEMBL625142,A549,,,,F,1,1,
,BAO_0000219,6384,N,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,Intermediate,646.0,80682,,12400,,9606.0,Homo sapiens,,CHEMBL625143,A549,,,,F,1,1,
,BAO_0000219,6385,N,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,Intermediate,646.0,80682,,3381,,9606.0,Homo sapiens,,CHEMBL625144,A549,,,,F,1,1,
,BAO_0000219,6386,N,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,Intermediate,646.0,80682,,17376,,9606.0,Homo sapiens,,CHEMBL622474,A549,,,,F,1,1,
,BAO_0000219,6387,N,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,Intermediate,646.0,80682,,10708,,9606.0,Homo sapiens,,CHEMBL884104,A549,,,,F,1,1,
,BAO_0000219,6388,U,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,Autocuration,,22226,,2964,,9606.0,Homo sapiens,,CHEMBL622475,,,,,F,1,0,
,BAO_0000218,6389,U,Compound was tested for oral bioavailability in dogs,Intermediate,,22224,,5005,,9615.0,Canis lupus familiaris,,CHEMBL622476,,,In vivo,,A,1,0,
,BAO_0000218,6390,N,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,Intermediate,,50588,,6229,,9615.0,Canis lupus familiaris,,CHEMBL875831,,,In vivo,,A,1,1,
,BAO_0000218,6391,N,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,Intermediate,,50588,,6229,,9615.0,Canis lupus familiaris,,CHEMBL622477,,,In vivo,,A,1,1,
,BAO_0000218,6392,N,Oral bioavailability in dog,Intermediate,,50588,,5374,,9615.0,Canis lupus familiaris,,CHEMBL622478,,,In vivo,,A,1,1,
,BAO_0000218,6393,N,Compound was tested for the oral bioavailability in dog; No availability,Intermediate,,50588,,5374,,9615.0,Canis lupus familiaris,,CHEMBL623172,,,In vivo,,A,1,1,
,BAO_0000218,6394,N,Oral bioavailability in dog (dose 5 mg/kg),Intermediate,,50588,,6265,,9615.0,Canis lupus familiaris,,CHEMBL623173,,,In vivo,,A,1,1,
,BAO_0000218,6395,N,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,Intermediate,,50588,,5654,,9615.0,Canis lupus familiaris,,CHEMBL623174,,,In vivo,,A,1,1,
,BAO_0000218,6396,N,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,Intermediate,,50588,,5654,,9615.0,Canis lupus familiaris,,CHEMBL623175,,,In vivo,,A,1,1,
,BAO_0000218,6397,N,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),Intermediate,,50588,,16456,,9615.0,Canis lupus familiaris,,CHEMBL623340,,,In vivo,,A,1,1,
,BAO_0000218,6398,N,Oral bioavailability in dog (dose 5 mg/kg),Intermediate,,50588,,5302,,9615.0,Canis lupus familiaris,,CHEMBL623341,,,In vivo,,A,1,1,
,BAO_0000218,6399,N,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),Intermediate,,50588,,3624,,9615.0,Canis lupus familiaris,,CHEMBL623342,,,In vivo,,A,1,1,
,BAO_0000218,6400,N,Oral bioavailability of active FTIs in dogs,Intermediate,,50588,,16452,,9615.0,Canis lupus familiaris,,CHEMBL623343,,,In vivo,,A,1,1,
,BAO_0000218,6401,N,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),Intermediate,,50588,,5802,,9615.0,Canis lupus familiaris,,CHEMBL623344,,,In vivo,,A,1,1,
,BAO_0000218,6402,N,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,Expert,,50588,,3598,,9615.0,Canis lupus familiaris,,CHEMBL623345,,,In vivo,,A,1,1,
,BAO_0000218,6403,N,Oral bioavailability in dog,Intermediate,,50588,,17839,,9615.0,Canis lupus familiaris,,CHEMBL875832,,,In vivo,,A,1,1,
,BAO_0000218,6404,N,Oral bioavailability in dog,Intermediate,,50588,,6762,,9615.0,Canis lupus familiaris,,CHEMBL623346,,,In vivo,,A,1,1,
,BAO_0000218,6405,N,Oral bioavailability in dog,Intermediate,,50588,,6821,,9615.0,Canis lupus familiaris,,CHEMBL623347,,,In vivo,,A,1,1,
,BAO_0000218,6406,N,Oral bioavailability of compound was determined in dog; Not tested,Intermediate,,50588,,6821,,9615.0,Canis lupus familiaris,,CHEMBL623348,,,In vivo,,A,1,1,
,BAO_0000218,6407,N,Oral bioavailability in dog,Intermediate,,50588,,5210,,9615.0,Canis lupus familiaris,,CHEMBL623349,,,In vivo,,A,1,1,
,BAO_0000218,6408,N,Oral bioavailability (10 mg/kg) was determined in dog,Intermediate,,50588,,6227,,9615.0,Canis lupus familiaris,,CHEMBL623350,,,In vivo,,A,1,1,
,BAO_0000218,6409,N,Oral bioavailability,Intermediate,,50588,,761,,9615.0,Canis lupus familiaris,,CHEMBL623351,,,In vivo,,A,1,1,
,BAO_0000218,6410,N,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),Intermediate,,50588,,761,,9615.0,Canis lupus familiaris,,CHEMBL623352,,,In vivo,,A,1,1,
,BAO_0000218,6411,N,Oral bioavailability administered in solution in rats,Intermediate,,50588,,761,,9615.0,Canis lupus familiaris,,CHEMBL623353,,,In vivo,,A,1,1,
,BAO_0000218,6412,N,Oral bioavailability after 30 mg/kg po dose in Dogs,Intermediate,,50588,,16907,,9615.0,Canis lupus familiaris,,CHEMBL875833,,,In vivo,,A,1,1,
,BAO_0000218,6413,N,Oral bioavailability at a dose of 1 mg/kg in dogs,Intermediate,,50588,,5474,,9615.0,Canis lupus familiaris,,CHEMBL623354,,,In vivo,,A,1,1,
,BAO_0000218,6414,N,Oral bioavailability in dog (dose 1 mg/kg p.o.),Intermediate,,50588,,6535,,9615.0,Canis lupus familiaris,,CHEMBL623355,,,In vivo,,A,1,1,
,BAO_0000218,6415,N,Oral bioavailability in Dog; ND = not determined,Intermediate,,50588,,6535,,9615.0,Canis lupus familiaris,,CHEMBL623356,,,In vivo,,A,1,1,
,BAO_0000218,6416,N,Oral bioavailability in dog,Intermediate,,50588,,3352,,9615.0,Canis lupus familiaris,,CHEMBL623357,,,In vivo,,A,1,1,
,BAO_0000218,6417,N,Oral bioavailability in dog,Intermediate,,50588,,6168,,9615.0,Canis lupus familiaris,,CHEMBL623358,,,In vivo,,A,1,1,
,BAO_0000218,6418,N,Oral bioavailability in dog,Intermediate,,50588,,5988,,9615.0,Canis lupus familiaris,,CHEMBL623359,,,In vivo,,A,1,1,
,BAO_0000218,6419,N,Oral bioavailability in dog,Intermediate,,50588,,4942,,9615.0,Canis lupus familiaris,,CHEMBL623360,,,In vivo,,A,1,1,
,BAO_0000218,6420,N,Oral bioavailability in dogs; No data,Intermediate,,50588,,4942,,9615.0,Canis lupus familiaris,,CHEMBL623361,,,In vivo,,A,1,1,
,BAO_0000218,6421,N,Oral bioavailability measured in dogs,Intermediate,,50588,,14541,,9615.0,Canis lupus familiaris,,CHEMBL623362,,,In vivo,,A,1,1,
,BAO_0000218,6422,N,Oral bioavailability in dog,Intermediate,,50588,,4449,,9615.0,Canis lupus familiaris,,CHEMBL623363,,,In vivo,,A,1,1,
,BAO_0000218,6423,N,Oral bioavailability was calculated in dog,Intermediate,,50588,,6057,,9615.0,Canis lupus familiaris,,CHEMBL623364,,,In vivo,,A,1,1,
,BAO_0000218,6424,N,Oral bioavailability after 0.3 mg/kg po administration in dog,Intermediate,,50588,,5600,,9615.0,Canis lupus familiaris,,CHEMBL875834,,,In vivo,,A,1,1,
,BAO_0000218,6425,N,Oral bioavailability in dog (i.v. dosing),Intermediate,,50588,,5542,,9615.0,Canis lupus familiaris,,CHEMBL623365,,,In vivo,,A,1,1,
,BAO_0000218,6426,N,Oral bioavailability in dog,Intermediate,,50588,,5542,,9615.0,Canis lupus familiaris,,CHEMBL623366,,,In vivo,,A,1,1,
,BAO_0000218,6427,N,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,Intermediate,,50588,,5546,,9615.0,Canis lupus familiaris,,CHEMBL623367,,,In vivo,,A,1,1,
,BAO_0000218,6428,N,Oral bioavailability in Beagle dogs,Intermediate,,50588,,4514,,9615.0,Canis lupus familiaris,,CHEMBL623368,,,In vivo,,A,1,1,
,BAO_0000218,6429,N,Oral bioavailability in dog,Intermediate,,50588,,3624,,9615.0,Canis lupus familiaris,,CHEMBL623369,,,In vivo,,A,1,1,
,BAO_0000218,6430,N,Oral bioavailability in dog,Intermediate,,50588,,3854,,9615.0,Canis lupus familiaris,,CHEMBL623370,,,In vivo,,A,1,1,
,BAO_0000218,6431,N,Oral bioavailability in dog,Intermediate,,50588,,5836,,9615.0,Canis lupus familiaris,,CHEMBL623371,,,In vivo,,A,1,1,
,BAO_0000218,6432,N,Oral bioavailability in dog,Intermediate,,50588,,5940,,9615.0,Canis lupus familiaris,,CHEMBL623372,,,In vivo,,A,1,1,
,BAO_0000218,6433,N,Oral bioavailability in dog,Intermediate,,50588,,6168,,9615.0,Canis lupus familiaris,,CHEMBL621351,,,In vivo,,A,1,1,
,BAO_0000218,6434,N,Oral bioavailability in dog,Intermediate,,50588,,6227,,9615.0,Canis lupus familiaris,,CHEMBL621352,,,In vivo,,A,1,1,
,BAO_0000218,6435,N,Oral bioavailability in dog,Intermediate,,50588,,6251,,9615.0,Canis lupus familiaris,,CHEMBL621353,,,In vivo,,A,1,1,
,BAO_0000218,6436,N,Oral bioavailability in dog,Intermediate,,50588,,6448,,9615.0,Canis lupus familiaris,,CHEMBL621354,,,In vivo,,A,1,1,
,BAO_0000218,6437,N,Oral bioavailability in dog,Intermediate,,50588,,6647,,9615.0,Canis lupus familiaris,,CHEMBL621355,,,In vivo,,A,1,1,
,BAO_0000218,6438,N,Oral bioavailability in dog,Intermediate,,50588,,5940,,9615.0,Canis lupus familiaris,,CHEMBL621356,,,In vivo,,A,1,1,
,BAO_0000218,6439,N,Oral bioavailability in dog,Intermediate,,50588,,933,,9615.0,Canis lupus familiaris,,CHEMBL621357,,,In vivo,,A,1,1,
,BAO_0000218,6440,N,Oral bioavailability in dog,Intermediate,,50588,,5210,,9615.0,Canis lupus familiaris,,CHEMBL621358,,,In vivo,,A,1,1,
,BAO_0000218,6441,N,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),Intermediate,,50588,,6642,,9615.0,Canis lupus familiaris,,CHEMBL621359,,,In vivo,,A,1,1,
,BAO_0000218,6442,N,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),Intermediate,,50588,,6641,,9615.0,Canis lupus familiaris,,CHEMBL621360,,,In vivo,,A,1,1,
,BAO_0000218,6443,N,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),Intermediate,,50588,,6642,,9615.0,Canis lupus familiaris,,CHEMBL621361,,,In vivo,,A,1,1,
,BAO_0000218,6444,N,Oral bioavailability in dog,Intermediate,,50588,,5472,,9615.0,Canis lupus familiaris,,CHEMBL621362,,,In vivo,,A,1,1,
,BAO_0000218,6445,N,Oral bioavailability in dog,Intermediate,,50588,,5985,,9615.0,Canis lupus familiaris,,CHEMBL621363,,,In vivo,,A,1,1,
,BAO_0000218,6446,N,Oral bioavailability in dog,Intermediate,,50588,,15660,,9615.0,Canis lupus familiaris,,CHEMBL621364,,,In vivo,,A,1,1,
,BAO_0000218,6447,N,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),Intermediate,,50588,,5530,,9615.0,Canis lupus familiaris,,CHEMBL621166,,,In vivo,,A,1,1,
,BAO_0000218,6448,N,Oral bioavailability in dog (dose 1 mg/kg i.v.),Intermediate,,50588,,5530,,9615.0,Canis lupus familiaris,,CHEMBL621167,,,In vivo,,A,1,1,
,BAO_0000218,6449,N,Oral bioavailability (F) in dogs,Intermediate,,50588,,6305,,9615.0,Canis lupus familiaris,,CHEMBL621168,,,In vivo,,A,1,1,
,BAO_0000218,6450,N,Oral bioavailability in dog,Intermediate,,50588,,5210,,9615.0,Canis lupus familiaris,,CHEMBL621169,,,In vivo,,A,1,1,
,BAO_0000218,6451,N,Bioavailability in dog,Intermediate,,50588,,5238,,9615.0,Canis lupus familiaris,,CHEMBL875950,,,In vivo,,A,1,1,
,BAO_0000218,6452,N,Oral bioavailability in dog (dose 10 mg/kg),Intermediate,,50588,,5668,,9615.0,Canis lupus familiaris,,CHEMBL621170,,,In vivo,,A,1,1,
,BAO_0000218,6453,N,Oral bioavailability after peroral administration at 5 mpk in Dog,Intermediate,,50588,,5668,,9615.0,Canis lupus familiaris,,CHEMBL621171,,,In vivo,,A,1,1,
,BAO_0000218,6454,N,Oral bioavailability in dog (dose 5 mg/kg),Intermediate,,50588,,5668,,9615.0,Canis lupus familiaris,,CHEMBL621172,,,In vivo,,A,1,1,
,BAO_0000218,6455,N,Oral bioavailability in dog (dose 10 mg/kg),Intermediate,,50588,,6084,,9615.0,Canis lupus familiaris,,CHEMBL621173,,,In vivo,,A,1,1,
Kidney,BAO_0000218,6456,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,Intermediate,42.0,50594,,6599,2113.0,10090.0,Mus musculus,,CHEMBL621174,CCRF S-180,,,,A,1,1,
Kidney,BAO_0000218,6457,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,Intermediate,42.0,50594,,6599,2113.0,10090.0,Mus musculus,,CHEMBL621175,CCRF S-180,,,,A,1,1,
Liver,BAO_0000218,6458,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,Intermediate,42.0,50594,,6599,2107.0,10090.0,Mus musculus,,CHEMBL621176,CCRF S-180,,,,A,1,1,
Liver,BAO_0000218,6459,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,Intermediate,42.0,50594,,6599,2107.0,10090.0,Mus musculus,,CHEMBL621177,CCRF S-180,,,,A,1,1,
Liver,BAO_0000218,6460,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,Intermediate,42.0,50594,,6599,2107.0,10090.0,Mus musculus,,CHEMBL621178,CCRF S-180,,,,A,1,1,
Liver,BAO_0000218,6461,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,Intermediate,42.0,50594,,6599,2107.0,10090.0,Mus musculus,,CHEMBL621179,CCRF S-180,,,,A,1,1,
Liver,BAO_0000218,6462,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,Intermediate,42.0,50594,,6599,2107.0,10090.0,Mus musculus,,CHEMBL621180,CCRF S-180,,,,A,1,1,
Lung,BAO_0000218,6463,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,Intermediate,42.0,50594,,6599,2048.0,10090.0,Mus musculus,,CHEMBL875951,CCRF S-180,,,,A,1,1,
Lung,BAO_0000218,6464,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,Intermediate,42.0,50594,,6599,2048.0,10090.0,Mus musculus,,CHEMBL621181,CCRF S-180,,,,A,1,1,
Lung,BAO_0000218,6465,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,Intermediate,42.0,50594,,6599,2048.0,10090.0,Mus musculus,,CHEMBL621182,CCRF S-180,,,,A,1,1,
Lung,BAO_0000218,6466,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,Intermediate,42.0,50594,,6599,2048.0,10090.0,Mus musculus,,CHEMBL621183,CCRF S-180,,,,A,1,1,
Lung,BAO_0000218,6467,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,Intermediate,42.0,50594,,6599,2048.0,10090.0,Mus musculus,,CHEMBL621184,CCRF S-180,,,,A,1,1,
,BAO_0000218,6468,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,Intermediate,42.0,50594,,6599,,10090.0,Mus musculus,,CHEMBL621185,CCRF S-180,,,,A,1,1,
,BAO_0000218,6469,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,Intermediate,42.0,50594,,6599,,10090.0,Mus musculus,,CHEMBL621186,CCRF S-180,,,,A,1,1,
,BAO_0000218,6470,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,Intermediate,42.0,50594,,6599,,10090.0,Mus musculus,,CHEMBL621187,CCRF S-180,,,,A,1,1,
,BAO_0000218,6471,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,Intermediate,42.0,50594,,6599,,10090.0,Mus musculus,,CHEMBL621188,CCRF S-180,,,,A,1,1,
,BAO_0000218,6472,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,Intermediate,42.0,50594,,6599,,10090.0,Mus musculus,,CHEMBL621189,CCRF S-180,,,,A,1,1,
Spleen,BAO_0000218,6473,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,Intermediate,42.0,50594,,6599,2106.0,10090.0,Mus musculus,,CHEMBL621190,CCRF S-180,,,,A,1,1,
Spleen,BAO_0000218,6474,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,Intermediate,42.0,50594,,6599,2106.0,10090.0,Mus musculus,,CHEMBL618520,CCRF S-180,,,,A,1,1,
Spleen,BAO_0000218,6475,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,Intermediate,42.0,50594,,6599,2106.0,10090.0,Mus musculus,,CHEMBL621739,CCRF S-180,,,,A,1,1,
Spleen,BAO_0000218,6476,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,Intermediate,42.0,50594,,6599,2106.0,10090.0,Mus musculus,,CHEMBL621740,CCRF S-180,,,,A,1,1,
Spleen,BAO_0000218,6477,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,Intermediate,42.0,50594,,6599,2106.0,10090.0,Mus musculus,,CHEMBL621741,CCRF S-180,,,,A,1,1,
,BAO_0000218,6478,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,Intermediate,42.0,50594,,6599,,10090.0,Mus musculus,,CHEMBL621742,CCRF S-180,,,,A,1,1,
,BAO_0000218,6479,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,Intermediate,42.0,50594,,6599,,10090.0,Mus musculus,,CHEMBL621743,CCRF S-180,,,,A,1,1,
,BAO_0000218,6480,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,Intermediate,42.0,50594,,6599,,10090.0,Mus musculus,,CHEMBL621744,CCRF S-180,,,,A,1,1,
,BAO_0000218,6481,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,Intermediate,42.0,50594,,6599,,10090.0,Mus musculus,,CHEMBL621745,CCRF S-180,,,,A,1,1,
,BAO_0000218,6482,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,Intermediate,42.0,50594,,6599,,10090.0,Mus musculus,,CHEMBL621746,CCRF S-180,,,,A,1,1,
,BAO_0000218,6483,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,Intermediate,42.0,50594,,6599,,10090.0,Mus musculus,,CHEMBL621747,CCRF S-180,,,,A,1,1,
,BAO_0000218,6484,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,Intermediate,42.0,50594,,6599,,10090.0,Mus musculus,,CHEMBL621748,CCRF S-180,,,,A,1,1,
,BAO_0000218,6485,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,Intermediate,42.0,50594,,6599,,10090.0,Mus musculus,,CHEMBL621749,CCRF S-180,,,,A,1,1,
,BAO_0000218,6486,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,Intermediate,42.0,50594,,6599,,10090.0,Mus musculus,,CHEMBL621750,CCRF S-180,,,,A,1,1,
,BAO_0000218,6487,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,Intermediate,42.0,50594,,6599,,10090.0,Mus musculus,,CHEMBL621751,CCRF S-180,,,,A,1,1,
Heart,BAO_0000218,6488,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,Intermediate,42.0,50594,,6599,948.0,10090.0,Mus musculus,,CHEMBL621752,CCRF S-180,,,,A,1,1,
Heart,BAO_0000218,6489,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,Intermediate,42.0,50594,,6599,948.0,10090.0,Mus musculus,,CHEMBL621753,CCRF S-180,,,,A,1,1,
Heart,BAO_0000218,6490,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,Intermediate,42.0,50594,,6599,948.0,10090.0,Mus musculus,,CHEMBL875955,CCRF S-180,,,,A,1,1,
Heart,BAO_0000218,6491,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,Intermediate,42.0,50594,,6599,948.0,10090.0,Mus musculus,,CHEMBL621754,CCRF S-180,,,,A,1,1,
Heart,BAO_0000218,6492,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,Intermediate,42.0,50594,,6599,948.0,10090.0,Mus musculus,,CHEMBL621755,CCRF S-180,,,,A,1,1,
Liver,BAO_0000218,6493,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,Intermediate,42.0,50594,,6599,2107.0,10090.0,Mus musculus,,CHEMBL621756,CCRF S-180,,,,A,1,1,
Liver,BAO_0000218,6494,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,Intermediate,42.0,50594,,6599,2107.0,10090.0,Mus musculus,,CHEMBL624199,CCRF S-180,,,,A,1,1,
Liver,BAO_0000218,6495,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,Intermediate,42.0,50594,,6599,2107.0,10090.0,Mus musculus,,CHEMBL624200,CCRF S-180,,,,A,1,1,
Liver,BAO_0000218,6496,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,Intermediate,42.0,50594,,6599,2107.0,10090.0,Mus musculus,,CHEMBL624375,CCRF S-180,,,,A,1,1,
Liver,BAO_0000218,6497,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,Intermediate,42.0,50594,,6599,2107.0,10090.0,Mus musculus,,CHEMBL624376,CCRF S-180,,,,A,1,1,
Lung,BAO_0000218,6498,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,Intermediate,42.0,50594,,6599,2048.0,10090.0,Mus musculus,,CHEMBL624377,CCRF S-180,,,,A,1,1,
Lung,BAO_0000218,6499,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,Intermediate,42.0,50594,,6599,2048.0,10090.0,Mus musculus,,CHEMBL624378,CCRF S-180,,,,A,1,1,
,BAO_0000218,6500,N,Compound tested for the antimicrobial activity against Acinetobacter anitratus,Intermediate,,50067,,12269,,107673.0,aeinetobacter anitrotap,,CHEMBL857901,,,,,F,1,1,
,BAO_0000218,6501,N,Compound tested for the antimicrobial activity against Acinetobacter anitratus,Intermediate,,50067,,12269,,107673.0,Acinetobacter calcoaceticus subsp. anitratus,,CHEMBL875274,,,,,F,1,1,
,BAO_0000218,6502,N,Compound tested for the antimicrobial activity against Acinetobacter anitratus,Intermediate,,50067,,12269,,107673.0,Acinetobacter calcoaceticus subsp. anitratus,,CHEMBL624379,,,,,F,1,1,
,BAO_0000218,6503,N,Compound tested for the antimicrobial activity against Acinetobacter anitratus,Intermediate,,50067,,12269,,107673.0,aeinetobacter anitrotap,,CHEMBL624380,,,,,F,1,1,
,BAO_0000218,6504,N,Activity against Acinetobacter calcoaceticus (AC54),Intermediate,,50192,,10624,,471.0,Acinetobacter calcoaceticus,,CHEMBL624381,,,,,F,1,1,
,BAO_0000218,6505,N,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,Intermediate,,50714,,17216,,28377.0,Anolis carolinensis,,CHEMBL624382,,,,,F,1,1,
,BAO_0000218,6506,N,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,Intermediate,,50714,,17216,,28377.0,Anolis carolinensis,,CHEMBL624383,,,,,F,1,1,
,BAO_0000218,6507,N,Chlorohexidine coefficient for Actinomyces naeslundii 631,Intermediate,,50296,,9560,,1655.0,Actinomyces naeslundii,,CHEMBL624384,,,,,F,1,1,
,BAO_0000218,6508,N,Chlorohexidine coefficient for Actinomyces naeslundii B74,Intermediate,,50296,,9560,,1655.0,Actinomyces naeslundii,,CHEMBL624385,,,,,F,1,1,
,BAO_0000218,6509,N,Chlorohexidine coefficient for Actinomyces naeslundii N/3,Intermediate,,50296,,9560,,1655.0,Actinomyces naeslundii,,CHEMBL624386,,,,,F,1,1,
,BAO_0000218,6510,N,Chlorohexidine coefficient for Actinomyces naeslundii N/9,Intermediate,,50296,,9560,,1655.0,Actinomyces naeslundii,,CHEMBL624387,,,,,F,1,1,
,BAO_0000218,6511,N,Plaque bactericidal index against Actinomyces naeslundii 631,Intermediate,,50296,,9560,,1655.0,Actinomyces naeslundii,,CHEMBL624388,,,,,F,1,1,
,BAO_0000218,6512,N,Plaque bactericidal index against Actinomyces naeslundii N/9,Intermediate,,50296,,9560,,1655.0,Actinomyces naeslundii,,CHEMBL624389,,,,,F,1,1,
,BAO_0000218,6513,N,Plaque bactericidal index against Actinomyces naeslundii B74,Intermediate,,50296,,9560,,1655.0,Actinomyces naeslundii,,CHEMBL624390,,,,,F,1,1,
,BAO_0000218,6514,N,Plaque bactericidal index against Actinomyces naeslundii N/3,Intermediate,,50296,,9560,,1655.0,Actinomyces naeslundii,,CHEMBL875275,,,,,F,1,1,
,BAO_0000218,6515,N,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,Intermediate,,50056,,114,,85549.0,Artemia salina,,CHEMBL624391,,,,,F,1,1,
,BAO_0000218,6516,N,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",Intermediate,,50056,,114,,85549.0,Artemia salina,,CHEMBL623636,,,,,F,1,1,
,BAO_0000218,6517,N,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,Intermediate,,50532,,10841,,6253.0,Ascaris suum,,CHEMBL623637,,,,,F,1,1,
,BAO_0000218,6518,N,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,Intermediate,,50532,,10841,,6253.0,Ascaris suum,,CHEMBL623638,,,,,F,1,1,
,BAO_0000218,6519,N,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,Intermediate,,50532,,10841,,6253.0,Ascaris suum,,CHEMBL623639,,,,,F,1,1,
,BAO_0000218,6520,N,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,Intermediate,,50532,,10841,,6253.0,Ascaris suum,,CHEMBL623640,,,,,F,1,1,
,BAO_0000218,6521,N,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,Intermediate,,50532,,10841,,6253.0,Ascaris suum,,CHEMBL623641,,,,,F,1,1,
,BAO_0000218,6522,N,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,Intermediate,,50532,,10841,,6253.0,Ascaris suum,,CHEMBL623642,,,,,F,1,1,
,BAO_0000218,6523,N,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,Intermediate,,50532,,10841,,6253.0,Ascaris suum,,CHEMBL623643,,,,,F,1,1,
,BAO_0000218,6524,N,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,Intermediate,,50532,,10841,,6253.0,Ascaris suum,,CHEMBL623644,,,,,F,1,1,
,BAO_0000218,6525,N,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,Intermediate,,50532,,10841,,6253.0,Ascaris suum,,CHEMBL623645,,,,,F,1,1,
,BAO_0000218,6526,N,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,Intermediate,,50532,,10841,,6253.0,Ascaris suum,,CHEMBL623646,,,,,F,1,1,
,BAO_0000218,6527,N,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,Intermediate,,50532,,10841,,6253.0,Ascaris suum,,CHEMBL623647,,,,,F,1,1,
,BAO_0000218,6528,N,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,Intermediate,,50532,,10841,,6253.0,Ascaris suum,,CHEMBL623648,,,,,F,1,1,
,BAO_0000218,6529,N,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,Intermediate,,50366,,8117,,1656.0,Actinomyces viscosus,,CHEMBL623649,,,,,F,1,1,
,BAO_0000218,6530,N,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,Intermediate,,50366,,8117,,1656.0,Actinomyces viscosus,,CHEMBL623650,,,,,F,1,1,
,BAO_0000218,6531,N,Chlorohexidine coefficient for Actinomyces viscosus 8A06,Intermediate,,50366,,9560,,1656.0,Actinomyces viscosus,,CHEMBL623651,,,,,F,1,1,
,BAO_0000218,6532,N,Chlorohexidine coefficient for Actinomyces viscosus M-100,Expert,,50366,,9560,,1656.0,Actinomyces viscosus,,CHEMBL623652,,,,,F,1,1,
,BAO_0000218,6533,N,Chlorohexidine coefficient for Actinomyces viscosus M-626,Intermediate,,50366,,9560,,1656.0,Actinomyces viscosus,,CHEMBL623653,,,,,F,1,1,
,BAO_0000218,6534,N,Chlorohexidine coefficient for Actinomyces viscosus T14V,Intermediate,,50366,,9560,,1656.0,Actinomyces viscosus,,CHEMBL623654,,,,,F,1,1,
,BAO_0000218,6535,N,Plaque bactericidal index against Actinomyces viscosus 8A06,Intermediate,,50366,,9560,,1656.0,Actinomyces viscosus,,CHEMBL623655,,,,,F,1,1,
,BAO_0000218,6536,N,Plaque bactericidal index against Actinomyces viscosus M-100,Intermediate,,50366,,9560,,1656.0,Actinomyces viscosus,,CHEMBL623656,,,,,F,1,1,
,BAO_0000218,6537,N,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,Expert,,50366,,9560,,1656.0,Actinomyces viscosus,,CHEMBL623657,,,,,F,1,1,
,BAO_0000218,6538,N,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",Intermediate,,50366,,9560,,1656.0,Actinomyces viscosus,,CHEMBL623658,,,,,F,1,1,
,BAO_0000218,6539,N,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",Intermediate,,50366,,9560,,1656.0,Actinomyces viscosus,,CHEMBL623659,,,,,F,1,1,
,BAO_0000218,6540,N,Plaque bactericidal index against Actinomyces viscosus 626,Intermediate,,50366,,9560,,1656.0,Actinomyces viscosus,,CHEMBL623660,,,,,F,1,1,
,BAO_0000218,6541,N,Plaque bactericidal index against Actinomyces viscosus T14V,Intermediate,,50366,,9560,,1656.0,Actinomyces viscosus,,CHEMBL623661,,,,,F,1,1,
,BAO_0000218,6542,N,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,Intermediate,,50535,,10986,,6277.0,Acanthocheilonema viteae,,CHEMBL875281,,,,,F,1,1,
,BAO_0000218,6543,N,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,Intermediate,,50535,,10986,,6277.0,Acanthocheilonema viteae,,CHEMBL623662,,,,,F,1,1,
,BAO_0000218,6544,N,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,Intermediate,,50535,,10986,,6277.0,Acanthocheilonema viteae,,CHEMBL623663,,,,,F,1,1,
,BAO_0000218,6545,N,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,Intermediate,,50535,,10986,,6277.0,Acanthocheilonema viteae,,CHEMBL623664,,,,,F,1,1,
,BAO_0000218,6546,N,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,Intermediate,,50535,,10986,,6277.0,Acanthocheilonema viteae,,CHEMBL623665,,,,,F,1,1,
,BAO_0000219,6547,N,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,Intermediate,165.0,80023,,10708,,9606.0,Homo sapiens,,CHEMBL621856,A673,,,,F,1,1,
,BAO_0000219,6548,N,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,Intermediate,645.0,80661,,10708,,9606.0,Homo sapiens,,CHEMBL620432,A704,,,,F,1,1,
,BAO_0000219,6549,U,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,Autocuration,,22226,,416,,10116.0,Rattus norvegicus,,CHEMBL620433,,,,,F,1,0,
,BAO_0000219,6550,N,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,Intermediate,625.0,80024,,14354,,10090.0,Mus musculus,,CHEMBL620434,A9,,,,F,1,1,
,BAO_0000219,6551,N,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,Intermediate,625.0,80024,,14354,,10090.0,Mus musculus,,CHEMBL620435,A9,,,,F,1,1,
,BAO_0000219,6552,N,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,Intermediate,625.0,80024,,5116,,9606.0,Homo sapiens,,CHEMBL620436,A9,,,,F,1,1,
,BAO_0000219,6553,N,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,Intermediate,625.0,80024,,5116,,9606.0,Homo sapiens,,CHEMBL876597,A9,,,,F,1,1,
,BAO_0000219,6554,N,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,Expert,874.0,81037,,15694,,9606.0,Homo sapiens,,CHEMBL620437,Human ovarian carcinoma cell line,,,,F,1,1,
,BAO_0000219,6555,N,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",Expert,625.0,80024,,13038,,10090.0,Mus musculus,,CHEMBL620438,A9,,,,F,1,1,
,BAO_0000219,6556,N,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,Expert,625.0,80024,,13038,,10090.0,Mus musculus,,CHEMBL620439,A9,,,,F,1,1,
,BAO_0000219,6557,N,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,Expert,625.0,80024,,10923,,10090.0,Mus musculus,,CHEMBL619657,A9,,,,F,1,1,
,BAO_0000219,6558,N,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,Intermediate,625.0,80024,,10923,,10090.0,Mus musculus,,CHEMBL619658,A9,,,,F,1,1,
,BAO_0000219,6559,N,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,Intermediate,625.0,80024,,10923,,10090.0,Mus musculus,,CHEMBL619659,A9,,,,F,1,1,
,BAO_0000019,6560,H,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",Expert,,10649,,10923,,,,,CHEMBL619660,,,,,F,1,8,
,BAO_0000219,6561,N,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,Intermediate,625.0,80024,,10923,,10090.0,Mus musculus,,CHEMBL619661,A9,,,,F,1,1,
,BAO_0000219,6562,N,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,Intermediate,625.0,80024,,10923,,10090.0,Mus musculus,,CHEMBL619662,A9,,,,F,1,1,
,BAO_0000219,6563,N,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,Intermediate,975.0,80663,,8158,,10029.0,Cricetulus griseus,,CHEMBL619663,AA6,,,,F,1,1,
,BAO_0000219,6564,U,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,Autocuration,,22226,,15494,,9606.0,Homo sapiens,,CHEMBL619664,,,,,F,1,0,
,BAO_0000219,6565,U,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",Autocuration,,22226,,15494,,9606.0,Homo sapiens,,CHEMBL619665,,,,,F,1,0,
,BAO_0000219,6566,N,Anti -HIV activity was measured against AA5/HIV-1(IIIB),Intermediate,974.0,80662,,12348,,9606.0,Homo sapiens,,CHEMBL883244,AA5,,,,F,1,1,
,BAO_0000219,6567,N,Cytotoxicity was measured against AA5/HIV-1(IIIB),Intermediate,974.0,80662,,12348,,9606.0,Homo sapiens,,CHEMBL884011,AA5,,,,F,1,1,
,BAO_0000219,6568,N,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,Intermediate,974.0,80662,,2726,,9606.0,Homo sapiens,,CHEMBL619666,AA5,,,,F,1,1,
,BAO_0000219,6569,N,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,Intermediate,379.0,80566,,2726,,9606.0,Homo sapiens,,CHEMBL619667,U-937,,,,F,1,1,
,BAO_0000219,6570,N,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,Intermediate,274.0,80578,,10747,,10029.0,Cricetulus griseus,,CHEMBL619668,UV4,,,,F,1,1,
,BAO_0000219,6571,N,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",Expert,185.0,80089,,11005,,10029.0,Cricetulus griseus,,CHEMBL619669,CHO-AA8,,,,F,1,1,
,BAO_0000219,6572,N,Average intracellular compound concentration when the hypoxic SER=1.6,Intermediate,185.0,80089,,12687,,10029.0,Cricetulus griseus,,CHEMBL876608,CHO-AA8,,,,F,1,1,
,BAO_0000219,6573,N,Average intracellular compound concentration when the hypoxic SER=1.6.,Intermediate,185.0,80089,,12687,,10029.0,Cricetulus griseus,,CHEMBL619670,CHO-AA8,,,,F,1,1,
,BAO_0000219,6574,N,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,Intermediate,185.0,80089,,12687,,10029.0,Cricetulus griseus,,CHEMBL619671,CHO-AA8,,,,F,1,1,
,BAO_0000219,6575,N,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,Intermediate,185.0,80089,,12687,,10029.0,Cricetulus griseus,,CHEMBL619672,CHO-AA8,,,,F,1,1,
,BAO_0000219,6576,N,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,Intermediate,185.0,80089,,12687,,10029.0,Cricetulus griseus,,CHEMBL619673,CHO-AA8,,,,F,1,1,
,BAO_0000219,6577,N,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",Intermediate,185.0,80089,,13436,,10029.0,Cricetulus griseus,,CHEMBL619674,CHO-AA8,,,,F,1,1,
,BAO_0000219,6578,N,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",Intermediate,185.0,80089,,13435,,10029.0,Cricetulus griseus,,CHEMBL619675,CHO-AA8,,,,F,1,1,
,BAO_0000219,6579,N,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,Intermediate,185.0,80089,,13302,,10029.0,Cricetulus griseus,,CHEMBL619676,CHO-AA8,,,,F,1,1,
,BAO_0000219,6580,N,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,Intermediate,185.0,80089,,12687,,10029.0,Cricetulus griseus,,CHEMBL619677,CHO-AA8,,,,F,1,1,
,BAO_0000219,6581,N,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,Intermediate,185.0,80089,,12687,,10029.0,Cricetulus griseus,,CHEMBL619678,CHO-AA8,,,,A,1,1,
,BAO_0000219,6582,N,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,Intermediate,185.0,80089,,12687,,10029.0,Cricetulus griseus,,CHEMBL619679,CHO-AA8,,,,A,1,1,
,BAO_0000219,6583,N,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,Expert,185.0,80089,,12878,,10029.0,Cricetulus griseus,,CHEMBL619680,CHO-AA8,,,,A,1,1,
,BAO_0000219,6584,N,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,Intermediate,185.0,80089,,12878,,10029.0,Cricetulus griseus,,CHEMBL621457,CHO-AA8,,,,A,1,1,
,BAO_0000219,6585,N,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,Expert,185.0,80089,,14367,,10029.0,Cricetulus griseus,,CHEMBL876609,CHO-AA8,,,,F,1,1,
,BAO_0000219,6586,N,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,Intermediate,185.0,80089,,14367,,10029.0,Cricetulus griseus,,CHEMBL621458,CHO-AA8,,,,F,1,1,
,BAO_0000219,6587,N,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,Expert,185.0,80089,,12398,,36483.0,hampster,,CHEMBL621459,CHO-AA8,,,,F,1,1,
,BAO_0000219,6588,N,Aerobic growth inhibition in Chinese hamster cell line AA8,Expert,185.0,80089,,12878,,10029.0,Cricetulus griseus,,CHEMBL621460,CHO-AA8,,,,F,1,1,
,BAO_0000219,6589,N,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,Expert,185.0,80089,,13820,,10029.0,Cricetulus griseus,,CHEMBL621461,CHO-AA8,,,,F,1,1,
,BAO_0000219,6590,N,Inhibition of growth under aerobic conditions in AA8 cells,Expert,185.0,80089,,13436,,10029.0,Cricetulus griseus,,CHEMBL621462,CHO-AA8,,,,F,1,1,
,BAO_0000218,6591,N,Oral bioavailability in dog (dose 10 mg/kg),Intermediate,,50588,,6084,,9615.0,Canis lupus familiaris,,CHEMBL621463,,,In vivo,,A,1,1,
,BAO_0000218,6592,N,Oral bioavailability in dog at 10 mg/kg of the compound,Intermediate,,50588,,5711,,9615.0,Canis lupus familiaris,,CHEMBL621464,,,In vivo,,A,1,1,
,BAO_0000218,6593,N,Oral bioavailability in dog (dose 5 uM/kg),Intermediate,,50588,,4353,,9615.0,Canis lupus familiaris,,CHEMBL621465,,,In vivo,,A,1,1,
,BAO_0000218,6594,N,Oral bioavailability in dog (dose 5 uM/kg),Intermediate,,50588,,4353,,9615.0,Canis lupus familiaris,,CHEMBL621466,,,In vivo,,A,1,1,
,BAO_0000218,6595,N,Oral bioavailability in dog (mongrel),Intermediate,,50588,,17800,,9615.0,Canis lupus familiaris,,CHEMBL621467,,,In vivo,,A,1,1,
,BAO_0000218,6596,N,Oral bioavailability in dog (dose 10 mg/kg),Intermediate,,50588,,3994,,9615.0,Canis lupus familiaris,,CHEMBL621468,,,In vivo,,A,1,1,
,BAO_0000218,6597,N,Oral bioavailability in dog (dose 10 mg/kg),Intermediate,,50588,,3994,,9615.0,Canis lupus familiaris,,CHEMBL876734,,,In vivo,,F,1,1,
,BAO_0000218,6598,N,Bioavailability in dog,Intermediate,,50588,,5145,,9615.0,Canis lupus familiaris,,CHEMBL618476,,,In vivo,,A,1,1,
,BAO_0000218,6599,N,Bioavailability in dog (dose 1 mg/kg i.v.),Intermediate,,50588,,16452,,9615.0,Canis lupus familiaris,,CHEMBL618477,,,In vivo,,A,1,1,
,BAO_0000218,6600,N,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),Intermediate,,50588,,16452,,9615.0,Canis lupus familiaris,,CHEMBL618478,,,In vivo,,A,1,1,
,BAO_0000218,6601,N,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,Intermediate,,50588,,5983,,9615.0,Canis lupus familiaris,,CHEMBL618479,,,In vivo,,A,1,1,
,BAO_0000218,6602,N,Bioavailability in dog,Intermediate,,50588,,4273,,9615.0,Canis lupus familiaris,,CHEMBL618480,,,In vivo,,A,1,1,
,BAO_0000218,6603,N,Bioavailability in dog (dose 3-10 mg/kg),Intermediate,,50588,,12500,,9615.0,Canis lupus familiaris,,CHEMBL618481,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6604,N,The compound was tested for bioavailability of compound in plasma of dog; Complete,Intermediate,,50588,,12500,1969.0,9615.0,Canis lupus familiaris,,CHEMBL618482,,,In vivo,,A,1,1,
,BAO_0000218,6605,N,Oral bioavailability in dog,Intermediate,,50588,,3639,,9615.0,Canis lupus familiaris,,CHEMBL618483,,,In vivo,,A,1,1,
,BAO_0000218,6606,N,Oral bioavailability in dog,Intermediate,,50588,,3880,,9615.0,Canis lupus familiaris,,CHEMBL618484,,,In vivo,,A,1,1,
,BAO_0000218,6607,N,Bioavailability in dog,Intermediate,,50588,,4838,,9615.0,Canis lupus familiaris,,CHEMBL618485,,,In vivo,,A,1,1,
,BAO_0000218,6608,N,oral bioavailability was measured in dogs,Intermediate,,50588,,15600,,9615.0,Canis lupus familiaris,,CHEMBL618486,,,In vivo,,A,1,1,
,BAO_0000218,6609,N,Compound was tested for plasma protein binding in dog; Not determined,Intermediate,,50588,,17248,,9615.0,Canis lupus familiaris,,CHEMBL618487,,,,,A,1,1,
,BAO_0000218,6610,N,Compound was tested for plasma protein binding of dog,Intermediate,,50588,,17248,,9615.0,Canis lupus familiaris,,CHEMBL618488,,,,,A,1,1,
,BAO_0000218,6611,N,Compound was tested for plasma protein binding of dog; Not determined,Intermediate,,50588,,17248,,9615.0,Canis lupus familiaris,,CHEMBL876735,,,,,A,1,1,
,BAO_0000218,6612,N,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,Intermediate,,50588,,17443,,9615.0,Canis lupus familiaris,,CHEMBL618489,,,,,A,1,1,
,BAO_0000218,6613,N,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,Intermediate,,50588,,4186,,9615.0,Canis lupus familiaris,,CHEMBL618490,,,In vivo,,A,1,1,
,BAO_0000218,6614,N,Half life was determined,Intermediate,,50588,,3749,,9615.0,Canis lupus familiaris,,CHEMBL618491,,,,,A,1,1,
,BAO_0000218,6615,N,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,Intermediate,,50588,,3249,,9615.0,Canis lupus familiaris,,CHEMBL618492,,,In vivo,,A,1,1,
,BAO_0000218,6616,N,Half life was evaluated in dog,Intermediate,,50588,,3022,,9615.0,Canis lupus familiaris,,CHEMBL873354,,,,,A,1,1,
,BAO_0000218,6617,N,Half life was determined,Intermediate,,50588,,3749,,9615.0,Canis lupus familiaris,,CHEMBL618493,,,,,A,1,1,
,BAO_0000218,6618,N,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),Intermediate,,50588,,2517,,9615.0,Canis lupus familiaris,,CHEMBL618494,,,In vivo,,A,1,1,
Heart,BAO_0000218,6619,N,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),Intermediate,,50588,,2517,948.0,9615.0,Canis lupus familiaris,,CHEMBL618495,,,In vivo,,A,1,1,
Kidney,BAO_0000218,6620,N,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),Intermediate,,50588,,2517,2113.0,9615.0,Canis lupus familiaris,,CHEMBL618496,,,In vivo,,A,1,1,
Liver,BAO_0000218,6621,N,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),Intermediate,,50588,,2517,2107.0,9615.0,Canis lupus familiaris,,CHEMBL618497,,,In vivo,,A,1,1,
Lung,BAO_0000218,6622,N,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),Intermediate,,50588,,2517,2048.0,9615.0,Canis lupus familiaris,,CHEMBL618498,,,In vivo,,A,1,1,
Spleen,BAO_0000218,6623,N,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),Intermediate,,50588,,2517,2106.0,9615.0,Canis lupus familiaris,,CHEMBL618499,,,In vivo,,A,1,1,
,BAO_0000218,6624,N,LogP in dog,Intermediate,,50588,,3639,,9615.0,Canis lupus familiaris,,CHEMBL876736,,,,,A,1,1,
,BAO_0000218,6625,N,Partition coefficient (logP),Intermediate,,50588,,6227,,9615.0,Canis lupus familiaris,,CHEMBL618500,,,,,A,1,1,
,BAO_0000218,6626,N,Partition coefficient in dog,Intermediate,,50588,,6227,,9615.0,Canis lupus familiaris,,CHEMBL857831,,,,,A,1,1,
,BAO_0000218,6627,N,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,Intermediate,,50588,,17764,,9615.0,Canis lupus familiaris,,CHEMBL618501,,,In vivo,,A,1,1,
,BAO_0000218,6628,N,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),Intermediate,,50588,,4809,,9615.0,Canis lupus familiaris,,CHEMBL618502,,,In vivo,,A,1,1,
,BAO_0000218,6629,N,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,Intermediate,,50588,,5600,,9615.0,Canis lupus familiaris,,CHEMBL618503,,,,,A,1,1,
,BAO_0000218,6630,N,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),Intermediate,,50588,,14294,,9615.0,Canis lupus familiaris,,CHEMBL618504,,,,,A,1,1,
,BAO_0000218,6631,N,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),Intermediate,,50588,,14294,,9615.0,Canis lupus familiaris,,CHEMBL618505,,,,,A,1,1,
,BAO_0000218,6632,N,Metabolism of compound in dog S9 microsomes; Trace,Intermediate,,50588,,14294,,9615.0,Canis lupus familiaris,,CHEMBL618506,,,,,A,1,1,
Liver,BAO_0000218,6633,N,In vitro metabolic potential in dog liver microsomes,Intermediate,,50588,,6251,2107.0,9615.0,Canis lupus familiaris,,CHEMBL618507,,,,,A,1,1,
,BAO_0000218,6634,N,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,Intermediate,,50588,,3748,,9615.0,Canis lupus familiaris,,CHEMBL876737,,,In vivo,,A,1,1,
,BAO_0000218,6635,N,Oral bioavailability in dog,Intermediate,,50588,,2713,,9615.0,Canis lupus familiaris,,CHEMBL618508,,,In vivo,,A,1,1,
,BAO_0000218,6636,N,Oral bioavailability in dog,Intermediate,,50588,,6512,,9615.0,Canis lupus familiaris,,CHEMBL618509,,,In vivo,,A,1,1,
,BAO_0000218,6637,N,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Intermediate,,50588,,6679,,9615.0,Canis lupus familiaris,,CHEMBL618510,,,In vivo,,A,1,1,
,BAO_0000218,6638,N,The compound was tested for bioavailability in dogs,Intermediate,,50588,,3749,,9615.0,Canis lupus familiaris,,CHEMBL618511,,,In vivo,,A,1,1,
,BAO_0000218,6639,N,The compound was tested for oral bioavailability in dogs,Intermediate,,50588,,3749,,9615.0,Canis lupus familiaris,,CHEMBL618512,,,In vivo,,A,1,1,
,BAO_0000218,6640,N,Oral bioavailability in dog,Intermediate,,50588,,6742,,9615.0,Canis lupus familiaris,,CHEMBL618513,,,In vivo,,A,1,1,
,BAO_0000218,6641,N,Compound was tested for percent protein binding (PB) in dog,Intermediate,,50588,,6227,,9615.0,Canis lupus familiaris,,CHEMBL618514,,,,,A,1,1,
,BAO_0000218,6642,N,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,Intermediate,,50588,,6874,,9615.0,Canis lupus familiaris,,CHEMBL620052,,,,,A,1,1,
Plasma,BAO_0000218,6643,N,Compound was evaluated for plasma clearance.,Intermediate,,50588,,2877,1969.0,9615.0,Canis lupus familiaris,,CHEMBL620053,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6644,N,The compound was tested for plasma clearance in dog,Intermediate,,50588,,12500,1969.0,9615.0,Canis lupus familiaris,,CHEMBL620054,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6645,N,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,Intermediate,,50588,,12500,1969.0,9615.0,Canis lupus familiaris,,CHEMBL620055,,,In vivo,,A,1,1,
,BAO_0000218,6646,N,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,Intermediate,,50588,,4709,,9615.0,Canis lupus familiaris,,CHEMBL620056,,,,,A,1,1,
Liver,BAO_0000218,6647,N,In vitro relative rate of metabolism was determined in dog liver microsomes,Intermediate,,50588,,5542,2107.0,9615.0,Canis lupus familiaris,,CHEMBL620057,,,,,A,1,1,
,BAO_0000218,6648,N,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,Intermediate,,50588,,17594,,9615.0,Canis lupus familiaris,,CHEMBL618939,,,In vivo,,A,1,1,
,BAO_0000218,6649,N,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,Intermediate,,50588,,2652,,9615.0,Canis lupus familiaris,,CHEMBL618940,,,In vivo,,A,1,1,
,BAO_0000218,6650,N,Half life after intravenous administration in dogs at 1.2 uM/kg,Intermediate,,50588,,17764,,9615.0,Canis lupus familiaris,,CHEMBL618941,,,In vivo,,A,1,1,
Lung,BAO_0000218,6651,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,Intermediate,42.0,50594,,6599,2048.0,10090.0,Mus musculus,,CHEMBL624473,CCRF S-180,,,,A,1,1,
Lung,BAO_0000218,6652,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,Intermediate,42.0,50594,,6599,2048.0,10090.0,Mus musculus,,CHEMBL624474,CCRF S-180,,,,A,1,1,
Lung,BAO_0000218,6653,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,Intermediate,42.0,50594,,6599,2048.0,10090.0,Mus musculus,,CHEMBL624475,CCRF S-180,,,,A,1,1,
,BAO_0000218,6654,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,Intermediate,42.0,50594,,6599,,10090.0,Mus musculus,,CHEMBL624476,CCRF S-180,,,,A,1,1,
,BAO_0000218,6655,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,Intermediate,42.0,50594,,6599,,10090.0,Mus musculus,,CHEMBL623478,CCRF S-180,,,,A,1,1,
,BAO_0000218,6656,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,Intermediate,42.0,50594,,6599,,10090.0,Mus musculus,,CHEMBL623479,CCRF S-180,,,,A,1,1,
,BAO_0000218,6657,N,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,Intermediate,42.0,50594,,6599,,10090.0,Mus musculus,,CHEMBL623480,CCRF S-180,,,,A,1,1,
,BAO_0000218,6658,N,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,Intermediate,42.0,50594,,6599,,10090.0,Mus musculus,,CHEMBL623481,CCRF S-180,,,,A,1,1,
Brain,BAO_0000218,6659,N,C2 in brain of mice at the oral dose of 50 mg/kg,Intermediate,,50594,,17641,955.0,10090.0,Mus musculus,,CHEMBL623482,,,,,A,1,1,
Kidney,BAO_0000218,6660,N,C2 in kidney of mice at the oral dose of 50 mg/kg,Intermediate,,50594,,17641,2113.0,10090.0,Mus musculus,,CHEMBL623483,,,,,A,1,1,
Liver,BAO_0000218,6661,N,C2 in liver of mice at the oral dose of 50 mg/kg,Intermediate,,50594,,17641,2107.0,10090.0,Mus musculus,,CHEMBL623484,,,,,A,1,1,
Lung,BAO_0000218,6662,N,C2 in lungs of mice at the oral dose of 50 mg/kg,Intermediate,,50594,,17641,2048.0,10090.0,Mus musculus,,CHEMBL623485,,,,,A,1,1,
Spleen,BAO_0000218,6663,N,C2 in spleen of mice at the oral dose of 50 mg/kg,Intermediate,,50594,,17641,2106.0,10090.0,Mus musculus,,CHEMBL623486,,,,,A,1,1,
,BAO_0000218,6664,N,Plasma clearance in mouse,Intermediate,,50594,,17852,,10090.0,Mus musculus,,CHEMBL623487,,,In vivo,,A,1,1,
,BAO_0000218,6665,N,Clearance of compound after intravenous administration in mice at 24 uM/kg,Intermediate,,50594,,17764,,10090.0,Mus musculus,,CHEMBL623488,,,In vivo,,A,1,1,
,BAO_0000218,6666,N,Clearance from mouse blood following i.v. administration of 10 mg/kg,Intermediate,,50594,,17837,,10090.0,Mus musculus,,CHEMBL623489,,,In vivo,,A,1,1,
,BAO_0000218,6667,N,Clearance was evaluated in mice after intravenous administration,Intermediate,,50594,,2675,,10090.0,Mus musculus,,CHEMBL875157,,,In vivo,,A,1,1,
,BAO_0000218,6668,N,Clearance was evaluated in mice after oral administration,Intermediate,,50594,,2675,,10090.0,Mus musculus,,CHEMBL623490,,,In vivo,,A,1,1,
,BAO_0000218,6669,N,Pharmacokinetic property (Plasma clearance) was measured in mouse,Intermediate,,50594,,4239,,10090.0,Mus musculus,,CHEMBL623491,,,In vivo,,A,1,1,
,BAO_0000218,6670,N,Plasma clearance of compound was determined at 40 mg/Kg,Intermediate,,50594,,17753,,10090.0,Mus musculus,,CHEMBL623492,,,In vivo,,A,1,1,
,BAO_0000218,6671,N,Plasma clearance of at 24 mg/Kg,Intermediate,,50594,,17753,,10090.0,Mus musculus,,CHEMBL623493,,,In vivo,,A,1,1,
,BAO_0000218,6672,N,Plasma clearance at 24 mg/Kg,Intermediate,,50594,,17753,,10090.0,Mus musculus,,CHEMBL623494,,,In vivo,,A,1,1,
,BAO_0000218,6673,N,Plasma clearance at 5 mg/Kg,Intermediate,,50594,,17753,,10090.0,Mus musculus,,CHEMBL623495,,,In vivo,,A,1,1,
,BAO_0000218,6674,N,Plasma clearance in mice,Intermediate,,50594,,5727,,10090.0,Mus musculus,,CHEMBL623496,,,In vivo,,A,1,1,
,BAO_0000218,6675,N,Plasma clearance value upon iv administration in mouse,Intermediate,,50594,,2862,,10090.0,Mus musculus,,CHEMBL623497,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6676,N,Total plasma clearance in mice,Intermediate,,50594,,5980,1969.0,10090.0,Mus musculus,,CHEMBL623498,,,In vivo,,A,1,1,
,BAO_0000218,6677,N,Clearance in mouse,Intermediate,,50594,,17592,,10090.0,Mus musculus,,CHEMBL623499,,,In vivo,,A,1,1,
,BAO_0000218,6678,N,Clearance value was determined,Intermediate,,50594,,17718,,10090.0,Mus musculus,,CHEMBL623500,,,In vivo,,A,1,1,
,BAO_0000218,6679,N,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,Intermediate,,50594,,16597,,10090.0,Mus musculus,,CHEMBL623501,,,In vivo,,A,1,1,
,BAO_0000100,6680,U,Calculated partition coefficient (clogP),Intermediate,,22229,,17384,,,,,CHEMBL875158,,,,,P,1,0,
,BAO_0000218,6681,N,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,Intermediate,,50594,,6062,,10090.0,Mus musculus,,CHEMBL623502,,,In vivo,,A,1,1,
,BAO_0000218,6682,N,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,Intermediate,,50594,,17734,,10090.0,Mus musculus,,CHEMBL623503,,,In vivo,,A,1,1,
,BAO_0000218,6683,N,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Intermediate,,50594,,6348,,10090.0,Mus musculus,,CHEMBL623504,,,In vivo,,A,1,1,
,BAO_0000218,6684,N,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,Intermediate,,50594,,5969,,10090.0,Mus musculus,,CHEMBL623505,,,In vivo,,A,1,1,
,BAO_0000218,6685,N,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,Intermediate,,50594,,5969,,10090.0,Mus musculus,,CHEMBL623506,,,In vivo,,A,1,1,
,BAO_0000218,6686,N,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,Intermediate,,50594,,5969,,10090.0,Mus musculus,,CHEMBL623507,,,In vivo,,A,1,1,
,BAO_0000218,6687,N,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,Intermediate,,50594,,16597,,10090.0,Mus musculus,,CHEMBL623508,,,In vivo,,A,1,1,
,BAO_0000218,6688,N,Cmax after oral administration at 30 mg/kg in ICR mouse,Intermediate,,50594,,5781,,10090.0,Mus musculus,,CHEMBL623509,,,In vivo,,A,1,1,
,BAO_0000218,6689,N,Cmax after peroral administration in mice at 2.4 uM/kg,Intermediate,,50594,,17764,,10090.0,Mus musculus,,CHEMBL875159,,,In vivo,,A,1,1,
Brain,BAO_0000218,6690,N,Cmax in brain of mice at the oral dose of 50 mg/kg,Intermediate,,50594,,17641,955.0,10090.0,Mus musculus,,CHEMBL623510,,,In vivo,,A,1,1,
Kidney,BAO_0000218,6691,N,Cmax in kidney of mice at the oral dose of 50 mg/kg,Intermediate,,50594,,17641,2113.0,10090.0,Mus musculus,,CHEMBL623511,,,In vivo,,A,1,1,
Liver,BAO_0000218,6692,N,Cmax in liver of mice at the oral dose of 50 mg/kg,Intermediate,,50594,,17641,2107.0,10090.0,Mus musculus,,CHEMBL623512,,,In vivo,,A,1,1,
Lung,BAO_0000218,6693,N,Cmax in lungs of mice at the oral dose of 50 mg/kg,Intermediate,,50594,,17641,2048.0,10090.0,Mus musculus,,CHEMBL623513,,,In vivo,,A,1,1,
,BAO_0000218,6694,N,Cmax in mice at 18 uM/kg i.p. administration,Intermediate,,50594,,17764,,10090.0,Mus musculus,,CHEMBL623514,,,In vivo,,F,1,1,
,BAO_0000218,6695,N,Cmax in mice at 23 uM/kg i.v. administration,Intermediate,,50594,,17764,,10090.0,Mus musculus,,CHEMBL622609,,,In vivo,,F,1,1,
,BAO_0000218,6696,N,Cmax in mice at 24 uM/kg i.p. administration,Intermediate,,50594,,17764,,10090.0,Mus musculus,,CHEMBL622610,,,In vivo,,F,1,1,
,BAO_0000218,6697,N,Cmax in mice at 25 uM/kg i.p. administration,Intermediate,,50594,,17764,,10090.0,Mus musculus,,CHEMBL621823,,,In vivo,,F,1,1,
,BAO_0000218,6698,N,Cmax in mice at 26 uM/kg i.p. administration,Intermediate,,50594,,17764,,10090.0,Mus musculus,,CHEMBL621824,,,In vivo,,F,1,1,
Spleen,BAO_0000218,6699,N,Cmax in spleen of mice at the oral dose of 50 mg/kg,Intermediate,,50594,,17641,2106.0,10090.0,Mus musculus,,CHEMBL621825,,,In vivo,,A,1,1,
,BAO_0000218,6700,N,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,Intermediate,,50594,,16597,,10090.0,Mus musculus,,CHEMBL621826,,,In vivo,,A,1,1,
,BAO_0000218,6701,N,Cmax value at a dose of 10 mg/kg peroral administration in mice.,Intermediate,,50594,,16597,,10090.0,Mus musculus,,CHEMBL621827,,,In vivo,,A,1,1,
,BAO_0000218,6702,N,Cmax value was determined,Intermediate,,50594,,5727,,10090.0,Mus musculus,,CHEMBL621828,,,In vivo,,A,1,1,
,BAO_0000218,6703,N,Cmax value in IRC mice,Intermediate,,50594,,5951,,10090.0,Mus musculus,,CHEMBL621829,,,In vivo,,A,1,1,
,BAO_0000218,6704,N,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,Intermediate,,50594,,5506,,10090.0,Mus musculus,,CHEMBL621830,,,In vivo,,A,1,1,
,BAO_0000218,6705,N,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,Intermediate,,50594,,5506,,10090.0,Mus musculus,,CHEMBL621831,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6706,N,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,Intermediate,,50594,,14239,1969.0,10090.0,Mus musculus,,CHEMBL621832,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6707,N,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",Intermediate,,50594,,4890,1969.0,10090.0,Mus musculus,,CHEMBL624579,,,In vivo,,A,1,1,
,BAO_0000218,6708,N,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,Intermediate,,50594,,429,,10090.0,Mus musculus,,CHEMBL624580,,,In vivo,,A,1,1,
,BAO_0000218,6709,N,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,Intermediate,,50535,,10986,,6277.0,Acanthocheilonema viteae,,CHEMBL624581,,,,,F,1,1,
,BAO_0000218,6710,N,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,Intermediate,,50535,,10986,,6277.0,Acanthocheilonema viteae,,CHEMBL624582,,,,,F,1,1,
,BAO_0000218,6711,N,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,Intermediate,,50535,,10986,,6277.0,Acanthocheilonema viteae,,CHEMBL624583,,,,,F,1,1,
,BAO_0000219,6712,N,Inhibitory activity against human tumor cell line A0375 melanoma.,Intermediate,455.0,80018,,13227,,9606.0,Homo sapiens,,CHEMBL624584,A-375,,,,F,1,1,
,BAO_0000249,6713,D,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,Expert,,12512,,4481,,10116.0,Rattus norvegicus,,CHEMBL624585,,,,Brain membranes,B,1,9,
,BAO_0000019,6714,D,Forskolin-induced cAMP production at human A1 adenosine receptor,Expert,,114,,16931,,9606.0,Homo sapiens,,CHEMBL875165,,,,,F,1,9,
,BAO_0000219,6715,H,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,Autocuration,449.0,114,,3850,,,,,CHEMBL619490,CHO,,,,F,1,8,
,BAO_0000219,6716,H,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,Autocuration,449.0,114,,3850,,,,,CHEMBL619491,CHO,,,,F,1,8,
,BAO_0000219,6717,H,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,Expert,449.0,114,,3850,,,,,CHEMBL619492,CHO,,,,F,1,8,
,BAO_0000219,6718,H,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,Expert,449.0,114,,3850,,,,,CHEMBL619493,CHO,,,,F,1,8,
,BAO_0000219,6719,H,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,Autocuration,449.0,114,,3850,,,,,CHEMBL619494,CHO,,,,F,1,8,
,BAO_0000219,6720,H,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,Autocuration,449.0,114,,3850,,,,,CHEMBL619495,CHO,,,,F,1,8,
,BAO_0000219,6721,H,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,Autocuration,449.0,114,,3850,,,,,CHEMBL619496,CHO,,,,F,1,8,
,BAO_0000219,6722,D,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,Expert,449.0,114,,3850,,9606.0,Homo sapiens,,CHEMBL619497,CHO,,,,F,1,9,
,BAO_0000219,6723,H,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,Autocuration,449.0,114,,3850,,,,,CHEMBL619498,CHO,,,,F,1,8,
,BAO_0000219,6724,H,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,Autocuration,449.0,114,,3850,,,,,CHEMBL619499,CHO,,,,F,1,8,
,BAO_0000219,6725,H,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,Expert,449.0,114,,3850,,,,,CHEMBL619500,CHO,,,,F,1,8,
,BAO_0000219,6726,H,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,Autocuration,449.0,114,,3850,,,,,CHEMBL619501,CHO,,,,F,1,8,
,BAO_0000219,6727,H,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,Expert,449.0,114,,3850,,,,,CHEMBL619502,CHO,,,,F,1,8,
,BAO_0000219,6728,H,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,Autocuration,449.0,114,,3850,,,,,CHEMBL619503,CHO,,,,F,1,8,
,BAO_0000219,6729,H,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,Autocuration,449.0,114,,3850,,,,,CHEMBL619504,CHO,,,,F,1,8,
,BAO_0000219,6730,H,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,Autocuration,449.0,114,,3850,,,,,CHEMBL621298,CHO,,,,F,1,8,
,BAO_0000219,6731,H,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,Expert,449.0,114,,3850,,,,,CHEMBL621299,CHO,,,,F,1,8,
,BAO_0000219,6732,H,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,Autocuration,449.0,114,,3850,,,,,CHEMBL621300,CHO,,,,F,1,8,
,BAO_0000219,6733,H,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,Autocuration,449.0,114,,3850,,,,,CHEMBL621301,CHO,,,,F,1,8,
,BAO_0000219,6734,H,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,Expert,449.0,114,,3850,,,,,CHEMBL621302,CHO,,,,F,1,8,
,BAO_0000219,6735,N,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,Intermediate,164.0,80013,,12680,,9986.0,Oryctolagus cuniculus,,CHEMBL621303,A10,,,,F,1,1,
,BAO_0000219,6736,U,In vitro potassium channel opening activity in A10 (smooth muscle) cells,Autocuration,164.0,22226,,1313,,10116.0,Rattus norvegicus,,CHEMBL621304,A10,,,,F,1,0,
,BAO_0000219,6737,U,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,Autocuration,164.0,22226,,1313,,10116.0,Rattus norvegicus,,CHEMBL621305,A10,,,,F,1,0,
,BAO_0000219,6738,N,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,Intermediate,164.0,80013,,17567,,10116.0,Rattus norvegicus,,CHEMBL621306,A10,,,,F,1,1,
,BAO_0000219,6739,N,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,Intermediate,164.0,80013,,17567,,10116.0,Rattus norvegicus,,CHEMBL618444,A10,,,,F,1,1,
,BAO_0000219,6740,N,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,Intermediate,164.0,80013,,11819,,10116.0,Rattus norvegicus,,CHEMBL618445,A10,,,,F,1,1,
,BAO_0000219,6741,N,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,Intermediate,185.0,80089,,13436,,10029.0,Cricetulus griseus,,CHEMBL618446,CHO-AA8,,,,F,1,1,
,BAO_0000219,6742,N,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,Intermediate,185.0,80089,,12687,,10029.0,Cricetulus griseus,,CHEMBL618447,CHO-AA8,,,,F,1,1,
,BAO_0000219,6743,N,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,Intermediate,185.0,80089,,12651,,10029.0,Cricetulus griseus,,CHEMBL618448,CHO-AA8,,,,F,1,1,
,BAO_0000219,6744,N,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,Intermediate,185.0,80089,,13300,,10029.0,Cricetulus griseus,,CHEMBL618449,CHO-AA8,,,,F,1,1,
,BAO_0000219,6745,N,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,Intermediate,185.0,80089,,15296,,10029.0,Cricetulus griseus,,CHEMBL618637,CHO-AA8,,,,F,1,1,
,BAO_0000219,6746,N,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",Intermediate,185.0,80089,,15328,,10029.0,Cricetulus griseus,,CHEMBL618638,CHO-AA8,,,,F,1,1,
,BAO_0000219,6747,N,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),Intermediate,185.0,80089,,13302,,10029.0,Cricetulus griseus,,CHEMBL618639,CHO-AA8,,,,F,1,1,
,BAO_0000219,6748,N,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",Expert,185.0,80089,,14367,,10029.0,Cricetulus griseus,,CHEMBL618640,CHO-AA8,,,,F,1,1,
,BAO_0000219,6749,N,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,Expert,185.0,80089,,17002,,10029.0,Cricetulus griseus,,CHEMBL618641,CHO-AA8,,,,F,1,1,
,BAO_0000219,6750,N,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,Intermediate,185.0,80089,,13436,,10029.0,Cricetulus griseus,,CHEMBL618642,CHO-AA8,,,,F,1,1,
,BAO_0000219,6751,N,Inhibitory activity against aerobic growth of AA8 cells.,Intermediate,185.0,80089,,13435,,10029.0,Cricetulus griseus,,CHEMBL618643,CHO-AA8,,,,F,1,1,
,BAO_0000219,6752,N,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,Intermediate,185.0,80089,,10503,,10029.0,Cricetulus griseus,,CHEMBL884013,CHO-AA8,,,,A,1,1,
,BAO_0000219,6753,N,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,Expert,185.0,80089,,10503,,10029.0,Cricetulus griseus,,CHEMBL622723,CHO-AA8,,,,F,1,1,
,BAO_0000219,6754,N,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,Intermediate,185.0,80089,,10503,,10029.0,Cricetulus griseus,,CHEMBL622724,CHO-AA8,,,,F,1,1,
,BAO_0000219,6755,N,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,Expert,185.0,80089,,15090,,10029.0,Cricetulus griseus,,CHEMBL622725,CHO-AA8,,,,F,1,1,
,BAO_0000219,6756,N,Cytotoxicity against AA8 cell line,Expert,185.0,80089,,10368,,10029.0,Cricetulus griseus,,CHEMBL622726,CHO-AA8,,,,F,1,1,
,BAO_0000219,6757,N,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),Intermediate,185.0,80089,,12651,,10029.0,Cricetulus griseus,,CHEMBL622727,CHO-AA8,,,,F,1,1,
,BAO_0000219,6758,N,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),Intermediate,185.0,80089,,12687,,10029.0,Cricetulus griseus,,CHEMBL622728,CHO-AA8,,,,A,1,1,
,BAO_0000219,6759,N,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),Intermediate,185.0,80089,,12687,,10029.0,Cricetulus griseus,,CHEMBL622729,CHO-AA8,,,,F,1,1,
,BAO_0000219,6760,N,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),Intermediate,185.0,80089,,12687,,10029.0,Cricetulus griseus,,CHEMBL622730,CHO-AA8,,,,A,1,1,
,BAO_0000219,6761,N,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,Intermediate,185.0,80089,,1890,,10029.0,Cricetulus griseus,,CHEMBL622731,CHO-AA8,,,,F,1,1,
,BAO_0000219,6762,N,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,Intermediate,185.0,80089,,10747,,10029.0,Cricetulus griseus,,CHEMBL622732,CHO-AA8,,,,F,1,1,
,BAO_0000219,6763,N,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,Intermediate,185.0,80089,,10747,,10029.0,Cricetulus griseus,,CHEMBL622733,CHO-AA8,,,,F,1,1,
,BAO_0000218,6764,U,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),Autocuration,,22224,,11616,,10029.0,Cricetulus griseus,,CHEMBL622734,,,,,F,1,0,
,BAO_0000219,6765,N,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,Expert,185.0,80089,,11616,,10029.0,Cricetulus griseus,,CHEMBL622735,CHO-AA8,,,,F,1,1,
,BAO_0000219,6766,U,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,Autocuration,185.0,22224,,3471,,10029.0,Cricetulus griseus,,CHEMBL618746,CHO-AA8,,,,F,1,0,
,BAO_0000219,6767,U,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,Autocuration,185.0,22224,,3471,,10029.0,Cricetulus griseus,,CHEMBL618747,CHO-AA8,,,,F,1,0,
,BAO_0000219,6768,U,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,Autocuration,185.0,22224,,3471,,10029.0,Cricetulus griseus,,CHEMBL620540,CHO-AA8,,,,F,1,0,
,BAO_0000219,6769,U,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,Autocuration,185.0,22224,,3471,,10029.0,Cricetulus griseus,,CHEMBL620541,CHO-AA8,,,,F,1,0,
,BAO_0000219,6770,U,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,Autocuration,185.0,22224,,3471,,10029.0,Cricetulus griseus,,CHEMBL620542,CHO-AA8,,,,F,1,0,
,BAO_0000219,6771,U,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,Autocuration,185.0,22224,,3471,,10029.0,Cricetulus griseus,,CHEMBL620543,CHO-AA8,,,,F,1,0,
,BAO_0000219,6772,U,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,Autocuration,185.0,22224,,3471,,10029.0,Cricetulus griseus,,CHEMBL618832,CHO-AA8,,,,F,1,0,
,BAO_0000219,6773,N,Concentration required to reduce AA8 cell survival by 10%,Expert,185.0,80089,,11616,,10029.0,Cricetulus griseus,,CHEMBL618833,CHO-AA8,,,,F,1,1,
,BAO_0000219,6774,U,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",Autocuration,185.0,22224,,2656,,10029.0,Cricetulus griseus,,CHEMBL618834,CHO-AA8,,,,F,1,0,
,BAO_0000219,6775,U,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,Autocuration,185.0,22224,,10518,,10029.0,Cricetulus griseus,,CHEMBL618835,CHO-AA8,,,,F,1,0,
,BAO_0000219,6776,U,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,Autocuration,185.0,22224,,10518,,10029.0,Cricetulus griseus,,CHEMBL618836,CHO-AA8,,,,F,1,0,
,BAO_0000219,6777,U,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,Autocuration,185.0,22224,,10518,,10029.0,Cricetulus griseus,,CHEMBL618837,CHO-AA8,,,,F,1,0,
,BAO_0000219,6778,U,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,Autocuration,185.0,22224,,10518,,10029.0,Cricetulus griseus,,CHEMBL618838,CHO-AA8,,,,F,1,0,
,BAO_0000219,6779,U,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,Autocuration,185.0,22224,,16156,,10029.0,Cricetulus griseus,,CHEMBL618839,CHO-AA8,,,,F,1,0,
,BAO_0000219,6780,U,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,Autocuration,185.0,22224,,2656,,10029.0,Cricetulus griseus,,CHEMBL618840,CHO-AA8,,,,F,1,0,
,BAO_0000019,6781,U,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",Autocuration,,22224,,11005,,10029.0,Cricetulus griseus,,CHEMBL618841,,,,,F,1,0,
,BAO_0000219,6782,U,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,Autocuration,185.0,22224,,11942,,10029.0,Cricetulus griseus,,CHEMBL618842,CHO-AA8,,,,F,1,0,
,BAO_0000219,6783,U,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,Autocuration,185.0,22224,,2128,,10029.0,Cricetulus griseus,,CHEMBL618843,CHO-AA8,,,,F,1,0,
,BAO_0000218,6784,N,Half life period after 15 mg/kg iv dose in Dogs,Intermediate,,50588,,16907,,9615.0,Canis lupus familiaris,,CHEMBL618844,,,In vivo,,A,1,1,
,BAO_0000218,6785,N,Half life period after 30 mg/kg po dose in Dogs,Intermediate,,50588,,16907,,9615.0,Canis lupus familiaris,,CHEMBL618845,,,In vivo,,A,1,1,
,BAO_0000218,6786,N,Half life was measured after oral 2b administration (tested in 6 dogs),Intermediate,,50588,,9579,,9615.0,Canis lupus familiaris,,CHEMBL618846,,,In vivo,,A,1,1,
,BAO_0000218,6787,N,Half life was measured in dog after oral 17b administration,Intermediate,,50588,,9579,,9615.0,Canis lupus familiaris,,CHEMBL618847,,,In vivo,,A,1,1,
,BAO_0000218,6788,N,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,Intermediate,,50588,,9579,,9615.0,Canis lupus familiaris,,CHEMBL618848,,,In vivo,,A,1,1,
,BAO_0000218,6789,N,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,Intermediate,,50588,,9579,,9615.0,Canis lupus familiaris,,CHEMBL618849,,,In vivo,,A,1,1,
,BAO_0000218,6790,N,Tmax value after 15 mg/kg iv dose in Dogs,Intermediate,,50588,,16907,,9615.0,Canis lupus familiaris,,CHEMBL618850,,,In vivo,,A,1,1,
,BAO_0000218,6791,N,Tmax value after 30 mg/kg po dose in Dogs,Intermediate,,50588,,16907,,9615.0,Canis lupus familiaris,,CHEMBL618851,,,In vivo,,A,1,1,
,BAO_0000218,6792,N,Compound was evaluated for its half life when administered intravenously in dog,Intermediate,,50588,,3184,,9615.0,Canis lupus familiaris,,CHEMBL873815,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6793,N,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),Intermediate,,50588,,5017,1969.0,9615.0,Canis lupus familiaris,,CHEMBL618852,,,In vivo,,A,1,1,
,BAO_0000218,6794,N,Elimination Half-life of compound was determined in dog,Intermediate,,50588,,6821,,9615.0,Canis lupus familiaris,,CHEMBL618853,,,,,A,1,1,
,BAO_0000218,6795,N,Half life of compound in dog following oral administration,Intermediate,,50588,,17839,,9615.0,Canis lupus familiaris,,CHEMBL618854,,,In vivo,,A,1,1,
,BAO_0000218,6796,N,Half life of compound was determined in dog,Intermediate,,50588,,17267,,9615.0,Canis lupus familiaris,,CHEMBL618855,,,,,A,1,1,
Blood,BAO_0000218,6797,N,Half life of compound was determined in dog blood,Intermediate,,50588,,4727,178.0,9615.0,Canis lupus familiaris,,CHEMBL618856,,,,,A,1,1,
,BAO_0000218,6798,N,Half life after oral and iv dosing in dogs,Intermediate,,50588,,5238,,9615.0,Canis lupus familiaris,,CHEMBL875827,,,In vivo,,A,1,1,
,BAO_0000218,6799,N,Half life in dogs in hours,Intermediate,,50588,,4942,,9615.0,Canis lupus familiaris,,CHEMBL618857,,,,,A,1,1,
,BAO_0000218,6800,N,Half life on i.v. administration of 2 mg/kg was measured in dog,Intermediate,,50588,,6505,,9615.0,Canis lupus familiaris,,CHEMBL618858,,,In vivo,,A,1,1,
,BAO_0000218,6801,N,t1/2 in dog after oral dose (1 mg/kg),Intermediate,,50588,,5130,,9615.0,Canis lupus familiaris,,CHEMBL618859,,,In vivo,,A,1,1,
,BAO_0000218,6802,N,Half life was evaluated in dog,Intermediate,,50588,,1475,,9615.0,Canis lupus familiaris,,CHEMBL618860,,,,,A,1,1,
,BAO_0000218,6803,N,Half life period of compound was determined after intravenous administration at 2 mg/kg,Intermediate,,50588,,17804,,9615.0,Canis lupus familiaris,,CHEMBL618861,,,In vivo,,A,1,1,
,BAO_0000218,6804,N,Half life period of compound was determined after peroral administration at 2 mg/kg,Intermediate,,50588,,17804,,9615.0,Canis lupus familiaris,,CHEMBL622539,,,In vivo,,A,1,1,
,BAO_0000218,6805,N,Half life period (10 mg/kg) was determined in dog,Intermediate,,50588,,6084,,9615.0,Canis lupus familiaris,,CHEMBL622540,,,In vivo,,A,1,1,
,BAO_0000218,6806,N,Half life period (10 mg/kg) was determined in dog,Intermediate,,50588,,6084,,9615.0,Canis lupus familiaris,,CHEMBL873803,,,In vivo,,A,1,1,
,BAO_0000218,6807,N,Half life period by iv administration in dog at a dose of 0.3 mg/kg,Intermediate,,50588,,5542,,9615.0,Canis lupus familiaris,,CHEMBL873804,,,In vivo,,A,1,1,
,BAO_0000218,6808,N,Half life period by po administration in dog at a dose of 0.3 mg/kg,Intermediate,,50588,,5542,,9615.0,Canis lupus familiaris,,CHEMBL624311,,,In vivo,,A,1,1,
,BAO_0000218,6809,N,Half life period in dog,Intermediate,,50588,,6084,,9615.0,Canis lupus familiaris,,CHEMBL624312,,,,,A,1,1,
,BAO_0000218,6810,N,Half life period in dogs after oral administration at 1 mg/kg,Intermediate,,50588,,6241,,9615.0,Canis lupus familiaris,,CHEMBL624313,,,In vivo,,A,1,1,
,BAO_0000218,6811,N,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,Intermediate,,50588,,1916,,9615.0,Canis lupus familiaris,,CHEMBL624314,,,In vivo,,A,1,1,
,BAO_0000218,6812,N,Half-life of compound was determined in dogs,Intermediate,,50588,,6621,,9615.0,Canis lupus familiaris,,CHEMBL624315,,,,,A,1,1,
Plasma,BAO_0000218,6813,N,Half-life in dog plasma,Intermediate,,50588,,1696,1969.0,9615.0,Canis lupus familiaris,,CHEMBL624316,,,,,A,1,1,
,BAO_0000218,6814,N,Half-life in mongrel dogs was determined,Intermediate,,50588,,17800,,9615.0,Canis lupus familiaris,,CHEMBL624317,,,,,A,1,1,
,BAO_0000218,6815,N,Half-life in dog upon oral administration,Intermediate,,50588,,17657,,9615.0,Canis lupus familiaris,,CHEMBL624318,,,In vivo,,A,1,1,
,BAO_0000218,6816,N,Half-life in dog upon oral administration; Unable to calculate,Intermediate,,50588,,17657,,9615.0,Canis lupus familiaris,,CHEMBL624319,,,In vivo,,A,1,1,
,BAO_0000218,6817,N,Half-life was measured in dog,Intermediate,,50588,,4239,,9615.0,Canis lupus familiaris,,CHEMBL624496,,,,,A,1,1,
,BAO_0000218,6818,N,Half-life was measured in dog,Intermediate,,50588,,5985,,9615.0,Canis lupus familiaris,,CHEMBL624497,,,,,A,1,1,
,BAO_0000218,6819,N,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,Intermediate,,50588,,9932,,9615.0,Canis lupus familiaris,,CHEMBL624498,,,,,A,1,1,
,BAO_0000218,6820,N,Oral half life was determined,Intermediate,,50588,,5199,,9615.0,Canis lupus familiaris,,CHEMBL624499,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6821,N,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,Intermediate,,50588,,5199,1969.0,9615.0,Canis lupus familiaris,,CHEMBL624500,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6822,N,Plasma half life was evaluated,Intermediate,,50588,,1475,1969.0,9615.0,Canis lupus familiaris,,CHEMBL624501,,,,,A,1,1,
Plasma,BAO_0000218,6823,N,Plasma half life was evaluated in Dog,Intermediate,,50588,,1475,1969.0,9615.0,Canis lupus familiaris,,CHEMBL623666,,,,,A,1,1,
Plasma,BAO_0000218,6824,N,Plasma half life was evaluated in dog,Intermediate,,50588,,1475,1969.0,9615.0,Canis lupus familiaris,,CHEMBL623667,,,,,A,1,1,
,BAO_0000218,6825,N,T1/2 (Half-life) was after oral administration at 5 mg/kg,Intermediate,,50588,,6316,,9615.0,Canis lupus familiaris,,CHEMBL623668,,,In vivo,,A,1,1,
,BAO_0000218,6826,N,Tested for the half life value in dog,Intermediate,,50588,,4883,,9615.0,Canis lupus familiaris,,CHEMBL623669,,,,,A,1,1,
,BAO_0000218,6827,N,Maximum time at the dose of 2 mg/kg in dog,Intermediate,,50588,,4727,,9615.0,Canis lupus familiaris,,CHEMBL623670,,,In vivo,,A,1,1,
,BAO_0000218,6828,N,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,Intermediate,,50588,,1916,,9615.0,Canis lupus familiaris,,CHEMBL623671,,,In vivo,,A,1,1,
Blood,BAO_0000218,6829,N,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Intermediate,,50588,,1337,178.0,9615.0,Canis lupus familiaris,,CHEMBL875945,,,In vivo,,A,1,1,
Blood,BAO_0000218,6830,N,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Intermediate,,50588,,1337,178.0,9615.0,Canis lupus familiaris,,CHEMBL623672,,,In vivo,,A,1,1,
,BAO_0000218,6831,N,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,Intermediate,,50588,,6265,,9615.0,Canis lupus familiaris,,CHEMBL623673,,,In vivo,,A,1,1,
,BAO_0000218,6832,N,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),Intermediate,,50588,,4809,,9615.0,Canis lupus familiaris,,CHEMBL623674,,,In vivo,,A,1,1,
,BAO_0000218,6833,N,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,Intermediate,,50588,,5983,,9615.0,Canis lupus familiaris,,CHEMBL623675,,,In vivo,,A,1,1,
,BAO_0000218,6834,N,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",Intermediate,,50588,,5313,,9615.0,Canis lupus familiaris,,CHEMBL872526,,,,,A,1,1,
,BAO_0000218,6835,N,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",Intermediate,,50588,,5313,,9615.0,Canis lupus familiaris,,CHEMBL623676,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6836,N,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,Intermediate,,50588,,17650,1969.0,9615.0,Canis lupus familiaris,,CHEMBL623677,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6837,N,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,Intermediate,,50588,,5199,1969.0,9615.0,Canis lupus familiaris,,CHEMBL623678,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6838,N,Time taken for maximum plasma concentration in dog,Intermediate,,50588,,933,1969.0,9615.0,Canis lupus familiaris,,CHEMBL623679,,,,,A,1,1,
,BAO_0000218,6839,N,Time to reach Cmax after oral administration to dogs,Intermediate,,50588,,16367,,9615.0,Canis lupus familiaris,,CHEMBL623680,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6840,N,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Intermediate,,50588,,6348,1969.0,9615.0,Canis lupus familiaris,,CHEMBL623681,,,In vivo,,A,1,1,
,BAO_0000218,6841,N,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,Intermediate,,50588,,6316,,9615.0,Canis lupus familiaris,,CHEMBL623682,,,In vivo,,A,1,1,
,BAO_0000218,6842,N,Tmax after peroral administration (1 mg/kg) was determined in dog,Intermediate,,50588,,6215,,9615.0,Canis lupus familiaris,,CHEMBL623683,,,In vivo,,A,1,1,
,BAO_0000218,6843,N,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,Expert,,50588,,3598,,9615.0,Canis lupus familiaris,,CHEMBL623684,,,In vivo,,A,1,1,
,BAO_0000218,6844,N,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,Intermediate,,50588,,4527,,9615.0,Canis lupus familiaris,,CHEMBL622745,,,In vivo,,A,1,1,
,BAO_0000218,6845,N,Tmax after peroral administration in dogs at 2.4 uM/kg,Intermediate,,50588,,17764,,9615.0,Canis lupus familiaris,,CHEMBL622746,,,In vivo,,A,1,1,
,BAO_0000218,6846,N,In vivo Cmax in mice at dose of 100 mg/kg,Intermediate,,50594,,5969,,10090.0,Mus musculus,,CHEMBL622747,,,In vivo,,A,1,1,
,BAO_0000218,6847,N,In vivo Cmax in mice at dose of 50 mg/kg,Intermediate,,50594,,5969,,10090.0,Mus musculus,,CHEMBL622748,,,In vivo,,A,1,1,
,BAO_0000218,6848,N,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,Intermediate,,50594,,4573,,10090.0,Mus musculus,,CHEMBL622749,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6849,N,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),Intermediate,,50594,,3277,1969.0,10090.0,Mus musculus,,CHEMBL622750,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6850,N,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,Intermediate,,50594,,17734,1969.0,10090.0,Mus musculus,,CHEMBL623411,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6851,N,Maximum concentration obtained in mouse plasma was determined,Intermediate,,50594,,3132,1969.0,10090.0,Mus musculus,,CHEMBL875946,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6852,N,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,Intermediate,,50594,,3132,1969.0,10090.0,Mus musculus,,CHEMBL623412,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6853,N,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Intermediate,,50594,,6348,1969.0,10090.0,Mus musculus,,CHEMBL623413,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6854,N,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,Intermediate,,50594,,17729,1969.0,10090.0,Mus musculus,,CHEMBL623414,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6855,N,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,Intermediate,,50594,,17729,1969.0,10090.0,Mus musculus,,CHEMBL623415,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6856,N,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,Intermediate,,50594,,17729,1969.0,10090.0,Mus musculus,,CHEMBL623416,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6857,N,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,Intermediate,,50594,,17728,1969.0,10090.0,Mus musculus,,CHEMBL623417,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6858,N,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,Intermediate,,50594,,17728,1969.0,10090.0,Mus musculus,,CHEMBL623418,,,In vivo,,A,1,1,
Plasma,BAO_0000218,6859,N,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,Intermediate,,50594,,17728,1969.0,10090.0,Mus musculus,,CHEMBL623419,,,In vivo,,A,1,1,
,BAO_0000218,6860,N,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,Intermediate,,50594,,4066,,10090.0,Mus musculus,,CHEMBL622816,,,In vivo,,A,1,1,
,BAO_0000218,6861,N,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,Intermediate,,50594,,6178,,10090.0,Mus musculus,,CHEMBL623313,,,In vivo,,A,1,1,
,BAO_0000218,6862,N,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,Intermediate,,50594,,6178,,10090.0,Mus musculus,,CHEMBL623314,,,In vivo,,A,1,1,
,BAO_0000218,6863,N,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,Intermediate,,50594,,3760,,10090.0,Mus musculus,,CHEMBL876788,,,In vivo,,A,1,1,
,BAO_0000218,6864,N,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,Intermediate,,50594,,3760,,10090.0,Mus musculus,,CHEMBL623315,,,In vivo,,A,1,1,
,BAO_0000218,6865,N,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,Intermediate,,50594,,3760,,10090.0,Mus musculus,,CHEMBL623316,,,In vivo,,A,1,1,
,BAO_0000218,6866,N,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,Intermediate,,50594,,3760,,10090.0,Mus musculus,,CHEMBL623317,,,In vivo,,A,1,1,
,BAO_0000218,6868,N,Cmax in male mice after 2 mg/kg oral dose,Intermediate,,50594,,5961,,10090.0,Mus musculus,,CHEMBL623319,,,In vivo,,A,1,1,
,BAO_0000218,6869,N,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,Intermediate,,50594,,6137,,10090.0,Mus musculus,,CHEMBL623320,,,In vivo,,A,1,1,
,BAO_0000218,6870,N,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,Intermediate,,50594,,3802,,10090.0,Mus musculus,,CHEMBL623321,,,In vivo,,A,1,1,
,BAO_0000218,6871,N,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,Intermediate,,50594,,3535,,10090.0,Mus musculus,,CHEMBL623322,,,,,A,1,1,
,BAO_0000218,6872,N,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,Intermediate,,50594,,3535,,10090.0,Mus musculus,,CHEMBL623323,,,,,A,1,1,
,BAO_0000218,6873,N,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,Intermediate,,50594,,3535,,10090.0,Mus musculus,,CHEMBL623324,,,,,A,1,1,
,BAO_0000218,6874,N,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,Intermediate,,50594,,3535,,10090.0,Mus musculus,,CHEMBL623325,,,,,A,1,1,
,BAO_0000218,6875,N,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,Intermediate,,50594,,3535,,10090.0,Mus musculus,,CHEMBL623326,,,,,A,1,1,
,BAO_0000218,6876,N,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,Intermediate,,50594,,3535,,10090.0,Mus musculus,,CHEMBL623327,,,,,A,1,1,
Plasma,BAO_0000218,6877,N,Maximum concentration in plasma upon oral administration in mouse,Intermediate,,50594,,2862,1969.0,10090.0,Mus musculus,,CHEMBL623328,,,,,A,1,1,
Plasma,BAO_0000218,6878,N,Maximum plasma concentration was evaluated in mice after oral administration,Intermediate,,50594,,2675,1969.0,10090.0,Mus musculus,,CHEMBL623329,,,,,A,1,1,
Plasma,BAO_0000218,6879,N,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,Intermediate,,50594,,2675,1969.0,10090.0,Mus musculus,,CHEMBL623330,,,In vivo,,A,1,1,
,BAO_0000218,6880,N,Dose at which the compound induced fecal excretion in mice,Intermediate,,50594,,5399,,10090.0,Mus musculus,,CHEMBL876789,,,,,A,1,1,
,BAO_0000219,6893,N,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,Expert,164.0,80013,,11819,,10116.0,Rattus norvegicus,,CHEMBL623333,A10,,,,F,1,1,
,BAO_0000219,6894,N,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,Expert,164.0,80013,,11819,,10116.0,Rattus norvegicus,,CHEMBL623334,A10,,,,F,1,1,
,BAO_0000219,6895,N,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,Expert,164.0,80013,,11819,,10116.0,Rattus norvegicus,,CHEMBL627536,A10,,,,F,1,1,
,BAO_0000219,6896,N,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,Expert,164.0,80013,,11819,,10116.0,Rattus norvegicus,,CHEMBL627537,A10,,,,F,1,1,
,BAO_0000219,6897,N,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),Intermediate,164.0,80013,,16361,,10116.0,Rattus norvegicus,,CHEMBL627538,A10,,,,F,1,1,
,BAO_0000219,6898,N,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,Intermediate,393.0,80655,,2288,,9606.0,Homo sapiens,,CHEMBL884106,A121,,,,F,1,1,
,BAO_0000219,6899,N,Anticancer activity against human ovarian carcinoma A121 cells,Intermediate,393.0,80655,,10404,,9606.0,Homo sapiens,,CHEMBL625294,A121,,,,F,1,1,
,BAO_0000219,6900,N,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,Intermediate,393.0,80655,,14790,,9606.0,Homo sapiens,,CHEMBL625295,A121,,,,F,1,1,
,BAO_0000219,6901,N,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,Intermediate,393.0,80655,,14790,,9606.0,Homo sapiens,,CHEMBL625296,A121,,,,F,1,1,
,BAO_0000219,6902,N,Growth inhibition of human ovarian carcinoma (A121) cell line,Expert,393.0,80655,,14253,,9606.0,Homo sapiens,,CHEMBL625297,A121,,,,F,1,1,
,BAO_0000219,6903,N,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,Expert,393.0,80655,,13617,,9606.0,Homo sapiens,,CHEMBL625298,A121,,,,F,1,1,
,BAO_0000219,6904,N,Cytotoxicity against human A121 ovarian cells,Intermediate,393.0,80655,,1003,,9606.0,Homo sapiens,,CHEMBL625960,A121,,,,F,1,1,
,BAO_0000219,6905,N,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,Intermediate,393.0,80655,,830,,9606.0,Homo sapiens,,CHEMBL625961,A121,,,,F,1,1,
,BAO_0000219,6906,N,In vitro cytotoxicity against human ovarian carcinoma A21,Intermediate,393.0,80655,,12307,,9606.0,Homo sapiens,,CHEMBL625962,A121,,,,F,1,1,
,BAO_0000219,6907,N,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,Intermediate,393.0,80655,,14254,,9606.0,Homo sapiens,,CHEMBL624717,A121,,,,F,1,1,
,BAO_0000219,6908,N,Inhibitory activity of compound against human A121 ovarian cell line.,Intermediate,393.0,80655,,13370,,9606.0,Homo sapiens,,CHEMBL624718,A121,,,,F,1,1,
,BAO_0000219,6909,N,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,Intermediate,393.0,80655,,14790,,9606.0,Homo sapiens,,CHEMBL624719,A121,,,,F,1,1,
,BAO_0000219,6910,N,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,Intermediate,393.0,80655,,3614,,9606.0,Homo sapiens,,CHEMBL624720,A121,,,,F,1,1,
,BAO_0000219,6911,N,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,Intermediate,622.0,80012,,2664,,9606.0,Homo sapiens,,CHEMBL624721,A 172,,,,F,1,1,
,BAO_0000219,6912,N,In vitro cytotoxicity against A172 human tumor cell lines.,Expert,622.0,80012,,2037,,9606.0,Homo sapiens,,CHEMBL624722,A 172,,,,F,1,1,
,BAO_0000219,6913,N,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,Intermediate,622.0,80012,,14539,,9606.0,Homo sapiens,,CHEMBL877597,A 172,,,,F,1,1,
,BAO_0000219,6914,N,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,Intermediate,622.0,80012,,2836,,9606.0,Homo sapiens,,CHEMBL624723,A 172,,,,F,1,1,
,BAO_0000219,6915,N,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,Intermediate,622.0,80012,,10708,,9606.0,Homo sapiens,,CHEMBL624724,A 172,,,,F,1,1,
,BAO_0000224,6916,H,Association constant against A2 adenosine receptor,Autocuration,,104729,,8975,,9615.0,Canis lupus familiaris,,CHEMBL624725,,,,,B,1,4,
,BAO_0000219,6917,N,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,Intermediate,1085.0,80656,,7645,,,fish,,CHEMBL624726,A2,,,,F,1,1,
,BAO_0000224,6918,D,Ratio of Ki for adenosine A2 and A1 receptor binding,Autocuration,,104713,,11377,,10116.0,Rattus norvegicus,,CHEMBL857535,,,,,B,1,5,
,BAO_0000219,6919,N,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,Expert,623.0,80014,,13528,,9606.0,Homo sapiens,,CHEMBL624727,A204,,,,F,1,1,
,BAO_0000219,6920,N,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,Expert,623.0,80014,,10160,,9606.0,Homo sapiens,,CHEMBL624728,A204,,,,F,1,1,
,BAO_0000219,6921,N,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,Intermediate,404.0,80015,,15144,,9606.0,Homo sapiens,,CHEMBL624729,A2058,,,,F,1,1,
,BAO_0000219,6922,N,Growth inhibition against Human squamous cell line(A 253),Intermediate,973.0,80657,,13160,,9606.0,Homo sapiens,,CHEMBL624730,A253 cell line,,,,F,1,1,
,BAO_0000219,6923,N,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,Intermediate,973.0,80657,,12898,,9606.0,Homo sapiens,,CHEMBL624731,A253 cell line,,,,F,1,1,
,BAO_0000219,6924,N,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,Intermediate,973.0,80657,,13069,,9606.0,Homo sapiens,,CHEMBL624732,A253 cell line,,,,F,1,1,
,BAO_0000219,6925,N,Growth inhibition of A253 cell lines.,Intermediate,973.0,80657,,15984,,9606.0,Homo sapiens,,CHEMBL883245,A253 cell line,,,,F,1,1,
,BAO_0000219,6926,N,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),Intermediate,973.0,80657,,15564,,9606.0,Homo sapiens,,CHEMBL624733,A253 cell line,,,,F,1,1,
,BAO_0000219,6927,N,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,Intermediate,973.0,80657,,15564,,9606.0,Homo sapiens,,CHEMBL624734,A253 cell line,,,,F,1,1,
,BAO_0000219,6928,N,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,Intermediate,973.0,80657,,15564,,9606.0,Homo sapiens,,CHEMBL624735,A253 cell line,,,,F,1,1,
,BAO_0000219,6929,N,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,Intermediate,478.0,81034,,4720,,9606.0,Homo sapiens,,CHEMBL621780,A2780,,,,F,1,1,
,BAO_0000219,6930,N,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,Intermediate,478.0,81034,,16112,,9606.0,Homo sapiens,,CHEMBL877598,A2780,,,,F,1,1,
,BAO_0000219,6931,N,Cytotoxic activity against A2780 human ovarian carcinoma cell line,Expert,478.0,81034,,16597,,9606.0,Homo sapiens,,CHEMBL621781,A2780,,,,F,1,1,
,BAO_0000219,6932,N,Cytotoxicity against human cancer cell lines A2780 (ovarian),Intermediate,478.0,81034,,16378,,9606.0,Homo sapiens,,CHEMBL621782,A2780,,,,F,1,1,
,BAO_0000219,6933,N,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,Expert,478.0,81034,,16085,,9606.0,Homo sapiens,,CHEMBL621783,A2780,,,,F,1,1,
,BAO_0000219,6934,N,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,Intermediate,478.0,81034,,16317,,9606.0,Homo sapiens,,CHEMBL621784,A2780,,,,F,1,1,
,BAO_0000219,6935,N,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),Intermediate,478.0,81034,,15748,,9606.0,Homo sapiens,,CHEMBL621785,A2780,,,,F,1,1,
,BAO_0000219,6936,N,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,Expert,478.0,81034,,16597,,9606.0,Homo sapiens,,CHEMBL621968,A2780,,,,F,1,1,
,BAO_0000219,6937,N,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,Expert,478.0,81034,,16597,,9606.0,Homo sapiens,,CHEMBL621969,A2780,,,,F,1,1,
,BAO_0000219,6938,N,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,Expert,478.0,81034,,16597,,9606.0,Homo sapiens,,CHEMBL621970,A2780,,,,F,1,1,
,BAO_0000219,6939,N,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,Intermediate,478.0,81034,,15608,,9606.0,Homo sapiens,,CHEMBL621971,A2780,,,,F,1,1,
,BAO_0000219,6940,N,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,Intermediate,478.0,81034,,15608,,9606.0,Homo sapiens,,CHEMBL621972,A2780,,,,F,1,1,
,BAO_0000219,6941,N,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,Intermediate,478.0,81034,,15608,,9606.0,Homo sapiens,,CHEMBL884108,A2780,,,,F,1,1,
,BAO_0000019,6942,U,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,Autocuration,,22224,,15296,,10029.0,Cricetulus griseus,,CHEMBL623826,,,,,F,1,0,
,BAO_0000219,6943,U,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,Autocuration,185.0,22224,,10251,,10029.0,Cricetulus griseus,,CHEMBL623827,CHO-AA8,,,,A,1,0,
,BAO_0000219,6944,U,Evaluated for growth inhibition of AA8 cells under aerobic conditions,Autocuration,185.0,22224,,10251,,10029.0,Cricetulus griseus,,CHEMBL623828,CHO-AA8,,,,F,1,0,
,BAO_0000219,6945,U,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,Autocuration,185.0,22224,,10251,,10029.0,Cricetulus griseus,,CHEMBL623829,CHO-AA8,,,,F,1,0,
,BAO_0000219,6946,U,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),Autocuration,185.0,22224,,10251,,10029.0,Cricetulus griseus,,CHEMBL623830,CHO-AA8,,,,F,1,0,
,BAO_0000019,6947,U,Growth inhibition against CHO-derived cell line AA8,Autocuration,,22224,,11858,,10029.0,Cricetulus griseus,,CHEMBL623831,,,,,F,1,0,
,BAO_0000219,6948,U,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],Autocuration,185.0,22224,,11858,,10029.0,Cricetulus griseus,,CHEMBL623832,CHO-AA8,,,,F,1,0,
,BAO_0000219,6949,N,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,Expert,185.0,80089,,11616,,36483.0,hampster,,CHEMBL623833,CHO-AA8,,,,F,1,1,
,BAO_0000219,6950,N,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,Expert,185.0,80089,,11616,,10029.0,Cricetulus griseus,,CHEMBL623834,CHO-AA8,,,,F,1,1,
,BAO_0000219,6951,U,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,Autocuration,185.0,22224,,10518,,10029.0,Cricetulus griseus,,CHEMBL623835,CHO-AA8,,,,F,1,0,
,BAO_0000219,6952,U,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,Autocuration,185.0,22224,,11396,,10029.0,Cricetulus griseus,,CHEMBL623836,CHO-AA8,,,,F,1,0,
,BAO_0000219,6953,U,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,Autocuration,185.0,22224,,10518,,10029.0,Cricetulus griseus,,CHEMBL623837,CHO-AA8,,,,F,1,0,
,BAO_0000219,6954,N,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,Expert,185.0,80089,,11616,,10029.0,Cricetulus griseus,,CHEMBL623838,CHO-AA8,,,,F,1,1,
,BAO_0000019,6955,H,compound was evaluated for association constant (Ka) of isolated serum protein AAG,Autocuration,,12675,,14837,,,,,CHEMBL623839,,,,,F,1,8,
,BAO_0000019,6956,H,Number of binding sites (n) of isolated serum protein AAG,Autocuration,,12675,,14837,,,,,CHEMBL623840,,,,,F,1,8,
,BAO_0000225,6957,M,Association constant for binding to AATT duplex,Intermediate,,22222,,16037,,,,,CHEMBL623841,,,,,B,1,3,
,BAO_0000219,6958,N,Inhibition of ABAE human fibroblast cell proliferation,Expert,416.0,100090,,16597,,9606.0,Homo sapiens,,CHEMBL623842,ABAE,,,,F,1,1,
,BAO_0000218,6959,N,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",Intermediate,1064.0,80668,,8831,,10090.0,Mus musculus,,CHEMBL623843,AC755,,,,F,1,1,
,BAO_0000218,6960,D,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,Expert,,102444,,13419,,9986.0,Oryctolagus cuniculus,,CHEMBL618669,,,,,F,1,9,
,BAO_0000218,6961,D,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,Expert,,102444,,13419,,9986.0,Oryctolagus cuniculus,,CHEMBL618670,,,In vivo,,F,1,9,
,BAO_0000357,6962,H,Inhibitory activity against angiotensin-converting enzyme (ACE).,Autocuration,,69,,15778,,,,,CHEMBL618671,,,,,B,1,8,
,BAO_0000357,6963,H,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,Autocuration,,69,,15778,,,,,CHEMBL618672,,,,,B,1,8,
,BAO_0000219,6964,N,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,Intermediate,978.0,80669,,12988,,9606.0,Homo sapiens,,CHEMBL618673,ACH-2 cell line,,,,F,1,1,
,BAO_0000219,6965,N,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),Intermediate,978.0,80669,,12988,,9606.0,Homo sapiens,,CHEMBL618674,ACH-2 cell line,,,,F,1,1,
,BAO_0000219,6966,U,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,Autocuration,998.0,22224,,12988,,11676.0,Human immunodeficiency virus 1,,CHEMBL618675,T cell line,,,,F,1,0,
,BAO_0000219,6967,U,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),Autocuration,998.0,22224,,12988,,11676.0,Human immunodeficiency virus 1,,CHEMBL618676,T cell line,,,,F,1,0,
,BAO_0000219,6968,U,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),Autocuration,998.0,22224,,12988,,11676.0,Human immunodeficiency virus 1,,CHEMBL618677,T cell line,,,,F,1,0,
,BAO_0000219,6969,N,Inhibition of growth of renal cancer ACHN cell line,Intermediate,626.0,80025,,11843,,9606.0,Homo sapiens,,CHEMBL618678,ACHN,,,,F,1,1,
,BAO_0000219,6970,N,Inhibition of growth of ACHN renal cancer cell line,Intermediate,626.0,80025,,16939,,9606.0,Homo sapiens,,CHEMBL618679,ACHN,,,,F,1,1,
,BAO_0000219,6971,N,Inhibitory concentration required against ACHN renal cancer cell line,Intermediate,626.0,80025,,4782,,9606.0,Homo sapiens,,CHEMBL618680,ACHN,,,,F,1,1,
,BAO_0000219,6972,N,Concentration required to inhibit growth of human renal (ACHN) cell line,Expert,626.0,80025,,6310,,9606.0,Homo sapiens,,CHEMBL618681,ACHN,,,,F,1,1,
,BAO_0000219,6973,N,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,Intermediate,626.0,80025,,6310,,9606.0,Homo sapiens,,CHEMBL618682,ACHN,,,,F,1,1,
,BAO_0000219,6974,N,Cytotoxic activity against ACHN Renal cancer cell line,Intermediate,626.0,80025,,12858,,9606.0,Homo sapiens,,CHEMBL618683,ACHN,,,,F,1,1,
,BAO_0000219,6975,N,Cytotoxicity evaluation against ACHN renal cancer cells,Intermediate,626.0,80025,,17380,,9606.0,Homo sapiens,,CHEMBL618684,ACHN,,,,F,1,1,
,BAO_0000219,6976,N,In vitro antitumor activity against human renal ACHN cell line,Intermediate,626.0,80025,,5858,,9606.0,Homo sapiens,,CHEMBL618685,ACHN,,,,F,1,1,
,BAO_0000219,6977,N,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,Intermediate,626.0,80025,,3838,,9606.0,Homo sapiens,,CHEMBL876499,ACHN,,,,F,1,1,
,BAO_0000219,6978,N,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,Intermediate,626.0,80025,,3838,,9606.0,Homo sapiens,,CHEMBL618686,ACHN,,,,F,1,1,
,BAO_0000219,6979,N,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",Intermediate,626.0,80025,,5406,,9606.0,Homo sapiens,,CHEMBL618687,ACHN,,,,F,1,1,
,BAO_0000219,6980,N,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,Intermediate,626.0,80025,,4071,,9606.0,Homo sapiens,,CHEMBL618688,ACHN,,,,F,1,1,
,BAO_0000219,6981,N,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,Expert,626.0,80025,,4071,,9606.0,Homo sapiens,,CHEMBL618689,ACHN,,,,F,1,1,
,BAO_0000219,6982,N,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,Intermediate,626.0,80025,,4071,,9606.0,Homo sapiens,,CHEMBL618690,ACHN,,,,F,1,1,
,BAO_0000219,6983,N,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,Intermediate,626.0,80025,,15002,,9606.0,Homo sapiens,,CHEMBL618691,ACHN,,,,F,1,1,
,BAO_0000219,6984,N,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),Intermediate,626.0,80025,,14769,,9606.0,Homo sapiens,,CHEMBL619373,ACHN,,,,F,1,1,
,BAO_0000219,6985,N,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",Intermediate,626.0,80025,,13958,,9606.0,Homo sapiens,,CHEMBL884008,ACHN,,,,F,1,1,
,BAO_0000219,6986,N,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,Intermediate,626.0,80025,,1665,,9606.0,Homo sapiens,,CHEMBL619374,ACHN,,,,F,1,1,
,BAO_0000219,6987,N,Compound was tested for the growth inhibition of ACHN renal tumor cell line,Intermediate,626.0,80025,,15354,,9606.0,Homo sapiens,,CHEMBL619375,ACHN,,,,F,1,1,
,BAO_0000219,6988,N,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,Intermediate,626.0,80025,,15354,,9606.0,Homo sapiens,,CHEMBL619376,ACHN,,,,F,1,1,
,BAO_0000219,6989,N,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,Intermediate,626.0,80025,,13978,,9606.0,Homo sapiens,,CHEMBL619377,ACHN,,,,F,1,1,
,BAO_0000219,6990,N,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,Intermediate,626.0,80025,,6798,,9606.0,Homo sapiens,,CHEMBL619378,ACHN,,,,F,1,1,
,BAO_0000218,6991,N,Tmax value after administration of 4 mg/Kg oral dose in dog,Intermediate,,50588,,2959,,9615.0,Canis lupus familiaris,,CHEMBL872527,,,In vivo,,A,1,1,
,BAO_0000218,6992,N,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",Intermediate,,50588,,9932,,9615.0,Canis lupus familiaris,,CHEMBL876500,,,,,A,1,1,
,BAO_0000218,6993,N,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,Intermediate,,50588,,5546,,9615.0,Canis lupus familiaris,,CHEMBL619379,,,,,A,1,1,
,BAO_0000218,6994,N,Volume distribution after 15 mg/kg iv dose in Dogs,Intermediate,,50588,,16907,,9615.0,Canis lupus familiaris,,CHEMBL619538,,,In vivo,,A,1,1,
,BAO_0000218,6995,N,Volume distribution after 30 mg/kg po dose in Dogs,Intermediate,,50588,,16907,,9615.0,Canis lupus familiaris,,CHEMBL619539,,,In vivo,,A,1,1,
,BAO_0000218,6996,N,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,Intermediate,,50588,,4257,,9615.0,Canis lupus familiaris,,CHEMBL619540,,,In vivo,,A,1,1,
,BAO_0000218,6997,N,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,Intermediate,,50588,,4305,,9615.0,Canis lupus familiaris,,CHEMBL619541,,,In vivo,,A,1,1,
,BAO_0000218,6998,N,Volume of distribution was evaluated in dog,Intermediate,,50588,,5472,,9615.0,Canis lupus familiaris,,CHEMBL619542,,,In vivo,,A,1,1,
,BAO_0000218,6999,N,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,Intermediate,,50588,,6062,,9615.0,Canis lupus familiaris,,CHEMBL619543,,,In vivo,,A,1,1,
,BAO_0000218,7000,N,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,Expert,,50588,,3598,,9615.0,Canis lupus familiaris,,CHEMBL619544,,,,,A,1,1,
,BAO_0000218,7001,N,The compound was tested for volume of distribution in dog,Intermediate,,50588,,12500,,9615.0,Canis lupus familiaris,,CHEMBL619545,,,In vivo,,A,1,1,
,BAO_0000218,7002,N,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,Intermediate,,50588,,12500,,9615.0,Canis lupus familiaris,,CHEMBL619546,,,In vivo,,A,1,1,
,BAO_0000218,7003,N,Vd (1 mg/kg) was determined in dog (in vivo),Intermediate,,50588,,6227,,9615.0,Canis lupus familiaris,,CHEMBL619547,,,In vivo,,A,1,1,
,BAO_0000218,7004,N,Vd in dog,Intermediate,,50588,,6227,,9615.0,Canis lupus familiaris,,CHEMBL619548,,,In vivo,,A,1,1,
,BAO_0000218,7005,N,Volume distribution was determined,Intermediate,,50588,,4219,,9615.0,Canis lupus familiaris,,CHEMBL619549,,,In vivo,,A,1,1,
,BAO_0000218,7006,N,Volume of distribution in dog,Intermediate,,50588,,1696,,9615.0,Canis lupus familiaris,,CHEMBL619550,,,In vivo,,A,1,1,
,BAO_0000218,7007,N,Volume of distribution by as 4 fold increase by iv administration in dogs,Intermediate,,50588,,5542,,9615.0,Canis lupus familiaris,,CHEMBL876501,,,In vivo,,A,1,1,
,BAO_0000218,7008,N,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,Intermediate,,50588,,5199,,9615.0,Canis lupus familiaris,,CHEMBL619551,,,In vivo,,A,1,1,
,BAO_0000218,7009,N,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Intermediate,,50588,,6348,,9615.0,Canis lupus familiaris,,CHEMBL619552,,,In vivo,,A,1,1,
,BAO_0000218,7010,N,Volume distribution at the dose of 2 mg/kg in dog,Intermediate,,50588,,4727,,9615.0,Canis lupus familiaris,,CHEMBL619553,,,In vivo,,A,1,1,
,BAO_0000218,7011,N,Steady state volume of distribution was determined,Intermediate,,50588,,16367,,9615.0,Canis lupus familiaris,,CHEMBL618722,,,In vivo,,A,1,1,
,BAO_0000218,7012,N,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,Intermediate,,50588,,2652,,9615.0,Canis lupus familiaris,,CHEMBL618723,,,In vivo,,A,1,1,
,BAO_0000218,7013,N,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,Intermediate,,50588,,16452,,9615.0,Canis lupus familiaris,,CHEMBL618724,,,In vivo,,A,1,1,
,BAO_0000218,7014,N,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,Intermediate,,50588,,16452,,9615.0,Canis lupus familiaris,,CHEMBL618725,,,In vivo,,A,1,1,
,BAO_0000218,7015,N,Bioavailability in dog (dose 1 mg/kg i.v.),Intermediate,,50588,,16452,,9615.0,Canis lupus familiaris,,CHEMBL618726,,,In vivo,,A,1,1,
,BAO_0000218,7016,N,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),Intermediate,,50588,,5334,,9615.0,Canis lupus familiaris,,CHEMBL618727,,,In vivo,,A,1,1,
,BAO_0000218,7017,N,Pharmacokinetic property (vdss) was measured in dog,Intermediate,,50588,,4239,,9615.0,Canis lupus familiaris,,CHEMBL624233,,,In vivo,,A,1,1,
,BAO_0000218,7018,N,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,Intermediate,,50588,,4709,,9615.0,Canis lupus familiaris,,CHEMBL624234,,,In vivo,,A,1,1,
,BAO_0000218,7019,N,Vdss was determined after iv 0.1 mg/kg administration in dog,Intermediate,,50588,,5600,,9615.0,Canis lupus familiaris,,CHEMBL624235,,,In vivo,,A,1,1,
,BAO_0000218,7020,N,Volume displacement was calculated in dog,Intermediate,,50588,,6057,,9615.0,Canis lupus familiaris,,CHEMBL624236,,,In vivo,,A,1,1,
,BAO_0000218,7021,N,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,Intermediate,,50588,,5654,,9615.0,Canis lupus familiaris,,CHEMBL624237,,,In vivo,,A,1,1,
,BAO_0000218,7022,N,Volume distribution constant was determined,Intermediate,,50588,,5505,,9615.0,Canis lupus familiaris,,CHEMBL624238,,,In vivo,,A,1,1,
,BAO_0000218,7023,N,Volume distribution at a dose of 1 uM/kg in dog was determined,Intermediate,,50588,,4527,,9615.0,Canis lupus familiaris,,CHEMBL624239,,,In vivo,,A,1,1,
,BAO_0000218,7024,N,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,Intermediate,,50588,,4521,,9615.0,Canis lupus familiaris,,CHEMBL875829,,,In vivo,,A,1,1,
,BAO_0000218,7025,N,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,Intermediate,,50588,,4521,,9615.0,Canis lupus familiaris,,CHEMBL624240,,,In vivo,,A,1,1,
,BAO_0000218,7026,N,Volume distribution (Vdss) was measured in dog,Intermediate,,50588,,15660,,9615.0,Canis lupus familiaris,,CHEMBL624241,,,In vivo,,A,1,1,
,BAO_0000218,7027,N,Volume distribution (Vdss) was measured in dog,Intermediate,,50588,,15660,,9615.0,Canis lupus familiaris,,CHEMBL624242,,,In vivo,,A,1,1,
,BAO_0000218,7028,N,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Intermediate,,50588,,6679,,9615.0,Canis lupus familiaris,,CHEMBL624243,,,In vivo,,A,1,1,
,BAO_0000218,7029,N,Volume of distribution in steady state was determined in dog,Intermediate,,50588,,5145,,9615.0,Canis lupus familiaris,,CHEMBL624244,,,In vivo,,A,1,1,
,BAO_0000218,7030,N,Volume of distribution of compound was determined in dog,Intermediate,,50588,,6821,,9615.0,Canis lupus familiaris,,CHEMBL624245,,,In vivo,,A,1,1,
,BAO_0000218,7031,N,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,Intermediate,,50588,,4137,,9615.0,Canis lupus familiaris,,CHEMBL624246,,,In vivo,,A,1,1,
,BAO_0000218,7032,N,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),Intermediate,,50588,,5334,,9615.0,Canis lupus familiaris,,CHEMBL624247,,,In vivo,,A,1,1,
,BAO_0000218,7033,N,Volume of distribution (Vdss) was measured in dog,Intermediate,,50588,,15660,,9615.0,Canis lupus familiaris,,CHEMBL624248,,,In vivo,,A,1,1,
,BAO_0000218,7034,N,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),Intermediate,,50588,,6642,,9615.0,Canis lupus familiaris,,CHEMBL624249,,,In vivo,,A,1,1,
,BAO_0000218,7035,N,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Intermediate,,50588,,6641,,9615.0,Canis lupus familiaris,,CHEMBL624250,,,In vivo,,A,1,1,
,BAO_0000218,7036,N,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Intermediate,,50588,,6642,,9615.0,Canis lupus familiaris,,CHEMBL624251,,,In vivo,,A,1,1,
,BAO_0000218,7037,N,Maximum rate of depolarization of the upstroke of the action potential,Intermediate,,50588,,11659,,9615.0,Canis lupus familiaris,,CHEMBL624252,,,,,A,1,1,
,BAO_0000218,7038,N,Steady state volume distribution in dog,Intermediate,,50588,,6448,,9615.0,Canis lupus familiaris,,CHEMBL624253,,,In vivo,,A,1,1,
,BAO_0000218,7039,N,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,Intermediate,,50588,,5474,,9615.0,Canis lupus familiaris,,CHEMBL624950,,,In vivo,,A,1,1,
,BAO_0000218,7040,N,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,Intermediate,,50588,,1466,,9615.0,Canis lupus familiaris,,CHEMBL624951,,,In vivo,,A,1,1,
,BAO_0000218,7041,N,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,Intermediate,,50588,,6535,,9615.0,Canis lupus familiaris,,CHEMBL875830,,,In vivo,,A,1,1,
,BAO_0000218,7042,N,Volume distribution in dog after administration of 1 mg/kg iv,Intermediate,,50588,,6535,,9615.0,Canis lupus familiaris,,CHEMBL624952,,,In vivo,,A,1,1,
,BAO_0000218,7043,N,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,Intermediate,,50588,,17764,,9615.0,Canis lupus familiaris,,CHEMBL624953,,,In vivo,,A,1,1,
,BAO_0000218,7044,N,Vss after intravenous administration (0.5 mg/kg) was determined in dog,Intermediate,,50588,,6215,,9615.0,Canis lupus familiaris,,CHEMBL624954,,,In vivo,,A,1,1,
,BAO_0000218,7045,N,Vss on i.v. administration of 2 mg/kg was measured in dog,Intermediate,,50588,,6505,,9615.0,Canis lupus familiaris,,CHEMBL624955,,,In vivo,,A,1,1,
,BAO_0000218,7046,N,Vss was determined,Intermediate,,50588,,3639,,9615.0,Canis lupus familiaris,,CHEMBL624956,,,,,A,1,1,
,BAO_0000218,7047,N,Vss in dog,Intermediate,,50588,,3639,,9615.0,Canis lupus familiaris,,CHEMBL625129,,,,,A,1,1,
,BAO_0000218,7048,N,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,Intermediate,,50588,,6062,,9615.0,Canis lupus familiaris,,CHEMBL625130,,,In vivo,,A,1,1,
,BAO_0000218,7049,N,Volume distribution in dogs,Intermediate,,50588,,4942,,9615.0,Canis lupus familiaris,,CHEMBL625131,,,In vivo,,A,1,1,
,BAO_0000218,7050,N,Volume of distribution in dog,Intermediate,,50588,,17796,,9615.0,Canis lupus familiaris,,CHEMBL625132,,,In vivo,,A,1,1,
,BAO_0000218,7051,N,Tested for the oral bioavailability in dog,Intermediate,,50588,,4883,,9615.0,Canis lupus familiaris,,CHEMBL872263,,,In vivo,,A,1,1,
,BAO_0000218,7060,N,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,Intermediate,,50594,,17837,,10090.0,Mus musculus,,CHEMBL624336,,,In vivo,,A,1,1,
,BAO_0000218,7061,N,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,Intermediate,,50594,,17729,,10090.0,Mus musculus,,CHEMBL624337,,,In vivo,,A,1,1,
,BAO_0000218,7062,N,Bioavailability after peroral administration of 50 mg/kg of dose in mice,Intermediate,,50594,,17729,,10090.0,Mus musculus,,CHEMBL624338,,,In vivo,,A,1,1,
,BAO_0000218,7063,N,Bioavailability was measured in mouse,Intermediate,,50594,,4239,,10090.0,Mus musculus,,CHEMBL624339,,,In vivo,,A,1,1,
,BAO_0000218,7064,N,Bioavailability in mouse,Intermediate,,50594,,17592,,10090.0,Mus musculus,,CHEMBL624340,,,In vivo,,A,1,1,
,BAO_0000218,7065,N,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Intermediate,,50594,,6348,,10090.0,Mus musculus,,CHEMBL624341,,,In vivo,,A,1,1,
,BAO_0000218,7066,N,Bioavailability in mouse,Intermediate,,50594,,2801,,10090.0,Mus musculus,,CHEMBL624342,,,In vivo,,A,1,1,
,BAO_0000218,7067,N,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,Intermediate,,50594,,2801,,10090.0,Mus musculus,,CHEMBL624343,,,In vivo,,A,1,1,
,BAO_0000218,7068,N,Oral bioavailability in mouse,Intermediate,,50594,,17718,,10090.0,Mus musculus,,CHEMBL624344,,,In vivo,,A,1,1,
,BAO_0000218,7069,N,Oral availability at 50 mg/kg po in male mice,Intermediate,,50594,,5727,,10090.0,Mus musculus,,CHEMBL624345,,,In vivo,,A,1,1,
,BAO_0000218,7070,N,Oral bioavailability in mouse (dose 10 mg/kg),Intermediate,,50594,,5302,,10090.0,Mus musculus,,CHEMBL624346,,,In vivo,,A,1,1,
,BAO_0000218,7071,N,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,Expert,,50594,,3598,,10090.0,Mus musculus,,CHEMBL624347,,,In vivo,,A,1,1,
,BAO_0000218,7072,N,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",Intermediate,,50594,,5961,,10090.0,Mus musculus,,CHEMBL624348,,,In vivo,,A,1,1,
,BAO_0000218,7074,N,Oral bioavailability in mouse,Intermediate,,50594,,6091,,10090.0,Mus musculus,,CHEMBL622754,,,In vivo,,A,1,1,
,BAO_0000218,7075,N,Oral bioavailability in vivo in mice;ND=Not determined,Intermediate,,50594,,6091,,10090.0,Mus musculus,,CHEMBL622755,,,In vivo,,A,1,1,
,BAO_0000218,7076,N,Oral bioavailability in mouse at 10 mg/kg of the compound,Intermediate,,50594,,5711,,10090.0,Mus musculus,,CHEMBL622756,,,In vivo,,A,1,1,
,BAO_0000218,7077,N,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),Intermediate,,50594,,17728,,10090.0,Mus musculus,,CHEMBL622757,,,In vivo,,A,1,1,
,BAO_0000218,7078,N,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),Intermediate,,50594,,17728,,10090.0,Mus musculus,,CHEMBL622758,,,In vivo,,A,1,1,
,BAO_0000218,7079,N,Tested for bioavailability of the compound,Intermediate,,50594,,3802,,10090.0,Mus musculus,,CHEMBL622759,,,In vivo,,A,1,1,
,BAO_0000218,7080,N,Tested for half life at the dose of 10 mg/kg when administered intravenously,Intermediate,,50594,,3802,,10090.0,Mus musculus,,CHEMBL622760,,,In vivo,,A,1,1,
Plasma,BAO_0000218,7081,N,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,Intermediate,,50594,,14029,1969.0,10090.0,Mus musculus,,CHEMBL622761,,,,,A,1,1,
Plasma,BAO_0000218,7082,N,The plasma half life of compound was determined on heparin prepared by human plasma. ,Intermediate,,50594,,14029,1969.0,10090.0,Mus musculus,,CHEMBL622762,,,,,A,1,1,
Plasma,BAO_0000218,7083,N,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,Intermediate,,50594,,14029,1969.0,10090.0,Mus musculus,,CHEMBL622763,,,,,A,1,1,
Plasma,BAO_0000218,7084,N,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,Intermediate,,50594,,14029,1969.0,10090.0,Mus musculus,,CHEMBL622764,,,,,A,1,1,
Plasma,BAO_0000218,7085,N,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,Intermediate,,50594,,14029,1969.0,10090.0,Mus musculus,,CHEMBL622765,,,,,A,1,1,
,BAO_0000218,7086,N,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,Intermediate,,50594,,17753,,10090.0,Mus musculus,,CHEMBL622766,,,,,F,1,1,
,BAO_0000218,7087,N,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,Intermediate,,50594,,17753,,10090.0,Mus musculus,,CHEMBL622767,,,,,A,1,1,
,BAO_0000218,7088,N,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,Intermediate,,50594,,17753,,10090.0,Mus musculus,,CHEMBL622768,,,,,A,1,1,
Blood,BAO_0000218,7089,N,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,50594,,10107,178.0,10090.0,Mus musculus,,CHEMBL875948,,,In vivo,,A,1,1,
Blood,BAO_0000218,7090,N,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Intermediate,,50594,,10107,178.0,10090.0,Mus musculus,,CHEMBL622769,,,In vivo,,A,1,1,
Blood,BAO_0000218,7091,N,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,50594,,10107,178.0,10090.0,Mus musculus,,CHEMBL622770,,,In vivo,,A,1,1,
Blood,BAO_0000218,7092,N,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,50594,,10107,178.0,10090.0,Mus musculus,,CHEMBL622771,,,In vivo,,A,1,1,
Blood,BAO_0000218,7093,N,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,50594,,10107,178.0,10090.0,Mus musculus,,CHEMBL622772,,,In vivo,,A,1,1,
Blood,BAO_0000218,7094,N,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,,50594,,10107,178.0,10090.0,Mus musculus,,CHEMBL622773,,,In vivo,,A,1,1,
Blood,BAO_0000218,7095,N,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,50594,,10107,178.0,10090.0,Mus musculus,,CHEMBL622774,,,In vivo,,A,1,1,
Bone,BAO_0000218,7096,N,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,50594,,10107,10000001.0,10090.0,Mus musculus,,CHEMBL621725,,,In vivo,,A,1,1,
Bone,BAO_0000218,7097,N,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Intermediate,,50594,,10107,10000001.0,10090.0,Mus musculus,,CHEMBL621726,,,In vivo,,A,1,1,
,BAO_0000219,7098,N,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,Intermediate,478.0,81034,,15608,,9606.0,Homo sapiens,,CHEMBL621727,A2780,,,,F,1,1,
,BAO_0000219,7099,N,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,Expert,478.0,81034,,3290,,9606.0,Homo sapiens,,CHEMBL622413,A2780,,,,F,1,1,
,BAO_0000219,7100,N,Compound was evaluated for cytotoxicity against A2780 cell line,Intermediate,478.0,81034,,2859,,9606.0,Homo sapiens,,CHEMBL622414,A2780,,,,F,1,1,
,BAO_0000219,7101,N,Inhibition of A2780 cell clonogenic assay,Expert,478.0,81034,,15688,,9606.0,Homo sapiens,,CHEMBL622415,A2780,,,,F,1,1,
,BAO_0000219,7102,N,Cytotoxic effect on ovarian cancer cell line (A2780),Expert,478.0,81034,,5642,,9606.0,Homo sapiens,,CHEMBL884001,A2780,,,,F,1,1,
,BAO_0000219,7103,N,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,Intermediate,478.0,81034,,6633,,9606.0,Homo sapiens,,CHEMBL622416,A2780,,,,F,1,1,
,BAO_0000219,7104,N,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",Intermediate,478.0,81034,,3906,,9606.0,Homo sapiens,,CHEMBL622417,A2780,,,,F,1,1,
,BAO_0000219,7105,N,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,Expert,478.0,81034,,6788,,9606.0,Homo sapiens,,CHEMBL622590,A2780,,,,F,1,1,
,BAO_0000219,7106,N,Antiproliferative activity against human A2780 cells,Expert,478.0,81034,,17582,,9606.0,Homo sapiens,,CHEMBL622591,A2780,,,,F,1,1,
,BAO_0000219,7107,N,Inhibition of human A2780 cell proliferation,Expert,478.0,81034,,17764,,9606.0,Homo sapiens,,CHEMBL622592,A2780,,,,F,1,1,
,BAO_0000219,7108,N,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,Expert,478.0,81034,,17764,,9606.0,Homo sapiens,,CHEMBL622593,A2780,,,,F,1,1,
,BAO_0000219,7109,N,Inhibition of human A2780 cell proliferation (No data),Expert,478.0,81034,,17764,,9606.0,Homo sapiens,,CHEMBL622594,A2780,,,,F,1,1,
,BAO_0000219,7110,N,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,Intermediate,478.0,81034,,2815,,9606.0,Homo sapiens,,CHEMBL622595,A2780,,,,F,1,1,
,BAO_0000219,7111,N,Compound was evaluated against human Ovarian carcinoma cell line A2780,Intermediate,478.0,81034,,16930,,9606.0,Homo sapiens,,CHEMBL622596,A2780,,,,F,1,1,
,BAO_0000219,7112,N,Growth inhibition against A2780 wild-type ovarian cell lines,Expert,478.0,81034,,17777,,9606.0,Homo sapiens,,CHEMBL622597,A2780,,,,F,1,1,
,BAO_0000219,7113,N,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,Intermediate,478.0,81034,,17777,,9606.0,Homo sapiens,,CHEMBL622598,A2780,,,,F,1,1,
,BAO_0000019,7114,D,Inhibition of tubulin polymerization in human ovarian cancer cell lines,Autocuration,,104766,,16936,,9606.0,Homo sapiens,,CHEMBL622599,,,,,F,1,5,
,BAO_0000219,7115,N,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,Intermediate,478.0,81034,,13759,,9606.0,Homo sapiens,,CHEMBL622600,A2780,,,,F,1,1,
,BAO_0000219,7116,N,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,Intermediate,478.0,81034,,13759,,9606.0,Homo sapiens,,CHEMBL622601,A2780,,,,F,1,1,
,BAO_0000219,7117,N,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,Intermediate,478.0,81034,,13759,,9606.0,Homo sapiens,,CHEMBL622602,A2780,,,,F,1,1,
,BAO_0000219,7118,N,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,Intermediate,478.0,81034,,13759,,9606.0,Homo sapiens,,CHEMBL622603,A2780,,,,F,1,1,
,BAO_0000219,7119,N,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,Intermediate,478.0,81034,,15292,,9606.0,Homo sapiens,,CHEMBL622604,A2780,,,,F,1,1,
,BAO_0000219,7120,N,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,Intermediate,478.0,81034,,15292,,9606.0,Homo sapiens,,CHEMBL622605,A2780,,,,F,1,1,
,BAO_0000219,7121,N,In vitro inhibition of human ovarian cell line A2780,Expert,478.0,81034,,15069,,9606.0,Homo sapiens,,CHEMBL622606,A2780,,,,F,1,1,
,BAO_0000219,7122,N,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",Expert,478.0,81034,,15069,,9606.0,Homo sapiens,,CHEMBL619463,A2780,,,,F,1,1,
,BAO_0000219,7123,N,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),Intermediate,478.0,81034,,14073,,9606.0,Homo sapiens,,CHEMBL619464,A2780,,,,F,1,1,
,BAO_0000219,7124,N,Concentration required to inhibit A2780-cell growth by 50%,Expert,478.0,81034,,14553,,9606.0,Homo sapiens,,CHEMBL619465,A2780,,,,F,1,1,
,BAO_0000219,7125,N,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,Expert,478.0,81034,,13040,,9606.0,Homo sapiens,,CHEMBL619466,A2780,,,,F,1,1,
,BAO_0000219,7126,N,Cytotoxic effect on human ovarian (A2780) cancer cell line,Expert,478.0,81034,,6891,,9606.0,Homo sapiens,,CHEMBL619467,A2780,,,,F,1,1,
,BAO_0000219,7127,N,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,Intermediate,478.0,81034,,15569,,9606.0,Homo sapiens,,CHEMBL619468,A2780,,,,F,1,1,
,BAO_0000219,7128,N,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,Expert,478.0,81034,,14190,,9606.0,Homo sapiens,,CHEMBL619469,A2780,,,,F,1,1,
,BAO_0000219,7129,N,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,Expert,478.0,81034,,15014,,9606.0,Homo sapiens,,CHEMBL619470,A2780,,,,F,1,1,
,BAO_0000219,7130,N,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,Intermediate,478.0,81034,,15014,,9606.0,Homo sapiens,,CHEMBL619471,A2780,,,,F,1,1,
,BAO_0000219,7131,N,Cytotoxicity against human ovarian carcinoma A2780 cell line,Intermediate,478.0,81034,,17496,,9606.0,Homo sapiens,,CHEMBL619472,A2780,,,,F,1,1,
,BAO_0000219,7132,N,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",Intermediate,478.0,81034,,13617,,9606.0,Homo sapiens,,CHEMBL619473,A2780,,,,F,1,1,
,BAO_0000219,7133,N,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",Intermediate,478.0,81034,,13617,,9606.0,Homo sapiens,,CHEMBL874368,A2780,,,,F,1,1,
,BAO_0000219,7134,N,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",Intermediate,478.0,81034,,13617,,9606.0,Homo sapiens,,CHEMBL884003,A2780,,,,F,1,1,
,BAO_0000219,7135,N,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",Intermediate,478.0,81034,,13617,,9606.0,Homo sapiens,,CHEMBL622690,A2780,,,,F,1,1,
,BAO_0000219,7136,N,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,Intermediate,478.0,81034,,17672,,9606.0,Homo sapiens,,CHEMBL622691,A2780,,,,F,1,1,
,BAO_0000219,7137,N,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,Intermediate,478.0,81034,,4544,,9606.0,Homo sapiens,,CHEMBL622692,A2780,,,,F,1,1,
,BAO_0000219,7138,N,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,Intermediate,478.0,81034,,4544,,9606.0,Homo sapiens,,CHEMBL623406,A2780,,,,F,1,1,
,BAO_0000219,7139,N,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",Intermediate,478.0,81034,,16317,,9606.0,Homo sapiens,,CHEMBL884004,A2780,,,,F,1,1,
,BAO_0000219,7140,N,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,Intermediate,478.0,81034,,15099,,9606.0,Homo sapiens,,CHEMBL623407,A2780,,,,F,1,1,
,BAO_0000219,7141,N,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,Intermediate,478.0,81034,,13978,,9606.0,Homo sapiens,,CHEMBL623408,A2780,,,,F,1,1,
,BAO_0000219,7142,N,In vitro antitumor activity against A2780 cell line.,Expert,478.0,81034,,12989,,9606.0,Homo sapiens,,CHEMBL623409,A2780,,,,F,1,1,
,BAO_0000219,7143,N,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,Intermediate,478.0,81034,,5574,,9606.0,Homo sapiens,,CHEMBL623410,A2780,,,,F,1,1,
,BAO_0000219,7144,N,In vitro cytotoxicity against A2780 human ovarian cancer cell line,Expert,478.0,81034,,13528,,9606.0,Homo sapiens,,CHEMBL623576,A2780,,,,F,1,1,
,BAO_0000219,7145,N,Inhibitory activity against kidney A-CHN tumor cell growth in culture,Intermediate,626.0,80025,,12782,,9606.0,Homo sapiens,,CHEMBL623577,ACHN,,,,F,1,1,
,BAO_0000219,7146,N,The IC50 value was measured on ACHN cell line in renal tumor type.,Intermediate,626.0,80025,,14255,,9606.0,Homo sapiens,,CHEMBL623578,ACHN,,,,F,1,1,
,BAO_0000219,7147,N,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,Intermediate,626.0,80025,,16364,,9606.0,Homo sapiens,,CHEMBL623579,ACHN,,,,F,1,1,
,BAO_0000219,7148,N,In vitro lethal concentration against most sensitive ACHN cell line,Expert,626.0,80025,,17376,,9606.0,Homo sapiens,,CHEMBL623580,ACHN,,,,F,1,1,
,BAO_0000219,7149,N,Tested for cytotoxic activity against renal cancer ACHN cell line,Intermediate,626.0,80025,,12016,,9606.0,Homo sapiens,,CHEMBL623581,ACHN,,,,F,1,1,
,BAO_0000219,7150,N,Compound tested for growth inhibition of renal cancer cell line ACHN,Intermediate,626.0,80025,,6058,,9606.0,Homo sapiens,,CHEMBL857456,ACHN,,,,F,1,1,
,BAO_0000219,7151,N,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,Intermediate,626.0,80025,,17708,,9606.0,Homo sapiens,,CHEMBL623582,ACHN,,,,F,1,1,
,BAO_0000219,7152,N,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,Intermediate,626.0,80025,,15176,,9606.0,Homo sapiens,,CHEMBL623583,ACHN,,,,F,1,1,
,BAO_0000219,7153,N,In vitro anticancer activity against ACHN renal cancer cell line,Intermediate,626.0,80025,,2806,,9606.0,Homo sapiens,,CHEMBL623584,ACHN,,,,F,1,1,
,BAO_0000219,7154,N,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,Intermediate,626.0,80025,,15300,,9606.0,Homo sapiens,,CHEMBL623585,ACHN,,,,F,1,1,
,BAO_0000219,7155,N,Percent selectivity was evaluated in renal ACHN cell lines,Intermediate,626.0,80025,,16364,,9606.0,Homo sapiens,,CHEMBL623586,ACHN,,,,F,1,1,
,BAO_0000219,7156,N,In vitro inhibitory activity against renal ACHN cancer cell line,Intermediate,626.0,80025,,13859,,9606.0,Homo sapiens,,CHEMBL623587,ACHN,,,,F,1,1,
,BAO_0000219,7157,N,Tested for cytotoxicity against ACHN cell lines in renal cancer,Intermediate,626.0,80025,,11970,,9606.0,Homo sapiens,,CHEMBL875279,ACHN,,,,F,1,1,
,BAO_0000219,7158,N,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,Intermediate,626.0,80025,,2450,,9606.0,Homo sapiens,,CHEMBL623588,ACHN,,,,F,1,1,
,BAO_0000219,7159,N,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,Intermediate,626.0,80025,,12696,,9606.0,Homo sapiens,,CHEMBL623589,ACHN,,,,F,1,1,
,BAO_0000219,7160,N,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,Intermediate,626.0,80025,,12400,,9606.0,Homo sapiens,,CHEMBL623590,ACHN,,,,F,1,1,
,BAO_0000219,7161,N,Cytotoxic effect on renal cancer line ACHN,Expert,626.0,80025,,12888,,9606.0,Homo sapiens,,CHEMBL623591,ACHN,,,,F,1,1,
,BAO_0000219,7162,N,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,Intermediate,626.0,80025,,3156,,9606.0,Homo sapiens,,CHEMBL623592,ACHN,,,,F,1,1,
,BAO_0000219,7163,N,In vitro inhibition of Renal Cancer ACHN cell lines,Intermediate,626.0,80025,,3381,,9606.0,Homo sapiens,,CHEMBL623593,ACHN,,,,F,1,1,
,BAO_0000219,7164,N,Antitumor activity against human renal adenocarcinoma ACHN cells,Intermediate,626.0,80025,,16747,,9606.0,Homo sapiens,,CHEMBL623594,ACHN,,,,F,1,1,
,BAO_0000219,7165,N,Antitumor activity against human renal adenocarcinoma ACHN cells.,Expert,626.0,80025,,16748,,9606.0,Homo sapiens,,CHEMBL621833,ACHN,,,,F,1,1,
,BAO_0000219,7166,N,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,Intermediate,626.0,80025,,12062,,9606.0,Homo sapiens,,CHEMBL621834,ACHN,,,,F,1,1,
,BAO_0000219,7167,N,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),Intermediate,626.0,80025,,14769,,9606.0,Homo sapiens,,CHEMBL621835,ACHN,,,,F,1,1,
,BAO_0000219,7168,N,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",Intermediate,626.0,80025,,15895,,9606.0,Homo sapiens,,CHEMBL621836,ACHN,,,,F,1,1,
,BAO_0000219,7169,N,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,Intermediate,626.0,80025,,17376,,9606.0,Homo sapiens,,CHEMBL621837,ACHN,,,,F,1,1,
,BAO_0000219,7170,N,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,Intermediate,626.0,80025,,14882,,9606.0,Homo sapiens,,CHEMBL875280,ACHN,,,,F,1,1,
,BAO_0000219,7171,N,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,Intermediate,626.0,80025,,14882,,9606.0,Homo sapiens,,CHEMBL621838,ACHN,,,,F,1,1,
,BAO_0000219,7172,N,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,Intermediate,626.0,80025,,15661,,9606.0,Homo sapiens,,CHEMBL621839,ACHN,,,,F,1,1,
,BAO_0000019,7173,U,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,Autocuration,,22224,,9680,,,,,CHEMBL621840,,,,,A,1,0,
,BAO_0000019,7174,H,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,Autocuration,,10647,,14579,,,,,CHEMBL621841,,,,,F,1,8,
,BAO_0000218,7175,N,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,Expert,468.0,50529,,17290,,10358.0,Cytomegalovirus,,CHEMBL622979,HEL,,,,F,1,1,
,BAO_0000218,7176,N,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,Intermediate,,50529,,17290,,10358.0,Cytomegalovirus,,CHEMBL876595,,,,,F,1,1,
,BAO_0000357,7177,H,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),Autocuration,,12159,,15891,,,,,CHEMBL620221,,,,,B,1,8,
,BAO_0000357,7178,H,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),Autocuration,,12159,,15890,,,,,CHEMBL620222,,,,,B,1,8,
,BAO_0000219,7179,N,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,Intermediate,979.0,80670,,3801,,9913.0,Bos taurus,,CHEMBL620506,ADDP cell line,,,,F,1,1,
,BAO_0000219,7180,N,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,Intermediate,980.0,80671,,9222,,10090.0,Mus musculus,,CHEMBL620507,ADJ/PC6,,,,F,1,1,
,BAO_0000219,7181,N,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,Intermediate,980.0,80671,,9222,,10090.0,Mus musculus,,CHEMBL620508,ADJ/PC6,,,,F,1,1,
,BAO_0000219,7182,N,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",Intermediate,980.0,80671,,7257,,10090.0,Mus musculus,,CHEMBL620509,ADJ/PC6,,,,F,1,1,
,BAO_0000219,7183,N,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,Intermediate,980.0,80671,,7257,,10090.0,Mus musculus,,CHEMBL620510,ADJ/PC6,,,,F,1,1,
,BAO_0000219,7184,N,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,Intermediate,980.0,80671,,7257,,10090.0,Mus musculus,,CHEMBL620511,ADJ/PC6,,,,A,1,1,
,BAO_0000219,7185,N,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,Intermediate,980.0,80671,,8084,,10090.0,Mus musculus,,CHEMBL620512,ADJ/PC6,,,,F,1,1,
,BAO_0000019,7186,U,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,Autocuration,,22224,,14943,,10090.0,Mus musculus,,CHEMBL620513,,,,,F,1,0,
,BAO_0000019,7187,U,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,Autocuration,,22224,,14943,,10090.0,Mus musculus,,CHEMBL620514,,,,,F,1,0,
,BAO_0000019,7188,U,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,Autocuration,,22224,,14943,,10090.0,Mus musculus,,CHEMBL620515,,,,,F,1,0,
,BAO_0000218,7189,U,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),Autocuration,,22224,,10524,,1423.0,Bacillus subtilis,,CHEMBL620516,,,In vivo,,A,1,0,
Plasma,BAO_0000218,7190,N,AUC value in dog after IV administration at a dose of 5 mg/kg,Intermediate,,50588,,3546,1969.0,9615.0,Canis lupus familiaris,,CHEMBL620517,,,,,A,1,1,
Plasma,BAO_0000218,7191,N,AUC value in dog after oral administration at a dose of 5 mg/kg,Intermediate,,50588,,3546,1969.0,9615.0,Canis lupus familiaris,,CHEMBL620518,,,,,A,1,1,
,BAO_0000218,7192,N,Cmax value in dog after oral administration at a dose of 5 mg/kg,Intermediate,,50588,,3546,,9615.0,Canis lupus familiaris,,CHEMBL620519,,,In vivo,,A,1,1,
,BAO_0000218,7193,N,Bioavailability in dog after oral administration at a dose of 5 mg/kg,Intermediate,,50588,,3546,,9615.0,Canis lupus familiaris,,CHEMBL621386,,,In vivo,,A,1,1,
,BAO_0000218,7194,N,Tmax value in dog after oral administration at a dose of 5 mg/kg,Intermediate,,50588,,3546,,9615.0,Canis lupus familiaris,,CHEMBL621387,,,In vivo,,A,1,1,
,BAO_0000218,7195,N,Compound was evaluated for its clearance when administered intravenously in dog,Intermediate,,50588,,3184,,9615.0,Canis lupus familiaris,,CHEMBL621388,,,In vivo,,A,1,1,
,BAO_0000218,7196,N,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,Intermediate,,50588,,16456,,9615.0,Canis lupus familiaris,,CHEMBL621389,,,In vivo,,A,1,1,
,BAO_0000218,7197,N,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),Intermediate,,50588,,4809,,9615.0,Canis lupus familiaris,,CHEMBL621390,,,In vivo,,A,1,1,
,BAO_0000100,7198,U,Calculated partition coefficient (clogP),Intermediate,,22229,,4219,,,,,CHEMBL621391,,,,,P,1,0,
,BAO_0000218,7199,N,Half life in dog,Intermediate,,50588,,3748,,9615.0,Canis lupus familiaris,,CHEMBL621392,,,,,A,1,1,
,BAO_0000218,7200,N,Time taken for EC90 was determined when tested in dog,Intermediate,,50588,,3132,,9615.0,Canis lupus familiaris,,CHEMBL621393,,,,,A,1,1,
,BAO_0000218,7201,N,Half life (iv) was determined,Intermediate,,50588,,4219,,9615.0,Canis lupus familiaris,,CHEMBL621394,,,,,A,1,1,
Liver,BAO_0000218,7202,N,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,Intermediate,,50588,,16907,2107.0,9615.0,Canis lupus familiaris,,CHEMBL621395,,,,,A,1,1,
,BAO_0000218,7203,N,Area under the curve was calculated in dog after iv administration,Intermediate,,50588,,6057,,9615.0,Canis lupus familiaris,,CHEMBL621396,,,,,A,1,1,
,BAO_0000218,7204,N,Area under the curve was calculated in dog after peroral administration,Intermediate,,50588,,6057,,9615.0,Canis lupus familiaris,,CHEMBL621397,,,,,A,1,1,
,BAO_0000218,7205,N,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,Intermediate,,50588,,17853,,9615.0,Canis lupus familiaris,,CHEMBL621398,,,,,A,1,1,
,BAO_0000218,7206,N,pKa was evaluated in dog,Intermediate,,50588,,3639,,9615.0,Canis lupus familiaris,,CHEMBL618818,,,,,A,1,1,
,BAO_0000218,7207,N,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,Intermediate,,50588,,14541,,9615.0,Canis lupus familiaris,,CHEMBL618819,,,,,A,1,1,
,BAO_0000218,7208,N,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,Intermediate,,50588,,16456,,9615.0,Canis lupus familiaris,,CHEMBL618820,,,In vivo,,A,1,1,
,BAO_0000218,7209,N,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,Intermediate,,50588,,16456,,9615.0,Canis lupus familiaris,,CHEMBL873810,,,In vivo,,A,1,1,
,BAO_0000218,7210,N,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,Intermediate,,50588,,2652,,9615.0,Canis lupus familiaris,,CHEMBL876606,,,In vivo,,A,1,1,
,BAO_0000218,7211,N,Compound was evaluated for the half-life (t 1/2) in hours,Intermediate,,50588,,3624,,9615.0,Canis lupus familiaris,,CHEMBL618821,,,,,A,1,1,
Blood,BAO_0000218,7212,N,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Intermediate,,50588,,1337,178.0,9615.0,Canis lupus familiaris,,CHEMBL618822,,,In vivo,,A,1,1,
Blood,BAO_0000218,7213,N,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Intermediate,,50588,,1337,178.0,9615.0,Canis lupus familiaris,,CHEMBL618823,,,In vivo,,A,1,1,
,BAO_0000218,7214,N,Half life after intravenous administration of 1 mg/kg in dog,Intermediate,,50588,,4709,,9615.0,Canis lupus familiaris,,CHEMBL618824,,,In vivo,,A,1,1,
,BAO_0000218,7215,N,Half life was measured in dog,Intermediate,,50588,,15660,,9615.0,Canis lupus familiaris,,CHEMBL618825,,,,,A,1,1,
,BAO_0000218,7216,N,Half life period in dog after 5 mg/kg dose,Intermediate,,50588,,5302,,9615.0,Canis lupus familiaris,,CHEMBL618826,,,In vivo,,A,1,1,
,BAO_0000218,7217,N,Half life period was evaluated in dog; 4-4.8,Intermediate,,50588,,17791,,9615.0,Canis lupus familiaris,,CHEMBL618827,,,,,A,1,1,
,BAO_0000218,7218,N,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Intermediate,,50588,,6348,,9615.0,Canis lupus familiaris,,CHEMBL618828,,,In vivo,,A,1,1,
,BAO_0000218,7219,N,Half-life was determined in dog after a3 mg/kg of iv dose,Intermediate,,50588,,4257,,9615.0,Canis lupus familiaris,,CHEMBL618829,,,In vivo,,A,1,1,
,BAO_0000218,7220,N,Half-life was determined,Intermediate,,50588,,3771,,9615.0,Canis lupus familiaris,,CHEMBL618830,,,,,A,1,1,
,BAO_0000218,7221,N,Half life in dogs,Intermediate,,50588,,6305,,9615.0,Canis lupus familiaris,,CHEMBL618831,,,,,A,1,1,
Plasma,BAO_0000218,7222,N,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,Intermediate,,50588,,13501,1969.0,9615.0,Canis lupus familiaris,,CHEMBL619489,,,In vivo,,A,1,1,
,BAO_0000218,7223,N,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,Intermediate,,50588,,17594,,9615.0,Canis lupus familiaris,,CHEMBL619649,,,In vivo,,A,1,1,
,BAO_0000218,7224,N,Compound was evaluated for the half life period after iv administration in Beagle dog.,Intermediate,,50588,,3045,,9615.0,Canis lupus familiaris,,CHEMBL876607,,,In vivo,,A,1,1,
,BAO_0000218,7225,N,Compound was evaluated for the half life period after oral administration in conscious dog.,Intermediate,,50588,,3043,,9615.0,Canis lupus familiaris,,CHEMBL619650,,,In vivo,,A,1,1,
,BAO_0000218,7226,N,Compound was tested for half life in dog,Intermediate,,50588,,4839,,9615.0,Canis lupus familiaris,,CHEMBL619651,,,,,A,1,1,
,BAO_0000218,7227,N,Compound was tested for its half life in dog,Intermediate,,50588,,4839,,9615.0,Canis lupus familiaris,,CHEMBL619652,,,,,A,1,1,
,BAO_0000218,7228,N,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,Intermediate,,50588,,5802,,9615.0,Canis lupus familiaris,,CHEMBL619653,,,In vivo,,A,1,1,
,BAO_0000218,7229,N,Half life of compound in dog was determined,Intermediate,,50588,,17839,,9615.0,Canis lupus familiaris,,CHEMBL619654,,,,,A,1,1,
,BAO_0000218,7230,N,Half life (iv) was determined,Intermediate,,50588,,4219,,9615.0,Canis lupus familiaris,,CHEMBL619655,,,In vivo,,A,1,1,
Blood,BAO_0000218,7231,N,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),Intermediate,,50588,,13966,178.0,9615.0,Canis lupus familiaris,,CHEMBL619656,,,,,A,1,1,
Plasma,BAO_0000218,7232,N,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,Intermediate,,50588,,3994,1969.0,9615.0,Canis lupus familiaris,,CHEMBL873812,,,In vivo,,A,1,1,
Plasma,BAO_0000218,7233,N,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,Intermediate,,50588,,3994,1969.0,9615.0,Canis lupus familiaris,,CHEMBL621365,,,In vivo,,F,1,1,
,BAO_0000218,7234,N,Half life in dog,Intermediate,,50588,,4453,,9615.0,Canis lupus familiaris,,CHEMBL621366,,,,,A,1,1,
Plasma,BAO_0000218,7235,N,Half life in dog plasma,Intermediate,,50588,,6535,1969.0,9615.0,Canis lupus familiaris,,CHEMBL621367,,,,,A,1,1,
Plasma,BAO_0000218,7236,N,Half life in dog plasma after administration of 0.25 mg/kg iv,Intermediate,,50588,,6535,1969.0,9615.0,Canis lupus familiaris,,CHEMBL621368,,,In vivo,,A,1,1,
Plasma,BAO_0000218,7237,N,Half life in dog plasma after administration of 1 mg/kg iv,Intermediate,,50588,,6535,1969.0,9615.0,Canis lupus familiaris,,CHEMBL621369,,,In vivo,,A,1,1,
Plasma,BAO_0000218,7238,N,Half life in dog plasma was determined at dose 10 mg/kg,Intermediate,,50588,,3132,1969.0,9615.0,Canis lupus familiaris,,CHEMBL621370,,,In vivo,,A,1,1,
,BAO_0000218,7239,N,Half life in dog was determined,Intermediate,,50588,,5374,,9615.0,Canis lupus familiaris,,CHEMBL621371,,,,,A,1,1,
,BAO_0000218,7240,N,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),Intermediate,,50588,,5007,,9615.0,Canis lupus familiaris,,CHEMBL621372,,,In vivo,,A,1,1,
Plasma,BAO_0000218,7241,N,Half life upon exposure to human plasma,Intermediate,,50588,,16907,1969.0,9615.0,Canis lupus familiaris,,CHEMBL621373,,,,,A,1,1,
,BAO_0000218,7242,N,Half life was calculated in dog,Intermediate,,50588,,6057,,9615.0,Canis lupus familiaris,,CHEMBL621374,,,,,A,1,1,
,BAO_0000218,7243,N,Half life was determined,Intermediate,,50588,,5006,,9615.0,Canis lupus familiaris,,CHEMBL621375,,,,,A,1,1,
,BAO_0000218,7244,N,Half life was determined,Intermediate,,50588,,5473,,9615.0,Canis lupus familiaris,,CHEMBL621376,,,,,A,1,1,
,BAO_0000218,7245,N,Half life by intravenous administration of 1.2 mg/kg in dog,Intermediate,,50588,,4368,,9615.0,Canis lupus familiaris,,CHEMBL619624,,,In vivo,,A,1,1,
,BAO_0000218,7246,N,Half life in dog,Intermediate,,50588,,6448,,9615.0,Canis lupus familiaris,,CHEMBL875840,,,,,A,1,1,
,BAO_0000218,7247,N,Half life in dog after intra venous administration of the compound,Intermediate,,50588,,4353,,9615.0,Canis lupus familiaris,,CHEMBL619625,,,,,A,1,1,
,BAO_0000218,7248,N,Half life in dog after intra venous administration of the compound; ND means Not determined,Intermediate,,50588,,4353,,9615.0,Canis lupus familiaris,,CHEMBL619626,,,,,A,1,1,
,BAO_0000218,7249,N,Half life in dog after po administration of the compound,Intermediate,,50588,,4353,,9615.0,Canis lupus familiaris,,CHEMBL619627,,,In vivo,,A,1,1,
,BAO_0000218,7250,N,Half life in dog after po administration of the compound; ND means Not determined,Intermediate,,50588,,4353,,9615.0,Canis lupus familiaris,,CHEMBL873817,,,In vivo,,A,1,1,
,BAO_0000218,7251,N,Half life in dog at the single oral dose of 1 mg/kg,Intermediate,,50588,,6265,,9615.0,Canis lupus familiaris,,CHEMBL619628,,,In vivo,,A,1,1,
,BAO_0000218,7252,N,Half life in dogs,Intermediate,,50588,,5006,,9615.0,Canis lupus familiaris,,CHEMBL619629,,,,,A,1,1,
,BAO_0000218,7253,N,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,Intermediate,,50588,,5356,,9615.0,Canis lupus familiaris,,CHEMBL619630,,,In vivo,,A,1,1,
,BAO_0000218,7254,N,Half life in rat,Intermediate,,50588,,405,,9615.0,Canis lupus familiaris,,CHEMBL619631,,,,,A,1,1,
,BAO_0000218,7255,N,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),Intermediate,,50588,,6642,,9615.0,Canis lupus familiaris,,CHEMBL619632,,,In vivo,,A,1,1,
Bone,BAO_0000218,7256,N,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,50594,,10107,10000001.0,10090.0,Mus musculus,,CHEMBL619633,,,In vivo,,A,1,1,
Bone,BAO_0000218,7257,N,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,50594,,10107,10000001.0,10090.0,Mus musculus,,CHEMBL875841,,,In vivo,,A,1,1,
Bone,BAO_0000218,7258,N,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,50594,,10107,10000001.0,10090.0,Mus musculus,,CHEMBL619634,,,In vivo,,A,1,1,
Bone,BAO_0000218,7259,N,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,,50594,,10107,10000001.0,10090.0,Mus musculus,,CHEMBL619635,,,In vivo,,A,1,1,
Bone,BAO_0000218,7260,N,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,50594,,10107,10000001.0,10090.0,Mus musculus,,CHEMBL619636,,,In vivo,,A,1,1,
Gut,BAO_0000218,7261,N,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,50594,,10107,10000004.0,10090.0,Mus musculus,,CHEMBL619637,,,In vivo,,A,1,1,
Gut,BAO_0000218,7262,N,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Intermediate,,50594,,10107,10000004.0,10090.0,Mus musculus,,CHEMBL619638,,,In vivo,,A,1,1,
Gut,BAO_0000218,7263,N,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,50594,,10107,10000004.0,10090.0,Mus musculus,,CHEMBL619639,,,In vivo,,A,1,1,
Gut,BAO_0000218,7264,N,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,50594,,10107,10000004.0,10090.0,Mus musculus,,CHEMBL619640,,,In vivo,,A,1,1,
Gut,BAO_0000218,7265,N,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,50594,,10107,10000004.0,10090.0,Mus musculus,,CHEMBL619641,,,In vivo,,A,1,1,
Gut,BAO_0000218,7266,N,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,,50594,,10107,10000004.0,10090.0,Mus musculus,,CHEMBL619642,,,In vivo,,A,1,1,
Gut,BAO_0000218,7267,N,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,50594,,10107,10000004.0,10090.0,Mus musculus,,CHEMBL619643,,,In vivo,,A,1,1,
Heart,BAO_0000218,7268,N,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,50594,,10107,948.0,10090.0,Mus musculus,,CHEMBL619644,,,In vivo,,A,1,1,
Heart,BAO_0000218,7269,N,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Intermediate,,50594,,10107,948.0,10090.0,Mus musculus,,CHEMBL621112,,,In vivo,,A,1,1,
Heart,BAO_0000218,7270,N,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,50594,,10107,948.0,10090.0,Mus musculus,,CHEMBL621113,,,In vivo,,A,1,1,
Heart,BAO_0000218,7271,N,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,50594,,10107,948.0,10090.0,Mus musculus,,CHEMBL621114,,,In vivo,,A,1,1,
Heart,BAO_0000218,7272,N,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,50594,,10107,948.0,10090.0,Mus musculus,,CHEMBL621115,,,In vivo,,A,1,1,
Heart,BAO_0000218,7273,N,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,,50594,,10107,948.0,10090.0,Mus musculus,,CHEMBL621116,,,In vivo,,A,1,1,
Heart,BAO_0000218,7274,N,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,50594,,10107,948.0,10090.0,Mus musculus,,CHEMBL621117,,,In vivo,,A,1,1,
Kidney,BAO_0000218,7275,N,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,50594,,10107,2113.0,10090.0,Mus musculus,,CHEMBL621118,,,In vivo,,A,1,1,
Kidney,BAO_0000218,7276,N,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Intermediate,,50594,,10107,2113.0,10090.0,Mus musculus,,CHEMBL621119,,,In vivo,,A,1,1,
Kidney,BAO_0000218,7277,N,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,50594,,10107,2113.0,10090.0,Mus musculus,,CHEMBL621120,,,In vivo,,A,1,1,
Kidney,BAO_0000218,7278,N,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,50594,,10107,2113.0,10090.0,Mus musculus,,CHEMBL621757,,,In vivo,,A,1,1,
Kidney,BAO_0000218,7279,N,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,50594,,10107,2113.0,10090.0,Mus musculus,,CHEMBL621758,,,In vivo,,A,1,1,
Kidney,BAO_0000218,7280,N,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,,50594,,10107,2113.0,10090.0,Mus musculus,,CHEMBL621759,,,In vivo,,A,1,1,
Kidney,BAO_0000218,7281,N,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,50594,,10107,2113.0,10090.0,Mus musculus,,CHEMBL621760,,,In vivo,,A,1,1,
Liver,BAO_0000218,7282,N,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,50594,,10107,2107.0,10090.0,Mus musculus,,CHEMBL621761,,,In vivo,,A,1,1,
Liver,BAO_0000218,7283,N,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Intermediate,,50594,,10107,2107.0,10090.0,Mus musculus,,CHEMBL621762,,,In vivo,,A,1,1,
Liver,BAO_0000218,7284,N,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,50594,,10107,2107.0,10090.0,Mus musculus,,CHEMBL621763,,,In vivo,,A,1,1,
Liver,BAO_0000218,7285,N,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,50594,,10107,2107.0,10090.0,Mus musculus,,CHEMBL624502,,,In vivo,,A,1,1,
Liver,BAO_0000218,7286,N,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,50594,,10107,2107.0,10090.0,Mus musculus,,CHEMBL624503,,,In vivo,,A,1,1,
Liver,BAO_0000218,7287,N,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,,50594,,10107,2107.0,10090.0,Mus musculus,,CHEMBL624504,,,In vivo,,A,1,1,
Liver,BAO_0000218,7288,N,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,50594,,10107,2107.0,10090.0,Mus musculus,,CHEMBL624505,,,In vivo,,A,1,1,
Lung,BAO_0000218,7289,N,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,50594,,10107,2048.0,10090.0,Mus musculus,,CHEMBL624506,,,In vivo,,A,1,1,
,BAO_0000219,7290,N,In vitro cytotoxicity against A2780 (human ovarian cancer),Intermediate,478.0,81034,,5895,,9606.0,Homo sapiens,,CHEMBL624507,A2780,,,,F,1,1,
,BAO_0000219,7291,N,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,Intermediate,478.0,81034,,6338,,9606.0,Homo sapiens,,CHEMBL624508,A2780,,,,F,1,1,
,BAO_0000219,7292,N,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,Intermediate,478.0,81034,,15163,,9606.0,Homo sapiens,,CHEMBL624509,A2780,,,,F,1,1,
,BAO_0000219,7293,N,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,Intermediate,478.0,81034,,15163,,9606.0,Homo sapiens,,CHEMBL624510,A2780,,,,F,1,1,
,BAO_0000219,7294,N,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,Expert,478.0,81034,,15000,,9606.0,Homo sapiens,,CHEMBL875956,A2780,,,,F,1,1,
,BAO_0000219,7295,N,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,Expert,478.0,81034,,15000,,9606.0,Homo sapiens,,CHEMBL839885,A2780,,,,F,1,1,
,BAO_0000219,7296,N,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,Expert,478.0,81034,,14729,,9606.0,Homo sapiens,,CHEMBL624511,A2780,,,,F,1,1,
,BAO_0000219,7297,N,In vitro cytotoxicity against A2780 cell line,Intermediate,478.0,81034,,17270,,9606.0,Homo sapiens,,CHEMBL624512,A2780,,,,F,1,1,
,BAO_0000219,7298,N,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,Intermediate,478.0,81034,,5685,,9606.0,Homo sapiens,,CHEMBL624513,A2780,,,,F,1,1,
,BAO_0000219,7299,N,In vitro inhibitory activity against human ovarian cancer A2780 cell line,Intermediate,478.0,81034,,3563,,9606.0,Homo sapiens,,CHEMBL624514,A2780,,,,F,1,1,
,BAO_0000218,7300,N,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,Intermediate,478.0,81034,,17753,,9606.0,Homo sapiens,,CHEMBL618547,A2780,,,,F,1,1,
,BAO_0000219,7301,N,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",Intermediate,478.0,81034,,16317,,9606.0,Homo sapiens,,CHEMBL618548,A2780,,,,F,1,1,
,BAO_0000219,7302,N,Inhibition of tubulin polymerization in analogy of ca.,Intermediate,478.0,81034,,16936,,9606.0,Homo sapiens,,CHEMBL618549,A2780,,,,F,1,1,
,BAO_0000219,7303,N,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,Intermediate,478.0,81034,,3801,,9606.0,Homo sapiens,,CHEMBL618550,A2780,,,,F,1,1,
,BAO_0000219,7304,N,Cytotoxic effect in ovarian cancer cell line (A2780),Expert,478.0,81034,,6181,,9606.0,Homo sapiens,,CHEMBL618551,A2780,,,,F,1,1,
,BAO_0000219,7305,N,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,Intermediate,478.0,81034,,5318,,9606.0,Homo sapiens,,CHEMBL618552,A2780,,,,F,1,1,
,BAO_0000219,7306,N,Tested for the cytotoxicity in A2780 ovarian cell line,Intermediate,478.0,81034,,4840,,9606.0,Homo sapiens,,CHEMBL618553,A2780,,,,F,1,1,
,BAO_0000219,7307,N,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),Intermediate,478.0,81034,,15748,,9606.0,Homo sapiens,,CHEMBL618554,A2780,,,,F,1,1,
,BAO_0000219,7308,N,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,Intermediate,478.0,81034,,15748,,9606.0,Homo sapiens,,CHEMBL618555,A2780,,,,F,1,1,
,BAO_0000219,7309,N,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,Intermediate,481.0,80017,,15748,,,,,CHEMBL618556,A2780cisR,,,,F,1,1,
,BAO_0000219,7310,N,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),Intermediate,481.0,80017,,15748,,,,,CHEMBL618557,A2780cisR,,,,F,1,1,
,BAO_0000219,7311,N,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,Intermediate,481.0,80017,,15748,,,,,CHEMBL618558,A2780cisR,,,,F,1,1,
,BAO_0000219,7312,N,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),Intermediate,481.0,80017,,15748,,,,,CHEMBL618559,A2780cisR,,,,F,1,1,
,BAO_0000218,7313,N,In vivo log of cells killed after administration of compound in A2780 cell line,Intermediate,478.0,81034,,17753,,9606.0,Homo sapiens,,CHEMBL618560,A2780,,,,F,1,1,
,BAO_0000218,7314,N,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,Intermediate,478.0,81034,,17753,,9606.0,Homo sapiens,,CHEMBL618561,A2780,,In vivo,,F,1,1,
,BAO_0000219,7315,N,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,Intermediate,478.0,81034,,16936,,9606.0,Homo sapiens,,CHEMBL618562,A2780,,,,F,1,1,
,BAO_0000219,7316,N,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,Intermediate,478.0,81034,,16936,,9606.0,Homo sapiens,,CHEMBL618563,A2780,,,,F,1,1,
,BAO_0000219,7317,N,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,Intermediate,478.0,81034,,16936,,9606.0,Homo sapiens,,CHEMBL618564,A2780,,,,F,1,1,
,BAO_0000219,7318,N,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,Intermediate,478.0,81034,,16936,,9606.0,Homo sapiens,,CHEMBL618565,A2780,,,,F,1,1,
,BAO_0000218,7319,N,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),Intermediate,478.0,81034,,17528,,9606.0,Homo sapiens,,CHEMBL618566,A2780,,,,F,1,1,
,BAO_0000219,7320,N,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,Intermediate,478.0,81034,,6633,,9606.0,Homo sapiens,,CHEMBL618567,A2780,,,,F,1,1,
,BAO_0000219,7321,N,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,Expert,478.0,81034,,15000,,9606.0,Homo sapiens,,CHEMBL618568,A2780,,,,F,1,1,
,BAO_0000219,7322,N,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,Expert,478.0,81034,,17528,,9606.0,Homo sapiens,,CHEMBL618569,A2780,,,,F,1,1,
,BAO_0000219,7323,N,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,Intermediate,478.0,81034,,16936,,9606.0,Homo sapiens,,CHEMBL621857,A2780,,,,F,1,1,
,BAO_0000219,7324,N,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,Intermediate,478.0,81034,,16936,,9606.0,Homo sapiens,,CHEMBL621858,A2780,,,,F,1,1,
,BAO_0000219,7325,N,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,Intermediate,478.0,81034,,16936,,9606.0,Homo sapiens,,CHEMBL621859,A2780,,,,F,1,1,
,BAO_0000219,7326,N,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",Intermediate,478.0,81034,,16936,,9606.0,Homo sapiens,,CHEMBL621860,A2780,,,,F,1,1,
,BAO_0000219,7327,N,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),Intermediate,478.0,81034,,16936,,9606.0,Homo sapiens,,CHEMBL621861,A2780,,,,F,1,1,
,BAO_0000219,7328,N,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",Expert,478.0,81034,,16936,,9606.0,Homo sapiens,,CHEMBL621862,A2780,,,,F,1,1,
,BAO_0000219,7329,N,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),Intermediate,478.0,81034,,16936,,9606.0,Homo sapiens,,CHEMBL621863,A2780,,,,F,1,1,
,BAO_0000219,7330,N,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),Intermediate,478.0,81034,,16936,,9606.0,Homo sapiens,,CHEMBL621864,A2780,,,,F,1,1,
,BAO_0000219,7331,N,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),Intermediate,478.0,81034,,16936,,9606.0,Homo sapiens,,CHEMBL621865,A2780,,,,F,1,1,
,BAO_0000219,7332,N,In vitro antiproliferative activity against A2780 cell line,Intermediate,478.0,81034,,17737,,10090.0,Mus musculus,,CHEMBL621866,A2780,,,,F,1,1,
,BAO_0000219,7333,N,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,Expert,478.0,81034,,17764,,10090.0,Mus musculus,,CHEMBL621867,A2780,,,,F,1,1,
,BAO_0000219,7334,N,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,Intermediate,478.0,81034,,3830,,9606.0,Homo sapiens,,CHEMBL621868,A2780,,,,F,1,1,
,BAO_0000219,7335,N,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,Intermediate,478.0,81034,,3829,,9606.0,Homo sapiens,,CHEMBL875282,A2780,,,,F,1,1,
,BAO_0000218,7336,N,Vc value in dog after IV administration at a dose of 5 mg/kg,Intermediate,,50588,,3546,,9615.0,Canis lupus familiaris,,CHEMBL621869,,,,,A,1,1,
,BAO_0000218,7337,N,Half life period in dog after IV administration at a dose of 5 mg/kg,Intermediate,,50588,,3546,,9615.0,Canis lupus familiaris,,CHEMBL621870,,,In vivo,,A,1,1,
,BAO_0000019,7338,U,Area under curve was determine after peroral administration at 10 mpk in Rhesus,Autocuration,,22224,,5668,,9527.0,Cercopithecidae,,CHEMBL621871,,,,,A,1,0,
Plasma,BAO_0000218,7339,U,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,22224,,3443,1969.0,9527.0,Cercopithecidae,,CHEMBL621243,,,,,A,1,0,
Plasma,BAO_0000218,7340,U,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,22224,,3443,1969.0,9527.0,Cercopithecidae,,CHEMBL621244,,,,,A,1,0,
,BAO_0000218,7341,U,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,Autocuration,,22224,,4256,,9541.0,Macaca fascicularis,,CHEMBL621245,,,In vivo,,A,1,0,
,BAO_0000218,7342,U,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,Autocuration,,22224,,4256,,9541.0,Macaca fascicularis,,CHEMBL621246,,,In vivo,,A,1,0,
,BAO_0000218,7343,U,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,Autocuration,,22224,,4256,,9541.0,Macaca fascicularis,,CHEMBL621247,,,In vivo,,A,1,0,
,BAO_0000218,7344,U,Oral Bioavailability in rat,Autocuration,,22224,,4256,,10116.0,Rattus norvegicus,,CHEMBL618386,,,In vivo,,A,1,0,
,BAO_0000218,7345,U,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,Autocuration,,22224,,1916,,9527.0,Cercopithecidae,,CHEMBL618387,,,,,A,1,0,
,BAO_0000218,7346,U,Area under curve value in monkey at a dose of 5 mg/kg,Autocuration,,22224,,5302,,9527.0,Cercopithecidae,,CHEMBL618388,,,,,A,1,0,
,BAO_0000218,7347,U,Area under curve was determined in monkey after a 3 mg/kg of oral dose,Autocuration,,22224,,4257,,9527.0,Cercopithecidae,,CHEMBL618389,,,,,A,1,0,
,BAO_0000019,7348,U,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,Autocuration,,22224,,5355,,9527.0,Cercopithecidae,,CHEMBL618574,,,,,A,1,0,
,BAO_0000019,7349,U,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,Autocuration,,22224,,5355,,9527.0,Cercopithecidae,,CHEMBL618575,,,,,A,1,0,
,BAO_0000019,7350,U,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,Autocuration,,22224,,5355,,9527.0,Cercopithecidae,,CHEMBL618576,,,,,A,1,0,
,BAO_0000218,7351,U,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,Autocuration,,22224,,6078,,9527.0,Cercopithecidae,,CHEMBL618577,,,,,A,1,0,
,BAO_0000218,7352,U,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,Autocuration,,22224,,6078,,9527.0,Cercopithecidae,,CHEMBL876487,,,,,A,1,0,
,BAO_0000218,7353,U,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,Autocuration,,22224,,6062,,9527.0,Cercopithecidae,,CHEMBL618578,,,,,A,1,0,
,BAO_0000218,7354,U,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,Autocuration,,22224,,2661,,9527.0,Cercopithecidae,,CHEMBL618579,,,,,A,1,0,
,BAO_0000019,7355,U,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,Autocuration,,22224,,2661,,9527.0,Cercopithecidae,,CHEMBL618580,,,,,A,1,0,
,BAO_0000218,7356,U,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,Autocuration,,22224,,5394,,9527.0,Cercopithecidae,,CHEMBL618581,,,,,A,1,0,
,BAO_0000218,7357,U,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,Autocuration,,22224,,4397,,9527.0,Cercopithecidae,,CHEMBL618582,,,,,A,1,0,
,BAO_0000218,7358,U,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,Autocuration,,22224,,17509,,9527.0,Cercopithecidae,,CHEMBL618583,,,,,A,1,0,
,BAO_0000218,7359,U,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,Autocuration,,22224,,17509,,9527.0,Cercopithecidae,,CHEMBL618584,,,,,A,1,0,
,BAO_0000218,7360,U,Oral AUCN in monkey (dosed at 0.5 mpk iv ),Autocuration,,22224,,6641,,9527.0,Cercopithecidae,,CHEMBL618585,,,In vivo,,A,1,0,
,BAO_0000218,7361,U,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),Autocuration,,22224,,5355,,9527.0,Cercopithecidae,,CHEMBL618586,,,,,A,1,0,
,BAO_0000218,7362,U,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,22224,,3443,,9527.0,Cercopithecidae,,CHEMBL618587,,,In vivo,,A,1,0,
,BAO_0000218,7363,U,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Autocuration,,22224,,3443,,9527.0,Cercopithecidae,,CHEMBL618588,,,In vivo,,A,1,0,
,BAO_0000019,7364,U,Binding towards monkey plasma protein at 10 uM,Autocuration,,22224,,17409,,9527.0,Cercopithecidae,,CHEMBL618589,,,,,A,1,0,
,BAO_0000019,7365,U,Binding towards monkey plasma protein at 100 uM,Autocuration,,22224,,17409,,9527.0,Cercopithecidae,,CHEMBL618590,,,,,A,1,0,
,BAO_0000218,7366,U,Apparent bioavailability in squirrel monkey was determined,Autocuration,,22224,,1052,,9527.0,Cercopithecidae,,CHEMBL872262,,,In vivo,,A,1,0,
,BAO_0000218,7367,U,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,Autocuration,,22224,,13501,,9527.0,Cercopithecidae,,CHEMBL618591,,,In vivo,,A,1,0,
,BAO_0000218,7368,U,Bioavailability in monkey (dose 2 mg/kg),Autocuration,,22224,,17509,,9443.0,monkey,,CHEMBL618592,,,In vivo,,A,1,0,
,BAO_0000218,7369,U,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,Autocuration,,22224,,5394,,9527.0,Cercopithecidae,,CHEMBL876488,,,In vivo,,A,1,0,
,BAO_0000218,7370,U,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,Autocuration,,22224,,2661,,9527.0,Cercopithecidae,,CHEMBL618593,,,In vivo,,A,1,0,
,BAO_0000218,7371,U,Bioavailability in monkey (i.d. dosing),Autocuration,,22224,,11219,,9443.0,monkey,,CHEMBL618594,,,In vivo,,A,1,0,
,BAO_0000218,7372,U,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,Autocuration,,22224,,3045,,9527.0,Cercopithecidae,,CHEMBL618595,,,In vivo,,A,1,0,
,BAO_0000019,7373,U,Clearance of the drug was measured in cynomolgus,Autocuration,,22224,,17796,,9527.0,Cercopithecidae,,CHEMBL621469,,,,,A,1,0,
,BAO_0000218,7374,U,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,Autocuration,,22224,,1399,,9527.0,Cercopithecidae,,CHEMBL621470,,,In vivo,,A,1,0,
,BAO_0000218,7375,U,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,Autocuration,,22224,,2661,,9527.0,Cercopithecidae,,CHEMBL621471,,,In vivo,,A,1,0,
Plasma,BAO_0000218,7376,U,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Autocuration,,22224,,5005,1969.0,9544.0,Macaca mulatta,,CHEMBL621472,,,In vivo,,A,1,0,
,BAO_0000218,7377,U,Plasma clearance in rhesus monkey was determined,Autocuration,,22224,,17267,,9527.0,Cercopithecidae,,CHEMBL621473,,,In vivo,,A,1,0,
,BAO_0000218,7378,U,Plasma clearance in monkey after administration of 1 mg/kg iv,Autocuration,,22224,,6535,,9527.0,Cercopithecidae,,CHEMBL621474,,,In vivo,,A,1,0,
,BAO_0000218,7379,U,Plasma clearance in cynomolgus monkey,Autocuration,,22224,,5922,,9527.0,Cercopithecidae,,CHEMBL621475,,,In vivo,,A,1,0,
,BAO_0000218,7380,U,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,Autocuration,,22224,,6221,,9527.0,Cercopithecidae,,CHEMBL621476,,,In vivo,,A,1,0,
,BAO_0000218,7381,U,Plasma clearance after peroral administration at 10 mpk in Rhesus,Autocuration,,22224,,5668,,9527.0,Cercopithecidae,,CHEMBL624290,,,In vivo,,A,1,0,
,BAO_0000218,7382,U,The total clearance was determined after intravenous administration in cynomolgus monkeys,Autocuration,,22224,,5355,,9527.0,Cercopithecidae,,CHEMBL624291,,,In vivo,,A,1,0,
,BAO_0000218,7383,U,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,Autocuration,,22224,,5355,,9527.0,Cercopithecidae,,CHEMBL624292,,,In vivo,,A,1,0,
,BAO_0000218,7384,U,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,Autocuration,,22224,,5355,,9527.0,Cercopithecidae,,CHEMBL624293,,,In vivo,,A,1,0,
,BAO_0000218,7385,U,Tested for Clearance upon iv administration to african green monkey,Autocuration,,22224,,4578,,9527.0,Cercopithecidae,,CHEMBL624294,,,In vivo,,A,1,0,
,BAO_0000218,7386,U,Clearance in monkey,Autocuration,,22224,,17592,,9527.0,Cercopithecidae,,CHEMBL624295,,,In vivo,,A,1,0,
,BAO_0000218,7387,N,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Intermediate,,50588,,6641,,9615.0,Canis lupus familiaris,,CHEMBL624296,,,In vivo,,A,1,1,
,BAO_0000218,7388,N,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),Intermediate,,50588,,6642,,9615.0,Canis lupus familiaris,,CHEMBL624297,,,In vivo,,A,1,1,
,BAO_0000218,7389,N,Half life was evaluated after intravenous administration to dogs,Intermediate,,50588,,16367,,9615.0,Canis lupus familiaris,,CHEMBL624298,,,In vivo,,A,1,1,
,BAO_0000218,7390,N,Half life was evaluated in dog,Intermediate,,50588,,5472,,9615.0,Canis lupus familiaris,,CHEMBL624299,,,,,A,1,1,
,BAO_0000218,7391,N,Half life was evaluated in dog,Intermediate,,50588,,5474,,9615.0,Canis lupus familiaris,,CHEMBL624300,,,,,A,1,1,
,BAO_0000218,7392,N,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,Intermediate,,50588,,5654,,9615.0,Canis lupus familiaris,,CHEMBL624301,,,In vivo,,A,1,1,
,BAO_0000218,7393,N,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),Intermediate,,50588,,6227,,9615.0,Canis lupus familiaris,,CHEMBL624302,,,In vivo,,A,1,1,
,BAO_0000218,7394,N,Half life period after intravenous administration in dog,Intermediate,,50588,,6227,,9615.0,Canis lupus familiaris,,CHEMBL876026,,,In vivo,,A,1,1,
,BAO_0000218,7395,N,Half life period after oral administration (2.5 mg/kg) in dog was determined,Intermediate,,50588,,6221,,9615.0,Canis lupus familiaris,,CHEMBL624303,,,In vivo,,A,1,1,
,BAO_0000218,7396,N,Half life period at a dose of 1 uM/kg in dog was determined,Intermediate,,50588,,4527,,9615.0,Canis lupus familiaris,,CHEMBL624304,,,,,A,1,1,
,BAO_0000218,7397,N,Half life period was determine after peroral administration at 10 mpk in dog,Intermediate,,50588,,5668,,9615.0,Canis lupus familiaris,,CHEMBL624305,,,In vivo,,A,1,1,
,BAO_0000218,7398,N,Half life period was determine after peroral administration at 5 mpk in dog,Intermediate,,50588,,5668,,9615.0,Canis lupus familiaris,,CHEMBL624306,,,In vivo,,A,1,1,
,BAO_0000218,7399,N,Half life period was determined,Intermediate,,50588,,3854,,9615.0,Canis lupus familiaris,,CHEMBL624307,,,,,A,1,1,
,BAO_0000218,7400,N,Half life period was determined,Intermediate,,50588,,5505,,9615.0,Canis lupus familiaris,,CHEMBL624308,,,,,A,1,1,
,BAO_0000218,7401,N,Half life period by iv administration in dog at a dose of 6 mg/kg,Intermediate,,50588,,6251,,9615.0,Canis lupus familiaris,,CHEMBL624309,,,In vivo,,A,1,1,
,BAO_0000218,7402,N,Half life period was evaluated in dog,Intermediate,,50588,,1918,,9615.0,Canis lupus familiaris,,CHEMBL624310,,,,,A,1,1,
,BAO_0000218,7403,N,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,Intermediate,,50588,,5546,,9615.0,Canis lupus familiaris,,CHEMBL625003,,,In vivo,,A,1,1,
,BAO_0000218,7404,N,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),Intermediate,,50588,,4809,,9615.0,Canis lupus familiaris,,CHEMBL625004,,,In vivo,,A,1,1,
,BAO_0000218,7405,N,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,Intermediate,,50588,,6215,,9615.0,Canis lupus familiaris,,CHEMBL625005,,,In vivo,,A,1,1,
,BAO_0000218,7406,N,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,Intermediate,,50588,,4527,,9615.0,Canis lupus familiaris,,CHEMBL873813,,,In vivo,,A,1,1,
,BAO_0000218,7407,N,Half-life after oral dose of compound at 3 mg/kg in dogs,Intermediate,,50588,,17594,,9615.0,Canis lupus familiaris,,CHEMBL625006,,,In vivo,,A,1,1,
,BAO_0000218,7408,N,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,Intermediate,,50588,,17839,,9615.0,Canis lupus familiaris,,CHEMBL625007,,,In vivo,,A,1,1,
,BAO_0000218,7409,N,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,Intermediate,,50588,,17839,,9615.0,Canis lupus familiaris,,CHEMBL876027,,,In vivo,,A,1,1,
,BAO_0000218,7410,N,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,Intermediate,,50588,,17839,,9615.0,Canis lupus familiaris,,CHEMBL625008,,,In vivo,,A,1,1,
,BAO_0000218,7411,N,Half-life of compound in dog following p.o. administration of 1 mg/kg,Intermediate,,50588,,17839,,9615.0,Canis lupus familiaris,,CHEMBL625009,,,In vivo,,A,1,1,
Plasma,BAO_0000218,7412,N,Half-life of compound in plasma of dog was determined,Intermediate,,50588,,5210,1969.0,9615.0,Canis lupus familiaris,,CHEMBL625010,,,,,A,1,1,
,BAO_0000218,7413,N,Half-life of compound was determined in dogs,Intermediate,,50588,,5210,,9615.0,Canis lupus familiaris,,CHEMBL625011,,,,,A,1,1,
,BAO_0000218,7414,N,Half-life after administration of 4 mg/Kg oral dose in dog,Intermediate,,50588,,2959,,9615.0,Canis lupus familiaris,,CHEMBL621553,,,In vivo,,A,1,1,
,BAO_0000218,7415,N,Half-life after intravenous administration of 1 mg/kg/h in dog,Intermediate,,50588,,4137,,9615.0,Canis lupus familiaris,,CHEMBL621554,,,In vivo,,A,1,1,
,BAO_0000218,7416,N,Half-life in Dog,Intermediate,,50588,,5064,,9615.0,Canis lupus familiaris,,CHEMBL621555,,,,,A,1,1,
,BAO_0000218,7417,N,Half-life in Dog,Intermediate,,50588,,5147,,9615.0,Canis lupus familiaris,,CHEMBL621556,,,,,A,1,1,
,BAO_0000218,7418,N,Half-life in dog,Intermediate,,50588,,5145,,9615.0,Canis lupus familiaris,,CHEMBL621557,,,,,A,1,1,
,BAO_0000218,7419,N,Half-life in dog after oral administration at 1 mg/kg,Intermediate,,50588,,6123,,9615.0,Canis lupus familiaris,,CHEMBL621558,,,In vivo,,A,1,1,
,BAO_0000218,7420,N,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,Intermediate,,50588,,6123,,9615.0,Canis lupus familiaris,,CHEMBL621559,,,In vivo,,A,1,1,
,BAO_0000218,7421,N,Half-life in dogs,Intermediate,,50588,,4333,,9615.0,Canis lupus familiaris,,CHEMBL621560,,,,,A,1,1,
,BAO_0000218,7422,N,Half-life in dogs; ND indicates not determined,Intermediate,,50588,,4333,,9615.0,Canis lupus familiaris,,CHEMBL876028,,,,,A,1,1,
Plasma,BAO_0000218,7423,N,Half-life in plasma of dog,Intermediate,,50588,,12500,1969.0,9615.0,Canis lupus familiaris,,CHEMBL621561,,,,,A,1,1,
Plasma,BAO_0000218,7424,N,Half-life in plasma of dog at dose of 3-10 mgkg,Intermediate,,50588,,12500,1969.0,9615.0,Canis lupus familiaris,,CHEMBL621562,,,,,A,1,1,
,BAO_0000218,7425,N,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,Intermediate,,50588,,6005,,9615.0,Canis lupus familiaris,,CHEMBL621563,,,In vivo,,A,1,1,
,BAO_0000218,7426,N,Half-life was measured in dog after an iv dose of 1 mg/kg,Intermediate,,50588,,6062,,9615.0,Canis lupus familiaris,,CHEMBL621564,,,In vivo,,A,1,1,
,BAO_0000218,7427,N,Half-life was measured in dogs after an oral dose of 10 uM/kg,Intermediate,,50588,,17650,,9615.0,Canis lupus familiaris,,CHEMBL621565,,,In vivo,,A,1,1,
,BAO_0000218,7428,N,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,Intermediate,,50588,,5530,,9615.0,Canis lupus familiaris,,CHEMBL621566,,,In vivo,,A,1,1,
,BAO_0000218,7429,N,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,Intermediate,,50588,,5530,,9615.0,Canis lupus familiaris,,CHEMBL621567,,,In vivo,,A,1,1,
,BAO_0000218,7430,N,Half-life of the compound after 0.3 mg/kg po administration in dog,Intermediate,,50588,,5600,,9615.0,Canis lupus familiaris,,CHEMBL622978,,,In vivo,,A,1,1,
,BAO_0000218,7431,N,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,Intermediate,,50588,,6039,,9615.0,Canis lupus familiaris,,CHEMBL873814,,,In vivo,,A,1,1,
,BAO_0000218,7432,N,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,Intermediate,,50588,,6039,,9615.0,Canis lupus familiaris,,CHEMBL623219,,,In vivo,,A,1,1,
,BAO_0000218,7433,N,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,Intermediate,,50588,,6039,,9615.0,Canis lupus familiaris,,CHEMBL624477,,,In vivo,,A,1,1,
,BAO_0000218,7434,N,t1/2 in dog,Intermediate,,50588,,6227,,9615.0,Canis lupus familiaris,,CHEMBL624478,,,,,A,1,1,
,BAO_0000218,7435,N,Half-life period measured in dogs,Intermediate,,50588,,14541,,9615.0,Canis lupus familiaris,,CHEMBL624479,,,,,A,1,1,
,BAO_0000218,7436,N,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,Intermediate,,50588,,4521,,9615.0,Canis lupus familiaris,,CHEMBL624480,,,In vivo,,A,1,1,
,BAO_0000218,7437,N,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,Intermediate,,50588,,4521,,9615.0,Canis lupus familiaris,,CHEMBL623595,,,In vivo,,A,1,1,
,BAO_0000218,7438,N,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Intermediate,,50588,,6679,,9615.0,Canis lupus familiaris,,CHEMBL623596,,,In vivo,,A,1,1,
Plasma,BAO_0000218,7439,N,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",Intermediate,,50588,,1116,1969.0,9615.0,Canis lupus familiaris,,CHEMBL623597,,,In vitro,,A,1,1,
,BAO_0000218,7440,N,In vivo half life period was calculated at 1 mg/kg in dog,Intermediate,,50588,,5444,,9615.0,Canis lupus familiaris,,CHEMBL623598,,,In vivo,,A,1,1,
,BAO_0000218,7441,N,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,Intermediate,,50588,,5444,,9615.0,Canis lupus familiaris,,CHEMBL623599,,,In vivo,,A,1,1,
,BAO_0000218,7442,N,Longer half-life in dog (i.v.) at 0.5 mpk,Intermediate,,50588,,17853,,9615.0,Canis lupus familiaris,,CHEMBL623600,,,In vivo,,A,1,1,
,BAO_0000218,7443,N,Oral bioavailability in dog (dose 5 uM/kg),Intermediate,,50588,,4353,,9615.0,Canis lupus familiaris,,CHEMBL623601,,,In vivo,,A,1,1,
,BAO_0000218,7444,N,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,Intermediate,,50588,,16452,,9615.0,Canis lupus familiaris,,CHEMBL623602,,,In vivo,,A,1,1,
,BAO_0000218,7445,N,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,Intermediate,,50588,,16452,,9615.0,Canis lupus familiaris,,CHEMBL623603,,,In vivo,,A,1,1,
,BAO_0000218,7446,N,Bioavailability in dog (dose 1 mg/kg i.v.),Intermediate,,50588,,16452,,9615.0,Canis lupus familiaris,,CHEMBL623604,,,In vivo,,A,1,1,
Lung,BAO_0000218,7447,N,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Intermediate,,50594,,10107,2048.0,10090.0,Mus musculus,,CHEMBL623605,,,In vivo,,A,1,1,
Lung,BAO_0000218,7448,N,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,50594,,10107,2048.0,10090.0,Mus musculus,,CHEMBL623606,,,In vivo,,A,1,1,
Lung,BAO_0000218,7449,N,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,50594,,10107,2048.0,10090.0,Mus musculus,,CHEMBL623607,,,In vivo,,A,1,1,
Lung,BAO_0000218,7450,N,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,50594,,10107,2048.0,10090.0,Mus musculus,,CHEMBL623608,,,In vivo,,A,1,1,
Lung,BAO_0000218,7451,N,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,,50594,,10107,2048.0,10090.0,Mus musculus,,CHEMBL623609,,,In vivo,,A,1,1,
Lung,BAO_0000218,7452,N,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,50594,,10107,2048.0,10090.0,Mus musculus,,CHEMBL623610,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,7453,N,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,50594,,10107,2385.0,10090.0,Mus musculus,,CHEMBL623611,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,7454,N,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Intermediate,,50594,,10107,2385.0,10090.0,Mus musculus,,CHEMBL623612,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,7455,N,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,50594,,10107,2385.0,10090.0,Mus musculus,,CHEMBL623613,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,7456,N,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,50594,,10107,2385.0,10090.0,Mus musculus,,CHEMBL623614,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,7457,N,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,50594,,10107,2385.0,10090.0,Mus musculus,,CHEMBL623615,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,7458,N,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,,50594,,10107,2385.0,10090.0,Mus musculus,,CHEMBL623616,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,7459,N,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,50594,,10107,2385.0,10090.0,Mus musculus,,CHEMBL623617,,,In vivo,,A,1,1,
Zone of skin,BAO_0000218,7460,N,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,50594,,10107,14.0,10090.0,Mus musculus,,CHEMBL875944,,,In vivo,,A,1,1,
Zone of skin,BAO_0000218,7461,N,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Intermediate,,50594,,10107,14.0,10090.0,Mus musculus,,CHEMBL623618,,,In vivo,,A,1,1,
Zone of skin,BAO_0000218,7462,N,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,50594,,10107,14.0,10090.0,Mus musculus,,CHEMBL623619,,,In vivo,,A,1,1,
Zone of skin,BAO_0000218,7463,N,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,50594,,10107,14.0,10090.0,Mus musculus,,CHEMBL623620,,,In vivo,,A,1,1,
Zone of skin,BAO_0000218,7464,N,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,50594,,10107,14.0,10090.0,Mus musculus,,CHEMBL623621,,,In vivo,,A,1,1,
Zone of skin,BAO_0000218,7465,N,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,,50594,,10107,14.0,10090.0,Mus musculus,,CHEMBL623622,,,In vivo,,A,1,1,
Zone of skin,BAO_0000218,7466,N,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,50594,,10107,14.0,10090.0,Mus musculus,,CHEMBL623623,,,In vivo,,A,1,1,
Spleen,BAO_0000218,7467,N,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,50594,,10107,2106.0,10090.0,Mus musculus,,CHEMBL623624,,,In vivo,,A,1,1,
Spleen,BAO_0000218,7468,N,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Intermediate,,50594,,10107,2106.0,10090.0,Mus musculus,,CHEMBL618521,,,In vivo,,A,1,1,
Spleen,BAO_0000218,7469,N,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,50594,,10107,2106.0,10090.0,Mus musculus,,CHEMBL618522,,,In vivo,,A,1,1,
Spleen,BAO_0000218,7470,N,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,50594,,10107,2106.0,10090.0,Mus musculus,,CHEMBL618523,,,In vivo,,A,1,1,
Spleen,BAO_0000218,7471,N,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,50594,,10107,2106.0,10090.0,Mus musculus,,CHEMBL618524,,,In vivo,,A,1,1,
Spleen,BAO_0000218,7472,N,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,,50594,,10107,2106.0,10090.0,Mus musculus,,CHEMBL618525,,,In vivo,,A,1,1,
Spleen,BAO_0000218,7473,N,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,50594,,10107,2106.0,10090.0,Mus musculus,,CHEMBL624586,,,In vivo,,A,1,1,
Stomach,BAO_0000218,7474,N,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Intermediate,,50594,,10107,945.0,10090.0,Mus musculus,,CHEMBL624587,,,In vivo,,A,1,1,
Stomach,BAO_0000218,7475,N,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Intermediate,,50594,,10107,945.0,10090.0,Mus musculus,,CHEMBL624588,,,In vivo,,A,1,1,
Stomach,BAO_0000218,7476,N,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Intermediate,,50594,,10107,945.0,10090.0,Mus musculus,,CHEMBL624589,,,In vivo,,A,1,1,
Stomach,BAO_0000218,7477,N,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Intermediate,,50594,,10107,945.0,10090.0,Mus musculus,,CHEMBL624590,,,In vivo,,A,1,1,
Stomach,BAO_0000218,7478,N,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Intermediate,,50594,,10107,945.0,10090.0,Mus musculus,,CHEMBL624591,,,In vivo,,A,1,1,
Stomach,BAO_0000218,7479,N,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Intermediate,,50594,,10107,945.0,10090.0,Mus musculus,,CHEMBL624592,,,In vivo,,A,1,1,
Stomach,BAO_0000218,7480,N,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Intermediate,,50594,,10107,945.0,10090.0,Mus musculus,,CHEMBL624593,,,In vivo,,A,1,1,
,BAO_0000218,7481,N,Oral bioavailability in rat,Intermediate,,50597,,4689,,10116.0,Rattus norvegicus,,CHEMBL624594,,,In vivo,,A,1,1,
,BAO_0000218,7482,N,Tested for the bioavailability in rat,Intermediate,,50597,,4950,,10116.0,Rattus norvegicus,,CHEMBL624595,,,In vivo,,A,1,1,
,BAO_0000218,7483,N,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),Intermediate,,50597,,5328,,10116.0,Rattus norvegicus,,CHEMBL624596,,,In vivo,,A,1,1,
,BAO_0000218,7484,N,Bioavailability in rat,Intermediate,,50597,,406,,10116.0,Rattus norvegicus,,CHEMBL624597,,,In vivo,,A,1,1,
,BAO_0000218,7485,N,Bioavailability in rat,Intermediate,,50597,,12500,,10116.0,Rattus norvegicus,,CHEMBL624598,,,In vivo,,A,1,1,
,BAO_0000218,7486,N,Bioavailability in rat (dose 3-10 mg/kg),Intermediate,,50597,,12500,,10116.0,Rattus norvegicus,,CHEMBL624599,,,In vivo,,A,1,1,
,BAO_0000218,7487,N,Bioavailability in rat,Intermediate,,50597,,5247,,10116.0,Rattus norvegicus,,CHEMBL875166,,,In vivo,,A,1,1,
Plasma,BAO_0000218,7488,N,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,Intermediate,,50597,,4186,1969.0,10116.0,Rattus norvegicus,,CHEMBL624600,,,In vivo,,A,1,1,
Plasma,BAO_0000218,7489,N,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,Intermediate,,50597,,4186,1969.0,10116.0,Rattus norvegicus,,CHEMBL624601,,,In vivo,,A,1,1,
,BAO_0000218,7490,N,Half life after oral administration was determined in rats at 6 mg/kg,Intermediate,,50597,,6647,,10116.0,Rattus norvegicus,,CHEMBL624602,,,In vivo,,A,1,1,
,BAO_0000218,7491,N,Half life was determined,Intermediate,,50597,,6484,,10116.0,Rattus norvegicus,,CHEMBL624603,,,,,A,1,1,
,BAO_0000218,7492,N,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,Intermediate,,50597,,3249,,10116.0,Rattus norvegicus,,CHEMBL624604,,,In vivo,,A,1,1,
Plasma,BAO_0000218,7493,N,Plasma half life in rat at oral dose 2.8 mg/mk body weight,Intermediate,,50597,,6281,1969.0,10116.0,Rattus norvegicus,,CHEMBL624605,,,In vivo,,A,1,1,
,BAO_0000218,7494,N,Half life in rats,Intermediate,,50597,,3307,,10116.0,Rattus norvegicus,,CHEMBL624606,,,,,A,1,1,
Blood,BAO_0000218,7495,N,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,Intermediate,,50597,,12058,178.0,10116.0,Rattus norvegicus,,CHEMBL624607,,,In vivo,,A,1,1,
,BAO_0000218,7496,N,Hill coefficient of the compound,Intermediate,,50597,,8833,,10116.0,Rattus norvegicus,,CHEMBL624608,,,,,A,1,1,
Blood,BAO_0000218,7497,N,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,Intermediate,,50597,,3193,178.0,10116.0,Rattus norvegicus,,CHEMBL624609,,,,,A,1,1,
Blood,BAO_0000218,7498,N,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,Intermediate,,50597,,3193,178.0,10116.0,Rattus norvegicus,,CHEMBL624610,,,,,A,1,1,
Blood,BAO_0000218,7499,N,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,Intermediate,,50597,,3193,178.0,10116.0,Rattus norvegicus,,CHEMBL624611,,,,,A,1,1,
Blood,BAO_0000218,7500,N,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,Intermediate,,50597,,3193,178.0,10116.0,Rattus norvegicus,,CHEMBL624612,,,,,A,1,1,
Blood,BAO_0000218,7501,N,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,Intermediate,,50597,,3193,178.0,10116.0,Rattus norvegicus,,CHEMBL875167,,,,,A,1,1,
Blood,BAO_0000218,7502,N,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,Intermediate,,50597,,3193,178.0,10116.0,Rattus norvegicus,,CHEMBL624613,,,,,A,1,1,
Blood,BAO_0000218,7503,N,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",Intermediate,,50597,,3193,178.0,10116.0,Rattus norvegicus,,CHEMBL624614,,,,,A,1,1,
,BAO_0000218,7504,N,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,Intermediate,,50597,,5960,,10116.0,Rattus norvegicus,,CHEMBL624392,,,,,A,1,1,
Brain,BAO_0000218,7505,N,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,Intermediate,,50597,,13950,955.0,10116.0,Rattus norvegicus,,CHEMBL624393,,,In vivo,,A,1,1,
Brain,BAO_0000218,7506,N,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,Intermediate,,50597,,13950,955.0,10116.0,Rattus norvegicus,,CHEMBL624394,,,In vivo,,A,1,1,
Brain,BAO_0000218,7507,N,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,Intermediate,,50597,,13950,955.0,10116.0,Rattus norvegicus,,CHEMBL624395,,,In vivo,,A,1,1,
Brain,BAO_0000218,7508,N,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,Intermediate,,50597,,13950,955.0,10116.0,Rattus norvegicus,,CHEMBL624396,,,In vivo,,A,1,1,
Brain,BAO_0000218,7509,N,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,Intermediate,,50597,,13950,955.0,10116.0,Rattus norvegicus,,CHEMBL624397,,,In vivo,,A,1,1,
Thyroid gland,BAO_0000218,7510,N,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,Intermediate,,50597,,13950,2046.0,10116.0,Rattus norvegicus,,CHEMBL624398,,,In vivo,,A,1,1,
Thyroid gland,BAO_0000218,7511,N,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,Intermediate,,50597,,13950,2046.0,10116.0,Rattus norvegicus,,CHEMBL624399,,,In vivo,,A,1,1,
Thyroid gland,BAO_0000218,7512,N,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,Intermediate,,50597,,13950,2046.0,10116.0,Rattus norvegicus,,CHEMBL624400,,,In vivo,,A,1,1,
Thyroid gland,BAO_0000218,7513,N,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,Intermediate,,50597,,13950,2046.0,10116.0,Rattus norvegicus,,CHEMBL624401,,,In vivo,,A,1,1,
Thyroid gland,BAO_0000218,7514,N,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,Intermediate,,50597,,13950,2046.0,10116.0,Rattus norvegicus,,CHEMBL624402,,,In vivo,,A,1,1,
Blood,BAO_0000218,7515,N,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Intermediate,,50597,,9866,178.0,10116.0,Rattus norvegicus,,CHEMBL624403,,,In vivo,,A,1,1,
Blood,BAO_0000218,7516,N,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,Intermediate,,50597,,9866,178.0,10116.0,Rattus norvegicus,,CHEMBL624404,,,In vivo,,A,1,1,
Blood,BAO_0000218,7517,N,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,Intermediate,,50597,,9866,178.0,10116.0,Rattus norvegicus,,CHEMBL624405,,,In vivo,,A,1,1,
Bone,BAO_0000218,7518,N,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Intermediate,,50597,,9866,10000001.0,10116.0,Rattus norvegicus,,CHEMBL624406,,,In vivo,,A,1,1,
Bone,BAO_0000218,7519,N,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,Intermediate,,50597,,9866,10000001.0,10116.0,Rattus norvegicus,,CHEMBL624407,,,In vivo,,A,1,1,
Bone,BAO_0000218,7520,N,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,Intermediate,,50597,,9866,10000001.0,10116.0,Rattus norvegicus,,CHEMBL624408,,,In vivo,,A,1,1,
Heart,BAO_0000218,7521,N,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Intermediate,,50597,,9866,948.0,10116.0,Rattus norvegicus,,CHEMBL618644,,,In vivo,,A,1,1,
Heart,BAO_0000218,7522,N,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,Intermediate,,50597,,9866,948.0,10116.0,Rattus norvegicus,,CHEMBL618645,,,In vivo,,A,1,1,
Heart,BAO_0000218,7523,N,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,Intermediate,,50597,,9866,948.0,10116.0,Rattus norvegicus,,CHEMBL618646,,,In vivo,,A,1,1,
Kidney,BAO_0000218,7524,N,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Intermediate,,50597,,9866,2113.0,10116.0,Rattus norvegicus,,CHEMBL618647,,,In vivo,,A,1,1,
Kidney,BAO_0000218,7525,N,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig,Intermediate,,50597,,9866,2113.0,10116.0,Rattus norvegicus,,CHEMBL618648,,,In vivo,,A,1,1,
Kidney,BAO_0000218,7526,N,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr,Intermediate,,50597,,9866,2113.0,10116.0,Rattus norvegicus,,CHEMBL618649,,,In vivo,,A,1,1,
Liver,BAO_0000218,7527,N,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Intermediate,,50597,,9866,2107.0,10116.0,Rattus norvegicus,,CHEMBL618650,,,In vivo,,A,1,1,
Liver,BAO_0000218,7528,N,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig,Intermediate,,50597,,9866,2107.0,10116.0,Rattus norvegicus,,CHEMBL618651,,,In vivo,,A,1,1,
Liver,BAO_0000218,7529,N,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr,Intermediate,,50597,,9866,2107.0,10116.0,Rattus norvegicus,,CHEMBL876497,,,In vivo,,A,1,1,
Lung,BAO_0000218,7530,N,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Intermediate,,50597,,9866,2048.0,10116.0,Rattus norvegicus,,CHEMBL618652,,,In vivo,,A,1,1,
Lung,BAO_0000218,7531,N,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig,Intermediate,,50597,,9866,2048.0,10116.0,Rattus norvegicus,,CHEMBL618653,,,In vivo,,A,1,1,
Lung,BAO_0000218,7532,N,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr,Intermediate,,50597,,9866,2048.0,10116.0,Rattus norvegicus,,CHEMBL618654,,,In vivo,,A,1,1,
,BAO_0000218,7533,N,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested,Intermediate,,50597,,6351,,10116.0,Rattus norvegicus,,CHEMBL618655,,,,,A,1,1,
,BAO_0000218,7534,N,Compound was tested for solubility in water,Intermediate,,50597,,1465,,10116.0,Rattus norvegicus,,CHEMBL618656,,,,,A,1,1,
,BAO_0000100,7535,U,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration),Intermediate,,22229,,5182,,,,,CHEMBL618657,,,,,P,1,0,
,BAO_0000218,7536,N,Solubility was determined,Intermediate,,50597,,17847,,10116.0,Rattus norvegicus,,CHEMBL618658,,,,,A,1,1,
,BAO_0000218,7537,N,solubility in water (ug/mL) at 37 degree C.,Intermediate,,50597,,15339,,10116.0,Rattus norvegicus,,CHEMBL618659,,,,,A,1,1,
,BAO_0000218,7538,N,First pass metabolism and metabolic bioavailability using rat hepatic microsomes,Intermediate,,50597,,5202,,10116.0,Rattus norvegicus,,CHEMBL618660,,,,,A,1,1,
,BAO_0000218,7539,N,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay,Intermediate,,50597,,1088,,10116.0,Rattus norvegicus,,CHEMBL618661,,,,,A,1,1,
,BAO_0000218,7540,N,Half life in rats,Intermediate,,50597,,3169,,10116.0,Rattus norvegicus,,CHEMBL873807,,,,,A,1,1,
,BAO_0000218,7541,N,Half life in Dawley rat,Intermediate,,50597,,5353,,10116.0,Rattus norvegicus,,CHEMBL618662,,,,,A,1,1,
,BAO_0000218,7542,N,Half life period after 3 mg/kg iv administration,Intermediate,,50597,,2864,,10116.0,Rattus norvegicus,,CHEMBL618663,,,In vivo,,A,1,1,
,BAO_0000218,7543,N,Half life period after 3 mg/kg iv administration in rat,Intermediate,,50597,,2864,,10116.0,Rattus norvegicus,,CHEMBL618664,,,In vivo,,A,1,1,
,BAO_0000218,7544,N,Half life period after 3 mg/kg iv administration in the rat,Intermediate,,50597,,2864,,10116.0,Rattus norvegicus,,CHEMBL618665,,,In vivo,,A,1,1,
,BAO_0000218,7545,N,Half life period in female Sprague-Dawley rats,Intermediate,,50597,,6362,,10116.0,Rattus norvegicus,,CHEMBL876498,,,,,A,1,1,
,BAO_0000218,7546,N,Half life period in rat,Intermediate,,50597,,6249,,10116.0,Rattus norvegicus,,CHEMBL618666,,,,,A,1,1,
,BAO_0000218,7547,N,Half-life in rats was determined,Intermediate,,50597,,3169,,10116.0,Rattus norvegicus,,CHEMBL620440,,,,,A,1,1,
,BAO_0000218,7548,N,Half-life in rats with metabolic oxidation,Intermediate,,50597,,3169,,10116.0,Rattus norvegicus,,CHEMBL620441,,,,,A,1,1,
,BAO_0000218,7549,N,Half-life in rats,Intermediate,,50597,,3169,,10116.0,Rattus norvegicus,,CHEMBL620442,,,,,A,1,1,
,BAO_0000218,7550,N,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,Intermediate,,50597,,17260,,10116.0,Rattus norvegicus,,CHEMBL620443,,,In vivo,,A,1,1,
,BAO_0000218,7551,N,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,Intermediate,,50597,,17260,,10116.0,Rattus norvegicus,,CHEMBL620444,,,In vivo,,A,1,1,
,BAO_0000218,7552,N,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,Intermediate,,50597,,17260,,10116.0,Rattus norvegicus,,CHEMBL620445,,,In vivo,,A,1,1,
,BAO_0000218,7553,N,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,Intermediate,,50597,,17260,,10116.0,Rattus norvegicus,,CHEMBL620446,,,In vivo,,A,1,1,
Plasma,BAO_0000218,7554,N,Biological half-life measured in plasma of rat,Intermediate,,50597,,2879,1969.0,10116.0,Rattus norvegicus,,CHEMBL620447,,,,,A,1,1,
Plasma,BAO_0000218,7555,N,Biological half-life measured in plasma of rat; 22-25,Intermediate,,50597,,2879,1969.0,10116.0,Rattus norvegicus,,CHEMBL621129,,,,,A,1,1,
Plasma,BAO_0000218,7556,N,Biological half-life measured in plasma of rat; 9-16,Intermediate,,50597,,2879,1969.0,10116.0,Rattus norvegicus,,CHEMBL621130,,,,,A,1,1,
,BAO_0000218,7557,N,Compound was evaluated for its half life when administered intravenously in rat,Intermediate,,50597,,3184,,10116.0,Rattus norvegicus,,CHEMBL873808,,,In vivo,,A,1,1,
,BAO_0000218,7558,N,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h,Intermediate,,50597,,4891,,10116.0,Rattus norvegicus,,CHEMBL876598,,,In vivo,,A,1,1,
,BAO_0000218,7559,N,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg,Intermediate,,50597,,429,,10116.0,Rattus norvegicus,,CHEMBL621131,,,In vivo,,A,1,1,
,BAO_0000218,7560,N,Half life (T1/2) after oral administration in rat,Intermediate,,50597,,5656,,10116.0,Rattus norvegicus,,CHEMBL621132,,,In vivo,,A,1,1,
,BAO_0000218,7561,N,Half life of compound after iv administration of 20 mg/kg dose in rat,Intermediate,,50597,,4413,,10116.0,Rattus norvegicus,,CHEMBL621133,,,In vivo,,A,1,1,
,BAO_0000218,7562,N,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,Expert,,50597,,3598,,10116.0,Rattus norvegicus,,CHEMBL621312,,,In vivo,,A,1,1,
,BAO_0000218,7563,N,Half life of compound was determined in rat,Intermediate,,50597,,17267,,10116.0,Rattus norvegicus,,CHEMBL621313,,,,,A,1,1,
Blood,BAO_0000218,7564,N,Half life of compound was determined in rat blood,Intermediate,,50597,,4727,178.0,10116.0,Rattus norvegicus,,CHEMBL621314,,,,,A,1,1,
,BAO_0000218,7565,N,Half life at 1 mg/kg was determined in rat,Intermediate,,50597,,17651,,10116.0,Rattus norvegicus,,CHEMBL621315,,,In vivo,,A,1,1,
,BAO_0000218,7566,N,Half life at 10 mg/kg was determined in rat,Intermediate,,50597,,17651,,10116.0,Rattus norvegicus,,CHEMBL621316,,,In vivo,,A,1,1,
,BAO_0000218,7567,N,Half life in rats,Intermediate,,50597,,401,,10116.0,Rattus norvegicus,,CHEMBL621317,,,,,A,1,1,
,BAO_0000218,7568,N,Half life in rats in hours,Intermediate,,50597,,4942,,10116.0,Rattus norvegicus,,CHEMBL621318,,,,,A,1,1,
,BAO_0000218,7569,N,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,Intermediate,,50597,,17735,,10116.0,Rattus norvegicus,,CHEMBL621319,,,In vivo,,A,1,1,
,BAO_0000218,7570,N,Half life was calculated at a single intravenous administration of 20 mg/kg in rat,Intermediate,,50597,,6056,,10116.0,Rattus norvegicus,,CHEMBL621377,,,In vivo,,A,1,1,
,BAO_0000218,7571,N,Half life was determined,Intermediate,,50597,,5213,,10116.0,Rattus norvegicus,,CHEMBL621378,,,,,A,1,1,
,BAO_0000218,7572,N,Half life after i.v. administration,Intermediate,,50597,,6616,,10116.0,Rattus norvegicus,,CHEMBL876599,,,In vivo,,A,1,1,
,BAO_0000218,7573,N,Half life in rat after intravenous administration at a concentration 0.5 mg/kg,Intermediate,,50597,,5937,,10116.0,Rattus norvegicus,,CHEMBL621379,,,In vivo,,A,1,1,
Plasma,BAO_0000218,7574,N,Half life in rat plasma,Intermediate,,50597,,5819,1969.0,10116.0,Rattus norvegicus,,CHEMBL621380,,,,,A,1,1,
Plasma,BAO_0000218,7575,N,Half life in rat plasma; Not detected,Intermediate,,50597,,5819,1969.0,10116.0,Rattus norvegicus,,CHEMBL621381,,,,,A,1,1,
,BAO_0000218,7576,N,Half life in rats,Intermediate,,50597,,6803,,10116.0,Rattus norvegicus,,CHEMBL618515,,,,,A,1,1,
,BAO_0000218,7577,N,Half life period of compound was determined after peroral administration,Intermediate,,50597,,17804,,10116.0,Rattus norvegicus,,CHEMBL618516,,,In vivo,,A,1,1,
,BAO_0000218,7578,N,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration,Intermediate,,50597,,17804,,10116.0,Rattus norvegicus,,CHEMBL618517,,,In vivo,,A,1,1,
,BAO_0000218,7579,N,Half life period in rat,Intermediate,,50597,,5948,,10116.0,Rattus norvegicus,,CHEMBL618518,,,,,A,1,1,
,BAO_0000218,7580,N,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,Intermediate,,50597,,1916,,10116.0,Rattus norvegicus,,CHEMBL618519,,,In vivo,,A,1,1,
,BAO_0000218,7581,N,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,Intermediate,,50597,,1916,,10116.0,Rattus norvegicus,,CHEMBL618698,,,In vivo,,A,1,1,
,BAO_0000218,7582,N,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available,Intermediate,,50597,,1916,,10116.0,Rattus norvegicus,,CHEMBL618862,,,In vivo,,A,1,1,
,BAO_0000218,7583,N,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,Intermediate,,50597,,4890,,10116.0,Rattus norvegicus,,CHEMBL618863,,,In vivo,,A,1,1,
,BAO_0000218,7584,N,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg,Intermediate,,50597,,17764,,10116.0,Rattus norvegicus,,CHEMBL618864,,,In vivo,,A,1,1,
,BAO_0000218,7585,N,Half life time in rat the dose of 2 mg/kg,Intermediate,,50597,,4727,,10116.0,Rattus norvegicus,,CHEMBL618865,,,In vivo,,A,1,1,
,BAO_0000218,7586,N,Half-life 24 hr after 10 mg/kg iv administration in rats,Intermediate,,50597,,17509,,10116.0,Rattus norvegicus,,CHEMBL618866,,,In vivo,,A,1,1,
,BAO_0000218,7587,N,Half-life 24 hr after 2 mg/kg iv administration in rats,Intermediate,,50597,,17509,,10116.0,Rattus norvegicus,,CHEMBL618867,,,In vivo,,A,1,1,
,BAO_0000218,7588,N,Half-life consistent with the observed metabolic steady state in rats,Intermediate,,50597,,6597,,10116.0,Rattus norvegicus,,CHEMBL875828,,,,,A,1,1,
,BAO_0000218,7589,N,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,Intermediate,,50597,,17735,,10116.0,Rattus norvegicus,,CHEMBL618868,,,In vivo,,A,1,1,
,BAO_0000218,7590,N,Half-life for oxidative metabolic stability was determined using male human,Intermediate,,50597,,6597,,10116.0,Rattus norvegicus,,CHEMBL618869,,,,,A,1,1,
,BAO_0000218,7591,N,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously",Intermediate,,50597,,17670,,10116.0,Rattus norvegicus,,CHEMBL618870,,,In vivo,,A,1,1,
Plasma,BAO_0000218,7592,N,Half-life in rat plasma,Intermediate,,50597,,1696,1969.0,10116.0,Rattus norvegicus,,CHEMBL618871,,,,,A,1,1,
Plasma,BAO_0000218,7593,N,Half-life in rat plasma was determined,Intermediate,,50597,,1742,1969.0,10116.0,Rattus norvegicus,,CHEMBL618872,,,,,A,1,1,
,BAO_0000218,7594,N,Half-life in rats was determined,Intermediate,,50597,,17800,,10116.0,Rattus norvegicus,,CHEMBL873816,,,,,A,1,1,
,BAO_0000218,7595,U,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog,Autocuration,,22224,,12923,,,,,CHEMBL618873,,,,,A,1,0,
,BAO_0000019,7596,U,Area under curve after oral dose of 0.1 mg//kg,Autocuration,,22224,,11954,,,,,CHEMBL621602,,,,,A,1,0,
,BAO_0000218,7597,U,Area under curve after oral dose of 0.3 mg/kg,Autocuration,,22224,,11954,,,,,CHEMBL621603,,,,,A,1,0,
,BAO_0000218,7598,U,Area under curve after oral dose of 1 mg/kg,Autocuration,,22224,,11954,,,,,CHEMBL621604,,,,,A,1,0,
,BAO_0000218,7599,U,Area under curve after oral dose of 10 mg/kg,Autocuration,,22224,,11954,,,,,CHEMBL621605,,,,,A,1,0,
,BAO_0000218,7600,U,Area under curve after oral dose of 23.4 mg/kg,Autocuration,,22224,,11954,,,,,CHEMBL621606,,,,,A,1,0,
,BAO_0000218,7601,U,Area under curve after oral dose of 3 mg/kg,Autocuration,,22224,,11954,,,,,CHEMBL621607,,,,,A,1,0,
,BAO_0000218,7602,U,Area under curve after oral dose of 3.87 mg/kg,Autocuration,,22224,,11954,,,,,CHEMBL621608,,,,,A,1,0,
,BAO_0000019,7603,U,Area under curve was determined,Autocuration,,22224,,5237,,,,,CHEMBL621609,,,,,A,1,0,
,BAO_0000218,7604,U,Area under curve at a dose of 10 mg/kg,Autocuration,,22224,,4026,,,,,CHEMBL621610,,,,,A,1,0,
,BAO_0000218,7605,N,Area under curve was determined; ND=No data,Intermediate,,50597,,5237,,10116.0,Rattus norvegicus,,CHEMBL621611,,,,,A,1,1,
,BAO_0000218,7606,N,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,Intermediate,,50597,,14793,,10116.0,Rattus norvegicus,,CHEMBL621612,,,,,A,1,1,
,BAO_0000218,7607,N,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,Intermediate,,50597,,14793,,10116.0,Rattus norvegicus,,CHEMBL622308,,,,,A,1,1,
,BAO_0000218,7608,N,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,Intermediate,,50597,,14793,,10116.0,Rattus norvegicus,,CHEMBL622309,,,,,A,1,1,
,BAO_0000218,7609,N,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours,Intermediate,,50597,,14793,,10116.0,Rattus norvegicus,,CHEMBL622310,,,,,A,1,1,
,BAO_0000218,7610,N,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,Intermediate,,50597,,14793,,10116.0,Rattus norvegicus,,CHEMBL622311,,,,,A,1,1,
,BAO_0000218,7611,N,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated,Intermediate,,50597,,14793,,10116.0,Rattus norvegicus,,CHEMBL622312,,,,,A,1,1,
,BAO_0000218,7612,N,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,Intermediate,,50597,,14793,,10116.0,Rattus norvegicus,,CHEMBL622931,,,,,A,1,1,
,BAO_0000218,7613,N,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated,Intermediate,,50597,,14793,,10116.0,Rattus norvegicus,,CHEMBL622932,,,,,A,1,1,
Plasma,BAO_0000218,7614,N,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,Intermediate,,50597,,14793,1969.0,10116.0,Rattus norvegicus,,CHEMBL622736,,,,,A,1,1,
Plasma,BAO_0000218,7615,N,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,Intermediate,,50597,,14793,1969.0,10116.0,Rattus norvegicus,,CHEMBL622737,,,,,A,1,1,
Plasma,BAO_0000218,7616,N,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,Intermediate,,50597,,14793,1969.0,10116.0,Rattus norvegicus,,CHEMBL622738,,,,,A,1,1,
Plasma,BAO_0000218,7617,N,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours,Intermediate,,50597,,14793,1969.0,10116.0,Rattus norvegicus,,CHEMBL622739,,,,,A,1,1,
Plasma,BAO_0000218,7618,N,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,Intermediate,,50597,,14793,1969.0,10116.0,Rattus norvegicus,,CHEMBL622740,,,,,A,1,1,
Plasma,BAO_0000218,7619,N,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours,Intermediate,,50597,,14793,1969.0,10116.0,Rattus norvegicus,,CHEMBL622741,,,,,A,1,1,
Plasma,BAO_0000218,7620,N,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,Intermediate,,50597,,14793,1969.0,10116.0,Rattus norvegicus,,CHEMBL622742,,,,,A,1,1,
Plasma,BAO_0000218,7621,N,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours,Intermediate,,50597,,14793,1969.0,10116.0,Rattus norvegicus,,CHEMBL622743,,,,,A,1,1,
Plasma,BAO_0000218,7622,N,AUC in mice,Intermediate,,50594,,11637,1969.0,10090.0,Mus musculus,,CHEMBL622744,,,,,A,1,1,
,BAO_0000019,7623,U,Area under curve was measured from the graph obtained from concentration Vs time,Autocuration,,22224,,11149,,,,,CHEMBL624134,,,,,A,1,0,
,BAO_0000019,7624,U,Area under curve value of compound per hour after oral administration,Autocuration,,22224,,10016,,,,,CHEMBL624135,,,,,A,1,0,
,BAO_0000218,7625,N,Area under curve was determined after oral administration in rats,Intermediate,,50597,,17796,,10116.0,Rattus norvegicus,,CHEMBL624136,,,,,A,1,1,
,BAO_0000218,7626,N,Area under curve was determined after oral administration in rats; No data,Intermediate,,50597,,17796,,10116.0,Rattus norvegicus,,CHEMBL624137,,,,,A,1,1,
,BAO_0000218,7627,N,Area under curve was determined after oral administration in rats;No data,Intermediate,,50597,,17796,,10116.0,Rattus norvegicus,,CHEMBL624320,,,,,A,1,1,
,BAO_0000218,7628,N,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,Intermediate,,50588,,12923,,9615.0,Canis lupus familiaris,,CHEMBL624321,,,,,A,1,1,
,BAO_0000218,7629,N,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats,Intermediate,,50597,,15372,,10116.0,Rattus norvegicus,,CHEMBL624322,,,,,A,1,1,
,BAO_0000218,7630,N,Area under curve was determined for the compound after iv dose of 5.06 in rats,Intermediate,,50597,,15372,,10116.0,Rattus norvegicus,,CHEMBL624323,,,,,A,1,1,
,BAO_0000218,7631,N,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats,Intermediate,,50597,,15372,,10116.0,Rattus norvegicus,,CHEMBL624324,,,,,A,1,1,
,BAO_0000218,7632,N,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats,Intermediate,,50597,,15372,,10116.0,Rattus norvegicus,,CHEMBL624325,,,,,A,1,1,
,BAO_0000218,7633,N,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats,Intermediate,,50597,,15372,,10116.0,Rattus norvegicus,,CHEMBL624326,,,,,A,1,1,
,BAO_0000218,7634,N,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats,Intermediate,,50597,,15372,,10116.0,Rattus norvegicus,,CHEMBL624327,,,,,A,1,1,
,BAO_0000218,7635,N,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats,Intermediate,,50597,,15372,,10116.0,Rattus norvegicus,,CHEMBL624328,,,,,A,1,1,
,BAO_0000218,7636,N,Area under curve was determined in Dogs after peroral administration,Intermediate,,50588,,14169,,9615.0,Canis lupus familiaris,,CHEMBL627848,,,,,A,1,1,
,BAO_0000218,7637,N,Area under curve was determined in Rats after peroral administration,Intermediate,,50597,,14169,,10116.0,Rattus norvegicus,,CHEMBL627849,,,,,A,1,1,
,BAO_0000218,7638,N,Area under curve was determined in carotid blood of rat when administered intradermally,Intermediate,,50597,,14258,,10116.0,Rattus norvegicus,,CHEMBL627850,,,,,A,1,1,
,BAO_0000218,7639,N,Area under curve was determined in portal blood of rat when administered intradermally,Intermediate,,50597,,14258,,10116.0,Rattus norvegicus,,CHEMBL627851,,,,,A,1,1,
,BAO_0000218,7640,N,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,Intermediate,,50594,,15011,,10090.0,Mus musculus,,CHEMBL627852,,,,,A,1,1,
,BAO_0000218,7641,N,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,Intermediate,,50594,,15011,,10090.0,Mus musculus,,CHEMBL627853,,,,,A,1,1,
,BAO_0000218,7642,N,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),Intermediate,,50594,,15011,,10090.0,Mus musculus,,CHEMBL627854,,,,,A,1,1,
,BAO_0000218,7643,N,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,Intermediate,,50594,,15011,,10090.0,Mus musculus,,CHEMBL627855,,,,,A,1,1,
,BAO_0000218,7644,N,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr),Intermediate,,50594,,15011,,10090.0,Mus musculus,,CHEMBL627856,,,,,A,1,1,
,BAO_0000218,7645,N,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,Intermediate,,50594,,15011,,10090.0,Mus musculus,,CHEMBL875339,,,,,A,1,1,
,BAO_0000218,7646,N,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr),Intermediate,,50594,,15011,,10090.0,Mus musculus,,CHEMBL627857,,,,,A,1,1,
Spleen,BAO_0000218,7647,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration,Intermediate,,50597,,11195,2106.0,10116.0,Rattus norvegicus,,CHEMBL627858,,,In vivo,,A,1,1,
Blood,BAO_0000218,7648,N,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ,Intermediate,,50597,,10130,178.0,10116.0,Rattus norvegicus,,CHEMBL627859,,,,,A,1,1,
Brain,BAO_0000218,7649,N,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ,Intermediate,,50597,,10130,955.0,10116.0,Rattus norvegicus,,CHEMBL627860,,,,,A,1,1,
Heart,BAO_0000218,7650,N,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ,Intermediate,,50597,,10130,948.0,10116.0,Rattus norvegicus,,CHEMBL627019,,,,,A,1,1,
Liver,BAO_0000218,7651,N,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ,Intermediate,,50597,,10130,2107.0,10116.0,Rattus norvegicus,,CHEMBL627020,,,,,A,1,1,
Lung,BAO_0000218,7652,N,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ,Intermediate,,50597,,10130,2048.0,10116.0,Rattus norvegicus,,CHEMBL627021,,,,,A,1,1,
Muscle tissue,BAO_0000218,7653,N,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ,Intermediate,,50597,,10130,2385.0,10116.0,Rattus norvegicus,,CHEMBL627022,,,,,A,1,1,
,BAO_0000218,7654,N,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ,Intermediate,,50597,,10130,,10116.0,Rattus norvegicus,,CHEMBL627023,,,,,A,1,1,
Spleen,BAO_0000218,7655,N,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ,Intermediate,,50597,,10130,2106.0,10116.0,Rattus norvegicus,,CHEMBL627024,,,,,A,1,1,
Thyroid gland,BAO_0000218,7656,N,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ,Intermediate,,50597,,10130,2046.0,10116.0,Rattus norvegicus,,CHEMBL627025,,,,,A,1,1,
Kidney,BAO_0000218,7657,N,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ,Intermediate,,50597,,10130,2113.0,10116.0,Rattus norvegicus,,CHEMBL627026,,,,,A,1,1,
Blood,BAO_0000218,7658,N,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ,Intermediate,,50597,,10130,178.0,10116.0,Rattus norvegicus,,CHEMBL627027,,,,,A,1,1,
Brain,BAO_0000218,7659,N,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ,Intermediate,,50597,,10130,955.0,10116.0,Rattus norvegicus,,CHEMBL627028,,,,,A,1,1,
Heart,BAO_0000218,7660,N,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ,Intermediate,,50597,,10130,948.0,10116.0,Rattus norvegicus,,CHEMBL627029,,,,,A,1,1,
Kidney,BAO_0000218,7661,N,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ,Intermediate,,50597,,10130,2113.0,10116.0,Rattus norvegicus,,CHEMBL627030,,,,,A,1,1,
Liver,BAO_0000218,7662,N,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ,Intermediate,,50597,,10130,2107.0,10116.0,Rattus norvegicus,,CHEMBL627031,,,,,A,1,1,
Lung,BAO_0000218,7663,N,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ,Intermediate,,50597,,10130,2048.0,10116.0,Rattus norvegicus,,CHEMBL627032,,,,,A,1,1,
Muscle tissue,BAO_0000218,7664,N,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ,Intermediate,,50597,,10130,2385.0,10116.0,Rattus norvegicus,,CHEMBL627033,,,,,A,1,1,
,BAO_0000218,7665,N,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ,Intermediate,,50597,,10130,,10116.0,Rattus norvegicus,,CHEMBL627034,,,,,A,1,1,
Spleen,BAO_0000218,7666,N,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ,Intermediate,,50597,,10130,2106.0,10116.0,Rattus norvegicus,,CHEMBL627035,,,,,A,1,1,
Thyroid gland,BAO_0000218,7667,N,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ,Intermediate,,50597,,10130,2046.0,10116.0,Rattus norvegicus,,CHEMBL627036,,,,,A,1,1,
Blood,BAO_0000218,7668,N,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ,Intermediate,,50597,,10130,178.0,10116.0,Rattus norvegicus,,CHEMBL875340,,,,,A,1,1,
Heart,BAO_0000218,7669,N,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ,Intermediate,,50597,,10130,948.0,10116.0,Rattus norvegicus,,CHEMBL627037,,,,,A,1,1,
Kidney,BAO_0000218,7670,N,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ,Intermediate,,50597,,10130,2113.0,10116.0,Rattus norvegicus,,CHEMBL627038,,,,,A,1,1,
Liver,BAO_0000218,7671,N,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ,Intermediate,,50597,,10130,2107.0,10116.0,Rattus norvegicus,,CHEMBL627039,,,,,A,1,1,
Muscle tissue,BAO_0000218,7672,N,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ,Intermediate,,50597,,10130,2385.0,10116.0,Rattus norvegicus,,CHEMBL627040,,,,,A,1,1,
Spleen,BAO_0000218,7673,N,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ,Intermediate,,50597,,10130,2106.0,10116.0,Rattus norvegicus,,CHEMBL624663,,,,,A,1,1,
Thyroid gland,BAO_0000218,7674,N,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ,Intermediate,,50597,,10130,2046.0,10116.0,Rattus norvegicus,,CHEMBL625963,,,,,A,1,1,
Brain,BAO_0000218,7675,N,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ,Intermediate,,50597,,10130,955.0,10116.0,Rattus norvegicus,,CHEMBL876799,,,,,A,1,1,
Lung,BAO_0000218,7676,N,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ,Intermediate,,50597,,10130,2048.0,10116.0,Rattus norvegicus,,CHEMBL626133,,,,,A,1,1,
,BAO_0000218,7677,N,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ,Intermediate,,50597,,10130,,10116.0,Rattus norvegicus,,CHEMBL626134,,,,,A,1,1,
,BAO_0000218,7678,N,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,Intermediate,,50597,,6295,,10116.0,Rattus norvegicus,,CHEMBL626135,,,,,A,1,1,
,BAO_0000218,7679,N,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,Intermediate,,50597,,6296,,10116.0,Rattus norvegicus,,CHEMBL626136,,,,,A,1,1,
,BAO_0000218,7680,N,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit,Intermediate,,50597,,6296,,10116.0,Rattus norvegicus,,CHEMBL626137,,,,,A,1,1,
,BAO_0000218,7681,N,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,Intermediate,,50597,,6295,,10116.0,Rattus norvegicus,,CHEMBL626138,,,,,A,1,1,
,BAO_0000218,7682,N,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,Intermediate,,50597,,6296,,10116.0,Rattus norvegicus,,CHEMBL626139,,,,,A,1,1,
,BAO_0000218,7683,N,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,Intermediate,,50597,,17260,,10116.0,Rattus norvegicus,,CHEMBL626140,,,In vivo,,A,1,1,
,BAO_0000218,7684,N,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,Intermediate,,50597,,17260,,10116.0,Rattus norvegicus,,CHEMBL626141,,,In vivo,,A,1,1,
,BAO_0000218,7685,N,C24h in rat p.o. at 20 mg/kg concentration,Intermediate,,50597,,17686,,10116.0,Rattus norvegicus,,CHEMBL626142,,,,,A,1,1,
Muscle tissue,BAO_0000218,7686,N,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Intermediate,,50597,,9866,2385.0,10116.0,Rattus norvegicus,,CHEMBL627930,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,7687,N,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig,Intermediate,,50597,,9866,2385.0,10116.0,Rattus norvegicus,,CHEMBL627931,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,7688,N,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr,Intermediate,,50597,,9866,2385.0,10116.0,Rattus norvegicus,,CHEMBL627932,,,In vivo,,A,1,1,
Spleen,BAO_0000218,7689,N,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Intermediate,,50597,,9866,2106.0,10116.0,Rattus norvegicus,,CHEMBL627933,,,In vivo,,A,1,1,
Spleen,BAO_0000218,7690,N,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig,Intermediate,,50597,,9866,2106.0,10116.0,Rattus norvegicus,,CHEMBL627934,,,In vivo,,A,1,1,
Spleen,BAO_0000218,7691,N,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr,Intermediate,,50597,,9866,2106.0,10116.0,Rattus norvegicus,,CHEMBL627935,,,In vivo,,A,1,1,
Blood,BAO_0000218,7692,N,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP,Intermediate,,50597,,9866,178.0,10116.0,Rattus norvegicus,,CHEMBL627936,,,In vivo,,A,1,1,
Blood,BAO_0000218,7693,N,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP,Intermediate,,50597,,9866,178.0,10116.0,Rattus norvegicus,,CHEMBL627937,,,In vivo,,A,1,1,
Blood,BAO_0000218,7694,N,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP,Intermediate,,50597,,9866,178.0,10116.0,Rattus norvegicus,,CHEMBL627938,,,In vivo,,A,1,1,
Blood,BAO_0000218,7695,N,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig,Intermediate,,50597,,9866,178.0,10116.0,Rattus norvegicus,,CHEMBL627939,,,In vivo,,A,1,1,
Blood,BAO_0000218,7696,N,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP,Intermediate,,50597,,9866,178.0,10116.0,Rattus norvegicus,,CHEMBL627940,,,In vivo,,A,1,1,
Blood,BAO_0000218,7697,N,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP,Intermediate,,50597,,9866,178.0,10116.0,Rattus norvegicus,,CHEMBL627941,,,In vivo,,A,1,1,
Blood,BAO_0000218,7698,N,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP,Intermediate,,50597,,9866,178.0,10116.0,Rattus norvegicus,,CHEMBL876800,,,In vivo,,A,1,1,
Blood,BAO_0000218,7699,N,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP,Intermediate,,50597,,9866,178.0,10116.0,Rattus norvegicus,,CHEMBL627942,,,In vivo,,A,1,1,
Blood,BAO_0000218,7700,N,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP,Intermediate,,50597,,9866,178.0,10116.0,Rattus norvegicus,,CHEMBL627943,,,In vivo,,A,1,1,
Blood,BAO_0000218,7701,N,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min,Intermediate,,50597,,9866,178.0,10116.0,Rattus norvegicus,,CHEMBL627944,,,In vivo,,A,1,1,
Blood,BAO_0000218,7702,N,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr,Intermediate,,50597,,9866,178.0,10116.0,Rattus norvegicus,,CHEMBL627945,,,In vivo,,A,1,1,
Blood,BAO_0000218,7703,N,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr,Intermediate,,50597,,9866,178.0,10116.0,Rattus norvegicus,,CHEMBL628584,,,In vivo,,A,1,1,
Blood,BAO_0000218,7704,N,Biodistribution in rat blood in the presence of GdDTPA at 15 min,Intermediate,,50597,,9866,178.0,10116.0,Rattus norvegicus,,CHEMBL628585,,,In vivo,,A,1,1,
Blood,BAO_0000218,7705,N,Biodistribution in rat blood in the presence of GdDTPA at 1 hr,Intermediate,,50597,,9866,178.0,10116.0,Rattus norvegicus,,CHEMBL628586,,,In vivo,,A,1,1,
Blood,BAO_0000218,7706,N,Biodistribution in rat blood in the presence of GdDTPA at 30 min,Intermediate,,50597,,9866,178.0,10116.0,Rattus norvegicus,,CHEMBL628587,,,In vivo,,A,1,1,
Blood,BAO_0000218,7707,N,Biodistribution in rat blood in the presence of GdDTPA at 4 hr,Intermediate,,50597,,9866,178.0,10116.0,Rattus norvegicus,,CHEMBL628588,,,In vivo,,A,1,1,
Blood,BAO_0000218,7708,N,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min,Intermediate,,50597,,9866,178.0,10116.0,Rattus norvegicus,,CHEMBL628589,,,In vivo,,A,1,1,
Blood,BAO_0000218,7709,N,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min,Intermediate,,50597,,9866,178.0,10116.0,Rattus norvegicus,,CHEMBL625304,,,In vivo,,A,1,1,
Blood,BAO_0000218,7710,N,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr,Intermediate,,50597,,9866,178.0,10116.0,Rattus norvegicus,,CHEMBL625305,,,In vivo,,A,1,1,
Blood,BAO_0000218,7711,N,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr,Intermediate,,50597,,9866,178.0,10116.0,Rattus norvegicus,,CHEMBL625306,,,In vivo,,A,1,1,
Blood,BAO_0000218,7712,N,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min,Intermediate,,50597,,9866,178.0,10116.0,Rattus norvegicus,,CHEMBL625307,,,In vivo,,A,1,1,
Blood,BAO_0000218,7713,N,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min,Intermediate,,50597,,9866,178.0,10116.0,Rattus norvegicus,,CHEMBL625308,,,In vivo,,A,1,1,
Blood,BAO_0000218,7714,N,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr,Intermediate,,50597,,9866,178.0,10116.0,Rattus norvegicus,,CHEMBL627740,,,In vivo,,A,1,1,
Blood,BAO_0000218,7715,N,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr,Intermediate,,50597,,9866,178.0,10116.0,Rattus norvegicus,,CHEMBL627741,,,In vivo,,A,1,1,
Blood,BAO_0000218,7716,N,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP,Intermediate,,50597,,9866,178.0,10116.0,Rattus norvegicus,,CHEMBL627742,,,In vivo,,A,1,1,
Blood,BAO_0000218,7717,N,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip,Intermediate,,50597,,9866,178.0,10116.0,Rattus norvegicus,,CHEMBL627743,,,In vivo,,A,1,1,
Blood,BAO_0000218,7718,N,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig,Intermediate,,50597,,9866,178.0,10116.0,Rattus norvegicus,,CHEMBL627744,,,In vivo,,A,1,1,
Bone,BAO_0000218,7719,N,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP,Intermediate,,50597,,9866,10000001.0,10116.0,Rattus norvegicus,,CHEMBL627745,,,In vivo,,A,1,1,
Bone,BAO_0000218,7720,N,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP,Intermediate,,50597,,9866,10000001.0,10116.0,Rattus norvegicus,,CHEMBL627746,,,In vivo,,A,1,1,
Bone,BAO_0000218,7721,N,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP,Intermediate,,50597,,9866,10000001.0,10116.0,Rattus norvegicus,,CHEMBL627747,,,In vivo,,A,1,1,
Bone,BAO_0000218,7722,N,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig,Intermediate,,50597,,9866,10000001.0,10116.0,Rattus norvegicus,,CHEMBL876810,,,In vivo,,A,1,1,
Bone,BAO_0000218,7723,N,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP,Intermediate,,50597,,9866,10000001.0,10116.0,Rattus norvegicus,,CHEMBL627748,,,In vivo,,A,1,1,
Bone,BAO_0000218,7724,N,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP,Intermediate,,50597,,9866,10000001.0,10116.0,Rattus norvegicus,,CHEMBL627749,,,In vivo,,A,1,1,
Bone,BAO_0000218,7725,N,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP,Intermediate,,50597,,9866,10000001.0,10116.0,Rattus norvegicus,,CHEMBL627750,,,In vivo,,A,1,1,
Bone,BAO_0000218,7726,N,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP,Intermediate,,50597,,9866,10000001.0,10116.0,Rattus norvegicus,,CHEMBL618728,,,In vivo,,A,1,1,
Bone,BAO_0000218,7727,N,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP,Intermediate,,50597,,9866,10000001.0,10116.0,Rattus norvegicus,,CHEMBL618729,,,In vivo,,A,1,1,
Bone,BAO_0000218,7728,N,Biodistribution in rat bone in the presence of GdDTPA at 15 min,Intermediate,,50597,,9866,10000001.0,10116.0,Rattus norvegicus,,CHEMBL618730,,,In vivo,,A,1,1,
Bone,BAO_0000218,7729,N,Biodistribution in rat bone in the presence of GdDTPA at 1 hr,Intermediate,,50597,,9866,10000001.0,10116.0,Rattus norvegicus,,CHEMBL618731,,,In vivo,,A,1,1,
Bone,BAO_0000218,7730,N,Biodistribution in rat bone in the presence of GdDTPA at 30 min,Intermediate,,50597,,9866,10000001.0,10116.0,Rattus norvegicus,,CHEMBL618732,,,In vivo,,A,1,1,
Bone,BAO_0000218,7731,N,Biodistribution in rat bone in the presence of GdDTPA at 4 hr,Intermediate,,50597,,9866,10000001.0,10116.0,Rattus norvegicus,,CHEMBL618733,,,In vivo,,A,1,1,
Bone,BAO_0000218,7732,N,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min,Intermediate,,50597,,9866,10000001.0,10116.0,Rattus norvegicus,,CHEMBL618734,,,In vivo,,A,1,1,
Bone,BAO_0000218,7733,N,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr,Intermediate,,50597,,9866,10000001.0,10116.0,Rattus norvegicus,,CHEMBL618735,,,In vivo,,A,1,1,
Bone,BAO_0000218,7734,N,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min,Intermediate,,50597,,9866,10000001.0,10116.0,Rattus norvegicus,,CHEMBL876602,,,In vivo,,A,1,1,
Bone,BAO_0000218,7735,N,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr,Intermediate,,50597,,9866,10000001.0,10116.0,Rattus norvegicus,,CHEMBL618736,,,In vivo,,A,1,1,
Bone,BAO_0000218,7736,N,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min,Intermediate,,50597,,9866,10000001.0,10116.0,Rattus norvegicus,,CHEMBL618737,,,In vivo,,A,1,1,
Bone,BAO_0000218,7737,N,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr,Intermediate,,50597,,9866,10000001.0,10116.0,Rattus norvegicus,,CHEMBL618738,,,In vivo,,A,1,1,
Bone,BAO_0000218,7738,N,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min,Intermediate,,50597,,9866,10000001.0,10116.0,Rattus norvegicus,,CHEMBL618739,,,In vivo,,A,1,1,
Bone,BAO_0000218,7739,N,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr,Intermediate,,50597,,9866,10000001.0,10116.0,Rattus norvegicus,,CHEMBL618740,,,In vivo,,A,1,1,
Bone,BAO_0000218,7740,N,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP,Intermediate,,50597,,9866,10000001.0,10116.0,Rattus norvegicus,,CHEMBL618741,,,In vivo,,A,1,1,
Bone,BAO_0000218,7741,N,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip,Intermediate,,50597,,9866,10000001.0,10116.0,Rattus norvegicus,,CHEMBL618742,,,In vivo,,A,1,1,
Bone,BAO_0000218,7742,N,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig,Intermediate,,50597,,9866,10000001.0,10116.0,Rattus norvegicus,,CHEMBL618743,,,In vivo,,A,1,1,
Plasma,BAO_0000218,7743,N,Half-life from rat plasma at a single oral dose of 25 mg/kg,Intermediate,,50597,,17752,1969.0,10116.0,Rattus norvegicus,,CHEMBL618744,,,In vivo,,A,1,1,
,BAO_0000218,7744,N,Half-life in male rat,Intermediate,,50597,,5610,,10116.0,Rattus norvegicus,,CHEMBL618745,,,,,A,1,1,
,BAO_0000218,7745,N,Half-life in rat after peroral administration at 10 mg/kg concentration,Intermediate,,50597,,5939,,10116.0,Rattus norvegicus,,CHEMBL620479,,,In vivo,,A,1,1,
,BAO_0000218,7746,N,Half-life in rat after peroral administration at 5 mg/kg concentration,Intermediate,,50597,,5939,,10116.0,Rattus norvegicus,,CHEMBL620480,,,In vivo,,A,1,1,
,BAO_0000218,7747,N,Half-life in rat at a dose of 3 mg/kg,Intermediate,,50597,,17771,,10116.0,Rattus norvegicus,,CHEMBL620481,,,In vivo,,A,1,1,
,BAO_0000218,7748,N,Half-life was evaluated in rats,Intermediate,,50597,,1974,,10116.0,Rattus norvegicus,,CHEMBL620482,,,,,A,1,1,
,BAO_0000218,7749,N,Half-life was measured in rat,Intermediate,,50597,,4239,,10116.0,Rattus norvegicus,,CHEMBL876603,,,,,A,1,1,
,BAO_0000218,7750,N,Half-life period for the compound was determined in rats at 50 mg/kg dose,Intermediate,,50597,,6681,,10116.0,Rattus norvegicus,,CHEMBL620483,,,In vivo,,A,1,1,
,BAO_0000218,7751,N,Half-life period in rats after intravenous administration at 5 mg/kg,Intermediate,,50597,,17752,,10116.0,Rattus norvegicus,,CHEMBL620484,,,In vivo,,A,1,1,
,BAO_0000218,7752,N,Half-life period in rat at 10 mg/kg,Intermediate,,50597,,6046,,10116.0,Rattus norvegicus,,CHEMBL620485,,,In vivo,,A,1,1,
,BAO_0000218,7753,N,"Half-life period was determined in rats at 10 mg/kg, p.o. dose",Intermediate,,50597,,6685,,10116.0,Rattus norvegicus,,CHEMBL620486,,,In vivo,,A,1,1,
,BAO_0000218,7754,N,"Half-life period was determined in rats at 20 mg/kg, i.p. dose",Intermediate,,50597,,6685,,10116.0,Rattus norvegicus,,CHEMBL620487,,,In vivo,,A,1,1,
,BAO_0000218,7755,N,"Half-life period was determined in rats at 2 mg/kg, i.v. dose",Intermediate,,50597,,6685,,10116.0,Rattus norvegicus,,CHEMBL620488,,,In vivo,,A,1,1,
,BAO_0000218,7756,N,Half-life time in rat the dose of 2 mg/kg,Intermediate,,50597,,4727,,10116.0,Rattus norvegicus,,CHEMBL620489,,,In vivo,,A,1,1,
,BAO_0000218,7757,N,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats,Intermediate,,50597,,1088,,10116.0,Rattus norvegicus,,CHEMBL620490,,,In vivo,,A,1,1,
,BAO_0000218,7758,N,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg,Intermediate,,50597,,5610,,10116.0,Rattus norvegicus,,CHEMBL620491,,,In vivo,,A,1,1,
Plasma,BAO_0000218,7759,N,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",Intermediate,,50597,,3032,1969.0,10116.0,Rattus norvegicus,,CHEMBL876604,,,In vivo,,A,1,1,
,BAO_0000218,7760,N,Oral half life was determined,Intermediate,,50597,,5199,,10116.0,Rattus norvegicus,,CHEMBL620492,,,In vivo,,A,1,1,
,BAO_0000218,7761,N,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration",Intermediate,,50597,,14941,,10116.0,Rattus norvegicus,,CHEMBL620493,,,In vivo,,A,1,1,
,BAO_0000218,7762,N,Pharmacokinetic property (t1/2) in rat,Intermediate,,50597,,4408,,10116.0,Rattus norvegicus,,CHEMBL620494,,,In vivo,,A,1,1,
Plasma,BAO_0000218,7763,N,Plasma elimination half-life was determined,Intermediate,,50597,,2552,1969.0,10116.0,Rattus norvegicus,,CHEMBL620495,,,,,A,1,1,
Plasma,BAO_0000218,7764,N,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,Intermediate,,50597,,5199,1969.0,10116.0,Rattus norvegicus,,CHEMBL620496,,,In vivo,,A,1,1,
Plasma,BAO_0000218,7765,N,Plasma half life was observed after intravenous administration in rat,Intermediate,,50597,,15662,1969.0,10116.0,Rattus norvegicus,,CHEMBL620497,,,In vivo,,A,1,1,
Plasma,BAO_0000218,7766,N,Plasma half-life was determined,Intermediate,,50597,,1465,1969.0,10116.0,Rattus norvegicus,,CHEMBL620498,,,,,A,1,1,
Plasma,BAO_0000218,7767,N,Plasma half-life following oral administration in Fisher rats,Intermediate,,50597,,1446,1969.0,10116.0,Rattus norvegicus,,CHEMBL620499,,,In vivo,,A,1,1,
Plasma,BAO_0000218,7768,N,Plasma half-life in rat,Intermediate,,50597,,6824,1969.0,10116.0,Rattus norvegicus,,CHEMBL620500,,,,,A,1,1,
Plasma,BAO_0000218,7769,N,Plasmatic Half-life after intravenous administration to rat,Intermediate,,50597,,17533,1969.0,10116.0,Rattus norvegicus,,CHEMBL873809,,,In vivo,,A,1,1,
,BAO_0000218,7770,N,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,Intermediate,,50597,,5979,,10116.0,Rattus norvegicus,,CHEMBL620501,,,In vivo,,A,1,1,
,BAO_0000218,7771,N,Terminal half life after intravenous administration (1 mg/kg) in rat,Intermediate,,50597,,4689,,10116.0,Rattus norvegicus,,CHEMBL620502,,,In vivo,,A,1,1,
,BAO_0000218,7772,N,Terminal half life in Rat at a oral dose of 5 mg/kg,Intermediate,,50597,,4689,,10116.0,Rattus norvegicus,,CHEMBL620503,,,In vivo,,A,1,1,
,BAO_0000218,7773,N,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,Intermediate,,50597,,2463,,10116.0,Rattus norvegicus,,CHEMBL620504,,,In vivo,,A,1,1,
,BAO_0000218,7774,N,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat,Intermediate,,50597,,4883,,10116.0,Rattus norvegicus,,CHEMBL876605,,,In vivo,,A,1,1,
,BAO_0000218,7775,N,Tested for half life value after oral administration at dosage of 4 mg/kg in rat,Intermediate,,50597,,4883,,10116.0,Rattus norvegicus,,CHEMBL620505,,,In vivo,,A,1,1,
Plasma,BAO_0000218,7776,N,plasma half life was observed after intravenous administration in rat,Intermediate,,50597,,15662,1969.0,10116.0,Rattus norvegicus,,CHEMBL873811,,,In vivo,,A,1,1,
,BAO_0000218,7777,N,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,Expert,,50597,,3598,,10116.0,Rattus norvegicus,,CHEMBL624016,,,In vivo,,A,1,1,
,BAO_0000218,7778,N,Half life of compound determined in rat,Intermediate,,50597,,4576,,10116.0,Rattus norvegicus,,CHEMBL624017,,,,,A,1,1,
,BAO_0000218,7779,N,Mean residence time determined in rat,Intermediate,,50597,,4576,,10116.0,Rattus norvegicus,,CHEMBL624018,,,,,A,1,1,
,BAO_0000218,7780,N,Plasma half life determined in rat,Intermediate,,50597,,4576,,10116.0,Rattus norvegicus,,CHEMBL624019,,,,,A,1,1,
Brain,BAO_0000218,7781,N,Compound was evaluated for Tmax in brain after intravenous administration in male rats,Intermediate,,50597,,4910,955.0,10116.0,Rattus norvegicus,,CHEMBL624020,,,In vivo,,A,1,1,
,BAO_0000218,7782,N,Compound was evaluated for pharmacokinetic parameter maximum time period,Intermediate,,50597,,4891,,10116.0,Rattus norvegicus,,CHEMBL624201,,,In vivo,,A,1,1,
,BAO_0000218,7783,N,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,Intermediate,,50597,,429,,10116.0,Rattus norvegicus,,CHEMBL872528,,,In vivo,,A,1,1,
,BAO_0000218,7784,N,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,Intermediate,,50597,,5974,,10116.0,Rattus norvegicus,,CHEMBL624202,,,In vivo,,A,1,1,
,BAO_0000218,7785,N,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,Intermediate,,50597,,5974,,10116.0,Rattus norvegicus,,CHEMBL624203,,,In vivo,,A,1,1,
,BAO_0000218,7786,N,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,Intermediate,,50597,,5974,,10116.0,Rattus norvegicus,,CHEMBL624350,,,In vivo,,A,1,1,
,BAO_0000218,7787,N,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,Intermediate,,50597,,5974,,10116.0,Rattus norvegicus,,CHEMBL621320,,,In vivo,,A,1,1,
,BAO_0000218,7788,N,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,Intermediate,,50597,,17582,,10116.0,Rattus norvegicus,,CHEMBL621321,,,In vivo,,A,1,1,
,BAO_0000218,7789,N,Maximum time (Tmax) required to reach Cmax in rats,Intermediate,,50597,,4026,,10116.0,Rattus norvegicus,,CHEMBL621322,,,,,A,1,1,
,BAO_0000218,7790,N,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,Intermediate,,50597,,4890,,10116.0,Rattus norvegicus,,CHEMBL621323,,,In vivo,,A,1,1,
,BAO_0000218,7791,N,Maximum time of clearance of compound in rats after peroral administration,Intermediate,,50597,,6571,,10116.0,Rattus norvegicus,,CHEMBL621324,,,In vivo,,A,1,1,
,BAO_0000218,7792,N,Maximum time at the dose of 2 mg/kg in rat,Intermediate,,50597,,4727,,10116.0,Rattus norvegicus,,CHEMBL621325,,,,,A,1,1,
Plasma,BAO_0000218,7793,N,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg,Intermediate,,50597,,17651,1969.0,10116.0,Rattus norvegicus,,CHEMBL875837,,,In vivo,,A,1,1,
Plasma,BAO_0000218,7794,N,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg,Intermediate,,50597,,17651,1969.0,10116.0,Rattus norvegicus,,CHEMBL621326,,,In vivo,,A,1,1,
,BAO_0000218,7795,N,Tmax in Guinea pig (PO dose),Intermediate,,50597,,14465,,10116.0,Rattus norvegicus,,CHEMBL621327,,,In vivo,,A,1,1,
,BAO_0000218,7796,N,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration",Intermediate,,50597,,14941,,10116.0,Rattus norvegicus,,CHEMBL621328,,,In vivo,,A,1,1,
,BAO_0000218,7797,N,Pharmacokinetic parameter (Tmax) in rat,Intermediate,,50597,,5960,,10116.0,Rattus norvegicus,,CHEMBL621329,,,In vivo,,A,1,1,
,BAO_0000218,7798,N,Pharmacokinetic parameter (Tmax) was estimated,Intermediate,,50597,,5022,,10116.0,Rattus norvegicus,,CHEMBL621330,,,In vivo,,A,1,1,
,BAO_0000218,7799,N,Pharmacokinetic property (Tmax) in rat,Intermediate,,50597,,4408,,10116.0,Rattus norvegicus,,CHEMBL621331,,,In vivo,,A,1,1,
,BAO_0000218,7800,N,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.,Intermediate,,50597,,5983,,10116.0,Rattus norvegicus,,CHEMBL621332,,,In vivo,,A,1,1,
,BAO_0000218,7801,N,T max in Rat at a oral dose of 5 mg/kg,Intermediate,,50597,,4689,,10116.0,Rattus norvegicus,,CHEMBL621333,,,In vivo,,A,1,1,
,BAO_0000218,7802,N,T max was determined at 10 mg/kg po dose in rats,Intermediate,,50597,,2792,,10116.0,Rattus norvegicus,,CHEMBL621334,,,In vivo,,A,1,1,
,BAO_0000218,7803,N,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr),Intermediate,,50594,,15011,,10090.0,Mus musculus,,CHEMBL621335,,,,,A,1,1,
,BAO_0000218,7804,N,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs,Intermediate,,50588,,14180,,9615.0,Canis lupus familiaris,,CHEMBL621336,,,,,A,1,1,
,BAO_0000218,7805,N,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats,Intermediate,,50597,,14180,,10116.0,Rattus norvegicus,,CHEMBL621337,,,,,A,1,1,
,BAO_0000218,7806,N,Area under curve was measured after i.v. administration into Beagle dog.,Intermediate,,50588,,14599,,9615.0,Canis lupus familiaris,,CHEMBL621338,,,,,A,1,1,
,BAO_0000218,7807,N,Area under curve was measured after iv administration into Beagle dog,Intermediate,,50588,,14599,,9615.0,Canis lupus familiaris,,CHEMBL875838,,,,,A,1,1,
,BAO_0000218,7808,N,Area under curve was measured after po administration into Beagle dog,Intermediate,,50588,,14599,,9615.0,Canis lupus familiaris,,CHEMBL621339,,,,,A,1,1,
,BAO_0000218,7809,N,Area under curve was measured after po administration into Beagle dog.,Intermediate,,50588,,14599,,9615.0,Canis lupus familiaris,,CHEMBL621340,,,,,A,1,1,
,BAO_0000218,7810,U,Area under curve was measured at peroral dose of 3 mg/kg,Autocuration,,22224,,15675,,,,,CHEMBL621341,,,,,A,1,0,
,BAO_0000019,7811,U,Area under curve was measured by using concentration Vs time,Autocuration,,22224,,12706,,,,,CHEMBL621342,,,,,A,1,0,
,BAO_0000019,7812,U,Area under curve was measured by using concentration Vs time; not tested,Autocuration,,22224,,12706,,,,,CHEMBL621343,,,,,A,1,0,
,BAO_0000218,7813,N,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg),Intermediate,,50594,,9750,,10090.0,Mus musculus,,CHEMBL621344,,,,,A,1,1,
,BAO_0000218,7814,N,Area under curve(AUC) was measured in mice after oral administration.,Intermediate,,50594,,9750,,10090.0,Mus musculus,,CHEMBL621345,,,,,A,1,1,
,BAO_0000019,7815,U,Area under curve(AUC) value of the compound,Autocuration,,22224,,14691,,,,,CHEMBL621346,,,,,A,1,0,
,BAO_0000218,7816,U,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration,Autocuration,,22224,,14691,,,,,CHEMBL621347,,,,,A,1,0,
,BAO_0000218,7817,N,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration,Intermediate,,50588,,14691,,9615.0,Canis lupus familiaris,,CHEMBL621348,,,,,A,1,1,
Blood,BAO_0000019,7818,U,Area under curve(carotid artery) was determined by the availability in blood,Autocuration,,22224,,2939,178.0,,,,CHEMBL621349,,,,,A,1,0,
Blood,BAO_0000019,7819,U,Area under curve(carotid artery) was determined by the availability in blood; ND means no data,Autocuration,,22224,,2939,178.0,,,,CHEMBL621350,,,,,A,1,0,
Blood,BAO_0000019,7820,U,Area under curve(carotid artery) was determined by the availability in blood; No data,Autocuration,,22224,,2939,178.0,,,,CHEMBL875839,,,,,A,1,0,
Blood,BAO_0000019,7821,U,Area under curve(portal vein) was determined by the availability in blood,Autocuration,,22224,,2939,178.0,,,,CHEMBL620211,,,,,A,1,0,
Blood,BAO_0000019,7822,U,Area under curve(portal vein) was determined by the availability in blood; ND means no data,Autocuration,,22224,,2939,178.0,,,,CHEMBL620212,,,,,A,1,0,
Blood,BAO_0000019,7823,U,Area under curve(portal vein) was determined by the availability in blood; No data,Autocuration,,22224,,2939,178.0,,,,CHEMBL620213,,,,,A,1,0,
Plasma,BAO_0000218,7824,N,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",Intermediate,,50797,,9552,1969.0,9544.0,Macaca mulatta,,CHEMBL620214,,,,,A,1,1,
Plasma,BAO_0000218,7825,N,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",Intermediate,,50797,,9552,1969.0,9544.0,Macaca mulatta,,CHEMBL620215,,,,,A,1,1,
Plasma,BAO_0000218,7826,N,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose,Intermediate,,50797,,9552,1969.0,9544.0,Macaca mulatta,,CHEMBL620216,,,,,A,1,1,
Plasma,BAO_0000218,7827,N,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose",Intermediate,,50588,,9552,1969.0,9615.0,Canis lupus familiaris,,CHEMBL620888,,,,,A,1,1,
Plasma,BAO_0000218,7828,N,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose",Intermediate,,50588,,9552,1969.0,9615.0,Canis lupus familiaris,,CHEMBL620889,,,,,A,1,1,
Plasma,BAO_0000019,7829,U,Area under plasma concentration vs time curve observed in rats for 0-3 h,Autocuration,,22224,,9552,1969.0,,,,CHEMBL620890,,,,,A,1,0,
Plasma,BAO_0000218,7830,N,Area under plasma time curve determined in male rat,Intermediate,,50597,,11911,1969.0,10116.0,Rattus norvegicus,,CHEMBL620891,,,,,A,1,1,
,BAO_0000019,7831,U,Area under the MAP curve measured over 5 min.,Autocuration,,22224,,16618,,,,,CHEMBL620892,,,,,A,1,0,
,BAO_0000218,7832,N,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice,Intermediate,,50594,,14387,,10090.0,Mus musculus,,CHEMBL621079,,,,,A,1,1,
,BAO_0000218,7833,N,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice,Intermediate,,50594,,14387,,10090.0,Mus musculus,,CHEMBL621080,,,,,A,1,1,
,BAO_0000218,7834,N,Area under the concentration vs time curve in dog at 10 mg/kg oral dose,Intermediate,,50588,,12836,,9615.0,Canis lupus familiaris,,CHEMBL621081,,,,,A,1,1,
,BAO_0000218,7835,N,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose,Intermediate,,100712,,12836,,10026.0,Cricetinae,,CHEMBL621082,,,,,A,1,1,
,BAO_0000218,7836,N,Area under the concentration vs time curve in rat at 10 mg/kg oral dose,Intermediate,,50597,,12836,,10116.0,Rattus norvegicus,,CHEMBL621083,,,,,A,1,1,
,BAO_0000218,7837,N,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs,Intermediate,,50588,,14339,,9615.0,Canis lupus familiaris,,CHEMBL621084,,,,,A,1,1,
,BAO_0000218,7838,N,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs,Intermediate,,50588,,14339,,9615.0,Canis lupus familiaris,,CHEMBL621085,,,,,A,1,1,
,BAO_0000218,7839,N,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs,Intermediate,,50588,,14339,,9615.0,Canis lupus familiaris,,CHEMBL621086,,,,,A,1,1,
,BAO_0000218,7840,N,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),Intermediate,,50588,,10524,,9615.0,Canis lupus familiaris,,CHEMBL621087,,,,,A,1,1,
,BAO_0000218,7841,N,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg),Intermediate,,50588,,9994,,9615.0,Canis lupus familiaris,,CHEMBL622607,,,,,A,1,1,
,BAO_0000218,7842,N,Serum AUC in marmosets (IV dose),Intermediate,,50588,,11325,,9615.0,Canis lupus familiaris,,CHEMBL622608,,,,,A,1,1,
,BAO_0000019,7843,U,Area under the curve after intravenous administration at a dose of 10 umol/kg,Autocuration,,22224,,12536,,,,,CHEMBL624481,,,,,A,1,0,
,BAO_0000019,7844,U,Area under the curve after intravenous administration at a dose of 2 umol/kg,Autocuration,,22224,,12536,,,,,CHEMBL624482,,,,,A,1,0,
,BAO_0000019,7845,U,Area under the curve after intravenous administration at a dose of 4 umol/kg,Autocuration,,22224,,12536,,,,,CHEMBL624483,,,,,A,1,0,
,BAO_0000019,7846,U,Area under the curve after intravenous administration at a dose of 40 umol/kg,Autocuration,,22224,,12536,,,,,CHEMBL624484,,,,,A,1,0,
,BAO_0000019,7847,U,Area under the curve after intravenous administration at a dose of 5 umol/kg,Autocuration,,22224,,12536,,,,,CHEMBL624485,,,,,A,1,0,
,BAO_0000218,7848,N,Area under the curve for fumarate salt was evaluated in F344 Rats.,Intermediate,,50597,,15556,,10116.0,Rattus norvegicus,,CHEMBL624486,,,,,A,1,1,
,BAO_0000019,7849,U,Area under the curve for the compound was calculated.,Autocuration,,22224,,2809,,,,,CHEMBL624487,,,,,A,1,0,
,BAO_0000019,7850,U,Area under the curve in concentration/ time,Autocuration,,22224,,9511,,,,,CHEMBL624488,,,,,A,1,0,
,BAO_0000218,7851,N,Area under the curve administered intraintestinal in rats.,Intermediate,,50597,,12818,,10116.0,Rattus norvegicus,,CHEMBL624489,,,,,A,1,1,
,BAO_0000218,7852,N,Area under the curve administered intravenously in rats.,Intermediate,,50597,,12818,,10116.0,Rattus norvegicus,,CHEMBL625184,,,,,A,1,1,
,BAO_0000019,7853,U,Area under the curve during intravenous administration,Autocuration,,22224,,15118,,,,,CHEMBL625185,,,,,A,1,0,
,BAO_0000019,7854,U,Area under the curve during intravenous administration; Not determined,Autocuration,,22224,,15118,,,,,CHEMBL875954,,,,,A,1,0,
,BAO_0000019,7855,U,Area under the curve during systemic administration,Autocuration,,22224,,15118,,,,,CHEMBL625186,,,,,A,1,0,
,BAO_0000019,7856,U,Area under the curve during systemic administration; Not determined,Autocuration,,22224,,15118,,,,,CHEMBL625187,,,,,A,1,0,
,BAO_0000019,7857,U,Area under the curve was calculated for the compound.,Autocuration,,22224,,2632,,,,,CHEMBL625188,,,,,A,1,0,
,BAO_0000218,7858,N,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs,Intermediate,,50588,,14346,,9615.0,Canis lupus familiaris,,CHEMBL625189,,,,,A,1,1,
,BAO_0000218,7859,N,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs,Intermediate,,50588,,14346,,9615.0,Canis lupus familiaris,,CHEMBL625190,,,,,A,1,1,
,BAO_0000218,7860,N,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats,Intermediate,,50597,,14346,,10116.0,Rattus norvegicus,,CHEMBL621733,,,,,A,1,1,
,BAO_0000218,7861,N,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats,Intermediate,,50597,,14346,,10116.0,Rattus norvegicus,,CHEMBL621734,,,,,A,1,1,
,BAO_0000218,7862,N,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats,Intermediate,,50597,,11149,,10116.0,Rattus norvegicus,,CHEMBL621735,,,,,A,1,1,
Plasma,BAO_0000218,7863,N,Clearance of the drug was measured in the plasma of rat; No data,Intermediate,,50597,,17796,1969.0,10116.0,Rattus norvegicus,,CHEMBL621736,,,,,A,1,1,
Plasma,BAO_0000218,7864,N,The pharmacokinetic parameter plasma clearance in vivo in rats,Intermediate,,50597,,5247,1969.0,10116.0,Rattus norvegicus,,CHEMBL621737,,,,,A,1,1,
,BAO_0000218,7865,N,Plasma clearance at the dose of 2 mg/kg in rat,Intermediate,,50597,,4727,,10116.0,Rattus norvegicus,,CHEMBL621738,,,,,A,1,1,
,BAO_0000218,7866,N,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,Intermediate,,50597,,5654,,10116.0,Rattus norvegicus,,CHEMBL622806,,,In vivo,,A,1,1,
,BAO_0000218,7867,N,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,Intermediate,,50597,,5654,,10116.0,Rattus norvegicus,,CHEMBL623519,,,In vivo,,A,1,1,
,BAO_0000218,7868,N,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,Intermediate,,50597,,17260,,10116.0,Rattus norvegicus,,CHEMBL623520,,,In vivo,,A,1,1,
,BAO_0000218,7869,N,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats,Intermediate,,50597,,17065,,10116.0,Rattus norvegicus,,CHEMBL623521,,,In vivo,,A,1,1,
,BAO_0000218,7870,N,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,Intermediate,,50597,,17671,,10116.0,Rattus norvegicus,,CHEMBL623522,,,In vivo,,A,1,1,
,BAO_0000218,7871,N,Clearance rate in rat,Intermediate,,50597,,6672,,10116.0,Rattus norvegicus,,CHEMBL623523,,,In vivo,,A,1,1,
,BAO_0000218,7872,N,Clearance rate in rat,Intermediate,,50597,,6673,,10116.0,Rattus norvegicus,,CHEMBL623690,,,In vivo,,A,1,1,
,BAO_0000218,7873,N,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,Intermediate,,50597,,5978,,10116.0,Rattus norvegicus,,CHEMBL623691,,,In vivo,,A,1,1,
,BAO_0000218,7874,N,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,Intermediate,,50597,,5978,,10116.0,Rattus norvegicus,,CHEMBL623692,,,In vivo,,A,1,1,
,BAO_0000218,7875,N,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,Intermediate,,50597,,5978,,10116.0,Rattus norvegicus,,CHEMBL623693,,,In vivo,,A,1,1,
,BAO_0000218,7876,N,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,Intermediate,,50597,,5978,,10116.0,Rattus norvegicus,,CHEMBL623694,,,In vivo,,A,1,1,
,BAO_0000218,7877,N,Clearance of compound after iv administration of 20 mg/kg dose in rat,Intermediate,,50597,,4413,,10116.0,Rattus norvegicus,,CHEMBL623695,,,In vivo,,A,1,1,
,BAO_0000218,7878,N,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats,Intermediate,,50597,,2661,,10116.0,Rattus norvegicus,,CHEMBL623696,,,In vivo,,A,1,1,
,BAO_0000218,7879,N,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats,Intermediate,,50597,,2661,,10116.0,Rattus norvegicus,,CHEMBL623697,,,In vivo,,A,1,1,
Plasma,BAO_0000218,7880,U,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Intermediate,,22224,,5005,1969.0,9544.0,Macaca mulatta,,CHEMBL623698,,,In vivo,,A,1,0,
Plasma,BAO_0000218,7881,U,Compound was tested for its plasma clearance rate in Sprague Dawley rats,Intermediate,,22224,,5005,1969.0,10116.0,Rattus norvegicus,,CHEMBL623699,,,In vivo,,A,1,0,
,BAO_0000218,7882,N,Mean (%CV) PK parameters for CL(mL/min/kg).,Intermediate,,50597,,15765,,10116.0,Rattus norvegicus,,CHEMBL623700,,,In vivo,,A,1,1,
,BAO_0000218,7883,N,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat,Intermediate,,50597,,3747,,10116.0,Rattus norvegicus,,CHEMBL623701,,,In vivo,,A,1,1,
Plasma,BAO_0000218,7884,N,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered,Intermediate,,50597,,16366,1969.0,10116.0,Rattus norvegicus,,CHEMBL623702,,,In vivo,,A,1,1,
,BAO_0000218,7885,N,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats,Intermediate,,50597,,4199,,10116.0,Rattus norvegicus,,CHEMBL623703,,,In vivo,,A,1,1,
,BAO_0000218,7886,N,Plasma clearance in rat was determined,Intermediate,,50597,,17267,,10116.0,Rattus norvegicus,,CHEMBL623704,,,In vivo,,A,1,1,
,BAO_0000218,7887,N,Plasma clearance in rat after administration of 2 mg/kg iv,Intermediate,,50597,,6535,,10116.0,Rattus norvegicus,,CHEMBL623705,,,In vivo,,A,1,1,
,BAO_0000218,7888,N,Plasma clearance in rat after administration of 2 mg/kg iv,Intermediate,,50597,,6535,,10116.0,Rattus norvegicus,,CHEMBL623706,,,In vivo,,A,1,1,
,BAO_0000218,7889,N,Plasma clearance was determined,Intermediate,,50597,,5041,,10116.0,Rattus norvegicus,,CHEMBL623707,,,In vivo,,A,1,1,
,BAO_0000218,7890,N,Plasma clearance in rat,Intermediate,,50597,,5960,,10116.0,Rattus norvegicus,,CHEMBL623708,,,In vivo,,A,1,1,
,BAO_0000218,7891,N,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg,Intermediate,,50597,,5937,,10116.0,Rattus norvegicus,,CHEMBL623709,,,In vivo,,A,1,1,
,BAO_0000218,7892,N,Plasma clearance in rat by iv administration,Intermediate,,50597,,5871,,10116.0,Rattus norvegicus,,CHEMBL623710,,,In vivo,,A,1,1,
,BAO_0000218,7893,N,Plasma clearance in rat by iv administration at a dose of 3 mg/kg,Intermediate,,50597,,5874,,10116.0,Rattus norvegicus,,CHEMBL623711,,,In vivo,,A,1,1,
,BAO_0000218,7894,N,Plasma clearance in rat p.o.,Intermediate,,50597,,6504,,10116.0,Rattus norvegicus,,CHEMBL623712,,,In vivo,,A,1,1,
,BAO_0000218,7895,N,Plasma clearance in rats,Intermediate,,50597,,6803,,10116.0,Rattus norvegicus,,CHEMBL623713,,,In vivo,,A,1,1,
,BAO_0000218,7896,N,Plasma clearance was determined; ND denotes no data,Intermediate,,50597,,5041,,10116.0,Rattus norvegicus,,CHEMBL623714,,,In vivo,,A,1,1,
,BAO_0000218,7897,N,Plasma clearance was determined; ND denotes not determined,Intermediate,,50597,,5041,,10116.0,Rattus norvegicus,,CHEMBL623715,,,In vivo,,A,1,1,
,BAO_0000218,7898,N,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,Intermediate,,50597,,1916,,10116.0,Rattus norvegicus,,CHEMBL623716,,,In vivo,,A,1,1,
,BAO_0000218,7899,N,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,Intermediate,,50597,,5199,,10116.0,Rattus norvegicus,,CHEMBL622980,,,In vivo,,A,1,1,
,BAO_0000218,7900,N,Plasma administration to rats,Intermediate,,50597,,16367,,10116.0,Rattus norvegicus,,CHEMBL622981,,,In vivo,,A,1,1,
,BAO_0000218,7901,N,Plasma clearance of the compound in female Sprague-Dawley rats,Intermediate,,50597,,6362,,10116.0,Rattus norvegicus,,CHEMBL622982,,,In vivo,,A,1,1,
,BAO_0000218,7902,N,Plasma clearance was observed after intravenous administration in rat,Intermediate,,50597,,15662,,10116.0,Rattus norvegicus,,CHEMBL622983,,,In vivo,,A,1,1,
,BAO_0000218,7903,N,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat,Intermediate,,50597,,6215,,10116.0,Rattus norvegicus,,CHEMBL622984,,,In vivo,,A,1,1,
,BAO_0000218,7904,N,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat,Intermediate,,50597,,1466,,10116.0,Rattus norvegicus,,CHEMBL622985,,,In vivo,,A,1,1,
Plasma,BAO_0000218,7905,N,plasma clearance was observed after intravenous administration in rat,Intermediate,,50597,,15662,1969.0,10116.0,Rattus norvegicus,,CHEMBL623631,,,In vivo,,A,1,1,
,BAO_0000218,7906,N,In vivo CL/F determined,Intermediate,,50597,,4723,,10116.0,Rattus norvegicus,,CHEMBL623632,,,In vivo,,A,1,1,
Plasma,BAO_0000218,7907,N,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats,Intermediate,,50597,,2792,1969.0,10116.0,Rattus norvegicus,,CHEMBL623633,,,In vivo,,A,1,1,
Plasma,BAO_0000218,7908,N,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats,Intermediate,,50597,,2792,1969.0,10116.0,Rattus norvegicus,,CHEMBL623634,,,In vivo,,A,1,1,
,BAO_0000218,7909,N,Compound was tested for the lower blood clearance in rat,Intermediate,,50597,,5213,,10116.0,Rattus norvegicus,,CHEMBL623635,,,In vivo,,A,1,1,
,BAO_0000218,7910,N,Evaluated for the low clearance in rat (in vivo),Intermediate,,50597,,4687,,10116.0,Rattus norvegicus,,CHEMBL621195,,,In vivo,,A,1,1,
,BAO_0000218,7911,N,Pharmacokinetic property (CLb)of the compound was determined in rat,Intermediate,,50597,,3371,,10116.0,Rattus norvegicus,,CHEMBL621196,,,In vivo,,A,1,1,
,BAO_0000218,7912,N,Rapid clearance after intravenous administration in rat was determined,Intermediate,,50597,,4690,,10116.0,Rattus norvegicus,,CHEMBL875287,,,In vivo,,A,1,1,
,BAO_0000218,7913,N,Clearance measured in rat,Intermediate,,50597,,5702,,10116.0,Rattus norvegicus,,CHEMBL621197,,,In vivo,,A,1,1,
Plasma,BAO_0000218,7914,N,Compound was evaluated for plasma clearance in rat,Intermediate,,50597,,740,1969.0,10116.0,Rattus norvegicus,,CHEMBL621198,,,In vivo,,A,1,1,
Plasma,BAO_0000218,7915,N,Low plasma clearance was calculated in rat,Intermediate,,50597,,4853,1969.0,10116.0,Rattus norvegicus,,CHEMBL621199,,,In vivo,,A,1,1,
,BAO_0000218,7916,N,Pharmacokinetic property (Clp) in rat,Intermediate,,50597,,5789,,10116.0,Rattus norvegicus,,CHEMBL621200,,,In vivo,,A,1,1,
,BAO_0000218,7917,N,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined,Intermediate,,50597,,4527,,10116.0,Rattus norvegicus,,CHEMBL621201,,,In vivo,,A,1,1,
,BAO_0000218,7918,N,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined,Intermediate,,50597,,4527,,10116.0,Rattus norvegicus,,CHEMBL621202,,,In vivo,,A,1,1,
,BAO_0000218,7919,N,Plasma clearance after IV dosing at 0.5 mg/kg in rat,Intermediate,,50597,,6518,,10116.0,Rattus norvegicus,,CHEMBL621203,,,In vivo,,A,1,1,
,BAO_0000218,7920,N,Plasma clearance after IV dosing at 1 mg/kg in rat,Intermediate,,50597,,6518,,10116.0,Rattus norvegicus,,CHEMBL621204,,,In vivo,,A,1,1,
Heart,BAO_0000218,7921,N,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP,Intermediate,,50597,,9866,948.0,10116.0,Rattus norvegicus,,CHEMBL621205,,,In vivo,,A,1,1,
Heart,BAO_0000218,7922,N,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP,Intermediate,,50597,,9866,948.0,10116.0,Rattus norvegicus,,CHEMBL621206,,,In vivo,,A,1,1,
Heart,BAO_0000218,7923,N,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP,Intermediate,,50597,,9866,948.0,10116.0,Rattus norvegicus,,CHEMBL621207,,,In vivo,,A,1,1,
Heart,BAO_0000218,7924,N,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP,Intermediate,,50597,,9866,948.0,10116.0,Rattus norvegicus,,CHEMBL621208,,,In vivo,,A,1,1,
Heart,BAO_0000218,7925,N,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig,Intermediate,,50597,,9866,948.0,10116.0,Rattus norvegicus,,CHEMBL621209,,,In vivo,,A,1,1,
Heart,BAO_0000218,7926,N,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP,Intermediate,,50597,,9866,948.0,10116.0,Rattus norvegicus,,CHEMBL876484,,,In vivo,,A,1,1,
Heart,BAO_0000218,7927,N,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP,Intermediate,,50597,,9866,948.0,10116.0,Rattus norvegicus,,CHEMBL621210,,,In vivo,,A,1,1,
Heart,BAO_0000218,7928,N,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP,Intermediate,,50597,,9866,948.0,10116.0,Rattus norvegicus,,CHEMBL621211,,,In vivo,,A,1,1,
Heart,BAO_0000218,7929,N,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP,Intermediate,,50597,,9866,948.0,10116.0,Rattus norvegicus,,CHEMBL621212,,,In vivo,,A,1,1,
Heart,BAO_0000218,7930,N,Biodistribution in rat heart in the presence of GdDTPA at 15 min,Intermediate,,50597,,9866,948.0,10116.0,Rattus norvegicus,,CHEMBL621213,,,In vivo,,A,1,1,
Heart,BAO_0000218,7931,N,Biodistribution in rat heart in the presence of GdDTPA at 1 hr,Intermediate,,50597,,9866,948.0,10116.0,Rattus norvegicus,,CHEMBL621214,,,In vivo,,A,1,1,
Heart,BAO_0000218,7932,N,Biodistribution in rat heart in the presence of GdDTPA at 30 min,Intermediate,,50597,,9866,948.0,10116.0,Rattus norvegicus,,CHEMBL621215,,,In vivo,,A,1,1,
Heart,BAO_0000218,7933,N,Biodistribution in rat heart in the presence of GdDTPA at 4 hr,Intermediate,,50597,,9866,948.0,10116.0,Rattus norvegicus,,CHEMBL621216,,,In vivo,,A,1,1,
Heart,BAO_0000218,7934,N,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr,Intermediate,,50597,,9866,948.0,10116.0,Rattus norvegicus,,CHEMBL621217,,,In vivo,,A,1,1,
Heart,BAO_0000218,7935,N,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min,Intermediate,,50597,,9866,948.0,10116.0,Rattus norvegicus,,CHEMBL621218,,,In vivo,,A,1,1,
Heart,BAO_0000218,7936,N,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr,Intermediate,,50597,,9866,948.0,10116.0,Rattus norvegicus,,CHEMBL621219,,,In vivo,,A,1,1,
Heart,BAO_0000218,7937,N,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min,Intermediate,,50597,,9866,948.0,10116.0,Rattus norvegicus,,CHEMBL621220,,,In vivo,,A,1,1,
Heart,BAO_0000218,7938,N,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr,Intermediate,,50597,,9866,948.0,10116.0,Rattus norvegicus,,CHEMBL621221,,,In vivo,,A,1,1,
Heart,BAO_0000218,7939,N,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min,Intermediate,,50597,,9866,948.0,10116.0,Rattus norvegicus,,CHEMBL621222,,,In vivo,,A,1,1,
Heart,BAO_0000218,7940,N,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr,Intermediate,,50597,,9866,948.0,10116.0,Rattus norvegicus,,CHEMBL621223,,,In vivo,,A,1,1,
Heart,BAO_0000218,7941,N,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min,Intermediate,,50597,,9866,948.0,10116.0,Rattus norvegicus,,CHEMBL876485,,,In vivo,,A,1,1,
Heart,BAO_0000218,7942,N,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP,Intermediate,,50597,,9866,948.0,10116.0,Rattus norvegicus,,CHEMBL621224,,,In vivo,,A,1,1,
Heart,BAO_0000218,7943,N,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip,Intermediate,,50597,,9866,948.0,10116.0,Rattus norvegicus,,CHEMBL621225,,,In vivo,,A,1,1,
Heart,BAO_0000218,7944,N,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig,Intermediate,,50597,,9866,948.0,10116.0,Rattus norvegicus,,CHEMBL621226,,,In vivo,,A,1,1,
Kidney,BAO_0000218,7945,N,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP,Intermediate,,50597,,9866,2113.0,10116.0,Rattus norvegicus,,CHEMBL621227,,,In vivo,,A,1,1,
Kidney,BAO_0000218,7946,N,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP,Intermediate,,50597,,9866,2113.0,10116.0,Rattus norvegicus,,CHEMBL621228,,,In vivo,,A,1,1,
Kidney,BAO_0000218,7947,N,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP,Intermediate,,50597,,9866,2113.0,10116.0,Rattus norvegicus,,CHEMBL621229,,,In vivo,,A,1,1,
Kidney,BAO_0000218,7948,N,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig,Intermediate,,50597,,9866,2113.0,10116.0,Rattus norvegicus,,CHEMBL621230,,,In vivo,,A,1,1,
Kidney,BAO_0000218,7949,N,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data,Intermediate,,50597,,9866,2113.0,10116.0,Rattus norvegicus,,CHEMBL621231,,,In vivo,,A,1,1,
Kidney,BAO_0000218,7950,N,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP,Intermediate,,50597,,9866,2113.0,10116.0,Rattus norvegicus,,CHEMBL621232,,,In vivo,,A,1,1,
Kidney,BAO_0000218,7951,N,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP,Intermediate,,50597,,9866,2113.0,10116.0,Rattus norvegicus,,CHEMBL621233,,,In vivo,,A,1,1,
Kidney,BAO_0000218,7952,N,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP,Intermediate,,50597,,9866,2113.0,10116.0,Rattus norvegicus,,CHEMBL621234,,,In vivo,,A,1,1,
Kidney,BAO_0000218,7953,N,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,Intermediate,,50597,,9866,2113.0,10116.0,Rattus norvegicus,,CHEMBL621235,,,In vivo,,A,1,1,
Kidney,BAO_0000218,7954,N,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP,Intermediate,,50597,,9866,2113.0,10116.0,Rattus norvegicus,,CHEMBL621236,,,In vivo,,A,1,1,
Kidney,BAO_0000218,7955,N,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip,Intermediate,,50597,,9866,2113.0,10116.0,Rattus norvegicus,,CHEMBL621237,,,In vivo,,A,1,1,
Kidney,BAO_0000218,7956,N,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig,Intermediate,,50597,,9866,2113.0,10116.0,Rattus norvegicus,,CHEMBL876486,,,In vivo,,A,1,1,
Intestine,BAO_0000218,7957,N,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr,Intermediate,,50597,,9866,160.0,10116.0,Rattus norvegicus,,CHEMBL622436,,,In vivo,,A,1,1,
Intestine,BAO_0000218,7958,N,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr,Intermediate,,50597,,9866,160.0,10116.0,Rattus norvegicus,,CHEMBL622437,,,In vivo,,A,1,1,
Intestine,BAO_0000218,7959,N,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr,Intermediate,,50597,,9866,160.0,10116.0,Rattus norvegicus,,CHEMBL622438,,,In vivo,,A,1,1,
Liver,BAO_0000218,7960,N,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min,Intermediate,,50597,,9866,2107.0,10116.0,Rattus norvegicus,,CHEMBL622439,,,In vivo,,A,1,1,
Liver,BAO_0000218,7961,N,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig,Intermediate,,50597,,9866,2107.0,10116.0,Rattus norvegicus,,CHEMBL622440,,,In vivo,,A,1,1,
Liver,BAO_0000218,7962,N,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig,Intermediate,,50597,,9866,2107.0,10116.0,Rattus norvegicus,,CHEMBL622441,,,In vivo,,A,1,1,
Liver,BAO_0000218,7963,N,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP,Intermediate,,50597,,9866,2107.0,10116.0,Rattus norvegicus,,CHEMBL622442,,,In vivo,,A,1,1,
Liver,BAO_0000218,7964,N,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP,Intermediate,,50597,,9866,2107.0,10116.0,Rattus norvegicus,,CHEMBL622443,,,In vivo,,A,1,1,
Liver,BAO_0000218,7965,N,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP,Intermediate,,50597,,9866,2107.0,10116.0,Rattus norvegicus,,CHEMBL622444,,,In vivo,,A,1,1,
Liver,BAO_0000218,7966,N,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP,Intermediate,,50597,,9866,2107.0,10116.0,Rattus norvegicus,,CHEMBL622445,,,In vivo,,A,1,1,
Liver,BAO_0000218,7967,N,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP,Intermediate,,50597,,9866,2107.0,10116.0,Rattus norvegicus,,CHEMBL622446,,,In vivo,,A,1,1,
Liver,BAO_0000218,7968,N,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP,Intermediate,,50597,,9866,2107.0,10116.0,Rattus norvegicus,,CHEMBL622447,,,In vivo,,A,1,1,
Liver,BAO_0000218,7969,N,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP,Intermediate,,50597,,9866,2107.0,10116.0,Rattus norvegicus,,CHEMBL622448,,,In vivo,,A,1,1,
Liver,BAO_0000218,7970,N,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,Intermediate,,50597,,9866,2107.0,10116.0,Rattus norvegicus,,CHEMBL622449,,,In vivo,,A,1,1,
Liver,BAO_0000218,7971,N,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr,Intermediate,,50597,,9866,2107.0,10116.0,Rattus norvegicus,,CHEMBL622450,,,In vivo,,A,1,1,
Liver,BAO_0000218,7972,N,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr,Intermediate,,50597,,9866,2107.0,10116.0,Rattus norvegicus,,CHEMBL622451,,,In vivo,,A,1,1,
Liver,BAO_0000218,7973,N,Biodistribution in rat liver in the presence of GdDTPA at 15 min,Intermediate,,50597,,9866,2107.0,10116.0,Rattus norvegicus,,CHEMBL622452,,,In vivo,,A,1,1,
Liver,BAO_0000218,7974,N,Biodistribution in rat liver in the presence of GdDTPA at 1 hr,Intermediate,,50597,,9866,2107.0,10116.0,Rattus norvegicus,,CHEMBL622453,,,In vivo,,A,1,1,
Liver,BAO_0000218,7975,N,Biodistribution in rat liver in the presence of GdDTPA at 30 min,Intermediate,,50597,,9866,2107.0,10116.0,Rattus norvegicus,,CHEMBL622454,,,In vivo,,A,1,1,
Liver,BAO_0000218,7976,N,Biodistribution in rat liver in the presence of GdDTPA at 4 hr,Intermediate,,50597,,9866,2107.0,10116.0,Rattus norvegicus,,CHEMBL622455,,,In vivo,,A,1,1,
Liver,BAO_0000218,7977,N,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min,Intermediate,,50597,,9866,2107.0,10116.0,Rattus norvegicus,,CHEMBL876024,,,In vivo,,A,1,1,
,BAO_0000218,7978,N,T max was determined at 3 mg/kg po dose in rats,Intermediate,,50597,,2792,,10116.0,Rattus norvegicus,,CHEMBL622456,,,In vivo,,A,1,1,
,BAO_0000218,7979,N,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose",Intermediate,,50597,,15078,,10116.0,Rattus norvegicus,,CHEMBL622457,,,In vivo,,A,1,1,
,BAO_0000218,7980,N,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose",Intermediate,,50597,,15078,,10116.0,Rattus norvegicus,,CHEMBL622458,,,In vivo,,A,1,1,
,BAO_0000218,7981,N,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg,Intermediate,,50597,,15022,,10116.0,Rattus norvegicus,,CHEMBL622459,,,,,A,1,1,
,BAO_0000218,7982,N,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg,Intermediate,,50597,,15022,,10116.0,Rattus norvegicus,,CHEMBL873343,,,,,A,1,1,
,BAO_0000218,7983,N,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg,Intermediate,,50597,,15022,,10116.0,Rattus norvegicus,,CHEMBL622460,,,,,A,1,1,
Plasma,BAO_0000218,7984,N,Time for maximum plasma concentration determined in rat,Intermediate,,50597,,4576,1969.0,10116.0,Rattus norvegicus,,CHEMBL622461,,,,,A,1,1,
Plasma,BAO_0000218,7985,N,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,Intermediate,,50597,,6681,1969.0,10116.0,Rattus norvegicus,,CHEMBL622462,,,In vivo,,A,1,1,
,BAO_0000218,7986,N,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat,Intermediate,,50597,,16365,,10116.0,Rattus norvegicus,,CHEMBL622463,,,In vivo,,A,1,1,
,BAO_0000218,7987,N,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat,Intermediate,,50597,,16365,,10116.0,Rattus norvegicus,,CHEMBL622464,,,In vivo,,A,1,1,
,BAO_0000218,7988,N,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg,Intermediate,,50597,,16365,,10116.0,Rattus norvegicus,,CHEMBL622465,,,In vivo,,A,1,1,
,BAO_0000218,7989,N,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat,Intermediate,,50597,,16365,,10116.0,Rattus norvegicus,,CHEMBL622466,,,In vivo,,A,1,1,
,BAO_0000218,7990,N,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg,Intermediate,,50597,,16365,,10116.0,Rattus norvegicus,,CHEMBL622467,,,In vivo,,A,1,1,
Plasma,BAO_0000218,7991,N,Time of maximum plasma concentration in rat,Intermediate,,50597,,6824,1969.0,10116.0,Rattus norvegicus,,CHEMBL622468,,,,,A,1,1,
Plasma,BAO_0000218,7992,N,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose",Intermediate,,50597,,6685,1969.0,10116.0,Rattus norvegicus,,CHEMBL876025,,,,,A,1,1,
Plasma,BAO_0000218,7993,N,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose",Intermediate,,50597,,6685,1969.0,10116.0,Rattus norvegicus,,CHEMBL622469,,,,,A,1,1,
Plasma,BAO_0000218,7994,N,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",Intermediate,,50597,,6685,1969.0,10116.0,Rattus norvegicus,,CHEMBL622470,,,,,A,1,1,
,BAO_0000218,7995,N,Time required to reach maximum concentration (Cmax) after oral administration in rat,Intermediate,,50597,,15662,,10116.0,Rattus norvegicus,,CHEMBL622471,,,In vivo,,A,1,1,
Plasma,BAO_0000218,7996,N,Time required to reach maximum concentration in rat plasma,Intermediate,,50597,,1742,1969.0,10116.0,Rattus norvegicus,,CHEMBL622472,,,,,A,1,1,
Plasma,BAO_0000218,7997,N,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,Intermediate,,50597,,2774,1969.0,10116.0,Rattus norvegicus,,CHEMBL622473,,,In vivo,,A,1,1,
Plasma,BAO_0000218,7998,N,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,Intermediate,,50597,,5199,1969.0,10116.0,Rattus norvegicus,,CHEMBL624282,,,In vivo,,A,1,1,
Plasma,BAO_0000218,7999,N,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,Intermediate,,50597,,12873,1969.0,10116.0,Rattus norvegicus,,CHEMBL624283,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8000,N,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,Intermediate,,50597,,12873,1969.0,10116.0,Rattus norvegicus,,CHEMBL624284,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8001,N,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,Intermediate,,50597,,1916,1969.0,10116.0,Rattus norvegicus,,CHEMBL624285,,,In vivo,,A,1,1,
,BAO_0000218,8002,N,Time to reach Cmax after oral administration to rats,Intermediate,,50597,,16367,,10116.0,Rattus norvegicus,,CHEMBL624286,,,In vivo,,A,1,1,
,BAO_0000218,8003,N,Time to reach Cmax when a dose of 1 mg/kg is administered orally,Intermediate,,50597,,16366,,10116.0,Rattus norvegicus,,CHEMBL624287,,,In vivo,,A,1,1,
,BAO_0000218,8004,N,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4,Intermediate,,50597,,216,,10116.0,Rattus norvegicus,,CHEMBL624288,,,,,A,1,1,
Plasma,BAO_0000218,8005,N,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable,Intermediate,,50597,,6410,1969.0,10116.0,Rattus norvegicus,,CHEMBL624289,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8006,N,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg,Intermediate,,50597,,6410,1969.0,10116.0,Rattus norvegicus,,CHEMBL873344,,,In vivo,,A,1,1,
,BAO_0000218,8007,N,Tmax after peroral administration (10 mg/kg) was determined in rat,Intermediate,,50597,,6215,,10116.0,Rattus norvegicus,,CHEMBL619623,,,In vivo,,A,1,1,
,BAO_0000218,8008,N,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg,Expert,,50597,,3598,,10116.0,Rattus norvegicus,,CHEMBL621399,,,In vivo,,A,1,1,
,BAO_0000218,8009,N,Tmax by oral administration at a dose of 100 uM/kg in rat was determined,Intermediate,,50597,,4527,,10116.0,Rattus norvegicus,,CHEMBL621400,,,In vivo,,A,1,1,
,BAO_0000218,8010,N,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously",Intermediate,,50597,,17670,,10116.0,Rattus norvegicus,,CHEMBL621401,,,In vivo,,A,1,1,
,BAO_0000218,8011,N,Tmax was determined,Intermediate,,50597,,1465,,10116.0,Rattus norvegicus,,CHEMBL621402,,,,,A,1,1,
,BAO_0000218,8012,N,Tmax was determined,Intermediate,,50597,,2552,,10116.0,Rattus norvegicus,,CHEMBL621403,,,,,A,1,1,
,BAO_0000218,8013,N,Tmax after oral administration in rat,Intermediate,,50597,,5656,,10116.0,Rattus norvegicus,,CHEMBL621121,,,In vivo,,A,1,1,
,BAO_0000218,8014,N,Tmax after peroral administration in rats at 2.4 uM/kg,Intermediate,,50597,,17764,,10116.0,Rattus norvegicus,,CHEMBL872525,,,In vivo,,A,1,1,
,BAO_0000218,8015,N,Tmax in male rat,Intermediate,,50597,,5610,,10116.0,Rattus norvegicus,,CHEMBL621122,,,,,A,1,1,
,BAO_0000218,8016,N,Tmax in rat at 10 mg/kg,Intermediate,,50597,,6046,,10116.0,Rattus norvegicus,,CHEMBL621123,,,In vivo,,A,1,1,
,BAO_0000218,8017,N,Tmax in rat by po administration at a dose of 40 mg/kg,Intermediate,,50597,,5874,,10116.0,Rattus norvegicus,,CHEMBL621124,,,In vivo,,A,1,1,
,BAO_0000218,8018,N,Tmax in rats,Intermediate,,50597,,17596,,10116.0,Rattus norvegicus,,CHEMBL621125,,,,,A,1,1,
,BAO_0000218,8019,N,Tmax was measured in rats after peroral administration at 5 mg/kg,Intermediate,,50597,,17804,,10116.0,Rattus norvegicus,,CHEMBL621126,,,In vivo,,A,1,1,
,BAO_0000218,8020,N,Tmax value after oral dose at a dose of 10 mg/kg in rats.,Intermediate,,50597,,1908,,10116.0,Rattus norvegicus,,CHEMBL621127,,,In vivo,,A,1,1,
,BAO_0000218,8021,N,Tmax value after administration of 20 mg/Kg oral dose in rat,Intermediate,,50597,,2959,,10116.0,Rattus norvegicus,,CHEMBL621128,,,In vivo,,A,1,1,
,BAO_0000218,8022,N,Tmax value at a dose of 10 mg/kg in male SD rats,Intermediate,,50597,,6757,,10116.0,Rattus norvegicus,,CHEMBL618263,,,In vivo,,A,1,1,
,BAO_0000218,8023,N,Tmax value at a dose of 100 mg/kg in male SD rats,Intermediate,,50597,,6757,,10116.0,Rattus norvegicus,,CHEMBL618264,,,In vivo,,A,1,1,
,BAO_0000218,8024,N,Tmax value at a dose of 50 mg/kg in male SD rats,Intermediate,,50597,,6757,,10116.0,Rattus norvegicus,,CHEMBL618265,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8025,N,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,Intermediate,,50597,,4186,1969.0,10116.0,Rattus norvegicus,,CHEMBL618266,,,In vivo,,A,1,1,
,BAO_0000218,8026,N,time required to reach maximum concentration (Cmax) after oral administration in rat,Intermediate,,50597,,15662,,10116.0,Rattus norvegicus,,CHEMBL618267,,,In vivo,,A,1,1,
Urine,BAO_0000218,8027,N,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr ),Intermediate,,50597,,429,1088.0,10116.0,Rattus norvegicus,,CHEMBL618450,,,,,A,1,1,
Urine,BAO_0000218,8028,N,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr),Intermediate,,50597,,429,1088.0,10116.0,Rattus norvegicus,,CHEMBL618451,,,,,A,1,1,
,BAO_0000218,8029,N,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,Intermediate,,50597,,5546,,10116.0,Rattus norvegicus,,CHEMBL618452,,,,,A,1,1,
Urine,BAO_0000218,8030,N,Amount of urine output was measured in rat at a dose of 1 mg/kg/po,Intermediate,,50597,,3173,1088.0,10116.0,Rattus norvegicus,,CHEMBL618453,,,,,A,1,1,
Urine,BAO_0000218,8031,N,Amount of urine output was measured in rat at a dose of 10 mg/kg/po,Intermediate,,50597,,3173,1088.0,10116.0,Rattus norvegicus,,CHEMBL618454,,,,,A,1,1,
Urine,BAO_0000218,8032,N,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested,Intermediate,,50597,,3173,1088.0,10116.0,Rattus norvegicus,,CHEMBL618455,,,,,A,1,1,
,BAO_0000218,8033,N,Volume of distribution was determined in rat after a 3 mg/kg of iv dose,Intermediate,,50597,,4257,,10116.0,Rattus norvegicus,,CHEMBL618456,,,In vivo,,A,1,1,
,BAO_0000218,8034,N,Compound distribution in rat tissues was determined,Intermediate,,50597,,6011,,10116.0,Rattus norvegicus,,CHEMBL618457,,,In vivo,,A,1,1,
,BAO_0000218,8035,N,Volume of distribution was evaluated in rat,Intermediate,,50597,,5472,,10116.0,Rattus norvegicus,,CHEMBL618458,,,In vivo,,A,1,1,
,BAO_0000218,8036,N,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats,Intermediate,,50597,,14346,,10116.0,Rattus norvegicus,,CHEMBL618459,,,,,A,1,1,
,BAO_0000218,8037,N,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats,Intermediate,,50597,,14346,,10116.0,Rattus norvegicus,,CHEMBL876733,,,,,A,1,1,
,BAO_0000218,8038,N,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs,Intermediate,,50588,,14346,,9615.0,Canis lupus familiaris,,CHEMBL618460,,,,,A,1,1,
,BAO_0000218,8039,N,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats,Intermediate,,50597,,14346,,10116.0,Rattus norvegicus,,CHEMBL618461,,,,,A,1,1,
,BAO_0000019,8040,U,Area under the curve was determined after oral administration (300 uM/Kg),Autocuration,,22224,,15469,,,,,CHEMBL618462,,,,,A,1,0,
,BAO_0000218,8041,N,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats,Intermediate,,50597,,14346,,10116.0,Rattus norvegicus,,CHEMBL618463,,,,,A,1,1,
,BAO_0000218,8042,N,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats,Intermediate,,50597,,14346,,10116.0,Rattus norvegicus,,CHEMBL618464,,,,,A,1,1,
,BAO_0000218,8043,N,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats,Intermediate,,50597,,14346,,10116.0,Rattus norvegicus,,CHEMBL618465,,,,,A,1,1,
,BAO_0000218,8044,N,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats,Intermediate,,50597,,14346,,10116.0,Rattus norvegicus,,CHEMBL618466,,,,,A,1,1,
,BAO_0000218,8045,N,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats,Intermediate,,50597,,14346,,10116.0,Rattus norvegicus,,CHEMBL618467,,,,,A,1,1,
,BAO_0000218,8046,N,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats,Intermediate,,50597,,15372,,10116.0,Rattus norvegicus,,CHEMBL618468,,,,,A,1,1,
Plasma,BAO_0000218,8047,N,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg,Intermediate,,50588,,12935,1969.0,9615.0,Canis lupus familiaris,,CHEMBL618469,,,,,A,1,1,
Plasma,BAO_0000218,8048,N,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg,Intermediate,,50588,,12935,1969.0,9615.0,Canis lupus familiaris,,CHEMBL618470,,,,,A,1,1,
,BAO_0000218,8049,U,Plasma drug AUC in rat (PO dose),Autocuration,,22224,,14813,,,,,CHEMBL618471,,,,,A,1,0,
,BAO_0000218,8050,N,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.,Intermediate,,50594,,15792,,10090.0,Mus musculus,,CHEMBL618472,,,,,A,1,1,
,BAO_0000218,8051,U,Area under was determined at a dose of 30 mg/kg,Autocuration,,22224,,3579,,,,,CHEMBL618473,,,,,A,1,0,
,BAO_0000218,8052,N,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret,Intermediate,,50506,,12487,,9669.0,Mustela putorius furo,,CHEMBL621699,,,,,A,1,1,
,BAO_0000218,8053,N,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat,Intermediate,,50597,,12487,,10116.0,Rattus norvegicus,,CHEMBL621700,,,,,A,1,1,
,BAO_0000218,8054,N,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat,Intermediate,,50597,,12487,,10116.0,Rattus norvegicus,,CHEMBL621701,,,,,A,1,1,
,BAO_0000218,8055,N,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret,Intermediate,,50506,,12487,,9669.0,Mustela putorius furo,,CHEMBL621702,,,,,A,1,1,
,BAO_0000218,8056,N,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog,Intermediate,,50588,,12487,,9615.0,Canis lupus familiaris,,CHEMBL621703,,,,,A,1,1,
,BAO_0000218,8057,N,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog,Intermediate,,50588,,12487,,9615.0,Canis lupus familiaris,,CHEMBL621704,,,,,A,1,1,
,BAO_0000218,8058,N,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)",Intermediate,,50597,,12902,,10116.0,Rattus norvegicus,,CHEMBL624259,,,,,A,1,1,
,BAO_0000218,8059,N,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)",Intermediate,,50597,,12902,,10116.0,Rattus norvegicus,,CHEMBL624260,,,,,A,1,1,
,BAO_0000218,8060,N,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)",Intermediate,,50597,,12902,,10116.0,Rattus norvegicus,,CHEMBL624430,,,,,A,1,1,
,BAO_0000218,8061,N,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)",Intermediate,,50597,,12902,,10116.0,Rattus norvegicus,,CHEMBL624431,,,,,A,1,1,
,BAO_0000218,8062,N,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)",Intermediate,,50597,,12902,,10116.0,Rattus norvegicus,,CHEMBL624432,,,,,A,1,1,
,BAO_0000218,8063,N,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)",Intermediate,,50597,,12902,,10116.0,Rattus norvegicus,,CHEMBL624433,,,,,A,1,1,
,BAO_0000218,8064,N,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)",Intermediate,,50597,,12902,,10116.0,Rattus norvegicus,,CHEMBL624434,,,,,A,1,1,
,BAO_0000218,8065,N,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)",Intermediate,,50597,,12902,,10116.0,Rattus norvegicus,,CHEMBL624435,,,,,A,1,1,
,BAO_0000218,8066,N,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose,Intermediate,,50594,,12745,,10090.0,Mus musculus,,CHEMBL618570,,,,,A,1,1,
,BAO_0000218,8067,N,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),Intermediate,,50594,,12745,,10090.0,Mus musculus,,CHEMBL618571,,,,,A,1,1,
,BAO_0000218,8068,N,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose,Intermediate,,50594,,12745,,10090.0,Mus musculus,,CHEMBL618572,,,,,A,1,1,
,BAO_0000218,8069,N,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),Intermediate,,50594,,12745,,10090.0,Mus musculus,,CHEMBL618573,,,,,A,1,1,
,BAO_0000218,8070,N,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose,Intermediate,,50594,,12745,,10090.0,Mus musculus,,CHEMBL619267,,,,,A,1,1,
,BAO_0000218,8071,N,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),Intermediate,,50594,,12745,,10090.0,Mus musculus,,CHEMBL619431,,,,,A,1,1,
,BAO_0000218,8072,N,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose,Intermediate,,50594,,12745,,10090.0,Mus musculus,,CHEMBL619432,,,,,A,1,1,
,BAO_0000218,8073,N,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),Intermediate,,50594,,12745,,10090.0,Mus musculus,,CHEMBL619433,,,,,A,1,1,
Plasma,BAO_0000218,8074,U,AUC in mice after oral dose (50 mg/kg),Autocuration,,22224,,13298,1969.0,,,,CHEMBL619434,,,,,A,1,0,
Serum,BAO_0000218,8075,N,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum,Intermediate,,50594,,12226,1977.0,10090.0,Mus musculus,,CHEMBL619435,,,,,A,1,1,
Plasma,BAO_0000019,8076,U,AUC (0-4 hr) ug/ml/h,Autocuration,,22224,,12634,1969.0,,,,CHEMBL619436,,,,,A,1,0,
,BAO_0000218,8077,N,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported,Intermediate,,50597,,14810,,10116.0,Rattus norvegicus,,CHEMBL619437,,,,,A,1,1,
,BAO_0000218,8078,U,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration,Autocuration,,22224,,13889,,,,,CHEMBL619438,,,,,A,1,0,
,BAO_0000218,8079,N,Compound was evaluated for Area under curve in mice,Intermediate,,50594,,10018,,10090.0,Mus musculus,,CHEMBL619439,,,,,A,1,1,
,BAO_0000218,8080,N,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,Intermediate,,50597,,8758,,10116.0,Rattus norvegicus,,CHEMBL619440,,,,,A,1,1,
,BAO_0000218,8081,U,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,Autocuration,,22224,,8758,,,,,CHEMBL619441,,,,,F,1,0,
,BAO_0000218,8082,N,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,Intermediate,,50597,,8758,,10116.0,Rattus norvegicus,,CHEMBL619442,,,,,A,1,1,
,BAO_0000019,8083,U,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1,Autocuration,,22224,,2249,,,,,CHEMBL875156,,,,,A,1,0,
,BAO_0000019,8084,U,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4,Autocuration,,22224,,2249,,,,,CHEMBL619443,,,,,A,1,0,
,BAO_0000019,8085,U,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1,Autocuration,,22224,,2249,,,,,CHEMBL619444,,,,,A,1,0,
,BAO_0000019,8086,U,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4,Autocuration,,22224,,2249,,,,,CHEMBL623464,,,,,A,1,0,
,BAO_0000218,8087,N,Compound was evaluated for area under curve when administered through oral route in mouse,Intermediate,,50594,,15115,,10090.0,Mus musculus,,CHEMBL623465,,,,,A,1,1,
,BAO_0000218,8088,N,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data,Intermediate,,50597,,6518,,10116.0,Rattus norvegicus,,CHEMBL623466,,,In vivo,,A,1,1,
,BAO_0000218,8089,N,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data,Intermediate,,50597,,6518,,10116.0,Rattus norvegicus,,CHEMBL623467,,,In vivo,,A,1,1,
,BAO_0000218,8090,N,Plasma clearance in rat,Intermediate,,50597,,6249,,10116.0,Rattus norvegicus,,CHEMBL623468,,,In vivo,,A,1,1,
,BAO_0000218,8091,N,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,Intermediate,,50597,,2463,,10116.0,Rattus norvegicus,,CHEMBL622660,,,In vivo,,A,1,1,
,BAO_0000218,8092,N,Plasma clearance rate in Sprague-Dawley rats,Intermediate,,50597,,4969,,10116.0,Rattus norvegicus,,CHEMBL622661,,,In vivo,,A,1,1,
,BAO_0000218,8093,N,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration,Intermediate,,50597,,17720,,10116.0,Rattus norvegicus,,CHEMBL622662,,,In vivo,,F,1,1,
,BAO_0000218,8094,N,Pharmacokinetic property (total body clearance) in rat,Intermediate,,50597,,3457,,10116.0,Rattus norvegicus,,CHEMBL622663,,,In vivo,,A,1,1,
,BAO_0000218,8095,N,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.,Intermediate,,50597,,5983,,10116.0,Rattus norvegicus,,CHEMBL622664,,,In vivo,,A,1,1,
,BAO_0000218,8096,N,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,Intermediate,,50597,,6295,,10116.0,Rattus norvegicus,,CHEMBL622665,,,,,A,1,1,
,BAO_0000218,8097,N,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,Intermediate,,50597,,6296,,10116.0,Rattus norvegicus,,CHEMBL622666,,,,,A,1,1,
,BAO_0000218,8098,N,Cl in rat i.v. at 2 mg/kg concentration,Intermediate,,50597,,17686,,10116.0,Rattus norvegicus,,CHEMBL621615,,,In vivo,,A,1,1,
,BAO_0000218,8099,N,Clearance of compound after intravenous administration in rats at 24 uM/kg,Intermediate,,50597,,17764,,10116.0,Rattus norvegicus,,CHEMBL621616,,,In vivo,,A,1,1,
,BAO_0000218,8100,N,Clearance was determined,Intermediate,,50597,,5503,,10116.0,Rattus norvegicus,,CHEMBL621617,,,In vivo,,A,1,1,
,BAO_0000218,8101,N,Clearance by intravenous administration of 3.4 mg/kg in rat,Intermediate,,50597,,4368,,10116.0,Rattus norvegicus,,CHEMBL621618,,,In vivo,,A,1,1,
,BAO_0000218,8102,N,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg,Intermediate,,50597,,6005,,10116.0,Rattus norvegicus,,CHEMBL621619,,,In vivo,,A,1,1,
,BAO_0000218,8103,N,Clearance rate after i.v. administration in rats,Intermediate,,50597,,5031,,10116.0,Rattus norvegicus,,CHEMBL621620,,,In vivo,,A,1,1,
,BAO_0000218,8104,N,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,Intermediate,,50597,,4890,,10116.0,Rattus norvegicus,,CHEMBL621786,,,In vivo,,A,1,1,
,BAO_0000218,8105,N,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,Intermediate,,50597,,5182,,10116.0,Rattus norvegicus,,CHEMBL621787,,,In vivo,,A,1,1,
,BAO_0000218,8106,N,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat,Intermediate,,50597,,5979,,10116.0,Rattus norvegicus,,CHEMBL621788,,,In vivo,,A,1,1,
,BAO_0000218,8107,N,Clearance (Cl) after oral administration in rat,Intermediate,,50597,,5656,,10116.0,Rattus norvegicus,,CHEMBL621789,,,In vivo,,A,1,1,
,BAO_0000218,8108,N,Compound clearance in rats was measured after intravenous administration at 3 mg/kg,Intermediate,,50597,,17804,,10116.0,Rattus norvegicus,,CHEMBL621790,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8109,N,Compound was tested for plasma clearance in rat,Intermediate,,50597,,4839,1969.0,10116.0,Rattus norvegicus,,CHEMBL621791,,,In vivo,,A,1,1,
,BAO_0000218,8110,N,In vitro microsome metabolism clearance in rat was determined,Intermediate,,50597,,5041,,10116.0,Rattus norvegicus,,CHEMBL621792,,,In vitro,Microsomes,A,1,1,
,BAO_0000218,8111,N,In vitro microsome metabolism clearance in rat was determined; ND denotes no data,Intermediate,,50597,,5041,,10116.0,Rattus norvegicus,,CHEMBL621793,,,In vitro,Microsomes,A,1,1,
,BAO_0000218,8112,N,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,Intermediate,,50597,,5974,,10116.0,Rattus norvegicus,,CHEMBL621794,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8113,N,In vivo plasma clearance was determined,Intermediate,,50597,,5496,1969.0,10116.0,Rattus norvegicus,,CHEMBL621795,,,In vivo,,A,1,1,
,BAO_0000218,8114,N,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats,Intermediate,,50597,,5739,,10116.0,Rattus norvegicus,,CHEMBL621796,,,In vivo,,A,1,1,
Liver,BAO_0000218,8115,N,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.,Intermediate,401.0,50597,,5676,2107.0,10116.0,Rattus norvegicus,,CHEMBL621797,Hepatocyte,,In vivo,,A,1,1,
,BAO_0000218,8116,N,Pharmacokinetic property (Plasma clearance) was measured in rat,Intermediate,,50597,,4239,,10116.0,Rattus norvegicus,,CHEMBL621798,,,In vivo,,A,1,1,
,BAO_0000218,8117,N,Pharmacokinetic property (clearance) in rat i.v.,Intermediate,,50597,,5676,,10116.0,Rattus norvegicus,,CHEMBL621799,,,In vivo,,A,1,1,
,BAO_0000218,8118,N,"Plasma Clearance was evaluated in rats, iv",Intermediate,,50597,,1918,,10116.0,Rattus norvegicus,,CHEMBL621800,,,In vivo,,A,1,1,
,BAO_0000218,8119,N,Plasma clearance (in vivo) in rats was determined,Intermediate,,50597,,17800,,10116.0,Rattus norvegicus,,CHEMBL621801,,,In vivo,,A,1,1,
,BAO_0000218,8120,N,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat,Intermediate,,50597,,6056,,10116.0,Rattus norvegicus,,CHEMBL621802,,,In vivo,,A,1,1,
,BAO_0000218,8121,N,Plasma clearance was determined,Intermediate,,50597,,5496,,10116.0,Rattus norvegicus,,CHEMBL618596,,,In vivo,,A,1,1,
,BAO_0000218,8122,N,Plasma clearance in rat after peroral administration at 10 mg/kg concentration,Intermediate,,50597,,5939,,10116.0,Rattus norvegicus,,CHEMBL618597,,,In vivo,,A,1,1,
,BAO_0000218,8123,N,Plasma clearance in rat after peroral administration at 5 mg/kg concentration,Intermediate,,50597,,5939,,10116.0,Rattus norvegicus,,CHEMBL618598,,,In vivo,,A,1,1,
,BAO_0000218,8124,N,Plasma clearance in rats,Intermediate,,50597,,17752,,10116.0,Rattus norvegicus,,CHEMBL618599,,,In vivo,,A,1,1,
,BAO_0000218,8125,N,Plasma clearance rate determined in rat,Intermediate,,50597,,4576,,10116.0,Rattus norvegicus,,CHEMBL618600,,,In vivo,,A,1,1,
,BAO_0000218,8126,N,Plasma clearance was determined in rat,Intermediate,,50597,,6011,,10116.0,Rattus norvegicus,,CHEMBL618601,,,In vivo,,A,1,1,
,BAO_0000218,8127,N,Plasma clearance was determined,Intermediate,,50597,,5510,,10116.0,Rattus norvegicus,,CHEMBL618602,,,In vivo,,A,1,1,
,BAO_0000218,8128,N,Plasma clearance value in rat,Intermediate,,50597,,5948,,10116.0,Rattus norvegicus,,CHEMBL618603,,,In vivo,,A,1,1,
Liver,BAO_0000218,8129,N,Clearance rate constant using isolated perfused rat liver (IPRL) assay,Intermediate,,50597,,6125,2107.0,10116.0,Rattus norvegicus,,CHEMBL618604,,,Ex vivo,,A,1,1,
,BAO_0000218,8130,N,Clearance in rat,Intermediate,,50597,,4839,,10116.0,Rattus norvegicus,,CHEMBL618605,,,In vivo,,A,1,1,
,BAO_0000218,8131,N,Total body clearance in rat i.v. at 2 mg/kg concentration,Intermediate,,50597,,17686,,10116.0,Rattus norvegicus,,CHEMBL618606,,,In vivo,,A,1,1,
,BAO_0000218,8132,N,Clearance of compound in rats after intravenous administration,Intermediate,,50597,,6571,,10116.0,Rattus norvegicus,,CHEMBL618607,,,In vivo,,A,1,1,
,BAO_0000218,8133,N,Clearance after iv administration to rats,Intermediate,,50597,,3364,,10116.0,Rattus norvegicus,,CHEMBL618608,,,In vivo,,A,1,1,
,BAO_0000218,8134,N,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,Intermediate,,50597,,13569,,10116.0,Rattus norvegicus,,CHEMBL618609,,,In vivo,,A,1,1,
,BAO_0000218,8135,N,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,Intermediate,,50597,,13569,,10116.0,Rattus norvegicus,,CHEMBL618610,,,In vivo,,A,1,1,
,BAO_0000218,8136,N,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,Intermediate,,50597,,13569,,10116.0,Rattus norvegicus,,CHEMBL618611,,,In vivo,,A,1,1,
,BAO_0000218,8137,N,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,Intermediate,,50597,,13569,,10116.0,Rattus norvegicus,,CHEMBL618612,,,In vivo,,A,1,1,
,BAO_0000218,8138,N,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,Intermediate,,50597,,13569,,10116.0,Rattus norvegicus,,CHEMBL618613,,,In vivo,,A,1,1,
,BAO_0000218,8139,N,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,Intermediate,,50597,,13569,,10116.0,Rattus norvegicus,,CHEMBL621076,,,In vivo,,A,1,1,
,BAO_0000218,8140,N,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,Intermediate,,50597,,13569,,10116.0,Rattus norvegicus,,CHEMBL621077,,,In vivo,,A,1,1,
,BAO_0000218,8141,N,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously",Intermediate,,50597,,17670,,10116.0,Rattus norvegicus,,CHEMBL621078,,,In vivo,,A,1,1,
,BAO_0000218,8142,N,Clearance in rat,Intermediate,,50597,,5970,,10116.0,Rattus norvegicus,,CHEMBL621251,,,In vivo,,A,1,1,
,BAO_0000218,8143,N,Clearance in rat after oral administration at 10 mg/kg,Intermediate,,50597,,6495,,10116.0,Rattus norvegicus,,CHEMBL621252,,,In vivo,,A,1,1,
,BAO_0000218,8144,N,Clearance in rat.,Intermediate,,50597,,4590,,10116.0,Rattus norvegicus,,CHEMBL621253,,,In vivo,,A,1,1,
,BAO_0000218,8145,N,Clearance rate following an oral dose of 20 mg/kg in rats,Intermediate,,50597,,6193,,10116.0,Rattus norvegicus,,CHEMBL621254,,,In vivo,,A,1,1,
,BAO_0000218,8146,N,Compound was evaluated for the rate of clearance in rat upon intravenous administration.,Intermediate,,50597,,2832,,10116.0,Rattus norvegicus,,CHEMBL621255,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8147,N,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing,Intermediate,,50597,,1052,1969.0,10116.0,Rattus norvegicus,,CHEMBL621256,,,In vivo,,A,1,1,
Liver,BAO_0000218,8148,N,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr,Intermediate,,50597,,9866,2107.0,10116.0,Rattus norvegicus,,CHEMBL621257,,,In vivo,,A,1,1,
Liver,BAO_0000218,8149,N,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min,Intermediate,,50597,,9866,2107.0,10116.0,Rattus norvegicus,,CHEMBL621258,,,In vivo,,A,1,1,
Liver,BAO_0000218,8150,N,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr,Intermediate,,50597,,9866,2107.0,10116.0,Rattus norvegicus,,CHEMBL621259,,,In vivo,,A,1,1,
Liver,BAO_0000218,8151,N,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min,Intermediate,,50597,,9866,2107.0,10116.0,Rattus norvegicus,,CHEMBL621260,,,In vivo,,A,1,1,
Liver,BAO_0000218,8152,N,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr,Intermediate,,50597,,9866,2107.0,10116.0,Rattus norvegicus,,CHEMBL876494,,,In vivo,,A,1,1,
Liver,BAO_0000218,8153,N,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min,Intermediate,,50597,,9866,2107.0,10116.0,Rattus norvegicus,,CHEMBL621261,,,In vivo,,A,1,1,
Liver,BAO_0000218,8154,N,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr,Intermediate,,50597,,9866,2107.0,10116.0,Rattus norvegicus,,CHEMBL621262,,,In vivo,,A,1,1,
Liver,BAO_0000218,8155,N,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP,Intermediate,,50597,,9866,2107.0,10116.0,Rattus norvegicus,,CHEMBL621263,,,In vivo,,A,1,1,
Liver,BAO_0000218,8156,N,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip,Intermediate,,50597,,9866,2107.0,10116.0,Rattus norvegicus,,CHEMBL621264,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,8157,N,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP,Intermediate,,50597,,9866,2385.0,10116.0,Rattus norvegicus,,CHEMBL621265,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,8158,N,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig,Intermediate,,50597,,9866,2385.0,10116.0,Rattus norvegicus,,CHEMBL621266,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,8159,N,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP,Intermediate,,50597,,9866,2385.0,10116.0,Rattus norvegicus,,CHEMBL621267,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,8160,N,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP,Intermediate,,50597,,9866,2385.0,10116.0,Rattus norvegicus,,CHEMBL621268,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,8161,N,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr,Intermediate,,50597,,9866,2385.0,10116.0,Rattus norvegicus,,CHEMBL621269,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,8162,N,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr,Intermediate,,50597,,9866,2385.0,10116.0,Rattus norvegicus,,CHEMBL621270,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,8163,N,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min,Intermediate,,50597,,9866,2385.0,10116.0,Rattus norvegicus,,CHEMBL621271,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,8164,N,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min,Intermediate,,50597,,9866,2385.0,10116.0,Rattus norvegicus,,CHEMBL621272,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,8165,N,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr,Intermediate,,50597,,9866,2385.0,10116.0,Rattus norvegicus,,CHEMBL621273,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,8166,N,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr,Intermediate,,50597,,9866,2385.0,10116.0,Rattus norvegicus,,CHEMBL621274,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,8167,N,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min,Intermediate,,50597,,9866,2385.0,10116.0,Rattus norvegicus,,CHEMBL876495,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,8168,N,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min,Intermediate,,50597,,9866,2385.0,10116.0,Rattus norvegicus,,CHEMBL621275,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,8169,N,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip,Intermediate,,50597,,9866,2385.0,10116.0,Rattus norvegicus,,CHEMBL621276,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,8170,N,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig,Intermediate,,50597,,9866,2385.0,10116.0,Rattus norvegicus,,CHEMBL621277,,,In vivo,,A,1,1,
Intestine,BAO_0000218,8171,N,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr,Intermediate,,50597,,9866,160.0,10116.0,Rattus norvegicus,,CHEMBL621278,,,In vivo,,A,1,1,
Intestine,BAO_0000218,8172,N,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr,Intermediate,,50597,,9866,160.0,10116.0,Rattus norvegicus,,CHEMBL621279,,,In vivo,,A,1,1,
Intestine,BAO_0000218,8173,N,Biodistribution in rat s. intestine in the presence of NCA (No carrier added),Intermediate,,50597,,9866,160.0,10116.0,Rattus norvegicus,,CHEMBL621280,,,In vivo,,A,1,1,
Spleen,BAO_0000218,8174,N,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP,Intermediate,,50597,,9866,2106.0,10116.0,Rattus norvegicus,,CHEMBL621281,,,In vivo,,A,1,1,
Spleen,BAO_0000218,8175,N,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data,Intermediate,,50597,,9866,2106.0,10116.0,Rattus norvegicus,,CHEMBL621282,,,In vivo,,A,1,1,
Spleen,BAO_0000218,8176,N,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data,Intermediate,,50597,,9866,2106.0,10116.0,Rattus norvegicus,,CHEMBL621283,,,In vivo,,A,1,1,
Spleen,BAO_0000218,8177,N,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP,Intermediate,,50597,,9866,2106.0,10116.0,Rattus norvegicus,,CHEMBL621284,,,In vivo,,A,1,1,
Spleen,BAO_0000218,8178,N,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min,Intermediate,,50597,,9866,2106.0,10116.0,Rattus norvegicus,,CHEMBL621285,,,In vivo,,A,1,1,
Spleen,BAO_0000218,8179,N,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr,Intermediate,,50597,,9866,2106.0,10116.0,Rattus norvegicus,,CHEMBL621286,,,In vivo,,A,1,1,
Spleen,BAO_0000218,8180,N,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr,Intermediate,,50597,,9866,2106.0,10116.0,Rattus norvegicus,,CHEMBL623220,,,In vivo,,A,1,1,
Spleen,BAO_0000218,8181,N,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip,Intermediate,,50597,,9866,2106.0,10116.0,Rattus norvegicus,,CHEMBL623221,,,In vivo,,A,1,1,
Spleen,BAO_0000218,8182,N,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig,Intermediate,,50597,,9866,2106.0,10116.0,Rattus norvegicus,,CHEMBL876029,,,In vivo,,A,1,1,
Stomach,BAO_0000218,8183,N,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min,Intermediate,,50597,,9866,945.0,10116.0,Rattus norvegicus,,CHEMBL623222,,,In vivo,,A,1,1,
Stomach,BAO_0000218,8184,N,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr,Intermediate,,50597,,9866,945.0,10116.0,Rattus norvegicus,,CHEMBL623223,,,In vivo,,A,1,1,
Stomach,BAO_0000218,8185,N,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data,Intermediate,,50597,,9866,945.0,10116.0,Rattus norvegicus,,CHEMBL621445,,,In vivo,,A,1,1,
Blood,BAO_0000218,8186,N,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,178.0,10116.0,Rattus norvegicus,,CHEMBL621446,,,In vivo,,A,1,1,
Blood,BAO_0000218,8187,N,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,178.0,10116.0,Rattus norvegicus,,CHEMBL621447,,,In vivo,,A,1,1,
Blood,BAO_0000218,8188,N,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,178.0,10116.0,Rattus norvegicus,,CHEMBL619681,,,In vivo,,A,1,1,
Blood,BAO_0000218,8189,N,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,178.0,10116.0,Rattus norvegicus,,CHEMBL619682,,,In vivo,,A,1,1,
Blood,BAO_0000218,8190,N,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,178.0,10116.0,Rattus norvegicus,,CHEMBL619683,,,In vivo,,A,1,1,
Brain,BAO_0000218,8191,N,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,955.0,10116.0,Rattus norvegicus,,CHEMBL619684,,,In vivo,,A,1,1,
Brain,BAO_0000218,8192,N,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,955.0,10116.0,Rattus norvegicus,,CHEMBL619685,,,In vivo,,A,1,1,
Brain,BAO_0000218,8193,N,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,955.0,10116.0,Rattus norvegicus,,CHEMBL619686,,,In vivo,,A,1,1,
Brain,BAO_0000218,8194,N,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,955.0,10116.0,Rattus norvegicus,,CHEMBL619687,,,In vivo,,A,1,1,
Brain,BAO_0000218,8195,N,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,955.0,10116.0,Rattus norvegicus,,CHEMBL619688,,,In vivo,,A,1,1,
Heart,BAO_0000218,8196,N,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,948.0,10116.0,Rattus norvegicus,,CHEMBL619689,,,In vivo,,A,1,1,
Heart,BAO_0000218,8197,N,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,948.0,10116.0,Rattus norvegicus,,CHEMBL619690,,,In vivo,,A,1,1,
Heart,BAO_0000218,8198,N,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,948.0,10116.0,Rattus norvegicus,,CHEMBL619691,,,In vivo,,A,1,1,
,BAO_0000218,8199,N,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg,Intermediate,,50597,,6062,,10116.0,Rattus norvegicus,,CHEMBL619692,,,In vivo,,A,1,1,
,BAO_0000218,8200,N,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg,Expert,,50597,,3598,,10116.0,Rattus norvegicus,,CHEMBL619693,,,,,A,1,1,
,BAO_0000218,8201,N,Vc value after IV dose at a dose of 5 mg/kg in rats.,Intermediate,,50597,,1908,,10116.0,Rattus norvegicus,,CHEMBL619694,,,In vivo,,A,1,1,
,BAO_0000218,8202,N,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration,Intermediate,,50597,,17596,,10116.0,Rattus norvegicus,,CHEMBL619695,,,In vivo,,A,1,1,
,BAO_0000218,8203,N,Compound was evaluated for pharmacokinetic parameter volume of distribution,Intermediate,,50597,,4891,,10116.0,Rattus norvegicus,,CHEMBL619696,,,In vivo,,A,1,1,
,BAO_0000218,8204,N,Compound was evaluated for volume of distribution in rat,Intermediate,,50597,,740,,10116.0,Rattus norvegicus,,CHEMBL619697,,,In vivo,,A,1,1,
,BAO_0000218,8205,N,Steady state volume distribution was determined; steady state(ss),Intermediate,,50597,,16366,,10116.0,Rattus norvegicus,,CHEMBL619698,,,In vivo,,A,1,1,
,BAO_0000218,8206,N,Steady state volume of distribution after iv administration to rats,Intermediate,,50597,,3364,,10116.0,Rattus norvegicus,,CHEMBL619699,,,In vivo,,A,1,1,
,BAO_0000218,8207,N,Steady state volume of distribution dosing at 3 mg/kg iv,Intermediate,,50597,,2552,,10116.0,Rattus norvegicus,,CHEMBL619700,,,In vivo,,A,1,1,
,BAO_0000218,8208,N,The compound was evaluated for volume of distribution in rat,Intermediate,,50597,,406,,10116.0,Rattus norvegicus,,CHEMBL619701,,,In vivo,,A,1,1,
,BAO_0000218,8209,N,The compound was tested for volume of distribution in rat,Intermediate,,50597,,12500,,10116.0,Rattus norvegicus,,CHEMBL619702,,,In vivo,,A,1,1,
,BAO_0000218,8210,N,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg,Intermediate,,50597,,12500,,10116.0,Rattus norvegicus,,CHEMBL620335,,,In vivo,,A,1,1,
,BAO_0000218,8211,N,Volume distribution (VD) after oral administration in rat,Intermediate,,50597,,5656,,10116.0,Rattus norvegicus,,CHEMBL620336,,,In vivo,,A,1,1,
,BAO_0000218,8212,N,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,Intermediate,,50597,,17671,,10116.0,Rattus norvegicus,,CHEMBL620337,,,In vivo,,A,1,1,
,BAO_0000218,8213,N,Volume distribution in rat,Intermediate,,50597,,1094,,10116.0,Rattus norvegicus,,CHEMBL620520,,,In vivo,,A,1,1,
,BAO_0000218,8214,N,Volume distribution in rat,Intermediate,,50597,,5833,,10116.0,Rattus norvegicus,,CHEMBL620521,,,In vivo,,A,1,1,
,BAO_0000218,8215,N,Volume distribution in rat after peroral administration at 10 mg/kg,Intermediate,,50597,,5939,,10116.0,Rattus norvegicus,,CHEMBL875825,,,In vivo,,A,1,1,
,BAO_0000218,8216,N,Volume distribution in rat after peroral administration at 5 mg/kg,Intermediate,,50597,,5939,,10116.0,Rattus norvegicus,,CHEMBL620522,,,In vivo,,A,1,1,
,BAO_0000218,8217,N,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg,Intermediate,,50597,,6005,,10116.0,Rattus norvegicus,,CHEMBL620523,,,In vivo,,A,1,1,
,BAO_0000218,8218,N,Volume of distribution in rat.,Intermediate,,50597,,1696,,10116.0,Rattus norvegicus,,CHEMBL620524,,,In vivo,,A,1,1,
,BAO_0000218,8219,N,Volume of distribution in rat,Intermediate,,50597,,6672,,10116.0,Rattus norvegicus,,CHEMBL620525,,,In vivo,,A,1,1,
,BAO_0000218,8220,N,Volume of distribution in rat,Intermediate,,50597,,6673,,10116.0,Rattus norvegicus,,CHEMBL620526,,,In vivo,,A,1,1,
,BAO_0000218,8221,N,Volume of distribution in rat by iv administration,Intermediate,,50597,,5871,,10116.0,Rattus norvegicus,,CHEMBL620527,,,In vivo,,A,1,1,
,BAO_0000218,8222,N,Volume of distribution in rats,Intermediate,,50597,,6803,,10116.0,Rattus norvegicus,,CHEMBL620528,,,In vivo,,A,1,1,
,BAO_0000218,8223,N,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,Intermediate,,50597,,5199,,10116.0,Rattus norvegicus,,CHEMBL620529,,,In vivo,,A,1,1,
,BAO_0000218,8224,N,Volume distribution at the dose of 2 mg/kg in rat,Intermediate,,50597,,4727,,10116.0,Rattus norvegicus,,CHEMBL620530,,,,,A,1,1,
,BAO_0000218,8225,N,Steady state volume of distribution was determined,Intermediate,,50597,,16367,,10116.0,Rattus norvegicus,,CHEMBL620531,,,In vivo,,A,1,1,
,BAO_0000218,8226,U,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Intermediate,,22224,,5005,,9544.0,Macaca mulatta,,CHEMBL620532,,,In vivo,,A,1,0,
,BAO_0000218,8227,U,Compound was tested for its plasma volume distribution in Sprague Dawley rats,Intermediate,,22224,,5005,,10116.0,Rattus norvegicus,,CHEMBL620533,,,In vivo,,A,1,0,
,BAO_0000218,8228,U,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined,Intermediate,,22224,,5005,,10116.0,Rattus norvegicus,,CHEMBL620534,,,In vivo,,A,1,0,
,BAO_0000218,8229,N,Mean (%CV) PK parameters for Vdss(mL/kg).,Intermediate,,50597,,15765,,10116.0,Rattus norvegicus,,CHEMBL620535,,,In vivo,,A,1,1,
,BAO_0000218,8230,N,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats,Intermediate,,50597,,2792,,10116.0,Rattus norvegicus,,CHEMBL875826,,,In vivo,,A,1,1,
,BAO_0000218,8231,N,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats,Intermediate,,50597,,2792,,10116.0,Rattus norvegicus,,CHEMBL620536,,,In vivo,,A,1,1,
,BAO_0000218,8232,N,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,Intermediate,,50597,,5334,,10116.0,Rattus norvegicus,,CHEMBL620537,,,In vivo,,A,1,1,
,BAO_0000218,8233,N,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined,Intermediate,,50597,,5334,,10116.0,Rattus norvegicus,,CHEMBL618526,,,In vivo,,A,1,1,
,BAO_0000218,8234,N,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats,Intermediate,,50597,,5739,,10116.0,Rattus norvegicus,,CHEMBL618527,,,In vivo,,A,1,1,
,BAO_0000218,8235,N,Pharmacokinetic property (Vdss) in rat,Intermediate,,50597,,5789,,10116.0,Rattus norvegicus,,CHEMBL618528,,,In vivo,,A,1,1,
,BAO_0000218,8236,N,Pharmacokinetic property (vdss) was measured in rat,Intermediate,,50597,,4239,,10116.0,Rattus norvegicus,,CHEMBL618529,,,In vivo,,A,1,1,
,BAO_0000218,8237,N,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat,Intermediate,,50597,,4709,,10116.0,Rattus norvegicus,,CHEMBL618530,,,In vivo,,A,1,1,
,BAO_0000218,8238,N,Volume of distribution in rat,Intermediate,,50597,,6642,,10116.0,Rattus norvegicus,,CHEMBL618531,,,In vivo,,A,1,1,
,BAO_0000218,8239,N,The pharmacokinetic parameter volume of distribution in vivo in rats,Intermediate,,50597,,5247,,10116.0,Rattus norvegicus,,CHEMBL618532,,,In vivo,,A,1,1,
,BAO_0000218,8240,N,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration,Intermediate,,50597,,17720,,10116.0,Rattus norvegicus,,CHEMBL618533,,,In vivo,,F,1,1,
,BAO_0000218,8241,N,Vdss in rat i.v. at 2 mg/kg concentration,Intermediate,,50597,,17686,,10116.0,Rattus norvegicus,,CHEMBL618534,,,In vivo,,A,1,1,
,BAO_0000218,8242,N,Volume distribution after intravenous administration (1 mg/kg) in rat,Intermediate,,50597,,4689,,10116.0,Rattus norvegicus,,CHEMBL618535,,,In vivo,,A,1,1,
,BAO_0000218,8243,N,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,Intermediate,,50597,,5654,,10116.0,Rattus norvegicus,,CHEMBL618536,,,In vivo,,A,1,1,
,BAO_0000218,8244,N,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,Intermediate,,50597,,5654,,10116.0,Rattus norvegicus,,CHEMBL618537,,,In vivo,,A,1,1,
,BAO_0000218,8245,N,Volume distribution at a dose of 10 uM/kg in rat was determined,Intermediate,,50597,,4527,,10116.0,Rattus norvegicus,,CHEMBL618538,,,In vivo,,A,1,1,
,BAO_0000218,8246,N,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,Intermediate,,50597,,4521,,10116.0,Rattus norvegicus,,CHEMBL618539,,,In vivo,,A,1,1,
,BAO_0000218,8247,N,Volume distribution was calculated in rat,Intermediate,,50597,,6057,,10116.0,Rattus norvegicus,,CHEMBL618540,,,In vivo,,A,1,1,
,BAO_0000218,8248,N,Volume distribution was determined,Intermediate,,50597,,5510,,10116.0,Rattus norvegicus,,CHEMBL618541,,,In vivo,,A,1,1,
,BAO_0000218,8249,N,Volume of distribution after intravenous administration was evaluated in rat,Intermediate,,50597,,2938,,10116.0,Rattus norvegicus,,CHEMBL618542,,,In vivo,,A,1,1,
,BAO_0000218,8250,N,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Intermediate,,50597,,6679,,10116.0,Rattus norvegicus,,CHEMBL622544,,,In vivo,,A,1,1,
,BAO_0000218,8251,N,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable",Intermediate,,50597,,6685,,10116.0,Rattus norvegicus,,CHEMBL622545,,,In vivo,,A,1,1,
,BAO_0000218,8252,N,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",Intermediate,,50597,,6685,,10116.0,Rattus norvegicus,,CHEMBL622546,,,In vivo,,A,1,1,
,BAO_0000218,8253,N,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose",Intermediate,,50597,,6685,,10116.0,Rattus norvegicus,,CHEMBL622547,,,In vivo,,A,1,1,
,BAO_0000218,8254,N,Volume of distribution in steady state was determined in rat,Intermediate,,50597,,5145,,10116.0,Rattus norvegicus,,CHEMBL622548,,,In vivo,,A,1,1,
,BAO_0000218,8255,N,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration,Intermediate,,50597,,6467,,10116.0,Rattus norvegicus,,CHEMBL622549,,,In vivo,,A,1,1,
,BAO_0000218,8256,N,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,Intermediate,,50597,,6467,,10116.0,Rattus norvegicus,,CHEMBL622550,,,In vivo,,A,1,1,
,BAO_0000218,8257,N,Compound was evaluated for area under curve when administered through oral route to mouse,Intermediate,,50594,,15115,,10090.0,Mus musculus,,CHEMBL622551,,,,,A,1,1,
,BAO_0000218,8258,N,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,Intermediate,,50597,,8758,,10116.0,Rattus norvegicus,,CHEMBL622552,,,,,A,1,1,
,BAO_0000218,8259,N,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,Intermediate,,50597,,8758,,10116.0,Rattus norvegicus,,CHEMBL622553,,,,,A,1,1,
,BAO_0000218,8260,U,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs,Autocuration,,22224,,8267,,,,,CHEMBL622554,,,In vivo,,F,1,0,
,BAO_0000218,8261,N,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs,Intermediate,,50588,,8267,,9615.0,Canis lupus familiaris,,CHEMBL622555,,,,,A,1,1,
,BAO_0000218,8262,N,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,Intermediate,,50594,,14239,,10090.0,Mus musculus,,CHEMBL622556,,,,,A,1,1,
,BAO_0000218,8263,N,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,Intermediate,,50594,,14239,,10090.0,Mus musculus,,CHEMBL622557,,,,,A,1,1,
Blood,BAO_0000218,8264,N,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice,Intermediate,,50594,,10754,178.0,10090.0,Mus musculus,,CHEMBL622558,,,,,A,1,1,
Blood,BAO_0000218,8265,N,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice,Intermediate,,50594,,10754,178.0,10090.0,Mus musculus,,CHEMBL622559,,,,,A,1,1,
,BAO_0000218,8266,N,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.,Intermediate,,50588,,10754,,9615.0,Canis lupus familiaris,,CHEMBL622560,,,,,A,1,1,
,BAO_0000218,8267,N,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose,Intermediate,,50597,,14681,,10116.0,Rattus norvegicus,,CHEMBL622561,,,,,A,1,1,
,BAO_0000218,8268,N,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. ,Intermediate,,50597,,14681,,10116.0,Rattus norvegicus,,CHEMBL622562,,,,,A,1,1,
,BAO_0000218,8269,N,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,Intermediate,,50597,,14681,,10116.0,Rattus norvegicus,,CHEMBL622563,,,,,A,1,1,
,BAO_0000019,8270,U,Concentration of compound in Central nervous system,Autocuration,,22224,,13118,,,,,CHEMBL622564,,,,,A,1,0,
,BAO_0000019,8271,U,Concentration of compound in Central nervous system; Not detectable,Autocuration,,22224,,13118,,,,,CHEMBL622565,,,,,A,1,0,
,BAO_0000218,8272,N,"Concentration of diester in the blood, following oral administration in mice",Intermediate,,50594,,13318,,10090.0,Mus musculus,,CHEMBL622566,,,,,A,1,1,
,BAO_0000218,8273,N,"Concentration of monoester in the blood, following oral administration in mice",Intermediate,,50594,,13318,,10090.0,Mus musculus,,CHEMBL624515,,,,,A,1,1,
,BAO_0000218,8274,N,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice,Intermediate,,50594,,13318,,10090.0,Mus musculus,,CHEMBL624516,,,,,A,1,1,
,BAO_0000019,8275,U,Evaluated for Pharmacokinetic property: Area under the curve,Autocuration,,22224,,15692,,,,,CHEMBL624517,,,,,A,1,0,
,BAO_0000218,8276,N,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice,Intermediate,,50594,,14839,,10090.0,Mus musculus,,CHEMBL624518,,,,,A,1,1,
,BAO_0000218,8277,N,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice,Intermediate,,100710,,14839,,9541.0,Macaca fascicularis,,CHEMBL624519,,,,,A,1,1,
,BAO_0000218,8278,N,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve,Intermediate,,100710,,14839,,9541.0,Macaca fascicularis,,CHEMBL624520,,,,,A,1,1,
,BAO_0000218,8279,N,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve,Intermediate,,100710,,14839,,9541.0,Macaca fascicularis,,CHEMBL624521,,,,,A,1,1,
,BAO_0000218,8280,N,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve,Intermediate,,100710,,14839,,9541.0,Macaca fascicularis,,CHEMBL624522,,,,,A,1,1,
,BAO_0000218,8281,N,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve,Intermediate,,100710,,14839,,9541.0,Macaca fascicularis,,CHEMBL624523,,,,,A,1,1,
,BAO_0000218,8282,N,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",Intermediate,,100710,,14839,,9541.0,Macaca fascicularis,,CHEMBL624409,,,,,A,1,1,
,BAO_0000218,8283,N,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)",Intermediate,,100710,,14839,,9541.0,Macaca fascicularis,,CHEMBL624410,,,,,A,1,1,
,BAO_0000218,8284,N,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",Intermediate,,100710,,14839,,9541.0,Macaca fascicularis,,CHEMBL624411,,,,,A,1,1,
,BAO_0000218,8285,N,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)",Intermediate,,100710,,14839,,9541.0,Macaca fascicularis,,CHEMBL623531,,,,,A,1,1,
,BAO_0000218,8286,N,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)",Intermediate,,100710,,14839,,9541.0,Macaca fascicularis,,CHEMBL623532,,,,,A,1,1,
,BAO_0000218,8287,N,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)",Intermediate,,100710,,14839,,9541.0,Macaca fascicularis,,CHEMBL623533,,,,,A,1,1,
,BAO_0000218,8288,N,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",Intermediate,,100710,,14839,,9541.0,Macaca fascicularis,,CHEMBL623534,,,,,A,1,1,
,BAO_0000218,8289,N,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve,Intermediate,,50594,,14839,,10090.0,Mus musculus,,CHEMBL623535,,,,,A,1,1,
,BAO_0000218,8290,N,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve,Intermediate,,50594,,14839,,10090.0,Mus musculus,,CHEMBL623536,,,,,A,1,1,
,BAO_0000218,8291,N,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve,Intermediate,,50594,,14839,,10090.0,Mus musculus,,CHEMBL623537,,,,,A,1,1,
,BAO_0000218,8292,N,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve,Intermediate,,50594,,14839,,10090.0,Mus musculus,,CHEMBL623538,,,,,A,1,1,
,BAO_0000218,8293,N,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve,Intermediate,,50594,,14839,,10090.0,Mus musculus,,CHEMBL623539,,,,,A,1,1,
,BAO_0000218,8294,N,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve,Intermediate,,50594,,14839,,10090.0,Mus musculus,,CHEMBL623540,,,,,A,1,1,
,BAO_0000218,8295,N,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined.",Intermediate,,50594,,14839,,10090.0,Mus musculus,,CHEMBL623541,,,,,A,1,1,
,BAO_0000218,8296,N,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)",Intermediate,,50594,,14839,,10090.0,Mus musculus,,CHEMBL623542,,,,,A,1,1,
,BAO_0000218,8297,N,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)",Intermediate,,50594,,14839,,10090.0,Mus musculus,,CHEMBL623543,,,,,A,1,1,
,BAO_0000218,8298,N,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined",Intermediate,,50594,,14839,,10090.0,Mus musculus,,CHEMBL623544,,,,,A,1,1,
,BAO_0000218,8299,N,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)",Intermediate,,50594,,14839,,10090.0,Mus musculus,,CHEMBL623545,,,,,A,1,1,
,BAO_0000218,8300,N,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)",Intermediate,,50594,,14839,,10090.0,Mus musculus,,CHEMBL623546,,,,,A,1,1,
Plasma,BAO_0000218,8301,N,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats,Intermediate,,50597,,5408,1969.0,10116.0,Rattus norvegicus,,CHEMBL623547,,,In vivo,,A,1,1,
,BAO_0000218,8302,N,High i.v. clearance in Dawley rats,Intermediate,,50597,,6827,,10116.0,Rattus norvegicus,,CHEMBL623548,,,In vivo,,A,1,1,
Liver,BAO_0000218,8303,N,In vitro clearance in rat liver microsomes,Intermediate,,50597,,17538,2107.0,10116.0,Rattus norvegicus,,CHEMBL623549,,,In vitro,Microsomes,A,1,1,
Liver,BAO_0000218,8304,N,Intrinsic clearance in rat liver microsomes was determined,Intermediate,,50597,,6331,2107.0,10116.0,Rattus norvegicus,,CHEMBL623550,,,In vitro,Microsomes,A,1,1,
Liver,BAO_0000218,8305,N,Intrinsic clearance in rat hepatocytes was determined,Intermediate,401.0,50597,,5948,2107.0,10116.0,Rattus norvegicus,,CHEMBL875276,Hepatocyte,,In vitro,,A,1,1,
,BAO_0000218,8306,N,Plasma Clearance was determined,Intermediate,,50597,,4026,,10116.0,Rattus norvegicus,,CHEMBL621872,,,In vivo,,A,1,1,
,BAO_0000218,8307,N,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined,Intermediate,,50597,,6647,,10116.0,Rattus norvegicus,,CHEMBL621873,,,In vivo,,A,1,1,
,BAO_0000218,8308,N,Plasma clearance in rat.,Intermediate,,50597,,1696,,10116.0,Rattus norvegicus,,CHEMBL621874,,,In vivo,,A,1,1,
,BAO_0000218,8309,N,Plasma clearance in rats,Intermediate,,50597,,6597,,10116.0,Rattus norvegicus,,CHEMBL621875,,,In vivo,,A,1,1,
,BAO_0000218,8310,N,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats,Intermediate,,50597,,347,,10116.0,Rattus norvegicus,,CHEMBL621876,,,In vivo,,A,1,1,
,BAO_0000218,8311,N,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration,Intermediate,,50597,,16423,,10116.0,Rattus norvegicus,,CHEMBL621877,,,In vivo,,A,1,1,
,BAO_0000218,8312,N,Plasma clearance was measured in rat,Intermediate,,50597,,2879,,10116.0,Rattus norvegicus,,CHEMBL621878,,,In vivo,,A,1,1,
,BAO_0000218,8313,N,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,Intermediate,,50597,,4883,,10116.0,Rattus norvegicus,,CHEMBL621879,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8314,N,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally",Intermediate,,50597,,5328,1969.0,10116.0,Rattus norvegicus,,CHEMBL621880,,,In vivo,,A,1,1,
,BAO_0000218,8315,N,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg,Intermediate,,50597,,5160,,10116.0,Rattus norvegicus,,CHEMBL621881,,,In vivo,,A,1,1,
,BAO_0000218,8316,N,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,Intermediate,,50597,,17582,,10116.0,Rattus norvegicus,,CHEMBL621882,,,In vivo,,A,1,1,
,BAO_0000218,8317,N,Total clearance at 1 mg/kg was determined in rat,Intermediate,,50597,,17651,,10116.0,Rattus norvegicus,,CHEMBL875283,,,In vivo,,A,1,1,
,BAO_0000218,8318,N,Total clearance at 10 mg/kg was determined in rat,Intermediate,,50597,,17651,,10116.0,Rattus norvegicus,,CHEMBL621883,,,In vivo,,A,1,1,
,BAO_0000218,8319,N,Clearance in rat,Intermediate,,50597,,6596,,10116.0,Rattus norvegicus,,CHEMBL621884,,,In vivo,,A,1,1,
,BAO_0000218,8320,N,Plasma clearance rate determined in rats,Intermediate,,50597,,4796,,10116.0,Rattus norvegicus,,CHEMBL621885,,,In vivo,,A,1,1,
,BAO_0000218,8321,N,Clearance of compound in rat was evaluated,Intermediate,,50597,,6850,,10116.0,Rattus norvegicus,,CHEMBL621886,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8322,N,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,Intermediate,,50597,,5932,1969.0,10116.0,Rattus norvegicus,,CHEMBL621887,,,In vivo,,A,1,1,
,BAO_0000218,8323,N,Pharmacokinetic property (blood clearance) in rat,Intermediate,,50597,,3371,,10116.0,Rattus norvegicus,,CHEMBL621888,,,In vivo,,A,1,1,
,BAO_0000218,8324,N,Plasma clearance in rat,Intermediate,,50597,,2083,,10116.0,Rattus norvegicus,,CHEMBL621889,,,In vivo,,A,1,1,
,BAO_0000218,8325,N,Plasma clearance in rats,Intermediate,,50597,,4942,,10116.0,Rattus norvegicus,,CHEMBL621890,,,In vivo,,A,1,1,
Liver,BAO_0000218,8326,N,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes,Intermediate,,50597,,6838,2107.0,10116.0,Rattus norvegicus,,CHEMBL621891,,,In vitro,Microsomes,A,1,1,
,BAO_0000218,8327,N,Clearance in Dawley rat,Intermediate,,50597,,5353,,10116.0,Rattus norvegicus,,CHEMBL621892,,,In vivo,,A,1,1,
,BAO_0000218,8328,N,Clearance rat,Intermediate,,50597,,6641,,10116.0,Rattus norvegicus,,CHEMBL621893,,,In vivo,,A,1,1,
,BAO_0000218,8329,N,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.),Intermediate,,50597,,6641,,10116.0,Rattus norvegicus,,CHEMBL621894,,,In vivo,,A,1,1,
,BAO_0000218,8330,N,Clearance rat; Not determined,Intermediate,,50597,,6641,,10116.0,Rattus norvegicus,,CHEMBL621895,,,In vivo,,A,1,1,
,BAO_0000218,8331,N,Clearance rate was determined in rat at a dose of 1 mpk i.v.,Intermediate,,50597,,6444,,10116.0,Rattus norvegicus,,CHEMBL875284,,,In vivo,,A,1,1,
,BAO_0000218,8332,N,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined,Intermediate,,50597,,6444,,10116.0,Rattus norvegicus,,CHEMBL618699,,,In vivo,,A,1,1,
,BAO_0000218,8333,N,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined,Intermediate,,50597,,6444,,10116.0,Rattus norvegicus,,CHEMBL618700,,,In vivo,,A,1,1,
,BAO_0000218,8334,N,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,Intermediate,,50597,,6211,,10116.0,Rattus norvegicus,,CHEMBL618701,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8335,N,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",Intermediate,,50597,,12873,1969.0,10116.0,Rattus norvegicus,,CHEMBL876600,,,In vivo,,A,1,1,
,BAO_0000218,8336,N,Clearance of compound in rat after 1 mg/kg i.v. administration,Intermediate,,50597,,6570,,10116.0,Rattus norvegicus,,CHEMBL618702,,,In vivo,,A,1,1,
,BAO_0000218,8337,N,Compound was evaluated for Hepatic clearance in rat,Intermediate,,50597,,3341,,10116.0,Rattus norvegicus,,CHEMBL618703,,,In vivo,,A,1,1,
,BAO_0000218,8338,N,In vivo clearance after 5 mg/kg dose,Intermediate,,50597,,4891,,10116.0,Rattus norvegicus,,CHEMBL618704,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8339,N,Compound was tested for plasma clearance in rats,Intermediate,,50597,,1094,1969.0,10116.0,Rattus norvegicus,,CHEMBL618705,,,In vivo,,A,1,1,
,BAO_0000218,8340,N,Hepatic clearance after intravenous administration was evaluated in rat,Intermediate,,50597,,2938,,10116.0,Rattus norvegicus,,CHEMBL618706,,,In vivo,,A,1,1,
,BAO_0000218,8341,N,Lower clearance in rat (i.v.) at 0.5 mpk,Intermediate,,50597,,17853,,10116.0,Rattus norvegicus,,CHEMBL618707,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8342,N,Pharmacokinetic parameter expressed as plasma clearance in rat,Intermediate,,50597,,6049,1969.0,10116.0,Rattus norvegicus,,CHEMBL618708,,,In vivo,,A,1,1,
,BAO_0000218,8343,N,Pharmacokinetic property (Clp) in rat,Intermediate,,50597,,5789,,10116.0,Rattus norvegicus,,CHEMBL618709,,,In vivo,,A,1,1,
,BAO_0000218,8344,N,Plasma clearance in Sprague-Dawley rats,Intermediate,,50597,,4514,,10116.0,Rattus norvegicus,,CHEMBL618710,,,In vivo,,A,1,1,
,BAO_0000218,8345,N,Plasma clearance (Clp) in rat,Intermediate,,50597,,6448,,10116.0,Rattus norvegicus,,CHEMBL618711,,,In vivo,,A,1,1,
,BAO_0000218,8346,N,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg,Intermediate,,50597,,6062,,10116.0,Rattus norvegicus,,CHEMBL618712,,,In vivo,,A,1,1,
,BAO_0000218,8347,N,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound,Intermediate,,50597,,5710,,10116.0,Rattus norvegicus,,CHEMBL618713,,,In vivo,,A,1,1,
,BAO_0000218,8348,N,Plasma clearance after intravenous administration of 1 mg/kg in rat,Intermediate,,50597,,4709,,10116.0,Rattus norvegicus,,CHEMBL618714,,,In vivo,,A,1,1,
,BAO_0000218,8349,N,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,Intermediate,,50597,,4521,,10116.0,Rattus norvegicus,,CHEMBL618715,,,In vivo,,A,1,1,
,BAO_0000218,8350,N,Plasma clearance in rat was determined,Intermediate,,50597,,1742,,10116.0,Rattus norvegicus,,CHEMBL618716,,,In vivo,,A,1,1,
,BAO_0000218,8351,N,Plasma clearance measured in rat,Intermediate,,50597,,6057,,10116.0,Rattus norvegicus,,CHEMBL876601,,,In vivo,,A,1,1,
,BAO_0000218,8352,N,Plasma clearance was calculated in rat,Intermediate,,50597,,6057,,10116.0,Rattus norvegicus,,CHEMBL618717,,,In vivo,,A,1,1,
,BAO_0000218,8353,N,Plasma clearance in rat,Intermediate,,50597,,5145,,10116.0,Rattus norvegicus,,CHEMBL618718,,,In vivo,,A,1,1,
,BAO_0000218,8354,N,Plasma clearance in rat,Intermediate,,50597,,5833,,10116.0,Rattus norvegicus,,CHEMBL618719,,,In vivo,,A,1,1,
,BAO_0000218,8355,N,Plasma clearance in rat,Intermediate,,50597,,6453,,10116.0,Rattus norvegicus,,CHEMBL618720,,,In vivo,,A,1,1,
,BAO_0000218,8356,N,Plasma clearance in rat,Intermediate,,50597,,6640,,10116.0,Rattus norvegicus,,CHEMBL618721,,,In vivo,,A,1,1,
,BAO_0000218,8357,N,Plasma clearance in rats,Intermediate,,50597,,6305,,10116.0,Rattus norvegicus,,CHEMBL621477,,,In vivo,,A,1,1,
,BAO_0000218,8358,N,Plasma clearance in rat,Intermediate,,50597,,6642,,10116.0,Rattus norvegicus,,CHEMBL621478,,,In vivo,,A,1,1,
,BAO_0000218,8359,N,Plasma clearance was evaluated in rat,Intermediate,,50597,,5472,,10116.0,Rattus norvegicus,,CHEMBL621479,,,In vivo,,A,1,1,
,BAO_0000218,8360,N,Plasma clearance was evaluated in rat; Not tested,Intermediate,,50597,,5472,,10116.0,Rattus norvegicus,,CHEMBL621480,,,In vivo,,A,1,1,
,BAO_0000218,8361,N,Plasma clearance rate was determined for the compound in rat,Intermediate,,50597,,5144,,10116.0,Rattus norvegicus,,CHEMBL621481,,,In vivo,,A,1,1,
,BAO_0000218,8362,N,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable",Intermediate,,50597,,6685,,10116.0,Rattus norvegicus,,CHEMBL621482,,,In vivo,,A,1,1,
,BAO_0000218,8363,N,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",Intermediate,,50597,,6685,,10116.0,Rattus norvegicus,,CHEMBL621483,,,In vivo,,A,1,1,
,BAO_0000218,8364,N,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose",Intermediate,,50597,,6685,,10116.0,Rattus norvegicus,,CHEMBL621484,,,In vivo,,A,1,1,
Heart,BAO_0000218,8365,N,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,948.0,10116.0,Rattus norvegicus,,CHEMBL621485,,,In vivo,,A,1,1,
Heart,BAO_0000218,8366,N,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,948.0,10116.0,Rattus norvegicus,,CHEMBL621486,,,In vivo,,A,1,1,
Intestine,BAO_0000218,8367,N,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,160.0,10116.0,Rattus norvegicus,,CHEMBL621487,,,In vivo,,A,1,1,
Intestine,BAO_0000218,8368,N,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,160.0,10116.0,Rattus norvegicus,,CHEMBL621488,,,In vivo,,A,1,1,
Intestine,BAO_0000218,8369,N,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,160.0,10116.0,Rattus norvegicus,,CHEMBL621489,,,In vivo,,A,1,1,
Intestine,BAO_0000218,8370,N,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,160.0,10116.0,Rattus norvegicus,,CHEMBL621490,,,In vivo,,A,1,1,
Intestine,BAO_0000218,8371,N,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,160.0,10116.0,Rattus norvegicus,,CHEMBL621491,,,In vivo,,A,1,1,
Kidney,BAO_0000218,8372,N,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,2113.0,10116.0,Rattus norvegicus,,CHEMBL621492,,,In vivo,,A,1,1,
Kidney,BAO_0000218,8373,N,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,2113.0,10116.0,Rattus norvegicus,,CHEMBL621493,,,In vivo,,A,1,1,
Kidney,BAO_0000218,8374,N,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,2113.0,10116.0,Rattus norvegicus,,CHEMBL621494,,,In vivo,,A,1,1,
Kidney,BAO_0000218,8375,N,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,2113.0,10116.0,Rattus norvegicus,,CHEMBL621495,,,In vivo,,A,1,1,
Kidney,BAO_0000218,8376,N,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,2113.0,10116.0,Rattus norvegicus,,CHEMBL621496,,,In vivo,,A,1,1,
Liver,BAO_0000218,8377,N,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,2107.0,10116.0,Rattus norvegicus,,CHEMBL621497,,,In vivo,,A,1,1,
Liver,BAO_0000218,8378,N,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,2107.0,10116.0,Rattus norvegicus,,CHEMBL621498,,,In vivo,,A,1,1,
Liver,BAO_0000218,8379,N,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,2107.0,10116.0,Rattus norvegicus,,CHEMBL621499,,,In vivo,,A,1,1,
Liver,BAO_0000218,8380,N,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,2107.0,10116.0,Rattus norvegicus,,CHEMBL618634,,,In vivo,,A,1,1,
Liver,BAO_0000218,8381,N,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,2107.0,10116.0,Rattus norvegicus,,CHEMBL618635,,,In vivo,,A,1,1,
Lung,BAO_0000218,8382,N,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,2048.0,10116.0,Rattus norvegicus,,CHEMBL618636,,,In vivo,,A,1,1,
Lung,BAO_0000218,8383,N,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,2048.0,10116.0,Rattus norvegicus,,CHEMBL619737,,,In vivo,,A,1,1,
Lung,BAO_0000218,8384,N,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,2048.0,10116.0,Rattus norvegicus,,CHEMBL619738,,,In vivo,,A,1,1,
Lung,BAO_0000218,8385,N,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,2048.0,10116.0,Rattus norvegicus,,CHEMBL624329,,,In vivo,,A,1,1,
Lung,BAO_0000218,8386,N,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,2048.0,10116.0,Rattus norvegicus,,CHEMBL624330,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,8387,N,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,2385.0,10116.0,Rattus norvegicus,,CHEMBL624331,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,8388,N,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,2385.0,10116.0,Rattus norvegicus,,CHEMBL624332,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,8389,N,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,2385.0,10116.0,Rattus norvegicus,,CHEMBL624333,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,8390,N,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,2385.0,10116.0,Rattus norvegicus,,CHEMBL624334,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,8391,N,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,2385.0,10116.0,Rattus norvegicus,,CHEMBL624335,,,In vivo,,A,1,1,
Spleen,BAO_0000218,8392,N,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,2106.0,10116.0,Rattus norvegicus,,CHEMBL620016,,,In vivo,,A,1,1,
Spleen,BAO_0000218,8393,N,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,2106.0,10116.0,Rattus norvegicus,,CHEMBL620169,,,In vivo,,A,1,1,
Spleen,BAO_0000218,8394,N,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,2106.0,10116.0,Rattus norvegicus,,CHEMBL620170,,,In vivo,,A,1,1,
Spleen,BAO_0000218,8395,N,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,2106.0,10116.0,Rattus norvegicus,,CHEMBL620171,,,In vivo,,A,1,1,
Spleen,BAO_0000218,8396,N,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,2106.0,10116.0,Rattus norvegicus,,CHEMBL620172,,,In vivo,,A,1,1,
Stomach,BAO_0000218,8397,N,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,945.0,10116.0,Rattus norvegicus,,CHEMBL620173,,,In vivo,,A,1,1,
Stomach,BAO_0000218,8398,N,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,945.0,10116.0,Rattus norvegicus,,CHEMBL620174,,,In vivo,,A,1,1,
Stomach,BAO_0000218,8399,N,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,945.0,10116.0,Rattus norvegicus,,CHEMBL620175,,,In vivo,,A,1,1,
Stomach,BAO_0000218,8400,N,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,945.0,10116.0,Rattus norvegicus,,CHEMBL620176,,,In vivo,,A,1,1,
Stomach,BAO_0000218,8401,N,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,945.0,10116.0,Rattus norvegicus,,CHEMBL620177,,,In vivo,,A,1,1,
Cerebellum,BAO_0000218,8402,N,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,2037.0,10116.0,Rattus norvegicus,,CHEMBL620178,,,,,A,1,1,
Cerebellum,BAO_0000218,8403,N,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,2037.0,10116.0,Rattus norvegicus,,CHEMBL620179,,,,,A,1,1,
,BAO_0000218,8404,N,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,,10116.0,Rattus norvegicus,,CHEMBL620180,,,,,A,1,1,
,BAO_0000218,8405,N,Volume of distribution of compound in rat after 1 mg/kg i.v. administration,Intermediate,,50597,,6570,,10116.0,Rattus norvegicus,,CHEMBL620181,,,In vivo,,A,1,1,
,BAO_0000218,8406,N,Volume of distribution of compound in rats after intravenous administration,Intermediate,,50597,,6571,,10116.0,Rattus norvegicus,,CHEMBL620182,,,In vivo,,A,1,1,
,BAO_0000218,8407,N,Volume of distribution in rat,Intermediate,,50597,,6453,,10116.0,Rattus norvegicus,,CHEMBL620183,,,In vivo,,A,1,1,
,BAO_0000218,8408,N,Volume of distribution was determined in rat at a dose of 1 mpk i.v.,Intermediate,,50597,,6444,,10116.0,Rattus norvegicus,,CHEMBL620184,,,In vivo,,A,1,1,
,BAO_0000218,8409,N,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined,Intermediate,,50597,,6444,,10116.0,Rattus norvegicus,,CHEMBL620185,,,In vivo,,A,1,1,
,BAO_0000218,8410,N,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined,Intermediate,,50597,,6444,,10116.0,Rattus norvegicus,,CHEMBL620186,,,In vivo,,A,1,1,
,BAO_0000218,8411,N,Volume of distribution was determined in Dawley rat,Intermediate,,50597,,5353,,10116.0,Rattus norvegicus,,CHEMBL620187,,,In vivo,,A,1,1,
,BAO_0000218,8412,N,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,Intermediate,,50597,,5334,,10116.0,Rattus norvegicus,,CHEMBL620188,,,In vivo,,A,1,1,
,BAO_0000218,8413,N,Volume of distribution was reported in Sprague-Dawley rat,Intermediate,,50597,,5334,,10116.0,Rattus norvegicus,,CHEMBL620189,,,In vivo,,A,1,1,
,BAO_0000218,8414,N,Volumes of distribution in rat after peroral administration,Intermediate,,50597,,6641,,10116.0,Rattus norvegicus,,CHEMBL620190,,,In vivo,,A,1,1,
,BAO_0000218,8415,N,Volumes of distribution in rat after po administration,Intermediate,,50597,,6641,,10116.0,Rattus norvegicus,,CHEMBL620191,,,In vivo,,A,1,1,
,BAO_0000218,8416,N,Volumes of distribution in rat after po administration; Not determined,Intermediate,,50597,,6641,,10116.0,Rattus norvegicus,,CHEMBL620192,,,In vivo,,A,1,1,
,BAO_0000218,8417,N,Pharmacokinetic property (Volume) in rat i.v.,Intermediate,,50597,,5676,,10116.0,Rattus norvegicus,,CHEMBL620193,,,In vivo,,A,1,1,
,BAO_0000218,8418,N,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously,Intermediate,,50597,,6410,,10116.0,Rattus norvegicus,,CHEMBL620194,,,In vivo,,A,1,1,
,BAO_0000218,8419,N,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously",Intermediate,,50597,,17670,,10116.0,Rattus norvegicus,,CHEMBL876730,,,In vivo,,A,1,1,
,BAO_0000218,8420,N,Volume distribution in rat after oral administration at 10 mg/kg,Intermediate,,50597,,6495,,10116.0,Rattus norvegicus,,CHEMBL620195,,,In vivo,,A,1,1,
,BAO_0000218,8421,N,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats,Intermediate,,50597,,5408,,10116.0,Rattus norvegicus,,CHEMBL620196,,,In vivo,,A,1,1,
,BAO_0000218,8422,N,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,Intermediate,,50597,,4883,,10116.0,Rattus norvegicus,,CHEMBL620197,,,In vivo,,A,1,1,
,BAO_0000218,8423,N,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined,Intermediate,,50597,,6647,,10116.0,Rattus norvegicus,,CHEMBL620198,,,In vivo,,A,1,1,
,BAO_0000218,8424,N,Volume of distribution in rats,Intermediate,,50597,,6495,,10116.0,Rattus norvegicus,,CHEMBL620199,,,In vivo,,A,1,1,
,BAO_0000218,8425,N,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats,Intermediate,,50597,,2661,,10116.0,Rattus norvegicus,,CHEMBL620200,,,In vivo,,A,1,1,
,BAO_0000218,8426,N,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats,Intermediate,,50597,,2661,,10116.0,Rattus norvegicus,,CHEMBL620201,,,In vivo,,A,1,1,
,BAO_0000218,8427,N,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,Intermediate,,50597,,5974,,10116.0,Rattus norvegicus,,CHEMBL620202,,,In vivo,,A,1,1,
,BAO_0000218,8428,N,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,Intermediate,,50597,,5974,,10116.0,Rattus norvegicus,,CHEMBL620203,,,In vivo,,A,1,1,
,BAO_0000218,8429,N,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value,Intermediate,,50597,,5974,,10116.0,Rattus norvegicus,,CHEMBL620204,,,In vivo,,A,1,1,
,BAO_0000218,8430,N,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,Intermediate,,50597,,5974,,10116.0,Rattus norvegicus,,CHEMBL620205,,,In vivo,,A,1,1,
,BAO_0000218,8431,N,Pharmacokinetic parameter (Vss) in rat,Intermediate,,50597,,5960,,10116.0,Rattus norvegicus,,CHEMBL624664,,,In vivo,,A,1,1,
,BAO_0000218,8432,N,Pharmacokinetic property (Volume) in rat i.v.,Intermediate,,50597,,5676,,10116.0,Rattus norvegicus,,CHEMBL624665,,,In vivo,,A,1,1,
,BAO_0000218,8433,N,Pharmacokinetic property (Vss) in rat,Intermediate,,50597,,5948,,10116.0,Rattus norvegicus,,CHEMBL624666,,,,,A,1,1,
,BAO_0000218,8434,N,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,Intermediate,,50597,,5979,,10116.0,Rattus norvegicus,,CHEMBL624667,,,In vivo,,A,1,1,
,BAO_0000218,8435,N,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat,Intermediate,,50597,,5978,,10116.0,Rattus norvegicus,,CHEMBL624668,,,In vivo,,A,1,1,
,BAO_0000218,8436,N,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,Intermediate,,50597,,5978,,10116.0,Rattus norvegicus,,CHEMBL624669,,,In vivo,,A,1,1,
,BAO_0000218,8437,N,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,Intermediate,,50597,,5978,,10116.0,Rattus norvegicus,,CHEMBL624670,,,In vivo,,A,1,1,
,BAO_0000218,8438,N,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,Intermediate,,50597,,5978,,10116.0,Rattus norvegicus,,CHEMBL624671,,,In vivo,,A,1,1,
,BAO_0000218,8439,N,Steady state volume distribution in rat,Intermediate,,50597,,6448,,10116.0,Rattus norvegicus,,CHEMBL624672,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8440,N,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv.",Intermediate,,50597,,12873,1969.0,10116.0,Rattus norvegicus,,CHEMBL624673,,,In vivo,,A,1,1,
,BAO_0000218,8441,N,Steady state volume of distribution determined in rat,Intermediate,,50597,,4576,,10116.0,Rattus norvegicus,,CHEMBL624674,,,In vivo,,A,1,1,
,BAO_0000218,8442,N,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,Intermediate,,50597,,17582,,10116.0,Rattus norvegicus,,CHEMBL624675,,,In vivo,,A,1,1,
,BAO_0000218,8443,N,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat,Intermediate,,50597,,1466,,10116.0,Rattus norvegicus,,CHEMBL621728,,,In vivo,,A,1,1,
,BAO_0000218,8444,N,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined,Intermediate,,50597,,5182,,10116.0,Rattus norvegicus,,CHEMBL621729,,,,,A,1,1,
,BAO_0000218,8445,N,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated,Intermediate,,50597,,5182,,10116.0,Rattus norvegicus,,CHEMBL621730,,,,,A,1,1,
,BAO_0000218,8446,N,Volume distribution in rat after administration of 2 mg/kg iv,Intermediate,,50597,,6535,,10116.0,Rattus norvegicus,,CHEMBL621731,,,In vivo,,A,1,1,
,BAO_0000218,8447,N,Volume distribution in rat after administration of 2 mg/kg iv,Intermediate,,50597,,6535,,10116.0,Rattus norvegicus,,CHEMBL621732,,,In vivo,,A,1,1,
,BAO_0000218,8448,N,Volume in steady state distribution value was determined,Intermediate,,50597,,5041,,10116.0,Rattus norvegicus,,CHEMBL621908,,,In vivo,,A,1,1,
,BAO_0000218,8449,N,Volume in steady state distribution value was determined; ND denotes no data,Intermediate,,50597,,5041,,10116.0,Rattus norvegicus,,CHEMBL875347,,,In vivo,,A,1,1,
,BAO_0000218,8450,N,Volume in steady state distribution value was determined; ND denotes not determined,Intermediate,,50597,,5041,,10116.0,Rattus norvegicus,,CHEMBL621909,,,In vivo,,A,1,1,
,BAO_0000218,8451,N,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats,Intermediate,,50597,,17065,,10116.0,Rattus norvegicus,,CHEMBL621910,,,In vivo,,A,1,1,
,BAO_0000218,8452,N,Volume of distribution at steady state was evaluated in rats,Intermediate,,50597,,6597,,10116.0,Rattus norvegicus,,CHEMBL621911,,,In vivo,,A,1,1,
,BAO_0000218,8453,N,Volume of distribution at steady state was observed after intravenous administration in rat,Intermediate,,50597,,15662,,10116.0,Rattus norvegicus,,CHEMBL621912,,,In vivo,,A,1,1,
,BAO_0000218,8454,N,Volume of distribution in steady state was determined in rat,Intermediate,,50597,,6485,,10116.0,Rattus norvegicus,,CHEMBL621913,,,In vivo,,A,1,1,
,BAO_0000218,8455,N,Volume of distribution in steady state was determined in rat,Intermediate,,50597,,17655,,10116.0,Rattus norvegicus,,CHEMBL621914,,,In vivo,,A,1,1,
,BAO_0000218,8456,N,Volume of distribution after i.v. administration,Intermediate,,50597,,6616,,10116.0,Rattus norvegicus,,CHEMBL621915,,,In vivo,,A,1,1,
,BAO_0000218,8457,N,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,Intermediate,,50597,,1916,,10116.0,Rattus norvegicus,,CHEMBL621916,,,In vivo,,A,1,1,
Liver,BAO_0000218,8458,N,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",Intermediate,,50594,,16438,2107.0,10090.0,Mus musculus,,CHEMBL621917,,,In vivo,,A,1,1,
Liver,BAO_0000218,8459,N,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,,50594,,16438,2107.0,10090.0,Mus musculus,,CHEMBL621918,,,In vivo,,A,1,1,
Spleen,BAO_0000218,8460,N,Biodistribution of compound (oxidized form) in spleen tissue,Intermediate,,50594,,16438,2106.0,10090.0,Mus musculus,,CHEMBL621919,,,In vivo,,A,1,1,
Spleen,BAO_0000218,8461,N,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Intermediate,,50594,,16438,2106.0,10090.0,Mus musculus,,CHEMBL621920,,,In vivo,,A,1,1,
Spleen,BAO_0000218,8462,N,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",Intermediate,,50594,,16438,2106.0,10090.0,Mus musculus,,CHEMBL621921,,,In vivo,,A,1,1,
Spleen,BAO_0000218,8463,N,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,,50594,,16438,2106.0,10090.0,Mus musculus,,CHEMBL622401,,,In vivo,,A,1,1,
Spleen,BAO_0000218,8464,N,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Intermediate,,50594,,16438,2106.0,10090.0,Mus musculus,,CHEMBL875348,,,In vivo,,A,1,1,
Spleen,BAO_0000218,8465,N,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",Intermediate,,50594,,16438,2106.0,10090.0,Mus musculus,,CHEMBL622402,,,In vivo,,A,1,1,
Blood,BAO_0000218,8466,N,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood,Intermediate,,50594,,16438,178.0,10090.0,Mus musculus,,CHEMBL622403,,,In vivo,,A,1,1,
Blood,BAO_0000218,8467,N,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,,50594,,16438,178.0,10090.0,Mus musculus,,CHEMBL622404,,,In vivo,,A,1,1,
Brain,BAO_0000218,8468,N,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues,Intermediate,,50594,,16438,955.0,10090.0,Mus musculus,,CHEMBL622405,,,In vivo,,A,1,1,
Brain,BAO_0000218,8469,N,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO",Intermediate,,50594,,16438,955.0,10090.0,Mus musculus,,CHEMBL622406,,,In vivo,,A,1,1,
Brain,BAO_0000218,8470,N,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,,50594,,16438,955.0,10090.0,Mus musculus,,CHEMBL622407,,,In vivo,,A,1,1,
Heart,BAO_0000218,8471,N,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues,Intermediate,,50594,,16438,948.0,10090.0,Mus musculus,,CHEMBL622408,,,In vivo,,A,1,1,
Heart,BAO_0000218,8472,N,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO",Intermediate,,50594,,16438,948.0,10090.0,Mus musculus,,CHEMBL622409,,,In vivo,,A,1,1,
Heart,BAO_0000218,8473,N,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,,50594,,16438,948.0,10090.0,Mus musculus,,CHEMBL622410,,,In vivo,,A,1,1,
Kidney,BAO_0000218,8474,N,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney,Intermediate,,50594,,16438,2113.0,10090.0,Mus musculus,,CHEMBL622411,,,In vivo,,A,1,1,
Kidney,BAO_0000218,8475,N,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO",Intermediate,,50594,,16438,2113.0,10090.0,Mus musculus,,CHEMBL627864,,,In vivo,,A,1,1,
Kidney,BAO_0000218,8476,N,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,,50594,,16438,2113.0,10090.0,Mus musculus,,CHEMBL627865,,,In vivo,,A,1,1,
Liver,BAO_0000218,8477,N,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver,Intermediate,,50594,,16438,2107.0,10090.0,Mus musculus,,CHEMBL627866,,,In vivo,,A,1,1,
Liver,BAO_0000218,8478,N,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,,50594,,16438,2107.0,10090.0,Mus musculus,,CHEMBL627751,,,In vivo,,A,1,1,
Spleen,BAO_0000218,8479,N,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen,Intermediate,,50594,,16438,2106.0,10090.0,Mus musculus,,CHEMBL627752,,,In vivo,,A,1,1,
Spleen,BAO_0000218,8480,N,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO",Intermediate,,50594,,16438,2106.0,10090.0,Mus musculus,,CHEMBL627753,,,In vivo,,A,1,1,
Spleen,BAO_0000218,8481,N,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Intermediate,,50594,,16438,2106.0,10090.0,Mus musculus,,CHEMBL627754,,,In vivo,,A,1,1,
,BAO_0000218,8482,N,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells,Intermediate,,50594,,12467,,10090.0,Mus musculus,,CHEMBL627755,,,,,A,1,1,
Brain,BAO_0000218,8483,N,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,955.0,10090.0,Mus musculus,,CHEMBL627756,,,In vivo,,A,1,1,
Brain,BAO_0000218,8484,N,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,955.0,10090.0,Mus musculus,,CHEMBL627757,,,In vivo,,A,1,1,
Brain,BAO_0000218,8485,N,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,955.0,10090.0,Mus musculus,,CHEMBL627758,,,In vivo,,A,1,1,
Brain,BAO_0000218,8486,N,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,955.0,10090.0,Mus musculus,,CHEMBL627759,,,In vivo,,A,1,1,
Brain,BAO_0000218,8487,N,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,955.0,10090.0,Mus musculus,,CHEMBL627760,,,In vivo,,A,1,1,
Brain,BAO_0000218,8488,N,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,955.0,10090.0,Mus musculus,,CHEMBL627761,,,In vivo,,A,1,1,
Heart,BAO_0000218,8489,N,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,948.0,10090.0,Mus musculus,,CHEMBL876811,,,In vivo,,A,1,1,
Heart,BAO_0000218,8490,N,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,948.0,10090.0,Mus musculus,,CHEMBL627762,,,In vivo,,A,1,1,
Heart,BAO_0000218,8491,N,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,948.0,10090.0,Mus musculus,,CHEMBL627763,,,In vivo,,A,1,1,
Heart,BAO_0000218,8492,N,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,948.0,10090.0,Mus musculus,,CHEMBL627764,,,In vivo,,A,1,1,
Heart,BAO_0000218,8493,N,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,948.0,10090.0,Mus musculus,,CHEMBL627765,,,In vivo,,A,1,1,
Heart,BAO_0000218,8494,N,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,948.0,10090.0,Mus musculus,,CHEMBL627766,,,In vivo,,A,1,1,
Kidney,BAO_0000218,8495,N,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,2113.0,10090.0,Mus musculus,,CHEMBL627767,,,In vivo,,A,1,1,
Kidney,BAO_0000218,8496,N,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,2113.0,10090.0,Mus musculus,,CHEMBL627768,,,In vivo,,A,1,1,
Kidney,BAO_0000218,8497,N,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,2113.0,10090.0,Mus musculus,,CHEMBL628422,,,In vivo,,A,1,1,
Kidney,BAO_0000218,8498,N,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,2113.0,10090.0,Mus musculus,,CHEMBL628423,,,In vivo,,A,1,1,
,BAO_0000218,8499,N,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat,Intermediate,,50597,,5089,,10116.0,Rattus norvegicus,,CHEMBL628424,,,In vivo,,A,1,1,
,BAO_0000218,8500,N,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat,Intermediate,,50597,,5089,,10116.0,Rattus norvegicus,,CHEMBL628425,,,In vivo,,A,1,1,
,BAO_0000218,8501,N,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose,Intermediate,,50597,,4257,,10116.0,Rattus norvegicus,,CHEMBL628426,,,In vivo,,A,1,1,
,BAO_0000218,8502,N,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Intermediate,,50597,,6679,,10116.0,Rattus norvegicus,,CHEMBL628427,,,In vivo,,A,1,1,
,BAO_0000218,8503,N,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,Intermediate,,50597,,5546,,10116.0,Rattus norvegicus,,CHEMBL626938,,,In vivo,,A,1,1,
,BAO_0000218,8504,N,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,Intermediate,,50597,,6141,,10116.0,Rattus norvegicus,,CHEMBL626939,,,In vivo,,A,1,1,
,BAO_0000218,8505,N,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,Intermediate,,50597,,5334,,10116.0,Rattus norvegicus,,CHEMBL626940,,,In vivo,,A,1,1,
,BAO_0000218,8506,N,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,Intermediate,,50597,,5334,,10116.0,Rattus norvegicus,,CHEMBL626941,,,In vivo,,A,1,1,
,BAO_0000218,8507,N,Plasma clearance was reported in Sprague-Dawley rat,Intermediate,,50597,,5334,,10116.0,Rattus norvegicus,,CHEMBL626942,,,In vivo,,A,1,1,
,BAO_0000218,8508,N,Plasma clearance after intravenous administration (1 mg/kg) in rat,Intermediate,,50597,,4689,,10116.0,Rattus norvegicus,,CHEMBL876812,,,In vivo,,A,1,1,
,BAO_0000218,8509,N,Plasma clearance of compound in rats was evaluated,Intermediate,,50597,,6848,,10116.0,Rattus norvegicus,,CHEMBL626943,,,In vivo,,A,1,1,
,BAO_0000218,8510,N,Plasma clearance of compound in rats was evaluated; ND indicates not determined,Intermediate,,50597,,6848,,10116.0,Rattus norvegicus,,CHEMBL626944,,,In vivo,,A,1,1,
,BAO_0000218,8511,N,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration,Intermediate,,50597,,6467,,10116.0,Rattus norvegicus,,CHEMBL626945,,,In vivo,,A,1,1,
,BAO_0000218,8512,N,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,Intermediate,,50597,,6467,,10116.0,Rattus norvegicus,,CHEMBL626946,,,In vivo,,A,1,1,
,BAO_0000218,8513,N,Plasma clearance rate in Sprague-Dawley rats,Intermediate,,50597,,4956,,10116.0,Rattus norvegicus,,CHEMBL626856,,,In vivo,,A,1,1,
,BAO_0000218,8514,N,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg),Intermediate,,50597,,5529,,10116.0,Rattus norvegicus,,CHEMBL626857,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8515,N,The compound was evaluated for plasma clearance in rat,Intermediate,,50597,,406,1969.0,10116.0,Rattus norvegicus,,CHEMBL626858,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8516,N,Total plasma clearance in rat,Intermediate,,50597,,17655,1969.0,10116.0,Rattus norvegicus,,CHEMBL627018,,,In vivo,,A,1,1,
Blood,BAO_0000218,8517,N,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.,Intermediate,,50597,,3293,178.0,10116.0,Rattus norvegicus,,CHEMBL625331,,,In vivo,,A,1,1,
Blood,BAO_0000218,8518,N,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined,Intermediate,,50597,,4075,178.0,10116.0,Rattus norvegicus,,CHEMBL625332,,,In vivo,,A,1,1,
,BAO_0000218,8519,N,C max was determined at 10 mg/kg po dose in rats,Intermediate,,50597,,2792,,10116.0,Rattus norvegicus,,CHEMBL877590,,,In vivo,,A,1,1,
,BAO_0000218,8520,N,C max was determined at 3 mg/kg po dose in rats,Intermediate,,50597,,2792,,10116.0,Rattus norvegicus,,CHEMBL625333,,,In vivo,,A,1,1,
,BAO_0000218,8521,N,Cmax after repeated oral dose of compound at 1 mg/kg in rats,Intermediate,,50597,,17594,,10116.0,Rattus norvegicus,,CHEMBL625334,,,In vivo,,A,1,1,
,BAO_0000218,8522,N,Cmax after single intravenous bolus of 1 mg/kg in rats,Intermediate,,50597,,17594,,10116.0,Rattus norvegicus,,CHEMBL625335,,,In vivo,,A,1,1,
,BAO_0000218,8523,N,Cmax of compound at 5 mg/kg after po administration was determined in rat,Intermediate,,50597,,4762,,10116.0,Rattus norvegicus,,CHEMBL625336,,,In vivo,,A,1,1,
,BAO_0000218,8524,N,Cmax 24 hr after 10 mg/kg oral administration in rats,Intermediate,,50597,,17509,,10116.0,Rattus norvegicus,,CHEMBL625337,,,In vivo,,A,1,1,
,BAO_0000218,8525,N,Cmax 24 hr after 2 mg/kg oral administration in rats,Intermediate,,50597,,17509,,10116.0,Rattus norvegicus,,CHEMBL625338,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8526,N,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat,Intermediate,,50597,,1466,1969.0,10116.0,Rattus norvegicus,,CHEMBL625339,,,In vivo,,A,1,1,
,BAO_0000218,8527,N,Cmax in rat after administration of 2 mg/kg iv,Intermediate,,50597,,6535,,10116.0,Rattus norvegicus,,CHEMBL625340,,,In vivo,,A,1,1,
,BAO_0000218,8528,N,Cmax in rat after administration of 2 mg/kg iv,Intermediate,,50597,,6535,,10116.0,Rattus norvegicus,,CHEMBL625341,,,In vivo,,A,1,1,
,BAO_0000218,8529,N,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg,Intermediate,,50597,,3169,,10116.0,Rattus norvegicus,,CHEMBL622687,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8530,N,Cmax wa determined in rat plasma at 30 mg/kg after po administration,Intermediate,,50597,,6515,1969.0,10116.0,Rattus norvegicus,,CHEMBL622688,,,In vivo,,A,1,1,
Blood,BAO_0000218,8531,N,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats,Intermediate,,50597,,11149,178.0,10116.0,Rattus norvegicus,,CHEMBL622689,,,In vivo,,A,1,1,
Blood,BAO_0000218,8532,N,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats,Intermediate,,50597,,11149,178.0,10116.0,Rattus norvegicus,,CHEMBL620295,,,In vivo,,A,1,1,
,BAO_0000218,8533,N,Cmax after 10 mg/kg oral administration in rat,Intermediate,,50597,,17858,,10116.0,Rattus norvegicus,,CHEMBL620296,,,In vivo,,A,1,1,
,BAO_0000218,8534,N,Cmax after IV dosing at 0.5 mg/kg in rat; no data,Intermediate,,50597,,6518,,10116.0,Rattus norvegicus,,CHEMBL620297,,,In vivo,,A,1,1,
,BAO_0000218,8535,N,Cmax after IV dosing at 1 mg/kg in rat; no data,Intermediate,,50597,,6518,,10116.0,Rattus norvegicus,,CHEMBL620298,,,In vivo,,A,1,1,
,BAO_0000218,8536,N,Cmax after oral administration at 20 mpk in rats,Intermediate,,50597,,4426,,10116.0,Rattus norvegicus,,CHEMBL620299,,,In vivo,,A,1,1,
,BAO_0000218,8537,N,Cmax after oral administration at 20 mpk in rats; Not performed.,Intermediate,,50597,,4426,,10116.0,Rattus norvegicus,,CHEMBL620300,,,In vivo,,A,1,1,
,BAO_0000218,8538,N,Cmax after oral administration at 20 mpk in rats d; Not performed.,Intermediate,,50597,,4426,,10116.0,Rattus norvegicus,,CHEMBL620301,,,In vivo,,A,1,1,
,BAO_0000218,8539,N,Cmax after oral administration in rat,Intermediate,,50597,,5656,,10116.0,Rattus norvegicus,,CHEMBL620302,,,In vivo,,A,1,1,
,BAO_0000218,8540,N,Cmax after oral administration at a dose of 2 mg/kg in rat,Intermediate,,50597,,6518,,10116.0,Rattus norvegicus,,CHEMBL620303,,,In vivo,,A,1,1,
,BAO_0000218,8541,N,Cmax after oral administration at a dose of 4 mg/kg in rat,Intermediate,,50597,,6518,,10116.0,Rattus norvegicus,,CHEMBL620304,,,In vivo,,A,1,1,
,BAO_0000218,8542,N,Cmax in rats after 20 mg/kg oral dose,Intermediate,,50597,,6113,,10116.0,Rattus norvegicus,,CHEMBL620305,,,In vivo,,A,1,1,
,BAO_0000218,8543,N,Cmax after peroral administration in rats at 2.4 uM/kg,Intermediate,,50597,,17764,,10116.0,Rattus norvegicus,,CHEMBL620306,,,In vivo,,A,1,1,
,BAO_0000218,8544,N,Cmax at the dose of 2 mg/Kg administered perorally in rats,Intermediate,,50597,,4756,,10116.0,Rattus norvegicus,,CHEMBL620307,,,In vivo,,A,1,1,
,BAO_0000218,8545,N,Cmax at the dose of 5 mg/Kg administered perorally in rats,Intermediate,,50597,,4756,,10116.0,Rattus norvegicus,,CHEMBL620308,,,In vivo,,A,1,1,
,BAO_0000218,8546,N,Cmax by administering at 20 mg/kg p.o. in rats,Intermediate,,50597,,6402,,10116.0,Rattus norvegicus,,CHEMBL620309,,,In vivo,,A,1,1,
,BAO_0000218,8547,N,Cmax in male rat,Intermediate,,50597,,5610,,10116.0,Rattus norvegicus,,CHEMBL620310,,,In vivo,,A,1,1,
,BAO_0000218,8548,N,Cmax in rat,Intermediate,,50597,,5207,,10116.0,Rattus norvegicus,,CHEMBL620311,,,In vivo,,A,1,1,
,BAO_0000218,8549,N,Cmax in rat,Intermediate,,50597,,6011,,10116.0,Rattus norvegicus,,CHEMBL620312,,,In vivo,,A,1,1,
,BAO_0000218,8550,N,Cmax in rat,Intermediate,,50597,,6504,,10116.0,Rattus norvegicus,,CHEMBL620313,,,In vivo,,A,1,1,
,BAO_0000218,8551,N,Cmax in rat at 10 mg/kg,Intermediate,,50597,,6046,,10116.0,Rattus norvegicus,,CHEMBL620314,,,In vivo,,A,1,1,
,BAO_0000218,8552,N,Cmax in rat at the dose of 1 mg/kg i.v.,Intermediate,,50597,,6504,,10116.0,Rattus norvegicus,,CHEMBL620315,,,In vivo,,A,1,1,
,BAO_0000218,8553,N,Cmax in rat by po administration at a dose of 40 mg/kg,Intermediate,,50597,,5874,,10116.0,Rattus norvegicus,,CHEMBL620316,,,In vivo,,A,1,1,
,BAO_0000218,8554,N,Cmax in rat p.o. at 20 mg/kg concentration,Intermediate,,50597,,17686,,10116.0,Rattus norvegicus,,CHEMBL620317,,,In vivo,,A,1,1,
,BAO_0000218,8555,N,Cmax in rats,Intermediate,,50597,,5836,,10116.0,Rattus norvegicus,,CHEMBL620318,,,In vivo,,A,1,1,
,BAO_0000218,8556,N,Cmax in rats,Intermediate,,50597,,17596,,10116.0,Rattus norvegicus,,CHEMBL620319,,,In vivo,,A,1,1,
,BAO_0000218,8557,N,Cmax was evaluated after 20 uM/kg of peroral administration,Intermediate,,50597,,16423,,10116.0,Rattus norvegicus,,CHEMBL620320,,,In vivo,,A,1,1,
,BAO_0000218,8558,N,Cmax was measured in rats after peroral administration at 3 mg/kg,Intermediate,,50597,,17804,,10116.0,Rattus norvegicus,,CHEMBL620321,,,In vivo,,A,1,1,
,BAO_0000218,8559,N,Cmax value after oral dose at a dose of 10 mg/kg in rats.,Intermediate,,50597,,1908,,10116.0,Rattus norvegicus,,CHEMBL620322,,,In vivo,,A,1,1,
,BAO_0000218,8560,N,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,,10116.0,Rattus norvegicus,,CHEMBL620323,,,,,A,1,1,
Frontal cortex,BAO_0000218,8561,N,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,1870.0,10116.0,Rattus norvegicus,,CHEMBL620324,,,,,A,1,1,
Frontal cortex,BAO_0000218,8562,N,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,1870.0,10116.0,Rattus norvegicus,,CHEMBL620325,,,,,A,1,1,
Hippocampus,BAO_0000218,8563,N,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,10000000.0,10116.0,Rattus norvegicus,,CHEMBL620326,,,,,A,1,1,
Hippocampus,BAO_0000218,8564,N,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,10000000.0,10116.0,Rattus norvegicus,,CHEMBL620327,,,,,A,1,1,
,BAO_0000218,8565,N,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,,10116.0,Rattus norvegicus,,CHEMBL620328,,,,,A,1,1,
,BAO_0000218,8566,N,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,,10116.0,Rattus norvegicus,,CHEMBL620329,,,,,A,1,1,
Midbrain,BAO_0000218,8567,N,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,1891.0,10116.0,Rattus norvegicus,,CHEMBL620330,,,,,A,1,1,
Midbrain,BAO_0000218,8568,N,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,1891.0,10116.0,Rattus norvegicus,,CHEMBL875286,,,,,A,1,1,
,BAO_0000218,8569,N,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,,10116.0,Rattus norvegicus,,CHEMBL620331,,,,,A,1,1,
,BAO_0000218,8570,N,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,,10116.0,Rattus norvegicus,,CHEMBL620332,,,,,A,1,1,
Striatum,BAO_0000218,8571,N,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,2435.0,10116.0,Rattus norvegicus,,CHEMBL620333,,,,,A,1,1,
Striatum,BAO_0000218,8572,N,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue,Intermediate,,50597,,13950,2435.0,10116.0,Rattus norvegicus,,CHEMBL620334,,,,,A,1,1,
Blood,BAO_0000218,8573,N,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,,50597,,16434,178.0,10116.0,Rattus norvegicus,,CHEMBL621015,,,,,A,1,1,
Blood,BAO_0000218,8574,N,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Intermediate,,50597,,16434,178.0,10116.0,Rattus norvegicus,,CHEMBL621016,,,,,A,1,1,
Blood,BAO_0000218,8575,N,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,,50597,,16434,178.0,10116.0,Rattus norvegicus,,CHEMBL621191,,,,,A,1,1,
Blood,BAO_0000218,8576,N,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,,50597,,16434,178.0,10116.0,Rattus norvegicus,,CHEMBL621192,,,,,A,1,1,
Blood,BAO_0000218,8577,N,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Intermediate,,50597,,16434,178.0,10116.0,Rattus norvegicus,,CHEMBL621193,,,,,A,1,1,
Blood,BAO_0000218,8578,N,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Intermediate,,50597,,16434,178.0,10116.0,Rattus norvegicus,,CHEMBL621194,,,,,A,1,1,
Blood,BAO_0000218,8579,N,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Intermediate,,50597,,16434,178.0,10116.0,Rattus norvegicus,,CHEMBL624204,,,,,A,1,1,
Blood,BAO_0000218,8580,N,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Intermediate,,50597,,16434,178.0,10116.0,Rattus norvegicus,,CHEMBL624205,,,,,A,1,1,
Blood,BAO_0000218,8581,N,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Intermediate,,50597,,16435,178.0,10116.0,Rattus norvegicus,,CHEMBL624206,,,,,A,1,1,
Blood,BAO_0000218,8582,N,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Intermediate,,50597,,16435,178.0,10116.0,Rattus norvegicus,,CHEMBL624207,,,,,A,1,1,
Blood,BAO_0000218,8583,N,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Intermediate,,50597,,16435,178.0,10116.0,Rattus norvegicus,,CHEMBL624208,,,,,A,1,1,
Blood,BAO_0000218,8584,N,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Intermediate,,50597,,16435,178.0,10116.0,Rattus norvegicus,,CHEMBL624209,,,,,A,1,1,
Blood,BAO_0000218,8585,N,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Intermediate,,50597,,16435,178.0,10116.0,Rattus norvegicus,,CHEMBL624210,,,,,A,1,1,
Blood,BAO_0000218,8586,N,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Intermediate,,50597,,16435,178.0,10116.0,Rattus norvegicus,,CHEMBL624211,,,,,A,1,1,
Blood,BAO_0000218,8587,N,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Intermediate,,50597,,16435,178.0,10116.0,Rattus norvegicus,,CHEMBL624212,,,,,A,1,1,
Blood,BAO_0000218,8588,N,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Intermediate,,50597,,16435,178.0,10116.0,Rattus norvegicus,,CHEMBL624213,,,,,A,1,1,
Blood,BAO_0000218,8589,N,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Intermediate,,50597,,16434,178.0,10116.0,Rattus norvegicus,,CHEMBL876611,,,,,A,1,1,
Blood,BAO_0000218,8590,N,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Intermediate,,50597,,16434,178.0,10116.0,Rattus norvegicus,,CHEMBL624214,,,,,A,1,1,
Blood,BAO_0000218,8591,N,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Intermediate,,50597,,16434,178.0,10116.0,Rattus norvegicus,,CHEMBL624215,,,,,A,1,1,
Blood,BAO_0000218,8592,N,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,,50597,,16435,178.0,10116.0,Rattus norvegicus,,CHEMBL624216,,,,,A,1,1,
Blood,BAO_0000218,8593,N,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,,50597,,16435,178.0,10116.0,Rattus norvegicus,,CHEMBL624217,,,,,A,1,1,
Blood,BAO_0000218,8594,N,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,,50597,,16435,178.0,10116.0,Rattus norvegicus,,CHEMBL624218,,,,,A,1,1,
Blood,BAO_0000218,8595,N,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,,50597,,16435,178.0,10116.0,Rattus norvegicus,,CHEMBL624219,,,,,A,1,1,
Blood,BAO_0000218,8596,N,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,,50597,,16435,178.0,10116.0,Rattus norvegicus,,CHEMBL624220,,,,,A,1,1,
Blood,BAO_0000218,8597,N,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,,50597,,16435,178.0,10116.0,Rattus norvegicus,,CHEMBL624221,,,,,A,1,1,
,BAO_0000218,8598,N,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,,50597,,16434,,10116.0,Rattus norvegicus,,CHEMBL624222,,,,,A,1,1,
,BAO_0000218,8599,N,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Intermediate,,50597,,16434,,10116.0,Rattus norvegicus,,CHEMBL624223,,,,,A,1,1,
,BAO_0000218,8600,N,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,,50597,,16434,,10116.0,Rattus norvegicus,,CHEMBL624224,,,,,A,1,1,
,BAO_0000218,8601,N,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,,50597,,16434,,10116.0,Rattus norvegicus,,CHEMBL624225,,,,,A,1,1,
,BAO_0000218,8602,N,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg,Intermediate,,50597,,17764,,10116.0,Rattus norvegicus,,CHEMBL622420,,,In vivo,,A,1,1,
,BAO_0000218,8603,N,Volume of steady state distribution after i.v. administration in rats,Intermediate,,50597,,5031,,10116.0,Rattus norvegicus,,CHEMBL622421,,,In vivo,,A,1,1,
,BAO_0000218,8604,N,Vss after intravenous administration (5.0 mg/kg) was determined in rat,Intermediate,,50597,,6215,,10116.0,Rattus norvegicus,,CHEMBL622422,,,In vivo,,A,1,1,
,BAO_0000218,8605,N,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,Intermediate,,50597,,17671,,10116.0,Rattus norvegicus,,CHEMBL622423,,,In vivo,,A,1,1,
,BAO_0000218,8606,N,Vss was determined,Intermediate,,50597,,17752,,10116.0,Rattus norvegicus,,CHEMBL622424,,,In vivo,,A,1,1,
,BAO_0000218,8607,N,Vss in rat,Intermediate,,50597,,6596,,10116.0,Rattus norvegicus,,CHEMBL622425,,,In vivo,,A,1,1,
,BAO_0000218,8608,N,Vss was evaluated after 10 uM/kg of intra arterial administration,Intermediate,,50597,,16423,,10116.0,Rattus norvegicus,,CHEMBL876612,,,In vivo,,A,1,1,
,BAO_0000218,8609,N,volume of distribution at steady state was observed after intravenous administration in rat,Intermediate,,50597,,15662,,10116.0,Rattus norvegicus,,CHEMBL622426,,,In vivo,,A,1,1,
,BAO_0000218,8610,N,Volume of distribution was measured in rat after an iv dose of 1 mg/kg,Intermediate,,50597,,6062,,10116.0,Rattus norvegicus,,CHEMBL622427,,,In vivo,,A,1,1,
,BAO_0000218,8611,N,Pharmacokinetic (PK) parameter Vz in rat,Intermediate,,50597,,5874,,10116.0,Rattus norvegicus,,CHEMBL622428,,,In vivo,,A,1,1,
,BAO_0000218,8612,N,Volume distribution in rats,Intermediate,,50597,,4942,,10116.0,Rattus norvegicus,,CHEMBL622429,,,In vivo,,A,1,1,
,BAO_0000218,8613,N,Volume of distribution in rat; No data,Intermediate,,50597,,17796,,10116.0,Rattus norvegicus,,CHEMBL622430,,,In vivo,,A,1,1,
,BAO_0000218,8614,N,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,Intermediate,,50597,,4890,,10116.0,Rattus norvegicus,,CHEMBL622431,,,In vivo,,A,1,1,
Ileum,BAO_0000218,8615,N,% absorption predicted from in vitro rat ileum transport studies,Intermediate,,50597,,15765,2116.0,10116.0,Rattus norvegicus,,CHEMBL622432,,,,,A,1,1,
,BAO_0000218,8616,N,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,Intermediate,,50597,,13569,,10116.0,Rattus norvegicus,,CHEMBL622433,,,In vivo,,A,1,1,
,BAO_0000218,8617,N,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,Intermediate,,50597,,13569,,10116.0,Rattus norvegicus,,CHEMBL622434,,,In vivo,,A,1,1,
,BAO_0000218,8618,N,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg,Intermediate,,50597,,13569,,10116.0,Rattus norvegicus,,CHEMBL622435,,,In vivo,,A,1,1,
,BAO_0000218,8619,N,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.),Intermediate,,50597,,13569,,10116.0,Rattus norvegicus,,CHEMBL618748,,,In vivo,,A,1,1,
,BAO_0000218,8620,N,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,Intermediate,,50597,,13569,,10116.0,Rattus norvegicus,,CHEMBL618749,,,In vivo,,A,1,1,
,BAO_0000218,8621,N,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,Intermediate,,50597,,13569,,10116.0,Rattus norvegicus,,CHEMBL618750,,,In vivo,,A,1,1,
,BAO_0000218,8622,N,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,Intermediate,,50597,,13569,,10116.0,Rattus norvegicus,,CHEMBL618751,,,In vivo,,A,1,1,
,BAO_0000218,8623,N,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,Intermediate,,50597,,13569,,10116.0,Rattus norvegicus,,CHEMBL618752,,,In vivo,,A,1,1,
,BAO_0000218,8624,N,Oral bioavailability in rat,Intermediate,,50597,,4576,,10116.0,Rattus norvegicus,,CHEMBL618753,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8625,N,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations,Intermediate,,50597,,750,1969.0,10116.0,Rattus norvegicus,,CHEMBL618754,,,In vivo,,A,1,1,
,BAO_0000218,8626,N,Oral bioavailability in rat,Intermediate,,50597,,750,,10116.0,Rattus norvegicus,,CHEMBL618755,,,In vivo,,A,1,1,
,BAO_0000218,8627,N,Oral bioavailability in rat,Intermediate,,50597,,4590,,10116.0,Rattus norvegicus,,CHEMBL618756,,,In vivo,,A,1,1,
,BAO_0000218,8628,N,Oral bioavailability in rat,Intermediate,,50597,,1716,,10116.0,Rattus norvegicus,,CHEMBL618757,,,In vivo,,A,1,1,
,BAO_0000218,8629,N,Bioavailability in rat,Intermediate,,50597,,1974,,10116.0,Rattus norvegicus,,CHEMBL618758,,,In vivo,,A,1,1,
,BAO_0000218,8630,N,Oral bioavailability in rat (dose 30 mg/kg),Intermediate,,50597,,4502,,10116.0,Rattus norvegicus,,CHEMBL621088,,,In vivo,,A,1,1,
,BAO_0000218,8631,N,Pharmacokinetic property (cLogP) in rat,Intermediate,,50597,,3371,,10116.0,Rattus norvegicus,,CHEMBL621089,,,,,A,1,1,
Blood,BAO_0000218,8632,N,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally,Intermediate,,50597,,9099,178.0,10116.0,Rattus norvegicus,,CHEMBL621090,,,,,F,1,1,
Blood,BAO_0000218,8633,N,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally,Intermediate,,50597,,9099,178.0,10116.0,Rattus norvegicus,,CHEMBL621091,,,,,F,1,1,
,BAO_0000218,8634,N,Clearance in rat.,Intermediate,,50597,,4590,,10116.0,Rattus norvegicus,,CHEMBL876731,,,In vivo,,A,1,1,
,BAO_0000218,8635,N,Compound was evaluated for its clearance when administered intravenously in rat,Intermediate,,50597,,3184,,10116.0,Rattus norvegicus,,CHEMBL621092,,,In vivo,,A,1,1,
,BAO_0000218,8636,N,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,Intermediate,,50597,,16456,,10116.0,Rattus norvegicus,,CHEMBL621093,,,In vivo,,A,1,1,
,BAO_0000218,8637,N,Blood: Brain distribution ratio is determined in rat,Intermediate,,50597,,4199,,10116.0,Rattus norvegicus,,CHEMBL621094,,,,,A,1,1,
,BAO_0000218,8638,N,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable,Intermediate,,50597,,4199,,10116.0,Rattus norvegicus,,CHEMBL621095,,,,,A,1,1,
,BAO_0000218,8639,N,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable,Intermediate,,50597,,4199,,10116.0,Rattus norvegicus,,CHEMBL621096,,,,,A,1,1,
Kidney,BAO_0000218,8640,N,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,50597,,8677,2113.0,10116.0,Rattus norvegicus,,CHEMBL621097,,,In vivo,,A,1,1,
,BAO_0000218,8641,N,Percent dose excreted in 0-48 hours administered ip to male rat,Intermediate,,50597,,7449,,10116.0,Rattus norvegicus,,CHEMBL621098,,,,,F,1,1,
Cerebellum,BAO_0000218,8642,N,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,2037.0,10116.0,Rattus norvegicus,,CHEMBL621099,,,,,A,1,1,
Cerebellum,BAO_0000218,8643,N,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,2037.0,10116.0,Rattus norvegicus,,CHEMBL621100,,,,,A,1,1,
Cerebellum,BAO_0000218,8644,N,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,,50597,,11977,2037.0,10116.0,Rattus norvegicus,,CHEMBL621101,,,,,A,1,1,
Cerebellum,BAO_0000218,8645,N,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,2037.0,10116.0,Rattus norvegicus,,CHEMBL621102,,,,,A,1,1,
Cerebellum,BAO_0000218,8646,N,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,2037.0,10116.0,Rattus norvegicus,,CHEMBL876732,,,,,A,1,1,
,BAO_0000218,8647,N,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,,10116.0,Rattus norvegicus,,CHEMBL621103,,,,,A,1,1,
,BAO_0000218,8648,N,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,,10116.0,Rattus norvegicus,,CHEMBL621104,,,,,A,1,1,
,BAO_0000218,8649,N,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,,50597,,11977,,10116.0,Rattus norvegicus,,CHEMBL621105,,,,,A,1,1,
,BAO_0000218,8650,N,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,,10116.0,Rattus norvegicus,,CHEMBL621106,,,,,A,1,1,
,BAO_0000218,8651,N,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,,10116.0,Rattus norvegicus,,CHEMBL621107,,,,,A,1,1,
,BAO_0000218,8652,N,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,,10116.0,Rattus norvegicus,,CHEMBL621108,,,,,A,1,1,
,BAO_0000218,8653,N,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,,10116.0,Rattus norvegicus,,CHEMBL621109,,,,,A,1,1,
Kidney,BAO_0000218,8654,N,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,2113.0,10090.0,Mus musculus,,CHEMBL621110,,,In vivo,,A,1,1,
Kidney,BAO_0000218,8655,N,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,2113.0,10090.0,Mus musculus,,CHEMBL621111,,,In vivo,,A,1,1,
Liver,BAO_0000218,8656,N,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,2107.0,10090.0,Mus musculus,,CHEMBL622541,,,In vivo,,A,1,1,
Liver,BAO_0000218,8657,N,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,2107.0,10090.0,Mus musculus,,CHEMBL622542,,,In vivo,,A,1,1,
Liver,BAO_0000218,8658,N,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,2107.0,10090.0,Mus musculus,,CHEMBL622543,,,In vivo,,A,1,1,
Liver,BAO_0000218,8659,N,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,2107.0,10090.0,Mus musculus,,CHEMBL624412,,,In vivo,,A,1,1,
Liver,BAO_0000218,8660,N,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,2107.0,10090.0,Mus musculus,,CHEMBL624413,,,In vivo,,A,1,1,
Liver,BAO_0000218,8661,N,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,2107.0,10090.0,Mus musculus,,CHEMBL624414,,,In vivo,,A,1,1,
Lung,BAO_0000218,8662,N,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,2048.0,10090.0,Mus musculus,,CHEMBL624415,,,In vivo,,A,1,1,
Lung,BAO_0000218,8663,N,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,2048.0,10090.0,Mus musculus,,CHEMBL624416,,,In vivo,,A,1,1,
Lung,BAO_0000218,8664,N,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,2048.0,10090.0,Mus musculus,,CHEMBL624417,,,In vivo,,A,1,1,
Lung,BAO_0000218,8665,N,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,2048.0,10090.0,Mus musculus,,CHEMBL624418,,,In vivo,,A,1,1,
Lung,BAO_0000218,8666,N,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,2048.0,10090.0,Mus musculus,,CHEMBL624419,,,In vivo,,A,1,1,
Lung,BAO_0000218,8667,N,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,2048.0,10090.0,Mus musculus,,CHEMBL624420,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,8668,N,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,2385.0,10090.0,Mus musculus,,CHEMBL624421,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,8669,N,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,2385.0,10090.0,Mus musculus,,CHEMBL624422,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,8670,N,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,2385.0,10090.0,Mus musculus,,CHEMBL624423,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,8671,N,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,2385.0,10090.0,Mus musculus,,CHEMBL625123,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,8672,N,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,2385.0,10090.0,Mus musculus,,CHEMBL625124,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,8673,N,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,2385.0,10090.0,Mus musculus,,CHEMBL625125,,,In vivo,,A,1,1,
Zone of skin,BAO_0000218,8674,N,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,14.0,10090.0,Mus musculus,,CHEMBL625126,,,In vivo,,A,1,1,
Zone of skin,BAO_0000218,8675,N,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,14.0,10090.0,Mus musculus,,CHEMBL626947,,,In vivo,,A,1,1,
Zone of skin,BAO_0000218,8676,N,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,14.0,10090.0,Mus musculus,,CHEMBL626948,,,In vivo,,A,1,1,
Zone of skin,BAO_0000218,8677,N,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,14.0,10090.0,Mus musculus,,CHEMBL626949,,,In vivo,,A,1,1,
Zone of skin,BAO_0000218,8678,N,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,14.0,10090.0,Mus musculus,,CHEMBL626950,,,In vivo,,A,1,1,
Zone of skin,BAO_0000218,8679,N,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,14.0,10090.0,Mus musculus,,CHEMBL626951,,,In vivo,,A,1,1,
Spleen,BAO_0000218,8680,N,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,2106.0,10090.0,Mus musculus,,CHEMBL626952,,,In vivo,,A,1,1,
Spleen,BAO_0000218,8681,N,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,2106.0,10090.0,Mus musculus,,CHEMBL626953,,,In vivo,,A,1,1,
Spleen,BAO_0000218,8682,N,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,2106.0,10090.0,Mus musculus,,CHEMBL626954,,,In vivo,,A,1,1,
Spleen,BAO_0000218,8683,N,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,2106.0,10090.0,Mus musculus,,CHEMBL626955,,,In vivo,,A,1,1,
Spleen,BAO_0000218,8684,N,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,2106.0,10090.0,Mus musculus,,CHEMBL626956,,,In vivo,,A,1,1,
Spleen,BAO_0000218,8685,N,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,2106.0,10090.0,Mus musculus,,CHEMBL626957,,,In vivo,,A,1,1,
Blood,BAO_0000218,8686,N,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,178.0,10090.0,Mus musculus,,CHEMBL626958,,,In vivo,,A,1,1,
Blood,BAO_0000218,8687,N,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,178.0,10090.0,Mus musculus,,CHEMBL626959,,,In vivo,,A,1,1,
Blood,BAO_0000218,8688,N,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,178.0,10090.0,Mus musculus,,CHEMBL626960,,,In vivo,,A,1,1,
Blood,BAO_0000218,8689,N,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,178.0,10090.0,Mus musculus,,CHEMBL626961,,,In vivo,,A,1,1,
Blood,BAO_0000218,8690,N,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,178.0,10090.0,Mus musculus,,CHEMBL627589,,,In vivo,,A,1,1,
Blood,BAO_0000218,8691,N,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY),Intermediate,,50594,,17208,178.0,10090.0,Mus musculus,,CHEMBL627590,,,In vivo,,A,1,1,
,BAO_0000218,8692,N,Time taken for EC90 was determined when tested in mouse,Intermediate,,50594,,3132,,10090.0,Mus musculus,,CHEMBL627591,,,,,A,1,1,
,BAO_0000218,8693,N,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg,Intermediate,,50594,,3132,,10090.0,Mus musculus,,CHEMBL627592,,,,,A,1,1,
,BAO_0000218,8694,N,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),Intermediate,,50594,,16597,,10090.0,Mus musculus,,CHEMBL627593,,,In vivo,,A,1,1,
,BAO_0000218,8695,N,Half life in mice,Intermediate,,50594,,5727,,10090.0,Mus musculus,,CHEMBL627594,,,,,A,1,1,
,BAO_0000218,8696,N,Half life period in mouse after 10 mg/Kg dose,Intermediate,,50594,,5302,,10090.0,Mus musculus,,CHEMBL876813,,,In vivo,,A,1,1,
,BAO_0000218,8697,N,Half life period in mouse after 10 mg/kg dose,Intermediate,,50594,,5302,,10090.0,Mus musculus,,CHEMBL627595,,,In vivo,,A,1,1,
,BAO_0000218,8698,N,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Intermediate,,50594,,6348,,10090.0,Mus musculus,,CHEMBL627596,,,In vivo,,A,1,1,
,BAO_0000218,8699,N,Cmax value at 5 mg/kg po was determined in rat,Intermediate,,50597,,5964,,10116.0,Rattus norvegicus,,CHEMBL627597,,,In vivo,,A,1,1,
,BAO_0000218,8700,N,Cmax value evaluated in rat,Intermediate,,50597,,6078,,10116.0,Rattus norvegicus,,CHEMBL627598,,,In vivo,,A,1,1,
Brain,BAO_0000218,8701,N,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain,Intermediate,,50597,,5206,955.0,10116.0,Rattus norvegicus,,CHEMBL627599,,,In vivo,,A,1,1,
,BAO_0000218,8702,N,Cmax value after administration of 20 mg/Kg oral dose in rat,Intermediate,,50597,,2959,,10116.0,Rattus norvegicus,,CHEMBL627600,,,In vivo,,A,1,1,
,BAO_0000218,8703,N,Cmax value at 1 mg/kg po in rat,Intermediate,,50597,,5964,,10116.0,Rattus norvegicus,,CHEMBL627601,,,In vivo,,A,1,1,
,BAO_0000218,8704,N,Cmax value at 5 mg/kg po in rat,Intermediate,,50597,,5964,,10116.0,Rattus norvegicus,,CHEMBL627776,,,In vivo,,A,1,1,
,BAO_0000218,8705,N,Cmax value at a dose of 10 mg/kg in male SD rats,Intermediate,,50597,,6757,,10116.0,Rattus norvegicus,,CHEMBL627777,,,In vivo,,A,1,1,
,BAO_0000218,8706,N,Cmax value at a dose of 100 mg/kg in male SD rats,Intermediate,,50597,,6757,,10116.0,Rattus norvegicus,,CHEMBL627778,,,In vivo,,A,1,1,
,BAO_0000218,8707,N,Cmax value at a dose of 50 mg/kg in male SD rats,Intermediate,,50597,,6757,,10116.0,Rattus norvegicus,,CHEMBL627779,,,In vivo,,A,1,1,
,BAO_0000218,8708,N,Cmax value in rats at 10 mg/kg,Intermediate,,50597,,17617,,10116.0,Rattus norvegicus,,CHEMBL876814,,,In vivo,,A,1,1,
,BAO_0000218,8709,N,Cmax value was evaluated in rats at a dose of 20 mg/kg,Intermediate,,50597,,1445,,10116.0,Rattus norvegicus,,CHEMBL627780,,,In vivo,,A,1,1,
,BAO_0000218,8710,N,Cmax value was determined after peroral administration of 20 mg/kg in rat,Intermediate,,50597,,6082,,10116.0,Rattus norvegicus,,CHEMBL627781,,,In vivo,,A,1,1,
,BAO_0000218,8711,N,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,Intermediate,,50597,,1446,,10116.0,Rattus norvegicus,,CHEMBL627782,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8712,N,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats,Intermediate,,50597,,5407,1969.0,10116.0,Rattus norvegicus,,CHEMBL627783,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8713,N,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration,Intermediate,,50597,,2690,1969.0,10116.0,Rattus norvegicus,,CHEMBL627784,,,In vivo,,A,1,1,
,BAO_0000218,8714,N,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats,Intermediate,,50597,,2661,,10116.0,Rattus norvegicus,,CHEMBL627785,,,In vivo,,A,1,1,
,BAO_0000218,8715,N,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats,Intermediate,,50597,,2661,,10116.0,Rattus norvegicus,,CHEMBL627786,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8716,N,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration,Intermediate,,50597,,4891,1969.0,10116.0,Rattus norvegicus,,CHEMBL627787,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8717,N,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr,Intermediate,,50597,,2807,1969.0,10116.0,Rattus norvegicus,,CHEMBL627788,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8718,N,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr,Intermediate,,50597,,2807,1969.0,10116.0,Rattus norvegicus,,CHEMBL626579,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8719,N,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr,Intermediate,,50597,,2807,1969.0,10116.0,Rattus norvegicus,,CHEMBL626580,,,In vivo,,A,1,1,
,BAO_0000218,8720,N,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg,Intermediate,,50597,,3634,,10116.0,Rattus norvegicus,,CHEMBL876815,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8721,N,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr,Intermediate,,50597,,1881,1969.0,10116.0,Rattus norvegicus,,CHEMBL626581,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8722,N,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr,Intermediate,,50597,,1881,1969.0,10116.0,Rattus norvegicus,,CHEMBL626582,,,In vivo,,A,1,1,
,BAO_0000218,8723,N,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg,Intermediate,,50597,,429,,10116.0,Rattus norvegicus,,CHEMBL626583,,,In vivo,,A,1,1,
,BAO_0000218,8724,N,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,Intermediate,,50597,,5974,,10116.0,Rattus norvegicus,,CHEMBL626205,,,In vivo,,A,1,1,
,BAO_0000218,8725,N,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,Intermediate,,50597,,5974,,10116.0,Rattus norvegicus,,CHEMBL626206,,,In vivo,,A,1,1,
,BAO_0000218,8726,N,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,Intermediate,,50597,,5974,,10116.0,Rattus norvegicus,,CHEMBL626207,,,In vivo,,A,1,1,
,BAO_0000218,8727,N,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,Intermediate,,50597,,5974,,10116.0,Rattus norvegicus,,CHEMBL623882,,,In vivo,,A,1,1,
,BAO_0000218,8728,N,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose,Intermediate,,50597,,17582,,10116.0,Rattus norvegicus,,CHEMBL623883,,,In vivo,,A,1,1,
,BAO_0000218,8729,N,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose,Intermediate,,50597,,17582,,10116.0,Rattus norvegicus,,CHEMBL623884,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8730,N,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",Intermediate,,50597,,3032,1969.0,10116.0,Rattus norvegicus,,CHEMBL623885,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8731,N,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg,Intermediate,,50597,,6295,1969.0,10116.0,Rattus norvegicus,,CHEMBL623886,,,In vivo,,A,1,1,
,BAO_0000218,8732,N,Maximal concentration in rat was determined,Intermediate,,50597,,6619,,10116.0,Rattus norvegicus,,CHEMBL623887,,,In vivo,,A,1,1,
,BAO_0000218,8733,N,Maximal concentration after i.v. administration,Intermediate,,50597,,6616,,10116.0,Rattus norvegicus,,CHEMBL623888,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8734,N,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg,Intermediate,,50597,,3249,1969.0,10116.0,Rattus norvegicus,,CHEMBL623889,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8735,N,Maximal plasma concentration in rat after oral administration at 50 mg/kg,Intermediate,,50597,,17791,1969.0,10116.0,Rattus norvegicus,,CHEMBL623890,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8736,N,Cmax in rat plasma after oral dose (50 mg/Kg),Intermediate,,50597,,17791,1969.0,10116.0,Rattus norvegicus,,CHEMBL623891,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8737,N,Maximal plasma concentration was determined.,Intermediate,,50597,,1360,1969.0,10116.0,Rattus norvegicus,,CHEMBL623892,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8738,N,Maximal plasma drug concentration was determined,Intermediate,,50597,,2552,1969.0,10116.0,Rattus norvegicus,,CHEMBL623893,,,In vivo,,A,1,1,
,BAO_0000218,8739,N,Maximal concentration in rats after peroral administration,Intermediate,,50597,,6571,,10116.0,Rattus norvegicus,,CHEMBL877616,,,In vivo,,A,1,1,
,BAO_0000218,8740,N,Maximum concentration in rat after 2 mg/kg peroral administration,Intermediate,,50597,,6570,,10116.0,Rattus norvegicus,,CHEMBL623894,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8741,N,Maximum concentration in rat plasma after 5 mg/kg oral gavage,Intermediate,,50597,,6567,1969.0,10116.0,Rattus norvegicus,,CHEMBL623895,,,In vivo,,A,1,1,
,BAO_0000218,8742,N,Maximum concentration of compound in rat was evaluated.,Intermediate,,50597,,3031,,10116.0,Rattus norvegicus,,CHEMBL623896,,,In vivo,,A,1,1,
,BAO_0000218,8743,N,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats,Intermediate,,50597,,3436,,10116.0,Rattus norvegicus,,CHEMBL623897,,,In vivo,,A,1,1,
,BAO_0000218,8744,N,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats,Intermediate,,50597,,3436,,10116.0,Rattus norvegicus,,CHEMBL623898,,,In vivo,,A,1,1,
,BAO_0000218,8745,N,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat,Intermediate,,50597,,2083,,10116.0,Rattus norvegicus,,CHEMBL623899,,,In vivo,,A,1,1,
,BAO_0000218,8746,N,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats,Intermediate,,50597,,3436,,10116.0,Rattus norvegicus,,CHEMBL623900,,,In vivo,,A,1,1,
,BAO_0000218,8747,N,Maximum concentration by oral administration at a dose of 100 uM/kg in rat was determined,Intermediate,,50597,,4527,,10116.0,Rattus norvegicus,,CHEMBL623901,,,In vivo,,A,1,1,
,BAO_0000218,8748,N,Maximum concentration was evaluated in rats,Intermediate,,50597,,1974,,10116.0,Rattus norvegicus,,CHEMBL623902,,,In vivo,,A,1,1,
Cerebrospinal fluid,BAO_0000218,8749,N,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats,Intermediate,,50597,,3307,1359.0,10116.0,Rattus norvegicus,,CHEMBL623903,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8750,N,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats,Intermediate,,50597,,3307,1969.0,10116.0,Rattus norvegicus,,CHEMBL623904,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8751,N,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,Intermediate,,50597,,1916,1969.0,10116.0,Rattus norvegicus,,CHEMBL877617,,,In vivo,,A,1,1,
,BAO_0000218,8752,N,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats,Intermediate,,50597,,1500,,10116.0,Rattus norvegicus,,CHEMBL623905,,,In vivo,,A,1,1,
,BAO_0000218,8753,N,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats,Intermediate,,50597,,1500,,10116.0,Rattus norvegicus,,CHEMBL623906,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8754,N,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,Intermediate,,50597,,4186,1969.0,10116.0,Rattus norvegicus,,CHEMBL623907,,,In vivo,,A,1,1,
,BAO_0000218,8755,N,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Intermediate,,50597,,16434,,10116.0,Rattus norvegicus,,CHEMBL623908,,,,,A,1,1,
,BAO_0000218,8756,N,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.,Intermediate,,50597,,16434,,10116.0,Rattus norvegicus,,CHEMBL623909,,,,,A,1,1,
,BAO_0000218,8757,N,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Intermediate,,50597,,16434,,10116.0,Rattus norvegicus,,CHEMBL623910,,,,,A,1,1,
,BAO_0000218,8758,N,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Intermediate,,50597,,16434,,10116.0,Rattus norvegicus,,CHEMBL623911,,,,,A,1,1,
,BAO_0000218,8759,N,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL623912,,,,,A,1,1,
,BAO_0000218,8760,N,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL624616,,,,,A,1,1,
,BAO_0000218,8761,N,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL624617,,,,,A,1,1,
,BAO_0000218,8762,N,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL624618,,,,,A,1,1,
,BAO_0000218,8763,N,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL624619,,,,,A,1,1,
,BAO_0000218,8764,N,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL624794,,,,,A,1,1,
,BAO_0000218,8765,N,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL624795,,,,,A,1,1,
,BAO_0000218,8766,N,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL623921,,,,,A,1,1,
,BAO_0000218,8767,N,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Intermediate,,50597,,16434,,10116.0,Rattus norvegicus,,CHEMBL623922,,,,,A,1,1,
,BAO_0000218,8768,N,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Intermediate,,50597,,16434,,10116.0,Rattus norvegicus,,CHEMBL623923,,,,,A,1,1,
,BAO_0000218,8769,N,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Intermediate,,50597,,16434,,10116.0,Rattus norvegicus,,CHEMBL623924,,,,,A,1,1,
,BAO_0000218,8770,N,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL623925,,,,,A,1,1,
,BAO_0000218,8771,N,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL623926,,,,,A,1,1,
,BAO_0000218,8772,N,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL623927,,,,,A,1,1,
,BAO_0000218,8773,N,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL623928,,,,,A,1,1,
,BAO_0000218,8774,N,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL623929,,,,,A,1,1,
,BAO_0000218,8775,N,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL623930,,,,,A,1,1,
Brain,BAO_0000218,8776,N,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,,50597,,16434,955.0,10116.0,Rattus norvegicus,,CHEMBL623931,,,,,A,1,1,
Brain,BAO_0000218,8777,N,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Intermediate,,50597,,16434,955.0,10116.0,Rattus norvegicus,,CHEMBL622165,,,,,A,1,1,
Brain,BAO_0000218,8778,N,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,,50597,,16434,955.0,10116.0,Rattus norvegicus,,CHEMBL621249,,,,,A,1,1,
Brain,BAO_0000218,8779,N,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,,50597,,16434,955.0,10116.0,Rattus norvegicus,,CHEMBL621250,,,,,A,1,1,
Brain,BAO_0000218,8780,N,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Intermediate,,50597,,16434,955.0,10116.0,Rattus norvegicus,,CHEMBL621448,,,,,A,1,1,
Brain,BAO_0000218,8781,N,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Intermediate,,50597,,16434,955.0,10116.0,Rattus norvegicus,,CHEMBL621449,,,,,A,1,1,
Brain,BAO_0000218,8782,N,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Intermediate,,50597,,16434,955.0,10116.0,Rattus norvegicus,,CHEMBL621450,,,,,A,1,1,
Brain,BAO_0000218,8783,N,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Intermediate,,50597,,16434,955.0,10116.0,Rattus norvegicus,,CHEMBL621451,,,,,A,1,1,
Brain,BAO_0000218,8784,N,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Intermediate,,50597,,16435,955.0,10116.0,Rattus norvegicus,,CHEMBL621452,,,,,A,1,1,
Brain,BAO_0000218,8785,N,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Intermediate,,50597,,16435,955.0,10116.0,Rattus norvegicus,,CHEMBL621453,,,,,A,1,1,
Brain,BAO_0000218,8786,N,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Intermediate,,50597,,16435,955.0,10116.0,Rattus norvegicus,,CHEMBL621454,,,,,A,1,1,
Brain,BAO_0000218,8787,N,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Intermediate,,50597,,16435,955.0,10116.0,Rattus norvegicus,,CHEMBL621455,,,,,A,1,1,
Brain,BAO_0000218,8788,N,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Intermediate,,50597,,16435,955.0,10116.0,Rattus norvegicus,,CHEMBL621456,,,,,A,1,1,
Brain,BAO_0000218,8789,N,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Intermediate,,50597,,16435,955.0,10116.0,Rattus norvegicus,,CHEMBL625145,,,,,A,1,1,
Brain,BAO_0000218,8790,N,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Intermediate,,50597,,16435,955.0,10116.0,Rattus norvegicus,,CHEMBL875847,,,,,A,1,1,
Brain,BAO_0000218,8791,N,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Intermediate,,50597,,16435,955.0,10116.0,Rattus norvegicus,,CHEMBL625146,,,,,A,1,1,
Brain,BAO_0000218,8792,N,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Intermediate,,50597,,16434,955.0,10116.0,Rattus norvegicus,,CHEMBL625147,,,,,A,1,1,
Brain,BAO_0000218,8793,N,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Intermediate,,50597,,16434,955.0,10116.0,Rattus norvegicus,,CHEMBL625148,,,,,A,1,1,
Brain,BAO_0000218,8794,N,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Intermediate,,50597,,16434,955.0,10116.0,Rattus norvegicus,,CHEMBL625149,,,,,A,1,1,
Brain,BAO_0000218,8795,N,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,,50597,,16435,955.0,10116.0,Rattus norvegicus,,CHEMBL625150,,,,,A,1,1,
Brain,BAO_0000218,8796,N,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,,50597,,16435,955.0,10116.0,Rattus norvegicus,,CHEMBL625151,,,,,A,1,1,
Brain,BAO_0000218,8797,N,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,,50597,,16435,955.0,10116.0,Rattus norvegicus,,CHEMBL625152,,,,,A,1,1,
Brain,BAO_0000218,8798,N,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,,50597,,16435,955.0,10116.0,Rattus norvegicus,,CHEMBL625153,,,,,A,1,1,
Brain,BAO_0000218,8799,N,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,,50597,,16435,955.0,10116.0,Rattus norvegicus,,CHEMBL625154,,,,,A,1,1,
Brain,BAO_0000218,8800,N,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,,50597,,16435,955.0,10116.0,Rattus norvegicus,,CHEMBL625155,,,,,A,1,1,
,BAO_0000218,8801,N,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,,50597,,11977,,10116.0,Rattus norvegicus,,CHEMBL625156,,,,,A,1,1,
,BAO_0000218,8802,N,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,,10116.0,Rattus norvegicus,,CHEMBL624354,,,,,A,1,1,
Hippocampus,BAO_0000218,8803,N,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,10000000.0,10116.0,Rattus norvegicus,,CHEMBL624355,,,,,A,1,1,
Hippocampus,BAO_0000218,8804,N,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,10000000.0,10116.0,Rattus norvegicus,,CHEMBL624356,,,,,A,1,1,
Hippocampus,BAO_0000218,8805,N,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,10000000.0,10116.0,Rattus norvegicus,,CHEMBL624357,,,,,A,1,1,
Hippocampus,BAO_0000218,8806,N,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,10000000.0,10116.0,Rattus norvegicus,,CHEMBL624358,,,,,A,1,1,
Striatum,BAO_0000218,8807,N,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,2435.0,10116.0,Rattus norvegicus,,CHEMBL624359,,,,,A,1,1,
Striatum,BAO_0000218,8808,N,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,2435.0,10116.0,Rattus norvegicus,,CHEMBL624360,,,,,A,1,1,
Striatum,BAO_0000218,8809,N,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,,50597,,11977,2435.0,10116.0,Rattus norvegicus,,CHEMBL624361,,,,,A,1,1,
Striatum,BAO_0000218,8810,N,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,2435.0,10116.0,Rattus norvegicus,,CHEMBL624362,,,,,A,1,1,
Striatum,BAO_0000218,8811,N,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,2435.0,10116.0,Rattus norvegicus,,CHEMBL624363,,,,,A,1,1,
Blood,BAO_0000218,8812,N,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,178.0,10116.0,Rattus norvegicus,,CHEMBL624364,,,In vivo,,A,1,1,
Blood,BAO_0000218,8813,N,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,178.0,10116.0,Rattus norvegicus,,CHEMBL624365,,,In vivo,,A,1,1,
Blood,BAO_0000218,8814,N,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,178.0,10116.0,Rattus norvegicus,,CHEMBL624366,,,In vivo,,A,1,1,
Blood,BAO_0000218,8815,N,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,178.0,10116.0,Rattus norvegicus,,CHEMBL624367,,,In vivo,,A,1,1,
Brain,BAO_0000218,8816,N,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,955.0,10116.0,Rattus norvegicus,,CHEMBL624368,,,In vivo,,A,1,1,
Brain,BAO_0000218,8817,N,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,955.0,10116.0,Rattus norvegicus,,CHEMBL624369,,,In vivo,,A,1,1,
Brain,BAO_0000218,8818,N,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,,50597,,11977,955.0,10116.0,Rattus norvegicus,,CHEMBL624370,,,In vivo,,A,1,1,
Brain,BAO_0000218,8819,N,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,955.0,10116.0,Rattus norvegicus,,CHEMBL625069,,,In vivo,,A,1,1,
Brain,BAO_0000218,8820,N,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,955.0,10116.0,Rattus norvegicus,,CHEMBL625070,,,In vivo,,A,1,1,
Heart,BAO_0000218,8821,N,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,948.0,10116.0,Rattus norvegicus,,CHEMBL626051,,,In vivo,,A,1,1,
Heart,BAO_0000218,8822,N,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,948.0,10116.0,Rattus norvegicus,,CHEMBL626052,,,In vivo,,A,1,1,
Heart,BAO_0000218,8823,N,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,,50597,,11977,948.0,10116.0,Rattus norvegicus,,CHEMBL626053,,,In vivo,,A,1,1,
Heart,BAO_0000218,8824,N,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,948.0,10116.0,Rattus norvegicus,,CHEMBL626054,,,In vivo,,A,1,1,
Heart,BAO_0000218,8825,N,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,948.0,10116.0,Rattus norvegicus,,CHEMBL626055,,,In vivo,,A,1,1,
Kidney,BAO_0000218,8826,N,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,2113.0,10116.0,Rattus norvegicus,,CHEMBL626056,,,In vivo,,A,1,1,
Kidney,BAO_0000218,8827,N,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,2113.0,10116.0,Rattus norvegicus,,CHEMBL626057,,,In vivo,,A,1,1,
Kidney,BAO_0000218,8828,N,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,2113.0,10116.0,Rattus norvegicus,,CHEMBL625193,,,In vivo,,A,1,1,
Kidney,BAO_0000218,8829,N,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,2113.0,10116.0,Rattus norvegicus,,CHEMBL625194,,,In vivo,,A,1,1,
Liver,BAO_0000218,8830,N,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,2107.0,10116.0,Rattus norvegicus,,CHEMBL625195,,,In vivo,,A,1,1,
Liver,BAO_0000218,8831,N,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,2107.0,10116.0,Rattus norvegicus,,CHEMBL625196,,,In vivo,,A,1,1,
Liver,BAO_0000218,8832,N,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,,50597,,11977,2107.0,10116.0,Rattus norvegicus,,CHEMBL625197,,,In vivo,,A,1,1,
Liver,BAO_0000218,8833,N,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,2107.0,10116.0,Rattus norvegicus,,CHEMBL625198,,,In vivo,,A,1,1,
Liver,BAO_0000218,8834,N,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,2107.0,10116.0,Rattus norvegicus,,CHEMBL627929,,,In vivo,,A,1,1,
Lung,BAO_0000218,8835,N,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,2048.0,10116.0,Rattus norvegicus,,CHEMBL627074,,,In vivo,,A,1,1,
Lung,BAO_0000218,8836,N,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,2048.0,10116.0,Rattus norvegicus,,CHEMBL627075,,,In vivo,,A,1,1,
Lung,BAO_0000218,8837,N,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,,50597,,11977,2048.0,10116.0,Rattus norvegicus,,CHEMBL627076,,,In vivo,,A,1,1,
Lung,BAO_0000218,8838,N,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,2048.0,10116.0,Rattus norvegicus,,CHEMBL627077,,,In vivo,,A,1,1,
Lung,BAO_0000218,8839,N,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,2048.0,10116.0,Rattus norvegicus,,CHEMBL627078,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,8840,N,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats),Intermediate,,50597,,11977,2385.0,10116.0,Rattus norvegicus,,CHEMBL627079,,,In vivo,,A,1,1,
,BAO_0000218,8841,N,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice,Intermediate,,50594,,4573,,10090.0,Mus musculus,,CHEMBL873824,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8842,N,Half life in mouse plasma was determined at dose 25 mg/kg,Intermediate,,50594,,3132,1969.0,10090.0,Mus musculus,,CHEMBL627080,,,In vivo,,A,1,1,
,BAO_0000218,8843,N,Half life was determined,Intermediate,,50594,,17718,,10090.0,Mus musculus,,CHEMBL627081,,,,,A,1,1,
,BAO_0000218,8844,N,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,Intermediate,,50594,,17728,,10090.0,Mus musculus,,CHEMBL627082,,,In vivo,,A,1,1,
,BAO_0000218,8845,N,Half-life in male mice after 1 mg/kg intravenous dose,Intermediate,,50594,,5961,,10090.0,Mus musculus,,CHEMBL627083,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8847,N,Half life in mice plasma,Intermediate,,50594,,17731,1969.0,10090.0,Mus musculus,,CHEMBL627085,,,,,A,1,1,
,BAO_0000218,8848,N,Half life in mouse,Intermediate,,50594,,17592,,10090.0,Mus musculus,,CHEMBL627086,,,,,A,1,1,
Plasma,BAO_0000218,8849,N,Half life in mouse plasma at dose 25 mg/kg,Intermediate,,50594,,3132,1969.0,10090.0,Mus musculus,,CHEMBL627087,,,In vivo,,A,1,1,
,BAO_0000218,8850,N,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined,Intermediate,,50594,,17729,,10090.0,Mus musculus,,CHEMBL627088,,,In vivo,,A,1,1,
,BAO_0000218,8851,N,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined,Intermediate,,50594,,17729,,10090.0,Mus musculus,,CHEMBL627089,,,In vivo,,A,1,1,
,BAO_0000218,8852,N,Half life when injected perorally in mice at a dose of 50 mg/kg was determined,Intermediate,,50594,,17729,,10090.0,Mus musculus,,CHEMBL627090,,,In vivo,,A,1,1,
,BAO_0000218,8853,N,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),Intermediate,,50594,,3277,,10090.0,Mus musculus,,CHEMBL627091,,,In vivo,,A,1,1,
,BAO_0000218,8854,N,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice",Intermediate,,50594,,3760,,10090.0,Mus musculus,,CHEMBL627092,,,In vivo,,A,1,1,
,BAO_0000218,8855,N,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice",Intermediate,,50594,,3760,,10090.0,Mus musculus,,CHEMBL876785,,,In vivo,,A,1,1,
,BAO_0000218,8856,N,Half-life by iv administration in mouse,Intermediate,,50594,,2862,,10090.0,Mus musculus,,CHEMBL627093,,,In vivo,,A,1,1,
,BAO_0000218,8857,N,Half-life by oral administration in mouse,Intermediate,,50594,,2862,,10090.0,Mus musculus,,CHEMBL627094,,,In vivo,,A,1,1,
,BAO_0000218,8858,N,Half-life in mice,Intermediate,,50594,,5980,,10090.0,Mus musculus,,CHEMBL627095,,,,,A,1,1,
Brain,BAO_0000218,8859,N,Half-life using mouse brain homogenate,Intermediate,,50594,,6159,955.0,10090.0,Mus musculus,,CHEMBL627096,,,,,A,1,1,
,BAO_0000218,8860,N,Half-life was measured in mice,Intermediate,,50594,,6254,,10090.0,Mus musculus,,CHEMBL627097,,,,,A,1,1,
,BAO_0000218,8861,N,Half-life was measured in mouse after an iv dose of 1 mg/kg,Intermediate,,50594,,6062,,10090.0,Mus musculus,,CHEMBL627098,,,In vivo,,A,1,1,
Blood,BAO_0000218,8862,N,Half-life period was determined in mouse blood,Intermediate,,50594,,1574,178.0,10090.0,Mus musculus,,CHEMBL627099,,,,,A,1,1,
Brain,BAO_0000218,8863,N,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain",Intermediate,,50594,,56,955.0,10090.0,Mus musculus,,CHEMBL627100,,,,,A,1,1,
Plasma,BAO_0000218,8864,N,Plasma half life in mouse,Intermediate,,50594,,993,1969.0,10090.0,Mus musculus,,CHEMBL627101,,,,,A,1,1,
,BAO_0000218,8865,N,Stability of the peptide in the presence of mouse serum,Intermediate,,50594,,6652,,10090.0,Mus musculus,,CHEMBL627102,,,,,A,1,1,
,BAO_0000218,8866,N,Terminal half life of compound was determined in mouse,Intermediate,,50594,,17852,,10090.0,Mus musculus,,CHEMBL627103,,,,,A,1,1,
,BAO_0000218,8867,N,Terminal half life was evaluated in mice after intravenous administration,Intermediate,,50594,,2675,,10090.0,Mus musculus,,CHEMBL627104,,,In vivo,,A,1,1,
,BAO_0000218,8868,N,Terminal half life was evaluated in mice after oral administration,Intermediate,,50594,,2675,,10090.0,Mus musculus,,CHEMBL627105,,,In vivo,,A,1,1,
,BAO_0000218,8869,N,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.,Intermediate,,50594,,499,,10090.0,Mus musculus,,CHEMBL876786,,,,,A,1,1,
,BAO_0000218,8870,N,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.,Intermediate,,50594,,499,,10090.0,Mus musculus,,CHEMBL873825,,,,,A,1,1,
,BAO_0000218,8871,N,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data,Intermediate,,50594,,499,,10090.0,Mus musculus,,CHEMBL627106,,,,,A,1,1,
,BAO_0000218,8872,N,half life period is evaluated by administering intravenously at 25 mg/kg in mice,Intermediate,,50594,,14239,,10090.0,Mus musculus,,CHEMBL626336,,,In vivo,,A,1,1,
,BAO_0000218,8873,N,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice",Intermediate,,50594,,5506,,10090.0,Mus musculus,,CHEMBL877462,,,In vivo,,A,1,1,
,BAO_0000218,8874,N,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable",Intermediate,,50594,,5506,,10090.0,Mus musculus,,CHEMBL626337,,,In vivo,,A,1,1,
,BAO_0000218,8875,N,Half life after intraperitoneal administration of 100 mg/kg in mice,Intermediate,,50594,,17734,,10090.0,Mus musculus,,CHEMBL626338,,,,,A,1,1,
,BAO_0000218,8876,N,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration,Intermediate,,50594,,17728,,10090.0,Mus musculus,,CHEMBL626339,,,In vivo,,A,1,1,
,BAO_0000218,8877,N,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,Intermediate,,50594,,17728,,10090.0,Mus musculus,,CHEMBL626340,,,In vivo,,A,1,1,
,BAO_0000218,8878,N,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration,Intermediate,,50594,,17728,,10090.0,Mus musculus,,CHEMBL625377,,,In vivo,,A,1,1,
,BAO_0000218,8879,N,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration,Intermediate,,50594,,17728,,10090.0,Mus musculus,,CHEMBL625378,,,In vivo,,A,1,1,
,BAO_0000218,8880,N,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration,Intermediate,,50594,,17728,,10090.0,Mus musculus,,CHEMBL625379,,,In vivo,,A,1,1,
,BAO_0000251,8881,U,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak),Autocuration,,22224,,14294,,9823.0,Sus scrofa,,CHEMBL625380,,,,Microsomes,A,1,0,
,BAO_0000251,8882,U,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak),Autocuration,,22224,,14294,,9823.0,Sus scrofa,,CHEMBL625381,,,,Microsomes,A,1,0,
,BAO_0000019,8883,U,Stability to porcine renal DHP-I,Autocuration,,22224,,6056,,9823.0,Sus scrofa,,CHEMBL625382,,,,,A,1,0,
,BAO_0000218,8884,U,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg,Autocuration,,22224,,1317,,9823.0,Sus scrofa,,CHEMBL873828,,,In vivo,,A,1,0,
,BAO_0000218,8885,U,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg,Autocuration,,22224,,1317,,9823.0,Sus scrofa,,CHEMBL625383,,,In vivo,,A,1,0,
,BAO_0000019,8886,U,Half-life of the parent prodrug in porcine esterase solution,Autocuration,,22224,,5229,,9823.0,Sus scrofa,,CHEMBL625384,,,,,A,1,0,
,BAO_0000019,8887,U,"First order rate constant, k was determined in in pig liver Esterase",Autocuration,,22224,,4231,,9823.0,Sus scrofa,,CHEMBL625385,,,,,A,1,0,
Liver,BAO_0000221,8888,U,Half life of the in pig liver Esterase,Autocuration,,22224,,4231,2107.0,9823.0,Sus scrofa,,CHEMBL625386,,,,,A,1,0,
Liver,BAO_0000221,8889,U,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase,Autocuration,,22224,,5318,2107.0,9823.0,Sus scrofa,,CHEMBL623571,,,,,A,1,0,
Liver,BAO_0000221,8890,U,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase,Autocuration,,22224,,5318,2107.0,9823.0,Sus scrofa,,CHEMBL623572,,,,,A,1,0,
Liver,BAO_0000221,8891,U,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase,Autocuration,,22224,,5318,2107.0,9823.0,Sus scrofa,,CHEMBL623573,,,,,A,1,0,
Liver,BAO_0000221,8892,U,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay,Autocuration,,22224,,3305,2107.0,9823.0,Sus scrofa,,CHEMBL623574,,,,,A,1,0,
Liver,BAO_0000221,8893,U,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined,Autocuration,,22224,,3305,2107.0,9823.0,Sus scrofa,,CHEMBL623575,,,,,A,1,0,
Liver,BAO_0000221,8894,U,Half-life in the presence of pig liver esterase(PLE) was evaluated.,Autocuration,,22224,,2842,2107.0,9823.0,Sus scrofa,,CHEMBL623749,,,,,A,1,0,
Liver,BAO_0000221,8895,U,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable,Autocuration,,22224,,2842,2107.0,9823.0,Sus scrofa,,CHEMBL623750,,,,,A,1,0,
Liver,BAO_0000221,8896,U,Half-life in vitro in pig liver,Autocuration,,22224,,889,2107.0,9823.0,Sus scrofa,,CHEMBL623751,,,In vitro,,A,1,0,
Liver,BAO_0000221,8897,U,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase,Autocuration,,22224,,1904,2107.0,9823.0,Sus scrofa,,CHEMBL623752,,,,,A,1,0,
Plasma,BAO_0000218,8898,N,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route,Intermediate,,50597,,4186,1969.0,10116.0,Rattus norvegicus,,CHEMBL623753,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8899,N,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,Intermediate,,50597,,2774,1969.0,10116.0,Rattus norvegicus,,CHEMBL623754,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8900,N,Maximum concentration in rat plasma was determined,Intermediate,,50597,,1742,1969.0,10116.0,Rattus norvegicus,,CHEMBL623755,,,In vivo,,A,1,1,
,BAO_0000218,8901,N,Maximum concentration in rats,Intermediate,,50597,,3169,,10116.0,Rattus norvegicus,,CHEMBL623756,,,In vivo,,A,1,1,
,BAO_0000218,8902,N,Maximum concentration in rats at 1-2 hours,Intermediate,,50597,,3169,,10116.0,Rattus norvegicus,,CHEMBL623757,,,In vivo,,A,1,1,
,BAO_0000218,8903,N,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally,Intermediate,,50597,,2081,,10116.0,Rattus norvegicus,,CHEMBL623758,,,In vivo,,A,1,1,
Brain,BAO_0000218,8904,N,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats,Intermediate,,50597,,3307,955.0,10116.0,Rattus norvegicus,,CHEMBL623759,,,In vivo,,A,1,1,
,BAO_0000218,8905,N,Maximum concentration at the dose of 2 mg/kg in rat,Intermediate,,50597,,4727,,10116.0,Rattus norvegicus,,CHEMBL623760,,,In vivo,,A,1,1,
,BAO_0000218,8906,N,Maximum concentration was evaluated in rats,Intermediate,,50597,,6597,,10116.0,Rattus norvegicus,,CHEMBL623761,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8907,N,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat,Intermediate,,50597,,16365,1969.0,10116.0,Rattus norvegicus,,CHEMBL623762,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8908,N,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat,Intermediate,,50597,,16365,1969.0,10116.0,Rattus norvegicus,,CHEMBL877594,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8909,N,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg,Intermediate,,50597,,16365,1969.0,10116.0,Rattus norvegicus,,CHEMBL623763,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8910,N,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg,Intermediate,,50597,,16365,1969.0,10116.0,Rattus norvegicus,,CHEMBL623764,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8911,N,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat,Intermediate,,50597,,16365,1969.0,10116.0,Rattus norvegicus,,CHEMBL623765,,,In vivo,,A,1,1,
Blood,BAO_0000218,8912,N,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration,Intermediate,,50597,,2591,178.0,10116.0,Rattus norvegicus,,CHEMBL623766,,,In vivo,,A,1,1,
Blood,BAO_0000218,8913,N,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration,Intermediate,,50597,,2591,178.0,10116.0,Rattus norvegicus,,CHEMBL623767,,,In vivo,,A,1,1,
Blood,BAO_0000218,8914,N,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration,Intermediate,,50597,,2591,178.0,10116.0,Rattus norvegicus,,CHEMBL623768,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8915,N,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat,Intermediate,,50597,,5978,1969.0,10116.0,Rattus norvegicus,,CHEMBL623769,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8916,N,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat,Intermediate,,50597,,5978,1969.0,10116.0,Rattus norvegicus,,CHEMBL623770,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8917,N,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat,Intermediate,,50597,,5978,1969.0,10116.0,Rattus norvegicus,,CHEMBL623771,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8918,N,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat,Intermediate,,50597,,5978,1969.0,10116.0,Rattus norvegicus,,CHEMBL623772,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8919,N,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat,Intermediate,,50597,,5978,1969.0,10116.0,Rattus norvegicus,,CHEMBL623773,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8920,N,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat,Intermediate,,50597,,5978,1969.0,10116.0,Rattus norvegicus,,CHEMBL623774,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8921,N,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat,Intermediate,,50597,,5978,1969.0,10116.0,Rattus norvegicus,,CHEMBL623775,,,In vivo,,A,1,1,
,BAO_0000218,8922,N,Cmax in rat (PO dose),Intermediate,,50597,,14465,,10116.0,Rattus norvegicus,,CHEMBL623776,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8923,N,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,,50597,,4723,1969.0,10116.0,Rattus norvegicus,,CHEMBL622191,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8924,N,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,,50597,,4723,1969.0,10116.0,Rattus norvegicus,,CHEMBL622192,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8925,N,Maximum plasma concentration determined in rat,Intermediate,,50597,,4576,1969.0,10116.0,Rattus norvegicus,,CHEMBL622193,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8926,N,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,Intermediate,,50597,,12873,1969.0,10116.0,Rattus norvegicus,,CHEMBL622194,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8927,N,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,Intermediate,,50597,,12873,1969.0,10116.0,Rattus norvegicus,,CHEMBL622195,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8928,N,Maximum plasma concentration in rat,Intermediate,,50597,,6824,1969.0,10116.0,Rattus norvegicus,,CHEMBL622196,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8929,N,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats,Intermediate,,50597,,17065,1969.0,10116.0,Rattus norvegicus,,CHEMBL622197,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8930,N,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min,Intermediate,,50597,,2932,1969.0,10116.0,Rattus norvegicus,,CHEMBL622198,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8931,N,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min,Intermediate,,50597,,2932,1969.0,10116.0,Rattus norvegicus,,CHEMBL622199,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8932,N,Maximum plasma concentration of compound was measured in rat,Intermediate,,50597,,2879,1969.0,10116.0,Rattus norvegicus,,CHEMBL622200,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8933,N,Maximum plasma concentration after 20 mg/kg oral administration in rat,Intermediate,,50597,,2864,1969.0,10116.0,Rattus norvegicus,,CHEMBL622201,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8934,N,Maximum plasma concentration after oral administration to rats,Intermediate,,50597,,16367,1969.0,10116.0,Rattus norvegicus,,CHEMBL623990,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8935,N,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,Intermediate,,50597,,17717,1969.0,10116.0,Rattus norvegicus,,CHEMBL623991,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8936,N,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously",Intermediate,,50597,,17717,1969.0,10116.0,Rattus norvegicus,,CHEMBL623992,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8937,N,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,Intermediate,,50597,,17717,1969.0,10116.0,Rattus norvegicus,,CHEMBL623993,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8938,N,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control,Intermediate,,50597,,17717,1969.0,10116.0,Rattus norvegicus,,CHEMBL623994,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8939,N,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration,Intermediate,,50597,,17720,1969.0,10116.0,Rattus norvegicus,,CHEMBL623995,,,In vivo,,F,1,1,
Plasma,BAO_0000218,8940,N,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration,Intermediate,,50597,,17720,1969.0,10116.0,Rattus norvegicus,,CHEMBL623996,,,In vivo,,F,1,1,
Plasma,BAO_0000218,8941,N,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration,Intermediate,,50597,,17720,1969.0,10116.0,Rattus norvegicus,,CHEMBL623997,,,In vivo,,F,1,1,
Plasma,BAO_0000218,8942,N,Maximum plasma concentration dosed orally in rats,Intermediate,,50597,,4516,1969.0,10116.0,Rattus norvegicus,,CHEMBL623998,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8943,N,Maximum plasma concentration dosed orally in rats after 6 hours,Intermediate,,50597,,4516,1969.0,10116.0,Rattus norvegicus,,CHEMBL623999,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8944,N,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected,Intermediate,,50597,,4516,1969.0,10116.0,Rattus norvegicus,,CHEMBL624000,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8945,N,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,Intermediate,,50597,,5199,1969.0,10116.0,Rattus norvegicus,,CHEMBL624001,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8946,N,Maximum plasma concentration in rat after po administration,Intermediate,,50597,,17538,1969.0,10116.0,Rattus norvegicus,,CHEMBL624002,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8947,N,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose",Intermediate,,50597,,6685,1969.0,10116.0,Rattus norvegicus,,CHEMBL624003,,,In vivo,,A,1,1,
Plasma,BAO_0000218,8948,N,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose",Intermediate,,50597,,6685,1969.0,10116.0,Rattus norvegicus,,CHEMBL624004,,,In vivo,,A,1,1,
Heart,BAO_0000218,8949,N,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,,50597,,16434,948.0,10116.0,Rattus norvegicus,,CHEMBL624005,,,,,A,1,1,
Heart,BAO_0000218,8950,N,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Intermediate,,50597,,16434,948.0,10116.0,Rattus norvegicus,,CHEMBL624006,,,,,A,1,1,
Heart,BAO_0000218,8951,N,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,,50597,,16434,948.0,10116.0,Rattus norvegicus,,CHEMBL624007,,,,,A,1,1,
Heart,BAO_0000218,8952,N,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,,50597,,16434,948.0,10116.0,Rattus norvegicus,,CHEMBL624008,,,,,A,1,1,
Heart,BAO_0000218,8953,N,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Intermediate,,50597,,16434,948.0,10116.0,Rattus norvegicus,,CHEMBL624009,,,,,A,1,1,
Heart,BAO_0000218,8954,N,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Intermediate,,50597,,16434,948.0,10116.0,Rattus norvegicus,,CHEMBL874387,,,,,A,1,1,
Heart,BAO_0000218,8955,N,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Intermediate,,50597,,16434,948.0,10116.0,Rattus norvegicus,,CHEMBL624010,,,,,A,1,1,
Heart,BAO_0000218,8956,N,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,Intermediate,,50597,,16434,948.0,10116.0,Rattus norvegicus,,CHEMBL624011,,,,,A,1,1,
Heart,BAO_0000218,8957,N,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Intermediate,,50597,,16435,948.0,10116.0,Rattus norvegicus,,CHEMBL624012,,,,,A,1,1,
Heart,BAO_0000218,8958,N,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Intermediate,,50597,,16435,948.0,10116.0,Rattus norvegicus,,CHEMBL624013,,,,,A,1,1,
Heart,BAO_0000218,8959,N,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Intermediate,,50597,,16435,948.0,10116.0,Rattus norvegicus,,CHEMBL624736,,,,,A,1,1,
Heart,BAO_0000218,8960,N,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Intermediate,,50597,,16435,948.0,10116.0,Rattus norvegicus,,CHEMBL624737,,,,,A,1,1,
Heart,BAO_0000218,8961,N,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Intermediate,,50597,,16434,948.0,10116.0,Rattus norvegicus,,CHEMBL624738,,,,,A,1,1,
Heart,BAO_0000218,8962,N,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Intermediate,,50597,,16434,948.0,10116.0,Rattus norvegicus,,CHEMBL624739,,,,,A,1,1,
Heart,BAO_0000218,8963,N,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Intermediate,,50597,,16434,948.0,10116.0,Rattus norvegicus,,CHEMBL624740,,,,,A,1,1,
Heart,BAO_0000218,8964,N,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,,50597,,16435,948.0,10116.0,Rattus norvegicus,,CHEMBL624896,,,,,A,1,1,
Heart,BAO_0000218,8965,N,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,,50597,,16435,948.0,10116.0,Rattus norvegicus,,CHEMBL624897,,,,,A,1,1,
Heart,BAO_0000218,8966,N,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,,50597,,16435,948.0,10116.0,Rattus norvegicus,,CHEMBL624108,,,,,A,1,1,
Heart,BAO_0000218,8967,N,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,,50597,,16435,948.0,10116.0,Rattus norvegicus,,CHEMBL624109,,,,,A,1,1,
Heart,BAO_0000218,8968,N,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,,50597,,16435,948.0,10116.0,Rattus norvegicus,,CHEMBL624110,,,,,A,1,1,
Heart,BAO_0000218,8969,N,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,,50597,,16435,948.0,10116.0,Rattus norvegicus,,CHEMBL624111,,,,,A,1,1,
Heart,BAO_0000218,8970,N,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Intermediate,,50597,,16435,948.0,10116.0,Rattus norvegicus,,CHEMBL624112,,,,,A,1,1,
Heart,BAO_0000218,8971,N,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Intermediate,,50597,,16435,948.0,10116.0,Rattus norvegicus,,CHEMBL624113,,,,,A,1,1,
Heart,BAO_0000218,8972,N,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Intermediate,,50597,,16435,948.0,10116.0,Rattus norvegicus,,CHEMBL619709,,,,,A,1,1,
Heart,BAO_0000218,8973,N,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Intermediate,,50597,,16435,948.0,10116.0,Rattus norvegicus,,CHEMBL619710,,,,,A,1,1,
Kidney,BAO_0000218,8974,N,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,,50597,,16434,2113.0,10116.0,Rattus norvegicus,,CHEMBL619711,,,,,A,1,1,
Kidney,BAO_0000218,8975,N,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Intermediate,,50597,,16434,2113.0,10116.0,Rattus norvegicus,,CHEMBL619712,,,,,A,1,1,
Kidney,BAO_0000218,8976,N,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,,50597,,16434,2113.0,10116.0,Rattus norvegicus,,CHEMBL619713,,,,,A,1,1,
Kidney,BAO_0000218,8977,N,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,,50597,,16434,2113.0,10116.0,Rattus norvegicus,,CHEMBL619714,,,,,A,1,1,
Kidney,BAO_0000218,8978,N,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Intermediate,,50597,,16434,2113.0,10116.0,Rattus norvegicus,,CHEMBL619715,,,,,A,1,1,
Kidney,BAO_0000218,8979,N,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Intermediate,,50597,,16434,2113.0,10116.0,Rattus norvegicus,,CHEMBL619716,,,,,A,1,1,
Kidney,BAO_0000218,8980,N,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Intermediate,,50597,,16434,2113.0,10116.0,Rattus norvegicus,,CHEMBL619717,,,,,A,1,1,
Kidney,BAO_0000218,8981,N,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Intermediate,,50597,,16434,2113.0,10116.0,Rattus norvegicus,,CHEMBL619718,,,,,A,1,1,
Kidney,BAO_0000218,8982,N,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Intermediate,,50597,,16435,2113.0,10116.0,Rattus norvegicus,,CHEMBL619719,,,,,A,1,1,
Kidney,BAO_0000218,8983,N,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Intermediate,,50597,,16435,2113.0,10116.0,Rattus norvegicus,,CHEMBL875329,,,,,A,1,1,
Kidney,BAO_0000218,8984,N,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Intermediate,,50597,,16435,2113.0,10116.0,Rattus norvegicus,,CHEMBL619720,,,,,A,1,1,
Kidney,BAO_0000218,8985,N,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Intermediate,,50597,,16435,2113.0,10116.0,Rattus norvegicus,,CHEMBL619721,,,,,A,1,1,
Kidney,BAO_0000218,8986,N,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Intermediate,,50597,,16435,2113.0,10116.0,Rattus norvegicus,,CHEMBL619722,,,,,A,1,1,
Kidney,BAO_0000218,8987,N,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Intermediate,,50597,,16435,2113.0,10116.0,Rattus norvegicus,,CHEMBL619723,,,,,A,1,1,
Kidney,BAO_0000218,8988,N,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Intermediate,,50597,,16435,2113.0,10116.0,Rattus norvegicus,,CHEMBL619724,,,,,A,1,1,
Kidney,BAO_0000218,8989,N,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Intermediate,,50597,,16435,2113.0,10116.0,Rattus norvegicus,,CHEMBL619725,,,,,A,1,1,
Kidney,BAO_0000218,8990,N,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Intermediate,,50597,,16434,2113.0,10116.0,Rattus norvegicus,,CHEMBL619726,,,,,A,1,1,
Kidney,BAO_0000218,8991,N,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Intermediate,,50597,,16434,2113.0,10116.0,Rattus norvegicus,,CHEMBL619727,,,,,A,1,1,
Kidney,BAO_0000218,8992,N,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Intermediate,,50597,,16434,2113.0,10116.0,Rattus norvegicus,,CHEMBL619728,,,,,A,1,1,
Kidney,BAO_0000218,8993,N,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,,50597,,16435,2113.0,10116.0,Rattus norvegicus,,CHEMBL619729,,,,,A,1,1,
Muscle tissue,BAO_0000218,8994,N,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,2385.0,10116.0,Rattus norvegicus,,CHEMBL619730,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,8995,N,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,2385.0,10116.0,Rattus norvegicus,,CHEMBL619731,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,8996,N,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,,50597,,11977,2385.0,10116.0,Rattus norvegicus,,CHEMBL619732,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,8997,N,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,2385.0,10116.0,Rattus norvegicus,,CHEMBL619733,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,8998,N,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,2385.0,10116.0,Rattus norvegicus,,CHEMBL619734,,,In vivo,,A,1,1,
Zone of skin,BAO_0000218,8999,N,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,14.0,10116.0,Rattus norvegicus,,CHEMBL619735,,,In vivo,,A,1,1,
Zone of skin,BAO_0000218,9000,N,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,14.0,10116.0,Rattus norvegicus,,CHEMBL875330,,,In vivo,,A,1,1,
Zone of skin,BAO_0000218,9001,N,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,,50597,,11977,14.0,10116.0,Rattus norvegicus,,CHEMBL628465,,,In vivo,,A,1,1,
Zone of skin,BAO_0000218,9002,N,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,14.0,10116.0,Rattus norvegicus,,CHEMBL628466,,,In vivo,,A,1,1,
Zone of skin,BAO_0000218,9003,N,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,14.0,10116.0,Rattus norvegicus,,CHEMBL628467,,,In vivo,,A,1,1,
Spleen,BAO_0000218,9004,N,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,2106.0,10116.0,Rattus norvegicus,,CHEMBL628468,,,In vivo,,A,1,1,
Spleen,BAO_0000218,9005,N,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,2106.0,10116.0,Rattus norvegicus,,CHEMBL628469,,,In vivo,,A,1,1,
Spleen,BAO_0000218,9006,N,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,,50597,,11977,2106.0,10116.0,Rattus norvegicus,,CHEMBL628470,,,In vivo,,A,1,1,
Spleen,BAO_0000218,9007,N,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,2106.0,10116.0,Rattus norvegicus,,CHEMBL628471,,,In vivo,,A,1,1,
Spleen,BAO_0000218,9008,N,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,2106.0,10116.0,Rattus norvegicus,,CHEMBL628472,,,In vivo,,A,1,1,
Thyroid gland,BAO_0000218,9009,N,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,2046.0,10116.0,Rattus norvegicus,,CHEMBL625191,,,In vivo,,A,1,1,
Thyroid gland,BAO_0000218,9010,N,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,2046.0,10116.0,Rattus norvegicus,,CHEMBL625192,,,In vivo,,A,1,1,
Thyroid gland,BAO_0000218,9011,N,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Intermediate,,50597,,11977,2046.0,10116.0,Rattus norvegicus,,CHEMBL875337,,,In vivo,,A,1,1,
Thyroid gland,BAO_0000218,9012,N,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,2046.0,10116.0,Rattus norvegicus,,CHEMBL626341,,,In vivo,,A,1,1,
Thyroid gland,BAO_0000218,9013,N,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,2046.0,10116.0,Rattus norvegicus,,CHEMBL626342,,,In vivo,,A,1,1,
Liver,BAO_0000218,9014,N,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Intermediate,,50597,,11977,2107.0,10116.0,Rattus norvegicus,,CHEMBL621943,,,In vivo,,A,1,1,
,BAO_0000218,9015,N,Half life in rats,Intermediate,,50597,,3748,,10116.0,Rattus norvegicus,,CHEMBL621944,,,,,A,1,1,
,BAO_0000218,9016,N,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily,Intermediate,,50597,,15765,,10116.0,Rattus norvegicus,,CHEMBL621945,,,,,A,1,1,
,BAO_0000218,9017,N,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver),Intermediate,,50597,,4871,,10116.0,Rattus norvegicus,,CHEMBL621946,,,,,A,1,1,
,BAO_0000218,9018,N,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined,Intermediate,,50597,,4871,,10116.0,Rattus norvegicus,,CHEMBL621947,,,,,A,1,1,
,BAO_0000218,9019,N,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver),Intermediate,,50597,,4872,,10116.0,Rattus norvegicus,,CHEMBL621948,,,,,A,1,1,
,BAO_0000218,9020,N,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined,Intermediate,,50597,,4872,,10116.0,Rattus norvegicus,,CHEMBL621949,,,,,A,1,1,
,BAO_0000218,9021,N,Rate constant (k) of clearance from isolated perfused rat liver (IPRL),Intermediate,,50597,,5413,,10116.0,Rattus norvegicus,,CHEMBL621950,,,,,A,1,1,
,BAO_0000218,9022,N,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined,Intermediate,,50597,,5413,,10116.0,Rattus norvegicus,,CHEMBL621951,,,,,A,1,1,
Blood,BAO_0000218,9023,N,Maximal blood concentration after oral administration of a 30 uM/kg dose of compound,Intermediate,,50597,,15272,178.0,10116.0,Rattus norvegicus,,CHEMBL621952,,,In vivo,,A,1,1,
Liver,BAO_0000218,9024,N,Stability (%) in rat liver microsomes,Intermediate,,50597,,4689,2107.0,10116.0,Rattus norvegicus,,CHEMBL621953,,,,,A,1,1,
,BAO_0000218,9025,N,Area under curve was calculated after intravenous administration,Intermediate,,50597,,6057,,10116.0,Rattus norvegicus,,CHEMBL621954,,,,,A,1,1,
,BAO_0000218,9026,N,Area under the curve was calculated after iv administration in rat,Intermediate,,50597,,6057,,10116.0,Rattus norvegicus,,CHEMBL621955,,,,,A,1,1,
,BAO_0000218,9027,N,Area under the curve was calculated in rat after peroral administration,Intermediate,,50597,,6057,,10116.0,Rattus norvegicus,,CHEMBL621956,,,,,A,1,1,
,BAO_0000218,9028,N,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,Intermediate,,50597,,6211,,10116.0,Rattus norvegicus,,CHEMBL621957,,,,,A,1,1,
,BAO_0000218,9029,N,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg,Intermediate,,50597,,5710,,10116.0,Rattus norvegicus,,CHEMBL621958,,,,,A,1,1,
,BAO_0000218,9030,N,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg,Intermediate,,50597,,5710,,10116.0,Rattus norvegicus,,CHEMBL621959,,,,,A,1,1,
,BAO_0000218,9031,N,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk,Intermediate,,50597,,17853,,10116.0,Rattus norvegicus,,CHEMBL621960,,,,,A,1,1,
,BAO_0000218,9032,N,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk,Intermediate,,50597,,17853,,10116.0,Rattus norvegicus,,CHEMBL621961,,,,,A,1,1,
,BAO_0000218,9033,N,p value of the compound,Intermediate,,50597,,15765,,10116.0,Rattus norvegicus,,CHEMBL621962,,,,,A,1,1,
,BAO_0000218,9034,N,p value of the compound,Intermediate,,50597,,15765,,10116.0,Rattus norvegicus,,CHEMBL876787,,,,,F,1,1,
,BAO_0000218,9035,N,p value of the compound,Intermediate,,50597,,15765,,10116.0,Rattus norvegicus,,CHEMBL621963,,,,,A,1,1,
Stomach,BAO_0000218,9036,N,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Intermediate,,50597,,6175,945.0,10116.0,Rattus norvegicus,,CHEMBL622637,,,,,A,1,1,
Stomach,BAO_0000218,9037,N,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Intermediate,,50597,,6175,945.0,10116.0,Rattus norvegicus,,CHEMBL622638,,,,,A,1,1,
Stomach,BAO_0000218,9038,N,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Intermediate,,50597,,6175,945.0,10116.0,Rattus norvegicus,,CHEMBL626561,,,,,A,1,1,
,BAO_0000019,9039,U,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic),Autocuration,,22224,,7991,,9986.0,Oryctolagus cuniculus,,CHEMBL626562,,,,,F,1,0,
,BAO_0000218,9040,U,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr ),Autocuration,,22224,,429,,9986.0,Oryctolagus cuniculus,,CHEMBL626563,,,,,A,1,0,
,BAO_0000218,9041,U,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr ),Autocuration,,22224,,429,,9986.0,Oryctolagus cuniculus,,CHEMBL626564,,,,,A,1,0,
,BAO_0000218,9042,U,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample,Autocuration,,22224,,6253,,9986.0,Oryctolagus cuniculus,,CHEMBL626565,,,In vivo,,A,1,0,
,BAO_0000218,9043,U,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample,Autocuration,,22224,,6253,,9986.0,Oryctolagus cuniculus,,CHEMBL626566,,,In vivo,,A,1,0,
,BAO_0000218,9044,U,Clearance rate in rabbits,Autocuration,,22224,,3615,,9986.0,Oryctolagus cuniculus,,CHEMBL626567,,,In vivo,,A,1,0,
,BAO_0000218,9045,U,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,Autocuration,,22224,,4059,,9986.0,Oryctolagus cuniculus,,CHEMBL626568,,,In vivo,,A,1,0,
,BAO_0000218,9046,U,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,Autocuration,,22224,,5124,,9986.0,Oryctolagus cuniculus,,CHEMBL626569,,,In vivo,,A,1,0,
,BAO_0000218,9047,U,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,Autocuration,,22224,,5124,,9986.0,Oryctolagus cuniculus,,CHEMBL626570,,,In vivo,,A,1,0,
,BAO_0000218,9048,U,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,Autocuration,,22224,,5124,,9986.0,Oryctolagus cuniculus,,CHEMBL626571,,,In vivo,,A,1,0,
,BAO_0000218,9049,U,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg,Autocuration,,22224,,429,,9986.0,Oryctolagus cuniculus,,CHEMBL626572,,,In vivo,,A,1,0,
Plasma,BAO_0000218,9050,U,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,Autocuration,,22224,,4059,1969.0,9986.0,Oryctolagus cuniculus,,CHEMBL626573,,,In vivo,,A,1,0,
Liver,BAO_0000251,9051,U,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2,Autocuration,,22224,,9659,2107.0,9986.0,Oryctolagus cuniculus,,CHEMBL626574,,,,Microsomes,A,1,0,
Liver,BAO_0000251,9052,U,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide,Autocuration,,22224,,9659,2107.0,9986.0,Oryctolagus cuniculus,,CHEMBL626575,,,,Microsomes,A,1,0,
,BAO_0000218,9053,U,Dose at which bioavailability of intravenously administered compound was tested in rabbit,Autocuration,,22224,,3639,,9986.0,Oryctolagus cuniculus,,CHEMBL626576,,,,,A,1,0,
,BAO_0000218,9054,U,Dose at which bioavailability of perorally administered compound was tested in rabbit,Autocuration,,22224,,3639,,9986.0,Oryctolagus cuniculus,,CHEMBL626577,,,,,A,1,0,
,BAO_0000218,9055,U,The compound was tested for its bioavailability in rabbit (by oral dosage).,Autocuration,,22224,,3639,,9986.0,Oryctolagus cuniculus,,CHEMBL626578,,,In vivo,,A,1,0,
,BAO_0000218,9056,U,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,Autocuration,,22224,,5124,,9986.0,Oryctolagus cuniculus,,CHEMBL625263,,,In vivo,,A,1,0,
,BAO_0000218,9057,U,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,Autocuration,,22224,,5124,,9986.0,Oryctolagus cuniculus,,CHEMBL625264,,,In vivo,,A,1,0,
,BAO_0000218,9058,U,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,Autocuration,,22224,,5124,,9986.0,Oryctolagus cuniculus,,CHEMBL625265,,,In vivo,,A,1,0,
,BAO_0000251,9059,U,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak),Autocuration,,22224,,14294,,9986.0,Oryctolagus cuniculus,,CHEMBL625266,,,,Microsomes,A,1,0,
,BAO_0000251,9060,U,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak),Autocuration,,22224,,14294,,9986.0,Oryctolagus cuniculus,,CHEMBL876796,,,,Microsomes,A,1,0,
,BAO_0000218,9061,U,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg,Autocuration,,22224,,429,,9986.0,Oryctolagus cuniculus,,CHEMBL625267,,,In vivo,,A,1,0,
Plasma,BAO_0000218,9062,U,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,Autocuration,,22224,,5124,1969.0,9986.0,Oryctolagus cuniculus,,CHEMBL625268,,,In vivo,,A,1,0,
Plasma,BAO_0000218,9063,U,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,Autocuration,,22224,,5124,1969.0,9986.0,Oryctolagus cuniculus,,CHEMBL625269,,,In vivo,,A,1,0,
Plasma,BAO_0000218,9064,U,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,Autocuration,,22224,,5124,1969.0,9986.0,Oryctolagus cuniculus,,CHEMBL624689,,,In vivo,,A,1,0,
,BAO_0000218,9065,U,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg,Autocuration,,22224,,429,,9986.0,Oryctolagus cuniculus,,CHEMBL624690,,,In vivo,,A,1,0,
Urine,BAO_0000218,9066,U,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr ),Autocuration,,22224,,429,1088.0,9986.0,Oryctolagus cuniculus,,CHEMBL624691,,,,,A,1,0,
Urine,BAO_0000218,9067,U,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr),Autocuration,,22224,,429,1088.0,9986.0,Oryctolagus cuniculus,,CHEMBL624692,,,,,A,1,0,
,BAO_0000218,9068,U,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.,Autocuration,,22224,,4059,,9986.0,Oryctolagus cuniculus,,CHEMBL624693,,,In vivo,,A,1,0,
,BAO_0000218,9069,U,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,Autocuration,,22224,,4137,,9986.0,Oryctolagus cuniculus,,CHEMBL624694,,,In vivo,,A,1,0,
,BAO_0000221,9070,U,In vitro Biological half-life in crude homogenate of rabbit renal cortex,Autocuration,,22224,,11672,,9986.0,Oryctolagus cuniculus,,CHEMBL877596,,,In vitro,,A,1,0,
,BAO_0000019,9071,U,Time within which only 10% of the drug was degraded,Autocuration,,22224,,12886,,9986.0,Oryctolagus cuniculus,,CHEMBL624695,,,,,A,1,0,
Liver,BAO_0000221,9072,U,Half life period in rabbit liver homogenate,Autocuration,,22224,,3853,2107.0,9986.0,Oryctolagus cuniculus,,CHEMBL624696,,,,,A,1,0,
,BAO_0000019,9073,U,Half life value in rabbits,Autocuration,,22224,,3615,,9986.0,Oryctolagus cuniculus,,CHEMBL624697,,,,,A,1,0,
Blood,BAO_0000218,9074,U,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample,Autocuration,,22224,,6253,178.0,9986.0,Oryctolagus cuniculus,,CHEMBL624698,,,In vivo,,A,1,0,
Blood,BAO_0000218,9075,U,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample,Autocuration,,22224,,6253,178.0,9986.0,Oryctolagus cuniculus,,CHEMBL624699,,,In vivo,,A,1,0,
,BAO_0000218,9076,U,Half-life period in rabbits following intravenous administration at 2 mg/kg,Autocuration,,22224,,6077,,9986.0,Oryctolagus cuniculus,,CHEMBL624700,,,In vivo,,A,1,0,
Plasma,BAO_0000218,9077,N,AUC 0-8 hr value in rats at 10 mg/kg,Intermediate,,50597,,17617,1969.0,10116.0,Rattus norvegicus,,CHEMBL622903,,,,,A,1,1,
Plasma,BAO_0000218,9078,N,AUC after administration at 2000 mg/kg/day in rats,Intermediate,,50597,,17594,1969.0,10116.0,Rattus norvegicus,,CHEMBL622904,,,,,A,1,1,
Plasma,BAO_0000218,9079,N,AUC of compound for a 2 mpk po dose of the sodium salt in rats.,Intermediate,,50597,,6149,1969.0,10116.0,Rattus norvegicus,,CHEMBL622905,,,,,A,1,1,
Plasma,BAO_0000218,9080,N,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,Intermediate,,50597,,17260,1969.0,10116.0,Rattus norvegicus,,CHEMBL622906,,,,,A,1,1,
Plasma,BAO_0000218,9081,N,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,Intermediate,,50597,,17260,1969.0,10116.0,Rattus norvegicus,,CHEMBL622907,,,,,A,1,1,
Plasma,BAO_0000218,9082,N,AUC in rat after oral administration at 10.5 mg/kg dose,Intermediate,,50597,,6644,1969.0,10116.0,Rattus norvegicus,,CHEMBL622908,,,,,A,1,1,
Plasma,BAO_0000218,9083,N,AUC in rat after oral administration at 11.2 mg/kg dose,Intermediate,,50597,,6644,1969.0,10116.0,Rattus norvegicus,,CHEMBL622909,,,,,A,1,1,
Plasma,BAO_0000218,9084,N,AUC in rat after oral administration at 9.7 mg/kg dose,Intermediate,,50597,,6644,1969.0,10116.0,Rattus norvegicus,,CHEMBL622910,,,,,A,1,1,
Brain,BAO_0000218,9085,N,AUC in rat brain after oral administration at 10 mg/kg,Intermediate,,50597,,6495,955.0,10116.0,Rattus norvegicus,,CHEMBL622911,,,,,A,1,1,
Plasma,BAO_0000218,9086,N,AUC in rat p.o.,Intermediate,,50597,,6504,1969.0,10116.0,Rattus norvegicus,,CHEMBL622912,,,,,A,1,1,
Plasma,BAO_0000218,9087,N,AUC in rat p.o. at 20 mg/kg concentration,Intermediate,,50597,,17686,1969.0,10116.0,Rattus norvegicus,,CHEMBL622913,,,,,A,1,1,
Plasma,BAO_0000218,9088,N,AUC in rat plasma after oral administration at 10 mg/kg,Intermediate,,50597,,6495,1969.0,10116.0,Rattus norvegicus,,CHEMBL622914,,,,,A,1,1,
Plasma,BAO_0000218,9089,N,AUC in rats,Intermediate,,50597,,216,1969.0,10116.0,Rattus norvegicus,,CHEMBL622915,,,,,A,1,1,
Plasma,BAO_0000218,9090,N,AUC value after IV dose at a dose of 5 mg/kg in rats.,Intermediate,,50597,,1908,1969.0,10116.0,Rattus norvegicus,,CHEMBL622916,,,,,A,1,1,
Plasma,BAO_0000218,9091,N,AUC value after oral dose at a dose of 10 mg/kg in rats.,Intermediate,,50597,,1908,1969.0,10116.0,Rattus norvegicus,,CHEMBL622917,,,,,A,1,1,
Plasma,BAO_0000218,9092,N,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable",Intermediate,,50597,,6685,1969.0,10116.0,Rattus norvegicus,,CHEMBL622918,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9093,N,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given,Intermediate,,50597,,216,1969.0,10116.0,Rattus norvegicus,,CHEMBL622919,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9094,N,Maximum plasma concentration was evaluated in rat,Intermediate,,50597,,6049,1969.0,10116.0,Rattus norvegicus,,CHEMBL622920,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9095,N,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,Intermediate,,50597,,2463,1969.0,10116.0,Rattus norvegicus,,CHEMBL622921,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9096,N,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,Intermediate,,50597,,6679,1969.0,10116.0,Rattus norvegicus,,CHEMBL622922,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9097,N,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,Intermediate,,50597,,6681,1969.0,10116.0,Rattus norvegicus,,CHEMBL622923,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9098,N,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,Intermediate,,50597,,4890,1969.0,10116.0,Rattus norvegicus,,CHEMBL877604,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9099,N,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg,Intermediate,,50597,,6410,1969.0,10116.0,Rattus norvegicus,,CHEMBL622924,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9100,N,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg,Intermediate,,50597,,6410,1969.0,10116.0,Rattus norvegicus,,CHEMBL622925,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9101,N,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally,Intermediate,,50597,,16366,1969.0,10116.0,Rattus norvegicus,,CHEMBL622926,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9102,N,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg,Intermediate,,50597,,6227,1969.0,10116.0,Rattus norvegicus,,CHEMBL623625,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9103,N,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg,Expert,,50597,,3598,1969.0,10116.0,Rattus norvegicus,,CHEMBL623626,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9104,N,Maximum plasma drug concentration was determined,Intermediate,,50597,,1465,1969.0,10116.0,Rattus norvegicus,,CHEMBL623627,,,In vivo,,A,1,1,
,BAO_0000218,9105,N,Maximum concentration by intravenous administration of 3.4 mg/kg in rat,Intermediate,,50597,,4368,,10116.0,Rattus norvegicus,,CHEMBL623628,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9106,N,Mean peak plasma concentration was observed after intravenous administration in rat,Intermediate,,50597,,15662,1969.0,10116.0,Rattus norvegicus,,CHEMBL623629,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9107,N,Mean peak plasma concentration was observed after oral administration in rat,Intermediate,,50597,,15662,1969.0,10116.0,Rattus norvegicus,,CHEMBL623630,,,In vivo,,A,1,1,
,BAO_0000218,9108,N,Peak concentration (Cmax) at a dose of 10 mg/kg in rats,Intermediate,,50597,,5355,,10116.0,Rattus norvegicus,,CHEMBL623804,,,In vivo,,A,1,1,
,BAO_0000218,9109,N,Peak concentration (Cmax) at a dose of 20 mg/kg in rats,Intermediate,,50597,,5355,,10116.0,Rattus norvegicus,,CHEMBL623805,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9110,N,Peak oral plasma concentration was determined in rats by oral administration,Intermediate,,50597,,1567,1969.0,10116.0,Rattus norvegicus,,CHEMBL623806,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9111,N,Peak plasma concentration (Cmax) was determined,Intermediate,,50597,,4026,1969.0,10116.0,Rattus norvegicus,,CHEMBL623807,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9112,N,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats,Intermediate,,50597,,6193,1969.0,10116.0,Rattus norvegicus,,CHEMBL623808,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9113,N,Peak plasma concentration (Cmax) in rats,Intermediate,,50597,,4026,1969.0,10116.0,Rattus norvegicus,,CHEMBL623809,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9114,N,Peak plasma concentration at 1 mg/kg peroral administration,Intermediate,,50597,,6485,1969.0,10116.0,Rattus norvegicus,,CHEMBL623810,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9115,N,Peak plasma concentration in rat,Intermediate,,50597,,17655,1969.0,10116.0,Rattus norvegicus,,CHEMBL623811,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9116,N,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration",Intermediate,,50597,,14941,1969.0,10116.0,Rattus norvegicus,,CHEMBL623812,,,In vivo,,A,1,1,
,BAO_0000218,9117,N,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg,Intermediate,,50597,,5394,,10116.0,Rattus norvegicus,,CHEMBL877605,,,In vivo,,A,1,1,
,BAO_0000218,9118,N,Pharmacokinetic property (Cmax) in rat,Intermediate,,50597,,4408,,10116.0,Rattus norvegicus,,CHEMBL623813,,,In vivo,,A,1,1,
,BAO_0000218,9119,N,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.,Intermediate,,50597,,5983,,10116.0,Rattus norvegicus,,CHEMBL623814,,,In vivo,,A,1,1,
,BAO_0000218,9120,N,Cmax in rat after 3mg/kg oral dose,Intermediate,,50597,,4878,,10116.0,Rattus norvegicus,,CHEMBL623815,,,In vivo,,A,1,1,
,BAO_0000218,9121,N,Clearance in Sprague-Dawley rats after 2mg/kg oral dose,Intermediate,,50597,,5862,,10116.0,Rattus norvegicus,,CHEMBL623816,,,In vivo,,A,1,1,Sprague-Dawley
,BAO_0000218,9122,N,Cmax in rats after 20 mg/kg oral dose,Intermediate,,50597,,4517,,10116.0,Rattus norvegicus,,CHEMBL623145,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9123,N,Cmax in rat plasma after 30mg/kg oral dose,Intermediate,,50597,,5932,1969.0,10116.0,Rattus norvegicus,,CHEMBL623146,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9124,N,Plasma concentration after oral administration of 100 mg/kg to rats,Intermediate,,50597,,5436,1969.0,10116.0,Rattus norvegicus,,CHEMBL623147,,,In vivo,,A,1,1,
Brain,BAO_0000218,9125,N,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,Intermediate,,50597,,4910,955.0,10116.0,Rattus norvegicus,,CHEMBL623042,,,In vivo,,A,1,1,
,BAO_0000218,9126,N,Tested for the Cmax in rat at 10 mg/kg per orally,Intermediate,,50597,,4950,,10116.0,Rattus norvegicus,,CHEMBL623043,,,In vivo,,A,1,1,
,BAO_0000218,9127,N,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",Intermediate,,50597,,15078,,10116.0,Rattus norvegicus,,CHEMBL623044,,,In vivo,,A,1,1,
,BAO_0000218,9128,N,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose",Intermediate,,50597,,15078,,10116.0,Rattus norvegicus,,CHEMBL623045,,,In vivo,,A,1,1,
,BAO_0000218,9129,N,Bioavailability as oral Cmax in rats at 30 mins,Intermediate,,50597,,3360,,10116.0,Rattus norvegicus,,CHEMBL623046,,,In vivo,,A,1,1,
,BAO_0000218,9130,N,Bioavailability as oral Cmax in rats at 6hr,Intermediate,,50597,,3360,,10116.0,Rattus norvegicus,,CHEMBL623226,,,In vivo,,A,1,1,
,BAO_0000218,9131,N,The maximum concentration of compound was measured at the dose of 100 umol/kg,Intermediate,,50597,,15022,,10116.0,Rattus norvegicus,,CHEMBL623227,,,In vivo,,A,1,1,
,BAO_0000218,9132,N,The maximum concentration of compound was measured at the dose of 300 umol/kg,Intermediate,,50597,,15022,,10116.0,Rattus norvegicus,,CHEMBL623228,,,In vivo,,A,1,1,
,BAO_0000218,9133,N,The maximum concentration of compound was measured at the dose of 30 umol/kg,Intermediate,,50597,,15022,,10116.0,Rattus norvegicus,,CHEMBL623229,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9134,N,The maximum plasma levels for the compounds were determined by LC-MS.,Intermediate,,50597,,5160,1969.0,10116.0,Rattus norvegicus,,CHEMBL623230,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9135,N,mean peak plasma concentration was observed after intravenous administration in rat,Intermediate,,50597,,15662,1969.0,10116.0,Rattus norvegicus,,CHEMBL623231,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9136,N,mean peak plasma concentration was observed after oral administration in rat,Intermediate,,50597,,15662,1969.0,10116.0,Rattus norvegicus,,CHEMBL623232,,,In vivo,,A,1,1,
,BAO_0000218,9137,N,Concentration in the plasma after intravenous administration of 1 mg/kg in rat,Intermediate,,50597,,4709,,10116.0,Rattus norvegicus,,CHEMBL623233,,,,,A,1,1,
,BAO_0000218,9138,N,Concentration in plasma (portal) following oral dose in rats at 0.25 hr,Intermediate,,50597,,3535,,10116.0,Rattus norvegicus,,CHEMBL623234,,,,,A,1,1,
,BAO_0000218,9139,N,Concentration in plasma (portal) following oral dose in rats at 1 hr,Intermediate,,50597,,3535,,10116.0,Rattus norvegicus,,CHEMBL623235,,,,,A,1,1,
,BAO_0000218,9140,N,Concentration in plasma (portal) following oral dose in rats at 2 hr,Intermediate,,50597,,3535,,10116.0,Rattus norvegicus,,CHEMBL623236,,,,,A,1,1,
,BAO_0000218,9141,N,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr,Intermediate,,50597,,3535,,10116.0,Rattus norvegicus,,CHEMBL623237,,,,,A,1,1,
,BAO_0000218,9142,N,Concentration in plasma (systemic) following oral dose in rats at 1 hr,Intermediate,,50597,,3535,,10116.0,Rattus norvegicus,,CHEMBL623238,,,,,A,1,1,
,BAO_0000218,9143,N,Concentration in plasma (systemic) following oral dose in rats at 2 hr,Intermediate,,50597,,3535,,10116.0,Rattus norvegicus,,CHEMBL623239,,,,,A,1,1,
Plasma,BAO_0000218,9144,U,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo,Intermediate,,22224,,5005,1969.0,10116.0,Rattus norvegicus,,CHEMBL623240,,,In vivo,,A,1,0,
Hypothalamus,BAO_0000218,9145,N,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours",Intermediate,,50597,,6326,1898.0,10116.0,Rattus norvegicus,,CHEMBL623241,,,,,A,1,1,
Hypothalamus,BAO_0000218,9146,N,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours",Intermediate,,50597,,6326,1898.0,10116.0,Rattus norvegicus,,CHEMBL623242,,,,,A,1,1,
,BAO_0000218,9147,N,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours",Intermediate,,50597,,6326,,10116.0,Rattus norvegicus,,CHEMBL874394,,,,,A,1,1,
,BAO_0000218,9148,N,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours",Intermediate,,50597,,6326,,10116.0,Rattus norvegicus,,CHEMBL623243,,,,,A,1,1,
,BAO_0000218,9149,N,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,,50597,,17411,,10116.0,Rattus norvegicus,,CHEMBL623244,,,,,A,1,1,
Kidney,BAO_0000218,9150,N,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,,50597,,16435,2113.0,10116.0,Rattus norvegicus,,CHEMBL623245,,,,,A,1,1,
Kidney,BAO_0000218,9151,N,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,,50597,,16435,2113.0,10116.0,Rattus norvegicus,,CHEMBL623246,,,,,A,1,1,
Kidney,BAO_0000218,9152,N,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,,50597,,16435,2113.0,10116.0,Rattus norvegicus,,CHEMBL623247,,,,,A,1,1,
Kidney,BAO_0000218,9153,N,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,,50597,,16435,2113.0,10116.0,Rattus norvegicus,,CHEMBL623248,,,,,A,1,1,
Kidney,BAO_0000218,9154,N,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,,50597,,16435,2113.0,10116.0,Rattus norvegicus,,CHEMBL623249,,,,,A,1,1,
Liver,BAO_0000218,9155,N,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,,50597,,16434,2107.0,10116.0,Rattus norvegicus,,CHEMBL625072,,,,,A,1,1,
Liver,BAO_0000218,9156,N,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Intermediate,,50597,,16434,2107.0,10116.0,Rattus norvegicus,,CHEMBL625073,,,,,A,1,1,
Liver,BAO_0000218,9157,N,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,,50597,,16434,2107.0,10116.0,Rattus norvegicus,,CHEMBL625074,,,,,A,1,1,
Liver,BAO_0000218,9158,N,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,,50597,,16434,2107.0,10116.0,Rattus norvegicus,,CHEMBL625075,,,,,A,1,1,
Liver,BAO_0000218,9159,N,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.,Intermediate,,50597,,16434,2107.0,10116.0,Rattus norvegicus,,CHEMBL625076,,,,,A,1,1,
Liver,BAO_0000218,9160,N,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Intermediate,,50597,,16434,2107.0,10116.0,Rattus norvegicus,,CHEMBL625077,,,,,A,1,1,
Liver,BAO_0000218,9161,N,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Intermediate,,50597,,16434,2107.0,10116.0,Rattus norvegicus,,CHEMBL625078,,,,,A,1,1,
Liver,BAO_0000218,9162,N,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Intermediate,,50597,,16434,2107.0,10116.0,Rattus norvegicus,,CHEMBL874395,,,,,A,1,1,
Liver,BAO_0000218,9163,N,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Intermediate,,50597,,16435,2107.0,10116.0,Rattus norvegicus,,CHEMBL625079,,,,,A,1,1,
Liver,BAO_0000218,9164,N,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Intermediate,,50597,,16435,2107.0,10116.0,Rattus norvegicus,,CHEMBL625080,,,,,A,1,1,
Liver,BAO_0000218,9165,N,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Intermediate,,50597,,16435,2107.0,10116.0,Rattus norvegicus,,CHEMBL625081,,,,,A,1,1,
Liver,BAO_0000218,9166,N,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Intermediate,,50597,,16435,2107.0,10116.0,Rattus norvegicus,,CHEMBL625082,,,,,A,1,1,
Liver,BAO_0000218,9167,N,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Intermediate,,50597,,16435,2107.0,10116.0,Rattus norvegicus,,CHEMBL625083,,,,,A,1,1,
Liver,BAO_0000218,9168,N,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Intermediate,,50597,,16435,2107.0,10116.0,Rattus norvegicus,,CHEMBL625084,,,,,A,1,1,
Liver,BAO_0000218,9169,N,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Intermediate,,50597,,16435,2107.0,10116.0,Rattus norvegicus,,CHEMBL625085,,,,,A,1,1,
Liver,BAO_0000218,9170,N,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Intermediate,,50597,,16435,2107.0,10116.0,Rattus norvegicus,,CHEMBL625086,,,,,A,1,1,
Liver,BAO_0000218,9171,N,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Intermediate,,50597,,16434,2107.0,10116.0,Rattus norvegicus,,CHEMBL625087,,,,,A,1,1,
Liver,BAO_0000218,9172,N,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Intermediate,,50597,,16434,2107.0,10116.0,Rattus norvegicus,,CHEMBL625088,,,,,A,1,1,
Liver,BAO_0000218,9173,N,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Intermediate,,50597,,16434,2107.0,10116.0,Rattus norvegicus,,CHEMBL622205,,,,,A,1,1,
Liver,BAO_0000218,9174,N,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,,50597,,16435,2107.0,10116.0,Rattus norvegicus,,CHEMBL622206,,,,,A,1,1,
Liver,BAO_0000218,9175,N,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,,50597,,16435,2107.0,10116.0,Rattus norvegicus,,CHEMBL622207,,,,,A,1,1,
Liver,BAO_0000218,9176,N,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,,50597,,16435,2107.0,10116.0,Rattus norvegicus,,CHEMBL622366,,,,,A,1,1,
Liver,BAO_0000218,9177,N,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,,50597,,16435,2107.0,10116.0,Rattus norvegicus,,CHEMBL622367,,,,,A,1,1,
Liver,BAO_0000218,9178,N,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,,50597,,16435,2107.0,10116.0,Rattus norvegicus,,CHEMBL875331,,,,,A,1,1,
Liver,BAO_0000218,9179,N,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,,50597,,16435,2107.0,10116.0,Rattus norvegicus,,CHEMBL622368,,,,,A,1,1,
Lung,BAO_0000218,9180,N,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,,50597,,16434,2048.0,10116.0,Rattus norvegicus,,CHEMBL622369,,,,,A,1,1,
Lung,BAO_0000218,9181,N,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Intermediate,,50597,,16434,2048.0,10116.0,Rattus norvegicus,,CHEMBL622370,,,,,A,1,1,
Lung,BAO_0000218,9182,N,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,,50597,,16434,2048.0,10116.0,Rattus norvegicus,,CHEMBL622371,,,,,A,1,1,
Lung,BAO_0000218,9183,N,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,,50597,,16434,2048.0,10116.0,Rattus norvegicus,,CHEMBL622372,,,,,A,1,1,
Lung,BAO_0000218,9184,N,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Intermediate,,50597,,16434,2048.0,10116.0,Rattus norvegicus,,CHEMBL622373,,,,,A,1,1,
Lung,BAO_0000218,9185,N,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Intermediate,,50597,,16434,2048.0,10116.0,Rattus norvegicus,,CHEMBL622374,,,,,A,1,1,
Lung,BAO_0000218,9186,N,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Intermediate,,50597,,16434,2048.0,10116.0,Rattus norvegicus,,CHEMBL622375,,,,,A,1,1,
Lung,BAO_0000218,9187,N,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,Intermediate,,50597,,16434,2048.0,10116.0,Rattus norvegicus,,CHEMBL622376,,,,,A,1,1,
Lung,BAO_0000218,9188,N,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Intermediate,,50597,,16435,2048.0,10116.0,Rattus norvegicus,,CHEMBL622377,,,,,A,1,1,
Lung,BAO_0000218,9189,N,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Intermediate,,50597,,16435,2048.0,10116.0,Rattus norvegicus,,CHEMBL622378,,,,,A,1,1,
Lung,BAO_0000218,9190,N,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Intermediate,,50597,,16435,2048.0,10116.0,Rattus norvegicus,,CHEMBL622379,,,,,A,1,1,
Lung,BAO_0000218,9191,N,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Intermediate,,50597,,16435,2048.0,10116.0,Rattus norvegicus,,CHEMBL622380,,,,,A,1,1,
Lung,BAO_0000218,9192,N,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Intermediate,,50597,,16435,2048.0,10116.0,Rattus norvegicus,,CHEMBL622381,,,,,A,1,1,
Lung,BAO_0000218,9193,N,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Intermediate,,50597,,16435,2048.0,10116.0,Rattus norvegicus,,CHEMBL622382,,,,,A,1,1,
Lung,BAO_0000218,9194,N,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min,Intermediate,,50597,,16434,2048.0,10116.0,Rattus norvegicus,,CHEMBL622383,,,,,A,1,1,
Stomach,BAO_0000218,9195,N,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Intermediate,,50597,,6175,945.0,10116.0,Rattus norvegicus,,CHEMBL875332,,,,,A,1,1,
Stomach,BAO_0000218,9196,N,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Intermediate,,50597,,6175,945.0,10116.0,Rattus norvegicus,,CHEMBL622384,,,,,A,1,1,
Stomach,BAO_0000218,9197,N,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Intermediate,,50597,,6175,945.0,10116.0,Rattus norvegicus,,CHEMBL622385,,,,,A,1,1,
Stomach,BAO_0000218,9198,N,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Intermediate,,50597,,6175,945.0,10116.0,Rattus norvegicus,,CHEMBL622386,,,,,A,1,1,
,BAO_0000218,9199,N,The compound was tested for the plasma binding in rat,Intermediate,,50597,,10839,,10116.0,Rattus norvegicus,,CHEMBL622387,,,,,A,1,1,
,BAO_0000218,9200,N,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)",Intermediate,,50597,,16459,,10116.0,Rattus norvegicus,,CHEMBL622388,,,,,A,1,1,
,BAO_0000218,9201,N,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)",Intermediate,,50597,,16459,,10116.0,Rattus norvegicus,,CHEMBL622389,,,,,A,1,1,
,BAO_0000218,9202,N,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)",Intermediate,,50597,,16459,,10116.0,Rattus norvegicus,,CHEMBL622390,,,,,A,1,1,
,BAO_0000218,9203,N,Plasma concentration after oral aministration at 1 hr. (10 mg/kg),Intermediate,,50597,,16459,,10116.0,Rattus norvegicus,,CHEMBL622391,,,,,A,1,1,
,BAO_0000218,9204,N,Plasma concentration after oral aministration at 2 hr. (10 mg/kg),Intermediate,,50597,,16459,,10116.0,Rattus norvegicus,,CHEMBL622392,,,,,A,1,1,
,BAO_0000218,9205,N,Plasma concentration after oral aministration at 4 hr. (10 mg/kg),Intermediate,,50597,,16459,,10116.0,Rattus norvegicus,,CHEMBL622393,,,,,A,1,1,
,BAO_0000218,9206,N,Plasma level at 2 hr after administration of the compound,Intermediate,,50597,,3278,,10116.0,Rattus norvegicus,,CHEMBL622394,,,,,A,1,1,
,BAO_0000218,9207,N,plasma level at 2 hr after administration of the compound,Intermediate,,50597,,3278,,10116.0,Rattus norvegicus,,CHEMBL622395,,,,,A,1,1,
Serum,BAO_0000218,9208,N,Stability in rat serum measured as % recovery at 1 min,Intermediate,,50597,,4684,1977.0,10116.0,Rattus norvegicus,,CHEMBL622396,,,,,A,1,1,
Serum,BAO_0000218,9209,N,Stability in rat serum measured as % recovery at 10 min,Intermediate,,50597,,4684,1977.0,10116.0,Rattus norvegicus,,CHEMBL624894,,,,,A,1,1,
Serum,BAO_0000218,9210,N,Stability in rat serum measured as % recovery at 10 mins,Intermediate,,50597,,4684,1977.0,10116.0,Rattus norvegicus,,CHEMBL624895,,,,,A,1,1,
Serum,BAO_0000218,9211,N,Stability in rat serum measured as % recovery at 2 hr,Intermediate,,50597,,4684,1977.0,10116.0,Rattus norvegicus,,CHEMBL624058,,,,,A,1,1,
Serum,BAO_0000218,9212,N,Stability in rat serum measured as % recovery at 3 min,Intermediate,,50597,,4684,1977.0,10116.0,Rattus norvegicus,,CHEMBL624059,,,,,A,1,1,
Serum,BAO_0000218,9213,N,Stability in rat serum measured as % recovery at 3 mins,Intermediate,,50597,,4684,1977.0,10116.0,Rattus norvegicus,,CHEMBL624060,,,,,A,1,1,
Serum,BAO_0000218,9214,N,Stability in rat serum measured as % recovery at 5 min,Intermediate,,50597,,4684,1977.0,10116.0,Rattus norvegicus,,CHEMBL624061,,,,,A,1,1,
Serum,BAO_0000218,9215,N,Stability in rat serum measured as % recovery at 5 mins,Intermediate,,50597,,4684,1977.0,10116.0,Rattus norvegicus,,CHEMBL624062,,,,,A,1,1,
,BAO_0000218,9216,N,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,Intermediate,,50597,,16456,,10116.0,Rattus norvegicus,,CHEMBL624063,,,In vivo,,A,1,1,
,BAO_0000218,9217,N,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,Intermediate,,50597,,16456,,10116.0,Rattus norvegicus,,CHEMBL624064,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9218,N,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma,Intermediate,,50597,,723,1969.0,10116.0,Rattus norvegicus,,CHEMBL624065,,,,,A,1,1,
Plasma,BAO_0000218,9219,N,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.,Intermediate,,50597,,723,1969.0,10116.0,Rattus norvegicus,,CHEMBL624066,,,,,A,1,1,
,BAO_0000218,9220,N,Half life tested in mature male rat at a dose of 30 mg/kg,Intermediate,,50597,,5160,,10116.0,Rattus norvegicus,,CHEMBL877490,,,In vivo,,A,1,1,
,BAO_0000218,9221,N,Half life after intravenous administration of 1 mg/kg in rat,Intermediate,,50597,,4709,,10116.0,Rattus norvegicus,,CHEMBL874442,,,In vivo,,A,1,1,
,BAO_0000218,9222,N,Half life period after administration (30 mg/kg) in rat,Intermediate,,50597,,5633,,10116.0,Rattus norvegicus,,CHEMBL626890,,,In vivo,,A,1,1,
,BAO_0000218,9223,N,Half life period in rat after 5 mg/Kg dose,Intermediate,,50597,,5302,,10116.0,Rattus norvegicus,,CHEMBL626891,,,In vivo,,A,1,1,
,BAO_0000218,9224,N,Half life period in rat after 5 mg/kg dose,Intermediate,,50597,,5302,,10116.0,Rattus norvegicus,,CHEMBL626892,,,In vivo,,A,1,1,
,BAO_0000218,9225,N,Half life period was determined,Intermediate,,50597,,17791,,10116.0,Rattus norvegicus,,CHEMBL626893,,,,,A,1,1,
,BAO_0000218,9226,N,Half life period was evaluated in rat,Intermediate,,50597,,17791,,10116.0,Rattus norvegicus,,CHEMBL626894,,,,,A,1,1,
,BAO_0000218,9227,N,Half life period was evaluated in rat; 0.5-1.0,Intermediate,,50597,,17791,,10116.0,Rattus norvegicus,,CHEMBL626895,,,,,A,1,1,
,BAO_0000218,9228,N,Half life period was evaluated in rat; 5.9-7.5,Intermediate,,50597,,17791,,10116.0,Rattus norvegicus,,CHEMBL626896,,,,,A,1,1,
Plasma,BAO_0000218,9229,N,Half-life in rat plasma,Intermediate,,50597,,14512,1969.0,10116.0,Rattus norvegicus,,CHEMBL626897,,,,,A,1,1,
,BAO_0000218,9230,N,Half-life time in rat was determined,Intermediate,,50597,,6230,,10116.0,Rattus norvegicus,,CHEMBL626898,,,,,A,1,1,
,BAO_0000218,9231,N,Terminal half-life after iv administration to rats,Intermediate,,50597,,3364,,10116.0,Rattus norvegicus,,CHEMBL626899,,,In vivo,,A,1,1,
,BAO_0000218,9232,N,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats,Intermediate,,50597,,6874,,10116.0,Rattus norvegicus,,CHEMBL626900,,,In vivo,,A,1,1,
,BAO_0000218,9233,N,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg,Intermediate,,50597,,857,,10116.0,Rattus norvegicus,,CHEMBL626901,,,,,A,1,1,
,BAO_0000218,9234,N,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv),Intermediate,,50597,,858,,10116.0,Rattus norvegicus,,CHEMBL626902,,,In vivo,,A,1,1,
,BAO_0000218,9235,N,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv),Intermediate,,50597,,858,,10116.0,Rattus norvegicus,,CHEMBL626903,,,In vivo,,A,1,1,
,BAO_0000218,9236,N,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats,Intermediate,,50597,,5355,,10116.0,Rattus norvegicus,,CHEMBL874443,,,In vivo,,A,1,1,
,BAO_0000218,9237,N,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats,Intermediate,,50597,,5355,,10116.0,Rattus norvegicus,,CHEMBL626904,,,In vivo,,A,1,1,
,BAO_0000218,9238,N,Half life in rats,Intermediate,,50597,,6305,,10116.0,Rattus norvegicus,,CHEMBL626905,,,,,A,1,1,
Plasma,BAO_0000218,9239,N,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat,Intermediate,,50597,,13501,1969.0,10116.0,Rattus norvegicus,,CHEMBL873830,,,In vivo,,A,1,1,
,BAO_0000218,9240,N,Apparent half-life after single intravenous bolus of 1 mg/kg in rats,Intermediate,,50597,,17594,,10116.0,Rattus norvegicus,,CHEMBL626906,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9241,N,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,Intermediate,,50597,,4186,1969.0,10116.0,Rattus norvegicus,,CHEMBL631076,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9242,N,Biological half-life was measured in plasma of rats,Intermediate,,50597,,2932,1969.0,10116.0,Rattus norvegicus,,CHEMBL631077,,,,,A,1,1,
,BAO_0000218,9243,N,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats,Intermediate,,50597,,17065,,10116.0,Rattus norvegicus,,CHEMBL631078,,,In vivo,,A,1,1,
,BAO_0000218,9244,N,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.,Intermediate,,50597,,15765,,10116.0,Rattus norvegicus,,CHEMBL631079,,,In vivo,,A,1,1,
,BAO_0000218,9245,N,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats,Intermediate,,50597,,2713,,10116.0,Rattus norvegicus,,CHEMBL631080,,,In vivo,,A,1,1,
,BAO_0000218,9246,N,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats,Intermediate,,50597,,2661,,10116.0,Rattus norvegicus,,CHEMBL631081,,,In vivo,,A,1,1,
,BAO_0000218,9247,N,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats,Intermediate,,50597,,2661,,10116.0,Rattus norvegicus,,CHEMBL631239,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9248,N,Compound was evaluated for plasma half life in rat,Intermediate,,50597,,740,1969.0,10116.0,Rattus norvegicus,,CHEMBL631240,,,,,A,1,1,
Plasma,BAO_0000218,9249,N,AUC value at a dose of 5 mg/kg (p.o.) in rats,Intermediate,,50597,,6597,1969.0,10116.0,Rattus norvegicus,,CHEMBL631241,,,,,A,1,1,
Plasma,BAO_0000218,9250,N,AUC value after administration of 20 mg/Kg oral dose in rat,Intermediate,,50597,,2959,1969.0,10116.0,Rattus norvegicus,,CHEMBL631242,,,,,A,1,1,
Plasma,BAO_0000218,9251,N,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats,Intermediate,,50597,,17594,1969.0,10116.0,Rattus norvegicus,,CHEMBL631243,,,,,A,1,1,
Plasma,BAO_0000218,9252,N,AUC0-96 after administration at 50 mg/kg,Intermediate,,50597,,17596,1969.0,10116.0,Rattus norvegicus,,CHEMBL874444,,,,,A,1,1,
Plasma,BAO_0000218,9253,N,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats,Intermediate,,50597,,17594,1969.0,10116.0,Rattus norvegicus,,CHEMBL631244,,,,,A,1,1,
,BAO_0000218,9254,N,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats.",Intermediate,,50597,,3293,,10116.0,Rattus norvegicus,,CHEMBL631245,,,,,A,1,1,
,BAO_0000218,9255,N,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats,Intermediate,,50597,,6757,,10116.0,Rattus norvegicus,,CHEMBL627162,,,,,A,1,1,
,BAO_0000218,9256,N,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats,Intermediate,,50597,,6757,,10116.0,Rattus norvegicus,,CHEMBL627163,,,,,A,1,1,
,BAO_0000218,9257,N,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats,Intermediate,,50597,,6757,,10116.0,Rattus norvegicus,,CHEMBL627164,,,,,A,1,1,
Kidney,BAO_0000218,9258,N,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney,Intermediate,,50597,,5979,2113.0,10116.0,Rattus norvegicus,,CHEMBL627165,,,,,A,1,1,
,BAO_0000218,9259,N,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver,Intermediate,,50597,,5979,,10116.0,Rattus norvegicus,,CHEMBL627166,,,,,A,1,1,
,BAO_0000218,9260,N,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung,Intermediate,,50597,,5979,,10116.0,Rattus norvegicus,,CHEMBL627167,,,,,A,1,1,
,BAO_0000218,9261,N,Area under curve (AUC) at a dose of 30 mg/kg in rats,Intermediate,,50597,,4026,,10116.0,Rattus norvegicus,,CHEMBL627822,,,,,A,1,1,
,BAO_0000218,9262,N,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,Intermediate,,50597,,5355,,10116.0,Rattus norvegicus,,CHEMBL627823,,,,,A,1,1,
,BAO_0000218,9263,N,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats,Intermediate,,50597,,5355,,10116.0,Rattus norvegicus,,CHEMBL627824,,,,,A,1,1,
,BAO_0000218,9264,N,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,Intermediate,,50597,,5355,,10116.0,Rattus norvegicus,,CHEMBL627825,,,,,A,1,1,
,BAO_0000218,9265,N,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat,Intermediate,,50597,,5633,,10116.0,Rattus norvegicus,,CHEMBL627826,,,,,A,1,1,
,BAO_0000218,9266,N,Area under curve (Pharmacokinetic property) was determined,Intermediate,,50597,,1716,,10116.0,Rattus norvegicus,,CHEMBL627827,,,,,A,1,1,
,BAO_0000218,9267,N,Area under curve (Pharmacokinetic property) of the compound; Not determined,Intermediate,,50597,,1716,,10116.0,Rattus norvegicus,,CHEMBL627828,,,,,A,1,1,
,BAO_0000218,9268,N,Area under curve after intravenous administration (1 mg/kg) in rat,Intermediate,,50597,,4689,,10116.0,Rattus norvegicus,,CHEMBL627829,,,,,A,1,1,
,BAO_0000218,9269,N,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined,Intermediate,,50597,,4527,,10116.0,Rattus norvegicus,,CHEMBL627830,,,,,A,1,1,
,BAO_0000218,9270,N,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined,Intermediate,,50597,,4527,,10116.0,Rattus norvegicus,,CHEMBL627831,,,,,A,1,1,
,BAO_0000218,9271,N,Area under curve in male SD rats was observed after oral administration in rat,Intermediate,,50597,,15662,,10116.0,Rattus norvegicus,,CHEMBL627832,,,,,A,1,1,
,BAO_0000218,9272,N,Area under curve of compound after iv administration of 20 mg/kg dose in rat,Intermediate,,50597,,4413,,10116.0,Rattus norvegicus,,CHEMBL627833,,,,,A,1,1,
,BAO_0000218,9273,N,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg,Expert,,50597,,3598,,10116.0,Rattus norvegicus,,CHEMBL627834,,,,,A,1,1,
,BAO_0000218,9274,N,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg,Expert,,50597,,3598,,10116.0,Rattus norvegicus,,CHEMBL628004,,,,,A,1,1,
,BAO_0000218,9275,N,Area under curve at 5 mg/kg po was determined in rat,Intermediate,,50597,,5964,,10116.0,Rattus norvegicus,,CHEMBL628005,,,,,A,1,1,
,BAO_0000218,9276,N,Area under curve in Rat at a oral dose of 5 mg/kg,Intermediate,,50597,,4689,,10116.0,Rattus norvegicus,,CHEMBL628006,,,,,A,1,1,
,BAO_0000218,9277,N,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,Intermediate,,50597,,4186,,10116.0,Rattus norvegicus,,CHEMBL628007,,,,,A,1,1,
,BAO_0000218,9278,N,Area under curve was determined,Intermediate,,50597,,5510,,10116.0,Rattus norvegicus,,CHEMBL625676,,,,,A,1,1,
,BAO_0000218,9279,N,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr,Intermediate,,50597,,17858,,10116.0,Rattus norvegicus,,CHEMBL631309,,,,,A,1,1,
,BAO_0000218,9280,N,Area under curve after intravenous administration at 3 mg/kg,Intermediate,,50597,,17804,,10116.0,Rattus norvegicus,,CHEMBL631310,,,,,A,1,1,
,BAO_0000218,9281,N,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h,Intermediate,,50597,,6106,,10116.0,Rattus norvegicus,,CHEMBL631311,,,,,A,1,1,
,BAO_0000218,9282,N,Area under curve at 4 hr in rat,Intermediate,,50597,,5964,,10116.0,Rattus norvegicus,,CHEMBL631312,,,,,A,1,1,
,BAO_0000218,9283,N,Area under curve at a dose of 30 mg/kg,Intermediate,,50597,,4026,,10116.0,Rattus norvegicus,,CHEMBL631313,,,,,A,1,1,
,BAO_0000218,9284,N,Area under curve at the dose of 2 mg/Kg administered perorally in rats,Intermediate,,50597,,4756,,10116.0,Rattus norvegicus,,CHEMBL631314,,,,,A,1,1,
,BAO_0000218,9285,N,Area under curve at the dose of 5 mg/Kg administered perorally in rats,Intermediate,,50597,,4756,,10116.0,Rattus norvegicus,,CHEMBL631315,,,,,A,1,1,
,BAO_0000218,9286,N,Area under curve for a 2-mpk po dose in SD rats,Intermediate,,50597,,5862,,10116.0,Rattus norvegicus,,CHEMBL631316,,,,,A,1,1,
,BAO_0000218,9287,N,Area under curve in SD rats,Intermediate,,50597,,5862,,10116.0,Rattus norvegicus,,CHEMBL631317,,,,,A,1,1,
,BAO_0000218,9288,N,Area under curve in rat after oral administration at 13 mg/kg dose,Intermediate,,50597,,6644,,10116.0,Rattus norvegicus,,CHEMBL874471,,,,,A,1,1,
,BAO_0000218,9289,N,Area under curve in rat by po administration at 0-24 hr,Intermediate,,50597,,5871,,10116.0,Rattus norvegicus,,CHEMBL631318,,,,,A,1,1,
Plasma,BAO_0000218,9290,N,Area under curve in rat plasma,Intermediate,,50597,,5919,1969.0,10116.0,Rattus norvegicus,,CHEMBL631319,,,,,A,1,1,
,BAO_0000218,9291,N,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg,Intermediate,,50597,,5939,,10116.0,Rattus norvegicus,,CHEMBL631320,,,,,A,1,1,
,BAO_0000218,9292,N,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg,Intermediate,,50597,,5939,,10116.0,Rattus norvegicus,,CHEMBL631321,,,,,A,1,1,
,BAO_0000218,9293,N,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously,Intermediate,,50597,,10,,10116.0,Rattus norvegicus,,CHEMBL631322,,,,,A,1,1,
,BAO_0000218,9294,N,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats,Intermediate,,50597,,11149,,10116.0,Rattus norvegicus,,CHEMBL631323,,,,,A,1,1,
,BAO_0000218,9295,N,Area under curve value in rat at a dose of 5 mg/kg,Intermediate,,50597,,5302,,10116.0,Rattus norvegicus,,CHEMBL631324,,,,,A,1,1,
,BAO_0000218,9296,N,Area under curve was determined after oral administration in rats,Intermediate,,50597,,17796,,10116.0,Rattus norvegicus,,CHEMBL631325,,,,,A,1,1,
,BAO_0000218,9297,N,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,Intermediate,,50597,,4890,,10116.0,Rattus norvegicus,,CHEMBL631326,,,,,A,1,1,
,BAO_0000218,9298,N,Area under curve was determined after peroral administration in rat,Intermediate,,50597,,6011,,10116.0,Rattus norvegicus,,CHEMBL631327,,,,,A,1,1,
,BAO_0000218,9299,N,Area under curve was determined at a dose 30 mpk administered orally.,Intermediate,,50597,,5375,,10116.0,Rattus norvegicus,,CHEMBL631328,,,,,A,1,1,
,BAO_0000218,9300,N,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg,Intermediate,,50597,,17764,,10116.0,Rattus norvegicus,,CHEMBL631329,,,,,A,1,1,
,BAO_0000218,9301,N,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat,Intermediate,,50597,,4368,,10116.0,Rattus norvegicus,,CHEMBL627217,,,,,A,1,1,
,BAO_0000218,9302,N,Area under curve was determined in male rat,Intermediate,,50597,,5610,,10116.0,Rattus norvegicus,,CHEMBL626352,,,,,A,1,1,
,BAO_0000218,9303,N,Area under curve was determined in rat after PO administration,Intermediate,,50597,,5833,,10116.0,Rattus norvegicus,,CHEMBL626353,,,,,A,1,1,
,BAO_0000218,9304,N,Area under curve was determined in rat after a 3 mg/kg of oral dose,Intermediate,,50597,,4257,,10116.0,Rattus norvegicus,,CHEMBL626354,,,,,A,1,1,
,BAO_0000218,9305,N,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg,Intermediate,,50597,,5937,,10116.0,Rattus norvegicus,,CHEMBL626355,,,,,A,1,1,
,BAO_0000218,9306,N,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg,Intermediate,,50597,,5932,,10116.0,Rattus norvegicus,,CHEMBL626356,,,,,A,1,1,
,BAO_0000218,9307,N,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active,Intermediate,,50597,,5932,,10116.0,Rattus norvegicus,,CHEMBL626357,,,,,A,1,1,
,BAO_0000218,9308,N,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,,50597,,17411,,10116.0,Rattus norvegicus,,CHEMBL626358,,,,,A,1,1,
,BAO_0000218,9309,N,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,,50597,,17411,,10116.0,Rattus norvegicus,,CHEMBL626359,,,,,A,1,1,
Plasma,BAO_0000218,9310,N,Peak plasma concentration in rat at a dose of 3 mg/kg,Intermediate,,50597,,17771,1969.0,10116.0,Rattus norvegicus,,CHEMBL626360,,,,,A,1,1,
,BAO_0000218,9311,N,Plasma concentration at 2 hr in rats was evaluated.,Intermediate,,50597,,1628,,10116.0,Rattus norvegicus,,CHEMBL626361,,,,,A,1,1,
,BAO_0000218,9312,N,Plasma concentration at 2 hr in rats was evaluated; Not available,Intermediate,,50597,,1628,,10116.0,Rattus norvegicus,,CHEMBL626362,,,,,A,1,1,
,BAO_0000218,9313,N,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,,50597,,17411,,10116.0,Rattus norvegicus,,CHEMBL626363,,,,,A,1,1,
,BAO_0000218,9314,N,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,Intermediate,,50597,,4910,,10116.0,Rattus norvegicus,,CHEMBL626970,,,,,A,1,1,
,BAO_0000218,9315,N,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats,Intermediate,,50597,,4910,,10116.0,Rattus norvegicus,,CHEMBL626971,,,,,A,1,1,
Plasma,BAO_0000218,9316,N,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,Intermediate,,50597,,4910,1969.0,10116.0,Rattus norvegicus,,CHEMBL626972,,,,,A,1,1,
Plasma,BAO_0000218,9317,N,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats,Intermediate,,50597,,4910,1969.0,10116.0,Rattus norvegicus,,CHEMBL626973,,,,,A,1,1,
Plasma,BAO_0000218,9318,N,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,Intermediate,,50597,,4910,1969.0,10116.0,Rattus norvegicus,,CHEMBL626974,,,,,A,1,1,
Plasma,BAO_0000218,9319,N,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats,Intermediate,,50597,,4910,1969.0,10116.0,Rattus norvegicus,,CHEMBL874592,,,,,A,1,1,
,BAO_0000218,9320,N,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C,Intermediate,,50597,,5510,,10116.0,Rattus norvegicus,,CHEMBL626975,,,,,A,1,1,
,BAO_0000218,9321,N,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound,Intermediate,,50597,,5510,,10116.0,Rattus norvegicus,,CHEMBL626976,,,,,A,1,1,
,BAO_0000218,9322,N,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined,Intermediate,,50597,,5510,,10116.0,Rattus norvegicus,,CHEMBL626977,,,,,A,1,1,
,BAO_0000218,9323,N,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested,Intermediate,,50597,,5510,,10116.0,Rattus norvegicus,,CHEMBL626978,,,,,A,1,1,
,BAO_0000218,9324,N,PK study was carried to determine the relative absorption ranking in rat.,Intermediate,,50597,,16427,,10116.0,Rattus norvegicus,,CHEMBL626979,,,,,A,1,1,
Plasma,BAO_0000218,9325,N,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg,Intermediate,,50597,,4689,1969.0,10116.0,Rattus norvegicus,,CHEMBL626980,,,In vivo,,A,1,1,
Blood,BAO_0000218,9326,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g",Intermediate,,50597,,11450,178.0,10116.0,Rattus norvegicus,,CHEMBL626981,,,,,A,1,1,
Blood,BAO_0000218,9327,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g",Intermediate,,50597,,11450,178.0,10116.0,Rattus norvegicus,,CHEMBL626982,,,,,A,1,1,
Blood,BAO_0000218,9328,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g",Intermediate,,50597,,11450,178.0,10116.0,Rattus norvegicus,,CHEMBL626983,,,,,A,1,1,
Blood,BAO_0000218,9329,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g",Intermediate,,50597,,11450,178.0,10116.0,Rattus norvegicus,,CHEMBL622522,,,,,A,1,1,
Blood,BAO_0000218,9330,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g",Intermediate,,50597,,11450,178.0,10116.0,Rattus norvegicus,,CHEMBL622523,,,,,A,1,1,
Blood,BAO_0000218,9331,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g",Intermediate,,50597,,11450,178.0,10116.0,Rattus norvegicus,,CHEMBL622524,,,,,A,1,1,
Brain,BAO_0000218,9332,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g",Intermediate,,50597,,11450,955.0,10116.0,Rattus norvegicus,,CHEMBL622525,,,,,A,1,1,
Brain,BAO_0000218,9333,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g",Intermediate,,50597,,11450,955.0,10116.0,Rattus norvegicus,,CHEMBL622526,,,,,A,1,1,
Brain,BAO_0000218,9334,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g",Intermediate,,50597,,11450,955.0,10116.0,Rattus norvegicus,,CHEMBL619849,,,,,A,1,1,
Brain,BAO_0000218,9335,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g",Intermediate,,50597,,11450,955.0,10116.0,Rattus norvegicus,,CHEMBL619850,,,,,A,1,1,
Brain,BAO_0000218,9336,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g",Intermediate,,50597,,11450,955.0,10116.0,Rattus norvegicus,,CHEMBL623864,,,,,A,1,1,
Brain,BAO_0000218,9337,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g",Intermediate,,50597,,11450,955.0,10116.0,Rattus norvegicus,,CHEMBL623865,,,,,A,1,1,
Heart,BAO_0000218,9338,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g",Intermediate,,50597,,11450,948.0,10116.0,Rattus norvegicus,,CHEMBL623866,,,,,A,1,1,
Heart,BAO_0000218,9339,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g",Intermediate,,50597,,11450,948.0,10116.0,Rattus norvegicus,,CHEMBL623867,,,,,A,1,1,
Heart,BAO_0000218,9340,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g",Intermediate,,50597,,11450,948.0,10116.0,Rattus norvegicus,,CHEMBL877615,,,,,A,1,1,
Heart,BAO_0000218,9341,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g",Intermediate,,50597,,11450,948.0,10116.0,Rattus norvegicus,,CHEMBL623868,,,,,A,1,1,
Heart,BAO_0000218,9342,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g",Intermediate,,50597,,11450,948.0,10116.0,Rattus norvegicus,,CHEMBL623869,,,,,A,1,1,
Heart,BAO_0000218,9343,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g",Intermediate,,50597,,11450,948.0,10116.0,Rattus norvegicus,,CHEMBL623870,,,,,A,1,1,
Lung,BAO_0000218,9344,N,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,Intermediate,,50597,,16434,2048.0,10116.0,Rattus norvegicus,,CHEMBL623871,,,,,A,1,1,
Lung,BAO_0000218,9345,N,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Intermediate,,50597,,16434,2048.0,10116.0,Rattus norvegicus,,CHEMBL623872,,,,,A,1,1,
Lung,BAO_0000218,9346,N,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,,50597,,16435,2048.0,10116.0,Rattus norvegicus,,CHEMBL622129,,,,,A,1,1,
Lung,BAO_0000218,9347,N,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,,50597,,16435,2048.0,10116.0,Rattus norvegicus,,CHEMBL622130,,,,,A,1,1,
Lung,BAO_0000218,9348,N,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,,50597,,16435,2048.0,10116.0,Rattus norvegicus,,CHEMBL622131,,,,,A,1,1,
Lung,BAO_0000218,9349,N,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,,50597,,16435,2048.0,10116.0,Rattus norvegicus,,CHEMBL622132,,,,,A,1,1,
Lung,BAO_0000218,9350,N,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,,50597,,16435,2048.0,10116.0,Rattus norvegicus,,CHEMBL622133,,,,,A,1,1,
Lung,BAO_0000218,9351,N,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,,50597,,16435,2048.0,10116.0,Rattus norvegicus,,CHEMBL622134,,,,,A,1,1,
Lung,BAO_0000218,9352,N,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Intermediate,,50597,,16435,2048.0,10116.0,Rattus norvegicus,,CHEMBL622135,,,,,A,1,1,
Lung,BAO_0000218,9353,N,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Intermediate,,50597,,16435,2048.0,10116.0,Rattus norvegicus,,CHEMBL622136,,,,,A,1,1,
Muscle tissue,BAO_0000218,9354,N,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,,50597,,16434,2385.0,10116.0,Rattus norvegicus,,CHEMBL622137,,,,,A,1,1,
Muscle tissue,BAO_0000218,9355,N,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Intermediate,,50597,,16434,2385.0,10116.0,Rattus norvegicus,,CHEMBL622138,,,,,A,1,1,
Muscle tissue,BAO_0000218,9356,N,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,,50597,,16434,2385.0,10116.0,Rattus norvegicus,,CHEMBL623017,,,,,A,1,1,
Muscle tissue,BAO_0000218,9357,N,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,,50597,,16434,2385.0,10116.0,Rattus norvegicus,,CHEMBL623018,,,,,A,1,1,
Muscle tissue,BAO_0000218,9358,N,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Intermediate,,50597,,16434,2385.0,10116.0,Rattus norvegicus,,CHEMBL623019,,,,,A,1,1,
Muscle tissue,BAO_0000218,9359,N,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Intermediate,,50597,,16434,2385.0,10116.0,Rattus norvegicus,,CHEMBL623020,,,,,A,1,1,
Muscle tissue,BAO_0000218,9360,N,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.,Intermediate,,50597,,16434,2385.0,10116.0,Rattus norvegicus,,CHEMBL623021,,,,,A,1,1,
Muscle tissue,BAO_0000218,9361,N,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,Intermediate,,50597,,16434,2385.0,10116.0,Rattus norvegicus,,CHEMBL623022,,,,,A,1,1,
Muscle tissue,BAO_0000218,9362,N,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Intermediate,,50597,,16435,2385.0,10116.0,Rattus norvegicus,,CHEMBL623023,,,,,A,1,1,
Muscle tissue,BAO_0000218,9363,N,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Intermediate,,50597,,16435,2385.0,10116.0,Rattus norvegicus,,CHEMBL623024,,,,,A,1,1,
Muscle tissue,BAO_0000218,9364,N,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Intermediate,,50597,,16435,2385.0,10116.0,Rattus norvegicus,,CHEMBL623025,,,,,A,1,1,
Muscle tissue,BAO_0000218,9365,N,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Intermediate,,50597,,16435,2385.0,10116.0,Rattus norvegicus,,CHEMBL620545,,,,,A,1,1,
Muscle tissue,BAO_0000218,9366,N,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Intermediate,,50597,,16435,2385.0,10116.0,Rattus norvegicus,,CHEMBL620546,,,,,A,1,1,
Muscle tissue,BAO_0000218,9367,N,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Intermediate,,50597,,16435,2385.0,10116.0,Rattus norvegicus,,CHEMBL620547,,,,,A,1,1,
Muscle tissue,BAO_0000218,9368,N,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Intermediate,,50597,,16435,2385.0,10116.0,Rattus norvegicus,,CHEMBL620548,,,,,A,1,1,
Muscle tissue,BAO_0000218,9369,N,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Intermediate,,50597,,16435,2385.0,10116.0,Rattus norvegicus,,CHEMBL620549,,,,,A,1,1,
Muscle tissue,BAO_0000218,9370,N,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Intermediate,,50597,,16434,2385.0,10116.0,Rattus norvegicus,,CHEMBL620550,,,,,A,1,1,
Muscle tissue,BAO_0000218,9371,N,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,Intermediate,,50597,,16434,2385.0,10116.0,Rattus norvegicus,,CHEMBL620551,,,,,A,1,1,
Muscle tissue,BAO_0000218,9372,N,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Intermediate,,50597,,16434,2385.0,10116.0,Rattus norvegicus,,CHEMBL620552,,,,,A,1,1,
Muscle tissue,BAO_0000218,9373,N,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,,50597,,16435,2385.0,10116.0,Rattus norvegicus,,CHEMBL620553,,,,,A,1,1,
Muscle tissue,BAO_0000218,9374,N,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,,50597,,16435,2385.0,10116.0,Rattus norvegicus,,CHEMBL620554,,,,,A,1,1,
Muscle tissue,BAO_0000218,9375,N,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,,50597,,16435,2385.0,10116.0,Rattus norvegicus,,CHEMBL875845,,,,,A,1,1,
Muscle tissue,BAO_0000218,9376,N,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,,50597,,16435,2385.0,10116.0,Rattus norvegicus,,CHEMBL620555,,,,,A,1,1,
Muscle tissue,BAO_0000218,9377,N,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,,50597,,16435,2385.0,10116.0,Rattus norvegicus,,CHEMBL620556,,,,,A,1,1,
Muscle tissue,BAO_0000218,9378,N,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,,50597,,16435,2385.0,10116.0,Rattus norvegicus,,CHEMBL620557,,,,,A,1,1,
,BAO_0000218,9379,N,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,,50597,,16434,,10116.0,Rattus norvegicus,,CHEMBL620558,,,,,A,1,1,
,BAO_0000218,9380,N,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Intermediate,,50597,,16434,,10116.0,Rattus norvegicus,,CHEMBL620559,,,,,A,1,1,
,BAO_0000218,9381,N,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,,50597,,16434,,10116.0,Rattus norvegicus,,CHEMBL622939,,,,,A,1,1,
,BAO_0000218,9382,N,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,,50597,,16434,,10116.0,Rattus norvegicus,,CHEMBL622940,,,,,A,1,1,
,BAO_0000218,9383,N,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Intermediate,,50597,,16434,,10116.0,Rattus norvegicus,,CHEMBL622941,,,,,A,1,1,
,BAO_0000218,9384,N,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Intermediate,,50597,,16434,,10116.0,Rattus norvegicus,,CHEMBL622942,,,,,A,1,1,
,BAO_0000218,9385,N,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Intermediate,,50597,,16434,,10116.0,Rattus norvegicus,,CHEMBL622943,,,,,A,1,1,
,BAO_0000218,9386,N,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Intermediate,,50597,,16434,,10116.0,Rattus norvegicus,,CHEMBL622944,,,,,A,1,1,
,BAO_0000218,9387,N,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL622945,,,,,A,1,1,
,BAO_0000218,9388,N,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL622946,,,,,A,1,1,
,BAO_0000218,9389,N,Compound was evaluated for terminal half life in rat,Intermediate,,50597,,3341,,10116.0,Rattus norvegicus,,CHEMBL622947,,,,,A,1,1,
Plasma,BAO_0000218,9390,N,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve,Intermediate,,50597,,3634,1969.0,10116.0,Rattus norvegicus,,CHEMBL622948,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9391,N,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve,Intermediate,,50597,,3634,1969.0,10116.0,Rattus norvegicus,,CHEMBL622949,,,In vivo,,A,1,1,
,BAO_0000218,9392,N,Compound was tested for its half life in rat,Intermediate,,50597,,4839,,10116.0,Rattus norvegicus,,CHEMBL622950,,,,,A,1,1,
Plasma,BAO_0000218,9393,U,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,Intermediate,,22224,,5005,1969.0,9544.0,Macaca mulatta,,CHEMBL622951,,,In vivo,,A,1,0,
Plasma,BAO_0000366,9394,U,Compound was tested for its plasma half life in Sprague Dawley rats,Intermediate,,22224,,5005,1969.0,10116.0,Rattus norvegicus,,CHEMBL622952,,,,,A,1,0,
Plasma,BAO_0000366,9395,U,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined,Intermediate,,22224,,5005,1969.0,10116.0,Rattus norvegicus,,CHEMBL622953,,,,,A,1,0,
Plasma,BAO_0000218,9396,N,Compound was tested for plasma half-life period in rat,Intermediate,,50597,,1094,1969.0,10116.0,Rattus norvegicus,,CHEMBL873818,,,,,A,1,1,
,BAO_0000218,9397,N,Elimination half life after i.v. administration of compound in rats,Intermediate,,50597,,5031,,10116.0,Rattus norvegicus,,CHEMBL622954,,,In vivo,,A,1,1,
,BAO_0000218,9398,N,Elimination half-life after IV dosing at 0.5 mg/kg in rat,Intermediate,,50597,,6518,,10116.0,Rattus norvegicus,,CHEMBL622955,,,In vivo,,A,1,1,
,BAO_0000218,9399,N,Elimination half-life after IV dosing at 1 mg/kg in rat,Intermediate,,50597,,6518,,10116.0,Rattus norvegicus,,CHEMBL875229,,,In vivo,,A,1,1,
,BAO_0000218,9400,N,Elimination half-life after oral administration at a dose of 2 mg/kg in rat,Intermediate,,50597,,6518,,10116.0,Rattus norvegicus,,CHEMBL622956,,,In vivo,,A,1,1,
,BAO_0000218,9401,N,Elimination half-life after oral administration at a dose of 4 mg/kg in rat,Intermediate,,50597,,6518,,10116.0,Rattus norvegicus,,CHEMBL622957,,,In vivo,,A,1,1,
Brain,BAO_0000218,9402,N,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,Intermediate,,50597,,5408,955.0,10116.0,Rattus norvegicus,,CHEMBL622958,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9403,N,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,Intermediate,,50597,,5408,1969.0,10116.0,Rattus norvegicus,,CHEMBL622959,,,In vivo,,A,1,1,
Brain,BAO_0000218,9404,N,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,Intermediate,,50597,,5408,955.0,10116.0,Rattus norvegicus,,CHEMBL622960,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9405,N,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,Intermediate,,50597,,5408,1969.0,10116.0,Rattus norvegicus,,CHEMBL622961,,,In vivo,,A,1,1,
,BAO_0000218,9406,N,Evaluated for the half life in rat (in vivo),Intermediate,,50597,,4687,,10116.0,Rattus norvegicus,,CHEMBL622962,,,In vivo,,A,1,1,
,BAO_0000218,9407,N,Hafl life in rat,Intermediate,,50597,,6640,,10116.0,Rattus norvegicus,,CHEMBL622963,,,,,A,1,1,
,BAO_0000218,9408,N,Hafl life rat,Intermediate,,50597,,6640,,10116.0,Rattus norvegicus,,CHEMBL622964,,,,,A,1,1,
,BAO_0000218,9409,N,Hafl life rat,Intermediate,,50597,,6641,,10116.0,Rattus norvegicus,,CHEMBL622965,,,,,A,1,1,
,BAO_0000218,9410,N,Hafl life rat; Not determined,Intermediate,,50597,,6640,,10116.0,Rattus norvegicus,,CHEMBL622966,,,,,A,1,1,
,BAO_0000218,9411,N,Hafl life rat; Not determined,Intermediate,,50597,,6641,,10116.0,Rattus norvegicus,,CHEMBL622967,,,,,A,1,1,
Kidney,BAO_0000218,9412,N,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,,50597,,17411,2113.0,10116.0,Rattus norvegicus,,CHEMBL622968,,,In vivo,,A,1,1,
Liver,BAO_0000218,9413,N,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,,50597,,17411,2107.0,10116.0,Rattus norvegicus,,CHEMBL622969,,,In vivo,,A,1,1,
Lung,BAO_0000218,9414,N,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,,50597,,17411,2048.0,10116.0,Rattus norvegicus,,CHEMBL875327,,,In vivo,,A,1,1,
,BAO_0000218,9415,N,Half life in rat after 1 mg/kg i.v. administration,Intermediate,,50597,,6570,,10116.0,Rattus norvegicus,,CHEMBL628638,,,In vivo,,A,1,1,
,BAO_0000218,9416,N,Half life in rat after 2 mg/kg peroral administration,Intermediate,,50597,,6570,,10116.0,Rattus norvegicus,,CHEMBL628639,,,In vivo,,A,1,1,
,BAO_0000218,9417,N,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,,50597,,17411,,10116.0,Rattus norvegicus,,CHEMBL625840,,,In vivo,,A,1,1,
,BAO_0000218,9418,N,Half life of 10 mg/kg oral dose determined in rats,Intermediate,,50597,,4722,,10116.0,Rattus norvegicus,,CHEMBL625841,,,In vivo,,A,1,1,
,BAO_0000218,9419,N,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,Intermediate,,50597,,5978,,10116.0,Rattus norvegicus,,CHEMBL625842,,,In vivo,,A,1,1,
,BAO_0000218,9420,N,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,,50597,,5978,,10116.0,Rattus norvegicus,,CHEMBL625843,,,In vivo,,A,1,1,
,BAO_0000218,9421,N,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,,50597,,5978,,10116.0,Rattus norvegicus,,CHEMBL625844,,,In vivo,,A,1,1,
,BAO_0000218,9422,N,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,,50597,,5978,,10116.0,Rattus norvegicus,,CHEMBL873822,,,In vivo,,A,1,1,
,BAO_0000218,9423,N,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,Intermediate,,50597,,5978,,10116.0,Rattus norvegicus,,CHEMBL625845,,,In vivo,,A,1,1,
,BAO_0000218,9424,N,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,Intermediate,,50597,,5978,,10116.0,Rattus norvegicus,,CHEMBL627059,,,In vivo,,A,1,1,
,BAO_0000218,9425,N,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,,50597,,5978,,10116.0,Rattus norvegicus,,CHEMBL627060,,,In vivo,,A,1,1,
,BAO_0000218,9426,N,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,Intermediate,,50597,,5978,,10116.0,Rattus norvegicus,,CHEMBL627061,,,In vivo,,A,1,1,
,BAO_0000218,9427,N,Half life of compound at 5 mg/kg after po administration was determined in rat,Intermediate,,50597,,4762,,10116.0,Rattus norvegicus,,CHEMBL627709,,,In vivo,,A,1,1,
,BAO_0000218,9428,N,Half life of compound determined after intravenous administration to rat,Intermediate,,50597,,5327,,10116.0,Rattus norvegicus,,CHEMBL627710,,,In vivo,,A,1,1,
,BAO_0000218,9429,N,Half life of compound was determined in rat,Intermediate,,50597,,4847,,10116.0,Rattus norvegicus,,CHEMBL627711,,,,,A,1,1,
Plasma,BAO_0000218,9430,N,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,Intermediate,,50597,,17720,1969.0,10116.0,Rattus norvegicus,,CHEMBL627712,,,In vivo,,A,1,1,
,BAO_0000218,9431,N,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,,50597,,4723,,10116.0,Rattus norvegicus,,CHEMBL627713,,,In vivo,,A,1,1,
,BAO_0000218,9432,N,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,,50597,,4723,,10116.0,Rattus norvegicus,,CHEMBL627714,,,In vivo,,A,1,1,
,BAO_0000218,9433,U,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,Intermediate,,22224,,4256,,9541.0,Macaca fascicularis,,CHEMBL627889,,,In vivo,,A,1,0,
,BAO_0000218,9434,U,Half life determined in rat by intravenous administration,Intermediate,,22224,,4256,,10116.0,Rattus norvegicus,,CHEMBL627890,,,In vivo,,A,1,0,
,BAO_0000218,9435,N,Half life determined in rats after iv administration,Intermediate,,50597,,4722,,10116.0,Rattus norvegicus,,CHEMBL627891,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9436,N,Half life in rat plasma after administration of 2 mg/kg iv,Intermediate,,50597,,6535,1969.0,10116.0,Rattus norvegicus,,CHEMBL627892,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9437,N,Half life in rat plasma after administration of 2 mg/kg iv,Intermediate,,50597,,6535,1969.0,10116.0,Rattus norvegicus,,CHEMBL627893,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9438,N,Half life in rat plasma was determined,Intermediate,,50597,,1435,1969.0,10116.0,Rattus norvegicus,,CHEMBL627894,,,,,A,1,1,
Plasma,BAO_0000218,9439,N,Half life in rat plasma was determined; NA means not applicable,Intermediate,,50597,,1435,1969.0,10116.0,Rattus norvegicus,,CHEMBL627895,,,,,A,1,1,
,BAO_0000218,9440,N,Half life in rat was tested,Intermediate,,50597,,5206,,10116.0,Rattus norvegicus,,CHEMBL627896,,,,,A,1,1,
Plasma,BAO_0000218,9441,N,Half life measured in rat plasma,Intermediate,,50597,,6080,1969.0,10116.0,Rattus norvegicus,,CHEMBL627897,,,,,A,1,1,
,BAO_0000218,9442,N,Half life recorded in rats,Intermediate,,50597,,4449,,10116.0,Rattus norvegicus,,CHEMBL627898,,,,,A,1,1,
,BAO_0000218,9443,N,Half life was calculated,Intermediate,,50597,,6057,,10116.0,Rattus norvegicus,,CHEMBL627899,,,,,A,1,1,
,BAO_0000218,9444,N,Half life was calculated in rat,Intermediate,,50597,,6057,,10116.0,Rattus norvegicus,,CHEMBL873823,,,,,A,1,1,
,BAO_0000218,9445,N,Half life was determined,Intermediate,,50597,,3747,,10116.0,Rattus norvegicus,,CHEMBL627900,,,,,A,1,1,
,BAO_0000218,9446,N,Half life after 10 mg/kg oral administration in rat,Intermediate,,50597,,17858,,10116.0,Rattus norvegicus,,CHEMBL627901,,,In vivo,,A,1,1,
,BAO_0000218,9447,N,Half life after administering orally a dose of 10 mg/kg to a fasting rat,Intermediate,,50597,,16365,,10116.0,Rattus norvegicus,,CHEMBL627902,,,In vivo,,A,1,1,
,BAO_0000218,9448,N,Half life after administering orally a dose of 30 mg/kg,Intermediate,,50597,,16365,,10116.0,Rattus norvegicus,,CHEMBL627903,,,In vivo,,A,1,1,
,BAO_0000218,9449,N,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats,Intermediate,,50597,,5031,,10116.0,Rattus norvegicus,,CHEMBL627904,,,,,A,1,1,
,BAO_0000218,9450,N,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours,Intermediate,,50597,,4722,,10116.0,Rattus norvegicus,,CHEMBL627905,,,,,A,1,1,
,BAO_0000218,9451,N,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat,Intermediate,,50597,,6078,,10116.0,Rattus norvegicus,,CHEMBL627906,,,,,A,1,1,
,BAO_0000218,9452,N,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat,Intermediate,,50597,,6078,,10116.0,Rattus norvegicus,,CHEMBL627907,,,,,A,1,1,
,BAO_0000218,9453,N,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg,Intermediate,,50597,,6078,,10116.0,Rattus norvegicus,,CHEMBL876783,,,,,A,1,1,
,BAO_0000218,9454,N,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined,Intermediate,,50597,,6078,,10116.0,Rattus norvegicus,,CHEMBL627908,,,,,A,1,1,
,BAO_0000218,9455,N,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats,Intermediate,,50597,,17065,,10116.0,Rattus norvegicus,,CHEMBL627909,,,,,A,1,1,
,BAO_0000218,9456,N,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats,Intermediate,,50597,,1353,,10116.0,Rattus norvegicus,,CHEMBL627910,,,,,A,1,1,
,BAO_0000218,9457,N,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1),Intermediate,,50597,,1353,,10116.0,Rattus norvegicus,,CHEMBL627911,,,,,A,1,1,
,BAO_0000218,9458,N,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2),Intermediate,,50597,,1353,,10116.0,Rattus norvegicus,,CHEMBL627912,,,,,A,1,1,
,BAO_0000218,9459,N,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5),Intermediate,,50597,,1353,,10116.0,Rattus norvegicus,,CHEMBL627913,,,,,A,1,1,
,BAO_0000218,9460,N,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10),Intermediate,,50597,,1353,,10116.0,Rattus norvegicus,,CHEMBL627914,,,,,A,1,1,
,BAO_0000218,9461,N,Area under the curve was evaluated after 10 uM/kg of intra arterial administration,Intermediate,,50597,,16423,,10116.0,Rattus norvegicus,,CHEMBL627915,,,,,A,1,1,
,BAO_0000218,9462,N,Area under the curve was evaluated after 20 uM/kg of peroral administration,Intermediate,,50597,,16423,,10116.0,Rattus norvegicus,,CHEMBL627916,,,,,A,1,1,
,BAO_0000218,9463,N,Area under the curve was measured in rat after an iv dose of 1 mg/kg,Intermediate,,50597,,6062,,10116.0,Rattus norvegicus,,CHEMBL627917,,,,,A,1,1,
,BAO_0000218,9464,N,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat,Intermediate,,50597,,6056,,10116.0,Rattus norvegicus,,CHEMBL627918,,,,,A,1,1,
,BAO_0000218,9465,N,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat,Intermediate,,50597,,5182,,10116.0,Rattus norvegicus,,CHEMBL627919,,,,,A,1,1,
,BAO_0000218,9466,N,Area under the curve was evaluated at an intravenous dose of 3 mg/kg,Intermediate,,50597,,6410,,10116.0,Rattus norvegicus,,CHEMBL627920,,,,,A,1,1,
,BAO_0000218,9467,N,Area under the curve was evaluated at an oral dose of 30 mg/kg,Intermediate,,50597,,6410,,10116.0,Rattus norvegicus,,CHEMBL627921,,,,,A,1,1,
,BAO_0000218,9468,N,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,,50597,,4723,,10116.0,Rattus norvegicus,,CHEMBL627922,,,,,A,1,1,
,BAO_0000218,9469,N,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,,50597,,4723,,10116.0,Rattus norvegicus,,CHEMBL876784,,,,,A,1,1,
,BAO_0000218,9470,N,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,,50597,,4723,,10116.0,Rattus norvegicus,,CHEMBL627923,,,,,A,1,1,
,BAO_0000218,9471,N,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,,50597,,4723,,10116.0,Rattus norvegicus,,CHEMBL626208,,,,,A,1,1,
,BAO_0000218,9472,N,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,,50597,,4723,,10116.0,Rattus norvegicus,,CHEMBL626209,,,,,A,1,1,
,BAO_0000218,9473,N,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,,50597,,4723,,10116.0,Rattus norvegicus,,CHEMBL626210,,,,,A,1,1,
Plasma,BAO_0000218,9474,N,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,Intermediate,,50597,,2463,1969.0,10116.0,Rattus norvegicus,,CHEMBL627994,,,,,A,1,1,
,BAO_0000218,9475,N,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat,Intermediate,,50597,,4709,,10116.0,Rattus norvegicus,,CHEMBL627995,,,,,A,1,1,
,BAO_0000218,9476,N,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined,Intermediate,,50597,,4075,,10116.0,Rattus norvegicus,,CHEMBL627996,,,,,A,1,1,
,BAO_0000218,9477,N,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured,Intermediate,,50597,,5394,,10116.0,Rattus norvegicus,,CHEMBL627997,,,,,A,1,1,
,BAO_0000218,9478,N,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats,Intermediate,,50597,,2661,,10116.0,Rattus norvegicus,,CHEMBL627998,,,,,A,1,1,
,BAO_0000218,9479,N,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats,Intermediate,,50597,,2661,,10116.0,Rattus norvegicus,,CHEMBL628640,,,,,A,1,1,
,BAO_0000218,9480,N,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats,Intermediate,,50597,,2661,,10116.0,Rattus norvegicus,,CHEMBL628641,,,,,A,1,1,
,BAO_0000218,9481,N,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats,Intermediate,,50597,,2661,,10116.0,Rattus norvegicus,,CHEMBL628642,,,,,A,1,1,
,BAO_0000218,9482,N,Compound was evaluated for area under the curve expressed as (h*ug/ml),Intermediate,,50597,,17791,,10116.0,Rattus norvegicus,,CHEMBL628643,,,,,A,1,1,
,BAO_0000218,9483,N,Compound was tested for area under curve in rat,Intermediate,,50597,,2591,,10116.0,Rattus norvegicus,,CHEMBL628644,,,,,A,1,1,
,BAO_0000218,9484,N,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours,Intermediate,,50597,,6567,,10116.0,Rattus norvegicus,,CHEMBL628645,,,,,A,1,1,
,BAO_0000218,9485,N,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,Intermediate,,50597,,6211,,10116.0,Rattus norvegicus,,CHEMBL628646,,,,,A,1,1,
,BAO_0000218,9486,N,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg),Intermediate,,50597,,5529,,10116.0,Rattus norvegicus,,CHEMBL628647,,,,,A,1,1,
,BAO_0000218,9487,N,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,Intermediate,,50597,,5408,,10116.0,Rattus norvegicus,,CHEMBL628648,,,,,A,1,1,
,BAO_0000218,9488,N,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,Intermediate,,50597,,5408,,10116.0,Rattus norvegicus,,CHEMBL625358,,,,,A,1,1,
,BAO_0000218,9489,N,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,Intermediate,,50597,,5408,,10116.0,Rattus norvegicus,,CHEMBL625359,,,,,A,1,1,
,BAO_0000218,9490,N,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,Intermediate,,50597,,5408,,10116.0,Rattus norvegicus,,CHEMBL625360,,,,,A,1,1,
,BAO_0000218,9491,N,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr ),Intermediate,,50597,,429,,10116.0,Rattus norvegicus,,CHEMBL625361,,,,,A,1,1,
,BAO_0000218,9492,N,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr ),Intermediate,,50597,,429,,10116.0,Rattus norvegicus,,CHEMBL625362,,,,,A,1,1,
,BAO_0000218,9493,N,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr),Intermediate,,50597,,429,,10116.0,Rattus norvegicus,,CHEMBL625363,,,,,A,1,1,
,BAO_0000218,9494,N,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,Intermediate,,50597,,4796,,10116.0,Rattus norvegicus,,CHEMBL625364,,,,,A,1,1,
,BAO_0000218,9495,N,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,Intermediate,,50597,,5974,,10116.0,Rattus norvegicus,,CHEMBL625365,,,,,A,1,1,
,BAO_0000218,9496,N,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,Intermediate,,50597,,5974,,10116.0,Rattus norvegicus,,CHEMBL625366,,,,,A,1,1,
,BAO_0000218,9497,N,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,Intermediate,,50597,,5974,,10116.0,Rattus norvegicus,,CHEMBL625367,,,,,A,1,1,
Kidney,BAO_0000218,9498,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g",Intermediate,,50597,,11450,2113.0,10116.0,Rattus norvegicus,,CHEMBL625368,,,,,A,1,1,
Kidney,BAO_0000218,9499,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g",Intermediate,,50597,,11450,2113.0,10116.0,Rattus norvegicus,,CHEMBL625369,,,,,A,1,1,
Kidney,BAO_0000218,9500,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g",Intermediate,,50597,,11450,2113.0,10116.0,Rattus norvegicus,,CHEMBL625370,,,,,A,1,1,
Kidney,BAO_0000218,9501,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g",Intermediate,,50597,,11450,2113.0,10116.0,Rattus norvegicus,,CHEMBL625371,,,,,A,1,1,
Kidney,BAO_0000218,9502,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g",Intermediate,,50597,,11450,2113.0,10116.0,Rattus norvegicus,,CHEMBL625372,,,,,A,1,1,
Kidney,BAO_0000218,9503,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g",Intermediate,,50597,,11450,2113.0,10116.0,Rattus norvegicus,,CHEMBL625373,,,,,A,1,1,
Liver,BAO_0000218,9504,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g",Intermediate,,50597,,11450,2107.0,10116.0,Rattus norvegicus,,CHEMBL625374,,,,,A,1,1,
Liver,BAO_0000218,9505,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g",Intermediate,,50597,,11450,2107.0,10116.0,Rattus norvegicus,,CHEMBL877593,,,,,A,1,1,
Liver,BAO_0000218,9506,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g",Intermediate,,50597,,11450,2107.0,10116.0,Rattus norvegicus,,CHEMBL625375,,,,,A,1,1,
Liver,BAO_0000218,9507,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g",Intermediate,,50597,,11450,2107.0,10116.0,Rattus norvegicus,,CHEMBL625376,,,,,A,1,1,
Liver,BAO_0000218,9508,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g",Intermediate,,50597,,11450,2107.0,10116.0,Rattus norvegicus,,CHEMBL621973,,,,,A,1,1,
Liver,BAO_0000218,9509,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g",Intermediate,,50597,,11450,2107.0,10116.0,Rattus norvegicus,,CHEMBL621974,,,,,A,1,1,
Lung,BAO_0000218,9510,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g",Intermediate,,50597,,11450,2048.0,10116.0,Rattus norvegicus,,CHEMBL621975,,,,,A,1,1,
Lung,BAO_0000218,9511,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g",Intermediate,,50597,,11450,2048.0,10116.0,Rattus norvegicus,,CHEMBL622166,,,,,A,1,1,
Lung,BAO_0000218,9512,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g",Intermediate,,50597,,11450,2048.0,10116.0,Rattus norvegicus,,CHEMBL622167,,,,,A,1,1,
Lung,BAO_0000218,9513,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g",Intermediate,,50597,,11450,2048.0,10116.0,Rattus norvegicus,,CHEMBL622168,,,,,A,1,1,
Lung,BAO_0000218,9514,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g",Intermediate,,50597,,11450,2048.0,10116.0,Rattus norvegicus,,CHEMBL622169,,,,,A,1,1,
Lung,BAO_0000218,9515,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g",Intermediate,,50597,,11450,2048.0,10116.0,Rattus norvegicus,,CHEMBL622170,,,,,A,1,1,
Thyroid gland,BAO_0000218,9516,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g",Intermediate,,50597,,11450,2046.0,10116.0,Rattus norvegicus,,CHEMBL622171,,,,,A,1,1,
Thyroid gland,BAO_0000218,9517,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g",Intermediate,,50597,,11450,2046.0,10116.0,Rattus norvegicus,,CHEMBL622172,,,,,A,1,1,
Thyroid gland,BAO_0000218,9518,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g",Intermediate,,50597,,11450,2046.0,10116.0,Rattus norvegicus,,CHEMBL622173,,,,,A,1,1,
Thyroid gland,BAO_0000218,9519,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g",Intermediate,,50597,,11450,2046.0,10116.0,Rattus norvegicus,,CHEMBL622174,,,,,A,1,1,
Thyroid gland,BAO_0000218,9520,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g",Intermediate,,50597,,11450,2046.0,10116.0,Rattus norvegicus,,CHEMBL622175,,,,,A,1,1,
Thyroid gland,BAO_0000218,9521,N,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g",Intermediate,,50597,,11450,2046.0,10116.0,Rattus norvegicus,,CHEMBL622176,,,,,A,1,1,
Thyroid gland,BAO_0000218,9522,N,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g",Intermediate,,50597,,11450,2046.0,10116.0,Rattus norvegicus,,CHEMBL622177,,,,,A,1,1,
Thyroid gland,BAO_0000218,9523,N,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g",Intermediate,,50597,,11450,2046.0,10116.0,Rattus norvegicus,,CHEMBL622178,,,,,A,1,1,
Thyroid gland,BAO_0000218,9524,N,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g",Intermediate,,50597,,11450,2046.0,10116.0,Rattus norvegicus,,CHEMBL622179,,,,,A,1,1,
Thyroid gland,BAO_0000218,9525,N,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g",Intermediate,,50597,,11450,2046.0,10116.0,Rattus norvegicus,,CHEMBL622180,,,,,A,1,1,
,BAO_0000218,9526,N,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL622181,,,,,A,1,1,
,BAO_0000218,9527,N,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL622182,,,,,A,1,1,
,BAO_0000218,9528,N,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL622183,,,,,A,1,1,
,BAO_0000218,9529,N,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL622184,,,,,A,1,1,
,BAO_0000218,9530,N,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL622185,,,,,A,1,1,
,BAO_0000218,9531,N,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL622186,,,,,A,1,1,
,BAO_0000218,9532,N,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Intermediate,,50597,,16434,,10116.0,Rattus norvegicus,,CHEMBL622187,,,,,A,1,1,
,BAO_0000218,9533,N,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,Intermediate,,50597,,16434,,10116.0,Rattus norvegicus,,CHEMBL625002,,,,,A,1,1,
,BAO_0000218,9534,N,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min,Intermediate,,50597,,16434,,10116.0,Rattus norvegicus,,CHEMBL622090,,,,,A,1,1,
,BAO_0000218,9535,N,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL622091,,,,,A,1,1,
,BAO_0000218,9536,N,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL622092,,,,,A,1,1,
,BAO_0000218,9537,N,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL622093,,,,,A,1,1,
,BAO_0000218,9538,N,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL622094,,,,,A,1,1,
,BAO_0000218,9539,N,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL622095,,,,,A,1,1,
,BAO_0000218,9540,N,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL622264,,,,,A,1,1,
Spleen,BAO_0000218,9541,N,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,,50597,,16434,2106.0,10116.0,Rattus norvegicus,,CHEMBL622265,,,,,A,1,1,
Spleen,BAO_0000218,9542,N,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Intermediate,,50597,,16434,2106.0,10116.0,Rattus norvegicus,,CHEMBL622266,,,,,A,1,1,
Spleen,BAO_0000218,9543,N,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,,50597,,16434,2106.0,10116.0,Rattus norvegicus,,CHEMBL622267,,,,,A,1,1,
Spleen,BAO_0000218,9544,N,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,,50597,,16434,2106.0,10116.0,Rattus norvegicus,,CHEMBL622268,,,,,A,1,1,
Spleen,BAO_0000218,9545,N,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Intermediate,,50597,,16434,2106.0,10116.0,Rattus norvegicus,,CHEMBL622269,,,,,A,1,1,
Spleen,BAO_0000218,9546,N,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Intermediate,,50597,,16434,2106.0,10116.0,Rattus norvegicus,,CHEMBL625071,,,,,A,1,1,
Spleen,BAO_0000218,9547,N,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Intermediate,,50597,,16434,2106.0,10116.0,Rattus norvegicus,,CHEMBL621621,,,,,A,1,1,
Spleen,BAO_0000218,9548,N,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Intermediate,,50597,,16434,2106.0,10116.0,Rattus norvegicus,,CHEMBL621622,,,,,A,1,1,
Spleen,BAO_0000218,9549,N,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Intermediate,,50597,,16435,2106.0,10116.0,Rattus norvegicus,,CHEMBL621623,,,,,A,1,1,
Spleen,BAO_0000218,9550,N,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Intermediate,,50597,,16435,2106.0,10116.0,Rattus norvegicus,,CHEMBL621624,,,,,A,1,1,
Spleen,BAO_0000218,9551,N,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Intermediate,,50597,,16435,2106.0,10116.0,Rattus norvegicus,,CHEMBL621625,,,,,A,1,1,
Spleen,BAO_0000218,9552,N,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Intermediate,,50597,,16435,2106.0,10116.0,Rattus norvegicus,,CHEMBL621626,,,,,A,1,1,
Spleen,BAO_0000218,9553,N,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Intermediate,,50597,,16435,2106.0,10116.0,Rattus norvegicus,,CHEMBL621627,,,,,A,1,1,
Spleen,BAO_0000218,9554,N,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Intermediate,,50597,,16435,2106.0,10116.0,Rattus norvegicus,,CHEMBL621628,,,,,A,1,1,
Spleen,BAO_0000218,9555,N,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Intermediate,,50597,,16435,2106.0,10116.0,Rattus norvegicus,,CHEMBL875328,,,,,A,1,1,
Spleen,BAO_0000218,9556,N,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Intermediate,,50597,,16435,2106.0,10116.0,Rattus norvegicus,,CHEMBL621629,,,,,A,1,1,
Spleen,BAO_0000218,9557,N,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Intermediate,,50597,,16434,2106.0,10116.0,Rattus norvegicus,,CHEMBL621630,,,,,A,1,1,
Spleen,BAO_0000218,9558,N,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Intermediate,,50597,,16434,2106.0,10116.0,Rattus norvegicus,,CHEMBL621631,,,,,A,1,1,
Spleen,BAO_0000218,9559,N,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Intermediate,,50597,,16434,2106.0,10116.0,Rattus norvegicus,,CHEMBL621632,,,,,A,1,1,
Spleen,BAO_0000218,9560,N,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,,50597,,16435,2106.0,10116.0,Rattus norvegicus,,CHEMBL621633,,,,,A,1,1,
Spleen,BAO_0000218,9561,N,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,,50597,,16435,2106.0,10116.0,Rattus norvegicus,,CHEMBL621634,,,,,A,1,1,
Spleen,BAO_0000218,9562,N,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,,50597,,16435,2106.0,10116.0,Rattus norvegicus,,CHEMBL621635,,,,,A,1,1,
Spleen,BAO_0000218,9563,N,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,,50597,,16435,2106.0,10116.0,Rattus norvegicus,,CHEMBL621636,,,,,A,1,1,
Spleen,BAO_0000218,9564,N,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,,50597,,16435,2106.0,10116.0,Rattus norvegicus,,CHEMBL621637,,,,,A,1,1,
Spleen,BAO_0000218,9565,N,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,,50597,,16435,2106.0,10116.0,Rattus norvegicus,,CHEMBL621638,,,,,A,1,1,
,BAO_0000218,9566,N,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,,50597,,16434,,10116.0,Rattus norvegicus,,CHEMBL618883,,,,,A,1,1,
,BAO_0000218,9567,N,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Intermediate,,50597,,16434,,10116.0,Rattus norvegicus,,CHEMBL618884,,,,,A,1,1,
,BAO_0000218,9568,N,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,,50597,,16434,,10116.0,Rattus norvegicus,,CHEMBL628627,,,,,A,1,1,
,BAO_0000218,9569,N,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,,50597,,16434,,10116.0,Rattus norvegicus,,CHEMBL628628,,,,,A,1,1,
,BAO_0000218,9570,N,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Intermediate,,50597,,16434,,10116.0,Rattus norvegicus,,CHEMBL628629,,,,,A,1,1,
,BAO_0000218,9571,N,Half life after administering orally a dose of 3 mg/kg,Intermediate,,50597,,16365,,10116.0,Rattus norvegicus,,CHEMBL628630,,,In vivo,,A,1,1,
,BAO_0000218,9572,N,Half life after administering orally a dose of 3 mg/kg to a fasting rat,Intermediate,,50597,,16365,,10116.0,Rattus norvegicus,,CHEMBL628631,,,In vivo,,A,1,1,
,BAO_0000218,9573,N,Half life after administering intravenously a dose of 1 mg/kg,Intermediate,,50597,,16365,,10116.0,Rattus norvegicus,,CHEMBL628632,,,In vivo,,A,1,1,
,BAO_0000218,9574,N,Half life after oral dosing in rats,Intermediate,,50597,,526,,10116.0,Rattus norvegicus,,CHEMBL628633,,,In vivo,,A,1,1,
,BAO_0000218,9575,N,Half life after the administered orally a dose of 1 mg/kg to a fasting rat,Intermediate,,50597,,16365,,10116.0,Rattus norvegicus,,CHEMBL628634,,,In vivo,,A,1,1,
,BAO_0000218,9576,N,Half life by intravenous administration of 3.4 mg/kg in rat,Intermediate,,50597,,4368,,10116.0,Rattus norvegicus,,CHEMBL627789,,,In vivo,,A,1,1,
,BAO_0000218,9577,N,Half life in rat,Intermediate,,50597,,3371,,10116.0,Rattus norvegicus,,CHEMBL627790,,,,,A,1,1,
,BAO_0000218,9578,N,Half life in rat,Intermediate,,50597,,6448,,10116.0,Rattus norvegicus,,CHEMBL627791,,,,,A,1,1,
,BAO_0000218,9579,N,Half life in rat,Intermediate,,50597,,6453,,10116.0,Rattus norvegicus,,CHEMBL627792,,,,,A,1,1,
,BAO_0000218,9580,N,Half life in rat after intravenous administration of the compound,Intermediate,,50597,,4353,,10116.0,Rattus norvegicus,,CHEMBL627793,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9581,N,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life,Intermediate,,50597,,4353,1969.0,10116.0,Rattus norvegicus,,CHEMBL627794,,,In vivo,,A,1,1,
,BAO_0000218,9582,N,Half life in rat after po administration of the compound,Intermediate,,50597,,4353,,10116.0,Rattus norvegicus,,CHEMBL627795,,,In vivo,,A,1,1,
,BAO_0000218,9583,N,Half life in rat after po administration of the compound; ND means Not determined,Intermediate,,50597,,4353,,10116.0,Rattus norvegicus,,CHEMBL627796,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9584,N,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life,Intermediate,,50597,,4353,1969.0,10116.0,Rattus norvegicus,,CHEMBL875335,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9585,N,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life,Intermediate,,50597,,4353,1969.0,10116.0,Rattus norvegicus,,CHEMBL627797,,,In vivo,,A,1,1,
,BAO_0000218,9586,N,Half life in rat i.v.,Intermediate,,50597,,5789,,10116.0,Rattus norvegicus,,CHEMBL627798,,,In vivo,,A,1,1,
,BAO_0000218,9587,N,Half life in rat i.v. at 2 mg/kg concentration,Intermediate,,50597,,17686,,10116.0,Rattus norvegicus,,CHEMBL627799,,,In vivo,,A,1,1,
,BAO_0000218,9588,N,Half life in rats,Intermediate,,50597,,6495,,10116.0,Rattus norvegicus,,CHEMBL627800,,,,,A,1,1,
,BAO_0000218,9589,N,Half life in rats after intravenous administration,Intermediate,,50597,,484,,10116.0,Rattus norvegicus,,CHEMBL627801,,,In vivo,,A,1,1,
,BAO_0000218,9590,N,Half life in rats at the dose of 1.0 mpk by i.v. administration,Intermediate,,50597,,6467,,10116.0,Rattus norvegicus,,CHEMBL627802,,,In vivo,,A,1,1,
,BAO_0000218,9591,N,Half life in rat,Expert,,50597,,6642,,10116.0,Rattus norvegicus,,CHEMBL627803,,,,,A,1,1,
,BAO_0000218,9592,N,Half life was evaluated after intravenous administration to rats,Intermediate,,50597,,16367,,10116.0,Rattus norvegicus,,CHEMBL873820,,,In vivo,,A,1,1,
,BAO_0000218,9593,N,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO),Intermediate,,50597,,1369,,10116.0,Rattus norvegicus,,CHEMBL627804,,,,,A,1,1,
,BAO_0000218,9594,N,Half life was evaluated in rat,Intermediate,,50597,,5472,,10116.0,Rattus norvegicus,,CHEMBL627805,,,,,A,1,1,
,BAO_0000218,9595,N,Half life was evaluated in rat,Intermediate,,50597,,6049,,10116.0,Rattus norvegicus,,CHEMBL627806,,,,,A,1,1,
,BAO_0000218,9596,N,Half life was evaluated in rat; Not tested,Intermediate,,50597,,5472,,10116.0,Rattus norvegicus,,CHEMBL627107,,,,,A,1,1,
,BAO_0000218,9597,N,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats,Intermediate,,50597,,16366,,10116.0,Rattus norvegicus,,CHEMBL627108,,,In vivo,,A,1,1,
,BAO_0000218,9598,N,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats,Intermediate,,50597,,11149,,10116.0,Rattus norvegicus,,CHEMBL627109,,,In vivo,,A,1,1,
Blood,BAO_0000218,9599,N,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats,Intermediate,,50597,,11149,178.0,10116.0,Rattus norvegicus,,CHEMBL627110,,,In vivo,,A,1,1,
,BAO_0000218,9600,U,Half life was measured in monkey at dose of 10 mg/kg by po administration,Intermediate,,22224,,2891,,9443.0,Primates,,CHEMBL627111,,,In vivo,,A,1,0,
,BAO_0000218,9601,U,Half life was measured in monkey at dose of 10 mg/kg by po administration,Intermediate,,22224,,2891,,9443.0,Primates,,CHEMBL627112,,,In vivo,,A,1,0,
,BAO_0000218,9602,U,Half life was measured in rat at dose of 30 mg/kg by iv administration,Intermediate,,22224,,2891,,10116.0,Rattus norvegicus,,CHEMBL627113,,,In vivo,,A,1,0,
,BAO_0000218,9603,U,Half life was measured in rat at dose of 30 mg/kg by po administration,Intermediate,,22224,,2891,,10116.0,Rattus norvegicus,,CHEMBL627114,,,In vivo,,A,1,0,
,BAO_0000218,9604,N,Half life (t1/2) was determined,Intermediate,,50597,,4026,,10116.0,Rattus norvegicus,,CHEMBL627115,,,,,A,1,1,
,BAO_0000218,9605,N,Half life period at a dose of 10 uM/kg in rat was determined,Intermediate,,50597,,4527,,10116.0,Rattus norvegicus,,CHEMBL627116,,,,,A,1,1,
,BAO_0000218,9606,N,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined,Intermediate,,50597,,4527,,10116.0,Rattus norvegicus,,CHEMBL627117,,,In vivo,,A,1,1,
,BAO_0000218,9607,N,Half life period was determined,Intermediate,,50597,,5503,,10116.0,Rattus norvegicus,,CHEMBL627118,,,,,A,1,1,
,BAO_0000218,9608,N,Half life period after intravenous administration at 20 mpk in rats,Intermediate,,50597,,4426,,10116.0,Rattus norvegicus,,CHEMBL627119,,,In vivo,,A,1,1,
,BAO_0000218,9609,N,Half life period after intravenous administration at 20 mpk in rats; Not performed.,Intermediate,,50597,,4426,,10116.0,Rattus norvegicus,,CHEMBL627120,,,In vivo,,A,1,1,
,BAO_0000218,9610,N,Half life period after intravenous administration in rat,Intermediate,,50597,,6109,,10116.0,Rattus norvegicus,,CHEMBL626922,,,In vivo,,A,1,1,
,BAO_0000218,9611,N,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,Intermediate,,50597,,5654,,10116.0,Rattus norvegicus,,CHEMBL626923,,,In vivo,,A,1,1,
,BAO_0000218,9612,N,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,Intermediate,,50597,,5654,,10116.0,Rattus norvegicus,,CHEMBL626924,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9613,N,Half life period in 80% rat plasma at 37 degree Centigrade,Intermediate,,50597,,4755,1969.0,10116.0,Rattus norvegicus,,CHEMBL626925,,,,,A,1,1,
,BAO_0000218,9614,N,Half life period in SD rats,Intermediate,,50597,,5862,,10116.0,Rattus norvegicus,,CHEMBL626926,,,,,A,1,1,
Plasma,BAO_0000218,9615,N,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4),Intermediate,,50597,,1515,1969.0,10116.0,Rattus norvegicus,,CHEMBL626927,,,,,A,1,1,
Plasma,BAO_0000218,9616,N,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4),Intermediate,,50597,,1515,1969.0,10116.0,Rattus norvegicus,,CHEMBL626928,,,,,A,1,1,
Plasma,BAO_0000218,9617,N,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,Intermediate,,50597,,1515,1969.0,10116.0,Rattus norvegicus,,CHEMBL626929,,,,,A,1,1,
Plasma,BAO_0000218,9618,N,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,Intermediate,,50597,,1515,1969.0,10116.0,Rattus norvegicus,,CHEMBL626930,,,,,A,1,1,
,BAO_0000218,9619,N,Half life period in rat,Intermediate,,50597,,5960,,10116.0,Rattus norvegicus,,CHEMBL626931,,,,,A,1,1,
,BAO_0000218,9620,N,Half life period in rat,Intermediate,,50597,,6103,,10116.0,Rattus norvegicus,,CHEMBL626932,,,,,A,1,1,
,BAO_0000218,9621,N,Half life period in rat,Intermediate,,50597,,6317,,10116.0,Rattus norvegicus,,CHEMBL626933,,,,,A,1,1,
,BAO_0000218,9622,N,Half life period in rat after oral administration at 10.5 mg/kg dose,Intermediate,,50597,,6644,,10116.0,Rattus norvegicus,,CHEMBL873826,,,In vivo,,A,1,1,
,BAO_0000218,9623,N,Half life period in rat after oral administration at 11.2 mg/kg dose,Intermediate,,50597,,6644,,10116.0,Rattus norvegicus,,CHEMBL626934,,,In vivo,,A,1,1,
,BAO_0000218,9624,N,Half life period in rat after oral administration at 13 mg/kg dose,Intermediate,,50597,,6644,,10116.0,Rattus norvegicus,,CHEMBL626935,,,In vivo,,A,1,1,
,BAO_0000218,9625,N,Half life period in rat after oral administration at 9.7 mg/kg dose,Intermediate,,50597,,6644,,10116.0,Rattus norvegicus,,CHEMBL626936,,,In vivo,,A,1,1,
,BAO_0000218,9626,N,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,Intermediate,,50597,,5974,,10116.0,Rattus norvegicus,,CHEMBL626937,,,,,A,1,1,
,BAO_0000218,9627,N,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,Intermediate,,50597,,6295,,10116.0,Rattus norvegicus,,CHEMBL625906,,,,,A,1,1,
,BAO_0000218,9628,N,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,Intermediate,,50597,,6296,,10116.0,Rattus norvegicus,,CHEMBL625907,,,,,A,1,1,
,BAO_0000218,9629,N,PK study was carried to determine AUC (area under curve) value in rat,Intermediate,,50597,,16427,,10116.0,Rattus norvegicus,,CHEMBL625908,,,,,A,1,1,
,BAO_0000218,9630,N,Pharmacokinetic parameter AUC after intravenous administration to rats,Intermediate,,50597,,16367,,10116.0,Rattus norvegicus,,CHEMBL625909,,,,,A,1,1,
,BAO_0000218,9631,N,Pharmacokinetic parameter AUC after oral administration to rats,Intermediate,,50597,,16367,,10116.0,Rattus norvegicus,,CHEMBL625910,,,,,A,1,1,
,BAO_0000218,9632,N,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg,Intermediate,,50597,,16365,,10116.0,Rattus norvegicus,,CHEMBL625911,,,,,A,1,1,
,BAO_0000218,9633,N,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat,Intermediate,,50597,,16365,,10116.0,Rattus norvegicus,,CHEMBL625912,,,,,A,1,1,
,BAO_0000218,9634,N,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat,Intermediate,,50597,,16365,,10116.0,Rattus norvegicus,,CHEMBL626538,,,,,A,1,1,
,BAO_0000218,9635,N,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally,Intermediate,,50597,,16365,,10116.0,Rattus norvegicus,,CHEMBL876794,,,,,A,1,1,
,BAO_0000218,9636,N,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally,Intermediate,,50597,,16365,,10116.0,Rattus norvegicus,,CHEMBL626539,,,,,A,1,1,
,BAO_0000218,9637,N,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat,Intermediate,,50597,,16365,,10116.0,Rattus norvegicus,,CHEMBL626540,,,,,A,1,1,
,BAO_0000218,9638,N,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg,Intermediate,,50597,,5394,,10116.0,Rattus norvegicus,,CHEMBL626541,,,,,A,1,1,
,BAO_0000218,9639,N,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg,Intermediate,,50597,,5394,,10116.0,Rattus norvegicus,,CHEMBL626542,,,,,A,1,1,
,BAO_0000218,9640,N,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats,Intermediate,,50597,,2792,,10116.0,Rattus norvegicus,,CHEMBL626543,,,,,A,1,1,
,BAO_0000218,9641,N,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats,Intermediate,,50597,,2792,,10116.0,Rattus norvegicus,,CHEMBL626544,,,,,A,1,1,
,BAO_0000218,9642,N,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats,Intermediate,,50597,,2792,,10116.0,Rattus norvegicus,,CHEMBL626545,,,,,A,1,1,
,BAO_0000218,9643,N,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats,Intermediate,,50597,,2792,,10116.0,Rattus norvegicus,,CHEMBL626546,,,,,A,1,1,
,BAO_0000218,9644,N,Pharmacokinetic parameter area under curve was reported,Intermediate,,50597,,5334,,10116.0,Rattus norvegicus,,CHEMBL626547,,,,,A,1,1,
,BAO_0000218,9645,N,Pharmacokinetic property (AUC) in rat,Intermediate,,50597,,4408,,10116.0,Rattus norvegicus,,CHEMBL626548,,,,,A,1,1,
,BAO_0000218,9646,N,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.,Intermediate,,50597,,5983,,10116.0,Rattus norvegicus,,CHEMBL626549,,,,,A,1,1,
,BAO_0000218,9647,N,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.,Intermediate,,50597,,4397,,10116.0,Rattus norvegicus,,CHEMBL626550,,,,,A,1,1,
,BAO_0000218,9648,N,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested,Intermediate,,50597,,4397,,10116.0,Rattus norvegicus,,CHEMBL626551,,,,,A,1,1,
,BAO_0000218,9649,N,Pharmacokinetic property was determined,Intermediate,,50597,,5491,,10116.0,Rattus norvegicus,,CHEMBL623777,,,,,A,1,1,
,BAO_0000218,9650,N,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg,Intermediate,,50597,,5491,,10116.0,Rattus norvegicus,,CHEMBL623778,,,,,A,1,1,
,BAO_0000218,9651,N,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested,Intermediate,,50597,,5491,,10116.0,Rattus norvegicus,,CHEMBL623779,,,,,A,1,1,
Plasma,BAO_0000218,9652,N,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,Intermediate,,50597,,4199,1969.0,10116.0,Rattus norvegicus,,CHEMBL623780,,,,,A,1,1,
Plasma,BAO_0000218,9653,N,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats,Intermediate,,50597,,4199,1969.0,10116.0,Rattus norvegicus,,CHEMBL622015,,,,,A,1,1,
Plasma,BAO_0000218,9654,N,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats,Intermediate,,50597,,4199,1969.0,10116.0,Rattus norvegicus,,CHEMBL622016,,,,,A,1,1,
,BAO_0000218,9655,N,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h",Intermediate,,50597,,5173,,10116.0,Rattus norvegicus,,CHEMBL622017,,,,,A,1,1,
,BAO_0000218,9656,N,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h",Intermediate,,50597,,5173,,10116.0,Rattus norvegicus,,CHEMBL622018,,,,,A,1,1,
,BAO_0000218,9657,N,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h",Intermediate,,50597,,5173,,10116.0,Rattus norvegicus,,CHEMBL622019,,,,,A,1,1,
,BAO_0000218,9658,N,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h",Intermediate,,50597,,5173,,10116.0,Rattus norvegicus,,CHEMBL622020,,,,,A,1,1,
,BAO_0000218,9659,N,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously,Intermediate,,50597,,16366,,10116.0,Rattus norvegicus,,CHEMBL622021,,,,,A,1,1,
,BAO_0000218,9660,N,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally,Intermediate,,50597,,16366,,10116.0,Rattus norvegicus,,CHEMBL622022,,,,,A,1,1,
,BAO_0000218,9661,N,Plasma concentration expressed as area under curve after intravenous administration was determined in rat,Intermediate,,50597,,5327,,10116.0,Rattus norvegicus,,CHEMBL622023,,,,,A,1,1,
,BAO_0000218,9662,N,Plasma concentration for the compound was determined in rats at 50 mg/kg dose,Intermediate,,50597,,6681,,10116.0,Rattus norvegicus,,CHEMBL622024,,,,,A,1,1,
,BAO_0000218,9663,N,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound),Intermediate,,50597,,12873,,10116.0,Rattus norvegicus,,CHEMBL622693,,,,,A,1,1,
,BAO_0000218,9664,N,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound),Intermediate,,50597,,12873,,10116.0,Rattus norvegicus,,CHEMBL622694,,,,,A,1,1,
,BAO_0000218,9665,N,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose",Intermediate,,50597,,6685,,10116.0,Rattus norvegicus,,CHEMBL622695,,,,,A,1,1,
,BAO_0000218,9666,N,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose",Intermediate,,50597,,6685,,10116.0,Rattus norvegicus,,CHEMBL622696,,,,,A,1,1,
,BAO_0000218,9667,N,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose",Intermediate,,50597,,6685,,10116.0,Rattus norvegicus,,CHEMBL622697,,,,,A,1,1,
,BAO_0000218,9668,N,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)",Intermediate,,50597,,6619,,10116.0,Rattus norvegicus,,CHEMBL622874,,,,,A,1,1,
,BAO_0000218,9669,N,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)",Intermediate,,50597,,6619,,10116.0,Rattus norvegicus,,CHEMBL622875,,,,,A,1,1,
,BAO_0000218,9670,N,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,Intermediate,,50597,,10363,,10116.0,Rattus norvegicus,,CHEMBL622876,,,,,A,1,1,
,BAO_0000218,9671,N,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,Intermediate,,50597,,4796,,10116.0,Rattus norvegicus,,CHEMBL622877,,,,,A,1,1,
,BAO_0000218,9672,N,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,Intermediate,,50597,,4910,,10116.0,Rattus norvegicus,,CHEMBL622878,,,,,A,1,1,
Plasma,BAO_0000218,9673,N,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats,Intermediate,,50597,,4910,1969.0,10116.0,Rattus norvegicus,,CHEMBL622879,,,,,A,1,1,
,BAO_0000218,9674,N,Tested for the pharmacokinetic parameter in rat and expressed as area under curve,Intermediate,,50597,,4839,,10116.0,Rattus norvegicus,,CHEMBL877602,,,,,A,1,1,
,BAO_0000218,9675,N,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",Intermediate,,50597,,15078,,10116.0,Rattus norvegicus,,CHEMBL622880,,,,,A,1,1,
,BAO_0000218,9676,N,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose",Intermediate,,50597,,15078,,10116.0,Rattus norvegicus,,CHEMBL622881,,,,,A,1,1,
,BAO_0000218,9677,N,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",Intermediate,,50597,,15078,,10116.0,Rattus norvegicus,,CHEMBL622882,,,,,A,1,1,
,BAO_0000218,9678,N,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose",Intermediate,,50597,,15078,,10116.0,Rattus norvegicus,,CHEMBL622883,,,,,A,1,1,
Thyroid gland,BAO_0000218,9679,N,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g",Intermediate,,50597,,11450,2046.0,10116.0,Rattus norvegicus,,CHEMBL622884,,,,,A,1,1,
Thyroid gland,BAO_0000218,9680,N,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g",Intermediate,,50597,,11450,2046.0,10116.0,Rattus norvegicus,,CHEMBL622885,,,,,A,1,1,
,BAO_0000218,9681,N,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,Intermediate,,50597,,8151,,10116.0,Rattus norvegicus,,CHEMBL622886,,,,,A,1,1,
,BAO_0000218,9682,N,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,Intermediate,,50597,,8151,,10116.0,Rattus norvegicus,,CHEMBL622887,,,,,A,1,1,
Urine,BAO_0000218,9683,N,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,Intermediate,,50597,,8151,1088.0,10116.0,Rattus norvegicus,,CHEMBL622888,,,,,A,1,1,
Blood,BAO_0000218,9684,N,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,50597,,8677,178.0,10116.0,Rattus norvegicus,,CHEMBL622889,,,In vivo,,A,1,1,
Blood,BAO_0000218,9685,N,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,50597,,8677,178.0,10116.0,Rattus norvegicus,,CHEMBL622890,,,In vivo,,A,1,1,
Blood,BAO_0000218,9686,N,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,50597,,8677,178.0,10116.0,Rattus norvegicus,,CHEMBL622891,,,In vivo,,A,1,1,
Blood,BAO_0000218,9687,N,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,50597,,8677,178.0,10116.0,Rattus norvegicus,,CHEMBL877603,,,In vivo,,A,1,1,
Brain,BAO_0000218,9688,N,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,50597,,8677,955.0,10116.0,Rattus norvegicus,,CHEMBL622892,,,In vivo,,A,1,1,
Brain,BAO_0000218,9689,N,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,50597,,8677,955.0,10116.0,Rattus norvegicus,,CHEMBL622893,,,In vivo,,A,1,1,
Brain,BAO_0000218,9690,N,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,50597,,8677,955.0,10116.0,Rattus norvegicus,,CHEMBL622894,,,In vivo,,A,1,1,
Brain,BAO_0000218,9691,N,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,50597,,8677,955.0,10116.0,Rattus norvegicus,,CHEMBL622895,,,In vivo,,A,1,1,
Brain,BAO_0000218,9692,N,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.,Intermediate,,50597,,8677,955.0,10116.0,Rattus norvegicus,,CHEMBL622896,,,In vivo,,A,1,1,
Heart,BAO_0000218,9693,N,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,50597,,8677,948.0,10116.0,Rattus norvegicus,,CHEMBL622897,,,In vivo,,A,1,1,
Heart,BAO_0000218,9694,N,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,50597,,8677,948.0,10116.0,Rattus norvegicus,,CHEMBL622898,,,In vivo,,A,1,1,
Heart,BAO_0000218,9695,N,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,50597,,8677,948.0,10116.0,Rattus norvegicus,,CHEMBL622899,,,In vivo,,A,1,1,
Kidney,BAO_0000218,9696,N,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,50597,,8677,2113.0,10116.0,Rattus norvegicus,,CHEMBL622900,,,In vivo,,A,1,1,
Kidney,BAO_0000218,9697,N,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,50597,,8677,2113.0,10116.0,Rattus norvegicus,,CHEMBL624114,,,In vivo,,A,1,1,
Kidney,BAO_0000218,9698,N,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,50597,,8677,2113.0,10116.0,Rattus norvegicus,,CHEMBL624115,,,In vivo,,A,1,1,
Kidney,BAO_0000218,9699,N,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,50597,,8677,2113.0,10116.0,Rattus norvegicus,,CHEMBL624116,,,In vivo,,A,1,1,
Liver,BAO_0000218,9700,N,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,50597,,8677,2107.0,10116.0,Rattus norvegicus,,CHEMBL624117,,,In vivo,,A,1,1,
Liver,BAO_0000218,9701,N,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,50597,,8677,2107.0,10116.0,Rattus norvegicus,,CHEMBL624118,,,In vivo,,A,1,1,
Liver,BAO_0000218,9702,N,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,50597,,8677,2107.0,10116.0,Rattus norvegicus,,CHEMBL624119,,,In vivo,,A,1,1,
Liver,BAO_0000218,9703,N,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,50597,,8677,2107.0,10116.0,Rattus norvegicus,,CHEMBL624120,,,In vivo,,A,1,1,
Lung,BAO_0000218,9704,N,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,50597,,8677,2048.0,10116.0,Rattus norvegicus,,CHEMBL624121,,,In vivo,,A,1,1,
Lung,BAO_0000218,9705,N,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,50597,,8677,2048.0,10116.0,Rattus norvegicus,,CHEMBL624122,,,In vivo,,A,1,1,
Lung,BAO_0000218,9706,N,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,50597,,8677,2048.0,10116.0,Rattus norvegicus,,CHEMBL624123,,,In vivo,,A,1,1,
Lung,BAO_0000218,9707,N,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,50597,,8677,2048.0,10116.0,Rattus norvegicus,,CHEMBL624124,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,9708,N,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,50597,,8677,2385.0,10116.0,Rattus norvegicus,,CHEMBL624125,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,9709,N,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,50597,,8677,2385.0,10116.0,Rattus norvegicus,,CHEMBL624126,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,9710,N,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,50597,,8677,2385.0,10116.0,Rattus norvegicus,,CHEMBL624127,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,9711,N,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,50597,,8677,2385.0,10116.0,Rattus norvegicus,,CHEMBL624128,,,In vivo,,A,1,1,
Zone of skin,BAO_0000218,9712,N,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,50597,,8677,14.0,10116.0,Rattus norvegicus,,CHEMBL624129,,,In vivo,,A,1,1,
Zone of skin,BAO_0000218,9713,N,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,50597,,8677,14.0,10116.0,Rattus norvegicus,,CHEMBL624130,,,In vivo,,A,1,1,
Zone of skin,BAO_0000218,9714,N,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,50597,,8677,14.0,10116.0,Rattus norvegicus,,CHEMBL622340,,,In vivo,,A,1,1,
Zone of skin,BAO_0000218,9715,N,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,50597,,8677,14.0,10116.0,Rattus norvegicus,,CHEMBL622341,,,In vivo,,A,1,1,
Intestine,BAO_0000218,9716,N,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,50597,,8677,160.0,10116.0,Rattus norvegicus,,CHEMBL622342,,,In vivo,,A,1,1,
Intestine,BAO_0000218,9717,N,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,50597,,8677,160.0,10116.0,Rattus norvegicus,,CHEMBL622343,,,In vivo,,A,1,1,
Intestine,BAO_0000218,9718,N,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,50597,,8677,160.0,10116.0,Rattus norvegicus,,CHEMBL622344,,,In vivo,,A,1,1,
Intestine,BAO_0000218,9719,N,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,50597,,8677,160.0,10116.0,Rattus norvegicus,,CHEMBL622345,,,In vivo,,A,1,1,
Spleen,BAO_0000218,9720,N,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,50597,,8677,2106.0,10116.0,Rattus norvegicus,,CHEMBL622346,,,In vivo,,A,1,1,
Spleen,BAO_0000218,9721,N,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,50597,,8677,2106.0,10116.0,Rattus norvegicus,,CHEMBL622347,,,In vivo,,A,1,1,
Spleen,BAO_0000218,9722,N,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,50597,,8677,2106.0,10116.0,Rattus norvegicus,,CHEMBL622348,,,In vivo,,A,1,1,
Spleen,BAO_0000218,9723,N,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,50597,,8677,2106.0,10116.0,Rattus norvegicus,,CHEMBL622349,,,In vivo,,A,1,1,
,BAO_0000218,9724,N,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Intermediate,,50597,,16434,,10116.0,Rattus norvegicus,,CHEMBL622350,,,,,A,1,1,
,BAO_0000218,9725,N,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Intermediate,,50597,,16434,,10116.0,Rattus norvegicus,,CHEMBL622351,,,,,A,1,1,
,BAO_0000218,9726,N,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Intermediate,,50597,,16434,,10116.0,Rattus norvegicus,,CHEMBL622352,,,,,A,1,1,
,BAO_0000218,9727,N,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL622353,,,,,A,1,1,
,BAO_0000218,9728,N,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL622354,,,,,A,1,1,
,BAO_0000218,9729,N,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL622355,,,,,A,1,1,
,BAO_0000218,9730,N,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL622356,,,,,A,1,1,
,BAO_0000218,9731,N,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL622357,,,,,A,1,1,
,BAO_0000218,9732,N,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL622358,,,,,A,1,1,
,BAO_0000218,9733,N,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL622359,,,,,A,1,1,
,BAO_0000218,9734,N,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL874393,,,,,A,1,1,
,BAO_0000218,9735,N,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Intermediate,,50597,,16434,,10116.0,Rattus norvegicus,,CHEMBL622872,,,,,A,1,1,
,BAO_0000218,9736,N,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Intermediate,,50597,,16434,,10116.0,Rattus norvegicus,,CHEMBL622873,,,,,A,1,1,
,BAO_0000218,9737,N,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Intermediate,,50597,,16434,,10116.0,Rattus norvegicus,,CHEMBL623047,,,,,A,1,1,
,BAO_0000218,9738,N,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL623048,,,,,A,1,1,
,BAO_0000218,9739,N,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL623049,,,,,A,1,1,
,BAO_0000218,9740,N,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL623050,,,,,A,1,1,
,BAO_0000218,9741,N,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL623051,,,,,A,1,1,
,BAO_0000218,9742,N,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL623052,,,,,A,1,1,
,BAO_0000218,9743,N,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL626343,,,,,A,1,1,
,BAO_0000218,9744,N,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Intermediate,,50597,,16434,,10116.0,Rattus norvegicus,,CHEMBL626344,,,,,A,1,1,
,BAO_0000218,9745,N,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Intermediate,,50597,,16434,,10116.0,Rattus norvegicus,,CHEMBL626345,,,,,A,1,1,
,BAO_0000218,9746,N,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Intermediate,,50597,,16434,,10116.0,Rattus norvegicus,,CHEMBL626346,,,,,A,1,1,
,BAO_0000218,9747,N,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Intermediate,,50597,,16434,,10116.0,Rattus norvegicus,,CHEMBL626347,,,,,A,1,1,
,BAO_0000218,9748,N,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Intermediate,,50597,,16434,,10116.0,Rattus norvegicus,,CHEMBL626348,,,,,A,1,1,
,BAO_0000218,9749,N,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Intermediate,,50597,,16434,,10116.0,Rattus norvegicus,,CHEMBL626349,,,,,A,1,1,
,BAO_0000218,9750,N,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL626350,,,,,F,1,1,
,BAO_0000218,9751,N,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL626351,,,,,A,1,1,
,BAO_0000218,9752,N,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL627650,,,,,A,1,1,
,BAO_0000218,9753,N,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL627651,,,,,F,1,1,
,BAO_0000218,9754,N,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL627652,,,,,A,1,1,
,BAO_0000218,9755,N,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Intermediate,,50597,,16435,,10116.0,Rattus norvegicus,,CHEMBL627653,,,,,A,1,1,
,BAO_0000218,9756,N,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval,Intermediate,,50597,,13091,,10116.0,Rattus norvegicus,,CHEMBL627654,,,,,A,1,1,
,BAO_0000218,9757,N,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval,Intermediate,,50597,,13091,,10116.0,Rattus norvegicus,,CHEMBL627835,,,,,A,1,1,
,BAO_0000218,9758,N,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval,Intermediate,,50597,,13091,,10116.0,Rattus norvegicus,,CHEMBL627836,,,,,A,1,1,
,BAO_0000218,9759,N,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval,Intermediate,,50597,,13091,,10116.0,Rattus norvegicus,,CHEMBL627837,,,,,A,1,1,
,BAO_0000218,9760,N,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval,Intermediate,,50597,,13091,,10116.0,Rattus norvegicus,,CHEMBL627838,,,,,A,1,1,
,BAO_0000218,9761,N,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval,Intermediate,,50597,,13091,,10116.0,Rattus norvegicus,,CHEMBL875338,,,,,A,1,1,
,BAO_0000218,9762,N,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval,Intermediate,,50597,,13091,,10116.0,Rattus norvegicus,,CHEMBL627839,,,,,A,1,1,
,BAO_0000218,9763,N,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval,Intermediate,,50597,,13091,,10116.0,Rattus norvegicus,,CHEMBL627840,,,,,A,1,1,
,BAO_0000218,9764,N,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval,Intermediate,,50597,,13091,,10116.0,Rattus norvegicus,,CHEMBL627841,,,,,A,1,1,
,BAO_0000218,9765,N,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval,Intermediate,,50597,,13091,,10116.0,Rattus norvegicus,,CHEMBL627842,,,,,A,1,1,
,BAO_0000218,9766,N,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval,Intermediate,,50597,,13091,,10116.0,Rattus norvegicus,,CHEMBL627843,,,,,A,1,1,
,BAO_0000218,9767,N,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval,Intermediate,,50597,,13091,,10116.0,Rattus norvegicus,,CHEMBL627844,,,,,A,1,1,
,BAO_0000218,9768,N,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval,Intermediate,,50597,,13091,,10116.0,Rattus norvegicus,,CHEMBL627845,,,,,A,1,1,
,BAO_0000218,9769,N,Half life period in rat by iv administration at a dose of 3 mg/kg,Intermediate,,50597,,5874,,10116.0,Rattus norvegicus,,CHEMBL627846,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9770,N,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4),Intermediate,,50597,,1515,1969.0,10116.0,Rattus norvegicus,,CHEMBL627847,,,,,A,1,1,
Plasma,BAO_0000218,9771,N,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4),Intermediate,,50597,,1515,1969.0,10116.0,Rattus norvegicus,,CHEMBL873821,,,,,A,1,1,
Plasma,BAO_0000218,9772,N,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,Intermediate,,50597,,1515,1969.0,10116.0,Rattus norvegicus,,CHEMBL626079,,,,,A,1,1,
Plasma,BAO_0000218,9773,N,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,Intermediate,,50597,,1515,1969.0,10116.0,Rattus norvegicus,,CHEMBL626080,,,,,A,1,1,
Plasma,BAO_0000218,9774,N,Half life period was evaluated in rat plasma,Intermediate,,50597,,5491,1969.0,10116.0,Rattus norvegicus,,CHEMBL626081,,,,,A,1,1,
Plasma,BAO_0000218,9775,N,Half life period was evaluated in rat plasma; Not tested,Intermediate,,50597,,5491,1969.0,10116.0,Rattus norvegicus,,CHEMBL875344,,,,,A,1,1,
,BAO_0000218,9776,N,Half life period was evaluated in rats,Intermediate,,50597,,1918,,10116.0,Rattus norvegicus,,CHEMBL626082,,,,,A,1,1,
,BAO_0000218,9777,N,"Half life period was evaluated in rats, iv",Intermediate,,50597,,1918,,10116.0,Rattus norvegicus,,CHEMBL626250,,,In vivo,,A,1,1,
,BAO_0000218,9778,N,Half life period after intravenous administration at 5 mg/kg in rat,Intermediate,,50597,,6113,,10116.0,Rattus norvegicus,,CHEMBL626251,,,In vivo,,A,1,1,
,BAO_0000218,9779,N,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,Intermediate,,50597,,5546,,10116.0,Rattus norvegicus,,CHEMBL626252,,,In vivo,,A,1,1,
,BAO_0000218,9780,N,Half life period was determined in rat after iv administration at a dose of 5 mg/kg,Intermediate,,50597,,5553,,10116.0,Rattus norvegicus,,CHEMBL626253,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9781,N,Half life stability of compound was evaluated in rat plasma,Intermediate,,50597,,4188,1969.0,10116.0,Rattus norvegicus,,CHEMBL626254,,,,,A,1,1,
,BAO_0000218,9782,N,Half life time after intravenous administration (5.0 mg/kg) was determined in rat,Intermediate,,50597,,6215,,10116.0,Rattus norvegicus,,CHEMBL626255,,,In vivo,,A,1,1,
,BAO_0000218,9783,N,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,Intermediate,,50597,,6141,,10116.0,Rattus norvegicus,,CHEMBL626256,,,In vivo,,A,1,1,
,BAO_0000218,9784,N,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,Intermediate,,50597,,5182,,10116.0,Rattus norvegicus,,CHEMBL626257,,,In vivo,,A,1,1,
,BAO_0000218,9785,N,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated,Intermediate,,50597,,5182,,10116.0,Rattus norvegicus,,CHEMBL626258,,,In vivo,,A,1,1,
,BAO_0000218,9786,N,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.,Intermediate,,50597,,5710,,10116.0,Rattus norvegicus,,CHEMBL626259,,,In vivo,,A,1,1,
,BAO_0000218,9787,N,Half in rat i.v.,Intermediate,,50597,,5789,,10116.0,Rattus norvegicus,,CHEMBL626260,,,In vivo,,A,1,1,
,BAO_0000218,9788,N,Half period in rat after intravenous administration,Intermediate,,50597,,6011,,10116.0,Rattus norvegicus,,CHEMBL875345,,,In vivo,,A,1,1,
,BAO_0000218,9789,N,Half-life after repeated oral dose of compound at 1 mg/kg in rats,Intermediate,,50597,,17594,,10116.0,Rattus norvegicus,,CHEMBL626261,,,In vivo,,A,1,1,
Liver,BAO_0000218,9790,N,Half-life measured in in vitro Cathepsin B assay in rat liver,Intermediate,,50597,,12357,2107.0,10116.0,Rattus norvegicus,,CHEMBL626262,,,In vitro,,A,1,1,
,BAO_0000218,9791,N,Half-life of compound was determined in rats,Intermediate,,50597,,5210,,10116.0,Rattus norvegicus,,CHEMBL626263,,,,,A,1,1,
,BAO_0000218,9792,N,Half-life at 10 mg/kg in rat upon intravenous administration,Intermediate,,50597,,17596,,10116.0,Rattus norvegicus,,CHEMBL625270,,,In vivo,,A,1,1,
,BAO_0000218,9793,N,Half-life determined in rat,Intermediate,,50597,,6672,,10116.0,Rattus norvegicus,,CHEMBL625271,,,,,A,1,1,
,BAO_0000218,9794,N,Half-life determined in rat,Intermediate,,50597,,6673,,10116.0,Rattus norvegicus,,CHEMBL625272,,,,,A,1,1,
Brain,BAO_0000218,9795,N,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats,Intermediate,,50597,,4910,955.0,10116.0,Rattus norvegicus,,CHEMBL625273,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9796,N,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma",Intermediate,,50597,,3741,1969.0,10116.0,Rattus norvegicus,,CHEMBL625274,,,,,A,1,1,
,BAO_0000218,9797,N,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,Intermediate,,50597,,17671,,10116.0,Rattus norvegicus,,CHEMBL625275,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9798,N,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats,Intermediate,,50597,,4910,1969.0,10116.0,Rattus norvegicus,,CHEMBL625276,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9799,N,Half-life in rat plasma,Intermediate,,50597,,17537,1969.0,10116.0,Rattus norvegicus,,CHEMBL625277,,,,,A,1,1,
Plasma,BAO_0000218,9800,N,Half-life in rat plasma was determined,Intermediate,,50597,,4965,1969.0,10116.0,Rattus norvegicus,,CHEMBL625278,,,,,A,1,1,
Plasma,BAO_0000218,9801,N,Half-life in rat plasma; Not tested,Intermediate,,50597,,17537,1969.0,10116.0,Rattus norvegicus,,CHEMBL625279,,,,,A,1,1,
Serum,BAO_0000218,9802,N,Half-life in rat serum,Intermediate,,50597,,6124,1977.0,10116.0,Rattus norvegicus,,CHEMBL625280,,,,,A,1,1,
Serum,BAO_0000218,9803,N,Half-life in rat serum; na is not available,Intermediate,,50597,,6124,1977.0,10116.0,Rattus norvegicus,,CHEMBL876797,,,,,A,1,1,
,BAO_0000218,9804,N,Half-life was calculated in rat,Intermediate,,50597,,6078,,10116.0,Rattus norvegicus,,CHEMBL625281,,,,,A,1,1,
Plasma,BAO_0000218,9805,N,Half-life was calculated in rat plasma,Intermediate,,50597,,17668,1969.0,10116.0,Rattus norvegicus,,CHEMBL873827,,,,,A,1,1,
,BAO_0000218,9806,N,Half-life was determined,Intermediate,,50597,,3185,,10116.0,Rattus norvegicus,,CHEMBL625282,,,,,A,1,1,
,BAO_0000218,9807,N,Half-life was determined,Intermediate,,50597,,4883,,10116.0,Rattus norvegicus,,CHEMBL625283,,,,,A,1,1,
,BAO_0000218,9808,N,Half-life after administration of 20 mg/Kg oral dose in rat,Intermediate,,50597,,2959,,10116.0,Rattus norvegicus,,CHEMBL625284,,,In vivo,,A,1,1,
,BAO_0000218,9809,N,Half-life after administration of 3.2 mg/kg intravenously in male rat,Intermediate,,50597,,4029,,10116.0,Rattus norvegicus,,CHEMBL625285,,,In vivo,,A,1,1,
,BAO_0000218,9810,N,Half-life after intravenous administration in female rat,Intermediate,,50597,,4029,,10116.0,Rattus norvegicus,,CHEMBL625286,,,In vivo,,A,1,1,
,BAO_0000218,9811,N,Half-life after intravenous administration in male rat,Intermediate,,50597,,4029,,10116.0,Rattus norvegicus,,CHEMBL625287,,,In vivo,,A,1,1,
,BAO_0000218,9812,N,Half-life after intravenous dose in rat,Intermediate,,50597,,6180,,10116.0,Rattus norvegicus,,CHEMBL625288,,,In vivo,,A,1,1,
Liver,BAO_0000218,9813,N,Half-life in a rat liver homogenate preparation,Intermediate,,50597,,1557,2107.0,10116.0,Rattus norvegicus,,CHEMBL625289,,,,,A,1,1,
Plasma,BAO_0000218,9814,N,Half-life in plasma of rat,Intermediate,,50597,,12500,1969.0,10116.0,Rattus norvegicus,,CHEMBL625290,,,,,A,1,1,
Plasma,BAO_0000218,9815,N,Half-life in plasma of rat at dose of 3-10 mgkg,Intermediate,,50597,,12500,1969.0,10116.0,Rattus norvegicus,,CHEMBL876798,,,,,A,1,1,
,BAO_0000218,9816,N,Half-life in rat,Intermediate,,50597,,5064,,10116.0,Rattus norvegicus,,CHEMBL625291,,,,,A,1,1,
,BAO_0000218,9817,N,Half-life in rat,Intermediate,,50597,,5145,,10116.0,Rattus norvegicus,,CHEMBL625292,,,,,A,1,1,
,BAO_0000218,9818,N,Half-life in rat,Intermediate,,50597,,5147,,10116.0,Rattus norvegicus,,CHEMBL625293,,,,,A,1,1,
,BAO_0000218,9819,N,Half-life in rat,Intermediate,,50597,,5833,,10116.0,Rattus norvegicus,,CHEMBL622832,,,,,A,1,1,
,BAO_0000218,9820,N,Half-life in rat,Intermediate,,50597,,6596,,10116.0,Rattus norvegicus,,CHEMBL622833,,,,,A,1,1,
,BAO_0000218,9821,N,Half-life in rat,Intermediate,,50597,,17655,,10116.0,Rattus norvegicus,,CHEMBL622834,,,,,A,1,1,
,BAO_0000218,9822,N,Half-life in rat after oral administration at 10 mg/kg,Intermediate,,50597,,6495,,10116.0,Rattus norvegicus,,CHEMBL622835,,,In vivo,,A,1,1,
,BAO_0000218,9823,N,Half-life in rat after po administration at a dose of 10 mg/kg,Intermediate,,50597,,17538,,10116.0,Rattus norvegicus,,CHEMBL622836,,,In vivo,,A,1,1,
,BAO_0000218,9824,N,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined,Intermediate,,50597,,17538,,10116.0,Rattus norvegicus,,CHEMBL622837,,,In vivo,,A,1,1,
,BAO_0000218,9825,N,Half-life in rat at 3 mg/kg dose administered intravenously,Intermediate,,50597,,10,,10116.0,Rattus norvegicus,,CHEMBL622838,,,In vivo,,A,1,1,
Brain,BAO_0000218,9826,N,Half-life in rat brain homogenate,Intermediate,,50597,,17669,955.0,10116.0,Rattus norvegicus,,CHEMBL622839,,,,,A,1,1,
Plasma,BAO_0000218,9827,N,Half-life in rat plasma,Intermediate,,50597,,17065,1969.0,10116.0,Rattus norvegicus,,CHEMBL622840,,,,,A,1,1,
,BAO_0000218,9828,N,Half-life in rats,Intermediate,,50597,,4333,,10116.0,Rattus norvegicus,,CHEMBL622841,,,,,A,1,1,
,BAO_0000218,9829,N,Half-life in Dawley rats,Intermediate,,50597,,6827,,10116.0,Rattus norvegicus,,CHEMBL622842,,,,,A,1,1,
Plasma,BAO_0000218,9830,N,Half-life in vitro in rat plasma,Intermediate,,50597,,889,1969.0,10116.0,Rattus norvegicus,,CHEMBL622843,,,In vitro,,A,1,1,
Plasma,BAO_0000218,9831,N,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours,Intermediate,,50597,,889,1969.0,10116.0,Rattus norvegicus,,CHEMBL622844,,,In vitro,,A,1,1,
,BAO_0000218,9832,N,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat",Intermediate,,50597,,3747,,10116.0,Rattus norvegicus,,CHEMBL622845,,,,,A,1,1,
,BAO_0000218,9833,N,The area under the curve of compound was measured at the dose of 100 umol/kg,Intermediate,,50597,,15022,,10116.0,Rattus norvegicus,,CHEMBL622846,,,,,A,1,1,
,BAO_0000218,9834,N,The area under the curve of compound was measured at the dose of 300 umol/kg,Intermediate,,50597,,15022,,10116.0,Rattus norvegicus,,CHEMBL622847,,,,,A,1,1,
,BAO_0000218,9835,N,The area under the curve of compound was measured at the dose of 30 umol/kg,Intermediate,,50597,,15022,,10116.0,Rattus norvegicus,,CHEMBL622848,,,,,A,1,1,
,BAO_0000218,9836,N,Bioavailability as oral AUC in rats,Intermediate,,50597,,3360,,10116.0,Rattus norvegicus,,CHEMBL622849,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9837,N,The plasma concentration versus time curve (AUC) was determined,Intermediate,,50597,,5334,1969.0,10116.0,Rattus norvegicus,,CHEMBL622850,,,,,A,1,1,
,BAO_0000218,9838,N,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,,50597,,17411,,10116.0,Rattus norvegicus,,CHEMBL876807,,,,,A,1,1,
,BAO_0000218,9839,N,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,,50597,,17411,,10116.0,Rattus norvegicus,,CHEMBL622851,,,,,A,1,1,
,BAO_0000218,9840,N,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,,50597,,17411,,10116.0,Rattus norvegicus,,CHEMBL622852,,,,,A,1,1,
,BAO_0000218,9841,N,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours,Intermediate,,50597,,6570,,10116.0,Rattus norvegicus,,CHEMBL622853,,,,,A,1,1,
,BAO_0000218,9842,N,Total concentration in rat after 2 mg/kg peroral administration in 24 hours,Intermediate,,50597,,6570,,10116.0,Rattus norvegicus,,CHEMBL622854,,,,,A,1,1,
,BAO_0000218,9843,N,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,Intermediate,,50597,,17411,,10116.0,Rattus norvegicus,,CHEMBL622855,,,,,A,1,1,
Plasma,BAO_0000218,9844,N,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration",Intermediate,,50597,,14941,1969.0,10116.0,Rattus norvegicus,,CHEMBL622856,,,,,A,1,1,
Plasma,BAO_0000218,9845,N,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration",Intermediate,,50597,,14941,1969.0,10116.0,Rattus norvegicus,,CHEMBL622857,,,,,A,1,1,
Plasma,BAO_0000218,9846,N,AUC in rat after po administration at a dose of 10 mg/kg,Intermediate,,50597,,17538,1969.0,10116.0,Rattus norvegicus,,CHEMBL622858,,,,,A,1,1,
Plasma,BAO_0000218,9847,N,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg,Intermediate,,50597,,17752,1969.0,10116.0,Rattus norvegicus,,CHEMBL622859,,,,,A,1,1,
,BAO_0000218,9848,N,Area under curve value 24 hr after 10 mg/kg iv administration in rats,Intermediate,,50597,,17509,,10116.0,Rattus norvegicus,,CHEMBL622860,,,,,A,1,1,
,BAO_0000218,9849,N,Area under curve value 24 hr after 10 mg/kg oral administration in rats,Intermediate,,50597,,17509,,10116.0,Rattus norvegicus,,CHEMBL622861,,,,,A,1,1,
,BAO_0000218,9850,N,Area under curve value 24 hr after 2 mg/kg iv administration in rats,Intermediate,,50597,,17509,,10116.0,Rattus norvegicus,,CHEMBL622862,,,,,A,1,1,
,BAO_0000218,9851,N,Area under curve value 24 hr after 2 mg/kg oral administration in rats,Intermediate,,50597,,17509,,10116.0,Rattus norvegicus,,CHEMBL622863,,,,,A,1,1,
,BAO_0000218,9852,N,Area under curve value 6 hr after po administration in rat,Intermediate,,50597,,17509,,10116.0,Rattus norvegicus,,CHEMBL623817,,,,,A,1,1,
,BAO_0000218,9853,N,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,Intermediate,,50597,,17717,,10116.0,Rattus norvegicus,,CHEMBL623818,,,,,A,1,1,
,BAO_0000218,9854,N,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously",Intermediate,,50597,,17717,,10116.0,Rattus norvegicus,,CHEMBL623819,,,,,A,1,1,
,BAO_0000218,9855,N,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,Intermediate,,50597,,17717,,10116.0,Rattus norvegicus,,CHEMBL623820,,,,,A,1,1,
,BAO_0000218,9856,N,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control,Intermediate,,50597,,17717,,10116.0,Rattus norvegicus,,CHEMBL623821,,,,,A,1,1,
Plasma,BAO_0000218,9857,N,AUC normalized for dose (AUCN) in rat,Intermediate,,50597,,6642,1969.0,10116.0,Rattus norvegicus,,CHEMBL623822,,,,,A,1,1,
,BAO_0000218,9858,N,Area under curve in rat after p.o. administration,Intermediate,,50597,,6640,,10116.0,Rattus norvegicus,,CHEMBL623823,,,,,A,1,1,
,BAO_0000218,9859,N,Area under curve in rat after p.o. administration,Intermediate,,50597,,6641,,10116.0,Rattus norvegicus,,CHEMBL623824,,,,,A,1,1,
,BAO_0000218,9860,N,Area under curve in rat after p.o. administration; Not determined,Intermediate,,50597,,6641,,10116.0,Rattus norvegicus,,CHEMBL623825,,,,,A,1,1,
,BAO_0000218,9861,N,Area under curve in rat after peroral administration,Intermediate,,50597,,6641,,10116.0,Rattus norvegicus,,CHEMBL622070,,,,,A,1,1,
,BAO_0000218,9862,N,Area under curve (carotid artery) value of the compound,Intermediate,,50597,,3603,,10116.0,Rattus norvegicus,,CHEMBL622071,,,,,A,1,1,
,BAO_0000218,9863,N,Bioavailability expressed as the area under curve of rat carotid artery,Intermediate,,50597,,3550,,10116.0,Rattus norvegicus,,CHEMBL622072,,,,,A,1,1,
,BAO_0000218,9864,N,Area under curve in male SD rats was observed after intravenous administration in rat,Intermediate,,50597,,15662,,10116.0,Rattus norvegicus,,CHEMBL622073,,,,,A,1,1,
,BAO_0000218,9865,N,Area under curve of the compound was determined,Intermediate,,50597,,17720,,10116.0,Rattus norvegicus,,CHEMBL622074,,,,,A,1,1,
,BAO_0000218,9866,N,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax,Intermediate,,50597,,5407,,10116.0,Rattus norvegicus,,CHEMBL622075,,,,,A,1,1,
Plasma,BAO_0000218,9867,N,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg,Intermediate,,50597,,17752,1969.0,10116.0,Rattus norvegicus,,CHEMBL622076,,,,,A,1,1,
Plasma,BAO_0000218,9868,N,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg,Intermediate,,50597,,17752,1969.0,10116.0,Rattus norvegicus,,CHEMBL622077,,,,,A,1,1,
,BAO_0000218,9869,N,Area under curve (portal vein) value of the compound,Intermediate,,50597,,3603,,10116.0,Rattus norvegicus,,CHEMBL622078,,,,,A,1,1,
,BAO_0000218,9870,N,Bioavailability expressed as the area under curve of rat portal vein,Intermediate,,50597,,3550,,10116.0,Rattus norvegicus,,CHEMBL622079,,,,,A,1,1,
Plasma,BAO_0000218,9871,N,Area Under plasma concentration time curve in rat upon peroral administration,Intermediate,,50597,,17655,1969.0,10116.0,Rattus norvegicus,,CHEMBL622080,,,,,A,1,1,
,BAO_0000218,9872,N,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats,Intermediate,,50597,,17582,,10116.0,Rattus norvegicus,,CHEMBL877612,,,,,A,1,1,
,BAO_0000218,9873,N,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats,Intermediate,,50597,,17582,,10116.0,Rattus norvegicus,,CHEMBL622081,,,,,A,1,1,
,BAO_0000218,9874,N,Compound was evaluated for oral bioavailability in rats,Intermediate,,50597,,17791,,10116.0,Rattus norvegicus,,CHEMBL622082,,,,,A,1,1,
,BAO_0000218,9875,N,Compound was evaluated for oral bioavailability in rats after iv administration,Intermediate,,50597,,17791,,10116.0,Rattus norvegicus,,CHEMBL622083,,,,,A,1,1,
,BAO_0000218,9876,N,Compound was evaluated for oral bioavailability in rats; 30-80,Intermediate,,50597,,17791,,10116.0,Rattus norvegicus,,CHEMBL622084,,,,,A,1,1,
,BAO_0000218,9877,N,Compound was evaluated for oral bioavailability in rats; 50-60,Intermediate,,50597,,17791,,10116.0,Rattus norvegicus,,CHEMBL622085,,,,,A,1,1,
,BAO_0000218,9878,N,Compound was evaluated for oral bioavailability in rats; no data,Intermediate,,50597,,17791,,10116.0,Rattus norvegicus,,CHEMBL622086,,,,,A,1,1,
,BAO_0000218,9879,N,Compound was evaluated for oral bioavailability in rats; peptide,Intermediate,,50597,,17791,,10116.0,Rattus norvegicus,,CHEMBL622087,,,,,A,1,1,
Blood,BAO_0000218,9880,N,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03",Intermediate,,50597,,7768,178.0,10116.0,Rattus norvegicus,,CHEMBL622088,,,,,A,1,1,
Blood,BAO_0000218,9881,N,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03",Intermediate,,50597,,7768,178.0,10116.0,Rattus norvegicus,,CHEMBL622089,,,,,A,1,1,
Blood,BAO_0000218,9882,N,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15",Intermediate,,50597,,7768,178.0,10116.0,Rattus norvegicus,,CHEMBL623685,,,,,A,1,1,
Blood,BAO_0000218,9883,N,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87",Intermediate,,50597,,7768,178.0,10116.0,Rattus norvegicus,,CHEMBL623686,,,,,A,1,1,
Stomach,BAO_0000218,9884,N,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,50597,,8677,945.0,10116.0,Rattus norvegicus,,CHEMBL623687,,,In vivo,,A,1,1,
Stomach,BAO_0000218,9885,N,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,50597,,8677,945.0,10116.0,Rattus norvegicus,,CHEMBL623688,,,In vivo,,A,1,1,
Stomach,BAO_0000218,9886,N,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,50597,,8677,945.0,10116.0,Rattus norvegicus,,CHEMBL623689,,,In vivo,,A,1,1,
Stomach,BAO_0000218,9887,N,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,50597,,8677,945.0,10116.0,Rattus norvegicus,,CHEMBL622485,,,In vivo,,A,1,1,
Thyroid gland,BAO_0000218,9888,N,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,50597,,8677,2046.0,10116.0,Rattus norvegicus,,CHEMBL622486,,,In vivo,,A,1,1,
Thyroid gland,BAO_0000218,9889,N,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,50597,,8677,2046.0,10116.0,Rattus norvegicus,,CHEMBL877613,,,In vivo,,A,1,1,
Thyroid gland,BAO_0000218,9890,N,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,50597,,8677,2046.0,10116.0,Rattus norvegicus,,CHEMBL622487,,,In vivo,,A,1,1,
Thyroid gland,BAO_0000218,9891,N,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,50597,,8677,2046.0,10116.0,Rattus norvegicus,,CHEMBL622488,,,In vivo,,A,1,1,
Heart,BAO_0000218,9892,N,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intermediate,,50597,,8677,948.0,10116.0,Rattus norvegicus,,CHEMBL622489,,,In vivo,,A,1,1,
Urine,BAO_0000218,9893,N,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,Intermediate,,50597,,6899,1088.0,10116.0,Rattus norvegicus,,CHEMBL622490,,,,,A,1,1,
Urine,BAO_0000218,9894,N,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,Intermediate,,50597,,6899,1088.0,10116.0,Rattus norvegicus,,CHEMBL622491,,,,,A,1,1,
Liver,BAO_0000218,9895,N,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver,Intermediate,,50597,,6899,2107.0,10116.0,Rattus norvegicus,,CHEMBL622492,,,,,A,1,1,
Urine,BAO_0000218,9896,N,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,Intermediate,,50597,,6899,1088.0,10116.0,Rattus norvegicus,,CHEMBL622493,,,,,A,1,1,
Urine,BAO_0000218,9897,N,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,Intermediate,,50597,,6899,1088.0,10116.0,Rattus norvegicus,,CHEMBL622494,,,,,A,1,1,
Muscle tissue,BAO_0000218,9898,N,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intermediate,,50597,,8677,2385.0,10116.0,Rattus norvegicus,,CHEMBL622495,,,,,A,1,1,
,BAO_0000218,9899,N,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney,Intermediate,,50597,,6899,,10116.0,Rattus norvegicus,,CHEMBL622496,,,,,A,1,1,
Urine,BAO_0000218,9900,N,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,Intermediate,,50597,,6899,1088.0,10116.0,Rattus norvegicus,,CHEMBL622497,,,,,A,1,1,
,BAO_0000218,9901,N,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats,Intermediate,,50597,,2189,,10116.0,Rattus norvegicus,,CHEMBL622498,,,,,A,1,1,
Urine,BAO_0000218,9902,N,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats,Intermediate,,50597,,2189,1088.0,10116.0,Rattus norvegicus,,CHEMBL624918,,,,,A,1,1,
Urine,BAO_0000218,9903,N,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data,Intermediate,,50597,,2189,1088.0,10116.0,Rattus norvegicus,,CHEMBL624919,,,,,A,1,1,
Blood,BAO_0000218,9904,N,Biodistribution of compound in rat blood after 5 min of administration,Intermediate,,50597,,10839,178.0,10116.0,Rattus norvegicus,,CHEMBL624920,,,In vivo,,A,1,1,
Blood,BAO_0000218,9905,N,Biodistribution of compound in rat blood after 5 min of administration.,Intermediate,,50597,,10839,178.0,10116.0,Rattus norvegicus,,CHEMBL624921,,,In vivo,,A,1,1,
Brain,BAO_0000218,9906,N,Biodistribution of compound in rat brain after 5 min of administration,Intermediate,,50597,,10839,955.0,10116.0,Rattus norvegicus,,CHEMBL624922,,,In vivo,,A,1,1,
Heart,BAO_0000218,9907,N,Biodistribution of compound in rat heart after 5 min of administration,Intermediate,,50597,,10839,948.0,10116.0,Rattus norvegicus,,CHEMBL624923,,,In vivo,,A,1,1,
Heart,BAO_0000218,9908,N,Biodistribution of compound in rat heart after 5 min of administration.,Intermediate,,50597,,10839,948.0,10116.0,Rattus norvegicus,,CHEMBL624924,,,In vivo,,A,1,1,
Kidney,BAO_0000218,9909,N,Biodistribution of compound in rat kidney after 5 min of administration,Intermediate,,50597,,10839,2113.0,10116.0,Rattus norvegicus,,CHEMBL624925,,,In vivo,,A,1,1,
Kidney,BAO_0000218,9910,N,Biodistribution of compound in rat kidney after 5 min of administration.,Intermediate,,50597,,10839,2113.0,10116.0,Rattus norvegicus,,CHEMBL624926,,,In vivo,,A,1,1,
Liver,BAO_0000218,9911,N,Biodistribution of compound in rat liver after 5 min of administration,Intermediate,,50597,,10839,2107.0,10116.0,Rattus norvegicus,,CHEMBL624927,,,In vivo,,A,1,1,
Liver,BAO_0000218,9912,N,Biodistribution of compound in rat liver after 5 min of administration.,Intermediate,,50597,,10839,2107.0,10116.0,Rattus norvegicus,,CHEMBL874402,,,In vivo,,A,1,1,
Lung,BAO_0000218,9913,N,Biodistribution of compound in rat lung after 5 min of administration,Intermediate,,50597,,10839,2048.0,10116.0,Rattus norvegicus,,CHEMBL624928,,,In vivo,,A,1,1,
Lung,BAO_0000218,9914,N,Biodistribution of compound in rat lung after 5 min of administration.,Intermediate,,50597,,10839,2048.0,10116.0,Rattus norvegicus,,CHEMBL624929,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,9915,N,Biodistribution of compound in rat muscle after 5 min of administration,Intermediate,,50597,,10839,2385.0,10116.0,Rattus norvegicus,,CHEMBL624930,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,9916,N,Biodistribution of compound in rat muscle after 5 min of administration.,Intermediate,,50597,,10839,2385.0,10116.0,Rattus norvegicus,,CHEMBL624931,,,In vivo,,A,1,1,
Heart,BAO_0000218,9917,N,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Intermediate,,50597,,4043,948.0,10116.0,Rattus norvegicus,,CHEMBL624932,,,,,A,1,1,
Heart,BAO_0000218,9918,N,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Intermediate,,50597,,4043,948.0,10116.0,Rattus norvegicus,,CHEMBL624933,,,,,A,1,1,
Liver,BAO_0000218,9919,N,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Intermediate,,50597,,4043,2107.0,10116.0,Rattus norvegicus,,CHEMBL624934,,,,,A,1,1,
Liver,BAO_0000218,9920,N,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Intermediate,,50597,,4043,2107.0,10116.0,Rattus norvegicus,,CHEMBL624935,,,,,A,1,1,
,BAO_0000218,9921,N,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Intermediate,,50597,,4043,,10116.0,Rattus norvegicus,,CHEMBL624936,,,,,A,1,1,
,BAO_0000218,9922,N,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Intermediate,,50597,,4043,,10116.0,Rattus norvegicus,,CHEMBL624937,,,,,A,1,1,
Spleen,BAO_0000218,9923,N,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Intermediate,,50597,,4043,2106.0,10116.0,Rattus norvegicus,,CHEMBL624938,,,,,A,1,1,
Spleen,BAO_0000218,9924,N,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Intermediate,,50597,,4043,2106.0,10116.0,Rattus norvegicus,,CHEMBL624939,,,,,A,1,1,
,BAO_0000218,9925,N,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Intermediate,,50597,,4043,,10116.0,Rattus norvegicus,,CHEMBL624940,,,,,A,1,1,
,BAO_0000218,9926,N,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Intermediate,,50597,,4043,,10116.0,Rattus norvegicus,,CHEMBL874403,,,,,A,1,1,
,BAO_0000218,9927,N,Compound was tested for the duration that the plasma drug concentrations remained above the IC95,Intermediate,,50597,,1446,,10116.0,Rattus norvegicus,,CHEMBL624941,,,,,A,1,1,
Urine,BAO_0000218,9928,N,Dose required to lower urine osmolality to 300 mOsm/kg in rat,Intermediate,,50597,,9971,1088.0,10116.0,Rattus norvegicus,,CHEMBL624942,,,,,A,1,1,
Urine,BAO_0000218,9929,N,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested,Intermediate,,50597,,9971,1088.0,10116.0,Rattus norvegicus,,CHEMBL624943,,,,,A,1,1,
,BAO_0000218,9930,N,% Bioavailability after 1 day of the drug administration in rats,Intermediate,,50597,,5765,,10116.0,Rattus norvegicus,,CHEMBL624944,,,In vivo,,A,1,1,
,BAO_0000218,9931,N,% Bioavailability after 4 day of the drug administration in rats,Intermediate,,50597,,5765,,10116.0,Rattus norvegicus,,CHEMBL624945,,,In vivo,,A,1,1,
,BAO_0000218,9932,N,Absolute bioavailability was evaluated in rat,Intermediate,,50597,,4257,,10116.0,Rattus norvegicus,,CHEMBL624946,,,In vivo,,A,1,1,
,BAO_0000218,9933,N,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval,Intermediate,,50597,,13091,,10116.0,Rattus norvegicus,,CHEMBL624947,,,,,A,1,1,
,BAO_0000218,9934,N,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval,Intermediate,,50597,,13091,,10116.0,Rattus norvegicus,,CHEMBL624948,,,,,A,1,1,
,BAO_0000218,9935,N,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval,Intermediate,,50597,,13091,,10116.0,Rattus norvegicus,,CHEMBL624949,,,,,A,1,1,
Kidney,BAO_0000218,9936,N,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval,Intermediate,,50597,,13091,2113.0,10116.0,Rattus norvegicus,,CHEMBL622025,,,,,A,1,1,
Kidney,BAO_0000218,9937,N,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval,Intermediate,,50597,,13091,2113.0,10116.0,Rattus norvegicus,,CHEMBL622026,,,,,A,1,1,
Kidney,BAO_0000218,9938,N,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval,Intermediate,,50597,,13091,2113.0,10116.0,Rattus norvegicus,,CHEMBL622027,,,,,A,1,1,
Kidney,BAO_0000218,9939,N,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval,Intermediate,,50597,,13091,2113.0,10116.0,Rattus norvegicus,,CHEMBL622028,,,,,A,1,1,
Liver,BAO_0000218,9940,N,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval,Intermediate,,50597,,13091,2107.0,10116.0,Rattus norvegicus,,CHEMBL622029,,,,,A,1,1,
Liver,BAO_0000218,9941,N,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval,Intermediate,,50597,,13091,2107.0,10116.0,Rattus norvegicus,,CHEMBL622208,,,,,A,1,1,
Liver,BAO_0000218,9942,N,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval,Intermediate,,50597,,13091,2107.0,10116.0,Rattus norvegicus,,CHEMBL622209,,,,,A,1,1,
Liver,BAO_0000218,9943,N,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval,Intermediate,,50597,,13091,2107.0,10116.0,Rattus norvegicus,,CHEMBL622210,,,,,A,1,1,
,BAO_0000218,9944,N,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval,Intermediate,,50597,,13091,,10116.0,Rattus norvegicus,,CHEMBL622211,,,,,A,1,1,
,BAO_0000218,9945,N,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval,Intermediate,,50597,,13091,,10116.0,Rattus norvegicus,,CHEMBL622212,,,,,A,1,1,
,BAO_0000218,9946,N,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval,Intermediate,,50597,,13091,,10116.0,Rattus norvegicus,,CHEMBL622213,,,,,A,1,1,
,BAO_0000218,9947,N,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval,Intermediate,,50597,,13091,,10116.0,Rattus norvegicus,,CHEMBL874404,,,,,A,1,1,
Muscle tissue,BAO_0000218,9948,N,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval,Intermediate,,50597,,13091,2385.0,10116.0,Rattus norvegicus,,CHEMBL620452,,,,,A,1,1,
Muscle tissue,BAO_0000218,9949,N,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval,Intermediate,,50597,,13091,2385.0,10116.0,Rattus norvegicus,,CHEMBL620453,,,,,A,1,1,
Muscle tissue,BAO_0000218,9950,N,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval,Intermediate,,50597,,13091,2385.0,10116.0,Rattus norvegicus,,CHEMBL620454,,,,,A,1,1,
Muscle tissue,BAO_0000218,9951,N,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval,Intermediate,,50597,,13091,2385.0,10116.0,Rattus norvegicus,,CHEMBL624067,,,,,A,1,1,
,BAO_0000218,9952,N,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval,Intermediate,,50597,,13091,,10116.0,Rattus norvegicus,,CHEMBL624068,,,,,A,1,1,
Female gonad,BAO_0000218,9953,N,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval,Intermediate,,50597,,13091,992.0,10116.0,Rattus norvegicus,,CHEMBL624069,,,,,A,1,1,
Female gonad,BAO_0000218,9954,N,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval,Intermediate,,50597,,13091,992.0,10116.0,Rattus norvegicus,,CHEMBL624070,,,,,A,1,1,
Female gonad,BAO_0000218,9955,N,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval,Intermediate,,50597,,13091,992.0,10116.0,Rattus norvegicus,,CHEMBL624071,,,,,A,1,1,
Uterus,BAO_0000218,9956,N,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval,Intermediate,,50597,,13091,995.0,10116.0,Rattus norvegicus,,CHEMBL624072,,,,,A,1,1,
Uterus,BAO_0000218,9957,N,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval,Intermediate,,50597,,13091,995.0,10116.0,Rattus norvegicus,,CHEMBL624073,,,,,A,1,1,
Uterus,BAO_0000218,9958,N,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval,Intermediate,,50597,,13091,995.0,10116.0,Rattus norvegicus,,CHEMBL624788,,,,,A,1,1,
Uterus,BAO_0000218,9959,N,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval,Intermediate,,50597,,13091,995.0,10116.0,Rattus norvegicus,,CHEMBL624789,,,,,A,1,1,
,BAO_0000218,9960,N,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval,Intermediate,,50597,,13091,,10116.0,Rattus norvegicus,,CHEMBL624790,,,,,A,1,1,
,BAO_0000218,9961,N,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval,Intermediate,,50597,,13091,,10116.0,Rattus norvegicus,,CHEMBL624791,,,,,A,1,1,
,BAO_0000218,9962,N,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval,Intermediate,,50597,,13091,,10116.0,Rattus norvegicus,,CHEMBL624792,,,,,A,1,1,
,BAO_0000218,9963,N,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval,Intermediate,,50597,,13091,,10116.0,Rattus norvegicus,,CHEMBL624793,,,,,A,1,1,
Muscle tissue,BAO_0000218,9964,N,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval,Intermediate,,50597,,13091,2385.0,10116.0,Rattus norvegicus,,CHEMBL877491,,,,,A,1,1,
Muscle tissue,BAO_0000218,9965,N,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval,Intermediate,,50597,,13091,2385.0,10116.0,Rattus norvegicus,,CHEMBL624957,,,,,A,1,1,
Muscle tissue,BAO_0000218,9966,N,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval,Intermediate,,50597,,13091,2385.0,10116.0,Rattus norvegicus,,CHEMBL624958,,,,,A,1,1,
Muscle tissue,BAO_0000218,9967,N,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval,Intermediate,,50597,,13091,2385.0,10116.0,Rattus norvegicus,,CHEMBL624959,,,,,A,1,1,
,BAO_0000218,9968,N,Dissociation constant was determined,Intermediate,,50597,,11977,,10116.0,Rattus norvegicus,,CHEMBL624960,,,,,A,1,1,
,BAO_0000218,9969,N,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration",Intermediate,,50597,,14941,,10116.0,Rattus norvegicus,,CHEMBL624961,,,,,A,1,1,
,BAO_0000218,9970,N,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",Intermediate,,50597,,15078,,10116.0,Rattus norvegicus,,CHEMBL624962,,,,,A,1,1,
,BAO_0000218,9971,N,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose",Intermediate,,50597,,15078,,10116.0,Rattus norvegicus,,CHEMBL624963,,,,,A,1,1,
,BAO_0000218,9972,N,Observed rate constant in 80% rat plasma at 37 degree Centigrade,Intermediate,,50597,,4755,,10116.0,Rattus norvegicus,,CHEMBL624964,,,,,A,1,1,
,BAO_0000218,9973,N,LogP value was evaluated in the in situ rat gut perfusion assay,Intermediate,,50597,,589,,10116.0,Rattus norvegicus,,CHEMBL624965,,,,,A,1,1,
,BAO_0000218,9974,N,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,Intermediate,,50597,,17582,,10116.0,Rattus norvegicus,,CHEMBL624966,,,In vivo,,A,1,1,
,BAO_0000218,9975,N,Mean residence time (Pharmacokinetic property) after i.v. administration in rats,Intermediate,,50597,,5031,,10116.0,Rattus norvegicus,,CHEMBL624967,,,In vivo,,A,1,1,
,BAO_0000218,9976,N,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg,Intermediate,,50597,,17764,,10116.0,Rattus norvegicus,,CHEMBL624968,,,In vivo,,A,1,1,
,BAO_0000218,9977,N,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration,Intermediate,,50597,,17720,,10116.0,Rattus norvegicus,,CHEMBL624969,,,,,A,1,1,
,BAO_0000218,9978,N,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose,Expert,,50597,,2862,,10116.0,Rattus norvegicus,,CHEMBL624970,,,,,F,1,1,
,BAO_0000218,9979,N,Half-life was evaluated after 10 uM/kg of intra arterial administration,Intermediate,,50597,,16423,,10116.0,Rattus norvegicus,,CHEMBL624971,,,,,A,1,1,
,BAO_0000218,9980,N,Half-life was evaluated after 20 uM/kg of peroral administration,Intermediate,,50597,,16423,,10116.0,Rattus norvegicus,,CHEMBL624972,,,In vivo,,A,1,1,
,BAO_0000218,9981,N,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg,Intermediate,,50597,,6005,,10116.0,Rattus norvegicus,,CHEMBL624973,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9982,N,Half-life was evaluated in plasma of rat,Intermediate,,50597,,2938,1969.0,10116.0,Rattus norvegicus,,CHEMBL624974,,,,,A,1,1,
,BAO_0000218,9983,N,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg,Intermediate,,50597,,6410,,10116.0,Rattus norvegicus,,CHEMBL624975,,,In vivo,,A,1,1,
,BAO_0000218,9984,N,Half-life was evaluated in rats at an oral dose of 30 mg/kg,Intermediate,,50597,,6410,,10116.0,Rattus norvegicus,,CHEMBL877492,,,In vivo,,A,1,1,
,BAO_0000218,9985,N,Half-life was measured in rat after an iv dose of 1 mg/kg,Intermediate,,50597,,6062,,10116.0,Rattus norvegicus,,CHEMBL624976,,,In vivo,,A,1,1,
,BAO_0000218,9986,N,Half-life period of compound in rats after peroral administration,Intermediate,,50597,,6571,,10116.0,Rattus norvegicus,,CHEMBL624977,,,In vivo,,A,1,1,
Plasma,BAO_0000218,9987,N,Half-life period of compound was measured in rat plasma.,Intermediate,,50597,,3136,1969.0,10116.0,Rattus norvegicus,,CHEMBL626848,,,,,A,1,1,
Plasma,BAO_0000218,9988,N,Half-life period of compound was measured in rat plasma; ND is not determined,Intermediate,,50597,,3136,1969.0,10116.0,Rattus norvegicus,,CHEMBL626849,,,,,A,1,1,
Plasma,BAO_0000218,9989,N,Half-life period of compound was measured in rat plasma; not determined,Intermediate,,50597,,3136,1969.0,10116.0,Rattus norvegicus,,CHEMBL626850,,,,,A,1,1,
,BAO_0000218,9990,N,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,Intermediate,,50597,,4521,,10116.0,Rattus norvegicus,,CHEMBL626851,,,In vivo,,A,1,1,
,BAO_0000218,9991,N,Half-life period in rat by iv administration,Intermediate,,50597,,5871,,10116.0,Rattus norvegicus,,CHEMBL626852,,,In vivo,,A,1,1,
,BAO_0000218,9992,N,Half-life period in rats following intravenous administration at 2 mg/kg,Intermediate,,50597,,6077,,10116.0,Rattus norvegicus,,CHEMBL626853,,,In vivo,,A,1,1,
,BAO_0000218,9993,N,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Intermediate,,50597,,6679,,10116.0,Rattus norvegicus,,CHEMBL626854,,,In vivo,,A,1,1,
,BAO_0000218,9994,N,Half-life period was determined for the compound in rat,Intermediate,,50597,,5144,,10116.0,Rattus norvegicus,,CHEMBL627486,,,,,A,1,1,
,BAO_0000218,9995,N,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously",Intermediate,,50597,,4498,,10116.0,Rattus norvegicus,,CHEMBL627487,,,In vivo,,A,1,1,
,BAO_0000218,9996,N,"Half-life period was evaluated in rat, after administering 10 mg/kg orally",Intermediate,,50597,,4498,,10116.0,Rattus norvegicus,,CHEMBL627488,,,In vivo,,A,1,1,
,BAO_0000218,9997,N,Half-life value after IV dose at a dose of 5 mg/kg in rats.,Intermediate,,50597,,1908,,10116.0,Rattus norvegicus,,CHEMBL627489,,,In vivo,,A,1,1,
,BAO_0000218,9998,N,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,Intermediate,,50597,,6211,,10116.0,Rattus norvegicus,,CHEMBL627490,,,In vivo,,A,1,1,
,BAO_0000218,9999,N,Half-life was determined in rat after intravenous administration (0.5 mg/kg),Intermediate,,50597,,5529,,10116.0,Rattus norvegicus,,CHEMBL873829,,,In vivo,,A,1,1,
,BAO_0000218,10000,N,Half-life was determined in rat at a dose of 1 mpk i.v.,Intermediate,,50597,,6444,,10116.0,Rattus norvegicus,,CHEMBL627655,,,In vivo,,A,1,1,
,BAO_0000218,10001,N,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined,Intermediate,,50597,,6444,,10116.0,Rattus norvegicus,,CHEMBL625994,,,In vivo,,A,1,1,
,BAO_0000218,10002,N,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined,Intermediate,,50597,,6444,,10116.0,Rattus norvegicus,,CHEMBL625995,,,In vivo,,A,1,1,
,BAO_0000218,10003,N,Half-life in rat,Intermediate,,50597,,5207,,10116.0,Rattus norvegicus,,CHEMBL625996,,,,,A,1,1,
Plasma,BAO_0000218,10004,N,In vitro half life in rat plasma,Intermediate,,50597,,530,1969.0,10116.0,Rattus norvegicus,,CHEMBL625850,,,In vitro,,A,1,1,
Plasma,BAO_0000218,10005,N,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma",Intermediate,,50597,,1116,1969.0,10116.0,Rattus norvegicus,,CHEMBL625851,,,In vitro,,A,1,1,
,BAO_0000218,10006,N,In vitro half life in rat,Intermediate,,50597,,3219,,10116.0,Rattus norvegicus,,CHEMBL625852,,,In vitro,,A,1,1,
,BAO_0000218,10007,N,In vivo half life period after intravenous administration in rat,Intermediate,,50597,,6109,,10116.0,Rattus norvegicus,,CHEMBL625853,,,In vivo,,A,1,1,
,BAO_0000218,10008,N,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats,Intermediate,,50597,,17582,,10116.0,Rattus norvegicus,,CHEMBL625854,,,In vivo,,A,1,1,
,BAO_0000218,10009,N,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,Intermediate,,50597,,17582,,10116.0,Rattus norvegicus,,CHEMBL874450,,,In vivo,,A,1,1,
,BAO_0000218,10010,N,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,Intermediate,,50597,,5974,,10116.0,Rattus norvegicus,,CHEMBL625855,,,In vivo,,A,1,1,
,BAO_0000218,10011,N,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,Intermediate,,50597,,5974,,10116.0,Rattus norvegicus,,CHEMBL625856,,,In vivo,,A,1,1,
,BAO_0000218,10012,N,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,Intermediate,,50597,,5974,,10116.0,Rattus norvegicus,,CHEMBL625857,,,In vivo,,A,1,1,
,BAO_0000218,10013,N,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,Intermediate,,50597,,5974,,10116.0,Rattus norvegicus,,CHEMBL873831,,,In vivo,,A,1,1,
,BAO_0000218,10014,N,Longer half-life in rat (i.v.) at 0.5 mpk,Intermediate,,50597,,17853,,10116.0,Rattus norvegicus,,CHEMBL625858,,,In vivo,,A,1,1,
,BAO_0000218,10015,N,Longer half-life in rat (p.o.) at 2.0 mpk,Intermediate,,50597,,17853,,10116.0,Rattus norvegicus,,CHEMBL625859,,,In vivo,,A,1,1,
,BAO_0000218,10016,N,Pharmacokinetic property (half life) in rat,Intermediate,,50597,,3457,,10116.0,Rattus norvegicus,,CHEMBL625860,,,,,A,1,1,
,BAO_0000218,10017,N,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats,Intermediate,,50597,,2792,,10116.0,Rattus norvegicus,,CHEMBL625861,,,In vivo,,A,1,1,
,BAO_0000218,10018,N,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats,Intermediate,,50597,,2792,,10116.0,Rattus norvegicus,,CHEMBL625862,,,In vivo,,A,1,1,
,BAO_0000218,10019,N,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats,Intermediate,,50597,,2792,,10116.0,Rattus norvegicus,,CHEMBL625863,,,In vivo,,A,1,1,
,BAO_0000218,10020,N,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats,Intermediate,,50597,,2792,,10116.0,Rattus norvegicus,,CHEMBL625864,,,In vivo,,A,1,1,
,BAO_0000218,10021,N,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats,Intermediate,,50597,,5739,,10116.0,Rattus norvegicus,,CHEMBL625865,,,In vivo,,A,1,1,
,BAO_0000218,10022,N,Pharmacokinetic half time was determined intravenously in rats.,Intermediate,,50597,,15765,,10116.0,Rattus norvegicus,,CHEMBL625866,,,In vivo,,A,1,1,
Plasma,BAO_0000218,10023,N,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours,Intermediate,,50597,,6567,1969.0,10116.0,Rattus norvegicus,,CHEMBL625867,,,In vivo,,A,1,1,
Plasma,BAO_0000218,10024,N,Plasma half life of hydrolysis of the compound,Intermediate,,50597,,2448,1969.0,10116.0,Rattus norvegicus,,CHEMBL625868,,,,,A,1,1,
Plasma,BAO_0000218,10025,N,Plasma half life was reported after a intravenous dose of 1 mg/kg in Dawley rat,Intermediate,,50597,,5423,1969.0,10116.0,Rattus norvegicus,,CHEMBL625869,,,In vivo,,A,1,1,
Plasma,BAO_0000218,10026,N,Plasma half life period was calculated in rat,Intermediate,,50597,,4853,1969.0,10116.0,Rattus norvegicus,,CHEMBL874451,,,,,A,1,1,
Plasma,BAO_0000218,10027,N,Plasma half-life in Sprague-Dawley rats,Intermediate,,50597,,4514,1969.0,10116.0,Rattus norvegicus,,CHEMBL625870,,,,,A,1,1,
Plasma,BAO_0000218,10028,N,Plasma half-life in Sprague-Dawley rats; Not determined,Intermediate,,50597,,4514,1969.0,10116.0,Rattus norvegicus,,CHEMBL625871,,,,,A,1,1,
Plasma,BAO_0000218,10029,N,Plasma half-life in rats,Intermediate,,50597,,1500,1969.0,10116.0,Rattus norvegicus,,CHEMBL625872,,,,,A,1,1,
Plasma,BAO_0000218,10030,N,Plasma half-life in rats; <MQL,Intermediate,,50597,,1500,1969.0,10116.0,Rattus norvegicus,,CHEMBL625873,,,,,A,1,1,
Plasma,BAO_0000218,10031,N,Plasma half-life period (0-8 h) was determined,Intermediate,,50597,,5334,1969.0,10116.0,Rattus norvegicus,,CHEMBL625874,,,,,A,1,1,
Plasma,BAO_0000218,10032,N,Plasma half-life period (0-8 h) was determined in Sprague-Dawley rat,Intermediate,,50597,,5334,1969.0,10116.0,Rattus norvegicus,,CHEMBL625875,,,,,A,1,1,
Plasma,BAO_0000218,10033,N,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,Intermediate,,50597,,5334,1969.0,10116.0,Rattus norvegicus,,CHEMBL625876,,,In vivo,,A,1,1,
Plasma,BAO_0000218,10034,N,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,Intermediate,,50597,,5334,1969.0,10116.0,Rattus norvegicus,,CHEMBL631258,,,In vivo,,A,1,1,
Plasma,BAO_0000218,10035,N,Plasma half-life was determined in Sprague-Dawley rats after 0-8 h administration of the compound,Intermediate,,50597,,4956,1969.0,10116.0,Rattus norvegicus,,CHEMBL631259,,,,,A,1,1,
Plasma,BAO_0000218,10036,N,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr administration of the compound; Not determined,Intermediate,,50597,,4956,1969.0,10116.0,Rattus norvegicus,,CHEMBL631260,,,,,A,1,1,
Blood,BAO_0000218,10037,N,"Distribution of radioactivity in blood of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.68-1.03",Intermediate,,50597,,7768,178.0,10116.0,Rattus norvegicus,,CHEMBL631261,,,,,A,1,1,
Blood,BAO_0000218,10038,N,"Distribution of radioactivity in blood of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.45-0.48",Intermediate,,50597,,7768,178.0,10116.0,Rattus norvegicus,,CHEMBL631262,,,,,A,1,1,
Blood,BAO_0000218,10039,N,"Distribution of radioactivity in blood of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range-0.81-1",Intermediate,,50597,,7768,178.0,10116.0,Rattus norvegicus,,CHEMBL631263,,,,,A,1,1,
,BAO_0000218,10040,N,"Distribution of radioactivity in brain tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.007-0.008",Intermediate,,50597,,7768,,10116.0,Rattus norvegicus,,CHEMBL631264,,,,,A,1,1,
,BAO_0000218,10041,N,"Distribution of radioactivity in brain tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.18-0.22",Intermediate,,50597,,7768,,10116.0,Rattus norvegicus,,CHEMBL631265,,,,,A,1,1,
,BAO_0000218,10042,N,"Distribution of radioactivity in brain tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.77-0.97",Intermediate,,50597,,7768,,10116.0,Rattus norvegicus,,CHEMBL631266,,,,,A,1,1,
,BAO_0000218,10043,N,"Distribution of radioactivity in brain tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.08-0.13",Intermediate,,50597,,7768,,10116.0,Rattus norvegicus,,CHEMBL631267,,,,,A,1,1,
,BAO_0000218,10044,N,"Distribution of radioactivity in brain tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.25-0.37",Intermediate,,50597,,7768,,10116.0,Rattus norvegicus,,CHEMBL631268,,,,,A,1,1,
,BAO_0000218,10045,N,"Distribution of radioactivity in brain tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.04",Intermediate,,50597,,7768,,10116.0,Rattus norvegicus,,CHEMBL631269,,,,,A,1,1,
,BAO_0000218,10046,N,"Distribution of radioactivity in brain tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.74-0.94",Intermediate,,50597,,7768,,10116.0,Rattus norvegicus,,CHEMBL631270,,,,,A,1,1,
Heart,BAO_0000218,10047,N,"Distribution of radioactivity in heart tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",Intermediate,,50597,,7768,948.0,10116.0,Rattus norvegicus,,CHEMBL631271,,,,,A,1,1,
Heart,BAO_0000218,10048,N,"Distribution of radioactivity in heart tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.5-0.63",Intermediate,,50597,,7768,948.0,10116.0,Rattus norvegicus,,CHEMBL631272,,,,,A,1,1,
Heart,BAO_0000218,10049,N,"Distribution of radioactivity in heart tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.35-1.55",Intermediate,,50597,,7768,948.0,10116.0,Rattus norvegicus,,CHEMBL631273,,,,,A,1,1,
Heart,BAO_0000218,10050,N,"Distribution of radioactivity in heart tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.24-0.38",Intermediate,,50597,,7768,948.0,10116.0,Rattus norvegicus,,CHEMBL631274,,,,,A,1,1,
Heart,BAO_0000218,10051,N,"Distribution of radioactivity in heart tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.55-0.82",Intermediate,,50597,,7768,948.0,10116.0,Rattus norvegicus,,CHEMBL631275,,,,,A,1,1,
Heart,BAO_0000218,10052,N,"Distribution of radioactivity in heart tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.16-0.2",Intermediate,,50597,,7768,948.0,10116.0,Rattus norvegicus,,CHEMBL626984,,,,,A,1,1,
Heart,BAO_0000218,10053,N,"Distribution of radioactivity in heart tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.13-1.29",Intermediate,,50597,,7768,948.0,10116.0,Rattus norvegicus,,CHEMBL626985,,,,,A,1,1,
Liver,BAO_0000218,10054,N,"Distribution of radioactivity in liver tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",Intermediate,,50597,,7768,2107.0,10116.0,Rattus norvegicus,,CHEMBL626986,,,,,A,1,1,
Liver,BAO_0000218,10055,N,"Distribution of radioactivity in liver tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.71-0.93",Intermediate,,50597,,7768,2107.0,10116.0,Rattus norvegicus,,CHEMBL626987,,,,,A,1,1,
Liver,BAO_0000218,10056,N,"Distribution of radioactivity in liver tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.91-3.53",Intermediate,,50597,,7768,2107.0,10116.0,Rattus norvegicus,,CHEMBL626988,,,,,A,1,1,
Liver,BAO_0000218,10057,N,"Distribution of radioactivity in liver tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.42-0.62",Intermediate,,50597,,7768,2107.0,10116.0,Rattus norvegicus,,CHEMBL626989,,,,,A,1,1,
Liver,BAO_0000218,10058,N,"Distribution of radioactivity in liver tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.97-1.41",Intermediate,,50597,,7768,2107.0,10116.0,Rattus norvegicus,,CHEMBL626990,,,,,A,1,1,
Liver,BAO_0000218,10059,N,"Distribution of radioactivity in liver tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.19-0.23",Intermediate,,50597,,7768,2107.0,10116.0,Rattus norvegicus,,CHEMBL626991,,,,,A,1,1,
Liver,BAO_0000218,10060,N,"Distribution of radioactivity in liver tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.49-2.82",Intermediate,,50597,,7768,2107.0,10116.0,Rattus norvegicus,,CHEMBL626992,,,,,A,1,1,
Lung,BAO_0000218,10061,N,"Distribution of radioactivity in lung tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.03",Intermediate,,50597,,7768,2048.0,10116.0,Rattus norvegicus,,CHEMBL626993,,,,,A,1,1,
Lung,BAO_0000218,10062,N,"Distribution of radioactivity in lung tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.66-0.77",Intermediate,,50597,,7768,2048.0,10116.0,Rattus norvegicus,,CHEMBL874593,,,,,A,1,1,
Lung,BAO_0000218,10063,N,"Distribution of radioactivity in lung tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.17-1.42",Intermediate,,50597,,7768,2048.0,10116.0,Rattus norvegicus,,CHEMBL626994,,,,,A,1,1,
Lung,BAO_0000218,10064,N,"Distribution of radioactivity in lung tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.47-0.58",Intermediate,,50597,,7768,2048.0,10116.0,Rattus norvegicus,,CHEMBL626995,,,,,A,1,1,
Lung,BAO_0000218,10065,N,"Distribution of radioactivity in lung tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.65-0.87",Intermediate,,50597,,7768,2048.0,10116.0,Rattus norvegicus,,CHEMBL626190,,,,,A,1,1,
Lung,BAO_0000218,10066,N,"Distribution of radioactivity in lung tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.28-0.31",Intermediate,,50597,,7768,2048.0,10116.0,Rattus norvegicus,,CHEMBL626191,,,,,A,1,1,
Lung,BAO_0000218,10067,N,"Distribution of radioactivity in lung tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.98-1.22",Intermediate,,50597,,7768,2048.0,10116.0,Rattus norvegicus,,CHEMBL626364,,,,,A,1,1,
Thyroid gland,BAO_0000218,10068,N,"Distribution of radioactivity in thyroid tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 406-499",Intermediate,,50597,,7768,2046.0,10116.0,Rattus norvegicus,,CHEMBL626365,,,,,A,1,1,
Thyroid gland,BAO_0000218,10069,N,"Distribution of radioactivity in thyroid tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 53.0-96",Intermediate,,50597,,7768,2046.0,10116.0,Rattus norvegicus,,CHEMBL626366,,,,,A,1,1,
Thyroid gland,BAO_0000218,10070,N,"Distribution of radioactivity in thyroid tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.65-8.0.8",Intermediate,,50597,,7768,2046.0,10116.0,Rattus norvegicus,,CHEMBL626367,,,,,A,1,1,
Thyroid gland,BAO_0000218,10071,N,"Distribution of radioactivity in thyroid tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 92-159",Intermediate,,50597,,7768,2046.0,10116.0,Rattus norvegicus,,CHEMBL626368,,,,,A,1,1,
Thyroid gland,BAO_0000218,10072,N,"Distribution of radioactivity in thyroid tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 18.74-30.84",Intermediate,,50597,,7768,2046.0,10116.0,Rattus norvegicus,,CHEMBL626369,,,,,A,1,1,
Thyroid gland,BAO_0000218,10073,N,"Distribution of radioactivity in thyroid tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 156-207",Intermediate,,50597,,7768,2046.0,10116.0,Rattus norvegicus,,CHEMBL626370,,,,,A,1,1,
,BAO_0000218,10074,N,"Bioavailability (F) was evaluated in rat, after administering 1 mg/kg intravenously",Intermediate,,50597,,4498,,10116.0,Rattus norvegicus,,CHEMBL626371,,,In vivo,,A,1,1,
,BAO_0000218,10075,N,"Bioavailability (F) was evaluated in rat, after administering 10 mg/kg orally",Intermediate,,50597,,4498,,10116.0,Rattus norvegicus,,CHEMBL626372,,,In vivo,,A,1,1,
,BAO_0000218,10076,N,Bioavailability after a dose of 10 mg/kg p.o.,Intermediate,,50597,,3603,,10116.0,Rattus norvegicus,,CHEMBL626373,,,In vivo,,A,1,1,
,BAO_0000218,10077,N,Bioavailability after peroral administration (10 mg/kg) was determined in rat,Intermediate,,50597,,6215,,10116.0,Rattus norvegicus,,CHEMBL626374,,,In vivo,,A,1,1,
,BAO_0000218,10078,N,Bioavailability in fasted male administration of 2 mg/Kg of compound p.o.,Intermediate,,50597,,5710,,10116.0,Rattus norvegicus,,CHEMBL626375,,,In vivo,,A,1,1,
,BAO_0000218,10079,N,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 2 mg/kg),Intermediate,,50597,,5710,,10116.0,Rattus norvegicus,,CHEMBL626376,,,In vivo,,A,1,1,
,BAO_0000218,10080,N,Bioavailability in rat po was determined,Intermediate,,50597,,5676,,10116.0,Rattus norvegicus,,CHEMBL626377,,,In vivo,,A,1,1,
,BAO_0000218,10081,N,Bioavailability of compound at 10 mg/kg in rat after oral administration,Intermediate,,50597,,17667,,10116.0,Rattus norvegicus,,CHEMBL626378,,,In vivo,,A,1,1,
,BAO_0000218,10082,N,Bioavailability of compound at 3 mg/kg in rat after i.v. administration,Intermediate,,50597,,17667,,10116.0,Rattus norvegicus,,CHEMBL626379,,,In vivo,,A,1,1,
,BAO_0000218,10083,N,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),Intermediate,,50597,,6848,,10116.0,Rattus norvegicus,,CHEMBL626380,,,In vivo,,A,1,1,
,BAO_0000218,10084,N,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),Intermediate,,50597,,6848,,10116.0,Rattus norvegicus,,CHEMBL626381,,,In vivo,,A,1,1,
,BAO_0000218,10085,N,Bioavailability in rat,Intermediate,,50597,,17267,,10116.0,Rattus norvegicus,,CHEMBL626382,,,In vivo,,A,1,1,
,BAO_0000218,10086,N,Bioavailability in rat (Sprague-Dawley) (female),Intermediate,,50597,,6362,,10116.0,Rattus norvegicus,,CHEMBL626383,,,In vivo,,A,1,1,
,BAO_0000218,10087,N,Bioavailability in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,Intermediate,,50597,,17671,,10116.0,Rattus norvegicus,,CHEMBL874652,,,In vivo,,A,1,1,
,BAO_0000218,10088,N,Bioavailability in rat (Sprague-Dawley) (male) (dose 10-20 mg/kg),Intermediate,,50597,,17671,,10116.0,Rattus norvegicus,,CHEMBL626384,,,In vivo,,A,1,1,
,BAO_0000218,10089,N,Bioavailability in rat (Sprague-Dawley) (male) (dose 1 mg/kg i.v. and 3 mg/kg p.o.) measured from 0.3 to 6 hr,Intermediate,,50597,,4333,,10116.0,Rattus norvegicus,,CHEMBL626385,,,In vivo,,A,1,1,
,BAO_0000218,10090,N,Bioavailability in rat at an oral dose of 2 mg/kg,Intermediate,,50597,,6077,,10116.0,Rattus norvegicus,,CHEMBL626386,,,In vivo,,A,1,1,
,BAO_0000218,10091,N,Bioavailability in rat,Intermediate,,50597,,3278,,10116.0,Rattus norvegicus,,CHEMBL626387,,,In vivo,,A,1,1,
,BAO_0000218,10092,N,Bioavailability in rat,Intermediate,,50597,,5964,,10116.0,Rattus norvegicus,,CHEMBL626388,,,In vivo,,A,1,1,
,BAO_0000218,10093,N,Bioavailability in rat,Intermediate,,50597,,4884,,10116.0,Rattus norvegicus,,CHEMBL626389,,,In vivo,,A,1,1,
,BAO_0000218,10094,N,Bioavailability in rat,Intermediate,,50597,,4905,,10116.0,Rattus norvegicus,,CHEMBL626390,,,In vivo,,A,1,1,
,BAO_0000218,10095,N,Bioavailability in rat was reported at the dose of 6 mg/kg in 25% PEG-300,Intermediate,,50597,,4884,,10116.0,Rattus norvegicus,,CHEMBL626391,,,In vivo,,A,1,1,
,BAO_0000218,10096,N,Bioavailability in rat,Intermediate,,50597,,6850,,10116.0,Rattus norvegicus,,CHEMBL626392,,,In vivo,,A,1,1,
,BAO_0000218,10097,N,Oral bioavailability in rat,Intermediate,,50597,,2864,,10116.0,Rattus norvegicus,,CHEMBL626393,,,In vivo,,A,1,1,
,BAO_0000218,10098,N,Bioavailability was determined in rat,Intermediate,,50597,,5780,,10116.0,Rattus norvegicus,,CHEMBL623026,,,In vivo,,A,1,1,
,BAO_0000218,10099,N,Bioavailability,Intermediate,,50597,,1465,,10116.0,Rattus norvegicus,,CHEMBL623027,,,In vivo,,A,1,1,
,BAO_0000218,10100,N,Bioavailability,Intermediate,,50597,,5199,,10116.0,Rattus norvegicus,,CHEMBL623028,,,In vivo,,A,1,1,
,BAO_0000218,10101,N,Bioavailability in rat after 1 day dosing,Intermediate,,50597,,5765,,10116.0,Rattus norvegicus,,CHEMBL623029,,,In vivo,,A,1,1,
,BAO_0000218,10102,N,Bioavailability in rat after 4 day dosing,Intermediate,,50597,,5765,,10116.0,Rattus norvegicus,,CHEMBL623030,,,In vivo,,A,1,1,
,BAO_0000218,10103,N,Bioavailability after IV dosing at 0.5 mg/kg in rat; no data,Intermediate,,50597,,6518,,10116.0,Rattus norvegicus,,CHEMBL623031,,,In vivo,,A,1,1,
,BAO_0000218,10104,N,Bioavailability after IV dosing at 1 mg/kg in rat; no data,Intermediate,,50597,,6518,,10116.0,Rattus norvegicus,,CHEMBL623032,,,In vivo,,A,1,1,
,BAO_0000218,10105,N,Bioavailability after oral administration at a dose of 2 mg/kg in rat,Intermediate,,50597,,6518,,10116.0,Rattus norvegicus,,CHEMBL623033,,,In vivo,,A,1,1,
,BAO_0000218,10106,N,Bioavailability after oral administration at a dose of 4 mg/kg in rat,Intermediate,,50597,,6518,,10116.0,Rattus norvegicus,,CHEMBL623034,,,In vivo,,A,1,1,
,BAO_0000218,10107,N,Bioavailability at 4 hr after administration of 5 mg/kg dose peroral in rat,Intermediate,,50597,,2083,,10116.0,Rattus norvegicus,,CHEMBL623035,,,In vivo,,A,1,1,
,BAO_0000218,10108,N,Bioavailability at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,Intermediate,,50597,,17260,,10116.0,Rattus norvegicus,,CHEMBL623036,,,In vivo,,A,1,1,
,BAO_0000218,10109,N,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),Intermediate,,50597,,4956,,10116.0,Rattus norvegicus,,CHEMBL623037,,,In vivo,,A,1,1,
,BAO_0000218,10110,N,Bioavailability by intravenous administration of 3.4 mg/kg in rat,Intermediate,,50597,,4368,,10116.0,Rattus norvegicus,,CHEMBL623038,,,In vivo,,A,1,1,
Plasma,BAO_0000218,10111,N,Bioavailability from rat plasma at a single oral dose of 25 mg/kg,Intermediate,,50597,,17752,1969.0,10116.0,Rattus norvegicus,,CHEMBL874385,,,In vivo,,A,1,1,
,BAO_0000218,10112,N,Bioavailability in rat (Fisher) (fasted),Intermediate,,50597,,1446,,10116.0,Rattus norvegicus,,CHEMBL623039,,,In vivo,,A,1,1,
,BAO_0000218,10113,U,Bioavailability in monkey after po administration of 10 mg/kg dose,Intermediate,,22224,,2891,,9443.0,Primates,,CHEMBL623040,,,In vivo,,A,1,0,
,BAO_0000218,10114,U,Oral bioavailability in monkey (dose 10 mg/kg),Intermediate,,22224,,2891,,9443.0,Primates,,CHEMBL623041,,,In vivo,,A,1,0,
,BAO_0000218,10115,N,Bioavailability in rat,Intermediate,,50597,,6672,,10116.0,Rattus norvegicus,,CHEMBL623741,,,In vivo,,A,1,1,
,BAO_0000218,10116,N,Bioavailability in rat,Intermediate,,50597,,6673,,10116.0,Rattus norvegicus,,CHEMBL623742,,,In vivo,,A,1,1,
,BAO_0000218,10117,N,Bioavailability in rat,Intermediate,,50597,,17655,,10116.0,Rattus norvegicus,,CHEMBL623743,,,In vivo,,A,1,1,
,BAO_0000218,10118,N,Bioavailability in rat,Intermediate,,50597,,17796,,10116.0,Rattus norvegicus,,CHEMBL623744,,,In vivo,,A,1,1,
,BAO_0000218,10119,N,Bioavailability in rat (dose 2.0 mg/kg p.o.),Intermediate,,50597,,17853,,10116.0,Rattus norvegicus,,CHEMBL623745,,,In vivo,,A,1,1,
,BAO_0000218,10120,N,Bioavailability in rat (dose 5 mg/kg p.o. and 1 mg/kg i.v.),Intermediate,,50597,,4521,,10116.0,Rattus norvegicus,,CHEMBL623746,,,In vivo,,A,1,1,
,BAO_0000218,10121,N,Oral bioavailability in rat (dose 5 mg/kg p.o.),Intermediate,,50597,,4940,,10116.0,Rattus norvegicus,,CHEMBL623747,,,In vivo,,A,1,1,
,BAO_0000218,10122,U,Bioavailability in rat after po administration of 30 mg/kg dose,Intermediate,,22224,,2891,,10116.0,Rattus norvegicus,,CHEMBL623748,,,In vivo,,A,1,0,
,BAO_0000218,10123,U,Bioavailability in rat after po administration of 30 mg/kg dose,Intermediate,,22224,,2891,,10116.0,Rattus norvegicus,,CHEMBL623916,,,In vivo,,A,1,0,
,BAO_0000218,10124,N,Bioavailability in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,Intermediate,,50597,,4521,,10116.0,Rattus norvegicus,,CHEMBL623917,,,In vivo,,A,1,1,
,BAO_0000218,10125,N,Bioavailability in rat (dose 2 mg/kg i.v.),Intermediate,,50597,,17686,,10116.0,Rattus norvegicus,,CHEMBL623918,,,In vivo,,A,1,1,
,BAO_0000218,10126,N,Bioavailability in rat,Intermediate,,50597,,17796,,10116.0,Rattus norvegicus,,CHEMBL874386,,,In vivo,,A,1,1,
Plasma,BAO_0000218,10127,N,Bioavailability in rat; Only traces detected in rat plasma,Intermediate,,50597,,17796,1969.0,10116.0,Rattus norvegicus,,CHEMBL623919,,,In vivo,,A,1,1,
,BAO_0000218,10128,N,Bioavailability in rat,Intermediate,,50597,,5064,,10116.0,Rattus norvegicus,,CHEMBL623920,,,In vivo,,A,1,1,
,BAO_0000218,10129,N,Bioavailability upon oral administration of compound,Intermediate,,50597,,5147,,10116.0,Rattus norvegicus,,CHEMBL623148,,,In vivo,,A,1,1,
,BAO_0000218,10130,N,Oral bioavailability in rat (Sprague-Dawley) (dose 15 mg/kg),Intermediate,,50597,,1916,,10116.0,Rattus norvegicus,,CHEMBL623149,,,In vivo,,A,1,1,
,BAO_0000218,10131,N,Bioavailability in rat,Intermediate,,50597,,6049,,10116.0,Rattus norvegicus,,CHEMBL623150,,,In vivo,,A,1,1,
,BAO_0000218,10132,N,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fasting state",Intermediate,,50597,,1445,,10116.0,Rattus norvegicus,,CHEMBL623151,,,In vivo,,A,1,1,
,BAO_0000218,10133,N,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fed state",Intermediate,,50597,,1445,,10116.0,Rattus norvegicus,,CHEMBL623152,,,In vivo,,A,1,1,
,BAO_0000218,10134,N,Streptococcal cell wall-washed arthritis model in rats at 3.0 mg/kg peroral dose,Expert,,50597,,2862,,10116.0,Rattus norvegicus,,CHEMBL623153,,,,,F,1,1,
,BAO_0000218,10135,N,Streptococcal cell wall-washed arthritis model in rats at 30.0 mg/kg peroral dose,Expert,,50597,,2862,,10116.0,Rattus norvegicus,,CHEMBL623154,,,,,F,1,1,
,BAO_0000218,10136,N,In vitro and metabolic stability was determined,Intermediate,,50597,,4194,,10116.0,Rattus norvegicus,,CHEMBL623155,,,,,A,1,1,
,BAO_0000218,10137,N,In vitro metabolic stability in rat hepatocytes,Intermediate,,50597,,4194,,10116.0,Rattus norvegicus,,CHEMBL623156,,,,,A,1,1,
,BAO_0000218,10138,N,In vitro metabolic stability in rat was measured as pmol/min/mg/protein,Intermediate,,50597,,5486,,10116.0,Rattus norvegicus,,CHEMBL623157,,,,,A,1,1,
Liver,BAO_0000218,10139,N,Metabolic rate for compound was observed in rat hepatocytes,Intermediate,401.0,50597,,17582,2107.0,10116.0,Rattus norvegicus,,CHEMBL623158,Hepatocyte,,In vitro,,A,1,1,
,BAO_0000218,10140,N,In vitro metabolic stability determined after 30 min of incubation in rat hepatic microsomes,Intermediate,,50597,,5600,,10116.0,Rattus norvegicus,,CHEMBL623159,,,,,A,1,1,
,BAO_0000218,10141,N,Metabolism of compound in rat S9 microsomes ('+''indicates <20% largest observed peak),Intermediate,,50597,,14294,,10116.0,Rattus norvegicus,,CHEMBL874390,,,,,A,1,1,
,BAO_0000218,10142,N,Metabolism of compound in rat S9 microsomes ('++++' indicates largest observed peak),Intermediate,,50597,,14294,,10116.0,Rattus norvegicus,,CHEMBL623160,,,,,A,1,1,
,BAO_0000218,10143,N,Metabolism of compound in rat S9 microsomes; Trace,Intermediate,,50597,,14294,,10116.0,Rattus norvegicus,,CHEMBL623161,,,,,A,1,1,
,BAO_0000218,10144,N,Metabolism was measured as percent loss at 4 hr in rat hepatocytes,Intermediate,,50597,,17847,,10116.0,Rattus norvegicus,,CHEMBL623162,,,,,A,1,1,
,BAO_0000218,10145,N,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HIAA,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL623163,,,,,A,1,1,
,BAO_0000218,10146,N,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HT,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL623164,,,,,A,1,1,
,BAO_0000218,10147,N,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DA,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL623165,,,,,A,1,1,
,BAO_0000218,10148,N,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DOPAC,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL623166,,,,,A,1,1,
,BAO_0000218,10149,N,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex HVA,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL624983,,,,,A,1,1,
,BAO_0000218,10150,N,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex NE,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL624984,,,,,A,1,1,
,BAO_0000218,10151,N,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Hippocampus 5-HIAA,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL624985,,,,,A,1,1,
,BAO_0000218,10152,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus 5-HT,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL622970,,,,,A,1,1,
,BAO_0000218,10153,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below level of detection,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL622971,,,,,A,1,1,
,BAO_0000218,10154,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below the levels of detection,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL622972,,,,,A,1,1,
,BAO_0000218,10155,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below level of detection,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL622973,,,,,A,1,1,
,BAO_0000218,10156,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below the levels of detection,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL622974,,,,,A,1,1,
,BAO_0000218,10157,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below level of detection,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL622975,,,,,A,1,1,
,BAO_0000218,10158,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below the levels of detection,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL622976,,,,,A,1,1,
,BAO_0000218,10159,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus NE,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL622977,,,,,A,1,1,
,BAO_0000218,10160,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HIAA,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL624351,,,,,A,1,1,
,BAO_0000218,10161,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HT,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL624352,,,,,A,1,1,
,BAO_0000218,10162,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL624353,,,,,A,1,1,
,BAO_0000218,10163,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DOPAC,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL622397,,,,,A,1,1,
,BAO_0000218,10164,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex HVA,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL622398,,,,,A,1,1,
,BAO_0000218,10165,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex NE,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL622399,,,,,A,1,1,
,BAO_0000218,10166,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL622400,,,,,A,1,1,
,BAO_0000218,10167,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HIAA,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL628428,,,,,A,1,1,
,BAO_0000218,10168,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HT,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL628590,,,,,A,1,1,
,BAO_0000218,10169,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below level of detection,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL628591,,,,,A,1,1,
,BAO_0000218,10170,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below the levels of detection,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL628592,,,,,A,1,1,
,BAO_0000218,10171,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL628593,,,,,A,1,1,
,BAO_0000218,10172,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL875333,,,,,A,1,1,
,BAO_0000218,10173,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL628594,,,,,A,1,1,
Plasma,BAO_0000218,10174,N,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr of administration,Intermediate,,50597,,4969,1969.0,10116.0,Rattus norvegicus,,CHEMBL628595,,,,,A,1,1,
Plasma,BAO_0000218,10175,N,Stability in rat plasma was determined,Intermediate,,50597,,6737,1969.0,10116.0,Rattus norvegicus,,CHEMBL628596,,,,,A,1,1,
Plasma,BAO_0000218,10176,N,Stability in rat plasma was determined; ND= no data,Intermediate,,50597,,6737,1969.0,10116.0,Rattus norvegicus,,CHEMBL628597,,,,,A,1,1,
Plasma,BAO_0000218,10177,N,Tested for plasma half life period in rat (0-8 hr),Intermediate,,50597,,5089,1969.0,10116.0,Rattus norvegicus,,CHEMBL628598,,,,,A,1,1,
Plasma,BAO_0000218,10178,N,Tested for plasma half life period in rat (0-8 hr); Not determined,Intermediate,,50597,,5089,1969.0,10116.0,Rattus norvegicus,,CHEMBL628599,,,,,A,1,1,
,BAO_0000218,10179,N,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in rat,Intermediate,,50597,,1466,,10116.0,Rattus norvegicus,,CHEMBL628600,,,In vivo,,A,1,1,
,BAO_0000218,10180,N,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in rat,Intermediate,,50597,,1466,,10116.0,Rattus norvegicus,,CHEMBL628601,,,In vivo,,A,1,1,
,BAO_0000218,10181,N,Tested for the half life in rat,Intermediate,,50597,,4950,,10116.0,Rattus norvegicus,,CHEMBL628602,,,,,A,1,1,
,BAO_0000218,10182,N,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase,Intermediate,,50597,,2412,,10116.0,Rattus norvegicus,,CHEMBL628603,,,In vitro,,A,1,1,
,BAO_0000218,10183,N,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase; ND=Not determined,Intermediate,,50597,,2412,,10116.0,Rattus norvegicus,,CHEMBL628604,,,In vitro,,A,1,1,
,BAO_0000218,10184,N,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase,Intermediate,,50597,,2412,,10116.0,Rattus norvegicus,,CHEMBL628605,,,In vitro,,A,1,1,
,BAO_0000218,10185,N,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase; ND=Not determined,Intermediate,,50597,,2412,,10116.0,Rattus norvegicus,,CHEMBL628606,,,In vitro,,A,1,1,
,BAO_0000218,10186,N,Tested in vitro for the time for half reactivation against rat small intestinal sucrase,Intermediate,,50597,,2412,,10116.0,Rattus norvegicus,,CHEMBL628607,,,In vitro,,A,1,1,
,BAO_0000218,10187,N,The biological half life the compound was measured at the dose of 100 umol/kg,Intermediate,,50597,,15022,,10116.0,Rattus norvegicus,,CHEMBL628608,,,,,A,1,1,
,BAO_0000218,10188,N,The biological half life the compound was measured at the dose of 30 umol/kg,Intermediate,,50597,,15022,,10116.0,Rattus norvegicus,,CHEMBL628609,,,,,A,1,1,
Plasma,BAO_0000218,10189,N,The compound was evaluated for plasma half life period in rat,Intermediate,,50597,,406,1969.0,10116.0,Rattus norvegicus,,CHEMBL628610,,,,,A,1,1,
,BAO_0000218,10190,N,"The half life value in female wistar rat at 100 mg/kg, p.o. dose",Intermediate,,50597,,15078,,10116.0,Rattus norvegicus,,CHEMBL873819,,,In vivo,,A,1,1,
,BAO_0000218,10191,N,"The half life value in male wistar rat at 100 mg/kg, p.o. dose",Intermediate,,50597,,15078,,10116.0,Rattus norvegicus,,CHEMBL628611,,,In vivo,,A,1,1,
,BAO_0000218,10192,N,The pharmacokinetic parameter half-life period in vivo in rats,Intermediate,,50597,,5247,,10116.0,Rattus norvegicus,,CHEMBL628612,,,In vivo,,A,1,1,
,BAO_0000218,10193,N,"The pharmacokinetic property, Half-life was determined",Intermediate,,50597,,5041,,10116.0,Rattus norvegicus,,CHEMBL628613,,,In vivo,,A,1,1,
,BAO_0000218,10194,N,"The pharmacokinetic property, Half-life in rat in vivo",Intermediate,,50597,,5041,,10116.0,Rattus norvegicus,,CHEMBL628614,,,In vivo,,A,1,1,
,BAO_0000218,10195,N,"The pharmacokinetic property, Half-life was determined; ND denotes no data",Intermediate,,50597,,5041,,10116.0,Rattus norvegicus,,CHEMBL628615,,,In vivo,,A,1,1,
,BAO_0000218,10196,N,"The pharmacokinetic property, Half-life was determined; ND denotes not determined",Intermediate,,50597,,5041,,10116.0,Rattus norvegicus,,CHEMBL628616,,,In vivo,,A,1,1,
Plasma,BAO_0000218,10197,N,The plasma half life period in rats,Intermediate,,50597,,3918,1969.0,10116.0,Rattus norvegicus,,CHEMBL627924,,,,,A,1,1,
Liver,BAO_0000218,10198,N,The release rate of the free drug from the substrate in rat liver lysosomal preparation by rat liver lysosomal assay,Intermediate,,50597,,2906,2107.0,10116.0,Rattus norvegicus,,CHEMBL627925,,,,,A,1,1,
,BAO_0000218,10199,N,half life in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,Intermediate,,50597,,6467,,10116.0,Rattus norvegicus,,CHEMBL627926,,,In vivo,,A,1,1,
,BAO_0000218,10200,N,t1/2 (apparent elimination)of the compound was determined,Intermediate,,50597,,5510,,10116.0,Rattus norvegicus,,CHEMBL627927,,,,,A,1,1,
,BAO_0000218,10201,N,t1/2 value in rat,Intermediate,,50597,,3788,,10116.0,Rattus norvegicus,,CHEMBL627928,,,,,A,1,1,
,BAO_0000218,10202,N,Half life in rat,Intermediate,,50597,,17796,,10116.0,Rattus norvegicus,,CHEMBL627539,,,,,A,1,1,
Plasma,BAO_0000218,10203,N,"Half life period calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",Intermediate,,50597,,12873,1969.0,10116.0,Rattus norvegicus,,CHEMBL876790,,,In vivo,,A,1,1,
,BAO_0000218,10204,N,Pharmacokinetic property (t1/2beta) was measured in rat at the dose of 0.32 mg/kg i.v.,Intermediate,,50597,,5983,,10116.0,Rattus norvegicus,,CHEMBL858186,,,In vivo,,A,1,1,
,BAO_0000218,10205,N,Half-life period in fasted rats,Intermediate,,50597,,15765,,10116.0,Rattus norvegicus,,CHEMBL627540,,,,,A,1,1,
,BAO_0000218,10206,N,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female wistar rats,Intermediate,,50597,,2661,,10116.0,Rattus norvegicus,,CHEMBL627541,,,In vivo,,A,1,1,
,BAO_0000218,10207,N,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to male wistar rats,Intermediate,,50597,,2661,,10116.0,Rattus norvegicus,,CHEMBL627715,,,In vivo,,A,1,1,
,BAO_0000218,10208,N,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,Intermediate,,50597,,429,,10116.0,Rattus norvegicus,,CHEMBL627716,,,In vivo,,A,1,1,
,BAO_0000218,10209,N,Maximum time required to achieve Cmax was determined in rat,Intermediate,,50597,,17655,,10116.0,Rattus norvegicus,,CHEMBL627717,,,,,A,1,1,
,BAO_0000218,10210,N,Time calculated to reach Cmax at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,Intermediate,,50597,,17717,,10116.0,Rattus norvegicus,,CHEMBL627718,,,In vivo,,A,1,1,
,BAO_0000218,10211,N,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,Intermediate,,50597,,17717,,10116.0,Rattus norvegicus,,CHEMBL627719,,,In vivo,,A,1,1,
,BAO_0000218,10212,N,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with control,Intermediate,,50597,,17717,,10116.0,Rattus norvegicus,,CHEMBL627720,,,In vivo,,A,1,1,
,BAO_0000218,10213,N,Time to reach maximum concentration in rat after 2 mg/kg peroral administration,Intermediate,,50597,,6570,,10116.0,Rattus norvegicus,,CHEMBL627721,,,In vivo,,A,1,1,
,BAO_0000218,10214,N,Time to reach maximum concentration in rat after 2 mg/kg peroral administration; 4-6,Intermediate,,50597,,6570,,10116.0,Rattus norvegicus,,CHEMBL627722,,,In vivo,,A,1,1,
,BAO_0000218,10215,N,Tmax of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,,50597,,5978,,10116.0,Rattus norvegicus,,CHEMBL627723,,,In vivo,,A,1,1,
,BAO_0000218,10216,N,Tmax of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,,50597,,5978,,10116.0,Rattus norvegicus,,CHEMBL626058,,,In vivo,,A,1,1,
,BAO_0000218,10217,N,Tmax of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,,50597,,5978,,10116.0,Rattus norvegicus,,CHEMBL626059,,,In vivo,,A,1,1,
,BAO_0000218,10218,N,Tmax of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,,50597,,5978,,10116.0,Rattus norvegicus,,CHEMBL626060,,,In vivo,,A,1,1,
Plasma,BAO_0000218,10219,N,Tmax at a dose of 4 mg/kg in Rat Plasma after iv administration,Intermediate,,50597,,17720,1969.0,10116.0,Rattus norvegicus,,CHEMBL626061,,,In vivo,,A,1,1,
,BAO_0000218,10220,N,Tmax determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,,50597,,4723,,10116.0,Rattus norvegicus,,CHEMBL876791,,,In vivo,,A,1,1,
,BAO_0000218,10221,N,Tmax determined after 3 mg/kg oral administration in potassium oxonate treated rats,Intermediate,,50597,,4723,,10116.0,Rattus norvegicus,,CHEMBL626062,,,In vivo,,A,1,1,
,BAO_0000218,10222,N,Tmax at the dose of 2 mg/Kg administered perorally in rats,Intermediate,,50597,,4756,,10116.0,Rattus norvegicus,,CHEMBL626063,,,In vivo,,A,1,1,
,BAO_0000218,10223,N,Tmax at the dose of 5 mg/Kg administered perorally in rats,Intermediate,,50597,,4756,,10116.0,Rattus norvegicus,,CHEMBL626064,,,In vivo,,A,1,1,
Plasma,BAO_0000218,10224,N,tmax at a dose of 100 mg/kg in Rat Plasma after iv administration,Intermediate,,50597,,17720,1969.0,10116.0,Rattus norvegicus,,CHEMBL626065,,,In vivo,,A,1,1,
Plasma,BAO_0000218,10225,N,tmax at a dose of 50 mg/kg in Rat Plasma after iv administration,Intermediate,,50597,,17720,1969.0,10116.0,Rattus norvegicus,,CHEMBL626066,,,In vivo,,A,1,1,
,BAO_0000218,10226,N,tmax upon peroral administration of 10.0 mg/Kg dose in rat,Intermediate,,50597,,1466,,10116.0,Rattus norvegicus,,CHEMBL626067,,,In vivo,,A,1,1,
,BAO_0000218,10227,N,Percent total excretion of 3-(thiomethyl)acetaminophen glucuronide,Intermediate,,50597,,7449,,10116.0,Rattus norvegicus,,CHEMBL626068,,,,,F,1,1,
,BAO_0000218,10228,N,Percent total excretion of 3-(thiomethyl)acetaminophen sulfate,Intermediate,,50597,,7449,,10116.0,Rattus norvegicus,,CHEMBL626069,,,,,F,1,1,
,BAO_0000218,10229,N,Percent total excretion of 3-methoxyacetaminophen glucuronide,Intermediate,,50597,,7449,,10116.0,Rattus norvegicus,,CHEMBL626070,,,,,F,1,1,
,BAO_0000218,10230,N,Percent total excretion of N-methoxyacetaminophen glucuronide,Intermediate,,50597,,7449,,10116.0,Rattus norvegicus,,CHEMBL626071,,,,,F,1,1,
,BAO_0000218,10231,N,Percent total excretion of N-methoxyacetaminophen sulfate,Intermediate,,50597,,7449,,10116.0,Rattus norvegicus,,CHEMBL626072,,,,,F,1,1,
,BAO_0000218,10232,N,Percent total excretion of acetaminophen,Intermediate,,50597,,7449,,10116.0,Rattus norvegicus,,CHEMBL626073,,,,,F,1,1,
Thyroid gland,BAO_0000218,10233,N,"Distribution of radioactivity in thyroid tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.19-7.22",Intermediate,,50597,,7768,2046.0,10116.0,Rattus norvegicus,,CHEMBL626741,,,,,A,1,1,
,BAO_0000218,10234,N,"Percent instability was measured by Rat S9 liver slice metabolism assay, in vitro",Intermediate,,50597,,17655,,10116.0,Rattus norvegicus,,CHEMBL626742,,,,,A,1,1,
,BAO_0000218,10235,N,Plasma clearance following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats,Intermediate,,50597,,17735,,10116.0,Rattus norvegicus,,CHEMBL626743,,,,,A,1,1,
,BAO_0000218,10236,N,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,Intermediate,,50597,,5960,,10116.0,Rattus norvegicus,,CHEMBL876792,,,,,A,1,1,
,BAO_0000218,10237,N,Volume of distribution following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,Intermediate,,50597,,17735,,10116.0,Rattus norvegicus,,CHEMBL626744,,,,,A,1,1,
,BAO_0000218,10238,N,Compound was tested for antidiuretic activity in rats,Intermediate,,50597,,7116,,10116.0,Rattus norvegicus,,CHEMBL626745,,,,,A,1,1,
Plasma,BAO_0000218,10239,N,AUC in rat after 3mg/kg oral dose,Intermediate,,50597,,4878,1969.0,10116.0,Rattus norvegicus,,CHEMBL626746,,,In vivo,,A,1,1,
,BAO_0000218,10240,N,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 10 mg/kg,Intermediate,,50597,,5939,,10116.0,Rattus norvegicus,,CHEMBL626747,,,,,A,1,1,
,BAO_0000218,10241,N,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 5 mg/kg,Intermediate,,50597,,5939,,10116.0,Rattus norvegicus,,CHEMBL626748,,,,,A,1,1,
,BAO_0000218,10242,N,Bioavailability administered orally at a dose of 10 mg/kg to rats,Intermediate,,50597,,16367,,10116.0,Rattus norvegicus,,CHEMBL626749,,,,,A,1,1,
,BAO_0000218,10243,N,Oral Bioavailability was determined,Intermediate,,50597,,16366,,10116.0,Rattus norvegicus,,CHEMBL626750,,,,,A,1,1,
,BAO_0000218,10244,N,Oral bioavailability in rat,Intermediate,,50597,,4426,,10116.0,Rattus norvegicus,,CHEMBL626751,,,,,A,1,1,
,BAO_0000218,10245,N,Oral bioavailability in rat; Not performed.,Intermediate,,50597,,4426,,10116.0,Rattus norvegicus,,CHEMBL626913,,,,,A,1,1,
,BAO_0000218,10246,N,Bioavailability,Intermediate,,50597,,5041,,10116.0,Rattus norvegicus,,CHEMBL626914,,,,,A,1,1,
,BAO_0000218,10247,N,Bioavailability was determined; ND denotes no data,Intermediate,,50597,,5041,,10116.0,Rattus norvegicus,,CHEMBL626915,,,,,A,1,1,
,BAO_0000218,10248,N,Biliary excretion when administered intravenously at a dose of 2.5 mg/kg in rats,Intermediate,,50597,,1500,,10116.0,Rattus norvegicus,,CHEMBL626916,,,,,A,1,1,
,BAO_0000218,10249,N,Biliary excretion when administered intravenously at a dose of 5 mg/kg in rats,Intermediate,,50597,,1500,,10116.0,Rattus norvegicus,,CHEMBL626917,,,,,A,1,1,
,BAO_0000218,10250,N,Binding towards rat plasma protein at 10 uM,Intermediate,,50597,,17409,,10116.0,Rattus norvegicus,,CHEMBL626918,,,,,A,1,1,
,BAO_0000218,10251,N,Binding towards rat plasma protein at 100 uM,Intermediate,,50597,,17409,,10116.0,Rattus norvegicus,,CHEMBL626919,,,,,A,1,1,
,BAO_0000218,10252,N,Bioavailability in rat (dose 20 mg/kg p.o.),Intermediate,,50597,,2959,,10116.0,Rattus norvegicus,,CHEMBL626920,,,In vivo,,A,1,1,
,BAO_0000218,10253,N,Bioavailability was determined after oral administration of compound 18 at a dose of 4 mg/kg to rat,Intermediate,,50597,,13501,,10116.0,Rattus norvegicus,,CHEMBL621976,,,In vivo,,A,1,1,
,BAO_0000218,10254,N,Bioavailability in rat after 5 mg/kg oral gavage,Intermediate,,50597,,6567,,10116.0,Rattus norvegicus,,CHEMBL877599,,,In vivo,,A,1,1,
,BAO_0000218,10255,N,Bioavailability in rat,Intermediate,,50597,,6571,,10116.0,Rattus norvegicus,,CHEMBL621977,,,In vivo,,A,1,1,
,BAO_0000218,10256,N,Bioavailability in rat (dose 1 mg/kg i.v.),Intermediate,,50597,,6715,,10116.0,Rattus norvegicus,,CHEMBL621978,,,In vivo,,A,1,1,
,BAO_0000218,10257,N,Bioavailability in rat (dose 3 mg/kg p.o.),Intermediate,,50597,,6715,,10116.0,Rattus norvegicus,,CHEMBL621979,,,In vivo,,A,1,1,
,BAO_0000218,10258,N,Oral bioavailability in rat,Intermediate,,50597,,2932,,10116.0,Rattus norvegicus,,CHEMBL621980,,,In vivo,,A,1,1,
,BAO_0000218,10259,N,Bioavailability of the compound in rats after administration of 30 mg/kg,Intermediate,,50597,,4171,,10116.0,Rattus norvegicus,,CHEMBL621981,,,In vivo,,A,1,1,
,BAO_0000218,10260,N,Bioavailability after administration of 10 mg/kg in rats,Intermediate,,50597,,17509,,10116.0,Rattus norvegicus,,CHEMBL621982,,,In vivo,,A,1,1,
,BAO_0000218,10261,N,Bioavailability after administration of 2 mg/kg in rats,Intermediate,,50597,,17509,,10116.0,Rattus norvegicus,,CHEMBL882953,,,In vivo,,A,1,1,
,BAO_0000218,10262,N,Bioavailability by oral administration at a dose of 100 uM/kg in rat was determined,Intermediate,,50597,,4527,,10116.0,Rattus norvegicus,,CHEMBL621983,,,In vivo,,A,1,1,
,BAO_0000218,10263,N,Bioavailability in dogs was determined; high,Intermediate,,50597,,4026,,10116.0,Rattus norvegicus,,CHEMBL621984,,,In vivo,,A,1,1,
,BAO_0000218,10264,N,Bioavailability in monkey after intravenous administration at 1 mpk,Intermediate,,50597,,6659,,10116.0,Rattus norvegicus,,CHEMBL621985,,,In vivo,,A,1,1,
,BAO_0000218,10265,N,Bioavailability in monkey after peroral administration at 10 mpk,Intermediate,,50597,,6659,,10116.0,Rattus norvegicus,,CHEMBL621986,,,In vivo,,A,1,1,
,BAO_0000218,10266,N,Bioavailability in rat after intravenous administration at 1 mpk,Intermediate,,50597,,6659,,10116.0,Rattus norvegicus,,CHEMBL621987,,,In vivo,,A,1,1,
,BAO_0000218,10267,N,Bioavailability in rat after intravenous administration at 2 mpk,Intermediate,,50597,,6659,,10116.0,Rattus norvegicus,,CHEMBL877600,,,In vivo,,F,1,1,
,BAO_0000218,10268,N,Bioavailability in rat after peroral administration at 30 mpk,Intermediate,,50597,,6659,,10116.0,Rattus norvegicus,,CHEMBL621988,,,In vivo,,A,1,1,
,BAO_0000218,10269,N,Bioavailability in rat after peroral administration at at 100 mpk,Intermediate,,50597,,6659,,10116.0,Rattus norvegicus,,CHEMBL621989,,,In vivo,,F,1,1,
,BAO_0000218,10270,N,Bioavailability in rats was evaluated,Intermediate,,50597,,6597,,10116.0,Rattus norvegicus,,CHEMBL621990,,,In vivo,,A,1,1,
,BAO_0000218,10271,N,Bioavailability was calculated after an intravenous dose of 0.3 mg/Kg in rats after 6 hr,Intermediate,,50597,,1202,,10116.0,Rattus norvegicus,,CHEMBL621991,,,In vivo,,A,1,1,
,BAO_0000218,10272,N,Bioavailability was calculated after an intravenous dose of 1 mg/Kg in rats after 6 hr,Intermediate,,50597,,1202,,10116.0,Rattus norvegicus,,CHEMBL621992,,,In vivo,,A,1,1,
,BAO_0000218,10273,N,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 4 hr,Intermediate,,50597,,1202,,10116.0,Rattus norvegicus,,CHEMBL621993,,,In vivo,,A,1,1,
,BAO_0000218,10274,N,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 6 hr,Intermediate,,50597,,1202,,10116.0,Rattus norvegicus,,CHEMBL621994,,,In vivo,,A,1,1,
,BAO_0000218,10275,N,Bioavailability in rat,Intermediate,,50597,,5207,,10116.0,Rattus norvegicus,,CHEMBL621995,,,In vivo,,A,1,1,
,BAO_0000218,10276,N,Bioavailability in rat,Intermediate,,50597,,5970,,10116.0,Rattus norvegicus,,CHEMBL621996,,,In vivo,,A,1,1,
,BAO_0000218,10277,N,Oral bioavailability in rat (dose 10 mg/kg),Intermediate,,50597,,17538,,10116.0,Rattus norvegicus,,CHEMBL621997,,,In vivo,,A,1,1,
,BAO_0000218,10278,N,Bioavailability in rat after po administration at a dose of 10 mg/kg; nd is not determined,Intermediate,,50597,,17538,,10116.0,Rattus norvegicus,,CHEMBL621998,,,In vivo,,A,1,1,
,BAO_0000218,10279,N,Bioavailability upon peroral administration of 10.0 mg/Kg dose in rat,Intermediate,,50597,,1466,,10116.0,Rattus norvegicus,,CHEMBL621999,,,In vivo,,A,1,1,
,BAO_0000218,10280,N,Oral bioavailability in rat,Intermediate,,50597,,2879,,10116.0,Rattus norvegicus,,CHEMBL622000,,,In vivo,,A,1,1,
,BAO_0000218,10281,N,Bioavailability was measured in rat after oral administration; 2-4,Intermediate,,50597,,2879,,10116.0,Rattus norvegicus,,CHEMBL622001,,,In vivo,,A,1,1,
,BAO_0000218,10282,N,Bioavailability was measured in rat after oral administration; 3-7,Intermediate,,50597,,2879,,10116.0,Rattus norvegicus,,CHEMBL622002,,,In vivo,,A,1,1,
,BAO_0000218,10283,N,Bioavailability in rat (intraduodenal administration),Intermediate,,50597,,3777,,10116.0,Rattus norvegicus,,CHEMBL622003,,,In vivo,,A,1,1,
,BAO_0000218,10284,N,Bioavailability in rat (intraduodenal administration),Intermediate,,50597,,3777,,10116.0,Rattus norvegicus,,CHEMBL877601,,,In vivo,,A,1,1,
,BAO_0000218,10285,N,Oral bioavailability in rat,Intermediate,,50597,,3777,,10116.0,Rattus norvegicus,,CHEMBL624871,,,In vivo,,A,1,1,
,BAO_0000218,10286,N,Oral bioavailability in rat,Intermediate,,50597,,3777,,10116.0,Rattus norvegicus,,CHEMBL622004,,,In vivo,,A,1,1,
,BAO_0000218,10287,N,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg p.o.),Intermediate,,50597,,5423,,10116.0,Rattus norvegicus,,CHEMBL882954,,,In vivo,,A,1,1,
,BAO_0000218,10288,N,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally,Intermediate,,50597,,16365,,10116.0,Rattus norvegicus,,CHEMBL622005,,,In vivo,,A,1,1,
,BAO_0000218,10289,N,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally to a fasting rat,Intermediate,,50597,,16365,,10116.0,Rattus norvegicus,,CHEMBL622006,,,In vivo,,A,1,1,
,BAO_0000218,10290,N,Bioavailability was measured in rat,Intermediate,,50597,,4239,,10116.0,Rattus norvegicus,,CHEMBL622007,,,In vivo,,A,1,1,
,BAO_0000218,10291,N,Bioavailability was reported,Intermediate,,50597,,5438,,10116.0,Rattus norvegicus,,CHEMBL622008,,,In vivo,,A,1,1,
,BAO_0000218,10292,N,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),Intermediate,,50597,,5334,,10116.0,Rattus norvegicus,,CHEMBL622009,,,In vivo,,A,1,1,
,BAO_0000218,10293,N,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),Intermediate,,50597,,5334,,10116.0,Rattus norvegicus,,CHEMBL622010,,,In vivo,,A,1,1,
,BAO_0000218,10294,N,Bioavailability was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,Intermediate,,50597,,4199,,10116.0,Rattus norvegicus,,CHEMBL622011,,,In vivo,,A,1,1,
,BAO_0000218,10295,N,Bioavailability in rat (dose 2 mg/kg in 1% methylcellulose p.o.),Intermediate,,50597,,4199,,10116.0,Rattus norvegicus,,CHEMBL622012,,,In vivo,,A,1,1,
,BAO_0000218,10296,N,Bioavailability in rat (dose 3 mg/kg in 1% methylcellulose ),Intermediate,,50597,,4199,,10116.0,Rattus norvegicus,,CHEMBL622013,,,In vivo,,A,1,1,
,BAO_0000218,10297,N,Bioavailability was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,Intermediate,,50597,,4890,,10116.0,Rattus norvegicus,,CHEMBL622014,,,In vivo,,A,1,1,
,BAO_0000218,10298,N,Bioavailability was determined at 3 mg/kg po dose in rats,Intermediate,,50597,,2792,,10116.0,Rattus norvegicus,,CHEMBL624749,,,In vivo,,A,1,1,
,BAO_0000218,10299,N,Oral bioavailability in rat (dose 2 mg/kg),Intermediate,,50597,,5529,,10116.0,Rattus norvegicus,,CHEMBL624750,,,In vivo,,A,1,1,
,BAO_0000218,10300,N,"Bioavailability was determined in rats at 10 mg/kg, p.o. dose",Intermediate,,50597,,6685,,10116.0,Rattus norvegicus,,CHEMBL624751,,,In vivo,,A,1,1,
,BAO_0000218,10301,N,"Bioavailability was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",Intermediate,,50597,,6685,,10116.0,Rattus norvegicus,,CHEMBL624752,,,In vivo,,A,1,1,
,BAO_0000218,10302,N,"Bioavailability was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",Intermediate,,50597,,6685,,10116.0,Rattus norvegicus,,CHEMBL624753,,,In vivo,,A,1,1,
,BAO_0000218,10303,N,Bioavailability was evaluated in rat after peroral administration at a dose of 1 mg/kg,Intermediate,,50597,,6005,,10116.0,Rattus norvegicus,,CHEMBL624754,,,In vivo,,A,1,1,
,BAO_0000218,10304,N,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,Intermediate,,50597,,6410,,10116.0,Rattus norvegicus,,CHEMBL624755,,,In vivo,,A,1,1,
,BAO_0000218,10305,N,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,Intermediate,,50597,,6410,,10116.0,Rattus norvegicus,,CHEMBL624756,,,In vivo,,A,1,1,
,BAO_0000218,10306,N,Bioavailability in rat,Intermediate,,50597,,6103,,10116.0,Rattus norvegicus,,CHEMBL624757,,,In vivo,,A,1,1,
,BAO_0000218,10307,N,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,Intermediate,,50597,,6410,,10116.0,Rattus norvegicus,,CHEMBL624758,,,In vivo,,A,1,1,
,BAO_0000218,10308,N,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,Intermediate,,50597,,6410,,10116.0,Rattus norvegicus,,CHEMBL622270,,,In vivo,,A,1,1,
,BAO_0000218,10309,N,Bioavailability in rat (Sprague-Dawley),Intermediate,,50597,,5353,,10116.0,Rattus norvegicus,,CHEMBL622271,,,In vivo,,A,1,1,
,BAO_0000218,10310,N,Bioavailability in rat at the dose of 2 mg/kg,Intermediate,,50597,,4727,,10116.0,Rattus norvegicus,,CHEMBL622272,,,In vivo,,A,1,1,
,BAO_0000218,10311,N,Oral bioavailability in rat,Intermediate,,50597,,17804,,10116.0,Rattus norvegicus,,CHEMBL622273,,,In vivo,,A,1,1,
,BAO_0000218,10312,N,Bioavailability in rat (cannulated) (dose 2 mg/kg),Intermediate,,50597,,5809,,10116.0,Rattus norvegicus,,CHEMBL622274,,,In vivo,,A,1,1,
,BAO_0000218,10313,N,Bioavailability value of compound in rats was determined after peroral administration,Intermediate,,50597,,17804,,10116.0,Rattus norvegicus,,CHEMBL622275,,,In vivo,,A,1,1,
,BAO_0000218,10314,N,Oral bioavailability in rat (dose 20 mg/kg),Intermediate,,50597,,3634,,10116.0,Rattus norvegicus,,CHEMBL622276,,,In vivo,,A,1,1,
,BAO_0000218,10315,N,Oral bioavailability in rat,Intermediate,,50597,,3341,,10116.0,Rattus norvegicus,,CHEMBL622277,,,In vivo,,A,1,1,
,BAO_0000218,10316,N,Oral bioavailability in rat (dose 5 mg/kg),Intermediate,,50597,,2690,,10116.0,Rattus norvegicus,,CHEMBL622278,,,In vivo,,A,1,1,
,BAO_0000218,10317,N,Oral bioavailability in rat,Intermediate,,50597,,3184,,10116.0,Rattus norvegicus,,CHEMBL622279,,,In vivo,,A,1,1,
,BAO_0000218,10318,N,Oral bioavailability in rat,Intermediate,,50597,,740,,10116.0,Rattus norvegicus,,CHEMBL622280,,,In vivo,,A,1,1,
,BAO_0000218,10319,N,Compound was evaluated for oral bioavailability in rats; 15-27 %,Intermediate,,50597,,1806,,10116.0,Rattus norvegicus,,CHEMBL624083,,,In vivo,,A,1,1,
,BAO_0000218,10320,N,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 18 h,Intermediate,,50597,,4891,,10116.0,Rattus norvegicus,,CHEMBL624084,,,In vivo,,A,1,1,
,BAO_0000218,10321,N,Compound was evaluated for pharmacokinetic property in rats after an oral dose of 10 mg/kg and the value was reported as oral bioavailability (F),Intermediate,,50597,,3634,,10116.0,Rattus norvegicus,,CHEMBL624085,,,In vivo,,A,1,1,
,BAO_0000218,10322,N,Compound was tested for bioavailability in rats,Intermediate,,50597,,64,,10116.0,Rattus norvegicus,,CHEMBL624086,,,In vivo,,A,1,1,
,BAO_0000218,10323,N,Bioavailability in rat,Intermediate,,50597,,4839,,10116.0,Rattus norvegicus,,CHEMBL624087,,,In vivo,,A,1,1,
,BAO_0000218,10324,N,Oral bioavailability in rat,Intermediate,,50597,,1094,,10116.0,Rattus norvegicus,,CHEMBL624088,,,In vivo,,A,1,1,
,BAO_0000218,10325,U,Compound was tested for oral bioavailability in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po.,Intermediate,,22224,,5005,,9544.0,Macaca mulatta,,CHEMBL624089,,,In vivo,,A,1,0,
,BAO_0000218,10326,U,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),Intermediate,,22224,,5005,,10116.0,Rattus norvegicus,,CHEMBL624090,,,In vivo,,A,1,0,
,BAO_0000218,10327,N,Evaluated for the bioavailability in rat (in vivo),Intermediate,,50597,,4687,,10116.0,Rattus norvegicus,,CHEMBL624091,,,In vivo,,A,1,1,
,BAO_0000218,10328,N,F value of compound in rats was determined after peroral administration,Intermediate,,50597,,17804,,10116.0,Rattus norvegicus,,CHEMBL624092,,,In vivo,,A,1,1,
,BAO_0000218,10329,N,In vivo Oral bioavailability (F)was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,Intermediate,,50597,,5974,,10116.0,Rattus norvegicus,,CHEMBL624093,,,In vivo,,A,1,1,
,BAO_0000218,10330,N,In vivo Oral bioavailability (F)was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,Intermediate,,50597,,5974,,10116.0,Rattus norvegicus,,CHEMBL624094,,,In vivo,,A,1,1,
,BAO_0000218,10331,N,In vivo Oral bioavailability (F)was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,Intermediate,,50597,,5974,,10116.0,Rattus norvegicus,,CHEMBL624095,,,In vivo,,A,1,1,
,BAO_0000218,10332,N,In vivo Oral bioavailability (F)was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,Intermediate,,50597,,5974,,10116.0,Rattus norvegicus,,CHEMBL624096,,,In vivo,,A,1,1,
,BAO_0000218,10333,N,"In vivo percent of absolute bioavailability obtained from blood plasma levels analyzed by means of GC/MS (dose 5 uM/kg i.v. and 40 uM/kg, p.o.)",Intermediate,,50597,,1088,,10116.0,Rattus norvegicus,,CHEMBL624097,,,In vivo,,A,1,1,
,BAO_0000218,10334,N,Maximum fall in carotid flow in rat,Intermediate,,50597,,1742,,10116.0,Rattus norvegicus,,CHEMBL624098,,,In vivo,,A,1,1,
,BAO_0000218,10335,N,Oral Bioavailability after intravenous administration (1 mg/kg) in rat,Intermediate,,50597,,4689,,10116.0,Rattus norvegicus,,CHEMBL874392,,,In vivo,,A,1,1,
,BAO_0000218,10336,N,Oral bioavailability in rat (dose 5 mg/kg),Intermediate,,50597,,2463,,10116.0,Rattus norvegicus,,CHEMBL624099,,,In vivo,,A,1,1,
,BAO_0000218,10337,N,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,Intermediate,,50597,,5654,,10116.0,Rattus norvegicus,,CHEMBL624100,,,In vivo,,A,1,1,
,BAO_0000218,10338,N,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,Intermediate,,50597,,5654,,10116.0,Rattus norvegicus,,CHEMBL624101,,,In vivo,,A,1,1,
,BAO_0000218,10339,N,Oral bioavailability in rat (male Wistar),Intermediate,,50597,,6874,,10116.0,Rattus norvegicus,,CHEMBL624102,,,In vivo,,A,1,1,
,BAO_0000218,10340,N,Oral bioavailability after administration (30 mg/kg) in rat; good,Intermediate,,50597,,5633,,10116.0,Rattus norvegicus,,CHEMBL624103,,,In vivo,,A,1,1,
,BAO_0000218,10341,N,Oral bioavailability at the dose of 2 mg/kg in rat,Intermediate,,50597,,5496,,10116.0,Rattus norvegicus,,CHEMBL624104,,,In vivo,,A,1,1,
,BAO_0000218,10342,N,Oral bioavailability determined in rats,Intermediate,,50597,,2358,,10116.0,Rattus norvegicus,,CHEMBL624105,,,In vivo,,A,1,1,
,BAO_0000218,10343,N,Oral bioavailability in rat (Sprague-Dawley) (male) (dose 50 mg/kg p.o.),Intermediate,,50597,,16456,,10116.0,Rattus norvegicus,,CHEMBL624106,,,In vivo,,A,1,1,
,BAO_0000218,10344,N,Oral bioavailability in rat (dose single 10 mg/kg),Intermediate,,50597,,5302,,10116.0,Rattus norvegicus,,CHEMBL624107,,,In vivo,,A,1,1,
,BAO_0000218,10345,N,Oral bioavailability in rat (dose single 10 mg/kg),Intermediate,,50597,,5302,,10116.0,Rattus norvegicus,,CHEMBL623943,,,In vivo,,A,1,1,
,BAO_0000218,10346,N,Oral bioavailability in rat (dose 5 mg/kg,Intermediate,,50597,,5302,,10116.0,Rattus norvegicus,,CHEMBL623944,,,In vivo,,A,1,1,
,BAO_0000218,10347,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL623945,,,,,A,1,1,
,BAO_0000218,10348,N,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus NE,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL623946,,,,,A,1,1,
,BAO_0000218,10349,N,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HIAA,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL623947,,,,,A,1,1,
,BAO_0000218,10350,N,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HT,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL623948,,,,,A,1,1,
,BAO_0000218,10351,N,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DA,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL623949,,,,,A,1,1,
,BAO_0000218,10352,N,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DOPAC,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL623950,,,,,A,1,1,
,BAO_0000218,10353,N,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex HVA,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL874398,,,,,A,1,1,
,BAO_0000218,10354,N,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex NE,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL623951,,,,,A,1,1,
,BAO_0000218,10355,N,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HIAA,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL623952,,,,,A,1,1,
,BAO_0000218,10356,N,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HT,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL623953,,,,,A,1,1,
,BAO_0000218,10357,N,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below level of detection,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL623954,,,,,A,1,1,
,BAO_0000218,10358,N,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below the levels of detection,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL623955,,,,,A,1,1,
,BAO_0000218,10359,N,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below level of detection,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL623956,,,,,A,1,1,
,BAO_0000218,10360,N,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below the levels of detection,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL627807,,,,,A,1,1,
,BAO_0000218,10361,N,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below level of detection,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL627808,,,,,A,1,1,
,BAO_0000218,10362,N,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below the levels of detection,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL627809,,,,,A,1,1,
,BAO_0000218,10363,N,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus NE,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL627810,,,,,A,1,1,
,BAO_0000218,10364,N,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HIAA",Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL627811,,,,,A,1,1,
,BAO_0000218,10365,N,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HT",Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL627812,,,,,A,1,1,
,BAO_0000218,10366,N,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DA",Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL627813,,,,,A,1,1,
,BAO_0000218,10367,N,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DOPAC",Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL627814,,,,,A,1,1,
,BAO_0000218,10368,N,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex HVA",Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL875336,,,,,A,1,1,
,BAO_0000218,10369,N,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex NE",Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL627815,,,,,A,1,1,
,BAO_0000218,10370,N,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus 5-HIAA",Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL627816,,,,,A,1,1,
,BAO_0000218,10371,N,"Momoamine and metabolic levels observed at 3 h postdrug against, at a dose of 20 mg/kg Hippocampus 5-HT",Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL627817,,,,,A,1,1,
,BAO_0000218,10372,N,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DA; below the levels of detection",Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL627818,,,,,A,1,1,
,BAO_0000218,10373,N,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection",Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL627819,,,,,A,1,1,
,BAO_0000218,10374,N,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection",Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL627820,,,,,A,1,1,
,BAO_0000218,10375,N,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus NE",Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL627821,,,,,A,1,1,
,BAO_0000218,10376,N,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HIAA,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL628464,,,,,A,1,1,
,BAO_0000218,10377,N,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HT,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL626239,,,,,A,1,1,
,BAO_0000218,10378,N,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex DA,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL626240,,,,,A,1,1,
,BAO_0000218,10379,N,Momoamine and metabolic levels observed at 3 h postdrug against at a dose of 20 mg/kg Frontal cortex DOPAC,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL626241,,,,,A,1,1,
,BAO_0000218,10380,N,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex HVA,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL626242,,,,,A,1,1,
,BAO_0000218,10381,N,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex NE,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL626243,,,,,A,1,1,
,BAO_0000218,10382,N,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HIAA,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL626244,,,,,A,1,1,
,BAO_0000218,10383,N,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HT; below level of detection,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL626907,,,,,A,1,1,
,BAO_0000218,10384,N,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DA; below level of detection,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL626908,,,,,A,1,1,
,BAO_0000218,10385,N,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL626909,,,,,A,1,1,
,BAO_0000218,10386,N,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL626910,,,,,A,1,1,
,BAO_0000218,10387,N,Percent total excretion of acetaminophen cysteine conjugate,Intermediate,,50597,,7449,,10116.0,Rattus norvegicus,,CHEMBL875342,,,,,F,1,1,
,BAO_0000218,10388,N,Percent total excretion of acetaminophen glucuronide,Intermediate,,50597,,7449,,10116.0,Rattus norvegicus,,CHEMBL626911,,,,,F,1,1,
,BAO_0000218,10389,N,Percent total excretion of acetaminophen sulfate,Intermediate,,50597,,7449,,10116.0,Rattus norvegicus,,CHEMBL626912,,,,,F,1,1,
,BAO_0000218,10390,N,Percent total excretion of acetaminophen-mercapturic acid,Intermediate,,50597,,7449,,10116.0,Rattus norvegicus,,CHEMBL627065,,,,,F,1,1,
Urine,BAO_0000218,10391,N,Amount of urine output was measured in rat at a dose of 10 mg/kg administered orally,Intermediate,,50597,,3172,1088.0,10116.0,Rattus norvegicus,,CHEMBL627066,,,,,A,1,1,
,BAO_0000218,10392,N,Volume of distribution in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,Intermediate,,50597,,16456,,10116.0,Rattus norvegicus,,CHEMBL627067,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,10393,U,Biodistribution of compound in rat muscle after 5 min of administration,Autocuration,,22224,,10839,2385.0,8656.0,ratrat,,CHEMBL627068,,,In vivo,,A,1,0,
Muscle tissue,BAO_0000218,10394,U,Biodistribution of compound in rat muscle after 5 min of administration.,Autocuration,,22224,,10839,2385.0,8656.0,ratrat,,CHEMBL627069,,,In vivo,,A,1,0,
,BAO_0000218,10395,U,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),Autocuration,,22224,,5334,,9940.0,Ovis aries,,CHEMBL627070,,,In vivo,,A,1,0,
,BAO_0000218,10396,U,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),Autocuration,,22224,,5334,,9940.0,Ovis aries,,CHEMBL627071,,,In vivo,,A,1,0,
,BAO_0000218,10397,U,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),Autocuration,,22224,,5334,,9940.0,Ovis aries,,CHEMBL627072,,,In vivo,,A,1,0,
,BAO_0000218,10398,U,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),Autocuration,,22224,,5334,,9940.0,Ovis aries,,CHEMBL627073,,,In vivo,,A,1,0,
,BAO_0000218,10399,U,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),Autocuration,,22224,,5334,,9940.0,Ovis aries,,CHEMBL625387,,,In vivo,,A,1,0,
,BAO_0000218,10400,U,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),Autocuration,,22224,,5334,,9940.0,Ovis aries,,CHEMBL625388,,,In vivo,,A,1,0,
Plasma,BAO_0000218,10401,U,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),Autocuration,,22224,,5334,1969.0,9940.0,Ovis aries,,CHEMBL625389,,,In vivo,,A,1,0,
Plasma,BAO_0000218,10402,U,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),Autocuration,,22224,,5334,1969.0,9940.0,Ovis aries,,CHEMBL875343,,,In vivo,,A,1,0,
,BAO_0000218,10403,N,Biological half life period of compound was measured against snake venom phosphodiesterase (SVPDE),Intermediate,,50497,,1735,,8570.0,Serpentes,,CHEMBL876795,,,,,A,1,1,
,BAO_0000218,10404,N,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards snake venom (SV-PDE) at a concentration of 4 microg,Intermediate,,50497,,1469,,8570.0,Serpentes,,CHEMBL626552,,,,,A,1,1,
,BAO_0000218,10405,N,Enzymatic stability was assessed with snake venom phosphodiesterase (SV PDE) exonuclase,Intermediate,,50497,,1336,,8570.0,Serpentes,,CHEMBL626553,,,,,A,1,1,
Plasma,BAO_0000366,10406,U,The human biological plasma half life of the compound,Autocuration,,22224,,12403,1969.0,9606.0,Homo sapiens,,CHEMBL626554,,,,,A,1,0,
Urine,BAO_0000218,10407,N,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,Intermediate,,50597,,8151,1088.0,10116.0,Rattus norvegicus,,CHEMBL626555,,,,,A,1,1,
,BAO_0000218,10408,N,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 120 min after iv administration compound,Intermediate,,50597,,8004,,10116.0,Rattus norvegicus,,CHEMBL626556,,,,,A,1,1,
,BAO_0000218,10409,N,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 15 after iv administration of compound,Intermediate,,50597,,8004,,10116.0,Rattus norvegicus,,CHEMBL626557,,,,,A,1,1,
,BAO_0000218,10410,N,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 240 min after iv administration compound,Intermediate,,50597,,8004,,10116.0,Rattus norvegicus,,CHEMBL626558,,,,,A,1,1,
,BAO_0000218,10411,N,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 30 min after iv administration of compound,Intermediate,,50597,,8004,,10116.0,Rattus norvegicus,,CHEMBL626559,,,,,A,1,1,
,BAO_0000218,10412,N,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 5 min after iv administration of compound,Intermediate,,50597,,8004,,10116.0,Rattus norvegicus,,CHEMBL626560,,,,,A,1,1,
,BAO_0000218,10413,N,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 60 min after iv administration of compound,Intermediate,,50597,,8004,,10116.0,Rattus norvegicus,,CHEMBL876803,,,,,A,1,1,
,BAO_0000218,10414,N,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 120 min after iv administration compound,Intermediate,,50597,,8004,,10116.0,Rattus norvegicus,,CHEMBL627964,,,,,A,1,1,
,BAO_0000218,10415,N,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 15 min after iv administration of compound,Intermediate,,50597,,8004,,10116.0,Rattus norvegicus,,CHEMBL627965,,,,,A,1,1,
,BAO_0000218,10416,N,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 240 min after iv administration compound,Intermediate,,50597,,8004,,10116.0,Rattus norvegicus,,CHEMBL627966,,,,,A,1,1,
,BAO_0000218,10417,N,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 30 min after iv administration of compound,Intermediate,,50597,,8004,,10116.0,Rattus norvegicus,,CHEMBL627967,,,,,A,1,1,
,BAO_0000218,10418,N,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 5 min after iv administration of compound,Intermediate,,50597,,8004,,10116.0,Rattus norvegicus,,CHEMBL627968,,,,,A,1,1,
,BAO_0000218,10419,N,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 60 min after iv administration of compound,Intermediate,,50597,,8004,,10116.0,Rattus norvegicus,,CHEMBL627969,,,,,A,1,1,
,BAO_0000218,10420,N,Distribution of Se-75 activity in Liver of female Sprague-Dawley Rat 5 min after iv administration of compound,Intermediate,,50597,,8004,,10116.0,Rattus norvegicus,,CHEMBL627970,,,,,A,1,1,
Blood,BAO_0000218,10421,N,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 120 min after iv administration of compound,Intermediate,,50597,,8004,178.0,10116.0,Rattus norvegicus,,CHEMBL627971,,,,,A,1,1,
Blood,BAO_0000218,10422,N,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 240 min after iv administration of compound,Intermediate,,50597,,8004,178.0,10116.0,Rattus norvegicus,,CHEMBL627972,,,,,A,1,1,
,BAO_0000357,10423,D,Dissociation constant against binding to human cyclophilin A,Expert,,180,,15917,,9606.0,Homo sapiens,,CHEMBL856029,,,,,B,1,9,
,BAO_0000019,10424,H,Michaelis-Menten constant for inhibitory activity against bovine liver glyoxalase II,Expert,,11591,,12396,,9913.0,Bos taurus,,CHEMBL627973,,,,,B,1,8,
,BAO_0000019,10425,U,-Log C was determined by performing the electroshock minimum test,Autocuration,,22224,,7065,,,,,CHEMBL627974,,,,,A,1,0,
,BAO_0000019,10426,U,-Log C was determined by performing the foot shock test,Autocuration,,22224,,7065,,,,,CHEMBL627975,,,,,A,1,0,
,BAO_0000019,10427,U,-Log C was determined by performing the incl screen test,Autocuration,,22224,,7065,,,,,CHEMBL627976,,,,,A,1,0,
,BAO_0000019,10428,U,-Log C was determined by performing the maximum electroshock test,Autocuration,,22224,,7065,,,,,CHEMBL627977,,,,,A,1,0,
,BAO_0000019,10429,U,-Log C was determined by performing the pentylenetetrazole test,Autocuration,,22224,,7065,,,,,CHEMBL627978,,,,,A,1,0,
,BAO_0000019,10430,U,Tested for experimental arotinoid inhibitory dose,Autocuration,,22224,,12415,,,,,CHEMBL627979,,,,,A,1,0,
,BAO_0000019,10431,U,Negative log transformed activity,Autocuration,,22224,,10256,,,,,CHEMBL876804,,,,,A,1,0,
,BAO_0000019,10432,U,"Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)",Autocuration,,22224,,7991,,,,,CHEMBL627980,,,,,A,1,0,
,BAO_0000218,10433,N,Dissociation constant was evaluated on guinea pig bladder at M3 muscarinic receptor,Intermediate,,50512,,14342,,10141.0,Cavia porcellus,,CHEMBL627981,,,,,A,1,1,
,BAO_0000218,10434,N,Dissociation constant was evaluated on guinea pig heart (force) at M2 muscarinic receptor,Intermediate,,50512,,14342,,10141.0,Cavia porcellus,,CHEMBL627982,,,,,A,1,1,
,BAO_0000218,10435,N,Dissociation constant was evaluated on guinea pig heart (rate) at M2 muscarinic receptor,Intermediate,,50512,,14342,,10141.0,Cavia porcellus,,CHEMBL627983,,,,,A,1,1,
Ileum,BAO_0000218,10436,N,Dissociation constant was evaluated on guinea pig ileum at M3 muscarinic receptor,Intermediate,,50512,,14342,2116.0,10141.0,Cavia porcellus,,CHEMBL627984,,,,,A,1,1,
,BAO_0000100,10437,U,Solubility in water was determined; values expressed as -log,Autocuration,,22229,,6047,,,,,CHEMBL627985,,,,,P,1,0,
,BAO_0000019,10438,U,Ratio of Kcat to that of Km was determined,Autocuration,,22224,,17269,,,,,CHEMBL627986,,,,,A,1,0,
,BAO_0000019,10439,U,Observed first order rate constant,Autocuration,,22224,,10026,,,,,CHEMBL627987,,,,,A,1,0,
,BAO_0000019,10440,U,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours,Autocuration,,22224,,14583,,,,,CHEMBL627988,,,,,A,1,0,
,BAO_0000218,10441,N,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female wistar rats,Intermediate,,50597,,2661,,10116.0,Rattus norvegicus,,CHEMBL627989,,,In vivo,,A,1,1,
,BAO_0000218,10442,N,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to male wistar rats,Intermediate,,50597,,2661,,10116.0,Rattus norvegicus,,CHEMBL627990,,,In vivo,,A,1,1,
,BAO_0000218,10443,N,Oral Bioavailability after administration of 10 mg/kg in male rat,Intermediate,,50597,,4029,,10116.0,Rattus norvegicus,,CHEMBL876805,,,In vivo,,A,1,1,
,BAO_0000218,10444,N,Oral bioavailability in rat (dose 10 mg/kg i.v. and 50 mg/kg p.o.),Intermediate,,50597,,17735,,10116.0,Rattus norvegicus,,CHEMBL627991,,,In vivo,,A,1,1,
,BAO_0000218,10445,N,Oral bioavailability in rat,Intermediate,,50597,,4576,,10116.0,Rattus norvegicus,,CHEMBL627992,,,In vivo,,A,1,1,
,BAO_0000218,10446,N,Oral bioavailability after oral (po) administration at a dose of 10 mg/kg was measured in rats,Intermediate,,50597,,17582,,10116.0,Rattus norvegicus,,CHEMBL627993,,,In vivo,,A,1,1,
,BAO_0000218,10447,N,Oral bioavailability at 1 mg/kg was determined in rat,Intermediate,,50597,,17651,,10116.0,Rattus norvegicus,,CHEMBL622817,,,In vivo,,A,1,1,
,BAO_0000218,10448,N,Oral bioavailability at 10 mg/kg was determined in rat,Intermediate,,50597,,17651,,10116.0,Rattus norvegicus,,CHEMBL622818,,,In vivo,,A,1,1,
,BAO_0000218,10449,N,"Oral bioavailability in fischer rats at 30 mg/kg dose, administered perorally",Intermediate,,50597,,17670,,10116.0,Rattus norvegicus,,CHEMBL622819,,,In vivo,,A,1,1,
,BAO_0000218,10450,N,Oral bioavailability in rat,Intermediate,,50597,,5045,,10116.0,Rattus norvegicus,,CHEMBL872267,,,In vivo,,A,1,1,
,BAO_0000218,10451,N,Oral bioavailability in rat,Intermediate,,50597,,1696,,10116.0,Rattus norvegicus,,CHEMBL622820,,,In vivo,,A,1,1,
,BAO_0000218,10452,N,Oral bioavailability after intravenous administration in rats at 24 uM/kg,Intermediate,,50597,,17764,,10116.0,Rattus norvegicus,,CHEMBL622821,,,In vivo,,A,1,1,
,BAO_0000218,10453,N,Oral bioavailability in rat,Intermediate,,50597,,6448,,10116.0,Rattus norvegicus,,CHEMBL622822,,,In vivo,,A,1,1,
,BAO_0000218,10454,N,Oral bioavailability in rat,Intermediate,,50597,,6596,,10116.0,Rattus norvegicus,,CHEMBL622823,,,In vivo,,A,1,1,
,BAO_0000218,10455,N,Oral bioavailability in rat,Intermediate,,50597,,17547,,10116.0,Rattus norvegicus,,CHEMBL622824,,,In vivo,,A,1,1,
,BAO_0000218,10456,N,Oral bioavailability in rat at a dose of 3 mg/kg,Intermediate,,50597,,17771,,10116.0,Rattus norvegicus,,CHEMBL622825,,,In vivo,,A,1,1,
,BAO_0000218,10457,N,Oral bioavailability in rat after oral administration at 10 mg/kg,Intermediate,,50597,,6495,,10116.0,Rattus norvegicus,,CHEMBL622901,,,In vivo,,A,1,1,
,BAO_0000218,10458,N,Oral bioavailability in rat,Intermediate,,50597,,4558,,10116.0,Rattus norvegicus,,CHEMBL622902,,,In vivo,,A,1,1,
,BAO_0000218,10459,N,Oral bioavailability in rat,Intermediate,,50597,,17596,,10116.0,Rattus norvegicus,,CHEMBL621844,,,In vivo,,A,1,1,
,BAO_0000218,10460,N,Oral bioavailability in Dawley rats,Intermediate,,50597,,6827,,10116.0,Rattus norvegicus,,CHEMBL621845,,,In vivo,,A,1,1,
,BAO_0000218,10461,N,Oral bioavailability,Intermediate,,50597,,4026,,10116.0,Rattus norvegicus,,CHEMBL621846,,,In vivo,,A,1,1,
,BAO_0000218,10462,N,Oral bioavailability in rat (dose 30 mg/kg),Intermediate,,50597,,10,,10116.0,Rattus norvegicus,,CHEMBL621847,,,In vivo,,A,1,1,
,BAO_0000218,10463,N,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,Intermediate,,50597,,17717,,10116.0,Rattus norvegicus,,CHEMBL877609,,,In vivo,,A,1,1,
,BAO_0000218,10464,N,Bioavailability in rat (dose 3 mg/kg i.v.),Intermediate,,50597,,17717,,10116.0,Rattus norvegicus,,CHEMBL621848,,,In vivo,,A,1,1,
,BAO_0000218,10465,N,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,Intermediate,,50597,,17717,,10116.0,Rattus norvegicus,,CHEMBL621849,,,In vivo,,A,1,1,
,BAO_0000218,10466,N,Oral bioavailability in rat (dose 60 mg/kg p.o.),Intermediate,,50597,,17717,,10116.0,Rattus norvegicus,,CHEMBL622030,,,In vivo,,A,1,1,
,BAO_0000218,10467,N,Percent oral bioavailability determined in rats,Intermediate,,50597,,4796,,10116.0,Rattus norvegicus,,CHEMBL622031,,,In vivo,,A,1,1,
,BAO_0000218,10468,N,Tested for percent bioavailability after oral administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,Intermediate,,50597,,4883,,10116.0,Rattus norvegicus,,CHEMBL622032,,,In vivo,,A,1,1,
,BAO_0000218,10469,N,The compound was evaluated for bioavailability in rats; 32-51,Intermediate,,50597,,2137,,10116.0,Rattus norvegicus,,CHEMBL622033,,,In vivo,,A,1,1,
,BAO_0000218,10470,N,Bioavailability in rat (dose 20 mg/kg p.o.),Intermediate,,50597,,2959,,10116.0,Rattus norvegicus,,CHEMBL622034,,,In vivo,,A,1,1,
,BAO_0000218,10471,N,Oral bioavailability in rat,Intermediate,,50597,,1361,,10116.0,Rattus norvegicus,,CHEMBL622035,,,In vivo,,A,1,1,
,BAO_0000218,10472,N,Bioavailability percent in rat at the dose of 2 mg/kg,Intermediate,,50597,,4727,,10116.0,Rattus norvegicus,,CHEMBL882966,,,In vivo,,A,1,1,
,BAO_0000218,10473,N,Bioavailability was evaluated after 20 uM/kg of peroral administration,Intermediate,,50597,,16423,,10116.0,Rattus norvegicus,,CHEMBL622036,,,In vivo,,A,1,1,
,BAO_0000218,10474,N,Oral bioavailability in rat,Intermediate,,50597,,5206,,10116.0,Rattus norvegicus,,CHEMBL622037,,,In vivo,,A,1,1,
,BAO_0000218,10475,N,Oral bioavailability in rat,Intermediate,,50597,,6448,,10116.0,Rattus norvegicus,,CHEMBL622038,,,In vivo,,A,1,1,
,BAO_0000218,10476,N,Bioavailability in rats,Intermediate,,50597,,17723,,10116.0,Rattus norvegicus,,CHEMBL622039,,,In vivo,,A,1,1,
Blood,BAO_0000218,10477,N,Biodistribution of radiolabeled compound in rat blood after 24 hr postinjection activity expressed as %ID/Organ,Intermediate,,50597,,17738,178.0,10116.0,Rattus norvegicus,,CHEMBL622040,,,In vivo,,A,1,1,
Blood,BAO_0000218,10478,N,Biodistribution of radiolabeled compound in rat blood after 24 hr activity expressed as %ID/Organ,Intermediate,,50597,,17738,178.0,10116.0,Rattus norvegicus,,CHEMBL622041,,,In vivo,,A,1,1,
Blood,BAO_0000218,10479,N,Biodistribution of radiolabeled compound in rat blood after 2 hr activity expressed as %ID/Organ,Intermediate,,50597,,17738,178.0,10116.0,Rattus norvegicus,,CHEMBL622042,,,In vivo,,A,1,1,
Blood,BAO_0000218,10480,N,Biodistribution of radiolabeled compound in rat blood after 30 min activity expressed as %ID/Organ,Intermediate,,50597,,17738,178.0,10116.0,Rattus norvegicus,,CHEMBL622043,,,In vivo,,A,1,1,
Blood,BAO_0000218,10481,N,Biodistribution of radiolabeled compound in rat blood after 5 min activity expressed as %ID/Organ,Intermediate,,50597,,17738,178.0,10116.0,Rattus norvegicus,,CHEMBL622044,,,In vivo,,A,1,1,
Bone,BAO_0000218,10482,N,Biodistribution of radiolabeled compound in rat bone after 24 hr activity expressed as %ID/Organ,Intermediate,,50597,,17738,10000001.0,10116.0,Rattus norvegicus,,CHEMBL622045,,,In vivo,,A,1,1,
Bone,BAO_0000218,10483,N,Biodistribution of radiolabeled compound in rat bone after 2 hr activity expressed as %ID/Organ,Intermediate,,50597,,17738,10000001.0,10116.0,Rattus norvegicus,,CHEMBL622046,,,In vivo,,A,1,1,
Bone,BAO_0000218,10484,N,Biodistribution of radiolabeled compound in rat bone after 30 min activity expressed as %ID/Organ,Intermediate,,50597,,17738,10000001.0,10116.0,Rattus norvegicus,,CHEMBL622047,,,In vivo,,A,1,1,
Bone,BAO_0000218,10485,N,Biodistribution of radiolabeled compound in rat bone after 5 min activity expressed as %ID/Organ,Intermediate,,50597,,17738,10000001.0,10116.0,Rattus norvegicus,,CHEMBL877610,,,In vivo,,A,1,1,
Brain,BAO_0000218,10486,N,Biodistribution of radiolabeled compound in rat brain after 24 hr activity expressed as %ID/Organ,Intermediate,,50597,,17738,955.0,10116.0,Rattus norvegicus,,CHEMBL622048,,,In vivo,,A,1,1,
Brain,BAO_0000218,10487,N,Biodistribution of radiolabeled compound in rat brain after 2 hr activity expressed as %ID/Organ,Intermediate,,50597,,17738,955.0,10116.0,Rattus norvegicus,,CHEMBL622049,,,In vivo,,A,1,1,
Brain,BAO_0000218,10488,N,Biodistribution of radiolabeled compound in rat brain after 30 min activity expressed as %ID/Organ,Intermediate,,50597,,17738,955.0,10116.0,Rattus norvegicus,,CHEMBL622050,,,In vivo,,A,1,1,
Brain,BAO_0000218,10489,N,Biodistribution of radiolabeled compound in rat brain after 5 min activity expressed as %ID/Organ,Intermediate,,50597,,17738,955.0,10116.0,Rattus norvegicus,,CHEMBL622051,,,In vivo,,A,1,1,
,BAO_0000218,10490,N,Biodistribution of radiolabeled compound in rat fat after 24 hr activity expressed as %ID/Organ,Intermediate,,50597,,17738,,10116.0,Rattus norvegicus,,CHEMBL622052,,,In vivo,,A,1,1,
,BAO_0000218,10491,N,Biodistribution of radiolabeled compound in rat fat after 2 hr activity expressed as %ID/Organ,Intermediate,,50597,,17738,,10116.0,Rattus norvegicus,,CHEMBL622053,,,In vivo,,A,1,1,
,BAO_0000218,10492,N,Biodistribution of radiolabeled compound in rat fat after 30 min activity expressed as %ID/Organ,Intermediate,,50597,,17738,,10116.0,Rattus norvegicus,,CHEMBL622054,,,In vivo,,A,1,1,
,BAO_0000218,10493,N,Biodistribution of radiolabeled compound in rat fat after 5 min activity expressed as %ID/Organ,Intermediate,,50597,,17738,,10116.0,Rattus norvegicus,,CHEMBL622055,,,In vivo,,A,1,1,
,BAO_0000218,10494,N,Oral bioavailability in rats was determined; High,Intermediate,,50597,,5237,,10116.0,Rattus norvegicus,,CHEMBL622056,,,In vivo,,A,1,1,
,BAO_0000218,10495,N,Oral bioavailability in the rat was determined,Intermediate,,50597,,5503,,10116.0,Rattus norvegicus,,CHEMBL622057,,,In vivo,,A,1,1,
,BAO_0000218,10496,N,Oral bioavailability measured by the ratio of intravenous to oral area under concentration.,Intermediate,,50597,,15765,,10116.0,Rattus norvegicus,,CHEMBL628008,,,In vivo,,A,1,1,
,BAO_0000218,10497,N,Oral bioavailability in rat (dose 10 mg/kg p.o. and 3 mg/kg i.v.),Intermediate,,50597,,15660,,10116.0,Rattus norvegicus,,CHEMBL622058,,,In vivo,,A,1,1,
,BAO_0000218,10498,N,Oral bioavailability of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,,50597,,5978,,10116.0,Rattus norvegicus,,CHEMBL622059,,,In vivo,,A,1,1,
,BAO_0000218,10499,N,Oral bioavailability of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,,50597,,5978,,10116.0,Rattus norvegicus,,CHEMBL622060,,,In vivo,,A,1,1,
,BAO_0000218,10500,N,Oral bioavailability of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,,50597,,5978,,10116.0,Rattus norvegicus,,CHEMBL622061,,,In vivo,,A,1,1,
,BAO_0000218,10501,N,Oral bioavailability of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,Intermediate,,50597,,5978,,10116.0,Rattus norvegicus,,CHEMBL622062,,,In vivo,,A,1,1,
,BAO_0000218,10502,N,Oral bioavailability of compound at a dose of 20 mg/kg was determined after oral administration in rat,Intermediate,,50597,,5656,,10116.0,Rattus norvegicus,,CHEMBL622063,,,In vivo,,A,1,1,
,BAO_0000218,10503,N,Oral bioavailability of compound determined in rat after iv administration at a dose of 10 mg/kg,Expert,,50597,,3598,,10116.0,Rattus norvegicus,,CHEMBL877611,,,In vivo,,A,1,1,
,BAO_0000218,10504,N,Oral bioavailability of compound in Sprague Dawley rats,Intermediate,,50597,,4216,,10116.0,Rattus norvegicus,,CHEMBL622064,,,In vivo,,A,1,1,
,BAO_0000218,10505,N,Oral bioavailability of compound in rat,Intermediate,,50597,,17839,,10116.0,Rattus norvegicus,,CHEMBL622065,,,In vivo,,A,1,1,
,BAO_0000218,10506,N,Oral bioavailability in rat (dose 2 mg/kg),Intermediate,,50597,,6570,,10116.0,Rattus norvegicus,,CHEMBL622066,,,In vivo,,A,1,1,
,BAO_0000218,10507,N,Oral bioavailability of compound in rat was determined,Intermediate,,50597,,5334,,10116.0,Rattus norvegicus,,CHEMBL622067,,,In vivo,,A,1,1,
,BAO_0000218,10508,N,Oral bioavailability of compound in rats,Intermediate,,50597,,6886,,10116.0,Rattus norvegicus,,CHEMBL622068,,,In vivo,,A,1,1,
,BAO_0000218,10509,N,Oral bioavailability of compound was determined in rats,Intermediate,,50597,,5210,,10116.0,Rattus norvegicus,,CHEMBL622069,,,In vivo,,A,1,1,
,BAO_0000218,10510,N,Oral bioavailability at a dose of 30 mg/kg in rats,Intermediate,,50597,,4170,,10116.0,Rattus norvegicus,,CHEMBL624796,,,In vivo,,A,1,1,
,BAO_0000218,10511,N,Oral bioavailability in rat (dose 10 mg/kg),Intermediate,,50597,,6028,,10116.0,Rattus norvegicus,,CHEMBL624797,,,In vivo,,A,1,1,
,BAO_0000218,10512,N,Oral bioavailability in rat (dose 10 mg/kg),Intermediate,,50597,,6028,,10116.0,Rattus norvegicus,,CHEMBL623053,,,In vivo,,A,1,1,
,BAO_0000218,10513,N,Oral bioavailability evaluated in rat,Intermediate,,50597,,6078,,10116.0,Rattus norvegicus,,CHEMBL623054,,,In vivo,,A,1,1,
,BAO_0000218,10514,N,Oral bioavailability in fasted rat,Intermediate,,50597,,6168,,10116.0,Rattus norvegicus,,CHEMBL623055,,,In vivo,,A,1,1,
,BAO_0000218,10515,N,Oral bioavailability in fed rat,Intermediate,,50597,,6168,,10116.0,Rattus norvegicus,,CHEMBL623056,,,In vivo,,A,1,1,
,BAO_0000218,10516,N,Oral bioavailability in rat (mature male) (dose 30 mg/kg),Intermediate,,50597,,5160,,10116.0,Rattus norvegicus,,CHEMBL623057,,,In vivo,,A,1,1,
,BAO_0000218,10517,N,Oral bioavailability in rat,Intermediate,,50597,,6057,,10116.0,Rattus norvegicus,,CHEMBL623058,,,In vivo,,A,1,1,
,BAO_0000218,10518,N,Oral bioavailability in rat (dose 10 mg/kg p.o.),Intermediate,,50597,,6535,,10116.0,Rattus norvegicus,,CHEMBL623059,,,In vivo,,A,1,1,
,BAO_0000218,10519,N,Oral bioavailability in rat after administration of 10 mg/kg po,Intermediate,,50597,,6535,,10116.0,Rattus norvegicus,,CHEMBL623060,,,In vivo,,A,1,1,
,BAO_0000218,10520,N,Oral bioavailability in rat,Intermediate,,50597,,4194,,10116.0,Rattus norvegicus,,CHEMBL623061,,,In vivo,,A,1,1,
,BAO_0000218,10521,N,Oral bioavailability in rat,Intermediate,,50597,,6230,,10116.0,Rattus norvegicus,,CHEMBL623062,,,In vivo,,A,1,1,
,BAO_0000218,10522,N,Oral bioavailability in rat,Intermediate,,50597,,6619,,10116.0,Rattus norvegicus,,CHEMBL623063,,,In vivo,,A,1,1,
,BAO_0000218,10523,N,Oral bioavailability in rat,Intermediate,,50597,,17607,,10116.0,Rattus norvegicus,,CHEMBL623064,,,In vivo,,A,1,1,
,BAO_0000218,10524,N,Oral bioavailability in ratrs,Intermediate,,50597,,4942,,10116.0,Rattus norvegicus,,CHEMBL623065,,,In vivo,,A,1,1,
,BAO_0000218,10525,N,Oral bioavailability in rat,Intermediate,,50597,,4942,,10116.0,Rattus norvegicus,,CHEMBL623066,,,In vivo,,A,1,1,
,BAO_0000218,10526,N,Oral bioavailability in rat,Intermediate,,50597,,6646,,10116.0,Rattus norvegicus,,CHEMBL623067,,,In vivo,,A,1,1,
,BAO_0000218,10527,N,Oral bioavailability in rats was determined; High,Intermediate,,50597,,5237,,10116.0,Rattus norvegicus,,CHEMBL623068,,,In vivo,,A,1,1,
,BAO_0000218,10528,N,Oral bioavailability in rat,Intermediate,,50597,,6646,,10116.0,Rattus norvegicus,,CHEMBL623069,,,In vivo,,A,1,1,
,BAO_0000218,10529,N,Oral bioavailability in rat,Intermediate,,50597,,4449,,10116.0,Rattus norvegicus,,CHEMBL623070,,,In vivo,,A,1,1,
,BAO_0000218,10530,N,Oral bioavailability was calculated in rat,Intermediate,,50597,,6057,,10116.0,Rattus norvegicus,,CHEMBL623071,,,In vivo,,A,1,1,
,BAO_0000218,10531,N,Oral bioavailability,Intermediate,,50597,,2552,,10116.0,Rattus norvegicus,,CHEMBL623072,,,In vivo,,A,1,1,
,BAO_0000218,10532,N,Oral bioavailability,Intermediate,,50597,,5496,,10116.0,Rattus norvegicus,,CHEMBL623073,,,In vivo,,A,1,1,
,BAO_0000218,10533,N,Oral bioavailability,Intermediate,,50597,,6484,,10116.0,Rattus norvegicus,,CHEMBL623074,,,In vivo,,A,1,1,
,BAO_0000218,10534,N,Oral bioavailability,Intermediate,,50597,,6485,,10116.0,Rattus norvegicus,,CHEMBL623075,,,In vivo,,A,1,1,
,BAO_0000218,10535,N,Oral bioavailability after i.v. administration,Intermediate,,50597,,6616,,10116.0,Rattus norvegicus,,CHEMBL623076,,,In vivo,,A,1,1,
,BAO_0000218,10536,N,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),Intermediate,,50597,,4969,,10116.0,Rattus norvegicus,,CHEMBL623077,,,In vivo,,A,1,1,
,BAO_0000218,10537,N,Oral bioavailability in rat (Sprague-Dawley),Intermediate,,50597,,5862,,10116.0,Rattus norvegicus,,CHEMBL623078,,,In vivo,,A,1,1,
,BAO_0000218,10538,N,Oral bioavailability in Sprague-Dawley rats,Intermediate,,50597,,4514,,10116.0,Rattus norvegicus,,CHEMBL623079,,,In vivo,,A,1,1,
,BAO_0000218,10539,N,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),Intermediate,,50597,,4514,,10116.0,Rattus norvegicus,,CHEMBL623080,,,In vivo,,A,1,1,
,BAO_0000218,10540,N,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),Intermediate,,50597,,4514,,10116.0,Rattus norvegicus,,CHEMBL623081,,,In vivo,,A,1,1,
,BAO_0000218,10541,N,Oral bioavailability in Sprague-Dawley rats at a dose of 2 mg/kg by po administration,Intermediate,,50597,,5546,,10116.0,Rattus norvegicus,,CHEMBL623082,,,In vivo,,A,1,1,
,BAO_0000218,10542,N,Oral bioavailability in fasted rat,Intermediate,,50597,,6168,,10116.0,Rattus norvegicus,,CHEMBL874400,,,In vivo,,A,1,1,
,BAO_0000218,10543,N,Oral bioavailability in fed rat,Intermediate,,50597,,6168,,10116.0,Rattus norvegicus,,CHEMBL623083,,,In vivo,,A,1,1,
,BAO_0000218,10544,N,Oral bioavailability in rat,Intermediate,,50597,,3624,,10116.0,Rattus norvegicus,,CHEMBL623084,,,In vivo,,A,1,1,
,BAO_0000218,10545,N,Oral bioavailability in rat,Intermediate,,50597,,5213,,10116.0,Rattus norvegicus,,CHEMBL623085,,,In vivo,,A,1,1,
,BAO_0000218,10546,N,Oral bioavailability in rat,Intermediate,,50597,,5496,,10116.0,Rattus norvegicus,,CHEMBL623086,,,In vivo,,A,1,1,
,BAO_0000218,10547,N,Oral bioavailability in rat,Intermediate,,50597,,5553,,10116.0,Rattus norvegicus,,CHEMBL623087,,,In vivo,,A,1,1,
,BAO_0000218,10548,N,Oral bioavailability in rat,Intermediate,,50597,,5833,,10116.0,Rattus norvegicus,,CHEMBL623088,,,In vivo,,A,1,1,
,BAO_0000218,10549,N,Oral bioavailability in rat,Intermediate,,50597,,5836,,10116.0,Rattus norvegicus,,CHEMBL623089,,,In vivo,,A,1,1,
,BAO_0000218,10550,N,Oral bioavailability in rat,Intermediate,,50597,,5865,,10116.0,Rattus norvegicus,,CHEMBL623090,,,In vivo,,A,1,1,
,BAO_0000218,10551,N,Oral bioavailability in rat,Intermediate,,50597,,5960,,10116.0,Rattus norvegicus,,CHEMBL623091,,,In vivo,,A,1,1,
,BAO_0000218,10552,N,Oral bioavailability in rat,Intermediate,,50597,,6249,,10116.0,Rattus norvegicus,,CHEMBL623092,,,In vivo,,A,1,1,
,BAO_0000218,10553,N,Oral bioavailability in rat,Intermediate,,50597,,6448,,10116.0,Rattus norvegicus,,CHEMBL623093,,,In vivo,,A,1,1,
,BAO_0000218,10554,N,Oral bioavailability in rat,Intermediate,,50597,,6453,,10116.0,Rattus norvegicus,,CHEMBL874401,,,In vivo,,A,1,1,
,BAO_0000218,10555,N,Oral bioavailability in rat,Intermediate,,50597,,6640,,10116.0,Rattus norvegicus,,CHEMBL623094,,,In vivo,,A,1,1,
,BAO_0000218,10556,N,Oral bioavailability in rat,Intermediate,,50597,,17607,,10116.0,Rattus norvegicus,,CHEMBL623095,,,In vivo,,A,1,1,
,BAO_0000218,10557,N,Oral bioavailability in rat after peroral administration at 10 mg/kg,Intermediate,,50597,,5939,,10116.0,Rattus norvegicus,,CHEMBL623096,,,In vivo,,A,1,1,
,BAO_0000218,10558,N,Oral bioavailability in rat after peroral administration at 5 mg/kg,Intermediate,,50597,,5939,,10116.0,Rattus norvegicus,,CHEMBL624913,,,In vivo,,A,1,1,
,BAO_0000218,10559,N,Oral bioavailability in rat (dose 2.8 mg/kg p.o.),Intermediate,,50597,,6281,,10116.0,Rattus norvegicus,,CHEMBL624914,,,In vivo,,A,1,1,
,BAO_0000218,10560,N,Oral bioavailability in rat by po administration at a dose of 40 mg/kg,Intermediate,,50597,,5874,,10116.0,Rattus norvegicus,,CHEMBL624915,,,In vivo,,A,1,1,
,BAO_0000218,10561,N,Oral bioavailability in rat; Not measured,Intermediate,,50597,,5213,,10116.0,Rattus norvegicus,,CHEMBL624916,,,In vivo,,A,1,1,
,BAO_0000218,10562,N,Oral bioavailability in rat,Intermediate,,50597,,4964,,10116.0,Rattus norvegicus,,CHEMBL624917,,,In vivo,,A,1,1,
,BAO_0000218,10563,N,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus NE,Intermediate,,50597,,11020,,10116.0,Rattus norvegicus,,CHEMBL625157,,,,,A,1,1,
Liver,BAO_0000218,10564,N,In vitro metabolic potential in rat liver microsomes,Intermediate,,50597,,6251,2107.0,10116.0,Rattus norvegicus,,CHEMBL625158,,,,,A,1,1,
,BAO_0000218,10565,N,"Oral availability was tested for plasma levels at a dose of 40 mg/kg, after 6 hr of in fed fisher rats.",Intermediate,,50597,,1568,,10116.0,Rattus norvegicus,,CHEMBL625159,,,In vivo,,A,1,1,
,BAO_0000218,10566,N,"In vivo percentage mean absolute bioavailability of compound in rat after an oral dose of 10 mg/kg (in water, N=4)",Intermediate,,50597,,3032,,10116.0,Rattus norvegicus,,CHEMBL625160,,,In vivo,,A,1,1,
,BAO_0000218,10567,N,Oral bioavailability of intravenously administered compound (3 mg/kg) was tested in rats,Intermediate,,50597,,3748,,10116.0,Rattus norvegicus,,CHEMBL625161,,,In vivo,,A,1,1,
,BAO_0000218,10568,N,Oral bioavailability in rat,Intermediate,,50597,,401,,10116.0,Rattus norvegicus,,CHEMBL625162,,,In vivo,,A,1,1,
,BAO_0000218,10569,N,Oral bioavailability in rat,Intermediate,,50597,,6512,,10116.0,Rattus norvegicus,,CHEMBL625163,,,In vivo,,A,1,1,
,BAO_0000218,10570,N,Oral bioavailability in rats at 10 mg/kg,Intermediate,,50597,,17617,,10116.0,Rattus norvegicus,,CHEMBL625164,,,In vivo,,A,1,1,
,BAO_0000218,10571,N,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,Intermediate,,50597,,6679,,10116.0,Rattus norvegicus,,CHEMBL625165,,,In vivo,,A,1,1,
,BAO_0000218,10572,N,Oral bioavailability in rat,Intermediate,,50597,,6742,,10116.0,Rattus norvegicus,,CHEMBL625166,,,In vivo,,A,1,1,
,BAO_0000218,10573,N,Tested for effective permeability across the rat intestinal membrane using mass balance analysis,Intermediate,,50597,,589,,10116.0,Rattus norvegicus,,CHEMBL625167,,,,,A,1,1,
,BAO_0000218,10574,N,Tested for effective permeability across the rat intestinal membrane using mass balance analysis at 0.01 mM concentration,Intermediate,,50597,,589,,10116.0,Rattus norvegicus,,CHEMBL625168,,,,,A,1,1,
,BAO_0000218,10575,N,Plasma clearance of the compound,Intermediate,,50597,,3185,,10116.0,Rattus norvegicus,,CHEMBL625169,,,In vivo,,A,1,1,
,BAO_0000218,10576,N,Plasma clearance at 10 mg/kg in rat upon intravenous administration,Intermediate,,50597,,17596,,10116.0,Rattus norvegicus,,CHEMBL626264,,,In vivo,,A,1,1,
,BAO_0000218,10577,N,Plasma clearance upon intravenous administration of 1 mg/Kg in rats,Intermediate,,50597,,2713,,10116.0,Rattus norvegicus,,CHEMBL626265,,,In vivo,,A,1,1,
Plasma,BAO_0000218,10578,N,The compound was tested for plasma clearance in rat,Intermediate,,50597,,12500,1969.0,10116.0,Rattus norvegicus,,CHEMBL626266,,,In vivo,,A,1,1,
Plasma,BAO_0000218,10579,N,The compound was tested for plasma clearance in rat at dose of 3-10 mgkg,Intermediate,,50597,,12500,1969.0,10116.0,Rattus norvegicus,,CHEMBL626267,,,In vivo,,A,1,1,
,BAO_0000218,10580,N,Plasma concentration upon oral administration of 1 mg/Kg in rats,Intermediate,,50597,,2713,,10116.0,Rattus norvegicus,,CHEMBL626268,,,,,A,1,1,
,BAO_0000218,10581,N,Peak plasma level between 0.5 and 1.0 hour in Dawley rats; value ranges from 1021-2551,Intermediate,,50597,,1446,,10116.0,Rattus norvegicus,,CHEMBL626269,,,,,A,1,1,
,BAO_0000218,10582,N,Plasma level after intravenous administration in rat model of FeCl3-induced carotid thrombosis,Intermediate,,50597,,6227,,10116.0,Rattus norvegicus,,CHEMBL626270,,,,,A,1,1,
,BAO_0000218,10583,N,Plasma protein binding was determined after intravenous administration of 1 mg/kg in rat,Intermediate,,50597,,4709,,10116.0,Rattus norvegicus,,CHEMBL626271,,,,,A,1,1,
,BAO_0000218,10584,N,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1",Intermediate,,50597,,5510,,10116.0,Rattus norvegicus,,CHEMBL626272,,,,,A,1,1,
,BAO_0000218,10585,N,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",Intermediate,,50597,,5510,,10116.0,Rattus norvegicus,,CHEMBL626273,,,,,A,1,1,
,BAO_0000218,10586,N,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",Intermediate,,50597,,5510,,10116.0,Rattus norvegicus,,CHEMBL875346,,,,,A,1,1,
,BAO_0000218,10587,N,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not stable",Intermediate,,50597,,5510,,10116.0,Rattus norvegicus,,CHEMBL626274,,,,,A,1,1,
,BAO_0000218,10588,N,Compound was tested for protein binding in rat plasma,Intermediate,,50597,,4514,,10116.0,Rattus norvegicus,,CHEMBL626275,,,,,A,1,1,
,BAO_0000218,10589,N,Compound was evaluated for absorption of radioligand following oral administration to bile duct cannulated rat. ,Intermediate,,50597,,2713,,10116.0,Rattus norvegicus,,CHEMBL624646,,,,,A,1,1,
,BAO_0000218,10590,N,Compound was evaluated for absorption of radioligand upon oral administration to bile duct cannulated rats,Intermediate,,50597,,2713,,10116.0,Rattus norvegicus,,CHEMBL624647,,,,,A,1,1,
Liver,BAO_0000218,10591,N,In vitro metabolism in rat liver microsomes was evaluated to determine diminishing of glucuronidation rate,Intermediate,,50597,,5340,2107.0,10116.0,Rattus norvegicus,,CHEMBL624648,,,,,A,1,1,
,BAO_0000218,10592,N,Area under curve ratio was determined (po/iv) in rat,Intermediate,,50597,,12058,,10116.0,Rattus norvegicus,,CHEMBL624649,,,,,A,1,1,
,BAO_0000218,10593,N,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 15 mins after i.v. administration,Intermediate,,50597,,11195,,10116.0,Rattus norvegicus,,CHEMBL624650,,,,,A,1,1,
,BAO_0000218,10594,N,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 2 mins after i.v. administration,Intermediate,,50597,,11195,,10116.0,Rattus norvegicus,,CHEMBL624651,,,,,A,1,1,
,BAO_0000218,10595,N,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 65 mins after i.v. administration,Intermediate,,50597,,11195,,10116.0,Rattus norvegicus,,CHEMBL624652,,,,,A,1,1,
,BAO_0000218,10596,N,Compound was tested for brain/plasma ratio after oral administration at 10 mg/kg,Intermediate,,50597,,6495,,10116.0,Rattus norvegicus,,CHEMBL624653,,,,,A,1,1,
,BAO_0000218,10597,N,Ratio of AUCbrain to AUCplasma,Intermediate,,50597,,6078,,10116.0,Rattus norvegicus,,CHEMBL624654,,,,,A,1,1,
,BAO_0000218,10598,N,Ratio of brain to plasma,Intermediate,,50597,,5656,,10116.0,Rattus norvegicus,,CHEMBL624655,,,,,A,1,1,
,BAO_0000218,10599,N,Ratio of the AUC values of brain and plasma after intravenous administration (4.7 mg/kg) to male rats was evaluated,Intermediate,,50597,,4910,,10116.0,Rattus norvegicus,,CHEMBL624656,,,,,A,1,1,
,BAO_0000218,10600,N,Ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,Intermediate,,50597,,4910,,10116.0,Rattus norvegicus,,CHEMBL624657,,,,,A,1,1,
,BAO_0000218,10601,N,Ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,Intermediate,,50597,,4910,,10116.0,Rattus norvegicus,,CHEMBL624658,,,,,A,1,1,
,BAO_0000218,10602,N,Selectivity ratio for biodistribution in brain and blood of rats after 15 minutes; Expressed as percent dose/gram ratio,Intermediate,,50597,,10130,,10116.0,Rattus norvegicus,,CHEMBL624659,,,,,A,1,1,
,BAO_0000218,10603,N,Selectivity ratio for biodistribution in brain and blood of rats after 2 minutes; Expressed as percent dose/gram ratio,Intermediate,,50597,,10130,,10116.0,Rattus norvegicus,,CHEMBL624660,,,,,A,1,1,
,BAO_0000218,10604,N,Selectivity ratio for biodistribution in brain and blood of rats after 60 minutes; Expressed as percent dose/gram ratio,Intermediate,,50597,,10130,,10116.0,Rattus norvegicus,,CHEMBL624661,,,,,A,1,1,
,BAO_0000218,10605,N,Steady state brain :blood ratio was determined,Intermediate,,50597,,5213,,10116.0,Rattus norvegicus,,CHEMBL624662,,,,,A,1,1,
,BAO_0000218,10606,N,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,Intermediate,,50597,,4910,,10116.0,Rattus norvegicus,,CHEMBL625199,,,,,A,1,1,
,BAO_0000218,10607,N,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,Intermediate,,50597,,4910,,10116.0,Rattus norvegicus,,CHEMBL625200,,,,,A,1,1,
,BAO_0000218,10608,N,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats,Intermediate,,50597,,4910,,10116.0,Rattus norvegicus,,CHEMBL625201,,,,,A,1,1,
,BAO_0000218,10609,N,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,Intermediate,,50597,,4910,,10116.0,Rattus norvegicus,,CHEMBL625202,,,,,A,1,1,
,BAO_0000218,10610,N,Percentage recovery after 3h incubation with rat hapatocytes was determined,Intermediate,,50597,,2083,,10116.0,Rattus norvegicus,,CHEMBL625203,,,,,A,1,1,
,BAO_0000218,10611,N,Percentage recovery in rat hepatic microsomal fractions under oxidative conditions after 1 hour,Intermediate,,50597,,2082,,10116.0,Rattus norvegicus,,CHEMBL625204,,,,,A,1,1,
,BAO_0000218,10612,N,Percentage recovery in rhesus monkey hepatic microsomal fractions under oxidative conditions after 1 hour,Intermediate,,50597,,2082,,10116.0,Rattus norvegicus,,CHEMBL625205,,,,,A,1,1,
,BAO_0000218,10613,N,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats,Intermediate,,50597,,6351,,10116.0,Rattus norvegicus,,CHEMBL625206,,,,,A,1,1,
,BAO_0000019,10614,U,"Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured, No site available for protein conjugation.",Autocuration,,22224,,14583,,,,,CHEMBL625207,,,,,A,1,0,
,BAO_0000019,10615,U,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured.,Autocuration,,22224,,14583,,,,,CHEMBL625208,,,,,A,1,0,
,BAO_0000218,10616,N,In vivo absorption in Caco-2 cell line monolayers was determined,Intermediate,495.0,50587,,4608,,9606.0,Homo sapiens,,CHEMBL625209,Caco-2,,,,A,1,1,
,BAO_0000100,10617,U,Calculated partition coefficient (clogP),Autocuration,,22229,,13668,,,,,CHEMBL625210,,,,,P,1,0,
,BAO_0000218,10618,N,Area under curve was determine after peroral administration at 10 mpk in Rat,Intermediate,,50597,,5669,,10116.0,Rattus norvegicus,,CHEMBL625211,,,,,A,1,1,
,BAO_0000218,10619,N,Area under curve was determine after peroral administration at 10 mpk in Rhesus,Intermediate,,50797,,5669,,9544.0,Macaca mulatta,,CHEMBL625212,,,,,A,1,1,
,BAO_0000218,10620,N,Area under curve was determine after peroral administration at 160 mpk in Rat,Intermediate,,50597,,5669,,10116.0,Rattus norvegicus,,CHEMBL625213,,,,,A,1,1,
,BAO_0000218,10621,N,Area under curve was determine after peroral administration at 20 mpk in Rat,Intermediate,,50597,,5669,,10116.0,Rattus norvegicus,,CHEMBL625214,,,,,A,1,1,
,BAO_0000218,10622,N,Area under curve was determine after peroral administration at 50 mpk in Rat,Intermediate,,50597,,5669,,10116.0,Rattus norvegicus,,CHEMBL874542,,,,,A,1,1,
,BAO_0000100,10623,U,Calculated partition coefficient (clogP) (AlogP),Autocuration,,22229,,6472,,,,,CHEMBL625215,,,,,P,1,0,
,BAO_0000019,10624,U,Activated partial thromboplastin time measured,Autocuration,,22224,,15106,,,,,CHEMBL625216,,,,,A,1,0,
,BAO_0000100,10625,U,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4),Autocuration,,22224,,15207,,,,,CHEMBL625217,,,,,P,1,0,
,BAO_0000100,10626,U,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4); ND=Not determined (AS mg/mL),Autocuration,,22224,,15207,,,,,CHEMBL625218,,,,,P,1,0,
Plasma,BAO_0000218,10627,N,AUC (Area under curve) was determined after intravenous administration at a dose 1 mg/kg in dog,Intermediate,,50588,,13941,1969.0,9615.0,Canis lupus familiaris,,CHEMBL622864,,,,,A,1,1,
Plasma,BAO_0000218,10628,N,AUC (Area under curve) was determined after intravenous administration at a dose 2 mg/kg in rat.,Intermediate,,50597,,13941,1969.0,10116.0,Rattus norvegicus,,CHEMBL622865,,,,,A,1,1,
Plasma,BAO_0000218,10629,N,AUC (Area under curve) was determined after peroral administration at a dose 10 mg/kg in rat.,Intermediate,,50597,,13941,1969.0,10116.0,Rattus norvegicus,,CHEMBL622866,,,,,A,1,1,
Plasma,BAO_0000218,10630,N,AUC (Area under curve) was determined after peroral administration at a dose 5 mg/kg in dog,Intermediate,,50588,,13941,1969.0,9615.0,Canis lupus familiaris,,CHEMBL622867,,,,,A,1,1,
Plasma,BAO_0000218,10631,N,AUC (ng h/mL) value after oral administration of 10 mg/kg in guinea pig.,Intermediate,,50512,,15240,1969.0,10141.0,Cavia porcellus,,CHEMBL876808,,,,,A,1,1,
Brain,BAO_0000019,10632,U,AUC in brain,Autocuration,,22224,,10655,955.0,,,,CHEMBL627725,,,,,A,1,0,
Serum,BAO_0000019,10633,U,AUC in serum,Autocuration,,22224,,10655,1977.0,,,,CHEMBL627726,,,,,A,1,0,
Plasma,BAO_0000019,10634,U,AUC was determined,Autocuration,,22224,,6504,1969.0,,,,CHEMBL627727,,,,,A,1,0,
Plasma,BAO_0000019,10635,U,AUC of the compound.,Autocuration,,22224,,10615,1969.0,,,,CHEMBL627728,,,,,A,1,0,
Plasma,BAO_0000019,10636,U,AUC value (0-4 hr),Autocuration,,22224,,10353,1969.0,,,,CHEMBL627729,,,,,A,1,0,
Plasma,BAO_0000019,10637,U,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 150 uMol/kg,",Autocuration,,22224,,14907,1969.0,,,,CHEMBL627730,,,,,A,1,0,
Plasma,BAO_0000019,10638,U,AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,Autocuration,,22224,,14907,1969.0,,,,CHEMBL627731,,,,,A,1,0,
Plasma,BAO_0000019,10639,U,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,",Autocuration,,22224,,14907,1969.0,,,,CHEMBL627732,,,,,A,1,0,
Plasma,BAO_0000019,10640,U,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 700 uMol/kg,",Autocuration,,22224,,14907,1969.0,,,,CHEMBL627733,,,,,A,1,0,
Plasma,BAO_0000218,10641,N,AUC(area under curve) was determined after intravenous administration in rats,Intermediate,,50597,,16359,1969.0,10116.0,Rattus norvegicus,,CHEMBL627734,,,,,A,1,1,
Plasma,BAO_0000218,10642,N,AUC(area under curve) was determined after oral administration in rats,Intermediate,,50597,,16359,1969.0,10116.0,Rattus norvegicus,,CHEMBL627735,,,,,A,1,1,
Plasma,BAO_0000218,10643,N,AUC(ng h/mL)values after oral administration of 10 mg/kg in guinea pig.,Intermediate,,50512,,15240,1969.0,10141.0,Cavia porcellus,,CHEMBL627736,,,,,A,1,1,
Plasma,BAO_0000218,10644,N,AUC(ng h/mL)values after oral administration of 10 mg/kg in rat.,Intermediate,,50597,,15240,1969.0,10116.0,Rattus norvegicus,,CHEMBL876809,,,,,A,1,1,
,BAO_0000019,10645,U,Area Under Curve after oral dosing of 100 uM/Kg,Autocuration,,22224,,15469,,,,,CHEMBL627737,,,,,A,1,0,
,BAO_0000019,10646,U,Area Under Curve after oral dosing of 30 uM/Kg,Autocuration,,22224,,15469,,,,,CHEMBL627738,,,,,A,1,0,
,BAO_0000019,10647,U,Area Under Curve was measured by ploting the graph between concentration verses time,Autocuration,,22224,,13520,,,,,CHEMBL627739,,,,,A,1,0,
,BAO_0000218,10648,N,Area under concentration-time curve of compound was determined in dog at 25 mg/kg orally,Intermediate,,50588,,17025,,9615.0,Canis lupus familiaris,,CHEMBL626143,,,,,A,1,1,
,BAO_0000218,10649,U,Area under concentration-time curve of compound was determined in monkey at 25 mg/kg orally,Autocuration,,22224,,17025,,314293.0,Simiiformes,,CHEMBL626144,,,,,A,1,0,
,BAO_0000218,10650,N,Area under concentration-time curve of compound was determined in rabbit at 25 mg/kg orally,Intermediate,,50592,,17025,,9986.0,Oryctolagus cuniculus,,CHEMBL626145,,,,,A,1,1,
,BAO_0000218,10651,N,Area under concentration-time curve of compound was determined in rat at 25 mg/kg orally,Intermediate,,50597,,17025,,10116.0,Rattus norvegicus,,CHEMBL626146,,,,,A,1,1,
Blood,BAO_0000218,10652,N,Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time,Intermediate,,50597,,12032,178.0,10116.0,Rattus norvegicus,,CHEMBL626147,,,,,A,1,1,
,BAO_0000019,10653,U,Area under curve (AUC) was determined,Autocuration,,22224,,10291,,,,,CHEMBL626148,,,,,A,1,0,
,BAO_0000218,10654,U,Area under curve (AUC) following ip administration at 1 mg/kg,Autocuration,,22224,,5767,,,,,CHEMBL626149,,,,,A,1,0,
,BAO_0000019,10655,U,Area under curve (AUC) was determined; ND is Not determined,Autocuration,,22224,,1434,,,,,CHEMBL626150,,,,,A,1,0,
,BAO_0000218,10656,N,Area under curve (AUC) was determined in dogs fed after intravenous administration of 25 mg/kg of the compound,Intermediate,,50588,,14925,,9615.0,Canis lupus familiaris,,CHEMBL626151,,,,,A,1,1,
,BAO_0000218,10657,N,Area under curve (AUC) was determined in dogs fed after oral administration of 25 mg/kg of the compound,Intermediate,,50588,,14925,,9615.0,Canis lupus familiaris,,CHEMBL626152,,,,,A,1,1,
,BAO_0000218,10658,N,Area under curve (AUC) was determined in fasted dogs after oral administration of 25 mg/kg of the compound,Intermediate,,50588,,14925,,9615.0,Canis lupus familiaris,,CHEMBL626153,,,,,A,1,1,
,BAO_0000019,10659,U,Area under curve (AUR) was determined,Autocuration,,22224,,1434,,,,,CHEMBL626154,,,,,A,1,0,
,BAO_0000019,10660,U,Area under curve at 1 uM/dg administered intravenously,Autocuration,,22224,,11883,,,,,CHEMBL626155,,,,,A,1,0,
,BAO_0000019,10661,U,Area under curve at 10 uM/dg administered perorally,Autocuration,,22224,,11883,,,,,CHEMBL626156,,,,,A,1,0,
,BAO_0000019,10662,U,Area under curve at 2 uM/dg administered intravenously,Autocuration,,22224,,11883,,,,,CHEMBL626157,,,,,A,1,0,
,BAO_0000019,10663,U,Area under curve at 20 uM/dg administered perorally,Autocuration,,22224,,11883,,,,,CHEMBL626158,,,,,A,1,0,
,BAO_0000218,10664,N,Area under curve at a peroral dose of 3 mg/kg in dog,Intermediate,,50588,,15233,,9615.0,Canis lupus familiaris,,CHEMBL626159,,,,,A,1,1,
,BAO_0000218,10665,N,Area under curve at a peroral dose of 3 mg/kg in rat,Intermediate,,50597,,15233,,10116.0,Rattus norvegicus,,CHEMBL626160,,,,,A,1,1,
,BAO_0000218,10666,N,Area under curve at an iv dose of 1 mg/kg in dog,Intermediate,,50588,,15233,,9615.0,Canis lupus familiaris,,CHEMBL626161,,,,,A,1,1,
,BAO_0000218,10667,N,Area under curve at an iv dose of 1 mg/kg in rat,Intermediate,,50597,,15233,,10116.0,Rattus norvegicus,,CHEMBL626162,,,,,A,1,1,
,BAO_0000019,10668,U,Area under curve gives the effective duration for the angiotensin II antagonist effect of the compound.,Autocuration,,22224,,12978,,,,,CHEMBL626163,,,,,A,1,0,
,BAO_0000019,10669,U,Area under curve gives the effective duration for the angiotensin II antagonist effect.,Autocuration,,22224,,12978,,,,,CHEMBL626164,,,,,A,1,0,
,BAO_0000218,10670,N,Area under curve measured as conc vs time after intravenous administration to mice.,Intermediate,,50594,,11355,,10090.0,Mus musculus,,CHEMBL626165,,,,,A,1,1,
,BAO_0000218,10671,N,Area under curve measured as conc vs time after peroral administration to mice.,Intermediate,,50594,,11355,,10090.0,Mus musculus,,CHEMBL626166,,,,,A,1,1,
,BAO_0000218,10672,N,Area under curve of acid 2a was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,Intermediate,,50588,,12923,,9615.0,Canis lupus familiaris,,CHEMBL626167,,,,,A,1,1,
,BAO_0000218,10673,N,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by capsule method in dog,Intermediate,,50588,,12923,,9615.0,Canis lupus familiaris,,CHEMBL626168,,,,,A,1,1,
,BAO_0000218,10674,N,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by gavage method in dog,Intermediate,,50588,,12923,,9615.0,Canis lupus familiaris,,CHEMBL877463,,,,,A,1,1,
,BAO_0000218,10675,N,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by capsule method in dog,Intermediate,,50588,,12923,,9615.0,Canis lupus familiaris,,CHEMBL626169,,,,,A,1,1,
Heart,BAO_0000218,10676,N,Biodistribution of radiolabeled compound in rat heart after 24 hr activity expressed as %ID/Organ,Intermediate,,50597,,17738,948.0,10116.0,Rattus norvegicus,,CHEMBL626170,,,In vivo,,A,1,1,
Heart,BAO_0000218,10677,N,Biodistribution of radiolabeled compound in rat heart after 2 hr activity expressed as %ID/Organ,Intermediate,,50597,,17738,948.0,10116.0,Rattus norvegicus,,CHEMBL626171,,,In vivo,,A,1,1,
Heart,BAO_0000218,10678,N,Biodistribution of radiolabeled compound in rat heart after 30 min activity expressed as %ID/Organ,Intermediate,,50597,,17738,948.0,10116.0,Rattus norvegicus,,CHEMBL626172,,,In vivo,,A,1,1,
Heart,BAO_0000218,10679,N,Biodistribution of radiolabeled compound in rat heart after 5 min activity expressed as %ID/Organ,Intermediate,,50597,,17738,948.0,10116.0,Rattus norvegicus,,CHEMBL626173,,,In vivo,,A,1,1,
Kidney,BAO_0000218,10680,N,Biodistribution of radiolabeled compound in rat kidney after 24 hr postinjection activity expressed as %ID/Organ,Intermediate,,50597,,17738,2113.0,10116.0,Rattus norvegicus,,CHEMBL626174,,,In vivo,,A,1,1,
Kidney,BAO_0000218,10681,N,Biodistribution of radiolabeled compound in rat kidney after 24 hr activity expressed as %ID/Organ,Intermediate,,50597,,17738,2113.0,10116.0,Rattus norvegicus,,CHEMBL626175,,,In vivo,,A,1,1,
Kidney,BAO_0000218,10682,N,Biodistribution of radiolabeled compound in rat kidney after 2 hr activity expressed as %ID/Organ,Intermediate,,50597,,17738,2113.0,10116.0,Rattus norvegicus,,CHEMBL626176,,,In vivo,,A,1,1,
Kidney,BAO_0000218,10683,N,Biodistribution of radiolabeled compound in rat kidney after 30 min activity expressed as %ID/Organ,Intermediate,,50597,,17738,2113.0,10116.0,Rattus norvegicus,,CHEMBL626177,,,In vivo,,A,1,1,
Kidney,BAO_0000218,10684,N,Biodistribution of radiolabeled compound in rat kidney after 5 min activity expressed as %ID/Organ,Intermediate,,50597,,17738,2113.0,10116.0,Rattus norvegicus,,CHEMBL622499,,,In vivo,,A,1,1,
Liver,BAO_0000218,10685,N,Biodistribution of radiolabeled compound in rat liver after 24 hr postinjection activity expressed as %ID/Organ,Intermediate,,50597,,17738,2107.0,10116.0,Rattus norvegicus,,CHEMBL622500,,,In vivo,,A,1,1,
Liver,BAO_0000218,10686,N,Biodistribution of radiolabeled compound in rat liver after 24 hr activity expressed as %ID/Organ,Intermediate,,50597,,17738,2107.0,10116.0,Rattus norvegicus,,CHEMBL622501,,,In vivo,,A,1,1,
Liver,BAO_0000218,10687,N,Biodistribution of radiolabeled compound in rat liver after 2 hr activity expressed as %ID/Organ,Intermediate,,50597,,17738,2107.0,10116.0,Rattus norvegicus,,CHEMBL622502,,,In vivo,,A,1,1,
Liver,BAO_0000218,10688,N,Biodistribution of radiolabeled compound in rat liver after 30 min activity expressed as %ID/Organ,Intermediate,,50597,,17738,2107.0,10116.0,Rattus norvegicus,,CHEMBL622503,,,In vivo,,A,1,1,
Liver,BAO_0000218,10689,N,Biodistribution of radiolabeled compound in rat liver after 5 min activity expressed as %ID/Organ,Intermediate,,50597,,17738,2107.0,10116.0,Rattus norvegicus,,CHEMBL877614,,,In vivo,,A,1,1,
Lung,BAO_0000218,10690,N,Biodistribution of radiolabeled compound in rat lung after 24 hr activity expressed as %ID/Organ,Intermediate,,50597,,17738,2048.0,10116.0,Rattus norvegicus,,CHEMBL624839,,,In vivo,,A,1,1,
Lung,BAO_0000218,10691,N,Biodistribution of radiolabeled compound in rat lung after 2 hr activity expressed as %ID/Organ,Intermediate,,50597,,17738,2048.0,10116.0,Rattus norvegicus,,CHEMBL624840,,,In vivo,,A,1,1,
Lung,BAO_0000218,10692,N,Biodistribution of radiolabeled compound in rat lung after 30 min activity expressed as %ID/Organ,Intermediate,,50597,,17738,2048.0,10116.0,Rattus norvegicus,,CHEMBL624841,,,In vivo,,A,1,1,
Lung,BAO_0000218,10693,N,Biodistribution of radiolabeled compound in rat lung after 5 min activity expressed as %ID/Organ,Intermediate,,50597,,17738,2048.0,10116.0,Rattus norvegicus,,CHEMBL624842,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,10694,N,Biodistribution of radiolabeled compound in rat muscle after 24 hr activity expressed as %ID/Organ,Intermediate,,50597,,17738,2385.0,10116.0,Rattus norvegicus,,CHEMBL624843,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,10695,N,Biodistribution of radiolabeled compound in rat muscle after 2 hr activity expressed as %ID/Organ,Intermediate,,50597,,17738,2385.0,10116.0,Rattus norvegicus,,CHEMBL624844,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,10696,N,Biodistribution of radiolabeled compound in rat muscle after 30 min activity expressed as %ID/Organ,Intermediate,,50597,,17738,2385.0,10116.0,Rattus norvegicus,,CHEMBL624845,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,10697,N,Biodistribution of radiolabeled compound in rat muscle after 5 min activity expressed as %ID/Organ,Intermediate,,50597,,17738,2385.0,10116.0,Rattus norvegicus,,CHEMBL621904,,,In vivo,,A,1,1,
Blood,BAO_0000218,10698,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 15 mins after i.v. administration,Intermediate,,50597,,11195,178.0,10116.0,Rattus norvegicus,,CHEMBL621905,,,In vivo,,A,1,1,
Blood,BAO_0000218,10699,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 2 mins after i.v. administration,Intermediate,,50597,,11195,178.0,10116.0,Rattus norvegicus,,CHEMBL874382,,,In vivo,,A,1,1,
Blood,BAO_0000218,10700,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 65 mins after i.v. administration,Intermediate,,50597,,11195,178.0,10116.0,Rattus norvegicus,,CHEMBL621906,,,In vivo,,A,1,1,
Brain,BAO_0000218,10701,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 15 mins after i.v. administration,Intermediate,,50597,,11195,955.0,10116.0,Rattus norvegicus,,CHEMBL621907,,,In vivo,,A,1,1,
Brain,BAO_0000218,10702,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 2 mins after i.v. administration,Intermediate,,50597,,11195,955.0,10116.0,Rattus norvegicus,,CHEMBL622096,,,In vivo,,A,1,1,
Brain,BAO_0000218,10703,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 65 mins after i.v. administration,Intermediate,,50597,,11195,955.0,10116.0,Rattus norvegicus,,CHEMBL622097,,,In vivo,,A,1,1,
Heart,BAO_0000218,10704,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 15 mins after i.v. administration,Intermediate,,50597,,11195,948.0,10116.0,Rattus norvegicus,,CHEMBL622098,,,In vivo,,A,1,1,
Heart,BAO_0000218,10705,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 2 mins after i.v. administration,Intermediate,,50597,,11195,948.0,10116.0,Rattus norvegicus,,CHEMBL622099,,,In vivo,,A,1,1,
Heart,BAO_0000218,10706,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 65 mins after i.v. administration,Intermediate,,50597,,11195,948.0,10116.0,Rattus norvegicus,,CHEMBL622100,,,In vivo,,A,1,1,
Kidney,BAO_0000218,10707,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 15 mins after i.v. administration,Intermediate,,50597,,11195,2113.0,10116.0,Rattus norvegicus,,CHEMBL622101,,,In vivo,,A,1,1,
Kidney,BAO_0000218,10708,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 2 mins after i.v. administration,Intermediate,,50597,,11195,2113.0,10116.0,Rattus norvegicus,,CHEMBL622102,,,In vivo,,A,1,1,
Kidney,BAO_0000218,10709,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 65 mins after i.v. administration,Intermediate,,50597,,11195,2113.0,10116.0,Rattus norvegicus,,CHEMBL622103,,,In vivo,,A,1,1,
Liver,BAO_0000218,10710,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 15 mins after i.v. administration,Intermediate,,50597,,11195,2107.0,10116.0,Rattus norvegicus,,CHEMBL622104,,,In vivo,,A,1,1,
Liver,BAO_0000218,10711,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 2 mins after i.v. administration,Intermediate,,50597,,11195,2107.0,10116.0,Rattus norvegicus,,CHEMBL622105,,,In vivo,,A,1,1,
Liver,BAO_0000218,10712,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 65 mins after i.v. administration,Intermediate,,50597,,11195,2107.0,10116.0,Rattus norvegicus,,CHEMBL622106,,,In vivo,,A,1,1,
Lung,BAO_0000218,10713,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 15 mins after i.v. administration,Intermediate,,50597,,11195,2048.0,10116.0,Rattus norvegicus,,CHEMBL622107,,,In vivo,,A,1,1,
Lung,BAO_0000218,10714,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 2 mins after i.v. administration,Intermediate,,50597,,11195,2048.0,10116.0,Rattus norvegicus,,CHEMBL622108,,,In vivo,,A,1,1,
Lung,BAO_0000218,10715,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 65 mins after i.v. administration,Intermediate,,50597,,11195,2048.0,10116.0,Rattus norvegicus,,CHEMBL622109,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,10716,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 15 mins after i.v. administration,Intermediate,,50597,,11195,2385.0,10116.0,Rattus norvegicus,,CHEMBL622110,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,10717,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 2 mins after i.v. administration,Intermediate,,50597,,11195,2385.0,10116.0,Rattus norvegicus,,CHEMBL622111,,,In vivo,,A,1,1,
Muscle tissue,BAO_0000218,10718,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 65 mins after i.v. administration,Intermediate,,50597,,11195,2385.0,10116.0,Rattus norvegicus,,CHEMBL874383,,,In vivo,,A,1,1,
Zone of skin,BAO_0000218,10719,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 15 mins after i.v. administration,Intermediate,,50597,,11195,14.0,10116.0,Rattus norvegicus,,CHEMBL622112,,,In vivo,,A,1,1,
Zone of skin,BAO_0000218,10720,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 2 mins after i.v. administration,Intermediate,,50597,,11195,14.0,10116.0,Rattus norvegicus,,CHEMBL622113,,,In vivo,,A,1,1,
Zone of skin,BAO_0000218,10721,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 65 mins after i.v. administration,Intermediate,,50597,,11195,14.0,10116.0,Rattus norvegicus,,CHEMBL622114,,,In vivo,,A,1,1,
Spleen,BAO_0000218,10722,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 15 mins after i.v. administration,Intermediate,,50597,,11195,2106.0,10116.0,Rattus norvegicus,,CHEMBL622115,,,In vivo,,A,1,1,
Spleen,BAO_0000218,10723,N,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 2 mins after i.v. administration,Intermediate,,50597,,11195,2106.0,10116.0,Rattus norvegicus,,CHEMBL622116,,,In vivo,,A,1,1,
,BAO_0000218,10724,N,Oral bioavailability in rat,Intermediate,,50597,,6193,,10116.0,Rattus norvegicus,,CHEMBL622117,,,In vivo,,A,1,1,
,BAO_0000218,10725,N,Oral bioavailability in rat,Intermediate,,50597,,6803,,10116.0,Rattus norvegicus,,CHEMBL622118,,,In vivo,,A,1,1,
,BAO_0000218,10726,N,Oral bioavailability in rats at 6 mg/kg,Intermediate,,50597,,6647,,10116.0,Rattus norvegicus,,CHEMBL622119,,,In vivo,,A,1,1,
,BAO_0000218,10727,N,Oral bioavailability in rat (dose 6 mg/kg),Intermediate,,50597,,6647,,10116.0,Rattus norvegicus,,CHEMBL622120,,,In vivo,,A,1,1,
,BAO_0000218,10728,N,Oral bioavailability in rats at 6 mg/kg dose; Not tested,Intermediate,,50597,,6647,,10116.0,Rattus norvegicus,,CHEMBL622121,,,In vivo,,A,1,1,
,BAO_0000218,10729,N,Oral bioavailability in rat,Intermediate,,50597,,6640,,10116.0,Rattus norvegicus,,CHEMBL622122,,,In vivo,,A,1,1,
,BAO_0000218,10730,N,Oral bioavailability in rat,Intermediate,,50597,,6641,,10116.0,Rattus norvegicus,,CHEMBL622123,,,In vivo,,A,1,1,
,BAO_0000218,10731,N,Oral bioavailability in rat,Intermediate,,50597,,6641,,10116.0,Rattus norvegicus,,CHEMBL622124,,,In vivo,,A,1,1,
,BAO_0000218,10732,N,Bioavailability in rat,Intermediate,,50597,,6642,,10116.0,Rattus norvegicus,,CHEMBL622125,,,In vivo,,A,1,1,
,BAO_0000218,10733,N,Oral bioavailability,Intermediate,,50597,,5472,,10116.0,Rattus norvegicus,,CHEMBL622126,,,In vivo,,A,1,1,
,BAO_0000218,10734,N,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),Intermediate,,50597,,6141,,10116.0,Rattus norvegicus,,CHEMBL620455,,,In vivo,,A,1,1,
,BAO_0000218,10735,N,Oral bioavailability in rat,Intermediate,,50597,,4390,,10116.0,Rattus norvegicus,,CHEMBL620456,,,In vivo,,A,1,1,
,BAO_0000218,10736,N,Oral bioavailability in rat,Intermediate,,50597,,5472,,10116.0,Rattus norvegicus,,CHEMBL620457,,,In vivo,,A,1,1,
,BAO_0000218,10737,N,Oral bioavailability was evaluated; Not tested,Intermediate,,50597,,5472,,10116.0,Rattus norvegicus,,CHEMBL620458,,,In vivo,,A,1,1,
,BAO_0000218,10738,N,Oral bioavailability,Intermediate,,50597,,5438,,10116.0,Rattus norvegicus,,CHEMBL620459,,,In vivo,,A,1,1,
,BAO_0000218,10739,N,Oral bioavailability in rat by oral dosing,Intermediate,,50597,,4883,,10116.0,Rattus norvegicus,,CHEMBL620460,,,In vivo,,A,1,1,
,BAO_0000218,10740,N,Oral bioavailability in rat (dose 10 mg/kg p.o.),Intermediate,,50597,,1908,,10116.0,Rattus norvegicus,,CHEMBL620461,,,In vivo,,A,1,1,
,BAO_0000218,10741,N,Oral bioavailability in rat (Sprague-Dawley),Intermediate,,50597,,4853,,10116.0,Rattus norvegicus,,CHEMBL620462,,,In vivo,,A,1,1,
,BAO_0000218,10742,N,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),Intermediate,,50597,,4853,,10116.0,Rattus norvegicus,,CHEMBL620463,,,In vivo,,A,1,1,
,BAO_0000218,10743,N,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),Intermediate,,50597,,4853,,10116.0,Rattus norvegicus,,CHEMBL620464,,,In vivo,,A,1,1,
,BAO_0000218,10744,N,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),Intermediate,,50597,,4853,,10116.0,Rattus norvegicus,,CHEMBL620465,,,In vivo,,A,1,1,
,BAO_0000218,10745,N,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg p.o.),Intermediate,,50597,,4853,,10116.0,Rattus norvegicus,,CHEMBL620466,,,In vivo,,A,1,1,
,BAO_0000218,10746,N,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 1 mg/kg,Intermediate,,50597,,4853,,10116.0,Rattus norvegicus,,CHEMBL620467,,,In vivo,,A,1,1,
,BAO_0000218,10747,N,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 2 mg/kg,Intermediate,,50597,,4853,,10116.0,Rattus norvegicus,,CHEMBL620468,,,In vivo,,A,1,1,
,BAO_0000218,10748,N,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in solution form,Intermediate,,50597,,12873,,10116.0,Rattus norvegicus,,CHEMBL620469,,,In vivo,,A,1,1,
,BAO_0000218,10749,N,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in suspension form,Intermediate,,50597,,12873,,10116.0,Rattus norvegicus,,CHEMBL620470,,,In vivo,,A,1,1,
,BAO_0000218,10750,N,Oral bioavailability in rat,Intermediate,,50597,,3169,,10116.0,Rattus norvegicus,,CHEMBL620471,,,In vivo,,A,1,1,
,BAO_0000218,10751,N,Oral bioavailability in rat,Intermediate,,50597,,6305,,10116.0,Rattus norvegicus,,CHEMBL620472,,,In vivo,,A,1,1,
,BAO_0000218,10752,N,Oral bioavailability of compound at 5 mg/kg after po administration was determined in rat,Intermediate,,50597,,4762,,10116.0,Rattus norvegicus,,CHEMBL620473,,,In vivo,,A,1,1,
,BAO_0000218,10753,N,Oral bioavailability in rat,Intermediate,,50597,,17847,,10116.0,Rattus norvegicus,,CHEMBL620474,,,In vivo,,A,1,1,
,BAO_0000218,10754,N,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 10 mg/kg),Intermediate,,50597,,6211,,10116.0,Rattus norvegicus,,CHEMBL620475,,,In vivo,,A,1,1,
,BAO_0000218,10755,N,Oral bioavailability in rat,Intermediate,,50597,,6011,,10116.0,Rattus norvegicus,,CHEMBL620476,,,In vivo,,A,1,1,
,BAO_0000218,10756,N,Oral bioavailability in rat,Intermediate,,50597,,6317,,10116.0,Rattus norvegicus,,CHEMBL620477,,,In vivo,,A,1,1,
,BAO_0000218,10757,N,Oral bioavailability in rat after oral administration at 10.5 mg/kg dose,Intermediate,,50597,,6644,,10116.0,Rattus norvegicus,,CHEMBL620478,,,In vivo,,A,1,1,
,BAO_0000218,10758,N,Oral bioavailability in rat after oral administration at 11.2 mg/kg dose,Intermediate,,50597,,6644,,10116.0,Rattus norvegicus,,CHEMBL618768,,,In vivo,,A,1,1,
,BAO_0000218,10759,N,Oral bioavailability in rat after oral administration at 13 mg/kg dose,Intermediate,,50597,,6644,,10116.0,Rattus norvegicus,,CHEMBL618769,,,In vivo,,A,1,1,
,BAO_0000218,10760,N,Oral bioavailability in rat after oral administration at 9.7 mg/kg dose,Intermediate,,50597,,6644,,10116.0,Rattus norvegicus,,CHEMBL618770,,,In vivo,,A,1,1,
,BAO_0000218,10761,N,Oral bioavailability (dose 20 mg/kg p.o.),Intermediate,,50597,,6113,,10116.0,Rattus norvegicus,,CHEMBL618771,,,In vivo,,A,1,1,
,BAO_0000218,10762,N,Oral bioavailability was determined in rat after oral administration at a concentration 1 mg/kg,Intermediate,,50597,,5937,,10116.0,Rattus norvegicus,,CHEMBL618772,,,In vivo,,A,1,1,
,BAO_0000218,10763,N,Oral bioavailability in rat at 10 mg/kg of the compound,Intermediate,,50597,,5711,,10116.0,Rattus norvegicus,,CHEMBL618773,,,In vivo,,A,1,1,
,BAO_0000218,10764,N,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,Intermediate,,50597,,17717,,10116.0,Rattus norvegicus,,CHEMBL875842,,,In vivo,,A,1,1,
,BAO_0000218,10765,N,Bioavailability in rat (dose 3 mg/kg i.v.),Intermediate,,50597,,17717,,10116.0,Rattus norvegicus,,CHEMBL618774,,,In vivo,,A,1,1,
,BAO_0000218,10766,N,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,Intermediate,,50597,,17717,,10116.0,Rattus norvegicus,,CHEMBL618775,,,In vivo,,A,1,1,
,BAO_0000218,10767,N,Oral bioavailability in rat (dose 60 mg/kg p.o.),Intermediate,,50597,,17717,,10116.0,Rattus norvegicus,,CHEMBL618776,,,In vivo,,A,1,1,
,BAO_0000218,10768,N,Percent bioavailability (F) in rats after iv administration,Intermediate,,50597,,4722,,10116.0,Rattus norvegicus,,CHEMBL618777,,,In vivo,,A,1,1,
,BAO_0000218,10769,N,Percent bioavailability (F) in rats after oral dose of 10 mg/kg,Intermediate,,50597,,4722,,10116.0,Rattus norvegicus,,CHEMBL618778,,,In vivo,,A,1,1,
,BAO_0000218,10770,N,Bioavailability in rat (dose 5 uM/kg p.o.),Intermediate,,50597,,4353,,10116.0,Rattus norvegicus,,CHEMBL618779,,,In vivo,,A,1,1,
,BAO_0000218,10771,N,Oral bioavailability,Intermediate,,50597,,15662,,10116.0,Rattus norvegicus,,CHEMBL618780,,,In vivo,,A,1,1,
,BAO_0000218,10772,N,Bioavailability in rat (dose 2 mg/kg p.o.),Intermediate,,50597,,4756,,10116.0,Rattus norvegicus,,CHEMBL618781,,,In vivo,,A,1,1,
,BAO_0000218,10773,N,Percent bioavailability at the dose of 5 mg/Kg administered perorally in rats,Intermediate,,50597,,4756,,10116.0,Rattus norvegicus,,CHEMBL618782,,,In vivo,,A,1,1,
,BAO_0000218,10774,N,Oral bioavailability in rat (dose 20 mg/kg),Intermediate,,50597,,3436,,10116.0,Rattus norvegicus,,CHEMBL618783,,,In vivo,,A,1,1,
,BAO_0000218,10775,N,Oral bioavailability in rat,Intermediate,,50597,,17800,,10116.0,Rattus norvegicus,,CHEMBL618784,,,In vivo,,A,1,1,
,BAO_0000218,10776,N,Percent oral bioavailability evaluated in rat,Intermediate,,50597,,15762,,10116.0,Rattus norvegicus,,CHEMBL618785,,,In vivo,,A,1,1,
,BAO_0000218,10777,N,Oral bioavailability in rat,Intermediate,,50597,,5089,,10116.0,Rattus norvegicus,,CHEMBL618786,,,In vivo,,A,1,1,
,BAO_0000218,10778,N,Percent oral bioavailability in rat; Not determined,Intermediate,,50597,,5089,,10116.0,Rattus norvegicus,,CHEMBL618787,,,In vivo,,A,1,1,
,BAO_0000218,10779,N,Oral bioavailability in rat,Intermediate,,50597,,3185,,10116.0,Rattus norvegicus,,CHEMBL618788,,,In vivo,,A,1,1,
,BAO_0000218,10780,N,Bioavailability in rat,Intermediate,,50597,,5145,,10116.0,Rattus norvegicus,,CHEMBL618789,,,In vivo,,A,1,1,
,BAO_0000218,10781,N,Pharmacokinetic property (oral bioavailability) in rat (dose given as a solution),Intermediate,,50597,,3457,,10116.0,Rattus norvegicus,,CHEMBL618790,,,In vivo,,A,1,1,
,BAO_0000218,10782,N,Pharmacokinetic property (oral bioavailability) in rat (dose given as a suspension),Intermediate,,50597,,3457,,10116.0,Rattus norvegicus,,CHEMBL618791,,,In vivo,,A,1,1,
,BAO_0000218,10783,N,Pharmacokinetic property (F) was measured in rat at the dose of 0.32 mg/kg,Intermediate,,50597,,5983,,10116.0,Rattus norvegicus,,CHEMBL875843,,,In vivo,,A,1,1,
,BAO_0000218,10784,N,Oral bioavailability in rat (dose 20 mg/kg p.o.),Intermediate,,50597,,5739,,10116.0,Rattus norvegicus,,CHEMBL618792,,,In vivo,,A,1,1,
,BAO_0000218,10785,N,Cmax at a dose of 30 mg/kg in rat,Intermediate,,50597,,3579,,10116.0,Rattus norvegicus,,CHEMBL623395,,,In vivo,,A,1,1,
,BAO_0000218,10786,U,Cmax in monkeys at a dose of 1 mg/kg,Autocuration,,22224,,17788,,314293.0,Simiiformes,,CHEMBL623396,,,In vivo,,A,1,0,
,BAO_0000218,10787,N,Cmax in rat,Intermediate,,50597,,14956,,10116.0,Rattus norvegicus,,CHEMBL623397,,,In vivo,,A,1,1,
,BAO_0000218,10788,N,Cmax in rats at a dose of 1 mg/kg,Intermediate,,50597,,17788,,10116.0,Rattus norvegicus,,CHEMBL623398,,,In vivo,,A,1,1,
,BAO_0000218,10789,N,Cmax was measured in mice after an oral dose of 50 mg/kg.,Intermediate,,50594,,9750,,10090.0,Mus musculus,,CHEMBL623399,,,In vivo,,A,1,1,
,BAO_0000218,10790,U,"Cmax value at a dose of 12.7 uM/kg, po",Autocuration,,22224,,12767,,,,,CHEMBL623400,,,In vivo,,A,1,0,
,BAO_0000218,10791,U,"Cmax value at a dose of 6.3 uM/kg, iv",Autocuration,,22224,,12767,,,,,CHEMBL623401,,,In vivo,,A,1,0,
,BAO_0000218,10792,U,"Cmax value at a dose of 7.1 uM/kg, iv",Autocuration,,22224,,12767,,,,,CHEMBL623402,,,In vivo,,A,1,0,
,BAO_0000218,10793,U,Cmax value of compound was determined after 1 hr,Autocuration,,22224,,12703,,,,,CHEMBL623403,,,In vivo,,A,1,0,
,BAO_0000218,10794,U,Cmax value of the compound,Autocuration,,22224,,15778,,,,,CHEMBL623404,,,In vivo,,A,1,0,
,BAO_0000218,10795,N,Cmax value administered intraintestinal in rats.,Intermediate,,50597,,12818,,10116.0,Rattus norvegicus,,CHEMBL625997,,,In vivo,,A,1,1,
,BAO_0000218,10796,N,Cmax value administered perorally was determined in rat; Not determined,Intermediate,,50597,,14964,,10116.0,Rattus norvegicus,,CHEMBL625998,,,In vivo,,A,1,1,
,BAO_0000218,10797,U,Cmax value at the dose of 2.3 mg/kg,Autocuration,,22224,,15808,,,,,CHEMBL625999,,,In vivo,,A,1,0,
,BAO_0000218,10798,U,Cmax value at the dose of 5 mg/kg,Autocuration,,22224,,15808,,,,,CHEMBL626000,,,In vivo,,A,1,0,
,BAO_0000218,10799,U,Cmax value in the period of 8 hr after dosing. ,Autocuration,,22224,,15778,,,,,CHEMBL626001,,,In vivo,,A,1,0,
,BAO_0000218,10800,U,Cmax value at a oral dose of 20 mg/kg; Not tested,Autocuration,,22224,,3715,,,,,CHEMBL626002,,,In vivo,,A,1,0,
,BAO_0000218,10801,U,Cmax value at a oral dose of 20 mg/kg,Autocuration,,22224,,3715,,,,,CHEMBL626003,,,In vivo,,A,1,0,
,BAO_0000218,10802,N,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,Intermediate,,50597,,1446,,10116.0,Rattus norvegicus,,CHEMBL626004,,,In vivo,,A,1,1,
,BAO_0000218,10803,N,Cmax(ng /mL)values after oral administration of 10 mg/kg in guinea pig.,Intermediate,,50512,,15240,,10141.0,Cavia porcellus,,CHEMBL626005,,,In vivo,,A,1,1,
,BAO_0000218,10804,N,Cmax(ng /mL)values after oral administration of 10 mg/kg in rat.,Intermediate,,50597,,15240,,10116.0,Rattus norvegicus,,CHEMBL626006,,,In vivo,,A,1,1,
Plasma,BAO_0000218,10805,N,Compound at a dose of 10 mg/kg was orally administered to rats and maximum plasma concentration was reported,Intermediate,,50597,,14810,1969.0,10116.0,Rattus norvegicus,,CHEMBL626007,,,In vivo,,A,1,1,
Plasma,BAO_0000218,10806,N,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,Intermediate,,50594,,14239,1969.0,10090.0,Mus musculus,,CHEMBL626008,,,In vivo,,A,1,1,
Liver,BAO_0000218,10807,N,Compound was evaluated for maximum plasma concentration levels in dogs for the orally delivered compound in 0.05 M citric acid,Intermediate,,50588,,12555,2107.0,9615.0,Canis lupus familiaris,,CHEMBL626009,,,In vivo,,A,1,1,
,BAO_0000218,10808,N,Compound was evaluated in vivo for its concentration after a peroral administration 40 mg/kg in dogs.,Intermediate,,50588,,10754,,9615.0,Canis lupus familiaris,,CHEMBL626010,,,In vivo,,A,1,1,
Blood,BAO_0000218,10809,N,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice,Intermediate,,50594,,10754,178.0,10090.0,Mus musculus,,CHEMBL626011,,,In vivo,,A,1,1,
Blood,BAO_0000218,10810,N,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice,Intermediate,,50594,,10754,178.0,10090.0,Mus musculus,,CHEMBL626012,,,In vivo,,A,1,1,
Blood,BAO_0000218,10811,N,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration of 40 mg/kg in mice,Intermediate,,50594,,10754,178.0,10090.0,Mus musculus,,CHEMBL626013,,,In vivo,,A,1,1,
Blood,BAO_0000218,10812,N,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice,Intermediate,,50594,,10754,178.0,10090.0,Mus musculus,,CHEMBL626014,,,In vivo,,A,1,1,
Blood,BAO_0000218,10813,N,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice.,Intermediate,,50594,,10754,178.0,10090.0,Mus musculus,,CHEMBL877496,,,In vivo,,A,1,1,
,BAO_0000218,10814,N,Compound was tested Growth Hormone(GH) release after 0.5 mg/kg administration (Po) in Beagle dogs,Intermediate,,50588,,14600,,9615.0,Canis lupus familiaris,,CHEMBL626015,,,In vivo,,F,1,1,
,BAO_0000218,10815,N,Compound was tested Growth Hormone(GH) release after 10 mg/kg administration (Po) in Beagle dogs,Intermediate,,50588,,14600,,9615.0,Canis lupus familiaris,,CHEMBL626016,,,In vivo,,F,1,1,
,BAO_0000218,10816,N,Compound was tested Growth Hormone(GH) release after 2.5 mg/kg administration (Po) in Beagle dogs,Intermediate,,50588,,14600,,9615.0,Canis lupus familiaris,,CHEMBL626017,,,In vivo,,F,1,1,
Plasma,BAO_0000218,10817,N,Bioavailability as maximal plasma concentration in dogs,Intermediate,,50588,,13543,1969.0,9615.0,Canis lupus familiaris,,CHEMBL626018,,,In vivo,,A,1,1,
Plasma,BAO_0000218,10818,N,Bioavailability as maximal plasma concentration in dogs,Intermediate,,50588,,13543,1969.0,9615.0,Canis lupus familiaris,,CHEMBL626692,,,In vivo,,A,1,1,
Plasma,BAO_0000218,10819,N,Bioavailability as maximal plasma concentration in rats,Intermediate,,50597,,13543,1969.0,10116.0,Rattus norvegicus,,CHEMBL626693,,,In vivo,,A,1,1,
Plasma,BAO_0000218,10820,U,Bioavailability as maximal plasma concentration in rats,Autocuration,,22224,,13543,1969.0,10116.0,Rattus norvegicus,,CHEMBL626694,,,In vivo,,A,1,0,
Blood,BAO_0000218,10821,N,Compound was tested for maximum blood concentration after 0.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,Intermediate,,50588,,14600,178.0,9615.0,Canis lupus familiaris,,CHEMBL626695,,,In vivo,,A,1,1,
Blood,BAO_0000218,10822,N,Compound was tested for maximum blood concentration after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,Intermediate,,50588,,14600,178.0,9615.0,Canis lupus familiaris,,CHEMBL626696,,,In vivo,,A,1,1,
Blood,BAO_0000218,10823,N,Compound was tested for maximum blood concentration after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,Intermediate,,50588,,14600,178.0,9615.0,Canis lupus familiaris,,CHEMBL626697,,,In vivo,,A,1,1,
Blood,BAO_0000218,10824,N,Compound was tested for maximum concentration in blood after 0.5 mg/kg administration (Po) in Beagle dogs; nd = Not Detectable,Intermediate,,50588,,14600,178.0,9615.0,Canis lupus familiaris,,CHEMBL626859,,,In vivo,,A,1,1,
Blood,BAO_0000218,10825,N,Compound was tested for maximum concentration in blood after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,Intermediate,,50588,,14600,178.0,9615.0,Canis lupus familiaris,,CHEMBL626860,,,In vivo,,A,1,1,
Blood,BAO_0000218,10826,N,Compound was tested for maximum concentration in blood after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,Intermediate,,50588,,14600,178.0,9615.0,Canis lupus familiaris,,CHEMBL626861,,,In vivo,,A,1,1,
,BAO_0000218,10827,N,Compound was tested for maximum observed concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,Intermediate,,50597,,14681,,10116.0,Rattus norvegicus,,CHEMBL626296,,,In vivo,,A,1,1,
,BAO_0000218,10828,U,Compound was tested for the max. conc. when administered perorally(po) 30 mg/kg,Autocuration,,22224,,15905,,,,,CHEMBL626297,,,In vivo,,A,1,0,
Plasma,BAO_0000218,10829,U,Compound was tested for the max. plasma conc. when administered intraperitoneally (ip) 30 mg/kg.,Autocuration,,22224,,15905,1969.0,,,,CHEMBL626298,,,In vivo,,A,1,0,
Plasma,BAO_0000218,10830,N,"Drug plasma level in rat was determined on the last day of dosing at 1,2,4.8 and 24 hr and ED50 was evaluated",Intermediate,,50597,,13304,1969.0,10116.0,Rattus norvegicus,,CHEMBL626299,,,In vivo,,A,1,1,
Plasma,BAO_0000218,10831,N,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats after 30 min.,Intermediate,,50597,,15137,1969.0,10116.0,Rattus norvegicus,,CHEMBL626300,,,In vivo,,A,1,1,
Plasma,BAO_0000218,10832,N,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats after 30 min.,Intermediate,,50597,,15137,1969.0,10116.0,Rattus norvegicus,,CHEMBL626301,,,In vivo,,A,1,1,
Plasma,BAO_0000218,10833,N,Effect of ip administration of compound on plasma concentration of corticosterone (CTS) in rats after 30 min.,Intermediate,,50597,,15137,1969.0,10116.0,Rattus norvegicus,,CHEMBL626962,,,In vivo,,A,1,1,
Plasma,BAO_0000218,10834,N,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats after 30 min.,Intermediate,,50597,,15137,1969.0,10116.0,Rattus norvegicus,,CHEMBL626963,,,In vivo,,A,1,1,
Plasma,BAO_0000218,10835,N,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats after 30 min.,Intermediate,,50597,,15137,1969.0,10116.0,Rattus norvegicus,,CHEMBL626964,,,In vivo,,A,1,1,
Plasma,BAO_0000218,10836,N,In vivo antitumor efficacy expressed as maximum plasma concentration 0.4 hr after a peroral dose of 25 mg/kg in cynomolgus monkeys,Intermediate,,100710,,14839,1969.0,9541.0,Macaca fascicularis,,CHEMBL626965,,,In vivo,,A,1,1,
Plasma,BAO_0000218,10837,N,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Intermediate,,50594,,14839,1969.0,10090.0,Mus musculus,,CHEMBL626966,,,In vivo,,A,1,1,
Plasma,BAO_0000218,10838,N,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Intermediate,,50594,,14839,1969.0,10090.0,Mus musculus,,CHEMBL626967,,,In vivo,,A,1,1,
Plasma,BAO_0000218,10839,N,In vivo antitumor efficacy expressed as maximum plasma concentration after a peroral dose of 10 mg/kg in cynomolgus monkeys,Intermediate,,100710,,14839,1969.0,9541.0,Macaca fascicularis,,CHEMBL626968,,,In vivo,,A,1,1,
Heart,BAO_0000218,10840,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.89-1.24,Intermediate,,50597,,8418,948.0,10116.0,Rattus norvegicus,,CHEMBL626969,,,,,A,1,1,
Heart,BAO_0000218,10841,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-2.58,Intermediate,,50597,,8418,948.0,10116.0,Rattus norvegicus,,CHEMBL627126,,,,,A,1,1,
Heart,BAO_0000218,10842,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.24-0.28,Intermediate,,50597,,8418,948.0,10116.0,Rattus norvegicus,,CHEMBL631276,,,,,A,1,1,
Heart,BAO_0000218,10843,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.52-0.62,Intermediate,,50597,,8418,948.0,10116.0,Rattus norvegicus,,CHEMBL631277,,,,,A,1,1,
Heart,BAO_0000218,10844,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.68-0.84,Intermediate,,50597,,8418,948.0,10116.0,Rattus norvegicus,,CHEMBL631278,,,,,A,1,1,
Heart,BAO_0000218,10845,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.75-1.03,Intermediate,,50597,,8418,948.0,10116.0,Rattus norvegicus,,CHEMBL874457,,,,,A,1,1,
Heart,BAO_0000218,10846,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.96-2.46,Intermediate,,50597,,8418,948.0,10116.0,Rattus norvegicus,,CHEMBL631279,,,,,A,1,1,
Heart,BAO_0000218,10847,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.36-0.42,Intermediate,,50597,,8418,948.0,10116.0,Rattus norvegicus,,CHEMBL631280,,,,,A,1,1,
Heart,BAO_0000218,10848,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.82,Intermediate,,50597,,8418,948.0,10116.0,Rattus norvegicus,,CHEMBL631281,,,,,A,1,1,
Heart,BAO_0000218,10849,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.24-1.46,Intermediate,,50597,,8418,948.0,10116.0,Rattus norvegicus,,CHEMBL631968,,,,,A,1,1,
Heart,BAO_0000218,10850,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.36-3.96,Intermediate,,50597,,8418,948.0,10116.0,Rattus norvegicus,,CHEMBL631969,,,,,A,1,1,
Heart,BAO_0000218,10851,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.24-0.29,Intermediate,,50597,,8418,948.0,10116.0,Rattus norvegicus,,CHEMBL631970,,,,,A,1,1,
Heart,BAO_0000218,10852,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.39-0.74,Intermediate,,50597,,8418,948.0,10116.0,Rattus norvegicus,,CHEMBL631971,,,,,A,1,1,
Heart,BAO_0000218,10853,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.79-0.85,Intermediate,,50597,,8418,948.0,10116.0,Rattus norvegicus,,CHEMBL631972,,,,,A,1,1,
Heart,BAO_0000218,10854,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.64-0.86,Intermediate,,50597,,8418,948.0,10116.0,Rattus norvegicus,,CHEMBL630435,,,,,A,1,1,
Heart,BAO_0000218,10855,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.68-2.23,Intermediate,,50597,,8418,948.0,10116.0,Rattus norvegicus,,CHEMBL630436,,,,,A,1,1,
Heart,BAO_0000218,10856,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.19-0.23,Intermediate,,50597,,8418,948.0,10116.0,Rattus norvegicus,,CHEMBL630437,,,,,A,1,1,
Heart,BAO_0000218,10857,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.22-0.29,Intermediate,,50597,,8418,948.0,10116.0,Rattus norvegicus,,CHEMBL630438,,,,,A,1,1,
Heart,BAO_0000218,10858,N,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.75,Intermediate,,50597,,8418,948.0,10116.0,Rattus norvegicus,,CHEMBL630439,,,,,A,1,1,
Kidney,BAO_0000218,10859,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.42-1.82,Intermediate,,50597,,8418,2113.0,10116.0,Rattus norvegicus,,CHEMBL630440,,,,,A,1,1,
Kidney,BAO_0000218,10860,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-3.12,Intermediate,,50597,,8418,2113.0,10116.0,Rattus norvegicus,,CHEMBL630441,,,,,A,1,1,
Kidney,BAO_0000218,10861,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.62-0.92,Intermediate,,50597,,8418,2113.0,10116.0,Rattus norvegicus,,CHEMBL630442,,,,,A,1,1,
Kidney,BAO_0000218,10862,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.12-2.04,Intermediate,,50597,,8418,2113.0,10116.0,Rattus norvegicus,,CHEMBL625234,,,,,A,1,1,
Kidney,BAO_0000218,10863,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.59-2.03,Intermediate,,50597,,8418,2113.0,10116.0,Rattus norvegicus,,CHEMBL625235,,,,,A,1,1,
Kidney,BAO_0000218,10864,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.14-1.4,Intermediate,,50597,,8418,2113.0,10116.0,Rattus norvegicus,,CHEMBL625236,,,,,A,1,1,
Kidney,BAO_0000218,10865,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.56-1.83,Intermediate,,50597,,8418,2113.0,10116.0,Rattus norvegicus,,CHEMBL625237,,,,,A,1,1,
Kidney,BAO_0000218,10866,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.73,Intermediate,,50597,,8418,2113.0,10116.0,Rattus norvegicus,,CHEMBL626125,,,,,A,1,1,
Kidney,BAO_0000218,10867,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.67-2.11,Intermediate,,50597,,8418,2113.0,10116.0,Rattus norvegicus,,CHEMBL626126,,,,,A,1,1,
Kidney,BAO_0000218,10868,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.64-3.43,Intermediate,,50597,,8418,2113.0,10116.0,Rattus norvegicus,,CHEMBL626127,,,,,A,1,1,
Kidney,BAO_0000218,10869,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.18-4.74,Intermediate,,50597,,8418,2113.0,10116.0,Rattus norvegicus,,CHEMBL626128,,,,,A,1,1,
Kidney,BAO_0000218,10870,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.62-1.13,Intermediate,,50597,,8418,2113.0,10116.0,Rattus norvegicus,,CHEMBL626129,,,,,A,1,1,
Kidney,BAO_0000218,10871,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.73-2.64,Intermediate,,50597,,8418,2113.0,10116.0,Rattus norvegicus,,CHEMBL626130,,,,,A,1,1,
Kidney,BAO_0000218,10872,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 13.02-19.07,Intermediate,,50597,,8418,2113.0,10116.0,Rattus norvegicus,,CHEMBL626131,,,,,A,1,1,
Kidney,BAO_0000218,10873,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.89-1.19,Intermediate,,50597,,8418,2113.0,10116.0,Rattus norvegicus,,CHEMBL626132,,,,,A,1,1,
Kidney,BAO_0000218,10874,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.17-1.48,Intermediate,,50597,,8418,2113.0,10116.0,Rattus norvegicus,,CHEMBL626752,,,,,A,1,1,
Kidney,BAO_0000218,10875,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.48-0.72,Intermediate,,50597,,8418,2113.0,10116.0,Rattus norvegicus,,CHEMBL626753,,,,,A,1,1,
Kidney,BAO_0000218,10876,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.57,Intermediate,,50597,,8418,2113.0,10116.0,Rattus norvegicus,,CHEMBL626754,,,,,A,1,1,
Kidney,BAO_0000218,10877,N,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.99-1.24,Intermediate,,50597,,8418,2113.0,10116.0,Rattus norvegicus,,CHEMBL626755,,,,,A,1,1,
Liver,BAO_0000218,10878,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.23-1.78,Intermediate,,50597,,8418,2107.0,10116.0,Rattus norvegicus,,CHEMBL626756,,,,,A,1,1,
Liver,BAO_0000218,10879,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.43-2.92,Intermediate,,50597,,8418,2107.0,10116.0,Rattus norvegicus,,CHEMBL626757,,,,,A,1,1,
Liver,BAO_0000218,10880,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.81-1.18,Intermediate,,50597,,8418,2107.0,10116.0,Rattus norvegicus,,CHEMBL626758,,,,,A,1,1,
Liver,BAO_0000218,10881,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.37-1.74,Intermediate,,50597,,8418,2107.0,10116.0,Rattus norvegicus,,CHEMBL626759,,,,,A,1,1,
Liver,BAO_0000218,10882,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 4.01-4.81,Intermediate,,50597,,8418,2107.0,10116.0,Rattus norvegicus,,CHEMBL626760,,,,,A,1,1,
,BAO_0000218,10883,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),Intermediate,,50588,,6996,,9615.0,Canis lupus familiaris,,CHEMBL626394,,,,,A,1,1,
,BAO_0000218,10884,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration,Intermediate,,50588,,6996,,9615.0,Canis lupus familiaris,,CHEMBL626395,,,,,A,1,1,
,BAO_0000218,10885,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration (0-6 hr),Intermediate,,50588,,6996,,9615.0,Canis lupus familiaris,,CHEMBL626396,,,,,A,1,1,
,BAO_0000218,10886,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),Intermediate,,50588,,6996,,9615.0,Canis lupus familiaris,,CHEMBL626397,,,,,A,1,1,
,BAO_0000218,10887,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),Intermediate,,50588,,6996,,9615.0,Canis lupus familiaris,,CHEMBL626398,,,,,A,1,1,
,BAO_0000218,10888,N,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),Intermediate,,50588,,6996,,9615.0,Canis lupus familiaris,,CHEMBL626399,,,,,A,1,1,
,BAO_0000218,10889,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration,Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL874653,,,,,A,1,1,
,BAO_0000218,10890,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL626400,,,,,A,1,1,
,BAO_0000218,10891,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL626401,,,,,A,1,1,
,BAO_0000218,10892,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL626402,,,,,A,1,1,
,BAO_0000218,10893,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL626403,,,,,A,1,1,
,BAO_0000218,10894,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL626404,,,,,A,1,1,
,BAO_0000218,10895,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration,Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL626405,,,,,A,1,1,
,BAO_0000218,10896,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL625529,,,,,A,1,1,
,BAO_0000218,10897,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL625530,,,,,A,1,1,
,BAO_0000218,10898,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL625531,,,,,A,1,1,
,BAO_0000218,10899,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL625532,,,,,A,1,1,
,BAO_0000218,10900,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL625533,,,,,A,1,1,
,BAO_0000218,10901,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration,Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL875474,,,,,A,1,1,
,BAO_0000218,10902,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL625534,,,,,A,1,1,
,BAO_0000218,10903,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL625535,,,,,A,1,1,
,BAO_0000218,10904,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL625536,,,,,A,1,1,
,BAO_0000218,10905,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL625537,,,,,A,1,1,
,BAO_0000218,10906,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL625538,,,,,A,1,1,
,BAO_0000218,10907,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration,Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL625539,,,,,A,1,1,
,BAO_0000218,10908,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL625540,,,,,A,1,1,
,BAO_0000218,10909,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL625541,,,,,A,1,1,
,BAO_0000218,10910,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL625542,,,,,A,1,1,
,BAO_0000218,10911,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL625543,,,,,A,1,1,
,BAO_0000218,10912,N,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL625544,,,,,A,1,1,
,BAO_0000218,10913,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.312 mg/kg after ip administration,Intermediate,,50588,,6996,,9615.0,Canis lupus familiaris,,CHEMBL625545,,,,,A,1,1,
,BAO_0000218,10914,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),Intermediate,,50588,,6996,,9615.0,Canis lupus familiaris,,CHEMBL625546,,,,,A,1,1,
,BAO_0000218,10915,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.625 mg/kg after ip administration,Intermediate,,50588,,6996,,9615.0,Canis lupus familiaris,,CHEMBL625547,,,,,A,1,1,
,BAO_0000218,10916,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),Intermediate,,50588,,6996,,9615.0,Canis lupus familiaris,,CHEMBL625548,,,,,A,1,1,
,BAO_0000218,10917,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),Intermediate,,50588,,6996,,9615.0,Canis lupus familiaris,,CHEMBL625549,,,,,A,1,1,
,BAO_0000218,10918,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),Intermediate,,50588,,6996,,9615.0,Canis lupus familiaris,,CHEMBL625550,,,,,A,1,1,
,BAO_0000218,10919,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),Intermediate,,50588,,6996,,9615.0,Canis lupus familiaris,,CHEMBL625551,,,,,A,1,1,
,BAO_0000218,10920,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),Intermediate,,50588,,6996,,9615.0,Canis lupus familiaris,,CHEMBL875475,,,,,A,1,1,
,BAO_0000218,10921,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),Intermediate,,50588,,6996,,9615.0,Canis lupus familiaris,,CHEMBL625552,,,,,A,1,1,
,BAO_0000218,10922,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),Intermediate,,50588,,6996,,9615.0,Canis lupus familiaris,,CHEMBL625553,,,,,A,1,1,
,BAO_0000218,10923,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),Intermediate,,50588,,6996,,9615.0,Canis lupus familiaris,,CHEMBL625554,,,,,A,1,1,
,BAO_0000218,10924,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),Intermediate,,50588,,6996,,9615.0,Canis lupus familiaris,,CHEMBL625555,,,,,A,1,1,
,BAO_0000218,10925,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),Intermediate,,50588,,6996,,9615.0,Canis lupus familiaris,,CHEMBL625556,,,,,A,1,1,
,BAO_0000218,10926,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration,Intermediate,,50588,,6996,,9615.0,Canis lupus familiaris,,CHEMBL624986,,,,,A,1,1,
,BAO_0000218,10927,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),Intermediate,,50588,,6996,,9615.0,Canis lupus familiaris,,CHEMBL624987,,,,,A,1,1,
,BAO_0000218,10928,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),Intermediate,,50588,,6996,,9615.0,Canis lupus familiaris,,CHEMBL624988,,,,,A,1,1,
Artery,BAO_0000218,10929,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -2/-14,Intermediate,,50588,,9025,1637.0,9615.0,Canis lupus familiaris,,CHEMBL624989,,,In vivo,,A,1,1,
Artery,BAO_0000218,10930,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -4/-4,Intermediate,,50588,,9025,1637.0,9615.0,Canis lupus familiaris,,CHEMBL624990,,,In vivo,,A,1,1,
Artery,BAO_0000218,10931,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; 4/7,Intermediate,,50588,,9025,1637.0,9615.0,Canis lupus familiaris,,CHEMBL874391,,,In vivo,,A,1,1,
Artery,BAO_0000218,10932,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3/10 range; -3/0/4,Intermediate,,50588,,9025,1637.0,9615.0,Canis lupus familiaris,,CHEMBL624991,,,In vivo,,A,1,1,
Artery,BAO_0000218,10933,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; -6/0,Intermediate,,50588,,9025,1637.0,9615.0,Canis lupus familiaris,,CHEMBL624992,,,In vivo,,A,1,1,
Artery,BAO_0000218,10934,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 10/31,Intermediate,,50588,,9025,1637.0,9615.0,Canis lupus familiaris,,CHEMBL624993,,,In vivo,,A,1,1,
Artery,BAO_0000218,10935,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 11/-19,Intermediate,,50588,,9025,1637.0,9615.0,Canis lupus familiaris,,CHEMBL624994,,,In vivo,,A,1,1,
Artery,BAO_0000218,10936,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 14/6,Intermediate,,50588,,9025,1637.0,9615.0,Canis lupus familiaris,,CHEMBL624995,,,In vivo,,A,1,1,
Artery,BAO_0000218,10937,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/25,Intermediate,,50588,,9025,1637.0,9615.0,Canis lupus familiaris,,CHEMBL624996,,,In vivo,,A,1,1,
Artery,BAO_0000218,10938,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/3,Intermediate,,50588,,9025,1637.0,9615.0,Canis lupus familiaris,,CHEMBL624997,,,In vivo,,A,1,1,
Artery,BAO_0000218,10939,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 2/16,Intermediate,,50588,,9025,1637.0,9615.0,Canis lupus familiaris,,CHEMBL624998,,,In vivo,,A,1,1,
Artery,BAO_0000218,10940,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 6/2,Intermediate,,50588,,9025,1637.0,9615.0,Canis lupus familiaris,,CHEMBL624999,,,In vivo,,A,1,1,
Artery,BAO_0000218,10941,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 7/26,Intermediate,,50588,,9025,1637.0,9615.0,Canis lupus familiaris,,CHEMBL882955,,,In vivo,,A,1,1,
Artery,BAO_0000218,10942,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/49,Intermediate,,50588,,9025,1637.0,9615.0,Canis lupus familiaris,,CHEMBL625000,,,In vivo,,A,1,1,
Artery,BAO_0000218,10943,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/8,Intermediate,,50588,,9025,1637.0,9615.0,Canis lupus familiaris,,CHEMBL625001,,,In vivo,,A,1,1,
Artery,BAO_0000218,10944,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 9/-18,Intermediate,,50588,,9025,1637.0,9615.0,Canis lupus familiaris,,CHEMBL625089,,,In vivo,,A,1,1,
Artery,BAO_0000218,10945,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/60 range; 13/23,Intermediate,,50588,,9025,1637.0,9615.0,Canis lupus familiaris,,CHEMBL625090,,,In vivo,,A,1,1,
Artery,BAO_0000218,10946,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3 range,Intermediate,,50588,,9025,1637.0,9615.0,Canis lupus familiaris,,CHEMBL625091,,,In vivo,,A,1,1,
Artery,BAO_0000218,10947,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3/10 range; -7/-11,Intermediate,,50588,,9025,1637.0,9615.0,Canis lupus familiaris,,CHEMBL625092,,,In vivo,,A,1,1,
Artery,BAO_0000218,10948,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 1/3 dose range; 6/-7,Intermediate,,50588,,9025,1637.0,9615.0,Canis lupus familiaris,,CHEMBL625093,,,In vivo,,A,1,1,
Artery,BAO_0000218,10949,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 10/30 dose range; -13/19,Intermediate,,50588,,9025,1637.0,9615.0,Canis lupus familiaris,,CHEMBL625094,,,In vivo,,A,1,1,
Artery,BAO_0000218,10950,N,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 3/10 dose range; 30/47,Intermediate,,50588,,9025,1637.0,9615.0,Canis lupus familiaris,,CHEMBL625095,,,In vivo,,A,1,1,
,BAO_0000218,10951,N,Compound was evaluated for its bioavailability in the dogs,Intermediate,,50588,,2249,,9615.0,Canis lupus familiaris,,CHEMBL625096,,,In vivo,,A,1,1,
,BAO_0000218,10952,N,Compound was evaluated for its bioavailability in the rats,Intermediate,,50597,,2249,,10116.0,Rattus norvegicus,,CHEMBL625097,,,In vivo,,A,1,1,
,BAO_0000218,10953,U,Compound was evaluated for oral bioavailability,Autocuration,,22224,,17515,,,,,CHEMBL882956,,,In vivo,,A,1,0,
,BAO_0000218,10954,N,Compound was evaluated for percentage of Oral bioavailability in rats,Intermediate,,50597,,14541,,10116.0,Rattus norvegicus,,CHEMBL625098,,,In vivo,,A,1,1,
,BAO_0000218,10955,U,Bioavailability in guinea pig,Autocuration,,22224,,12797,,10141.0,Cavia porcellus,,CHEMBL625099,,,In vivo,,A,1,0,
,BAO_0000218,10956,N,Compound was evaluated for the oral bioavailability in rat,Intermediate,,50597,,12797,,10116.0,Rattus norvegicus,,CHEMBL625100,,,In vivo,,A,1,1,
,BAO_0000218,10957,N,Compound was evaluated for the oral bioavailability in dog,Intermediate,,50588,,12797,,9615.0,Canis lupus familiaris,,CHEMBL625101,,,In vivo,,A,1,1,
,BAO_0000218,10958,N,Compound was evaluated for the oral bioavailability in rat,Intermediate,,50597,,12797,,10116.0,Rattus norvegicus,,CHEMBL874396,,,In vivo,,A,1,1,
,BAO_0000218,10959,U,Bioavailability in dog (dosed i.v.),Autocuration,,22224,,11727,,9615.0,Canis lupus familiaris,,CHEMBL625102,,,In vivo,,F,1,0,
,BAO_0000218,10960,N,Compound was tested for in vivo bioavailability in dog,Intermediate,,50588,,13249,,9615.0,Canis lupus familiaris,,CHEMBL625103,,,In vivo,,A,1,1,
,BAO_0000218,10961,N,Compound was tested for in vivo bioavailability in hamsters,Intermediate,,100712,,13249,,10026.0,Cricetinae,,CHEMBL625104,,,In vivo,,A,1,1,
,BAO_0000218,10962,U,Compound was tested for in vivo bioavailability in monkey,Autocuration,,22224,,13249,,314293.0,Simiiformes,,CHEMBL625105,,,In vivo,,A,1,0,
,BAO_0000218,10963,N,Compound was tested for in vivo bioavailability in rat,Intermediate,,50597,,13249,,10116.0,Rattus norvegicus,,CHEMBL625106,,,In vivo,,A,1,1,
,BAO_0000218,10964,U,Oral bioavailability in mouse,Autocuration,,22224,,9552,,10090.0,Mus musculus,,CHEMBL625107,,,In vivo,,A,1,0,
,BAO_0000218,10965,N,Compound was tested for percent of oral bioavailability in mice; 56-74,Intermediate,,50594,,9552,,10090.0,Mus musculus,,CHEMBL625108,,,In vivo,,A,1,1,
,BAO_0000218,10966,U,Oral bioavailability in mouse (nude) (dose of 25 mg/kg),Autocuration,,22224,,14839,,10090.0,Mus musculus,,CHEMBL625109,,,In vivo,,A,1,0,
,BAO_0000218,10967,U,Bioavailability in cynomolgus monkey (dose 25 mg/kg i.v.),Autocuration,,22224,,14839,,9541.0,Macaca fascicularis,,CHEMBL625110,,,In vivo,,A,1,0,
,BAO_0000218,10968,U,Bioavailability in cynomolgus monkey (dose 5 mg/kg i.v.),Autocuration,,22224,,14839,,9541.0,Macaca fascicularis,,CHEMBL625111,,,In vivo,,A,1,0,
,BAO_0000218,10969,N,Oral bioavailability in mouse (nude) (dose 25 mg/kg i.v.),Intermediate,,50594,,14839,,10090.0,Mus musculus,,CHEMBL625112,,,In vivo,,A,1,1,
,BAO_0000218,10970,N,Oral bioavailability in nude mice,Intermediate,,50594,,14839,,10090.0,Mus musculus,,CHEMBL875334,,,In vivo,,A,1,1,
,BAO_0000218,10971,U,Bioavailability in monkey (i.d. dosing),Autocuration,,22224,,11219,,9443.0,Primates,,CHEMBL628617,,,In vivo,,A,1,0,
,BAO_0000218,10972,U,Bioavailability in rat,Autocuration,,22224,,9552,,10116.0,Rattus norvegicus,,CHEMBL628618,,,In vivo,,A,1,0,
,BAO_0000218,10973,U,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 10%,Autocuration,,22224,,11732,,,,,CHEMBL628619,,,In vivo,,A,1,0,
,BAO_0000218,10974,U,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 20%,Autocuration,,22224,,11732,,,,,CHEMBL628620,,,In vivo,,A,1,0,
,BAO_0000218,10975,N,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",Intermediate,,100710,,14839,,9541.0,Macaca fascicularis,,CHEMBL628621,,,In vivo,,A,1,1,
,BAO_0000218,10976,N,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",Intermediate,,100710,,14839,,9541.0,Macaca fascicularis,,CHEMBL628622,,,In vivo,,A,1,1,
,BAO_0000218,10977,N,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",Intermediate,,100710,,14839,,9541.0,Macaca fascicularis,,CHEMBL628623,,,In vivo,,A,1,1,
Plasma,BAO_0000218,10978,N,Maximal plasma concentration in cynomolgus monkeys after 10 mg/kg oral dose,Intermediate,,100710,,14839,1969.0,9541.0,Macaca fascicularis,,CHEMBL628624,,,In vivo,,A,1,1,
Plasma,BAO_0000218,10979,N,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Intermediate,,50594,,14839,1969.0,10090.0,Mus musculus,,CHEMBL628625,,,In vivo,,A,1,1,
Plasma,BAO_0000218,10980,N,Maximal plasma concentration in cynomolgus monkeys after 5 mg/kg oral dose,Intermediate,,100710,,14839,1969.0,9541.0,Macaca fascicularis,,CHEMBL628626,,,In vivo,,A,1,1,
Plasma,BAO_0000218,10981,N,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Intermediate,,50594,,14839,1969.0,10090.0,Mus musculus,,CHEMBL627041,,,In vivo,,A,1,1,
Plasma,BAO_0000218,10982,N,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Intermediate,,50594,,14839,1969.0,10090.0,Mus musculus,,CHEMBL627042,,,In vivo,,A,1,1,
Plasma,BAO_0000218,10983,N,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Intermediate,,50594,,14839,1969.0,10090.0,Mus musculus,,CHEMBL627043,,,In vivo,,A,1,1,
Plasma,BAO_0000218,10984,U,In vivo evaluation of maximum plasma concentration at a dose of 10 mg/kg,Autocuration,,22224,,13932,1969.0,,,,CHEMBL627044,,,In vivo,,A,1,0,
Plasma,BAO_0000218,10985,N,Cmax in mouse plasma,Intermediate,,50594,,11637,1969.0,10090.0,Mus musculus,,CHEMBL627045,,,In vivo,,A,1,1,
Plasma,BAO_0000218,10986,U,Max plasma concentration was measured by 40 mg/kg dose of peroral administration.,Autocuration,,22224,,11637,1969.0,,,,CHEMBL627046,,,In vivo,,A,1,0,
Plasma,BAO_0000218,10987,N,Maximal plasma concentration in rat,Intermediate,,50597,,13960,1969.0,10116.0,Rattus norvegicus,,CHEMBL627047,,,In vivo,,A,1,1,
Plasma,BAO_0000218,10988,N,Maximal plasma level when administered 1 mg/kg perorally (po) in rat,Intermediate,,50597,,15905,1969.0,10116.0,Rattus norvegicus,,CHEMBL627048,,,In vivo,,A,1,1,
,BAO_0000218,10989,N,Maximum concentration at an intraduodenal dose of 5.2 mg/kg in rat,Intermediate,,50597,,14062,,10116.0,Rattus norvegicus,,CHEMBL627049,,,In vivo,,A,1,1,
,BAO_0000218,10990,N,Maximum concentration at an intraduodenal dose of 6.6 mg/kg in rat,Intermediate,,50597,,14062,,10116.0,Rattus norvegicus,,CHEMBL627050,,,In vivo,,A,1,1,
,BAO_0000218,10991,N,Maximum concentration at an intravenous dose of 5.5 mg/kg in rat,Intermediate,,50597,,14062,,10116.0,Rattus norvegicus,,CHEMBL627051,,,In vivo,,A,1,1,
,BAO_0000218,10992,N,Maximum concentration at an intravenous dose of 6.5 mg/kg in rat,Intermediate,,50597,,14062,,10116.0,Rattus norvegicus,,CHEMBL627052,,,In vivo,,A,1,1,
,BAO_0000218,10993,N,Maximum concentration at an peroral dose of 6.2 mg/kg in rat,Intermediate,,50597,,14062,,10116.0,Rattus norvegicus,,CHEMBL627053,,,In vivo,,A,1,1,
,BAO_0000218,10994,N,Maximum concentration at an peroral dose of 6.3 mg/kg in rat,Intermediate,,50597,,14062,,10116.0,Rattus norvegicus,,CHEMBL627054,,,In vivo,,A,1,1,
,BAO_0000218,10995,N,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,Intermediate,,50594,,15011,,10090.0,Mus musculus,,CHEMBL627055,,,In vivo,,A,1,1,
,BAO_0000218,10996,N,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,Intermediate,,50594,,15011,,10090.0,Mus musculus,,CHEMBL627056,,,In vivo,,A,1,1,
,BAO_0000218,10997,N,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),Intermediate,,50594,,15011,,10090.0,Mus musculus,,CHEMBL627057,,,In vivo,,A,1,1,
,BAO_0000218,10998,N,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,Intermediate,,50594,,15011,,10090.0,Mus musculus,,CHEMBL627058,,,In vivo,,A,1,1,
,BAO_0000218,10999,N,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,Intermediate,,50594,,15011,,10090.0,Mus musculus,,CHEMBL626211,,,In vivo,,A,1,1,
,BAO_0000218,11000,U,Maximum Concentration of the compound.,Autocuration,,22224,,10291,,,,,CHEMBL626212,,,In vivo,,A,1,0,
,BAO_0000218,11001,N,Maximum Concentration was measured after iv administration into Beagle dog,Intermediate,,50588,,14599,,9615.0,Canis lupus familiaris,,CHEMBL626213,,,In vivo,,A,1,1,
,BAO_0000218,11002,N,Maximum Concentration was measured after iv administration into Beagle dog.,Intermediate,,50588,,14599,,9615.0,Canis lupus familiaris,,CHEMBL626214,,,In vivo,,A,1,1,
,BAO_0000218,11003,N,Maximum Concentration was measured after po administration into Beagle dog,Intermediate,,50588,,14599,,9615.0,Canis lupus familiaris,,CHEMBL626215,,,In vivo,,A,1,1,
,BAO_0000218,11004,N,Maximum Concentration was measured after po administration into Beagle dog.,Intermediate,,50588,,14599,,9615.0,Canis lupus familiaris,,CHEMBL626216,,,In vivo,,A,1,1,
Blood,BAO_0000218,11005,U,Maximum blood level reached after an dose of 10.6 uM/kg intravenously,Autocuration,,22224,,12767,178.0,,,,CHEMBL626217,,,In vivo,,A,1,0,
Blood,BAO_0000218,11006,U,Maximum blood level reached after an iv dose of 12.2 uM/kg,Autocuration,,22224,,12767,178.0,,,,CHEMBL626218,,,In vivo,,A,1,0,
Blood,BAO_0000218,11007,U,Maximum blood level reached after an oral dose 14.7 uM/kg oral route,Autocuration,,22224,,12767,178.0,,,,CHEMBL626219,,,In vivo,,A,1,0,
Blood,BAO_0000218,11008,U,Maximum blood level reached after an oral dose of 14.7 uM/kg intravenous route,Autocuration,,22224,,12767,178.0,,,,CHEMBL626220,,,In vivo,,A,1,0,
Blood,BAO_0000218,11009,U,Maximum blood level reached after an oral dose of 5.0 mg/kg,Autocuration,,22224,,12767,178.0,,,,CHEMBL626221,,,In vivo,,A,1,0,
Blood,BAO_0000218,11010,U,Maximum blood level reached at dose of 10.6 uM/kg orally,Autocuration,,22224,,12767,178.0,,,,CHEMBL626222,,,In vivo,,A,1,0,
,BAO_0000218,11011,N,Maximum concentration (Cmax) in guinea pigs at 2 mg/kg after oral administration,Intermediate,,50512,,14706,,10141.0,Cavia porcellus,,CHEMBL626223,,,In vivo,,A,1,1,
,BAO_0000218,11012,N,Maximum concentration (Cmax) in guinea pigs at 3 mg/kg after oral administration,Intermediate,,50512,,14706,,10141.0,Cavia porcellus,,CHEMBL626224,,,In vivo,,A,1,1,
Brain,BAO_0000218,11013,N,Maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg,Intermediate,,50597,,14793,955.0,10116.0,Rattus norvegicus,,CHEMBL626225,,,In vivo,,A,1,1,
Brain,BAO_0000218,11014,N,Maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg,Intermediate,,50597,,14793,955.0,10116.0,Rattus norvegicus,,CHEMBL626226,,,In vivo,,A,1,1,
Brain,BAO_0000218,11015,N,Maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg,Intermediate,,50597,,14793,955.0,10116.0,Rattus norvegicus,,CHEMBL626227,,,In vivo,,A,1,1,
Brain,BAO_0000218,11016,N,Maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg,Intermediate,,50597,,14793,955.0,10116.0,Rattus norvegicus,,CHEMBL626228,,,In vivo,,A,1,1,
,BAO_0000218,11017,N,Maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,Intermediate,,50597,,14793,,10116.0,Rattus norvegicus,,CHEMBL626229,,,In vivo,,A,1,1,
,BAO_0000218,11018,N,Maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg,Intermediate,,50597,,14793,,10116.0,Rattus norvegicus,,CHEMBL626921,,,In vivo,,A,1,1,
,BAO_0000218,11019,N,Maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg,Intermediate,,50597,,14793,,10116.0,Rattus norvegicus,,CHEMBL876793,,,In vivo,,A,1,1,
,BAO_0000218,11020,N,Maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg,Intermediate,,50597,,14793,,10116.0,Rattus norvegicus,,CHEMBL625309,,,In vivo,,A,1,1,
,BAO_0000218,11021,N,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),Intermediate,,50278,,10524,,1423.0,Bacillus subtilis,,CHEMBL625310,,,In vivo,,A,1,1,
,BAO_0000218,11022,U,Maximum concentration determined in monkeys dosed intravenously with 30 mg/kg,Autocuration,,22224,,11871,,314293.0,Simiiformes,,CHEMBL625311,,,In vivo,,A,1,0,
,BAO_0000218,11023,N,Maximum concentration determined in rats dosed intravenously with 20 mg/kg,Intermediate,,50597,,11871,,10116.0,Rattus norvegicus,,CHEMBL625312,,,In vivo,,A,1,1,
,BAO_0000218,11024,U,Maximum concentration for the bioavailability at a dose of 20 mg/kg administered orally,Autocuration,,22224,,3437,,,,,CHEMBL625313,,,In vivo,,A,1,0,
,BAO_0000218,11025,N,Maximum concentration in male CD-1 mice after sc administration of 20 mg/kg,Intermediate,,50594,,12038,,10090.0,Mus musculus,,CHEMBL625314,,,In vivo,,A,1,1,
,BAO_0000218,11026,N,Maximum concentration in male rats after iv administration of 20 mg/kg,Intermediate,,50597,,12038,,10116.0,Rattus norvegicus,,CHEMBL625315,,,In vivo,,A,1,1,
Liver,BAO_0000218,11027,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.06-1.29,Intermediate,,50597,,8418,2107.0,10116.0,Rattus norvegicus,,CHEMBL625316,,,,,A,1,1,
Liver,BAO_0000218,11028,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.77-2.08,Intermediate,,50597,,8418,2107.0,10116.0,Rattus norvegicus,,CHEMBL625317,,,,,A,1,1,
Liver,BAO_0000218,11029,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.89,Intermediate,,50597,,8418,2107.0,10116.0,Rattus norvegicus,,CHEMBL625318,,,,,A,1,1,
Liver,BAO_0000218,11030,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.57-1.66,Intermediate,,50597,,8418,2107.0,10116.0,Rattus norvegicus,,CHEMBL625319,,,,,A,1,1,
Liver,BAO_0000218,11031,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.06-2.71,Intermediate,,50597,,8418,2107.0,10116.0,Rattus norvegicus,,CHEMBL625320,,,,,A,1,1,
Liver,BAO_0000218,11032,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.98-3.22,Intermediate,,50597,,8418,2107.0,10116.0,Rattus norvegicus,,CHEMBL625321,,,,,A,1,1,
Liver,BAO_0000218,11033,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.73-1.45,Intermediate,,50597,,8418,2107.0,10116.0,Rattus norvegicus,,CHEMBL625322,,,,,A,1,1,
Liver,BAO_0000218,11034,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.03-1.31,Intermediate,,50597,,8418,2107.0,10116.0,Rattus norvegicus,,CHEMBL876801,,,,,A,1,1,
Liver,BAO_0000218,11035,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 6.76-10.44,Intermediate,,50597,,8418,2107.0,10116.0,Rattus norvegicus,,CHEMBL625323,,,,,A,1,1,
Liver,BAO_0000218,11036,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.47-1.17,Intermediate,,50597,,8418,2107.0,10116.0,Rattus norvegicus,,CHEMBL625324,,,,,A,1,1,
Liver,BAO_0000218,11037,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.12-1.44,Intermediate,,50597,,8418,2107.0,10116.0,Rattus norvegicus,,CHEMBL625325,,,,,A,1,1,
Liver,BAO_0000218,11038,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.38-0.57,Intermediate,,50597,,8418,2107.0,10116.0,Rattus norvegicus,,CHEMBL625326,,,,,A,1,1,
Liver,BAO_0000218,11039,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.75-1.14,Intermediate,,50597,,8418,2107.0,10116.0,Rattus norvegicus,,CHEMBL625327,,,,,A,1,1,
Liver,BAO_0000218,11040,N,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 1.36-1.74,Intermediate,,50597,,8418,2107.0,10116.0,Rattus norvegicus,,CHEMBL625328,,,,,A,1,1,
Lung,BAO_0000218,11041,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.5,Intermediate,,50597,,8418,2048.0,10116.0,Rattus norvegicus,,CHEMBL625329,,,,,A,1,1,
Lung,BAO_0000218,11042,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 3.10-3.77,Intermediate,,50597,,8418,2048.0,10116.0,Rattus norvegicus,,CHEMBL625330,,,,,A,1,1,
Lung,BAO_0000218,11043,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.4-0.54,Intermediate,,50597,,8418,2048.0,10116.0,Rattus norvegicus,,CHEMBL627774,,,,,A,1,1,
Lung,BAO_0000218,11044,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.58-0.86,Intermediate,,50597,,8418,2048.0,10116.0,Rattus norvegicus,,CHEMBL627775,,,,,A,1,1,
Lung,BAO_0000218,11045,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.77-0.86,Intermediate,,50597,,8418,2048.0,10116.0,Rattus norvegicus,,CHEMBL627949,,,,,A,1,1,
Lung,BAO_0000218,11046,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.86-1.13,Intermediate,,50597,,8418,2048.0,10116.0,Rattus norvegicus,,CHEMBL627950,,,,,A,1,1,
Lung,BAO_0000218,11047,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 2.26-2.89,Intermediate,,50597,,8418,2048.0,10116.0,Rattus norvegicus,,CHEMBL627951,,,,,A,1,1,
Lung,BAO_0000218,11048,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.7,Intermediate,,50597,,8418,2048.0,10116.0,Rattus norvegicus,,CHEMBL627952,,,,,A,1,1,
Lung,BAO_0000218,11049,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.6-0.66,Intermediate,,50597,,8418,2048.0,10116.0,Rattus norvegicus,,CHEMBL627953,,,,,A,1,1,
Lung,BAO_0000218,11050,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.35-1.74,Intermediate,,50597,,8418,2048.0,10116.0,Rattus norvegicus,,CHEMBL627954,,,,,A,1,1,
Lung,BAO_0000218,11051,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.62-7.08,Intermediate,,50597,,8418,2048.0,10116.0,Rattus norvegicus,,CHEMBL627955,,,,,A,1,1,
Lung,BAO_0000218,11052,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.47-0.56,Intermediate,,50597,,8418,2048.0,10116.0,Rattus norvegicus,,CHEMBL627956,,,,,A,1,1,
Lung,BAO_0000218,11053,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.54-1.07,Intermediate,,50597,,8418,2048.0,10116.0,Rattus norvegicus,,CHEMBL876802,,,,,A,1,1,
Lung,BAO_0000218,11054,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.76-0.91,Intermediate,,50597,,8418,2048.0,10116.0,Rattus norvegicus,,CHEMBL627957,,,,,A,1,1,
Lung,BAO_0000218,11055,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.61-0.86,Intermediate,,50597,,8418,2048.0,10116.0,Rattus norvegicus,,CHEMBL627958,,,,,A,1,1,
Lung,BAO_0000218,11056,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 2.11-3.79,Intermediate,,50597,,8418,2048.0,10116.0,Rattus norvegicus,,CHEMBL627959,,,,,A,1,1,
Lung,BAO_0000218,11057,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.3-0.36,Intermediate,,50597,,8418,2048.0,10116.0,Rattus norvegicus,,CHEMBL627960,,,,,A,1,1,
Lung,BAO_0000218,11058,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.36-0.44,Intermediate,,50597,,8418,2048.0,10116.0,Rattus norvegicus,,CHEMBL627961,,,,,A,1,1,
Lung,BAO_0000218,11059,N,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.5-0.65,Intermediate,,50597,,8418,2048.0,10116.0,Rattus norvegicus,,CHEMBL627962,,,,,A,1,1,
,BAO_0000218,11060,N,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,Intermediate,,50597,,9796,,10116.0,Rattus norvegicus,,CHEMBL627963,,,,,A,1,1,
,BAO_0000218,11061,N,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,Intermediate,,50597,,9796,,10116.0,Rattus norvegicus,,CHEMBL624759,,,,,A,1,1,
,BAO_0000218,11062,N,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,Intermediate,,50597,,9796,,10116.0,Rattus norvegicus,,CHEMBL624760,,,,,A,1,1,
,BAO_0000218,11063,N,Distribution of radiolabeled compound in intestinal contents of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,Intermediate,,50597,,9796,,10116.0,Rattus norvegicus,,CHEMBL624761,,,,,A,1,1,
,BAO_0000218,11064,N,Distribution of radiolabeled compound in intestinal contents of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,Intermediate,,50597,,9796,,10116.0,Rattus norvegicus,,CHEMBL877607,,,,,A,1,1,
Liver,BAO_0000218,11065,N,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,Intermediate,,50597,,9796,2107.0,10116.0,Rattus norvegicus,,CHEMBL624762,,,,,A,1,1,
Liver,BAO_0000218,11066,N,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,Intermediate,,50597,,9796,2107.0,10116.0,Rattus norvegicus,,CHEMBL624763,,,,,A,1,1,
Liver,BAO_0000218,11067,N,Distribution of radiolabeled compound in liver of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,Intermediate,,50597,,9796,2107.0,10116.0,Rattus norvegicus,,CHEMBL624764,,,,,A,1,1,
Liver,BAO_0000218,11068,N,Distribution of radiolabeled compound in liver of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,Intermediate,,50597,,9796,2107.0,10116.0,Rattus norvegicus,,CHEMBL624765,,,,,A,1,1,
Liver,BAO_0000218,11069,N,Distribution of radiolabeled compound in liver of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,Intermediate,,50597,,9796,2107.0,10116.0,Rattus norvegicus,,CHEMBL624766,,,,,A,1,1,
,BAO_0000218,11070,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),Intermediate,,50588,,6996,,9615.0,Canis lupus familiaris,,CHEMBL624767,,,,,A,1,1,
,BAO_0000218,11071,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration,Intermediate,,50588,,6996,,9615.0,Canis lupus familiaris,,CHEMBL624768,,,,,A,1,1,
,BAO_0000218,11072,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),Intermediate,,50588,,6996,,9615.0,Canis lupus familiaris,,CHEMBL624769,,,,,A,1,1,
,BAO_0000218,11073,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),Intermediate,,50588,,6996,,9615.0,Canis lupus familiaris,,CHEMBL624770,,,,,A,1,1,
,BAO_0000218,11074,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),Intermediate,,50588,,6996,,9615.0,Canis lupus familiaris,,CHEMBL624771,,,,,A,1,1,
,BAO_0000218,11075,N,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),Intermediate,,50588,,6996,,9615.0,Canis lupus familiaris,,CHEMBL624772,,,,,A,1,1,
,BAO_0000218,11076,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration,Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL624773,,,,,A,1,1,
,BAO_0000218,11077,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL624774,,,,,A,1,1,
,BAO_0000218,11078,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL624775,,,,,A,1,1,
,BAO_0000218,11079,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL624776,,,,,A,1,1,
,BAO_0000218,11080,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL624777,,,,,A,1,1,
,BAO_0000218,11081,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL624778,,,,,A,1,1,
,BAO_0000218,11082,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration,Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL624779,,,,,A,1,1,
,BAO_0000218,11083,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL624780,,,,,A,1,1,
,BAO_0000218,11084,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL624781,,,,,A,1,1,
,BAO_0000218,11085,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL877608,,,,,A,1,1,
,BAO_0000218,11086,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL624782,,,,,A,1,1,
,BAO_0000218,11087,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL624783,,,,,A,1,1,
,BAO_0000218,11088,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration,Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL624784,,,,,A,1,1,
,BAO_0000218,11089,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL624785,,,,,A,1,1,
,BAO_0000218,11090,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL624786,,,,,A,1,1,
,BAO_0000218,11091,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL624787,,,,,A,1,1,
,BAO_0000218,11092,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL628676,,,,,A,1,1,
,BAO_0000218,11093,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration,Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL621842,,,,,A,1,1,
,BAO_0000218,11094,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL621843,,,,,A,1,1,
,BAO_0000218,11095,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL623873,,,,,A,1,1,
,BAO_0000218,11096,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL623874,,,,,A,1,1,
,BAO_0000218,11097,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL623875,,,,,A,1,1,
,BAO_0000218,11098,N,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),Intermediate,,50597,,6996,,10116.0,Rattus norvegicus,,CHEMBL623876,,,,,A,1,1,
,BAO_0000218,11099,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.312 mg/kg after ip administration,Intermediate,,50588,,6996,,9615.0,Canis lupus familiaris,,CHEMBL623877,,,,,A,1,1,
,BAO_0000218,11100,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),Intermediate,,50588,,6996,,9615.0,Canis lupus familiaris,,CHEMBL623878,,,,,A,1,1,
,BAO_0000218,11101,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.625 mg/kg after ip administration,Intermediate,,50588,,6996,,9615.0,Canis lupus familiaris,,CHEMBL623879,,,,,A,1,1,
,BAO_0000218,11102,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),Intermediate,,50588,,6996,,9615.0,Canis lupus familiaris,,CHEMBL623880,,,,,A,1,1,
,BAO_0000218,11103,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),Intermediate,,50588,,6996,,9615.0,Canis lupus familiaris,,CHEMBL623881,,,,,A,1,1,
,BAO_0000218,11104,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),Intermediate,,50588,,6996,,9615.0,Canis lupus familiaris,,CHEMBL623957,,,,,A,1,1,
,BAO_0000218,11105,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),Intermediate,,50588,,6996,,9615.0,Canis lupus familiaris,,CHEMBL623958,,,,,A,1,1,
,BAO_0000218,11106,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),Intermediate,,50588,,6996,,9615.0,Canis lupus familiaris,,CHEMBL623959,,,,,A,1,1,
,BAO_0000218,11107,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),Intermediate,,50588,,6996,,9615.0,Canis lupus familiaris,,CHEMBL623960,,,,,A,1,1,
,BAO_0000218,11108,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),Intermediate,,50588,,6996,,9615.0,Canis lupus familiaris,,CHEMBL623961,,,,,A,1,1,
,BAO_0000218,11109,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),Intermediate,,50588,,6996,,9615.0,Canis lupus familiaris,,CHEMBL623962,,,,,A,1,1,
,BAO_0000218,11110,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),Intermediate,,50588,,6996,,9615.0,Canis lupus familiaris,,CHEMBL624676,,,,,A,1,1,
,BAO_0000218,11111,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),Intermediate,,50588,,6996,,9615.0,Canis lupus familiaris,,CHEMBL624677,,,,,A,1,1,
,BAO_0000218,11112,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration,Intermediate,,50588,,6996,,9615.0,Canis lupus familiaris,,CHEMBL624678,,,,,A,1,1,
,BAO_0000218,11113,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),Intermediate,,50588,,6996,,9615.0,Canis lupus familiaris,,CHEMBL624679,,,,,A,1,1,
,BAO_0000218,11114,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),Intermediate,,50588,,6996,,9615.0,Canis lupus familiaris,,CHEMBL624680,,,,,A,1,1,
,BAO_0000218,11115,U,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 27%,Autocuration,,22224,,11732,,,,,CHEMBL624849,,,In vivo,,A,1,0,
,BAO_0000218,11116,U,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 4%,Autocuration,,22224,,11732,,,,,CHEMBL624850,,,In vivo,,A,1,0,
,BAO_0000218,11117,U,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 54%,Autocuration,,22224,,11732,,,,,CHEMBL874399,,,In vivo,,A,1,0,
,BAO_0000218,11118,U,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 72%,Autocuration,,22224,,11732,,,,,CHEMBL624851,,,In vivo,,A,1,0,
,BAO_0000218,11119,U,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 76%,Autocuration,,22224,,11732,,,,,CHEMBL624852,,,In vivo,,A,1,0,
,BAO_0000218,11120,U,Oral bioavailability in rat (dose 10 mg/kg),Autocuration,,22224,,13359,,10116.0,Rattus norvegicus,,CHEMBL624853,,,In vivo,,A,1,0,
,BAO_0000218,11121,U,Oral bioavailability in rat (Sprague-Dawley),Autocuration,,22224,,16618,,10116.0,Rattus norvegicus,,CHEMBL624854,,,In vivo,,A,1,0,
,BAO_0000218,11122,U,Oral bioavailability in rat,Autocuration,,22224,,13960,,10116.0,Rattus norvegicus,,CHEMBL624855,,,In vivo,,A,1,0,
,BAO_0000218,11123,U,Oral bioavailability in rats was determined in vivo,Autocuration,,22224,,13917,,10116.0,Rattus norvegicus,,CHEMBL624856,,,In vivo,,A,1,0,
,BAO_0000218,11124,U,Oral bioavailability in dog,Autocuration,,22224,,14266,,9615.0,Canis lupus familiaris,,CHEMBL882957,,,In vivo,,A,1,0,
,BAO_0000218,11125,U,Oral bioavailability of compound in monkey,Autocuration,,22224,,12359,,314293.0,Simiiformes,,CHEMBL624857,,,In vivo,,A,1,0,
,BAO_0000218,11126,N,Oral bioavailability of compound in rat,Intermediate,,50597,,12359,,10116.0,Rattus norvegicus,,CHEMBL622202,,,In vivo,,A,1,1,
,BAO_0000218,11127,U,Bioavailability in rat of PMEA prodrug,Autocuration,,22224,,12359,,10116.0,Rattus norvegicus,,CHEMBL622203,,,In vivo,,A,1,0,
,BAO_0000218,11128,N,Oral bioavailability of compound was evaluated relative to that of PMEA in rat; Not determined due to lack of solubility,Intermediate,,50597,,12359,,10116.0,Rattus norvegicus,,CHEMBL625522,,,In vivo,,A,1,1,
,BAO_0000218,11129,U,Serum conc at 3 hours following 25 mg/kg dose,Autocuration,,22224,,10791,,9544.0,Macaca mulatta,,CHEMBL622868,,,In vivo,,A,1,0,
Urine,BAO_0000218,11130,U,Urine conc 0-5 hours following 25 mg/kg dose,Autocuration,,22224,,10791,1088.0,9544.0,Macaca mulatta,,CHEMBL622869,,,In vivo,,A,1,0,
Urine,BAO_0000218,11131,U,Urine conc 0-24 hours following 25 mg/kg dose,Autocuration,,22224,,10791,1088.0,9544.0,Macaca mulatta,,CHEMBL622870,,,In vivo,,A,1,0,
,BAO_0000218,11132,U,Oral bioavailability in African green monkeys; 20-25,Autocuration,,22224,,138,,9534.0,Chlorocebus aethiops,,CHEMBL622871,,,In vivo,,A,1,0,
,BAO_0000218,11133,N,Oral bioavailability in cynomolgus monkey.,Intermediate,,100710,,14521,,9541.0,Macaca fascicularis,,CHEMBL620560,,,In vivo,,A,1,1,
,BAO_0000218,11134,U,Oral bioavailability in dog,Autocuration,,22224,,13953,,9615.0,Canis lupus familiaris,,CHEMBL620561,,,In vivo,,A,1,0,
,BAO_0000218,11135,N,Oral bioavailability in dog at 10 mg/kg oral dose,Intermediate,,50588,,12836,,9615.0,Canis lupus familiaris,,CHEMBL620562,,,In vivo,,A,1,1,
,BAO_0000218,11136,N,Oral bioavailability in hamster at 10 mg/kg oral dose,Intermediate,,100712,,12836,,10026.0,Cricetinae,,CHEMBL620563,,,In vivo,,A,1,1,
,BAO_0000218,11137,N,Oral bioavailability in rat at 10 mg/kg oral dose,Intermediate,,50597,,12836,,10116.0,Rattus norvegicus,,CHEMBL620564,,,In vivo,,A,1,1,
,BAO_0000218,11138,U,Oral bioavailability in rat,Autocuration,,22224,,14521,,10116.0,Rattus norvegicus,,CHEMBL872265,,,In vivo,,A,1,0,
,BAO_0000218,11139,U,Oral bioavailability in rat,Autocuration,,22224,,13953,,10116.0,Rattus norvegicus,,CHEMBL620565,,,In vivo,,A,1,0,
,BAO_0000218,11140,U,Oral bioavailability,Autocuration,,22224,,6799,,9347.0,Eutheria,,CHEMBL620566,,,In vivo,,A,1,0,
,BAO_0000218,11141,U,Oral bioavailability was determined; range 49-102%,Autocuration,,22224,,11311,,,,,CHEMBL620567,,,In vivo,,A,1,0,
,BAO_0000218,11142,N,Oral bioavailability was determined in dogs,Intermediate,,50588,,4013,,9615.0,Canis lupus familiaris,,CHEMBL620568,,,In vivo,,A,1,1,
,BAO_0000218,11143,U,Oral bioavailability in rat,Autocuration,,22224,,4013,,10116.0,Rattus norvegicus,,CHEMBL620569,,,In vivo,,A,1,0,
,BAO_0000218,11144,U,Oral bioavailability,Autocuration,,22224,,17591,,9347.0,Eutheria,,CHEMBL620570,,,In vivo,,A,1,0,
,BAO_0000218,11145,U,Oral bioavailability was determined; Not orally available,Autocuration,,22224,,17591,,,,,CHEMBL620571,,,In vivo,,A,1,0,
,BAO_0000218,11146,N,Percent bioavailability was administered by using 0.4% Methyl cellulose (MC) as vehicle to nude mice at a dose of 25 mg/kg (micronized sample),Intermediate,,50594,,15011,,10090.0,Mus musculus,,CHEMBL620572,,,In vivo,,A,1,1,
,BAO_0000218,11147,U,Bioavailability in mouse (nude) (dose 0.4% Methylcellulose (MC) as vehicle 25 mg/kg),Autocuration,,22224,,15011,,10090.0,Mus musculus,,CHEMBL620573,,,In vivo,,A,1,0,
,BAO_0000218,11148,U,Bioavailability in mouse (nude) using 20% aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle 25 mg/kg,Autocuration,,22224,,15011,,10090.0,Mus musculus,,CHEMBL620574,,,In vivo,,A,1,0,
,BAO_0000218,11149,U,Oral bioavailability in Rhesus monkey,Autocuration,,22224,,9552,,9544.0,Macaca mulatta,,CHEMBL620575,,,In vivo,,A,1,0,
,BAO_0000218,11150,U,Oral bioavailability in dog (female mongrel),Autocuration,,22224,,9552,,9615.0,Canis lupus familiaris,,CHEMBL620576,,,In vivo,,A,1,0,
,BAO_0000218,11151,U,Percent oral bioavailability of perorally administered compound (30 mg/kg) was tested,Autocuration,,22224,,3639,,,,,CHEMBL875846,,,In vivo,,A,1,0,
,BAO_0000218,11152,U,Oral bioavailability in dog,Autocuration,,22224,,13397,,9615.0,Canis lupus familiaris,,CHEMBL620577,,,In vivo,,A,1,0,
,BAO_0000218,11153,U,Percentage Bioavailability was evaluated.,Autocuration,,22224,,3031,,,,,CHEMBL620578,,,In vivo,,A,1,0,
,BAO_0000218,11154,U,Bioavailability in rat administered i.d.,Autocuration,,22224,,12818,,10116.0,Rattus norvegicus,,CHEMBL620579,,,In vivo,,A,1,0,
,BAO_0000218,11155,U,Bioavailability,Autocuration,,22224,,4847,,9347.0,Eutheria,,CHEMBL621248,,,In vivo,,A,1,0,
,BAO_0000218,11156,U,Bioavailability in dog (male Beagle) i.v. administration,Autocuration,,22224,,12421,,9615.0,Canis lupus familiaris,,CHEMBL625390,,,In vivo,,A,1,0,
,BAO_0000218,11157,U,"Bioavailability in rat (dose 20 mg/kg p.o. in 1% methocel, and 5 mg/kg i.v. in PEG400)",Autocuration,,22224,,11966,,10116.0,Rattus norvegicus,,CHEMBL625391,,,In vivo,,A,1,0,
,BAO_0000218,11158,U,Bioavailability in monkey (dose 10 mg/kg i.d. or 0.3 mg/kg i.v.),Autocuration,,22224,,11218,,9443.0,Primates,,CHEMBL872266,,,In vivo,,A,1,0,
,BAO_0000218,11159,U,Oral bioavailability in rat (Sprague-Dawley) (male),Autocuration,,22224,,13129,,10116.0,Rattus norvegicus,,CHEMBL625392,,,In vivo,,A,1,0,
,BAO_0000218,11160,N,The oral bioavailability was measured on rats after oral administration,Intermediate,,50597,,12350,,10116.0,Rattus norvegicus,,CHEMBL625393,,,In vivo,,A,1,1,
,BAO_0000218,11161,N,Bioavailability was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,Intermediate,,50597,,2231,,10116.0,Rattus norvegicus,,CHEMBL625394,,,In vivo,,A,1,1,
,BAO_0000218,11162,N,Bioavailability was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,Intermediate,,50797,,2231,,9544.0,Macaca mulatta,,CHEMBL625395,,,In vivo,,A,1,1,
,BAO_0000218,11163,U,Bioavailability in rat (dose 10 mg/kg i.d.),Autocuration,,22224,,12187,,10116.0,Rattus norvegicus,,CHEMBL625396,,,In vivo,,A,1,0,
,BAO_0000218,11164,U,Bioavailability in dog (male Beagle) i.v. administration,Autocuration,,22224,,12421,,9615.0,Canis lupus familiaris,,CHEMBL625397,,,In vivo,,A,1,0,
,BAO_0000218,11165,N,Biodistribution in CD-1 mice was determined after 1 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,50594,,13256,,10090.0,Mus musculus,,CHEMBL625398,,,In vivo,,A,1,1,
Blood,BAO_0000218,11166,N,Biodistribution in CD-1 mice was determined after 1 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,50594,,13256,178.0,10090.0,Mus musculus,,CHEMBL625399,,,In vivo,,A,1,1,
Cerebellum,BAO_0000218,11167,N,Biodistribution in CD-1 mice was determined after 1 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,50594,,13256,2037.0,10090.0,Mus musculus,,CHEMBL626074,,,In vivo,,A,1,1,
,BAO_0000218,11168,N,Biodistribution in CD-1 mice was determined after 1 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),Intermediate,,50594,,13256,,10090.0,Mus musculus,,CHEMBL626075,,,In vivo,,A,1,1,
Plasma,BAO_0000218,11169,N,Maximum concentration in plasma (Cmax) was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,Intermediate,,50597,,2231,1969.0,10116.0,Rattus norvegicus,,CHEMBL626076,,,In vivo,,A,1,1,
Plasma,BAO_0000218,11170,N,Maximum concentration in plasma (Cmax) was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,Intermediate,,50797,,2231,1969.0,9544.0,Macaca mulatta,,CHEMBL626077,,,In vivo,,A,1,1,
Blood,BAO_0000218,11171,N,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 1 mg/kg in rat (normalized to a 1 mg/kg dose),Intermediate,,50597,,12178,178.0,10116.0,Rattus norvegicus,,CHEMBL626078,,,In vivo,,A,1,1,
Blood,BAO_0000218,11172,U,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 2.5 mg/kg in rat (normalized to a 1 mg/kg dose),Autocuration,,22224,,12178,178.0,,,,CHEMBL625846,,,In vivo,,A,1,0,
Blood,BAO_0000218,11173,U,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 5.0 mg/kg GP (normalized to a 1 mg/kg dose),Autocuration,,22224,,12178,178.0,,,,CHEMBL625847,,,In vivo,,A,1,0,
,BAO_0000218,11174,N,Maximum concentration observed in rats at an oral dose of 50 mg/kg,Expert,,50597,,15633,,10116.0,Rattus norvegicus,,CHEMBL625848,,,In vivo,,A,1,1,
Plasma,BAO_0000218,11175,N,Maximum concentration of compound in plasma administered orally to rats,Intermediate,,50597,,14258,1969.0,10116.0,Rattus norvegicus,,CHEMBL625849,,,In vivo,,A,1,1,
Plasma,BAO_0000218,11176,N,"Maximum concentration (10 mg/kg, orally) in plasma of dogs",Intermediate,,50588,,14224,1969.0,9615.0,Canis lupus familiaris,,CHEMBL626023,,,In vivo,,A,1,1,
Plasma,BAO_0000218,11177,N,"Maximum concentration (10 mg/kg, perorally) in plasma of dogs",Intermediate,,50588,,14224,1969.0,9615.0,Canis lupus familiaris,,CHEMBL626024,,,In vivo,,A,1,1,
Plasma,BAO_0000218,11178,N,"Maximum concentration (5 mg/kg, intravenously) in plasma of dogs",Intermediate,,50588,,14224,1969.0,9615.0,Canis lupus familiaris,,CHEMBL626025,,,In vivo,,A,1,1,
,BAO_0000218,11179,U,Maximum concentration after 10 mg/kg by oral administration,Autocuration,,22224,,5566,,,,,CHEMBL626026,,,In vivo,,A,1,0,
,BAO_0000218,11180,U,Maximum concentration at a dose of 1.5 mg/kg,Autocuration,,22224,,16935,,,,,CHEMBL626027,,,In vivo,,A,1,0,
,BAO_0000218,11181,U,Maximum concentration at a dose of 2.0 mg/kg,Autocuration,,22224,,16935,,,,,CHEMBL626028,,,In vivo,,A,1,0,
Plasma,BAO_0000218,11182,N,Maximum concentration in dog plasma,Intermediate,,50588,,14224,1969.0,9615.0,Canis lupus familiaris,,CHEMBL626029,,,In vivo,,A,1,1,
Plasma,BAO_0000218,11183,U,Maximum concentration in plasma after administration of 10 umol/kg dose perorally,Autocuration,,22224,,12536,1969.0,,,,CHEMBL626030,,,In vivo,,A,1,0,
Plasma,BAO_0000218,11184,U,Maximum concentration in plasma after administration of 2 umol/kg dose intravenously,Autocuration,,22224,,12536,1969.0,,,,CHEMBL626031,,,In vivo,,A,1,0,
Plasma,BAO_0000218,11185,U,Maximum concentration in plasma after administration of 4 umol/kg dose intravenously,Autocuration,,22224,,12536,1969.0,,,,CHEMBL626032,,,In vivo,,A,1,0,
Plasma,BAO_0000218,11186,U,Maximum concentration in plasma after administration of 40 umol/kg dose perorally,Autocuration,,22224,,12536,1969.0,,,,CHEMBL626033,,,In vivo,,A,1,0,
Plasma,BAO_0000218,11187,U,Maximum concentration in plasma after administration of 5 umol/kg dose intravenously,Autocuration,,22224,,12536,1969.0,,,,CHEMBL626034,,,In vivo,,A,1,0,
Plasma,BAO_0000218,11188,N,Maximum concentration in plasma after oral administration in dog (25 mg/kg),Intermediate,,50588,,9994,1969.0,9615.0,Canis lupus familiaris,,CHEMBL626035,,,In vivo,,A,1,1,
Plasma,BAO_0000218,11189,U,Maximum concentration in plasma at Tmax,Autocuration,,22224,,1434,1969.0,,,,CHEMBL626036,,,In vivo,,A,1,0,
Plasma,BAO_0000218,11190,N,Maximum concentration in plasma recorded 0-6 hr post dose in dog at 10 mg/kg oral dose,Expert,,50588,,12836,1969.0,9615.0,Canis lupus familiaris,,CHEMBL626037,,,In vivo,,A,1,1,
Plasma,BAO_0000218,11191,N,Maximum concentration in plasma recorded in the period 0-6 hr post dose in hamster at 10 mg/kg oral dose,Intermediate,,100712,,12836,1969.0,10026.0,Cricetinae,,CHEMBL626038,,,In vivo,,A,1,1,
Plasma,BAO_0000218,11192,N,Maximum concentration in plasma recorded in the period 0-6 hr post dose in rat at 10 mg/kg oral dose,Intermediate,,50597,,12836,1969.0,10116.0,Rattus norvegicus,,CHEMBL626039,,,In vivo,,A,1,1,
Plasma,BAO_0000218,11193,N,Maximum concentration in plasma was determined by oral administration to rats at 20 mg/kg,Intermediate,,50597,,12545,1969.0,10116.0,Rattus norvegicus,,CHEMBL626040,,,In vivo,,A,1,1,
Plasma,BAO_0000218,11194,N,Maximum concentration present in the rabbit plasma following peroral administration of 10 mg/kg,Intermediate,,50592,,13856,1969.0,9986.0,Oryctolagus cuniculus,,CHEMBL626041,,,In vivo,,A,1,1,
,BAO_0000218,11195,U,Maximum concentration was calculated,Autocuration,,22224,,3550,,,,,CHEMBL626042,,,In vivo,,A,1,0,
,BAO_0000218,11196,U,Maximum concentration was calculated.,Autocuration,,22224,,2632,,,,,CHEMBL626043,,,In vivo,,A,1,0,
,BAO_0000218,11197,U,Maximum concentration at a peroral dose of 10 mg/kg,Autocuration,,22224,,5566,,,,,CHEMBL626044,,,In vivo,,A,1,0,
,BAO_0000218,11198,U,Maximum concentration of the drug at 10 uM/dg administered perorally,Autocuration,,22224,,11883,,,,,CHEMBL626045,,,In vivo,,A,1,0,
,BAO_0000218,11199,U,Maximum concentration of the drug at 2 uM/dg administered intravenously,Autocuration,,22224,,11883,,,,,CHEMBL626046,,,In vivo,,A,1,0,
Plasma,BAO_0000218,11200,N,"Maximum concentration of the unchanged compound in dog plasma, recorded in the period 0-6 hr post dose.",Intermediate,,50588,,14122,1969.0,9615.0,Canis lupus familiaris,,CHEMBL626047,,,In vivo,,A,1,1,
Plasma,BAO_0000218,11201,N,"Maximum concentration of the unchanged compound in hamster plasma, recorded in the period 0-6 hr post dose.",Intermediate,,100712,,14122,1969.0,10026.0,Cricetinae,,CHEMBL626048,,,In vivo,,A,1,1,
Plasma,BAO_0000218,11202,N,"Maximum concentration of the unchanged compound in rat plasma, recorded in the period 0-6 hr post dose.",Intermediate,,50597,,14122,1969.0,10116.0,Rattus norvegicus,,CHEMBL626049,,,In vivo,,A,1,1,
Plasma,BAO_0000218,11203,N,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 60 mg/kg oral dose,Intermediate,,50597,,12542,1969.0,10116.0,Rattus norvegicus,,CHEMBL626050,,,In vivo,,A,1,1,
Plasma,BAO_0000218,11204,N,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in dog at 5 mg/kg oral dose,Intermediate,,50588,,12542,1969.0,9615.0,Canis lupus familiaris,,CHEMBL874541,,,In vivo,,A,1,1,
Plasma,BAO_0000218,11205,N,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in hamster at 40 mg/kg oral dose,Intermediate,,100712,,12542,1969.0,10026.0,Cricetinae,,CHEMBL622826,,,In vivo,,A,1,1,
Plasma,BAO_0000218,11206,N,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose to hamster at 40 mg/kg oral dose,Intermediate,,100712,,12542,1969.0,10026.0,Cricetinae,,CHEMBL622827,,,In vivo,,A,1,1,
Plasma,BAO_0000218,11207,N,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 25 mg/kg oral dose,Intermediate,,50597,,12542,1969.0,10116.0,Rattus norvegicus,,CHEMBL622828,,,In vivo,,A,1,1,
Plasma,BAO_0000218,11208,N,Maximum concentration of unchanged drug in rat plasma in the period 0-24 hr after dosing,Intermediate,,50597,,14080,1969.0,10116.0,Rattus norvegicus,,CHEMBL622829,,,In vivo,,A,1,1,
,BAO_0000218,11209,N,Maximum concentration reached following intravenous administration in male rat,Intermediate,,50597,,11911,,10116.0,Rattus norvegicus,,CHEMBL876806,,,In vivo,,A,1,1,
,BAO_0000218,11210,N,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog,Intermediate,,50588,,13204,,9615.0,Canis lupus familiaris,,CHEMBL622830,,,In vivo,,A,1,1,
,BAO_0000218,11211,N,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats,Intermediate,,50597,,13204,,10116.0,Rattus norvegicus,,CHEMBL622831,,,In vivo,,A,1,1,
,BAO_0000218,11212,N,Maximum concentration was measured after peroral administration of 10 mg/kg of drug in male Beagle dogs,Intermediate,,50588,,14346,,9615.0,Canis lupus familiaris,,CHEMBL626794,,,In vivo,,A,1,1,
,BAO_0000218,11213,N,Maximum concentration was measured after peroral administration of 5.0 mg/kg of drug in male Dawley rats,Intermediate,,50597,,14346,,10116.0,Rattus norvegicus,,CHEMBL626795,,,In vivo,,A,1,1,
,BAO_0000218,11214,N,Maximum concentration was measured after peroral administration of 5.1 mg/kg of drug in male Dawley rats,Intermediate,,50597,,14346,,10116.0,Rattus norvegicus,,CHEMBL626796,,,In vivo,,A,1,1,
,BAO_0000218,11215,N,Maximum concentration was measured after peroral administration of 5.2 mg/kg of drug in male Dawley rats,Intermediate,,50597,,14346,,10116.0,Rattus norvegicus,,CHEMBL626797,,,In vivo,,A,1,1,
,BAO_0000218,11216,N,Maximum drug concentration is determined after oral dosing in rats.,Intermediate,,50597,,14127,,10116.0,Rattus norvegicus,,CHEMBL626798,,,In vivo,,A,1,1,
,BAO_0000218,11217,N,Maximum observed concentration in oral (5 mg/kg) fasted dogs,Intermediate,,50588,,14339,,9615.0,Canis lupus familiaris,,CHEMBL626799,,,In vivo,,A,1,1,
,BAO_0000218,11218,N,Maximum observed concentration in oral (5 mg/kg) fed dogs,Intermediate,,50588,,14339,,9615.0,Canis lupus familiaris,,CHEMBL626800,,,In vivo,,A,1,1,
Plasma,BAO_0000218,11219,U,Maximum plasma concentration,Autocuration,,22224,,13494,1969.0,,,,CHEMBL626801,,,In vivo,,A,1,0,
Plasma,BAO_0000218,11220,N,Maximum plasma concentration (Cmax) was determined in rats after intraduodenal administration of the drug,Intermediate,,50597,,14925,1969.0,10116.0,Rattus norvegicus,,CHEMBL876816,,,In vivo,,A,1,1,
Plasma,BAO_0000218,11221,N,Maximum plasma concentration following oral administration of 26.3 mg/kg in rats,Intermediate,,50597,,14474,1969.0,10116.0,Rattus norvegicus,,CHEMBL626802,,,In vivo,,A,1,1,
Plasma,BAO_0000218,11222,N,Maximum plasma concentration following oral administration of 3.8 mg/kg in Beagle dog,Intermediate,,50588,,14474,1969.0,9615.0,Canis lupus familiaris,,CHEMBL626803,,,In vivo,,A,1,1,
Plasma,BAO_0000218,11223,U,Maximum plasma concentration following oral administration of 30 umol/kg,Autocuration,,22224,,13917,1969.0,,,,CHEMBL626804,,,In vivo,,A,1,0,
Plasma,BAO_0000218,11224,N,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose,Intermediate,,50597,,9796,1969.0,10116.0,Rattus norvegicus,,CHEMBL626805,,,,,A,1,1,
Plasma,BAO_0000218,11225,N,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,Intermediate,,50597,,9796,1969.0,10116.0,Rattus norvegicus,,CHEMBL626309,,,,,A,1,1,
Plasma,BAO_0000218,11226,N,Distribution of radiolabeled compound in plasma of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,Intermediate,,50597,,9796,1969.0,10116.0,Rattus norvegicus,,CHEMBL626310,,,,,A,1,1,
Plasma,BAO_0000218,11227,N,Distribution of radiolabeled compound in plasma of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,Intermediate,,50597,,9796,1969.0,10116.0,Rattus norvegicus,,CHEMBL626311,,,,,A,1,1,
Plasma,BAO_0000218,11228,N,Distribution of radiolabeled compound in plasma of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,Intermediate,,50597,,9796,1969.0,10116.0,Rattus norvegicus,,CHEMBL626312,,,,,A,1,1,
Uterus,BAO_0000218,11229,N,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,Intermediate,,50597,,9796,995.0,10116.0,Rattus norvegicus,,CHEMBL626313,,,,,A,1,1,
Uterus,BAO_0000218,11230,N,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,Intermediate,,50597,,9796,995.0,10116.0,Rattus norvegicus,,CHEMBL626314,,,,,A,1,1,
Uterus,BAO_0000218,11231,N,Distribution of radiolabeled compound in uterus of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,Intermediate,,50597,,9796,995.0,10116.0,Rattus norvegicus,,CHEMBL626315,,,,,A,1,1,
Uterus,BAO_0000218,11232,N,Distribution of radiolabeled compound in uterus of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,Intermediate,,50597,,9796,995.0,10116.0,Rattus norvegicus,,CHEMBL626316,,,,,A,1,1,
Uterus,BAO_0000218,11233,N,Distribution of radiolabeled compound in uterus of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,Intermediate,,50597,,9796,995.0,10116.0,Rattus norvegicus,,CHEMBL626317,,,,,A,1,1,
,BAO_0000218,11234,N,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Minus (-),Intermediate,,50597,,8363,,10116.0,Rattus norvegicus,,CHEMBL626318,,,,,A,1,1,
,BAO_0000218,11235,N,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Plus (+),Intermediate,,50597,,8363,,10116.0,Rattus norvegicus,,CHEMBL626319,,,,,A,1,1,
,BAO_0000218,11236,N,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Minus (-),Intermediate,,50597,,8363,,10116.0,Rattus norvegicus,,CHEMBL626320,,,,,A,1,1,
,BAO_0000218,11237,N,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Plus (+),Intermediate,,50597,,8363,,10116.0,Rattus norvegicus,,CHEMBL875053,,,,,A,1,1,
,BAO_0000218,11238,N,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Minus (-),Intermediate,,50597,,8363,,10116.0,Rattus norvegicus,,CHEMBL626321,,,,,A,1,1,
,BAO_0000218,11239,N,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Plus (+),Intermediate,,50597,,8363,,10116.0,Rattus norvegicus,,CHEMBL626322,,,,,A,1,1,
,BAO_0000218,11240,N,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Minus (-),Intermediate,,50597,,8363,,10116.0,Rattus norvegicus,,CHEMBL626323,,,,,A,1,1,
,BAO_0000218,11241,N,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Plus (+),Intermediate,,50597,,8363,,10116.0,Rattus norvegicus,,CHEMBL626324,,,,,A,1,1,
,BAO_0000218,11242,N,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Minus (-),Intermediate,,50597,,8363,,10116.0,Rattus norvegicus,,CHEMBL626325,,,,,A,1,1,
,BAO_0000218,11243,N,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Plus (+),Intermediate,,50597,,8363,,10116.0,Rattus norvegicus,,CHEMBL626326,,,,,A,1,1,
,BAO_0000218,11244,N,Distribution of rat erythrocytes for tube 7 on rate of aging in 2 mL of cell suspension; Plus (+),Intermediate,,50597,,8363,,10116.0,Rattus norvegicus,,CHEMBL626327,,,,,A,1,1,
,BAO_0000218,11245,N,Distribution of rat erythrocytes for tube 1 on rate of aging in 2 mL of cell suspension; Minus (-),Intermediate,,50597,,8363,,10116.0,Rattus norvegicus,,CHEMBL626328,,,,,A,1,1,
Blood,BAO_0000218,11246,N,"Distribution in blood of rat 5 min after intravenous administration, injected dose/gm",Intermediate,,50597,,8684,178.0,10116.0,Rattus norvegicus,,CHEMBL626329,,,,,A,1,1,
Blood,BAO_0000218,11247,N,"Distribution in blood of rat, 15 min after intravenous administration, injected dose/gm",Intermediate,,50597,,8684,178.0,10116.0,Rattus norvegicus,,CHEMBL626330,,,,,A,1,1,
Blood,BAO_0000218,11248,N,"Distribution in blood of rat, 1 hr after intravenous administration, injected dose/gm",Intermediate,,50597,,8684,178.0,10116.0,Rattus norvegicus,,CHEMBL626331,,,,,A,1,1,
Blood,BAO_0000218,11249,N,"Distribution in blood of rat, 2 hr after intravenous administration, injected dose/gm",Intermediate,,50597,,8684,178.0,10116.0,Rattus norvegicus,,CHEMBL626332,,,,,A,1,1,
Blood,BAO_0000218,11250,N,"Distribution in blood of rat, 30 min after intravenous administration, injected dose/gm",Intermediate,,50597,,8684,178.0,10116.0,Rattus norvegicus,,CHEMBL626333,,,,,A,1,1,
Blood,BAO_0000218,11251,N,"Distribution in blood of rat, 4 hr after intravenous administration, injected dose/gm",Intermediate,,50597,,8684,178.0,10116.0,Rattus norvegicus,,CHEMBL626334,,,,,A,1,1,
Blood,BAO_0000218,11252,N,"Distribution in blood of rat, 6 hr after intravenous administration, injected dose/gm",Intermediate,,50597,,8684,178.0,10116.0,Rattus norvegicus,,CHEMBL626335,,,,,A,1,1,
Blood,BAO_0000218,11253,N,"Distribution in blood of rat, 8 hr after intravenous administration, injected dose/gm",Intermediate,,50597,,8684,178.0,10116.0,Rattus norvegicus,,CHEMBL624798,,,,,A,1,1,
Brain,BAO_0000218,11254,N,"Distribution in brain of rat, 15 min after intravenous administered, injected dose/gm",Intermediate,,50597,,8684,955.0,10116.0,Rattus norvegicus,,CHEMBL624799,,,,,A,1,1,
Brain,BAO_0000218,11255,N,"Distribution in brain of rat, 1 hr after intravenous administered, injected dose/gm",Intermediate,,50597,,8684,955.0,10116.0,Rattus norvegicus,,CHEMBL624800,,,,,A,1,1,
Brain,BAO_0000218,11256,N,"Distribution in brain of rat, 2 hr after intravenous administered, injected dose/gm",Intermediate,,50597,,8684,955.0,10116.0,Rattus norvegicus,,CHEMBL624801,,,,,A,1,1,
Brain,BAO_0000218,11257,N,"Distribution in brain of rat, 30 min after intravenous administered, injected dose/gm",Intermediate,,50597,,8684,955.0,10116.0,Rattus norvegicus,,CHEMBL624802,,,,,A,1,1,
Brain,BAO_0000218,11258,N,"Distribution in brain of rat, 4 hr after intravenous administered, injected dose/gm",Intermediate,,50597,,8684,955.0,10116.0,Rattus norvegicus,,CHEMBL624803,,,,,A,1,1,
Brain,BAO_0000218,11259,N,"Distribution in brain of rat, 5 min after intravenous administered, injected dose/gm",Intermediate,,50597,,8684,955.0,10116.0,Rattus norvegicus,,CHEMBL624804,,,,,A,1,1,
Brain,BAO_0000218,11260,N,"Distribution in brain of rat, 6 hr after intravenous administered, injected dose/gm",Intermediate,,50597,,8684,955.0,10116.0,Rattus norvegicus,,CHEMBL624805,,,,,A,1,1,
Brain,BAO_0000218,11261,N,"Distribution in brain of rat, 8 hr after intravenous administered, injected dose/gm",Intermediate,,50597,,8684,955.0,10116.0,Rattus norvegicus,,CHEMBL624806,,,,,A,1,1,
,BAO_0000218,11262,N,"Distribution in rat fat 15 min after intravenous administration, injected dose/gm",Intermediate,,50597,,8684,,10116.0,Rattus norvegicus,,CHEMBL624807,,,,,A,1,1,
,BAO_0000218,11263,N,"Distribution in rat fat 1 hr after intravenous administration, injected dose/gm",Intermediate,,50597,,8684,,10116.0,Rattus norvegicus,,CHEMBL624808,,,,,A,1,1,
,BAO_0000218,11264,N,"Distribution in rat fat 2 hr after intravenous administration, injected dose/gm",Intermediate,,50597,,8684,,10116.0,Rattus norvegicus,,CHEMBL624809,,,,,A,1,1,
,BAO_0000218,11265,N,"Distribution in rat fat 30 min after intravenous administration, injected dose/gm",Intermediate,,50597,,8684,,10116.0,Rattus norvegicus,,CHEMBL624810,,,,,A,1,1,
,BAO_0000218,11266,N,"Distribution in rat fat 4 hr after intravenous administration, injected dose/gm",Intermediate,,50597,,8684,,10116.0,Rattus norvegicus,,CHEMBL877618,,,,,A,1,1,
,BAO_0000218,11267,N,"Distribution in rat fat 5 min after intravenous administration, injected dose/gm",Intermediate,,50597,,8684,,10116.0,Rattus norvegicus,,CHEMBL624811,,,,,A,1,1,
,BAO_0000218,11268,N,"Distribution in rat fat 6 hr after intravenous administration, injected dose/gm",Intermediate,,50597,,8684,,10116.0,Rattus norvegicus,,CHEMBL624812,,,,,A,1,1,
,BAO_0000218,11269,N,"Distribution in rat fat 8 hr after intravenous administration, injected dose/gm",Intermediate,,50597,,8684,,10116.0,Rattus norvegicus,,CHEMBL624813,,,,,A,1,1,
,BAO_0000218,11270,N,"Distribution in rat heart 15 min after intravenous administration, injected dose/gm",Intermediate,,50597,,8684,,10116.0,Rattus norvegicus,,CHEMBL624814,,,,,A,1,1,
,BAO_0000218,11271,N,"Distribution in rat heart 1 hr after intravenous administration, injected dose/gm",Intermediate,,50597,,8684,,10116.0,Rattus norvegicus,,CHEMBL624815,,,,,A,1,1,
,BAO_0000218,11272,N,"Distribution in rat heart 2 hr after intravenous administration, injected dose/gm",Intermediate,,50597,,8684,,10116.0,Rattus norvegicus,,CHEMBL624816,,,,,A,1,1,
,BAO_0000218,11273,N,"Distribution in rat heart 30 min after intravenous administration, injected dose/gm",Intermediate,,50597,,8684,,10116.0,Rattus norvegicus,,CHEMBL624817,,,,,A,1,1,
,BAO_0000218,11274,N,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),Intermediate,,50588,,6996,,9615.0,Canis lupus familiaris,,CHEMBL624818,,,,,A,1,1,
